{"answers": [{"answer_start": [28], "text": ["48 genes"]}, {"answer_start": [28], "text": ["48 genes"]}, {"answer_start": [28], "text": ["48 genes"]}, {"answer_start": [28], "text": ["48 genes"]}, {"answer_start": [28], "text": ["48 genes"]}, {"answer_start": [28], "text": ["48 genes"]}, {"answer_start": [28], "text": ["48 genes"]}, {"answer_start": [28], "text": ["48 genes"]}, {"answer_start": [28], "text": ["48 genes"]}, {"answer_start": [28], "text": ["48 genes"]}, {"answer_start": [28], "text": ["48 genes"]}, {"answer_start": [28], "text": ["48 genes"]}, {"answer_start": [28], "text": ["48 genes"]}, {"answer_start": [28], "text": ["48 genes"]}, {"answer_start": [28], "text": ["48 genes"]}, {"answer_start": [28], "text": ["48 genes"]}, {"answer_start": [28], "text": ["48 genes"]}, {"answer_start": [28], "text": ["48 genes"]}, {"answer_start": [28], "text": ["48 genes"]}, {"answer_start": [28], "text": ["48 genes"]}, {"answer_start": [28], "text": ["48 genes"]}, {"answer_start": [28], "text": ["48 genes"]}, {"answer_start": [28], "text": ["48 genes"]}, {"answer_start": [28], "text": ["48 genes"]}, {"answer_start": [28], "text": ["48 genes"]}, {"answer_start": [28], "text": ["48 genes"]}, {"answer_start": [28], "text": ["48 genes"]}, {"answer_start": [28], "text": ["48 genes"]}, {"answer_start": [28], "text": ["48 genes"]}, {"answer_start": [28], "text": ["48 genes"]}, {"answer_start": [28], "text": ["48 genes"]}, {"answer_start": [28], "text": ["48 genes"]}, {"answer_start": [28], "text": ["48 genes"]}, {"answer_start": [28], "text": ["48 genes"]}, {"answer_start": [28], "text": ["48 genes"]}, {"answer_start": [28], "text": ["48 genes"]}, {"answer_start": [28], "text": ["48 genes"]}, {"answer_start": [28], "text": ["48 genes"]}, {"answer_start": [28], "text": ["48 genes"]}, {"answer_start": [28], "text": ["48 genes"]}, {"answer_start": [28], "text": ["48 genes"]}, {"answer_start": [28], "text": ["48 genes"]}, {"answer_start": [28], "text": ["48 genes"]}, {"answer_start": [28], "text": ["48 genes"]}, {"answer_start": [28], "text": ["48 genes"]}, {"answer_start": [28], "text": ["48 genes"]}, {"answer_start": [28], "text": ["48 genes"]}, {"answer_start": [28], "text": ["48 genes"]}, {"answer_start": [28], "text": ["48 genes"]}, {"answer_start": [131], "text": ["48 genes"]}, {"answer_start": [131], "text": ["48 genes"]}, {"answer_start": [131], "text": ["48 genes"]}, {"answer_start": [131], "text": ["48 genes"]}, {"answer_start": [131], "text": ["48 genes"]}, {"answer_start": [131], "text": ["48 genes"]}, {"answer_start": [131], "text": ["48 genes"]}, {"answer_start": [131], "text": ["48 genes"]}, {"answer_start": [131], "text": ["48 genes"]}, {"answer_start": [131], "text": ["48 genes"]}, {"answer_start": [131], "text": ["48 genes"]}, {"answer_start": [131], "text": ["48 genes"]}, {"answer_start": [131], "text": ["48 genes"]}, {"answer_start": [131], "text": ["48 genes"]}, {"answer_start": [131], "text": ["48 genes"]}, {"answer_start": [131], "text": ["48 genes"]}, {"answer_start": [131], "text": ["48 genes"]}, {"answer_start": [131], "text": ["48 genes"]}, {"answer_start": [131], "text": ["48 genes"]}, {"answer_start": [131], "text": ["48 genes"]}, {"answer_start": [131], "text": ["48 genes"]}, {"answer_start": [131], "text": ["48 genes"]}, {"answer_start": [131], "text": ["48 genes"]}, {"answer_start": [131], "text": ["48 genes"]}, {"answer_start": [131], "text": ["48 genes"]}, {"answer_start": [131], "text": ["48 genes"]}, {"answer_start": [131], "text": ["48 genes"]}, {"answer_start": [131], "text": ["48 genes"]}, {"answer_start": [131], "text": ["48 genes"]}, {"answer_start": [131], "text": ["48 genes"]}, {"answer_start": [131], "text": ["48 genes"]}, {"answer_start": [131], "text": ["48 genes"]}, {"answer_start": [131], "text": ["48 genes"]}, {"answer_start": [131], "text": ["48 genes"]}, {"answer_start": [131], "text": ["48 genes"]}, {"answer_start": [131], "text": ["48 genes"]}, {"answer_start": [131], "text": ["48 genes"]}, {"answer_start": [131], "text": ["48 genes"]}, {"answer_start": [131], "text": ["48 genes"]}, {"answer_start": [131], "text": ["48 genes"]}, {"answer_start": [131], "text": ["48 genes"]}, {"answer_start": [131], "text": ["48 genes"]}, {"answer_start": [131], "text": ["48 genes"]}, {"answer_start": [131], "text": ["48 genes"]}, {"answer_start": [131], "text": ["48 genes"]}, {"answer_start": [131], "text": ["48 genes"]}, {"answer_start": [131], "text": ["48 genes"]}, {"answer_start": [131], "text": ["48 genes"]}, {"answer_start": [131], "text": ["48 genes"]}, {"answer_start": [117], "text": ["48 genes"]}, {"answer_start": [117], "text": ["48 genes"]}, {"answer_start": [117], "text": ["48 genes"]}, {"answer_start": [117], "text": ["48 genes"]}, {"answer_start": [117], "text": ["48 genes"]}, {"answer_start": [117], "text": ["48 genes"]}, {"answer_start": [117], "text": ["48 genes"]}, {"answer_start": [117], "text": ["48 genes"]}, {"answer_start": [117], "text": ["48 genes"]}, {"answer_start": [117], "text": ["48 genes"]}, {"answer_start": [117], "text": ["48 genes"]}, {"answer_start": [117], "text": ["48 genes"]}, {"answer_start": [117], "text": ["48 genes"]}, {"answer_start": [117], "text": ["48 genes"]}, {"answer_start": [117], "text": ["48 genes"]}, {"answer_start": [117], "text": ["48 genes"]}, {"answer_start": [117], "text": ["48 genes"]}, {"answer_start": [117], "text": ["48 genes"]}, {"answer_start": [117], "text": ["48 genes"]}, {"answer_start": [117], "text": ["48 genes"]}, {"answer_start": [117], "text": ["48 genes"]}, {"answer_start": [117], "text": ["48 genes"]}, {"answer_start": [117], "text": ["48 genes"]}, {"answer_start": [117], "text": ["48 genes"]}, {"answer_start": [117], "text": ["48 genes"]}, {"answer_start": [117], "text": ["48 genes"]}, {"answer_start": [117], "text": ["48 genes"]}, {"answer_start": [117], "text": ["48 genes"]}, {"answer_start": [117], "text": ["48 genes"]}, {"answer_start": [117], "text": ["48 genes"]}, {"answer_start": [117], "text": ["48 genes"]}, {"answer_start": [117], "text": ["48 genes"]}, {"answer_start": [117], "text": ["48 genes"]}, {"answer_start": [117], "text": ["48 genes"]}, {"answer_start": [117], "text": ["48 genes"]}, {"answer_start": [117], "text": ["48 genes"]}, {"answer_start": [117], "text": ["48 genes"]}, {"answer_start": [117], "text": ["48 genes"]}, {"answer_start": [117], "text": ["48 genes"]}, {"answer_start": [117], "text": ["48 genes"]}, {"answer_start": [117], "text": ["48 genes"]}, {"answer_start": [117], "text": ["48 genes"]}, {"answer_start": [117], "text": ["48 genes"]}, {"answer_start": [117], "text": ["48 genes"]}, {"answer_start": [117], "text": ["48 genes"]}, {"answer_start": [117], "text": ["48 genes"]}, {"answer_start": [117], "text": ["48 genes"]}, {"answer_start": [117], "text": ["48 genes"]}, {"answer_start": [117], "text": ["48 genes"]}, {"answer_start": [101], "text": ["48 genes"]}, {"answer_start": [101], "text": ["48 genes"]}, {"answer_start": [101], "text": ["48 genes"]}, {"answer_start": [101], "text": ["48 genes"]}, {"answer_start": [101], "text": ["48 genes"]}, {"answer_start": [101], "text": ["48 genes"]}, {"answer_start": [101], "text": ["48 genes"]}, {"answer_start": [101], "text": ["48 genes"]}, {"answer_start": [101], "text": ["48 genes"]}, {"answer_start": [101], "text": ["48 genes"]}, {"answer_start": [101], "text": ["48 genes"]}, {"answer_start": [101], "text": ["48 genes"]}, {"answer_start": [101], "text": ["48 genes"]}, {"answer_start": [101], "text": ["48 genes"]}, {"answer_start": [101], "text": ["48 genes"]}, {"answer_start": [101], "text": ["48 genes"]}, {"answer_start": [101], "text": ["48 genes"]}, {"answer_start": [101], "text": ["48 genes"]}, {"answer_start": [101], "text": ["48 genes"]}, {"answer_start": [101], "text": ["48 genes"]}, {"answer_start": [101], "text": ["48 genes"]}, {"answer_start": [101], "text": ["48 genes"]}, {"answer_start": [101], "text": ["48 genes"]}, {"answer_start": [101], "text": ["48 genes"]}, {"answer_start": [101], "text": ["48 genes"]}, {"answer_start": [101], "text": ["48 genes"]}, {"answer_start": [101], "text": ["48 genes"]}, {"answer_start": [101], "text": ["48 genes"]}, {"answer_start": [101], "text": ["48 genes"]}, {"answer_start": [101], "text": ["48 genes"]}, {"answer_start": [101], "text": ["48 genes"]}, {"answer_start": [101], "text": ["48 genes"]}, {"answer_start": [101], "text": ["48 genes"]}, {"answer_start": [101], "text": ["48 genes"]}, {"answer_start": [101], "text": ["48 genes"]}, {"answer_start": [101], "text": ["48 genes"]}, {"answer_start": [101], "text": ["48 genes"]}, {"answer_start": [101], "text": ["48 genes"]}, {"answer_start": [101], "text": ["48 genes"]}, {"answer_start": [101], "text": ["48 genes"]}, {"answer_start": [101], "text": ["48 genes"]}, {"answer_start": [101], "text": ["48 genes"]}, {"answer_start": [101], "text": ["48 genes"]}, {"answer_start": [101], "text": ["48 genes"]}, {"answer_start": [101], "text": ["48 genes"]}, {"answer_start": [101], "text": ["48 genes"]}, {"answer_start": [101], "text": ["48 genes"]}, {"answer_start": [101], "text": ["48 genes"]}, {"answer_start": [101], "text": ["48 genes"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [50], "text": ["stress urinary incontinence"]}, {"answer_start": [50], "text": ["stress urinary incontinence"]}, {"answer_start": [50], "text": ["stress urinary incontinence"]}, {"answer_start": [50], "text": ["stress urinary incontinence"]}, {"answer_start": [50], "text": ["stress urinary incontinence"]}, {"answer_start": [50], "text": ["stress urinary incontinence"]}, {"answer_start": [50], "text": ["stress urinary incontinence"]}, {"answer_start": [50], "text": ["stress urinary incontinence"]}, {"answer_start": [50], "text": ["stress urinary incontinence"]}, {"answer_start": [50], "text": ["stress urinary incontinence"]}, {"answer_start": [50], "text": ["stress urinary incontinence"]}, {"answer_start": [50], "text": ["stress urinary incontinence"]}, {"answer_start": [50], "text": ["stress urinary incontinence"]}, {"answer_start": [50], "text": ["stress urinary incontinence"]}, {"answer_start": [50], "text": ["stress urinary incontinence"]}, {"answer_start": [50], "text": ["stress urinary incontinence"]}, {"answer_start": [50], "text": ["stress urinary incontinence"]}, {"answer_start": [50], "text": ["stress urinary incontinence"]}, {"answer_start": [50], "text": ["stress urinary incontinence"]}, {"answer_start": [50], "text": ["stress urinary incontinence"]}, {"answer_start": [50], "text": ["stress urinary incontinence"]}, {"answer_start": [50], "text": ["stress urinary incontinence"]}, {"answer_start": [50], "text": ["stress urinary incontinence"]}, {"answer_start": [50], "text": ["stress urinary incontinence"]}, {"answer_start": [50], "text": ["stress urinary incontinence"]}, {"answer_start": [50], "text": ["stress urinary incontinence"]}, {"answer_start": [50], "text": ["stress urinary incontinence"]}, {"answer_start": [50], "text": ["stress urinary incontinence"]}, {"answer_start": [50], "text": ["stress urinary incontinence"]}, {"answer_start": [86], "text": ["stress urinary incontinence"]}, {"answer_start": [86], "text": ["stress urinary incontinence"]}, {"answer_start": [86], "text": ["stress urinary incontinence"]}, {"answer_start": [86], "text": ["stress urinary incontinence"]}, {"answer_start": [86], "text": ["stress urinary incontinence"]}, {"answer_start": [86], "text": ["stress urinary incontinence"]}, {"answer_start": [86], "text": ["stress urinary incontinence"]}, {"answer_start": [86], "text": ["stress urinary incontinence"]}, {"answer_start": [86], "text": ["stress urinary incontinence"]}, {"answer_start": [86], "text": ["stress urinary incontinence"]}, {"answer_start": [86], "text": ["stress urinary incontinence"]}, {"answer_start": [86], "text": ["stress urinary incontinence"]}, {"answer_start": [86], "text": ["stress urinary incontinence"]}, {"answer_start": [86], "text": ["stress urinary incontinence"]}, {"answer_start": [86], "text": ["stress urinary incontinence"]}, {"answer_start": [86], "text": ["stress urinary incontinence"]}, {"answer_start": [86], "text": ["stress urinary incontinence"]}, {"answer_start": [86], "text": ["stress urinary incontinence"]}, {"answer_start": [86], "text": ["stress urinary incontinence"]}, {"answer_start": [86], "text": ["stress urinary incontinence"]}, {"answer_start": [86], "text": ["stress urinary incontinence"]}, {"answer_start": [86], "text": ["stress urinary incontinence"]}, {"answer_start": [86], "text": ["stress urinary incontinence"]}, {"answer_start": [86], "text": ["stress urinary incontinence"]}, {"answer_start": [86], "text": ["stress urinary incontinence"]}, {"answer_start": [86], "text": ["stress urinary incontinence"]}, {"answer_start": [86], "text": ["stress urinary incontinence"]}, {"answer_start": [86], "text": ["stress urinary incontinence"]}, {"answer_start": [86], "text": ["stress urinary incontinence"]}, {"answer_start": [69], "text": ["stress urinary incontinence"]}, {"answer_start": [69], "text": ["stress urinary incontinence"]}, {"answer_start": [69], "text": ["stress urinary incontinence"]}, {"answer_start": [69], "text": ["stress urinary incontinence"]}, {"answer_start": [69], "text": ["stress urinary incontinence"]}, {"answer_start": [69], "text": ["stress urinary incontinence"]}, {"answer_start": [69], "text": ["stress urinary incontinence"]}, {"answer_start": [69], "text": ["stress urinary incontinence"]}, {"answer_start": [69], "text": ["stress urinary incontinence"]}, {"answer_start": [69], "text": ["stress urinary incontinence"]}, {"answer_start": [69], "text": ["stress urinary incontinence"]}, {"answer_start": [69], "text": ["stress urinary incontinence"]}, {"answer_start": [69], "text": ["stress urinary incontinence"]}, {"answer_start": [69], "text": ["stress urinary incontinence"]}, {"answer_start": [69], "text": ["stress urinary incontinence"]}, {"answer_start": [69], "text": ["stress urinary incontinence"]}, {"answer_start": [69], "text": ["stress urinary incontinence"]}, {"answer_start": [69], "text": ["stress urinary incontinence"]}, {"answer_start": [69], "text": ["stress urinary incontinence"]}, {"answer_start": [69], "text": ["stress urinary incontinence"]}, {"answer_start": [69], "text": ["stress urinary incontinence"]}, {"answer_start": [69], "text": ["stress urinary incontinence"]}, {"answer_start": [69], "text": ["stress urinary incontinence"]}, {"answer_start": [69], "text": ["stress urinary incontinence"]}, {"answer_start": [69], "text": ["stress urinary incontinence"]}, {"answer_start": [69], "text": ["stress urinary incontinence"]}, {"answer_start": [69], "text": ["stress urinary incontinence"]}, {"answer_start": [69], "text": ["stress urinary incontinence"]}, {"answer_start": [69], "text": ["stress urinary incontinence"]}, {"answer_start": [82], "text": ["stress urinary incontinence"]}, {"answer_start": [82], "text": ["stress urinary incontinence"]}, {"answer_start": [82], "text": ["stress urinary incontinence"]}, {"answer_start": [82], "text": ["stress urinary incontinence"]}, {"answer_start": [82], "text": ["stress urinary incontinence"]}, {"answer_start": [82], "text": ["stress urinary incontinence"]}, {"answer_start": [82], "text": ["stress urinary incontinence"]}, {"answer_start": [82], "text": ["stress urinary incontinence"]}, {"answer_start": [82], "text": ["stress urinary incontinence"]}, {"answer_start": [82], "text": ["stress urinary incontinence"]}, {"answer_start": [82], "text": ["stress urinary incontinence"]}, {"answer_start": [82], "text": ["stress urinary incontinence"]}, {"answer_start": [82], "text": ["stress urinary incontinence"]}, {"answer_start": [82], "text": ["stress urinary incontinence"]}, {"answer_start": [82], "text": ["stress urinary incontinence"]}, {"answer_start": [82], "text": ["stress urinary incontinence"]}, {"answer_start": [82], "text": ["stress urinary incontinence"]}, {"answer_start": [82], "text": ["stress urinary incontinence"]}, {"answer_start": [82], "text": ["stress urinary incontinence"]}, {"answer_start": [82], "text": ["stress urinary incontinence"]}, {"answer_start": [82], "text": ["stress urinary incontinence"]}, {"answer_start": [82], "text": ["stress urinary incontinence"]}, {"answer_start": [82], "text": ["stress urinary incontinence"]}, {"answer_start": [82], "text": ["stress urinary incontinence"]}, {"answer_start": [82], "text": ["stress urinary incontinence"]}, {"answer_start": [82], "text": ["stress urinary incontinence"]}, {"answer_start": [82], "text": ["stress urinary incontinence"]}, {"answer_start": [82], "text": ["stress urinary incontinence"]}, {"answer_start": [82], "text": ["stress urinary incontinence"]}, {"answer_start": [58], "text": ["stress urinary incontinence"]}, {"answer_start": [58], "text": ["stress urinary incontinence"]}, {"answer_start": [58], "text": ["stress urinary incontinence"]}, {"answer_start": [58], "text": ["stress urinary incontinence"]}, {"answer_start": [58], "text": ["stress urinary incontinence"]}, {"answer_start": [58], "text": ["stress urinary incontinence"]}, {"answer_start": [58], "text": ["stress urinary incontinence"]}, {"answer_start": [58], "text": ["stress urinary incontinence"]}, {"answer_start": [58], "text": ["stress urinary incontinence"]}, {"answer_start": [58], "text": ["stress urinary incontinence"]}, {"answer_start": [58], "text": ["stress urinary incontinence"]}, {"answer_start": [58], "text": ["stress urinary incontinence"]}, {"answer_start": [58], "text": ["stress urinary incontinence"]}, {"answer_start": [58], "text": ["stress urinary incontinence"]}, {"answer_start": [58], "text": ["stress urinary incontinence"]}, {"answer_start": [58], "text": ["stress urinary incontinence"]}, {"answer_start": [58], "text": ["stress urinary incontinence"]}, {"answer_start": [58], "text": ["stress urinary incontinence"]}, {"answer_start": [58], "text": ["stress urinary incontinence"]}, {"answer_start": [58], "text": ["stress urinary incontinence"]}, {"answer_start": [58], "text": ["stress urinary incontinence"]}, {"answer_start": [58], "text": ["stress urinary incontinence"]}, {"answer_start": [58], "text": ["stress urinary incontinence"]}, {"answer_start": [58], "text": ["stress urinary incontinence"]}, {"answer_start": [58], "text": ["stress urinary incontinence"]}, {"answer_start": [58], "text": ["stress urinary incontinence"]}, {"answer_start": [58], "text": ["stress urinary incontinence"]}, {"answer_start": [58], "text": ["stress urinary incontinence"]}, {"answer_start": [58], "text": ["stress urinary incontinence"]}, {"answer_start": [124], "text": ["stress urinary incontinence"]}, {"answer_start": [124], "text": ["stress urinary incontinence"]}, {"answer_start": [124], "text": ["stress urinary incontinence"]}, {"answer_start": [124], "text": ["stress urinary incontinence"]}, {"answer_start": [124], "text": ["stress urinary incontinence"]}, {"answer_start": [124], "text": ["stress urinary incontinence"]}, {"answer_start": [124], "text": ["stress urinary incontinence"]}, {"answer_start": [124], "text": ["stress urinary incontinence"]}, {"answer_start": [124], "text": ["stress urinary incontinence"]}, {"answer_start": [124], "text": ["stress urinary incontinence"]}, {"answer_start": [124], "text": ["stress urinary incontinence"]}, {"answer_start": [124], "text": ["stress urinary incontinence"]}, {"answer_start": [124], "text": ["stress urinary incontinence"]}, {"answer_start": [124], "text": ["stress urinary incontinence"]}, {"answer_start": [124], "text": ["stress urinary incontinence"]}, {"answer_start": [124], "text": ["stress urinary incontinence"]}, {"answer_start": [124], "text": ["stress urinary incontinence"]}, {"answer_start": [124], "text": ["stress urinary incontinence"]}, {"answer_start": [124], "text": ["stress urinary incontinence"]}, {"answer_start": [124], "text": ["stress urinary incontinence"]}, {"answer_start": [124], "text": ["stress urinary incontinence"]}, {"answer_start": [124], "text": ["stress urinary incontinence"]}, {"answer_start": [124], "text": ["stress urinary incontinence"]}, {"answer_start": [124], "text": ["stress urinary incontinence"]}, {"answer_start": [124], "text": ["stress urinary incontinence"]}, {"answer_start": [124], "text": ["stress urinary incontinence"]}, {"answer_start": [124], "text": ["stress urinary incontinence"]}, {"answer_start": [124], "text": ["stress urinary incontinence"]}, {"answer_start": [124], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [70], "text": ["stress urinary incontinence"]}, {"answer_start": [37], "text": ["stress urinary incontinence"]}, {"answer_start": [37], "text": ["stress urinary incontinence"]}, {"answer_start": [37], "text": ["stress urinary incontinence"]}, {"answer_start": [37], "text": ["stress urinary incontinence"]}, {"answer_start": [37], "text": ["stress urinary incontinence"]}, {"answer_start": [37], "text": ["stress urinary incontinence"]}, {"answer_start": [37], "text": ["stress urinary incontinence"]}, {"answer_start": [37], "text": ["stress urinary incontinence"]}, {"answer_start": [37], "text": ["stress urinary incontinence"]}, {"answer_start": [37], "text": ["stress urinary incontinence"]}, {"answer_start": [37], "text": ["stress urinary incontinence"]}, {"answer_start": [37], "text": ["stress urinary incontinence"]}, {"answer_start": [37], "text": ["stress urinary incontinence"]}, {"answer_start": [37], "text": ["stress urinary incontinence"]}, {"answer_start": [37], "text": ["stress urinary incontinence"]}, {"answer_start": [37], "text": ["stress urinary incontinence"]}, {"answer_start": [37], "text": ["stress urinary incontinence"]}, {"answer_start": [37], "text": ["stress urinary incontinence"]}, {"answer_start": [37], "text": ["stress urinary incontinence"]}, {"answer_start": [37], "text": ["stress urinary incontinence"]}, {"answer_start": [37], "text": ["stress urinary incontinence"]}, {"answer_start": [37], "text": ["stress urinary incontinence"]}, {"answer_start": [37], "text": ["stress urinary incontinence"]}, {"answer_start": [37], "text": ["stress urinary incontinence"]}, {"answer_start": [37], "text": ["stress urinary incontinence"]}, {"answer_start": [37], "text": ["stress urinary incontinence"]}, {"answer_start": [37], "text": ["stress urinary incontinence"]}, {"answer_start": [37], "text": ["stress urinary incontinence"]}, {"answer_start": [37], "text": ["stress urinary incontinence"]}, {"answer_start": [63], "text": ["four"]}, {"answer_start": [63], "text": ["four"]}, {"answer_start": [63], "text": ["four"]}, {"answer_start": [63], "text": ["four"]}, {"answer_start": [63], "text": ["four"]}, {"answer_start": [63], "text": ["four"]}, {"answer_start": [63], "text": ["four"]}, {"answer_start": [63], "text": ["four"]}, {"answer_start": [63], "text": ["four"]}, {"answer_start": [63], "text": ["four"]}, {"answer_start": [63], "text": ["four"]}, {"answer_start": [63], "text": ["four"]}, {"answer_start": [63], "text": ["four"]}, {"answer_start": [63], "text": ["four"]}, {"answer_start": [63], "text": ["four"]}, {"answer_start": [63], "text": ["four"]}, {"answer_start": [63], "text": ["four"]}, {"answer_start": [63], "text": ["four"]}, {"answer_start": [63], "text": ["four"]}, {"answer_start": [63], "text": ["four"]}, {"answer_start": [63], "text": ["four"]}, {"answer_start": [63], "text": ["four"]}, {"answer_start": [63], "text": ["four"]}, {"answer_start": [63], "text": ["four"]}, {"answer_start": [63], "text": ["four"]}, {"answer_start": [63], "text": ["four"]}, {"answer_start": [0], "text": ["circularized oligodeoxynucleotides"]}, {"answer_start": [0], "text": ["circularized oligodeoxynucleotides"]}, {"answer_start": [0], "text": ["circularized oligodeoxynucleotides"]}, {"answer_start": [0], "text": ["circularized oligodeoxynucleotides"]}, {"answer_start": [0], "text": ["circularized oligodeoxynucleotides"]}, {"answer_start": [0], "text": ["circularized oligodeoxynucleotides"]}, {"answer_start": [0], "text": ["circularized oligodeoxynucleotides"]}, {"answer_start": [0], "text": ["circularized oligodeoxynucleotides"]}, {"answer_start": [0], "text": ["circularized oligodeoxynucleotides"]}, {"answer_start": [0], "text": ["circularized oligodeoxynucleotides"]}, {"answer_start": [0], "text": ["circularized oligodeoxynucleotides"]}, {"answer_start": [0], "text": ["circularized oligodeoxynucleotides"]}, {"answer_start": [0], "text": ["circularized oligodeoxynucleotides"]}, {"answer_start": [0], "text": ["circularized oligodeoxynucleotides"]}, {"answer_start": [0], "text": ["circularized oligodeoxynucleotides"]}, {"answer_start": [0], "text": ["circularized oligodeoxynucleotides"]}, {"answer_start": [134], "text": ["hepatocyte growth factor"]}, {"answer_start": [134], "text": ["hepatocyte growth factor"]}, {"answer_start": [134], "text": ["hepatocyte growth factor"]}, {"answer_start": [134], "text": ["hepatocyte growth factor"]}, {"answer_start": [134], "text": ["hepatocyte growth factor"]}, {"answer_start": [134], "text": ["hepatocyte growth factor"]}, {"answer_start": [134], "text": ["hepatocyte growth factor"]}, {"answer_start": [134], "text": ["hepatocyte growth factor"]}, {"answer_start": [134], "text": ["hepatocyte growth factor"]}, {"answer_start": [134], "text": ["hepatocyte growth factor"]}, {"answer_start": [134], "text": ["hepatocyte growth factor"]}, {"answer_start": [134], "text": ["hepatocyte growth factor"]}, {"answer_start": [134], "text": ["hepatocyte growth factor"]}, {"answer_start": [134], "text": ["hepatocyte growth factor"]}, {"answer_start": [134], "text": ["hepatocyte growth factor"]}, {"answer_start": [134], "text": ["hepatocyte growth factor"]}, {"answer_start": [134], "text": ["hepatocyte growth factor"]}, {"answer_start": [134], "text": ["hepatocyte growth factor"]}, {"answer_start": [134], "text": ["hepatocyte growth factor"]}, {"answer_start": [134], "text": ["hepatocyte growth factor"]}, {"answer_start": [134], "text": ["hepatocyte growth factor"]}, {"answer_start": [134], "text": ["hepatocyte growth factor"]}, {"answer_start": [134], "text": ["hepatocyte growth factor"]}, {"answer_start": [94], "text": ["hepatocyte growth factor"]}, {"answer_start": [94], "text": ["hepatocyte growth factor"]}, {"answer_start": [94], "text": ["hepatocyte growth factor"]}, {"answer_start": [94], "text": ["hepatocyte growth factor"]}, {"answer_start": [94], "text": ["hepatocyte growth factor"]}, {"answer_start": [94], "text": ["hepatocyte growth factor"]}, {"answer_start": [94], "text": ["hepatocyte growth factor"]}, {"answer_start": [94], "text": ["hepatocyte growth factor"]}, {"answer_start": [94], "text": ["hepatocyte growth factor"]}, {"answer_start": [94], "text": ["hepatocyte growth factor"]}, {"answer_start": [94], "text": ["hepatocyte growth factor"]}, {"answer_start": [94], "text": ["hepatocyte growth factor"]}, {"answer_start": [94], "text": ["hepatocyte growth factor"]}, {"answer_start": [94], "text": ["hepatocyte growth factor"]}, {"answer_start": [94], "text": ["hepatocyte growth factor"]}, {"answer_start": [94], "text": ["hepatocyte growth factor"]}, {"answer_start": [94], "text": ["hepatocyte growth factor"]}, {"answer_start": [94], "text": ["hepatocyte growth factor"]}, {"answer_start": [94], "text": ["hepatocyte growth factor"]}, {"answer_start": [94], "text": ["hepatocyte growth factor"]}, {"answer_start": [94], "text": ["hepatocyte growth factor"]}, {"answer_start": [94], "text": ["hepatocyte growth factor"]}, {"answer_start": [94], "text": ["hepatocyte growth factor"]}, {"answer_start": [4], "text": ["hepatocyte growth factor"]}, {"answer_start": [4], "text": ["hepatocyte growth factor"]}, {"answer_start": [4], "text": ["hepatocyte growth factor"]}, {"answer_start": [4], "text": ["hepatocyte growth factor"]}, {"answer_start": [4], "text": ["hepatocyte growth factor"]}, {"answer_start": [4], "text": ["hepatocyte growth factor"]}, {"answer_start": [4], "text": ["hepatocyte growth factor"]}, {"answer_start": [4], "text": ["hepatocyte growth factor"]}, {"answer_start": [4], "text": ["hepatocyte growth factor"]}, {"answer_start": [4], "text": ["hepatocyte growth factor"]}, {"answer_start": [4], "text": ["hepatocyte growth factor"]}, {"answer_start": [4], "text": ["hepatocyte growth factor"]}, {"answer_start": [4], "text": ["hepatocyte growth factor"]}, {"answer_start": [4], "text": ["hepatocyte growth factor"]}, {"answer_start": [4], "text": ["hepatocyte growth factor"]}, {"answer_start": [4], "text": ["hepatocyte growth factor"]}, {"answer_start": [4], "text": ["hepatocyte growth factor"]}, {"answer_start": [4], "text": ["hepatocyte growth factor"]}, {"answer_start": [4], "text": ["hepatocyte growth factor"]}, {"answer_start": [4], "text": ["hepatocyte growth factor"]}, {"answer_start": [4], "text": ["hepatocyte growth factor"]}, {"answer_start": [4], "text": ["hepatocyte growth factor"]}, {"answer_start": [4], "text": ["hepatocyte growth factor"]}, {"answer_start": [4], "text": ["hepatocyte growth factor"]}, {"answer_start": [4], "text": ["hepatocyte growth factor"]}, {"answer_start": [4], "text": ["hepatocyte growth factor"]}, {"answer_start": [4], "text": ["hepatocyte growth factor"]}, {"answer_start": [4], "text": ["hepatocyte growth factor"]}, {"answer_start": [4], "text": ["hepatocyte growth factor"]}, {"answer_start": [4], "text": ["hepatocyte growth factor"]}, {"answer_start": [4], "text": ["hepatocyte growth factor"]}, {"answer_start": [4], "text": ["hepatocyte growth factor"]}, {"answer_start": [4], "text": ["hepatocyte growth factor"]}, {"answer_start": [4], "text": ["hepatocyte growth factor"]}, {"answer_start": [4], "text": ["hepatocyte growth factor"]}, {"answer_start": [4], "text": ["hepatocyte growth factor"]}, {"answer_start": [4], "text": ["hepatocyte growth factor"]}, {"answer_start": [4], "text": ["hepatocyte growth factor"]}, {"answer_start": [4], "text": ["hepatocyte growth factor"]}, {"answer_start": [4], "text": ["hepatocyte growth factor"]}, {"answer_start": [4], "text": ["hepatocyte growth factor"]}, {"answer_start": [4], "text": ["hepatocyte growth factor"]}, {"answer_start": [4], "text": ["hepatocyte growth factor"]}, {"answer_start": [4], "text": ["hepatocyte growth factor"]}, {"answer_start": [4], "text": ["hepatocyte growth factor"]}, {"answer_start": [4], "text": ["hepatocyte growth factor"]}, {"answer_start": [107], "text": ["hepatocyte growth factor"]}, {"answer_start": [107], "text": ["hepatocyte growth factor"]}, {"answer_start": [107], "text": ["hepatocyte growth factor"]}, {"answer_start": [107], "text": ["hepatocyte growth factor"]}, {"answer_start": [107], "text": ["hepatocyte growth factor"]}, {"answer_start": [107], "text": ["hepatocyte growth factor"]}, {"answer_start": [107], "text": ["hepatocyte growth factor"]}, {"answer_start": [107], "text": ["hepatocyte growth factor"]}, {"answer_start": [107], "text": ["hepatocyte growth factor"]}, {"answer_start": [107], "text": ["hepatocyte growth factor"]}, {"answer_start": [107], "text": ["hepatocyte growth factor"]}, {"answer_start": [107], "text": ["hepatocyte growth factor"]}, {"answer_start": [107], "text": ["hepatocyte growth factor"]}, {"answer_start": [107], "text": ["hepatocyte growth factor"]}, {"answer_start": [107], "text": ["hepatocyte growth factor"]}, {"answer_start": [107], "text": ["hepatocyte growth factor"]}, {"answer_start": [107], "text": ["hepatocyte growth factor"]}, {"answer_start": [107], "text": ["hepatocyte growth factor"]}, {"answer_start": [107], "text": ["hepatocyte growth factor"]}, {"answer_start": [107], "text": ["hepatocyte growth factor"]}, {"answer_start": [107], "text": ["hepatocyte growth factor"]}, {"answer_start": [107], "text": ["hepatocyte growth factor"]}, {"answer_start": [107], "text": ["hepatocyte growth factor"]}, {"answer_start": [118], "text": ["hepatocyte growth factor"]}, {"answer_start": [118], "text": ["hepatocyte growth factor"]}, {"answer_start": [118], "text": ["hepatocyte growth factor"]}, {"answer_start": [118], "text": ["hepatocyte growth factor"]}, {"answer_start": [118], "text": ["hepatocyte growth factor"]}, {"answer_start": [118], "text": ["hepatocyte growth factor"]}, {"answer_start": [118], "text": ["hepatocyte growth factor"]}, {"answer_start": [118], "text": ["hepatocyte growth factor"]}, {"answer_start": [118], "text": ["hepatocyte growth factor"]}, {"answer_start": [118], "text": ["hepatocyte growth factor"]}, {"answer_start": [118], "text": ["hepatocyte growth factor"]}, {"answer_start": [118], "text": ["hepatocyte growth factor"]}, {"answer_start": [118], "text": ["hepatocyte growth factor"]}, {"answer_start": [118], "text": ["hepatocyte growth factor"]}, {"answer_start": [118], "text": ["hepatocyte growth factor"]}, {"answer_start": [118], "text": ["hepatocyte growth factor"]}, {"answer_start": [118], "text": ["hepatocyte growth factor"]}, {"answer_start": [118], "text": ["hepatocyte growth factor"]}, {"answer_start": [118], "text": ["hepatocyte growth factor"]}, {"answer_start": [118], "text": ["hepatocyte growth factor"]}, {"answer_start": [118], "text": ["hepatocyte growth factor"]}, {"answer_start": [118], "text": ["hepatocyte growth factor"]}, {"answer_start": [118], "text": ["hepatocyte growth factor"]}, {"answer_start": [117], "text": ["hepatocyte growth factor"]}, {"answer_start": [117], "text": ["hepatocyte growth factor"]}, {"answer_start": [117], "text": ["hepatocyte growth factor"]}, {"answer_start": [117], "text": ["hepatocyte growth factor"]}, {"answer_start": [117], "text": ["hepatocyte growth factor"]}, {"answer_start": [117], "text": ["hepatocyte growth factor"]}, {"answer_start": [117], "text": ["hepatocyte growth factor"]}, {"answer_start": [117], "text": ["hepatocyte growth factor"]}, {"answer_start": [117], "text": ["hepatocyte growth factor"]}, {"answer_start": [117], "text": ["hepatocyte growth factor"]}, {"answer_start": [117], "text": ["hepatocyte growth factor"]}, {"answer_start": [117], "text": ["hepatocyte growth factor"]}, {"answer_start": [117], "text": ["hepatocyte growth factor"]}, {"answer_start": [117], "text": ["hepatocyte growth factor"]}, {"answer_start": [117], "text": ["hepatocyte growth factor"]}, {"answer_start": [117], "text": ["hepatocyte growth factor"]}, {"answer_start": [117], "text": ["hepatocyte growth factor"]}, {"answer_start": [117], "text": ["hepatocyte growth factor"]}, {"answer_start": [117], "text": ["hepatocyte growth factor"]}, {"answer_start": [117], "text": ["hepatocyte growth factor"]}, {"answer_start": [117], "text": ["hepatocyte growth factor"]}, {"answer_start": [117], "text": ["hepatocyte growth factor"]}, {"answer_start": [117], "text": ["hepatocyte growth factor"]}, {"answer_start": [78], "text": ["hepatocyte growth factor"]}, {"answer_start": [78], "text": ["hepatocyte growth factor"]}, {"answer_start": [78], "text": ["hepatocyte growth factor"]}, {"answer_start": [78], "text": ["hepatocyte growth factor"]}, {"answer_start": [78], "text": ["hepatocyte growth factor"]}, {"answer_start": [78], "text": ["hepatocyte growth factor"]}, {"answer_start": [78], "text": ["hepatocyte growth factor"]}, {"answer_start": [78], "text": ["hepatocyte growth factor"]}, {"answer_start": [78], "text": ["hepatocyte growth factor"]}, {"answer_start": [78], "text": ["hepatocyte growth factor"]}, {"answer_start": [78], "text": ["hepatocyte growth factor"]}, {"answer_start": [78], "text": ["hepatocyte growth factor"]}, {"answer_start": [78], "text": ["hepatocyte growth factor"]}, {"answer_start": [78], "text": ["hepatocyte growth factor"]}, {"answer_start": [78], "text": ["hepatocyte growth factor"]}, {"answer_start": [78], "text": ["hepatocyte growth factor"]}, {"answer_start": [78], "text": ["hepatocyte growth factor"]}, {"answer_start": [78], "text": ["hepatocyte growth factor"]}, {"answer_start": [78], "text": ["hepatocyte growth factor"]}, {"answer_start": [78], "text": ["hepatocyte growth factor"]}, {"answer_start": [78], "text": ["hepatocyte growth factor"]}, {"answer_start": [78], "text": ["hepatocyte growth factor"]}, {"answer_start": [78], "text": ["hepatocyte growth factor"]}, {"answer_start": [49], "text": ["dabigatran"]}, {"answer_start": [49], "text": ["dabigatran"]}, {"answer_start": [49], "text": ["dabigatran"]}, {"answer_start": [49], "text": ["dabigatran"]}, {"answer_start": [49], "text": ["dabigatran"]}, {"answer_start": [49], "text": ["dabigatran"]}, {"answer_start": [49], "text": ["dabigatran"]}, {"answer_start": [49], "text": ["dabigatran"]}, {"answer_start": [49], "text": ["dabigatran"]}, {"answer_start": [49], "text": ["dabigatran"]}, {"answer_start": [49], "text": ["dabigatran"]}, {"answer_start": [49], "text": ["dabigatran"]}, {"answer_start": [49], "text": ["dabigatran"]}, {"answer_start": [49], "text": ["dabigatran"]}, {"answer_start": [49], "text": ["dabigatran"]}, {"answer_start": [49], "text": ["dabigatran"]}, {"answer_start": [49], "text": ["dabigatran"]}, {"answer_start": [49], "text": ["dabigatran"]}, {"answer_start": [49], "text": ["dabigatran"]}, {"answer_start": [49], "text": ["dabigatran"]}, {"answer_start": [49], "text": ["dabigatran"]}, {"answer_start": [49], "text": ["dabigatran"]}, {"answer_start": [49], "text": ["dabigatran"]}, {"answer_start": [49], "text": ["dabigatran"]}, {"answer_start": [49], "text": ["dabigatran"]}, {"answer_start": [49], "text": ["dabigatran"]}, {"answer_start": [49], "text": ["dabigatran"]}, {"answer_start": [49], "text": ["dabigatran"]}, {"answer_start": [49], "text": ["dabigatran"]}, {"answer_start": [49], "text": ["dabigatran"]}, {"answer_start": [49], "text": ["dabigatran"]}, {"answer_start": [49], "text": ["dabigatran"]}, {"answer_start": [150], "text": ["dabigatran"]}, {"answer_start": [150], "text": ["dabigatran"]}, {"answer_start": [150], "text": ["dabigatran"]}, {"answer_start": [150], "text": ["dabigatran"]}, {"answer_start": [150], "text": ["dabigatran"]}, {"answer_start": [150], "text": ["dabigatran"]}, {"answer_start": [150], "text": ["dabigatran"]}, {"answer_start": [150], "text": ["dabigatran"]}, {"answer_start": [150], "text": ["dabigatran"]}, {"answer_start": [150], "text": ["dabigatran"]}, {"answer_start": [150], "text": ["dabigatran"]}, {"answer_start": [150], "text": ["dabigatran"]}, {"answer_start": [150], "text": ["dabigatran"]}, {"answer_start": [150], "text": ["dabigatran"]}, {"answer_start": [150], "text": ["dabigatran"]}, {"answer_start": [150], "text": ["dabigatran"]}, {"answer_start": [150], "text": ["dabigatran"]}, {"answer_start": [150], "text": ["dabigatran"]}, {"answer_start": [150], "text": ["dabigatran"]}, {"answer_start": [150], "text": ["dabigatran"]}, {"answer_start": [150], "text": ["dabigatran"]}, {"answer_start": [150], "text": ["dabigatran"]}, {"answer_start": [150], "text": ["dabigatran"]}, {"answer_start": [150], "text": ["dabigatran"]}, {"answer_start": [150], "text": ["dabigatran"]}, {"answer_start": [150], "text": ["dabigatran"]}, {"answer_start": [150], "text": ["dabigatran"]}, {"answer_start": [150], "text": ["dabigatran"]}, {"answer_start": [150], "text": ["dabigatran"]}, {"answer_start": [150], "text": ["dabigatran"]}, {"answer_start": [150], "text": ["dabigatran"]}, {"answer_start": [150], "text": ["dabigatran"]}, {"answer_start": [117], "text": ["dabigatran"]}, {"answer_start": [117], "text": ["dabigatran"]}, {"answer_start": [117], "text": ["dabigatran"]}, {"answer_start": [117], "text": ["dabigatran"]}, {"answer_start": [117], "text": ["dabigatran"]}, {"answer_start": [117], "text": ["dabigatran"]}, {"answer_start": [117], "text": ["dabigatran"]}, {"answer_start": [117], "text": ["dabigatran"]}, {"answer_start": [117], "text": ["dabigatran"]}, {"answer_start": [117], "text": ["dabigatran"]}, {"answer_start": [117], "text": ["dabigatran"]}, {"answer_start": [117], "text": ["dabigatran"]}, {"answer_start": [117], "text": ["dabigatran"]}, {"answer_start": [117], "text": ["dabigatran"]}, {"answer_start": [117], "text": ["dabigatran"]}, {"answer_start": [117], "text": ["dabigatran"]}, {"answer_start": [117], "text": ["dabigatran"]}, {"answer_start": [117], "text": ["dabigatran"]}, {"answer_start": [117], "text": ["dabigatran"]}, {"answer_start": [117], "text": ["dabigatran"]}, {"answer_start": [117], "text": ["dabigatran"]}, {"answer_start": [117], "text": ["dabigatran"]}, {"answer_start": [117], "text": ["dabigatran"]}, {"answer_start": [117], "text": ["dabigatran"]}, {"answer_start": [117], "text": ["dabigatran"]}, {"answer_start": [117], "text": ["dabigatran"]}, {"answer_start": [117], "text": ["dabigatran"]}, {"answer_start": [117], "text": ["dabigatran"]}, {"answer_start": [117], "text": ["dabigatran"]}, {"answer_start": [117], "text": ["dabigatran"]}, {"answer_start": [117], "text": ["dabigatran"]}, {"answer_start": [117], "text": ["dabigatran"]}, {"answer_start": [143], "text": ["dabigatran"]}, {"answer_start": [143], "text": ["dabigatran"]}, {"answer_start": [143], "text": ["dabigatran"]}, {"answer_start": [143], "text": ["dabigatran"]}, {"answer_start": [143], "text": ["dabigatran"]}, {"answer_start": [143], "text": ["dabigatran"]}, {"answer_start": [143], "text": ["dabigatran"]}, {"answer_start": [143], "text": ["dabigatran"]}, {"answer_start": [143], "text": ["dabigatran"]}, {"answer_start": [143], "text": ["dabigatran"]}, {"answer_start": [143], "text": ["dabigatran"]}, {"answer_start": [143], "text": ["dabigatran"]}, {"answer_start": [143], "text": ["dabigatran"]}, {"answer_start": [143], "text": ["dabigatran"]}, {"answer_start": [143], "text": ["dabigatran"]}, {"answer_start": [143], "text": ["dabigatran"]}, {"answer_start": [143], "text": ["dabigatran"]}, {"answer_start": [143], "text": ["dabigatran"]}, {"answer_start": [143], "text": ["dabigatran"]}, {"answer_start": [143], "text": ["dabigatran"]}, {"answer_start": [143], "text": ["dabigatran"]}, {"answer_start": [143], "text": ["dabigatran"]}, {"answer_start": [143], "text": ["dabigatran"]}, {"answer_start": [143], "text": ["dabigatran"]}, {"answer_start": [143], "text": ["dabigatran"]}, {"answer_start": [143], "text": ["dabigatran"]}, {"answer_start": [143], "text": ["dabigatran"]}, {"answer_start": [143], "text": ["dabigatran"]}, {"answer_start": [143], "text": ["dabigatran"]}, {"answer_start": [143], "text": ["dabigatran"]}, {"answer_start": [143], "text": ["dabigatran"]}, {"answer_start": [143], "text": ["dabigatran"]}, {"answer_start": [58], "text": ["dabigatran"]}, {"answer_start": [58], "text": ["dabigatran"]}, {"answer_start": [58], "text": ["dabigatran"]}, {"answer_start": [58], "text": ["dabigatran"]}, {"answer_start": [58], "text": ["dabigatran"]}, {"answer_start": [58], "text": ["dabigatran"]}, {"answer_start": [58], "text": ["dabigatran"]}, {"answer_start": [58], "text": ["dabigatran"]}, {"answer_start": [58], "text": ["dabigatran"]}, {"answer_start": [58], "text": ["dabigatran"]}, {"answer_start": [58], "text": ["dabigatran"]}, {"answer_start": [58], "text": ["dabigatran"]}, {"answer_start": [58], "text": ["dabigatran"]}, {"answer_start": [58], "text": ["dabigatran"]}, {"answer_start": [58], "text": ["dabigatran"]}, {"answer_start": [58], "text": ["dabigatran"]}, {"answer_start": [58], "text": ["dabigatran"]}, {"answer_start": [58], "text": ["dabigatran"]}, {"answer_start": [58], "text": ["dabigatran"]}, {"answer_start": [58], "text": ["dabigatran"]}, {"answer_start": [58], "text": ["dabigatran"]}, {"answer_start": [58], "text": ["dabigatran"]}, {"answer_start": [58], "text": ["dabigatran"]}, {"answer_start": [58], "text": ["dabigatran"]}, {"answer_start": [58], "text": ["dabigatran"]}, {"answer_start": [58], "text": ["dabigatran"]}, {"answer_start": [58], "text": ["dabigatran"]}, {"answer_start": [58], "text": ["dabigatran"]}, {"answer_start": [58], "text": ["dabigatran"]}, {"answer_start": [58], "text": ["dabigatran"]}, {"answer_start": [58], "text": ["dabigatran"]}, {"answer_start": [58], "text": ["dabigatran"]}, {"answer_start": [104], "text": ["dabigatran"]}, {"answer_start": [104], "text": ["dabigatran"]}, {"answer_start": [104], "text": ["dabigatran"]}, {"answer_start": [104], "text": ["dabigatran"]}, {"answer_start": [104], "text": ["dabigatran"]}, {"answer_start": [104], "text": ["dabigatran"]}, {"answer_start": [104], "text": ["dabigatran"]}, {"answer_start": [104], "text": ["dabigatran"]}, {"answer_start": [104], "text": ["dabigatran"]}, {"answer_start": [104], "text": ["dabigatran"]}, {"answer_start": [104], "text": ["dabigatran"]}, {"answer_start": [104], "text": ["dabigatran"]}, {"answer_start": [104], "text": ["dabigatran"]}, {"answer_start": [104], "text": ["dabigatran"]}, {"answer_start": [104], "text": ["dabigatran"]}, {"answer_start": [104], "text": ["dabigatran"]}, {"answer_start": [104], "text": ["dabigatran"]}, {"answer_start": [104], "text": ["dabigatran"]}, {"answer_start": [104], "text": ["dabigatran"]}, {"answer_start": [104], "text": ["dabigatran"]}, {"answer_start": [104], "text": ["dabigatran"]}, {"answer_start": [104], "text": ["dabigatran"]}, {"answer_start": [104], "text": ["dabigatran"]}, {"answer_start": [104], "text": ["dabigatran"]}, {"answer_start": [104], "text": ["dabigatran"]}, {"answer_start": [104], "text": ["dabigatran"]}, {"answer_start": [104], "text": ["dabigatran"]}, {"answer_start": [104], "text": ["dabigatran"]}, {"answer_start": [104], "text": ["dabigatran"]}, {"answer_start": [104], "text": ["dabigatran"]}, {"answer_start": [104], "text": ["dabigatran"]}, {"answer_start": [104], "text": ["dabigatran"]}, {"answer_start": [71], "text": ["dabigatran"]}, {"answer_start": [71], "text": ["dabigatran"]}, {"answer_start": [71], "text": ["dabigatran"]}, {"answer_start": [71], "text": ["dabigatran"]}, {"answer_start": [71], "text": ["dabigatran"]}, {"answer_start": [71], "text": ["dabigatran"]}, {"answer_start": [71], "text": ["dabigatran"]}, {"answer_start": [71], "text": ["dabigatran"]}, {"answer_start": [71], "text": ["dabigatran"]}, {"answer_start": [71], "text": ["dabigatran"]}, {"answer_start": [71], "text": ["dabigatran"]}, {"answer_start": [71], "text": ["dabigatran"]}, {"answer_start": [71], "text": ["dabigatran"]}, {"answer_start": [71], "text": ["dabigatran"]}, {"answer_start": [71], "text": ["dabigatran"]}, {"answer_start": [71], "text": ["dabigatran"]}, {"answer_start": [71], "text": ["dabigatran"]}, {"answer_start": [71], "text": ["dabigatran"]}, {"answer_start": [71], "text": ["dabigatran"]}, {"answer_start": [71], "text": ["dabigatran"]}, {"answer_start": [71], "text": ["dabigatran"]}, {"answer_start": [71], "text": ["dabigatran"]}, {"answer_start": [71], "text": ["dabigatran"]}, {"answer_start": [71], "text": ["dabigatran"]}, {"answer_start": [71], "text": ["dabigatran"]}, {"answer_start": [71], "text": ["dabigatran"]}, {"answer_start": [71], "text": ["dabigatran"]}, {"answer_start": [71], "text": ["dabigatran"]}, {"answer_start": [71], "text": ["dabigatran"]}, {"answer_start": [71], "text": ["dabigatran"]}, {"answer_start": [71], "text": ["dabigatran"]}, {"answer_start": [71], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [142], "text": ["dabigatran"]}, {"answer_start": [45], "text": ["dabigatran"]}, {"answer_start": [45], "text": ["dabigatran"]}, {"answer_start": [45], "text": ["dabigatran"]}, {"answer_start": [45], "text": ["dabigatran"]}, {"answer_start": [45], "text": ["dabigatran"]}, {"answer_start": [45], "text": ["dabigatran"]}, {"answer_start": [45], "text": ["dabigatran"]}, {"answer_start": [45], "text": ["dabigatran"]}, {"answer_start": [45], "text": ["dabigatran"]}, {"answer_start": [45], "text": ["dabigatran"]}, {"answer_start": [45], "text": ["dabigatran"]}, {"answer_start": [45], "text": ["dabigatran"]}, {"answer_start": [45], "text": ["dabigatran"]}, {"answer_start": [45], "text": ["dabigatran"]}, {"answer_start": [45], "text": ["dabigatran"]}, {"answer_start": [45], "text": ["dabigatran"]}, {"answer_start": [45], "text": ["dabigatran"]}, {"answer_start": [45], "text": ["dabigatran"]}, {"answer_start": [45], "text": ["dabigatran"]}, {"answer_start": [45], "text": ["dabigatran"]}, {"answer_start": [45], "text": ["dabigatran"]}, {"answer_start": [45], "text": ["dabigatran"]}, {"answer_start": [45], "text": ["dabigatran"]}, {"answer_start": [45], "text": ["dabigatran"]}, {"answer_start": [45], "text": ["dabigatran"]}, {"answer_start": [45], "text": ["dabigatran"]}, {"answer_start": [45], "text": ["dabigatran"]}, {"answer_start": [45], "text": ["dabigatran"]}, {"answer_start": [45], "text": ["dabigatran"]}, {"answer_start": [45], "text": ["dabigatran"]}, {"answer_start": [45], "text": ["dabigatran"]}, {"answer_start": [45], "text": ["dabigatran"]}, {"answer_start": [23], "text": ["dabigatran"]}, {"answer_start": [23], "text": ["dabigatran"]}, {"answer_start": [23], "text": ["dabigatran"]}, {"answer_start": [23], "text": ["dabigatran"]}, {"answer_start": [23], "text": ["dabigatran"]}, {"answer_start": [23], "text": ["dabigatran"]}, {"answer_start": [23], "text": ["dabigatran"]}, {"answer_start": [23], "text": ["dabigatran"]}, {"answer_start": [23], "text": ["dabigatran"]}, {"answer_start": [23], "text": ["dabigatran"]}, {"answer_start": [23], "text": ["dabigatran"]}, {"answer_start": [23], "text": ["dabigatran"]}, {"answer_start": [23], "text": ["dabigatran"]}, {"answer_start": [23], "text": ["dabigatran"]}, {"answer_start": [23], "text": ["dabigatran"]}, {"answer_start": [23], "text": ["dabigatran"]}, {"answer_start": [23], "text": ["dabigatran"]}, {"answer_start": [23], "text": ["dabigatran"]}, {"answer_start": [23], "text": ["dabigatran"]}, {"answer_start": [23], "text": ["dabigatran"]}, {"answer_start": [23], "text": ["dabigatran"]}, {"answer_start": [23], "text": ["dabigatran"]}, {"answer_start": [23], "text": ["dabigatran"]}, {"answer_start": [23], "text": ["dabigatran"]}, {"answer_start": [23], "text": ["dabigatran"]}, {"answer_start": [23], "text": ["dabigatran"]}, {"answer_start": [23], "text": ["dabigatran"]}, {"answer_start": [23], "text": ["dabigatran"]}, {"answer_start": [23], "text": ["dabigatran"]}, {"answer_start": [23], "text": ["dabigatran"]}, {"answer_start": [23], "text": ["dabigatran"]}, {"answer_start": [23], "text": ["dabigatran"]}, {"answer_start": [87], "text": ["dabigatran"]}, {"answer_start": [87], "text": ["dabigatran"]}, {"answer_start": [87], "text": ["dabigatran"]}, {"answer_start": [87], "text": ["dabigatran"]}, {"answer_start": [87], "text": ["dabigatran"]}, {"answer_start": [87], "text": ["dabigatran"]}, {"answer_start": [87], "text": ["dabigatran"]}, {"answer_start": [87], "text": ["dabigatran"]}, {"answer_start": [87], "text": ["dabigatran"]}, {"answer_start": [87], "text": ["dabigatran"]}, {"answer_start": [87], "text": ["dabigatran"]}, {"answer_start": [87], "text": ["dabigatran"]}, {"answer_start": [87], "text": ["dabigatran"]}, {"answer_start": [87], "text": ["dabigatran"]}, {"answer_start": [87], "text": ["dabigatran"]}, {"answer_start": [87], "text": ["dabigatran"]}, {"answer_start": [87], "text": ["dabigatran"]}, {"answer_start": [87], "text": ["dabigatran"]}, {"answer_start": [87], "text": ["dabigatran"]}, {"answer_start": [87], "text": ["dabigatran"]}, {"answer_start": [87], "text": ["dabigatran"]}, {"answer_start": [87], "text": ["dabigatran"]}, {"answer_start": [87], "text": ["dabigatran"]}, {"answer_start": [87], "text": ["dabigatran"]}, {"answer_start": [87], "text": ["dabigatran"]}, {"answer_start": [87], "text": ["dabigatran"]}, {"answer_start": [87], "text": ["dabigatran"]}, {"answer_start": [87], "text": ["dabigatran"]}, {"answer_start": [87], "text": ["dabigatran"]}, {"answer_start": [87], "text": ["dabigatran"]}, {"answer_start": [87], "text": ["dabigatran"]}, {"answer_start": [87], "text": ["dabigatran"]}, {"answer_start": [135], "text": ["dabigatran"]}, {"answer_start": [135], "text": ["dabigatran"]}, {"answer_start": [135], "text": ["dabigatran"]}, {"answer_start": [135], "text": ["dabigatran"]}, {"answer_start": [135], "text": ["dabigatran"]}, {"answer_start": [135], "text": ["dabigatran"]}, {"answer_start": [135], "text": ["dabigatran"]}, {"answer_start": [135], "text": ["dabigatran"]}, {"answer_start": [135], "text": ["dabigatran"]}, {"answer_start": [135], "text": ["dabigatran"]}, {"answer_start": [135], "text": ["dabigatran"]}, {"answer_start": [135], "text": ["dabigatran"]}, {"answer_start": [135], "text": ["dabigatran"]}, {"answer_start": [135], "text": ["dabigatran"]}, {"answer_start": [135], "text": ["dabigatran"]}, {"answer_start": [135], "text": ["dabigatran"]}, {"answer_start": [135], "text": ["dabigatran"]}, {"answer_start": [135], "text": ["dabigatran"]}, {"answer_start": [135], "text": ["dabigatran"]}, {"answer_start": [135], "text": ["dabigatran"]}, {"answer_start": [135], "text": ["dabigatran"]}, {"answer_start": [135], "text": ["dabigatran"]}, {"answer_start": [135], "text": ["dabigatran"]}, {"answer_start": [135], "text": ["dabigatran"]}, {"answer_start": [135], "text": ["dabigatran"]}, {"answer_start": [135], "text": ["dabigatran"]}, {"answer_start": [135], "text": ["dabigatran"]}, {"answer_start": [135], "text": ["dabigatran"]}, {"answer_start": [135], "text": ["dabigatran"]}, {"answer_start": [135], "text": ["dabigatran"]}, {"answer_start": [135], "text": ["dabigatran"]}, {"answer_start": [135], "text": ["dabigatran"]}, {"answer_start": [132], "text": ["dabigatran"]}, {"answer_start": [132], "text": ["dabigatran"]}, {"answer_start": [132], "text": ["dabigatran"]}, {"answer_start": [132], "text": ["dabigatran"]}, {"answer_start": [132], "text": ["dabigatran"]}, {"answer_start": [132], "text": ["dabigatran"]}, {"answer_start": [132], "text": ["dabigatran"]}, {"answer_start": [132], "text": ["dabigatran"]}, {"answer_start": [132], "text": ["dabigatran"]}, {"answer_start": [132], "text": ["dabigatran"]}, {"answer_start": [132], "text": ["dabigatran"]}, {"answer_start": [132], "text": ["dabigatran"]}, {"answer_start": [132], "text": ["dabigatran"]}, {"answer_start": [132], "text": ["dabigatran"]}, {"answer_start": [132], "text": ["dabigatran"]}, {"answer_start": [132], "text": ["dabigatran"]}, {"answer_start": [132], "text": ["dabigatran"]}, {"answer_start": [132], "text": ["dabigatran"]}, {"answer_start": [132], "text": ["dabigatran"]}, {"answer_start": [132], "text": ["dabigatran"]}, {"answer_start": [132], "text": ["dabigatran"]}, {"answer_start": [132], "text": ["dabigatran"]}, {"answer_start": [132], "text": ["dabigatran"]}, {"answer_start": [132], "text": ["dabigatran"]}, {"answer_start": [132], "text": ["dabigatran"]}, {"answer_start": [132], "text": ["dabigatran"]}, {"answer_start": [132], "text": ["dabigatran"]}, {"answer_start": [132], "text": ["dabigatran"]}, {"answer_start": [132], "text": ["dabigatran"]}, {"answer_start": [132], "text": ["dabigatran"]}, {"answer_start": [132], "text": ["dabigatran"]}, {"answer_start": [132], "text": ["dabigatran"]}, {"answer_start": [56, 132], "text": ["dabigatran", "dabigatran"]}, {"answer_start": [56, 132], "text": ["dabigatran", "dabigatran"]}, {"answer_start": [56, 132], "text": ["dabigatran", "dabigatran"]}, {"answer_start": [56, 132], "text": ["dabigatran", "dabigatran"]}, {"answer_start": [56, 132], "text": ["dabigatran", "dabigatran"]}, {"answer_start": [56, 132], "text": ["dabigatran", "dabigatran"]}, {"answer_start": [56, 132], "text": ["dabigatran", "dabigatran"]}, {"answer_start": [56, 132], "text": ["dabigatran", "dabigatran"]}, {"answer_start": [56, 132], "text": ["dabigatran", "dabigatran"]}, {"answer_start": [56, 132], "text": ["dabigatran", "dabigatran"]}, {"answer_start": [56, 132], "text": ["dabigatran", "dabigatran"]}, {"answer_start": [56, 132], "text": ["dabigatran", "dabigatran"]}, {"answer_start": [56, 132], "text": ["dabigatran", "dabigatran"]}, {"answer_start": [56, 132], "text": ["dabigatran", "dabigatran"]}, {"answer_start": [56, 132], "text": ["dabigatran", "dabigatran"]}, {"answer_start": [56, 132], "text": ["dabigatran", "dabigatran"]}, {"answer_start": [56, 132], "text": ["dabigatran", "dabigatran"]}, {"answer_start": [56, 132], "text": ["dabigatran", "dabigatran"]}, {"answer_start": [56, 132], "text": ["dabigatran", "dabigatran"]}, {"answer_start": [56, 132], "text": ["dabigatran", "dabigatran"]}, {"answer_start": [56, 132], "text": ["dabigatran", "dabigatran"]}, {"answer_start": [56, 132], "text": ["dabigatran", "dabigatran"]}, {"answer_start": [56, 132], "text": ["dabigatran", "dabigatran"]}, {"answer_start": [56, 132], "text": ["dabigatran", "dabigatran"]}, {"answer_start": [56, 132], "text": ["dabigatran", "dabigatran"]}, {"answer_start": [56, 132], "text": ["dabigatran", "dabigatran"]}, {"answer_start": [56, 132], "text": ["dabigatran", "dabigatran"]}, {"answer_start": [56, 132], "text": ["dabigatran", "dabigatran"]}, {"answer_start": [56, 132], "text": ["dabigatran", "dabigatran"]}, {"answer_start": [56, 132], "text": ["dabigatran", "dabigatran"]}, {"answer_start": [56, 132], "text": ["dabigatran", "dabigatran"]}, {"answer_start": [56, 132], "text": ["dabigatran", "dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [127], "text": ["dabigatran"]}, {"answer_start": [127], "text": ["dabigatran"]}, {"answer_start": [127], "text": ["dabigatran"]}, {"answer_start": [127], "text": ["dabigatran"]}, {"answer_start": [127], "text": ["dabigatran"]}, {"answer_start": [127], "text": ["dabigatran"]}, {"answer_start": [127], "text": ["dabigatran"]}, {"answer_start": [127], "text": ["dabigatran"]}, {"answer_start": [127], "text": ["dabigatran"]}, {"answer_start": [127], "text": ["dabigatran"]}, {"answer_start": [127], "text": ["dabigatran"]}, {"answer_start": [127], "text": ["dabigatran"]}, {"answer_start": [127], "text": ["dabigatran"]}, {"answer_start": [127], "text": ["dabigatran"]}, {"answer_start": [127], "text": ["dabigatran"]}, {"answer_start": [127], "text": ["dabigatran"]}, {"answer_start": [127], "text": ["dabigatran"]}, {"answer_start": [127], "text": ["dabigatran"]}, {"answer_start": [127], "text": ["dabigatran"]}, {"answer_start": [127], "text": ["dabigatran"]}, {"answer_start": [127], "text": ["dabigatran"]}, {"answer_start": [127], "text": ["dabigatran"]}, {"answer_start": [127], "text": ["dabigatran"]}, {"answer_start": [127], "text": ["dabigatran"]}, {"answer_start": [127], "text": ["dabigatran"]}, {"answer_start": [127], "text": ["dabigatran"]}, {"answer_start": [127], "text": ["dabigatran"]}, {"answer_start": [127], "text": ["dabigatran"]}, {"answer_start": [127], "text": ["dabigatran"]}, {"answer_start": [127], "text": ["dabigatran"]}, {"answer_start": [127], "text": ["dabigatran"]}, {"answer_start": [127], "text": ["dabigatran"]}, {"answer_start": [42], "text": ["dabigatran"]}, {"answer_start": [42], "text": ["dabigatran"]}, {"answer_start": [42], "text": ["dabigatran"]}, {"answer_start": [42], "text": ["dabigatran"]}, {"answer_start": [42], "text": ["dabigatran"]}, {"answer_start": [42], "text": ["dabigatran"]}, {"answer_start": [42], "text": ["dabigatran"]}, {"answer_start": [42], "text": ["dabigatran"]}, {"answer_start": [42], "text": ["dabigatran"]}, {"answer_start": [42], "text": ["dabigatran"]}, {"answer_start": [42], "text": ["dabigatran"]}, {"answer_start": [42], "text": ["dabigatran"]}, {"answer_start": [42], "text": ["dabigatran"]}, {"answer_start": [42], "text": ["dabigatran"]}, {"answer_start": [42], "text": ["dabigatran"]}, {"answer_start": [42], "text": ["dabigatran"]}, {"answer_start": [42], "text": ["dabigatran"]}, {"answer_start": [42], "text": ["dabigatran"]}, {"answer_start": [42], "text": ["dabigatran"]}, {"answer_start": [42], "text": ["dabigatran"]}, {"answer_start": [42], "text": ["dabigatran"]}, {"answer_start": [42], "text": ["dabigatran"]}, {"answer_start": [42], "text": ["dabigatran"]}, {"answer_start": [42], "text": ["dabigatran"]}, {"answer_start": [42], "text": ["dabigatran"]}, {"answer_start": [42], "text": ["dabigatran"]}, {"answer_start": [42], "text": ["dabigatran"]}, {"answer_start": [42], "text": ["dabigatran"]}, {"answer_start": [42], "text": ["dabigatran"]}, {"answer_start": [42], "text": ["dabigatran"]}, {"answer_start": [42], "text": ["dabigatran"]}, {"answer_start": [42], "text": ["dabigatran"]}, {"answer_start": [116], "text": ["dabigatran"]}, {"answer_start": [116], "text": ["dabigatran"]}, {"answer_start": [116], "text": ["dabigatran"]}, {"answer_start": [116], "text": ["dabigatran"]}, {"answer_start": [116], "text": ["dabigatran"]}, {"answer_start": [116], "text": ["dabigatran"]}, {"answer_start": [116], "text": ["dabigatran"]}, {"answer_start": [116], "text": ["dabigatran"]}, {"answer_start": [116], "text": ["dabigatran"]}, {"answer_start": [116], "text": ["dabigatran"]}, {"answer_start": [116], "text": ["dabigatran"]}, {"answer_start": [116], "text": ["dabigatran"]}, {"answer_start": [116], "text": ["dabigatran"]}, {"answer_start": [116], "text": ["dabigatran"]}, {"answer_start": [116], "text": ["dabigatran"]}, {"answer_start": [116], "text": ["dabigatran"]}, {"answer_start": [116], "text": ["dabigatran"]}, {"answer_start": [116], "text": ["dabigatran"]}, {"answer_start": [116], "text": ["dabigatran"]}, {"answer_start": [116], "text": ["dabigatran"]}, {"answer_start": [116], "text": ["dabigatran"]}, {"answer_start": [116], "text": ["dabigatran"]}, {"answer_start": [116], "text": ["dabigatran"]}, {"answer_start": [116], "text": ["dabigatran"]}, {"answer_start": [116], "text": ["dabigatran"]}, {"answer_start": [116], "text": ["dabigatran"]}, {"answer_start": [116], "text": ["dabigatran"]}, {"answer_start": [116], "text": ["dabigatran"]}, {"answer_start": [116], "text": ["dabigatran"]}, {"answer_start": [116], "text": ["dabigatran"]}, {"answer_start": [116], "text": ["dabigatran"]}, {"answer_start": [116], "text": ["dabigatran"]}, {"answer_start": [91], "text": ["dabigatran"]}, {"answer_start": [91], "text": ["dabigatran"]}, {"answer_start": [91], "text": ["dabigatran"]}, {"answer_start": [91], "text": ["dabigatran"]}, {"answer_start": [91], "text": ["dabigatran"]}, {"answer_start": [91], "text": ["dabigatran"]}, {"answer_start": [91], "text": ["dabigatran"]}, {"answer_start": [91], "text": ["dabigatran"]}, {"answer_start": [91], "text": ["dabigatran"]}, {"answer_start": [91], "text": ["dabigatran"]}, {"answer_start": [91], "text": ["dabigatran"]}, {"answer_start": [91], "text": ["dabigatran"]}, {"answer_start": [91], "text": ["dabigatran"]}, {"answer_start": [91], "text": ["dabigatran"]}, {"answer_start": [91], "text": ["dabigatran"]}, {"answer_start": [91], "text": ["dabigatran"]}, {"answer_start": [91], "text": ["dabigatran"]}, {"answer_start": [91], "text": ["dabigatran"]}, {"answer_start": [91], "text": ["dabigatran"]}, {"answer_start": [91], "text": ["dabigatran"]}, {"answer_start": [91], "text": ["dabigatran"]}, {"answer_start": [91], "text": ["dabigatran"]}, {"answer_start": [91], "text": ["dabigatran"]}, {"answer_start": [91], "text": ["dabigatran"]}, {"answer_start": [91], "text": ["dabigatran"]}, {"answer_start": [91], "text": ["dabigatran"]}, {"answer_start": [91], "text": ["dabigatran"]}, {"answer_start": [91], "text": ["dabigatran"]}, {"answer_start": [91], "text": ["dabigatran"]}, {"answer_start": [91], "text": ["dabigatran"]}, {"answer_start": [91], "text": ["dabigatran"]}, {"answer_start": [91], "text": ["dabigatran"]}, {"answer_start": [115], "text": ["dabigatran"]}, {"answer_start": [115], "text": ["dabigatran"]}, {"answer_start": [115], "text": ["dabigatran"]}, {"answer_start": [115], "text": ["dabigatran"]}, {"answer_start": [115], "text": ["dabigatran"]}, {"answer_start": [115], "text": ["dabigatran"]}, {"answer_start": [115], "text": ["dabigatran"]}, {"answer_start": [115], "text": ["dabigatran"]}, {"answer_start": [115], "text": ["dabigatran"]}, {"answer_start": [115], "text": ["dabigatran"]}, {"answer_start": [115], "text": ["dabigatran"]}, {"answer_start": [115], "text": ["dabigatran"]}, {"answer_start": [115], "text": ["dabigatran"]}, {"answer_start": [115], "text": ["dabigatran"]}, {"answer_start": [115], "text": ["dabigatran"]}, {"answer_start": [115], "text": ["dabigatran"]}, {"answer_start": [115], "text": ["dabigatran"]}, {"answer_start": [115], "text": ["dabigatran"]}, {"answer_start": [115], "text": ["dabigatran"]}, {"answer_start": [115], "text": ["dabigatran"]}, {"answer_start": [115], "text": ["dabigatran"]}, {"answer_start": [115], "text": ["dabigatran"]}, {"answer_start": [115], "text": ["dabigatran"]}, {"answer_start": [115], "text": ["dabigatran"]}, {"answer_start": [115], "text": ["dabigatran"]}, {"answer_start": [115], "text": ["dabigatran"]}, {"answer_start": [115], "text": ["dabigatran"]}, {"answer_start": [115], "text": ["dabigatran"]}, {"answer_start": [115], "text": ["dabigatran"]}, {"answer_start": [115], "text": ["dabigatran"]}, {"answer_start": [115], "text": ["dabigatran"]}, {"answer_start": [115], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [112], "text": ["dabigatran"]}, {"answer_start": [112], "text": ["dabigatran"]}, {"answer_start": [112], "text": ["dabigatran"]}, {"answer_start": [112], "text": ["dabigatran"]}, {"answer_start": [112], "text": ["dabigatran"]}, {"answer_start": [112], "text": ["dabigatran"]}, {"answer_start": [112], "text": ["dabigatran"]}, {"answer_start": [112], "text": ["dabigatran"]}, {"answer_start": [112], "text": ["dabigatran"]}, {"answer_start": [112], "text": ["dabigatran"]}, {"answer_start": [112], "text": ["dabigatran"]}, {"answer_start": [112], "text": ["dabigatran"]}, {"answer_start": [112], "text": ["dabigatran"]}, {"answer_start": [112], "text": ["dabigatran"]}, {"answer_start": [112], "text": ["dabigatran"]}, {"answer_start": [112], "text": ["dabigatran"]}, {"answer_start": [112], "text": ["dabigatran"]}, {"answer_start": [112], "text": ["dabigatran"]}, {"answer_start": [112], "text": ["dabigatran"]}, {"answer_start": [112], "text": ["dabigatran"]}, {"answer_start": [112], "text": ["dabigatran"]}, {"answer_start": [112], "text": ["dabigatran"]}, {"answer_start": [112], "text": ["dabigatran"]}, {"answer_start": [112], "text": ["dabigatran"]}, {"answer_start": [112], "text": ["dabigatran"]}, {"answer_start": [112], "text": ["dabigatran"]}, {"answer_start": [112], "text": ["dabigatran"]}, {"answer_start": [112], "text": ["dabigatran"]}, {"answer_start": [112], "text": ["dabigatran"]}, {"answer_start": [112], "text": ["dabigatran"]}, {"answer_start": [112], "text": ["dabigatran"]}, {"answer_start": [112], "text": ["dabigatran"]}, {"answer_start": [102], "text": ["dabigatran"]}, {"answer_start": [102], "text": ["dabigatran"]}, {"answer_start": [102], "text": ["dabigatran"]}, {"answer_start": [102], "text": ["dabigatran"]}, {"answer_start": [102], "text": ["dabigatran"]}, {"answer_start": [102], "text": ["dabigatran"]}, {"answer_start": [102], "text": ["dabigatran"]}, {"answer_start": [102], "text": ["dabigatran"]}, {"answer_start": [102], "text": ["dabigatran"]}, {"answer_start": [102], "text": ["dabigatran"]}, {"answer_start": [102], "text": ["dabigatran"]}, {"answer_start": [102], "text": ["dabigatran"]}, {"answer_start": [102], "text": ["dabigatran"]}, {"answer_start": [102], "text": ["dabigatran"]}, {"answer_start": [102], "text": ["dabigatran"]}, {"answer_start": [102], "text": ["dabigatran"]}, {"answer_start": [102], "text": ["dabigatran"]}, {"answer_start": [102], "text": ["dabigatran"]}, {"answer_start": [102], "text": ["dabigatran"]}, {"answer_start": [102], "text": ["dabigatran"]}, {"answer_start": [102], "text": ["dabigatran"]}, {"answer_start": [102], "text": ["dabigatran"]}, {"answer_start": [102], "text": ["dabigatran"]}, {"answer_start": [102], "text": ["dabigatran"]}, {"answer_start": [102], "text": ["dabigatran"]}, {"answer_start": [102], "text": ["dabigatran"]}, {"answer_start": [102], "text": ["dabigatran"]}, {"answer_start": [102], "text": ["dabigatran"]}, {"answer_start": [102], "text": ["dabigatran"]}, {"answer_start": [102], "text": ["dabigatran"]}, {"answer_start": [102], "text": ["dabigatran"]}, {"answer_start": [102], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [90], "text": ["dabigatran"]}, {"answer_start": [64], "text": ["dabigatran"]}, {"answer_start": [64], "text": ["dabigatran"]}, {"answer_start": [64], "text": ["dabigatran"]}, {"answer_start": [64], "text": ["dabigatran"]}, {"answer_start": [64], "text": ["dabigatran"]}, {"answer_start": [64], "text": ["dabigatran"]}, {"answer_start": [64], "text": ["dabigatran"]}, {"answer_start": [64], "text": ["dabigatran"]}, {"answer_start": [64], "text": ["dabigatran"]}, {"answer_start": [64], "text": ["dabigatran"]}, {"answer_start": [64], "text": ["dabigatran"]}, {"answer_start": [64], "text": ["dabigatran"]}, {"answer_start": [64], "text": ["dabigatran"]}, {"answer_start": [64], "text": ["dabigatran"]}, {"answer_start": [64], "text": ["dabigatran"]}, {"answer_start": [64], "text": ["dabigatran"]}, {"answer_start": [64], "text": ["dabigatran"]}, {"answer_start": [64], "text": ["dabigatran"]}, {"answer_start": [64], "text": ["dabigatran"]}, {"answer_start": [64], "text": ["dabigatran"]}, {"answer_start": [64], "text": ["dabigatran"]}, {"answer_start": [64], "text": ["dabigatran"]}, {"answer_start": [64], "text": ["dabigatran"]}, {"answer_start": [64], "text": ["dabigatran"]}, {"answer_start": [64], "text": ["dabigatran"]}, {"answer_start": [64], "text": ["dabigatran"]}, {"answer_start": [64], "text": ["dabigatran"]}, {"answer_start": [64], "text": ["dabigatran"]}, {"answer_start": [64], "text": ["dabigatran"]}, {"answer_start": [64], "text": ["dabigatran"]}, {"answer_start": [64], "text": ["dabigatran"]}, {"answer_start": [64], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [0], "text": ["dabigatran"]}, {"answer_start": [18], "text": ["dabigatran"]}, {"answer_start": [18], "text": ["dabigatran"]}, {"answer_start": [18], "text": ["dabigatran"]}, {"answer_start": [18], "text": ["dabigatran"]}, {"answer_start": [18], "text": ["dabigatran"]}, {"answer_start": [18], "text": ["dabigatran"]}, {"answer_start": [18], "text": ["dabigatran"]}, {"answer_start": [18], "text": ["dabigatran"]}, {"answer_start": [18], "text": ["dabigatran"]}, {"answer_start": [18], "text": ["dabigatran"]}, {"answer_start": [18], "text": ["dabigatran"]}, {"answer_start": [18], "text": ["dabigatran"]}, {"answer_start": [18], "text": ["dabigatran"]}, {"answer_start": [18], "text": ["dabigatran"]}, {"answer_start": [18], "text": ["dabigatran"]}, {"answer_start": [18], "text": ["dabigatran"]}, {"answer_start": [18], "text": ["dabigatran"]}, {"answer_start": [18], "text": ["dabigatran"]}, {"answer_start": [18], "text": ["dabigatran"]}, {"answer_start": [18], "text": ["dabigatran"]}, {"answer_start": [18], "text": ["dabigatran"]}, {"answer_start": [18], "text": ["dabigatran"]}, {"answer_start": [18], "text": ["dabigatran"]}, {"answer_start": [18], "text": ["dabigatran"]}, {"answer_start": [18], "text": ["dabigatran"]}, {"answer_start": [18], "text": ["dabigatran"]}, {"answer_start": [18], "text": ["dabigatran"]}, {"answer_start": [18], "text": ["dabigatran"]}, {"answer_start": [18], "text": ["dabigatran"]}, {"answer_start": [18], "text": ["dabigatran"]}, {"answer_start": [18], "text": ["dabigatran"]}, {"answer_start": [18], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [61], "text": ["dabigatran"]}, {"answer_start": [72], "text": ["dabigatran"]}, {"answer_start": [72], "text": ["dabigatran"]}, {"answer_start": [72], "text": ["dabigatran"]}, {"answer_start": [72], "text": ["dabigatran"]}, {"answer_start": [72], "text": ["dabigatran"]}, {"answer_start": [72], "text": ["dabigatran"]}, {"answer_start": [72], "text": ["dabigatran"]}, {"answer_start": [72], "text": ["dabigatran"]}, {"answer_start": [72], "text": ["dabigatran"]}, {"answer_start": [72], "text": ["dabigatran"]}, {"answer_start": [72], "text": ["dabigatran"]}, {"answer_start": [72], "text": ["dabigatran"]}, {"answer_start": [72], "text": ["dabigatran"]}, {"answer_start": [72], "text": ["dabigatran"]}, {"answer_start": [72], "text": ["dabigatran"]}, {"answer_start": [72], "text": ["dabigatran"]}, {"answer_start": [72], "text": ["dabigatran"]}, {"answer_start": [72], "text": ["dabigatran"]}, {"answer_start": [72], "text": ["dabigatran"]}, {"answer_start": [72], "text": ["dabigatran"]}, {"answer_start": [72], "text": ["dabigatran"]}, {"answer_start": [72], "text": ["dabigatran"]}, {"answer_start": [72], "text": ["dabigatran"]}, {"answer_start": [72], "text": ["dabigatran"]}, {"answer_start": [72], "text": ["dabigatran"]}, {"answer_start": [72], "text": ["dabigatran"]}, {"answer_start": [72], "text": ["dabigatran"]}, {"answer_start": [72], "text": ["dabigatran"]}, {"answer_start": [72], "text": ["dabigatran"]}, {"answer_start": [72], "text": ["dabigatran"]}, {"answer_start": [72], "text": ["dabigatran"]}, {"answer_start": [72], "text": ["dabigatran"]}, {"answer_start": [27], "text": ["dabigatran"]}, {"answer_start": [27], "text": ["dabigatran"]}, {"answer_start": [27], "text": ["dabigatran"]}, {"answer_start": [27], "text": ["dabigatran"]}, {"answer_start": [27], "text": ["dabigatran"]}, {"answer_start": [27], "text": ["dabigatran"]}, {"answer_start": [27], "text": ["dabigatran"]}, {"answer_start": [27], "text": ["dabigatran"]}, {"answer_start": [27], "text": ["dabigatran"]}, {"answer_start": [27], "text": ["dabigatran"]}, {"answer_start": [27], "text": ["dabigatran"]}, {"answer_start": [27], "text": ["dabigatran"]}, {"answer_start": [27], "text": ["dabigatran"]}, {"answer_start": [27], "text": ["dabigatran"]}, {"answer_start": [27], "text": ["dabigatran"]}, {"answer_start": [27], "text": ["dabigatran"]}, {"answer_start": [27], "text": ["dabigatran"]}, {"answer_start": [27], "text": ["dabigatran"]}, {"answer_start": [27], "text": ["dabigatran"]}, {"answer_start": [27], "text": ["dabigatran"]}, {"answer_start": [27], "text": ["dabigatran"]}, {"answer_start": [27], "text": ["dabigatran"]}, {"answer_start": [27], "text": ["dabigatran"]}, {"answer_start": [27], "text": ["dabigatran"]}, {"answer_start": [27], "text": ["dabigatran"]}, {"answer_start": [27], "text": ["dabigatran"]}, {"answer_start": [27], "text": ["dabigatran"]}, {"answer_start": [27], "text": ["dabigatran"]}, {"answer_start": [27], "text": ["dabigatran"]}, {"answer_start": [27], "text": ["dabigatran"]}, {"answer_start": [27], "text": ["dabigatran"]}, {"answer_start": [27], "text": ["dabigatran"]}, {"answer_start": [48], "text": ["dabigatran"]}, {"answer_start": [48], "text": ["dabigatran"]}, {"answer_start": [48], "text": ["dabigatran"]}, {"answer_start": [48], "text": ["dabigatran"]}, {"answer_start": [48], "text": ["dabigatran"]}, {"answer_start": [48], "text": ["dabigatran"]}, {"answer_start": [48], "text": ["dabigatran"]}, {"answer_start": [48], "text": ["dabigatran"]}, {"answer_start": [48], "text": ["dabigatran"]}, {"answer_start": [48], "text": ["dabigatran"]}, {"answer_start": [48], "text": ["dabigatran"]}, {"answer_start": [48], "text": ["dabigatran"]}, {"answer_start": [48], "text": ["dabigatran"]}, {"answer_start": [48], "text": ["dabigatran"]}, {"answer_start": [48], "text": ["dabigatran"]}, {"answer_start": [48], "text": ["dabigatran"]}, {"answer_start": [48], "text": ["dabigatran"]}, {"answer_start": [48], "text": ["dabigatran"]}, {"answer_start": [48], "text": ["dabigatran"]}, {"answer_start": [48], "text": ["dabigatran"]}, {"answer_start": [48], "text": ["dabigatran"]}, {"answer_start": [48], "text": ["dabigatran"]}, {"answer_start": [48], "text": ["dabigatran"]}, {"answer_start": [48], "text": ["dabigatran"]}, {"answer_start": [48], "text": ["dabigatran"]}, {"answer_start": [48], "text": ["dabigatran"]}, {"answer_start": [48], "text": ["dabigatran"]}, {"answer_start": [48], "text": ["dabigatran"]}, {"answer_start": [48], "text": ["dabigatran"]}, {"answer_start": [48], "text": ["dabigatran"]}, {"answer_start": [48], "text": ["dabigatran"]}, {"answer_start": [48], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [50], "text": ["dabigatran"]}, {"answer_start": [37], "text": ["dabigatran"]}, {"answer_start": [37], "text": ["dabigatran"]}, {"answer_start": [37], "text": ["dabigatran"]}, {"answer_start": [37], "text": ["dabigatran"]}, {"answer_start": [37], "text": ["dabigatran"]}, {"answer_start": [37], "text": ["dabigatran"]}, {"answer_start": [37], "text": ["dabigatran"]}, {"answer_start": [37], "text": ["dabigatran"]}, {"answer_start": [37], "text": ["dabigatran"]}, {"answer_start": [37], "text": ["dabigatran"]}, {"answer_start": [37], "text": ["dabigatran"]}, {"answer_start": [37], "text": ["dabigatran"]}, {"answer_start": [37], "text": ["dabigatran"]}, {"answer_start": [37], "text": ["dabigatran"]}, {"answer_start": [37], "text": ["dabigatran"]}, {"answer_start": [37], "text": ["dabigatran"]}, {"answer_start": [37], "text": ["dabigatran"]}, {"answer_start": [37], "text": ["dabigatran"]}, {"answer_start": [37], "text": ["dabigatran"]}, {"answer_start": [37], "text": ["dabigatran"]}, {"answer_start": [37], "text": ["dabigatran"]}, {"answer_start": [37], "text": ["dabigatran"]}, {"answer_start": [37], "text": ["dabigatran"]}, {"answer_start": [37], "text": ["dabigatran"]}, {"answer_start": [37], "text": ["dabigatran"]}, {"answer_start": [37], "text": ["dabigatran"]}, {"answer_start": [37], "text": ["dabigatran"]}, {"answer_start": [37], "text": ["dabigatran"]}, {"answer_start": [37], "text": ["dabigatran"]}, {"answer_start": [37], "text": ["dabigatran"]}, {"answer_start": [37], "text": ["dabigatran"]}, {"answer_start": [37], "text": ["dabigatran"]}, {"answer_start": [41], "text": ["intravenous drug abuse"]}, {"answer_start": [41], "text": ["intravenous drug abuse"]}, {"answer_start": [41], "text": ["intravenous drug abuse"]}, {"answer_start": [41], "text": ["intravenous drug abuse"]}, {"answer_start": [41], "text": ["intravenous drug abuse"]}, {"answer_start": [41], "text": ["intravenous drug abuse"]}, {"answer_start": [41], "text": ["intravenous drug abuse"]}, {"answer_start": [41], "text": ["intravenous drug abuse"]}, {"answer_start": [41], "text": ["intravenous drug abuse"]}, {"answer_start": [41], "text": ["intravenous drug abuse"]}, {"answer_start": [41], "text": ["intravenous drug abuse"]}, {"answer_start": [41], "text": ["intravenous drug abuse"]}, {"answer_start": [41], "text": ["intravenous drug abuse"]}, {"answer_start": [41], "text": ["intravenous drug abuse"]}, {"answer_start": [41], "text": ["intravenous drug abuse"]}, {"answer_start": [41], "text": ["intravenous drug abuse"]}, {"answer_start": [55], "text": ["intravenous drug abuse"]}, {"answer_start": [55], "text": ["intravenous drug abuse"]}, {"answer_start": [55], "text": ["intravenous drug abuse"]}, {"answer_start": [55], "text": ["intravenous drug abuse"]}, {"answer_start": [55], "text": ["intravenous drug abuse"]}, {"answer_start": [55], "text": ["intravenous drug abuse"]}, {"answer_start": [55], "text": ["intravenous drug abuse"]}, {"answer_start": [55], "text": ["intravenous drug abuse"]}, {"answer_start": [55], "text": ["intravenous drug abuse"]}, {"answer_start": [55], "text": ["intravenous drug abuse"]}, {"answer_start": [55], "text": ["intravenous drug abuse"]}, {"answer_start": [55], "text": ["intravenous drug abuse"]}, {"answer_start": [55], "text": ["intravenous drug abuse"]}, {"answer_start": [55], "text": ["intravenous drug abuse"]}, {"answer_start": [55], "text": ["intravenous drug abuse"]}, {"answer_start": [55], "text": ["intravenous drug abuse"]}, {"answer_start": [53], "text": ["intravenous drug abuse"]}, {"answer_start": [53], "text": ["intravenous drug abuse"]}, {"answer_start": [53], "text": ["intravenous drug abuse"]}, {"answer_start": [53], "text": ["intravenous drug abuse"]}, {"answer_start": [53], "text": ["intravenous drug abuse"]}, {"answer_start": [53], "text": ["intravenous drug abuse"]}, {"answer_start": [53], "text": ["intravenous drug abuse"]}, {"answer_start": [53], "text": ["intravenous drug abuse"]}, {"answer_start": [53], "text": ["intravenous drug abuse"]}, {"answer_start": [53], "text": ["intravenous drug abuse"]}, {"answer_start": [53], "text": ["intravenous drug abuse"]}, {"answer_start": [53], "text": ["intravenous drug abuse"]}, {"answer_start": [53], "text": ["intravenous drug abuse"]}, {"answer_start": [53], "text": ["intravenous drug abuse"]}, {"answer_start": [53], "text": ["intravenous drug abuse"]}, {"answer_start": [53], "text": ["intravenous drug abuse"]}, {"answer_start": [41], "text": ["intravenous drug abuse"]}, {"answer_start": [41], "text": ["intravenous drug abuse"]}, {"answer_start": [41], "text": ["intravenous drug abuse"]}, {"answer_start": [41], "text": ["intravenous drug abuse"]}, {"answer_start": [41], "text": ["intravenous drug abuse"]}, {"answer_start": [41], "text": ["intravenous drug abuse"]}, {"answer_start": [41], "text": ["intravenous drug abuse"]}, {"answer_start": [41], "text": ["intravenous drug abuse"]}, {"answer_start": [41], "text": ["intravenous drug abuse"]}, {"answer_start": [41], "text": ["intravenous drug abuse"]}, {"answer_start": [41], "text": ["intravenous drug abuse"]}, {"answer_start": [41], "text": ["intravenous drug abuse"]}, {"answer_start": [41], "text": ["intravenous drug abuse"]}, {"answer_start": [41], "text": ["intravenous drug abuse"]}, {"answer_start": [41], "text": ["intravenous drug abuse"]}, {"answer_start": [41], "text": ["intravenous drug abuse"]}, {"answer_start": [55], "text": ["intravenous drug abuse"]}, {"answer_start": [55], "text": ["intravenous drug abuse"]}, {"answer_start": [55], "text": ["intravenous drug abuse"]}, {"answer_start": [55], "text": ["intravenous drug abuse"]}, {"answer_start": [55], "text": ["intravenous drug abuse"]}, {"answer_start": [55], "text": ["intravenous drug abuse"]}, {"answer_start": [55], "text": ["intravenous drug abuse"]}, {"answer_start": [55], "text": ["intravenous drug abuse"]}, {"answer_start": [55], "text": ["intravenous drug abuse"]}, {"answer_start": [55], "text": ["intravenous drug abuse"]}, {"answer_start": [55], "text": ["intravenous drug abuse"]}, {"answer_start": [55], "text": ["intravenous drug abuse"]}, {"answer_start": [55], "text": ["intravenous drug abuse"]}, {"answer_start": [55], "text": ["intravenous drug abuse"]}, {"answer_start": [55], "text": ["intravenous drug abuse"]}, {"answer_start": [55], "text": ["intravenous drug abuse"]}, {"answer_start": [1138], "text": ["glioblastoma multiforme"]}, {"answer_start": [1138], "text": ["glioblastoma multiforme"]}, {"answer_start": [1138], "text": ["glioblastoma multiforme"]}, {"answer_start": [1138], "text": ["glioblastoma multiforme"]}, {"answer_start": [1138], "text": ["glioblastoma multiforme"]}, {"answer_start": [1138], "text": ["glioblastoma multiforme"]}, {"answer_start": [1138], "text": ["glioblastoma multiforme"]}, {"answer_start": [1138], "text": ["glioblastoma multiforme"]}, {"answer_start": [657], "text": ["glioblastoma multiforme"]}, {"answer_start": [657], "text": ["glioblastoma multiforme"]}, {"answer_start": [657], "text": ["glioblastoma multiforme"]}, {"answer_start": [657], "text": ["glioblastoma multiforme"]}, {"answer_start": [657], "text": ["glioblastoma multiforme"]}, {"answer_start": [657], "text": ["glioblastoma multiforme"]}, {"answer_start": [657], "text": ["glioblastoma multiforme"]}, {"answer_start": [657], "text": ["glioblastoma multiforme"]}, {"answer_start": [0], "text": ["glioblastoma multiforme"]}, {"answer_start": [0], "text": ["glioblastoma multiforme"]}, {"answer_start": [0], "text": ["glioblastoma multiforme"]}, {"answer_start": [0], "text": ["glioblastoma multiforme"]}, {"answer_start": [0], "text": ["glioblastoma multiforme"]}, {"answer_start": [0], "text": ["glioblastoma multiforme"]}, {"answer_start": [0], "text": ["glioblastoma multiforme"]}, {"answer_start": [0], "text": ["glioblastoma multiforme"]}, {"answer_start": [165], "text": ["glioblastoma multiforme"]}, {"answer_start": [165], "text": ["glioblastoma multiforme"]}, {"answer_start": [165], "text": ["glioblastoma multiforme"]}, {"answer_start": [165], "text": ["glioblastoma multiforme"]}, {"answer_start": [165], "text": ["glioblastoma multiforme"]}, {"answer_start": [165], "text": ["glioblastoma multiforme"]}, {"answer_start": [165], "text": ["glioblastoma multiforme"]}, {"answer_start": [165], "text": ["glioblastoma multiforme"]}, {"answer_start": [64], "text": ["glioblastoma multiforme"]}, {"answer_start": [64], "text": ["glioblastoma multiforme"]}, {"answer_start": [64], "text": ["glioblastoma multiforme"]}, {"answer_start": [64], "text": ["glioblastoma multiforme"]}, {"answer_start": [64], "text": ["glioblastoma multiforme"]}, {"answer_start": [64], "text": ["glioblastoma multiforme"]}, {"answer_start": [64], "text": ["glioblastoma multiforme"]}, {"answer_start": [64], "text": ["glioblastoma multiforme"]}, {"answer_start": [37], "text": ["glioblastoma multiforme"]}, {"answer_start": [37], "text": ["glioblastoma multiforme"]}, {"answer_start": [37], "text": ["glioblastoma multiforme"]}, {"answer_start": [37], "text": ["glioblastoma multiforme"]}, {"answer_start": [37], "text": ["glioblastoma multiforme"]}, {"answer_start": [37], "text": ["glioblastoma multiforme"]}, {"answer_start": [37], "text": ["glioblastoma multiforme"]}, {"answer_start": [37], "text": ["glioblastoma multiforme"]}, {"answer_start": [0], "text": ["glioblastoma multiforme"]}, {"answer_start": [0], "text": ["glioblastoma multiforme"]}, {"answer_start": [0], "text": ["glioblastoma multiforme"]}, {"answer_start": [0], "text": ["glioblastoma multiforme"]}, {"answer_start": [0], "text": ["glioblastoma multiforme"]}, {"answer_start": [0], "text": ["glioblastoma multiforme"]}, {"answer_start": [0], "text": ["glioblastoma multiforme"]}, {"answer_start": [0], "text": ["glioblastoma multiforme"]}, {"answer_start": [35], "text": ["glioblastoma multiforme"]}, {"answer_start": [35], "text": ["glioblastoma multiforme"]}, {"answer_start": [35], "text": ["glioblastoma multiforme"]}, {"answer_start": [35], "text": ["glioblastoma multiforme"]}, {"answer_start": [35], "text": ["glioblastoma multiforme"]}, {"answer_start": [35], "text": ["glioblastoma multiforme"]}, {"answer_start": [35], "text": ["glioblastoma multiforme"]}, {"answer_start": [35], "text": ["glioblastoma multiforme"]}, {"answer_start": [50], "text": ["glioblastoma multiforme"]}, {"answer_start": [50], "text": ["glioblastoma multiforme"]}, {"answer_start": [50], "text": ["glioblastoma multiforme"]}, {"answer_start": [50], "text": ["glioblastoma multiforme"]}, {"answer_start": [50], "text": ["glioblastoma multiforme"]}, {"answer_start": [50], "text": ["glioblastoma multiforme"]}, {"answer_start": [50], "text": ["glioblastoma multiforme"]}, {"answer_start": [50], "text": ["glioblastoma multiforme"]}, {"answer_start": [16], "text": ["glioblastoma multiforme"]}, {"answer_start": [16], "text": ["glioblastoma multiforme"]}, {"answer_start": [16], "text": ["glioblastoma multiforme"]}, {"answer_start": [16], "text": ["glioblastoma multiforme"]}, {"answer_start": [16], "text": ["glioblastoma multiforme"]}, {"answer_start": [16], "text": ["glioblastoma multiforme"]}, {"answer_start": [16], "text": ["glioblastoma multiforme"]}, {"answer_start": [16], "text": ["glioblastoma multiforme"]}, {"answer_start": [4, 171, 384, 477, 834], "text": ["recount2", "recount2", "recount2", "recount2", "recount2"]}, {"answer_start": [4, 171, 384, 477, 834], "text": ["recount2", "recount2", "recount2", "recount2", "recount2"]}, {"answer_start": [4, 171, 384, 477, 834], "text": ["recount2", "recount2", "recount2", "recount2", "recount2"]}, {"answer_start": [4, 171, 384, 477, 834], "text": ["recount2", "recount2", "recount2", "recount2", "recount2"]}, {"answer_start": [4, 171, 384, 477, 834], "text": ["recount2", "recount2", "recount2", "recount2", "recount2"]}, {"answer_start": [4, 171, 384, 477, 834], "text": ["recount2", "recount2", "recount2", "recount2", "recount2"]}, {"answer_start": [4, 171, 384, 477, 834], "text": ["recount2", "recount2", "recount2", "recount2", "recount2"]}, {"answer_start": [4, 171, 384, 477, 834], "text": ["recount2", "recount2", "recount2", "recount2", "recount2"]}, {"answer_start": [4, 171, 384, 477, 834], "text": ["recount2", "recount2", "recount2", "recount2", "recount2"]}, {"answer_start": [4, 171, 384, 477, 834], "text": ["recount2", "recount2", "recount2", "recount2", "recount2"]}, {"answer_start": [4, 171, 384, 477, 834], "text": ["recount2", "recount2", "recount2", "recount2", "recount2"]}, {"answer_start": [4, 171, 384, 477, 834], "text": ["recount2", "recount2", "recount2", "recount2", "recount2"]}, {"answer_start": [4, 171, 384, 477, 834], "text": ["recount2", "recount2", "recount2", "recount2", "recount2"]}, {"answer_start": [4, 171, 384, 477, 834], "text": ["recount2", "recount2", "recount2", "recount2", "recount2"]}, {"answer_start": [4, 171, 384, 477, 834], "text": ["recount2", "recount2", "recount2", "recount2", "recount2"]}, {"answer_start": [4, 171, 384, 477, 834], "text": ["recount2", "recount2", "recount2", "recount2", "recount2"]}, {"answer_start": [4, 171, 384, 477, 834], "text": ["recount2", "recount2", "recount2", "recount2", "recount2"]}, {"answer_start": [4, 171, 384, 477, 834], "text": ["recount2", "recount2", "recount2", "recount2", "recount2"]}, {"answer_start": [4, 171, 384, 477, 834], "text": ["recount2", "recount2", "recount2", "recount2", "recount2"]}, {"answer_start": [4, 171, 384, 477, 834], "text": ["recount2", "recount2", "recount2", "recount2", "recount2"]}, {"answer_start": [4, 171, 384, 477, 834], "text": ["recount2", "recount2", "recount2", "recount2", "recount2"]}, {"answer_start": [4, 171, 384, 477, 834], "text": ["recount2", "recount2", "recount2", "recount2", "recount2"]}, {"answer_start": [4, 171, 384, 477, 834], "text": ["recount2", "recount2", "recount2", "recount2", "recount2"]}, {"answer_start": [4, 171, 384, 477, 834], "text": ["recount2", "recount2", "recount2", "recount2", "recount2"]}, {"answer_start": [4, 171, 384, 477, 834], "text": ["recount2", "recount2", "recount2", "recount2", "recount2"]}, {"answer_start": [4, 171, 384, 477, 834], "text": ["recount2", "recount2", "recount2", "recount2", "recount2"]}, {"answer_start": [4, 171, 384, 477, 834], "text": ["recount2", "recount2", "recount2", "recount2", "recount2"]}, {"answer_start": [4, 171, 384, 477, 834], "text": ["recount2", "recount2", "recount2", "recount2", "recount2"]}, {"answer_start": [4, 171, 384, 477, 834], "text": ["recount2", "recount2", "recount2", "recount2", "recount2"]}, {"answer_start": [4, 171, 384, 477, 834], "text": ["recount2", "recount2", "recount2", "recount2", "recount2"]}, {"answer_start": [4, 171, 384, 477, 834], "text": ["recount2", "recount2", "recount2", "recount2", "recount2"]}, {"answer_start": [4, 171, 384, 477, 834], "text": ["recount2", "recount2", "recount2", "recount2", "recount2"]}, {"answer_start": [4, 171, 384, 477, 834], "text": ["recount2", "recount2", "recount2", "recount2", "recount2"]}, {"answer_start": [4, 171, 384, 477, 834], "text": ["recount2", "recount2", "recount2", "recount2", "recount2"]}, {"answer_start": [4, 171, 384, 477, 834], "text": ["recount2", "recount2", "recount2", "recount2", "recount2"]}, {"answer_start": [4, 171, 384, 477, 834], "text": ["recount2", "recount2", "recount2", "recount2", "recount2"]}, {"answer_start": [4, 171, 384, 477, 834], "text": ["recount2", "recount2", "recount2", "recount2", "recount2"]}, {"answer_start": [4, 171, 384, 477, 834], "text": ["recount2", "recount2", "recount2", "recount2", "recount2"]}, {"answer_start": [4, 171, 384, 477, 834], "text": ["recount2", "recount2", "recount2", "recount2", "recount2"]}, {"answer_start": [4, 171, 384, 477, 834], "text": ["recount2", "recount2", "recount2", "recount2", "recount2"]}, {"answer_start": [4, 171, 384, 477, 834], "text": ["recount2", "recount2", "recount2", "recount2", "recount2"]}, {"answer_start": [4, 171, 384, 477, 834], "text": ["recount2", "recount2", "recount2", "recount2", "recount2"]}, {"answer_start": [4, 171, 384, 477, 834], "text": ["recount2", "recount2", "recount2", "recount2", "recount2"]}, {"answer_start": [4, 171, 384, 477, 834], "text": ["recount2", "recount2", "recount2", "recount2", "recount2"]}, {"answer_start": [4], "text": ["recount2"]}, {"answer_start": [4], "text": ["recount2"]}, {"answer_start": [4], "text": ["recount2"]}, {"answer_start": [4], "text": ["recount2"]}, {"answer_start": [4], "text": ["recount2"]}, {"answer_start": [4], "text": ["recount2"]}, {"answer_start": [4], "text": ["recount2"]}, {"answer_start": [4], "text": ["recount2"]}, {"answer_start": [4], "text": ["recount2"]}, {"answer_start": [4], "text": ["recount2"]}, {"answer_start": [4], "text": ["recount2"]}, {"answer_start": [4], "text": ["recount2"]}, {"answer_start": [4], "text": ["recount2"]}, {"answer_start": [4], "text": ["recount2"]}, {"answer_start": [4], "text": ["recount2"]}, {"answer_start": [4], "text": ["recount2"]}, {"answer_start": [4], "text": ["recount2"]}, {"answer_start": [4], "text": ["recount2"]}, {"answer_start": [4], "text": ["recount2"]}, {"answer_start": [4], "text": ["recount2"]}, {"answer_start": [4], "text": ["recount2"]}, {"answer_start": [4], "text": ["recount2"]}, {"answer_start": [4], "text": ["recount2"]}, {"answer_start": [4], "text": ["recount2"]}, {"answer_start": [4], "text": ["recount2"]}, {"answer_start": [4], "text": ["recount2"]}, {"answer_start": [4], "text": ["recount2"]}, {"answer_start": [4], "text": ["recount2"]}, {"answer_start": [4], "text": ["recount2"]}, {"answer_start": [4], "text": ["recount2"]}, {"answer_start": [4], "text": ["recount2"]}, {"answer_start": [4], "text": ["recount2"]}, {"answer_start": [4], "text": ["recount2"]}, {"answer_start": [4], "text": ["recount2"]}, {"answer_start": [4], "text": ["recount2"]}, {"answer_start": [4], "text": ["recount2"]}, {"answer_start": [4], "text": ["recount2"]}, {"answer_start": [4], "text": ["recount2"]}, {"answer_start": [4], "text": ["recount2"]}, {"answer_start": [4], "text": ["recount2"]}, {"answer_start": [4], "text": ["recount2"]}, {"answer_start": [4], "text": ["recount2"]}, {"answer_start": [4], "text": ["recount2"]}, {"answer_start": [4], "text": ["recount2"]}, {"answer_start": [1095, 1244], "text": ["convergent", "convergent"]}, {"answer_start": [1095, 1244], "text": ["convergent", "convergent"]}, {"answer_start": [1095, 1244], "text": ["convergent", "convergent"]}, {"answer_start": [1095, 1244], "text": ["convergent", "convergent"]}, {"answer_start": [1095, 1244], "text": ["convergent", "convergent"]}, {"answer_start": [1095, 1244], "text": ["convergent", "convergent"]}, {"answer_start": [1095, 1244], "text": ["convergent", "convergent"]}, {"answer_start": [1095, 1244], "text": ["convergent", "convergent"]}, {"answer_start": [1095, 1244], "text": ["convergent", "convergent"]}, {"answer_start": [1095, 1244], "text": ["convergent", "convergent"]}, {"answer_start": [1095, 1244], "text": ["convergent", "convergent"]}, {"answer_start": [1095, 1244], "text": ["convergent", "convergent"]}, {"answer_start": [1095, 1244], "text": ["convergent", "convergent"]}, {"answer_start": [1095, 1244], "text": ["convergent", "convergent"]}, {"answer_start": [1095, 1244], "text": ["convergent", "convergent"]}, {"answer_start": [1095, 1244], "text": ["convergent", "convergent"]}, {"answer_start": [1095, 1244], "text": ["convergent", "convergent"]}, {"answer_start": [1095, 1244], "text": ["convergent", "convergent"]}, {"answer_start": [1095, 1244], "text": ["convergent", "convergent"]}, {"answer_start": [1095, 1244], "text": ["convergent", "convergent"]}, {"answer_start": [1095, 1244], "text": ["convergent", "convergent"]}, {"answer_start": [1095, 1244], "text": ["convergent", "convergent"]}, {"answer_start": [1095, 1244], "text": ["convergent", "convergent"]}, {"answer_start": [1095, 1244], "text": ["convergent", "convergent"]}, {"answer_start": [1095, 1244], "text": ["convergent", "convergent"]}, {"answer_start": [1095, 1244], "text": ["convergent", "convergent"]}, {"answer_start": [1095, 1244], "text": ["convergent", "convergent"]}, {"answer_start": [367, 629], "text": ["convergent", "convergent"]}, {"answer_start": [367, 629], "text": ["convergent", "convergent"]}, {"answer_start": [367, 629], "text": ["convergent", "convergent"]}, {"answer_start": [367, 629], "text": ["convergent", "convergent"]}, {"answer_start": [367, 629], "text": ["convergent", "convergent"]}, {"answer_start": [367, 629], "text": ["convergent", "convergent"]}, {"answer_start": [367, 629], "text": ["convergent", "convergent"]}, {"answer_start": [367, 629], "text": ["convergent", "convergent"]}, {"answer_start": [367, 629], "text": ["convergent", "convergent"]}, {"answer_start": [367, 629], "text": ["convergent", "convergent"]}, {"answer_start": [367, 629], "text": ["convergent", "convergent"]}, {"answer_start": [367, 629], "text": ["convergent", "convergent"]}, {"answer_start": [367, 629], "text": ["convergent", "convergent"]}, {"answer_start": [367, 629], "text": ["convergent", "convergent"]}, {"answer_start": [367, 629], "text": ["convergent", "convergent"]}, {"answer_start": [367, 629], "text": ["convergent", "convergent"]}, {"answer_start": [367, 629], "text": ["convergent", "convergent"]}, {"answer_start": [367, 629], "text": ["convergent", "convergent"]}, {"answer_start": [367, 629], "text": ["convergent", "convergent"]}, {"answer_start": [367, 629], "text": ["convergent", "convergent"]}, {"answer_start": [367, 629], "text": ["convergent", "convergent"]}, {"answer_start": [367, 629], "text": ["convergent", "convergent"]}, {"answer_start": [367, 629], "text": ["convergent", "convergent"]}, {"answer_start": [367, 629], "text": ["convergent", "convergent"]}, {"answer_start": [367, 629], "text": ["convergent", "convergent"]}, {"answer_start": [367, 629], "text": ["convergent", "convergent"]}, {"answer_start": [367, 629], "text": ["convergent", "convergent"]}, {"answer_start": [91], "text": ["convergent"]}, {"answer_start": [91], "text": ["convergent"]}, {"answer_start": [91], "text": ["convergent"]}, {"answer_start": [91], "text": ["convergent"]}, {"answer_start": [91], "text": ["convergent"]}, {"answer_start": [91], "text": ["convergent"]}, {"answer_start": [91], "text": ["convergent"]}, {"answer_start": [91], "text": ["convergent"]}, {"answer_start": [91], "text": ["convergent"]}, {"answer_start": [91], "text": ["convergent"]}, {"answer_start": [91], "text": ["convergent"]}, {"answer_start": [91], "text": ["convergent"]}, {"answer_start": [91], "text": ["convergent"]}, {"answer_start": [91], "text": ["convergent"]}, {"answer_start": [91], "text": ["convergent"]}, {"answer_start": [91], "text": ["convergent"]}, {"answer_start": [91], "text": ["convergent"]}, {"answer_start": [91], "text": ["convergent"]}, {"answer_start": [91], "text": ["convergent"]}, {"answer_start": [91], "text": ["convergent"]}, {"answer_start": [91], "text": ["convergent"]}, {"answer_start": [91], "text": ["convergent"]}, {"answer_start": [91], "text": ["convergent"]}, {"answer_start": [91], "text": ["convergent"]}, {"answer_start": [91], "text": ["convergent"]}, {"answer_start": [91], "text": ["convergent"]}, {"answer_start": [91], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [126], "text": ["convergent"]}, {"answer_start": [59], "text": ["convergent"]}, {"answer_start": [59], "text": ["convergent"]}, {"answer_start": [59], "text": ["convergent"]}, {"answer_start": [59], "text": ["convergent"]}, {"answer_start": [59], "text": ["convergent"]}, {"answer_start": [59], "text": ["convergent"]}, {"answer_start": [59], "text": ["convergent"]}, {"answer_start": [59], "text": ["convergent"]}, {"answer_start": [59], "text": ["convergent"]}, {"answer_start": [59], "text": ["convergent"]}, {"answer_start": [59], "text": ["convergent"]}, {"answer_start": [59], "text": ["convergent"]}, {"answer_start": [59], "text": ["convergent"]}, {"answer_start": [59], "text": ["convergent"]}, {"answer_start": [59], "text": ["convergent"]}, {"answer_start": [59], "text": ["convergent"]}, {"answer_start": [59], "text": ["convergent"]}, {"answer_start": [59], "text": ["convergent"]}, {"answer_start": [59], "text": ["convergent"]}, {"answer_start": [59], "text": ["convergent"]}, {"answer_start": [59], "text": ["convergent"]}, {"answer_start": [59], "text": ["convergent"]}, {"answer_start": [59], "text": ["convergent"]}, {"answer_start": [59], "text": ["convergent"]}, {"answer_start": [59], "text": ["convergent"]}, {"answer_start": [59], "text": ["convergent"]}, {"answer_start": [59], "text": ["convergent"]}, {"answer_start": [53], "text": ["eight"]}, {"answer_start": [53], "text": ["eight"]}, {"answer_start": [53], "text": ["eight"]}, {"answer_start": [53], "text": ["eight"]}, {"answer_start": [53], "text": ["eight"]}, {"answer_start": [53], "text": ["eight"]}, {"answer_start": [53], "text": ["eight"]}, {"answer_start": [53], "text": ["eight"]}, {"answer_start": [53], "text": ["eight"]}, {"answer_start": [53], "text": ["eight"]}, {"answer_start": [53], "text": ["eight"]}, {"answer_start": [53], "text": ["eight"]}, {"answer_start": [53], "text": ["eight"]}, {"answer_start": [53], "text": ["eight"]}, {"answer_start": [53], "text": ["eight"]}, {"answer_start": [53], "text": ["eight"]}, {"answer_start": [53], "text": ["eight"]}, {"answer_start": [53], "text": ["eight"]}, {"answer_start": [53], "text": ["eight"]}, {"answer_start": [53], "text": ["eight"]}, {"answer_start": [53], "text": ["eight"]}, {"answer_start": [53], "text": ["eight"]}, {"answer_start": [53], "text": ["eight"]}, {"answer_start": [0, 439, 665], "text": ["chordomas", "chordomas", "chordomas"]}, {"answer_start": [0, 439, 665], "text": ["chordomas", "chordomas", "chordomas"]}, {"answer_start": [0, 439, 665], "text": ["chordomas", "chordomas", "chordomas"]}, {"answer_start": [0, 439, 665], "text": ["chordomas", "chordomas", "chordomas"]}, {"answer_start": [0, 439, 665], "text": ["chordomas", "chordomas", "chordomas"]}, {"answer_start": [0, 439, 665], "text": ["chordomas", "chordomas", "chordomas"]}, {"answer_start": [0, 439, 665], "text": ["chordomas", "chordomas", "chordomas"]}, {"answer_start": [0, 439, 665], "text": ["chordomas", "chordomas", "chordomas"]}, {"answer_start": [0, 439, 665], "text": ["chordomas", "chordomas", "chordomas"]}, {"answer_start": [0, 439, 665], "text": ["chordomas", "chordomas", "chordomas"]}, {"answer_start": [0, 439, 665], "text": ["chordomas", "chordomas", "chordomas"]}, {"answer_start": [0, 439, 665], "text": ["chordomas", "chordomas", "chordomas"]}, {"answer_start": [0, 439, 665], "text": ["chordomas", "chordomas", "chordomas"]}, {"answer_start": [0, 439, 665], "text": ["chordomas", "chordomas", "chordomas"]}, {"answer_start": [0, 439, 665], "text": ["chordomas", "chordomas", "chordomas"]}, {"answer_start": [0, 439, 665], "text": ["chordomas", "chordomas", "chordomas"]}, {"answer_start": [0, 439, 665], "text": ["chordomas", "chordomas", "chordomas"]}, {"answer_start": [0, 439, 665], "text": ["chordomas", "chordomas", "chordomas"]}, {"answer_start": [0, 439, 665], "text": ["chordomas", "chordomas", "chordomas"]}, {"answer_start": [0, 439, 665], "text": ["chordomas", "chordomas", "chordomas"]}, {"answer_start": [0, 439, 665], "text": ["chordomas", "chordomas", "chordomas"]}, {"answer_start": [0, 439, 665], "text": ["chordomas", "chordomas", "chordomas"]}, {"answer_start": [0, 439, 665], "text": ["chordomas", "chordomas", "chordomas"]}, {"answer_start": [0, 439, 665], "text": ["chordomas", "chordomas", "chordomas"]}, {"answer_start": [0, 439, 665], "text": ["chordomas", "chordomas", "chordomas"]}, {"answer_start": [0, 439, 665], "text": ["chordomas", "chordomas", "chordomas"]}, {"answer_start": [0, 439, 665], "text": ["chordomas", "chordomas", "chordomas"]}, {"answer_start": [0, 439, 665], "text": ["chordomas", "chordomas", "chordomas"]}, {"answer_start": [0, 439, 665], "text": ["chordomas", "chordomas", "chordomas"]}, {"answer_start": [0, 439, 665], "text": ["chordomas", "chordomas", "chordomas"]}, {"answer_start": [0, 439, 665], "text": ["chordomas", "chordomas", "chordomas"]}, {"answer_start": [0, 439, 665], "text": ["chordomas", "chordomas", "chordomas"]}, {"answer_start": [0, 439, 665], "text": ["chordomas", "chordomas", "chordomas"]}, {"answer_start": [0, 439, 665], "text": ["chordomas", "chordomas", "chordomas"]}, {"answer_start": [0, 439, 665], "text": ["chordomas", "chordomas", "chordomas"]}, {"answer_start": [0, 439, 665], "text": ["chordomas", "chordomas", "chordomas"]}, {"answer_start": [0, 439, 665], "text": ["chordomas", "chordomas", "chordomas"]}, {"answer_start": [0, 439, 665], "text": ["chordomas", "chordomas", "chordomas"]}, {"answer_start": [0, 439, 665], "text": ["chordomas", "chordomas", "chordomas"]}, {"answer_start": [0, 439, 665], "text": ["chordomas", "chordomas", "chordomas"]}, {"answer_start": [0, 439, 665], "text": ["chordomas", "chordomas", "chordomas"]}, {"answer_start": [0, 439, 665], "text": ["chordomas", "chordomas", "chordomas"]}, {"answer_start": [0, 439, 665], "text": ["chordomas", "chordomas", "chordomas"]}, {"answer_start": [0, 439, 665], "text": ["chordomas", "chordomas", "chordomas"]}, {"answer_start": [0, 439, 665], "text": ["chordomas", "chordomas", "chordomas"]}, {"answer_start": [0, 439, 665], "text": ["chordomas", "chordomas", "chordomas"]}, {"answer_start": [0, 439, 665], "text": ["chordomas", "chordomas", "chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [196], "text": ["chordomas"]}, {"answer_start": [136], "text": ["chordomas"]}, {"answer_start": [136], "text": ["chordomas"]}, {"answer_start": [136], "text": ["chordomas"]}, {"answer_start": [136], "text": ["chordomas"]}, {"answer_start": [136], "text": ["chordomas"]}, {"answer_start": [136], "text": ["chordomas"]}, {"answer_start": [136], "text": ["chordomas"]}, {"answer_start": [136], "text": ["chordomas"]}, {"answer_start": [136], "text": ["chordomas"]}, {"answer_start": [136], "text": ["chordomas"]}, {"answer_start": [136], "text": ["chordomas"]}, {"answer_start": [136], "text": ["chordomas"]}, {"answer_start": [136], "text": ["chordomas"]}, {"answer_start": [136], "text": ["chordomas"]}, {"answer_start": [136], "text": ["chordomas"]}, {"answer_start": [136], "text": ["chordomas"]}, {"answer_start": [136], "text": ["chordomas"]}, {"answer_start": [136], "text": ["chordomas"]}, {"answer_start": [136], "text": ["chordomas"]}, {"answer_start": [136], "text": ["chordomas"]}, {"answer_start": [136], "text": ["chordomas"]}, {"answer_start": [136], "text": ["chordomas"]}, {"answer_start": [136], "text": ["chordomas"]}, {"answer_start": [136], "text": ["chordomas"]}, {"answer_start": [136], "text": ["chordomas"]}, {"answer_start": [136], "text": ["chordomas"]}, {"answer_start": [136], "text": ["chordomas"]}, {"answer_start": [136], "text": ["chordomas"]}, {"answer_start": [136], "text": ["chordomas"]}, {"answer_start": [136], "text": ["chordomas"]}, {"answer_start": [136], "text": ["chordomas"]}, {"answer_start": [136], "text": ["chordomas"]}, {"answer_start": [136], "text": ["chordomas"]}, {"answer_start": [136], "text": ["chordomas"]}, {"answer_start": [136], "text": ["chordomas"]}, {"answer_start": [136], "text": ["chordomas"]}, {"answer_start": [136], "text": ["chordomas"]}, {"answer_start": [136], "text": ["chordomas"]}, {"answer_start": [136], "text": ["chordomas"]}, {"answer_start": [136], "text": ["chordomas"]}, {"answer_start": [136], "text": ["chordomas"]}, {"answer_start": [136], "text": ["chordomas"]}, {"answer_start": [136], "text": ["chordomas"]}, {"answer_start": [136], "text": ["chordomas"]}, {"answer_start": [136], "text": ["chordomas"]}, {"answer_start": [136], "text": ["chordomas"]}, {"answer_start": [136], "text": ["chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [77, 67], "text": ["chordomas", "childhood chordomas"]}, {"answer_start": [104], "text": ["obstructive sleep apnea"]}, {"answer_start": [104], "text": ["obstructive sleep apnea"]}, {"answer_start": [104], "text": ["obstructive sleep apnea"]}, {"answer_start": [104], "text": ["obstructive sleep apnea"]}, {"answer_start": [104], "text": ["obstructive sleep apnea"]}, {"answer_start": [104], "text": ["obstructive sleep apnea"]}, {"answer_start": [104], "text": ["obstructive sleep apnea"]}, {"answer_start": [104], "text": ["obstructive sleep apnea"]}, {"answer_start": [104], "text": ["obstructive sleep apnea"]}, {"answer_start": [104], "text": ["obstructive sleep apnea"]}, {"answer_start": [104], "text": ["obstructive sleep apnea"]}, {"answer_start": [104], "text": ["obstructive sleep apnea"]}, {"answer_start": [104], "text": ["obstructive sleep apnea"]}, {"answer_start": [104], "text": ["obstructive sleep apnea"]}, {"answer_start": [104], "text": ["obstructive sleep apnea"]}, {"answer_start": [104], "text": ["obstructive sleep apnea"]}, {"answer_start": [104], "text": ["obstructive sleep apnea"]}, {"answer_start": [104], "text": ["obstructive sleep apnea"]}, {"answer_start": [104], "text": ["obstructive sleep apnea"]}, {"answer_start": [104], "text": ["obstructive sleep apnea"]}, {"answer_start": [104], "text": ["obstructive sleep apnea"]}, {"answer_start": [104], "text": ["obstructive sleep apnea"]}, {"answer_start": [104], "text": ["obstructive sleep apnea"]}, {"answer_start": [104], "text": ["obstructive sleep apnea"]}, {"answer_start": [104], "text": ["obstructive sleep apnea"]}, {"answer_start": [104], "text": ["obstructive sleep apnea"]}, {"answer_start": [104], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [71], "text": ["obstructive sleep apnea"]}, {"answer_start": [71], "text": ["obstructive sleep apnea"]}, {"answer_start": [71], "text": ["obstructive sleep apnea"]}, {"answer_start": [71], "text": ["obstructive sleep apnea"]}, {"answer_start": [71], "text": ["obstructive sleep apnea"]}, {"answer_start": [71], "text": ["obstructive sleep apnea"]}, {"answer_start": [71], "text": ["obstructive sleep apnea"]}, {"answer_start": [71], "text": ["obstructive sleep apnea"]}, {"answer_start": [71], "text": ["obstructive sleep apnea"]}, {"answer_start": [71], "text": ["obstructive sleep apnea"]}, {"answer_start": [71], "text": ["obstructive sleep apnea"]}, {"answer_start": [71], "text": ["obstructive sleep apnea"]}, {"answer_start": [71], "text": ["obstructive sleep apnea"]}, {"answer_start": [71], "text": ["obstructive sleep apnea"]}, {"answer_start": [71], "text": ["obstructive sleep apnea"]}, {"answer_start": [71], "text": ["obstructive sleep apnea"]}, {"answer_start": [71], "text": ["obstructive sleep apnea"]}, {"answer_start": [71], "text": ["obstructive sleep apnea"]}, {"answer_start": [71], "text": ["obstructive sleep apnea"]}, {"answer_start": [71], "text": ["obstructive sleep apnea"]}, {"answer_start": [71], "text": ["obstructive sleep apnea"]}, {"answer_start": [71], "text": ["obstructive sleep apnea"]}, {"answer_start": [71], "text": ["obstructive sleep apnea"]}, {"answer_start": [71], "text": ["obstructive sleep apnea"]}, {"answer_start": [71], "text": ["obstructive sleep apnea"]}, {"answer_start": [71], "text": ["obstructive sleep apnea"]}, {"answer_start": [71], "text": ["obstructive sleep apnea"]}, {"answer_start": [346], "text": ["obstructive sleep apnea"]}, {"answer_start": [346], "text": ["obstructive sleep apnea"]}, {"answer_start": [346], "text": ["obstructive sleep apnea"]}, {"answer_start": [346], "text": ["obstructive sleep apnea"]}, {"answer_start": [346], "text": ["obstructive sleep apnea"]}, {"answer_start": [346], "text": ["obstructive sleep apnea"]}, {"answer_start": [346], "text": ["obstructive sleep apnea"]}, {"answer_start": [346], "text": ["obstructive sleep apnea"]}, {"answer_start": [346], "text": ["obstructive sleep apnea"]}, {"answer_start": [346], "text": ["obstructive sleep apnea"]}, {"answer_start": [346], "text": ["obstructive sleep apnea"]}, {"answer_start": [346], "text": ["obstructive sleep apnea"]}, {"answer_start": [346], "text": ["obstructive sleep apnea"]}, {"answer_start": [346], "text": ["obstructive sleep apnea"]}, {"answer_start": [346], "text": ["obstructive sleep apnea"]}, {"answer_start": [346], "text": ["obstructive sleep apnea"]}, {"answer_start": [346], "text": ["obstructive sleep apnea"]}, {"answer_start": [346], "text": ["obstructive sleep apnea"]}, {"answer_start": [346], "text": ["obstructive sleep apnea"]}, {"answer_start": [346], "text": ["obstructive sleep apnea"]}, {"answer_start": [346], "text": ["obstructive sleep apnea"]}, {"answer_start": [346], "text": ["obstructive sleep apnea"]}, {"answer_start": [346], "text": ["obstructive sleep apnea"]}, {"answer_start": [346], "text": ["obstructive sleep apnea"]}, {"answer_start": [346], "text": ["obstructive sleep apnea"]}, {"answer_start": [346], "text": ["obstructive sleep apnea"]}, {"answer_start": [346], "text": ["obstructive sleep apnea"]}, {"answer_start": [190], "text": ["obstructive sleep apnea"]}, {"answer_start": [190], "text": ["obstructive sleep apnea"]}, {"answer_start": [190], "text": ["obstructive sleep apnea"]}, {"answer_start": [190], "text": ["obstructive sleep apnea"]}, {"answer_start": [190], "text": ["obstructive sleep apnea"]}, {"answer_start": [190], "text": ["obstructive sleep apnea"]}, {"answer_start": [190], "text": ["obstructive sleep apnea"]}, {"answer_start": [190], "text": ["obstructive sleep apnea"]}, {"answer_start": [190], "text": ["obstructive sleep apnea"]}, {"answer_start": [190], "text": ["obstructive sleep apnea"]}, {"answer_start": [190], "text": ["obstructive sleep apnea"]}, {"answer_start": [190], "text": ["obstructive sleep apnea"]}, {"answer_start": [190], "text": ["obstructive sleep apnea"]}, {"answer_start": [190], "text": ["obstructive sleep apnea"]}, {"answer_start": [190], "text": ["obstructive sleep apnea"]}, {"answer_start": [190], "text": ["obstructive sleep apnea"]}, {"answer_start": [190], "text": ["obstructive sleep apnea"]}, {"answer_start": [190], "text": ["obstructive sleep apnea"]}, {"answer_start": [190], "text": ["obstructive sleep apnea"]}, {"answer_start": [190], "text": ["obstructive sleep apnea"]}, {"answer_start": [190], "text": ["obstructive sleep apnea"]}, {"answer_start": [190], "text": ["obstructive sleep apnea"]}, {"answer_start": [190], "text": ["obstructive sleep apnea"]}, {"answer_start": [190], "text": ["obstructive sleep apnea"]}, {"answer_start": [190], "text": ["obstructive sleep apnea"]}, {"answer_start": [190], "text": ["obstructive sleep apnea"]}, {"answer_start": [190], "text": ["obstructive sleep apnea"]}, {"answer_start": [150], "text": ["obstructive sleep apnea"]}, {"answer_start": [150], "text": ["obstructive sleep apnea"]}, {"answer_start": [150], "text": ["obstructive sleep apnea"]}, {"answer_start": [150], "text": ["obstructive sleep apnea"]}, {"answer_start": [150], "text": ["obstructive sleep apnea"]}, {"answer_start": [150], "text": ["obstructive sleep apnea"]}, {"answer_start": [150], "text": ["obstructive sleep apnea"]}, {"answer_start": [150], "text": ["obstructive sleep apnea"]}, {"answer_start": [150], "text": ["obstructive sleep apnea"]}, {"answer_start": [150], "text": ["obstructive sleep apnea"]}, {"answer_start": [150], "text": ["obstructive sleep apnea"]}, {"answer_start": [150], "text": ["obstructive sleep apnea"]}, {"answer_start": [150], "text": ["obstructive sleep apnea"]}, {"answer_start": [150], "text": ["obstructive sleep apnea"]}, {"answer_start": [150], "text": ["obstructive sleep apnea"]}, {"answer_start": [150], "text": ["obstructive sleep apnea"]}, {"answer_start": [150], "text": ["obstructive sleep apnea"]}, {"answer_start": [150], "text": ["obstructive sleep apnea"]}, {"answer_start": [150], "text": ["obstructive sleep apnea"]}, {"answer_start": [150], "text": ["obstructive sleep apnea"]}, {"answer_start": [150], "text": ["obstructive sleep apnea"]}, {"answer_start": [150], "text": ["obstructive sleep apnea"]}, {"answer_start": [150], "text": ["obstructive sleep apnea"]}, {"answer_start": [150], "text": ["obstructive sleep apnea"]}, {"answer_start": [150], "text": ["obstructive sleep apnea"]}, {"answer_start": [150], "text": ["obstructive sleep apnea"]}, {"answer_start": [150], "text": ["obstructive sleep apnea"]}, {"answer_start": [275], "text": ["obstructive sleep apnea"]}, {"answer_start": [275], "text": ["obstructive sleep apnea"]}, {"answer_start": [275], "text": ["obstructive sleep apnea"]}, {"answer_start": [275], "text": ["obstructive sleep apnea"]}, {"answer_start": [275], "text": ["obstructive sleep apnea"]}, {"answer_start": [275], "text": ["obstructive sleep apnea"]}, {"answer_start": [275], "text": ["obstructive sleep apnea"]}, {"answer_start": [275], "text": ["obstructive sleep apnea"]}, {"answer_start": [275], "text": ["obstructive sleep apnea"]}, {"answer_start": [275], "text": ["obstructive sleep apnea"]}, {"answer_start": [275], "text": ["obstructive sleep apnea"]}, {"answer_start": [275], "text": ["obstructive sleep apnea"]}, {"answer_start": [275], "text": ["obstructive sleep apnea"]}, {"answer_start": [275], "text": ["obstructive sleep apnea"]}, {"answer_start": [275], "text": ["obstructive sleep apnea"]}, {"answer_start": [275], "text": ["obstructive sleep apnea"]}, {"answer_start": [275], "text": ["obstructive sleep apnea"]}, {"answer_start": [275], "text": ["obstructive sleep apnea"]}, {"answer_start": [275], "text": ["obstructive sleep apnea"]}, {"answer_start": [275], "text": ["obstructive sleep apnea"]}, {"answer_start": [275], "text": ["obstructive sleep apnea"]}, {"answer_start": [275], "text": ["obstructive sleep apnea"]}, {"answer_start": [275], "text": ["obstructive sleep apnea"]}, {"answer_start": [275], "text": ["obstructive sleep apnea"]}, {"answer_start": [275], "text": ["obstructive sleep apnea"]}, {"answer_start": [275], "text": ["obstructive sleep apnea"]}, {"answer_start": [275], "text": ["obstructive sleep apnea"]}, {"answer_start": [53], "text": ["obstructive sleep apnea"]}, {"answer_start": [53], "text": ["obstructive sleep apnea"]}, {"answer_start": [53], "text": ["obstructive sleep apnea"]}, {"answer_start": [53], "text": ["obstructive sleep apnea"]}, {"answer_start": [53], "text": ["obstructive sleep apnea"]}, {"answer_start": [53], "text": ["obstructive sleep apnea"]}, {"answer_start": [53], "text": ["obstructive sleep apnea"]}, {"answer_start": [53], "text": ["obstructive sleep apnea"]}, {"answer_start": [53], "text": ["obstructive sleep apnea"]}, {"answer_start": [53], "text": ["obstructive sleep apnea"]}, {"answer_start": [53], "text": ["obstructive sleep apnea"]}, {"answer_start": [53], "text": ["obstructive sleep apnea"]}, {"answer_start": [53], "text": ["obstructive sleep apnea"]}, {"answer_start": [53], "text": ["obstructive sleep apnea"]}, {"answer_start": [53], "text": ["obstructive sleep apnea"]}, {"answer_start": [53], "text": ["obstructive sleep apnea"]}, {"answer_start": [53], "text": ["obstructive sleep apnea"]}, {"answer_start": [53], "text": ["obstructive sleep apnea"]}, {"answer_start": [53], "text": ["obstructive sleep apnea"]}, {"answer_start": [53], "text": ["obstructive sleep apnea"]}, {"answer_start": [53], "text": ["obstructive sleep apnea"]}, {"answer_start": [53], "text": ["obstructive sleep apnea"]}, {"answer_start": [53], "text": ["obstructive sleep apnea"]}, {"answer_start": [53], "text": ["obstructive sleep apnea"]}, {"answer_start": [53], "text": ["obstructive sleep apnea"]}, {"answer_start": [53], "text": ["obstructive sleep apnea"]}, {"answer_start": [53], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [197], "text": ["obstructive sleep apnea"]}, {"answer_start": [197], "text": ["obstructive sleep apnea"]}, {"answer_start": [197], "text": ["obstructive sleep apnea"]}, {"answer_start": [197], "text": ["obstructive sleep apnea"]}, {"answer_start": [197], "text": ["obstructive sleep apnea"]}, {"answer_start": [197], "text": ["obstructive sleep apnea"]}, {"answer_start": [197], "text": ["obstructive sleep apnea"]}, {"answer_start": [197], "text": ["obstructive sleep apnea"]}, {"answer_start": [197], "text": ["obstructive sleep apnea"]}, {"answer_start": [197], "text": ["obstructive sleep apnea"]}, {"answer_start": [197], "text": ["obstructive sleep apnea"]}, {"answer_start": [197], "text": ["obstructive sleep apnea"]}, {"answer_start": [197], "text": ["obstructive sleep apnea"]}, {"answer_start": [197], "text": ["obstructive sleep apnea"]}, {"answer_start": [197], "text": ["obstructive sleep apnea"]}, {"answer_start": [197], "text": ["obstructive sleep apnea"]}, {"answer_start": [197], "text": ["obstructive sleep apnea"]}, {"answer_start": [197], "text": ["obstructive sleep apnea"]}, {"answer_start": [197], "text": ["obstructive sleep apnea"]}, {"answer_start": [197], "text": ["obstructive sleep apnea"]}, {"answer_start": [197], "text": ["obstructive sleep apnea"]}, {"answer_start": [197], "text": ["obstructive sleep apnea"]}, {"answer_start": [197], "text": ["obstructive sleep apnea"]}, {"answer_start": [197], "text": ["obstructive sleep apnea"]}, {"answer_start": [197], "text": ["obstructive sleep apnea"]}, {"answer_start": [197], "text": ["obstructive sleep apnea"]}, {"answer_start": [197], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [143], "text": ["obstructive sleep apnea"]}, {"answer_start": [143], "text": ["obstructive sleep apnea"]}, {"answer_start": [143], "text": ["obstructive sleep apnea"]}, {"answer_start": [143], "text": ["obstructive sleep apnea"]}, {"answer_start": [143], "text": ["obstructive sleep apnea"]}, {"answer_start": [143], "text": ["obstructive sleep apnea"]}, {"answer_start": [143], "text": ["obstructive sleep apnea"]}, {"answer_start": [143], "text": ["obstructive sleep apnea"]}, {"answer_start": [143], "text": ["obstructive sleep apnea"]}, {"answer_start": [143], "text": ["obstructive sleep apnea"]}, {"answer_start": [143], "text": ["obstructive sleep apnea"]}, {"answer_start": [143], "text": ["obstructive sleep apnea"]}, {"answer_start": [143], "text": ["obstructive sleep apnea"]}, {"answer_start": [143], "text": ["obstructive sleep apnea"]}, {"answer_start": [143], "text": ["obstructive sleep apnea"]}, {"answer_start": [143], "text": ["obstructive sleep apnea"]}, {"answer_start": [143], "text": ["obstructive sleep apnea"]}, {"answer_start": [143], "text": ["obstructive sleep apnea"]}, {"answer_start": [143], "text": ["obstructive sleep apnea"]}, {"answer_start": [143], "text": ["obstructive sleep apnea"]}, {"answer_start": [143], "text": ["obstructive sleep apnea"]}, {"answer_start": [143], "text": ["obstructive sleep apnea"]}, {"answer_start": [143], "text": ["obstructive sleep apnea"]}, {"answer_start": [143], "text": ["obstructive sleep apnea"]}, {"answer_start": [143], "text": ["obstructive sleep apnea"]}, {"answer_start": [143], "text": ["obstructive sleep apnea"]}, {"answer_start": [143], "text": ["obstructive sleep apnea"]}, {"answer_start": [108], "text": ["obstructive sleep apnea"]}, {"answer_start": [108], "text": ["obstructive sleep apnea"]}, {"answer_start": [108], "text": ["obstructive sleep apnea"]}, {"answer_start": [108], "text": ["obstructive sleep apnea"]}, {"answer_start": [108], "text": ["obstructive sleep apnea"]}, {"answer_start": [108], "text": ["obstructive sleep apnea"]}, {"answer_start": [108], "text": ["obstructive sleep apnea"]}, {"answer_start": [108], "text": ["obstructive sleep apnea"]}, {"answer_start": [108], "text": ["obstructive sleep apnea"]}, {"answer_start": [108], "text": ["obstructive sleep apnea"]}, {"answer_start": [108], "text": ["obstructive sleep apnea"]}, {"answer_start": [108], "text": ["obstructive sleep apnea"]}, {"answer_start": [108], "text": ["obstructive sleep apnea"]}, {"answer_start": [108], "text": ["obstructive sleep apnea"]}, {"answer_start": [108], "text": ["obstructive sleep apnea"]}, {"answer_start": [108], "text": ["obstructive sleep apnea"]}, {"answer_start": [108], "text": ["obstructive sleep apnea"]}, {"answer_start": [108], "text": ["obstructive sleep apnea"]}, {"answer_start": [108], "text": ["obstructive sleep apnea"]}, {"answer_start": [108], "text": ["obstructive sleep apnea"]}, {"answer_start": [108], "text": ["obstructive sleep apnea"]}, {"answer_start": [108], "text": ["obstructive sleep apnea"]}, {"answer_start": [108], "text": ["obstructive sleep apnea"]}, {"answer_start": [108], "text": ["obstructive sleep apnea"]}, {"answer_start": [108], "text": ["obstructive sleep apnea"]}, {"answer_start": [108], "text": ["obstructive sleep apnea"]}, {"answer_start": [108], "text": ["obstructive sleep apnea"]}, {"answer_start": [66], "text": ["obstructive sleep apnea"]}, {"answer_start": [66], "text": ["obstructive sleep apnea"]}, {"answer_start": [66], "text": ["obstructive sleep apnea"]}, {"answer_start": [66], "text": ["obstructive sleep apnea"]}, {"answer_start": [66], "text": ["obstructive sleep apnea"]}, {"answer_start": [66], "text": ["obstructive sleep apnea"]}, {"answer_start": [66], "text": ["obstructive sleep apnea"]}, {"answer_start": [66], "text": ["obstructive sleep apnea"]}, {"answer_start": [66], "text": ["obstructive sleep apnea"]}, {"answer_start": [66], "text": ["obstructive sleep apnea"]}, {"answer_start": [66], "text": ["obstructive sleep apnea"]}, {"answer_start": [66], "text": ["obstructive sleep apnea"]}, {"answer_start": [66], "text": ["obstructive sleep apnea"]}, {"answer_start": [66], "text": ["obstructive sleep apnea"]}, {"answer_start": [66], "text": ["obstructive sleep apnea"]}, {"answer_start": [66], "text": ["obstructive sleep apnea"]}, {"answer_start": [66], "text": ["obstructive sleep apnea"]}, {"answer_start": [66], "text": ["obstructive sleep apnea"]}, {"answer_start": [66], "text": ["obstructive sleep apnea"]}, {"answer_start": [66], "text": ["obstructive sleep apnea"]}, {"answer_start": [66], "text": ["obstructive sleep apnea"]}, {"answer_start": [66], "text": ["obstructive sleep apnea"]}, {"answer_start": [66], "text": ["obstructive sleep apnea"]}, {"answer_start": [66], "text": ["obstructive sleep apnea"]}, {"answer_start": [66], "text": ["obstructive sleep apnea"]}, {"answer_start": [66], "text": ["obstructive sleep apnea"]}, {"answer_start": [66], "text": ["obstructive sleep apnea"]}, {"answer_start": [93], "text": ["obstructive sleep apnea"]}, {"answer_start": [93], "text": ["obstructive sleep apnea"]}, {"answer_start": [93], "text": ["obstructive sleep apnea"]}, {"answer_start": [93], "text": ["obstructive sleep apnea"]}, {"answer_start": [93], "text": ["obstructive sleep apnea"]}, {"answer_start": [93], "text": ["obstructive sleep apnea"]}, {"answer_start": [93], "text": ["obstructive sleep apnea"]}, {"answer_start": [93], "text": ["obstructive sleep apnea"]}, {"answer_start": [93], "text": ["obstructive sleep apnea"]}, {"answer_start": [93], "text": ["obstructive sleep apnea"]}, {"answer_start": [93], "text": ["obstructive sleep apnea"]}, {"answer_start": [93], "text": ["obstructive sleep apnea"]}, {"answer_start": [93], "text": ["obstructive sleep apnea"]}, {"answer_start": [93], "text": ["obstructive sleep apnea"]}, {"answer_start": [93], "text": ["obstructive sleep apnea"]}, {"answer_start": [93], "text": ["obstructive sleep apnea"]}, {"answer_start": [93], "text": ["obstructive sleep apnea"]}, {"answer_start": [93], "text": ["obstructive sleep apnea"]}, {"answer_start": [93], "text": ["obstructive sleep apnea"]}, {"answer_start": [93], "text": ["obstructive sleep apnea"]}, {"answer_start": [93], "text": ["obstructive sleep apnea"]}, {"answer_start": [93], "text": ["obstructive sleep apnea"]}, {"answer_start": [93], "text": ["obstructive sleep apnea"]}, {"answer_start": [93], "text": ["obstructive sleep apnea"]}, {"answer_start": [93], "text": ["obstructive sleep apnea"]}, {"answer_start": [93], "text": ["obstructive sleep apnea"]}, {"answer_start": [93], "text": ["obstructive sleep apnea"]}, {"answer_start": [90], "text": ["obstructive sleep apnea"]}, {"answer_start": [90], "text": ["obstructive sleep apnea"]}, {"answer_start": [90], "text": ["obstructive sleep apnea"]}, {"answer_start": [90], "text": ["obstructive sleep apnea"]}, {"answer_start": [90], "text": ["obstructive sleep apnea"]}, {"answer_start": [90], "text": ["obstructive sleep apnea"]}, {"answer_start": [90], "text": ["obstructive sleep apnea"]}, {"answer_start": [90], "text": ["obstructive sleep apnea"]}, {"answer_start": [90], "text": ["obstructive sleep apnea"]}, {"answer_start": [90], "text": ["obstructive sleep apnea"]}, {"answer_start": [90], "text": ["obstructive sleep apnea"]}, {"answer_start": [90], "text": ["obstructive sleep apnea"]}, {"answer_start": [90], "text": ["obstructive sleep apnea"]}, {"answer_start": [90], "text": ["obstructive sleep apnea"]}, {"answer_start": [90], "text": ["obstructive sleep apnea"]}, {"answer_start": [90], "text": ["obstructive sleep apnea"]}, {"answer_start": [90], "text": ["obstructive sleep apnea"]}, {"answer_start": [90], "text": ["obstructive sleep apnea"]}, {"answer_start": [90], "text": ["obstructive sleep apnea"]}, {"answer_start": [90], "text": ["obstructive sleep apnea"]}, {"answer_start": [90], "text": ["obstructive sleep apnea"]}, {"answer_start": [90], "text": ["obstructive sleep apnea"]}, {"answer_start": [90], "text": ["obstructive sleep apnea"]}, {"answer_start": [90], "text": ["obstructive sleep apnea"]}, {"answer_start": [90], "text": ["obstructive sleep apnea"]}, {"answer_start": [90], "text": ["obstructive sleep apnea"]}, {"answer_start": [90], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [96], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [84], "text": ["obstructive sleep apnea"]}, {"answer_start": [78], "text": ["obstructive sleep apnea"]}, {"answer_start": [78], "text": ["obstructive sleep apnea"]}, {"answer_start": [78], "text": ["obstructive sleep apnea"]}, {"answer_start": [78], "text": ["obstructive sleep apnea"]}, {"answer_start": [78], "text": ["obstructive sleep apnea"]}, {"answer_start": [78], "text": ["obstructive sleep apnea"]}, {"answer_start": [78], "text": ["obstructive sleep apnea"]}, {"answer_start": [78], "text": ["obstructive sleep apnea"]}, {"answer_start": [78], "text": ["obstructive sleep apnea"]}, {"answer_start": [78], "text": ["obstructive sleep apnea"]}, {"answer_start": [78], "text": ["obstructive sleep apnea"]}, {"answer_start": [78], "text": ["obstructive sleep apnea"]}, {"answer_start": [78], "text": ["obstructive sleep apnea"]}, {"answer_start": [78], "text": ["obstructive sleep apnea"]}, {"answer_start": [78], "text": ["obstructive sleep apnea"]}, {"answer_start": [78], "text": ["obstructive sleep apnea"]}, {"answer_start": [78], "text": ["obstructive sleep apnea"]}, {"answer_start": [78], "text": ["obstructive sleep apnea"]}, {"answer_start": [78], "text": ["obstructive sleep apnea"]}, {"answer_start": [78], "text": ["obstructive sleep apnea"]}, {"answer_start": [78], "text": ["obstructive sleep apnea"]}, {"answer_start": [78], "text": ["obstructive sleep apnea"]}, {"answer_start": [78], "text": ["obstructive sleep apnea"]}, {"answer_start": [78], "text": ["obstructive sleep apnea"]}, {"answer_start": [78], "text": ["obstructive sleep apnea"]}, {"answer_start": [78], "text": ["obstructive sleep apnea"]}, {"answer_start": [78], "text": ["obstructive sleep apnea"]}, {"answer_start": [382, 1914], "text": ["streptococcal pharyngitis", "streptococcal pharyngitis"]}, {"answer_start": [382, 1914], "text": ["streptococcal pharyngitis", "streptococcal pharyngitis"]}, {"answer_start": [382, 1914], "text": ["streptococcal pharyngitis", "streptococcal pharyngitis"]}, {"answer_start": [382, 1914], "text": ["streptococcal pharyngitis", "streptococcal pharyngitis"]}, {"answer_start": [382, 1914], "text": ["streptococcal pharyngitis", "streptococcal pharyngitis"]}, {"answer_start": [382, 1914], "text": ["streptococcal pharyngitis", "streptococcal pharyngitis"]}, {"answer_start": [382, 1914], "text": ["streptococcal pharyngitis", "streptococcal pharyngitis"]}, {"answer_start": [382, 1914], "text": ["streptococcal pharyngitis", "streptococcal pharyngitis"]}, {"answer_start": [382, 1914], "text": ["streptococcal pharyngitis", "streptococcal pharyngitis"]}, {"answer_start": [382, 1914], "text": ["streptococcal pharyngitis", "streptococcal pharyngitis"]}, {"answer_start": [382, 1914], "text": ["streptococcal pharyngitis", "streptococcal pharyngitis"]}, {"answer_start": [382, 1914], "text": ["streptococcal pharyngitis", "streptococcal pharyngitis"]}, {"answer_start": [382, 1914], "text": ["streptococcal pharyngitis", "streptococcal pharyngitis"]}, {"answer_start": [382, 1914], "text": ["streptococcal pharyngitis", "streptococcal pharyngitis"]}, {"answer_start": [382, 1914], "text": ["streptococcal pharyngitis", "streptococcal pharyngitis"]}, {"answer_start": [382, 1914], "text": ["streptococcal pharyngitis", "streptococcal pharyngitis"]}, {"answer_start": [382, 1914], "text": ["streptococcal pharyngitis", "streptococcal pharyngitis"]}, {"answer_start": [382, 1914], "text": ["streptococcal pharyngitis", "streptococcal pharyngitis"]}, {"answer_start": [382, 1914], "text": ["streptococcal pharyngitis", "streptococcal pharyngitis"]}, {"answer_start": [382, 1914], "text": ["streptococcal pharyngitis", "streptococcal pharyngitis"]}, {"answer_start": [382, 1914], "text": ["streptococcal pharyngitis", "streptococcal pharyngitis"]}, {"answer_start": [382, 1914], "text": ["streptococcal pharyngitis", "streptococcal pharyngitis"]}, {"answer_start": [382, 1914], "text": ["streptococcal pharyngitis", "streptococcal pharyngitis"]}, {"answer_start": [382, 1914], "text": ["streptococcal pharyngitis", "streptococcal pharyngitis"]}, {"answer_start": [382, 1914], "text": ["streptococcal pharyngitis", "streptococcal pharyngitis"]}, {"answer_start": [382, 1914], "text": ["streptococcal pharyngitis", "streptococcal pharyngitis"]}, {"answer_start": [382, 1914], "text": ["streptococcal pharyngitis", "streptococcal pharyngitis"]}, {"answer_start": [382, 1914], "text": ["streptococcal pharyngitis", "streptococcal pharyngitis"]}, {"answer_start": [382, 1914], "text": ["streptococcal pharyngitis", "streptococcal pharyngitis"]}, {"answer_start": [382, 1914], "text": ["streptococcal pharyngitis", "streptococcal pharyngitis"]}, {"answer_start": [382, 1914], "text": ["streptococcal pharyngitis", "streptococcal pharyngitis"]}, {"answer_start": [382, 1914], "text": ["streptococcal pharyngitis", "streptococcal pharyngitis"]}, {"answer_start": [382, 1914], "text": ["streptococcal pharyngitis", "streptococcal pharyngitis"]}, {"answer_start": [382, 1914], "text": ["streptococcal pharyngitis", "streptococcal pharyngitis"]}, {"answer_start": [382, 1914], "text": ["streptococcal pharyngitis", "streptococcal pharyngitis"]}, {"answer_start": [382, 1914], "text": ["streptococcal pharyngitis", "streptococcal pharyngitis"]}, {"answer_start": [382, 1914], "text": ["streptococcal pharyngitis", "streptococcal pharyngitis"]}, {"answer_start": [382, 1914], "text": ["streptococcal pharyngitis", "streptococcal pharyngitis"]}, {"answer_start": [382, 1914], "text": ["streptococcal pharyngitis", "streptococcal pharyngitis"]}, {"answer_start": [382, 1914], "text": ["streptococcal pharyngitis", "streptococcal pharyngitis"]}, {"answer_start": [382, 1914], "text": ["streptococcal pharyngitis", "streptococcal pharyngitis"]}, {"answer_start": [1220], "text": ["streptococcal pharyngitis"]}, {"answer_start": [1220], "text": ["streptococcal pharyngitis"]}, {"answer_start": [1220], "text": ["streptococcal pharyngitis"]}, {"answer_start": [1220], "text": ["streptococcal pharyngitis"]}, {"answer_start": [1220], "text": ["streptococcal pharyngitis"]}, {"answer_start": [1220], "text": ["streptococcal pharyngitis"]}, {"answer_start": [1220], "text": ["streptococcal pharyngitis"]}, {"answer_start": [1220], "text": ["streptococcal pharyngitis"]}, {"answer_start": [1220], "text": ["streptococcal pharyngitis"]}, {"answer_start": [1220], "text": ["streptococcal pharyngitis"]}, {"answer_start": [1220], "text": ["streptococcal pharyngitis"]}, {"answer_start": [1220], "text": ["streptococcal pharyngitis"]}, {"answer_start": [1220], "text": ["streptococcal pharyngitis"]}, {"answer_start": [1220], "text": ["streptococcal pharyngitis"]}, {"answer_start": [1220], "text": ["streptococcal pharyngitis"]}, {"answer_start": [1220], "text": ["streptococcal pharyngitis"]}, {"answer_start": [1220], "text": ["streptococcal pharyngitis"]}, {"answer_start": [1220], "text": ["streptococcal pharyngitis"]}, {"answer_start": [1220], "text": ["streptococcal pharyngitis"]}, {"answer_start": [1220], "text": ["streptococcal pharyngitis"]}, {"answer_start": [1220], "text": ["streptococcal pharyngitis"]}, {"answer_start": [1220], "text": ["streptococcal pharyngitis"]}, {"answer_start": [1220], "text": ["streptococcal pharyngitis"]}, {"answer_start": [1220], "text": ["streptococcal pharyngitis"]}, {"answer_start": [1220], "text": ["streptococcal pharyngitis"]}, {"answer_start": [1220], "text": ["streptococcal pharyngitis"]}, {"answer_start": [1220], "text": ["streptococcal pharyngitis"]}, {"answer_start": [1220], "text": ["streptococcal pharyngitis"]}, {"answer_start": [1220], "text": ["streptococcal pharyngitis"]}, {"answer_start": [1220], "text": ["streptococcal pharyngitis"]}, {"answer_start": [1220], "text": ["streptococcal pharyngitis"]}, {"answer_start": [1220], "text": ["streptococcal pharyngitis"]}, {"answer_start": [1220], "text": ["streptococcal pharyngitis"]}, {"answer_start": [1220], "text": ["streptococcal pharyngitis"]}, {"answer_start": [1220], "text": ["streptococcal pharyngitis"]}, {"answer_start": [1220], "text": ["streptococcal pharyngitis"]}, {"answer_start": [1220], "text": ["streptococcal pharyngitis"]}, {"answer_start": [1220], "text": ["streptococcal pharyngitis"]}, {"answer_start": [1220], "text": ["streptococcal pharyngitis"]}, {"answer_start": [1220], "text": ["streptococcal pharyngitis"]}, {"answer_start": [1220], "text": ["streptococcal pharyngitis"]}, {"answer_start": [406], "text": ["streptococcal pharyngitis"]}, {"answer_start": [406], "text": ["streptococcal pharyngitis"]}, {"answer_start": [406], "text": ["streptococcal pharyngitis"]}, {"answer_start": [406], "text": ["streptococcal pharyngitis"]}, {"answer_start": [406], "text": ["streptococcal pharyngitis"]}, {"answer_start": [406], "text": ["streptococcal pharyngitis"]}, {"answer_start": [406], "text": ["streptococcal pharyngitis"]}, {"answer_start": [406], "text": ["streptococcal pharyngitis"]}, {"answer_start": [406], "text": ["streptococcal pharyngitis"]}, {"answer_start": [406], "text": ["streptococcal pharyngitis"]}, {"answer_start": [406], "text": ["streptococcal pharyngitis"]}, {"answer_start": [406], "text": ["streptococcal pharyngitis"]}, {"answer_start": [406], "text": ["streptococcal pharyngitis"]}, {"answer_start": [406], "text": ["streptococcal pharyngitis"]}, {"answer_start": [406], "text": ["streptococcal pharyngitis"]}, {"answer_start": [406], "text": ["streptococcal pharyngitis"]}, {"answer_start": [406], "text": ["streptococcal pharyngitis"]}, {"answer_start": [406], "text": ["streptococcal pharyngitis"]}, {"answer_start": [406], "text": ["streptococcal pharyngitis"]}, {"answer_start": [406], "text": ["streptococcal pharyngitis"]}, {"answer_start": [406], "text": ["streptococcal pharyngitis"]}, {"answer_start": [406], "text": ["streptococcal pharyngitis"]}, {"answer_start": [406], "text": ["streptococcal pharyngitis"]}, {"answer_start": [406], "text": ["streptococcal pharyngitis"]}, {"answer_start": [406], "text": ["streptococcal pharyngitis"]}, {"answer_start": [406], "text": ["streptococcal pharyngitis"]}, {"answer_start": [406], "text": ["streptococcal pharyngitis"]}, {"answer_start": [406], "text": ["streptococcal pharyngitis"]}, {"answer_start": [406], "text": ["streptococcal pharyngitis"]}, {"answer_start": [406], "text": ["streptococcal pharyngitis"]}, {"answer_start": [406], "text": ["streptococcal pharyngitis"]}, {"answer_start": [406], "text": ["streptococcal pharyngitis"]}, {"answer_start": [406], "text": ["streptococcal pharyngitis"]}, {"answer_start": [406], "text": ["streptococcal pharyngitis"]}, {"answer_start": [406], "text": ["streptococcal pharyngitis"]}, {"answer_start": [406], "text": ["streptococcal pharyngitis"]}, {"answer_start": [406], "text": ["streptococcal pharyngitis"]}, {"answer_start": [406], "text": ["streptococcal pharyngitis"]}, {"answer_start": [406], "text": ["streptococcal pharyngitis"]}, {"answer_start": [406], "text": ["streptococcal pharyngitis"]}, {"answer_start": [406], "text": ["streptococcal pharyngitis"]}, {"answer_start": [57], "text": ["streptococcal pharyngitis"]}, {"answer_start": [57], "text": ["streptococcal pharyngitis"]}, {"answer_start": [57], "text": ["streptococcal pharyngitis"]}, {"answer_start": [57], "text": ["streptococcal pharyngitis"]}, {"answer_start": [57], "text": ["streptococcal pharyngitis"]}, {"answer_start": [57], "text": ["streptococcal pharyngitis"]}, {"answer_start": [57], "text": ["streptococcal pharyngitis"]}, {"answer_start": [57], "text": ["streptococcal pharyngitis"]}, {"answer_start": [57], "text": ["streptococcal pharyngitis"]}, {"answer_start": [57], "text": ["streptococcal pharyngitis"]}, {"answer_start": [57], "text": ["streptococcal pharyngitis"]}, {"answer_start": [57], "text": ["streptococcal pharyngitis"]}, {"answer_start": [57], "text": ["streptococcal pharyngitis"]}, {"answer_start": [57], "text": ["streptococcal pharyngitis"]}, {"answer_start": [57], "text": ["streptococcal pharyngitis"]}, {"answer_start": [57], "text": ["streptococcal pharyngitis"]}, {"answer_start": [57], "text": ["streptococcal pharyngitis"]}, {"answer_start": [57], "text": ["streptococcal pharyngitis"]}, {"answer_start": [57], "text": ["streptococcal pharyngitis"]}, {"answer_start": [57], "text": ["streptococcal pharyngitis"]}, {"answer_start": [57], "text": ["streptococcal pharyngitis"]}, {"answer_start": [57], "text": ["streptococcal pharyngitis"]}, {"answer_start": [57], "text": ["streptococcal pharyngitis"]}, {"answer_start": [57], "text": ["streptococcal pharyngitis"]}, {"answer_start": [57], "text": ["streptococcal pharyngitis"]}, {"answer_start": [57], "text": ["streptococcal pharyngitis"]}, {"answer_start": [57], "text": ["streptococcal pharyngitis"]}, {"answer_start": [57], "text": ["streptococcal pharyngitis"]}, {"answer_start": [57], "text": ["streptococcal pharyngitis"]}, {"answer_start": [57], "text": ["streptococcal pharyngitis"]}, {"answer_start": [57], "text": ["streptococcal pharyngitis"]}, {"answer_start": [57], "text": ["streptococcal pharyngitis"]}, {"answer_start": [57], "text": ["streptococcal pharyngitis"]}, {"answer_start": [57], "text": ["streptococcal pharyngitis"]}, {"answer_start": [57], "text": ["streptococcal pharyngitis"]}, {"answer_start": [57], "text": ["streptococcal pharyngitis"]}, {"answer_start": [57], "text": ["streptococcal pharyngitis"]}, {"answer_start": [57], "text": ["streptococcal pharyngitis"]}, {"answer_start": [57], "text": ["streptococcal pharyngitis"]}, {"answer_start": [57], "text": ["streptococcal pharyngitis"]}, {"answer_start": [57], "text": ["streptococcal pharyngitis"]}, {"answer_start": [59], "text": ["streptococcal pharyngitis"]}, {"answer_start": [59], "text": ["streptococcal pharyngitis"]}, {"answer_start": [59], "text": ["streptococcal pharyngitis"]}, {"answer_start": [59], "text": ["streptococcal pharyngitis"]}, {"answer_start": [59], "text": ["streptococcal pharyngitis"]}, {"answer_start": [59], "text": ["streptococcal pharyngitis"]}, {"answer_start": [59], "text": ["streptococcal pharyngitis"]}, {"answer_start": [59], "text": ["streptococcal pharyngitis"]}, {"answer_start": [59], "text": ["streptococcal pharyngitis"]}, {"answer_start": [59], "text": ["streptococcal pharyngitis"]}, {"answer_start": [59], "text": ["streptococcal pharyngitis"]}, {"answer_start": [59], "text": ["streptococcal pharyngitis"]}, {"answer_start": [59], "text": ["streptococcal pharyngitis"]}, {"answer_start": [59], "text": ["streptococcal pharyngitis"]}, {"answer_start": [59], "text": ["streptococcal pharyngitis"]}, {"answer_start": [59], "text": ["streptococcal pharyngitis"]}, {"answer_start": [59], "text": ["streptococcal pharyngitis"]}, {"answer_start": [59], "text": ["streptococcal pharyngitis"]}, {"answer_start": [59], "text": ["streptococcal pharyngitis"]}, {"answer_start": [59], "text": ["streptococcal pharyngitis"]}, {"answer_start": [59], "text": ["streptococcal pharyngitis"]}, {"answer_start": [59], "text": ["streptococcal pharyngitis"]}, {"answer_start": [59], "text": ["streptococcal pharyngitis"]}, {"answer_start": [59], "text": ["streptococcal pharyngitis"]}, {"answer_start": [59], "text": ["streptococcal pharyngitis"]}, {"answer_start": [59], "text": ["streptococcal pharyngitis"]}, {"answer_start": [59], "text": ["streptococcal pharyngitis"]}, {"answer_start": [59], "text": ["streptococcal pharyngitis"]}, {"answer_start": [59], "text": ["streptococcal pharyngitis"]}, {"answer_start": [59], "text": ["streptococcal pharyngitis"]}, {"answer_start": [59], "text": ["streptococcal pharyngitis"]}, {"answer_start": [59], "text": ["streptococcal pharyngitis"]}, {"answer_start": [59], "text": ["streptococcal pharyngitis"]}, {"answer_start": [59], "text": ["streptococcal pharyngitis"]}, {"answer_start": [59], "text": ["streptococcal pharyngitis"]}, {"answer_start": [59], "text": ["streptococcal pharyngitis"]}, {"answer_start": [59], "text": ["streptococcal pharyngitis"]}, {"answer_start": [59], "text": ["streptococcal pharyngitis"]}, {"answer_start": [59], "text": ["streptococcal pharyngitis"]}, {"answer_start": [59], "text": ["streptococcal pharyngitis"]}, {"answer_start": [59], "text": ["streptococcal pharyngitis"]}, {"answer_start": [152], "text": ["streptococcal pharyngitis"]}, {"answer_start": [152], "text": ["streptococcal pharyngitis"]}, {"answer_start": [152], "text": ["streptococcal pharyngitis"]}, {"answer_start": [152], "text": ["streptococcal pharyngitis"]}, {"answer_start": [152], "text": ["streptococcal pharyngitis"]}, {"answer_start": [152], "text": ["streptococcal pharyngitis"]}, {"answer_start": [152], "text": ["streptococcal pharyngitis"]}, {"answer_start": [152], "text": ["streptococcal pharyngitis"]}, {"answer_start": [152], "text": ["streptococcal pharyngitis"]}, {"answer_start": [152], "text": ["streptococcal pharyngitis"]}, {"answer_start": [152], "text": ["streptococcal pharyngitis"]}, {"answer_start": [152], "text": ["streptococcal pharyngitis"]}, {"answer_start": [152], "text": ["streptococcal pharyngitis"]}, {"answer_start": [152], "text": ["streptococcal pharyngitis"]}, {"answer_start": [152], "text": ["streptococcal pharyngitis"]}, {"answer_start": [152], "text": ["streptococcal pharyngitis"]}, {"answer_start": [152], "text": ["streptococcal pharyngitis"]}, {"answer_start": [152], "text": ["streptococcal pharyngitis"]}, {"answer_start": [152], "text": ["streptococcal pharyngitis"]}, {"answer_start": [152], "text": ["streptococcal pharyngitis"]}, {"answer_start": [152], "text": ["streptococcal pharyngitis"]}, {"answer_start": [152], "text": ["streptococcal pharyngitis"]}, {"answer_start": [152], "text": ["streptococcal pharyngitis"]}, {"answer_start": [152], "text": ["streptococcal pharyngitis"]}, {"answer_start": [152], "text": ["streptococcal pharyngitis"]}, {"answer_start": [152], "text": ["streptococcal pharyngitis"]}, {"answer_start": [152], "text": ["streptococcal pharyngitis"]}, {"answer_start": [152], "text": ["streptococcal pharyngitis"]}, {"answer_start": [152], "text": ["streptococcal pharyngitis"]}, {"answer_start": [152], "text": ["streptococcal pharyngitis"]}, {"answer_start": [152], "text": ["streptococcal pharyngitis"]}, {"answer_start": [152], "text": ["streptococcal pharyngitis"]}, {"answer_start": [152], "text": ["streptococcal pharyngitis"]}, {"answer_start": [152], "text": ["streptococcal pharyngitis"]}, {"answer_start": [152], "text": ["streptococcal pharyngitis"]}, {"answer_start": [152], "text": ["streptococcal pharyngitis"]}, {"answer_start": [152], "text": ["streptococcal pharyngitis"]}, {"answer_start": [152], "text": ["streptococcal pharyngitis"]}, {"answer_start": [152], "text": ["streptococcal pharyngitis"]}, {"answer_start": [152], "text": ["streptococcal pharyngitis"]}, {"answer_start": [152], "text": ["streptococcal pharyngitis"]}, {"answer_start": [110], "text": ["streptococcal pharyngitis"]}, {"answer_start": [110], "text": ["streptococcal pharyngitis"]}, {"answer_start": [110], "text": ["streptococcal pharyngitis"]}, {"answer_start": [110], "text": ["streptococcal pharyngitis"]}, {"answer_start": [110], "text": ["streptococcal pharyngitis"]}, {"answer_start": [110], "text": ["streptococcal pharyngitis"]}, {"answer_start": [110], "text": ["streptococcal pharyngitis"]}, {"answer_start": [110], "text": ["streptococcal pharyngitis"]}, {"answer_start": [110], "text": ["streptococcal pharyngitis"]}, {"answer_start": [110], "text": ["streptococcal pharyngitis"]}, {"answer_start": [110], "text": ["streptococcal pharyngitis"]}, {"answer_start": [110], "text": ["streptococcal pharyngitis"]}, {"answer_start": [110], "text": ["streptococcal pharyngitis"]}, {"answer_start": [110], "text": ["streptococcal pharyngitis"]}, {"answer_start": [110], "text": ["streptococcal pharyngitis"]}, {"answer_start": [110], "text": ["streptococcal pharyngitis"]}, {"answer_start": [110], "text": ["streptococcal pharyngitis"]}, {"answer_start": [110], "text": ["streptococcal pharyngitis"]}, {"answer_start": [110], "text": ["streptococcal pharyngitis"]}, {"answer_start": [110], "text": ["streptococcal pharyngitis"]}, {"answer_start": [110], "text": ["streptococcal pharyngitis"]}, {"answer_start": [110], "text": ["streptococcal pharyngitis"]}, {"answer_start": [110], "text": ["streptococcal pharyngitis"]}, {"answer_start": [110], "text": ["streptococcal pharyngitis"]}, {"answer_start": [110], "text": ["streptococcal pharyngitis"]}, {"answer_start": [110], "text": ["streptococcal pharyngitis"]}, {"answer_start": [110], "text": ["streptococcal pharyngitis"]}, {"answer_start": [110], "text": ["streptococcal pharyngitis"]}, {"answer_start": [110], "text": ["streptococcal pharyngitis"]}, {"answer_start": [110], "text": ["streptococcal pharyngitis"]}, {"answer_start": [110], "text": ["streptococcal pharyngitis"]}, {"answer_start": [110], "text": ["streptococcal pharyngitis"]}, {"answer_start": [110], "text": ["streptococcal pharyngitis"]}, {"answer_start": [110], "text": ["streptococcal pharyngitis"]}, {"answer_start": [110], "text": ["streptococcal pharyngitis"]}, {"answer_start": [110], "text": ["streptococcal pharyngitis"]}, {"answer_start": [110], "text": ["streptococcal pharyngitis"]}, {"answer_start": [110], "text": ["streptococcal pharyngitis"]}, {"answer_start": [110], "text": ["streptococcal pharyngitis"]}, {"answer_start": [110], "text": ["streptococcal pharyngitis"]}, {"answer_start": [110], "text": ["streptococcal pharyngitis"]}, {"answer_start": [140], "text": ["streptococcal pharyngitis"]}, {"answer_start": [140], "text": ["streptococcal pharyngitis"]}, {"answer_start": [140], "text": ["streptococcal pharyngitis"]}, {"answer_start": [140], "text": ["streptococcal pharyngitis"]}, {"answer_start": [140], "text": ["streptococcal pharyngitis"]}, {"answer_start": [140], "text": ["streptococcal pharyngitis"]}, {"answer_start": [140], "text": ["streptococcal pharyngitis"]}, {"answer_start": [140], "text": ["streptococcal pharyngitis"]}, {"answer_start": [140], "text": ["streptococcal pharyngitis"]}, {"answer_start": [140], "text": ["streptococcal pharyngitis"]}, {"answer_start": [140], "text": ["streptococcal pharyngitis"]}, {"answer_start": [140], "text": ["streptococcal pharyngitis"]}, {"answer_start": [140], "text": ["streptococcal pharyngitis"]}, {"answer_start": [140], "text": ["streptococcal pharyngitis"]}, {"answer_start": [140], "text": ["streptococcal pharyngitis"]}, {"answer_start": [140], "text": ["streptococcal pharyngitis"]}, {"answer_start": [140], "text": ["streptococcal pharyngitis"]}, {"answer_start": [140], "text": ["streptococcal pharyngitis"]}, {"answer_start": [140], "text": ["streptococcal pharyngitis"]}, {"answer_start": [140], "text": ["streptococcal pharyngitis"]}, {"answer_start": [140], "text": ["streptococcal pharyngitis"]}, {"answer_start": [140], "text": ["streptococcal pharyngitis"]}, {"answer_start": [140], "text": ["streptococcal pharyngitis"]}, {"answer_start": [140], "text": ["streptococcal pharyngitis"]}, {"answer_start": [140], "text": ["streptococcal pharyngitis"]}, {"answer_start": [140], "text": ["streptococcal pharyngitis"]}, {"answer_start": [140], "text": ["streptococcal pharyngitis"]}, {"answer_start": [140], "text": ["streptococcal pharyngitis"]}, {"answer_start": [140], "text": ["streptococcal pharyngitis"]}, {"answer_start": [140], "text": ["streptococcal pharyngitis"]}, {"answer_start": [140], "text": ["streptococcal pharyngitis"]}, {"answer_start": [140], "text": ["streptococcal pharyngitis"]}, {"answer_start": [140], "text": ["streptococcal pharyngitis"]}, {"answer_start": [140], "text": ["streptococcal pharyngitis"]}, {"answer_start": [140], "text": ["streptococcal pharyngitis"]}, {"answer_start": [140], "text": ["streptococcal pharyngitis"]}, {"answer_start": [140], "text": ["streptococcal pharyngitis"]}, {"answer_start": [140], "text": ["streptococcal pharyngitis"]}, {"answer_start": [140], "text": ["streptococcal pharyngitis"]}, {"answer_start": [140], "text": ["streptococcal pharyngitis"]}, {"answer_start": [140], "text": ["streptococcal pharyngitis"]}, {"answer_start": [132], "text": ["streptococcal pharyngitis"]}, {"answer_start": [132], "text": ["streptococcal pharyngitis"]}, {"answer_start": [132], "text": ["streptococcal pharyngitis"]}, {"answer_start": [132], "text": ["streptococcal pharyngitis"]}, {"answer_start": [132], "text": ["streptococcal pharyngitis"]}, {"answer_start": [132], "text": ["streptococcal pharyngitis"]}, {"answer_start": [132], "text": ["streptococcal pharyngitis"]}, {"answer_start": [132], "text": ["streptococcal pharyngitis"]}, {"answer_start": [132], "text": ["streptococcal pharyngitis"]}, {"answer_start": [132], "text": ["streptococcal pharyngitis"]}, {"answer_start": [132], "text": ["streptococcal pharyngitis"]}, {"answer_start": [132], "text": ["streptococcal pharyngitis"]}, {"answer_start": [132], "text": ["streptococcal pharyngitis"]}, {"answer_start": [132], "text": ["streptococcal pharyngitis"]}, {"answer_start": [132], "text": ["streptococcal pharyngitis"]}, {"answer_start": [132], "text": ["streptococcal pharyngitis"]}, {"answer_start": [132], "text": ["streptococcal pharyngitis"]}, {"answer_start": [132], "text": ["streptococcal pharyngitis"]}, {"answer_start": [132], "text": ["streptococcal pharyngitis"]}, {"answer_start": [132], "text": ["streptococcal pharyngitis"]}, {"answer_start": [132], "text": ["streptococcal pharyngitis"]}, {"answer_start": [132], "text": ["streptococcal pharyngitis"]}, {"answer_start": [132], "text": ["streptococcal pharyngitis"]}, {"answer_start": [132], "text": ["streptococcal pharyngitis"]}, {"answer_start": [132], "text": ["streptococcal pharyngitis"]}, {"answer_start": [132], "text": ["streptococcal pharyngitis"]}, {"answer_start": [132], "text": ["streptococcal pharyngitis"]}, {"answer_start": [132], "text": ["streptococcal pharyngitis"]}, {"answer_start": [132], "text": ["streptococcal pharyngitis"]}, {"answer_start": [132], "text": ["streptococcal pharyngitis"]}, {"answer_start": [132], "text": ["streptococcal pharyngitis"]}, {"answer_start": [132], "text": ["streptococcal pharyngitis"]}, {"answer_start": [132], "text": ["streptococcal pharyngitis"]}, {"answer_start": [132], "text": ["streptococcal pharyngitis"]}, {"answer_start": [132], "text": ["streptococcal pharyngitis"]}, {"answer_start": [132], "text": ["streptococcal pharyngitis"]}, {"answer_start": [132], "text": ["streptococcal pharyngitis"]}, {"answer_start": [132], "text": ["streptococcal pharyngitis"]}, {"answer_start": [132], "text": ["streptococcal pharyngitis"]}, {"answer_start": [132], "text": ["streptococcal pharyngitis"]}, {"answer_start": [132], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [32], "text": ["streptococcal pharyngitis"]}, {"answer_start": [30, 212], "text": ["pneumoperitoneum", "pneumoperitoneum"]}, {"answer_start": [30, 212], "text": ["pneumoperitoneum", "pneumoperitoneum"]}, {"answer_start": [30, 212], "text": ["pneumoperitoneum", "pneumoperitoneum"]}, {"answer_start": [30, 212], "text": ["pneumoperitoneum", "pneumoperitoneum"]}, {"answer_start": [30, 212], "text": ["pneumoperitoneum", "pneumoperitoneum"]}, {"answer_start": [30, 212], "text": ["pneumoperitoneum", "pneumoperitoneum"]}, {"answer_start": [30, 212], "text": ["pneumoperitoneum", "pneumoperitoneum"]}, {"answer_start": [30, 212], "text": ["pneumoperitoneum", "pneumoperitoneum"]}, {"answer_start": [30, 212], "text": ["pneumoperitoneum", "pneumoperitoneum"]}, {"answer_start": [30, 212], "text": ["pneumoperitoneum", "pneumoperitoneum"]}, {"answer_start": [30, 212], "text": ["pneumoperitoneum", "pneumoperitoneum"]}, {"answer_start": [30, 212], "text": ["pneumoperitoneum", "pneumoperitoneum"]}, {"answer_start": [30, 212], "text": ["pneumoperitoneum", "pneumoperitoneum"]}, {"answer_start": [30, 212], "text": ["pneumoperitoneum", "pneumoperitoneum"]}, {"answer_start": [30, 212], "text": ["pneumoperitoneum", "pneumoperitoneum"]}, {"answer_start": [30, 212], "text": ["pneumoperitoneum", "pneumoperitoneum"]}, {"answer_start": [30, 212], "text": ["pneumoperitoneum", "pneumoperitoneum"]}, {"answer_start": [30, 212], "text": ["pneumoperitoneum", "pneumoperitoneum"]}, {"answer_start": [30, 212], "text": ["pneumoperitoneum", "pneumoperitoneum"]}, {"answer_start": [30, 212], "text": ["pneumoperitoneum", "pneumoperitoneum"]}, {"answer_start": [30, 212], "text": ["pneumoperitoneum", "pneumoperitoneum"]}, {"answer_start": [30, 212], "text": ["pneumoperitoneum", "pneumoperitoneum"]}, {"answer_start": [30, 212], "text": ["pneumoperitoneum", "pneumoperitoneum"]}, {"answer_start": [30, 212], "text": ["pneumoperitoneum", "pneumoperitoneum"]}, {"answer_start": [30, 212], "text": ["pneumoperitoneum", "pneumoperitoneum"]}, {"answer_start": [30, 212], "text": ["pneumoperitoneum", "pneumoperitoneum"]}, {"answer_start": [30, 212], "text": ["pneumoperitoneum", "pneumoperitoneum"]}, {"answer_start": [30, 212], "text": ["pneumoperitoneum", "pneumoperitoneum"]}, {"answer_start": [30, 212], "text": ["pneumoperitoneum", "pneumoperitoneum"]}, {"answer_start": [30, 212], "text": ["pneumoperitoneum", "pneumoperitoneum"]}, {"answer_start": [30, 212], "text": ["pneumoperitoneum", "pneumoperitoneum"]}, {"answer_start": [30, 212], "text": ["pneumoperitoneum", "pneumoperitoneum"]}, {"answer_start": [30, 212], "text": ["pneumoperitoneum", "pneumoperitoneum"]}, {"answer_start": [30, 212], "text": ["pneumoperitoneum", "pneumoperitoneum"]}, {"answer_start": [30, 212], "text": ["pneumoperitoneum", "pneumoperitoneum"]}, {"answer_start": [30, 212], "text": ["pneumoperitoneum", "pneumoperitoneum"]}, {"answer_start": [30, 212], "text": ["pneumoperitoneum", "pneumoperitoneum"]}, {"answer_start": [30, 212], "text": ["pneumoperitoneum", "pneumoperitoneum"]}, {"answer_start": [30, 212], "text": ["pneumoperitoneum", "pneumoperitoneum"]}, {"answer_start": [30, 212], "text": ["pneumoperitoneum", "pneumoperitoneum"]}, {"answer_start": [30, 212], "text": ["pneumoperitoneum", "pneumoperitoneum"]}, {"answer_start": [30, 212], "text": ["pneumoperitoneum", "pneumoperitoneum"]}, {"answer_start": [30, 212], "text": ["pneumoperitoneum", "pneumoperitoneum"]}, {"answer_start": [30, 212], "text": ["pneumoperitoneum", "pneumoperitoneum"]}, {"answer_start": [30, 212], "text": ["pneumoperitoneum", "pneumoperitoneum"]}, {"answer_start": [30, 212], "text": ["pneumoperitoneum", "pneumoperitoneum"]}, {"answer_start": [30, 212], "text": ["pneumoperitoneum", "pneumoperitoneum"]}, {"answer_start": [30, 212], "text": ["pneumoperitoneum", "pneumoperitoneum"]}, {"answer_start": [30, 212], "text": ["pneumoperitoneum", "pneumoperitoneum"]}, {"answer_start": [176], "text": ["pneumoperitoneum"]}, {"answer_start": [176], "text": ["pneumoperitoneum"]}, {"answer_start": [176], "text": ["pneumoperitoneum"]}, {"answer_start": [176], "text": ["pneumoperitoneum"]}, {"answer_start": [176], "text": ["pneumoperitoneum"]}, {"answer_start": [176], "text": ["pneumoperitoneum"]}, {"answer_start": [176], "text": ["pneumoperitoneum"]}, {"answer_start": [176], "text": ["pneumoperitoneum"]}, {"answer_start": [176], "text": ["pneumoperitoneum"]}, {"answer_start": [176], "text": ["pneumoperitoneum"]}, {"answer_start": [176], "text": ["pneumoperitoneum"]}, {"answer_start": [176], "text": ["pneumoperitoneum"]}, {"answer_start": [176], "text": ["pneumoperitoneum"]}, {"answer_start": [176], "text": ["pneumoperitoneum"]}, {"answer_start": [176], "text": ["pneumoperitoneum"]}, {"answer_start": [176], "text": ["pneumoperitoneum"]}, {"answer_start": [176], "text": ["pneumoperitoneum"]}, {"answer_start": [176], "text": ["pneumoperitoneum"]}, {"answer_start": [176], "text": ["pneumoperitoneum"]}, {"answer_start": [176], "text": ["pneumoperitoneum"]}, {"answer_start": [176], "text": ["pneumoperitoneum"]}, {"answer_start": [176], "text": ["pneumoperitoneum"]}, {"answer_start": [176], "text": ["pneumoperitoneum"]}, {"answer_start": [176], "text": ["pneumoperitoneum"]}, {"answer_start": [176], "text": ["pneumoperitoneum"]}, {"answer_start": [176], "text": ["pneumoperitoneum"]}, {"answer_start": [176], "text": ["pneumoperitoneum"]}, {"answer_start": [176], "text": ["pneumoperitoneum"]}, {"answer_start": [176], "text": ["pneumoperitoneum"]}, {"answer_start": [176], "text": ["pneumoperitoneum"]}, {"answer_start": [176], "text": ["pneumoperitoneum"]}, {"answer_start": [176], "text": ["pneumoperitoneum"]}, {"answer_start": [176], "text": ["pneumoperitoneum"]}, {"answer_start": [176], "text": ["pneumoperitoneum"]}, {"answer_start": [176], "text": ["pneumoperitoneum"]}, {"answer_start": [176], "text": ["pneumoperitoneum"]}, {"answer_start": [176], "text": ["pneumoperitoneum"]}, {"answer_start": [176], "text": ["pneumoperitoneum"]}, {"answer_start": [176], "text": ["pneumoperitoneum"]}, {"answer_start": [176], "text": ["pneumoperitoneum"]}, {"answer_start": [176], "text": ["pneumoperitoneum"]}, {"answer_start": [176], "text": ["pneumoperitoneum"]}, {"answer_start": [176], "text": ["pneumoperitoneum"]}, {"answer_start": [176], "text": ["pneumoperitoneum"]}, {"answer_start": [176], "text": ["pneumoperitoneum"]}, {"answer_start": [176], "text": ["pneumoperitoneum"]}, {"answer_start": [176], "text": ["pneumoperitoneum"]}, {"answer_start": [176], "text": ["pneumoperitoneum"]}, {"answer_start": [176], "text": ["pneumoperitoneum"]}, {"answer_start": [70], "text": ["cancer"]}, {"answer_start": [70], "text": ["cancer"]}, {"answer_start": [70], "text": ["cancer"]}, {"answer_start": [70], "text": ["cancer"]}, {"answer_start": [70], "text": ["cancer"]}, {"answer_start": [70], "text": ["cancer"]}, {"answer_start": [70], "text": ["cancer"]}, {"answer_start": [70], "text": ["cancer"]}, {"answer_start": [70], "text": ["cancer"]}, {"answer_start": [70], "text": ["cancer"]}, {"answer_start": [70], "text": ["cancer"]}, {"answer_start": [70], "text": ["cancer"]}, {"answer_start": [70], "text": ["cancer"]}, {"answer_start": [70], "text": ["cancer"]}, {"answer_start": [70], "text": ["cancer"]}, {"answer_start": [70], "text": ["cancer"]}, {"answer_start": [70], "text": ["cancer"]}, {"answer_start": [206], "text": ["cancer"]}, {"answer_start": [206], "text": ["cancer"]}, {"answer_start": [206], "text": ["cancer"]}, {"answer_start": [206], "text": ["cancer"]}, {"answer_start": [206], "text": ["cancer"]}, {"answer_start": [206], "text": ["cancer"]}, {"answer_start": [206], "text": ["cancer"]}, {"answer_start": [206], "text": ["cancer"]}, {"answer_start": [206], "text": ["cancer"]}, {"answer_start": [206], "text": ["cancer"]}, {"answer_start": [206], "text": ["cancer"]}, {"answer_start": [206], "text": ["cancer"]}, {"answer_start": [206], "text": ["cancer"]}, {"answer_start": [206], "text": ["cancer"]}, {"answer_start": [206], "text": ["cancer"]}, {"answer_start": [206], "text": ["cancer"]}, {"answer_start": [206], "text": ["cancer"]}, {"answer_start": [161], "text": ["cancer"]}, {"answer_start": [161], "text": ["cancer"]}, {"answer_start": [161], "text": ["cancer"]}, {"answer_start": [161], "text": ["cancer"]}, {"answer_start": [161], "text": ["cancer"]}, {"answer_start": [161], "text": ["cancer"]}, {"answer_start": [161], "text": ["cancer"]}, {"answer_start": [161], "text": ["cancer"]}, {"answer_start": [161], "text": ["cancer"]}, {"answer_start": [161], "text": ["cancer"]}, {"answer_start": [161], "text": ["cancer"]}, {"answer_start": [161], "text": ["cancer"]}, {"answer_start": [161], "text": ["cancer"]}, {"answer_start": [161], "text": ["cancer"]}, {"answer_start": [161], "text": ["cancer"]}, {"answer_start": [161], "text": ["cancer"]}, {"answer_start": [161], "text": ["cancer"]}, {"answer_start": [223], "text": ["cancer"]}, {"answer_start": [223], "text": ["cancer"]}, {"answer_start": [223], "text": ["cancer"]}, {"answer_start": [223], "text": ["cancer"]}, {"answer_start": [223], "text": ["cancer"]}, {"answer_start": [223], "text": ["cancer"]}, {"answer_start": [223], "text": ["cancer"]}, {"answer_start": [223], "text": ["cancer"]}, {"answer_start": [223], "text": ["cancer"]}, {"answer_start": [223], "text": ["cancer"]}, {"answer_start": [223], "text": ["cancer"]}, {"answer_start": [223], "text": ["cancer"]}, {"answer_start": [223], "text": ["cancer"]}, {"answer_start": [223], "text": ["cancer"]}, {"answer_start": [223], "text": ["cancer"]}, {"answer_start": [223], "text": ["cancer"]}, {"answer_start": [223], "text": ["cancer"]}, {"answer_start": [120, 217], "text": ["cancer", "cancer"]}, {"answer_start": [120, 217], "text": ["cancer", "cancer"]}, {"answer_start": [120, 217], "text": ["cancer", "cancer"]}, {"answer_start": [120, 217], "text": ["cancer", "cancer"]}, {"answer_start": [120, 217], "text": ["cancer", "cancer"]}, {"answer_start": [120, 217], "text": ["cancer", "cancer"]}, {"answer_start": [120, 217], "text": ["cancer", "cancer"]}, {"answer_start": [120, 217], "text": ["cancer", "cancer"]}, {"answer_start": [120, 217], "text": ["cancer", "cancer"]}, {"answer_start": [120, 217], "text": ["cancer", "cancer"]}, {"answer_start": [120, 217], "text": ["cancer", "cancer"]}, {"answer_start": [120, 217], "text": ["cancer", "cancer"]}, {"answer_start": [120, 217], "text": ["cancer", "cancer"]}, {"answer_start": [120, 217], "text": ["cancer", "cancer"]}, {"answer_start": [120, 217], "text": ["cancer", "cancer"]}, {"answer_start": [120, 217], "text": ["cancer", "cancer"]}, {"answer_start": [120, 217], "text": ["cancer", "cancer"]}, {"answer_start": [180], "text": ["cancer"]}, {"answer_start": [180], "text": ["cancer"]}, {"answer_start": [180], "text": ["cancer"]}, {"answer_start": [180], "text": ["cancer"]}, {"answer_start": [180], "text": ["cancer"]}, {"answer_start": [180], "text": ["cancer"]}, {"answer_start": [180], "text": ["cancer"]}, {"answer_start": [180], "text": ["cancer"]}, {"answer_start": [180], "text": ["cancer"]}, {"answer_start": [180], "text": ["cancer"]}, {"answer_start": [180], "text": ["cancer"]}, {"answer_start": [180], "text": ["cancer"]}, {"answer_start": [180], "text": ["cancer"]}, {"answer_start": [180], "text": ["cancer"]}, {"answer_start": [180], "text": ["cancer"]}, {"answer_start": [180], "text": ["cancer"]}, {"answer_start": [180], "text": ["cancer"]}, {"answer_start": [139], "text": ["cancer"]}, {"answer_start": [139], "text": ["cancer"]}, {"answer_start": [139], "text": ["cancer"]}, {"answer_start": [139], "text": ["cancer"]}, {"answer_start": [139], "text": ["cancer"]}, {"answer_start": [139], "text": ["cancer"]}, {"answer_start": [139], "text": ["cancer"]}, {"answer_start": [139], "text": ["cancer"]}, {"answer_start": [139], "text": ["cancer"]}, {"answer_start": [139], "text": ["cancer"]}, {"answer_start": [139], "text": ["cancer"]}, {"answer_start": [139], "text": ["cancer"]}, {"answer_start": [139], "text": ["cancer"]}, {"answer_start": [139], "text": ["cancer"]}, {"answer_start": [139], "text": ["cancer"]}, {"answer_start": [139], "text": ["cancer"]}, {"answer_start": [139], "text": ["cancer"]}, {"answer_start": [34], "text": ["cancer"]}, {"answer_start": [34], "text": ["cancer"]}, {"answer_start": [34], "text": ["cancer"]}, {"answer_start": [34], "text": ["cancer"]}, {"answer_start": [34], "text": ["cancer"]}, {"answer_start": [34], "text": ["cancer"]}, {"answer_start": [34], "text": ["cancer"]}, {"answer_start": [34], "text": ["cancer"]}, {"answer_start": [34], "text": ["cancer"]}, {"answer_start": [34], "text": ["cancer"]}, {"answer_start": [34], "text": ["cancer"]}, {"answer_start": [34], "text": ["cancer"]}, {"answer_start": [34], "text": ["cancer"]}, {"answer_start": [34], "text": ["cancer"]}, {"answer_start": [34], "text": ["cancer"]}, {"answer_start": [34], "text": ["cancer"]}, {"answer_start": [34], "text": ["cancer"]}, {"answer_start": [147], "text": ["cancer"]}, {"answer_start": [147], "text": ["cancer"]}, {"answer_start": [147], "text": ["cancer"]}, {"answer_start": [147], "text": ["cancer"]}, {"answer_start": [147], "text": ["cancer"]}, {"answer_start": [147], "text": ["cancer"]}, {"answer_start": [147], "text": ["cancer"]}, {"answer_start": [147], "text": ["cancer"]}, {"answer_start": [147], "text": ["cancer"]}, {"answer_start": [147], "text": ["cancer"]}, {"answer_start": [147], "text": ["cancer"]}, {"answer_start": [147], "text": ["cancer"]}, {"answer_start": [147], "text": ["cancer"]}, {"answer_start": [147], "text": ["cancer"]}, {"answer_start": [147], "text": ["cancer"]}, {"answer_start": [147], "text": ["cancer"]}, {"answer_start": [147], "text": ["cancer"]}, {"answer_start": [132], "text": ["cancer"]}, {"answer_start": [132], "text": ["cancer"]}, {"answer_start": [132], "text": ["cancer"]}, {"answer_start": [132], "text": ["cancer"]}, {"answer_start": [132], "text": ["cancer"]}, {"answer_start": [132], "text": ["cancer"]}, {"answer_start": [132], "text": ["cancer"]}, {"answer_start": [132], "text": ["cancer"]}, {"answer_start": [132], "text": ["cancer"]}, {"answer_start": [132], "text": ["cancer"]}, {"answer_start": [132], "text": ["cancer"]}, {"answer_start": [132], "text": ["cancer"]}, {"answer_start": [132], "text": ["cancer"]}, {"answer_start": [132], "text": ["cancer"]}, {"answer_start": [132], "text": ["cancer"]}, {"answer_start": [132], "text": ["cancer"]}, {"answer_start": [132], "text": ["cancer"]}, {"answer_start": [142], "text": ["cancer"]}, {"answer_start": [142], "text": ["cancer"]}, {"answer_start": [142], "text": ["cancer"]}, {"answer_start": [142], "text": ["cancer"]}, {"answer_start": [142], "text": ["cancer"]}, {"answer_start": [142], "text": ["cancer"]}, {"answer_start": [142], "text": ["cancer"]}, {"answer_start": [142], "text": ["cancer"]}, {"answer_start": [142], "text": ["cancer"]}, {"answer_start": [142], "text": ["cancer"]}, {"answer_start": [142], "text": ["cancer"]}, {"answer_start": [142], "text": ["cancer"]}, {"answer_start": [142], "text": ["cancer"]}, {"answer_start": [142], "text": ["cancer"]}, {"answer_start": [142], "text": ["cancer"]}, {"answer_start": [142], "text": ["cancer"]}, {"answer_start": [142], "text": ["cancer"]}, {"answer_start": [62], "text": ["cancer"]}, {"answer_start": [62], "text": ["cancer"]}, {"answer_start": [62], "text": ["cancer"]}, {"answer_start": [62], "text": ["cancer"]}, {"answer_start": [62], "text": ["cancer"]}, {"answer_start": [62], "text": ["cancer"]}, {"answer_start": [62], "text": ["cancer"]}, {"answer_start": [62], "text": ["cancer"]}, {"answer_start": [62], "text": ["cancer"]}, {"answer_start": [62], "text": ["cancer"]}, {"answer_start": [62], "text": ["cancer"]}, {"answer_start": [62], "text": ["cancer"]}, {"answer_start": [62], "text": ["cancer"]}, {"answer_start": [62], "text": ["cancer"]}, {"answer_start": [62], "text": ["cancer"]}, {"answer_start": [62], "text": ["cancer"]}, {"answer_start": [62], "text": ["cancer"]}, {"answer_start": [103], "text": ["cancer"]}, {"answer_start": [103], "text": ["cancer"]}, {"answer_start": [103], "text": ["cancer"]}, {"answer_start": [103], "text": ["cancer"]}, {"answer_start": [103], "text": ["cancer"]}, {"answer_start": [103], "text": ["cancer"]}, {"answer_start": [103], "text": ["cancer"]}, {"answer_start": [103], "text": ["cancer"]}, {"answer_start": [103], "text": ["cancer"]}, {"answer_start": [103], "text": ["cancer"]}, {"answer_start": [103], "text": ["cancer"]}, {"answer_start": [103], "text": ["cancer"]}, {"answer_start": [103], "text": ["cancer"]}, {"answer_start": [103], "text": ["cancer"]}, {"answer_start": [103], "text": ["cancer"]}, {"answer_start": [103], "text": ["cancer"]}, {"answer_start": [103], "text": ["cancer"]}, {"answer_start": [25], "text": ["cancer"]}, {"answer_start": [25], "text": ["cancer"]}, {"answer_start": [25], "text": ["cancer"]}, {"answer_start": [25], "text": ["cancer"]}, {"answer_start": [25], "text": ["cancer"]}, {"answer_start": [25], "text": ["cancer"]}, {"answer_start": [25], "text": ["cancer"]}, {"answer_start": [25], "text": ["cancer"]}, {"answer_start": [25], "text": ["cancer"]}, {"answer_start": [25], "text": ["cancer"]}, {"answer_start": [25], "text": ["cancer"]}, {"answer_start": [25], "text": ["cancer"]}, {"answer_start": [25], "text": ["cancer"]}, {"answer_start": [25], "text": ["cancer"]}, {"answer_start": [25], "text": ["cancer"]}, {"answer_start": [25], "text": ["cancer"]}, {"answer_start": [25], "text": ["cancer"]}, {"answer_start": [52], "text": ["cancer"]}, {"answer_start": [52], "text": ["cancer"]}, {"answer_start": [52], "text": ["cancer"]}, {"answer_start": [52], "text": ["cancer"]}, {"answer_start": [52], "text": ["cancer"]}, {"answer_start": [52], "text": ["cancer"]}, {"answer_start": [52], "text": ["cancer"]}, {"answer_start": [52], "text": ["cancer"]}, {"answer_start": [52], "text": ["cancer"]}, {"answer_start": [52], "text": ["cancer"]}, {"answer_start": [52], "text": ["cancer"]}, {"answer_start": [52], "text": ["cancer"]}, {"answer_start": [52], "text": ["cancer"]}, {"answer_start": [52], "text": ["cancer"]}, {"answer_start": [52], "text": ["cancer"]}, {"answer_start": [52], "text": ["cancer"]}, {"answer_start": [52], "text": ["cancer"]}, {"answer_start": [70], "text": ["cancer"]}, {"answer_start": [70], "text": ["cancer"]}, {"answer_start": [70], "text": ["cancer"]}, {"answer_start": [70], "text": ["cancer"]}, {"answer_start": [70], "text": ["cancer"]}, {"answer_start": [70], "text": ["cancer"]}, {"answer_start": [70], "text": ["cancer"]}, {"answer_start": [70], "text": ["cancer"]}, {"answer_start": [70], "text": ["cancer"]}, {"answer_start": [70], "text": ["cancer"]}, {"answer_start": [70], "text": ["cancer"]}, {"answer_start": [70], "text": ["cancer"]}, {"answer_start": [70], "text": ["cancer"]}, {"answer_start": [70], "text": ["cancer"]}, {"answer_start": [70], "text": ["cancer"]}, {"answer_start": [70], "text": ["cancer"]}, {"answer_start": [70], "text": ["cancer"]}, {"answer_start": [47], "text": ["cancer"]}, {"answer_start": [47], "text": ["cancer"]}, {"answer_start": [47], "text": ["cancer"]}, {"answer_start": [47], "text": ["cancer"]}, {"answer_start": [47], "text": ["cancer"]}, {"answer_start": [47], "text": ["cancer"]}, {"answer_start": [47], "text": ["cancer"]}, {"answer_start": [47], "text": ["cancer"]}, {"answer_start": [47], "text": ["cancer"]}, {"answer_start": [47], "text": ["cancer"]}, {"answer_start": [47], "text": ["cancer"]}, {"answer_start": [47], "text": ["cancer"]}, {"answer_start": [47], "text": ["cancer"]}, {"answer_start": [47], "text": ["cancer"]}, {"answer_start": [47], "text": ["cancer"]}, {"answer_start": [47], "text": ["cancer"]}, {"answer_start": [47], "text": ["cancer"]}, {"answer_start": [15], "text": ["pneumonia"]}, {"answer_start": [15], "text": ["pneumonia"]}, {"answer_start": [15], "text": ["pneumonia"]}, {"answer_start": [15], "text": ["pneumonia"]}, {"answer_start": [15], "text": ["pneumonia"]}, {"answer_start": [15], "text": ["pneumonia"]}, {"answer_start": [15], "text": ["pneumonia"]}, {"answer_start": [15], "text": ["pneumonia"]}, {"answer_start": [15], "text": ["pneumonia"]}, {"answer_start": [15], "text": ["pneumonia"]}, {"answer_start": [15], "text": ["pneumonia"]}, {"answer_start": [15], "text": ["pneumonia"]}, {"answer_start": [15], "text": ["pneumonia"]}, {"answer_start": [15], "text": ["pneumonia"]}, {"answer_start": [15], "text": ["pneumonia"]}, {"answer_start": [15], "text": ["pneumonia"]}, {"answer_start": [15], "text": ["pneumonia"]}, {"answer_start": [15], "text": ["pneumonia"]}, {"answer_start": [15], "text": ["pneumonia"]}, {"answer_start": [15], "text": ["pneumonia"]}, {"answer_start": [15], "text": ["pneumonia"]}, {"answer_start": [15], "text": ["pneumonia"]}, {"answer_start": [15], "text": ["pneumonia"]}, {"answer_start": [15], "text": ["pneumonia"]}, {"answer_start": [15], "text": ["pneumonia"]}, {"answer_start": [15], "text": ["pneumonia"]}, {"answer_start": [15], "text": ["pneumonia"]}, {"answer_start": [15], "text": ["pneumonia"]}, {"answer_start": [15], "text": ["pneumonia"]}, {"answer_start": [15], "text": ["pneumonia"]}, {"answer_start": [15], "text": ["pneumonia"]}, {"answer_start": [15], "text": ["pneumonia"]}, {"answer_start": [15], "text": ["pneumonia"]}, {"answer_start": [15], "text": ["pneumonia"]}, {"answer_start": [15], "text": ["pneumonia"]}, {"answer_start": [116], "text": ["pneumonia"]}, {"answer_start": [116], "text": ["pneumonia"]}, {"answer_start": [116], "text": ["pneumonia"]}, {"answer_start": [116], "text": ["pneumonia"]}, {"answer_start": [116], "text": ["pneumonia"]}, {"answer_start": [116], "text": ["pneumonia"]}, {"answer_start": [116], "text": ["pneumonia"]}, {"answer_start": [116], "text": ["pneumonia"]}, {"answer_start": [116], "text": ["pneumonia"]}, {"answer_start": [116], "text": ["pneumonia"]}, {"answer_start": [116], "text": ["pneumonia"]}, {"answer_start": [116], "text": ["pneumonia"]}, {"answer_start": [116], "text": ["pneumonia"]}, {"answer_start": [116], "text": ["pneumonia"]}, {"answer_start": [116], "text": ["pneumonia"]}, {"answer_start": [116], "text": ["pneumonia"]}, {"answer_start": [116], "text": ["pneumonia"]}, {"answer_start": [116], "text": ["pneumonia"]}, {"answer_start": [116], "text": ["pneumonia"]}, {"answer_start": [116], "text": ["pneumonia"]}, {"answer_start": [116], "text": ["pneumonia"]}, {"answer_start": [116], "text": ["pneumonia"]}, {"answer_start": [116], "text": ["pneumonia"]}, {"answer_start": [116], "text": ["pneumonia"]}, {"answer_start": [116], "text": ["pneumonia"]}, {"answer_start": [116], "text": ["pneumonia"]}, {"answer_start": [116], "text": ["pneumonia"]}, {"answer_start": [116], "text": ["pneumonia"]}, {"answer_start": [116], "text": ["pneumonia"]}, {"answer_start": [116], "text": ["pneumonia"]}, {"answer_start": [116], "text": ["pneumonia"]}, {"answer_start": [116], "text": ["pneumonia"]}, {"answer_start": [116], "text": ["pneumonia"]}, {"answer_start": [116], "text": ["pneumonia"]}, {"answer_start": [116], "text": ["pneumonia"]}, {"answer_start": [29], "text": ["pneumonia"]}, {"answer_start": [29], "text": ["pneumonia"]}, {"answer_start": [29], "text": ["pneumonia"]}, {"answer_start": [29], "text": ["pneumonia"]}, {"answer_start": [29], "text": ["pneumonia"]}, {"answer_start": [29], "text": ["pneumonia"]}, {"answer_start": [29], "text": ["pneumonia"]}, {"answer_start": [29], "text": ["pneumonia"]}, {"answer_start": [29], "text": ["pneumonia"]}, {"answer_start": [29], "text": ["pneumonia"]}, {"answer_start": [29], "text": ["pneumonia"]}, {"answer_start": [29], "text": ["pneumonia"]}, {"answer_start": [29], "text": ["pneumonia"]}, {"answer_start": [29], "text": ["pneumonia"]}, {"answer_start": [29], "text": ["pneumonia"]}, {"answer_start": [29], "text": ["pneumonia"]}, {"answer_start": [29], "text": ["pneumonia"]}, {"answer_start": [29], "text": ["pneumonia"]}, {"answer_start": [29], "text": ["pneumonia"]}, {"answer_start": [29], "text": ["pneumonia"]}, {"answer_start": [29], "text": ["pneumonia"]}, {"answer_start": [29], "text": ["pneumonia"]}, {"answer_start": [29], "text": ["pneumonia"]}, {"answer_start": [29], "text": ["pneumonia"]}, {"answer_start": [29], "text": ["pneumonia"]}, {"answer_start": [29], "text": ["pneumonia"]}, {"answer_start": [29], "text": ["pneumonia"]}, {"answer_start": [29], "text": ["pneumonia"]}, {"answer_start": [29], "text": ["pneumonia"]}, {"answer_start": [29], "text": ["pneumonia"]}, {"answer_start": [29], "text": ["pneumonia"]}, {"answer_start": [29], "text": ["pneumonia"]}, {"answer_start": [29], "text": ["pneumonia"]}, {"answer_start": [29], "text": ["pneumonia"]}, {"answer_start": [29], "text": ["pneumonia"]}, {"answer_start": [84], "text": ["pneumonia"]}, {"answer_start": [84], "text": ["pneumonia"]}, {"answer_start": [84], "text": ["pneumonia"]}, {"answer_start": [84], "text": ["pneumonia"]}, {"answer_start": [84], "text": ["pneumonia"]}, {"answer_start": [84], "text": ["pneumonia"]}, {"answer_start": [84], "text": ["pneumonia"]}, {"answer_start": [84], "text": ["pneumonia"]}, {"answer_start": [84], "text": ["pneumonia"]}, {"answer_start": [84], "text": ["pneumonia"]}, {"answer_start": [84], "text": ["pneumonia"]}, {"answer_start": [84], "text": ["pneumonia"]}, {"answer_start": [84], "text": ["pneumonia"]}, {"answer_start": [84], "text": ["pneumonia"]}, {"answer_start": [84], "text": ["pneumonia"]}, {"answer_start": [84], "text": ["pneumonia"]}, {"answer_start": [84], "text": ["pneumonia"]}, {"answer_start": [84], "text": ["pneumonia"]}, {"answer_start": [84], "text": ["pneumonia"]}, {"answer_start": [84], "text": ["pneumonia"]}, {"answer_start": [84], "text": ["pneumonia"]}, {"answer_start": [84], "text": ["pneumonia"]}, {"answer_start": [84], "text": ["pneumonia"]}, {"answer_start": [84], "text": ["pneumonia"]}, {"answer_start": [84], "text": ["pneumonia"]}, {"answer_start": [84], "text": ["pneumonia"]}, {"answer_start": [84], "text": ["pneumonia"]}, {"answer_start": [84], "text": ["pneumonia"]}, {"answer_start": [84], "text": ["pneumonia"]}, {"answer_start": [84], "text": ["pneumonia"]}, {"answer_start": [84], "text": ["pneumonia"]}, {"answer_start": [84], "text": ["pneumonia"]}, {"answer_start": [84], "text": ["pneumonia"]}, {"answer_start": [84], "text": ["pneumonia"]}, {"answer_start": [84], "text": ["pneumonia"]}, {"answer_start": [123], "text": ["pneumonia"]}, {"answer_start": [123], "text": ["pneumonia"]}, {"answer_start": [123], "text": ["pneumonia"]}, {"answer_start": [123], "text": ["pneumonia"]}, {"answer_start": [123], "text": ["pneumonia"]}, {"answer_start": [123], "text": ["pneumonia"]}, {"answer_start": [123], "text": ["pneumonia"]}, {"answer_start": [123], "text": ["pneumonia"]}, {"answer_start": [123], "text": ["pneumonia"]}, {"answer_start": [123], "text": ["pneumonia"]}, {"answer_start": [123], "text": ["pneumonia"]}, {"answer_start": [123], "text": ["pneumonia"]}, {"answer_start": [123], "text": ["pneumonia"]}, {"answer_start": [123], "text": ["pneumonia"]}, {"answer_start": [123], "text": ["pneumonia"]}, {"answer_start": [123], "text": ["pneumonia"]}, {"answer_start": [123], "text": ["pneumonia"]}, {"answer_start": [123], "text": ["pneumonia"]}, {"answer_start": [123], "text": ["pneumonia"]}, {"answer_start": [123], "text": ["pneumonia"]}, {"answer_start": [123], "text": ["pneumonia"]}, {"answer_start": [123], "text": ["pneumonia"]}, {"answer_start": [123], "text": ["pneumonia"]}, {"answer_start": [123], "text": ["pneumonia"]}, {"answer_start": [123], "text": ["pneumonia"]}, {"answer_start": [123], "text": ["pneumonia"]}, {"answer_start": [123], "text": ["pneumonia"]}, {"answer_start": [123], "text": ["pneumonia"]}, {"answer_start": [123], "text": ["pneumonia"]}, {"answer_start": [123], "text": ["pneumonia"]}, {"answer_start": [123], "text": ["pneumonia"]}, {"answer_start": [123], "text": ["pneumonia"]}, {"answer_start": [123], "text": ["pneumonia"]}, {"answer_start": [123], "text": ["pneumonia"]}, {"answer_start": [123], "text": ["pneumonia"]}, {"answer_start": [11, 134], "text": ["pneumonia", "pneumonia"]}, {"answer_start": [11, 134], "text": ["pneumonia", "pneumonia"]}, {"answer_start": [11, 134], "text": ["pneumonia", "pneumonia"]}, {"answer_start": [11, 134], "text": ["pneumonia", "pneumonia"]}, {"answer_start": [11, 134], "text": ["pneumonia", "pneumonia"]}, {"answer_start": [11, 134], "text": ["pneumonia", "pneumonia"]}, {"answer_start": [11, 134], "text": ["pneumonia", "pneumonia"]}, {"answer_start": [11, 134], "text": ["pneumonia", "pneumonia"]}, {"answer_start": [11, 134], "text": ["pneumonia", "pneumonia"]}, {"answer_start": [11, 134], "text": ["pneumonia", "pneumonia"]}, {"answer_start": [11, 134], "text": ["pneumonia", "pneumonia"]}, {"answer_start": [11, 134], "text": ["pneumonia", "pneumonia"]}, {"answer_start": [11, 134], "text": ["pneumonia", "pneumonia"]}, {"answer_start": [11, 134], "text": ["pneumonia", "pneumonia"]}, {"answer_start": [11, 134], "text": ["pneumonia", "pneumonia"]}, {"answer_start": [11, 134], "text": ["pneumonia", "pneumonia"]}, {"answer_start": [11, 134], "text": ["pneumonia", "pneumonia"]}, {"answer_start": [11, 134], "text": ["pneumonia", "pneumonia"]}, {"answer_start": [11, 134], "text": ["pneumonia", "pneumonia"]}, {"answer_start": [11, 134], "text": ["pneumonia", "pneumonia"]}, {"answer_start": [11, 134], "text": ["pneumonia", "pneumonia"]}, {"answer_start": [11, 134], "text": ["pneumonia", "pneumonia"]}, {"answer_start": [11, 134], "text": ["pneumonia", "pneumonia"]}, {"answer_start": [11, 134], "text": ["pneumonia", "pneumonia"]}, {"answer_start": [11, 134], "text": ["pneumonia", "pneumonia"]}, {"answer_start": [11, 134], "text": ["pneumonia", "pneumonia"]}, {"answer_start": [11, 134], "text": ["pneumonia", "pneumonia"]}, {"answer_start": [11, 134], "text": ["pneumonia", "pneumonia"]}, {"answer_start": [11, 134], "text": ["pneumonia", "pneumonia"]}, {"answer_start": [11, 134], "text": ["pneumonia", "pneumonia"]}, {"answer_start": [11, 134], "text": ["pneumonia", "pneumonia"]}, {"answer_start": [11, 134], "text": ["pneumonia", "pneumonia"]}, {"answer_start": [11, 134], "text": ["pneumonia", "pneumonia"]}, {"answer_start": [11, 134], "text": ["pneumonia", "pneumonia"]}, {"answer_start": [11, 134], "text": ["pneumonia", "pneumonia"]}, {"answer_start": [79], "text": ["pneumonia"]}, {"answer_start": [79], "text": ["pneumonia"]}, {"answer_start": [79], "text": ["pneumonia"]}, {"answer_start": [79], "text": ["pneumonia"]}, {"answer_start": [79], "text": ["pneumonia"]}, {"answer_start": [79], "text": ["pneumonia"]}, {"answer_start": [79], "text": ["pneumonia"]}, {"answer_start": [79], "text": ["pneumonia"]}, {"answer_start": [79], "text": ["pneumonia"]}, {"answer_start": [79], "text": ["pneumonia"]}, {"answer_start": [79], "text": ["pneumonia"]}, {"answer_start": [79], "text": ["pneumonia"]}, {"answer_start": [79], "text": ["pneumonia"]}, {"answer_start": [79], "text": ["pneumonia"]}, {"answer_start": [79], "text": ["pneumonia"]}, {"answer_start": [79], "text": ["pneumonia"]}, {"answer_start": [79], "text": ["pneumonia"]}, {"answer_start": [79], "text": ["pneumonia"]}, {"answer_start": [79], "text": ["pneumonia"]}, {"answer_start": [79], "text": ["pneumonia"]}, {"answer_start": [79], "text": ["pneumonia"]}, {"answer_start": [79], "text": ["pneumonia"]}, {"answer_start": [79], "text": ["pneumonia"]}, {"answer_start": [79], "text": ["pneumonia"]}, {"answer_start": [79], "text": ["pneumonia"]}, {"answer_start": [79], "text": ["pneumonia"]}, {"answer_start": [79], "text": ["pneumonia"]}, {"answer_start": [79], "text": ["pneumonia"]}, {"answer_start": [79], "text": ["pneumonia"]}, {"answer_start": [79], "text": ["pneumonia"]}, {"answer_start": [79], "text": ["pneumonia"]}, {"answer_start": [79], "text": ["pneumonia"]}, {"answer_start": [79], "text": ["pneumonia"]}, {"answer_start": [79], "text": ["pneumonia"]}, {"answer_start": [79], "text": ["pneumonia"]}, {"answer_start": [0], "text": ["borderline personality disorder"]}, {"answer_start": [0], "text": ["borderline personality disorder"]}, {"answer_start": [0], "text": ["borderline personality disorder"]}, {"answer_start": [0], "text": ["borderline personality disorder"]}, {"answer_start": [0], "text": ["borderline personality disorder"]}, {"answer_start": [0], "text": ["borderline personality disorder"]}, {"answer_start": [0], "text": ["borderline personality disorder"]}, {"answer_start": [0], "text": ["borderline personality disorder"]}, {"answer_start": [0], "text": ["borderline personality disorder"]}, {"answer_start": [0], "text": ["borderline personality disorder"]}, {"answer_start": [0], "text": ["borderline personality disorder"]}, {"answer_start": [0], "text": ["borderline personality disorder"]}, {"answer_start": [0], "text": ["borderline personality disorder"]}, {"answer_start": [0], "text": ["borderline personality disorder"]}, {"answer_start": [0], "text": ["borderline personality disorder"]}, {"answer_start": [0], "text": ["borderline personality disorder"]}, {"answer_start": [0], "text": ["borderline personality disorder"]}, {"answer_start": [0], "text": ["borderline personality disorder"]}, {"answer_start": [106], "text": ["borderline personality disorder"]}, {"answer_start": [106], "text": ["borderline personality disorder"]}, {"answer_start": [106], "text": ["borderline personality disorder"]}, {"answer_start": [106], "text": ["borderline personality disorder"]}, {"answer_start": [106], "text": ["borderline personality disorder"]}, {"answer_start": [106], "text": ["borderline personality disorder"]}, {"answer_start": [106], "text": ["borderline personality disorder"]}, {"answer_start": [106], "text": ["borderline personality disorder"]}, {"answer_start": [106], "text": ["borderline personality disorder"]}, {"answer_start": [106], "text": ["borderline personality disorder"]}, {"answer_start": [106], "text": ["borderline personality disorder"]}, {"answer_start": [106], "text": ["borderline personality disorder"]}, {"answer_start": [106], "text": ["borderline personality disorder"]}, {"answer_start": [106], "text": ["borderline personality disorder"]}, {"answer_start": [106], "text": ["borderline personality disorder"]}, {"answer_start": [106], "text": ["borderline personality disorder"]}, {"answer_start": [106], "text": ["borderline personality disorder"]}, {"answer_start": [106], "text": ["borderline personality disorder"]}, {"answer_start": [44, 221], "text": ["borderline personality disorder", "borderline personality disorder"]}, {"answer_start": [44, 221], "text": ["borderline personality disorder", "borderline personality disorder"]}, {"answer_start": [44, 221], "text": ["borderline personality disorder", "borderline personality disorder"]}, {"answer_start": [44, 221], "text": ["borderline personality disorder", "borderline personality disorder"]}, {"answer_start": [44, 221], "text": ["borderline personality disorder", "borderline personality disorder"]}, {"answer_start": [44, 221], "text": ["borderline personality disorder", "borderline personality disorder"]}, {"answer_start": [44, 221], "text": ["borderline personality disorder", "borderline personality disorder"]}, {"answer_start": [44, 221], "text": ["borderline personality disorder", "borderline personality disorder"]}, {"answer_start": [44, 221], "text": ["borderline personality disorder", "borderline personality disorder"]}, {"answer_start": [44, 221], "text": ["borderline personality disorder", "borderline personality disorder"]}, {"answer_start": [44, 221], "text": ["borderline personality disorder", "borderline personality disorder"]}, {"answer_start": [44, 221], "text": ["borderline personality disorder", "borderline personality disorder"]}, {"answer_start": [44, 221], "text": ["borderline personality disorder", "borderline personality disorder"]}, {"answer_start": [44, 221], "text": ["borderline personality disorder", "borderline personality disorder"]}, {"answer_start": [44, 221], "text": ["borderline personality disorder", "borderline personality disorder"]}, {"answer_start": [44, 221], "text": ["borderline personality disorder", "borderline personality disorder"]}, {"answer_start": [44, 221], "text": ["borderline personality disorder", "borderline personality disorder"]}, {"answer_start": [44, 221], "text": ["borderline personality disorder", "borderline personality disorder"]}, {"answer_start": [89], "text": ["borderline personality disorder"]}, {"answer_start": [89], "text": ["borderline personality disorder"]}, {"answer_start": [89], "text": ["borderline personality disorder"]}, {"answer_start": [89], "text": ["borderline personality disorder"]}, {"answer_start": [89], "text": ["borderline personality disorder"]}, {"answer_start": [89], "text": ["borderline personality disorder"]}, {"answer_start": [89], "text": ["borderline personality disorder"]}, {"answer_start": [89], "text": ["borderline personality disorder"]}, {"answer_start": [89], "text": ["borderline personality disorder"]}, {"answer_start": [89], "text": ["borderline personality disorder"]}, {"answer_start": [89], "text": ["borderline personality disorder"]}, {"answer_start": [89], "text": ["borderline personality disorder"]}, {"answer_start": [89], "text": ["borderline personality disorder"]}, {"answer_start": [89], "text": ["borderline personality disorder"]}, {"answer_start": [89], "text": ["borderline personality disorder"]}, {"answer_start": [89], "text": ["borderline personality disorder"]}, {"answer_start": [89], "text": ["borderline personality disorder"]}, {"answer_start": [89], "text": ["borderline personality disorder"]}, {"answer_start": [145], "text": ["borderline personality disorder"]}, {"answer_start": [145], "text": ["borderline personality disorder"]}, {"answer_start": [145], "text": ["borderline personality disorder"]}, {"answer_start": [145], "text": ["borderline personality disorder"]}, {"answer_start": [145], "text": ["borderline personality disorder"]}, {"answer_start": [145], "text": ["borderline personality disorder"]}, {"answer_start": [145], "text": ["borderline personality disorder"]}, {"answer_start": [145], "text": ["borderline personality disorder"]}, {"answer_start": [145], "text": ["borderline personality disorder"]}, {"answer_start": [145], "text": ["borderline personality disorder"]}, {"answer_start": [145], "text": ["borderline personality disorder"]}, {"answer_start": [145], "text": ["borderline personality disorder"]}, {"answer_start": [145], "text": ["borderline personality disorder"]}, {"answer_start": [145], "text": ["borderline personality disorder"]}, {"answer_start": [145], "text": ["borderline personality disorder"]}, {"answer_start": [145], "text": ["borderline personality disorder"]}, {"answer_start": [145], "text": ["borderline personality disorder"]}, {"answer_start": [145], "text": ["borderline personality disorder"]}, {"answer_start": [79], "text": ["borderline personality disorder"]}, {"answer_start": [79], "text": ["borderline personality disorder"]}, {"answer_start": [79], "text": ["borderline personality disorder"]}, {"answer_start": [79], "text": ["borderline personality disorder"]}, {"answer_start": [79], "text": ["borderline personality disorder"]}, {"answer_start": [79], "text": ["borderline personality disorder"]}, {"answer_start": [79], "text": ["borderline personality disorder"]}, {"answer_start": [79], "text": ["borderline personality disorder"]}, {"answer_start": [79], "text": ["borderline personality disorder"]}, {"answer_start": [79], "text": ["borderline personality disorder"]}, {"answer_start": [79], "text": ["borderline personality disorder"]}, {"answer_start": [79], "text": ["borderline personality disorder"]}, {"answer_start": [79], "text": ["borderline personality disorder"]}, {"answer_start": [79], "text": ["borderline personality disorder"]}, {"answer_start": [79], "text": ["borderline personality disorder"]}, {"answer_start": [79], "text": ["borderline personality disorder"]}, {"answer_start": [79], "text": ["borderline personality disorder"]}, {"answer_start": [79], "text": ["borderline personality disorder"]}, {"answer_start": [192], "text": ["borderline personality disorder"]}, {"answer_start": [192], "text": ["borderline personality disorder"]}, {"answer_start": [192], "text": ["borderline personality disorder"]}, {"answer_start": [192], "text": ["borderline personality disorder"]}, {"answer_start": [192], "text": ["borderline personality disorder"]}, {"answer_start": [192], "text": ["borderline personality disorder"]}, {"answer_start": [192], "text": ["borderline personality disorder"]}, {"answer_start": [192], "text": ["borderline personality disorder"]}, {"answer_start": [192], "text": ["borderline personality disorder"]}, {"answer_start": [192], "text": ["borderline personality disorder"]}, {"answer_start": [192], "text": ["borderline personality disorder"]}, {"answer_start": [192], "text": ["borderline personality disorder"]}, {"answer_start": [192], "text": ["borderline personality disorder"]}, {"answer_start": [192], "text": ["borderline personality disorder"]}, {"answer_start": [192], "text": ["borderline personality disorder"]}, {"answer_start": [192], "text": ["borderline personality disorder"]}, {"answer_start": [192], "text": ["borderline personality disorder"]}, {"answer_start": [192], "text": ["borderline personality disorder"]}, {"answer_start": [144], "text": ["borderline personality disorder"]}, {"answer_start": [144], "text": ["borderline personality disorder"]}, {"answer_start": [144], "text": ["borderline personality disorder"]}, {"answer_start": [144], "text": ["borderline personality disorder"]}, {"answer_start": [144], "text": ["borderline personality disorder"]}, {"answer_start": [144], "text": ["borderline personality disorder"]}, {"answer_start": [144], "text": ["borderline personality disorder"]}, {"answer_start": [144], "text": ["borderline personality disorder"]}, {"answer_start": [144], "text": ["borderline personality disorder"]}, {"answer_start": [144], "text": ["borderline personality disorder"]}, {"answer_start": [144], "text": ["borderline personality disorder"]}, {"answer_start": [144], "text": ["borderline personality disorder"]}, {"answer_start": [144], "text": ["borderline personality disorder"]}, {"answer_start": [144], "text": ["borderline personality disorder"]}, {"answer_start": [144], "text": ["borderline personality disorder"]}, {"answer_start": [144], "text": ["borderline personality disorder"]}, {"answer_start": [144], "text": ["borderline personality disorder"]}, {"answer_start": [144], "text": ["borderline personality disorder"]}, {"answer_start": [103], "text": ["borderline personality disorder"]}, {"answer_start": [103], "text": ["borderline personality disorder"]}, {"answer_start": [103], "text": ["borderline personality disorder"]}, {"answer_start": [103], "text": ["borderline personality disorder"]}, {"answer_start": [103], "text": ["borderline personality disorder"]}, {"answer_start": [103], "text": ["borderline personality disorder"]}, {"answer_start": [103], "text": ["borderline personality disorder"]}, {"answer_start": [103], "text": ["borderline personality disorder"]}, {"answer_start": [103], "text": ["borderline personality disorder"]}, {"answer_start": [103], "text": ["borderline personality disorder"]}, {"answer_start": [103], "text": ["borderline personality disorder"]}, {"answer_start": [103], "text": ["borderline personality disorder"]}, {"answer_start": [103], "text": ["borderline personality disorder"]}, {"answer_start": [103], "text": ["borderline personality disorder"]}, {"answer_start": [103], "text": ["borderline personality disorder"]}, {"answer_start": [103], "text": ["borderline personality disorder"]}, {"answer_start": [103], "text": ["borderline personality disorder"]}, {"answer_start": [103], "text": ["borderline personality disorder"]}, {"answer_start": [41], "text": ["borderline personality disorder"]}, {"answer_start": [41], "text": ["borderline personality disorder"]}, {"answer_start": [41], "text": ["borderline personality disorder"]}, {"answer_start": [41], "text": ["borderline personality disorder"]}, {"answer_start": [41], "text": ["borderline personality disorder"]}, {"answer_start": [41], "text": ["borderline personality disorder"]}, {"answer_start": [41], "text": ["borderline personality disorder"]}, {"answer_start": [41], "text": ["borderline personality disorder"]}, {"answer_start": [41], "text": ["borderline personality disorder"]}, {"answer_start": [41], "text": ["borderline personality disorder"]}, {"answer_start": [41], "text": ["borderline personality disorder"]}, {"answer_start": [41], "text": ["borderline personality disorder"]}, {"answer_start": [41], "text": ["borderline personality disorder"]}, {"answer_start": [41], "text": ["borderline personality disorder"]}, {"answer_start": [41], "text": ["borderline personality disorder"]}, {"answer_start": [41], "text": ["borderline personality disorder"]}, {"answer_start": [41], "text": ["borderline personality disorder"]}, {"answer_start": [41], "text": ["borderline personality disorder"]}, {"answer_start": [64], "text": ["borderline personality disorder"]}, {"answer_start": [64], "text": ["borderline personality disorder"]}, {"answer_start": [64], "text": ["borderline personality disorder"]}, {"answer_start": [64], "text": ["borderline personality disorder"]}, {"answer_start": [64], "text": ["borderline personality disorder"]}, {"answer_start": [64], "text": ["borderline personality disorder"]}, {"answer_start": [64], "text": ["borderline personality disorder"]}, {"answer_start": [64], "text": ["borderline personality disorder"]}, {"answer_start": [64], "text": ["borderline personality disorder"]}, {"answer_start": [64], "text": ["borderline personality disorder"]}, {"answer_start": [64], "text": ["borderline personality disorder"]}, {"answer_start": [64], "text": ["borderline personality disorder"]}, {"answer_start": [64], "text": ["borderline personality disorder"]}, {"answer_start": [64], "text": ["borderline personality disorder"]}, {"answer_start": [64], "text": ["borderline personality disorder"]}, {"answer_start": [64], "text": ["borderline personality disorder"]}, {"answer_start": [64], "text": ["borderline personality disorder"]}, {"answer_start": [64], "text": ["borderline personality disorder"]}, {"answer_start": [109], "text": ["borderline personality disorder"]}, {"answer_start": [109], "text": ["borderline personality disorder"]}, {"answer_start": [109], "text": ["borderline personality disorder"]}, {"answer_start": [109], "text": ["borderline personality disorder"]}, {"answer_start": [109], "text": ["borderline personality disorder"]}, {"answer_start": [109], "text": ["borderline personality disorder"]}, {"answer_start": [109], "text": ["borderline personality disorder"]}, {"answer_start": [109], "text": ["borderline personality disorder"]}, {"answer_start": [109], "text": ["borderline personality disorder"]}, {"answer_start": [109], "text": ["borderline personality disorder"]}, {"answer_start": [109], "text": ["borderline personality disorder"]}, {"answer_start": [109], "text": ["borderline personality disorder"]}, {"answer_start": [109], "text": ["borderline personality disorder"]}, {"answer_start": [109], "text": ["borderline personality disorder"]}, {"answer_start": [109], "text": ["borderline personality disorder"]}, {"answer_start": [109], "text": ["borderline personality disorder"]}, {"answer_start": [109], "text": ["borderline personality disorder"]}, {"answer_start": [109], "text": ["borderline personality disorder"]}, {"answer_start": [139], "text": ["borderline personality disorder"]}, {"answer_start": [139], "text": ["borderline personality disorder"]}, {"answer_start": [139], "text": ["borderline personality disorder"]}, {"answer_start": [139], "text": ["borderline personality disorder"]}, {"answer_start": [139], "text": ["borderline personality disorder"]}, {"answer_start": [139], "text": ["borderline personality disorder"]}, {"answer_start": [139], "text": ["borderline personality disorder"]}, {"answer_start": [139], "text": ["borderline personality disorder"]}, {"answer_start": [139], "text": ["borderline personality disorder"]}, {"answer_start": [139], "text": ["borderline personality disorder"]}, {"answer_start": [139], "text": ["borderline personality disorder"]}, {"answer_start": [139], "text": ["borderline personality disorder"]}, {"answer_start": [139], "text": ["borderline personality disorder"]}, {"answer_start": [139], "text": ["borderline personality disorder"]}, {"answer_start": [139], "text": ["borderline personality disorder"]}, {"answer_start": [139], "text": ["borderline personality disorder"]}, {"answer_start": [139], "text": ["borderline personality disorder"]}, {"answer_start": [139], "text": ["borderline personality disorder"]}, {"answer_start": [128], "text": ["borderline personality disorder"]}, {"answer_start": [128], "text": ["borderline personality disorder"]}, {"answer_start": [128], "text": ["borderline personality disorder"]}, {"answer_start": [128], "text": ["borderline personality disorder"]}, {"answer_start": [128], "text": ["borderline personality disorder"]}, {"answer_start": [128], "text": ["borderline personality disorder"]}, {"answer_start": [128], "text": ["borderline personality disorder"]}, {"answer_start": [128], "text": ["borderline personality disorder"]}, {"answer_start": [128], "text": ["borderline personality disorder"]}, {"answer_start": [128], "text": ["borderline personality disorder"]}, {"answer_start": [128], "text": ["borderline personality disorder"]}, {"answer_start": [128], "text": ["borderline personality disorder"]}, {"answer_start": [128], "text": ["borderline personality disorder"]}, {"answer_start": [128], "text": ["borderline personality disorder"]}, {"answer_start": [128], "text": ["borderline personality disorder"]}, {"answer_start": [128], "text": ["borderline personality disorder"]}, {"answer_start": [128], "text": ["borderline personality disorder"]}, {"answer_start": [128], "text": ["borderline personality disorder"]}, {"answer_start": [137], "text": ["borderline personality disorder"]}, {"answer_start": [137], "text": ["borderline personality disorder"]}, {"answer_start": [137], "text": ["borderline personality disorder"]}, {"answer_start": [137], "text": ["borderline personality disorder"]}, {"answer_start": [137], "text": ["borderline personality disorder"]}, {"answer_start": [137], "text": ["borderline personality disorder"]}, {"answer_start": [137], "text": ["borderline personality disorder"]}, {"answer_start": [137], "text": ["borderline personality disorder"]}, {"answer_start": [137], "text": ["borderline personality disorder"]}, {"answer_start": [137], "text": ["borderline personality disorder"]}, {"answer_start": [137], "text": ["borderline personality disorder"]}, {"answer_start": [137], "text": ["borderline personality disorder"]}, {"answer_start": [137], "text": ["borderline personality disorder"]}, {"answer_start": [137], "text": ["borderline personality disorder"]}, {"answer_start": [137], "text": ["borderline personality disorder"]}, {"answer_start": [137], "text": ["borderline personality disorder"]}, {"answer_start": [137], "text": ["borderline personality disorder"]}, {"answer_start": [137], "text": ["borderline personality disorder"]}, {"answer_start": [85], "text": ["borderline personality disorder"]}, {"answer_start": [85], "text": ["borderline personality disorder"]}, {"answer_start": [85], "text": ["borderline personality disorder"]}, {"answer_start": [85], "text": ["borderline personality disorder"]}, {"answer_start": [85], "text": ["borderline personality disorder"]}, {"answer_start": [85], "text": ["borderline personality disorder"]}, {"answer_start": [85], "text": ["borderline personality disorder"]}, {"answer_start": [85], "text": ["borderline personality disorder"]}, {"answer_start": [85], "text": ["borderline personality disorder"]}, {"answer_start": [85], "text": ["borderline personality disorder"]}, {"answer_start": [85], "text": ["borderline personality disorder"]}, {"answer_start": [85], "text": ["borderline personality disorder"]}, {"answer_start": [85], "text": ["borderline personality disorder"]}, {"answer_start": [85], "text": ["borderline personality disorder"]}, {"answer_start": [85], "text": ["borderline personality disorder"]}, {"answer_start": [85], "text": ["borderline personality disorder"]}, {"answer_start": [85], "text": ["borderline personality disorder"]}, {"answer_start": [85], "text": ["borderline personality disorder"]}, {"answer_start": [81], "text": ["borderline personality disorder"]}, {"answer_start": [81], "text": ["borderline personality disorder"]}, {"answer_start": [81], "text": ["borderline personality disorder"]}, {"answer_start": [81], "text": ["borderline personality disorder"]}, {"answer_start": [81], "text": ["borderline personality disorder"]}, {"answer_start": [81], "text": ["borderline personality disorder"]}, {"answer_start": [81], "text": ["borderline personality disorder"]}, {"answer_start": [81], "text": ["borderline personality disorder"]}, {"answer_start": [81], "text": ["borderline personality disorder"]}, {"answer_start": [81], "text": ["borderline personality disorder"]}, {"answer_start": [81], "text": ["borderline personality disorder"]}, {"answer_start": [81], "text": ["borderline personality disorder"]}, {"answer_start": [81], "text": ["borderline personality disorder"]}, {"answer_start": [81], "text": ["borderline personality disorder"]}, {"answer_start": [81], "text": ["borderline personality disorder"]}, {"answer_start": [81], "text": ["borderline personality disorder"]}, {"answer_start": [81], "text": ["borderline personality disorder"]}, {"answer_start": [81], "text": ["borderline personality disorder"]}, {"answer_start": [105], "text": ["borderline personality disorder"]}, {"answer_start": [105], "text": ["borderline personality disorder"]}, {"answer_start": [105], "text": ["borderline personality disorder"]}, {"answer_start": [105], "text": ["borderline personality disorder"]}, {"answer_start": [105], "text": ["borderline personality disorder"]}, {"answer_start": [105], "text": ["borderline personality disorder"]}, {"answer_start": [105], "text": ["borderline personality disorder"]}, {"answer_start": [105], "text": ["borderline personality disorder"]}, {"answer_start": [105], "text": ["borderline personality disorder"]}, {"answer_start": [105], "text": ["borderline personality disorder"]}, {"answer_start": [105], "text": ["borderline personality disorder"]}, {"answer_start": [105], "text": ["borderline personality disorder"]}, {"answer_start": [105], "text": ["borderline personality disorder"]}, {"answer_start": [105], "text": ["borderline personality disorder"]}, {"answer_start": [105], "text": ["borderline personality disorder"]}, {"answer_start": [105], "text": ["borderline personality disorder"]}, {"answer_start": [105], "text": ["borderline personality disorder"]}, {"answer_start": [105], "text": ["borderline personality disorder"]}, {"answer_start": [36], "text": ["borderline personality disorder"]}, {"answer_start": [36], "text": ["borderline personality disorder"]}, {"answer_start": [36], "text": ["borderline personality disorder"]}, {"answer_start": [36], "text": ["borderline personality disorder"]}, {"answer_start": [36], "text": ["borderline personality disorder"]}, {"answer_start": [36], "text": ["borderline personality disorder"]}, {"answer_start": [36], "text": ["borderline personality disorder"]}, {"answer_start": [36], "text": ["borderline personality disorder"]}, {"answer_start": [36], "text": ["borderline personality disorder"]}, {"answer_start": [36], "text": ["borderline personality disorder"]}, {"answer_start": [36], "text": ["borderline personality disorder"]}, {"answer_start": [36], "text": ["borderline personality disorder"]}, {"answer_start": [36], "text": ["borderline personality disorder"]}, {"answer_start": [36], "text": ["borderline personality disorder"]}, {"answer_start": [36], "text": ["borderline personality disorder"]}, {"answer_start": [36], "text": ["borderline personality disorder"]}, {"answer_start": [36], "text": ["borderline personality disorder"]}, {"answer_start": [36], "text": ["borderline personality disorder"]}, {"answer_start": [39], "text": ["borderline personality disorder"]}, {"answer_start": [39], "text": ["borderline personality disorder"]}, {"answer_start": [39], "text": ["borderline personality disorder"]}, {"answer_start": [39], "text": ["borderline personality disorder"]}, {"answer_start": [39], "text": ["borderline personality disorder"]}, {"answer_start": [39], "text": ["borderline personality disorder"]}, {"answer_start": [39], "text": ["borderline personality disorder"]}, {"answer_start": [39], "text": ["borderline personality disorder"]}, {"answer_start": [39], "text": ["borderline personality disorder"]}, {"answer_start": [39], "text": ["borderline personality disorder"]}, {"answer_start": [39], "text": ["borderline personality disorder"]}, {"answer_start": [39], "text": ["borderline personality disorder"]}, {"answer_start": [39], "text": ["borderline personality disorder"]}, {"answer_start": [39], "text": ["borderline personality disorder"]}, {"answer_start": [39], "text": ["borderline personality disorder"]}, {"answer_start": [39], "text": ["borderline personality disorder"]}, {"answer_start": [39], "text": ["borderline personality disorder"]}, {"answer_start": [39], "text": ["borderline personality disorder"]}, {"answer_start": [173], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [173], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [173], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [173], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [173], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [173], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [173], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [173], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [173], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [173], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [173], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [173], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [173], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [173], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [173], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [173], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [173], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [173], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [173], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [173], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [173], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [173], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [173], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [173], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [173], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [173], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [173], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [173], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [173], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [140], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [140], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [140], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [140], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [140], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [140], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [140], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [140], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [140], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [140], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [140], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [140], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [140], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [140], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [140], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [140], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [140], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [140], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [140], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [140], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [140], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [140], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [140], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [140], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [140], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [140], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [140], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [140], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [140], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [254], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [254], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [254], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [254], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [254], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [254], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [254], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [254], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [254], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [254], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [254], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [254], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [254], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [254], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [254], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [254], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [254], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [254], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [254], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [254], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [254], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [254], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [254], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [254], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [254], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [254], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [254], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [254], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [254], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [82, 312], "text": ["diabetic foot osteomyelitis", "diabetic foot osteomyelitis"]}, {"answer_start": [82, 312], "text": ["diabetic foot osteomyelitis", "diabetic foot osteomyelitis"]}, {"answer_start": [82, 312], "text": ["diabetic foot osteomyelitis", "diabetic foot osteomyelitis"]}, {"answer_start": [82, 312], "text": ["diabetic foot osteomyelitis", "diabetic foot osteomyelitis"]}, {"answer_start": [82, 312], "text": ["diabetic foot osteomyelitis", "diabetic foot osteomyelitis"]}, {"answer_start": [82, 312], "text": ["diabetic foot osteomyelitis", "diabetic foot osteomyelitis"]}, {"answer_start": [82, 312], "text": ["diabetic foot osteomyelitis", "diabetic foot osteomyelitis"]}, {"answer_start": [82, 312], "text": ["diabetic foot osteomyelitis", "diabetic foot osteomyelitis"]}, {"answer_start": [82, 312], "text": ["diabetic foot osteomyelitis", "diabetic foot osteomyelitis"]}, {"answer_start": [82, 312], "text": ["diabetic foot osteomyelitis", "diabetic foot osteomyelitis"]}, {"answer_start": [82, 312], "text": ["diabetic foot osteomyelitis", "diabetic foot osteomyelitis"]}, {"answer_start": [82, 312], "text": ["diabetic foot osteomyelitis", "diabetic foot osteomyelitis"]}, {"answer_start": [82, 312], "text": ["diabetic foot osteomyelitis", "diabetic foot osteomyelitis"]}, {"answer_start": [82, 312], "text": ["diabetic foot osteomyelitis", "diabetic foot osteomyelitis"]}, {"answer_start": [82, 312], "text": ["diabetic foot osteomyelitis", "diabetic foot osteomyelitis"]}, {"answer_start": [82, 312], "text": ["diabetic foot osteomyelitis", "diabetic foot osteomyelitis"]}, {"answer_start": [82, 312], "text": ["diabetic foot osteomyelitis", "diabetic foot osteomyelitis"]}, {"answer_start": [82, 312], "text": ["diabetic foot osteomyelitis", "diabetic foot osteomyelitis"]}, {"answer_start": [82, 312], "text": ["diabetic foot osteomyelitis", "diabetic foot osteomyelitis"]}, {"answer_start": [82, 312], "text": ["diabetic foot osteomyelitis", "diabetic foot osteomyelitis"]}, {"answer_start": [82, 312], "text": ["diabetic foot osteomyelitis", "diabetic foot osteomyelitis"]}, {"answer_start": [82, 312], "text": ["diabetic foot osteomyelitis", "diabetic foot osteomyelitis"]}, {"answer_start": [82, 312], "text": ["diabetic foot osteomyelitis", "diabetic foot osteomyelitis"]}, {"answer_start": [82, 312], "text": ["diabetic foot osteomyelitis", "diabetic foot osteomyelitis"]}, {"answer_start": [82, 312], "text": ["diabetic foot osteomyelitis", "diabetic foot osteomyelitis"]}, {"answer_start": [82, 312], "text": ["diabetic foot osteomyelitis", "diabetic foot osteomyelitis"]}, {"answer_start": [82, 312], "text": ["diabetic foot osteomyelitis", "diabetic foot osteomyelitis"]}, {"answer_start": [82, 312], "text": ["diabetic foot osteomyelitis", "diabetic foot osteomyelitis"]}, {"answer_start": [82, 312], "text": ["diabetic foot osteomyelitis", "diabetic foot osteomyelitis"]}, {"answer_start": [167], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [167], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [167], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [167], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [167], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [167], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [167], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [167], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [167], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [167], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [167], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [167], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [167], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [167], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [167], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [167], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [167], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [167], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [167], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [167], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [167], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [167], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [167], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [167], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [167], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [167], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [167], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [167], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [167], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [166], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [166], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [166], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [166], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [166], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [166], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [166], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [166], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [166], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [166], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [166], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [166], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [166], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [166], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [166], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [166], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [166], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [166], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [166], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [166], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [166], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [166], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [166], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [166], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [166], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [166], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [166], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [166], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [166], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [154], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [154], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [154], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [154], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [154], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [154], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [154], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [154], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [154], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [154], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [154], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [154], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [154], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [154], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [154], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [154], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [154], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [154], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [154], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [154], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [154], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [154], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [154], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [154], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [154], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [154], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [154], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [154], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [154], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [47], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [47], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [47], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [47], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [47], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [47], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [47], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [47], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [47], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [47], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [47], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [47], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [47], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [47], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [47], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [47], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [47], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [47], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [47], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [47], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [47], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [47], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [47], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [47], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [47], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [47], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [47], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [47], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [47], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [11], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [11], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [11], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [11], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [11], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [11], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [11], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [11], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [11], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [11], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [11], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [11], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [11], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [11], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [11], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [11], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [11], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [11], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [11], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [11], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [11], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [11], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [11], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [11], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [11], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [11], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [11], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [11], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [11], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [82], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [82], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [82], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [82], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [82], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [82], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [82], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [82], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [82], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [82], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [82], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [82], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [82], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [82], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [82], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [82], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [82], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [82], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [82], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [82], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [82], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [82], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [82], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [82], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [82], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [82], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [82], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [82], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [82], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [34], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [34], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [34], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [34], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [34], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [34], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [34], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [34], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [34], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [34], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [34], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [34], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [34], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [34], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [34], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [34], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [34], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [34], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [34], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [34], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [34], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [34], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [34], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [34], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [34], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [34], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [34], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [34], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [34], "text": ["diabetic foot osteomyelitis"]}, {"answer_start": [78], "text": ["patent foramen ovale"]}, {"answer_start": [78], "text": ["patent foramen ovale"]}, {"answer_start": [78], "text": ["patent foramen ovale"]}, {"answer_start": [78], "text": ["patent foramen ovale"]}, {"answer_start": [78], "text": ["patent foramen ovale"]}, {"answer_start": [78], "text": ["patent foramen ovale"]}, {"answer_start": [78], "text": ["patent foramen ovale"]}, {"answer_start": [78], "text": ["patent foramen ovale"]}, {"answer_start": [78], "text": ["patent foramen ovale"]}, {"answer_start": [78], "text": ["patent foramen ovale"]}, {"answer_start": [78], "text": ["patent foramen ovale"]}, {"answer_start": [78], "text": ["patent foramen ovale"]}, {"answer_start": [78], "text": ["patent foramen ovale"]}, {"answer_start": [78], "text": ["patent foramen ovale"]}, {"answer_start": [78], "text": ["patent foramen ovale"]}, {"answer_start": [78], "text": ["patent foramen ovale"]}, {"answer_start": [78], "text": ["patent foramen ovale"]}, {"answer_start": [78], "text": ["patent foramen ovale"]}, {"answer_start": [78], "text": ["patent foramen ovale"]}, {"answer_start": [78], "text": ["patent foramen ovale"]}, {"answer_start": [78], "text": ["patent foramen ovale"]}, {"answer_start": [78], "text": ["patent foramen ovale"]}, {"answer_start": [78], "text": ["patent foramen ovale"]}, {"answer_start": [78], "text": ["patent foramen ovale"]}, {"answer_start": [78], "text": ["patent foramen ovale"]}, {"answer_start": [78], "text": ["patent foramen ovale"]}, {"answer_start": [78], "text": ["patent foramen ovale"]}, {"answer_start": [78], "text": ["patent foramen ovale"]}, {"answer_start": [78], "text": ["patent foramen ovale"]}, {"answer_start": [78], "text": ["patent foramen ovale"]}, {"answer_start": [78], "text": ["patent foramen ovale"]}, {"answer_start": [78], "text": ["patent foramen ovale"]}, {"answer_start": [78], "text": ["patent foramen ovale"]}, {"answer_start": [78], "text": ["patent foramen ovale"]}, {"answer_start": [78], "text": ["patent foramen ovale"]}, {"answer_start": [78], "text": ["patent foramen ovale"]}, {"answer_start": [78], "text": ["patent foramen ovale"]}, {"answer_start": [78], "text": ["patent foramen ovale"]}, {"answer_start": [78], "text": ["patent foramen ovale"]}, {"answer_start": [0], "text": ["patent foramen ovale"]}, {"answer_start": [0], "text": ["patent foramen ovale"]}, {"answer_start": [0], "text": ["patent foramen ovale"]}, {"answer_start": [0], "text": ["patent foramen ovale"]}, {"answer_start": [0], "text": ["patent foramen ovale"]}, {"answer_start": [0], "text": ["patent foramen ovale"]}, {"answer_start": [0], "text": ["patent foramen ovale"]}, {"answer_start": [0], "text": ["patent foramen ovale"]}, {"answer_start": [0], "text": ["patent foramen ovale"]}, {"answer_start": [0], "text": ["patent foramen ovale"]}, {"answer_start": [0], "text": ["patent foramen ovale"]}, {"answer_start": [0], "text": ["patent foramen ovale"]}, {"answer_start": [0], "text": ["patent foramen ovale"]}, {"answer_start": [0], "text": ["patent foramen ovale"]}, {"answer_start": [0], "text": ["patent foramen ovale"]}, {"answer_start": [0], "text": ["patent foramen ovale"]}, {"answer_start": [0], "text": ["patent foramen ovale"]}, {"answer_start": [0], "text": ["patent foramen ovale"]}, {"answer_start": [0], "text": ["patent foramen ovale"]}, {"answer_start": [0], "text": ["patent foramen ovale"]}, {"answer_start": [0], "text": ["patent foramen ovale"]}, {"answer_start": [0], "text": ["patent foramen ovale"]}, {"answer_start": [0], "text": ["patent foramen ovale"]}, {"answer_start": [0], "text": ["patent foramen ovale"]}, {"answer_start": [0], "text": ["patent foramen ovale"]}, {"answer_start": [0], "text": ["patent foramen ovale"]}, {"answer_start": [0], "text": ["patent foramen ovale"]}, {"answer_start": [0], "text": ["patent foramen ovale"]}, {"answer_start": [0], "text": ["patent foramen ovale"]}, {"answer_start": [0], "text": ["patent foramen ovale"]}, {"answer_start": [0], "text": ["patent foramen ovale"]}, {"answer_start": [0], "text": ["patent foramen ovale"]}, {"answer_start": [0], "text": ["patent foramen ovale"]}, {"answer_start": [0], "text": ["patent foramen ovale"]}, {"answer_start": [0], "text": ["patent foramen ovale"]}, {"answer_start": [0], "text": ["patent foramen ovale"]}, {"answer_start": [0], "text": ["patent foramen ovale"]}, {"answer_start": [0], "text": ["patent foramen ovale"]}, {"answer_start": [0], "text": ["patent foramen ovale"]}, {"answer_start": [60], "text": ["hypoglycemia"]}, {"answer_start": [60], "text": ["hypoglycemia"]}, {"answer_start": [60], "text": ["hypoglycemia"]}, {"answer_start": [60], "text": ["hypoglycemia"]}, {"answer_start": [60], "text": ["hypoglycemia"]}, {"answer_start": [60], "text": ["hypoglycemia"]}, {"answer_start": [60], "text": ["hypoglycemia"]}, {"answer_start": [60], "text": ["hypoglycemia"]}, {"answer_start": [60], "text": ["hypoglycemia"]}, {"answer_start": [60], "text": ["hypoglycemia"]}, {"answer_start": [60], "text": ["hypoglycemia"]}, {"answer_start": [60], "text": ["hypoglycemia"]}, {"answer_start": [60], "text": ["hypoglycemia"]}, {"answer_start": [60], "text": ["hypoglycemia"]}, {"answer_start": [60], "text": ["hypoglycemia"]}, {"answer_start": [60], "text": ["hypoglycemia"]}, {"answer_start": [60], "text": ["hypoglycemia"]}, {"answer_start": [60], "text": ["hypoglycemia"]}, {"answer_start": [103], "text": ["hypoglycemia"]}, {"answer_start": [103], "text": ["hypoglycemia"]}, {"answer_start": [103], "text": ["hypoglycemia"]}, {"answer_start": [103], "text": ["hypoglycemia"]}, {"answer_start": [103], "text": ["hypoglycemia"]}, {"answer_start": [103], "text": ["hypoglycemia"]}, {"answer_start": [103], "text": ["hypoglycemia"]}, {"answer_start": [103], "text": ["hypoglycemia"]}, {"answer_start": [103], "text": ["hypoglycemia"]}, {"answer_start": [103], "text": ["hypoglycemia"]}, {"answer_start": [103], "text": ["hypoglycemia"]}, {"answer_start": [103], "text": ["hypoglycemia"]}, {"answer_start": [103], "text": ["hypoglycemia"]}, {"answer_start": [103], "text": ["hypoglycemia"]}, {"answer_start": [103], "text": ["hypoglycemia"]}, {"answer_start": [103], "text": ["hypoglycemia"]}, {"answer_start": [103], "text": ["hypoglycemia"]}, {"answer_start": [103], "text": ["hypoglycemia"]}, {"answer_start": [110], "text": ["hypoglycemia"]}, {"answer_start": [110], "text": ["hypoglycemia"]}, {"answer_start": [110], "text": ["hypoglycemia"]}, {"answer_start": [110], "text": ["hypoglycemia"]}, {"answer_start": [110], "text": ["hypoglycemia"]}, {"answer_start": [110], "text": ["hypoglycemia"]}, {"answer_start": [110], "text": ["hypoglycemia"]}, {"answer_start": [110], "text": ["hypoglycemia"]}, {"answer_start": [110], "text": ["hypoglycemia"]}, {"answer_start": [110], "text": ["hypoglycemia"]}, {"answer_start": [110], "text": ["hypoglycemia"]}, {"answer_start": [110], "text": ["hypoglycemia"]}, {"answer_start": [110], "text": ["hypoglycemia"]}, {"answer_start": [110], "text": ["hypoglycemia"]}, {"answer_start": [110], "text": ["hypoglycemia"]}, {"answer_start": [110], "text": ["hypoglycemia"]}, {"answer_start": [110], "text": ["hypoglycemia"]}, {"answer_start": [110], "text": ["hypoglycemia"]}, {"answer_start": [85], "text": ["hypoglycemia"]}, {"answer_start": [85], "text": ["hypoglycemia"]}, {"answer_start": [85], "text": ["hypoglycemia"]}, {"answer_start": [85], "text": ["hypoglycemia"]}, {"answer_start": [85], "text": ["hypoglycemia"]}, {"answer_start": [85], "text": ["hypoglycemia"]}, {"answer_start": [85], "text": ["hypoglycemia"]}, {"answer_start": [85], "text": ["hypoglycemia"]}, {"answer_start": [85], "text": ["hypoglycemia"]}, {"answer_start": [85], "text": ["hypoglycemia"]}, {"answer_start": [85], "text": ["hypoglycemia"]}, {"answer_start": [85], "text": ["hypoglycemia"]}, {"answer_start": [85], "text": ["hypoglycemia"]}, {"answer_start": [85], "text": ["hypoglycemia"]}, {"answer_start": [85], "text": ["hypoglycemia"]}, {"answer_start": [85], "text": ["hypoglycemia"]}, {"answer_start": [85], "text": ["hypoglycemia"]}, {"answer_start": [85], "text": ["hypoglycemia"]}, {"answer_start": [132], "text": ["hypoglycemia"]}, {"answer_start": [132], "text": ["hypoglycemia"]}, {"answer_start": [132], "text": ["hypoglycemia"]}, {"answer_start": [132], "text": ["hypoglycemia"]}, {"answer_start": [132], "text": ["hypoglycemia"]}, {"answer_start": [132], "text": ["hypoglycemia"]}, {"answer_start": [132], "text": ["hypoglycemia"]}, {"answer_start": [132], "text": ["hypoglycemia"]}, {"answer_start": [132], "text": ["hypoglycemia"]}, {"answer_start": [132], "text": ["hypoglycemia"]}, {"answer_start": [132], "text": ["hypoglycemia"]}, {"answer_start": [132], "text": ["hypoglycemia"]}, {"answer_start": [132], "text": ["hypoglycemia"]}, {"answer_start": [132], "text": ["hypoglycemia"]}, {"answer_start": [132], "text": ["hypoglycemia"]}, {"answer_start": [132], "text": ["hypoglycemia"]}, {"answer_start": [132], "text": ["hypoglycemia"]}, {"answer_start": [132], "text": ["hypoglycemia"]}, {"answer_start": [96], "text": ["hypoglycemia"]}, {"answer_start": [96], "text": ["hypoglycemia"]}, {"answer_start": [96], "text": ["hypoglycemia"]}, {"answer_start": [96], "text": ["hypoglycemia"]}, {"answer_start": [96], "text": ["hypoglycemia"]}, {"answer_start": [96], "text": ["hypoglycemia"]}, {"answer_start": [96], "text": ["hypoglycemia"]}, {"answer_start": [96], "text": ["hypoglycemia"]}, {"answer_start": [96], "text": ["hypoglycemia"]}, {"answer_start": [96], "text": ["hypoglycemia"]}, {"answer_start": [96], "text": ["hypoglycemia"]}, {"answer_start": [96], "text": ["hypoglycemia"]}, {"answer_start": [96], "text": ["hypoglycemia"]}, {"answer_start": [96], "text": ["hypoglycemia"]}, {"answer_start": [96], "text": ["hypoglycemia"]}, {"answer_start": [96], "text": ["hypoglycemia"]}, {"answer_start": [96], "text": ["hypoglycemia"]}, {"answer_start": [96], "text": ["hypoglycemia"]}, {"answer_start": [89], "text": ["hypoglycemia"]}, {"answer_start": [89], "text": ["hypoglycemia"]}, {"answer_start": [89], "text": ["hypoglycemia"]}, {"answer_start": [89], "text": ["hypoglycemia"]}, {"answer_start": [89], "text": ["hypoglycemia"]}, {"answer_start": [89], "text": ["hypoglycemia"]}, {"answer_start": [89], "text": ["hypoglycemia"]}, {"answer_start": [89], "text": ["hypoglycemia"]}, {"answer_start": [89], "text": ["hypoglycemia"]}, {"answer_start": [89], "text": ["hypoglycemia"]}, {"answer_start": [89], "text": ["hypoglycemia"]}, {"answer_start": [89], "text": ["hypoglycemia"]}, {"answer_start": [89], "text": ["hypoglycemia"]}, {"answer_start": [89], "text": ["hypoglycemia"]}, {"answer_start": [89], "text": ["hypoglycemia"]}, {"answer_start": [89], "text": ["hypoglycemia"]}, {"answer_start": [89], "text": ["hypoglycemia"]}, {"answer_start": [89], "text": ["hypoglycemia"]}, {"answer_start": [89], "text": ["hypoglycemia"]}, {"answer_start": [89], "text": ["hypoglycemia"]}, {"answer_start": [89], "text": ["hypoglycemia"]}, {"answer_start": [89], "text": ["hypoglycemia"]}, {"answer_start": [89], "text": ["hypoglycemia"]}, {"answer_start": [89], "text": ["hypoglycemia"]}, {"answer_start": [89], "text": ["hypoglycemia"]}, {"answer_start": [89], "text": ["hypoglycemia"]}, {"answer_start": [89], "text": ["hypoglycemia"]}, {"answer_start": [89], "text": ["hypoglycemia"]}, {"answer_start": [89], "text": ["hypoglycemia"]}, {"answer_start": [89], "text": ["hypoglycemia"]}, {"answer_start": [89], "text": ["hypoglycemia"]}, {"answer_start": [89], "text": ["hypoglycemia"]}, {"answer_start": [89], "text": ["hypoglycemia"]}, {"answer_start": [89], "text": ["hypoglycemia"]}, {"answer_start": [89], "text": ["hypoglycemia"]}, {"answer_start": [89], "text": ["hypoglycemia"]}, {"answer_start": [67], "text": ["hypoglycemia"]}, {"answer_start": [67], "text": ["hypoglycemia"]}, {"answer_start": [67], "text": ["hypoglycemia"]}, {"answer_start": [67], "text": ["hypoglycemia"]}, {"answer_start": [67], "text": ["hypoglycemia"]}, {"answer_start": [67], "text": ["hypoglycemia"]}, {"answer_start": [67], "text": ["hypoglycemia"]}, {"answer_start": [67], "text": ["hypoglycemia"]}, {"answer_start": [67], "text": ["hypoglycemia"]}, {"answer_start": [67], "text": ["hypoglycemia"]}, {"answer_start": [67], "text": ["hypoglycemia"]}, {"answer_start": [67], "text": ["hypoglycemia"]}, {"answer_start": [67], "text": ["hypoglycemia"]}, {"answer_start": [67], "text": ["hypoglycemia"]}, {"answer_start": [67], "text": ["hypoglycemia"]}, {"answer_start": [67], "text": ["hypoglycemia"]}, {"answer_start": [67], "text": ["hypoglycemia"]}, {"answer_start": [67], "text": ["hypoglycemia"]}, {"answer_start": [73], "text": ["hypoglycemia"]}, {"answer_start": [73], "text": ["hypoglycemia"]}, {"answer_start": [73], "text": ["hypoglycemia"]}, {"answer_start": [73], "text": ["hypoglycemia"]}, {"answer_start": [73], "text": ["hypoglycemia"]}, {"answer_start": [73], "text": ["hypoglycemia"]}, {"answer_start": [73], "text": ["hypoglycemia"]}, {"answer_start": [73], "text": ["hypoglycemia"]}, {"answer_start": [73], "text": ["hypoglycemia"]}, {"answer_start": [73], "text": ["hypoglycemia"]}, {"answer_start": [73], "text": ["hypoglycemia"]}, {"answer_start": [73], "text": ["hypoglycemia"]}, {"answer_start": [73], "text": ["hypoglycemia"]}, {"answer_start": [73], "text": ["hypoglycemia"]}, {"answer_start": [73], "text": ["hypoglycemia"]}, {"answer_start": [73], "text": ["hypoglycemia"]}, {"answer_start": [73], "text": ["hypoglycemia"]}, {"answer_start": [73], "text": ["hypoglycemia"]}, {"answer_start": [2], "text": ["hypoglycemia"]}, {"answer_start": [2], "text": ["hypoglycemia"]}, {"answer_start": [2], "text": ["hypoglycemia"]}, {"answer_start": [2], "text": ["hypoglycemia"]}, {"answer_start": [2], "text": ["hypoglycemia"]}, {"answer_start": [2], "text": ["hypoglycemia"]}, {"answer_start": [2], "text": ["hypoglycemia"]}, {"answer_start": [2], "text": ["hypoglycemia"]}, {"answer_start": [2], "text": ["hypoglycemia"]}, {"answer_start": [2], "text": ["hypoglycemia"]}, {"answer_start": [2], "text": ["hypoglycemia"]}, {"answer_start": [2], "text": ["hypoglycemia"]}, {"answer_start": [2], "text": ["hypoglycemia"]}, {"answer_start": [2], "text": ["hypoglycemia"]}, {"answer_start": [2], "text": ["hypoglycemia"]}, {"answer_start": [2], "text": ["hypoglycemia"]}, {"answer_start": [2], "text": ["hypoglycemia"]}, {"answer_start": [2], "text": ["hypoglycemia"]}, {"answer_start": [39], "text": ["hypoglycemia"]}, {"answer_start": [39], "text": ["hypoglycemia"]}, {"answer_start": [39], "text": ["hypoglycemia"]}, {"answer_start": [39], "text": ["hypoglycemia"]}, {"answer_start": [39], "text": ["hypoglycemia"]}, {"answer_start": [39], "text": ["hypoglycemia"]}, {"answer_start": [39], "text": ["hypoglycemia"]}, {"answer_start": [39], "text": ["hypoglycemia"]}, {"answer_start": [39], "text": ["hypoglycemia"]}, {"answer_start": [39], "text": ["hypoglycemia"]}, {"answer_start": [39], "text": ["hypoglycemia"]}, {"answer_start": [39], "text": ["hypoglycemia"]}, {"answer_start": [39], "text": ["hypoglycemia"]}, {"answer_start": [39], "text": ["hypoglycemia"]}, {"answer_start": [39], "text": ["hypoglycemia"]}, {"answer_start": [39], "text": ["hypoglycemia"]}, {"answer_start": [39], "text": ["hypoglycemia"]}, {"answer_start": [39], "text": ["hypoglycemia"]}, {"answer_start": [17], "text": ["rabies"]}, {"answer_start": [17], "text": ["rabies"]}, {"answer_start": [17], "text": ["rabies"]}, {"answer_start": [17], "text": ["rabies"]}, {"answer_start": [17], "text": ["rabies"]}, {"answer_start": [17], "text": ["rabies"]}, {"answer_start": [17], "text": ["rabies"]}, {"answer_start": [17], "text": ["rabies"]}, {"answer_start": [17], "text": ["rabies"]}, {"answer_start": [17], "text": ["rabies"]}, {"answer_start": [17], "text": ["rabies"]}, {"answer_start": [17], "text": ["rabies"]}, {"answer_start": [17], "text": ["rabies"]}, {"answer_start": [17], "text": ["rabies"]}, {"answer_start": [17], "text": ["rabies"]}, {"answer_start": [17], "text": ["rabies"]}, {"answer_start": [17], "text": ["rabies"]}, {"answer_start": [17], "text": ["rabies"]}, {"answer_start": [17], "text": ["rabies"]}, {"answer_start": [17], "text": ["rabies"]}, {"answer_start": [17], "text": ["rabies"]}, {"answer_start": [17], "text": ["rabies"]}, {"answer_start": [17], "text": ["rabies"]}, {"answer_start": [17], "text": ["rabies"]}, {"answer_start": [17], "text": ["rabies"]}, {"answer_start": [17], "text": ["rabies"]}, {"answer_start": [17], "text": ["rabies"]}, {"answer_start": [17], "text": ["rabies"]}, {"answer_start": [17], "text": ["rabies"]}, {"answer_start": [17], "text": ["rabies"]}, {"answer_start": [17], "text": ["rabies"]}, {"answer_start": [17], "text": ["rabies"]}, {"answer_start": [17], "text": ["rabies"]}, {"answer_start": [17], "text": ["rabies"]}, {"answer_start": [215], "text": ["rabies"]}, {"answer_start": [215], "text": ["rabies"]}, {"answer_start": [215], "text": ["rabies"]}, {"answer_start": [215], "text": ["rabies"]}, {"answer_start": [215], "text": ["rabies"]}, {"answer_start": [215], "text": ["rabies"]}, {"answer_start": [215], "text": ["rabies"]}, {"answer_start": [215], "text": ["rabies"]}, {"answer_start": [215], "text": ["rabies"]}, {"answer_start": [215], "text": ["rabies"]}, {"answer_start": [215], "text": ["rabies"]}, {"answer_start": [215], "text": ["rabies"]}, {"answer_start": [215], "text": ["rabies"]}, {"answer_start": [215], "text": ["rabies"]}, {"answer_start": [215], "text": ["rabies"]}, {"answer_start": [215], "text": ["rabies"]}, {"answer_start": [215], "text": ["rabies"]}, {"answer_start": [215], "text": ["rabies"]}, {"answer_start": [215], "text": ["rabies"]}, {"answer_start": [215], "text": ["rabies"]}, {"answer_start": [215], "text": ["rabies"]}, {"answer_start": [215], "text": ["rabies"]}, {"answer_start": [215], "text": ["rabies"]}, {"answer_start": [215], "text": ["rabies"]}, {"answer_start": [215], "text": ["rabies"]}, {"answer_start": [215], "text": ["rabies"]}, {"answer_start": [215], "text": ["rabies"]}, {"answer_start": [215], "text": ["rabies"]}, {"answer_start": [215], "text": ["rabies"]}, {"answer_start": [215], "text": ["rabies"]}, {"answer_start": [215], "text": ["rabies"]}, {"answer_start": [215], "text": ["rabies"]}, {"answer_start": [215], "text": ["rabies"]}, {"answer_start": [215], "text": ["rabies"]}, {"answer_start": [0], "text": ["rabies"]}, {"answer_start": [0], "text": ["rabies"]}, {"answer_start": [0], "text": ["rabies"]}, {"answer_start": [0], "text": ["rabies"]}, {"answer_start": [0], "text": ["rabies"]}, {"answer_start": [0], "text": ["rabies"]}, {"answer_start": [0], "text": ["rabies"]}, {"answer_start": [0], "text": ["rabies"]}, {"answer_start": [0], "text": ["rabies"]}, {"answer_start": [0], "text": ["rabies"]}, {"answer_start": [0], "text": ["rabies"]}, {"answer_start": [0], "text": ["rabies"]}, {"answer_start": [0], "text": ["rabies"]}, {"answer_start": [0], "text": ["rabies"]}, {"answer_start": [0], "text": ["rabies"]}, {"answer_start": [0], "text": ["rabies"]}, {"answer_start": [0], "text": ["rabies"]}, {"answer_start": [0], "text": ["rabies"]}, {"answer_start": [0], "text": ["rabies"]}, {"answer_start": [0], "text": ["rabies"]}, {"answer_start": [0], "text": ["rabies"]}, {"answer_start": [0], "text": ["rabies"]}, {"answer_start": [0], "text": ["rabies"]}, {"answer_start": [0], "text": ["rabies"]}, {"answer_start": [0], "text": ["rabies"]}, {"answer_start": [0], "text": ["rabies"]}, {"answer_start": [0], "text": ["rabies"]}, {"answer_start": [0], "text": ["rabies"]}, {"answer_start": [0], "text": ["rabies"]}, {"answer_start": [0], "text": ["rabies"]}, {"answer_start": [0], "text": ["rabies"]}, {"answer_start": [0], "text": ["rabies"]}, {"answer_start": [0], "text": ["rabies"]}, {"answer_start": [0], "text": ["rabies"]}, {"answer_start": [180], "text": ["rabies"]}, {"answer_start": [180], "text": ["rabies"]}, {"answer_start": [180], "text": ["rabies"]}, {"answer_start": [180], "text": ["rabies"]}, {"answer_start": [180], "text": ["rabies"]}, {"answer_start": [180], "text": ["rabies"]}, {"answer_start": [180], "text": ["rabies"]}, {"answer_start": [180], "text": ["rabies"]}, {"answer_start": [180], "text": ["rabies"]}, {"answer_start": [180], "text": ["rabies"]}, {"answer_start": [180], "text": ["rabies"]}, {"answer_start": [180], "text": ["rabies"]}, {"answer_start": [180], "text": ["rabies"]}, {"answer_start": [180], "text": ["rabies"]}, {"answer_start": [180], "text": ["rabies"]}, {"answer_start": [180], "text": ["rabies"]}, {"answer_start": [180], "text": ["rabies"]}, {"answer_start": [180], "text": ["rabies"]}, {"answer_start": [180], "text": ["rabies"]}, {"answer_start": [180], "text": ["rabies"]}, {"answer_start": [180], "text": ["rabies"]}, {"answer_start": [180], "text": ["rabies"]}, {"answer_start": [180], "text": ["rabies"]}, {"answer_start": [180], "text": ["rabies"]}, {"answer_start": [180], "text": ["rabies"]}, {"answer_start": [180], "text": ["rabies"]}, {"answer_start": [180], "text": ["rabies"]}, {"answer_start": [180], "text": ["rabies"]}, {"answer_start": [180], "text": ["rabies"]}, {"answer_start": [180], "text": ["rabies"]}, {"answer_start": [180], "text": ["rabies"]}, {"answer_start": [180], "text": ["rabies"]}, {"answer_start": [180], "text": ["rabies"]}, {"answer_start": [180], "text": ["rabies"]}, {"answer_start": [62, 167], "text": ["rabies", "rabies"]}, {"answer_start": [62, 167], "text": ["rabies", "rabies"]}, {"answer_start": [62, 167], "text": ["rabies", "rabies"]}, {"answer_start": [62, 167], "text": ["rabies", "rabies"]}, {"answer_start": [62, 167], "text": ["rabies", "rabies"]}, {"answer_start": [62, 167], "text": ["rabies", "rabies"]}, {"answer_start": [62, 167], "text": ["rabies", "rabies"]}, {"answer_start": [62, 167], "text": ["rabies", "rabies"]}, {"answer_start": [62, 167], "text": ["rabies", "rabies"]}, {"answer_start": [62, 167], "text": ["rabies", "rabies"]}, {"answer_start": [62, 167], "text": ["rabies", "rabies"]}, {"answer_start": [62, 167], "text": ["rabies", "rabies"]}, {"answer_start": [62, 167], "text": ["rabies", "rabies"]}, {"answer_start": [62, 167], "text": ["rabies", "rabies"]}, {"answer_start": [62, 167], "text": ["rabies", "rabies"]}, {"answer_start": [62, 167], "text": ["rabies", "rabies"]}, {"answer_start": [62, 167], "text": ["rabies", "rabies"]}, {"answer_start": [62, 167], "text": ["rabies", "rabies"]}, {"answer_start": [62, 167], "text": ["rabies", "rabies"]}, {"answer_start": [62, 167], "text": ["rabies", "rabies"]}, {"answer_start": [62, 167], "text": ["rabies", "rabies"]}, {"answer_start": [62, 167], "text": ["rabies", "rabies"]}, {"answer_start": [62, 167], "text": ["rabies", "rabies"]}, {"answer_start": [62, 167], "text": ["rabies", "rabies"]}, {"answer_start": [62, 167], "text": ["rabies", "rabies"]}, {"answer_start": [62, 167], "text": ["rabies", "rabies"]}, {"answer_start": [62, 167], "text": ["rabies", "rabies"]}, {"answer_start": [62, 167], "text": ["rabies", "rabies"]}, {"answer_start": [62, 167], "text": ["rabies", "rabies"]}, {"answer_start": [62, 167], "text": ["rabies", "rabies"]}, {"answer_start": [62, 167], "text": ["rabies", "rabies"]}, {"answer_start": [62, 167], "text": ["rabies", "rabies"]}, {"answer_start": [62, 167], "text": ["rabies", "rabies"]}, {"answer_start": [62, 167], "text": ["rabies", "rabies"]}, {"answer_start": [58], "text": ["rabies"]}, {"answer_start": [58], "text": ["rabies"]}, {"answer_start": [58], "text": ["rabies"]}, {"answer_start": [58], "text": ["rabies"]}, {"answer_start": [58], "text": ["rabies"]}, {"answer_start": [58], "text": ["rabies"]}, {"answer_start": [58], "text": ["rabies"]}, {"answer_start": [58], "text": ["rabies"]}, {"answer_start": [58], "text": ["rabies"]}, {"answer_start": [58], "text": ["rabies"]}, {"answer_start": [58], "text": ["rabies"]}, {"answer_start": [58], "text": ["rabies"]}, {"answer_start": [58], "text": ["rabies"]}, {"answer_start": [58], "text": ["rabies"]}, {"answer_start": [58], "text": ["rabies"]}, {"answer_start": [58], "text": ["rabies"]}, {"answer_start": [58], "text": ["rabies"]}, {"answer_start": [58], "text": ["rabies"]}, {"answer_start": [58], "text": ["rabies"]}, {"answer_start": [58], "text": ["rabies"]}, {"answer_start": [58], "text": ["rabies"]}, {"answer_start": [58], "text": ["rabies"]}, {"answer_start": [58], "text": ["rabies"]}, {"answer_start": [58], "text": ["rabies"]}, {"answer_start": [58], "text": ["rabies"]}, {"answer_start": [58], "text": ["rabies"]}, {"answer_start": [58], "text": ["rabies"]}, {"answer_start": [58], "text": ["rabies"]}, {"answer_start": [58], "text": ["rabies"]}, {"answer_start": [58], "text": ["rabies"]}, {"answer_start": [58], "text": ["rabies"]}, {"answer_start": [58], "text": ["rabies"]}, {"answer_start": [58], "text": ["rabies"]}, {"answer_start": [58], "text": ["rabies"]}, {"answer_start": [24], "text": ["rabies"]}, {"answer_start": [24], "text": ["rabies"]}, {"answer_start": [24], "text": ["rabies"]}, {"answer_start": [24], "text": ["rabies"]}, {"answer_start": [24], "text": ["rabies"]}, {"answer_start": [24], "text": ["rabies"]}, {"answer_start": [24], "text": ["rabies"]}, {"answer_start": [24], "text": ["rabies"]}, {"answer_start": [24], "text": ["rabies"]}, {"answer_start": [24], "text": ["rabies"]}, {"answer_start": [24], "text": ["rabies"]}, {"answer_start": [24], "text": ["rabies"]}, {"answer_start": [24], "text": ["rabies"]}, {"answer_start": [24], "text": ["rabies"]}, {"answer_start": [24], "text": ["rabies"]}, {"answer_start": [24], "text": ["rabies"]}, {"answer_start": [24], "text": ["rabies"]}, {"answer_start": [24], "text": ["rabies"]}, {"answer_start": [24], "text": ["rabies"]}, {"answer_start": [24], "text": ["rabies"]}, {"answer_start": [24], "text": ["rabies"]}, {"answer_start": [24], "text": ["rabies"]}, {"answer_start": [24], "text": ["rabies"]}, {"answer_start": [24], "text": ["rabies"]}, {"answer_start": [24], "text": ["rabies"]}, {"answer_start": [24], "text": ["rabies"]}, {"answer_start": [24], "text": ["rabies"]}, {"answer_start": [24], "text": ["rabies"]}, {"answer_start": [24], "text": ["rabies"]}, {"answer_start": [24], "text": ["rabies"]}, {"answer_start": [24], "text": ["rabies"]}, {"answer_start": [24], "text": ["rabies"]}, {"answer_start": [24], "text": ["rabies"]}, {"answer_start": [24], "text": ["rabies"]}, {"answer_start": [26], "text": ["rabies"]}, {"answer_start": [26], "text": ["rabies"]}, {"answer_start": [26], "text": ["rabies"]}, {"answer_start": [26], "text": ["rabies"]}, {"answer_start": [26], "text": ["rabies"]}, {"answer_start": [26], "text": ["rabies"]}, {"answer_start": [26], "text": ["rabies"]}, {"answer_start": [26], "text": ["rabies"]}, {"answer_start": [26], "text": ["rabies"]}, {"answer_start": [26], "text": ["rabies"]}, {"answer_start": [26], "text": ["rabies"]}, {"answer_start": [26], "text": ["rabies"]}, {"answer_start": [26], "text": ["rabies"]}, {"answer_start": [26], "text": ["rabies"]}, {"answer_start": [26], "text": ["rabies"]}, {"answer_start": [26], "text": ["rabies"]}, {"answer_start": [26], "text": ["rabies"]}, {"answer_start": [26], "text": ["rabies"]}, {"answer_start": [26], "text": ["rabies"]}, {"answer_start": [26], "text": ["rabies"]}, {"answer_start": [26], "text": ["rabies"]}, {"answer_start": [26], "text": ["rabies"]}, {"answer_start": [26], "text": ["rabies"]}, {"answer_start": [26], "text": ["rabies"]}, {"answer_start": [26], "text": ["rabies"]}, {"answer_start": [26], "text": ["rabies"]}, {"answer_start": [26], "text": ["rabies"]}, {"answer_start": [26], "text": ["rabies"]}, {"answer_start": [26], "text": ["rabies"]}, {"answer_start": [26], "text": ["rabies"]}, {"answer_start": [26], "text": ["rabies"]}, {"answer_start": [26], "text": ["rabies"]}, {"answer_start": [26], "text": ["rabies"]}, {"answer_start": [26], "text": ["rabies"]}, {"answer_start": [49], "text": ["rabies"]}, {"answer_start": [49], "text": ["rabies"]}, {"answer_start": [49], "text": ["rabies"]}, {"answer_start": [49], "text": ["rabies"]}, {"answer_start": [49], "text": ["rabies"]}, {"answer_start": [49], "text": ["rabies"]}, {"answer_start": [49], "text": ["rabies"]}, {"answer_start": [49], "text": ["rabies"]}, {"answer_start": [49], "text": ["rabies"]}, {"answer_start": [49], "text": ["rabies"]}, {"answer_start": [49], "text": ["rabies"]}, {"answer_start": [49], "text": ["rabies"]}, {"answer_start": [49], "text": ["rabies"]}, {"answer_start": [49], "text": ["rabies"]}, {"answer_start": [49], "text": ["rabies"]}, {"answer_start": [49], "text": ["rabies"]}, {"answer_start": [49], "text": ["rabies"]}, {"answer_start": [49], "text": ["rabies"]}, {"answer_start": [49], "text": ["rabies"]}, {"answer_start": [49], "text": ["rabies"]}, {"answer_start": [49], "text": ["rabies"]}, {"answer_start": [49], "text": ["rabies"]}, {"answer_start": [49], "text": ["rabies"]}, {"answer_start": [49], "text": ["rabies"]}, {"answer_start": [49], "text": ["rabies"]}, {"answer_start": [49], "text": ["rabies"]}, {"answer_start": [49], "text": ["rabies"]}, {"answer_start": [49], "text": ["rabies"]}, {"answer_start": [49], "text": ["rabies"]}, {"answer_start": [49], "text": ["rabies"]}, {"answer_start": [49], "text": ["rabies"]}, {"answer_start": [49], "text": ["rabies"]}, {"answer_start": [49], "text": ["rabies"]}, {"answer_start": [49], "text": ["rabies"]}, {"answer_start": [56], "text": ["rabies"]}, {"answer_start": [56], "text": ["rabies"]}, {"answer_start": [56], "text": ["rabies"]}, {"answer_start": [56], "text": ["rabies"]}, {"answer_start": [56], "text": ["rabies"]}, {"answer_start": [56], "text": ["rabies"]}, {"answer_start": [56], "text": ["rabies"]}, {"answer_start": [56], "text": ["rabies"]}, {"answer_start": [56], "text": ["rabies"]}, {"answer_start": [56], "text": ["rabies"]}, {"answer_start": [56], "text": ["rabies"]}, {"answer_start": [56], "text": ["rabies"]}, {"answer_start": [56], "text": ["rabies"]}, {"answer_start": [56], "text": ["rabies"]}, {"answer_start": [56], "text": ["rabies"]}, {"answer_start": [56], "text": ["rabies"]}, {"answer_start": [56], "text": ["rabies"]}, {"answer_start": [56], "text": ["rabies"]}, {"answer_start": [56], "text": ["rabies"]}, {"answer_start": [56], "text": ["rabies"]}, {"answer_start": [56], "text": ["rabies"]}, {"answer_start": [56], "text": ["rabies"]}, {"answer_start": [56], "text": ["rabies"]}, {"answer_start": [56], "text": ["rabies"]}, {"answer_start": [56], "text": ["rabies"]}, {"answer_start": [56], "text": ["rabies"]}, {"answer_start": [56], "text": ["rabies"]}, {"answer_start": [56], "text": ["rabies"]}, {"answer_start": [56], "text": ["rabies"]}, {"answer_start": [56], "text": ["rabies"]}, {"answer_start": [56], "text": ["rabies"]}, {"answer_start": [56], "text": ["rabies"]}, {"answer_start": [56], "text": ["rabies"]}, {"answer_start": [56], "text": ["rabies"]}, {"answer_start": [48], "text": ["rabies"]}, {"answer_start": [48], "text": ["rabies"]}, {"answer_start": [48], "text": ["rabies"]}, {"answer_start": [48], "text": ["rabies"]}, {"answer_start": [48], "text": ["rabies"]}, {"answer_start": [48], "text": ["rabies"]}, {"answer_start": [48], "text": ["rabies"]}, {"answer_start": [48], "text": ["rabies"]}, {"answer_start": [48], "text": ["rabies"]}, {"answer_start": [48], "text": ["rabies"]}, {"answer_start": [48], "text": ["rabies"]}, {"answer_start": [48], "text": ["rabies"]}, {"answer_start": [48], "text": ["rabies"]}, {"answer_start": [48], "text": ["rabies"]}, {"answer_start": [48], "text": ["rabies"]}, {"answer_start": [48], "text": ["rabies"]}, {"answer_start": [48], "text": ["rabies"]}, {"answer_start": [48], "text": ["rabies"]}, {"answer_start": [48], "text": ["rabies"]}, {"answer_start": [48], "text": ["rabies"]}, {"answer_start": [48], "text": ["rabies"]}, {"answer_start": [48], "text": ["rabies"]}, {"answer_start": [48], "text": ["rabies"]}, {"answer_start": [48], "text": ["rabies"]}, {"answer_start": [48], "text": ["rabies"]}, {"answer_start": [48], "text": ["rabies"]}, {"answer_start": [48], "text": ["rabies"]}, {"answer_start": [48], "text": ["rabies"]}, {"answer_start": [48], "text": ["rabies"]}, {"answer_start": [48], "text": ["rabies"]}, {"answer_start": [48], "text": ["rabies"]}, {"answer_start": [48], "text": ["rabies"]}, {"answer_start": [48], "text": ["rabies"]}, {"answer_start": [48], "text": ["rabies"]}, {"answer_start": [33], "text": ["automated cryopreservation and storage system"]}, {"answer_start": [33], "text": ["automated cryopreservation and storage system"]}, {"answer_start": [33], "text": ["automated cryopreservation and storage system"]}, {"answer_start": [33], "text": ["automated cryopreservation and storage system"]}, {"answer_start": [33], "text": ["automated cryopreservation and storage system"]}, {"answer_start": [17], "text": ["membrane-free microcompartments"]}, {"answer_start": [17], "text": ["membrane-free microcompartments"]}, {"answer_start": [17], "text": ["membrane-free microcompartments"]}, {"answer_start": [17], "text": ["membrane-free microcompartments"]}, {"answer_start": [17], "text": ["membrane-free microcompartments"]}, {"answer_start": [17], "text": ["membrane-free microcompartments"]}, {"answer_start": [17], "text": ["membrane-free microcompartments"]}, {"answer_start": [17], "text": ["membrane-free microcompartments"]}, {"answer_start": [17], "text": ["membrane-free microcompartments"]}, {"answer_start": [17], "text": ["membrane-free microcompartments"]}, {"answer_start": [17], "text": ["membrane-free microcompartments"]}, {"answer_start": [17], "text": ["membrane-free microcompartments"]}, {"answer_start": [17], "text": ["membrane-free microcompartments"]}, {"answer_start": [17], "text": ["membrane-free microcompartments"]}, {"answer_start": [17], "text": ["membrane-free microcompartments"]}, {"answer_start": [17], "text": ["membrane-free microcompartments"]}, {"answer_start": [17], "text": ["membrane-free microcompartments"]}, {"answer_start": [17], "text": ["membrane-free microcompartments"]}, {"answer_start": [17], "text": ["membrane-free microcompartments"]}, {"answer_start": [17], "text": ["membrane-free microcompartments"]}, {"answer_start": [17], "text": ["membrane-free microcompartments"]}, {"answer_start": [17], "text": ["membrane-free microcompartments"]}, {"answer_start": [17], "text": ["membrane-free microcompartments"]}, {"answer_start": [17], "text": ["membrane-free microcompartments"]}, {"answer_start": [17], "text": ["membrane-free microcompartments"]}, {"answer_start": [17], "text": ["membrane-free microcompartments"]}, {"answer_start": [128], "text": ["100 nm"]}, {"answer_start": [128], "text": ["100 nm"]}, {"answer_start": [128], "text": ["100 nm"]}, {"answer_start": [128], "text": ["100 nm"]}, {"answer_start": [128], "text": ["100 nm"]}, {"answer_start": [128], "text": ["100 nm"]}, {"answer_start": [128], "text": ["100 nm"]}, {"answer_start": [128], "text": ["100 nm"]}, {"answer_start": [128], "text": ["100 nm"]}, {"answer_start": [128], "text": ["100 nm"]}, {"answer_start": [128], "text": ["100 nm"]}, {"answer_start": [128], "text": ["100 nm"]}, {"answer_start": [128], "text": ["100 nm"]}, {"answer_start": [128], "text": ["100 nm"]}, {"answer_start": [128], "text": ["100 nm"]}, {"answer_start": [128], "text": ["100 nm"]}, {"answer_start": [128], "text": ["100 nm"]}, {"answer_start": [128], "text": ["100 nm"]}, {"answer_start": [128], "text": ["100 nm"]}, {"answer_start": [190], "text": ["bone metabolism"]}, {"answer_start": [190], "text": ["bone metabolism"]}, {"answer_start": [190], "text": ["bone metabolism"]}, {"answer_start": [190], "text": ["bone metabolism"]}, {"answer_start": [190], "text": ["bone metabolism"]}, {"answer_start": [190], "text": ["bone metabolism"]}, {"answer_start": [190], "text": ["bone metabolism"]}, {"answer_start": [190], "text": ["bone metabolism"]}, {"answer_start": [190], "text": ["bone metabolism"]}, {"answer_start": [190], "text": ["bone metabolism"]}, {"answer_start": [190], "text": ["bone metabolism"]}, {"answer_start": [190], "text": ["bone metabolism"]}, {"answer_start": [190], "text": ["bone metabolism"]}, {"answer_start": [190], "text": ["bone metabolism"]}, {"answer_start": [190], "text": ["bone metabolism"]}, {"answer_start": [190], "text": ["bone metabolism"]}, {"answer_start": [190], "text": ["bone metabolism"]}, {"answer_start": [190], "text": ["bone metabolism"]}, {"answer_start": [64], "text": ["bone metabolism"]}, {"answer_start": [64], "text": ["bone metabolism"]}, {"answer_start": [64], "text": ["bone metabolism"]}, {"answer_start": [64], "text": ["bone metabolism"]}, {"answer_start": [64], "text": ["bone metabolism"]}, {"answer_start": [64], "text": ["bone metabolism"]}, {"answer_start": [64], "text": ["bone metabolism"]}, {"answer_start": [64], "text": ["bone metabolism"]}, {"answer_start": [64], "text": ["bone metabolism"]}, {"answer_start": [64], "text": ["bone metabolism"]}, {"answer_start": [64], "text": ["bone metabolism"]}, {"answer_start": [64], "text": ["bone metabolism"]}, {"answer_start": [64], "text": ["bone metabolism"]}, {"answer_start": [64], "text": ["bone metabolism"]}, {"answer_start": [64], "text": ["bone metabolism"]}, {"answer_start": [64], "text": ["bone metabolism"]}, {"answer_start": [64], "text": ["bone metabolism"]}, {"answer_start": [64], "text": ["bone metabolism"]}, {"answer_start": [242], "text": ["pulmonary embolism"]}, {"answer_start": [242], "text": ["pulmonary embolism"]}, {"answer_start": [242], "text": ["pulmonary embolism"]}, {"answer_start": [242], "text": ["pulmonary embolism"]}, {"answer_start": [242], "text": ["pulmonary embolism"]}, {"answer_start": [242], "text": ["pulmonary embolism"]}, {"answer_start": [242], "text": ["pulmonary embolism"]}, {"answer_start": [242], "text": ["pulmonary embolism"]}, {"answer_start": [242], "text": ["pulmonary embolism"]}, {"answer_start": [242], "text": ["pulmonary embolism"]}, {"answer_start": [242], "text": ["pulmonary embolism"]}, {"answer_start": [242], "text": ["pulmonary embolism"]}, {"answer_start": [242], "text": ["pulmonary embolism"]}, {"answer_start": [242], "text": ["pulmonary embolism"]}, {"answer_start": [242], "text": ["pulmonary embolism"]}, {"answer_start": [242], "text": ["pulmonary embolism"]}, {"answer_start": [242], "text": ["pulmonary embolism"]}, {"answer_start": [242], "text": ["pulmonary embolism"]}, {"answer_start": [242], "text": ["pulmonary embolism"]}, {"answer_start": [242], "text": ["pulmonary embolism"]}, {"answer_start": [242], "text": ["pulmonary embolism"]}, {"answer_start": [315], "text": ["pulmonary embolism"]}, {"answer_start": [315], "text": ["pulmonary embolism"]}, {"answer_start": [315], "text": ["pulmonary embolism"]}, {"answer_start": [315], "text": ["pulmonary embolism"]}, {"answer_start": [315], "text": ["pulmonary embolism"]}, {"answer_start": [315], "text": ["pulmonary embolism"]}, {"answer_start": [315], "text": ["pulmonary embolism"]}, {"answer_start": [315], "text": ["pulmonary embolism"]}, {"answer_start": [315], "text": ["pulmonary embolism"]}, {"answer_start": [315], "text": ["pulmonary embolism"]}, {"answer_start": [315], "text": ["pulmonary embolism"]}, {"answer_start": [315], "text": ["pulmonary embolism"]}, {"answer_start": [315], "text": ["pulmonary embolism"]}, {"answer_start": [315], "text": ["pulmonary embolism"]}, {"answer_start": [315], "text": ["pulmonary embolism"]}, {"answer_start": [315], "text": ["pulmonary embolism"]}, {"answer_start": [315], "text": ["pulmonary embolism"]}, {"answer_start": [315], "text": ["pulmonary embolism"]}, {"answer_start": [315], "text": ["pulmonary embolism"]}, {"answer_start": [315], "text": ["pulmonary embolism"]}, {"answer_start": [315], "text": ["pulmonary embolism"]}, {"answer_start": [161], "text": ["pulmonary embolism"]}, {"answer_start": [161], "text": ["pulmonary embolism"]}, {"answer_start": [161], "text": ["pulmonary embolism"]}, {"answer_start": [161], "text": ["pulmonary embolism"]}, {"answer_start": [161], "text": ["pulmonary embolism"]}, {"answer_start": [161], "text": ["pulmonary embolism"]}, {"answer_start": [161], "text": ["pulmonary embolism"]}, {"answer_start": [161], "text": ["pulmonary embolism"]}, {"answer_start": [161], "text": ["pulmonary embolism"]}, {"answer_start": [161], "text": ["pulmonary embolism"]}, {"answer_start": [161], "text": ["pulmonary embolism"]}, {"answer_start": [161], "text": ["pulmonary embolism"]}, {"answer_start": [161], "text": ["pulmonary embolism"]}, {"answer_start": [161], "text": ["pulmonary embolism"]}, {"answer_start": [161], "text": ["pulmonary embolism"]}, {"answer_start": [161], "text": ["pulmonary embolism"]}, {"answer_start": [161], "text": ["pulmonary embolism"]}, {"answer_start": [161], "text": ["pulmonary embolism"]}, {"answer_start": [161], "text": ["pulmonary embolism"]}, {"answer_start": [161], "text": ["pulmonary embolism"]}, {"answer_start": [161], "text": ["pulmonary embolism"]}, {"answer_start": [168], "text": ["pulmonary embolism"]}, {"answer_start": [168], "text": ["pulmonary embolism"]}, {"answer_start": [168], "text": ["pulmonary embolism"]}, {"answer_start": [168], "text": ["pulmonary embolism"]}, {"answer_start": [168], "text": ["pulmonary embolism"]}, {"answer_start": [168], "text": ["pulmonary embolism"]}, {"answer_start": [168], "text": ["pulmonary embolism"]}, {"answer_start": [168], "text": ["pulmonary embolism"]}, {"answer_start": [168], "text": ["pulmonary embolism"]}, {"answer_start": [168], "text": ["pulmonary embolism"]}, {"answer_start": [168], "text": ["pulmonary embolism"]}, {"answer_start": [168], "text": ["pulmonary embolism"]}, {"answer_start": [168], "text": ["pulmonary embolism"]}, {"answer_start": [168], "text": ["pulmonary embolism"]}, {"answer_start": [168], "text": ["pulmonary embolism"]}, {"answer_start": [168], "text": ["pulmonary embolism"]}, {"answer_start": [168], "text": ["pulmonary embolism"]}, {"answer_start": [168], "text": ["pulmonary embolism"]}, {"answer_start": [168], "text": ["pulmonary embolism"]}, {"answer_start": [168], "text": ["pulmonary embolism"]}, {"answer_start": [168], "text": ["pulmonary embolism"]}, {"answer_start": [78], "text": ["pulmonary embolism"]}, {"answer_start": [78], "text": ["pulmonary embolism"]}, {"answer_start": [78], "text": ["pulmonary embolism"]}, {"answer_start": [78], "text": ["pulmonary embolism"]}, {"answer_start": [78], "text": ["pulmonary embolism"]}, {"answer_start": [78], "text": ["pulmonary embolism"]}, {"answer_start": [78], "text": ["pulmonary embolism"]}, {"answer_start": [78], "text": ["pulmonary embolism"]}, {"answer_start": [78], "text": ["pulmonary embolism"]}, {"answer_start": [78], "text": ["pulmonary embolism"]}, {"answer_start": [78], "text": ["pulmonary embolism"]}, {"answer_start": [78], "text": ["pulmonary embolism"]}, {"answer_start": [78], "text": ["pulmonary embolism"]}, {"answer_start": [78], "text": ["pulmonary embolism"]}, {"answer_start": [78], "text": ["pulmonary embolism"]}, {"answer_start": [78], "text": ["pulmonary embolism"]}, {"answer_start": [78], "text": ["pulmonary embolism"]}, {"answer_start": [78], "text": ["pulmonary embolism"]}, {"answer_start": [78], "text": ["pulmonary embolism"]}, {"answer_start": [78], "text": ["pulmonary embolism"]}, {"answer_start": [78], "text": ["pulmonary embolism"]}, {"answer_start": [43, 86], "text": ["pulmonary embolism", "pulmonary embolism"]}, {"answer_start": [43, 86], "text": ["pulmonary embolism", "pulmonary embolism"]}, {"answer_start": [43, 86], "text": ["pulmonary embolism", "pulmonary embolism"]}, {"answer_start": [43, 86], "text": ["pulmonary embolism", "pulmonary embolism"]}, {"answer_start": [43, 86], "text": ["pulmonary embolism", "pulmonary embolism"]}, {"answer_start": [43, 86], "text": ["pulmonary embolism", "pulmonary embolism"]}, {"answer_start": [43, 86], "text": ["pulmonary embolism", "pulmonary embolism"]}, {"answer_start": [43, 86], "text": ["pulmonary embolism", "pulmonary embolism"]}, {"answer_start": [43, 86], "text": ["pulmonary embolism", "pulmonary embolism"]}, {"answer_start": [43, 86], "text": ["pulmonary embolism", "pulmonary embolism"]}, {"answer_start": [43, 86], "text": ["pulmonary embolism", "pulmonary embolism"]}, {"answer_start": [43, 86], "text": ["pulmonary embolism", "pulmonary embolism"]}, {"answer_start": [43, 86], "text": ["pulmonary embolism", "pulmonary embolism"]}, {"answer_start": [43, 86], "text": ["pulmonary embolism", "pulmonary embolism"]}, {"answer_start": [43, 86], "text": ["pulmonary embolism", "pulmonary embolism"]}, {"answer_start": [43, 86], "text": ["pulmonary embolism", "pulmonary embolism"]}, {"answer_start": [43, 86], "text": ["pulmonary embolism", "pulmonary embolism"]}, {"answer_start": [43, 86], "text": ["pulmonary embolism", "pulmonary embolism"]}, {"answer_start": [43, 86], "text": ["pulmonary embolism", "pulmonary embolism"]}, {"answer_start": [43, 86], "text": ["pulmonary embolism", "pulmonary embolism"]}, {"answer_start": [43, 86], "text": ["pulmonary embolism", "pulmonary embolism"]}, {"answer_start": [57], "text": ["pulmonary embolism"]}, {"answer_start": [57], "text": ["pulmonary embolism"]}, {"answer_start": [57], "text": ["pulmonary embolism"]}, {"answer_start": [57], "text": ["pulmonary embolism"]}, {"answer_start": [57], "text": ["pulmonary embolism"]}, {"answer_start": [57], "text": ["pulmonary embolism"]}, {"answer_start": [57], "text": ["pulmonary embolism"]}, {"answer_start": [57], "text": ["pulmonary embolism"]}, {"answer_start": [57], "text": ["pulmonary embolism"]}, {"answer_start": [57], "text": ["pulmonary embolism"]}, {"answer_start": [57], "text": ["pulmonary embolism"]}, {"answer_start": [57], "text": ["pulmonary embolism"]}, {"answer_start": [57], "text": ["pulmonary embolism"]}, {"answer_start": [57], "text": ["pulmonary embolism"]}, {"answer_start": [57], "text": ["pulmonary embolism"]}, {"answer_start": [57], "text": ["pulmonary embolism"]}, {"answer_start": [57], "text": ["pulmonary embolism"]}, {"answer_start": [57], "text": ["pulmonary embolism"]}, {"answer_start": [57], "text": ["pulmonary embolism"]}, {"answer_start": [57], "text": ["pulmonary embolism"]}, {"answer_start": [57], "text": ["pulmonary embolism"]}, {"answer_start": [86], "text": ["pulmonary embolism"]}, {"answer_start": [86], "text": ["pulmonary embolism"]}, {"answer_start": [86], "text": ["pulmonary embolism"]}, {"answer_start": [86], "text": ["pulmonary embolism"]}, {"answer_start": [86], "text": ["pulmonary embolism"]}, {"answer_start": [86], "text": ["pulmonary embolism"]}, {"answer_start": [86], "text": ["pulmonary embolism"]}, {"answer_start": [86], "text": ["pulmonary embolism"]}, {"answer_start": [86], "text": ["pulmonary embolism"]}, {"answer_start": [86], "text": ["pulmonary embolism"]}, {"answer_start": [86], "text": ["pulmonary embolism"]}, {"answer_start": [86], "text": ["pulmonary embolism"]}, {"answer_start": [86], "text": ["pulmonary embolism"]}, {"answer_start": [86], "text": ["pulmonary embolism"]}, {"answer_start": [86], "text": ["pulmonary embolism"]}, {"answer_start": [86], "text": ["pulmonary embolism"]}, {"answer_start": [86], "text": ["pulmonary embolism"]}, {"answer_start": [86], "text": ["pulmonary embolism"]}, {"answer_start": [86], "text": ["pulmonary embolism"]}, {"answer_start": [86], "text": ["pulmonary embolism"]}, {"answer_start": [86], "text": ["pulmonary embolism"]}, {"answer_start": [76], "text": ["pulmonary embolism"]}, {"answer_start": [76], "text": ["pulmonary embolism"]}, {"answer_start": [76], "text": ["pulmonary embolism"]}, {"answer_start": [76], "text": ["pulmonary embolism"]}, {"answer_start": [76], "text": ["pulmonary embolism"]}, {"answer_start": [76], "text": ["pulmonary embolism"]}, {"answer_start": [76], "text": ["pulmonary embolism"]}, {"answer_start": [76], "text": ["pulmonary embolism"]}, {"answer_start": [76], "text": ["pulmonary embolism"]}, {"answer_start": [76], "text": ["pulmonary embolism"]}, {"answer_start": [76], "text": ["pulmonary embolism"]}, {"answer_start": [76], "text": ["pulmonary embolism"]}, {"answer_start": [76], "text": ["pulmonary embolism"]}, {"answer_start": [76], "text": ["pulmonary embolism"]}, {"answer_start": [76], "text": ["pulmonary embolism"]}, {"answer_start": [76], "text": ["pulmonary embolism"]}, {"answer_start": [76], "text": ["pulmonary embolism"]}, {"answer_start": [76], "text": ["pulmonary embolism"]}, {"answer_start": [76], "text": ["pulmonary embolism"]}, {"answer_start": [76], "text": ["pulmonary embolism"]}, {"answer_start": [76], "text": ["pulmonary embolism"]}, {"answer_start": [164, 470], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [164, 470], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [164, 470], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [164, 470], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [164, 470], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [164, 470], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [164, 470], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [164, 470], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [164, 470], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [164, 470], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [164, 470], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [164, 470], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [164, 470], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [164, 470], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [164, 470], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [164, 470], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [164, 470], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [164, 470], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [164, 470], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [164, 470], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [164, 470], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [164, 470], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [164, 470], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [164, 470], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [164, 470], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [164, 470], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [164, 470], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [164, 470], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [164, 470], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [164, 470], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [180, 439], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [180, 439], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [180, 439], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [180, 439], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [180, 439], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [180, 439], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [180, 439], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [180, 439], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [180, 439], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [180, 439], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [180, 439], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [180, 439], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [180, 439], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [180, 439], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [180, 439], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [180, 439], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [180, 439], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [180, 439], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [180, 439], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [180, 439], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [180, 439], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [180, 439], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [180, 439], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [180, 439], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [180, 439], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [180, 439], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [180, 439], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [180, 439], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [180, 439], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [180, 439], "text": ["neuroblastoma", "neuroblastoma"]}, {"answer_start": [312], "text": ["neuroblastoma"]}, {"answer_start": [312], "text": ["neuroblastoma"]}, {"answer_start": [312], "text": ["neuroblastoma"]}, {"answer_start": [312], "text": ["neuroblastoma"]}, {"answer_start": [312], "text": ["neuroblastoma"]}, {"answer_start": [312], "text": ["neuroblastoma"]}, {"answer_start": [312], "text": ["neuroblastoma"]}, {"answer_start": [312], "text": ["neuroblastoma"]}, {"answer_start": [312], "text": ["neuroblastoma"]}, {"answer_start": [312], "text": ["neuroblastoma"]}, {"answer_start": [312], "text": ["neuroblastoma"]}, {"answer_start": [312], "text": ["neuroblastoma"]}, {"answer_start": [312], "text": ["neuroblastoma"]}, {"answer_start": [312], "text": ["neuroblastoma"]}, {"answer_start": [312], "text": ["neuroblastoma"]}, {"answer_start": [312], "text": ["neuroblastoma"]}, {"answer_start": [312], "text": ["neuroblastoma"]}, {"answer_start": [312], "text": ["neuroblastoma"]}, {"answer_start": [312], "text": ["neuroblastoma"]}, {"answer_start": [312], "text": ["neuroblastoma"]}, {"answer_start": [312], "text": ["neuroblastoma"]}, {"answer_start": [312], "text": ["neuroblastoma"]}, {"answer_start": [312], "text": ["neuroblastoma"]}, {"answer_start": [312], "text": ["neuroblastoma"]}, {"answer_start": [312], "text": ["neuroblastoma"]}, {"answer_start": [312], "text": ["neuroblastoma"]}, {"answer_start": [312], "text": ["neuroblastoma"]}, {"answer_start": [312], "text": ["neuroblastoma"]}, {"answer_start": [312], "text": ["neuroblastoma"]}, {"answer_start": [312], "text": ["neuroblastoma"]}, {"answer_start": [302], "text": ["neuroblastoma"]}, {"answer_start": [302], "text": ["neuroblastoma"]}, {"answer_start": [302], "text": ["neuroblastoma"]}, {"answer_start": [302], "text": ["neuroblastoma"]}, {"answer_start": [302], "text": ["neuroblastoma"]}, {"answer_start": [302], "text": ["neuroblastoma"]}, {"answer_start": [302], "text": ["neuroblastoma"]}, {"answer_start": [302], "text": ["neuroblastoma"]}, {"answer_start": [302], "text": ["neuroblastoma"]}, {"answer_start": [302], "text": ["neuroblastoma"]}, {"answer_start": [302], "text": ["neuroblastoma"]}, {"answer_start": [302], "text": ["neuroblastoma"]}, {"answer_start": [302], "text": ["neuroblastoma"]}, {"answer_start": [302], "text": ["neuroblastoma"]}, {"answer_start": [302], "text": ["neuroblastoma"]}, {"answer_start": [302], "text": ["neuroblastoma"]}, {"answer_start": [302], "text": ["neuroblastoma"]}, {"answer_start": [302], "text": ["neuroblastoma"]}, {"answer_start": [302], "text": ["neuroblastoma"]}, {"answer_start": [302], "text": ["neuroblastoma"]}, {"answer_start": [302], "text": ["neuroblastoma"]}, {"answer_start": [302], "text": ["neuroblastoma"]}, {"answer_start": [302], "text": ["neuroblastoma"]}, {"answer_start": [302], "text": ["neuroblastoma"]}, {"answer_start": [302], "text": ["neuroblastoma"]}, {"answer_start": [302], "text": ["neuroblastoma"]}, {"answer_start": [302], "text": ["neuroblastoma"]}, {"answer_start": [302], "text": ["neuroblastoma"]}, {"answer_start": [302], "text": ["neuroblastoma"]}, {"answer_start": [302], "text": ["neuroblastoma"]}, {"answer_start": [278], "text": ["neuroblastoma"]}, {"answer_start": [278], "text": ["neuroblastoma"]}, {"answer_start": [278], "text": ["neuroblastoma"]}, {"answer_start": [278], "text": ["neuroblastoma"]}, {"answer_start": [278], "text": ["neuroblastoma"]}, {"answer_start": [278], "text": ["neuroblastoma"]}, {"answer_start": [278], "text": ["neuroblastoma"]}, {"answer_start": [278], "text": ["neuroblastoma"]}, {"answer_start": [278], "text": ["neuroblastoma"]}, {"answer_start": [278], "text": ["neuroblastoma"]}, {"answer_start": [278], "text": ["neuroblastoma"]}, {"answer_start": [278], "text": ["neuroblastoma"]}, {"answer_start": [278], "text": ["neuroblastoma"]}, {"answer_start": [278], "text": ["neuroblastoma"]}, {"answer_start": [278], "text": ["neuroblastoma"]}, {"answer_start": [278], "text": ["neuroblastoma"]}, {"answer_start": [278], "text": ["neuroblastoma"]}, {"answer_start": [278], "text": ["neuroblastoma"]}, {"answer_start": [278], "text": ["neuroblastoma"]}, {"answer_start": [278], "text": ["neuroblastoma"]}, {"answer_start": [278], "text": ["neuroblastoma"]}, {"answer_start": [278], "text": ["neuroblastoma"]}, {"answer_start": [278], "text": ["neuroblastoma"]}, {"answer_start": [278], "text": ["neuroblastoma"]}, {"answer_start": [278], "text": ["neuroblastoma"]}, {"answer_start": [278], "text": ["neuroblastoma"]}, {"answer_start": [278], "text": ["neuroblastoma"]}, {"answer_start": [278], "text": ["neuroblastoma"]}, {"answer_start": [278], "text": ["neuroblastoma"]}, {"answer_start": [278], "text": ["neuroblastoma"]}, {"answer_start": [169], "text": ["neuroblastoma"]}, {"answer_start": [169], "text": ["neuroblastoma"]}, {"answer_start": [169], "text": ["neuroblastoma"]}, {"answer_start": [169], "text": ["neuroblastoma"]}, {"answer_start": [169], "text": ["neuroblastoma"]}, {"answer_start": [169], "text": ["neuroblastoma"]}, {"answer_start": [169], "text": ["neuroblastoma"]}, {"answer_start": [169], "text": ["neuroblastoma"]}, {"answer_start": [169], "text": ["neuroblastoma"]}, {"answer_start": [169], "text": ["neuroblastoma"]}, {"answer_start": [169], "text": ["neuroblastoma"]}, {"answer_start": [169], "text": ["neuroblastoma"]}, {"answer_start": [169], "text": ["neuroblastoma"]}, {"answer_start": [169], "text": ["neuroblastoma"]}, {"answer_start": [169], "text": ["neuroblastoma"]}, {"answer_start": [169], "text": ["neuroblastoma"]}, {"answer_start": [169], "text": ["neuroblastoma"]}, {"answer_start": [169], "text": ["neuroblastoma"]}, {"answer_start": [169], "text": ["neuroblastoma"]}, {"answer_start": [169], "text": ["neuroblastoma"]}, {"answer_start": [169], "text": ["neuroblastoma"]}, {"answer_start": [169], "text": ["neuroblastoma"]}, {"answer_start": [169], "text": ["neuroblastoma"]}, {"answer_start": [169], "text": ["neuroblastoma"]}, {"answer_start": [169], "text": ["neuroblastoma"]}, {"answer_start": [169], "text": ["neuroblastoma"]}, {"answer_start": [169], "text": ["neuroblastoma"]}, {"answer_start": [169], "text": ["neuroblastoma"]}, {"answer_start": [169], "text": ["neuroblastoma"]}, {"answer_start": [169], "text": ["neuroblastoma"]}, {"answer_start": [179], "text": ["neuroblastoma"]}, {"answer_start": [179], "text": ["neuroblastoma"]}, {"answer_start": [179], "text": ["neuroblastoma"]}, {"answer_start": [179], "text": ["neuroblastoma"]}, {"answer_start": [179], "text": ["neuroblastoma"]}, {"answer_start": [179], "text": ["neuroblastoma"]}, {"answer_start": [179], "text": ["neuroblastoma"]}, {"answer_start": [179], "text": ["neuroblastoma"]}, {"answer_start": [179], "text": ["neuroblastoma"]}, {"answer_start": [179], "text": ["neuroblastoma"]}, {"answer_start": [179], "text": ["neuroblastoma"]}, {"answer_start": [179], "text": ["neuroblastoma"]}, {"answer_start": [179], "text": ["neuroblastoma"]}, {"answer_start": [179], "text": ["neuroblastoma"]}, {"answer_start": [179], "text": ["neuroblastoma"]}, {"answer_start": [179], "text": ["neuroblastoma"]}, {"answer_start": [179], "text": ["neuroblastoma"]}, {"answer_start": [179], "text": ["neuroblastoma"]}, {"answer_start": [179], "text": ["neuroblastoma"]}, {"answer_start": [179], "text": ["neuroblastoma"]}, {"answer_start": [179], "text": ["neuroblastoma"]}, {"answer_start": [179], "text": ["neuroblastoma"]}, {"answer_start": [179], "text": ["neuroblastoma"]}, {"answer_start": [179], "text": ["neuroblastoma"]}, {"answer_start": [179], "text": ["neuroblastoma"]}, {"answer_start": [179], "text": ["neuroblastoma"]}, {"answer_start": [179], "text": ["neuroblastoma"]}, {"answer_start": [179], "text": ["neuroblastoma"]}, {"answer_start": [179], "text": ["neuroblastoma"]}, {"answer_start": [179], "text": ["neuroblastoma"]}, {"answer_start": [267], "text": ["neuroblastoma"]}, {"answer_start": [267], "text": ["neuroblastoma"]}, {"answer_start": [267], "text": ["neuroblastoma"]}, {"answer_start": [267], "text": ["neuroblastoma"]}, {"answer_start": [267], "text": ["neuroblastoma"]}, {"answer_start": [267], "text": ["neuroblastoma"]}, {"answer_start": [267], "text": ["neuroblastoma"]}, {"answer_start": [267], "text": ["neuroblastoma"]}, {"answer_start": [267], "text": ["neuroblastoma"]}, {"answer_start": [267], "text": ["neuroblastoma"]}, {"answer_start": [267], "text": ["neuroblastoma"]}, {"answer_start": [267], "text": ["neuroblastoma"]}, {"answer_start": [267], "text": ["neuroblastoma"]}, {"answer_start": [267], "text": ["neuroblastoma"]}, {"answer_start": [267], "text": ["neuroblastoma"]}, {"answer_start": [267], "text": ["neuroblastoma"]}, {"answer_start": [267], "text": ["neuroblastoma"]}, {"answer_start": [267], "text": ["neuroblastoma"]}, {"answer_start": [267], "text": ["neuroblastoma"]}, {"answer_start": [267], "text": ["neuroblastoma"]}, {"answer_start": [267], "text": ["neuroblastoma"]}, {"answer_start": [267], "text": ["neuroblastoma"]}, {"answer_start": [267], "text": ["neuroblastoma"]}, {"answer_start": [267], "text": ["neuroblastoma"]}, {"answer_start": [267], "text": ["neuroblastoma"]}, {"answer_start": [267], "text": ["neuroblastoma"]}, {"answer_start": [267], "text": ["neuroblastoma"]}, {"answer_start": [267], "text": ["neuroblastoma"]}, {"answer_start": [267], "text": ["neuroblastoma"]}, {"answer_start": [267], "text": ["neuroblastoma"]}, {"answer_start": [161], "text": ["neuroblastoma"]}, {"answer_start": [161], "text": ["neuroblastoma"]}, {"answer_start": [161], "text": ["neuroblastoma"]}, {"answer_start": [161], "text": ["neuroblastoma"]}, {"answer_start": [161], "text": ["neuroblastoma"]}, {"answer_start": [161], "text": ["neuroblastoma"]}, {"answer_start": [161], "text": ["neuroblastoma"]}, {"answer_start": [161], "text": ["neuroblastoma"]}, {"answer_start": [161], "text": ["neuroblastoma"]}, {"answer_start": [161], "text": ["neuroblastoma"]}, {"answer_start": [161], "text": ["neuroblastoma"]}, {"answer_start": [161], "text": ["neuroblastoma"]}, {"answer_start": [161], "text": ["neuroblastoma"]}, {"answer_start": [161], "text": ["neuroblastoma"]}, {"answer_start": [161], "text": ["neuroblastoma"]}, {"answer_start": [161], "text": ["neuroblastoma"]}, {"answer_start": [161], "text": ["neuroblastoma"]}, {"answer_start": [161], "text": ["neuroblastoma"]}, {"answer_start": [161], "text": ["neuroblastoma"]}, {"answer_start": [161], "text": ["neuroblastoma"]}, {"answer_start": [161], "text": ["neuroblastoma"]}, {"answer_start": [161], "text": ["neuroblastoma"]}, {"answer_start": [161], "text": ["neuroblastoma"]}, {"answer_start": [161], "text": ["neuroblastoma"]}, {"answer_start": [161], "text": ["neuroblastoma"]}, {"answer_start": [161], "text": ["neuroblastoma"]}, {"answer_start": [161], "text": ["neuroblastoma"]}, {"answer_start": [161], "text": ["neuroblastoma"]}, {"answer_start": [161], "text": ["neuroblastoma"]}, {"answer_start": [161], "text": ["neuroblastoma"]}, {"answer_start": [210], "text": ["neuroblastoma"]}, {"answer_start": [210], "text": ["neuroblastoma"]}, {"answer_start": [210], "text": ["neuroblastoma"]}, {"answer_start": [210], "text": ["neuroblastoma"]}, {"answer_start": [210], "text": ["neuroblastoma"]}, {"answer_start": [210], "text": ["neuroblastoma"]}, {"answer_start": [210], "text": ["neuroblastoma"]}, {"answer_start": [210], "text": ["neuroblastoma"]}, {"answer_start": [210], "text": ["neuroblastoma"]}, {"answer_start": [210], "text": ["neuroblastoma"]}, {"answer_start": [210], "text": ["neuroblastoma"]}, {"answer_start": [210], "text": ["neuroblastoma"]}, {"answer_start": [210], "text": ["neuroblastoma"]}, {"answer_start": [210], "text": ["neuroblastoma"]}, {"answer_start": [210], "text": ["neuroblastoma"]}, {"answer_start": [210], "text": ["neuroblastoma"]}, {"answer_start": [210], "text": ["neuroblastoma"]}, {"answer_start": [210], "text": ["neuroblastoma"]}, {"answer_start": [210], "text": ["neuroblastoma"]}, {"answer_start": [210], "text": ["neuroblastoma"]}, {"answer_start": [210], "text": ["neuroblastoma"]}, {"answer_start": [210], "text": ["neuroblastoma"]}, {"answer_start": [210], "text": ["neuroblastoma"]}, {"answer_start": [210], "text": ["neuroblastoma"]}, {"answer_start": [210], "text": ["neuroblastoma"]}, {"answer_start": [210], "text": ["neuroblastoma"]}, {"answer_start": [210], "text": ["neuroblastoma"]}, {"answer_start": [210], "text": ["neuroblastoma"]}, {"answer_start": [210], "text": ["neuroblastoma"]}, {"answer_start": [210], "text": ["neuroblastoma"]}, {"answer_start": [180], "text": ["neuroblastoma"]}, {"answer_start": [180], "text": ["neuroblastoma"]}, {"answer_start": [180], "text": ["neuroblastoma"]}, {"answer_start": [180], "text": ["neuroblastoma"]}, {"answer_start": [180], "text": ["neuroblastoma"]}, {"answer_start": [180], "text": ["neuroblastoma"]}, {"answer_start": [180], "text": ["neuroblastoma"]}, {"answer_start": [180], "text": ["neuroblastoma"]}, {"answer_start": [180], "text": ["neuroblastoma"]}, {"answer_start": [180], "text": ["neuroblastoma"]}, {"answer_start": [180], "text": ["neuroblastoma"]}, {"answer_start": [180], "text": ["neuroblastoma"]}, {"answer_start": [180], "text": ["neuroblastoma"]}, {"answer_start": [180], "text": ["neuroblastoma"]}, {"answer_start": [180], "text": ["neuroblastoma"]}, {"answer_start": [180], "text": ["neuroblastoma"]}, {"answer_start": [180], "text": ["neuroblastoma"]}, {"answer_start": [180], "text": ["neuroblastoma"]}, {"answer_start": [180], "text": ["neuroblastoma"]}, {"answer_start": [180], "text": ["neuroblastoma"]}, {"answer_start": [180], "text": ["neuroblastoma"]}, {"answer_start": [180], "text": ["neuroblastoma"]}, {"answer_start": [180], "text": ["neuroblastoma"]}, {"answer_start": [180], "text": ["neuroblastoma"]}, {"answer_start": [180], "text": ["neuroblastoma"]}, {"answer_start": [180], "text": ["neuroblastoma"]}, {"answer_start": [180], "text": ["neuroblastoma"]}, {"answer_start": [180], "text": ["neuroblastoma"]}, {"answer_start": [180], "text": ["neuroblastoma"]}, {"answer_start": [180], "text": ["neuroblastoma"]}, {"answer_start": [181], "text": ["neuroblastoma"]}, {"answer_start": [181], "text": ["neuroblastoma"]}, {"answer_start": [181], "text": ["neuroblastoma"]}, {"answer_start": [181], "text": ["neuroblastoma"]}, {"answer_start": [181], "text": ["neuroblastoma"]}, {"answer_start": [181], "text": ["neuroblastoma"]}, {"answer_start": [181], "text": ["neuroblastoma"]}, {"answer_start": [181], "text": ["neuroblastoma"]}, {"answer_start": [181], "text": ["neuroblastoma"]}, {"answer_start": [181], "text": ["neuroblastoma"]}, {"answer_start": [181], "text": ["neuroblastoma"]}, {"answer_start": [181], "text": ["neuroblastoma"]}, {"answer_start": [181], "text": ["neuroblastoma"]}, {"answer_start": [181], "text": ["neuroblastoma"]}, {"answer_start": [181], "text": ["neuroblastoma"]}, {"answer_start": [181], "text": ["neuroblastoma"]}, {"answer_start": [181], "text": ["neuroblastoma"]}, {"answer_start": [181], "text": ["neuroblastoma"]}, {"answer_start": [181], "text": ["neuroblastoma"]}, {"answer_start": [181], "text": ["neuroblastoma"]}, {"answer_start": [181], "text": ["neuroblastoma"]}, {"answer_start": [181], "text": ["neuroblastoma"]}, {"answer_start": [181], "text": ["neuroblastoma"]}, {"answer_start": [181], "text": ["neuroblastoma"]}, {"answer_start": [181], "text": ["neuroblastoma"]}, {"answer_start": [181], "text": ["neuroblastoma"]}, {"answer_start": [181], "text": ["neuroblastoma"]}, {"answer_start": [181], "text": ["neuroblastoma"]}, {"answer_start": [181], "text": ["neuroblastoma"]}, {"answer_start": [181], "text": ["neuroblastoma"]}, {"answer_start": [173], "text": ["neuroblastoma"]}, {"answer_start": [173], "text": ["neuroblastoma"]}, {"answer_start": [173], "text": ["neuroblastoma"]}, {"answer_start": [173], "text": ["neuroblastoma"]}, {"answer_start": [173], "text": ["neuroblastoma"]}, {"answer_start": [173], "text": ["neuroblastoma"]}, {"answer_start": [173], "text": ["neuroblastoma"]}, {"answer_start": [173], "text": ["neuroblastoma"]}, {"answer_start": [173], "text": ["neuroblastoma"]}, {"answer_start": [173], "text": ["neuroblastoma"]}, {"answer_start": [173], "text": ["neuroblastoma"]}, {"answer_start": [173], "text": ["neuroblastoma"]}, {"answer_start": [173], "text": ["neuroblastoma"]}, {"answer_start": [173], "text": ["neuroblastoma"]}, {"answer_start": [173], "text": ["neuroblastoma"]}, {"answer_start": [173], "text": ["neuroblastoma"]}, {"answer_start": [173], "text": ["neuroblastoma"]}, {"answer_start": [173], "text": ["neuroblastoma"]}, {"answer_start": [173], "text": ["neuroblastoma"]}, {"answer_start": [173], "text": ["neuroblastoma"]}, {"answer_start": [173], "text": ["neuroblastoma"]}, {"answer_start": [173], "text": ["neuroblastoma"]}, {"answer_start": [173], "text": ["neuroblastoma"]}, {"answer_start": [173], "text": ["neuroblastoma"]}, {"answer_start": [173], "text": ["neuroblastoma"]}, {"answer_start": [173], "text": ["neuroblastoma"]}, {"answer_start": [173], "text": ["neuroblastoma"]}, {"answer_start": [173], "text": ["neuroblastoma"]}, {"answer_start": [173], "text": ["neuroblastoma"]}, {"answer_start": [173], "text": ["neuroblastoma"]}, {"answer_start": [163], "text": ["neuroblastoma"]}, {"answer_start": [163], "text": ["neuroblastoma"]}, {"answer_start": [163], "text": ["neuroblastoma"]}, {"answer_start": [163], "text": ["neuroblastoma"]}, {"answer_start": [163], "text": ["neuroblastoma"]}, {"answer_start": [163], "text": ["neuroblastoma"]}, {"answer_start": [163], "text": ["neuroblastoma"]}, {"answer_start": [163], "text": ["neuroblastoma"]}, {"answer_start": [163], "text": ["neuroblastoma"]}, {"answer_start": [163], "text": ["neuroblastoma"]}, {"answer_start": [163], "text": ["neuroblastoma"]}, {"answer_start": [163], "text": ["neuroblastoma"]}, {"answer_start": [163], "text": ["neuroblastoma"]}, {"answer_start": [163], "text": ["neuroblastoma"]}, {"answer_start": [163], "text": ["neuroblastoma"]}, {"answer_start": [163], "text": ["neuroblastoma"]}, {"answer_start": [163], "text": ["neuroblastoma"]}, {"answer_start": [163], "text": ["neuroblastoma"]}, {"answer_start": [163], "text": ["neuroblastoma"]}, {"answer_start": [163], "text": ["neuroblastoma"]}, {"answer_start": [163], "text": ["neuroblastoma"]}, {"answer_start": [163], "text": ["neuroblastoma"]}, {"answer_start": [163], "text": ["neuroblastoma"]}, {"answer_start": [163], "text": ["neuroblastoma"]}, {"answer_start": [163], "text": ["neuroblastoma"]}, {"answer_start": [163], "text": ["neuroblastoma"]}, {"answer_start": [163], "text": ["neuroblastoma"]}, {"answer_start": [163], "text": ["neuroblastoma"]}, {"answer_start": [163], "text": ["neuroblastoma"]}, {"answer_start": [163], "text": ["neuroblastoma"]}, {"answer_start": [148], "text": ["neuroblastoma"]}, {"answer_start": [148], "text": ["neuroblastoma"]}, {"answer_start": [148], "text": ["neuroblastoma"]}, {"answer_start": [148], "text": ["neuroblastoma"]}, {"answer_start": [148], "text": ["neuroblastoma"]}, {"answer_start": [148], "text": ["neuroblastoma"]}, {"answer_start": [148], "text": ["neuroblastoma"]}, {"answer_start": [148], "text": ["neuroblastoma"]}, {"answer_start": [148], "text": ["neuroblastoma"]}, {"answer_start": [148], "text": ["neuroblastoma"]}, {"answer_start": [148], "text": ["neuroblastoma"]}, {"answer_start": [148], "text": ["neuroblastoma"]}, {"answer_start": [148], "text": ["neuroblastoma"]}, {"answer_start": [148], "text": ["neuroblastoma"]}, {"answer_start": [148], "text": ["neuroblastoma"]}, {"answer_start": [148], "text": ["neuroblastoma"]}, {"answer_start": [148], "text": ["neuroblastoma"]}, {"answer_start": [148], "text": ["neuroblastoma"]}, {"answer_start": [148], "text": ["neuroblastoma"]}, {"answer_start": [148], "text": ["neuroblastoma"]}, {"answer_start": [148], "text": ["neuroblastoma"]}, {"answer_start": [148], "text": ["neuroblastoma"]}, {"answer_start": [148], "text": ["neuroblastoma"]}, {"answer_start": [148], "text": ["neuroblastoma"]}, {"answer_start": [148], "text": ["neuroblastoma"]}, {"answer_start": [148], "text": ["neuroblastoma"]}, {"answer_start": [148], "text": ["neuroblastoma"]}, {"answer_start": [148], "text": ["neuroblastoma"]}, {"answer_start": [148], "text": ["neuroblastoma"]}, {"answer_start": [148], "text": ["neuroblastoma"]}, {"answer_start": [60], "text": ["neuroblastoma"]}, {"answer_start": [60], "text": ["neuroblastoma"]}, {"answer_start": [60], "text": ["neuroblastoma"]}, {"answer_start": [60], "text": ["neuroblastoma"]}, {"answer_start": [60], "text": ["neuroblastoma"]}, {"answer_start": [60], "text": ["neuroblastoma"]}, {"answer_start": [60], "text": ["neuroblastoma"]}, {"answer_start": [60], "text": ["neuroblastoma"]}, {"answer_start": [60], "text": ["neuroblastoma"]}, {"answer_start": [60], "text": ["neuroblastoma"]}, {"answer_start": [60], "text": ["neuroblastoma"]}, {"answer_start": [60], "text": ["neuroblastoma"]}, {"answer_start": [60], "text": ["neuroblastoma"]}, {"answer_start": [60], "text": ["neuroblastoma"]}, {"answer_start": [60], "text": ["neuroblastoma"]}, {"answer_start": [60], "text": ["neuroblastoma"]}, {"answer_start": [60], "text": ["neuroblastoma"]}, {"answer_start": [60], "text": ["neuroblastoma"]}, {"answer_start": [60], "text": ["neuroblastoma"]}, {"answer_start": [60], "text": ["neuroblastoma"]}, {"answer_start": [60], "text": ["neuroblastoma"]}, {"answer_start": [60], "text": ["neuroblastoma"]}, {"answer_start": [60], "text": ["neuroblastoma"]}, {"answer_start": [60], "text": ["neuroblastoma"]}, {"answer_start": [60], "text": ["neuroblastoma"]}, {"answer_start": [60], "text": ["neuroblastoma"]}, {"answer_start": [60], "text": ["neuroblastoma"]}, {"answer_start": [60], "text": ["neuroblastoma"]}, {"answer_start": [60], "text": ["neuroblastoma"]}, {"answer_start": [60], "text": ["neuroblastoma"]}, {"answer_start": [124], "text": ["neuroblastoma"]}, {"answer_start": [124], "text": ["neuroblastoma"]}, {"answer_start": [124], "text": ["neuroblastoma"]}, {"answer_start": [124], "text": ["neuroblastoma"]}, {"answer_start": [124], "text": ["neuroblastoma"]}, {"answer_start": [124], "text": ["neuroblastoma"]}, {"answer_start": [124], "text": ["neuroblastoma"]}, {"answer_start": [124], "text": ["neuroblastoma"]}, {"answer_start": [124], "text": ["neuroblastoma"]}, {"answer_start": [124], "text": ["neuroblastoma"]}, {"answer_start": [124], "text": ["neuroblastoma"]}, {"answer_start": [124], "text": ["neuroblastoma"]}, {"answer_start": [124], "text": ["neuroblastoma"]}, {"answer_start": [124], "text": ["neuroblastoma"]}, {"answer_start": [124], "text": ["neuroblastoma"]}, {"answer_start": [124], "text": ["neuroblastoma"]}, {"answer_start": [124], "text": ["neuroblastoma"]}, {"answer_start": [124], "text": ["neuroblastoma"]}, {"answer_start": [124], "text": ["neuroblastoma"]}, {"answer_start": [124], "text": ["neuroblastoma"]}, {"answer_start": [124], "text": ["neuroblastoma"]}, {"answer_start": [124], "text": ["neuroblastoma"]}, {"answer_start": [124], "text": ["neuroblastoma"]}, {"answer_start": [124], "text": ["neuroblastoma"]}, {"answer_start": [124], "text": ["neuroblastoma"]}, {"answer_start": [124], "text": ["neuroblastoma"]}, {"answer_start": [124], "text": ["neuroblastoma"]}, {"answer_start": [124], "text": ["neuroblastoma"]}, {"answer_start": [124], "text": ["neuroblastoma"]}, {"answer_start": [124], "text": ["neuroblastoma"]}, {"answer_start": [36], "text": ["neuroblastoma"]}, {"answer_start": [36], "text": ["neuroblastoma"]}, {"answer_start": [36], "text": ["neuroblastoma"]}, {"answer_start": [36], "text": ["neuroblastoma"]}, {"answer_start": [36], "text": ["neuroblastoma"]}, {"answer_start": [36], "text": ["neuroblastoma"]}, {"answer_start": [36], "text": ["neuroblastoma"]}, {"answer_start": [36], "text": ["neuroblastoma"]}, {"answer_start": [36], "text": ["neuroblastoma"]}, {"answer_start": [36], "text": ["neuroblastoma"]}, {"answer_start": [36], "text": ["neuroblastoma"]}, {"answer_start": [36], "text": ["neuroblastoma"]}, {"answer_start": [36], "text": ["neuroblastoma"]}, {"answer_start": [36], "text": ["neuroblastoma"]}, {"answer_start": [36], "text": ["neuroblastoma"]}, {"answer_start": [36], "text": ["neuroblastoma"]}, {"answer_start": [36], "text": ["neuroblastoma"]}, {"answer_start": [36], "text": ["neuroblastoma"]}, {"answer_start": [36], "text": ["neuroblastoma"]}, {"answer_start": [36], "text": ["neuroblastoma"]}, {"answer_start": [36], "text": ["neuroblastoma"]}, {"answer_start": [36], "text": ["neuroblastoma"]}, {"answer_start": [36], "text": ["neuroblastoma"]}, {"answer_start": [36], "text": ["neuroblastoma"]}, {"answer_start": [36], "text": ["neuroblastoma"]}, {"answer_start": [36], "text": ["neuroblastoma"]}, {"answer_start": [36], "text": ["neuroblastoma"]}, {"answer_start": [36], "text": ["neuroblastoma"]}, {"answer_start": [36], "text": ["neuroblastoma"]}, {"answer_start": [36], "text": ["neuroblastoma"]}, {"answer_start": [134], "text": ["neuroblastoma"]}, {"answer_start": [134], "text": ["neuroblastoma"]}, {"answer_start": [134], "text": ["neuroblastoma"]}, {"answer_start": [134], "text": ["neuroblastoma"]}, {"answer_start": [134], "text": ["neuroblastoma"]}, {"answer_start": [134], "text": ["neuroblastoma"]}, {"answer_start": [134], "text": ["neuroblastoma"]}, {"answer_start": [134], "text": ["neuroblastoma"]}, {"answer_start": [134], "text": ["neuroblastoma"]}, {"answer_start": [134], "text": ["neuroblastoma"]}, {"answer_start": [134], "text": ["neuroblastoma"]}, {"answer_start": [134], "text": ["neuroblastoma"]}, {"answer_start": [134], "text": ["neuroblastoma"]}, {"answer_start": [134], "text": ["neuroblastoma"]}, {"answer_start": [134], "text": ["neuroblastoma"]}, {"answer_start": [134], "text": ["neuroblastoma"]}, {"answer_start": [134], "text": ["neuroblastoma"]}, {"answer_start": [134], "text": ["neuroblastoma"]}, {"answer_start": [134], "text": ["neuroblastoma"]}, {"answer_start": [134], "text": ["neuroblastoma"]}, {"answer_start": [134], "text": ["neuroblastoma"]}, {"answer_start": [134], "text": ["neuroblastoma"]}, {"answer_start": [134], "text": ["neuroblastoma"]}, {"answer_start": [134], "text": ["neuroblastoma"]}, {"answer_start": [134], "text": ["neuroblastoma"]}, {"answer_start": [134], "text": ["neuroblastoma"]}, {"answer_start": [134], "text": ["neuroblastoma"]}, {"answer_start": [134], "text": ["neuroblastoma"]}, {"answer_start": [134], "text": ["neuroblastoma"]}, {"answer_start": [134], "text": ["neuroblastoma"]}, {"answer_start": [107], "text": ["neuroblastoma"]}, {"answer_start": [107], "text": ["neuroblastoma"]}, {"answer_start": [107], "text": ["neuroblastoma"]}, {"answer_start": [107], "text": ["neuroblastoma"]}, {"answer_start": [107], "text": ["neuroblastoma"]}, {"answer_start": [107], "text": ["neuroblastoma"]}, {"answer_start": [107], "text": ["neuroblastoma"]}, {"answer_start": [107], "text": ["neuroblastoma"]}, {"answer_start": [107], "text": ["neuroblastoma"]}, {"answer_start": [107], "text": ["neuroblastoma"]}, {"answer_start": [107], "text": ["neuroblastoma"]}, {"answer_start": [107], "text": ["neuroblastoma"]}, {"answer_start": [107], "text": ["neuroblastoma"]}, {"answer_start": [107], "text": ["neuroblastoma"]}, {"answer_start": [107], "text": ["neuroblastoma"]}, {"answer_start": [107], "text": ["neuroblastoma"]}, {"answer_start": [107], "text": ["neuroblastoma"]}, {"answer_start": [107], "text": ["neuroblastoma"]}, {"answer_start": [107], "text": ["neuroblastoma"]}, {"answer_start": [107], "text": ["neuroblastoma"]}, {"answer_start": [107], "text": ["neuroblastoma"]}, {"answer_start": [107], "text": ["neuroblastoma"]}, {"answer_start": [107], "text": ["neuroblastoma"]}, {"answer_start": [107], "text": ["neuroblastoma"]}, {"answer_start": [107], "text": ["neuroblastoma"]}, {"answer_start": [107], "text": ["neuroblastoma"]}, {"answer_start": [107], "text": ["neuroblastoma"]}, {"answer_start": [107], "text": ["neuroblastoma"]}, {"answer_start": [107], "text": ["neuroblastoma"]}, {"answer_start": [107], "text": ["neuroblastoma"]}, {"answer_start": [67], "text": ["neuroblastoma"]}, {"answer_start": [67], "text": ["neuroblastoma"]}, {"answer_start": [67], "text": ["neuroblastoma"]}, {"answer_start": [67], "text": ["neuroblastoma"]}, {"answer_start": [67], "text": ["neuroblastoma"]}, {"answer_start": [67], "text": ["neuroblastoma"]}, {"answer_start": [67], "text": ["neuroblastoma"]}, {"answer_start": [67], "text": ["neuroblastoma"]}, {"answer_start": [67], "text": ["neuroblastoma"]}, {"answer_start": [67], "text": ["neuroblastoma"]}, {"answer_start": [67], "text": ["neuroblastoma"]}, {"answer_start": [67], "text": ["neuroblastoma"]}, {"answer_start": [67], "text": ["neuroblastoma"]}, {"answer_start": [67], "text": ["neuroblastoma"]}, {"answer_start": [67], "text": ["neuroblastoma"]}, {"answer_start": [67], "text": ["neuroblastoma"]}, {"answer_start": [67], "text": ["neuroblastoma"]}, {"answer_start": [67], "text": ["neuroblastoma"]}, {"answer_start": [67], "text": ["neuroblastoma"]}, {"answer_start": [67], "text": ["neuroblastoma"]}, {"answer_start": [67], "text": ["neuroblastoma"]}, {"answer_start": [67], "text": ["neuroblastoma"]}, {"answer_start": [67], "text": ["neuroblastoma"]}, {"answer_start": [67], "text": ["neuroblastoma"]}, {"answer_start": [67], "text": ["neuroblastoma"]}, {"answer_start": [67], "text": ["neuroblastoma"]}, {"answer_start": [67], "text": ["neuroblastoma"]}, {"answer_start": [67], "text": ["neuroblastoma"]}, {"answer_start": [67], "text": ["neuroblastoma"]}, {"answer_start": [67], "text": ["neuroblastoma"]}, {"answer_start": [35], "text": ["neuroblastoma"]}, {"answer_start": [35], "text": ["neuroblastoma"]}, {"answer_start": [35], "text": ["neuroblastoma"]}, {"answer_start": [35], "text": ["neuroblastoma"]}, {"answer_start": [35], "text": ["neuroblastoma"]}, {"answer_start": [35], "text": ["neuroblastoma"]}, {"answer_start": [35], "text": ["neuroblastoma"]}, {"answer_start": [35], "text": ["neuroblastoma"]}, {"answer_start": [35], "text": ["neuroblastoma"]}, {"answer_start": [35], "text": ["neuroblastoma"]}, {"answer_start": [35], "text": ["neuroblastoma"]}, {"answer_start": [35], "text": ["neuroblastoma"]}, {"answer_start": [35], "text": ["neuroblastoma"]}, {"answer_start": [35], "text": ["neuroblastoma"]}, {"answer_start": [35], "text": ["neuroblastoma"]}, {"answer_start": [35], "text": ["neuroblastoma"]}, {"answer_start": [35], "text": ["neuroblastoma"]}, {"answer_start": [35], "text": ["neuroblastoma"]}, {"answer_start": [35], "text": ["neuroblastoma"]}, {"answer_start": [35], "text": ["neuroblastoma"]}, {"answer_start": [35], "text": ["neuroblastoma"]}, {"answer_start": [35], "text": ["neuroblastoma"]}, {"answer_start": [35], "text": ["neuroblastoma"]}, {"answer_start": [35], "text": ["neuroblastoma"]}, {"answer_start": [35], "text": ["neuroblastoma"]}, {"answer_start": [35], "text": ["neuroblastoma"]}, {"answer_start": [35], "text": ["neuroblastoma"]}, {"answer_start": [35], "text": ["neuroblastoma"]}, {"answer_start": [35], "text": ["neuroblastoma"]}, {"answer_start": [35], "text": ["neuroblastoma"]}, {"answer_start": [78, 169], "text": ["tuberculosis", "tuberculosis"]}, {"answer_start": [78, 169], "text": ["tuberculosis", "tuberculosis"]}, {"answer_start": [78, 169], "text": ["tuberculosis", "tuberculosis"]}, {"answer_start": [78, 169], "text": ["tuberculosis", "tuberculosis"]}, {"answer_start": [78, 169], "text": ["tuberculosis", "tuberculosis"]}, {"answer_start": [78, 169], "text": ["tuberculosis", "tuberculosis"]}, {"answer_start": [78, 169], "text": ["tuberculosis", "tuberculosis"]}, {"answer_start": [78, 169], "text": ["tuberculosis", "tuberculosis"]}, {"answer_start": [78, 169], "text": ["tuberculosis", "tuberculosis"]}, {"answer_start": [78, 169], "text": ["tuberculosis", "tuberculosis"]}, {"answer_start": [78, 169], "text": ["tuberculosis", "tuberculosis"]}, {"answer_start": [78, 169], "text": ["tuberculosis", "tuberculosis"]}, {"answer_start": [78, 169], "text": ["tuberculosis", "tuberculosis"]}, {"answer_start": [78, 169], "text": ["tuberculosis", "tuberculosis"]}, {"answer_start": [78, 169], "text": ["tuberculosis", "tuberculosis"]}, {"answer_start": [78, 169], "text": ["tuberculosis", "tuberculosis"]}, {"answer_start": [78, 169], "text": ["tuberculosis", "tuberculosis"]}, {"answer_start": [78, 169], "text": ["tuberculosis", "tuberculosis"]}, {"answer_start": [78, 169], "text": ["tuberculosis", "tuberculosis"]}, {"answer_start": [78, 169], "text": ["tuberculosis", "tuberculosis"]}, {"answer_start": [78, 169], "text": ["tuberculosis", "tuberculosis"]}, {"answer_start": [78, 169], "text": ["tuberculosis", "tuberculosis"]}, {"answer_start": [78, 169], "text": ["tuberculosis", "tuberculosis"]}, {"answer_start": [78, 169], "text": ["tuberculosis", "tuberculosis"]}, {"answer_start": [78, 169], "text": ["tuberculosis", "tuberculosis"]}, {"answer_start": [78, 169], "text": ["tuberculosis", "tuberculosis"]}, {"answer_start": [78, 169], "text": ["tuberculosis", "tuberculosis"]}, {"answer_start": [78, 169], "text": ["tuberculosis", "tuberculosis"]}, {"answer_start": [78, 169], "text": ["tuberculosis", "tuberculosis"]}, {"answer_start": [78, 169], "text": ["tuberculosis", "tuberculosis"]}, {"answer_start": [78, 169], "text": ["tuberculosis", "tuberculosis"]}, {"answer_start": [78, 169], "text": ["tuberculosis", "tuberculosis"]}, {"answer_start": [78, 169], "text": ["tuberculosis", "tuberculosis"]}, {"answer_start": [78, 169], "text": ["tuberculosis", "tuberculosis"]}, {"answer_start": [78, 169], "text": ["tuberculosis", "tuberculosis"]}, {"answer_start": [117, 166, 250], "text": ["tuberculosis", "tuberculosis", "tuberculosis"]}, {"answer_start": [117, 166, 250], "text": ["tuberculosis", "tuberculosis", "tuberculosis"]}, {"answer_start": [117, 166, 250], "text": ["tuberculosis", "tuberculosis", "tuberculosis"]}, {"answer_start": [117, 166, 250], "text": ["tuberculosis", "tuberculosis", "tuberculosis"]}, {"answer_start": [117, 166, 250], "text": ["tuberculosis", "tuberculosis", "tuberculosis"]}, {"answer_start": [117, 166, 250], "text": ["tuberculosis", "tuberculosis", "tuberculosis"]}, {"answer_start": [117, 166, 250], "text": ["tuberculosis", "tuberculosis", "tuberculosis"]}, {"answer_start": [117, 166, 250], "text": ["tuberculosis", "tuberculosis", "tuberculosis"]}, {"answer_start": [117, 166, 250], "text": ["tuberculosis", "tuberculosis", "tuberculosis"]}, {"answer_start": [117, 166, 250], "text": ["tuberculosis", "tuberculosis", "tuberculosis"]}, {"answer_start": [117, 166, 250], "text": ["tuberculosis", "tuberculosis", "tuberculosis"]}, {"answer_start": [117, 166, 250], "text": ["tuberculosis", "tuberculosis", "tuberculosis"]}, {"answer_start": [117, 166, 250], "text": ["tuberculosis", "tuberculosis", "tuberculosis"]}, {"answer_start": [117, 166, 250], "text": ["tuberculosis", "tuberculosis", "tuberculosis"]}, {"answer_start": [117, 166, 250], "text": ["tuberculosis", "tuberculosis", "tuberculosis"]}, {"answer_start": [117, 166, 250], "text": ["tuberculosis", "tuberculosis", "tuberculosis"]}, {"answer_start": [117, 166, 250], "text": ["tuberculosis", "tuberculosis", "tuberculosis"]}, {"answer_start": [117, 166, 250], "text": ["tuberculosis", "tuberculosis", "tuberculosis"]}, {"answer_start": [117, 166, 250], "text": ["tuberculosis", "tuberculosis", "tuberculosis"]}, {"answer_start": [117, 166, 250], "text": ["tuberculosis", "tuberculosis", "tuberculosis"]}, {"answer_start": [117, 166, 250], "text": ["tuberculosis", "tuberculosis", "tuberculosis"]}, {"answer_start": [117, 166, 250], "text": ["tuberculosis", "tuberculosis", "tuberculosis"]}, {"answer_start": [117, 166, 250], "text": ["tuberculosis", "tuberculosis", "tuberculosis"]}, {"answer_start": [117, 166, 250], "text": ["tuberculosis", "tuberculosis", "tuberculosis"]}, {"answer_start": [117, 166, 250], "text": ["tuberculosis", "tuberculosis", "tuberculosis"]}, {"answer_start": [117, 166, 250], "text": ["tuberculosis", "tuberculosis", "tuberculosis"]}, {"answer_start": [117, 166, 250], "text": ["tuberculosis", "tuberculosis", "tuberculosis"]}, {"answer_start": [117, 166, 250], "text": ["tuberculosis", "tuberculosis", "tuberculosis"]}, {"answer_start": [117, 166, 250], "text": ["tuberculosis", "tuberculosis", "tuberculosis"]}, {"answer_start": [117, 166, 250], "text": ["tuberculosis", "tuberculosis", "tuberculosis"]}, {"answer_start": [117, 166, 250], "text": ["tuberculosis", "tuberculosis", "tuberculosis"]}, {"answer_start": [117, 166, 250], "text": ["tuberculosis", "tuberculosis", "tuberculosis"]}, {"answer_start": [117, 166, 250], "text": ["tuberculosis", "tuberculosis", "tuberculosis"]}, {"answer_start": [117, 166, 250], "text": ["tuberculosis", "tuberculosis", "tuberculosis"]}, {"answer_start": [117, 166, 250], "text": ["tuberculosis", "tuberculosis", "tuberculosis"]}, {"answer_start": [18], "text": ["tuberculosis"]}, {"answer_start": [18], "text": ["tuberculosis"]}, {"answer_start": [18], "text": ["tuberculosis"]}, {"answer_start": [18], "text": ["tuberculosis"]}, {"answer_start": [18], "text": ["tuberculosis"]}, {"answer_start": [18], "text": ["tuberculosis"]}, {"answer_start": [18], "text": ["tuberculosis"]}, {"answer_start": [18], "text": ["tuberculosis"]}, {"answer_start": [18], "text": ["tuberculosis"]}, {"answer_start": [18], "text": ["tuberculosis"]}, {"answer_start": [18], "text": ["tuberculosis"]}, {"answer_start": [18], "text": ["tuberculosis"]}, {"answer_start": [18], "text": ["tuberculosis"]}, {"answer_start": [18], "text": ["tuberculosis"]}, {"answer_start": [18], "text": ["tuberculosis"]}, {"answer_start": [18], "text": ["tuberculosis"]}, {"answer_start": [18], "text": ["tuberculosis"]}, {"answer_start": [18], "text": ["tuberculosis"]}, {"answer_start": [18], "text": ["tuberculosis"]}, {"answer_start": [18], "text": ["tuberculosis"]}, {"answer_start": [18], "text": ["tuberculosis"]}, {"answer_start": [18], "text": ["tuberculosis"]}, {"answer_start": [18], "text": ["tuberculosis"]}, {"answer_start": [18], "text": ["tuberculosis"]}, {"answer_start": [18], "text": ["tuberculosis"]}, {"answer_start": [18], "text": ["tuberculosis"]}, {"answer_start": [18], "text": ["tuberculosis"]}, {"answer_start": [18], "text": ["tuberculosis"]}, {"answer_start": [18], "text": ["tuberculosis"]}, {"answer_start": [18], "text": ["tuberculosis"]}, {"answer_start": [18], "text": ["tuberculosis"]}, {"answer_start": [18], "text": ["tuberculosis"]}, {"answer_start": [18], "text": ["tuberculosis"]}, {"answer_start": [18], "text": ["tuberculosis"]}, {"answer_start": [18], "text": ["tuberculosis"]}, {"answer_start": [102], "text": ["tuberculosis"]}, {"answer_start": [102], "text": ["tuberculosis"]}, {"answer_start": [102], "text": ["tuberculosis"]}, {"answer_start": [102], "text": ["tuberculosis"]}, {"answer_start": [102], "text": ["tuberculosis"]}, {"answer_start": [102], "text": ["tuberculosis"]}, {"answer_start": [102], "text": ["tuberculosis"]}, {"answer_start": [102], "text": ["tuberculosis"]}, {"answer_start": [102], "text": ["tuberculosis"]}, {"answer_start": [102], "text": ["tuberculosis"]}, {"answer_start": [102], "text": ["tuberculosis"]}, {"answer_start": [102], "text": ["tuberculosis"]}, {"answer_start": [102], "text": ["tuberculosis"]}, {"answer_start": [102], "text": ["tuberculosis"]}, {"answer_start": [102], "text": ["tuberculosis"]}, {"answer_start": [102], "text": ["tuberculosis"]}, {"answer_start": [102], "text": ["tuberculosis"]}, {"answer_start": [102], "text": ["tuberculosis"]}, {"answer_start": [102], "text": ["tuberculosis"]}, {"answer_start": [102], "text": ["tuberculosis"]}, {"answer_start": [102], "text": ["tuberculosis"]}, {"answer_start": [102], "text": ["tuberculosis"]}, {"answer_start": [102], "text": ["tuberculosis"]}, {"answer_start": [102], "text": ["tuberculosis"]}, {"answer_start": [102], "text": ["tuberculosis"]}, {"answer_start": [102], "text": ["tuberculosis"]}, {"answer_start": [102], "text": ["tuberculosis"]}, {"answer_start": [102], "text": ["tuberculosis"]}, {"answer_start": [102], "text": ["tuberculosis"]}, {"answer_start": [102], "text": ["tuberculosis"]}, {"answer_start": [102], "text": ["tuberculosis"]}, {"answer_start": [102], "text": ["tuberculosis"]}, {"answer_start": [102], "text": ["tuberculosis"]}, {"answer_start": [102], "text": ["tuberculosis"]}, {"answer_start": [102], "text": ["tuberculosis"]}, {"answer_start": [7], "text": ["tuberculosis"]}, {"answer_start": [7], "text": ["tuberculosis"]}, {"answer_start": [7], "text": ["tuberculosis"]}, {"answer_start": [7], "text": ["tuberculosis"]}, {"answer_start": [7], "text": ["tuberculosis"]}, {"answer_start": [7], "text": ["tuberculosis"]}, {"answer_start": [7], "text": ["tuberculosis"]}, {"answer_start": [7], "text": ["tuberculosis"]}, {"answer_start": [7], "text": ["tuberculosis"]}, {"answer_start": [7], "text": ["tuberculosis"]}, {"answer_start": [7], "text": ["tuberculosis"]}, {"answer_start": [7], "text": ["tuberculosis"]}, {"answer_start": [7], "text": ["tuberculosis"]}, {"answer_start": [7], "text": ["tuberculosis"]}, {"answer_start": [7], "text": ["tuberculosis"]}, {"answer_start": [7], "text": ["tuberculosis"]}, {"answer_start": [7], "text": ["tuberculosis"]}, {"answer_start": [7], "text": ["tuberculosis"]}, {"answer_start": [7], "text": ["tuberculosis"]}, {"answer_start": [7], "text": ["tuberculosis"]}, {"answer_start": [7], "text": ["tuberculosis"]}, {"answer_start": [7], "text": ["tuberculosis"]}, {"answer_start": [7], "text": ["tuberculosis"]}, {"answer_start": [7], "text": ["tuberculosis"]}, {"answer_start": [7], "text": ["tuberculosis"]}, {"answer_start": [7], "text": ["tuberculosis"]}, {"answer_start": [7], "text": ["tuberculosis"]}, {"answer_start": [7], "text": ["tuberculosis"]}, {"answer_start": [7], "text": ["tuberculosis"]}, {"answer_start": [7], "text": ["tuberculosis"]}, {"answer_start": [7], "text": ["tuberculosis"]}, {"answer_start": [7], "text": ["tuberculosis"]}, {"answer_start": [7], "text": ["tuberculosis"]}, {"answer_start": [7], "text": ["tuberculosis"]}, {"answer_start": [7], "text": ["tuberculosis"]}, {"answer_start": [278], "text": ["median"]}, {"answer_start": [278], "text": ["median"]}, {"answer_start": [278], "text": ["median"]}, {"answer_start": [278], "text": ["median"]}, {"answer_start": [278], "text": ["median"]}, {"answer_start": [278], "text": ["median"]}, {"answer_start": [278], "text": ["median"]}, {"answer_start": [278], "text": ["median"]}, {"answer_start": [117], "text": ["median"]}, {"answer_start": [117], "text": ["median"]}, {"answer_start": [117], "text": ["median"]}, {"answer_start": [117], "text": ["median"]}, {"answer_start": [117], "text": ["median"]}, {"answer_start": [117], "text": ["median"]}, {"answer_start": [117], "text": ["median"]}, {"answer_start": [117], "text": ["median"]}, {"answer_start": [138], "text": ["median"]}, {"answer_start": [138], "text": ["median"]}, {"answer_start": [138], "text": ["median"]}, {"answer_start": [138], "text": ["median"]}, {"answer_start": [138], "text": ["median"]}, {"answer_start": [138], "text": ["median"]}, {"answer_start": [138], "text": ["median"]}, {"answer_start": [138], "text": ["median"]}, {"answer_start": [49], "text": ["median"]}, {"answer_start": [49], "text": ["median"]}, {"answer_start": [49], "text": ["median"]}, {"answer_start": [49], "text": ["median"]}, {"answer_start": [49], "text": ["median"]}, {"answer_start": [49], "text": ["median"]}, {"answer_start": [49], "text": ["median"]}, {"answer_start": [49], "text": ["median"]}, {"answer_start": [16], "text": ["median"]}, {"answer_start": [16], "text": ["median"]}, {"answer_start": [16], "text": ["median"]}, {"answer_start": [16], "text": ["median"]}, {"answer_start": [16], "text": ["median"]}, {"answer_start": [16], "text": ["median"]}, {"answer_start": [16], "text": ["median"]}, {"answer_start": [16], "text": ["median"]}, {"answer_start": [19], "text": ["median"]}, {"answer_start": [19], "text": ["median"]}, {"answer_start": [19], "text": ["median"]}, {"answer_start": [19], "text": ["median"]}, {"answer_start": [19], "text": ["median"]}, {"answer_start": [19], "text": ["median"]}, {"answer_start": [19], "text": ["median"]}, {"answer_start": [19], "text": ["median"]}, {"answer_start": [82], "text": ["median"]}, {"answer_start": [82], "text": ["median"]}, {"answer_start": [82], "text": ["median"]}, {"answer_start": [82], "text": ["median"]}, {"answer_start": [82], "text": ["median"]}, {"answer_start": [82], "text": ["median"]}, {"answer_start": [82], "text": ["median"]}, {"answer_start": [82], "text": ["median"]}, {"answer_start": [48], "text": ["median"]}, {"answer_start": [48], "text": ["median"]}, {"answer_start": [48], "text": ["median"]}, {"answer_start": [48], "text": ["median"]}, {"answer_start": [48], "text": ["median"]}, {"answer_start": [48], "text": ["median"]}, {"answer_start": [48], "text": ["median"]}, {"answer_start": [48], "text": ["median"]}, {"answer_start": [70], "text": ["median"]}, {"answer_start": [70], "text": ["median"]}, {"answer_start": [70], "text": ["median"]}, {"answer_start": [70], "text": ["median"]}, {"answer_start": [70], "text": ["median"]}, {"answer_start": [70], "text": ["median"]}, {"answer_start": [70], "text": ["median"]}, {"answer_start": [70], "text": ["median"]}, {"answer_start": [51], "text": ["median"]}, {"answer_start": [51], "text": ["median"]}, {"answer_start": [51], "text": ["median"]}, {"answer_start": [51], "text": ["median"]}, {"answer_start": [51], "text": ["median"]}, {"answer_start": [51], "text": ["median"]}, {"answer_start": [51], "text": ["median"]}, {"answer_start": [51], "text": ["median"]}, {"answer_start": [25], "text": ["median"]}, {"answer_start": [25], "text": ["median"]}, {"answer_start": [25], "text": ["median"]}, {"answer_start": [25], "text": ["median"]}, {"answer_start": [25], "text": ["median"]}, {"answer_start": [25], "text": ["median"]}, {"answer_start": [25], "text": ["median"]}, {"answer_start": [25], "text": ["median"]}, {"answer_start": [33], "text": ["foot"]}, {"answer_start": [33], "text": ["foot"]}, {"answer_start": [33], "text": ["foot"]}, {"answer_start": [33], "text": ["foot"]}, {"answer_start": [33], "text": ["foot"]}, {"answer_start": [33], "text": ["foot"]}, {"answer_start": [33], "text": ["foot"]}, {"answer_start": [33], "text": ["foot"]}, {"answer_start": [33], "text": ["foot"]}, {"answer_start": [33], "text": ["foot"]}, {"answer_start": [33], "text": ["foot"]}, {"answer_start": [33], "text": ["foot"]}, {"answer_start": [33], "text": ["foot"]}, {"answer_start": [33], "text": ["foot"]}, {"answer_start": [33], "text": ["foot"]}, {"answer_start": [33], "text": ["foot"]}, {"answer_start": [33], "text": ["foot"]}, {"answer_start": [33], "text": ["foot"]}, {"answer_start": [33], "text": ["foot"]}, {"answer_start": [33], "text": ["foot"]}, {"answer_start": [33], "text": ["foot"]}, {"answer_start": [33], "text": ["foot"]}, {"answer_start": [33], "text": ["foot"]}, {"answer_start": [33], "text": ["foot"]}, {"answer_start": [33], "text": ["foot"]}, {"answer_start": [33], "text": ["foot"]}, {"answer_start": [33], "text": ["foot"]}, {"answer_start": [33], "text": ["foot"]}, {"answer_start": [33], "text": ["foot"]}, {"answer_start": [33], "text": ["foot"]}, {"answer_start": [33], "text": ["foot"]}, {"answer_start": [33], "text": ["foot"]}, {"answer_start": [33], "text": ["foot"]}, {"answer_start": [33], "text": ["foot"]}, {"answer_start": [33], "text": ["foot"]}, {"answer_start": [33], "text": ["foot"]}, {"answer_start": [33], "text": ["foot"]}, {"answer_start": [100], "text": ["foot"]}, {"answer_start": [100], "text": ["foot"]}, {"answer_start": [100], "text": ["foot"]}, {"answer_start": [100], "text": ["foot"]}, {"answer_start": [100], "text": ["foot"]}, {"answer_start": [100], "text": ["foot"]}, {"answer_start": [100], "text": ["foot"]}, {"answer_start": [100], "text": ["foot"]}, {"answer_start": [100], "text": ["foot"]}, {"answer_start": [100], "text": ["foot"]}, {"answer_start": [100], "text": ["foot"]}, {"answer_start": [100], "text": ["foot"]}, {"answer_start": [100], "text": ["foot"]}, {"answer_start": [100], "text": ["foot"]}, {"answer_start": [100], "text": ["foot"]}, {"answer_start": [100], "text": ["foot"]}, {"answer_start": [100], "text": ["foot"]}, {"answer_start": [100], "text": ["foot"]}, {"answer_start": [100], "text": ["foot"]}, {"answer_start": [100], "text": ["foot"]}, {"answer_start": [100], "text": ["foot"]}, {"answer_start": [100], "text": ["foot"]}, {"answer_start": [100], "text": ["foot"]}, {"answer_start": [100], "text": ["foot"]}, {"answer_start": [100], "text": ["foot"]}, {"answer_start": [100], "text": ["foot"]}, {"answer_start": [100], "text": ["foot"]}, {"answer_start": [100], "text": ["foot"]}, {"answer_start": [100], "text": ["foot"]}, {"answer_start": [100], "text": ["foot"]}, {"answer_start": [100], "text": ["foot"]}, {"answer_start": [100], "text": ["foot"]}, {"answer_start": [100], "text": ["foot"]}, {"answer_start": [100], "text": ["foot"]}, {"answer_start": [100], "text": ["foot"]}, {"answer_start": [100], "text": ["foot"]}, {"answer_start": [100], "text": ["foot"]}, {"answer_start": [8], "text": ["proximity extension immunoassay"]}, {"answer_start": [8], "text": ["proximity extension immunoassay"]}, {"answer_start": [8], "text": ["proximity extension immunoassay"]}, {"answer_start": [8], "text": ["proximity extension immunoassay"]}, {"answer_start": [8], "text": ["proximity extension immunoassay"]}, {"answer_start": [8], "text": ["proximity extension immunoassay"]}, {"answer_start": [8], "text": ["proximity extension immunoassay"]}, {"answer_start": [8], "text": ["proximity extension immunoassay"]}, {"answer_start": [8], "text": ["proximity extension immunoassay"]}, {"answer_start": [8], "text": ["proximity extension immunoassay"]}, {"answer_start": [8], "text": ["proximity extension immunoassay"]}, {"answer_start": [8], "text": ["proximity extension immunoassay"]}, {"answer_start": [8], "text": ["proximity extension immunoassay"]}, {"answer_start": [8], "text": ["proximity extension immunoassay"]}, {"answer_start": [8], "text": ["proximity extension immunoassay"]}, {"answer_start": [8], "text": ["proximity extension immunoassay"]}, {"answer_start": [23], "text": ["proximity extension immunoassay"]}, {"answer_start": [23], "text": ["proximity extension immunoassay"]}, {"answer_start": [23], "text": ["proximity extension immunoassay"]}, {"answer_start": [23], "text": ["proximity extension immunoassay"]}, {"answer_start": [23], "text": ["proximity extension immunoassay"]}, {"answer_start": [23], "text": ["proximity extension immunoassay"]}, {"answer_start": [23], "text": ["proximity extension immunoassay"]}, {"answer_start": [23], "text": ["proximity extension immunoassay"]}, {"answer_start": [23], "text": ["proximity extension immunoassay"]}, {"answer_start": [23], "text": ["proximity extension immunoassay"]}, {"answer_start": [23], "text": ["proximity extension immunoassay"]}, {"answer_start": [23], "text": ["proximity extension immunoassay"]}, {"answer_start": [23], "text": ["proximity extension immunoassay"]}, {"answer_start": [23], "text": ["proximity extension immunoassay"]}, {"answer_start": [23], "text": ["proximity extension immunoassay"]}, {"answer_start": [23], "text": ["proximity extension immunoassay"]}, {"answer_start": [100], "text": ["100%"]}, {"answer_start": [100], "text": ["100%"]}, {"answer_start": [100], "text": ["100%"]}, {"answer_start": [100], "text": ["100%"]}, {"answer_start": [100], "text": ["100%"]}, {"answer_start": [100], "text": ["100%"]}, {"answer_start": [100], "text": ["100%"]}, {"answer_start": [100], "text": ["100%"]}, {"answer_start": [100], "text": ["100%"]}, {"answer_start": [100], "text": ["100%"]}, {"answer_start": [100], "text": ["100%"]}, {"answer_start": [100], "text": ["100%"]}, {"answer_start": [100], "text": ["100%"]}, {"answer_start": [100], "text": ["100%"]}, {"answer_start": [100], "text": ["100%"]}, {"answer_start": [100], "text": ["100%"]}, {"answer_start": [100], "text": ["100%"]}, {"answer_start": [100], "text": ["100%"]}, {"answer_start": [100], "text": ["100%"]}, {"answer_start": [100], "text": ["100%"]}, {"answer_start": [100], "text": ["100%"]}, {"answer_start": [100], "text": ["100%"]}, {"answer_start": [100], "text": ["100%"]}, {"answer_start": [100], "text": ["100%"]}, {"answer_start": [100], "text": ["100%"]}, {"answer_start": [100], "text": ["100%"]}, {"answer_start": [100], "text": ["100%"]}, {"answer_start": [100], "text": ["100%"]}, {"answer_start": [100], "text": ["100%"]}, {"answer_start": [100], "text": ["100%"]}, {"answer_start": [100], "text": ["100%"]}, {"answer_start": [100], "text": ["100%"]}, {"answer_start": [100], "text": ["100%"]}, {"answer_start": [100], "text": ["100%"]}, {"answer_start": [100], "text": ["100%"]}, {"answer_start": [100], "text": ["100%"]}, {"answer_start": [100], "text": ["100%"]}, {"answer_start": [100], "text": ["100%"]}, {"answer_start": [126, 137], "text": ["chromosome 2", "2"]}, {"answer_start": [126, 137], "text": ["chromosome 2", "2"]}, {"answer_start": [126, 137], "text": ["chromosome 2", "2"]}, {"answer_start": [126, 137], "text": ["chromosome 2", "2"]}, {"answer_start": [126, 137], "text": ["chromosome 2", "2"]}, {"answer_start": [126, 137], "text": ["chromosome 2", "2"]}, {"answer_start": [126, 137], "text": ["chromosome 2", "2"]}, {"answer_start": [126, 137], "text": ["chromosome 2", "2"]}, {"answer_start": [126, 137], "text": ["chromosome 2", "2"]}, {"answer_start": [126, 137], "text": ["chromosome 2", "2"]}, {"answer_start": [126, 137], "text": ["chromosome 2", "2"]}, {"answer_start": [126, 137], "text": ["chromosome 2", "2"]}, {"answer_start": [126, 137], "text": ["chromosome 2", "2"]}, {"answer_start": [102, 113], "text": ["chromosome 2", "2"]}, {"answer_start": [102, 113], "text": ["chromosome 2", "2"]}, {"answer_start": [102, 113], "text": ["chromosome 2", "2"]}, {"answer_start": [102, 113], "text": ["chromosome 2", "2"]}, {"answer_start": [102, 113], "text": ["chromosome 2", "2"]}, {"answer_start": [102, 113], "text": ["chromosome 2", "2"]}, {"answer_start": [102, 113], "text": ["chromosome 2", "2"]}, {"answer_start": [102, 113], "text": ["chromosome 2", "2"]}, {"answer_start": [102, 113], "text": ["chromosome 2", "2"]}, {"answer_start": [102, 113], "text": ["chromosome 2", "2"]}, {"answer_start": [102, 113], "text": ["chromosome 2", "2"]}, {"answer_start": [102, 113], "text": ["chromosome 2", "2"]}, {"answer_start": [102, 113], "text": ["chromosome 2", "2"]}, {"answer_start": [6, 17], "text": ["chromosome 2", "2"]}, {"answer_start": [6, 17], "text": ["chromosome 2", "2"]}, {"answer_start": [6, 17], "text": ["chromosome 2", "2"]}, {"answer_start": [6, 17], "text": ["chromosome 2", "2"]}, {"answer_start": [6, 17], "text": ["chromosome 2", "2"]}, {"answer_start": [6, 17], "text": ["chromosome 2", "2"]}, {"answer_start": [6, 17], "text": ["chromosome 2", "2"]}, {"answer_start": [6, 17], "text": ["chromosome 2", "2"]}, {"answer_start": [6, 17], "text": ["chromosome 2", "2"]}, {"answer_start": [6, 17], "text": ["chromosome 2", "2"]}, {"answer_start": [6, 17], "text": ["chromosome 2", "2"]}, {"answer_start": [6, 17], "text": ["chromosome 2", "2"]}, {"answer_start": [6, 17], "text": ["chromosome 2", "2"]}, {"answer_start": [95, 106], "text": ["chromosome 2", "2"]}, {"answer_start": [95, 106], "text": ["chromosome 2", "2"]}, {"answer_start": [95, 106], "text": ["chromosome 2", "2"]}, {"answer_start": [95, 106], "text": ["chromosome 2", "2"]}, {"answer_start": [95, 106], "text": ["chromosome 2", "2"]}, {"answer_start": [95, 106], "text": ["chromosome 2", "2"]}, {"answer_start": [95, 106], "text": ["chromosome 2", "2"]}, {"answer_start": [95, 106], "text": ["chromosome 2", "2"]}, {"answer_start": [95, 106], "text": ["chromosome 2", "2"]}, {"answer_start": [95, 106], "text": ["chromosome 2", "2"]}, {"answer_start": [95, 106], "text": ["chromosome 2", "2"]}, {"answer_start": [95, 106], "text": ["chromosome 2", "2"]}, {"answer_start": [95, 106], "text": ["chromosome 2", "2"]}, {"answer_start": [198, 55, 209], "text": ["chromosome 2", "2", "2"]}, {"answer_start": [198, 55, 209], "text": ["chromosome 2", "2", "2"]}, {"answer_start": [198, 55, 209], "text": ["chromosome 2", "2", "2"]}, {"answer_start": [198, 55, 209], "text": ["chromosome 2", "2", "2"]}, {"answer_start": [198, 55, 209], "text": ["chromosome 2", "2", "2"]}, {"answer_start": [198, 55, 209], "text": ["chromosome 2", "2", "2"]}, {"answer_start": [198, 55, 209], "text": ["chromosome 2", "2", "2"]}, {"answer_start": [198, 55, 209], "text": ["chromosome 2", "2", "2"]}, {"answer_start": [198, 55, 209], "text": ["chromosome 2", "2", "2"]}, {"answer_start": [198, 55, 209], "text": ["chromosome 2", "2", "2"]}, {"answer_start": [198, 55, 209], "text": ["chromosome 2", "2", "2"]}, {"answer_start": [198, 55, 209], "text": ["chromosome 2", "2", "2"]}, {"answer_start": [198, 55, 209], "text": ["chromosome 2", "2", "2"]}, {"answer_start": [117, 128], "text": ["chromosome 2", "2"]}, {"answer_start": [117, 128], "text": ["chromosome 2", "2"]}, {"answer_start": [117, 128], "text": ["chromosome 2", "2"]}, {"answer_start": [117, 128], "text": ["chromosome 2", "2"]}, {"answer_start": [117, 128], "text": ["chromosome 2", "2"]}, {"answer_start": [117, 128], "text": ["chromosome 2", "2"]}, {"answer_start": [117, 128], "text": ["chromosome 2", "2"]}, {"answer_start": [117, 128], "text": ["chromosome 2", "2"]}, {"answer_start": [117, 128], "text": ["chromosome 2", "2"]}, {"answer_start": [117, 128], "text": ["chromosome 2", "2"]}, {"answer_start": [117, 128], "text": ["chromosome 2", "2"]}, {"answer_start": [117, 128], "text": ["chromosome 2", "2"]}, {"answer_start": [117, 128], "text": ["chromosome 2", "2"]}, {"answer_start": [6, 17], "text": ["chromosome 2", "2"]}, {"answer_start": [6, 17], "text": ["chromosome 2", "2"]}, {"answer_start": [6, 17], "text": ["chromosome 2", "2"]}, {"answer_start": [6, 17], "text": ["chromosome 2", "2"]}, {"answer_start": [6, 17], "text": ["chromosome 2", "2"]}, {"answer_start": [6, 17], "text": ["chromosome 2", "2"]}, {"answer_start": [6, 17], "text": ["chromosome 2", "2"]}, {"answer_start": [6, 17], "text": ["chromosome 2", "2"]}, {"answer_start": [6, 17], "text": ["chromosome 2", "2"]}, {"answer_start": [6, 17], "text": ["chromosome 2", "2"]}, {"answer_start": [6, 17], "text": ["chromosome 2", "2"]}, {"answer_start": [6, 17], "text": ["chromosome 2", "2"]}, {"answer_start": [6, 17], "text": ["chromosome 2", "2"]}, {"answer_start": [6, 17], "text": ["chromosome 2", "2"]}, {"answer_start": [6, 17], "text": ["chromosome 2", "2"]}, {"answer_start": [6, 17], "text": ["chromosome 2", "2"]}, {"answer_start": [6, 17], "text": ["chromosome 2", "2"]}, {"answer_start": [6, 17], "text": ["chromosome 2", "2"]}, {"answer_start": [6, 17], "text": ["chromosome 2", "2"]}, {"answer_start": [6, 17], "text": ["chromosome 2", "2"]}, {"answer_start": [6, 17], "text": ["chromosome 2", "2"]}, {"answer_start": [6, 17], "text": ["chromosome 2", "2"]}, {"answer_start": [6, 17], "text": ["chromosome 2", "2"]}, {"answer_start": [6, 17], "text": ["chromosome 2", "2"]}, {"answer_start": [6, 17], "text": ["chromosome 2", "2"]}, {"answer_start": [6, 17], "text": ["chromosome 2", "2"]}, {"answer_start": [86, 97], "text": ["chromosome 2", "2"]}, {"answer_start": [86, 97], "text": ["chromosome 2", "2"]}, {"answer_start": [86, 97], "text": ["chromosome 2", "2"]}, {"answer_start": [86, 97], "text": ["chromosome 2", "2"]}, {"answer_start": [86, 97], "text": ["chromosome 2", "2"]}, {"answer_start": [86, 97], "text": ["chromosome 2", "2"]}, {"answer_start": [86, 97], "text": ["chromosome 2", "2"]}, {"answer_start": [86, 97], "text": ["chromosome 2", "2"]}, {"answer_start": [86, 97], "text": ["chromosome 2", "2"]}, {"answer_start": [86, 97], "text": ["chromosome 2", "2"]}, {"answer_start": [86, 97], "text": ["chromosome 2", "2"]}, {"answer_start": [86, 97], "text": ["chromosome 2", "2"]}, {"answer_start": [86, 97], "text": ["chromosome 2", "2"]}, {"answer_start": [88, 99], "text": ["chromosome 2", "2"]}, {"answer_start": [88, 99], "text": ["chromosome 2", "2"]}, {"answer_start": [88, 99], "text": ["chromosome 2", "2"]}, {"answer_start": [88, 99], "text": ["chromosome 2", "2"]}, {"answer_start": [88, 99], "text": ["chromosome 2", "2"]}, {"answer_start": [88, 99], "text": ["chromosome 2", "2"]}, {"answer_start": [88, 99], "text": ["chromosome 2", "2"]}, {"answer_start": [88, 99], "text": ["chromosome 2", "2"]}, {"answer_start": [88, 99], "text": ["chromosome 2", "2"]}, {"answer_start": [88, 99], "text": ["chromosome 2", "2"]}, {"answer_start": [88, 99], "text": ["chromosome 2", "2"]}, {"answer_start": [88, 99], "text": ["chromosome 2", "2"]}, {"answer_start": [88, 99], "text": ["chromosome 2", "2"]}, {"answer_start": [23, 34], "text": ["chromosome 2", "2"]}, {"answer_start": [23, 34], "text": ["chromosome 2", "2"]}, {"answer_start": [23, 34], "text": ["chromosome 2", "2"]}, {"answer_start": [23, 34], "text": ["chromosome 2", "2"]}, {"answer_start": [23, 34], "text": ["chromosome 2", "2"]}, {"answer_start": [23, 34], "text": ["chromosome 2", "2"]}, {"answer_start": [23, 34], "text": ["chromosome 2", "2"]}, {"answer_start": [23, 34], "text": ["chromosome 2", "2"]}, {"answer_start": [23, 34], "text": ["chromosome 2", "2"]}, {"answer_start": [23, 34], "text": ["chromosome 2", "2"]}, {"answer_start": [23, 34], "text": ["chromosome 2", "2"]}, {"answer_start": [23, 34], "text": ["chromosome 2", "2"]}, {"answer_start": [23, 34], "text": ["chromosome 2", "2"]}, {"answer_start": [16, 27], "text": ["chromosome 2", "2"]}, {"answer_start": [16, 27], "text": ["chromosome 2", "2"]}, {"answer_start": [16, 27], "text": ["chromosome 2", "2"]}, {"answer_start": [16, 27], "text": ["chromosome 2", "2"]}, {"answer_start": [16, 27], "text": ["chromosome 2", "2"]}, {"answer_start": [16, 27], "text": ["chromosome 2", "2"]}, {"answer_start": [16, 27], "text": ["chromosome 2", "2"]}, {"answer_start": [16, 27], "text": ["chromosome 2", "2"]}, {"answer_start": [16, 27], "text": ["chromosome 2", "2"]}, {"answer_start": [16, 27], "text": ["chromosome 2", "2"]}, {"answer_start": [16, 27], "text": ["chromosome 2", "2"]}, {"answer_start": [16, 27], "text": ["chromosome 2", "2"]}, {"answer_start": [16, 27], "text": ["chromosome 2", "2"]}, {"answer_start": [14], "text": ["2-4%"]}, {"answer_start": [14], "text": ["2-4%"]}, {"answer_start": [14], "text": ["2-4%"]}, {"answer_start": [14], "text": ["2-4%"]}, {"answer_start": [14], "text": ["2-4%"]}, {"answer_start": [14], "text": ["2-4%"]}, {"answer_start": [14], "text": ["2-4%"]}, {"answer_start": [14], "text": ["2-4%"]}, {"answer_start": [14], "text": ["2-4%"]}, {"answer_start": [14], "text": ["2-4%"]}, {"answer_start": [14], "text": ["2-4%"]}, {"answer_start": [14], "text": ["2-4%"]}, {"answer_start": [14], "text": ["2-4%"]}, {"answer_start": [14], "text": ["2-4%"]}, {"answer_start": [14], "text": ["2-4%"]}, {"answer_start": [46], "text": ["enhancers"]}, {"answer_start": [46], "text": ["enhancers"]}, {"answer_start": [46], "text": ["enhancers"]}, {"answer_start": [46], "text": ["enhancers"]}, {"answer_start": [46], "text": ["enhancers"]}, {"answer_start": [46], "text": ["enhancers"]}, {"answer_start": [46], "text": ["enhancers"]}, {"answer_start": [46], "text": ["enhancers"]}, {"answer_start": [46], "text": ["enhancers"]}, {"answer_start": [46], "text": ["enhancers"]}, {"answer_start": [46], "text": ["enhancers"]}, {"answer_start": [46], "text": ["enhancers"]}, {"answer_start": [46], "text": ["enhancers"]}, {"answer_start": [46], "text": ["enhancers"]}, {"answer_start": [46], "text": ["enhancers"]}, {"answer_start": [46], "text": ["enhancers"]}, {"answer_start": [46], "text": ["enhancers"]}, {"answer_start": [46], "text": ["enhancers"]}, {"answer_start": [46], "text": ["enhancers"]}, {"answer_start": [46], "text": ["enhancers"]}, {"answer_start": [46], "text": ["enhancers"]}, {"answer_start": [46], "text": ["enhancers"]}, {"answer_start": [46], "text": ["enhancers"]}, {"answer_start": [46], "text": ["enhancers"]}, {"answer_start": [120], "text": ["enhancers"]}, {"answer_start": [120], "text": ["enhancers"]}, {"answer_start": [120], "text": ["enhancers"]}, {"answer_start": [120], "text": ["enhancers"]}, {"answer_start": [120], "text": ["enhancers"]}, {"answer_start": [120], "text": ["enhancers"]}, {"answer_start": [120], "text": ["enhancers"]}, {"answer_start": [120], "text": ["enhancers"]}, {"answer_start": [120], "text": ["enhancers"]}, {"answer_start": [120], "text": ["enhancers"]}, {"answer_start": [120], "text": ["enhancers"]}, {"answer_start": [120], "text": ["enhancers"]}, {"answer_start": [120], "text": ["enhancers"]}, {"answer_start": [120], "text": ["enhancers"]}, {"answer_start": [120], "text": ["enhancers"]}, {"answer_start": [120], "text": ["enhancers"]}, {"answer_start": [120], "text": ["enhancers"]}, {"answer_start": [120], "text": ["enhancers"]}, {"answer_start": [120], "text": ["enhancers"]}, {"answer_start": [120], "text": ["enhancers"]}, {"answer_start": [120], "text": ["enhancers"]}, {"answer_start": [120], "text": ["enhancers"]}, {"answer_start": [120], "text": ["enhancers"]}, {"answer_start": [120], "text": ["enhancers"]}, {"answer_start": [103], "text": ["enhancers"]}, {"answer_start": [103], "text": ["enhancers"]}, {"answer_start": [103], "text": ["enhancers"]}, {"answer_start": [103], "text": ["enhancers"]}, {"answer_start": [103], "text": ["enhancers"]}, {"answer_start": [103], "text": ["enhancers"]}, {"answer_start": [103], "text": ["enhancers"]}, {"answer_start": [103], "text": ["enhancers"]}, {"answer_start": [103], "text": ["enhancers"]}, {"answer_start": [103], "text": ["enhancers"]}, {"answer_start": [103], "text": ["enhancers"]}, {"answer_start": [103], "text": ["enhancers"]}, {"answer_start": [103], "text": ["enhancers"]}, {"answer_start": [103], "text": ["enhancers"]}, {"answer_start": [103], "text": ["enhancers"]}, {"answer_start": [103], "text": ["enhancers"]}, {"answer_start": [103], "text": ["enhancers"]}, {"answer_start": [103], "text": ["enhancers"]}, {"answer_start": [103], "text": ["enhancers"]}, {"answer_start": [103], "text": ["enhancers"]}, {"answer_start": [103], "text": ["enhancers"]}, {"answer_start": [103], "text": ["enhancers"]}, {"answer_start": [103], "text": ["enhancers"]}, {"answer_start": [103], "text": ["enhancers"]}, {"answer_start": [34], "text": ["enhancers"]}, {"answer_start": [34], "text": ["enhancers"]}, {"answer_start": [34], "text": ["enhancers"]}, {"answer_start": [34], "text": ["enhancers"]}, {"answer_start": [34], "text": ["enhancers"]}, {"answer_start": [34], "text": ["enhancers"]}, {"answer_start": [34], "text": ["enhancers"]}, {"answer_start": [34], "text": ["enhancers"]}, {"answer_start": [34], "text": ["enhancers"]}, {"answer_start": [34], "text": ["enhancers"]}, {"answer_start": [34], "text": ["enhancers"]}, {"answer_start": [34], "text": ["enhancers"]}, {"answer_start": [34], "text": ["enhancers"]}, {"answer_start": [34], "text": ["enhancers"]}, {"answer_start": [34], "text": ["enhancers"]}, {"answer_start": [34], "text": ["enhancers"]}, {"answer_start": [34], "text": ["enhancers"]}, {"answer_start": [34], "text": ["enhancers"]}, {"answer_start": [34], "text": ["enhancers"]}, {"answer_start": [34], "text": ["enhancers"]}, {"answer_start": [34], "text": ["enhancers"]}, {"answer_start": [34], "text": ["enhancers"]}, {"answer_start": [34], "text": ["enhancers"]}, {"answer_start": [34], "text": ["enhancers"]}, {"answer_start": [87], "text": ["personally normalized plasma protein profiles"]}, {"answer_start": [87], "text": ["personally normalized plasma protein profiles"]}, {"answer_start": [87], "text": ["personally normalized plasma protein profiles"]}, {"answer_start": [87], "text": ["personally normalized plasma protein profiles"]}, {"answer_start": [87], "text": ["personally normalized plasma protein profiles"]}], "context": ["during this phase, at least 48 genes, collectively named dormancy survival regulator (dosr) regulon, are important for the long-term survival of bacilli under a non-respiring state, a condition that bacilli encounter inside granulomatous lesions.", "during this phase, at least 48 genes, collectively named dormancy survival regulator (dosr) regulon, are important for the long-term survival of bacilli under a non-respiring state, a condition that bacilli encounter inside granulomatous lesions.", "during this phase, at least 48 genes, collectively named dormancy survival regulator (dosr) regulon, are important for the long-term survival of bacilli under a non-respiring state, a condition that bacilli encounter inside granulomatous lesions.", "during this phase, at least 48 genes, collectively named dormancy survival regulator (dosr) regulon, are important for the long-term survival of bacilli under a non-respiring state, a condition that bacilli encounter inside granulomatous lesions.", "during this phase, at least 48 genes, collectively named dormancy survival regulator (dosr) regulon, are important for the long-term survival of bacilli under a non-respiring state, a condition that bacilli encounter inside granulomatous lesions.", "during this phase, at least 48 genes, collectively named dormancy survival regulator (dosr) regulon, are important for the long-term survival of bacilli under a non-respiring state, a condition that bacilli encounter inside granulomatous lesions.", "during this phase, at least 48 genes, collectively named dormancy survival regulator (dosr) regulon, are important for the long-term survival of bacilli under a non-respiring state, a condition that bacilli encounter inside granulomatous lesions.", "during this phase, at least 48 genes, collectively named dormancy survival regulator (dosr) regulon, are important for the long-term survival of bacilli under a non-respiring state, a condition that bacilli encounter inside granulomatous lesions.", "during this phase, at least 48 genes, collectively named dormancy survival regulator (dosr) regulon, are important for the long-term survival of bacilli under a non-respiring state, a condition that bacilli encounter inside granulomatous lesions.", "during this phase, at least 48 genes, collectively named dormancy survival regulator (dosr) regulon, are important for the long-term survival of bacilli under a non-respiring state, a condition that bacilli encounter inside granulomatous lesions.", "during this phase, at least 48 genes, collectively named dormancy survival regulator (dosr) regulon, are important for the long-term survival of bacilli under a non-respiring state, a condition that bacilli encounter inside granulomatous lesions.", "during this phase, at least 48 genes, collectively named dormancy survival regulator (dosr) regulon, are important for the long-term survival of bacilli under a non-respiring state, a condition that bacilli encounter inside granulomatous lesions.", "during this phase, at least 48 genes, collectively named dormancy survival regulator (dosr) regulon, are important for the long-term survival of bacilli under a non-respiring state, a condition that bacilli encounter inside granulomatous lesions.", "during this phase, at least 48 genes, collectively named dormancy survival regulator (dosr) regulon, are important for the long-term survival of bacilli under a non-respiring state, a condition that bacilli encounter inside granulomatous lesions.", "during this phase, at least 48 genes, collectively named dormancy survival regulator (dosr) regulon, are important for the long-term survival of bacilli under a non-respiring state, a condition that bacilli encounter inside granulomatous lesions.", "during this phase, at least 48 genes, collectively named dormancy survival regulator (dosr) regulon, are important for the long-term survival of bacilli under a non-respiring state, a condition that bacilli encounter inside granulomatous lesions.", "during this phase, at least 48 genes, collectively named dormancy survival regulator (dosr) regulon, are important for the long-term survival of bacilli under a non-respiring state, a condition that bacilli encounter inside granulomatous lesions.", "during this phase, at least 48 genes, collectively named dormancy survival regulator (dosr) regulon, are important for the long-term survival of bacilli under a non-respiring state, a condition that bacilli encounter inside granulomatous lesions.", "during this phase, at least 48 genes, collectively named dormancy survival regulator (dosr) regulon, are important for the long-term survival of bacilli under a non-respiring state, a condition that bacilli encounter inside granulomatous lesions.", "during this phase, at least 48 genes, collectively named dormancy survival regulator (dosr) regulon, are important for the long-term survival of bacilli under a non-respiring state, a condition that bacilli encounter inside granulomatous lesions.", "during this phase, at least 48 genes, collectively named dormancy survival regulator (dosr) regulon, are important for the long-term survival of bacilli under a non-respiring state, a condition that bacilli encounter inside granulomatous lesions.", "during this phase, at least 48 genes, collectively named dormancy survival regulator (dosr) regulon, are important for the long-term survival of bacilli under a non-respiring state, a condition that bacilli encounter inside granulomatous lesions.", "during this phase, at least 48 genes, collectively named dormancy survival regulator (dosr) regulon, are important for the long-term survival of bacilli under a non-respiring state, a condition that bacilli encounter inside granulomatous lesions.", "during this phase, at least 48 genes, collectively named dormancy survival regulator (dosr) regulon, are important for the long-term survival of bacilli under a non-respiring state, a condition that bacilli encounter inside granulomatous lesions.", "during this phase, at least 48 genes, collectively named dormancy survival regulator (dosr) regulon, are important for the long-term survival of bacilli under a non-respiring state, a condition that bacilli encounter inside granulomatous lesions.", "during this phase, at least 48 genes, collectively named dormancy survival regulator (dosr) regulon, are important for the long-term survival of bacilli under a non-respiring state, a condition that bacilli encounter inside granulomatous lesions.", "during this phase, at least 48 genes, collectively named dormancy survival regulator (dosr) regulon, are important for the long-term survival of bacilli under a non-respiring state, a condition that bacilli encounter inside granulomatous lesions.", "during this phase, at least 48 genes, collectively named dormancy survival regulator (dosr) regulon, are important for the long-term survival of bacilli under a non-respiring state, a condition that bacilli encounter inside granulomatous lesions.", "during this phase, at least 48 genes, collectively named dormancy survival regulator (dosr) regulon, are important for the long-term survival of bacilli under a non-respiring state, a condition that bacilli encounter inside granulomatous lesions.", "during this phase, at least 48 genes, collectively named dormancy survival regulator (dosr) regulon, are important for the long-term survival of bacilli under a non-respiring state, a condition that bacilli encounter inside granulomatous lesions.", "during this phase, at least 48 genes, collectively named dormancy survival regulator (dosr) regulon, are important for the long-term survival of bacilli under a non-respiring state, a condition that bacilli encounter inside granulomatous lesions.", "during this phase, at least 48 genes, collectively named dormancy survival regulator (dosr) regulon, are important for the long-term survival of bacilli under a non-respiring state, a condition that bacilli encounter inside granulomatous lesions.", "during this phase, at least 48 genes, collectively named dormancy survival regulator (dosr) regulon, are important for the long-term survival of bacilli under a non-respiring state, a condition that bacilli encounter inside granulomatous lesions.", "during this phase, at least 48 genes, collectively named dormancy survival regulator (dosr) regulon, are important for the long-term survival of bacilli under a non-respiring state, a condition that bacilli encounter inside granulomatous lesions.", "during this phase, at least 48 genes, collectively named dormancy survival regulator (dosr) regulon, are important for the long-term survival of bacilli under a non-respiring state, a condition that bacilli encounter inside granulomatous lesions.", "during this phase, at least 48 genes, collectively named dormancy survival regulator (dosr) regulon, are important for the long-term survival of bacilli under a non-respiring state, a condition that bacilli encounter inside granulomatous lesions.", "during this phase, at least 48 genes, collectively named dormancy survival regulator (dosr) regulon, are important for the long-term survival of bacilli under a non-respiring state, a condition that bacilli encounter inside granulomatous lesions.", "during this phase, at least 48 genes, collectively named dormancy survival regulator (dosr) regulon, are important for the long-term survival of bacilli under a non-respiring state, a condition that bacilli encounter inside granulomatous lesions.", "during this phase, at least 48 genes, collectively named dormancy survival regulator (dosr) regulon, are important for the long-term survival of bacilli under a non-respiring state, a condition that bacilli encounter inside granulomatous lesions.", "during this phase, at least 48 genes, collectively named dormancy survival regulator (dosr) regulon, are important for the long-term survival of bacilli under a non-respiring state, a condition that bacilli encounter inside granulomatous lesions.", "during this phase, at least 48 genes, collectively named dormancy survival regulator (dosr) regulon, are important for the long-term survival of bacilli under a non-respiring state, a condition that bacilli encounter inside granulomatous lesions.", "during this phase, at least 48 genes, collectively named dormancy survival regulator (dosr) regulon, are important for the long-term survival of bacilli under a non-respiring state, a condition that bacilli encounter inside granulomatous lesions.", "during this phase, at least 48 genes, collectively named dormancy survival regulator (dosr) regulon, are important for the long-term survival of bacilli under a non-respiring state, a condition that bacilli encounter inside granulomatous lesions.", "during this phase, at least 48 genes, collectively named dormancy survival regulator (dosr) regulon, are important for the long-term survival of bacilli under a non-respiring state, a condition that bacilli encounter inside granulomatous lesions.", "during this phase, at least 48 genes, collectively named dormancy survival regulator (dosr) regulon, are important for the long-term survival of bacilli under a non-respiring state, a condition that bacilli encounter inside granulomatous lesions.", "during this phase, at least 48 genes, collectively named dormancy survival regulator (dosr) regulon, are important for the long-term survival of bacilli under a non-respiring state, a condition that bacilli encounter inside granulomatous lesions.", "during this phase, at least 48 genes, collectively named dormancy survival regulator (dosr) regulon, are important for the long-term survival of bacilli under a non-respiring state, a condition that bacilli encounter inside granulomatous lesions.", "during this phase, at least 48 genes, collectively named dormancy survival regulator (dosr) regulon, are important for the long-term survival of bacilli under a non-respiring state, a condition that bacilli encounter inside granulomatous lesions.", "during this phase, at least 48 genes, collectively named dormancy survival regulator (dosr) regulon, are important for the long-term survival of bacilli under a non-respiring state, a condition that bacilli encounter inside granulomatous lesions.", "in silico analysis of the dosr regulon in bcg and m. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical.", "in silico analysis of the dosr regulon in bcg and m. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical.", "in silico analysis of the dosr regulon in bcg and m. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical.", "in silico analysis of the dosr regulon in bcg and m. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical.", "in silico analysis of the dosr regulon in bcg and m. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical.", "in silico analysis of the dosr regulon in bcg and m. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical.", "in silico analysis of the dosr regulon in bcg and m. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical.", "in silico analysis of the dosr regulon in bcg and m. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical.", "in silico analysis of the dosr regulon in bcg and m. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical.", "in silico analysis of the dosr regulon in bcg and m. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical.", "in silico analysis of the dosr regulon in bcg and m. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical.", "in silico analysis of the dosr regulon in bcg and m. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical.", "in silico analysis of the dosr regulon in bcg and m. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical.", "in silico analysis of the dosr regulon in bcg and m. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical.", "in silico analysis of the dosr regulon in bcg and m. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical.", "in silico analysis of the dosr regulon in bcg and m. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical.", "in silico analysis of the dosr regulon in bcg and m. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical.", "in silico analysis of the dosr regulon in bcg and m. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical.", "in silico analysis of the dosr regulon in bcg and m. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical.", "in silico analysis of the dosr regulon in bcg and m. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical.", "in silico analysis of the dosr regulon in bcg and m. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical.", "in silico analysis of the dosr regulon in bcg and m. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical.", "in silico analysis of the dosr regulon in bcg and m. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical.", "in silico analysis of the dosr regulon in bcg and m. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical.", "in silico analysis of the dosr regulon in bcg and m. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical.", "in silico analysis of the dosr regulon in bcg and m. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical.", "in silico analysis of the dosr regulon in bcg and m. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical.", "in silico analysis of the dosr regulon in bcg and m. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical.", "in silico analysis of the dosr regulon in bcg and m. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical.", "in silico analysis of the dosr regulon in bcg and m. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical.", "in silico analysis of the dosr regulon in bcg and m. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical.", "in silico analysis of the dosr regulon in bcg and m. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical.", "in silico analysis of the dosr regulon in bcg and m. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical.", "in silico analysis of the dosr regulon in bcg and m. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical.", "in silico analysis of the dosr regulon in bcg and m. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical.", "in silico analysis of the dosr regulon in bcg and m. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical.", "in silico analysis of the dosr regulon in bcg and m. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical.", "in silico analysis of the dosr regulon in bcg and m. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical.", "in silico analysis of the dosr regulon in bcg and m. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical.", "in silico analysis of the dosr regulon in bcg and m. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical.", "in silico analysis of the dosr regulon in bcg and m. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical.", "in silico analysis of the dosr regulon in bcg and m. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical.", "in silico analysis of the dosr regulon in bcg and m. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical.", "in silico analysis of the dosr regulon in bcg and m. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical.", "in silico analysis of the dosr regulon in bcg and m. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical.", "in silico analysis of the dosr regulon in bcg and m. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical.", "in silico analysis of the dosr regulon in bcg and m. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical.", "in silico analysis of the dosr regulon in bcg and m. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical.", "in silico analysis of the dosr regulon in bcg and m. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical.", "dosr/devr of m. tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "dosr/devr of m. tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "dosr/devr of m. tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "dosr/devr of m. tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "dosr/devr of m. tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "dosr/devr of m. tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "dosr/devr of m. tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "dosr/devr of m. tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "dosr/devr of m. tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "dosr/devr of m. tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "dosr/devr of m. tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "dosr/devr of m. tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "dosr/devr of m. tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "dosr/devr of m. tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "dosr/devr of m. tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "dosr/devr of m. tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "dosr/devr of m. tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "dosr/devr of m. tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "dosr/devr of m. tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "dosr/devr of m. tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "dosr/devr of m. tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "dosr/devr of m. tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "dosr/devr of m. tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "dosr/devr of m. tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "dosr/devr of m. tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "dosr/devr of m. tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "dosr/devr of m. tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "dosr/devr of m. tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "dosr/devr of m. tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "dosr/devr of m. tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "dosr/devr of m. tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "dosr/devr of m. tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "dosr/devr of m. tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "dosr/devr of m. tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "dosr/devr of m. tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "dosr/devr of m. tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "dosr/devr of m. tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "dosr/devr of m. tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "dosr/devr of m. tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "dosr/devr of m. tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "dosr/devr of m. tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "dosr/devr of m. tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "dosr/devr of m. tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "dosr/devr of m. tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "dosr/devr of m. tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "dosr/devr of m. tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "dosr/devr of m. tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "dosr/devr of m. tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "dosr/devr of m. tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "tuberculosis is a two component dormancy survival response regulator which induces the expression of 48 genes.", "purpose: to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.methods: two hundred grade i or ii female sui patients with sui symptom were examined by reviewing medical history; physical examination; urethral mobility as assessed by q-tip test; stress test; and cystometry, including vlpp measurement.", "purpose: to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.methods: two hundred grade i or ii female sui patients with sui symptom were examined by reviewing medical history; physical examination; urethral mobility as assessed by q-tip test; stress test; and cystometry, including vlpp measurement.", "purpose: to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.methods: two hundred grade i or ii female sui patients with sui symptom were examined by reviewing medical history; physical examination; urethral mobility as assessed by q-tip test; stress test; and cystometry, including vlpp measurement.", "purpose: to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.methods: two hundred grade i or ii female sui patients with sui symptom were examined by reviewing medical history; physical examination; urethral mobility as assessed by q-tip test; stress test; and cystometry, including vlpp measurement.", "purpose: to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.methods: two hundred grade i or ii female sui patients with sui symptom were examined by reviewing medical history; physical examination; urethral mobility as assessed by q-tip test; stress test; and cystometry, including vlpp measurement.", "purpose: to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.methods: two hundred grade i or ii female sui patients with sui symptom were examined by reviewing medical history; physical examination; urethral mobility as assessed by q-tip test; stress test; and cystometry, including vlpp measurement.", "purpose: to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.methods: two hundred grade i or ii female sui patients with sui symptom were examined by reviewing medical history; physical examination; urethral mobility as assessed by q-tip test; stress test; and cystometry, including vlpp measurement.", "purpose: to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.methods: two hundred grade i or ii female sui patients with sui symptom were examined by reviewing medical history; physical examination; urethral mobility as assessed by q-tip test; stress test; and cystometry, including vlpp measurement.", "purpose: to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.methods: two hundred grade i or ii female sui patients with sui symptom were examined by reviewing medical history; physical examination; urethral mobility as assessed by q-tip test; stress test; and cystometry, including vlpp measurement.", "purpose: to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.methods: two hundred grade i or ii female sui patients with sui symptom were examined by reviewing medical history; physical examination; urethral mobility as assessed by q-tip test; stress test; and cystometry, including vlpp measurement.", "purpose: to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.methods: two hundred grade i or ii female sui patients with sui symptom were examined by reviewing medical history; physical examination; urethral mobility as assessed by q-tip test; stress test; and cystometry, including vlpp measurement.", "purpose: to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.methods: two hundred grade i or ii female sui patients with sui symptom were examined by reviewing medical history; physical examination; urethral mobility as assessed by q-tip test; stress test; and cystometry, including vlpp measurement.", "purpose: to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.methods: two hundred grade i or ii female sui patients with sui symptom were examined by reviewing medical history; physical examination; urethral mobility as assessed by q-tip test; stress test; and cystometry, including vlpp measurement.", "purpose: to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.methods: two hundred grade i or ii female sui patients with sui symptom were examined by reviewing medical history; physical examination; urethral mobility as assessed by q-tip test; stress test; and cystometry, including vlpp measurement.", "purpose: to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.methods: two hundred grade i or ii female sui patients with sui symptom were examined by reviewing medical history; physical examination; urethral mobility as assessed by q-tip test; stress test; and cystometry, including vlpp measurement.", "purpose: to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.methods: two hundred grade i or ii female sui patients with sui symptom were examined by reviewing medical history; physical examination; urethral mobility as assessed by q-tip test; stress test; and cystometry, including vlpp measurement.", "purpose: to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.methods: two hundred grade i or ii female sui patients with sui symptom were examined by reviewing medical history; physical examination; urethral mobility as assessed by q-tip test; stress test; and cystometry, including vlpp measurement.", "purpose: to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.methods: two hundred grade i or ii female sui patients with sui symptom were examined by reviewing medical history; physical examination; urethral mobility as assessed by q-tip test; stress test; and cystometry, including vlpp measurement.", "purpose: to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.methods: two hundred grade i or ii female sui patients with sui symptom were examined by reviewing medical history; physical examination; urethral mobility as assessed by q-tip test; stress test; and cystometry, including vlpp measurement.", "purpose: to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.methods: two hundred grade i or ii female sui patients with sui symptom were examined by reviewing medical history; physical examination; urethral mobility as assessed by q-tip test; stress test; and cystometry, including vlpp measurement.", "purpose: to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.methods: two hundred grade i or ii female sui patients with sui symptom were examined by reviewing medical history; physical examination; urethral mobility as assessed by q-tip test; stress test; and cystometry, including vlpp measurement.", "purpose: to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.methods: two hundred grade i or ii female sui patients with sui symptom were examined by reviewing medical history; physical examination; urethral mobility as assessed by q-tip test; stress test; and cystometry, including vlpp measurement.", "purpose: to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.methods: two hundred grade i or ii female sui patients with sui symptom were examined by reviewing medical history; physical examination; urethral mobility as assessed by q-tip test; stress test; and cystometry, including vlpp measurement.", "purpose: to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.methods: two hundred grade i or ii female sui patients with sui symptom were examined by reviewing medical history; physical examination; urethral mobility as assessed by q-tip test; stress test; and cystometry, including vlpp measurement.", "purpose: to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.methods: two hundred grade i or ii female sui patients with sui symptom were examined by reviewing medical history; physical examination; urethral mobility as assessed by q-tip test; stress test; and cystometry, including vlpp measurement.", "purpose: to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.methods: two hundred grade i or ii female sui patients with sui symptom were examined by reviewing medical history; physical examination; urethral mobility as assessed by q-tip test; stress test; and cystometry, including vlpp measurement.", "purpose: to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.methods: two hundred grade i or ii female sui patients with sui symptom were examined by reviewing medical history; physical examination; urethral mobility as assessed by q-tip test; stress test; and cystometry, including vlpp measurement.", "purpose: to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.methods: two hundred grade i or ii female sui patients with sui symptom were examined by reviewing medical history; physical examination; urethral mobility as assessed by q-tip test; stress test; and cystometry, including vlpp measurement.", "purpose: to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.methods: two hundred grade i or ii female sui patients with sui symptom were examined by reviewing medical history; physical examination; urethral mobility as assessed by q-tip test; stress test; and cystometry, including vlpp measurement.", "methods: a total of 25 women affected by clinical stress urinary incontinence (sui) were enrolled. after undergoing urodynamic assessment, pelvic organ prolapse quantification, urine culture, q-tip test, and stress test, each subject underwent color doppler ultrasonography to record clitoral blood flow and emg of the urethral sphincter with a needle electrode inserted through the mucosa into the muscle tissue before surgery.", "methods: a total of 25 women affected by clinical stress urinary incontinence (sui) were enrolled. after undergoing urodynamic assessment, pelvic organ prolapse quantification, urine culture, q-tip test, and stress test, each subject underwent color doppler ultrasonography to record clitoral blood flow and emg of the urethral sphincter with a needle electrode inserted through the mucosa into the muscle tissue before surgery.", "methods: a total of 25 women affected by clinical stress urinary incontinence (sui) were enrolled. after undergoing urodynamic assessment, pelvic organ prolapse quantification, urine culture, q-tip test, and stress test, each subject underwent color doppler ultrasonography to record clitoral blood flow and emg of the urethral sphincter with a needle electrode inserted through the mucosa into the muscle tissue before surgery.", "methods: a total of 25 women affected by clinical stress urinary incontinence (sui) were enrolled. after undergoing urodynamic assessment, pelvic organ prolapse quantification, urine culture, q-tip test, and stress test, each subject underwent color doppler ultrasonography to record clitoral blood flow and emg of the urethral sphincter with a needle electrode inserted through the mucosa into the muscle tissue before surgery.", "methods: a total of 25 women affected by clinical stress urinary incontinence (sui) were enrolled. after undergoing urodynamic assessment, pelvic organ prolapse quantification, urine culture, q-tip test, and stress test, each subject underwent color doppler ultrasonography to record clitoral blood flow and emg of the urethral sphincter with a needle electrode inserted through the mucosa into the muscle tissue before surgery.", "methods: a total of 25 women affected by clinical stress urinary incontinence (sui) were enrolled. after undergoing urodynamic assessment, pelvic organ prolapse quantification, urine culture, q-tip test, and stress test, each subject underwent color doppler ultrasonography to record clitoral blood flow and emg of the urethral sphincter with a needle electrode inserted through the mucosa into the muscle tissue before surgery.", "methods: a total of 25 women affected by clinical stress urinary incontinence (sui) were enrolled. after undergoing urodynamic assessment, pelvic organ prolapse quantification, urine culture, q-tip test, and stress test, each subject underwent color doppler ultrasonography to record clitoral blood flow and emg of the urethral sphincter with a needle electrode inserted through the mucosa into the muscle tissue before surgery.", "methods: a total of 25 women affected by clinical stress urinary incontinence (sui) were enrolled. after undergoing urodynamic assessment, pelvic organ prolapse quantification, urine culture, q-tip test, and stress test, each subject underwent color doppler ultrasonography to record clitoral blood flow and emg of the urethral sphincter with a needle electrode inserted through the mucosa into the muscle tissue before surgery.", "methods: a total of 25 women affected by clinical stress urinary incontinence (sui) were enrolled. after undergoing urodynamic assessment, pelvic organ prolapse quantification, urine culture, q-tip test, and stress test, each subject underwent color doppler ultrasonography to record clitoral blood flow and emg of the urethral sphincter with a needle electrode inserted through the mucosa into the muscle tissue before surgery.", "methods: a total of 25 women affected by clinical stress urinary incontinence (sui) were enrolled. after undergoing urodynamic assessment, pelvic organ prolapse quantification, urine culture, q-tip test, and stress test, each subject underwent color doppler ultrasonography to record clitoral blood flow and emg of the urethral sphincter with a needle electrode inserted through the mucosa into the muscle tissue before surgery.", "methods: a total of 25 women affected by clinical stress urinary incontinence (sui) were enrolled. after undergoing urodynamic assessment, pelvic organ prolapse quantification, urine culture, q-tip test, and stress test, each subject underwent color doppler ultrasonography to record clitoral blood flow and emg of the urethral sphincter with a needle electrode inserted through the mucosa into the muscle tissue before surgery.", "methods: a total of 25 women affected by clinical stress urinary incontinence (sui) were enrolled. after undergoing urodynamic assessment, pelvic organ prolapse quantification, urine culture, q-tip test, and stress test, each subject underwent color doppler ultrasonography to record clitoral blood flow and emg of the urethral sphincter with a needle electrode inserted through the mucosa into the muscle tissue before surgery.", "methods: a total of 25 women affected by clinical stress urinary incontinence (sui) were enrolled. after undergoing urodynamic assessment, pelvic organ prolapse quantification, urine culture, q-tip test, and stress test, each subject underwent color doppler ultrasonography to record clitoral blood flow and emg of the urethral sphincter with a needle electrode inserted through the mucosa into the muscle tissue before surgery.", "methods: a total of 25 women affected by clinical stress urinary incontinence (sui) were enrolled. after undergoing urodynamic assessment, pelvic organ prolapse quantification, urine culture, q-tip test, and stress test, each subject underwent color doppler ultrasonography to record clitoral blood flow and emg of the urethral sphincter with a needle electrode inserted through the mucosa into the muscle tissue before surgery.", "methods: a total of 25 women affected by clinical stress urinary incontinence (sui) were enrolled. after undergoing urodynamic assessment, pelvic organ prolapse quantification, urine culture, q-tip test, and stress test, each subject underwent color doppler ultrasonography to record clitoral blood flow and emg of the urethral sphincter with a needle electrode inserted through the mucosa into the muscle tissue before surgery.", "methods: a total of 25 women affected by clinical stress urinary incontinence (sui) were enrolled. after undergoing urodynamic assessment, pelvic organ prolapse quantification, urine culture, q-tip test, and stress test, each subject underwent color doppler ultrasonography to record clitoral blood flow and emg of the urethral sphincter with a needle electrode inserted through the mucosa into the muscle tissue before surgery.", "methods: a total of 25 women affected by clinical stress urinary incontinence (sui) were enrolled. after undergoing urodynamic assessment, pelvic organ prolapse quantification, urine culture, q-tip test, and stress test, each subject underwent color doppler ultrasonography to record clitoral blood flow and emg of the urethral sphincter with a needle electrode inserted through the mucosa into the muscle tissue before surgery.", "methods: a total of 25 women affected by clinical stress urinary incontinence (sui) were enrolled. after undergoing urodynamic assessment, pelvic organ prolapse quantification, urine culture, q-tip test, and stress test, each subject underwent color doppler ultrasonography to record clitoral blood flow and emg of the urethral sphincter with a needle electrode inserted through the mucosa into the muscle tissue before surgery.", "methods: a total of 25 women affected by clinical stress urinary incontinence (sui) were enrolled. after undergoing urodynamic assessment, pelvic organ prolapse quantification, urine culture, q-tip test, and stress test, each subject underwent color doppler ultrasonography to record clitoral blood flow and emg of the urethral sphincter with a needle electrode inserted through the mucosa into the muscle tissue before surgery.", "methods: a total of 25 women affected by clinical stress urinary incontinence (sui) were enrolled. after undergoing urodynamic assessment, pelvic organ prolapse quantification, urine culture, q-tip test, and stress test, each subject underwent color doppler ultrasonography to record clitoral blood flow and emg of the urethral sphincter with a needle electrode inserted through the mucosa into the muscle tissue before surgery.", "methods: a total of 25 women affected by clinical stress urinary incontinence (sui) were enrolled. after undergoing urodynamic assessment, pelvic organ prolapse quantification, urine culture, q-tip test, and stress test, each subject underwent color doppler ultrasonography to record clitoral blood flow and emg of the urethral sphincter with a needle electrode inserted through the mucosa into the muscle tissue before surgery.", "methods: a total of 25 women affected by clinical stress urinary incontinence (sui) were enrolled. after undergoing urodynamic assessment, pelvic organ prolapse quantification, urine culture, q-tip test, and stress test, each subject underwent color doppler ultrasonography to record clitoral blood flow and emg of the urethral sphincter with a needle electrode inserted through the mucosa into the muscle tissue before surgery.", "methods: a total of 25 women affected by clinical stress urinary incontinence (sui) were enrolled. after undergoing urodynamic assessment, pelvic organ prolapse quantification, urine culture, q-tip test, and stress test, each subject underwent color doppler ultrasonography to record clitoral blood flow and emg of the urethral sphincter with a needle electrode inserted through the mucosa into the muscle tissue before surgery.", "methods: a total of 25 women affected by clinical stress urinary incontinence (sui) were enrolled. after undergoing urodynamic assessment, pelvic organ prolapse quantification, urine culture, q-tip test, and stress test, each subject underwent color doppler ultrasonography to record clitoral blood flow and emg of the urethral sphincter with a needle electrode inserted through the mucosa into the muscle tissue before surgery.", "methods: a total of 25 women affected by clinical stress urinary incontinence (sui) were enrolled. after undergoing urodynamic assessment, pelvic organ prolapse quantification, urine culture, q-tip test, and stress test, each subject underwent color doppler ultrasonography to record clitoral blood flow and emg of the urethral sphincter with a needle electrode inserted through the mucosa into the muscle tissue before surgery.", "methods: a total of 25 women affected by clinical stress urinary incontinence (sui) were enrolled. after undergoing urodynamic assessment, pelvic organ prolapse quantification, urine culture, q-tip test, and stress test, each subject underwent color doppler ultrasonography to record clitoral blood flow and emg of the urethral sphincter with a needle electrode inserted through the mucosa into the muscle tissue before surgery.", "methods: a total of 25 women affected by clinical stress urinary incontinence (sui) were enrolled. after undergoing urodynamic assessment, pelvic organ prolapse quantification, urine culture, q-tip test, and stress test, each subject underwent color doppler ultrasonography to record clitoral blood flow and emg of the urethral sphincter with a needle electrode inserted through the mucosa into the muscle tissue before surgery.", "methods: a total of 25 women affected by clinical stress urinary incontinence (sui) were enrolled. after undergoing urodynamic assessment, pelvic organ prolapse quantification, urine culture, q-tip test, and stress test, each subject underwent color doppler ultrasonography to record clitoral blood flow and emg of the urethral sphincter with a needle electrode inserted through the mucosa into the muscle tissue before surgery.", "methods: a total of 25 women affected by clinical stress urinary incontinence (sui) were enrolled. after undergoing urodynamic assessment, pelvic organ prolapse quantification, urine culture, q-tip test, and stress test, each subject underwent color doppler ultrasonography to record clitoral blood flow and emg of the urethral sphincter with a needle electrode inserted through the mucosa into the muscle tissue before surgery.", "materials and methods: one hundred patients suffering from clinical and/or urodynamic stress urinary incontinence (sui) were randomized into biological material tot (pelvilace\u00ae to) or synthetic material tot (align\u00aeto urethral support system) groups. preoperative and at 1 year postoperative urogynecological symptom assessment, 1-h pad test, 4-day bladder diary, stress test, q-tip test, and urodynamics were performed.", "materials and methods: one hundred patients suffering from clinical and/or urodynamic stress urinary incontinence (sui) were randomized into biological material tot (pelvilace\u00ae to) or synthetic material tot (align\u00aeto urethral support system) groups. preoperative and at 1 year postoperative urogynecological symptom assessment, 1-h pad test, 4-day bladder diary, stress test, q-tip test, and urodynamics were performed.", "materials and methods: one hundred patients suffering from clinical and/or urodynamic stress urinary incontinence (sui) were randomized into biological material tot (pelvilace\u00ae to) or synthetic material tot (align\u00aeto urethral support system) groups. preoperative and at 1 year postoperative urogynecological symptom assessment, 1-h pad test, 4-day bladder diary, stress test, q-tip test, and urodynamics were performed.", "materials and methods: one hundred patients suffering from clinical and/or urodynamic stress urinary incontinence (sui) were randomized into biological material tot (pelvilace\u00ae to) or synthetic material tot (align\u00aeto urethral support system) groups. preoperative and at 1 year postoperative urogynecological symptom assessment, 1-h pad test, 4-day bladder diary, stress test, q-tip test, and urodynamics were performed.", "materials and methods: one hundred patients suffering from clinical and/or urodynamic stress urinary incontinence (sui) were randomized into biological material tot (pelvilace\u00ae to) or synthetic material tot (align\u00aeto urethral support system) groups. preoperative and at 1 year postoperative urogynecological symptom assessment, 1-h pad test, 4-day bladder diary, stress test, q-tip test, and urodynamics were performed.", "materials and methods: one hundred patients suffering from clinical and/or urodynamic stress urinary incontinence (sui) were randomized into biological material tot (pelvilace\u00ae to) or synthetic material tot (align\u00aeto urethral support system) groups. preoperative and at 1 year postoperative urogynecological symptom assessment, 1-h pad test, 4-day bladder diary, stress test, q-tip test, and urodynamics were performed.", "materials and methods: one hundred patients suffering from clinical and/or urodynamic stress urinary incontinence (sui) were randomized into biological material tot (pelvilace\u00ae to) or synthetic material tot (align\u00aeto urethral support system) groups. preoperative and at 1 year postoperative urogynecological symptom assessment, 1-h pad test, 4-day bladder diary, stress test, q-tip test, and urodynamics were performed.", "materials and methods: one hundred patients suffering from clinical and/or urodynamic stress urinary incontinence (sui) were randomized into biological material tot (pelvilace\u00ae to) or synthetic material tot (align\u00aeto urethral support system) groups. preoperative and at 1 year postoperative urogynecological symptom assessment, 1-h pad test, 4-day bladder diary, stress test, q-tip test, and urodynamics were performed.", "materials and methods: one hundred patients suffering from clinical and/or urodynamic stress urinary incontinence (sui) were randomized into biological material tot (pelvilace\u00ae to) or synthetic material tot (align\u00aeto urethral support system) groups. preoperative and at 1 year postoperative urogynecological symptom assessment, 1-h pad test, 4-day bladder diary, stress test, q-tip test, and urodynamics were performed.", "materials and methods: one hundred patients suffering from clinical and/or urodynamic stress urinary incontinence (sui) were randomized into biological material tot (pelvilace\u00ae to) or synthetic material tot (align\u00aeto urethral support system) groups. preoperative and at 1 year postoperative urogynecological symptom assessment, 1-h pad test, 4-day bladder diary, stress test, q-tip test, and urodynamics were performed.", "materials and methods: one hundred patients suffering from clinical and/or urodynamic stress urinary incontinence (sui) were randomized into biological material tot (pelvilace\u00ae to) or synthetic material tot (align\u00aeto urethral support system) groups. preoperative and at 1 year postoperative urogynecological symptom assessment, 1-h pad test, 4-day bladder diary, stress test, q-tip test, and urodynamics were performed.", "materials and methods: one hundred patients suffering from clinical and/or urodynamic stress urinary incontinence (sui) were randomized into biological material tot (pelvilace\u00ae to) or synthetic material tot (align\u00aeto urethral support system) groups. preoperative and at 1 year postoperative urogynecological symptom assessment, 1-h pad test, 4-day bladder diary, stress test, q-tip test, and urodynamics were performed.", "materials and methods: one hundred patients suffering from clinical and/or urodynamic stress urinary incontinence (sui) were randomized into biological material tot (pelvilace\u00ae to) or synthetic material tot (align\u00aeto urethral support system) groups. preoperative and at 1 year postoperative urogynecological symptom assessment, 1-h pad test, 4-day bladder diary, stress test, q-tip test, and urodynamics were performed.", "materials and methods: one hundred patients suffering from clinical and/or urodynamic stress urinary incontinence (sui) were randomized into biological material tot (pelvilace\u00ae to) or synthetic material tot (align\u00aeto urethral support system) groups. preoperative and at 1 year postoperative urogynecological symptom assessment, 1-h pad test, 4-day bladder diary, stress test, q-tip test, and urodynamics were performed.", "materials and methods: one hundred patients suffering from clinical and/or urodynamic stress urinary incontinence (sui) were randomized into biological material tot (pelvilace\u00ae to) or synthetic material tot (align\u00aeto urethral support system) groups. preoperative and at 1 year postoperative urogynecological symptom assessment, 1-h pad test, 4-day bladder diary, stress test, q-tip test, and urodynamics were performed.", "materials and methods: one hundred patients suffering from clinical and/or urodynamic stress urinary incontinence (sui) were randomized into biological material tot (pelvilace\u00ae to) or synthetic material tot (align\u00aeto urethral support system) groups. preoperative and at 1 year postoperative urogynecological symptom assessment, 1-h pad test, 4-day bladder diary, stress test, q-tip test, and urodynamics were performed.", "materials and methods: one hundred patients suffering from clinical and/or urodynamic stress urinary incontinence (sui) were randomized into biological material tot (pelvilace\u00ae to) or synthetic material tot (align\u00aeto urethral support system) groups. preoperative and at 1 year postoperative urogynecological symptom assessment, 1-h pad test, 4-day bladder diary, stress test, q-tip test, and urodynamics were performed.", "materials and methods: one hundred patients suffering from clinical and/or urodynamic stress urinary incontinence (sui) were randomized into biological material tot (pelvilace\u00ae to) or synthetic material tot (align\u00aeto urethral support system) groups. preoperative and at 1 year postoperative urogynecological symptom assessment, 1-h pad test, 4-day bladder diary, stress test, q-tip test, and urodynamics were performed.", "materials and methods: one hundred patients suffering from clinical and/or urodynamic stress urinary incontinence (sui) were randomized into biological material tot (pelvilace\u00ae to) or synthetic material tot (align\u00aeto urethral support system) groups. preoperative and at 1 year postoperative urogynecological symptom assessment, 1-h pad test, 4-day bladder diary, stress test, q-tip test, and urodynamics were performed.", "materials and methods: one hundred patients suffering from clinical and/or urodynamic stress urinary incontinence (sui) were randomized into biological material tot (pelvilace\u00ae to) or synthetic material tot (align\u00aeto urethral support system) groups. preoperative and at 1 year postoperative urogynecological symptom assessment, 1-h pad test, 4-day bladder diary, stress test, q-tip test, and urodynamics were performed.", "materials and methods: one hundred patients suffering from clinical and/or urodynamic stress urinary incontinence (sui) were randomized into biological material tot (pelvilace\u00ae to) or synthetic material tot (align\u00aeto urethral support system) groups. preoperative and at 1 year postoperative urogynecological symptom assessment, 1-h pad test, 4-day bladder diary, stress test, q-tip test, and urodynamics were performed.", "materials and methods: one hundred patients suffering from clinical and/or urodynamic stress urinary incontinence (sui) were randomized into biological material tot (pelvilace\u00ae to) or synthetic material tot (align\u00aeto urethral support system) groups. preoperative and at 1 year postoperative urogynecological symptom assessment, 1-h pad test, 4-day bladder diary, stress test, q-tip test, and urodynamics were performed.", "materials and methods: one hundred patients suffering from clinical and/or urodynamic stress urinary incontinence (sui) were randomized into biological material tot (pelvilace\u00ae to) or synthetic material tot (align\u00aeto urethral support system) groups. preoperative and at 1 year postoperative urogynecological symptom assessment, 1-h pad test, 4-day bladder diary, stress test, q-tip test, and urodynamics were performed.", "materials and methods: one hundred patients suffering from clinical and/or urodynamic stress urinary incontinence (sui) were randomized into biological material tot (pelvilace\u00ae to) or synthetic material tot (align\u00aeto urethral support system) groups. preoperative and at 1 year postoperative urogynecological symptom assessment, 1-h pad test, 4-day bladder diary, stress test, q-tip test, and urodynamics were performed.", "materials and methods: one hundred patients suffering from clinical and/or urodynamic stress urinary incontinence (sui) were randomized into biological material tot (pelvilace\u00ae to) or synthetic material tot (align\u00aeto urethral support system) groups. preoperative and at 1 year postoperative urogynecological symptom assessment, 1-h pad test, 4-day bladder diary, stress test, q-tip test, and urodynamics were performed.", "materials and methods: one hundred patients suffering from clinical and/or urodynamic stress urinary incontinence (sui) were randomized into biological material tot (pelvilace\u00ae to) or synthetic material tot (align\u00aeto urethral support system) groups. preoperative and at 1 year postoperative urogynecological symptom assessment, 1-h pad test, 4-day bladder diary, stress test, q-tip test, and urodynamics were performed.", "materials and methods: one hundred patients suffering from clinical and/or urodynamic stress urinary incontinence (sui) were randomized into biological material tot (pelvilace\u00ae to) or synthetic material tot (align\u00aeto urethral support system) groups. preoperative and at 1 year postoperative urogynecological symptom assessment, 1-h pad test, 4-day bladder diary, stress test, q-tip test, and urodynamics were performed.", "materials and methods: one hundred patients suffering from clinical and/or urodynamic stress urinary incontinence (sui) were randomized into biological material tot (pelvilace\u00ae to) or synthetic material tot (align\u00aeto urethral support system) groups. preoperative and at 1 year postoperative urogynecological symptom assessment, 1-h pad test, 4-day bladder diary, stress test, q-tip test, and urodynamics were performed.", "materials and methods: one hundred patients suffering from clinical and/or urodynamic stress urinary incontinence (sui) were randomized into biological material tot (pelvilace\u00ae to) or synthetic material tot (align\u00aeto urethral support system) groups. preoperative and at 1 year postoperative urogynecological symptom assessment, 1-h pad test, 4-day bladder diary, stress test, q-tip test, and urodynamics were performed.", "purpose to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.", "purpose to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.", "purpose to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.", "purpose to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.", "purpose to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.", "purpose to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.", "purpose to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.", "purpose to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.", "purpose to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.", "purpose to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.", "purpose to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.", "purpose to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.", "purpose to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.", "purpose to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.", "purpose to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.", "purpose to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.", "purpose to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.", "purpose to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.", "purpose to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.", "purpose to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.", "purpose to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.", "purpose to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.", "purpose to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.", "purpose to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.", "purpose to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.", "purpose to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.", "purpose to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.", "purpose to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.", "purpose to clarify the association between clinically defined simple stress urinary incontinence (sui) symptoms and urodynamic sui, we examined the relationship between valsalva leak point pressure (vlpp) as measured by the q-tip test and stamey grade in simple female sui.", "study design: 141 women who agreed to undergo midurethral sling operations due to stress urinary incontinence with hypermobile urethra were enrolled in this non-randomized prospective observational study. preoperatively, urethral mobility was measured by q tip test.", "study design: 141 women who agreed to undergo midurethral sling operations due to stress urinary incontinence with hypermobile urethra were enrolled in this non-randomized prospective observational study. preoperatively, urethral mobility was measured by q tip test.", "study design: 141 women who agreed to undergo midurethral sling operations due to stress urinary incontinence with hypermobile urethra were enrolled in this non-randomized prospective observational study. preoperatively, urethral mobility was measured by q tip test.", "study design: 141 women who agreed to undergo midurethral sling operations due to stress urinary incontinence with hypermobile urethra were enrolled in this non-randomized prospective observational study. preoperatively, urethral mobility was measured by q tip test.", "study design: 141 women who agreed to undergo midurethral sling operations due to stress urinary incontinence with hypermobile urethra were enrolled in this non-randomized prospective observational study. preoperatively, urethral mobility was measured by q tip test.", "study design: 141 women who agreed to undergo midurethral sling operations due to stress urinary incontinence with hypermobile urethra were enrolled in this non-randomized prospective observational study. preoperatively, urethral mobility was measured by q tip test.", "study design: 141 women who agreed to undergo midurethral sling operations due to stress urinary incontinence with hypermobile urethra were enrolled in this non-randomized prospective observational study. preoperatively, urethral mobility was measured by q tip test.", "study design: 141 women who agreed to undergo midurethral sling operations due to stress urinary incontinence with hypermobile urethra were enrolled in this non-randomized prospective observational study. preoperatively, urethral mobility was measured by q tip test.", "study design: 141 women who agreed to undergo midurethral sling operations due to stress urinary incontinence with hypermobile urethra were enrolled in this non-randomized prospective observational study. preoperatively, urethral mobility was measured by q tip test.", "study design: 141 women who agreed to undergo midurethral sling operations due to stress urinary incontinence with hypermobile urethra were enrolled in this non-randomized prospective observational study. preoperatively, urethral mobility was measured by q tip test.", "study design: 141 women who agreed to undergo midurethral sling operations due to stress urinary incontinence with hypermobile urethra were enrolled in this non-randomized prospective observational study. preoperatively, urethral mobility was measured by q tip test.", "study design: 141 women who agreed to undergo midurethral sling operations due to stress urinary incontinence with hypermobile urethra were enrolled in this non-randomized prospective observational study. preoperatively, urethral mobility was measured by q tip test.", "study design: 141 women who agreed to undergo midurethral sling operations due to stress urinary incontinence with hypermobile urethra were enrolled in this non-randomized prospective observational study. preoperatively, urethral mobility was measured by q tip test.", "study design: 141 women who agreed to undergo midurethral sling operations due to stress urinary incontinence with hypermobile urethra were enrolled in this non-randomized prospective observational study. preoperatively, urethral mobility was measured by q tip test.", "study design: 141 women who agreed to undergo midurethral sling operations due to stress urinary incontinence with hypermobile urethra were enrolled in this non-randomized prospective observational study. preoperatively, urethral mobility was measured by q tip test.", "study design: 141 women who agreed to undergo midurethral sling operations due to stress urinary incontinence with hypermobile urethra were enrolled in this non-randomized prospective observational study. preoperatively, urethral mobility was measured by q tip test.", "study design: 141 women who agreed to undergo midurethral sling operations due to stress urinary incontinence with hypermobile urethra were enrolled in this non-randomized prospective observational study. preoperatively, urethral mobility was measured by q tip test.", "study design: 141 women who agreed to undergo midurethral sling operations due to stress urinary incontinence with hypermobile urethra were enrolled in this non-randomized prospective observational study. preoperatively, urethral mobility was measured by q tip test.", "study design: 141 women who agreed to undergo midurethral sling operations due to stress urinary incontinence with hypermobile urethra were enrolled in this non-randomized prospective observational study. preoperatively, urethral mobility was measured by q tip test.", "study design: 141 women who agreed to undergo midurethral sling operations due to stress urinary incontinence with hypermobile urethra were enrolled in this non-randomized prospective observational study. preoperatively, urethral mobility was measured by q tip test.", "study design: 141 women who agreed to undergo midurethral sling operations due to stress urinary incontinence with hypermobile urethra were enrolled in this non-randomized prospective observational study. preoperatively, urethral mobility was measured by q tip test.", "study design: 141 women who agreed to undergo midurethral sling operations due to stress urinary incontinence with hypermobile urethra were enrolled in this non-randomized prospective observational study. preoperatively, urethral mobility was measured by q tip test.", "study design: 141 women who agreed to undergo midurethral sling operations due to stress urinary incontinence with hypermobile urethra were enrolled in this non-randomized prospective observational study. preoperatively, urethral mobility was measured by q tip test.", "study design: 141 women who agreed to undergo midurethral sling operations due to stress urinary incontinence with hypermobile urethra were enrolled in this non-randomized prospective observational study. preoperatively, urethral mobility was measured by q tip test.", "study design: 141 women who agreed to undergo midurethral sling operations due to stress urinary incontinence with hypermobile urethra were enrolled in this non-randomized prospective observational study. preoperatively, urethral mobility was measured by q tip test.", "study design: 141 women who agreed to undergo midurethral sling operations due to stress urinary incontinence with hypermobile urethra were enrolled in this non-randomized prospective observational study. preoperatively, urethral mobility was measured by q tip test.", "study design: 141 women who agreed to undergo midurethral sling operations due to stress urinary incontinence with hypermobile urethra were enrolled in this non-randomized prospective observational study. preoperatively, urethral mobility was measured by q tip test.", "study design: 141 women who agreed to undergo midurethral sling operations due to stress urinary incontinence with hypermobile urethra were enrolled in this non-randomized prospective observational study. preoperatively, urethral mobility was measured by q tip test.", "study design: 141 women who agreed to undergo midurethral sling operations due to stress urinary incontinence with hypermobile urethra were enrolled in this non-randomized prospective observational study. preoperatively, urethral mobility was measured by q tip test.", "fifteen women with a clinical and urodynamic diagnosis of stress urinary incontinence had a negative q-tip test (greater than or equal to 30 degrees q-tip angle change on straining).", "fifteen women with a clinical and urodynamic diagnosis of stress urinary incontinence had a negative q-tip test (greater than or equal to 30 degrees q-tip angle change on straining).", "fifteen women with a clinical and urodynamic diagnosis of stress urinary incontinence had a negative q-tip test (greater than or equal to 30 degrees q-tip angle change on straining).", "fifteen women with a clinical and urodynamic diagnosis of stress urinary incontinence had a negative q-tip test (greater than or equal to 30 degrees q-tip angle change on straining).", "fifteen women with a clinical and urodynamic diagnosis of stress urinary incontinence had a negative q-tip test (greater than or equal to 30 degrees q-tip angle change on straining).", "fifteen women with a clinical and urodynamic diagnosis of stress urinary incontinence had a negative q-tip test (greater than or equal to 30 degrees q-tip angle change on straining).", "fifteen women with a clinical and urodynamic diagnosis of stress urinary incontinence had a negative q-tip test (greater than or equal to 30 degrees q-tip angle change on straining).", "fifteen women with a clinical and urodynamic diagnosis of stress urinary incontinence had a negative q-tip test (greater than or equal to 30 degrees q-tip angle change on straining).", "fifteen women with a clinical and urodynamic diagnosis of stress urinary incontinence had a negative q-tip test (greater than or equal to 30 degrees q-tip angle change on straining).", "fifteen women with a clinical and urodynamic diagnosis of stress urinary incontinence had a negative q-tip test (greater than or equal to 30 degrees q-tip angle change on straining).", "fifteen women with a clinical and urodynamic diagnosis of stress urinary incontinence had a negative q-tip test (greater than or equal to 30 degrees q-tip angle change on straining).", "fifteen women with a clinical and urodynamic diagnosis of stress urinary incontinence had a negative q-tip test (greater than or equal to 30 degrees q-tip angle change on straining).", "fifteen women with a clinical and urodynamic diagnosis of stress urinary incontinence had a negative q-tip test (greater than or equal to 30 degrees q-tip angle change on straining).", "fifteen women with a clinical and urodynamic diagnosis of stress urinary incontinence had a negative q-tip test (greater than or equal to 30 degrees q-tip angle change on straining).", "fifteen women with a clinical and urodynamic diagnosis of stress urinary incontinence had a negative q-tip test (greater than or equal to 30 degrees q-tip angle change on straining).", "fifteen women with a clinical and urodynamic diagnosis of stress urinary incontinence had a negative q-tip test (greater than or equal to 30 degrees q-tip angle change on straining).", "fifteen women with a clinical and urodynamic diagnosis of stress urinary incontinence had a negative q-tip test (greater than or equal to 30 degrees q-tip angle change on straining).", "fifteen women with a clinical and urodynamic diagnosis of stress urinary incontinence had a negative q-tip test (greater than or equal to 30 degrees q-tip angle change on straining).", "fifteen women with a clinical and urodynamic diagnosis of stress urinary incontinence had a negative q-tip test (greater than or equal to 30 degrees q-tip angle change on straining).", "fifteen women with a clinical and urodynamic diagnosis of stress urinary incontinence had a negative q-tip test (greater than or equal to 30 degrees q-tip angle change on straining).", "fifteen women with a clinical and urodynamic diagnosis of stress urinary incontinence had a negative q-tip test (greater than or equal to 30 degrees q-tip angle change on straining).", "fifteen women with a clinical and urodynamic diagnosis of stress urinary incontinence had a negative q-tip test (greater than or equal to 30 degrees q-tip angle change on straining).", "fifteen women with a clinical and urodynamic diagnosis of stress urinary incontinence had a negative q-tip test (greater than or equal to 30 degrees q-tip angle change on straining).", "fifteen women with a clinical and urodynamic diagnosis of stress urinary incontinence had a negative q-tip test (greater than or equal to 30 degrees q-tip angle change on straining).", "fifteen women with a clinical and urodynamic diagnosis of stress urinary incontinence had a negative q-tip test (greater than or equal to 30 degrees q-tip angle change on straining).", "fifteen women with a clinical and urodynamic diagnosis of stress urinary incontinence had a negative q-tip test (greater than or equal to 30 degrees q-tip angle change on straining).", "fifteen women with a clinical and urodynamic diagnosis of stress urinary incontinence had a negative q-tip test (greater than or equal to 30 degrees q-tip angle change on straining).", "fifteen women with a clinical and urodynamic diagnosis of stress urinary incontinence had a negative q-tip test (greater than or equal to 30 degrees q-tip angle change on straining).", "fifteen women with a clinical and urodynamic diagnosis of stress urinary incontinence had a negative q-tip test (greater than or equal to 30 degrees q-tip angle change on straining).", "simple clinical tests for support of the urethrovesical junction, such as the q tip test, are non-specific in patients with stress urinary incontinence.", "simple clinical tests for support of the urethrovesical junction, such as the q tip test, are non-specific in patients with stress urinary incontinence.", "simple clinical tests for support of the urethrovesical junction, such as the q tip test, are non-specific in patients with stress urinary incontinence.", "simple clinical tests for support of the urethrovesical junction, such as the q tip test, are non-specific in patients with stress urinary incontinence.", "simple clinical tests for support of the urethrovesical junction, such as the q tip test, are non-specific in patients with stress urinary incontinence.", "simple clinical tests for support of the urethrovesical junction, such as the q tip test, are non-specific in patients with stress urinary incontinence.", "simple clinical tests for support of the urethrovesical junction, such as the q tip test, are non-specific in patients with stress urinary incontinence.", "simple clinical tests for support of the urethrovesical junction, such as the q tip test, are non-specific in patients with stress urinary incontinence.", "simple clinical tests for support of the urethrovesical junction, such as the q tip test, are non-specific in patients with stress urinary incontinence.", "simple clinical tests for support of the urethrovesical junction, such as the q tip test, are non-specific in patients with stress urinary incontinence.", "simple clinical tests for support of the urethrovesical junction, such as the q tip test, are non-specific in patients with stress urinary incontinence.", "simple clinical tests for support of the urethrovesical junction, such as the q tip test, are non-specific in patients with stress urinary incontinence.", "simple clinical tests for support of the urethrovesical junction, such as the q tip test, are non-specific in patients with stress urinary incontinence.", "simple clinical tests for support of the urethrovesical junction, such as the q tip test, are non-specific in patients with stress urinary incontinence.", "simple clinical tests for support of the urethrovesical junction, such as the q tip test, are non-specific in patients with stress urinary incontinence.", "simple clinical tests for support of the urethrovesical junction, such as the q tip test, are non-specific in patients with stress urinary incontinence.", "simple clinical tests for support of the urethrovesical junction, such as the q tip test, are non-specific in patients with stress urinary incontinence.", "simple clinical tests for support of the urethrovesical junction, such as the q tip test, are non-specific in patients with stress urinary incontinence.", "simple clinical tests for support of the urethrovesical junction, such as the q tip test, are non-specific in patients with stress urinary incontinence.", "simple clinical tests for support of the urethrovesical junction, such as the q tip test, are non-specific in patients with stress urinary incontinence.", "simple clinical tests for support of the urethrovesical junction, such as the q tip test, are non-specific in patients with stress urinary incontinence.", "simple clinical tests for support of the urethrovesical junction, such as the q tip test, are non-specific in patients with stress urinary incontinence.", "simple clinical tests for support of the urethrovesical junction, such as the q tip test, are non-specific in patients with stress urinary incontinence.", "simple clinical tests for support of the urethrovesical junction, such as the q tip test, are non-specific in patients with stress urinary incontinence.", "simple clinical tests for support of the urethrovesical junction, such as the q tip test, are non-specific in patients with stress urinary incontinence.", "simple clinical tests for support of the urethrovesical junction, such as the q tip test, are non-specific in patients with stress urinary incontinence.", "simple clinical tests for support of the urethrovesical junction, such as the q tip test, are non-specific in patients with stress urinary incontinence.", "simple clinical tests for support of the urethrovesical junction, such as the q tip test, are non-specific in patients with stress urinary incontinence.", "simple clinical tests for support of the urethrovesical junction, such as the q tip test, are non-specific in patients with stress urinary incontinence.", "valsalva leak point pressure-associated q-tip angle and simple female stress urinary incontinence symptoms.", "valsalva leak point pressure-associated q-tip angle and simple female stress urinary incontinence symptoms.", "valsalva leak point pressure-associated q-tip angle and simple female stress urinary incontinence symptoms.", "valsalva leak point pressure-associated q-tip angle and simple female stress urinary incontinence symptoms.", "valsalva leak point pressure-associated q-tip angle and simple female stress urinary incontinence symptoms.", "valsalva leak point pressure-associated q-tip angle and simple female stress urinary incontinence symptoms.", "valsalva leak point pressure-associated q-tip angle and simple female stress urinary incontinence symptoms.", "valsalva leak point pressure-associated q-tip angle and simple female stress urinary incontinence symptoms.", "valsalva leak point pressure-associated q-tip angle and simple female stress urinary incontinence symptoms.", "valsalva leak point pressure-associated q-tip angle and simple female stress urinary incontinence symptoms.", "valsalva leak point pressure-associated q-tip angle and simple female stress urinary incontinence symptoms.", "valsalva leak point pressure-associated q-tip angle and simple female stress urinary incontinence symptoms.", "valsalva leak point pressure-associated q-tip angle and simple female stress urinary incontinence symptoms.", "valsalva leak point pressure-associated q-tip angle and simple female stress urinary incontinence symptoms.", "valsalva leak point pressure-associated q-tip angle and simple female stress urinary incontinence symptoms.", "valsalva leak point pressure-associated q-tip angle and simple female stress urinary incontinence symptoms.", "valsalva leak point pressure-associated q-tip angle and simple female stress urinary incontinence symptoms.", "valsalva leak point pressure-associated q-tip angle and simple female stress urinary incontinence symptoms.", "valsalva leak point pressure-associated q-tip angle and simple female stress urinary incontinence symptoms.", "valsalva leak point pressure-associated q-tip angle and simple female stress urinary incontinence symptoms.", "valsalva leak point pressure-associated q-tip angle and simple female stress urinary incontinence symptoms.", "valsalva leak point pressure-associated q-tip angle and simple female stress urinary incontinence symptoms.", "valsalva leak point pressure-associated q-tip angle and simple female stress urinary incontinence symptoms.", "valsalva leak point pressure-associated q-tip angle and simple female stress urinary incontinence symptoms.", "valsalva leak point pressure-associated q-tip angle and simple female stress urinary incontinence symptoms.", "valsalva leak point pressure-associated q-tip angle and simple female stress urinary incontinence symptoms.", "valsalva leak point pressure-associated q-tip angle and simple female stress urinary incontinence symptoms.", "valsalva leak point pressure-associated q-tip angle and simple female stress urinary incontinence symptoms.", "valsalva leak point pressure-associated q-tip angle and simple female stress urinary incontinence symptoms.", "role of the q-tip test in evaluating stress urinary incontinence.", "role of the q-tip test in evaluating stress urinary incontinence.", "role of the q-tip test in evaluating stress urinary incontinence.", "role of the q-tip test in evaluating stress urinary incontinence.", "role of the q-tip test in evaluating stress urinary incontinence.", "role of the q-tip test in evaluating stress urinary incontinence.", "role of the q-tip test in evaluating stress urinary incontinence.", "role of the q-tip test in evaluating stress urinary incontinence.", "role of the q-tip test in evaluating stress urinary incontinence.", "role of the q-tip test in evaluating stress urinary incontinence.", "role of the q-tip test in evaluating stress urinary incontinence.", "role of the q-tip test in evaluating stress urinary incontinence.", "role of the q-tip test in evaluating stress urinary incontinence.", "role of the q-tip test in evaluating stress urinary incontinence.", "role of the q-tip test in evaluating stress urinary incontinence.", "role of the q-tip test in evaluating stress urinary incontinence.", "role of the q-tip test in evaluating stress urinary incontinence.", "role of the q-tip test in evaluating stress urinary incontinence.", "role of the q-tip test in evaluating stress urinary incontinence.", "role of the q-tip test in evaluating stress urinary incontinence.", "role of the q-tip test in evaluating stress urinary incontinence.", "role of the q-tip test in evaluating stress urinary incontinence.", "role of the q-tip test in evaluating stress urinary incontinence.", "role of the q-tip test in evaluating stress urinary incontinence.", "role of the q-tip test in evaluating stress urinary incontinence.", "role of the q-tip test in evaluating stress urinary incontinence.", "role of the q-tip test in evaluating stress urinary incontinence.", "role of the q-tip test in evaluating stress urinary incontinence.", "role of the q-tip test in evaluating stress urinary incontinence.", "the groucho-related genes (grg) of the mouse comprise at least four family members.", "the groucho-related genes (grg) of the mouse comprise at least four family members.", "the groucho-related genes (grg) of the mouse comprise at least four family members.", "the groucho-related genes (grg) of the mouse comprise at least four family members.", "the groucho-related genes (grg) of the mouse comprise at least four family members.", "the groucho-related genes (grg) of the mouse comprise at least four family members.", "the groucho-related genes (grg) of the mouse comprise at least four family members.", "the groucho-related genes (grg) of the mouse comprise at least four family members.", "the groucho-related genes (grg) of the mouse comprise at least four family members.", "the groucho-related genes (grg) of the mouse comprise at least four family members.", "the groucho-related genes (grg) of the mouse comprise at least four family members.", "the groucho-related genes (grg) of the mouse comprise at least four family members.", "the groucho-related genes (grg) of the mouse comprise at least four family members.", "the groucho-related genes (grg) of the mouse comprise at least four family members.", "the groucho-related genes (grg) of the mouse comprise at least four family members.", "the groucho-related genes (grg) of the mouse comprise at least four family members.", "the groucho-related genes (grg) of the mouse comprise at least four family members.", "the groucho-related genes (grg) of the mouse comprise at least four family members.", "the groucho-related genes (grg) of the mouse comprise at least four family members.", "the groucho-related genes (grg) of the mouse comprise at least four family members.", "the groucho-related genes (grg) of the mouse comprise at least four family members.", "the groucho-related genes (grg) of the mouse comprise at least four family members.", "the groucho-related genes (grg) of the mouse comprise at least four family members.", "the groucho-related genes (grg) of the mouse comprise at least four family members.", "the groucho-related genes (grg) of the mouse comprise at least four family members.", "the groucho-related genes (grg) of the mouse comprise at least four family members.", "circularized oligodeoxynucleotides (coligos)", "circularized oligodeoxynucleotides (coligos)", "circularized oligodeoxynucleotides (coligos)", "circularized oligodeoxynucleotides (coligos)", "circularized oligodeoxynucleotides (coligos)", "circularized oligodeoxynucleotides (coligos)", "circularized oligodeoxynucleotides (coligos)", "circularized oligodeoxynucleotides (coligos)", "circularized oligodeoxynucleotides (coligos)", "circularized oligodeoxynucleotides (coligos)", "circularized oligodeoxynucleotides (coligos)", "circularized oligodeoxynucleotides (coligos)", "circularized oligodeoxynucleotides (coligos)", "circularized oligodeoxynucleotides (coligos)", "circularized oligodeoxynucleotides (coligos)", "circularized oligodeoxynucleotides (coligos)", "purpose to evaluate the efficacy, safety, biomarkers, and pharmacokinetics of rilotumumab, a fully human, monoclonal antibody against hepatocyte growth factor (hgf)/scatter factor, combined with mitoxantrone and prednisone (mp) in patients with castration-resistant prostate cancer (crpc).", "purpose to evaluate the efficacy, safety, biomarkers, and pharmacokinetics of rilotumumab, a fully human, monoclonal antibody against hepatocyte growth factor (hgf)/scatter factor, combined with mitoxantrone and prednisone (mp) in patients with castration-resistant prostate cancer (crpc).", "purpose to evaluate the efficacy, safety, biomarkers, and pharmacokinetics of rilotumumab, a fully human, monoclonal antibody against hepatocyte growth factor (hgf)/scatter factor, combined with mitoxantrone and prednisone (mp) in patients with castration-resistant prostate cancer (crpc).", "purpose to evaluate the efficacy, safety, biomarkers, and pharmacokinetics of rilotumumab, a fully human, monoclonal antibody against hepatocyte growth factor (hgf)/scatter factor, combined with mitoxantrone and prednisone (mp) in patients with castration-resistant prostate cancer (crpc).", "purpose to evaluate the efficacy, safety, biomarkers, and pharmacokinetics of rilotumumab, a fully human, monoclonal antibody against hepatocyte growth factor (hgf)/scatter factor, combined with mitoxantrone and prednisone (mp) in patients with castration-resistant prostate cancer (crpc).", "purpose to evaluate the efficacy, safety, biomarkers, and pharmacokinetics of rilotumumab, a fully human, monoclonal antibody against hepatocyte growth factor (hgf)/scatter factor, combined with mitoxantrone and prednisone (mp) in patients with castration-resistant prostate cancer (crpc).", "purpose to evaluate the efficacy, safety, biomarkers, and pharmacokinetics of rilotumumab, a fully human, monoclonal antibody against hepatocyte growth factor (hgf)/scatter factor, combined with mitoxantrone and prednisone (mp) in patients with castration-resistant prostate cancer (crpc).", "purpose to evaluate the efficacy, safety, biomarkers, and pharmacokinetics of rilotumumab, a fully human, monoclonal antibody against hepatocyte growth factor (hgf)/scatter factor, combined with mitoxantrone and prednisone (mp) in patients with castration-resistant prostate cancer (crpc).", "purpose to evaluate the efficacy, safety, biomarkers, and pharmacokinetics of rilotumumab, a fully human, monoclonal antibody against hepatocyte growth factor (hgf)/scatter factor, combined with mitoxantrone and prednisone (mp) in patients with castration-resistant prostate cancer (crpc).", "purpose to evaluate the efficacy, safety, biomarkers, and pharmacokinetics of rilotumumab, a fully human, monoclonal antibody against hepatocyte growth factor (hgf)/scatter factor, combined with mitoxantrone and prednisone (mp) in patients with castration-resistant prostate cancer (crpc).", "purpose to evaluate the efficacy, safety, biomarkers, and pharmacokinetics of rilotumumab, a fully human, monoclonal antibody against hepatocyte growth factor (hgf)/scatter factor, combined with mitoxantrone and prednisone (mp) in patients with castration-resistant prostate cancer (crpc).", "purpose to evaluate the efficacy, safety, biomarkers, and pharmacokinetics of rilotumumab, a fully human, monoclonal antibody against hepatocyte growth factor (hgf)/scatter factor, combined with mitoxantrone and prednisone (mp) in patients with castration-resistant prostate cancer (crpc).", "purpose to evaluate the efficacy, safety, biomarkers, and pharmacokinetics of rilotumumab, a fully human, monoclonal antibody against hepatocyte growth factor (hgf)/scatter factor, combined with mitoxantrone and prednisone (mp) in patients with castration-resistant prostate cancer (crpc).", "purpose to evaluate the efficacy, safety, biomarkers, and pharmacokinetics of rilotumumab, a fully human, monoclonal antibody against hepatocyte growth factor (hgf)/scatter factor, combined with mitoxantrone and prednisone (mp) in patients with castration-resistant prostate cancer (crpc).", "purpose to evaluate the efficacy, safety, biomarkers, and pharmacokinetics of rilotumumab, a fully human, monoclonal antibody against hepatocyte growth factor (hgf)/scatter factor, combined with mitoxantrone and prednisone (mp) in patients with castration-resistant prostate cancer (crpc).", "purpose to evaluate the efficacy, safety, biomarkers, and pharmacokinetics of rilotumumab, a fully human, monoclonal antibody against hepatocyte growth factor (hgf)/scatter factor, combined with mitoxantrone and prednisone (mp) in patients with castration-resistant prostate cancer (crpc).", "purpose to evaluate the efficacy, safety, biomarkers, and pharmacokinetics of rilotumumab, a fully human, monoclonal antibody against hepatocyte growth factor (hgf)/scatter factor, combined with mitoxantrone and prednisone (mp) in patients with castration-resistant prostate cancer (crpc).", "purpose to evaluate the efficacy, safety, biomarkers, and pharmacokinetics of rilotumumab, a fully human, monoclonal antibody against hepatocyte growth factor (hgf)/scatter factor, combined with mitoxantrone and prednisone (mp) in patients with castration-resistant prostate cancer (crpc).", "purpose to evaluate the efficacy, safety, biomarkers, and pharmacokinetics of rilotumumab, a fully human, monoclonal antibody against hepatocyte growth factor (hgf)/scatter factor, combined with mitoxantrone and prednisone (mp) in patients with castration-resistant prostate cancer (crpc).", "purpose to evaluate the efficacy, safety, biomarkers, and pharmacokinetics of rilotumumab, a fully human, monoclonal antibody against hepatocyte growth factor (hgf)/scatter factor, combined with mitoxantrone and prednisone (mp) in patients with castration-resistant prostate cancer (crpc).", "purpose to evaluate the efficacy, safety, biomarkers, and pharmacokinetics of rilotumumab, a fully human, monoclonal antibody against hepatocyte growth factor (hgf)/scatter factor, combined with mitoxantrone and prednisone (mp) in patients with castration-resistant prostate cancer (crpc).", "purpose to evaluate the efficacy, safety, biomarkers, and pharmacokinetics of rilotumumab, a fully human, monoclonal antibody against hepatocyte growth factor (hgf)/scatter factor, combined with mitoxantrone and prednisone (mp) in patients with castration-resistant prostate cancer (crpc).", "purpose to evaluate the efficacy, safety, biomarkers, and pharmacokinetics of rilotumumab, a fully human, monoclonal antibody against hepatocyte growth factor (hgf)/scatter factor, combined with mitoxantrone and prednisone (mp) in patients with castration-resistant prostate cancer (crpc).", "rilotumumab is an investigational, fully human, monoclonal antibody immunoglobulin g2 against hepatocyte growth factor (hgf) that blocks the binding of hgf to its receptor met and has shown trends toward improved survival in a phase 2 clinical trial in gastric cancer.", "rilotumumab is an investigational, fully human, monoclonal antibody immunoglobulin g2 against hepatocyte growth factor (hgf) that blocks the binding of hgf to its receptor met and has shown trends toward improved survival in a phase 2 clinical trial in gastric cancer.", "rilotumumab is an investigational, fully human, monoclonal antibody immunoglobulin g2 against hepatocyte growth factor (hgf) that blocks the binding of hgf to its receptor met and has shown trends toward improved survival in a phase 2 clinical trial in gastric cancer.", "rilotumumab is an investigational, fully human, monoclonal antibody immunoglobulin g2 against hepatocyte growth factor (hgf) that blocks the binding of hgf to its receptor met and has shown trends toward improved survival in a phase 2 clinical trial in gastric cancer.", "rilotumumab is an investigational, fully human, monoclonal antibody immunoglobulin g2 against hepatocyte growth factor (hgf) that blocks the binding of hgf to its receptor met and has shown trends toward improved survival in a phase 2 clinical trial in gastric cancer.", "rilotumumab is an investigational, fully human, monoclonal antibody immunoglobulin g2 against hepatocyte growth factor (hgf) that blocks the binding of hgf to its receptor met and has shown trends toward improved survival in a phase 2 clinical trial in gastric cancer.", "rilotumumab is an investigational, fully human, monoclonal antibody immunoglobulin g2 against hepatocyte growth factor (hgf) that blocks the binding of hgf to its receptor met and has shown trends toward improved survival in a phase 2 clinical trial in gastric cancer.", "rilotumumab is an investigational, fully human, monoclonal antibody immunoglobulin g2 against hepatocyte growth factor (hgf) that blocks the binding of hgf to its receptor met and has shown trends toward improved survival in a phase 2 clinical trial in gastric cancer.", "rilotumumab is an investigational, fully human, monoclonal antibody immunoglobulin g2 against hepatocyte growth factor (hgf) that blocks the binding of hgf to its receptor met and has shown trends toward improved survival in a phase 2 clinical trial in gastric cancer.", "rilotumumab is an investigational, fully human, monoclonal antibody immunoglobulin g2 against hepatocyte growth factor (hgf) that blocks the binding of hgf to its receptor met and has shown trends toward improved survival in a phase 2 clinical trial in gastric cancer.", "rilotumumab is an investigational, fully human, monoclonal antibody immunoglobulin g2 against hepatocyte growth factor (hgf) that blocks the binding of hgf to its receptor met and has shown trends toward improved survival in a phase 2 clinical trial in gastric cancer.", "rilotumumab is an investigational, fully human, monoclonal antibody immunoglobulin g2 against hepatocyte growth factor (hgf) that blocks the binding of hgf to its receptor met and has shown trends toward improved survival in a phase 2 clinical trial in gastric cancer.", "rilotumumab is an investigational, fully human, monoclonal antibody immunoglobulin g2 against hepatocyte growth factor (hgf) that blocks the binding of hgf to its receptor met and has shown trends toward improved survival in a phase 2 clinical trial in gastric cancer.", "rilotumumab is an investigational, fully human, monoclonal antibody immunoglobulin g2 against hepatocyte growth factor (hgf) that blocks the binding of hgf to its receptor met and has shown trends toward improved survival in a phase 2 clinical trial in gastric cancer.", "rilotumumab is an investigational, fully human, monoclonal antibody immunoglobulin g2 against hepatocyte growth factor (hgf) that blocks the binding of hgf to its receptor met and has shown trends toward improved survival in a phase 2 clinical trial in gastric cancer.", "rilotumumab is an investigational, fully human, monoclonal antibody immunoglobulin g2 against hepatocyte growth factor (hgf) that blocks the binding of hgf to its receptor met and has shown trends toward improved survival in a phase 2 clinical trial in gastric cancer.", "rilotumumab is an investigational, fully human, monoclonal antibody immunoglobulin g2 against hepatocyte growth factor (hgf) that blocks the binding of hgf to its receptor met and has shown trends toward improved survival in a phase 2 clinical trial in gastric cancer.", "rilotumumab is an investigational, fully human, monoclonal antibody immunoglobulin g2 against hepatocyte growth factor (hgf) that blocks the binding of hgf to its receptor met and has shown trends toward improved survival in a phase 2 clinical trial in gastric cancer.", "rilotumumab is an investigational, fully human, monoclonal antibody immunoglobulin g2 against hepatocyte growth factor (hgf) that blocks the binding of hgf to its receptor met and has shown trends toward improved survival in a phase 2 clinical trial in gastric cancer.", "rilotumumab is an investigational, fully human, monoclonal antibody immunoglobulin g2 against hepatocyte growth factor (hgf) that blocks the binding of hgf to its receptor met and has shown trends toward improved survival in a phase 2 clinical trial in gastric cancer.", "rilotumumab is an investigational, fully human, monoclonal antibody immunoglobulin g2 against hepatocyte growth factor (hgf) that blocks the binding of hgf to its receptor met and has shown trends toward improved survival in a phase 2 clinical trial in gastric cancer.", "rilotumumab is an investigational, fully human, monoclonal antibody immunoglobulin g2 against hepatocyte growth factor (hgf) that blocks the binding of hgf to its receptor met and has shown trends toward improved survival in a phase 2 clinical trial in gastric cancer.", "rilotumumab is an investigational, fully human, monoclonal antibody immunoglobulin g2 against hepatocyte growth factor (hgf) that blocks the binding of hgf to its receptor met and has shown trends toward improved survival in a phase 2 clinical trial in gastric cancer.", "the hepatocyte growth factor receptor (met) was targeted in untreated patients in a phase iii trial with moab rilotumumab, with or without ct, but the study was stopped because of mortality excess in the rilotumumab arm.", "the hepatocyte growth factor receptor (met) was targeted in untreated patients in a phase iii trial with moab rilotumumab, with or without ct, but the study was stopped because of mortality excess in the rilotumumab arm.", "the hepatocyte growth factor receptor (met) was targeted in untreated patients in a phase iii trial with moab rilotumumab, with or without ct, but the study was stopped because of mortality excess in the rilotumumab arm.", "the hepatocyte growth factor receptor (met) was targeted in untreated patients in a phase iii trial with moab rilotumumab, with or without ct, but the study was stopped because of mortality excess in the rilotumumab arm.", "the hepatocyte growth factor receptor (met) was targeted in untreated patients in a phase iii trial with moab rilotumumab, with or without ct, but the study was stopped because of mortality excess in the rilotumumab arm.", "the hepatocyte growth factor receptor (met) was targeted in untreated patients in a phase iii trial with moab rilotumumab, with or without ct, but the study was stopped because of mortality excess in the rilotumumab arm.", "the hepatocyte growth factor receptor (met) was targeted in untreated patients in a phase iii trial with moab rilotumumab, with or without ct, but the study was stopped because of mortality excess in the rilotumumab arm.", "the hepatocyte growth factor receptor (met) was targeted in untreated patients in a phase iii trial with moab rilotumumab, with or without ct, but the study was stopped because of mortality excess in the rilotumumab arm.", "the hepatocyte growth factor receptor (met) was targeted in untreated patients in a phase iii trial with moab rilotumumab, with or without ct, but the study was stopped because of mortality excess in the rilotumumab arm.", "the hepatocyte growth factor receptor (met) was targeted in untreated patients in a phase iii trial with moab rilotumumab, with or without ct, but the study was stopped because of mortality excess in the rilotumumab arm.", "the hepatocyte growth factor receptor (met) was targeted in untreated patients in a phase iii trial with moab rilotumumab, with or without ct, but the study was stopped because of mortality excess in the rilotumumab arm.", "the hepatocyte growth factor receptor (met) was targeted in untreated patients in a phase iii trial with moab rilotumumab, with or without ct, but the study was stopped because of mortality excess in the rilotumumab arm.", "the hepatocyte growth factor receptor (met) was targeted in untreated patients in a phase iii trial with moab rilotumumab, with or without ct, but the study was stopped because of mortality excess in the rilotumumab arm.", "the hepatocyte growth factor receptor (met) was targeted in untreated patients in a phase iii trial with moab rilotumumab, with or without ct, but the study was stopped because of mortality excess in the rilotumumab arm.", "the hepatocyte growth factor receptor (met) was targeted in untreated patients in a phase iii trial with moab rilotumumab, with or without ct, but the study was stopped because of mortality excess in the rilotumumab arm.", "the hepatocyte growth factor receptor (met) was targeted in untreated patients in a phase iii trial with moab rilotumumab, with or without ct, but the study was stopped because of mortality excess in the rilotumumab arm.", "the hepatocyte growth factor receptor (met) was targeted in untreated patients in a phase iii trial with moab rilotumumab, with or without ct, but the study was stopped because of mortality excess in the rilotumumab arm.", "the hepatocyte growth factor receptor (met) was targeted in untreated patients in a phase iii trial with moab rilotumumab, with or without ct, but the study was stopped because of mortality excess in the rilotumumab arm.", "the hepatocyte growth factor receptor (met) was targeted in untreated patients in a phase iii trial with moab rilotumumab, with or without ct, but the study was stopped because of mortality excess in the rilotumumab arm.", "the hepatocyte growth factor receptor (met) was targeted in untreated patients in a phase iii trial with moab rilotumumab, with or without ct, but the study was stopped because of mortality excess in the rilotumumab arm.", "the hepatocyte growth factor receptor (met) was targeted in untreated patients in a phase iii trial with moab rilotumumab, with or without ct, but the study was stopped because of mortality excess in the rilotumumab arm.", "the hepatocyte growth factor receptor (met) was targeted in untreated patients in a phase iii trial with moab rilotumumab, with or without ct, but the study was stopped because of mortality excess in the rilotumumab arm.", "the hepatocyte growth factor receptor (met) was targeted in untreated patients in a phase iii trial with moab rilotumumab, with or without ct, but the study was stopped because of mortality excess in the rilotumumab arm.", "the hepatocyte growth factor (hgf) binding antibody rilotumumab (amg102) was modified for use as a89zr-based immuno-pet imaging agent to noninvasively determine the local levels of hgf protein in tumors.", "the hepatocyte growth factor (hgf) binding antibody rilotumumab (amg102) was modified for use as a89zr-based immuno-pet imaging agent to noninvasively determine the local levels of hgf protein in tumors.", "the hepatocyte growth factor (hgf) binding antibody rilotumumab (amg102) was modified for use as a89zr-based immuno-pet imaging agent to noninvasively determine the local levels of hgf protein in tumors.", "the hepatocyte growth factor (hgf) binding antibody rilotumumab (amg102) was modified for use as a89zr-based immuno-pet imaging agent to noninvasively determine the local levels of hgf protein in tumors.", "the hepatocyte growth factor (hgf) binding antibody rilotumumab (amg102) was modified for use as a89zr-based immuno-pet imaging agent to noninvasively determine the local levels of hgf protein in tumors.", "the hepatocyte growth factor (hgf) binding antibody rilotumumab (amg102) was modified for use as a89zr-based immuno-pet imaging agent to noninvasively determine the local levels of hgf protein in tumors.", "the hepatocyte growth factor (hgf) binding antibody rilotumumab (amg102) was modified for use as a89zr-based immuno-pet imaging agent to noninvasively determine the local levels of hgf protein in tumors.", "the hepatocyte growth factor (hgf) binding antibody rilotumumab (amg102) was modified for use as a89zr-based immuno-pet imaging agent to noninvasively determine the local levels of hgf protein in tumors.", "the hepatocyte growth factor (hgf) binding antibody rilotumumab (amg102) was modified for use as a89zr-based immuno-pet imaging agent to noninvasively determine the local levels of hgf protein in tumors.", "the hepatocyte growth factor (hgf) binding antibody rilotumumab (amg102) was modified for use as a89zr-based immuno-pet imaging agent to noninvasively determine the local levels of hgf protein in tumors.", "the hepatocyte growth factor (hgf) binding antibody rilotumumab (amg102) was modified for use as a89zr-based immuno-pet imaging agent to noninvasively determine the local levels of hgf protein in tumors.", "the hepatocyte growth factor (hgf) binding antibody rilotumumab (amg102) was modified for use as a89zr-based immuno-pet imaging agent to noninvasively determine the local levels of hgf protein in tumors.", "the hepatocyte growth factor (hgf) binding antibody rilotumumab (amg102) was modified for use as a89zr-based immuno-pet imaging agent to noninvasively determine the local levels of hgf protein in tumors.", "the hepatocyte growth factor (hgf) binding antibody rilotumumab (amg102) was modified for use as a89zr-based immuno-pet imaging agent to noninvasively determine the local levels of hgf protein in tumors.", "the hepatocyte growth factor (hgf) binding antibody rilotumumab (amg102) was modified for use as a89zr-based immuno-pet imaging agent to noninvasively determine the local levels of hgf protein in tumors.", "the hepatocyte growth factor (hgf) binding antibody rilotumumab (amg102) was modified for use as a89zr-based immuno-pet imaging agent to noninvasively determine the local levels of hgf protein in tumors.", "the hepatocyte growth factor (hgf) binding antibody rilotumumab (amg102) was modified for use as a89zr-based immuno-pet imaging agent to noninvasively determine the local levels of hgf protein in tumors.", "the hepatocyte growth factor (hgf) binding antibody rilotumumab (amg102) was modified for use as a89zr-based immuno-pet imaging agent to noninvasively determine the local levels of hgf protein in tumors.", "the hepatocyte growth factor (hgf) binding antibody rilotumumab (amg102) was modified for use as a89zr-based immuno-pet imaging agent to noninvasively determine the local levels of hgf protein in tumors.", "the hepatocyte growth factor (hgf) binding antibody rilotumumab (amg102) was modified for use as a89zr-based immuno-pet imaging agent to noninvasively determine the local levels of hgf protein in tumors.", "the hepatocyte growth factor (hgf) binding antibody rilotumumab (amg102) was modified for use as a89zr-based immuno-pet imaging agent to noninvasively determine the local levels of hgf protein in tumors.", "the hepatocyte growth factor (hgf) binding antibody rilotumumab (amg102) was modified for use as a89zr-based immuno-pet imaging agent to noninvasively determine the local levels of hgf protein in tumors.", "the hepatocyte growth factor (hgf) binding antibody rilotumumab (amg102) was modified for use as a89zr-based immuno-pet imaging agent to noninvasively determine the local levels of hgf protein in tumors.", "furthermore, negative study data have been published for rilotumumab and ficlatuzumab, both of which block hepatocyte growth factor binding to the mesenchymal-epithelial transition (met) receptor.", "furthermore, negative study data have been published for rilotumumab and ficlatuzumab, both of which block hepatocyte growth factor binding to the mesenchymal-epithelial transition (met) receptor.", "furthermore, negative study data have been published for rilotumumab and ficlatuzumab, both of which block hepatocyte growth factor binding to the mesenchymal-epithelial transition (met) receptor.", "furthermore, negative study data have been published for rilotumumab and ficlatuzumab, both of which block hepatocyte growth factor binding to the mesenchymal-epithelial transition (met) receptor.", "furthermore, negative study data have been published for rilotumumab and ficlatuzumab, both of which block hepatocyte growth factor binding to the mesenchymal-epithelial transition (met) receptor.", "furthermore, negative study data have been published for rilotumumab and ficlatuzumab, both of which block hepatocyte growth factor binding to the mesenchymal-epithelial transition (met) receptor.", "furthermore, negative study data have been published for rilotumumab and ficlatuzumab, both of which block hepatocyte growth factor binding to the mesenchymal-epithelial transition (met) receptor.", "furthermore, negative study data have been published for rilotumumab and ficlatuzumab, both of which block hepatocyte growth factor binding to the mesenchymal-epithelial transition (met) receptor.", "furthermore, negative study data have been published for rilotumumab and ficlatuzumab, both of which block hepatocyte growth factor binding to the mesenchymal-epithelial transition (met) receptor.", "furthermore, negative study data have been published for rilotumumab and ficlatuzumab, both of which block hepatocyte growth factor binding to the mesenchymal-epithelial transition (met) receptor.", "furthermore, negative study data have been published for rilotumumab and ficlatuzumab, both of which block hepatocyte growth factor binding to the mesenchymal-epithelial transition (met) receptor.", "furthermore, negative study data have been published for rilotumumab and ficlatuzumab, both of which block hepatocyte growth factor binding to the mesenchymal-epithelial transition (met) receptor.", "furthermore, negative study data have been published for rilotumumab and ficlatuzumab, both of which block hepatocyte growth factor binding to the mesenchymal-epithelial transition (met) receptor.", "furthermore, negative study data have been published for rilotumumab and ficlatuzumab, both of which block hepatocyte growth factor binding to the mesenchymal-epithelial transition (met) receptor.", "furthermore, negative study data have been published for rilotumumab and ficlatuzumab, both of which block hepatocyte growth factor binding to the mesenchymal-epithelial transition (met) receptor.", "furthermore, negative study data have been published for rilotumumab and ficlatuzumab, both of which block hepatocyte growth factor binding to the mesenchymal-epithelial transition (met) receptor.", "furthermore, negative study data have been published for rilotumumab and ficlatuzumab, both of which block hepatocyte growth factor binding to the mesenchymal-epithelial transition (met) receptor.", "furthermore, negative study data have been published for rilotumumab and ficlatuzumab, both of which block hepatocyte growth factor binding to the mesenchymal-epithelial transition (met) receptor.", "furthermore, negative study data have been published for rilotumumab and ficlatuzumab, both of which block hepatocyte growth factor binding to the mesenchymal-epithelial transition (met) receptor.", "furthermore, negative study data have been published for rilotumumab and ficlatuzumab, both of which block hepatocyte growth factor binding to the mesenchymal-epithelial transition (met) receptor.", "furthermore, negative study data have been published for rilotumumab and ficlatuzumab, both of which block hepatocyte growth factor binding to the mesenchymal-epithelial transition (met) receptor.", "furthermore, negative study data have been published for rilotumumab and ficlatuzumab, both of which block hepatocyte growth factor binding to the mesenchymal-epithelial transition (met) receptor.", "furthermore, negative study data have been published for rilotumumab and ficlatuzumab, both of which block hepatocyte growth factor binding to the mesenchymal-epithelial transition (met) receptor.", "background: rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the met receptor, hepatocyte growth factor (hgf).", "background: rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the met receptor, hepatocyte growth factor (hgf).", "background: rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the met receptor, hepatocyte growth factor (hgf).", "background: rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the met receptor, hepatocyte growth factor (hgf).", "background: rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the met receptor, hepatocyte growth factor (hgf).", "background: rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the met receptor, hepatocyte growth factor (hgf).", "background: rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the met receptor, hepatocyte growth factor (hgf).", "background: rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the met receptor, hepatocyte growth factor (hgf).", "background: rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the met receptor, hepatocyte growth factor (hgf).", "background: rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the met receptor, hepatocyte growth factor (hgf).", "background: rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the met receptor, hepatocyte growth factor (hgf).", "background: rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the met receptor, hepatocyte growth factor (hgf).", "background: rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the met receptor, hepatocyte growth factor (hgf).", "background: rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the met receptor, hepatocyte growth factor (hgf).", "background: rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the met receptor, hepatocyte growth factor (hgf).", "background: rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the met receptor, hepatocyte growth factor (hgf).", "background: rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the met receptor, hepatocyte growth factor (hgf).", "background: rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the met receptor, hepatocyte growth factor (hgf).", "background: rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the met receptor, hepatocyte growth factor (hgf).", "background: rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the met receptor, hepatocyte growth factor (hgf).", "background: rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the met receptor, hepatocyte growth factor (hgf).", "background: rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the met receptor, hepatocyte growth factor (hgf).", "background: rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the met receptor, hepatocyte growth factor (hgf).", "background rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the met receptor, hepatocyte growth factor (hgf).", "background rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the met receptor, hepatocyte growth factor (hgf).", "background rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the met receptor, hepatocyte growth factor (hgf).", "background rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the met receptor, hepatocyte growth factor (hgf).", "background rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the met receptor, hepatocyte growth factor (hgf).", "background rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the met receptor, hepatocyte growth factor (hgf).", "background rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the met receptor, hepatocyte growth factor (hgf).", "background rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the met receptor, hepatocyte growth factor (hgf).", "background rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the met receptor, hepatocyte growth factor (hgf).", "background rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the met receptor, hepatocyte growth factor (hgf).", "background rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the met receptor, hepatocyte growth factor (hgf).", "background rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the met receptor, hepatocyte growth factor (hgf).", "background rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the met receptor, hepatocyte growth factor (hgf).", "background rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the met receptor, hepatocyte growth factor (hgf).", "background rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the met receptor, hepatocyte growth factor (hgf).", "background rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the met receptor, hepatocyte growth factor (hgf).", "background rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the met receptor, hepatocyte growth factor (hgf).", "background rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the met receptor, hepatocyte growth factor (hgf).", "background rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the met receptor, hepatocyte growth factor (hgf).", "background rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the met receptor, hepatocyte growth factor (hgf).", "background rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the met receptor, hepatocyte growth factor (hgf).", "background rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the met receptor, hepatocyte growth factor (hgf).", "background rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the met receptor, hepatocyte growth factor (hgf).", "purpose rilotumumab is an investigational, fully human monoclonal antibody to hepatocyte growth factor.", "purpose rilotumumab is an investigational, fully human monoclonal antibody to hepatocyte growth factor.", "purpose rilotumumab is an investigational, fully human monoclonal antibody to hepatocyte growth factor.", "purpose rilotumumab is an investigational, fully human monoclonal antibody to hepatocyte growth factor.", "purpose rilotumumab is an investigational, fully human monoclonal antibody to hepatocyte growth factor.", "purpose rilotumumab is an investigational, fully human monoclonal antibody to hepatocyte growth factor.", "purpose rilotumumab is an investigational, fully human monoclonal antibody to hepatocyte growth factor.", "purpose rilotumumab is an investigational, fully human monoclonal antibody to hepatocyte growth factor.", "purpose rilotumumab is an investigational, fully human monoclonal antibody to hepatocyte growth factor.", "purpose rilotumumab is an investigational, fully human monoclonal antibody to hepatocyte growth factor.", "purpose rilotumumab is an investigational, fully human monoclonal antibody to hepatocyte growth factor.", "purpose rilotumumab is an investigational, fully human monoclonal antibody to hepatocyte growth factor.", "purpose rilotumumab is an investigational, fully human monoclonal antibody to hepatocyte growth factor.", "purpose rilotumumab is an investigational, fully human monoclonal antibody to hepatocyte growth factor.", "purpose rilotumumab is an investigational, fully human monoclonal antibody to hepatocyte growth factor.", "purpose rilotumumab is an investigational, fully human monoclonal antibody to hepatocyte growth factor.", "purpose rilotumumab is an investigational, fully human monoclonal antibody to hepatocyte growth factor.", "purpose rilotumumab is an investigational, fully human monoclonal antibody to hepatocyte growth factor.", "purpose rilotumumab is an investigational, fully human monoclonal antibody to hepatocyte growth factor.", "purpose rilotumumab is an investigational, fully human monoclonal antibody to hepatocyte growth factor.", "purpose rilotumumab is an investigational, fully human monoclonal antibody to hepatocyte growth factor.", "purpose rilotumumab is an investigational, fully human monoclonal antibody to hepatocyte growth factor.", "purpose rilotumumab is an investigational, fully human monoclonal antibody to hepatocyte growth factor.", "idarucizumab immediately and completely reversed dabigatran-induced anticoagulation in a dose-dependent manner; the mean ratio of day 4 auec2-12 to day 3 auec2-12 for dtt was 1\u00b701 with placebo, 0\u00b726 with 1 g idarucizumab (74% reduction), 0\u00b706 with 2 g idarucizumab (94% reduction), 0\u00b702 with 4 g idarucizumab (98% reduction), and 0\u00b701 with 5 g plus 2\u00b75 g idarucizumab (99% reduction).", "idarucizumab immediately and completely reversed dabigatran-induced anticoagulation in a dose-dependent manner; the mean ratio of day 4 auec2-12 to day 3 auec2-12 for dtt was 1\u00b701 with placebo, 0\u00b726 with 1 g idarucizumab (74% reduction), 0\u00b706 with 2 g idarucizumab (94% reduction), 0\u00b702 with 4 g idarucizumab (98% reduction), and 0\u00b701 with 5 g plus 2\u00b75 g idarucizumab (99% reduction).", "idarucizumab immediately and completely reversed dabigatran-induced anticoagulation in a dose-dependent manner; the mean ratio of day 4 auec2-12 to day 3 auec2-12 for dtt was 1\u00b701 with placebo, 0\u00b726 with 1 g idarucizumab (74% reduction), 0\u00b706 with 2 g idarucizumab (94% reduction), 0\u00b702 with 4 g idarucizumab (98% reduction), and 0\u00b701 with 5 g plus 2\u00b75 g idarucizumab (99% reduction).", "idarucizumab immediately and completely reversed dabigatran-induced anticoagulation in a dose-dependent manner; the mean ratio of day 4 auec2-12 to day 3 auec2-12 for dtt was 1\u00b701 with placebo, 0\u00b726 with 1 g idarucizumab (74% reduction), 0\u00b706 with 2 g idarucizumab (94% reduction), 0\u00b702 with 4 g idarucizumab (98% reduction), and 0\u00b701 with 5 g plus 2\u00b75 g idarucizumab (99% reduction).", "idarucizumab immediately and completely reversed dabigatran-induced anticoagulation in a dose-dependent manner; the mean ratio of day 4 auec2-12 to day 3 auec2-12 for dtt was 1\u00b701 with placebo, 0\u00b726 with 1 g idarucizumab (74% reduction), 0\u00b706 with 2 g idarucizumab (94% reduction), 0\u00b702 with 4 g idarucizumab (98% reduction), and 0\u00b701 with 5 g plus 2\u00b75 g idarucizumab (99% reduction).", "idarucizumab immediately and completely reversed dabigatran-induced anticoagulation in a dose-dependent manner; the mean ratio of day 4 auec2-12 to day 3 auec2-12 for dtt was 1\u00b701 with placebo, 0\u00b726 with 1 g idarucizumab (74% reduction), 0\u00b706 with 2 g idarucizumab (94% reduction), 0\u00b702 with 4 g idarucizumab (98% reduction), and 0\u00b701 with 5 g plus 2\u00b75 g idarucizumab (99% reduction).", "idarucizumab immediately and completely reversed dabigatran-induced anticoagulation in a dose-dependent manner; the mean ratio of day 4 auec2-12 to day 3 auec2-12 for dtt was 1\u00b701 with placebo, 0\u00b726 with 1 g idarucizumab (74% reduction), 0\u00b706 with 2 g idarucizumab (94% reduction), 0\u00b702 with 4 g idarucizumab (98% reduction), and 0\u00b701 with 5 g plus 2\u00b75 g idarucizumab (99% reduction).", "idarucizumab immediately and completely reversed dabigatran-induced anticoagulation in a dose-dependent manner; the mean ratio of day 4 auec2-12 to day 3 auec2-12 for dtt was 1\u00b701 with placebo, 0\u00b726 with 1 g idarucizumab (74% reduction), 0\u00b706 with 2 g idarucizumab (94% reduction), 0\u00b702 with 4 g idarucizumab (98% reduction), and 0\u00b701 with 5 g plus 2\u00b75 g idarucizumab (99% reduction).", "idarucizumab immediately and completely reversed dabigatran-induced anticoagulation in a dose-dependent manner; the mean ratio of day 4 auec2-12 to day 3 auec2-12 for dtt was 1\u00b701 with placebo, 0\u00b726 with 1 g idarucizumab (74% reduction), 0\u00b706 with 2 g idarucizumab (94% reduction), 0\u00b702 with 4 g idarucizumab (98% reduction), and 0\u00b701 with 5 g plus 2\u00b75 g idarucizumab (99% reduction).", "idarucizumab immediately and completely reversed dabigatran-induced anticoagulation in a dose-dependent manner; the mean ratio of day 4 auec2-12 to day 3 auec2-12 for dtt was 1\u00b701 with placebo, 0\u00b726 with 1 g idarucizumab (74% reduction), 0\u00b706 with 2 g idarucizumab (94% reduction), 0\u00b702 with 4 g idarucizumab (98% reduction), and 0\u00b701 with 5 g plus 2\u00b75 g idarucizumab (99% reduction).", "idarucizumab immediately and completely reversed dabigatran-induced anticoagulation in a dose-dependent manner; the mean ratio of day 4 auec2-12 to day 3 auec2-12 for dtt was 1\u00b701 with placebo, 0\u00b726 with 1 g idarucizumab (74% reduction), 0\u00b706 with 2 g idarucizumab (94% reduction), 0\u00b702 with 4 g idarucizumab (98% reduction), and 0\u00b701 with 5 g plus 2\u00b75 g idarucizumab (99% reduction).", "idarucizumab immediately and completely reversed dabigatran-induced anticoagulation in a dose-dependent manner; the mean ratio of day 4 auec2-12 to day 3 auec2-12 for dtt was 1\u00b701 with placebo, 0\u00b726 with 1 g idarucizumab (74% reduction), 0\u00b706 with 2 g idarucizumab (94% reduction), 0\u00b702 with 4 g idarucizumab (98% reduction), and 0\u00b701 with 5 g plus 2\u00b75 g idarucizumab (99% reduction).", "idarucizumab immediately and completely reversed dabigatran-induced anticoagulation in a dose-dependent manner; the mean ratio of day 4 auec2-12 to day 3 auec2-12 for dtt was 1\u00b701 with placebo, 0\u00b726 with 1 g idarucizumab (74% reduction), 0\u00b706 with 2 g idarucizumab (94% reduction), 0\u00b702 with 4 g idarucizumab (98% reduction), and 0\u00b701 with 5 g plus 2\u00b75 g idarucizumab (99% reduction).", "idarucizumab immediately and completely reversed dabigatran-induced anticoagulation in a dose-dependent manner; the mean ratio of day 4 auec2-12 to day 3 auec2-12 for dtt was 1\u00b701 with placebo, 0\u00b726 with 1 g idarucizumab (74% reduction), 0\u00b706 with 2 g idarucizumab (94% reduction), 0\u00b702 with 4 g idarucizumab (98% reduction), and 0\u00b701 with 5 g plus 2\u00b75 g idarucizumab (99% reduction).", "idarucizumab immediately and completely reversed dabigatran-induced anticoagulation in a dose-dependent manner; the mean ratio of day 4 auec2-12 to day 3 auec2-12 for dtt was 1\u00b701 with placebo, 0\u00b726 with 1 g idarucizumab (74% reduction), 0\u00b706 with 2 g idarucizumab (94% reduction), 0\u00b702 with 4 g idarucizumab (98% reduction), and 0\u00b701 with 5 g plus 2\u00b75 g idarucizumab (99% reduction).", "idarucizumab immediately and completely reversed dabigatran-induced anticoagulation in a dose-dependent manner; the mean ratio of day 4 auec2-12 to day 3 auec2-12 for dtt was 1\u00b701 with placebo, 0\u00b726 with 1 g idarucizumab (74% reduction), 0\u00b706 with 2 g idarucizumab (94% reduction), 0\u00b702 with 4 g idarucizumab (98% reduction), and 0\u00b701 with 5 g plus 2\u00b75 g idarucizumab (99% reduction).", "idarucizumab immediately and completely reversed dabigatran-induced anticoagulation in a dose-dependent manner; the mean ratio of day 4 auec2-12 to day 3 auec2-12 for dtt was 1\u00b701 with placebo, 0\u00b726 with 1 g idarucizumab (74% reduction), 0\u00b706 with 2 g idarucizumab (94% reduction), 0\u00b702 with 4 g idarucizumab (98% reduction), and 0\u00b701 with 5 g plus 2\u00b75 g idarucizumab (99% reduction).", "idarucizumab immediately and completely reversed dabigatran-induced anticoagulation in a dose-dependent manner; the mean ratio of day 4 auec2-12 to day 3 auec2-12 for dtt was 1\u00b701 with placebo, 0\u00b726 with 1 g idarucizumab (74% reduction), 0\u00b706 with 2 g idarucizumab (94% reduction), 0\u00b702 with 4 g idarucizumab (98% reduction), and 0\u00b701 with 5 g plus 2\u00b75 g idarucizumab (99% reduction).", "idarucizumab immediately and completely reversed dabigatran-induced anticoagulation in a dose-dependent manner; the mean ratio of day 4 auec2-12 to day 3 auec2-12 for dtt was 1\u00b701 with placebo, 0\u00b726 with 1 g idarucizumab (74% reduction), 0\u00b706 with 2 g idarucizumab (94% reduction), 0\u00b702 with 4 g idarucizumab (98% reduction), and 0\u00b701 with 5 g plus 2\u00b75 g idarucizumab (99% reduction).", "idarucizumab immediately and completely reversed dabigatran-induced anticoagulation in a dose-dependent manner; the mean ratio of day 4 auec2-12 to day 3 auec2-12 for dtt was 1\u00b701 with placebo, 0\u00b726 with 1 g idarucizumab (74% reduction), 0\u00b706 with 2 g idarucizumab (94% reduction), 0\u00b702 with 4 g idarucizumab (98% reduction), and 0\u00b701 with 5 g plus 2\u00b75 g idarucizumab (99% reduction).", "idarucizumab immediately and completely reversed dabigatran-induced anticoagulation in a dose-dependent manner; the mean ratio of day 4 auec2-12 to day 3 auec2-12 for dtt was 1\u00b701 with placebo, 0\u00b726 with 1 g idarucizumab (74% reduction), 0\u00b706 with 2 g idarucizumab (94% reduction), 0\u00b702 with 4 g idarucizumab (98% reduction), and 0\u00b701 with 5 g plus 2\u00b75 g idarucizumab (99% reduction).", "idarucizumab immediately and completely reversed dabigatran-induced anticoagulation in a dose-dependent manner; the mean ratio of day 4 auec2-12 to day 3 auec2-12 for dtt was 1\u00b701 with placebo, 0\u00b726 with 1 g idarucizumab (74% reduction), 0\u00b706 with 2 g idarucizumab (94% reduction), 0\u00b702 with 4 g idarucizumab (98% reduction), and 0\u00b701 with 5 g plus 2\u00b75 g idarucizumab (99% reduction).", "idarucizumab immediately and completely reversed dabigatran-induced anticoagulation in a dose-dependent manner; the mean ratio of day 4 auec2-12 to day 3 auec2-12 for dtt was 1\u00b701 with placebo, 0\u00b726 with 1 g idarucizumab (74% reduction), 0\u00b706 with 2 g idarucizumab (94% reduction), 0\u00b702 with 4 g idarucizumab (98% reduction), and 0\u00b701 with 5 g plus 2\u00b75 g idarucizumab (99% reduction).", "idarucizumab immediately and completely reversed dabigatran-induced anticoagulation in a dose-dependent manner; the mean ratio of day 4 auec2-12 to day 3 auec2-12 for dtt was 1\u00b701 with placebo, 0\u00b726 with 1 g idarucizumab (74% reduction), 0\u00b706 with 2 g idarucizumab (94% reduction), 0\u00b702 with 4 g idarucizumab (98% reduction), and 0\u00b701 with 5 g plus 2\u00b75 g idarucizumab (99% reduction).", "idarucizumab immediately and completely reversed dabigatran-induced anticoagulation in a dose-dependent manner; the mean ratio of day 4 auec2-12 to day 3 auec2-12 for dtt was 1\u00b701 with placebo, 0\u00b726 with 1 g idarucizumab (74% reduction), 0\u00b706 with 2 g idarucizumab (94% reduction), 0\u00b702 with 4 g idarucizumab (98% reduction), and 0\u00b701 with 5 g plus 2\u00b75 g idarucizumab (99% reduction).", "idarucizumab immediately and completely reversed dabigatran-induced anticoagulation in a dose-dependent manner; the mean ratio of day 4 auec2-12 to day 3 auec2-12 for dtt was 1\u00b701 with placebo, 0\u00b726 with 1 g idarucizumab (74% reduction), 0\u00b706 with 2 g idarucizumab (94% reduction), 0\u00b702 with 4 g idarucizumab (98% reduction), and 0\u00b701 with 5 g plus 2\u00b75 g idarucizumab (99% reduction).", "idarucizumab immediately and completely reversed dabigatran-induced anticoagulation in a dose-dependent manner; the mean ratio of day 4 auec2-12 to day 3 auec2-12 for dtt was 1\u00b701 with placebo, 0\u00b726 with 1 g idarucizumab (74% reduction), 0\u00b706 with 2 g idarucizumab (94% reduction), 0\u00b702 with 4 g idarucizumab (98% reduction), and 0\u00b701 with 5 g plus 2\u00b75 g idarucizumab (99% reduction).", "idarucizumab immediately and completely reversed dabigatran-induced anticoagulation in a dose-dependent manner; the mean ratio of day 4 auec2-12 to day 3 auec2-12 for dtt was 1\u00b701 with placebo, 0\u00b726 with 1 g idarucizumab (74% reduction), 0\u00b706 with 2 g idarucizumab (94% reduction), 0\u00b702 with 4 g idarucizumab (98% reduction), and 0\u00b701 with 5 g plus 2\u00b75 g idarucizumab (99% reduction).", "idarucizumab immediately and completely reversed dabigatran-induced anticoagulation in a dose-dependent manner; the mean ratio of day 4 auec2-12 to day 3 auec2-12 for dtt was 1\u00b701 with placebo, 0\u00b726 with 1 g idarucizumab (74% reduction), 0\u00b706 with 2 g idarucizumab (94% reduction), 0\u00b702 with 4 g idarucizumab (98% reduction), and 0\u00b701 with 5 g plus 2\u00b75 g idarucizumab (99% reduction).", "idarucizumab immediately and completely reversed dabigatran-induced anticoagulation in a dose-dependent manner; the mean ratio of day 4 auec2-12 to day 3 auec2-12 for dtt was 1\u00b701 with placebo, 0\u00b726 with 1 g idarucizumab (74% reduction), 0\u00b706 with 2 g idarucizumab (94% reduction), 0\u00b702 with 4 g idarucizumab (98% reduction), and 0\u00b701 with 5 g plus 2\u00b75 g idarucizumab (99% reduction).", "idarucizumab immediately and completely reversed dabigatran-induced anticoagulation in a dose-dependent manner; the mean ratio of day 4 auec2-12 to day 3 auec2-12 for dtt was 1\u00b701 with placebo, 0\u00b726 with 1 g idarucizumab (74% reduction), 0\u00b706 with 2 g idarucizumab (94% reduction), 0\u00b702 with 4 g idarucizumab (98% reduction), and 0\u00b701 with 5 g plus 2\u00b75 g idarucizumab (99% reduction).", "idarucizumab immediately and completely reversed dabigatran-induced anticoagulation in a dose-dependent manner; the mean ratio of day 4 auec2-12 to day 3 auec2-12 for dtt was 1\u00b701 with placebo, 0\u00b726 with 1 g idarucizumab (74% reduction), 0\u00b706 with 2 g idarucizumab (94% reduction), 0\u00b702 with 4 g idarucizumab (98% reduction), and 0\u00b701 with 5 g plus 2\u00b75 g idarucizumab (99% reduction).", "we also discuss reversal strategies, both specific and nonspecific, for each drug, including the preferential use of idarucizumab for the reversal of dabigatran and two agents, andexanet and ciraparantag, currently under development for the reversal of rivaroxaban, apixaban, and edoxaban.", "we also discuss reversal strategies, both specific and nonspecific, for each drug, including the preferential use of idarucizumab for the reversal of dabigatran and two agents, andexanet and ciraparantag, currently under development for the reversal of rivaroxaban, apixaban, and edoxaban.", "we also discuss reversal strategies, both specific and nonspecific, for each drug, including the preferential use of idarucizumab for the reversal of dabigatran and two agents, andexanet and ciraparantag, currently under development for the reversal of rivaroxaban, apixaban, and edoxaban.", "we also discuss reversal strategies, both specific and nonspecific, for each drug, including the preferential use of idarucizumab for the reversal of dabigatran and two agents, andexanet and ciraparantag, currently under development for the reversal of rivaroxaban, apixaban, and edoxaban.", "we also discuss reversal strategies, both specific and nonspecific, for each drug, including the preferential use of idarucizumab for the reversal of dabigatran and two agents, andexanet and ciraparantag, currently under development for the reversal of rivaroxaban, apixaban, and edoxaban.", "we also discuss reversal strategies, both specific and nonspecific, for each drug, including the preferential use of idarucizumab for the reversal of dabigatran and two agents, andexanet and ciraparantag, currently under development for the reversal of rivaroxaban, apixaban, and edoxaban.", "we also discuss reversal strategies, both specific and nonspecific, for each drug, including the preferential use of idarucizumab for the reversal of dabigatran and two agents, andexanet and ciraparantag, currently under development for the reversal of rivaroxaban, apixaban, and edoxaban.", "we also discuss reversal strategies, both specific and nonspecific, for each drug, including the preferential use of idarucizumab for the reversal of dabigatran and two agents, andexanet and ciraparantag, currently under development for the reversal of rivaroxaban, apixaban, and edoxaban.", "we also discuss reversal strategies, both specific and nonspecific, for each drug, including the preferential use of idarucizumab for the reversal of dabigatran and two agents, andexanet and ciraparantag, currently under development for the reversal of rivaroxaban, apixaban, and edoxaban.", "we also discuss reversal strategies, both specific and nonspecific, for each drug, including the preferential use of idarucizumab for the reversal of dabigatran and two agents, andexanet and ciraparantag, currently under development for the reversal of rivaroxaban, apixaban, and edoxaban.", "we also discuss reversal strategies, both specific and nonspecific, for each drug, including the preferential use of idarucizumab for the reversal of dabigatran and two agents, andexanet and ciraparantag, currently under development for the reversal of rivaroxaban, apixaban, and edoxaban.", "we also discuss reversal strategies, both specific and nonspecific, for each drug, including the preferential use of idarucizumab for the reversal of dabigatran and two agents, andexanet and ciraparantag, currently under development for the reversal of rivaroxaban, apixaban, and edoxaban.", "we also discuss reversal strategies, both specific and nonspecific, for each drug, including the preferential use of idarucizumab for the reversal of dabigatran and two agents, andexanet and ciraparantag, currently under development for the reversal of rivaroxaban, apixaban, and edoxaban.", "we also discuss reversal strategies, both specific and nonspecific, for each drug, including the preferential use of idarucizumab for the reversal of dabigatran and two agents, andexanet and ciraparantag, currently under development for the reversal of rivaroxaban, apixaban, and edoxaban.", "we also discuss reversal strategies, both specific and nonspecific, for each drug, including the preferential use of idarucizumab for the reversal of dabigatran and two agents, andexanet and ciraparantag, currently under development for the reversal of rivaroxaban, apixaban, and edoxaban.", "we also discuss reversal strategies, both specific and nonspecific, for each drug, including the preferential use of idarucizumab for the reversal of dabigatran and two agents, andexanet and ciraparantag, currently under development for the reversal of rivaroxaban, apixaban, and edoxaban.", "we also discuss reversal strategies, both specific and nonspecific, for each drug, including the preferential use of idarucizumab for the reversal of dabigatran and two agents, andexanet and ciraparantag, currently under development for the reversal of rivaroxaban, apixaban, and edoxaban.", "we also discuss reversal strategies, both specific and nonspecific, for each drug, including the preferential use of idarucizumab for the reversal of dabigatran and two agents, andexanet and ciraparantag, currently under development for the reversal of rivaroxaban, apixaban, and edoxaban.", "we also discuss reversal strategies, both specific and nonspecific, for each drug, including the preferential use of idarucizumab for the reversal of dabigatran and two agents, andexanet and ciraparantag, currently under development for the reversal of rivaroxaban, apixaban, and edoxaban.", "we also discuss reversal strategies, both specific and nonspecific, for each drug, including the preferential use of idarucizumab for the reversal of dabigatran and two agents, andexanet and ciraparantag, currently under development for the reversal of rivaroxaban, apixaban, and edoxaban.", "we also discuss reversal strategies, both specific and nonspecific, for each drug, including the preferential use of idarucizumab for the reversal of dabigatran and two agents, andexanet and ciraparantag, currently under development for the reversal of rivaroxaban, apixaban, and edoxaban.", "we also discuss reversal strategies, both specific and nonspecific, for each drug, including the preferential use of idarucizumab for the reversal of dabigatran and two agents, andexanet and ciraparantag, currently under development for the reversal of rivaroxaban, apixaban, and edoxaban.", "we also discuss reversal strategies, both specific and nonspecific, for each drug, including the preferential use of idarucizumab for the reversal of dabigatran and two agents, andexanet and ciraparantag, currently under development for the reversal of rivaroxaban, apixaban, and edoxaban.", "we also discuss reversal strategies, both specific and nonspecific, for each drug, including the preferential use of idarucizumab for the reversal of dabigatran and two agents, andexanet and ciraparantag, currently under development for the reversal of rivaroxaban, apixaban, and edoxaban.", "we also discuss reversal strategies, both specific and nonspecific, for each drug, including the preferential use of idarucizumab for the reversal of dabigatran and two agents, andexanet and ciraparantag, currently under development for the reversal of rivaroxaban, apixaban, and edoxaban.", "we also discuss reversal strategies, both specific and nonspecific, for each drug, including the preferential use of idarucizumab for the reversal of dabigatran and two agents, andexanet and ciraparantag, currently under development for the reversal of rivaroxaban, apixaban, and edoxaban.", "we also discuss reversal strategies, both specific and nonspecific, for each drug, including the preferential use of idarucizumab for the reversal of dabigatran and two agents, andexanet and ciraparantag, currently under development for the reversal of rivaroxaban, apixaban, and edoxaban.", "we also discuss reversal strategies, both specific and nonspecific, for each drug, including the preferential use of idarucizumab for the reversal of dabigatran and two agents, andexanet and ciraparantag, currently under development for the reversal of rivaroxaban, apixaban, and edoxaban.", "we also discuss reversal strategies, both specific and nonspecific, for each drug, including the preferential use of idarucizumab for the reversal of dabigatran and two agents, andexanet and ciraparantag, currently under development for the reversal of rivaroxaban, apixaban, and edoxaban.", "we also discuss reversal strategies, both specific and nonspecific, for each drug, including the preferential use of idarucizumab for the reversal of dabigatran and two agents, andexanet and ciraparantag, currently under development for the reversal of rivaroxaban, apixaban, and edoxaban.", "we also discuss reversal strategies, both specific and nonspecific, for each drug, including the preferential use of idarucizumab for the reversal of dabigatran and two agents, andexanet and ciraparantag, currently under development for the reversal of rivaroxaban, apixaban, and edoxaban.", "we also discuss reversal strategies, both specific and nonspecific, for each drug, including the preferential use of idarucizumab for the reversal of dabigatran and two agents, andexanet and ciraparantag, currently under development for the reversal of rivaroxaban, apixaban, and edoxaban.", "the administration of 5\u2009g of intravenous idarucizumab promptly and completely reversed the anticoagulant activity of dabigatran as assessed by routine and specific coagulation assays (aptt from to 75 to 26\u2009s, pt from 26 to 11\u2009s and diluted thrombin time from 92 to 27\u2009s).", "the administration of 5\u2009g of intravenous idarucizumab promptly and completely reversed the anticoagulant activity of dabigatran as assessed by routine and specific coagulation assays (aptt from to 75 to 26\u2009s, pt from 26 to 11\u2009s and diluted thrombin time from 92 to 27\u2009s).", "the administration of 5\u2009g of intravenous idarucizumab promptly and completely reversed the anticoagulant activity of dabigatran as assessed by routine and specific coagulation assays (aptt from to 75 to 26\u2009s, pt from 26 to 11\u2009s and diluted thrombin time from 92 to 27\u2009s).", "the administration of 5\u2009g of intravenous idarucizumab promptly and completely reversed the anticoagulant activity of dabigatran as assessed by routine and specific coagulation assays (aptt from to 75 to 26\u2009s, pt from 26 to 11\u2009s and diluted thrombin time from 92 to 27\u2009s).", "the administration of 5\u2009g of intravenous idarucizumab promptly and completely reversed the anticoagulant activity of dabigatran as assessed by routine and specific coagulation assays (aptt from to 75 to 26\u2009s, pt from 26 to 11\u2009s and diluted thrombin time from 92 to 27\u2009s).", "the administration of 5\u2009g of intravenous idarucizumab promptly and completely reversed the anticoagulant activity of dabigatran as assessed by routine and specific coagulation assays (aptt from to 75 to 26\u2009s, pt from 26 to 11\u2009s and diluted thrombin time from 92 to 27\u2009s).", "the administration of 5\u2009g of intravenous idarucizumab promptly and completely reversed the anticoagulant activity of dabigatran as assessed by routine and specific coagulation assays (aptt from to 75 to 26\u2009s, pt from 26 to 11\u2009s and diluted thrombin time from 92 to 27\u2009s).", "the administration of 5\u2009g of intravenous idarucizumab promptly and completely reversed the anticoagulant activity of dabigatran as assessed by routine and specific coagulation assays (aptt from to 75 to 26\u2009s, pt from 26 to 11\u2009s and diluted thrombin time from 92 to 27\u2009s).", "the administration of 5\u2009g of intravenous idarucizumab promptly and completely reversed the anticoagulant activity of dabigatran as assessed by routine and specific coagulation assays (aptt from to 75 to 26\u2009s, pt from 26 to 11\u2009s and diluted thrombin time from 92 to 27\u2009s).", "the administration of 5\u2009g of intravenous idarucizumab promptly and completely reversed the anticoagulant activity of dabigatran as assessed by routine and specific coagulation assays (aptt from to 75 to 26\u2009s, pt from 26 to 11\u2009s and diluted thrombin time from 92 to 27\u2009s).", "the administration of 5\u2009g of intravenous idarucizumab promptly and completely reversed the anticoagulant activity of dabigatran as assessed by routine and specific coagulation assays (aptt from to 75 to 26\u2009s, pt from 26 to 11\u2009s and diluted thrombin time from 92 to 27\u2009s).", "the administration of 5\u2009g of intravenous idarucizumab promptly and completely reversed the anticoagulant activity of dabigatran as assessed by routine and specific coagulation assays (aptt from to 75 to 26\u2009s, pt from 26 to 11\u2009s and diluted thrombin time from 92 to 27\u2009s).", "the administration of 5\u2009g of intravenous idarucizumab promptly and completely reversed the anticoagulant activity of dabigatran as assessed by routine and specific coagulation assays (aptt from to 75 to 26\u2009s, pt from 26 to 11\u2009s and diluted thrombin time from 92 to 27\u2009s).", "the administration of 5\u2009g of intravenous idarucizumab promptly and completely reversed the anticoagulant activity of dabigatran as assessed by routine and specific coagulation assays (aptt from to 75 to 26\u2009s, pt from 26 to 11\u2009s and diluted thrombin time from 92 to 27\u2009s).", "the administration of 5\u2009g of intravenous idarucizumab promptly and completely reversed the anticoagulant activity of dabigatran as assessed by routine and specific coagulation assays (aptt from to 75 to 26\u2009s, pt from 26 to 11\u2009s and diluted thrombin time from 92 to 27\u2009s).", "the administration of 5\u2009g of intravenous idarucizumab promptly and completely reversed the anticoagulant activity of dabigatran as assessed by routine and specific coagulation assays (aptt from to 75 to 26\u2009s, pt from 26 to 11\u2009s and diluted thrombin time from 92 to 27\u2009s).", "the administration of 5\u2009g of intravenous idarucizumab promptly and completely reversed the anticoagulant activity of dabigatran as assessed by routine and specific coagulation assays (aptt from to 75 to 26\u2009s, pt from 26 to 11\u2009s and diluted thrombin time from 92 to 27\u2009s).", "the administration of 5\u2009g of intravenous idarucizumab promptly and completely reversed the anticoagulant activity of dabigatran as assessed by routine and specific coagulation assays (aptt from to 75 to 26\u2009s, pt from 26 to 11\u2009s and diluted thrombin time from 92 to 27\u2009s).", "the administration of 5\u2009g of intravenous idarucizumab promptly and completely reversed the anticoagulant activity of dabigatran as assessed by routine and specific coagulation assays (aptt from to 75 to 26\u2009s, pt from 26 to 11\u2009s and diluted thrombin time from 92 to 27\u2009s).", "the administration of 5\u2009g of intravenous idarucizumab promptly and completely reversed the anticoagulant activity of dabigatran as assessed by routine and specific coagulation assays (aptt from to 75 to 26\u2009s, pt from 26 to 11\u2009s and diluted thrombin time from 92 to 27\u2009s).", "the administration of 5\u2009g of intravenous idarucizumab promptly and completely reversed the anticoagulant activity of dabigatran as assessed by routine and specific coagulation assays (aptt from to 75 to 26\u2009s, pt from 26 to 11\u2009s and diluted thrombin time from 92 to 27\u2009s).", "the administration of 5\u2009g of intravenous idarucizumab promptly and completely reversed the anticoagulant activity of dabigatran as assessed by routine and specific coagulation assays (aptt from to 75 to 26\u2009s, pt from 26 to 11\u2009s and diluted thrombin time from 92 to 27\u2009s).", "the administration of 5\u2009g of intravenous idarucizumab promptly and completely reversed the anticoagulant activity of dabigatran as assessed by routine and specific coagulation assays (aptt from to 75 to 26\u2009s, pt from 26 to 11\u2009s and diluted thrombin time from 92 to 27\u2009s).", "the administration of 5\u2009g of intravenous idarucizumab promptly and completely reversed the anticoagulant activity of dabigatran as assessed by routine and specific coagulation assays (aptt from to 75 to 26\u2009s, pt from 26 to 11\u2009s and diluted thrombin time from 92 to 27\u2009s).", "the administration of 5\u2009g of intravenous idarucizumab promptly and completely reversed the anticoagulant activity of dabigatran as assessed by routine and specific coagulation assays (aptt from to 75 to 26\u2009s, pt from 26 to 11\u2009s and diluted thrombin time from 92 to 27\u2009s).", "the administration of 5\u2009g of intravenous idarucizumab promptly and completely reversed the anticoagulant activity of dabigatran as assessed by routine and specific coagulation assays (aptt from to 75 to 26\u2009s, pt from 26 to 11\u2009s and diluted thrombin time from 92 to 27\u2009s).", "the administration of 5\u2009g of intravenous idarucizumab promptly and completely reversed the anticoagulant activity of dabigatran as assessed by routine and specific coagulation assays (aptt from to 75 to 26\u2009s, pt from 26 to 11\u2009s and diluted thrombin time from 92 to 27\u2009s).", "the administration of 5\u2009g of intravenous idarucizumab promptly and completely reversed the anticoagulant activity of dabigatran as assessed by routine and specific coagulation assays (aptt from to 75 to 26\u2009s, pt from 26 to 11\u2009s and diluted thrombin time from 92 to 27\u2009s).", "the administration of 5\u2009g of intravenous idarucizumab promptly and completely reversed the anticoagulant activity of dabigatran as assessed by routine and specific coagulation assays (aptt from to 75 to 26\u2009s, pt from 26 to 11\u2009s and diluted thrombin time from 92 to 27\u2009s).", "the administration of 5\u2009g of intravenous idarucizumab promptly and completely reversed the anticoagulant activity of dabigatran as assessed by routine and specific coagulation assays (aptt from to 75 to 26\u2009s, pt from 26 to 11\u2009s and diluted thrombin time from 92 to 27\u2009s).", "the administration of 5\u2009g of intravenous idarucizumab promptly and completely reversed the anticoagulant activity of dabigatran as assessed by routine and specific coagulation assays (aptt from to 75 to 26\u2009s, pt from 26 to 11\u2009s and diluted thrombin time from 92 to 27\u2009s).", "the administration of 5\u2009g of intravenous idarucizumab promptly and completely reversed the anticoagulant activity of dabigatran as assessed by routine and specific coagulation assays (aptt from to 75 to 26\u2009s, pt from 26 to 11\u2009s and diluted thrombin time from 92 to 27\u2009s).", "to evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this agent.", "to evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this agent.", "to evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this agent.", "to evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this agent.", "to evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this agent.", "to evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this agent.", "to evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this agent.", "to evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this agent.", "to evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this agent.", "to evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this agent.", "to evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this agent.", "to evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this agent.", "to evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this agent.", "to evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this agent.", "to evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this agent.", "to evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this agent.", "to evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this agent.", "to evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this agent.", "to evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this agent.", "to evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this agent.", "to evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this agent.", "to evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this agent.", "to evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this agent.", "to evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this agent.", "to evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this agent.", "to evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this agent.", "to evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this agent.", "to evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this agent.", "to evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this agent.", "to evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this agent.", "to evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this agent.", "to evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this agent.", "new oral anticoagulants such as apixaban, rivaroxaban, or dabigatran may be preferred to vitamin k antagonists in patients without cancer or renal failure, more so after the development of reversal agents such as idarucizumab and andexanet alfa.", "new oral anticoagulants such as apixaban, rivaroxaban, or dabigatran may be preferred to vitamin k antagonists in patients without cancer or renal failure, more so after the development of reversal agents such as idarucizumab and andexanet alfa.", "new oral anticoagulants such as apixaban, rivaroxaban, or dabigatran may be preferred to vitamin k antagonists in patients without cancer or renal failure, more so after the development of reversal agents such as idarucizumab and andexanet alfa.", "new oral anticoagulants such as apixaban, rivaroxaban, or dabigatran may be preferred to vitamin k antagonists in patients without cancer or renal failure, more so after the development of reversal agents such as idarucizumab and andexanet alfa.", "new oral anticoagulants such as apixaban, rivaroxaban, or dabigatran may be preferred to vitamin k antagonists in patients without cancer or renal failure, more so after the development of reversal agents such as idarucizumab and andexanet alfa.", "new oral anticoagulants such as apixaban, rivaroxaban, or dabigatran may be preferred to vitamin k antagonists in patients without cancer or renal failure, more so after the development of reversal agents such as idarucizumab and andexanet alfa.", "new oral anticoagulants such as apixaban, rivaroxaban, or dabigatran may be preferred to vitamin k antagonists in patients without cancer or renal failure, more so after the development of reversal agents such as idarucizumab and andexanet alfa.", "new oral anticoagulants such as apixaban, rivaroxaban, or dabigatran may be preferred to vitamin k antagonists in patients without cancer or renal failure, more so after the development of reversal agents such as idarucizumab and andexanet alfa.", "new oral anticoagulants such as apixaban, rivaroxaban, or dabigatran may be preferred to vitamin k antagonists in patients without cancer or renal failure, more so after the development of reversal agents such as idarucizumab and andexanet alfa.", "new oral anticoagulants such as apixaban, rivaroxaban, or dabigatran may be preferred to vitamin k antagonists in patients without cancer or renal failure, more so after the development of reversal agents such as idarucizumab and andexanet alfa.", "new oral anticoagulants such as apixaban, rivaroxaban, or dabigatran may be preferred to vitamin k antagonists in patients without cancer or renal failure, more so after the development of reversal agents such as idarucizumab and andexanet alfa.", "new oral anticoagulants such as apixaban, rivaroxaban, or dabigatran may be preferred to vitamin k antagonists in patients without cancer or renal failure, more so after the development of reversal agents such as idarucizumab and andexanet alfa.", "new oral anticoagulants such as apixaban, rivaroxaban, or dabigatran may be preferred to vitamin k antagonists in patients without cancer or renal failure, more so after the development of reversal agents such as idarucizumab and andexanet alfa.", "new oral anticoagulants such as apixaban, rivaroxaban, or dabigatran may be preferred to vitamin k antagonists in patients without cancer or renal failure, more so after the development of reversal agents such as idarucizumab and andexanet alfa.", "new oral anticoagulants such as apixaban, rivaroxaban, or dabigatran may be preferred to vitamin k antagonists in patients without cancer or renal failure, more so after the development of reversal agents such as idarucizumab and andexanet alfa.", "new oral anticoagulants such as apixaban, rivaroxaban, or dabigatran may be preferred to vitamin k antagonists in patients without cancer or renal failure, more so after the development of reversal agents such as idarucizumab and andexanet alfa.", "new oral anticoagulants such as apixaban, rivaroxaban, or dabigatran may be preferred to vitamin k antagonists in patients without cancer or renal failure, more so after the development of reversal agents such as idarucizumab and andexanet alfa.", "new oral anticoagulants such as apixaban, rivaroxaban, or dabigatran may be preferred to vitamin k antagonists in patients without cancer or renal failure, more so after the development of reversal agents such as idarucizumab and andexanet alfa.", "new oral anticoagulants such as apixaban, rivaroxaban, or dabigatran may be preferred to vitamin k antagonists in patients without cancer or renal failure, more so after the development of reversal agents such as idarucizumab and andexanet alfa.", "new oral anticoagulants such as apixaban, rivaroxaban, or dabigatran may be preferred to vitamin k antagonists in patients without cancer or renal failure, more so after the development of reversal agents such as idarucizumab and andexanet alfa.", "new oral anticoagulants such as apixaban, rivaroxaban, or dabigatran may be preferred to vitamin k antagonists in patients without cancer or renal failure, more so after the development of reversal agents such as idarucizumab and andexanet alfa.", "new oral anticoagulants such as apixaban, rivaroxaban, or dabigatran may be preferred to vitamin k antagonists in patients without cancer or renal failure, more so after the development of reversal agents such as idarucizumab and andexanet alfa.", "new oral anticoagulants such as apixaban, rivaroxaban, or dabigatran may be preferred to vitamin k antagonists in patients without cancer or renal failure, more so after the development of reversal agents such as idarucizumab and andexanet alfa.", "new oral anticoagulants such as apixaban, rivaroxaban, or dabigatran may be preferred to vitamin k antagonists in patients without cancer or renal failure, more so after the development of reversal agents such as idarucizumab and andexanet alfa.", "new oral anticoagulants such as apixaban, rivaroxaban, or dabigatran may be preferred to vitamin k antagonists in patients without cancer or renal failure, more so after the development of reversal agents such as idarucizumab and andexanet alfa.", "new oral anticoagulants such as apixaban, rivaroxaban, or dabigatran may be preferred to vitamin k antagonists in patients without cancer or renal failure, more so after the development of reversal agents such as idarucizumab and andexanet alfa.", "new oral anticoagulants such as apixaban, rivaroxaban, or dabigatran may be preferred to vitamin k antagonists in patients without cancer or renal failure, more so after the development of reversal agents such as idarucizumab and andexanet alfa.", "new oral anticoagulants such as apixaban, rivaroxaban, or dabigatran may be preferred to vitamin k antagonists in patients without cancer or renal failure, more so after the development of reversal agents such as idarucizumab and andexanet alfa.", "new oral anticoagulants such as apixaban, rivaroxaban, or dabigatran may be preferred to vitamin k antagonists in patients without cancer or renal failure, more so after the development of reversal agents such as idarucizumab and andexanet alfa.", "new oral anticoagulants such as apixaban, rivaroxaban, or dabigatran may be preferred to vitamin k antagonists in patients without cancer or renal failure, more so after the development of reversal agents such as idarucizumab and andexanet alfa.", "new oral anticoagulants such as apixaban, rivaroxaban, or dabigatran may be preferred to vitamin k antagonists in patients without cancer or renal failure, more so after the development of reversal agents such as idarucizumab and andexanet alfa.", "new oral anticoagulants such as apixaban, rivaroxaban, or dabigatran may be preferred to vitamin k antagonists in patients without cancer or renal failure, more so after the development of reversal agents such as idarucizumab and andexanet alfa.", "effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase ib study.", "effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase ib study.", "effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase ib study.", "effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase ib study.", "effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase ib study.", "effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase ib study.", "effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase ib study.", "effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase ib study.", "effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase ib study.", "effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase ib study.", "effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase ib study.", "effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase ib study.", "effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase ib study.", "effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase ib study.", "effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase ib study.", "effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase ib study.", "effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase ib study.", "effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase ib study.", "effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase ib study.", "effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase ib study.", "effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase ib study.", "effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase ib study.", "effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase ib study.", "effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase ib study.", "effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase ib study.", "effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase ib study.", "effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase ib study.", "effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase ib study.", "effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase ib study.", "effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase ib study.", "effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase ib study.", "effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase ib study.", "idarucizumab resulted in immediate, complete and sustained reversal of dabigatran anticoagulant activity, and was safe and well tolerated in middle-aged, elderly and renally impaired volunteers.", "idarucizumab resulted in immediate, complete and sustained reversal of dabigatran anticoagulant activity, and was safe and well tolerated in middle-aged, elderly and renally impaired volunteers.", "idarucizumab resulted in immediate, complete and sustained reversal of dabigatran anticoagulant activity, and was safe and well tolerated in middle-aged, elderly and renally impaired volunteers.", "idarucizumab resulted in immediate, complete and sustained reversal of dabigatran anticoagulant activity, and was safe and well tolerated in middle-aged, elderly and renally impaired volunteers.", "idarucizumab resulted in immediate, complete and sustained reversal of dabigatran anticoagulant activity, and was safe and well tolerated in middle-aged, elderly and renally impaired volunteers.", "idarucizumab resulted in immediate, complete and sustained reversal of dabigatran anticoagulant activity, and was safe and well tolerated in middle-aged, elderly and renally impaired volunteers.", "idarucizumab resulted in immediate, complete and sustained reversal of dabigatran anticoagulant activity, and was safe and well tolerated in middle-aged, elderly and renally impaired volunteers.", "idarucizumab resulted in immediate, complete and sustained reversal of dabigatran anticoagulant activity, and was safe and well tolerated in middle-aged, elderly and renally impaired volunteers.", "idarucizumab resulted in immediate, complete and sustained reversal of dabigatran anticoagulant activity, and was safe and well tolerated in middle-aged, elderly and renally impaired volunteers.", "idarucizumab resulted in immediate, complete and sustained reversal of dabigatran anticoagulant activity, and was safe and well tolerated in middle-aged, elderly and renally impaired volunteers.", "idarucizumab resulted in immediate, complete and sustained reversal of dabigatran anticoagulant activity, and was safe and well tolerated in middle-aged, elderly and renally impaired volunteers.", "idarucizumab resulted in immediate, complete and sustained reversal of dabigatran anticoagulant activity, and was safe and well tolerated in middle-aged, elderly and renally impaired volunteers.", "idarucizumab resulted in immediate, complete and sustained reversal of dabigatran anticoagulant activity, and was safe and well tolerated in middle-aged, elderly and renally impaired volunteers.", "idarucizumab resulted in immediate, complete and sustained reversal of dabigatran anticoagulant activity, and was safe and well tolerated in middle-aged, elderly and renally impaired volunteers.", "idarucizumab resulted in immediate, complete and sustained reversal of dabigatran anticoagulant activity, and was safe and well tolerated in middle-aged, elderly and renally impaired volunteers.", "idarucizumab resulted in immediate, complete and sustained reversal of dabigatran anticoagulant activity, and was safe and well tolerated in middle-aged, elderly and renally impaired volunteers.", "idarucizumab resulted in immediate, complete and sustained reversal of dabigatran anticoagulant activity, and was safe and well tolerated in middle-aged, elderly and renally impaired volunteers.", "idarucizumab resulted in immediate, complete and sustained reversal of dabigatran anticoagulant activity, and was safe and well tolerated in middle-aged, elderly and renally impaired volunteers.", "idarucizumab resulted in immediate, complete and sustained reversal of dabigatran anticoagulant activity, and was safe and well tolerated in middle-aged, elderly and renally impaired volunteers.", "idarucizumab resulted in immediate, complete and sustained reversal of dabigatran anticoagulant activity, and was safe and well tolerated in middle-aged, elderly and renally impaired volunteers.", "idarucizumab resulted in immediate, complete and sustained reversal of dabigatran anticoagulant activity, and was safe and well tolerated in middle-aged, elderly and renally impaired volunteers.", "idarucizumab resulted in immediate, complete and sustained reversal of dabigatran anticoagulant activity, and was safe and well tolerated in middle-aged, elderly and renally impaired volunteers.", "idarucizumab resulted in immediate, complete and sustained reversal of dabigatran anticoagulant activity, and was safe and well tolerated in middle-aged, elderly and renally impaired volunteers.", "idarucizumab resulted in immediate, complete and sustained reversal of dabigatran anticoagulant activity, and was safe and well tolerated in middle-aged, elderly and renally impaired volunteers.", "idarucizumab resulted in immediate, complete and sustained reversal of dabigatran anticoagulant activity, and was safe and well tolerated in middle-aged, elderly and renally impaired volunteers.", "idarucizumab resulted in immediate, complete and sustained reversal of dabigatran anticoagulant activity, and was safe and well tolerated in middle-aged, elderly and renally impaired volunteers.", "idarucizumab resulted in immediate, complete and sustained reversal of dabigatran anticoagulant activity, and was safe and well tolerated in middle-aged, elderly and renally impaired volunteers.", "idarucizumab resulted in immediate, complete and sustained reversal of dabigatran anticoagulant activity, and was safe and well tolerated in middle-aged, elderly and renally impaired volunteers.", "idarucizumab resulted in immediate, complete and sustained reversal of dabigatran anticoagulant activity, and was safe and well tolerated in middle-aged, elderly and renally impaired volunteers.", "idarucizumab resulted in immediate, complete and sustained reversal of dabigatran anticoagulant activity, and was safe and well tolerated in middle-aged, elderly and renally impaired volunteers.", "idarucizumab resulted in immediate, complete and sustained reversal of dabigatran anticoagulant activity, and was safe and well tolerated in middle-aged, elderly and renally impaired volunteers.", "idarucizumab resulted in immediate, complete and sustained reversal of dabigatran anticoagulant activity, and was safe and well tolerated in middle-aged, elderly and renally impaired volunteers.", "a randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.", "a randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.", "a randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.", "a randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.", "a randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.", "a randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.", "a randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.", "a randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.", "a randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.", "a randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.", "a randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.", "a randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.", "a randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.", "a randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.", "a randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.", "a randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.", "a randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.", "a randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.", "a randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.", "a randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.", "a randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.", "a randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.", "a randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.", "a randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.", "a randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.", "a randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.", "a randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.", "a randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.", "a randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.", "a randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.", "a randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.", "a randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.", "results idarucizumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran.", "results idarucizumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran.", "results idarucizumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran.", "results idarucizumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran.", "results idarucizumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran.", "results idarucizumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran.", "results idarucizumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran.", "results idarucizumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran.", "results idarucizumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran.", "results idarucizumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran.", "results idarucizumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran.", "results idarucizumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran.", "results idarucizumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran.", "results idarucizumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran.", "results idarucizumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran.", "results idarucizumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran.", "results idarucizumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran.", "results idarucizumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran.", "results idarucizumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran.", "results idarucizumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran.", "results idarucizumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran.", "results idarucizumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran.", "results idarucizumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran.", "results idarucizumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran.", "results idarucizumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran.", "results idarucizumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran.", "results idarucizumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran.", "results idarucizumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran.", "results idarucizumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran.", "results idarucizumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran.", "results idarucizumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran.", "results idarucizumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran.", "idarucizumab, an antibody fragment targeting dabigatran, is the first specific antidote for a noac to be approved, but real-world experience is limited.", "idarucizumab, an antibody fragment targeting dabigatran, is the first specific antidote for a noac to be approved, but real-world experience is limited.", "idarucizumab, an antibody fragment targeting dabigatran, is the first specific antidote for a noac to be approved, but real-world experience is limited.", "idarucizumab, an antibody fragment targeting dabigatran, is the first specific antidote for a noac to be approved, but real-world experience is limited.", "idarucizumab, an antibody fragment targeting dabigatran, is the first specific antidote for a noac to be approved, but real-world experience is limited.", "idarucizumab, an antibody fragment targeting dabigatran, is the first specific antidote for a noac to be approved, but real-world experience is limited.", "idarucizumab, an antibody fragment targeting dabigatran, is the first specific antidote for a noac to be approved, but real-world experience is limited.", "idarucizumab, an antibody fragment targeting dabigatran, is the first specific antidote for a noac to be approved, but real-world experience is limited.", "idarucizumab, an antibody fragment targeting dabigatran, is the first specific antidote for a noac to be approved, but real-world experience is limited.", "idarucizumab, an antibody fragment targeting dabigatran, is the first specific antidote for a noac to be approved, but real-world experience is limited.", "idarucizumab, an antibody fragment targeting dabigatran, is the first specific antidote for a noac to be approved, but real-world experience is limited.", "idarucizumab, an antibody fragment targeting dabigatran, is the first specific antidote for a noac to be approved, but real-world experience is limited.", "idarucizumab, an antibody fragment targeting dabigatran, is the first specific antidote for a noac to be approved, but real-world experience is limited.", "idarucizumab, an antibody fragment targeting dabigatran, is the first specific antidote for a noac to be approved, but real-world experience is limited.", "idarucizumab, an antibody fragment targeting dabigatran, is the first specific antidote for a noac to be approved, but real-world experience is limited.", "idarucizumab, an antibody fragment targeting dabigatran, is the first specific antidote for a noac to be approved, but real-world experience is limited.", "idarucizumab, an antibody fragment targeting dabigatran, is the first specific antidote for a noac to be approved, but real-world experience is limited.", "idarucizumab, an antibody fragment targeting dabigatran, is the first specific antidote for a noac to be approved, but real-world experience is limited.", "idarucizumab, an antibody fragment targeting dabigatran, is the first specific antidote for a noac to be approved, but real-world experience is limited.", "idarucizumab, an antibody fragment targeting dabigatran, is the first specific antidote for a noac to be approved, but real-world experience is limited.", "idarucizumab, an antibody fragment targeting dabigatran, is the first specific antidote for a noac to be approved, but real-world experience is limited.", "idarucizumab, an antibody fragment targeting dabigatran, is the first specific antidote for a noac to be approved, but real-world experience is limited.", "idarucizumab, an antibody fragment targeting dabigatran, is the first specific antidote for a noac to be approved, but real-world experience is limited.", "idarucizumab, an antibody fragment targeting dabigatran, is the first specific antidote for a noac to be approved, but real-world experience is limited.", "idarucizumab, an antibody fragment targeting dabigatran, is the first specific antidote for a noac to be approved, but real-world experience is limited.", "idarucizumab, an antibody fragment targeting dabigatran, is the first specific antidote for a noac to be approved, but real-world experience is limited.", "idarucizumab, an antibody fragment targeting dabigatran, is the first specific antidote for a noac to be approved, but real-world experience is limited.", "idarucizumab, an antibody fragment targeting dabigatran, is the first specific antidote for a noac to be approved, but real-world experience is limited.", "idarucizumab, an antibody fragment targeting dabigatran, is the first specific antidote for a noac to be approved, but real-world experience is limited.", "idarucizumab, an antibody fragment targeting dabigatran, is the first specific antidote for a noac to be approved, but real-world experience is limited.", "idarucizumab, an antibody fragment targeting dabigatran, is the first specific antidote for a noac to be approved, but real-world experience is limited.", "idarucizumab, an antibody fragment targeting dabigatran, is the first specific antidote for a noac to be approved, but real-world experience is limited.", "conclusion reversal of dabigatran etexilate using idarucizumab was safe and successful with no recombinant tissue plasminogen activator interactions.", "conclusion reversal of dabigatran etexilate using idarucizumab was safe and successful with no recombinant tissue plasminogen activator interactions.", "conclusion reversal of dabigatran etexilate using idarucizumab was safe and successful with no recombinant tissue plasminogen activator interactions.", "conclusion reversal of dabigatran etexilate using idarucizumab was safe and successful with no recombinant tissue plasminogen activator interactions.", "conclusion reversal of dabigatran etexilate using idarucizumab was safe and successful with no recombinant tissue plasminogen activator interactions.", "conclusion reversal of dabigatran etexilate using idarucizumab was safe and successful with no recombinant tissue plasminogen activator interactions.", "conclusion reversal of dabigatran etexilate using idarucizumab was safe and successful with no recombinant tissue plasminogen activator interactions.", "conclusion reversal of dabigatran etexilate using idarucizumab was safe and successful with no recombinant tissue plasminogen activator interactions.", "conclusion reversal of dabigatran etexilate using idarucizumab was safe and successful with no recombinant tissue plasminogen activator interactions.", "conclusion reversal of dabigatran etexilate using idarucizumab was safe and successful with no recombinant tissue plasminogen activator interactions.", "conclusion reversal of dabigatran etexilate using idarucizumab was safe and successful with no recombinant tissue plasminogen activator interactions.", "conclusion reversal of dabigatran etexilate using idarucizumab was safe and successful with no recombinant tissue plasminogen activator interactions.", "conclusion reversal of dabigatran etexilate using idarucizumab was safe and successful with no recombinant tissue plasminogen activator interactions.", "conclusion reversal of dabigatran etexilate using idarucizumab was safe and successful with no recombinant tissue plasminogen activator interactions.", "conclusion reversal of dabigatran etexilate using idarucizumab was safe and successful with no recombinant tissue plasminogen activator interactions.", "conclusion reversal of dabigatran etexilate using idarucizumab was safe and successful with no recombinant tissue plasminogen activator interactions.", "conclusion reversal of dabigatran etexilate using idarucizumab was safe and successful with no recombinant tissue plasminogen activator interactions.", "conclusion reversal of dabigatran etexilate using idarucizumab was safe and successful with no recombinant tissue plasminogen activator interactions.", "conclusion reversal of dabigatran etexilate using idarucizumab was safe and successful with no recombinant tissue plasminogen activator interactions.", "conclusion reversal of dabigatran etexilate using idarucizumab was safe and successful with no recombinant tissue plasminogen activator interactions.", "conclusion reversal of dabigatran etexilate using idarucizumab was safe and successful with no recombinant tissue plasminogen activator interactions.", "conclusion reversal of dabigatran etexilate using idarucizumab was safe and successful with no recombinant tissue plasminogen activator interactions.", "conclusion reversal of dabigatran etexilate using idarucizumab was safe and successful with no recombinant tissue plasminogen activator interactions.", "conclusion reversal of dabigatran etexilate using idarucizumab was safe and successful with no recombinant tissue plasminogen activator interactions.", "conclusion reversal of dabigatran etexilate using idarucizumab was safe and successful with no recombinant tissue plasminogen activator interactions.", "conclusion reversal of dabigatran etexilate using idarucizumab was safe and successful with no recombinant tissue plasminogen activator interactions.", "conclusion reversal of dabigatran etexilate using idarucizumab was safe and successful with no recombinant tissue plasminogen activator interactions.", "conclusion reversal of dabigatran etexilate using idarucizumab was safe and successful with no recombinant tissue plasminogen activator interactions.", "conclusion reversal of dabigatran etexilate using idarucizumab was safe and successful with no recombinant tissue plasminogen activator interactions.", "conclusion reversal of dabigatran etexilate using idarucizumab was safe and successful with no recombinant tissue plasminogen activator interactions.", "conclusion reversal of dabigatran etexilate using idarucizumab was safe and successful with no recombinant tissue plasminogen activator interactions.", "conclusion reversal of dabigatran etexilate using idarucizumab was safe and successful with no recombinant tissue plasminogen activator interactions.", "idarucizumab is a specific antidote targeted to reverse the direct thrombin inhibitor, dabigatran, which was recently approved for use in the usa.", "idarucizumab is a specific antidote targeted to reverse the direct thrombin inhibitor, dabigatran, which was recently approved for use in the usa.", "idarucizumab is a specific antidote targeted to reverse the direct thrombin inhibitor, dabigatran, which was recently approved for use in the usa.", "idarucizumab is a specific antidote targeted to reverse the direct thrombin inhibitor, dabigatran, which was recently approved for use in the usa.", "idarucizumab is a specific antidote targeted to reverse the direct thrombin inhibitor, dabigatran, which was recently approved for use in the usa.", "idarucizumab is a specific antidote targeted to reverse the direct thrombin inhibitor, dabigatran, which was recently approved for use in the usa.", "idarucizumab is a specific antidote targeted to reverse the direct thrombin inhibitor, dabigatran, which was recently approved for use in the usa.", "idarucizumab is a specific antidote targeted to reverse the direct thrombin inhibitor, dabigatran, which was recently approved for use in the usa.", "idarucizumab is a specific antidote targeted to reverse the direct thrombin inhibitor, dabigatran, which was recently approved for use in the usa.", "idarucizumab is a specific antidote targeted to reverse the direct thrombin inhibitor, dabigatran, which was recently approved for use in the usa.", "idarucizumab is a specific antidote targeted to reverse the direct thrombin inhibitor, dabigatran, which was recently approved for use in the usa.", "idarucizumab is a specific antidote targeted to reverse the direct thrombin inhibitor, dabigatran, which was recently approved for use in the usa.", "idarucizumab is a specific antidote targeted to reverse the direct thrombin inhibitor, dabigatran, which was recently approved for use in the usa.", "idarucizumab is a specific antidote targeted to reverse the direct thrombin inhibitor, dabigatran, which was recently approved for use in the usa.", "idarucizumab is a specific antidote targeted to reverse the direct thrombin inhibitor, dabigatran, which was recently approved for use in the usa.", "idarucizumab is a specific antidote targeted to reverse the direct thrombin inhibitor, dabigatran, which was recently approved for use in the usa.", "idarucizumab is a specific antidote targeted to reverse the direct thrombin inhibitor, dabigatran, which was recently approved for use in the usa.", "idarucizumab is a specific antidote targeted to reverse the direct thrombin inhibitor, dabigatran, which was recently approved for use in the usa.", "idarucizumab is a specific antidote targeted to reverse the direct thrombin inhibitor, dabigatran, which was recently approved for use in the usa.", "idarucizumab is a specific antidote targeted to reverse the direct thrombin inhibitor, dabigatran, which was recently approved for use in the usa.", "idarucizumab is a specific antidote targeted to reverse the direct thrombin inhibitor, dabigatran, which was recently approved for use in the usa.", "idarucizumab is a specific antidote targeted to reverse the direct thrombin inhibitor, dabigatran, which was recently approved for use in the usa.", "idarucizumab is a specific antidote targeted to reverse the direct thrombin inhibitor, dabigatran, which was recently approved for use in the usa.", "idarucizumab is a specific antidote targeted to reverse the direct thrombin inhibitor, dabigatran, which was recently approved for use in the usa.", "idarucizumab is a specific antidote targeted to reverse the direct thrombin inhibitor, dabigatran, which was recently approved for use in the usa.", "idarucizumab is a specific antidote targeted to reverse the direct thrombin inhibitor, dabigatran, which was recently approved for use in the usa.", "idarucizumab is a specific antidote targeted to reverse the direct thrombin inhibitor, dabigatran, which was recently approved for use in the usa.", "idarucizumab is a specific antidote targeted to reverse the direct thrombin inhibitor, dabigatran, which was recently approved for use in the usa.", "idarucizumab is a specific antidote targeted to reverse the direct thrombin inhibitor, dabigatran, which was recently approved for use in the usa.", "idarucizumab is a specific antidote targeted to reverse the direct thrombin inhibitor, dabigatran, which was recently approved for use in the usa.", "idarucizumab is a specific antidote targeted to reverse the direct thrombin inhibitor, dabigatran, which was recently approved for use in the usa.", "idarucizumab is a specific antidote targeted to reverse the direct thrombin inhibitor, dabigatran, which was recently approved for use in the usa.", "in 2015, the humanized monoclonal antibody fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran.", "in 2015, the humanized monoclonal antibody fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran.", "in 2015, the humanized monoclonal antibody fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran.", "in 2015, the humanized monoclonal antibody fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran.", "in 2015, the humanized monoclonal antibody fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran.", "in 2015, the humanized monoclonal antibody fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran.", "in 2015, the humanized monoclonal antibody fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran.", "in 2015, the humanized monoclonal antibody fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran.", "in 2015, the humanized monoclonal antibody fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran.", "in 2015, the humanized monoclonal antibody fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran.", "in 2015, the humanized monoclonal antibody fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran.", "in 2015, the humanized monoclonal antibody fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran.", "in 2015, the humanized monoclonal antibody fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran.", "in 2015, the humanized monoclonal antibody fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran.", "in 2015, the humanized monoclonal antibody fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran.", "in 2015, the humanized monoclonal antibody fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran.", "in 2015, the humanized monoclonal antibody fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran.", "in 2015, the humanized monoclonal antibody fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran.", "in 2015, the humanized monoclonal antibody fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran.", "in 2015, the humanized monoclonal antibody fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran.", "in 2015, the humanized monoclonal antibody fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran.", "in 2015, the humanized monoclonal antibody fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran.", "in 2015, the humanized monoclonal antibody fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran.", "in 2015, the humanized monoclonal antibody fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran.", "in 2015, the humanized monoclonal antibody fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran.", "in 2015, the humanized monoclonal antibody fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran.", "in 2015, the humanized monoclonal antibody fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran.", "in 2015, the humanized monoclonal antibody fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran.", "in 2015, the humanized monoclonal antibody fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran.", "in 2015, the humanized monoclonal antibody fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran.", "in 2015, the humanized monoclonal antibody fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran.", "in 2015, the humanized monoclonal antibody fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran.", "so far only one reversal agent has been approved by the food and drug administration (fda), idarucizumab for one of the doacs i.e., dabigatran.", "so far only one reversal agent has been approved by the food and drug administration (fda), idarucizumab for one of the doacs i.e., dabigatran.", "so far only one reversal agent has been approved by the food and drug administration (fda), idarucizumab for one of the doacs i.e., dabigatran.", "so far only one reversal agent has been approved by the food and drug administration (fda), idarucizumab for one of the doacs i.e., dabigatran.", "so far only one reversal agent has been approved by the food and drug administration (fda), idarucizumab for one of the doacs i.e., dabigatran.", "so far only one reversal agent has been approved by the food and drug administration (fda), idarucizumab for one of the doacs i.e., dabigatran.", "so far only one reversal agent has been approved by the food and drug administration (fda), idarucizumab for one of the doacs i.e., dabigatran.", "so far only one reversal agent has been approved by the food and drug administration (fda), idarucizumab for one of the doacs i.e., dabigatran.", "so far only one reversal agent has been approved by the food and drug administration (fda), idarucizumab for one of the doacs i.e., dabigatran.", "so far only one reversal agent has been approved by the food and drug administration (fda), idarucizumab for one of the doacs i.e., dabigatran.", "so far only one reversal agent has been approved by the food and drug administration (fda), idarucizumab for one of the doacs i.e., dabigatran.", "so far only one reversal agent has been approved by the food and drug administration (fda), idarucizumab for one of the doacs i.e., dabigatran.", "so far only one reversal agent has been approved by the food and drug administration (fda), idarucizumab for one of the doacs i.e., dabigatran.", "so far only one reversal agent has been approved by the food and drug administration (fda), idarucizumab for one of the doacs i.e., dabigatran.", "so far only one reversal agent has been approved by the food and drug administration (fda), idarucizumab for one of the doacs i.e., dabigatran.", "so far only one reversal agent has been approved by the food and drug administration (fda), idarucizumab for one of the doacs i.e., dabigatran.", "so far only one reversal agent has been approved by the food and drug administration (fda), idarucizumab for one of the doacs i.e., dabigatran.", "so far only one reversal agent has been approved by the food and drug administration (fda), idarucizumab for one of the doacs i.e., dabigatran.", "so far only one reversal agent has been approved by the food and drug administration (fda), idarucizumab for one of the doacs i.e., dabigatran.", "so far only one reversal agent has been approved by the food and drug administration (fda), idarucizumab for one of the doacs i.e., dabigatran.", "so far only one reversal agent has been approved by the food and drug administration (fda), idarucizumab for one of the doacs i.e., dabigatran.", "so far only one reversal agent has been approved by the food and drug administration (fda), idarucizumab for one of the doacs i.e., dabigatran.", "so far only one reversal agent has been approved by the food and drug administration (fda), idarucizumab for one of the doacs i.e., dabigatran.", "so far only one reversal agent has been approved by the food and drug administration (fda), idarucizumab for one of the doacs i.e., dabigatran.", "so far only one reversal agent has been approved by the food and drug administration (fda), idarucizumab for one of the doacs i.e., dabigatran.", "so far only one reversal agent has been approved by the food and drug administration (fda), idarucizumab for one of the doacs i.e., dabigatran.", "so far only one reversal agent has been approved by the food and drug administration (fda), idarucizumab for one of the doacs i.e., dabigatran.", "so far only one reversal agent has been approved by the food and drug administration (fda), idarucizumab for one of the doacs i.e., dabigatran.", "so far only one reversal agent has been approved by the food and drug administration (fda), idarucizumab for one of the doacs i.e., dabigatran.", "so far only one reversal agent has been approved by the food and drug administration (fda), idarucizumab for one of the doacs i.e., dabigatran.", "so far only one reversal agent has been approved by the food and drug administration (fda), idarucizumab for one of the doacs i.e., dabigatran.", "so far only one reversal agent has been approved by the food and drug administration (fda), idarucizumab for one of the doacs i.e., dabigatran.", "idarucizumab, a monoclonal antibody fragment that binds dabigatran with high affinity, is in development as a specific antidote for dabigatran.", "idarucizumab, a monoclonal antibody fragment that binds dabigatran with high affinity, is in development as a specific antidote for dabigatran.", "idarucizumab, a monoclonal antibody fragment that binds dabigatran with high affinity, is in development as a specific antidote for dabigatran.", "idarucizumab, a monoclonal antibody fragment that binds dabigatran with high affinity, is in development as a specific antidote for dabigatran.", "idarucizumab, a monoclonal antibody fragment that binds dabigatran with high affinity, is in development as a specific antidote for dabigatran.", "idarucizumab, a monoclonal antibody fragment that binds dabigatran with high affinity, is in development as a specific antidote for dabigatran.", "idarucizumab, a monoclonal antibody fragment that binds dabigatran with high affinity, is in development as a specific antidote for dabigatran.", "idarucizumab, a monoclonal antibody fragment that binds dabigatran with high affinity, is in development as a specific antidote for dabigatran.", "idarucizumab, a monoclonal antibody fragment that binds dabigatran with high affinity, is in development as a specific antidote for dabigatran.", "idarucizumab, a monoclonal antibody fragment that binds dabigatran with high affinity, is in development as a specific antidote for dabigatran.", "idarucizumab, a monoclonal antibody fragment that binds dabigatran with high affinity, is in development as a specific antidote for dabigatran.", "idarucizumab, a monoclonal antibody fragment that binds dabigatran with high affinity, is in development as a specific antidote for dabigatran.", "idarucizumab, a monoclonal antibody fragment that binds dabigatran with high affinity, is in development as a specific antidote for dabigatran.", "idarucizumab, a monoclonal antibody fragment that binds dabigatran with high affinity, is in development as a specific antidote for dabigatran.", "idarucizumab, a monoclonal antibody fragment that binds dabigatran with high affinity, is in development as a specific antidote for dabigatran.", "idarucizumab, a monoclonal antibody fragment that binds dabigatran with high affinity, is in development as a specific antidote for dabigatran.", "idarucizumab, a monoclonal antibody fragment that binds dabigatran with high affinity, is in development as a specific antidote for dabigatran.", "idarucizumab, a monoclonal antibody fragment that binds dabigatran with high affinity, is in development as a specific antidote for dabigatran.", "idarucizumab, a monoclonal antibody fragment that binds dabigatran with high affinity, is in development as a specific antidote for dabigatran.", "idarucizumab, a monoclonal antibody fragment that binds dabigatran with high affinity, is in development as a specific antidote for dabigatran.", "idarucizumab, a monoclonal antibody fragment that binds dabigatran with high affinity, is in development as a specific antidote for dabigatran.", "idarucizumab, a monoclonal antibody fragment that binds dabigatran with high affinity, is in development as a specific antidote for dabigatran.", "idarucizumab, a monoclonal antibody fragment that binds dabigatran with high affinity, is in development as a specific antidote for dabigatran.", "idarucizumab, a monoclonal antibody fragment that binds dabigatran with high affinity, is in development as a specific antidote for dabigatran.", "idarucizumab, a monoclonal antibody fragment that binds dabigatran with high affinity, is in development as a specific antidote for dabigatran.", "idarucizumab, a monoclonal antibody fragment that binds dabigatran with high affinity, is in development as a specific antidote for dabigatran.", "idarucizumab, a monoclonal antibody fragment that binds dabigatran with high affinity, is in development as a specific antidote for dabigatran.", "idarucizumab, a monoclonal antibody fragment that binds dabigatran with high affinity, is in development as a specific antidote for dabigatran.", "idarucizumab, a monoclonal antibody fragment that binds dabigatran with high affinity, is in development as a specific antidote for dabigatran.", "idarucizumab, a monoclonal antibody fragment that binds dabigatran with high affinity, is in development as a specific antidote for dabigatran.", "idarucizumab, a monoclonal antibody fragment that binds dabigatran with high affinity, is in development as a specific antidote for dabigatran.", "idarucizumab, a monoclonal antibody fragment that binds dabigatran with high affinity, is in development as a specific antidote for dabigatran.", "dabigatran etexilate (de) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idarucizumab.", "dabigatran etexilate (de) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idarucizumab.", "dabigatran etexilate (de) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idarucizumab.", "dabigatran etexilate (de) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idarucizumab.", "dabigatran etexilate (de) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idarucizumab.", "dabigatran etexilate (de) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idarucizumab.", "dabigatran etexilate (de) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idarucizumab.", "dabigatran etexilate (de) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idarucizumab.", "dabigatran etexilate (de) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idarucizumab.", "dabigatran etexilate (de) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idarucizumab.", "dabigatran etexilate (de) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idarucizumab.", "dabigatran etexilate (de) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idarucizumab.", "dabigatran etexilate (de) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idarucizumab.", "dabigatran etexilate (de) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idarucizumab.", "dabigatran etexilate (de) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idarucizumab.", "dabigatran etexilate (de) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idarucizumab.", "dabigatran etexilate (de) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idarucizumab.", "dabigatran etexilate (de) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idarucizumab.", "dabigatran etexilate (de) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idarucizumab.", "dabigatran etexilate (de) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idarucizumab.", "dabigatran etexilate (de) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idarucizumab.", "dabigatran etexilate (de) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idarucizumab.", "dabigatran etexilate (de) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idarucizumab.", "dabigatran etexilate (de) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idarucizumab.", "dabigatran etexilate (de) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idarucizumab.", "dabigatran etexilate (de) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idarucizumab.", "dabigatran etexilate (de) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idarucizumab.", "dabigatran etexilate (de) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idarucizumab.", "dabigatran etexilate (de) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idarucizumab.", "dabigatran etexilate (de) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idarucizumab.", "dabigatran etexilate (de) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idarucizumab.", "dabigatran etexilate (de) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idarucizumab.", "in this article, we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran..", "in this article, we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran..", "in this article, we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran..", "in this article, we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran..", "in this article, we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran..", "in this article, we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran..", "in this article, we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran..", "in this article, we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran..", "in this article, we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran..", "in this article, we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran..", "in this article, we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran..", "in this article, we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran..", "in this article, we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran..", "in this article, we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran..", "in this article, we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran..", "in this article, we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran..", "in this article, we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran..", "in this article, we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran..", "in this article, we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran..", "in this article, we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran..", "in this article, we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran..", "in this article, we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran..", "in this article, we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran..", "in this article, we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran..", "in this article, we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran..", "in this article, we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran..", "in this article, we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran..", "in this article, we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran..", "in this article, we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran..", "in this article, we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran..", "in this article, we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran..", "in this article, we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran..", "idarucizumab also reversed the effects of dabigatran and, unlike pccs, was not associated with over-correction of thrombin generation.", "idarucizumab also reversed the effects of dabigatran and, unlike pccs, was not associated with over-correction of thrombin generation.", "idarucizumab also reversed the effects of dabigatran and, unlike pccs, was not associated with over-correction of thrombin generation.", "idarucizumab also reversed the effects of dabigatran and, unlike pccs, was not associated with over-correction of thrombin generation.", "idarucizumab also reversed the effects of dabigatran and, unlike pccs, was not associated with over-correction of thrombin generation.", "idarucizumab also reversed the effects of dabigatran and, unlike pccs, was not associated with over-correction of thrombin generation.", "idarucizumab also reversed the effects of dabigatran and, unlike pccs, was not associated with over-correction of thrombin generation.", "idarucizumab also reversed the effects of dabigatran and, unlike pccs, was not associated with over-correction of thrombin generation.", "idarucizumab also reversed the effects of dabigatran and, unlike pccs, was not associated with over-correction of thrombin generation.", "idarucizumab also reversed the effects of dabigatran and, unlike pccs, was not associated with over-correction of thrombin generation.", "idarucizumab also reversed the effects of dabigatran and, unlike pccs, was not associated with over-correction of thrombin generation.", "idarucizumab also reversed the effects of dabigatran and, unlike pccs, was not associated with over-correction of thrombin generation.", "idarucizumab also reversed the effects of dabigatran and, unlike pccs, was not associated with over-correction of thrombin generation.", "idarucizumab also reversed the effects of dabigatran and, unlike pccs, was not associated with over-correction of thrombin generation.", "idarucizumab also reversed the effects of dabigatran and, unlike pccs, was not associated with over-correction of thrombin generation.", "idarucizumab also reversed the effects of dabigatran and, unlike pccs, was not associated with over-correction of thrombin generation.", "idarucizumab also reversed the effects of dabigatran and, unlike pccs, was not associated with over-correction of thrombin generation.", "idarucizumab also reversed the effects of dabigatran and, unlike pccs, was not associated with over-correction of thrombin generation.", "idarucizumab also reversed the effects of dabigatran and, unlike pccs, was not associated with over-correction of thrombin generation.", "idarucizumab also reversed the effects of dabigatran and, unlike pccs, was not associated with over-correction of thrombin generation.", "idarucizumab also reversed the effects of dabigatran and, unlike pccs, was not associated with over-correction of thrombin generation.", "idarucizumab also reversed the effects of dabigatran and, unlike pccs, was not associated with over-correction of thrombin generation.", "idarucizumab also reversed the effects of dabigatran and, unlike pccs, was not associated with over-correction of thrombin generation.", "idarucizumab also reversed the effects of dabigatran and, unlike pccs, was not associated with over-correction of thrombin generation.", "idarucizumab also reversed the effects of dabigatran and, unlike pccs, was not associated with over-correction of thrombin generation.", "idarucizumab also reversed the effects of dabigatran and, unlike pccs, was not associated with over-correction of thrombin generation.", "idarucizumab also reversed the effects of dabigatran and, unlike pccs, was not associated with over-correction of thrombin generation.", "idarucizumab also reversed the effects of dabigatran and, unlike pccs, was not associated with over-correction of thrombin generation.", "idarucizumab also reversed the effects of dabigatran and, unlike pccs, was not associated with over-correction of thrombin generation.", "idarucizumab also reversed the effects of dabigatran and, unlike pccs, was not associated with over-correction of thrombin generation.", "idarucizumab also reversed the effects of dabigatran and, unlike pccs, was not associated with over-correction of thrombin generation.", "idarucizumab also reversed the effects of dabigatran and, unlike pccs, was not associated with over-correction of thrombin generation.", "this was until the recent the food and drug administration approval of idarucizumab, a potential reversal agent for dabigatran.", "this was until the recent the food and drug administration approval of idarucizumab, a potential reversal agent for dabigatran.", "this was until the recent the food and drug administration approval of idarucizumab, a potential reversal agent for dabigatran.", "this was until the recent the food and drug administration approval of idarucizumab, a potential reversal agent for dabigatran.", "this was until the recent the food and drug administration approval of idarucizumab, a potential reversal agent for dabigatran.", "this was until the recent the food and drug administration approval of idarucizumab, a potential reversal agent for dabigatran.", "this was until the recent the food and drug administration approval of idarucizumab, a potential reversal agent for dabigatran.", "this was until the recent the food and drug administration approval of idarucizumab, a potential reversal agent for dabigatran.", "this was until the recent the food and drug administration approval of idarucizumab, a potential reversal agent for dabigatran.", "this was until the recent the food and drug administration approval of idarucizumab, a potential reversal agent for dabigatran.", "this was until the recent the food and drug administration approval of idarucizumab, a potential reversal agent for dabigatran.", "this was until the recent the food and drug administration approval of idarucizumab, a potential reversal agent for dabigatran.", "this was until the recent the food and drug administration approval of idarucizumab, a potential reversal agent for dabigatran.", "this was until the recent the food and drug administration approval of idarucizumab, a potential reversal agent for dabigatran.", "this was until the recent the food and drug administration approval of idarucizumab, a potential reversal agent for dabigatran.", "this was until the recent the food and drug administration approval of idarucizumab, a potential reversal agent for dabigatran.", "this was until the recent the food and drug administration approval of idarucizumab, a potential reversal agent for dabigatran.", "this was until the recent the food and drug administration approval of idarucizumab, a potential reversal agent for dabigatran.", "this was until the recent the food and drug administration approval of idarucizumab, a potential reversal agent for dabigatran.", "this was until the recent the food and drug administration approval of idarucizumab, a potential reversal agent for dabigatran.", "this was until the recent the food and drug administration approval of idarucizumab, a potential reversal agent for dabigatran.", "this was until the recent the food and drug administration approval of idarucizumab, a potential reversal agent for dabigatran.", "this was until the recent the food and drug administration approval of idarucizumab, a potential reversal agent for dabigatran.", "this was until the recent the food and drug administration approval of idarucizumab, a potential reversal agent for dabigatran.", "this was until the recent the food and drug administration approval of idarucizumab, a potential reversal agent for dabigatran.", "this was until the recent the food and drug administration approval of idarucizumab, a potential reversal agent for dabigatran.", "this was until the recent the food and drug administration approval of idarucizumab, a potential reversal agent for dabigatran.", "this was until the recent the food and drug administration approval of idarucizumab, a potential reversal agent for dabigatran.", "this was until the recent the food and drug administration approval of idarucizumab, a potential reversal agent for dabigatran.", "this was until the recent the food and drug administration approval of idarucizumab, a potential reversal agent for dabigatran.", "this was until the recent the food and drug administration approval of idarucizumab, a potential reversal agent for dabigatran.", "this was until the recent the food and drug administration approval of idarucizumab, a potential reversal agent for dabigatran.", "background and objectives: idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives: idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives: idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives: idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives: idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives: idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives: idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives: idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives: idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives: idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives: idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives: idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives: idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives: idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives: idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives: idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives: idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives: idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives: idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives: idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives: idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives: idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives: idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives: idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives: idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives: idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives: idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives: idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives: idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives: idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives: idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives: idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "idarucizumab is a targeted reversal agent that is approved for the urgent reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a targeted reversal agent that is approved for the urgent reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a targeted reversal agent that is approved for the urgent reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a targeted reversal agent that is approved for the urgent reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a targeted reversal agent that is approved for the urgent reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a targeted reversal agent that is approved for the urgent reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a targeted reversal agent that is approved for the urgent reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a targeted reversal agent that is approved for the urgent reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a targeted reversal agent that is approved for the urgent reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a targeted reversal agent that is approved for the urgent reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a targeted reversal agent that is approved for the urgent reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a targeted reversal agent that is approved for the urgent reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a targeted reversal agent that is approved for the urgent reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a targeted reversal agent that is approved for the urgent reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a targeted reversal agent that is approved for the urgent reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a targeted reversal agent that is approved for the urgent reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a targeted reversal agent that is approved for the urgent reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a targeted reversal agent that is approved for the urgent reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a targeted reversal agent that is approved for the urgent reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a targeted reversal agent that is approved for the urgent reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a targeted reversal agent that is approved for the urgent reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a targeted reversal agent that is approved for the urgent reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a targeted reversal agent that is approved for the urgent reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a targeted reversal agent that is approved for the urgent reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a targeted reversal agent that is approved for the urgent reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a targeted reversal agent that is approved for the urgent reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a targeted reversal agent that is approved for the urgent reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a targeted reversal agent that is approved for the urgent reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a targeted reversal agent that is approved for the urgent reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a targeted reversal agent that is approved for the urgent reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a targeted reversal agent that is approved for the urgent reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a targeted reversal agent that is approved for the urgent reversal of the anticoagulant effects of dabigatran.", "background and objectives idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "background and objectives idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "idarucizumab neutralised plasma concentrations of dabigatran, and reversed the effects of the drug on coagulation variables.", "idarucizumab neutralised plasma concentrations of dabigatran, and reversed the effects of the drug on coagulation variables.", "idarucizumab neutralised plasma concentrations of dabigatran, and reversed the effects of the drug on coagulation variables.", "idarucizumab neutralised plasma concentrations of dabigatran, and reversed the effects of the drug on coagulation variables.", "idarucizumab neutralised plasma concentrations of dabigatran, and reversed the effects of the drug on coagulation variables.", "idarucizumab neutralised plasma concentrations of dabigatran, and reversed the effects of the drug on coagulation variables.", "idarucizumab neutralised plasma concentrations of dabigatran, and reversed the effects of the drug on coagulation variables.", "idarucizumab neutralised plasma concentrations of dabigatran, and reversed the effects of the drug on coagulation variables.", "idarucizumab neutralised plasma concentrations of dabigatran, and reversed the effects of the drug on coagulation variables.", "idarucizumab neutralised plasma concentrations of dabigatran, and reversed the effects of the drug on coagulation variables.", "idarucizumab neutralised plasma concentrations of dabigatran, and reversed the effects of the drug on coagulation variables.", "idarucizumab neutralised plasma concentrations of dabigatran, and reversed the effects of the drug on coagulation variables.", "idarucizumab neutralised plasma concentrations of dabigatran, and reversed the effects of the drug on coagulation variables.", "idarucizumab neutralised plasma concentrations of dabigatran, and reversed the effects of the drug on coagulation variables.", "idarucizumab neutralised plasma concentrations of dabigatran, and reversed the effects of the drug on coagulation variables.", "idarucizumab neutralised plasma concentrations of dabigatran, and reversed the effects of the drug on coagulation variables.", "idarucizumab neutralised plasma concentrations of dabigatran, and reversed the effects of the drug on coagulation variables.", "idarucizumab neutralised plasma concentrations of dabigatran, and reversed the effects of the drug on coagulation variables.", "idarucizumab neutralised plasma concentrations of dabigatran, and reversed the effects of the drug on coagulation variables.", "idarucizumab neutralised plasma concentrations of dabigatran, and reversed the effects of the drug on coagulation variables.", "idarucizumab neutralised plasma concentrations of dabigatran, and reversed the effects of the drug on coagulation variables.", "idarucizumab neutralised plasma concentrations of dabigatran, and reversed the effects of the drug on coagulation variables.", "idarucizumab neutralised plasma concentrations of dabigatran, and reversed the effects of the drug on coagulation variables.", "idarucizumab neutralised plasma concentrations of dabigatran, and reversed the effects of the drug on coagulation variables.", "idarucizumab neutralised plasma concentrations of dabigatran, and reversed the effects of the drug on coagulation variables.", "idarucizumab neutralised plasma concentrations of dabigatran, and reversed the effects of the drug on coagulation variables.", "idarucizumab neutralised plasma concentrations of dabigatran, and reversed the effects of the drug on coagulation variables.", "idarucizumab neutralised plasma concentrations of dabigatran, and reversed the effects of the drug on coagulation variables.", "idarucizumab neutralised plasma concentrations of dabigatran, and reversed the effects of the drug on coagulation variables.", "idarucizumab neutralised plasma concentrations of dabigatran, and reversed the effects of the drug on coagulation variables.", "idarucizumab neutralised plasma concentrations of dabigatran, and reversed the effects of the drug on coagulation variables.", "idarucizumab neutralised plasma concentrations of dabigatran, and reversed the effects of the drug on coagulation variables.", "conclusions: the initial data suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran.", "conclusions: the initial data suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran.", "conclusions: the initial data suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran.", "conclusions: the initial data suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran.", "conclusions: the initial data suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran.", "conclusions: the initial data suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran.", "conclusions: the initial data suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran.", "conclusions: the initial data suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran.", "conclusions: the initial data suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran.", "conclusions: the initial data suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran.", "conclusions: the initial data suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran.", "conclusions: the initial data suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran.", "conclusions: the initial data suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran.", "conclusions: the initial data suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran.", "conclusions: the initial data suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran.", "conclusions: the initial data suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran.", "conclusions: the initial data suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran.", "conclusions: the initial data suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran.", "conclusions: the initial data suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran.", "conclusions: the initial data suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran.", "conclusions: the initial data suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran.", "conclusions: the initial data suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran.", "conclusions: the initial data suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran.", "conclusions: the initial data suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran.", "conclusions: the initial data suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran.", "conclusions: the initial data suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran.", "conclusions: the initial data suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran.", "conclusions: the initial data suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran.", "conclusions: the initial data suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran.", "conclusions: the initial data suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran.", "conclusions: the initial data suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran.", "conclusions: the initial data suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran.", "idarucizumab is a humanized monoclonal antibody fragment for reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a humanized monoclonal antibody fragment for reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a humanized monoclonal antibody fragment for reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a humanized monoclonal antibody fragment for reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a humanized monoclonal antibody fragment for reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a humanized monoclonal antibody fragment for reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a humanized monoclonal antibody fragment for reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a humanized monoclonal antibody fragment for reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a humanized monoclonal antibody fragment for reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a humanized monoclonal antibody fragment for reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a humanized monoclonal antibody fragment for reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a humanized monoclonal antibody fragment for reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a humanized monoclonal antibody fragment for reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a humanized monoclonal antibody fragment for reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a humanized monoclonal antibody fragment for reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a humanized monoclonal antibody fragment for reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a humanized monoclonal antibody fragment for reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a humanized monoclonal antibody fragment for reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a humanized monoclonal antibody fragment for reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a humanized monoclonal antibody fragment for reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a humanized monoclonal antibody fragment for reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a humanized monoclonal antibody fragment for reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a humanized monoclonal antibody fragment for reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a humanized monoclonal antibody fragment for reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a humanized monoclonal antibody fragment for reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a humanized monoclonal antibody fragment for reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a humanized monoclonal antibody fragment for reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a humanized monoclonal antibody fragment for reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a humanized monoclonal antibody fragment for reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a humanized monoclonal antibody fragment for reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a humanized monoclonal antibody fragment for reversal of the anticoagulant effects of dabigatran.", "idarucizumab is a humanized monoclonal antibody fragment for reversal of the anticoagulant effects of dabigatran.", "idarucizumab, a monoclonal antibody fragment, directly binds dabigatran etexilate and neutralizes its activity.", "idarucizumab, a monoclonal antibody fragment, directly binds dabigatran etexilate and neutralizes its activity.", "idarucizumab, a monoclonal antibody fragment, directly binds dabigatran etexilate and neutralizes its activity.", "idarucizumab, a monoclonal antibody fragment, directly binds dabigatran etexilate and neutralizes its activity.", "idarucizumab, a monoclonal antibody fragment, directly binds dabigatran etexilate and neutralizes its activity.", "idarucizumab, a monoclonal antibody fragment, directly binds dabigatran etexilate and neutralizes its activity.", "idarucizumab, a monoclonal antibody fragment, directly binds dabigatran etexilate and neutralizes its activity.", "idarucizumab, a monoclonal antibody fragment, directly binds dabigatran etexilate and neutralizes its activity.", "idarucizumab, a monoclonal antibody fragment, directly binds dabigatran etexilate and neutralizes its activity.", "idarucizumab, a monoclonal antibody fragment, directly binds dabigatran etexilate and neutralizes its activity.", "idarucizumab, a monoclonal antibody fragment, directly binds dabigatran etexilate and neutralizes its activity.", "idarucizumab, a monoclonal antibody fragment, directly binds dabigatran etexilate and neutralizes its activity.", "idarucizumab, a monoclonal antibody fragment, directly binds dabigatran etexilate and neutralizes its activity.", "idarucizumab, a monoclonal antibody fragment, directly binds dabigatran etexilate and neutralizes its activity.", "idarucizumab, a monoclonal antibody fragment, directly binds dabigatran etexilate and neutralizes its activity.", "idarucizumab, a monoclonal antibody fragment, directly binds dabigatran etexilate and neutralizes its activity.", "idarucizumab, a monoclonal antibody fragment, directly binds dabigatran etexilate and neutralizes its activity.", "idarucizumab, a monoclonal antibody fragment, directly binds dabigatran etexilate and neutralizes its activity.", "idarucizumab, a monoclonal antibody fragment, directly binds dabigatran etexilate and neutralizes its activity.", "idarucizumab, a monoclonal antibody fragment, directly binds dabigatran etexilate and neutralizes its activity.", "idarucizumab, a monoclonal antibody fragment, directly binds dabigatran etexilate and neutralizes its activity.", "idarucizumab, a monoclonal antibody fragment, directly binds dabigatran etexilate and neutralizes its activity.", "idarucizumab, a monoclonal antibody fragment, directly binds dabigatran etexilate and neutralizes its activity.", "idarucizumab, a monoclonal antibody fragment, directly binds dabigatran etexilate and neutralizes its activity.", "idarucizumab, a monoclonal antibody fragment, directly binds dabigatran etexilate and neutralizes its activity.", "idarucizumab, a monoclonal antibody fragment, directly binds dabigatran etexilate and neutralizes its activity.", "idarucizumab, a monoclonal antibody fragment, directly binds dabigatran etexilate and neutralizes its activity.", "idarucizumab, a monoclonal antibody fragment, directly binds dabigatran etexilate and neutralizes its activity.", "idarucizumab, a monoclonal antibody fragment, directly binds dabigatran etexilate and neutralizes its activity.", "idarucizumab, a monoclonal antibody fragment, directly binds dabigatran etexilate and neutralizes its activity.", "idarucizumab, a monoclonal antibody fragment, directly binds dabigatran etexilate and neutralizes its activity.", "idarucizumab, a monoclonal antibody fragment, directly binds dabigatran etexilate and neutralizes its activity.", "idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran.", "idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran.", "idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran.", "idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran.", "idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran.", "idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran.", "idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran.", "idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran.", "idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran.", "idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran.", "idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran.", "idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran.", "idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran.", "idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran.", "idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran.", "idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran.", "idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran.", "idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran.", "idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran.", "idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran.", "idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran.", "idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran.", "idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran.", "idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran.", "idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran.", "idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran.", "idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran.", "idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran.", "idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran.", "idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran.", "idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran.", "idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran.", "idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.", "dabigatran etexilate is an oral thrombin inhibitor that can be reversed by idarucizumab.", "dabigatran etexilate is an oral thrombin inhibitor that can be reversed by idarucizumab.", "dabigatran etexilate is an oral thrombin inhibitor that can be reversed by idarucizumab.", "dabigatran etexilate is an oral thrombin inhibitor that can be reversed by idarucizumab.", "dabigatran etexilate is an oral thrombin inhibitor that can be reversed by idarucizumab.", "dabigatran etexilate is an oral thrombin inhibitor that can be reversed by idarucizumab.", "dabigatran etexilate is an oral thrombin inhibitor that can be reversed by idarucizumab.", "dabigatran etexilate is an oral thrombin inhibitor that can be reversed by idarucizumab.", "dabigatran etexilate is an oral thrombin inhibitor that can be reversed by idarucizumab.", "dabigatran etexilate is an oral thrombin inhibitor that can be reversed by idarucizumab.", "dabigatran etexilate is an oral thrombin inhibitor that can be reversed by idarucizumab.", "dabigatran etexilate is an oral thrombin inhibitor that can be reversed by idarucizumab.", "dabigatran etexilate is an oral thrombin inhibitor that can be reversed by idarucizumab.", "dabigatran etexilate is an oral thrombin inhibitor that can be reversed by idarucizumab.", "dabigatran etexilate is an oral thrombin inhibitor that can be reversed by idarucizumab.", "dabigatran etexilate is an oral thrombin inhibitor that can be reversed by idarucizumab.", "dabigatran etexilate is an oral thrombin inhibitor that can be reversed by idarucizumab.", "dabigatran etexilate is an oral thrombin inhibitor that can be reversed by idarucizumab.", "dabigatran etexilate is an oral thrombin inhibitor that can be reversed by idarucizumab.", "dabigatran etexilate is an oral thrombin inhibitor that can be reversed by idarucizumab.", "dabigatran etexilate is an oral thrombin inhibitor that can be reversed by idarucizumab.", "dabigatran etexilate is an oral thrombin inhibitor that can be reversed by idarucizumab.", "dabigatran etexilate is an oral thrombin inhibitor that can be reversed by idarucizumab.", "dabigatran etexilate is an oral thrombin inhibitor that can be reversed by idarucizumab.", "dabigatran etexilate is an oral thrombin inhibitor that can be reversed by idarucizumab.", "dabigatran etexilate is an oral thrombin inhibitor that can be reversed by idarucizumab.", "dabigatran etexilate is an oral thrombin inhibitor that can be reversed by idarucizumab.", "dabigatran etexilate is an oral thrombin inhibitor that can be reversed by idarucizumab.", "dabigatran etexilate is an oral thrombin inhibitor that can be reversed by idarucizumab.", "dabigatran etexilate is an oral thrombin inhibitor that can be reversed by idarucizumab.", "dabigatran etexilate is an oral thrombin inhibitor that can be reversed by idarucizumab.", "dabigatran etexilate is an oral thrombin inhibitor that can be reversed by idarucizumab.", "in ich related to dabigatran, anticoagulation can be rapidly reversed with idarucizumab.", "in ich related to dabigatran, anticoagulation can be rapidly reversed with idarucizumab.", "in ich related to dabigatran, anticoagulation can be rapidly reversed with idarucizumab.", "in ich related to dabigatran, anticoagulation can be rapidly reversed with idarucizumab.", "in ich related to dabigatran, anticoagulation can be rapidly reversed with idarucizumab.", "in ich related to dabigatran, anticoagulation can be rapidly reversed with idarucizumab.", "in ich related to dabigatran, anticoagulation can be rapidly reversed with idarucizumab.", "in ich related to dabigatran, anticoagulation can be rapidly reversed with idarucizumab.", "in ich related to dabigatran, anticoagulation can be rapidly reversed with idarucizumab.", "in ich related to dabigatran, anticoagulation can be rapidly reversed with idarucizumab.", "in ich related to dabigatran, anticoagulation can be rapidly reversed with idarucizumab.", "in ich related to dabigatran, anticoagulation can be rapidly reversed with idarucizumab.", "in ich related to dabigatran, anticoagulation can be rapidly reversed with idarucizumab.", "in ich related to dabigatran, anticoagulation can be rapidly reversed with idarucizumab.", "in ich related to dabigatran, anticoagulation can be rapidly reversed with idarucizumab.", "in ich related to dabigatran, anticoagulation can be rapidly reversed with idarucizumab.", "in ich related to dabigatran, anticoagulation can be rapidly reversed with idarucizumab.", "in ich related to dabigatran, anticoagulation can be rapidly reversed with idarucizumab.", "in ich related to dabigatran, anticoagulation can be rapidly reversed with idarucizumab.", "in ich related to dabigatran, anticoagulation can be rapidly reversed with idarucizumab.", "in ich related to dabigatran, anticoagulation can be rapidly reversed with idarucizumab.", "in ich related to dabigatran, anticoagulation can be rapidly reversed with idarucizumab.", "in ich related to dabigatran, anticoagulation can be rapidly reversed with idarucizumab.", "in ich related to dabigatran, anticoagulation can be rapidly reversed with idarucizumab.", "in ich related to dabigatran, anticoagulation can be rapidly reversed with idarucizumab.", "in ich related to dabigatran, anticoagulation can be rapidly reversed with idarucizumab.", "in ich related to dabigatran, anticoagulation can be rapidly reversed with idarucizumab.", "in ich related to dabigatran, anticoagulation can be rapidly reversed with idarucizumab.", "in ich related to dabigatran, anticoagulation can be rapidly reversed with idarucizumab.", "in ich related to dabigatran, anticoagulation can be rapidly reversed with idarucizumab.", "in ich related to dabigatran, anticoagulation can be rapidly reversed with idarucizumab.", "in ich related to dabigatran, anticoagulation can be rapidly reversed with idarucizumab.", "idarucizumab completely reversed the anticoagulant effect of dabigatran within minutes.", "idarucizumab completely reversed the anticoagulant effect of dabigatran within minutes.", "idarucizumab completely reversed the anticoagulant effect of dabigatran within minutes.", "idarucizumab completely reversed the anticoagulant effect of dabigatran within minutes.", "idarucizumab completely reversed the anticoagulant effect of dabigatran within minutes.", "idarucizumab completely reversed the anticoagulant effect of dabigatran within minutes.", "idarucizumab completely reversed the anticoagulant effect of dabigatran within minutes.", "idarucizumab completely reversed the anticoagulant effect of dabigatran within minutes.", "idarucizumab completely reversed the anticoagulant effect of dabigatran within minutes.", "idarucizumab completely reversed the anticoagulant effect of dabigatran within minutes.", "idarucizumab completely reversed the anticoagulant effect of dabigatran within minutes.", "idarucizumab completely reversed the anticoagulant effect of dabigatran within minutes.", "idarucizumab completely reversed the anticoagulant effect of dabigatran within minutes.", "idarucizumab completely reversed the anticoagulant effect of dabigatran within minutes.", "idarucizumab completely reversed the anticoagulant effect of dabigatran within minutes.", "idarucizumab completely reversed the anticoagulant effect of dabigatran within minutes.", "idarucizumab completely reversed the anticoagulant effect of dabigatran within minutes.", "idarucizumab completely reversed the anticoagulant effect of dabigatran within minutes.", "idarucizumab completely reversed the anticoagulant effect of dabigatran within minutes.", "idarucizumab completely reversed the anticoagulant effect of dabigatran within minutes.", "idarucizumab completely reversed the anticoagulant effect of dabigatran within minutes.", "idarucizumab completely reversed the anticoagulant effect of dabigatran within minutes.", "idarucizumab completely reversed the anticoagulant effect of dabigatran within minutes.", "idarucizumab completely reversed the anticoagulant effect of dabigatran within minutes.", "idarucizumab completely reversed the anticoagulant effect of dabigatran within minutes.", "idarucizumab completely reversed the anticoagulant effect of dabigatran within minutes.", "idarucizumab completely reversed the anticoagulant effect of dabigatran within minutes.", "idarucizumab completely reversed the anticoagulant effect of dabigatran within minutes.", "idarucizumab completely reversed the anticoagulant effect of dabigatran within minutes.", "idarucizumab completely reversed the anticoagulant effect of dabigatran within minutes.", "idarucizumab completely reversed the anticoagulant effect of dabigatran within minutes.", "idarucizumab completely reversed the anticoagulant effect of dabigatran within minutes.", "idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran.", "idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran.", "idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran.", "idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran.", "idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran.", "idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran.", "idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran.", "idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran.", "idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran.", "idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran.", "idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran.", "idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran.", "idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran.", "idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran.", "idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran.", "idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran.", "idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran.", "idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran.", "idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran.", "idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran.", "idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran.", "idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran.", "idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran.", "idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran.", "idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran.", "idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran.", "idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran.", "idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran.", "idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran.", "idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran.", "idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran.", "idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran.", "idarucizumab for reversing dabigatran-induced anticoagulation: a systematic review.", "idarucizumab for reversing dabigatran-induced anticoagulation: a systematic review.", "idarucizumab for reversing dabigatran-induced anticoagulation: a systematic review.", "idarucizumab for reversing dabigatran-induced anticoagulation: a systematic review.", "idarucizumab for reversing dabigatran-induced anticoagulation: a systematic review.", "idarucizumab for reversing dabigatran-induced anticoagulation: a systematic review.", "idarucizumab for reversing dabigatran-induced anticoagulation: a systematic review.", "idarucizumab for reversing dabigatran-induced anticoagulation: a systematic review.", "idarucizumab for reversing dabigatran-induced anticoagulation: a systematic review.", "idarucizumab for reversing dabigatran-induced anticoagulation: a systematic review.", "idarucizumab for reversing dabigatran-induced anticoagulation: a systematic review.", "idarucizumab for reversing dabigatran-induced anticoagulation: a systematic review.", "idarucizumab for reversing dabigatran-induced anticoagulation: a systematic review.", "idarucizumab for reversing dabigatran-induced anticoagulation: a systematic review.", "idarucizumab for reversing dabigatran-induced anticoagulation: a systematic review.", "idarucizumab for reversing dabigatran-induced anticoagulation: a systematic review.", "idarucizumab for reversing dabigatran-induced anticoagulation: a systematic review.", "idarucizumab for reversing dabigatran-induced anticoagulation: a systematic review.", "idarucizumab for reversing dabigatran-induced anticoagulation: a systematic review.", "idarucizumab for reversing dabigatran-induced anticoagulation: a systematic review.", "idarucizumab for reversing dabigatran-induced anticoagulation: a systematic review.", "idarucizumab for reversing dabigatran-induced anticoagulation: a systematic review.", "idarucizumab for reversing dabigatran-induced anticoagulation: a systematic review.", "idarucizumab for reversing dabigatran-induced anticoagulation: a systematic review.", "idarucizumab for reversing dabigatran-induced anticoagulation: a systematic review.", "idarucizumab for reversing dabigatran-induced anticoagulation: a systematic review.", "idarucizumab for reversing dabigatran-induced anticoagulation: a systematic review.", "idarucizumab for reversing dabigatran-induced anticoagulation: a systematic review.", "idarucizumab for reversing dabigatran-induced anticoagulation: a systematic review.", "idarucizumab for reversing dabigatran-induced anticoagulation: a systematic review.", "idarucizumab for reversing dabigatran-induced anticoagulation: a systematic review.", "idarucizumab for reversing dabigatran-induced anticoagulation: a systematic review.", "idarucizumab is an antibody fragment that binds dabigatran with high affinity.", "idarucizumab is an antibody fragment that binds dabigatran with high affinity.", "idarucizumab is an antibody fragment that binds dabigatran with high affinity.", "idarucizumab is an antibody fragment that binds dabigatran with high affinity.", "idarucizumab is an antibody fragment that binds dabigatran with high affinity.", "idarucizumab is an antibody fragment that binds dabigatran with high affinity.", "idarucizumab is an antibody fragment that binds dabigatran with high affinity.", "idarucizumab is an antibody fragment that binds dabigatran with high affinity.", "idarucizumab is an antibody fragment that binds dabigatran with high affinity.", "idarucizumab is an antibody fragment that binds dabigatran with high affinity.", "idarucizumab is an antibody fragment that binds dabigatran with high affinity.", "idarucizumab is an antibody fragment that binds dabigatran with high affinity.", "idarucizumab is an antibody fragment that binds dabigatran with high affinity.", "idarucizumab is an antibody fragment that binds dabigatran with high affinity.", "idarucizumab is an antibody fragment that binds dabigatran with high affinity.", "idarucizumab is an antibody fragment that binds dabigatran with high affinity.", "idarucizumab is an antibody fragment that binds dabigatran with high affinity.", "idarucizumab is an antibody fragment that binds dabigatran with high affinity.", "idarucizumab is an antibody fragment that binds dabigatran with high affinity.", "idarucizumab is an antibody fragment that binds dabigatran with high affinity.", "idarucizumab is an antibody fragment that binds dabigatran with high affinity.", "idarucizumab is an antibody fragment that binds dabigatran with high affinity.", "idarucizumab is an antibody fragment that binds dabigatran with high affinity.", "idarucizumab is an antibody fragment that binds dabigatran with high affinity.", "idarucizumab is an antibody fragment that binds dabigatran with high affinity.", "idarucizumab is an antibody fragment that binds dabigatran with high affinity.", "idarucizumab is an antibody fragment that binds dabigatran with high affinity.", "idarucizumab is an antibody fragment that binds dabigatran with high affinity.", "idarucizumab is an antibody fragment that binds dabigatran with high affinity.", "idarucizumab is an antibody fragment that binds dabigatran with high affinity.", "idarucizumab is an antibody fragment that binds dabigatran with high affinity.", "idarucizumab is an antibody fragment that binds dabigatran with high affinity.", "introduction idarucizumab is a reversal agent for dabigatran etexilate.", "introduction idarucizumab is a reversal agent for dabigatran etexilate.", "introduction idarucizumab is a reversal agent for dabigatran etexilate.", "introduction idarucizumab is a reversal agent for dabigatran etexilate.", "introduction idarucizumab is a reversal agent for dabigatran etexilate.", "introduction idarucizumab is a reversal agent for dabigatran etexilate.", "introduction idarucizumab is a reversal agent for dabigatran etexilate.", "introduction idarucizumab is a reversal agent for dabigatran etexilate.", "introduction idarucizumab is a reversal agent for dabigatran etexilate.", "introduction idarucizumab is a reversal agent for dabigatran etexilate.", "introduction idarucizumab is a reversal agent for dabigatran etexilate.", "introduction idarucizumab is a reversal agent for dabigatran etexilate.", "introduction idarucizumab is a reversal agent for dabigatran etexilate.", "introduction idarucizumab is a reversal agent for dabigatran etexilate.", "introduction idarucizumab is a reversal agent for dabigatran etexilate.", "introduction idarucizumab is a reversal agent for dabigatran etexilate.", "introduction idarucizumab is a reversal agent for dabigatran etexilate.", "introduction idarucizumab is a reversal agent for dabigatran etexilate.", "introduction idarucizumab is a reversal agent for dabigatran etexilate.", "introduction idarucizumab is a reversal agent for dabigatran etexilate.", "introduction idarucizumab is a reversal agent for dabigatran etexilate.", "introduction idarucizumab is a reversal agent for dabigatran etexilate.", "introduction idarucizumab is a reversal agent for dabigatran etexilate.", "introduction idarucizumab is a reversal agent for dabigatran etexilate.", "introduction idarucizumab is a reversal agent for dabigatran etexilate.", "introduction idarucizumab is a reversal agent for dabigatran etexilate.", "introduction idarucizumab is a reversal agent for dabigatran etexilate.", "introduction idarucizumab is a reversal agent for dabigatran etexilate.", "introduction idarucizumab is a reversal agent for dabigatran etexilate.", "introduction idarucizumab is a reversal agent for dabigatran etexilate.", "introduction idarucizumab is a reversal agent for dabigatran etexilate.", "introduction idarucizumab is a reversal agent for dabigatran etexilate.", "idarucizumab is a reversal agent for dabigatran etexilate.", "idarucizumab is a reversal agent for dabigatran etexilate.", "idarucizumab is a reversal agent for dabigatran etexilate.", "idarucizumab is a reversal agent for dabigatran etexilate.", "idarucizumab is a reversal agent for dabigatran etexilate.", "idarucizumab is a reversal agent for dabigatran etexilate.", "idarucizumab is a reversal agent for dabigatran etexilate.", "idarucizumab is a reversal agent for dabigatran etexilate.", "idarucizumab is a reversal agent for dabigatran etexilate.", "idarucizumab is a reversal agent for dabigatran etexilate.", "idarucizumab is a reversal agent for dabigatran etexilate.", "idarucizumab is a reversal agent for dabigatran etexilate.", "idarucizumab is a reversal agent for dabigatran etexilate.", "idarucizumab is a reversal agent for dabigatran etexilate.", "idarucizumab is a reversal agent for dabigatran etexilate.", "idarucizumab is a reversal agent for dabigatran etexilate.", "idarucizumab is a reversal agent for dabigatran etexilate.", "idarucizumab is a reversal agent for dabigatran etexilate.", "idarucizumab is a reversal agent for dabigatran etexilate.", "idarucizumab is a reversal agent for dabigatran etexilate.", "idarucizumab is a reversal agent for dabigatran etexilate.", "idarucizumab is a reversal agent for dabigatran etexilate.", "idarucizumab is a reversal agent for dabigatran etexilate.", "idarucizumab is a reversal agent for dabigatran etexilate.", "idarucizumab is a reversal agent for dabigatran etexilate.", "idarucizumab is a reversal agent for dabigatran etexilate.", "idarucizumab is a reversal agent for dabigatran etexilate.", "idarucizumab is a reversal agent for dabigatran etexilate.", "idarucizumab is a reversal agent for dabigatran etexilate.", "idarucizumab is a reversal agent for dabigatran etexilate.", "idarucizumab is a reversal agent for dabigatran etexilate.", "idarucizumab is a reversal agent for dabigatran etexilate.", "puffy hand syndrome is a complication of intravenous drug abuse which has no current available treatment arm and forearm edema are voluminous and cause functional and aesthetic disturbances we report two cases successfully treated by low stretch bandages a 40 year old man and a 34 year old woman both intravenous drug users with puffy hand syndrome were hospitalized for 11 days treatment included daily multilayer bandaging lymphedema volumes calculated by utilizing the formula for a truncated cone decreased by 16 on the left side and 12 on the right side for the first patient and 31 and 17 for the second hand circumference decreased 4 3 cm on the left side and 3 2 cm on the right side in case 1 and 2 5 cm and 1 9 cm respectively for case 2 the patients were taught self bandaging techniques during their hospital stays elastic gloves were fitted at the end of treatment reduction of lymphedema volume remained stable after 18 months in one patient while for the second patient further treatment and hospitalization were required due to poor compliance the pathogenesis of this edema is probably multifactorial venous lymphatic insufficiency and the direct toxicity of injected drugs lymphedema treatment currently consists of low stretch bandaging and wearing elastic garments which is effective in decreasing the volume of puffy hand syndrome.", "puffy hand syndrome is a complication of intravenous drug abuse which has no current available treatment arm and forearm edema are voluminous and cause functional and aesthetic disturbances we report two cases successfully treated by low stretch bandages a 40 year old man and a 34 year old woman both intravenous drug users with puffy hand syndrome were hospitalized for 11 days treatment included daily multilayer bandaging lymphedema volumes calculated by utilizing the formula for a truncated cone decreased by 16 on the left side and 12 on the right side for the first patient and 31 and 17 for the second hand circumference decreased 4 3 cm on the left side and 3 2 cm on the right side in case 1 and 2 5 cm and 1 9 cm respectively for case 2 the patients were taught self bandaging techniques during their hospital stays elastic gloves were fitted at the end of treatment reduction of lymphedema volume remained stable after 18 months in one patient while for the second patient further treatment and hospitalization were required due to poor compliance the pathogenesis of this edema is probably multifactorial venous lymphatic insufficiency and the direct toxicity of injected drugs lymphedema treatment currently consists of low stretch bandaging and wearing elastic garments which is effective in decreasing the volume of puffy hand syndrome.", "puffy hand syndrome is a complication of intravenous drug abuse which has no current available treatment arm and forearm edema are voluminous and cause functional and aesthetic disturbances we report two cases successfully treated by low stretch bandages a 40 year old man and a 34 year old woman both intravenous drug users with puffy hand syndrome were hospitalized for 11 days treatment included daily multilayer bandaging lymphedema volumes calculated by utilizing the formula for a truncated cone decreased by 16 on the left side and 12 on the right side for the first patient and 31 and 17 for the second hand circumference decreased 4 3 cm on the left side and 3 2 cm on the right side in case 1 and 2 5 cm and 1 9 cm respectively for case 2 the patients were taught self bandaging techniques during their hospital stays elastic gloves were fitted at the end of treatment reduction of lymphedema volume remained stable after 18 months in one patient while for the second patient further treatment and hospitalization were required due to poor compliance the pathogenesis of this edema is probably multifactorial venous lymphatic insufficiency and the direct toxicity of injected drugs lymphedema treatment currently consists of low stretch bandaging and wearing elastic garments which is effective in decreasing the volume of puffy hand syndrome.", "puffy hand syndrome is a complication of intravenous drug abuse which has no current available treatment arm and forearm edema are voluminous and cause functional and aesthetic disturbances we report two cases successfully treated by low stretch bandages a 40 year old man and a 34 year old woman both intravenous drug users with puffy hand syndrome were hospitalized for 11 days treatment included daily multilayer bandaging lymphedema volumes calculated by utilizing the formula for a truncated cone decreased by 16 on the left side and 12 on the right side for the first patient and 31 and 17 for the second hand circumference decreased 4 3 cm on the left side and 3 2 cm on the right side in case 1 and 2 5 cm and 1 9 cm respectively for case 2 the patients were taught self bandaging techniques during their hospital stays elastic gloves were fitted at the end of treatment reduction of lymphedema volume remained stable after 18 months in one patient while for the second patient further treatment and hospitalization were required due to poor compliance the pathogenesis of this edema is probably multifactorial venous lymphatic insufficiency and the direct toxicity of injected drugs lymphedema treatment currently consists of low stretch bandaging and wearing elastic garments which is effective in decreasing the volume of puffy hand syndrome.", "puffy hand syndrome is a complication of intravenous drug abuse which has no current available treatment arm and forearm edema are voluminous and cause functional and aesthetic disturbances we report two cases successfully treated by low stretch bandages a 40 year old man and a 34 year old woman both intravenous drug users with puffy hand syndrome were hospitalized for 11 days treatment included daily multilayer bandaging lymphedema volumes calculated by utilizing the formula for a truncated cone decreased by 16 on the left side and 12 on the right side for the first patient and 31 and 17 for the second hand circumference decreased 4 3 cm on the left side and 3 2 cm on the right side in case 1 and 2 5 cm and 1 9 cm respectively for case 2 the patients were taught self bandaging techniques during their hospital stays elastic gloves were fitted at the end of treatment reduction of lymphedema volume remained stable after 18 months in one patient while for the second patient further treatment and hospitalization were required due to poor compliance the pathogenesis of this edema is probably multifactorial venous lymphatic insufficiency and the direct toxicity of injected drugs lymphedema treatment currently consists of low stretch bandaging and wearing elastic garments which is effective in decreasing the volume of puffy hand syndrome.", "puffy hand syndrome is a complication of intravenous drug abuse which has no current available treatment arm and forearm edema are voluminous and cause functional and aesthetic disturbances we report two cases successfully treated by low stretch bandages a 40 year old man and a 34 year old woman both intravenous drug users with puffy hand syndrome were hospitalized for 11 days treatment included daily multilayer bandaging lymphedema volumes calculated by utilizing the formula for a truncated cone decreased by 16 on the left side and 12 on the right side for the first patient and 31 and 17 for the second hand circumference decreased 4 3 cm on the left side and 3 2 cm on the right side in case 1 and 2 5 cm and 1 9 cm respectively for case 2 the patients were taught self bandaging techniques during their hospital stays elastic gloves were fitted at the end of treatment reduction of lymphedema volume remained stable after 18 months in one patient while for the second patient further treatment and hospitalization were required due to poor compliance the pathogenesis of this edema is probably multifactorial venous lymphatic insufficiency and the direct toxicity of injected drugs lymphedema treatment currently consists of low stretch bandaging and wearing elastic garments which is effective in decreasing the volume of puffy hand syndrome.", "puffy hand syndrome is a complication of intravenous drug abuse which has no current available treatment arm and forearm edema are voluminous and cause functional and aesthetic disturbances we report two cases successfully treated by low stretch bandages a 40 year old man and a 34 year old woman both intravenous drug users with puffy hand syndrome were hospitalized for 11 days treatment included daily multilayer bandaging lymphedema volumes calculated by utilizing the formula for a truncated cone decreased by 16 on the left side and 12 on the right side for the first patient and 31 and 17 for the second hand circumference decreased 4 3 cm on the left side and 3 2 cm on the right side in case 1 and 2 5 cm and 1 9 cm respectively for case 2 the patients were taught self bandaging techniques during their hospital stays elastic gloves were fitted at the end of treatment reduction of lymphedema volume remained stable after 18 months in one patient while for the second patient further treatment and hospitalization were required due to poor compliance the pathogenesis of this edema is probably multifactorial venous lymphatic insufficiency and the direct toxicity of injected drugs lymphedema treatment currently consists of low stretch bandaging and wearing elastic garments which is effective in decreasing the volume of puffy hand syndrome.", "puffy hand syndrome is a complication of intravenous drug abuse which has no current available treatment arm and forearm edema are voluminous and cause functional and aesthetic disturbances we report two cases successfully treated by low stretch bandages a 40 year old man and a 34 year old woman both intravenous drug users with puffy hand syndrome were hospitalized for 11 days treatment included daily multilayer bandaging lymphedema volumes calculated by utilizing the formula for a truncated cone decreased by 16 on the left side and 12 on the right side for the first patient and 31 and 17 for the second hand circumference decreased 4 3 cm on the left side and 3 2 cm on the right side in case 1 and 2 5 cm and 1 9 cm respectively for case 2 the patients were taught self bandaging techniques during their hospital stays elastic gloves were fitted at the end of treatment reduction of lymphedema volume remained stable after 18 months in one patient while for the second patient further treatment and hospitalization were required due to poor compliance the pathogenesis of this edema is probably multifactorial venous lymphatic insufficiency and the direct toxicity of injected drugs lymphedema treatment currently consists of low stretch bandaging and wearing elastic garments which is effective in decreasing the volume of puffy hand syndrome.", "puffy hand syndrome is a complication of intravenous drug abuse which has no current available treatment arm and forearm edema are voluminous and cause functional and aesthetic disturbances we report two cases successfully treated by low stretch bandages a 40 year old man and a 34 year old woman both intravenous drug users with puffy hand syndrome were hospitalized for 11 days treatment included daily multilayer bandaging lymphedema volumes calculated by utilizing the formula for a truncated cone decreased by 16 on the left side and 12 on the right side for the first patient and 31 and 17 for the second hand circumference decreased 4 3 cm on the left side and 3 2 cm on the right side in case 1 and 2 5 cm and 1 9 cm respectively for case 2 the patients were taught self bandaging techniques during their hospital stays elastic gloves were fitted at the end of treatment reduction of lymphedema volume remained stable after 18 months in one patient while for the second patient further treatment and hospitalization were required due to poor compliance the pathogenesis of this edema is probably multifactorial venous lymphatic insufficiency and the direct toxicity of injected drugs lymphedema treatment currently consists of low stretch bandaging and wearing elastic garments which is effective in decreasing the volume of puffy hand syndrome.", "puffy hand syndrome is a complication of intravenous drug abuse which has no current available treatment arm and forearm edema are voluminous and cause functional and aesthetic disturbances we report two cases successfully treated by low stretch bandages a 40 year old man and a 34 year old woman both intravenous drug users with puffy hand syndrome were hospitalized for 11 days treatment included daily multilayer bandaging lymphedema volumes calculated by utilizing the formula for a truncated cone decreased by 16 on the left side and 12 on the right side for the first patient and 31 and 17 for the second hand circumference decreased 4 3 cm on the left side and 3 2 cm on the right side in case 1 and 2 5 cm and 1 9 cm respectively for case 2 the patients were taught self bandaging techniques during their hospital stays elastic gloves were fitted at the end of treatment reduction of lymphedema volume remained stable after 18 months in one patient while for the second patient further treatment and hospitalization were required due to poor compliance the pathogenesis of this edema is probably multifactorial venous lymphatic insufficiency and the direct toxicity of injected drugs lymphedema treatment currently consists of low stretch bandaging and wearing elastic garments which is effective in decreasing the volume of puffy hand syndrome.", "puffy hand syndrome is a complication of intravenous drug abuse which has no current available treatment arm and forearm edema are voluminous and cause functional and aesthetic disturbances we report two cases successfully treated by low stretch bandages a 40 year old man and a 34 year old woman both intravenous drug users with puffy hand syndrome were hospitalized for 11 days treatment included daily multilayer bandaging lymphedema volumes calculated by utilizing the formula for a truncated cone decreased by 16 on the left side and 12 on the right side for the first patient and 31 and 17 for the second hand circumference decreased 4 3 cm on the left side and 3 2 cm on the right side in case 1 and 2 5 cm and 1 9 cm respectively for case 2 the patients were taught self bandaging techniques during their hospital stays elastic gloves were fitted at the end of treatment reduction of lymphedema volume remained stable after 18 months in one patient while for the second patient further treatment and hospitalization were required due to poor compliance the pathogenesis of this edema is probably multifactorial venous lymphatic insufficiency and the direct toxicity of injected drugs lymphedema treatment currently consists of low stretch bandaging and wearing elastic garments which is effective in decreasing the volume of puffy hand syndrome.", "puffy hand syndrome is a complication of intravenous drug abuse which has no current available treatment arm and forearm edema are voluminous and cause functional and aesthetic disturbances we report two cases successfully treated by low stretch bandages a 40 year old man and a 34 year old woman both intravenous drug users with puffy hand syndrome were hospitalized for 11 days treatment included daily multilayer bandaging lymphedema volumes calculated by utilizing the formula for a truncated cone decreased by 16 on the left side and 12 on the right side for the first patient and 31 and 17 for the second hand circumference decreased 4 3 cm on the left side and 3 2 cm on the right side in case 1 and 2 5 cm and 1 9 cm respectively for case 2 the patients were taught self bandaging techniques during their hospital stays elastic gloves were fitted at the end of treatment reduction of lymphedema volume remained stable after 18 months in one patient while for the second patient further treatment and hospitalization were required due to poor compliance the pathogenesis of this edema is probably multifactorial venous lymphatic insufficiency and the direct toxicity of injected drugs lymphedema treatment currently consists of low stretch bandaging and wearing elastic garments which is effective in decreasing the volume of puffy hand syndrome.", "puffy hand syndrome is a complication of intravenous drug abuse which has no current available treatment arm and forearm edema are voluminous and cause functional and aesthetic disturbances we report two cases successfully treated by low stretch bandages a 40 year old man and a 34 year old woman both intravenous drug users with puffy hand syndrome were hospitalized for 11 days treatment included daily multilayer bandaging lymphedema volumes calculated by utilizing the formula for a truncated cone decreased by 16 on the left side and 12 on the right side for the first patient and 31 and 17 for the second hand circumference decreased 4 3 cm on the left side and 3 2 cm on the right side in case 1 and 2 5 cm and 1 9 cm respectively for case 2 the patients were taught self bandaging techniques during their hospital stays elastic gloves were fitted at the end of treatment reduction of lymphedema volume remained stable after 18 months in one patient while for the second patient further treatment and hospitalization were required due to poor compliance the pathogenesis of this edema is probably multifactorial venous lymphatic insufficiency and the direct toxicity of injected drugs lymphedema treatment currently consists of low stretch bandaging and wearing elastic garments which is effective in decreasing the volume of puffy hand syndrome.", "puffy hand syndrome is a complication of intravenous drug abuse which has no current available treatment arm and forearm edema are voluminous and cause functional and aesthetic disturbances we report two cases successfully treated by low stretch bandages a 40 year old man and a 34 year old woman both intravenous drug users with puffy hand syndrome were hospitalized for 11 days treatment included daily multilayer bandaging lymphedema volumes calculated by utilizing the formula for a truncated cone decreased by 16 on the left side and 12 on the right side for the first patient and 31 and 17 for the second hand circumference decreased 4 3 cm on the left side and 3 2 cm on the right side in case 1 and 2 5 cm and 1 9 cm respectively for case 2 the patients were taught self bandaging techniques during their hospital stays elastic gloves were fitted at the end of treatment reduction of lymphedema volume remained stable after 18 months in one patient while for the second patient further treatment and hospitalization were required due to poor compliance the pathogenesis of this edema is probably multifactorial venous lymphatic insufficiency and the direct toxicity of injected drugs lymphedema treatment currently consists of low stretch bandaging and wearing elastic garments which is effective in decreasing the volume of puffy hand syndrome.", "puffy hand syndrome is a complication of intravenous drug abuse which has no current available treatment arm and forearm edema are voluminous and cause functional and aesthetic disturbances we report two cases successfully treated by low stretch bandages a 40 year old man and a 34 year old woman both intravenous drug users with puffy hand syndrome were hospitalized for 11 days treatment included daily multilayer bandaging lymphedema volumes calculated by utilizing the formula for a truncated cone decreased by 16 on the left side and 12 on the right side for the first patient and 31 and 17 for the second hand circumference decreased 4 3 cm on the left side and 3 2 cm on the right side in case 1 and 2 5 cm and 1 9 cm respectively for case 2 the patients were taught self bandaging techniques during their hospital stays elastic gloves were fitted at the end of treatment reduction of lymphedema volume remained stable after 18 months in one patient while for the second patient further treatment and hospitalization were required due to poor compliance the pathogenesis of this edema is probably multifactorial venous lymphatic insufficiency and the direct toxicity of injected drugs lymphedema treatment currently consists of low stretch bandaging and wearing elastic garments which is effective in decreasing the volume of puffy hand syndrome.", "puffy hand syndrome is a complication of intravenous drug abuse which has no current available treatment arm and forearm edema are voluminous and cause functional and aesthetic disturbances we report two cases successfully treated by low stretch bandages a 40 year old man and a 34 year old woman both intravenous drug users with puffy hand syndrome were hospitalized for 11 days treatment included daily multilayer bandaging lymphedema volumes calculated by utilizing the formula for a truncated cone decreased by 16 on the left side and 12 on the right side for the first patient and 31 and 17 for the second hand circumference decreased 4 3 cm on the left side and 3 2 cm on the right side in case 1 and 2 5 cm and 1 9 cm respectively for case 2 the patients were taught self bandaging techniques during their hospital stays elastic gloves were fitted at the end of treatment reduction of lymphedema volume remained stable after 18 months in one patient while for the second patient further treatment and hospitalization were required due to poor compliance the pathogenesis of this edema is probably multifactorial venous lymphatic insufficiency and the direct toxicity of injected drugs lymphedema treatment currently consists of low stretch bandaging and wearing elastic garments which is effective in decreasing the volume of puffy hand syndrome.", "puffy hand syndrome is an unrecognized complication of intravenous drug abuse this painless syndrome appears during or after a long period of drug addiction it involves the hands and sometimes the forearms and may cause functional aesthetic and social disturbances when the hand volume is important physiopathological mechanisms of the puffy hand syndrome are unclear and include venous and lymphatic insufficiencies infectious complications and direct toxicity of injected drugs and their adulterants low stretch bandage and elastic garment usually used in lymphedema treatment are proposed to treat the puffy hand syndrome.", "puffy hand syndrome is an unrecognized complication of intravenous drug abuse this painless syndrome appears during or after a long period of drug addiction it involves the hands and sometimes the forearms and may cause functional aesthetic and social disturbances when the hand volume is important physiopathological mechanisms of the puffy hand syndrome are unclear and include venous and lymphatic insufficiencies infectious complications and direct toxicity of injected drugs and their adulterants low stretch bandage and elastic garment usually used in lymphedema treatment are proposed to treat the puffy hand syndrome.", "puffy hand syndrome is an unrecognized complication of intravenous drug abuse this painless syndrome appears during or after a long period of drug addiction it involves the hands and sometimes the forearms and may cause functional aesthetic and social disturbances when the hand volume is important physiopathological mechanisms of the puffy hand syndrome are unclear and include venous and lymphatic insufficiencies infectious complications and direct toxicity of injected drugs and their adulterants low stretch bandage and elastic garment usually used in lymphedema treatment are proposed to treat the puffy hand syndrome.", "puffy hand syndrome is an unrecognized complication of intravenous drug abuse this painless syndrome appears during or after a long period of drug addiction it involves the hands and sometimes the forearms and may cause functional aesthetic and social disturbances when the hand volume is important physiopathological mechanisms of the puffy hand syndrome are unclear and include venous and lymphatic insufficiencies infectious complications and direct toxicity of injected drugs and their adulterants low stretch bandage and elastic garment usually used in lymphedema treatment are proposed to treat the puffy hand syndrome.", "puffy hand syndrome is an unrecognized complication of intravenous drug abuse this painless syndrome appears during or after a long period of drug addiction it involves the hands and sometimes the forearms and may cause functional aesthetic and social disturbances when the hand volume is important physiopathological mechanisms of the puffy hand syndrome are unclear and include venous and lymphatic insufficiencies infectious complications and direct toxicity of injected drugs and their adulterants low stretch bandage and elastic garment usually used in lymphedema treatment are proposed to treat the puffy hand syndrome.", "puffy hand syndrome is an unrecognized complication of intravenous drug abuse this painless syndrome appears during or after a long period of drug addiction it involves the hands and sometimes the forearms and may cause functional aesthetic and social disturbances when the hand volume is important physiopathological mechanisms of the puffy hand syndrome are unclear and include venous and lymphatic insufficiencies infectious complications and direct toxicity of injected drugs and their adulterants low stretch bandage and elastic garment usually used in lymphedema treatment are proposed to treat the puffy hand syndrome.", "puffy hand syndrome is an unrecognized complication of intravenous drug abuse this painless syndrome appears during or after a long period of drug addiction it involves the hands and sometimes the forearms and may cause functional aesthetic and social disturbances when the hand volume is important physiopathological mechanisms of the puffy hand syndrome are unclear and include venous and lymphatic insufficiencies infectious complications and direct toxicity of injected drugs and their adulterants low stretch bandage and elastic garment usually used in lymphedema treatment are proposed to treat the puffy hand syndrome.", "puffy hand syndrome is an unrecognized complication of intravenous drug abuse this painless syndrome appears during or after a long period of drug addiction it involves the hands and sometimes the forearms and may cause functional aesthetic and social disturbances when the hand volume is important physiopathological mechanisms of the puffy hand syndrome are unclear and include venous and lymphatic insufficiencies infectious complications and direct toxicity of injected drugs and their adulterants low stretch bandage and elastic garment usually used in lymphedema treatment are proposed to treat the puffy hand syndrome.", "puffy hand syndrome is an unrecognized complication of intravenous drug abuse this painless syndrome appears during or after a long period of drug addiction it involves the hands and sometimes the forearms and may cause functional aesthetic and social disturbances when the hand volume is important physiopathological mechanisms of the puffy hand syndrome are unclear and include venous and lymphatic insufficiencies infectious complications and direct toxicity of injected drugs and their adulterants low stretch bandage and elastic garment usually used in lymphedema treatment are proposed to treat the puffy hand syndrome.", "puffy hand syndrome is an unrecognized complication of intravenous drug abuse this painless syndrome appears during or after a long period of drug addiction it involves the hands and sometimes the forearms and may cause functional aesthetic and social disturbances when the hand volume is important physiopathological mechanisms of the puffy hand syndrome are unclear and include venous and lymphatic insufficiencies infectious complications and direct toxicity of injected drugs and their adulterants low stretch bandage and elastic garment usually used in lymphedema treatment are proposed to treat the puffy hand syndrome.", "puffy hand syndrome is an unrecognized complication of intravenous drug abuse this painless syndrome appears during or after a long period of drug addiction it involves the hands and sometimes the forearms and may cause functional aesthetic and social disturbances when the hand volume is important physiopathological mechanisms of the puffy hand syndrome are unclear and include venous and lymphatic insufficiencies infectious complications and direct toxicity of injected drugs and their adulterants low stretch bandage and elastic garment usually used in lymphedema treatment are proposed to treat the puffy hand syndrome.", "puffy hand syndrome is an unrecognized complication of intravenous drug abuse this painless syndrome appears during or after a long period of drug addiction it involves the hands and sometimes the forearms and may cause functional aesthetic and social disturbances when the hand volume is important physiopathological mechanisms of the puffy hand syndrome are unclear and include venous and lymphatic insufficiencies infectious complications and direct toxicity of injected drugs and their adulterants low stretch bandage and elastic garment usually used in lymphedema treatment are proposed to treat the puffy hand syndrome.", "puffy hand syndrome is an unrecognized complication of intravenous drug abuse this painless syndrome appears during or after a long period of drug addiction it involves the hands and sometimes the forearms and may cause functional aesthetic and social disturbances when the hand volume is important physiopathological mechanisms of the puffy hand syndrome are unclear and include venous and lymphatic insufficiencies infectious complications and direct toxicity of injected drugs and their adulterants low stretch bandage and elastic garment usually used in lymphedema treatment are proposed to treat the puffy hand syndrome.", "puffy hand syndrome is an unrecognized complication of intravenous drug abuse this painless syndrome appears during or after a long period of drug addiction it involves the hands and sometimes the forearms and may cause functional aesthetic and social disturbances when the hand volume is important physiopathological mechanisms of the puffy hand syndrome are unclear and include venous and lymphatic insufficiencies infectious complications and direct toxicity of injected drugs and their adulterants low stretch bandage and elastic garment usually used in lymphedema treatment are proposed to treat the puffy hand syndrome.", "puffy hand syndrome is an unrecognized complication of intravenous drug abuse this painless syndrome appears during or after a long period of drug addiction it involves the hands and sometimes the forearms and may cause functional aesthetic and social disturbances when the hand volume is important physiopathological mechanisms of the puffy hand syndrome are unclear and include venous and lymphatic insufficiencies infectious complications and direct toxicity of injected drugs and their adulterants low stretch bandage and elastic garment usually used in lymphedema treatment are proposed to treat the puffy hand syndrome.", "puffy hand syndrome is an unrecognized complication of intravenous drug abuse this painless syndrome appears during or after a long period of drug addiction it involves the hands and sometimes the forearms and may cause functional aesthetic and social disturbances when the hand volume is important physiopathological mechanisms of the puffy hand syndrome are unclear and include venous and lymphatic insufficiencies infectious complications and direct toxicity of injected drugs and their adulterants low stretch bandage and elastic garment usually used in lymphedema treatment are proposed to treat the puffy hand syndrome.", "background: puffy hand syndrome is a complication of intravenous drug abuse, which has no current available treatment.", "background: puffy hand syndrome is a complication of intravenous drug abuse, which has no current available treatment.", "background: puffy hand syndrome is a complication of intravenous drug abuse, which has no current available treatment.", "background: puffy hand syndrome is a complication of intravenous drug abuse, which has no current available treatment.", "background: puffy hand syndrome is a complication of intravenous drug abuse, which has no current available treatment.", "background: puffy hand syndrome is a complication of intravenous drug abuse, which has no current available treatment.", "background: puffy hand syndrome is a complication of intravenous drug abuse, which has no current available treatment.", "background: puffy hand syndrome is a complication of intravenous drug abuse, which has no current available treatment.", "background: puffy hand syndrome is a complication of intravenous drug abuse, which has no current available treatment.", "background: puffy hand syndrome is a complication of intravenous drug abuse, which has no current available treatment.", "background: puffy hand syndrome is a complication of intravenous drug abuse, which has no current available treatment.", "background: puffy hand syndrome is a complication of intravenous drug abuse, which has no current available treatment.", "background: puffy hand syndrome is a complication of intravenous drug abuse, which has no current available treatment.", "background: puffy hand syndrome is a complication of intravenous drug abuse, which has no current available treatment.", "background: puffy hand syndrome is a complication of intravenous drug abuse, which has no current available treatment.", "background: puffy hand syndrome is a complication of intravenous drug abuse, which has no current available treatment.", "puffy hand syndrome is a complication of intravenous drug abuse, which has no current available treatment.", "puffy hand syndrome is a complication of intravenous drug abuse, which has no current available treatment.", "puffy hand syndrome is a complication of intravenous drug abuse, which has no current available treatment.", "puffy hand syndrome is a complication of intravenous drug abuse, which has no current available treatment.", "puffy hand syndrome is a complication of intravenous drug abuse, which has no current available treatment.", "puffy hand syndrome is a complication of intravenous drug abuse, which has no current available treatment.", "puffy hand syndrome is a complication of intravenous drug abuse, which has no current available treatment.", "puffy hand syndrome is a complication of intravenous drug abuse, which has no current available treatment.", "puffy hand syndrome is a complication of intravenous drug abuse, which has no current available treatment.", "puffy hand syndrome is a complication of intravenous drug abuse, which has no current available treatment.", "puffy hand syndrome is a complication of intravenous drug abuse, which has no current available treatment.", "puffy hand syndrome is a complication of intravenous drug abuse, which has no current available treatment.", "puffy hand syndrome is a complication of intravenous drug abuse, which has no current available treatment.", "puffy hand syndrome is a complication of intravenous drug abuse, which has no current available treatment.", "puffy hand syndrome is a complication of intravenous drug abuse, which has no current available treatment.", "puffy hand syndrome is a complication of intravenous drug abuse, which has no current available treatment.", "puffy hand syndrome is an unrecognized complication of intravenous drug abuse.", "puffy hand syndrome is an unrecognized complication of intravenous drug abuse.", "puffy hand syndrome is an unrecognized complication of intravenous drug abuse.", "puffy hand syndrome is an unrecognized complication of intravenous drug abuse.", "puffy hand syndrome is an unrecognized complication of intravenous drug abuse.", "puffy hand syndrome is an unrecognized complication of intravenous drug abuse.", "puffy hand syndrome is an unrecognized complication of intravenous drug abuse.", "puffy hand syndrome is an unrecognized complication of intravenous drug abuse.", "puffy hand syndrome is an unrecognized complication of intravenous drug abuse.", "puffy hand syndrome is an unrecognized complication of intravenous drug abuse.", "puffy hand syndrome is an unrecognized complication of intravenous drug abuse.", "puffy hand syndrome is an unrecognized complication of intravenous drug abuse.", "puffy hand syndrome is an unrecognized complication of intravenous drug abuse.", "puffy hand syndrome is an unrecognized complication of intravenous drug abuse.", "puffy hand syndrome is an unrecognized complication of intravenous drug abuse.", "puffy hand syndrome is an unrecognized complication of intravenous drug abuse.", "in humans high grade gliomas may infiltrate across the corpus callosum resulting in bihemispheric lesions that may have symmetrical winged like appearances this particular tumor manifestation has been coined a butterfly glioma bg while canine and human gliomas share many neuroradiological and pathological features the bg morphology has not been previously reported in dogs here we describe the magnetic resonance imaging mri characteristics of bg in three dogs and review the potential differential diagnoses based on neuroimaging findings all dogs presented for generalized seizures and interictal neurological deficits referable to multifocal or diffuse forebrain disease mri examinations revealed asymmetrical 2 3 or symmetrical 1 3 bihemispheric intra axial mass lesions that predominantly affected the frontoparietal lobes that were associated with extensive perilesional edema and involvement of the corpus callosum the masses displayed heterogeneous t1 t2 and fluid attenuated inversion recovery signal intensities variable contrast enhancement 2 3 and mass effect all tumors demonstrated classical histopathological features of glioblastoma multiforme gbm including glial cell pseudopalisading serpentine necrosis microvascular proliferation as well as invasion of the corpus callosum by neoplastic astrocytes although rare gbm should be considered a differential diagnosis in dogs with an mri evidence of asymmetric or symmetric bilateral intra axial cerebral mass lesions with signal characteristics compatible with glioma.", "in humans high grade gliomas may infiltrate across the corpus callosum resulting in bihemispheric lesions that may have symmetrical winged like appearances this particular tumor manifestation has been coined a butterfly glioma bg while canine and human gliomas share many neuroradiological and pathological features the bg morphology has not been previously reported in dogs here we describe the magnetic resonance imaging mri characteristics of bg in three dogs and review the potential differential diagnoses based on neuroimaging findings all dogs presented for generalized seizures and interictal neurological deficits referable to multifocal or diffuse forebrain disease mri examinations revealed asymmetrical 2 3 or symmetrical 1 3 bihemispheric intra axial mass lesions that predominantly affected the frontoparietal lobes that were associated with extensive perilesional edema and involvement of the corpus callosum the masses displayed heterogeneous t1 t2 and fluid attenuated inversion recovery signal intensities variable contrast enhancement 2 3 and mass effect all tumors demonstrated classical histopathological features of glioblastoma multiforme gbm including glial cell pseudopalisading serpentine necrosis microvascular proliferation as well as invasion of the corpus callosum by neoplastic astrocytes although rare gbm should be considered a differential diagnosis in dogs with an mri evidence of asymmetric or symmetric bilateral intra axial cerebral mass lesions with signal characteristics compatible with glioma.", "in humans high grade gliomas may infiltrate across the corpus callosum resulting in bihemispheric lesions that may have symmetrical winged like appearances this particular tumor manifestation has been coined a butterfly glioma bg while canine and human gliomas share many neuroradiological and pathological features the bg morphology has not been previously reported in dogs here we describe the magnetic resonance imaging mri characteristics of bg in three dogs and review the potential differential diagnoses based on neuroimaging findings all dogs presented for generalized seizures and interictal neurological deficits referable to multifocal or diffuse forebrain disease mri examinations revealed asymmetrical 2 3 or symmetrical 1 3 bihemispheric intra axial mass lesions that predominantly affected the frontoparietal lobes that were associated with extensive perilesional edema and involvement of the corpus callosum the masses displayed heterogeneous t1 t2 and fluid attenuated inversion recovery signal intensities variable contrast enhancement 2 3 and mass effect all tumors demonstrated classical histopathological features of glioblastoma multiforme gbm including glial cell pseudopalisading serpentine necrosis microvascular proliferation as well as invasion of the corpus callosum by neoplastic astrocytes although rare gbm should be considered a differential diagnosis in dogs with an mri evidence of asymmetric or symmetric bilateral intra axial cerebral mass lesions with signal characteristics compatible with glioma.", "in humans high grade gliomas may infiltrate across the corpus callosum resulting in bihemispheric lesions that may have symmetrical winged like appearances this particular tumor manifestation has been coined a butterfly glioma bg while canine and human gliomas share many neuroradiological and pathological features the bg morphology has not been previously reported in dogs here we describe the magnetic resonance imaging mri characteristics of bg in three dogs and review the potential differential diagnoses based on neuroimaging findings all dogs presented for generalized seizures and interictal neurological deficits referable to multifocal or diffuse forebrain disease mri examinations revealed asymmetrical 2 3 or symmetrical 1 3 bihemispheric intra axial mass lesions that predominantly affected the frontoparietal lobes that were associated with extensive perilesional edema and involvement of the corpus callosum the masses displayed heterogeneous t1 t2 and fluid attenuated inversion recovery signal intensities variable contrast enhancement 2 3 and mass effect all tumors demonstrated classical histopathological features of glioblastoma multiforme gbm including glial cell pseudopalisading serpentine necrosis microvascular proliferation as well as invasion of the corpus callosum by neoplastic astrocytes although rare gbm should be considered a differential diagnosis in dogs with an mri evidence of asymmetric or symmetric bilateral intra axial cerebral mass lesions with signal characteristics compatible with glioma.", "in humans high grade gliomas may infiltrate across the corpus callosum resulting in bihemispheric lesions that may have symmetrical winged like appearances this particular tumor manifestation has been coined a butterfly glioma bg while canine and human gliomas share many neuroradiological and pathological features the bg morphology has not been previously reported in dogs here we describe the magnetic resonance imaging mri characteristics of bg in three dogs and review the potential differential diagnoses based on neuroimaging findings all dogs presented for generalized seizures and interictal neurological deficits referable to multifocal or diffuse forebrain disease mri examinations revealed asymmetrical 2 3 or symmetrical 1 3 bihemispheric intra axial mass lesions that predominantly affected the frontoparietal lobes that were associated with extensive perilesional edema and involvement of the corpus callosum the masses displayed heterogeneous t1 t2 and fluid attenuated inversion recovery signal intensities variable contrast enhancement 2 3 and mass effect all tumors demonstrated classical histopathological features of glioblastoma multiforme gbm including glial cell pseudopalisading serpentine necrosis microvascular proliferation as well as invasion of the corpus callosum by neoplastic astrocytes although rare gbm should be considered a differential diagnosis in dogs with an mri evidence of asymmetric or symmetric bilateral intra axial cerebral mass lesions with signal characteristics compatible with glioma.", "in humans high grade gliomas may infiltrate across the corpus callosum resulting in bihemispheric lesions that may have symmetrical winged like appearances this particular tumor manifestation has been coined a butterfly glioma bg while canine and human gliomas share many neuroradiological and pathological features the bg morphology has not been previously reported in dogs here we describe the magnetic resonance imaging mri characteristics of bg in three dogs and review the potential differential diagnoses based on neuroimaging findings all dogs presented for generalized seizures and interictal neurological deficits referable to multifocal or diffuse forebrain disease mri examinations revealed asymmetrical 2 3 or symmetrical 1 3 bihemispheric intra axial mass lesions that predominantly affected the frontoparietal lobes that were associated with extensive perilesional edema and involvement of the corpus callosum the masses displayed heterogeneous t1 t2 and fluid attenuated inversion recovery signal intensities variable contrast enhancement 2 3 and mass effect all tumors demonstrated classical histopathological features of glioblastoma multiforme gbm including glial cell pseudopalisading serpentine necrosis microvascular proliferation as well as invasion of the corpus callosum by neoplastic astrocytes although rare gbm should be considered a differential diagnosis in dogs with an mri evidence of asymmetric or symmetric bilateral intra axial cerebral mass lesions with signal characteristics compatible with glioma.", "in humans high grade gliomas may infiltrate across the corpus callosum resulting in bihemispheric lesions that may have symmetrical winged like appearances this particular tumor manifestation has been coined a butterfly glioma bg while canine and human gliomas share many neuroradiological and pathological features the bg morphology has not been previously reported in dogs here we describe the magnetic resonance imaging mri characteristics of bg in three dogs and review the potential differential diagnoses based on neuroimaging findings all dogs presented for generalized seizures and interictal neurological deficits referable to multifocal or diffuse forebrain disease mri examinations revealed asymmetrical 2 3 or symmetrical 1 3 bihemispheric intra axial mass lesions that predominantly affected the frontoparietal lobes that were associated with extensive perilesional edema and involvement of the corpus callosum the masses displayed heterogeneous t1 t2 and fluid attenuated inversion recovery signal intensities variable contrast enhancement 2 3 and mass effect all tumors demonstrated classical histopathological features of glioblastoma multiforme gbm including glial cell pseudopalisading serpentine necrosis microvascular proliferation as well as invasion of the corpus callosum by neoplastic astrocytes although rare gbm should be considered a differential diagnosis in dogs with an mri evidence of asymmetric or symmetric bilateral intra axial cerebral mass lesions with signal characteristics compatible with glioma.", "in humans high grade gliomas may infiltrate across the corpus callosum resulting in bihemispheric lesions that may have symmetrical winged like appearances this particular tumor manifestation has been coined a butterfly glioma bg while canine and human gliomas share many neuroradiological and pathological features the bg morphology has not been previously reported in dogs here we describe the magnetic resonance imaging mri characteristics of bg in three dogs and review the potential differential diagnoses based on neuroimaging findings all dogs presented for generalized seizures and interictal neurological deficits referable to multifocal or diffuse forebrain disease mri examinations revealed asymmetrical 2 3 or symmetrical 1 3 bihemispheric intra axial mass lesions that predominantly affected the frontoparietal lobes that were associated with extensive perilesional edema and involvement of the corpus callosum the masses displayed heterogeneous t1 t2 and fluid attenuated inversion recovery signal intensities variable contrast enhancement 2 3 and mass effect all tumors demonstrated classical histopathological features of glioblastoma multiforme gbm including glial cell pseudopalisading serpentine necrosis microvascular proliferation as well as invasion of the corpus callosum by neoplastic astrocytes although rare gbm should be considered a differential diagnosis in dogs with an mri evidence of asymmetric or symmetric bilateral intra axial cerebral mass lesions with signal characteristics compatible with glioma.", "the authors report a case of neuronal ceroid lipofuscinosis kufs disease confirmed by stereotactically obtained brain biopsy findings and initially diagnosed as a butterfly glioma the presenting symptoms in the 64 year old patient were mental alterations with progressive dementia followed by muscular atrophy and myoclonia with distal preponderance the mild initial disturbances of coordination increased and the patient developed a markedly ataxic gait computerized tomography ct scanning and magnetic resonance imaging revealed generalized cerebral atrophy and a bifrontal space occupying lesion involving the callosum the original clearcut diagnosis of glioblastoma multiforme based on ct scans was unexpectedly disproved by examination of stereotactically obtained brain biopsy specimens which revealed a neuronal ceroid lipofuscinosis kufs disease to the authors knowledge this is the first report of a case presenting with both diffuse brain atrophy and localized accumulation of neuronal lipofuscin mimicking a mass lesion on radiological studies.", "the authors report a case of neuronal ceroid lipofuscinosis kufs disease confirmed by stereotactically obtained brain biopsy findings and initially diagnosed as a butterfly glioma the presenting symptoms in the 64 year old patient were mental alterations with progressive dementia followed by muscular atrophy and myoclonia with distal preponderance the mild initial disturbances of coordination increased and the patient developed a markedly ataxic gait computerized tomography ct scanning and magnetic resonance imaging revealed generalized cerebral atrophy and a bifrontal space occupying lesion involving the callosum the original clearcut diagnosis of glioblastoma multiforme based on ct scans was unexpectedly disproved by examination of stereotactically obtained brain biopsy specimens which revealed a neuronal ceroid lipofuscinosis kufs disease to the authors knowledge this is the first report of a case presenting with both diffuse brain atrophy and localized accumulation of neuronal lipofuscin mimicking a mass lesion on radiological studies.", "the authors report a case of neuronal ceroid lipofuscinosis kufs disease confirmed by stereotactically obtained brain biopsy findings and initially diagnosed as a butterfly glioma the presenting symptoms in the 64 year old patient were mental alterations with progressive dementia followed by muscular atrophy and myoclonia with distal preponderance the mild initial disturbances of coordination increased and the patient developed a markedly ataxic gait computerized tomography ct scanning and magnetic resonance imaging revealed generalized cerebral atrophy and a bifrontal space occupying lesion involving the callosum the original clearcut diagnosis of glioblastoma multiforme based on ct scans was unexpectedly disproved by examination of stereotactically obtained brain biopsy specimens which revealed a neuronal ceroid lipofuscinosis kufs disease to the authors knowledge this is the first report of a case presenting with both diffuse brain atrophy and localized accumulation of neuronal lipofuscin mimicking a mass lesion on radiological studies.", "the authors report a case of neuronal ceroid lipofuscinosis kufs disease confirmed by stereotactically obtained brain biopsy findings and initially diagnosed as a butterfly glioma the presenting symptoms in the 64 year old patient were mental alterations with progressive dementia followed by muscular atrophy and myoclonia with distal preponderance the mild initial disturbances of coordination increased and the patient developed a markedly ataxic gait computerized tomography ct scanning and magnetic resonance imaging revealed generalized cerebral atrophy and a bifrontal space occupying lesion involving the callosum the original clearcut diagnosis of glioblastoma multiforme based on ct scans was unexpectedly disproved by examination of stereotactically obtained brain biopsy specimens which revealed a neuronal ceroid lipofuscinosis kufs disease to the authors knowledge this is the first report of a case presenting with both diffuse brain atrophy and localized accumulation of neuronal lipofuscin mimicking a mass lesion on radiological studies.", "the authors report a case of neuronal ceroid lipofuscinosis kufs disease confirmed by stereotactically obtained brain biopsy findings and initially diagnosed as a butterfly glioma the presenting symptoms in the 64 year old patient were mental alterations with progressive dementia followed by muscular atrophy and myoclonia with distal preponderance the mild initial disturbances of coordination increased and the patient developed a markedly ataxic gait computerized tomography ct scanning and magnetic resonance imaging revealed generalized cerebral atrophy and a bifrontal space occupying lesion involving the callosum the original clearcut diagnosis of glioblastoma multiforme based on ct scans was unexpectedly disproved by examination of stereotactically obtained brain biopsy specimens which revealed a neuronal ceroid lipofuscinosis kufs disease to the authors knowledge this is the first report of a case presenting with both diffuse brain atrophy and localized accumulation of neuronal lipofuscin mimicking a mass lesion on radiological studies.", "the authors report a case of neuronal ceroid lipofuscinosis kufs disease confirmed by stereotactically obtained brain biopsy findings and initially diagnosed as a butterfly glioma the presenting symptoms in the 64 year old patient were mental alterations with progressive dementia followed by muscular atrophy and myoclonia with distal preponderance the mild initial disturbances of coordination increased and the patient developed a markedly ataxic gait computerized tomography ct scanning and magnetic resonance imaging revealed generalized cerebral atrophy and a bifrontal space occupying lesion involving the callosum the original clearcut diagnosis of glioblastoma multiforme based on ct scans was unexpectedly disproved by examination of stereotactically obtained brain biopsy specimens which revealed a neuronal ceroid lipofuscinosis kufs disease to the authors knowledge this is the first report of a case presenting with both diffuse brain atrophy and localized accumulation of neuronal lipofuscin mimicking a mass lesion on radiological studies.", "the authors report a case of neuronal ceroid lipofuscinosis kufs disease confirmed by stereotactically obtained brain biopsy findings and initially diagnosed as a butterfly glioma the presenting symptoms in the 64 year old patient were mental alterations with progressive dementia followed by muscular atrophy and myoclonia with distal preponderance the mild initial disturbances of coordination increased and the patient developed a markedly ataxic gait computerized tomography ct scanning and magnetic resonance imaging revealed generalized cerebral atrophy and a bifrontal space occupying lesion involving the callosum the original clearcut diagnosis of glioblastoma multiforme based on ct scans was unexpectedly disproved by examination of stereotactically obtained brain biopsy specimens which revealed a neuronal ceroid lipofuscinosis kufs disease to the authors knowledge this is the first report of a case presenting with both diffuse brain atrophy and localized accumulation of neuronal lipofuscin mimicking a mass lesion on radiological studies.", "the authors report a case of neuronal ceroid lipofuscinosis kufs disease confirmed by stereotactically obtained brain biopsy findings and initially diagnosed as a butterfly glioma the presenting symptoms in the 64 year old patient were mental alterations with progressive dementia followed by muscular atrophy and myoclonia with distal preponderance the mild initial disturbances of coordination increased and the patient developed a markedly ataxic gait computerized tomography ct scanning and magnetic resonance imaging revealed generalized cerebral atrophy and a bifrontal space occupying lesion involving the callosum the original clearcut diagnosis of glioblastoma multiforme based on ct scans was unexpectedly disproved by examination of stereotactically obtained brain biopsy specimens which revealed a neuronal ceroid lipofuscinosis kufs disease to the authors knowledge this is the first report of a case presenting with both diffuse brain atrophy and localized accumulation of neuronal lipofuscin mimicking a mass lesion on radiological studies.", "glioblastoma multiforme gbm the most common malignant brain tumor of adults is relatively rare in children in a gbm affecting a 16 year old boy the tumor spread across the corpus callosum butterfly glioma this type of bilateral hemispheric growth has previously been thought to result from spread along the white matter tracts two samples obtained from opposite sides of the same tumor were analyzed comprehensively for loss of heterozygosity loh and microsatellite instability msi amplification of egfr and mdm2 was studied by means of multiplex polymerase chain reaction exons 5 6 7 and 8 of tp53 were screened for mutations by sequencing in neither specimen were molecular alterations found in the egfr mdm2 or tp53 genes the specimen obtained from the right hemisphere exhibited a high level of msi and loh in chromosome arms 5q 9p and 13q the specimen from the left hemisphere exhibited loh in chromosome arms 3p 5q 9p 9q 10p 10q and 13q here we propose four plausible hypothetical scenarios underlying the tumorigenesis of this gbm.", "glioblastoma multiforme gbm the most common malignant brain tumor of adults is relatively rare in children in a gbm affecting a 16 year old boy the tumor spread across the corpus callosum butterfly glioma this type of bilateral hemispheric growth has previously been thought to result from spread along the white matter tracts two samples obtained from opposite sides of the same tumor were analyzed comprehensively for loss of heterozygosity loh and microsatellite instability msi amplification of egfr and mdm2 was studied by means of multiplex polymerase chain reaction exons 5 6 7 and 8 of tp53 were screened for mutations by sequencing in neither specimen were molecular alterations found in the egfr mdm2 or tp53 genes the specimen obtained from the right hemisphere exhibited a high level of msi and loh in chromosome arms 5q 9p and 13q the specimen from the left hemisphere exhibited loh in chromosome arms 3p 5q 9p 9q 10p 10q and 13q here we propose four plausible hypothetical scenarios underlying the tumorigenesis of this gbm.", "glioblastoma multiforme gbm the most common malignant brain tumor of adults is relatively rare in children in a gbm affecting a 16 year old boy the tumor spread across the corpus callosum butterfly glioma this type of bilateral hemispheric growth has previously been thought to result from spread along the white matter tracts two samples obtained from opposite sides of the same tumor were analyzed comprehensively for loss of heterozygosity loh and microsatellite instability msi amplification of egfr and mdm2 was studied by means of multiplex polymerase chain reaction exons 5 6 7 and 8 of tp53 were screened for mutations by sequencing in neither specimen were molecular alterations found in the egfr mdm2 or tp53 genes the specimen obtained from the right hemisphere exhibited a high level of msi and loh in chromosome arms 5q 9p and 13q the specimen from the left hemisphere exhibited loh in chromosome arms 3p 5q 9p 9q 10p 10q and 13q here we propose four plausible hypothetical scenarios underlying the tumorigenesis of this gbm.", "glioblastoma multiforme gbm the most common malignant brain tumor of adults is relatively rare in children in a gbm affecting a 16 year old boy the tumor spread across the corpus callosum butterfly glioma this type of bilateral hemispheric growth has previously been thought to result from spread along the white matter tracts two samples obtained from opposite sides of the same tumor were analyzed comprehensively for loss of heterozygosity loh and microsatellite instability msi amplification of egfr and mdm2 was studied by means of multiplex polymerase chain reaction exons 5 6 7 and 8 of tp53 were screened for mutations by sequencing in neither specimen were molecular alterations found in the egfr mdm2 or tp53 genes the specimen obtained from the right hemisphere exhibited a high level of msi and loh in chromosome arms 5q 9p and 13q the specimen from the left hemisphere exhibited loh in chromosome arms 3p 5q 9p 9q 10p 10q and 13q here we propose four plausible hypothetical scenarios underlying the tumorigenesis of this gbm.", "glioblastoma multiforme gbm the most common malignant brain tumor of adults is relatively rare in children in a gbm affecting a 16 year old boy the tumor spread across the corpus callosum butterfly glioma this type of bilateral hemispheric growth has previously been thought to result from spread along the white matter tracts two samples obtained from opposite sides of the same tumor were analyzed comprehensively for loss of heterozygosity loh and microsatellite instability msi amplification of egfr and mdm2 was studied by means of multiplex polymerase chain reaction exons 5 6 7 and 8 of tp53 were screened for mutations by sequencing in neither specimen were molecular alterations found in the egfr mdm2 or tp53 genes the specimen obtained from the right hemisphere exhibited a high level of msi and loh in chromosome arms 5q 9p and 13q the specimen from the left hemisphere exhibited loh in chromosome arms 3p 5q 9p 9q 10p 10q and 13q here we propose four plausible hypothetical scenarios underlying the tumorigenesis of this gbm.", "glioblastoma multiforme gbm the most common malignant brain tumor of adults is relatively rare in children in a gbm affecting a 16 year old boy the tumor spread across the corpus callosum butterfly glioma this type of bilateral hemispheric growth has previously been thought to result from spread along the white matter tracts two samples obtained from opposite sides of the same tumor were analyzed comprehensively for loss of heterozygosity loh and microsatellite instability msi amplification of egfr and mdm2 was studied by means of multiplex polymerase chain reaction exons 5 6 7 and 8 of tp53 were screened for mutations by sequencing in neither specimen were molecular alterations found in the egfr mdm2 or tp53 genes the specimen obtained from the right hemisphere exhibited a high level of msi and loh in chromosome arms 5q 9p and 13q the specimen from the left hemisphere exhibited loh in chromosome arms 3p 5q 9p 9q 10p 10q and 13q here we propose four plausible hypothetical scenarios underlying the tumorigenesis of this gbm.", "glioblastoma multiforme gbm the most common malignant brain tumor of adults is relatively rare in children in a gbm affecting a 16 year old boy the tumor spread across the corpus callosum butterfly glioma this type of bilateral hemispheric growth has previously been thought to result from spread along the white matter tracts two samples obtained from opposite sides of the same tumor were analyzed comprehensively for loss of heterozygosity loh and microsatellite instability msi amplification of egfr and mdm2 was studied by means of multiplex polymerase chain reaction exons 5 6 7 and 8 of tp53 were screened for mutations by sequencing in neither specimen were molecular alterations found in the egfr mdm2 or tp53 genes the specimen obtained from the right hemisphere exhibited a high level of msi and loh in chromosome arms 5q 9p and 13q the specimen from the left hemisphere exhibited loh in chromosome arms 3p 5q 9p 9q 10p 10q and 13q here we propose four plausible hypothetical scenarios underlying the tumorigenesis of this gbm.", "glioblastoma multiforme gbm the most common malignant brain tumor of adults is relatively rare in children in a gbm affecting a 16 year old boy the tumor spread across the corpus callosum butterfly glioma this type of bilateral hemispheric growth has previously been thought to result from spread along the white matter tracts two samples obtained from opposite sides of the same tumor were analyzed comprehensively for loss of heterozygosity loh and microsatellite instability msi amplification of egfr and mdm2 was studied by means of multiplex polymerase chain reaction exons 5 6 7 and 8 of tp53 were screened for mutations by sequencing in neither specimen were molecular alterations found in the egfr mdm2 or tp53 genes the specimen obtained from the right hemisphere exhibited a high level of msi and loh in chromosome arms 5q 9p and 13q the specimen from the left hemisphere exhibited loh in chromosome arms 3p 5q 9p 9q 10p 10q and 13q here we propose four plausible hypothetical scenarios underlying the tumorigenesis of this gbm.", "a 54 year old man presented with change in behaviour nocturnal enuresis abnormal limb movement and headache of one week s duration the diagnosis of butterfly glioma glioblastoma multiforme was made based on imaging characteristics and was further confirmed by biopsy findings as the corpus callosum is usually resistant to infiltration by tumours a mass that involves and crosses the corpus callosum is suggestive of an aggressive neoplasm other neoplastic and non neoplastic conditions that may involve the corpus callosum and mimic a butterfly glioma as well as associated imaging features are discussed.", "a 54 year old man presented with change in behaviour nocturnal enuresis abnormal limb movement and headache of one week s duration the diagnosis of butterfly glioma glioblastoma multiforme was made based on imaging characteristics and was further confirmed by biopsy findings as the corpus callosum is usually resistant to infiltration by tumours a mass that involves and crosses the corpus callosum is suggestive of an aggressive neoplasm other neoplastic and non neoplastic conditions that may involve the corpus callosum and mimic a butterfly glioma as well as associated imaging features are discussed.", "a 54 year old man presented with change in behaviour nocturnal enuresis abnormal limb movement and headache of one week s duration the diagnosis of butterfly glioma glioblastoma multiforme was made based on imaging characteristics and was further confirmed by biopsy findings as the corpus callosum is usually resistant to infiltration by tumours a mass that involves and crosses the corpus callosum is suggestive of an aggressive neoplasm other neoplastic and non neoplastic conditions that may involve the corpus callosum and mimic a butterfly glioma as well as associated imaging features are discussed.", "a 54 year old man presented with change in behaviour nocturnal enuresis abnormal limb movement and headache of one week s duration the diagnosis of butterfly glioma glioblastoma multiforme was made based on imaging characteristics and was further confirmed by biopsy findings as the corpus callosum is usually resistant to infiltration by tumours a mass that involves and crosses the corpus callosum is suggestive of an aggressive neoplasm other neoplastic and non neoplastic conditions that may involve the corpus callosum and mimic a butterfly glioma as well as associated imaging features are discussed.", "a 54 year old man presented with change in behaviour nocturnal enuresis abnormal limb movement and headache of one week s duration the diagnosis of butterfly glioma glioblastoma multiforme was made based on imaging characteristics and was further confirmed by biopsy findings as the corpus callosum is usually resistant to infiltration by tumours a mass that involves and crosses the corpus callosum is suggestive of an aggressive neoplasm other neoplastic and non neoplastic conditions that may involve the corpus callosum and mimic a butterfly glioma as well as associated imaging features are discussed.", "a 54 year old man presented with change in behaviour nocturnal enuresis abnormal limb movement and headache of one week s duration the diagnosis of butterfly glioma glioblastoma multiforme was made based on imaging characteristics and was further confirmed by biopsy findings as the corpus callosum is usually resistant to infiltration by tumours a mass that involves and crosses the corpus callosum is suggestive of an aggressive neoplasm other neoplastic and non neoplastic conditions that may involve the corpus callosum and mimic a butterfly glioma as well as associated imaging features are discussed.", "a 54 year old man presented with change in behaviour nocturnal enuresis abnormal limb movement and headache of one week s duration the diagnosis of butterfly glioma glioblastoma multiforme was made based on imaging characteristics and was further confirmed by biopsy findings as the corpus callosum is usually resistant to infiltration by tumours a mass that involves and crosses the corpus callosum is suggestive of an aggressive neoplasm other neoplastic and non neoplastic conditions that may involve the corpus callosum and mimic a butterfly glioma as well as associated imaging features are discussed.", "a 54 year old man presented with change in behaviour nocturnal enuresis abnormal limb movement and headache of one week s duration the diagnosis of butterfly glioma glioblastoma multiforme was made based on imaging characteristics and was further confirmed by biopsy findings as the corpus callosum is usually resistant to infiltration by tumours a mass that involves and crosses the corpus callosum is suggestive of an aggressive neoplasm other neoplastic and non neoplastic conditions that may involve the corpus callosum and mimic a butterfly glioma as well as associated imaging features are discussed.", "all tumors demonstrated classical histopathological features of glioblastoma multiforme (gbm), including glial cell pseudopalisading, serpentine necrosis, microvascular proliferation as well as invasion of the corpus callosum by neoplastic astrocytes.", "all tumors demonstrated classical histopathological features of glioblastoma multiforme (gbm), including glial cell pseudopalisading, serpentine necrosis, microvascular proliferation as well as invasion of the corpus callosum by neoplastic astrocytes.", "all tumors demonstrated classical histopathological features of glioblastoma multiforme (gbm), including glial cell pseudopalisading, serpentine necrosis, microvascular proliferation as well as invasion of the corpus callosum by neoplastic astrocytes.", "all tumors demonstrated classical histopathological features of glioblastoma multiforme (gbm), including glial cell pseudopalisading, serpentine necrosis, microvascular proliferation as well as invasion of the corpus callosum by neoplastic astrocytes.", "all tumors demonstrated classical histopathological features of glioblastoma multiforme (gbm), including glial cell pseudopalisading, serpentine necrosis, microvascular proliferation as well as invasion of the corpus callosum by neoplastic astrocytes.", "all tumors demonstrated classical histopathological features of glioblastoma multiforme (gbm), including glial cell pseudopalisading, serpentine necrosis, microvascular proliferation as well as invasion of the corpus callosum by neoplastic astrocytes.", "all tumors demonstrated classical histopathological features of glioblastoma multiforme (gbm), including glial cell pseudopalisading, serpentine necrosis, microvascular proliferation as well as invasion of the corpus callosum by neoplastic astrocytes.", "all tumors demonstrated classical histopathological features of glioblastoma multiforme (gbm), including glial cell pseudopalisading, serpentine necrosis, microvascular proliferation as well as invasion of the corpus callosum by neoplastic astrocytes.", "the original \"clearcut\" diagnosis of glioblastoma multiforme, based on ct scans, was unexpectedly disproved by examination of stereotactically obtained brain biopsy specimens, which revealed a neuronal ceroid lipofuscinosis (kufs' disease).", "the original \"clearcut\" diagnosis of glioblastoma multiforme, based on ct scans, was unexpectedly disproved by examination of stereotactically obtained brain biopsy specimens, which revealed a neuronal ceroid lipofuscinosis (kufs' disease).", "the original \"clearcut\" diagnosis of glioblastoma multiforme, based on ct scans, was unexpectedly disproved by examination of stereotactically obtained brain biopsy specimens, which revealed a neuronal ceroid lipofuscinosis (kufs' disease).", "the original \"clearcut\" diagnosis of glioblastoma multiforme, based on ct scans, was unexpectedly disproved by examination of stereotactically obtained brain biopsy specimens, which revealed a neuronal ceroid lipofuscinosis (kufs' disease).", "the original \"clearcut\" diagnosis of glioblastoma multiforme, based on ct scans, was unexpectedly disproved by examination of stereotactically obtained brain biopsy specimens, which revealed a neuronal ceroid lipofuscinosis (kufs' disease).", "the original \"clearcut\" diagnosis of glioblastoma multiforme, based on ct scans, was unexpectedly disproved by examination of stereotactically obtained brain biopsy specimens, which revealed a neuronal ceroid lipofuscinosis (kufs' disease).", "the original \"clearcut\" diagnosis of glioblastoma multiforme, based on ct scans, was unexpectedly disproved by examination of stereotactically obtained brain biopsy specimens, which revealed a neuronal ceroid lipofuscinosis (kufs' disease).", "the original \"clearcut\" diagnosis of glioblastoma multiforme, based on ct scans, was unexpectedly disproved by examination of stereotactically obtained brain biopsy specimens, which revealed a neuronal ceroid lipofuscinosis (kufs' disease).", "glioblastoma multiforme (gbm), the most common malignant brain tumor of adults, is relatively rare in children. in a gbm affecting a 16-year-old boy, the tumor spread across the corpus callosum (butterfly glioma).", "glioblastoma multiforme (gbm), the most common malignant brain tumor of adults, is relatively rare in children. in a gbm affecting a 16-year-old boy, the tumor spread across the corpus callosum (butterfly glioma).", "glioblastoma multiforme (gbm), the most common malignant brain tumor of adults, is relatively rare in children. in a gbm affecting a 16-year-old boy, the tumor spread across the corpus callosum (butterfly glioma).", "glioblastoma multiforme (gbm), the most common malignant brain tumor of adults, is relatively rare in children. in a gbm affecting a 16-year-old boy, the tumor spread across the corpus callosum (butterfly glioma).", "glioblastoma multiforme (gbm), the most common malignant brain tumor of adults, is relatively rare in children. in a gbm affecting a 16-year-old boy, the tumor spread across the corpus callosum (butterfly glioma).", "glioblastoma multiforme (gbm), the most common malignant brain tumor of adults, is relatively rare in children. in a gbm affecting a 16-year-old boy, the tumor spread across the corpus callosum (butterfly glioma).", "glioblastoma multiforme (gbm), the most common malignant brain tumor of adults, is relatively rare in children. in a gbm affecting a 16-year-old boy, the tumor spread across the corpus callosum (butterfly glioma).", "glioblastoma multiforme (gbm), the most common malignant brain tumor of adults, is relatively rare in children. in a gbm affecting a 16-year-old boy, the tumor spread across the corpus callosum (butterfly glioma).", "the diagnosis of butterfly glioma (glioblastoma multiforme) was made based on imaging characteristics and was further confirmed by biopsy findings.", "the diagnosis of butterfly glioma (glioblastoma multiforme) was made based on imaging characteristics and was further confirmed by biopsy findings.", "the diagnosis of butterfly glioma (glioblastoma multiforme) was made based on imaging characteristics and was further confirmed by biopsy findings.", "the diagnosis of butterfly glioma (glioblastoma multiforme) was made based on imaging characteristics and was further confirmed by biopsy findings.", "the diagnosis of butterfly glioma (glioblastoma multiforme) was made based on imaging characteristics and was further confirmed by biopsy findings.", "the diagnosis of butterfly glioma (glioblastoma multiforme) was made based on imaging characteristics and was further confirmed by biopsy findings.", "the diagnosis of butterfly glioma (glioblastoma multiforme) was made based on imaging characteristics and was further confirmed by biopsy findings.", "the diagnosis of butterfly glioma (glioblastoma multiforme) was made based on imaging characteristics and was further confirmed by biopsy findings.", "clinics in diagnostic imaging 175 corpus callosum glioblastoma multiforme gbm butterfly glioma", "clinics in diagnostic imaging 175 corpus callosum glioblastoma multiforme gbm butterfly glioma", "clinics in diagnostic imaging 175 corpus callosum glioblastoma multiforme gbm butterfly glioma", "clinics in diagnostic imaging 175 corpus callosum glioblastoma multiforme gbm butterfly glioma", "clinics in diagnostic imaging 175 corpus callosum glioblastoma multiforme gbm butterfly glioma", "clinics in diagnostic imaging 175 corpus callosum glioblastoma multiforme gbm butterfly glioma", "clinics in diagnostic imaging 175 corpus callosum glioblastoma multiforme gbm butterfly glioma", "clinics in diagnostic imaging 175 corpus callosum glioblastoma multiforme gbm butterfly glioma", "corpus callosum glioblastoma multiforme (gbm): butterfly glioma.", "corpus callosum glioblastoma multiforme (gbm): butterfly glioma.", "corpus callosum glioblastoma multiforme (gbm): butterfly glioma.", "corpus callosum glioblastoma multiforme (gbm): butterfly glioma.", "corpus callosum glioblastoma multiforme (gbm): butterfly glioma.", "corpus callosum glioblastoma multiforme (gbm): butterfly glioma.", "corpus callosum glioblastoma multiforme (gbm): butterfly glioma.", "corpus callosum glioblastoma multiforme (gbm): butterfly glioma.", "the recount2 resource is composed of over 70 000 uniformly processed human rna seq samples spanning tcga and sra including gtex the processed data can be accessed via the recount2 website and the bioconductor package this workflow explains in detail how to use the package and how to integrate it with other bioconductor packages for several analyses that can be carried out with the recount2 resource in particular we describe how the coverage count matrices were computed in recount2 as well as different ways of obtaining public metadata which can facilitate downstream analyses step by step directions show how to do a gene level differential expression analysis visualize base level genome coverage data and perform an analyses at multiple feature levels this workflow thus provides further information to understand the data in recount2 and a compendium of r code to use the data.", "the recount2 resource is composed of over 70 000 uniformly processed human rna seq samples spanning tcga and sra including gtex the processed data can be accessed via the recount2 website and the bioconductor package this workflow explains in detail how to use the package and how to integrate it with other bioconductor packages for several analyses that can be carried out with the recount2 resource in particular we describe how the coverage count matrices were computed in recount2 as well as different ways of obtaining public metadata which can facilitate downstream analyses step by step directions show how to do a gene level differential expression analysis visualize base level genome coverage data and perform an analyses at multiple feature levels this workflow thus provides further information to understand the data in recount2 and a compendium of r code to use the data.", "the recount2 resource is composed of over 70 000 uniformly processed human rna seq samples spanning tcga and sra including gtex the processed data can be accessed via the recount2 website and the bioconductor package this workflow explains in detail how to use the package and how to integrate it with other bioconductor packages for several analyses that can be carried out with the recount2 resource in particular we describe how the coverage count matrices were computed in recount2 as well as different ways of obtaining public metadata which can facilitate downstream analyses step by step directions show how to do a gene level differential expression analysis visualize base level genome coverage data and perform an analyses at multiple feature levels this workflow thus provides further information to understand the data in recount2 and a compendium of r code to use the data.", "the recount2 resource is composed of over 70 000 uniformly processed human rna seq samples spanning tcga and sra including gtex the processed data can be accessed via the recount2 website and the bioconductor package this workflow explains in detail how to use the package and how to integrate it with other bioconductor packages for several analyses that can be carried out with the recount2 resource in particular we describe how the coverage count matrices were computed in recount2 as well as different ways of obtaining public metadata which can facilitate downstream analyses step by step directions show how to do a gene level differential expression analysis visualize base level genome coverage data and perform an analyses at multiple feature levels this workflow thus provides further information to understand the data in recount2 and a compendium of r code to use the data.", "the recount2 resource is composed of over 70 000 uniformly processed human rna seq samples spanning tcga and sra including gtex the processed data can be accessed via the recount2 website and the bioconductor package this workflow explains in detail how to use the package and how to integrate it with other bioconductor packages for several analyses that can be carried out with the recount2 resource in particular we describe how the coverage count matrices were computed in recount2 as well as different ways of obtaining public metadata which can facilitate downstream analyses step by step directions show how to do a gene level differential expression analysis visualize base level genome coverage data and perform an analyses at multiple feature levels this workflow thus provides further information to understand the data in recount2 and a compendium of r code to use the data.", "the recount2 resource is composed of over 70 000 uniformly processed human rna seq samples spanning tcga and sra including gtex the processed data can be accessed via the recount2 website and the bioconductor package this workflow explains in detail how to use the package and how to integrate it with other bioconductor packages for several analyses that can be carried out with the recount2 resource in particular we describe how the coverage count matrices were computed in recount2 as well as different ways of obtaining public metadata which can facilitate downstream analyses step by step directions show how to do a gene level differential expression analysis visualize base level genome coverage data and perform an analyses at multiple feature levels this workflow thus provides further information to understand the data in recount2 and a compendium of r code to use the data.", "the recount2 resource is composed of over 70 000 uniformly processed human rna seq samples spanning tcga and sra including gtex the processed data can be accessed via the recount2 website and the bioconductor package this workflow explains in detail how to use the package and how to integrate it with other bioconductor packages for several analyses that can be carried out with the recount2 resource in particular we describe how the coverage count matrices were computed in recount2 as well as different ways of obtaining public metadata which can facilitate downstream analyses step by step directions show how to do a gene level differential expression analysis visualize base level genome coverage data and perform an analyses at multiple feature levels this workflow thus provides further information to understand the data in recount2 and a compendium of r code to use the data.", "the recount2 resource is composed of over 70 000 uniformly processed human rna seq samples spanning tcga and sra including gtex the processed data can be accessed via the recount2 website and the bioconductor package this workflow explains in detail how to use the package and how to integrate it with other bioconductor packages for several analyses that can be carried out with the recount2 resource in particular we describe how the coverage count matrices were computed in recount2 as well as different ways of obtaining public metadata which can facilitate downstream analyses step by step directions show how to do a gene level differential expression analysis visualize base level genome coverage data and perform an analyses at multiple feature levels this workflow thus provides further information to understand the data in recount2 and a compendium of r code to use the data.", "the recount2 resource is composed of over 70 000 uniformly processed human rna seq samples spanning tcga and sra including gtex the processed data can be accessed via the recount2 website and the bioconductor package this workflow explains in detail how to use the package and how to integrate it with other bioconductor packages for several analyses that can be carried out with the recount2 resource in particular we describe how the coverage count matrices were computed in recount2 as well as different ways of obtaining public metadata which can facilitate downstream analyses step by step directions show how to do a gene level differential expression analysis visualize base level genome coverage data and perform an analyses at multiple feature levels this workflow thus provides further information to understand the data in recount2 and a compendium of r code to use the data.", "the recount2 resource is composed of over 70 000 uniformly processed human rna seq samples spanning tcga and sra including gtex the processed data can be accessed via the recount2 website and the bioconductor package this workflow explains in detail how to use the package and how to integrate it with other bioconductor packages for several analyses that can be carried out with the recount2 resource in particular we describe how the coverage count matrices were computed in recount2 as well as different ways of obtaining public metadata which can facilitate downstream analyses step by step directions show how to do a gene level differential expression analysis visualize base level genome coverage data and perform an analyses at multiple feature levels this workflow thus provides further information to understand the data in recount2 and a compendium of r code to use the data.", "the recount2 resource is composed of over 70 000 uniformly processed human rna seq samples spanning tcga and sra including gtex the processed data can be accessed via the recount2 website and the bioconductor package this workflow explains in detail how to use the package and how to integrate it with other bioconductor packages for several analyses that can be carried out with the recount2 resource in particular we describe how the coverage count matrices were computed in recount2 as well as different ways of obtaining public metadata which can facilitate downstream analyses step by step directions show how to do a gene level differential expression analysis visualize base level genome coverage data and perform an analyses at multiple feature levels this workflow thus provides further information to understand the data in recount2 and a compendium of r code to use the data.", "the recount2 resource is composed of over 70 000 uniformly processed human rna seq samples spanning tcga and sra including gtex the processed data can be accessed via the recount2 website and the bioconductor package this workflow explains in detail how to use the package and how to integrate it with other bioconductor packages for several analyses that can be carried out with the recount2 resource in particular we describe how the coverage count matrices were computed in recount2 as well as different ways of obtaining public metadata which can facilitate downstream analyses step by step directions show how to do a gene level differential expression analysis visualize base level genome coverage data and perform an analyses at multiple feature levels this workflow thus provides further information to understand the data in recount2 and a compendium of r code to use the data.", "the recount2 resource is composed of over 70 000 uniformly processed human rna seq samples spanning tcga and sra including gtex the processed data can be accessed via the recount2 website and the bioconductor package this workflow explains in detail how to use the package and how to integrate it with other bioconductor packages for several analyses that can be carried out with the recount2 resource in particular we describe how the coverage count matrices were computed in recount2 as well as different ways of obtaining public metadata which can facilitate downstream analyses step by step directions show how to do a gene level differential expression analysis visualize base level genome coverage data and perform an analyses at multiple feature levels this workflow thus provides further information to understand the data in recount2 and a compendium of r code to use the data.", "the recount2 resource is composed of over 70 000 uniformly processed human rna seq samples spanning tcga and sra including gtex the processed data can be accessed via the recount2 website and the bioconductor package this workflow explains in detail how to use the package and how to integrate it with other bioconductor packages for several analyses that can be carried out with the recount2 resource in particular we describe how the coverage count matrices were computed in recount2 as well as different ways of obtaining public metadata which can facilitate downstream analyses step by step directions show how to do a gene level differential expression analysis visualize base level genome coverage data and perform an analyses at multiple feature levels this workflow thus provides further information to understand the data in recount2 and a compendium of r code to use the data.", "the recount2 resource is composed of over 70 000 uniformly processed human rna seq samples spanning tcga and sra including gtex the processed data can be accessed via the recount2 website and the bioconductor package this workflow explains in detail how to use the package and how to integrate it with other bioconductor packages for several analyses that can be carried out with the recount2 resource in particular we describe how the coverage count matrices were computed in recount2 as well as different ways of obtaining public metadata which can facilitate downstream analyses step by step directions show how to do a gene level differential expression analysis visualize base level genome coverage data and perform an analyses at multiple feature levels this workflow thus provides further information to understand the data in recount2 and a compendium of r code to use the data.", "the recount2 resource is composed of over 70 000 uniformly processed human rna seq samples spanning tcga and sra including gtex the processed data can be accessed via the recount2 website and the bioconductor package this workflow explains in detail how to use the package and how to integrate it with other bioconductor packages for several analyses that can be carried out with the recount2 resource in particular we describe how the coverage count matrices were computed in recount2 as well as different ways of obtaining public metadata which can facilitate downstream analyses step by step directions show how to do a gene level differential expression analysis visualize base level genome coverage data and perform an analyses at multiple feature levels this workflow thus provides further information to understand the data in recount2 and a compendium of r code to use the data.", "the recount2 resource is composed of over 70 000 uniformly processed human rna seq samples spanning tcga and sra including gtex the processed data can be accessed via the recount2 website and the bioconductor package this workflow explains in detail how to use the package and how to integrate it with other bioconductor packages for several analyses that can be carried out with the recount2 resource in particular we describe how the coverage count matrices were computed in recount2 as well as different ways of obtaining public metadata which can facilitate downstream analyses step by step directions show how to do a gene level differential expression analysis visualize base level genome coverage data and perform an analyses at multiple feature levels this workflow thus provides further information to understand the data in recount2 and a compendium of r code to use the data.", "the recount2 resource is composed of over 70 000 uniformly processed human rna seq samples spanning tcga and sra including gtex the processed data can be accessed via the recount2 website and the bioconductor package this workflow explains in detail how to use the package and how to integrate it with other bioconductor packages for several analyses that can be carried out with the recount2 resource in particular we describe how the coverage count matrices were computed in recount2 as well as different ways of obtaining public metadata which can facilitate downstream analyses step by step directions show how to do a gene level differential expression analysis visualize base level genome coverage data and perform an analyses at multiple feature levels this workflow thus provides further information to understand the data in recount2 and a compendium of r code to use the data.", "the recount2 resource is composed of over 70 000 uniformly processed human rna seq samples spanning tcga and sra including gtex the processed data can be accessed via the recount2 website and the bioconductor package this workflow explains in detail how to use the package and how to integrate it with other bioconductor packages for several analyses that can be carried out with the recount2 resource in particular we describe how the coverage count matrices were computed in recount2 as well as different ways of obtaining public metadata which can facilitate downstream analyses step by step directions show how to do a gene level differential expression analysis visualize base level genome coverage data and perform an analyses at multiple feature levels this workflow thus provides further information to understand the data in recount2 and a compendium of r code to use the data.", "the recount2 resource is composed of over 70 000 uniformly processed human rna seq samples spanning tcga and sra including gtex the processed data can be accessed via the recount2 website and the bioconductor package this workflow explains in detail how to use the package and how to integrate it with other bioconductor packages for several analyses that can be carried out with the recount2 resource in particular we describe how the coverage count matrices were computed in recount2 as well as different ways of obtaining public metadata which can facilitate downstream analyses step by step directions show how to do a gene level differential expression analysis visualize base level genome coverage data and perform an analyses at multiple feature levels this workflow thus provides further information to understand the data in recount2 and a compendium of r code to use the data.", "the recount2 resource is composed of over 70 000 uniformly processed human rna seq samples spanning tcga and sra including gtex the processed data can be accessed via the recount2 website and the bioconductor package this workflow explains in detail how to use the package and how to integrate it with other bioconductor packages for several analyses that can be carried out with the recount2 resource in particular we describe how the coverage count matrices were computed in recount2 as well as different ways of obtaining public metadata which can facilitate downstream analyses step by step directions show how to do a gene level differential expression analysis visualize base level genome coverage data and perform an analyses at multiple feature levels this workflow thus provides further information to understand the data in recount2 and a compendium of r code to use the data.", "the recount2 resource is composed of over 70 000 uniformly processed human rna seq samples spanning tcga and sra including gtex the processed data can be accessed via the recount2 website and the bioconductor package this workflow explains in detail how to use the package and how to integrate it with other bioconductor packages for several analyses that can be carried out with the recount2 resource in particular we describe how the coverage count matrices were computed in recount2 as well as different ways of obtaining public metadata which can facilitate downstream analyses step by step directions show how to do a gene level differential expression analysis visualize base level genome coverage data and perform an analyses at multiple feature levels this workflow thus provides further information to understand the data in recount2 and a compendium of r code to use the data.", "the recount2 resource is composed of over 70 000 uniformly processed human rna seq samples spanning tcga and sra including gtex the processed data can be accessed via the recount2 website and the bioconductor package this workflow explains in detail how to use the package and how to integrate it with other bioconductor packages for several analyses that can be carried out with the recount2 resource in particular we describe how the coverage count matrices were computed in recount2 as well as different ways of obtaining public metadata which can facilitate downstream analyses step by step directions show how to do a gene level differential expression analysis visualize base level genome coverage data and perform an analyses at multiple feature levels this workflow thus provides further information to understand the data in recount2 and a compendium of r code to use the data.", "the recount2 resource is composed of over 70 000 uniformly processed human rna seq samples spanning tcga and sra including gtex the processed data can be accessed via the recount2 website and the bioconductor package this workflow explains in detail how to use the package and how to integrate it with other bioconductor packages for several analyses that can be carried out with the recount2 resource in particular we describe how the coverage count matrices were computed in recount2 as well as different ways of obtaining public metadata which can facilitate downstream analyses step by step directions show how to do a gene level differential expression analysis visualize base level genome coverage data and perform an analyses at multiple feature levels this workflow thus provides further information to understand the data in recount2 and a compendium of r code to use the data.", "the recount2 resource is composed of over 70 000 uniformly processed human rna seq samples spanning tcga and sra including gtex the processed data can be accessed via the recount2 website and the bioconductor package this workflow explains in detail how to use the package and how to integrate it with other bioconductor packages for several analyses that can be carried out with the recount2 resource in particular we describe how the coverage count matrices were computed in recount2 as well as different ways of obtaining public metadata which can facilitate downstream analyses step by step directions show how to do a gene level differential expression analysis visualize base level genome coverage data and perform an analyses at multiple feature levels this workflow thus provides further information to understand the data in recount2 and a compendium of r code to use the data.", "the recount2 resource is composed of over 70 000 uniformly processed human rna seq samples spanning tcga and sra including gtex the processed data can be accessed via the recount2 website and the bioconductor package this workflow explains in detail how to use the package and how to integrate it with other bioconductor packages for several analyses that can be carried out with the recount2 resource in particular we describe how the coverage count matrices were computed in recount2 as well as different ways of obtaining public metadata which can facilitate downstream analyses step by step directions show how to do a gene level differential expression analysis visualize base level genome coverage data and perform an analyses at multiple feature levels this workflow thus provides further information to understand the data in recount2 and a compendium of r code to use the data.", "the recount2 resource is composed of over 70 000 uniformly processed human rna seq samples spanning tcga and sra including gtex the processed data can be accessed via the recount2 website and the bioconductor package this workflow explains in detail how to use the package and how to integrate it with other bioconductor packages for several analyses that can be carried out with the recount2 resource in particular we describe how the coverage count matrices were computed in recount2 as well as different ways of obtaining public metadata which can facilitate downstream analyses step by step directions show how to do a gene level differential expression analysis visualize base level genome coverage data and perform an analyses at multiple feature levels this workflow thus provides further information to understand the data in recount2 and a compendium of r code to use the data.", "the recount2 resource is composed of over 70 000 uniformly processed human rna seq samples spanning tcga and sra including gtex the processed data can be accessed via the recount2 website and the bioconductor package this workflow explains in detail how to use the package and how to integrate it with other bioconductor packages for several analyses that can be carried out with the recount2 resource in particular we describe how the coverage count matrices were computed in recount2 as well as different ways of obtaining public metadata which can facilitate downstream analyses step by step directions show how to do a gene level differential expression analysis visualize base level genome coverage data and perform an analyses at multiple feature levels this workflow thus provides further information to understand the data in recount2 and a compendium of r code to use the data.", "the recount2 resource is composed of over 70 000 uniformly processed human rna seq samples spanning tcga and sra including gtex the processed data can be accessed via the recount2 website and the bioconductor package this workflow explains in detail how to use the package and how to integrate it with other bioconductor packages for several analyses that can be carried out with the recount2 resource in particular we describe how the coverage count matrices were computed in recount2 as well as different ways of obtaining public metadata which can facilitate downstream analyses step by step directions show how to do a gene level differential expression analysis visualize base level genome coverage data and perform an analyses at multiple feature levels this workflow thus provides further information to understand the data in recount2 and a compendium of r code to use the data.", "the recount2 resource is composed of over 70 000 uniformly processed human rna seq samples spanning tcga and sra including gtex the processed data can be accessed via the recount2 website and the bioconductor package this workflow explains in detail how to use the package and how to integrate it with other bioconductor packages for several analyses that can be carried out with the recount2 resource in particular we describe how the coverage count matrices were computed in recount2 as well as different ways of obtaining public metadata which can facilitate downstream analyses step by step directions show how to do a gene level differential expression analysis visualize base level genome coverage data and perform an analyses at multiple feature levels this workflow thus provides further information to understand the data in recount2 and a compendium of r code to use the data.", "the recount2 resource is composed of over 70 000 uniformly processed human rna seq samples spanning tcga and sra including gtex the processed data can be accessed via the recount2 website and the bioconductor package this workflow explains in detail how to use the package and how to integrate it with other bioconductor packages for several analyses that can be carried out with the recount2 resource in particular we describe how the coverage count matrices were computed in recount2 as well as different ways of obtaining public metadata which can facilitate downstream analyses step by step directions show how to do a gene level differential expression analysis visualize base level genome coverage data and perform an analyses at multiple feature levels this workflow thus provides further information to understand the data in recount2 and a compendium of r code to use the data.", "the recount2 resource is composed of over 70 000 uniformly processed human rna seq samples spanning tcga and sra including gtex the processed data can be accessed via the recount2 website and the bioconductor package this workflow explains in detail how to use the package and how to integrate it with other bioconductor packages for several analyses that can be carried out with the recount2 resource in particular we describe how the coverage count matrices were computed in recount2 as well as different ways of obtaining public metadata which can facilitate downstream analyses step by step directions show how to do a gene level differential expression analysis visualize base level genome coverage data and perform an analyses at multiple feature levels this workflow thus provides further information to understand the data in recount2 and a compendium of r code to use the data.", "the recount2 resource is composed of over 70 000 uniformly processed human rna seq samples spanning tcga and sra including gtex the processed data can be accessed via the recount2 website and the bioconductor package this workflow explains in detail how to use the package and how to integrate it with other bioconductor packages for several analyses that can be carried out with the recount2 resource in particular we describe how the coverage count matrices were computed in recount2 as well as different ways of obtaining public metadata which can facilitate downstream analyses step by step directions show how to do a gene level differential expression analysis visualize base level genome coverage data and perform an analyses at multiple feature levels this workflow thus provides further information to understand the data in recount2 and a compendium of r code to use the data.", "the recount2 resource is composed of over 70 000 uniformly processed human rna seq samples spanning tcga and sra including gtex the processed data can be accessed via the recount2 website and the bioconductor package this workflow explains in detail how to use the package and how to integrate it with other bioconductor packages for several analyses that can be carried out with the recount2 resource in particular we describe how the coverage count matrices were computed in recount2 as well as different ways of obtaining public metadata which can facilitate downstream analyses step by step directions show how to do a gene level differential expression analysis visualize base level genome coverage data and perform an analyses at multiple feature levels this workflow thus provides further information to understand the data in recount2 and a compendium of r code to use the data.", "the recount2 resource is composed of over 70 000 uniformly processed human rna seq samples spanning tcga and sra including gtex the processed data can be accessed via the recount2 website and the bioconductor package this workflow explains in detail how to use the package and how to integrate it with other bioconductor packages for several analyses that can be carried out with the recount2 resource in particular we describe how the coverage count matrices were computed in recount2 as well as different ways of obtaining public metadata which can facilitate downstream analyses step by step directions show how to do a gene level differential expression analysis visualize base level genome coverage data and perform an analyses at multiple feature levels this workflow thus provides further information to understand the data in recount2 and a compendium of r code to use the data.", "the recount2 resource is composed of over 70 000 uniformly processed human rna seq samples spanning tcga and sra including gtex the processed data can be accessed via the recount2 website and the bioconductor package this workflow explains in detail how to use the package and how to integrate it with other bioconductor packages for several analyses that can be carried out with the recount2 resource in particular we describe how the coverage count matrices were computed in recount2 as well as different ways of obtaining public metadata which can facilitate downstream analyses step by step directions show how to do a gene level differential expression analysis visualize base level genome coverage data and perform an analyses at multiple feature levels this workflow thus provides further information to understand the data in recount2 and a compendium of r code to use the data.", "the recount2 resource is composed of over 70 000 uniformly processed human rna seq samples spanning tcga and sra including gtex the processed data can be accessed via the recount2 website and the bioconductor package this workflow explains in detail how to use the package and how to integrate it with other bioconductor packages for several analyses that can be carried out with the recount2 resource in particular we describe how the coverage count matrices were computed in recount2 as well as different ways of obtaining public metadata which can facilitate downstream analyses step by step directions show how to do a gene level differential expression analysis visualize base level genome coverage data and perform an analyses at multiple feature levels this workflow thus provides further information to understand the data in recount2 and a compendium of r code to use the data.", "the recount2 resource is composed of over 70 000 uniformly processed human rna seq samples spanning tcga and sra including gtex the processed data can be accessed via the recount2 website and the bioconductor package this workflow explains in detail how to use the package and how to integrate it with other bioconductor packages for several analyses that can be carried out with the recount2 resource in particular we describe how the coverage count matrices were computed in recount2 as well as different ways of obtaining public metadata which can facilitate downstream analyses step by step directions show how to do a gene level differential expression analysis visualize base level genome coverage data and perform an analyses at multiple feature levels this workflow thus provides further information to understand the data in recount2 and a compendium of r code to use the data.", "the recount2 resource is composed of over 70 000 uniformly processed human rna seq samples spanning tcga and sra including gtex the processed data can be accessed via the recount2 website and the bioconductor package this workflow explains in detail how to use the package and how to integrate it with other bioconductor packages for several analyses that can be carried out with the recount2 resource in particular we describe how the coverage count matrices were computed in recount2 as well as different ways of obtaining public metadata which can facilitate downstream analyses step by step directions show how to do a gene level differential expression analysis visualize base level genome coverage data and perform an analyses at multiple feature levels this workflow thus provides further information to understand the data in recount2 and a compendium of r code to use the data.", "the recount2 resource is composed of over 70 000 uniformly processed human rna seq samples spanning tcga and sra including gtex the processed data can be accessed via the recount2 website and the bioconductor package this workflow explains in detail how to use the package and how to integrate it with other bioconductor packages for several analyses that can be carried out with the recount2 resource in particular we describe how the coverage count matrices were computed in recount2 as well as different ways of obtaining public metadata which can facilitate downstream analyses step by step directions show how to do a gene level differential expression analysis visualize base level genome coverage data and perform an analyses at multiple feature levels this workflow thus provides further information to understand the data in recount2 and a compendium of r code to use the data.", "the recount2 resource is composed of over 70 000 uniformly processed human rna seq samples spanning tcga and sra including gtex the processed data can be accessed via the recount2 website and the bioconductor package this workflow explains in detail how to use the package and how to integrate it with other bioconductor packages for several analyses that can be carried out with the recount2 resource in particular we describe how the coverage count matrices were computed in recount2 as well as different ways of obtaining public metadata which can facilitate downstream analyses step by step directions show how to do a gene level differential expression analysis visualize base level genome coverage data and perform an analyses at multiple feature levels this workflow thus provides further information to understand the data in recount2 and a compendium of r code to use the data.", "the recount2 resource is composed of over 70 000 uniformly processed human rna seq samples spanning tcga and sra including gtex the processed data can be accessed via the recount2 website and the bioconductor package this workflow explains in detail how to use the package and how to integrate it with other bioconductor packages for several analyses that can be carried out with the recount2 resource in particular we describe how the coverage count matrices were computed in recount2 as well as different ways of obtaining public metadata which can facilitate downstream analyses step by step directions show how to do a gene level differential expression analysis visualize base level genome coverage data and perform an analyses at multiple feature levels this workflow thus provides further information to understand the data in recount2 and a compendium of r code to use the data.", "the recount2 resource is composed of over 70 000 uniformly processed human rna seq samples spanning tcga and sra including gtex the processed data can be accessed via the recount2 website and the bioconductor package this workflow explains in detail how to use the package and how to integrate it with other bioconductor packages for several analyses that can be carried out with the recount2 resource in particular we describe how the coverage count matrices were computed in recount2 as well as different ways of obtaining public metadata which can facilitate downstream analyses step by step directions show how to do a gene level differential expression analysis visualize base level genome coverage data and perform an analyses at multiple feature levels this workflow thus provides further information to understand the data in recount2 and a compendium of r code to use the data.", "the recount2 resource is composed of over 70 000 uniformly processed human rna seq samples spanning tcga and sra including gtex the processed data can be accessed via the recount2 website and the bioconductor package this workflow explains in detail how to use the package and how to integrate it with other bioconductor packages for several analyses that can be carried out with the recount2 resource in particular we describe how the coverage count matrices were computed in recount2 as well as different ways of obtaining public metadata which can facilitate downstream analyses step by step directions show how to do a gene level differential expression analysis visualize base level genome coverage data and perform an analyses at multiple feature levels this workflow thus provides further information to understand the data in recount2 and a compendium of r code to use the data.", "the recount2 resource is composed of over 70,000 uniformly processed human rna-seq samples spanning tcga and sra, including gtex.", "the recount2 resource is composed of over 70,000 uniformly processed human rna-seq samples spanning tcga and sra, including gtex.", "the recount2 resource is composed of over 70,000 uniformly processed human rna-seq samples spanning tcga and sra, including gtex.", "the recount2 resource is composed of over 70,000 uniformly processed human rna-seq samples spanning tcga and sra, including gtex.", "the recount2 resource is composed of over 70,000 uniformly processed human rna-seq samples spanning tcga and sra, including gtex.", "the recount2 resource is composed of over 70,000 uniformly processed human rna-seq samples spanning tcga and sra, including gtex.", "the recount2 resource is composed of over 70,000 uniformly processed human rna-seq samples spanning tcga and sra, including gtex.", "the recount2 resource is composed of over 70,000 uniformly processed human rna-seq samples spanning tcga and sra, including gtex.", "the recount2 resource is composed of over 70,000 uniformly processed human rna-seq samples spanning tcga and sra, including gtex.", "the recount2 resource is composed of over 70,000 uniformly processed human rna-seq samples spanning tcga and sra, including gtex.", "the recount2 resource is composed of over 70,000 uniformly processed human rna-seq samples spanning tcga and sra, including gtex.", "the recount2 resource is composed of over 70,000 uniformly processed human rna-seq samples spanning tcga and sra, including gtex.", "the recount2 resource is composed of over 70,000 uniformly processed human rna-seq samples spanning tcga and sra, including gtex.", "the recount2 resource is composed of over 70,000 uniformly processed human rna-seq samples spanning tcga and sra, including gtex.", "the recount2 resource is composed of over 70,000 uniformly processed human rna-seq samples spanning tcga and sra, including gtex.", "the recount2 resource is composed of over 70,000 uniformly processed human rna-seq samples spanning tcga and sra, including gtex.", "the recount2 resource is composed of over 70,000 uniformly processed human rna-seq samples spanning tcga and sra, including gtex.", "the recount2 resource is composed of over 70,000 uniformly processed human rna-seq samples spanning tcga and sra, including gtex.", "the recount2 resource is composed of over 70,000 uniformly processed human rna-seq samples spanning tcga and sra, including gtex.", "the recount2 resource is composed of over 70,000 uniformly processed human rna-seq samples spanning tcga and sra, including gtex.", "the recount2 resource is composed of over 70,000 uniformly processed human rna-seq samples spanning tcga and sra, including gtex.", "the recount2 resource is composed of over 70,000 uniformly processed human rna-seq samples spanning tcga and sra, including gtex.", "the recount2 resource is composed of over 70,000 uniformly processed human rna-seq samples spanning tcga and sra, including gtex.", "the recount2 resource is composed of over 70,000 uniformly processed human rna-seq samples spanning tcga and sra, including gtex.", "the recount2 resource is composed of over 70,000 uniformly processed human rna-seq samples spanning tcga and sra, including gtex.", "the recount2 resource is composed of over 70,000 uniformly processed human rna-seq samples spanning tcga and sra, including gtex.", "the recount2 resource is composed of over 70,000 uniformly processed human rna-seq samples spanning tcga and sra, including gtex.", "the recount2 resource is composed of over 70,000 uniformly processed human rna-seq samples spanning tcga and sra, including gtex.", "the recount2 resource is composed of over 70,000 uniformly processed human rna-seq samples spanning tcga and sra, including gtex.", "the recount2 resource is composed of over 70,000 uniformly processed human rna-seq samples spanning tcga and sra, including gtex.", "the recount2 resource is composed of over 70,000 uniformly processed human rna-seq samples spanning tcga and sra, including gtex.", "the recount2 resource is composed of over 70,000 uniformly processed human rna-seq samples spanning tcga and sra, including gtex.", "the recount2 resource is composed of over 70,000 uniformly processed human rna-seq samples spanning tcga and sra, including gtex.", "the recount2 resource is composed of over 70,000 uniformly processed human rna-seq samples spanning tcga and sra, including gtex.", "the recount2 resource is composed of over 70,000 uniformly processed human rna-seq samples spanning tcga and sra, including gtex.", "the recount2 resource is composed of over 70,000 uniformly processed human rna-seq samples spanning tcga and sra, including gtex.", "the recount2 resource is composed of over 70,000 uniformly processed human rna-seq samples spanning tcga and sra, including gtex.", "the recount2 resource is composed of over 70,000 uniformly processed human rna-seq samples spanning tcga and sra, including gtex.", "the recount2 resource is composed of over 70,000 uniformly processed human rna-seq samples spanning tcga and sra, including gtex.", "the recount2 resource is composed of over 70,000 uniformly processed human rna-seq samples spanning tcga and sra, including gtex.", "the recount2 resource is composed of over 70,000 uniformly processed human rna-seq samples spanning tcga and sra, including gtex.", "the recount2 resource is composed of over 70,000 uniformly processed human rna-seq samples spanning tcga and sra, including gtex.", "the recount2 resource is composed of over 70,000 uniformly processed human rna-seq samples spanning tcga and sra, including gtex.", "the recount2 resource is composed of over 70,000 uniformly processed human rna-seq samples spanning tcga and sra, including gtex.", "we recently used in situ hi c to create kilobase resolution 3d maps of mammalian genomes here we combine these maps with new hi c microscopy and genome editing experiments to study the physical structure of chromatin fibers domains and loops we find that the observed contact domains are inconsistent with the equilibrium state for an ordinary condensed polymer combining hi c data and novel mathematical theorems we show that contact domains are also not consistent with a fractal globule instead we use physical simulations to study two models of genome folding in one intermonomer attraction during polymer condensation leads to formation of an anisotropic tension globule in the other ccctc binding factor ctcf and cohesin act together to extrude unknotted loops during interphase both models are consistent with the observed contact domains and with the observation that contact domains tend to form inside loops however the extrusion model explains a far wider array of observations such as why loops tend not to overlap and why the ctcf binding motifs at pairs of loop anchors lie in the convergent orientation finally we perform 13 genome editing experiments examining the effect of altering ctcf binding sites on chromatin folding the convergent rule correctly predicts the affected loops in every case moreover the extrusion model accurately predicts in silico the 3d maps resulting from each experiment using only the location of ctcf binding sites in the wt thus we show that it is possible to disrupt restore and move loops and domains using targeted mutations as small as a single base pair.", "we recently used in situ hi c to create kilobase resolution 3d maps of mammalian genomes here we combine these maps with new hi c microscopy and genome editing experiments to study the physical structure of chromatin fibers domains and loops we find that the observed contact domains are inconsistent with the equilibrium state for an ordinary condensed polymer combining hi c data and novel mathematical theorems we show that contact domains are also not consistent with a fractal globule instead we use physical simulations to study two models of genome folding in one intermonomer attraction during polymer condensation leads to formation of an anisotropic tension globule in the other ccctc binding factor ctcf and cohesin act together to extrude unknotted loops during interphase both models are consistent with the observed contact domains and with the observation that contact domains tend to form inside loops however the extrusion model explains a far wider array of observations such as why loops tend not to overlap and why the ctcf binding motifs at pairs of loop anchors lie in the convergent orientation finally we perform 13 genome editing experiments examining the effect of altering ctcf binding sites on chromatin folding the convergent rule correctly predicts the affected loops in every case moreover the extrusion model accurately predicts in silico the 3d maps resulting from each experiment using only the location of ctcf binding sites in the wt thus we show that it is possible to disrupt restore and move loops and domains using targeted mutations as small as a single base pair.", "we recently used in situ hi c to create kilobase resolution 3d maps of mammalian genomes here we combine these maps with new hi c microscopy and genome editing experiments to study the physical structure of chromatin fibers domains and loops we find that the observed contact domains are inconsistent with the equilibrium state for an ordinary condensed polymer combining hi c data and novel mathematical theorems we show that contact domains are also not consistent with a fractal globule instead we use physical simulations to study two models of genome folding in one intermonomer attraction during polymer condensation leads to formation of an anisotropic tension globule in the other ccctc binding factor ctcf and cohesin act together to extrude unknotted loops during interphase both models are consistent with the observed contact domains and with the observation that contact domains tend to form inside loops however the extrusion model explains a far wider array of observations such as why loops tend not to overlap and why the ctcf binding motifs at pairs of loop anchors lie in the convergent orientation finally we perform 13 genome editing experiments examining the effect of altering ctcf binding sites on chromatin folding the convergent rule correctly predicts the affected loops in every case moreover the extrusion model accurately predicts in silico the 3d maps resulting from each experiment using only the location of ctcf binding sites in the wt thus we show that it is possible to disrupt restore and move loops and domains using targeted mutations as small as a single base pair.", "we recently used in situ hi c to create kilobase resolution 3d maps of mammalian genomes here we combine these maps with new hi c microscopy and genome editing experiments to study the physical structure of chromatin fibers domains and loops we find that the observed contact domains are inconsistent with the equilibrium state for an ordinary condensed polymer combining hi c data and novel mathematical theorems we show that contact domains are also not consistent with a fractal globule instead we use physical simulations to study two models of genome folding in one intermonomer attraction during polymer condensation leads to formation of an anisotropic tension globule in the other ccctc binding factor ctcf and cohesin act together to extrude unknotted loops during interphase both models are consistent with the observed contact domains and with the observation that contact domains tend to form inside loops however the extrusion model explains a far wider array of observations such as why loops tend not to overlap and why the ctcf binding motifs at pairs of loop anchors lie in the convergent orientation finally we perform 13 genome editing experiments examining the effect of altering ctcf binding sites on chromatin folding the convergent rule correctly predicts the affected loops in every case moreover the extrusion model accurately predicts in silico the 3d maps resulting from each experiment using only the location of ctcf binding sites in the wt thus we show that it is possible to disrupt restore and move loops and domains using targeted mutations as small as a single base pair.", "we recently used in situ hi c to create kilobase resolution 3d maps of mammalian genomes here we combine these maps with new hi c microscopy and genome editing experiments to study the physical structure of chromatin fibers domains and loops we find that the observed contact domains are inconsistent with the equilibrium state for an ordinary condensed polymer combining hi c data and novel mathematical theorems we show that contact domains are also not consistent with a fractal globule instead we use physical simulations to study two models of genome folding in one intermonomer attraction during polymer condensation leads to formation of an anisotropic tension globule in the other ccctc binding factor ctcf and cohesin act together to extrude unknotted loops during interphase both models are consistent with the observed contact domains and with the observation that contact domains tend to form inside loops however the extrusion model explains a far wider array of observations such as why loops tend not to overlap and why the ctcf binding motifs at pairs of loop anchors lie in the convergent orientation finally we perform 13 genome editing experiments examining the effect of altering ctcf binding sites on chromatin folding the convergent rule correctly predicts the affected loops in every case moreover the extrusion model accurately predicts in silico the 3d maps resulting from each experiment using only the location of ctcf binding sites in the wt thus we show that it is possible to disrupt restore and move loops and domains using targeted mutations as small as a single base pair.", "we recently used in situ hi c to create kilobase resolution 3d maps of mammalian genomes here we combine these maps with new hi c microscopy and genome editing experiments to study the physical structure of chromatin fibers domains and loops we find that the observed contact domains are inconsistent with the equilibrium state for an ordinary condensed polymer combining hi c data and novel mathematical theorems we show that contact domains are also not consistent with a fractal globule instead we use physical simulations to study two models of genome folding in one intermonomer attraction during polymer condensation leads to formation of an anisotropic tension globule in the other ccctc binding factor ctcf and cohesin act together to extrude unknotted loops during interphase both models are consistent with the observed contact domains and with the observation that contact domains tend to form inside loops however the extrusion model explains a far wider array of observations such as why loops tend not to overlap and why the ctcf binding motifs at pairs of loop anchors lie in the convergent orientation finally we perform 13 genome editing experiments examining the effect of altering ctcf binding sites on chromatin folding the convergent rule correctly predicts the affected loops in every case moreover the extrusion model accurately predicts in silico the 3d maps resulting from each experiment using only the location of ctcf binding sites in the wt thus we show that it is possible to disrupt restore and move loops and domains using targeted mutations as small as a single base pair.", "we recently used in situ hi c to create kilobase resolution 3d maps of mammalian genomes here we combine these maps with new hi c microscopy and genome editing experiments to study the physical structure of chromatin fibers domains and loops we find that the observed contact domains are inconsistent with the equilibrium state for an ordinary condensed polymer combining hi c data and novel mathematical theorems we show that contact domains are also not consistent with a fractal globule instead we use physical simulations to study two models of genome folding in one intermonomer attraction during polymer condensation leads to formation of an anisotropic tension globule in the other ccctc binding factor ctcf and cohesin act together to extrude unknotted loops during interphase both models are consistent with the observed contact domains and with the observation that contact domains tend to form inside loops however the extrusion model explains a far wider array of observations such as why loops tend not to overlap and why the ctcf binding motifs at pairs of loop anchors lie in the convergent orientation finally we perform 13 genome editing experiments examining the effect of altering ctcf binding sites on chromatin folding the convergent rule correctly predicts the affected loops in every case moreover the extrusion model accurately predicts in silico the 3d maps resulting from each experiment using only the location of ctcf binding sites in the wt thus we show that it is possible to disrupt restore and move loops and domains using targeted mutations as small as a single base pair.", "we recently used in situ hi c to create kilobase resolution 3d maps of mammalian genomes here we combine these maps with new hi c microscopy and genome editing experiments to study the physical structure of chromatin fibers domains and loops we find that the observed contact domains are inconsistent with the equilibrium state for an ordinary condensed polymer combining hi c data and novel mathematical theorems we show that contact domains are also not consistent with a fractal globule instead we use physical simulations to study two models of genome folding in one intermonomer attraction during polymer condensation leads to formation of an anisotropic tension globule in the other ccctc binding factor ctcf and cohesin act together to extrude unknotted loops during interphase both models are consistent with the observed contact domains and with the observation that contact domains tend to form inside loops however the extrusion model explains a far wider array of observations such as why loops tend not to overlap and why the ctcf binding motifs at pairs of loop anchors lie in the convergent orientation finally we perform 13 genome editing experiments examining the effect of altering ctcf binding sites on chromatin folding the convergent rule correctly predicts the affected loops in every case moreover the extrusion model accurately predicts in silico the 3d maps resulting from each experiment using only the location of ctcf binding sites in the wt thus we show that it is possible to disrupt restore and move loops and domains using targeted mutations as small as a single base pair.", "we recently used in situ hi c to create kilobase resolution 3d maps of mammalian genomes here we combine these maps with new hi c microscopy and genome editing experiments to study the physical structure of chromatin fibers domains and loops we find that the observed contact domains are inconsistent with the equilibrium state for an ordinary condensed polymer combining hi c data and novel mathematical theorems we show that contact domains are also not consistent with a fractal globule instead we use physical simulations to study two models of genome folding in one intermonomer attraction during polymer condensation leads to formation of an anisotropic tension globule in the other ccctc binding factor ctcf and cohesin act together to extrude unknotted loops during interphase both models are consistent with the observed contact domains and with the observation that contact domains tend to form inside loops however the extrusion model explains a far wider array of observations such as why loops tend not to overlap and why the ctcf binding motifs at pairs of loop anchors lie in the convergent orientation finally we perform 13 genome editing experiments examining the effect of altering ctcf binding sites on chromatin folding the convergent rule correctly predicts the affected loops in every case moreover the extrusion model accurately predicts in silico the 3d maps resulting from each experiment using only the location of ctcf binding sites in the wt thus we show that it is possible to disrupt restore and move loops and domains using targeted mutations as small as a single base pair.", "we recently used in situ hi c to create kilobase resolution 3d maps of mammalian genomes here we combine these maps with new hi c microscopy and genome editing experiments to study the physical structure of chromatin fibers domains and loops we find that the observed contact domains are inconsistent with the equilibrium state for an ordinary condensed polymer combining hi c data and novel mathematical theorems we show that contact domains are also not consistent with a fractal globule instead we use physical simulations to study two models of genome folding in one intermonomer attraction during polymer condensation leads to formation of an anisotropic tension globule in the other ccctc binding factor ctcf and cohesin act together to extrude unknotted loops during interphase both models are consistent with the observed contact domains and with the observation that contact domains tend to form inside loops however the extrusion model explains a far wider array of observations such as why loops tend not to overlap and why the ctcf binding motifs at pairs of loop anchors lie in the convergent orientation finally we perform 13 genome editing experiments examining the effect of altering ctcf binding sites on chromatin folding the convergent rule correctly predicts the affected loops in every case moreover the extrusion model accurately predicts in silico the 3d maps resulting from each experiment using only the location of ctcf binding sites in the wt thus we show that it is possible to disrupt restore and move loops and domains using targeted mutations as small as a single base pair.", "we recently used in situ hi c to create kilobase resolution 3d maps of mammalian genomes here we combine these maps with new hi c microscopy and genome editing experiments to study the physical structure of chromatin fibers domains and loops we find that the observed contact domains are inconsistent with the equilibrium state for an ordinary condensed polymer combining hi c data and novel mathematical theorems we show that contact domains are also not consistent with a fractal globule instead we use physical simulations to study two models of genome folding in one intermonomer attraction during polymer condensation leads to formation of an anisotropic tension globule in the other ccctc binding factor ctcf and cohesin act together to extrude unknotted loops during interphase both models are consistent with the observed contact domains and with the observation that contact domains tend to form inside loops however the extrusion model explains a far wider array of observations such as why loops tend not to overlap and why the ctcf binding motifs at pairs of loop anchors lie in the convergent orientation finally we perform 13 genome editing experiments examining the effect of altering ctcf binding sites on chromatin folding the convergent rule correctly predicts the affected loops in every case moreover the extrusion model accurately predicts in silico the 3d maps resulting from each experiment using only the location of ctcf binding sites in the wt thus we show that it is possible to disrupt restore and move loops and domains using targeted mutations as small as a single base pair.", "we recently used in situ hi c to create kilobase resolution 3d maps of mammalian genomes here we combine these maps with new hi c microscopy and genome editing experiments to study the physical structure of chromatin fibers domains and loops we find that the observed contact domains are inconsistent with the equilibrium state for an ordinary condensed polymer combining hi c data and novel mathematical theorems we show that contact domains are also not consistent with a fractal globule instead we use physical simulations to study two models of genome folding in one intermonomer attraction during polymer condensation leads to formation of an anisotropic tension globule in the other ccctc binding factor ctcf and cohesin act together to extrude unknotted loops during interphase both models are consistent with the observed contact domains and with the observation that contact domains tend to form inside loops however the extrusion model explains a far wider array of observations such as why loops tend not to overlap and why the ctcf binding motifs at pairs of loop anchors lie in the convergent orientation finally we perform 13 genome editing experiments examining the effect of altering ctcf binding sites on chromatin folding the convergent rule correctly predicts the affected loops in every case moreover the extrusion model accurately predicts in silico the 3d maps resulting from each experiment using only the location of ctcf binding sites in the wt thus we show that it is possible to disrupt restore and move loops and domains using targeted mutations as small as a single base pair.", "we recently used in situ hi c to create kilobase resolution 3d maps of mammalian genomes here we combine these maps with new hi c microscopy and genome editing experiments to study the physical structure of chromatin fibers domains and loops we find that the observed contact domains are inconsistent with the equilibrium state for an ordinary condensed polymer combining hi c data and novel mathematical theorems we show that contact domains are also not consistent with a fractal globule instead we use physical simulations to study two models of genome folding in one intermonomer attraction during polymer condensation leads to formation of an anisotropic tension globule in the other ccctc binding factor ctcf and cohesin act together to extrude unknotted loops during interphase both models are consistent with the observed contact domains and with the observation that contact domains tend to form inside loops however the extrusion model explains a far wider array of observations such as why loops tend not to overlap and why the ctcf binding motifs at pairs of loop anchors lie in the convergent orientation finally we perform 13 genome editing experiments examining the effect of altering ctcf binding sites on chromatin folding the convergent rule correctly predicts the affected loops in every case moreover the extrusion model accurately predicts in silico the 3d maps resulting from each experiment using only the location of ctcf binding sites in the wt thus we show that it is possible to disrupt restore and move loops and domains using targeted mutations as small as a single base pair.", "we recently used in situ hi c to create kilobase resolution 3d maps of mammalian genomes here we combine these maps with new hi c microscopy and genome editing experiments to study the physical structure of chromatin fibers domains and loops we find that the observed contact domains are inconsistent with the equilibrium state for an ordinary condensed polymer combining hi c data and novel mathematical theorems we show that contact domains are also not consistent with a fractal globule instead we use physical simulations to study two models of genome folding in one intermonomer attraction during polymer condensation leads to formation of an anisotropic tension globule in the other ccctc binding factor ctcf and cohesin act together to extrude unknotted loops during interphase both models are consistent with the observed contact domains and with the observation that contact domains tend to form inside loops however the extrusion model explains a far wider array of observations such as why loops tend not to overlap and why the ctcf binding motifs at pairs of loop anchors lie in the convergent orientation finally we perform 13 genome editing experiments examining the effect of altering ctcf binding sites on chromatin folding the convergent rule correctly predicts the affected loops in every case moreover the extrusion model accurately predicts in silico the 3d maps resulting from each experiment using only the location of ctcf binding sites in the wt thus we show that it is possible to disrupt restore and move loops and domains using targeted mutations as small as a single base pair.", "we recently used in situ hi c to create kilobase resolution 3d maps of mammalian genomes here we combine these maps with new hi c microscopy and genome editing experiments to study the physical structure of chromatin fibers domains and loops we find that the observed contact domains are inconsistent with the equilibrium state for an ordinary condensed polymer combining hi c data and novel mathematical theorems we show that contact domains are also not consistent with a fractal globule instead we use physical simulations to study two models of genome folding in one intermonomer attraction during polymer condensation leads to formation of an anisotropic tension globule in the other ccctc binding factor ctcf and cohesin act together to extrude unknotted loops during interphase both models are consistent with the observed contact domains and with the observation that contact domains tend to form inside loops however the extrusion model explains a far wider array of observations such as why loops tend not to overlap and why the ctcf binding motifs at pairs of loop anchors lie in the convergent orientation finally we perform 13 genome editing experiments examining the effect of altering ctcf binding sites on chromatin folding the convergent rule correctly predicts the affected loops in every case moreover the extrusion model accurately predicts in silico the 3d maps resulting from each experiment using only the location of ctcf binding sites in the wt thus we show that it is possible to disrupt restore and move loops and domains using targeted mutations as small as a single base pair.", "we recently used in situ hi c to create kilobase resolution 3d maps of mammalian genomes here we combine these maps with new hi c microscopy and genome editing experiments to study the physical structure of chromatin fibers domains and loops we find that the observed contact domains are inconsistent with the equilibrium state for an ordinary condensed polymer combining hi c data and novel mathematical theorems we show that contact domains are also not consistent with a fractal globule instead we use physical simulations to study two models of genome folding in one intermonomer attraction during polymer condensation leads to formation of an anisotropic tension globule in the other ccctc binding factor ctcf and cohesin act together to extrude unknotted loops during interphase both models are consistent with the observed contact domains and with the observation that contact domains tend to form inside loops however the extrusion model explains a far wider array of observations such as why loops tend not to overlap and why the ctcf binding motifs at pairs of loop anchors lie in the convergent orientation finally we perform 13 genome editing experiments examining the effect of altering ctcf binding sites on chromatin folding the convergent rule correctly predicts the affected loops in every case moreover the extrusion model accurately predicts in silico the 3d maps resulting from each experiment using only the location of ctcf binding sites in the wt thus we show that it is possible to disrupt restore and move loops and domains using targeted mutations as small as a single base pair.", "we recently used in situ hi c to create kilobase resolution 3d maps of mammalian genomes here we combine these maps with new hi c microscopy and genome editing experiments to study the physical structure of chromatin fibers domains and loops we find that the observed contact domains are inconsistent with the equilibrium state for an ordinary condensed polymer combining hi c data and novel mathematical theorems we show that contact domains are also not consistent with a fractal globule instead we use physical simulations to study two models of genome folding in one intermonomer attraction during polymer condensation leads to formation of an anisotropic tension globule in the other ccctc binding factor ctcf and cohesin act together to extrude unknotted loops during interphase both models are consistent with the observed contact domains and with the observation that contact domains tend to form inside loops however the extrusion model explains a far wider array of observations such as why loops tend not to overlap and why the ctcf binding motifs at pairs of loop anchors lie in the convergent orientation finally we perform 13 genome editing experiments examining the effect of altering ctcf binding sites on chromatin folding the convergent rule correctly predicts the affected loops in every case moreover the extrusion model accurately predicts in silico the 3d maps resulting from each experiment using only the location of ctcf binding sites in the wt thus we show that it is possible to disrupt restore and move loops and domains using targeted mutations as small as a single base pair.", "we recently used in situ hi c to create kilobase resolution 3d maps of mammalian genomes here we combine these maps with new hi c microscopy and genome editing experiments to study the physical structure of chromatin fibers domains and loops we find that the observed contact domains are inconsistent with the equilibrium state for an ordinary condensed polymer combining hi c data and novel mathematical theorems we show that contact domains are also not consistent with a fractal globule instead we use physical simulations to study two models of genome folding in one intermonomer attraction during polymer condensation leads to formation of an anisotropic tension globule in the other ccctc binding factor ctcf and cohesin act together to extrude unknotted loops during interphase both models are consistent with the observed contact domains and with the observation that contact domains tend to form inside loops however the extrusion model explains a far wider array of observations such as why loops tend not to overlap and why the ctcf binding motifs at pairs of loop anchors lie in the convergent orientation finally we perform 13 genome editing experiments examining the effect of altering ctcf binding sites on chromatin folding the convergent rule correctly predicts the affected loops in every case moreover the extrusion model accurately predicts in silico the 3d maps resulting from each experiment using only the location of ctcf binding sites in the wt thus we show that it is possible to disrupt restore and move loops and domains using targeted mutations as small as a single base pair.", "we recently used in situ hi c to create kilobase resolution 3d maps of mammalian genomes here we combine these maps with new hi c microscopy and genome editing experiments to study the physical structure of chromatin fibers domains and loops we find that the observed contact domains are inconsistent with the equilibrium state for an ordinary condensed polymer combining hi c data and novel mathematical theorems we show that contact domains are also not consistent with a fractal globule instead we use physical simulations to study two models of genome folding in one intermonomer attraction during polymer condensation leads to formation of an anisotropic tension globule in the other ccctc binding factor ctcf and cohesin act together to extrude unknotted loops during interphase both models are consistent with the observed contact domains and with the observation that contact domains tend to form inside loops however the extrusion model explains a far wider array of observations such as why loops tend not to overlap and why the ctcf binding motifs at pairs of loop anchors lie in the convergent orientation finally we perform 13 genome editing experiments examining the effect of altering ctcf binding sites on chromatin folding the convergent rule correctly predicts the affected loops in every case moreover the extrusion model accurately predicts in silico the 3d maps resulting from each experiment using only the location of ctcf binding sites in the wt thus we show that it is possible to disrupt restore and move loops and domains using targeted mutations as small as a single base pair.", "we recently used in situ hi c to create kilobase resolution 3d maps of mammalian genomes here we combine these maps with new hi c microscopy and genome editing experiments to study the physical structure of chromatin fibers domains and loops we find that the observed contact domains are inconsistent with the equilibrium state for an ordinary condensed polymer combining hi c data and novel mathematical theorems we show that contact domains are also not consistent with a fractal globule instead we use physical simulations to study two models of genome folding in one intermonomer attraction during polymer condensation leads to formation of an anisotropic tension globule in the other ccctc binding factor ctcf and cohesin act together to extrude unknotted loops during interphase both models are consistent with the observed contact domains and with the observation that contact domains tend to form inside loops however the extrusion model explains a far wider array of observations such as why loops tend not to overlap and why the ctcf binding motifs at pairs of loop anchors lie in the convergent orientation finally we perform 13 genome editing experiments examining the effect of altering ctcf binding sites on chromatin folding the convergent rule correctly predicts the affected loops in every case moreover the extrusion model accurately predicts in silico the 3d maps resulting from each experiment using only the location of ctcf binding sites in the wt thus we show that it is possible to disrupt restore and move loops and domains using targeted mutations as small as a single base pair.", "we recently used in situ hi c to create kilobase resolution 3d maps of mammalian genomes here we combine these maps with new hi c microscopy and genome editing experiments to study the physical structure of chromatin fibers domains and loops we find that the observed contact domains are inconsistent with the equilibrium state for an ordinary condensed polymer combining hi c data and novel mathematical theorems we show that contact domains are also not consistent with a fractal globule instead we use physical simulations to study two models of genome folding in one intermonomer attraction during polymer condensation leads to formation of an anisotropic tension globule in the other ccctc binding factor ctcf and cohesin act together to extrude unknotted loops during interphase both models are consistent with the observed contact domains and with the observation that contact domains tend to form inside loops however the extrusion model explains a far wider array of observations such as why loops tend not to overlap and why the ctcf binding motifs at pairs of loop anchors lie in the convergent orientation finally we perform 13 genome editing experiments examining the effect of altering ctcf binding sites on chromatin folding the convergent rule correctly predicts the affected loops in every case moreover the extrusion model accurately predicts in silico the 3d maps resulting from each experiment using only the location of ctcf binding sites in the wt thus we show that it is possible to disrupt restore and move loops and domains using targeted mutations as small as a single base pair.", "we recently used in situ hi c to create kilobase resolution 3d maps of mammalian genomes here we combine these maps with new hi c microscopy and genome editing experiments to study the physical structure of chromatin fibers domains and loops we find that the observed contact domains are inconsistent with the equilibrium state for an ordinary condensed polymer combining hi c data and novel mathematical theorems we show that contact domains are also not consistent with a fractal globule instead we use physical simulations to study two models of genome folding in one intermonomer attraction during polymer condensation leads to formation of an anisotropic tension globule in the other ccctc binding factor ctcf and cohesin act together to extrude unknotted loops during interphase both models are consistent with the observed contact domains and with the observation that contact domains tend to form inside loops however the extrusion model explains a far wider array of observations such as why loops tend not to overlap and why the ctcf binding motifs at pairs of loop anchors lie in the convergent orientation finally we perform 13 genome editing experiments examining the effect of altering ctcf binding sites on chromatin folding the convergent rule correctly predicts the affected loops in every case moreover the extrusion model accurately predicts in silico the 3d maps resulting from each experiment using only the location of ctcf binding sites in the wt thus we show that it is possible to disrupt restore and move loops and domains using targeted mutations as small as a single base pair.", "we recently used in situ hi c to create kilobase resolution 3d maps of mammalian genomes here we combine these maps with new hi c microscopy and genome editing experiments to study the physical structure of chromatin fibers domains and loops we find that the observed contact domains are inconsistent with the equilibrium state for an ordinary condensed polymer combining hi c data and novel mathematical theorems we show that contact domains are also not consistent with a fractal globule instead we use physical simulations to study two models of genome folding in one intermonomer attraction during polymer condensation leads to formation of an anisotropic tension globule in the other ccctc binding factor ctcf and cohesin act together to extrude unknotted loops during interphase both models are consistent with the observed contact domains and with the observation that contact domains tend to form inside loops however the extrusion model explains a far wider array of observations such as why loops tend not to overlap and why the ctcf binding motifs at pairs of loop anchors lie in the convergent orientation finally we perform 13 genome editing experiments examining the effect of altering ctcf binding sites on chromatin folding the convergent rule correctly predicts the affected loops in every case moreover the extrusion model accurately predicts in silico the 3d maps resulting from each experiment using only the location of ctcf binding sites in the wt thus we show that it is possible to disrupt restore and move loops and domains using targeted mutations as small as a single base pair.", "we recently used in situ hi c to create kilobase resolution 3d maps of mammalian genomes here we combine these maps with new hi c microscopy and genome editing experiments to study the physical structure of chromatin fibers domains and loops we find that the observed contact domains are inconsistent with the equilibrium state for an ordinary condensed polymer combining hi c data and novel mathematical theorems we show that contact domains are also not consistent with a fractal globule instead we use physical simulations to study two models of genome folding in one intermonomer attraction during polymer condensation leads to formation of an anisotropic tension globule in the other ccctc binding factor ctcf and cohesin act together to extrude unknotted loops during interphase both models are consistent with the observed contact domains and with the observation that contact domains tend to form inside loops however the extrusion model explains a far wider array of observations such as why loops tend not to overlap and why the ctcf binding motifs at pairs of loop anchors lie in the convergent orientation finally we perform 13 genome editing experiments examining the effect of altering ctcf binding sites on chromatin folding the convergent rule correctly predicts the affected loops in every case moreover the extrusion model accurately predicts in silico the 3d maps resulting from each experiment using only the location of ctcf binding sites in the wt thus we show that it is possible to disrupt restore and move loops and domains using targeted mutations as small as a single base pair.", "we recently used in situ hi c to create kilobase resolution 3d maps of mammalian genomes here we combine these maps with new hi c microscopy and genome editing experiments to study the physical structure of chromatin fibers domains and loops we find that the observed contact domains are inconsistent with the equilibrium state for an ordinary condensed polymer combining hi c data and novel mathematical theorems we show that contact domains are also not consistent with a fractal globule instead we use physical simulations to study two models of genome folding in one intermonomer attraction during polymer condensation leads to formation of an anisotropic tension globule in the other ccctc binding factor ctcf and cohesin act together to extrude unknotted loops during interphase both models are consistent with the observed contact domains and with the observation that contact domains tend to form inside loops however the extrusion model explains a far wider array of observations such as why loops tend not to overlap and why the ctcf binding motifs at pairs of loop anchors lie in the convergent orientation finally we perform 13 genome editing experiments examining the effect of altering ctcf binding sites on chromatin folding the convergent rule correctly predicts the affected loops in every case moreover the extrusion model accurately predicts in silico the 3d maps resulting from each experiment using only the location of ctcf binding sites in the wt thus we show that it is possible to disrupt restore and move loops and domains using targeted mutations as small as a single base pair.", "we recently used in situ hi c to create kilobase resolution 3d maps of mammalian genomes here we combine these maps with new hi c microscopy and genome editing experiments to study the physical structure of chromatin fibers domains and loops we find that the observed contact domains are inconsistent with the equilibrium state for an ordinary condensed polymer combining hi c data and novel mathematical theorems we show that contact domains are also not consistent with a fractal globule instead we use physical simulations to study two models of genome folding in one intermonomer attraction during polymer condensation leads to formation of an anisotropic tension globule in the other ccctc binding factor ctcf and cohesin act together to extrude unknotted loops during interphase both models are consistent with the observed contact domains and with the observation that contact domains tend to form inside loops however the extrusion model explains a far wider array of observations such as why loops tend not to overlap and why the ctcf binding motifs at pairs of loop anchors lie in the convergent orientation finally we perform 13 genome editing experiments examining the effect of altering ctcf binding sites on chromatin folding the convergent rule correctly predicts the affected loops in every case moreover the extrusion model accurately predicts in silico the 3d maps resulting from each experiment using only the location of ctcf binding sites in the wt thus we show that it is possible to disrupt restore and move loops and domains using targeted mutations as small as a single base pair.", "we recently used in situ hi c to create kilobase resolution 3d maps of mammalian genomes here we combine these maps with new hi c microscopy and genome editing experiments to study the physical structure of chromatin fibers domains and loops we find that the observed contact domains are inconsistent with the equilibrium state for an ordinary condensed polymer combining hi c data and novel mathematical theorems we show that contact domains are also not consistent with a fractal globule instead we use physical simulations to study two models of genome folding in one intermonomer attraction during polymer condensation leads to formation of an anisotropic tension globule in the other ccctc binding factor ctcf and cohesin act together to extrude unknotted loops during interphase both models are consistent with the observed contact domains and with the observation that contact domains tend to form inside loops however the extrusion model explains a far wider array of observations such as why loops tend not to overlap and why the ctcf binding motifs at pairs of loop anchors lie in the convergent orientation finally we perform 13 genome editing experiments examining the effect of altering ctcf binding sites on chromatin folding the convergent rule correctly predicts the affected loops in every case moreover the extrusion model accurately predicts in silico the 3d maps resulting from each experiment using only the location of ctcf binding sites in the wt thus we show that it is possible to disrupt restore and move loops and domains using targeted mutations as small as a single base pair.", "ccctc binding factor ctcf is an architectural protein involved in the three dimensional 3d organization of chromatin in this study we assayed the 3d genomic contact profiles of a large number of ctcf binding sites with high resolution 4c seq as recently reported our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner to directly test this we used crispr cas9 genome editing to delete core ctcf binding sites in three loci including the ctcf site in the sox2 super enhancer in all instances ctcf and cohesin recruitment were lost and chromatin loops with distal convergent ctcf sites were disrupted or destabilized re insertion of oppositely oriented ctcf recognition sequences restored ctcf and cohesin recruitment but did not re establish chromatin loops we conclude that ctcf binding polarity plays a functional role in the formation of higher order chromatin structure.", "ccctc binding factor ctcf is an architectural protein involved in the three dimensional 3d organization of chromatin in this study we assayed the 3d genomic contact profiles of a large number of ctcf binding sites with high resolution 4c seq as recently reported our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner to directly test this we used crispr cas9 genome editing to delete core ctcf binding sites in three loci including the ctcf site in the sox2 super enhancer in all instances ctcf and cohesin recruitment were lost and chromatin loops with distal convergent ctcf sites were disrupted or destabilized re insertion of oppositely oriented ctcf recognition sequences restored ctcf and cohesin recruitment but did not re establish chromatin loops we conclude that ctcf binding polarity plays a functional role in the formation of higher order chromatin structure.", "ccctc binding factor ctcf is an architectural protein involved in the three dimensional 3d organization of chromatin in this study we assayed the 3d genomic contact profiles of a large number of ctcf binding sites with high resolution 4c seq as recently reported our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner to directly test this we used crispr cas9 genome editing to delete core ctcf binding sites in three loci including the ctcf site in the sox2 super enhancer in all instances ctcf and cohesin recruitment were lost and chromatin loops with distal convergent ctcf sites were disrupted or destabilized re insertion of oppositely oriented ctcf recognition sequences restored ctcf and cohesin recruitment but did not re establish chromatin loops we conclude that ctcf binding polarity plays a functional role in the formation of higher order chromatin structure.", "ccctc binding factor ctcf is an architectural protein involved in the three dimensional 3d organization of chromatin in this study we assayed the 3d genomic contact profiles of a large number of ctcf binding sites with high resolution 4c seq as recently reported our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner to directly test this we used crispr cas9 genome editing to delete core ctcf binding sites in three loci including the ctcf site in the sox2 super enhancer in all instances ctcf and cohesin recruitment were lost and chromatin loops with distal convergent ctcf sites were disrupted or destabilized re insertion of oppositely oriented ctcf recognition sequences restored ctcf and cohesin recruitment but did not re establish chromatin loops we conclude that ctcf binding polarity plays a functional role in the formation of higher order chromatin structure.", "ccctc binding factor ctcf is an architectural protein involved in the three dimensional 3d organization of chromatin in this study we assayed the 3d genomic contact profiles of a large number of ctcf binding sites with high resolution 4c seq as recently reported our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner to directly test this we used crispr cas9 genome editing to delete core ctcf binding sites in three loci including the ctcf site in the sox2 super enhancer in all instances ctcf and cohesin recruitment were lost and chromatin loops with distal convergent ctcf sites were disrupted or destabilized re insertion of oppositely oriented ctcf recognition sequences restored ctcf and cohesin recruitment but did not re establish chromatin loops we conclude that ctcf binding polarity plays a functional role in the formation of higher order chromatin structure.", "ccctc binding factor ctcf is an architectural protein involved in the three dimensional 3d organization of chromatin in this study we assayed the 3d genomic contact profiles of a large number of ctcf binding sites with high resolution 4c seq as recently reported our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner to directly test this we used crispr cas9 genome editing to delete core ctcf binding sites in three loci including the ctcf site in the sox2 super enhancer in all instances ctcf and cohesin recruitment were lost and chromatin loops with distal convergent ctcf sites were disrupted or destabilized re insertion of oppositely oriented ctcf recognition sequences restored ctcf and cohesin recruitment but did not re establish chromatin loops we conclude that ctcf binding polarity plays a functional role in the formation of higher order chromatin structure.", "ccctc binding factor ctcf is an architectural protein involved in the three dimensional 3d organization of chromatin in this study we assayed the 3d genomic contact profiles of a large number of ctcf binding sites with high resolution 4c seq as recently reported our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner to directly test this we used crispr cas9 genome editing to delete core ctcf binding sites in three loci including the ctcf site in the sox2 super enhancer in all instances ctcf and cohesin recruitment were lost and chromatin loops with distal convergent ctcf sites were disrupted or destabilized re insertion of oppositely oriented ctcf recognition sequences restored ctcf and cohesin recruitment but did not re establish chromatin loops we conclude that ctcf binding polarity plays a functional role in the formation of higher order chromatin structure.", "ccctc binding factor ctcf is an architectural protein involved in the three dimensional 3d organization of chromatin in this study we assayed the 3d genomic contact profiles of a large number of ctcf binding sites with high resolution 4c seq as recently reported our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner to directly test this we used crispr cas9 genome editing to delete core ctcf binding sites in three loci including the ctcf site in the sox2 super enhancer in all instances ctcf and cohesin recruitment were lost and chromatin loops with distal convergent ctcf sites were disrupted or destabilized re insertion of oppositely oriented ctcf recognition sequences restored ctcf and cohesin recruitment but did not re establish chromatin loops we conclude that ctcf binding polarity plays a functional role in the formation of higher order chromatin structure.", "ccctc binding factor ctcf is an architectural protein involved in the three dimensional 3d organization of chromatin in this study we assayed the 3d genomic contact profiles of a large number of ctcf binding sites with high resolution 4c seq as recently reported our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner to directly test this we used crispr cas9 genome editing to delete core ctcf binding sites in three loci including the ctcf site in the sox2 super enhancer in all instances ctcf and cohesin recruitment were lost and chromatin loops with distal convergent ctcf sites were disrupted or destabilized re insertion of oppositely oriented ctcf recognition sequences restored ctcf and cohesin recruitment but did not re establish chromatin loops we conclude that ctcf binding polarity plays a functional role in the formation of higher order chromatin structure.", "ccctc binding factor ctcf is an architectural protein involved in the three dimensional 3d organization of chromatin in this study we assayed the 3d genomic contact profiles of a large number of ctcf binding sites with high resolution 4c seq as recently reported our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner to directly test this we used crispr cas9 genome editing to delete core ctcf binding sites in three loci including the ctcf site in the sox2 super enhancer in all instances ctcf and cohesin recruitment were lost and chromatin loops with distal convergent ctcf sites were disrupted or destabilized re insertion of oppositely oriented ctcf recognition sequences restored ctcf and cohesin recruitment but did not re establish chromatin loops we conclude that ctcf binding polarity plays a functional role in the formation of higher order chromatin structure.", "ccctc binding factor ctcf is an architectural protein involved in the three dimensional 3d organization of chromatin in this study we assayed the 3d genomic contact profiles of a large number of ctcf binding sites with high resolution 4c seq as recently reported our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner to directly test this we used crispr cas9 genome editing to delete core ctcf binding sites in three loci including the ctcf site in the sox2 super enhancer in all instances ctcf and cohesin recruitment were lost and chromatin loops with distal convergent ctcf sites were disrupted or destabilized re insertion of oppositely oriented ctcf recognition sequences restored ctcf and cohesin recruitment but did not re establish chromatin loops we conclude that ctcf binding polarity plays a functional role in the formation of higher order chromatin structure.", "ccctc binding factor ctcf is an architectural protein involved in the three dimensional 3d organization of chromatin in this study we assayed the 3d genomic contact profiles of a large number of ctcf binding sites with high resolution 4c seq as recently reported our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner to directly test this we used crispr cas9 genome editing to delete core ctcf binding sites in three loci including the ctcf site in the sox2 super enhancer in all instances ctcf and cohesin recruitment were lost and chromatin loops with distal convergent ctcf sites were disrupted or destabilized re insertion of oppositely oriented ctcf recognition sequences restored ctcf and cohesin recruitment but did not re establish chromatin loops we conclude that ctcf binding polarity plays a functional role in the formation of higher order chromatin structure.", "ccctc binding factor ctcf is an architectural protein involved in the three dimensional 3d organization of chromatin in this study we assayed the 3d genomic contact profiles of a large number of ctcf binding sites with high resolution 4c seq as recently reported our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner to directly test this we used crispr cas9 genome editing to delete core ctcf binding sites in three loci including the ctcf site in the sox2 super enhancer in all instances ctcf and cohesin recruitment were lost and chromatin loops with distal convergent ctcf sites were disrupted or destabilized re insertion of oppositely oriented ctcf recognition sequences restored ctcf and cohesin recruitment but did not re establish chromatin loops we conclude that ctcf binding polarity plays a functional role in the formation of higher order chromatin structure.", "ccctc binding factor ctcf is an architectural protein involved in the three dimensional 3d organization of chromatin in this study we assayed the 3d genomic contact profiles of a large number of ctcf binding sites with high resolution 4c seq as recently reported our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner to directly test this we used crispr cas9 genome editing to delete core ctcf binding sites in three loci including the ctcf site in the sox2 super enhancer in all instances ctcf and cohesin recruitment were lost and chromatin loops with distal convergent ctcf sites were disrupted or destabilized re insertion of oppositely oriented ctcf recognition sequences restored ctcf and cohesin recruitment but did not re establish chromatin loops we conclude that ctcf binding polarity plays a functional role in the formation of higher order chromatin structure.", "ccctc binding factor ctcf is an architectural protein involved in the three dimensional 3d organization of chromatin in this study we assayed the 3d genomic contact profiles of a large number of ctcf binding sites with high resolution 4c seq as recently reported our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner to directly test this we used crispr cas9 genome editing to delete core ctcf binding sites in three loci including the ctcf site in the sox2 super enhancer in all instances ctcf and cohesin recruitment were lost and chromatin loops with distal convergent ctcf sites were disrupted or destabilized re insertion of oppositely oriented ctcf recognition sequences restored ctcf and cohesin recruitment but did not re establish chromatin loops we conclude that ctcf binding polarity plays a functional role in the formation of higher order chromatin structure.", "ccctc binding factor ctcf is an architectural protein involved in the three dimensional 3d organization of chromatin in this study we assayed the 3d genomic contact profiles of a large number of ctcf binding sites with high resolution 4c seq as recently reported our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner to directly test this we used crispr cas9 genome editing to delete core ctcf binding sites in three loci including the ctcf site in the sox2 super enhancer in all instances ctcf and cohesin recruitment were lost and chromatin loops with distal convergent ctcf sites were disrupted or destabilized re insertion of oppositely oriented ctcf recognition sequences restored ctcf and cohesin recruitment but did not re establish chromatin loops we conclude that ctcf binding polarity plays a functional role in the formation of higher order chromatin structure.", "ccctc binding factor ctcf is an architectural protein involved in the three dimensional 3d organization of chromatin in this study we assayed the 3d genomic contact profiles of a large number of ctcf binding sites with high resolution 4c seq as recently reported our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner to directly test this we used crispr cas9 genome editing to delete core ctcf binding sites in three loci including the ctcf site in the sox2 super enhancer in all instances ctcf and cohesin recruitment were lost and chromatin loops with distal convergent ctcf sites were disrupted or destabilized re insertion of oppositely oriented ctcf recognition sequences restored ctcf and cohesin recruitment but did not re establish chromatin loops we conclude that ctcf binding polarity plays a functional role in the formation of higher order chromatin structure.", "ccctc binding factor ctcf is an architectural protein involved in the three dimensional 3d organization of chromatin in this study we assayed the 3d genomic contact profiles of a large number of ctcf binding sites with high resolution 4c seq as recently reported our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner to directly test this we used crispr cas9 genome editing to delete core ctcf binding sites in three loci including the ctcf site in the sox2 super enhancer in all instances ctcf and cohesin recruitment were lost and chromatin loops with distal convergent ctcf sites were disrupted or destabilized re insertion of oppositely oriented ctcf recognition sequences restored ctcf and cohesin recruitment but did not re establish chromatin loops we conclude that ctcf binding polarity plays a functional role in the formation of higher order chromatin structure.", "ccctc binding factor ctcf is an architectural protein involved in the three dimensional 3d organization of chromatin in this study we assayed the 3d genomic contact profiles of a large number of ctcf binding sites with high resolution 4c seq as recently reported our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner to directly test this we used crispr cas9 genome editing to delete core ctcf binding sites in three loci including the ctcf site in the sox2 super enhancer in all instances ctcf and cohesin recruitment were lost and chromatin loops with distal convergent ctcf sites were disrupted or destabilized re insertion of oppositely oriented ctcf recognition sequences restored ctcf and cohesin recruitment but did not re establish chromatin loops we conclude that ctcf binding polarity plays a functional role in the formation of higher order chromatin structure.", "ccctc binding factor ctcf is an architectural protein involved in the three dimensional 3d organization of chromatin in this study we assayed the 3d genomic contact profiles of a large number of ctcf binding sites with high resolution 4c seq as recently reported our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner to directly test this we used crispr cas9 genome editing to delete core ctcf binding sites in three loci including the ctcf site in the sox2 super enhancer in all instances ctcf and cohesin recruitment were lost and chromatin loops with distal convergent ctcf sites were disrupted or destabilized re insertion of oppositely oriented ctcf recognition sequences restored ctcf and cohesin recruitment but did not re establish chromatin loops we conclude that ctcf binding polarity plays a functional role in the formation of higher order chromatin structure.", "ccctc binding factor ctcf is an architectural protein involved in the three dimensional 3d organization of chromatin in this study we assayed the 3d genomic contact profiles of a large number of ctcf binding sites with high resolution 4c seq as recently reported our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner to directly test this we used crispr cas9 genome editing to delete core ctcf binding sites in three loci including the ctcf site in the sox2 super enhancer in all instances ctcf and cohesin recruitment were lost and chromatin loops with distal convergent ctcf sites were disrupted or destabilized re insertion of oppositely oriented ctcf recognition sequences restored ctcf and cohesin recruitment but did not re establish chromatin loops we conclude that ctcf binding polarity plays a functional role in the formation of higher order chromatin structure.", "ccctc binding factor ctcf is an architectural protein involved in the three dimensional 3d organization of chromatin in this study we assayed the 3d genomic contact profiles of a large number of ctcf binding sites with high resolution 4c seq as recently reported our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner to directly test this we used crispr cas9 genome editing to delete core ctcf binding sites in three loci including the ctcf site in the sox2 super enhancer in all instances ctcf and cohesin recruitment were lost and chromatin loops with distal convergent ctcf sites were disrupted or destabilized re insertion of oppositely oriented ctcf recognition sequences restored ctcf and cohesin recruitment but did not re establish chromatin loops we conclude that ctcf binding polarity plays a functional role in the formation of higher order chromatin structure.", "ccctc binding factor ctcf is an architectural protein involved in the three dimensional 3d organization of chromatin in this study we assayed the 3d genomic contact profiles of a large number of ctcf binding sites with high resolution 4c seq as recently reported our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner to directly test this we used crispr cas9 genome editing to delete core ctcf binding sites in three loci including the ctcf site in the sox2 super enhancer in all instances ctcf and cohesin recruitment were lost and chromatin loops with distal convergent ctcf sites were disrupted or destabilized re insertion of oppositely oriented ctcf recognition sequences restored ctcf and cohesin recruitment but did not re establish chromatin loops we conclude that ctcf binding polarity plays a functional role in the formation of higher order chromatin structure.", "ccctc binding factor ctcf is an architectural protein involved in the three dimensional 3d organization of chromatin in this study we assayed the 3d genomic contact profiles of a large number of ctcf binding sites with high resolution 4c seq as recently reported our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner to directly test this we used crispr cas9 genome editing to delete core ctcf binding sites in three loci including the ctcf site in the sox2 super enhancer in all instances ctcf and cohesin recruitment were lost and chromatin loops with distal convergent ctcf sites were disrupted or destabilized re insertion of oppositely oriented ctcf recognition sequences restored ctcf and cohesin recruitment but did not re establish chromatin loops we conclude that ctcf binding polarity plays a functional role in the formation of higher order chromatin structure.", "ccctc binding factor ctcf is an architectural protein involved in the three dimensional 3d organization of chromatin in this study we assayed the 3d genomic contact profiles of a large number of ctcf binding sites with high resolution 4c seq as recently reported our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner to directly test this we used crispr cas9 genome editing to delete core ctcf binding sites in three loci including the ctcf site in the sox2 super enhancer in all instances ctcf and cohesin recruitment were lost and chromatin loops with distal convergent ctcf sites were disrupted or destabilized re insertion of oppositely oriented ctcf recognition sequences restored ctcf and cohesin recruitment but did not re establish chromatin loops we conclude that ctcf binding polarity plays a functional role in the formation of higher order chromatin structure.", "ccctc binding factor ctcf is an architectural protein involved in the three dimensional 3d organization of chromatin in this study we assayed the 3d genomic contact profiles of a large number of ctcf binding sites with high resolution 4c seq as recently reported our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner to directly test this we used crispr cas9 genome editing to delete core ctcf binding sites in three loci including the ctcf site in the sox2 super enhancer in all instances ctcf and cohesin recruitment were lost and chromatin loops with distal convergent ctcf sites were disrupted or destabilized re insertion of oppositely oriented ctcf recognition sequences restored ctcf and cohesin recruitment but did not re establish chromatin loops we conclude that ctcf binding polarity plays a functional role in the formation of higher order chromatin structure.", "ccctc binding factor ctcf is an architectural protein involved in the three dimensional 3d organization of chromatin in this study we assayed the 3d genomic contact profiles of a large number of ctcf binding sites with high resolution 4c seq as recently reported our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner to directly test this we used crispr cas9 genome editing to delete core ctcf binding sites in three loci including the ctcf site in the sox2 super enhancer in all instances ctcf and cohesin recruitment were lost and chromatin loops with distal convergent ctcf sites were disrupted or destabilized re insertion of oppositely oriented ctcf recognition sequences restored ctcf and cohesin recruitment but did not re establish chromatin loops we conclude that ctcf binding polarity plays a functional role in the formation of higher order chromatin structure.", "in all instances, ctcf and cohesin recruitment were lost, and chromatin loops with distal, convergent ctcf sites were disrupted or destabilized.", "in all instances, ctcf and cohesin recruitment were lost, and chromatin loops with distal, convergent ctcf sites were disrupted or destabilized.", "in all instances, ctcf and cohesin recruitment were lost, and chromatin loops with distal, convergent ctcf sites were disrupted or destabilized.", "in all instances, ctcf and cohesin recruitment were lost, and chromatin loops with distal, convergent ctcf sites were disrupted or destabilized.", "in all instances, ctcf and cohesin recruitment were lost, and chromatin loops with distal, convergent ctcf sites were disrupted or destabilized.", "in all instances, ctcf and cohesin recruitment were lost, and chromatin loops with distal, convergent ctcf sites were disrupted or destabilized.", "in all instances, ctcf and cohesin recruitment were lost, and chromatin loops with distal, convergent ctcf sites were disrupted or destabilized.", "in all instances, ctcf and cohesin recruitment were lost, and chromatin loops with distal, convergent ctcf sites were disrupted or destabilized.", "in all instances, ctcf and cohesin recruitment were lost, and chromatin loops with distal, convergent ctcf sites were disrupted or destabilized.", "in all instances, ctcf and cohesin recruitment were lost, and chromatin loops with distal, convergent ctcf sites were disrupted or destabilized.", "in all instances, ctcf and cohesin recruitment were lost, and chromatin loops with distal, convergent ctcf sites were disrupted or destabilized.", "in all instances, ctcf and cohesin recruitment were lost, and chromatin loops with distal, convergent ctcf sites were disrupted or destabilized.", "in all instances, ctcf and cohesin recruitment were lost, and chromatin loops with distal, convergent ctcf sites were disrupted or destabilized.", "in all instances, ctcf and cohesin recruitment were lost, and chromatin loops with distal, convergent ctcf sites were disrupted or destabilized.", "in all instances, ctcf and cohesin recruitment were lost, and chromatin loops with distal, convergent ctcf sites were disrupted or destabilized.", "in all instances, ctcf and cohesin recruitment were lost, and chromatin loops with distal, convergent ctcf sites were disrupted or destabilized.", "in all instances, ctcf and cohesin recruitment were lost, and chromatin loops with distal, convergent ctcf sites were disrupted or destabilized.", "in all instances, ctcf and cohesin recruitment were lost, and chromatin loops with distal, convergent ctcf sites were disrupted or destabilized.", "in all instances, ctcf and cohesin recruitment were lost, and chromatin loops with distal, convergent ctcf sites were disrupted or destabilized.", "in all instances, ctcf and cohesin recruitment were lost, and chromatin loops with distal, convergent ctcf sites were disrupted or destabilized.", "in all instances, ctcf and cohesin recruitment were lost, and chromatin loops with distal, convergent ctcf sites were disrupted or destabilized.", "in all instances, ctcf and cohesin recruitment were lost, and chromatin loops with distal, convergent ctcf sites were disrupted or destabilized.", "in all instances, ctcf and cohesin recruitment were lost, and chromatin loops with distal, convergent ctcf sites were disrupted or destabilized.", "in all instances, ctcf and cohesin recruitment were lost, and chromatin loops with distal, convergent ctcf sites were disrupted or destabilized.", "in all instances, ctcf and cohesin recruitment were lost, and chromatin loops with distal, convergent ctcf sites were disrupted or destabilized.", "in all instances, ctcf and cohesin recruitment were lost, and chromatin loops with distal, convergent ctcf sites were disrupted or destabilized.", "in all instances, ctcf and cohesin recruitment were lost, and chromatin loops with distal, convergent ctcf sites were disrupted or destabilized.", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner.", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner.", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner.", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner.", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner.", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner.", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner.", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner.", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner.", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner.", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner.", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner.", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner.", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner.", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner.", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner.", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner.", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner.", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner.", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner.", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner.", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner.", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner.", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner.", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner.", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner.", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner.", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner", "as recently reported, our data also suggest that chromatin loops preferentially form between ctcf binding sites oriented in a convergent manner", "ctcf sites at loop anchors occur predominantly (>90%) in a convergent orientation, with the asymmetric motifs \"facing\" one another.", "ctcf sites at loop anchors occur predominantly (>90%) in a convergent orientation, with the asymmetric motifs \"facing\" one another.", "ctcf sites at loop anchors occur predominantly (>90%) in a convergent orientation, with the asymmetric motifs \"facing\" one another.", "ctcf sites at loop anchors occur predominantly (>90%) in a convergent orientation, with the asymmetric motifs \"facing\" one another.", "ctcf sites at loop anchors occur predominantly (>90%) in a convergent orientation, with the asymmetric motifs \"facing\" one another.", "ctcf sites at loop anchors occur predominantly (>90%) in a convergent orientation, with the asymmetric motifs \"facing\" one another.", "ctcf sites at loop anchors occur predominantly (>90%) in a convergent orientation, with the asymmetric motifs \"facing\" one another.", "ctcf sites at loop anchors occur predominantly (>90%) in a convergent orientation, with the asymmetric motifs \"facing\" one another.", "ctcf sites at loop anchors occur predominantly (>90%) in a convergent orientation, with the asymmetric motifs \"facing\" one another.", "ctcf sites at loop anchors occur predominantly (>90%) in a convergent orientation, with the asymmetric motifs \"facing\" one another.", "ctcf sites at loop anchors occur predominantly (>90%) in a convergent orientation, with the asymmetric motifs \"facing\" one another.", "ctcf sites at loop anchors occur predominantly (>90%) in a convergent orientation, with the asymmetric motifs \"facing\" one another.", "ctcf sites at loop anchors occur predominantly (>90%) in a convergent orientation, with the asymmetric motifs \"facing\" one another.", "ctcf sites at loop anchors occur predominantly (>90%) in a convergent orientation, with the asymmetric motifs \"facing\" one another.", "ctcf sites at loop anchors occur predominantly (>90%) in a convergent orientation, with the asymmetric motifs \"facing\" one another.", "ctcf sites at loop anchors occur predominantly (>90%) in a convergent orientation, with the asymmetric motifs \"facing\" one another.", "ctcf sites at loop anchors occur predominantly (>90%) in a convergent orientation, with the asymmetric motifs \"facing\" one another.", "ctcf sites at loop anchors occur predominantly (>90%) in a convergent orientation, with the asymmetric motifs \"facing\" one another.", "ctcf sites at loop anchors occur predominantly (>90%) in a convergent orientation, with the asymmetric motifs \"facing\" one another.", "ctcf sites at loop anchors occur predominantly (>90%) in a convergent orientation, with the asymmetric motifs \"facing\" one another.", "ctcf sites at loop anchors occur predominantly (>90%) in a convergent orientation, with the asymmetric motifs \"facing\" one another.", "ctcf sites at loop anchors occur predominantly (>90%) in a convergent orientation, with the asymmetric motifs \"facing\" one another.", "ctcf sites at loop anchors occur predominantly (>90%) in a convergent orientation, with the asymmetric motifs \"facing\" one another.", "ctcf sites at loop anchors occur predominantly (>90%) in a convergent orientation, with the asymmetric motifs \"facing\" one another.", "ctcf sites at loop anchors occur predominantly (>90%) in a convergent orientation, with the asymmetric motifs \"facing\" one another.", "ctcf sites at loop anchors occur predominantly (>90%) in a convergent orientation, with the asymmetric motifs \"facing\" one another.", "ctcf sites at loop anchors occur predominantly (>90%) in a convergent orientation, with the asymmetric motifs \"facing\" one another.", "we have assessed the effects of nap (davunetide), an eight-amino acid peptide that decreases tau hyperphosphorylation, in mice overexpressing wild-type human \u03b1-synuclein (thy1-asyn mice), a model that recapitulates aspects of pd.", "we have assessed the effects of nap (davunetide), an eight-amino acid peptide that decreases tau hyperphosphorylation, in mice overexpressing wild-type human \u03b1-synuclein (thy1-asyn mice), a model that recapitulates aspects of pd.", "we have assessed the effects of nap (davunetide), an eight-amino acid peptide that decreases tau hyperphosphorylation, in mice overexpressing wild-type human \u03b1-synuclein (thy1-asyn mice), a model that recapitulates aspects of pd.", "we have assessed the effects of nap (davunetide), an eight-amino acid peptide that decreases tau hyperphosphorylation, in mice overexpressing wild-type human \u03b1-synuclein (thy1-asyn mice), a model that recapitulates aspects of pd.", "we have assessed the effects of nap (davunetide), an eight-amino acid peptide that decreases tau hyperphosphorylation, in mice overexpressing wild-type human \u03b1-synuclein (thy1-asyn mice), a model that recapitulates aspects of pd.", "we have assessed the effects of nap (davunetide), an eight-amino acid peptide that decreases tau hyperphosphorylation, in mice overexpressing wild-type human \u03b1-synuclein (thy1-asyn mice), a model that recapitulates aspects of pd.", "we have assessed the effects of nap (davunetide), an eight-amino acid peptide that decreases tau hyperphosphorylation, in mice overexpressing wild-type human \u03b1-synuclein (thy1-asyn mice), a model that recapitulates aspects of pd.", "we have assessed the effects of nap (davunetide), an eight-amino acid peptide that decreases tau hyperphosphorylation, in mice overexpressing wild-type human \u03b1-synuclein (thy1-asyn mice), a model that recapitulates aspects of pd.", "we have assessed the effects of nap (davunetide), an eight-amino acid peptide that decreases tau hyperphosphorylation, in mice overexpressing wild-type human \u03b1-synuclein (thy1-asyn mice), a model that recapitulates aspects of pd.", "we have assessed the effects of nap (davunetide), an eight-amino acid peptide that decreases tau hyperphosphorylation, in mice overexpressing wild-type human \u03b1-synuclein (thy1-asyn mice), a model that recapitulates aspects of pd.", "we have assessed the effects of nap (davunetide), an eight-amino acid peptide that decreases tau hyperphosphorylation, in mice overexpressing wild-type human \u03b1-synuclein (thy1-asyn mice), a model that recapitulates aspects of pd.", "we have assessed the effects of nap (davunetide), an eight-amino acid peptide that decreases tau hyperphosphorylation, in mice overexpressing wild-type human \u03b1-synuclein (thy1-asyn mice), a model that recapitulates aspects of pd.", "we have assessed the effects of nap (davunetide), an eight-amino acid peptide that decreases tau hyperphosphorylation, in mice overexpressing wild-type human \u03b1-synuclein (thy1-asyn mice), a model that recapitulates aspects of pd.", "we have assessed the effects of nap (davunetide), an eight-amino acid peptide that decreases tau hyperphosphorylation, in mice overexpressing wild-type human \u03b1-synuclein (thy1-asyn mice), a model that recapitulates aspects of pd.", "we have assessed the effects of nap (davunetide), an eight-amino acid peptide that decreases tau hyperphosphorylation, in mice overexpressing wild-type human \u03b1-synuclein (thy1-asyn mice), a model that recapitulates aspects of pd.", "we have assessed the effects of nap (davunetide), an eight-amino acid peptide that decreases tau hyperphosphorylation, in mice overexpressing wild-type human \u03b1-synuclein (thy1-asyn mice), a model that recapitulates aspects of pd.", "we have assessed the effects of nap (davunetide), an eight-amino acid peptide that decreases tau hyperphosphorylation, in mice overexpressing wild-type human \u03b1-synuclein (thy1-asyn mice), a model that recapitulates aspects of pd.", "we have assessed the effects of nap (davunetide), an eight-amino acid peptide that decreases tau hyperphosphorylation, in mice overexpressing wild-type human \u03b1-synuclein (thy1-asyn mice), a model that recapitulates aspects of pd.", "we have assessed the effects of nap (davunetide), an eight-amino acid peptide that decreases tau hyperphosphorylation, in mice overexpressing wild-type human \u03b1-synuclein (thy1-asyn mice), a model that recapitulates aspects of pd.", "we have assessed the effects of nap (davunetide), an eight-amino acid peptide that decreases tau hyperphosphorylation, in mice overexpressing wild-type human \u03b1-synuclein (thy1-asyn mice), a model that recapitulates aspects of pd.", "we have assessed the effects of nap (davunetide), an eight-amino acid peptide that decreases tau hyperphosphorylation, in mice overexpressing wild-type human \u03b1-synuclein (thy1-asyn mice), a model that recapitulates aspects of pd.", "we have assessed the effects of nap (davunetide), an eight-amino acid peptide that decreases tau hyperphosphorylation, in mice overexpressing wild-type human \u03b1-synuclein (thy1-asyn mice), a model that recapitulates aspects of pd.", "we have assessed the effects of nap (davunetide), an eight-amino acid peptide that decreases tau hyperphosphorylation, in mice overexpressing wild-type human \u03b1-synuclein (thy1-asyn mice), a model that recapitulates aspects of pd.", "chordomas arise in the skull base and spine and usually occur in adults and are rare in the pediatric population cases of chordoma in pediatric age are often poorly differentiated showing cytologic atypia increased cellularity and mitosis and their aggressive behavior is associated with a high incidence of metastatic spread and a short patient survival recent studies have described loss of smarcb1 ini1 protein in poorly differentiated chordomas associated not with point mutations but with smarcb1 ini1 gene deletions instead in this study we considered immunohistochemistry and smarcb1 ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas 7 classic and 1 poorly differentiated we performed immunohistochemical tests for ini1 brachyury s100 and cytokeratins and conducted a genetic analysis on the smarcb1 coding sequence nm 003073 using the sanger method and multiplex ligation dependent probe amplification to detect abnormal copy numbers of the gene locus all 8 cases were positive for brachyury whereas there was no nuclear smarcb1 ini1 expression in 4 of the 8 cases including the poorly differentiated chordoma genetic analysis identified a missense mutation in 2 cases and a nonsense mutation associated with loss of smarcb1 ini1 protein and features of poorly differentiated tumor in 1 these mutations were novel variants occurring in heterozygosity and they were judged to be pathogenic by 3 different bioinformatic tools in 7 of 8 cases we performed multiplex ligation dependent probe amplification and 3 cases showed deletions at the smarcb1 locus our results confirm the pathogenic involvement of smarcb1 ini1 in childhood chordoma we also describe 3 novel pathogenic mutations.", "chordomas arise in the skull base and spine and usually occur in adults and are rare in the pediatric population cases of chordoma in pediatric age are often poorly differentiated showing cytologic atypia increased cellularity and mitosis and their aggressive behavior is associated with a high incidence of metastatic spread and a short patient survival recent studies have described loss of smarcb1 ini1 protein in poorly differentiated chordomas associated not with point mutations but with smarcb1 ini1 gene deletions instead in this study we considered immunohistochemistry and smarcb1 ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas 7 classic and 1 poorly differentiated we performed immunohistochemical tests for ini1 brachyury s100 and cytokeratins and conducted a genetic analysis on the smarcb1 coding sequence nm 003073 using the sanger method and multiplex ligation dependent probe amplification to detect abnormal copy numbers of the gene locus all 8 cases were positive for brachyury whereas there was no nuclear smarcb1 ini1 expression in 4 of the 8 cases including the poorly differentiated chordoma genetic analysis identified a missense mutation in 2 cases and a nonsense mutation associated with loss of smarcb1 ini1 protein and features of poorly differentiated tumor in 1 these mutations were novel variants occurring in heterozygosity and they were judged to be pathogenic by 3 different bioinformatic tools in 7 of 8 cases we performed multiplex ligation dependent probe amplification and 3 cases showed deletions at the smarcb1 locus our results confirm the pathogenic involvement of smarcb1 ini1 in childhood chordoma we also describe 3 novel pathogenic mutations.", "chordomas arise in the skull base and spine and usually occur in adults and are rare in the pediatric population cases of chordoma in pediatric age are often poorly differentiated showing cytologic atypia increased cellularity and mitosis and their aggressive behavior is associated with a high incidence of metastatic spread and a short patient survival recent studies have described loss of smarcb1 ini1 protein in poorly differentiated chordomas associated not with point mutations but with smarcb1 ini1 gene deletions instead in this study we considered immunohistochemistry and smarcb1 ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas 7 classic and 1 poorly differentiated we performed immunohistochemical tests for ini1 brachyury s100 and cytokeratins and conducted a genetic analysis on the smarcb1 coding sequence nm 003073 using the sanger method and multiplex ligation dependent probe amplification to detect abnormal copy numbers of the gene locus all 8 cases were positive for brachyury whereas there was no nuclear smarcb1 ini1 expression in 4 of the 8 cases including the poorly differentiated chordoma genetic analysis identified a missense mutation in 2 cases and a nonsense mutation associated with loss of smarcb1 ini1 protein and features of poorly differentiated tumor in 1 these mutations were novel variants occurring in heterozygosity and they were judged to be pathogenic by 3 different bioinformatic tools in 7 of 8 cases we performed multiplex ligation dependent probe amplification and 3 cases showed deletions at the smarcb1 locus our results confirm the pathogenic involvement of smarcb1 ini1 in childhood chordoma we also describe 3 novel pathogenic mutations.", "chordomas arise in the skull base and spine and usually occur in adults and are rare in the pediatric population cases of chordoma in pediatric age are often poorly differentiated showing cytologic atypia increased cellularity and mitosis and their aggressive behavior is associated with a high incidence of metastatic spread and a short patient survival recent studies have described loss of smarcb1 ini1 protein in poorly differentiated chordomas associated not with point mutations but with smarcb1 ini1 gene deletions instead in this study we considered immunohistochemistry and smarcb1 ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas 7 classic and 1 poorly differentiated we performed immunohistochemical tests for ini1 brachyury s100 and cytokeratins and conducted a genetic analysis on the smarcb1 coding sequence nm 003073 using the sanger method and multiplex ligation dependent probe amplification to detect abnormal copy numbers of the gene locus all 8 cases were positive for brachyury whereas there was no nuclear smarcb1 ini1 expression in 4 of the 8 cases including the poorly differentiated chordoma genetic analysis identified a missense mutation in 2 cases and a nonsense mutation associated with loss of smarcb1 ini1 protein and features of poorly differentiated tumor in 1 these mutations were novel variants occurring in heterozygosity and they were judged to be pathogenic by 3 different bioinformatic tools in 7 of 8 cases we performed multiplex ligation dependent probe amplification and 3 cases showed deletions at the smarcb1 locus our results confirm the pathogenic involvement of smarcb1 ini1 in childhood chordoma we also describe 3 novel pathogenic mutations.", "chordomas arise in the skull base and spine and usually occur in adults and are rare in the pediatric population cases of chordoma in pediatric age are often poorly differentiated showing cytologic atypia increased cellularity and mitosis and their aggressive behavior is associated with a high incidence of metastatic spread and a short patient survival recent studies have described loss of smarcb1 ini1 protein in poorly differentiated chordomas associated not with point mutations but with smarcb1 ini1 gene deletions instead in this study we considered immunohistochemistry and smarcb1 ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas 7 classic and 1 poorly differentiated we performed immunohistochemical tests for ini1 brachyury s100 and cytokeratins and conducted a genetic analysis on the smarcb1 coding sequence nm 003073 using the sanger method and multiplex ligation dependent probe amplification to detect abnormal copy numbers of the gene locus all 8 cases were positive for brachyury whereas there was no nuclear smarcb1 ini1 expression in 4 of the 8 cases including the poorly differentiated chordoma genetic analysis identified a missense mutation in 2 cases and a nonsense mutation associated with loss of smarcb1 ini1 protein and features of poorly differentiated tumor in 1 these mutations were novel variants occurring in heterozygosity and they were judged to be pathogenic by 3 different bioinformatic tools in 7 of 8 cases we performed multiplex ligation dependent probe amplification and 3 cases showed deletions at the smarcb1 locus our results confirm the pathogenic involvement of smarcb1 ini1 in childhood chordoma we also describe 3 novel pathogenic mutations.", "chordomas arise in the skull base and spine and usually occur in adults and are rare in the pediatric population cases of chordoma in pediatric age are often poorly differentiated showing cytologic atypia increased cellularity and mitosis and their aggressive behavior is associated with a high incidence of metastatic spread and a short patient survival recent studies have described loss of smarcb1 ini1 protein in poorly differentiated chordomas associated not with point mutations but with smarcb1 ini1 gene deletions instead in this study we considered immunohistochemistry and smarcb1 ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas 7 classic and 1 poorly differentiated we performed immunohistochemical tests for ini1 brachyury s100 and cytokeratins and conducted a genetic analysis on the smarcb1 coding sequence nm 003073 using the sanger method and multiplex ligation dependent probe amplification to detect abnormal copy numbers of the gene locus all 8 cases were positive for brachyury whereas there was no nuclear smarcb1 ini1 expression in 4 of the 8 cases including the poorly differentiated chordoma genetic analysis identified a missense mutation in 2 cases and a nonsense mutation associated with loss of smarcb1 ini1 protein and features of poorly differentiated tumor in 1 these mutations were novel variants occurring in heterozygosity and they were judged to be pathogenic by 3 different bioinformatic tools in 7 of 8 cases we performed multiplex ligation dependent probe amplification and 3 cases showed deletions at the smarcb1 locus our results confirm the pathogenic involvement of smarcb1 ini1 in childhood chordoma we also describe 3 novel pathogenic mutations.", "chordomas arise in the skull base and spine and usually occur in adults and are rare in the pediatric population cases of chordoma in pediatric age are often poorly differentiated showing cytologic atypia increased cellularity and mitosis and their aggressive behavior is associated with a high incidence of metastatic spread and a short patient survival recent studies have described loss of smarcb1 ini1 protein in poorly differentiated chordomas associated not with point mutations but with smarcb1 ini1 gene deletions instead in this study we considered immunohistochemistry and smarcb1 ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas 7 classic and 1 poorly differentiated we performed immunohistochemical tests for ini1 brachyury s100 and cytokeratins and conducted a genetic analysis on the smarcb1 coding sequence nm 003073 using the sanger method and multiplex ligation dependent probe amplification to detect abnormal copy numbers of the gene locus all 8 cases were positive for brachyury whereas there was no nuclear smarcb1 ini1 expression in 4 of the 8 cases including the poorly differentiated chordoma genetic analysis identified a missense mutation in 2 cases and a nonsense mutation associated with loss of smarcb1 ini1 protein and features of poorly differentiated tumor in 1 these mutations were novel variants occurring in heterozygosity and they were judged to be pathogenic by 3 different bioinformatic tools in 7 of 8 cases we performed multiplex ligation dependent probe amplification and 3 cases showed deletions at the smarcb1 locus our results confirm the pathogenic involvement of smarcb1 ini1 in childhood chordoma we also describe 3 novel pathogenic mutations.", "chordomas arise in the skull base and spine and usually occur in adults and are rare in the pediatric population cases of chordoma in pediatric age are often poorly differentiated showing cytologic atypia increased cellularity and mitosis and their aggressive behavior is associated with a high incidence of metastatic spread and a short patient survival recent studies have described loss of smarcb1 ini1 protein in poorly differentiated chordomas associated not with point mutations but with smarcb1 ini1 gene deletions instead in this study we considered immunohistochemistry and smarcb1 ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas 7 classic and 1 poorly differentiated we performed immunohistochemical tests for ini1 brachyury s100 and cytokeratins and conducted a genetic analysis on the smarcb1 coding sequence nm 003073 using the sanger method and multiplex ligation dependent probe amplification to detect abnormal copy numbers of the gene locus all 8 cases were positive for brachyury whereas there was no nuclear smarcb1 ini1 expression in 4 of the 8 cases including the poorly differentiated chordoma genetic analysis identified a missense mutation in 2 cases and a nonsense mutation associated with loss of smarcb1 ini1 protein and features of poorly differentiated tumor in 1 these mutations were novel variants occurring in heterozygosity and they were judged to be pathogenic by 3 different bioinformatic tools in 7 of 8 cases we performed multiplex ligation dependent probe amplification and 3 cases showed deletions at the smarcb1 locus our results confirm the pathogenic involvement of smarcb1 ini1 in childhood chordoma we also describe 3 novel pathogenic mutations.", "chordomas arise in the skull base and spine and usually occur in adults and are rare in the pediatric population cases of chordoma in pediatric age are often poorly differentiated showing cytologic atypia increased cellularity and mitosis and their aggressive behavior is associated with a high incidence of metastatic spread and a short patient survival recent studies have described loss of smarcb1 ini1 protein in poorly differentiated chordomas associated not with point mutations but with smarcb1 ini1 gene deletions instead in this study we considered immunohistochemistry and smarcb1 ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas 7 classic and 1 poorly differentiated we performed immunohistochemical tests for ini1 brachyury s100 and cytokeratins and conducted a genetic analysis on the smarcb1 coding sequence nm 003073 using the sanger method and multiplex ligation dependent probe amplification to detect abnormal copy numbers of the gene locus all 8 cases were positive for brachyury whereas there was no nuclear smarcb1 ini1 expression in 4 of the 8 cases including the poorly differentiated chordoma genetic analysis identified a missense mutation in 2 cases and a nonsense mutation associated with loss of smarcb1 ini1 protein and features of poorly differentiated tumor in 1 these mutations were novel variants occurring in heterozygosity and they were judged to be pathogenic by 3 different bioinformatic tools in 7 of 8 cases we performed multiplex ligation dependent probe amplification and 3 cases showed deletions at the smarcb1 locus our results confirm the pathogenic involvement of smarcb1 ini1 in childhood chordoma we also describe 3 novel pathogenic mutations.", "chordomas arise in the skull base and spine and usually occur in adults and are rare in the pediatric population cases of chordoma in pediatric age are often poorly differentiated showing cytologic atypia increased cellularity and mitosis and their aggressive behavior is associated with a high incidence of metastatic spread and a short patient survival recent studies have described loss of smarcb1 ini1 protein in poorly differentiated chordomas associated not with point mutations but with smarcb1 ini1 gene deletions instead in this study we considered immunohistochemistry and smarcb1 ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas 7 classic and 1 poorly differentiated we performed immunohistochemical tests for ini1 brachyury s100 and cytokeratins and conducted a genetic analysis on the smarcb1 coding sequence nm 003073 using the sanger method and multiplex ligation dependent probe amplification to detect abnormal copy numbers of the gene locus all 8 cases were positive for brachyury whereas there was no nuclear smarcb1 ini1 expression in 4 of the 8 cases including the poorly differentiated chordoma genetic analysis identified a missense mutation in 2 cases and a nonsense mutation associated with loss of smarcb1 ini1 protein and features of poorly differentiated tumor in 1 these mutations were novel variants occurring in heterozygosity and they were judged to be pathogenic by 3 different bioinformatic tools in 7 of 8 cases we performed multiplex ligation dependent probe amplification and 3 cases showed deletions at the smarcb1 locus our results confirm the pathogenic involvement of smarcb1 ini1 in childhood chordoma we also describe 3 novel pathogenic mutations.", "chordomas arise in the skull base and spine and usually occur in adults and are rare in the pediatric population cases of chordoma in pediatric age are often poorly differentiated showing cytologic atypia increased cellularity and mitosis and their aggressive behavior is associated with a high incidence of metastatic spread and a short patient survival recent studies have described loss of smarcb1 ini1 protein in poorly differentiated chordomas associated not with point mutations but with smarcb1 ini1 gene deletions instead in this study we considered immunohistochemistry and smarcb1 ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas 7 classic and 1 poorly differentiated we performed immunohistochemical tests for ini1 brachyury s100 and cytokeratins and conducted a genetic analysis on the smarcb1 coding sequence nm 003073 using the sanger method and multiplex ligation dependent probe amplification to detect abnormal copy numbers of the gene locus all 8 cases were positive for brachyury whereas there was no nuclear smarcb1 ini1 expression in 4 of the 8 cases including the poorly differentiated chordoma genetic analysis identified a missense mutation in 2 cases and a nonsense mutation associated with loss of smarcb1 ini1 protein and features of poorly differentiated tumor in 1 these mutations were novel variants occurring in heterozygosity and they were judged to be pathogenic by 3 different bioinformatic tools in 7 of 8 cases we performed multiplex ligation dependent probe amplification and 3 cases showed deletions at the smarcb1 locus our results confirm the pathogenic involvement of smarcb1 ini1 in childhood chordoma we also describe 3 novel pathogenic mutations.", "chordomas arise in the skull base and spine and usually occur in adults and are rare in the pediatric population cases of chordoma in pediatric age are often poorly differentiated showing cytologic atypia increased cellularity and mitosis and their aggressive behavior is associated with a high incidence of metastatic spread and a short patient survival recent studies have described loss of smarcb1 ini1 protein in poorly differentiated chordomas associated not with point mutations but with smarcb1 ini1 gene deletions instead in this study we considered immunohistochemistry and smarcb1 ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas 7 classic and 1 poorly differentiated we performed immunohistochemical tests for ini1 brachyury s100 and cytokeratins and conducted a genetic analysis on the smarcb1 coding sequence nm 003073 using the sanger method and multiplex ligation dependent probe amplification to detect abnormal copy numbers of the gene locus all 8 cases were positive for brachyury whereas there was no nuclear smarcb1 ini1 expression in 4 of the 8 cases including the poorly differentiated chordoma genetic analysis identified a missense mutation in 2 cases and a nonsense mutation associated with loss of smarcb1 ini1 protein and features of poorly differentiated tumor in 1 these mutations were novel variants occurring in heterozygosity and they were judged to be pathogenic by 3 different bioinformatic tools in 7 of 8 cases we performed multiplex ligation dependent probe amplification and 3 cases showed deletions at the smarcb1 locus our results confirm the pathogenic involvement of smarcb1 ini1 in childhood chordoma we also describe 3 novel pathogenic mutations.", "chordomas arise in the skull base and spine and usually occur in adults and are rare in the pediatric population cases of chordoma in pediatric age are often poorly differentiated showing cytologic atypia increased cellularity and mitosis and their aggressive behavior is associated with a high incidence of metastatic spread and a short patient survival recent studies have described loss of smarcb1 ini1 protein in poorly differentiated chordomas associated not with point mutations but with smarcb1 ini1 gene deletions instead in this study we considered immunohistochemistry and smarcb1 ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas 7 classic and 1 poorly differentiated we performed immunohistochemical tests for ini1 brachyury s100 and cytokeratins and conducted a genetic analysis on the smarcb1 coding sequence nm 003073 using the sanger method and multiplex ligation dependent probe amplification to detect abnormal copy numbers of the gene locus all 8 cases were positive for brachyury whereas there was no nuclear smarcb1 ini1 expression in 4 of the 8 cases including the poorly differentiated chordoma genetic analysis identified a missense mutation in 2 cases and a nonsense mutation associated with loss of smarcb1 ini1 protein and features of poorly differentiated tumor in 1 these mutations were novel variants occurring in heterozygosity and they were judged to be pathogenic by 3 different bioinformatic tools in 7 of 8 cases we performed multiplex ligation dependent probe amplification and 3 cases showed deletions at the smarcb1 locus our results confirm the pathogenic involvement of smarcb1 ini1 in childhood chordoma we also describe 3 novel pathogenic mutations.", "chordomas arise in the skull base and spine and usually occur in adults and are rare in the pediatric population cases of chordoma in pediatric age are often poorly differentiated showing cytologic atypia increased cellularity and mitosis and their aggressive behavior is associated with a high incidence of metastatic spread and a short patient survival recent studies have described loss of smarcb1 ini1 protein in poorly differentiated chordomas associated not with point mutations but with smarcb1 ini1 gene deletions instead in this study we considered immunohistochemistry and smarcb1 ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas 7 classic and 1 poorly differentiated we performed immunohistochemical tests for ini1 brachyury s100 and cytokeratins and conducted a genetic analysis on the smarcb1 coding sequence nm 003073 using the sanger method and multiplex ligation dependent probe amplification to detect abnormal copy numbers of the gene locus all 8 cases were positive for brachyury whereas there was no nuclear smarcb1 ini1 expression in 4 of the 8 cases including the poorly differentiated chordoma genetic analysis identified a missense mutation in 2 cases and a nonsense mutation associated with loss of smarcb1 ini1 protein and features of poorly differentiated tumor in 1 these mutations were novel variants occurring in heterozygosity and they were judged to be pathogenic by 3 different bioinformatic tools in 7 of 8 cases we performed multiplex ligation dependent probe amplification and 3 cases showed deletions at the smarcb1 locus our results confirm the pathogenic involvement of smarcb1 ini1 in childhood chordoma we also describe 3 novel pathogenic mutations.", "chordomas arise in the skull base and spine and usually occur in adults and are rare in the pediatric population cases of chordoma in pediatric age are often poorly differentiated showing cytologic atypia increased cellularity and mitosis and their aggressive behavior is associated with a high incidence of metastatic spread and a short patient survival recent studies have described loss of smarcb1 ini1 protein in poorly differentiated chordomas associated not with point mutations but with smarcb1 ini1 gene deletions instead in this study we considered immunohistochemistry and smarcb1 ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas 7 classic and 1 poorly differentiated we performed immunohistochemical tests for ini1 brachyury s100 and cytokeratins and conducted a genetic analysis on the smarcb1 coding sequence nm 003073 using the sanger method and multiplex ligation dependent probe amplification to detect abnormal copy numbers of the gene locus all 8 cases were positive for brachyury whereas there was no nuclear smarcb1 ini1 expression in 4 of the 8 cases including the poorly differentiated chordoma genetic analysis identified a missense mutation in 2 cases and a nonsense mutation associated with loss of smarcb1 ini1 protein and features of poorly differentiated tumor in 1 these mutations were novel variants occurring in heterozygosity and they were judged to be pathogenic by 3 different bioinformatic tools in 7 of 8 cases we performed multiplex ligation dependent probe amplification and 3 cases showed deletions at the smarcb1 locus our results confirm the pathogenic involvement of smarcb1 ini1 in childhood chordoma we also describe 3 novel pathogenic mutations.", "chordomas arise in the skull base and spine and usually occur in adults and are rare in the pediatric population cases of chordoma in pediatric age are often poorly differentiated showing cytologic atypia increased cellularity and mitosis and their aggressive behavior is associated with a high incidence of metastatic spread and a short patient survival recent studies have described loss of smarcb1 ini1 protein in poorly differentiated chordomas associated not with point mutations but with smarcb1 ini1 gene deletions instead in this study we considered immunohistochemistry and smarcb1 ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas 7 classic and 1 poorly differentiated we performed immunohistochemical tests for ini1 brachyury s100 and cytokeratins and conducted a genetic analysis on the smarcb1 coding sequence nm 003073 using the sanger method and multiplex ligation dependent probe amplification to detect abnormal copy numbers of the gene locus all 8 cases were positive for brachyury whereas there was no nuclear smarcb1 ini1 expression in 4 of the 8 cases including the poorly differentiated chordoma genetic analysis identified a missense mutation in 2 cases and a nonsense mutation associated with loss of smarcb1 ini1 protein and features of poorly differentiated tumor in 1 these mutations were novel variants occurring in heterozygosity and they were judged to be pathogenic by 3 different bioinformatic tools in 7 of 8 cases we performed multiplex ligation dependent probe amplification and 3 cases showed deletions at the smarcb1 locus our results confirm the pathogenic involvement of smarcb1 ini1 in childhood chordoma we also describe 3 novel pathogenic mutations.", "chordomas arise in the skull base and spine and usually occur in adults and are rare in the pediatric population cases of chordoma in pediatric age are often poorly differentiated showing cytologic atypia increased cellularity and mitosis and their aggressive behavior is associated with a high incidence of metastatic spread and a short patient survival recent studies have described loss of smarcb1 ini1 protein in poorly differentiated chordomas associated not with point mutations but with smarcb1 ini1 gene deletions instead in this study we considered immunohistochemistry and smarcb1 ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas 7 classic and 1 poorly differentiated we performed immunohistochemical tests for ini1 brachyury s100 and cytokeratins and conducted a genetic analysis on the smarcb1 coding sequence nm 003073 using the sanger method and multiplex ligation dependent probe amplification to detect abnormal copy numbers of the gene locus all 8 cases were positive for brachyury whereas there was no nuclear smarcb1 ini1 expression in 4 of the 8 cases including the poorly differentiated chordoma genetic analysis identified a missense mutation in 2 cases and a nonsense mutation associated with loss of smarcb1 ini1 protein and features of poorly differentiated tumor in 1 these mutations were novel variants occurring in heterozygosity and they were judged to be pathogenic by 3 different bioinformatic tools in 7 of 8 cases we performed multiplex ligation dependent probe amplification and 3 cases showed deletions at the smarcb1 locus our results confirm the pathogenic involvement of smarcb1 ini1 in childhood chordoma we also describe 3 novel pathogenic mutations.", "chordomas arise in the skull base and spine and usually occur in adults and are rare in the pediatric population cases of chordoma in pediatric age are often poorly differentiated showing cytologic atypia increased cellularity and mitosis and their aggressive behavior is associated with a high incidence of metastatic spread and a short patient survival recent studies have described loss of smarcb1 ini1 protein in poorly differentiated chordomas associated not with point mutations but with smarcb1 ini1 gene deletions instead in this study we considered immunohistochemistry and smarcb1 ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas 7 classic and 1 poorly differentiated we performed immunohistochemical tests for ini1 brachyury s100 and cytokeratins and conducted a genetic analysis on the smarcb1 coding sequence nm 003073 using the sanger method and multiplex ligation dependent probe amplification to detect abnormal copy numbers of the gene locus all 8 cases were positive for brachyury whereas there was no nuclear smarcb1 ini1 expression in 4 of the 8 cases including the poorly differentiated chordoma genetic analysis identified a missense mutation in 2 cases and a nonsense mutation associated with loss of smarcb1 ini1 protein and features of poorly differentiated tumor in 1 these mutations were novel variants occurring in heterozygosity and they were judged to be pathogenic by 3 different bioinformatic tools in 7 of 8 cases we performed multiplex ligation dependent probe amplification and 3 cases showed deletions at the smarcb1 locus our results confirm the pathogenic involvement of smarcb1 ini1 in childhood chordoma we also describe 3 novel pathogenic mutations.", "chordomas arise in the skull base and spine and usually occur in adults and are rare in the pediatric population cases of chordoma in pediatric age are often poorly differentiated showing cytologic atypia increased cellularity and mitosis and their aggressive behavior is associated with a high incidence of metastatic spread and a short patient survival recent studies have described loss of smarcb1 ini1 protein in poorly differentiated chordomas associated not with point mutations but with smarcb1 ini1 gene deletions instead in this study we considered immunohistochemistry and smarcb1 ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas 7 classic and 1 poorly differentiated we performed immunohistochemical tests for ini1 brachyury s100 and cytokeratins and conducted a genetic analysis on the smarcb1 coding sequence nm 003073 using the sanger method and multiplex ligation dependent probe amplification to detect abnormal copy numbers of the gene locus all 8 cases were positive for brachyury whereas there was no nuclear smarcb1 ini1 expression in 4 of the 8 cases including the poorly differentiated chordoma genetic analysis identified a missense mutation in 2 cases and a nonsense mutation associated with loss of smarcb1 ini1 protein and features of poorly differentiated tumor in 1 these mutations were novel variants occurring in heterozygosity and they were judged to be pathogenic by 3 different bioinformatic tools in 7 of 8 cases we performed multiplex ligation dependent probe amplification and 3 cases showed deletions at the smarcb1 locus our results confirm the pathogenic involvement of smarcb1 ini1 in childhood chordoma we also describe 3 novel pathogenic mutations.", "chordomas arise in the skull base and spine and usually occur in adults and are rare in the pediatric population cases of chordoma in pediatric age are often poorly differentiated showing cytologic atypia increased cellularity and mitosis and their aggressive behavior is associated with a high incidence of metastatic spread and a short patient survival recent studies have described loss of smarcb1 ini1 protein in poorly differentiated chordomas associated not with point mutations but with smarcb1 ini1 gene deletions instead in this study we considered immunohistochemistry and smarcb1 ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas 7 classic and 1 poorly differentiated we performed immunohistochemical tests for ini1 brachyury s100 and cytokeratins and conducted a genetic analysis on the smarcb1 coding sequence nm 003073 using the sanger method and multiplex ligation dependent probe amplification to detect abnormal copy numbers of the gene locus all 8 cases were positive for brachyury whereas there was no nuclear smarcb1 ini1 expression in 4 of the 8 cases including the poorly differentiated chordoma genetic analysis identified a missense mutation in 2 cases and a nonsense mutation associated with loss of smarcb1 ini1 protein and features of poorly differentiated tumor in 1 these mutations were novel variants occurring in heterozygosity and they were judged to be pathogenic by 3 different bioinformatic tools in 7 of 8 cases we performed multiplex ligation dependent probe amplification and 3 cases showed deletions at the smarcb1 locus our results confirm the pathogenic involvement of smarcb1 ini1 in childhood chordoma we also describe 3 novel pathogenic mutations.", "chordomas arise in the skull base and spine and usually occur in adults and are rare in the pediatric population cases of chordoma in pediatric age are often poorly differentiated showing cytologic atypia increased cellularity and mitosis and their aggressive behavior is associated with a high incidence of metastatic spread and a short patient survival recent studies have described loss of smarcb1 ini1 protein in poorly differentiated chordomas associated not with point mutations but with smarcb1 ini1 gene deletions instead in this study we considered immunohistochemistry and smarcb1 ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas 7 classic and 1 poorly differentiated we performed immunohistochemical tests for ini1 brachyury s100 and cytokeratins and conducted a genetic analysis on the smarcb1 coding sequence nm 003073 using the sanger method and multiplex ligation dependent probe amplification to detect abnormal copy numbers of the gene locus all 8 cases were positive for brachyury whereas there was no nuclear smarcb1 ini1 expression in 4 of the 8 cases including the poorly differentiated chordoma genetic analysis identified a missense mutation in 2 cases and a nonsense mutation associated with loss of smarcb1 ini1 protein and features of poorly differentiated tumor in 1 these mutations were novel variants occurring in heterozygosity and they were judged to be pathogenic by 3 different bioinformatic tools in 7 of 8 cases we performed multiplex ligation dependent probe amplification and 3 cases showed deletions at the smarcb1 locus our results confirm the pathogenic involvement of smarcb1 ini1 in childhood chordoma we also describe 3 novel pathogenic mutations.", "chordomas arise in the skull base and spine and usually occur in adults and are rare in the pediatric population cases of chordoma in pediatric age are often poorly differentiated showing cytologic atypia increased cellularity and mitosis and their aggressive behavior is associated with a high incidence of metastatic spread and a short patient survival recent studies have described loss of smarcb1 ini1 protein in poorly differentiated chordomas associated not with point mutations but with smarcb1 ini1 gene deletions instead in this study we considered immunohistochemistry and smarcb1 ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas 7 classic and 1 poorly differentiated we performed immunohistochemical tests for ini1 brachyury s100 and cytokeratins and conducted a genetic analysis on the smarcb1 coding sequence nm 003073 using the sanger method and multiplex ligation dependent probe amplification to detect abnormal copy numbers of the gene locus all 8 cases were positive for brachyury whereas there was no nuclear smarcb1 ini1 expression in 4 of the 8 cases including the poorly differentiated chordoma genetic analysis identified a missense mutation in 2 cases and a nonsense mutation associated with loss of smarcb1 ini1 protein and features of poorly differentiated tumor in 1 these mutations were novel variants occurring in heterozygosity and they were judged to be pathogenic by 3 different bioinformatic tools in 7 of 8 cases we performed multiplex ligation dependent probe amplification and 3 cases showed deletions at the smarcb1 locus our results confirm the pathogenic involvement of smarcb1 ini1 in childhood chordoma we also describe 3 novel pathogenic mutations.", "chordomas arise in the skull base and spine and usually occur in adults and are rare in the pediatric population cases of chordoma in pediatric age are often poorly differentiated showing cytologic atypia increased cellularity and mitosis and their aggressive behavior is associated with a high incidence of metastatic spread and a short patient survival recent studies have described loss of smarcb1 ini1 protein in poorly differentiated chordomas associated not with point mutations but with smarcb1 ini1 gene deletions instead in this study we considered immunohistochemistry and smarcb1 ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas 7 classic and 1 poorly differentiated we performed immunohistochemical tests for ini1 brachyury s100 and cytokeratins and conducted a genetic analysis on the smarcb1 coding sequence nm 003073 using the sanger method and multiplex ligation dependent probe amplification to detect abnormal copy numbers of the gene locus all 8 cases were positive for brachyury whereas there was no nuclear smarcb1 ini1 expression in 4 of the 8 cases including the poorly differentiated chordoma genetic analysis identified a missense mutation in 2 cases and a nonsense mutation associated with loss of smarcb1 ini1 protein and features of poorly differentiated tumor in 1 these mutations were novel variants occurring in heterozygosity and they were judged to be pathogenic by 3 different bioinformatic tools in 7 of 8 cases we performed multiplex ligation dependent probe amplification and 3 cases showed deletions at the smarcb1 locus our results confirm the pathogenic involvement of smarcb1 ini1 in childhood chordoma we also describe 3 novel pathogenic mutations.", "chordomas arise in the skull base and spine and usually occur in adults and are rare in the pediatric population cases of chordoma in pediatric age are often poorly differentiated showing cytologic atypia increased cellularity and mitosis and their aggressive behavior is associated with a high incidence of metastatic spread and a short patient survival recent studies have described loss of smarcb1 ini1 protein in poorly differentiated chordomas associated not with point mutations but with smarcb1 ini1 gene deletions instead in this study we considered immunohistochemistry and smarcb1 ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas 7 classic and 1 poorly differentiated we performed immunohistochemical tests for ini1 brachyury s100 and cytokeratins and conducted a genetic analysis on the smarcb1 coding sequence nm 003073 using the sanger method and multiplex ligation dependent probe amplification to detect abnormal copy numbers of the gene locus all 8 cases were positive for brachyury whereas there was no nuclear smarcb1 ini1 expression in 4 of the 8 cases including the poorly differentiated chordoma genetic analysis identified a missense mutation in 2 cases and a nonsense mutation associated with loss of smarcb1 ini1 protein and features of poorly differentiated tumor in 1 these mutations were novel variants occurring in heterozygosity and they were judged to be pathogenic by 3 different bioinformatic tools in 7 of 8 cases we performed multiplex ligation dependent probe amplification and 3 cases showed deletions at the smarcb1 locus our results confirm the pathogenic involvement of smarcb1 ini1 in childhood chordoma we also describe 3 novel pathogenic mutations.", "chordomas arise in the skull base and spine and usually occur in adults and are rare in the pediatric population cases of chordoma in pediatric age are often poorly differentiated showing cytologic atypia increased cellularity and mitosis and their aggressive behavior is associated with a high incidence of metastatic spread and a short patient survival recent studies have described loss of smarcb1 ini1 protein in poorly differentiated chordomas associated not with point mutations but with smarcb1 ini1 gene deletions instead in this study we considered immunohistochemistry and smarcb1 ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas 7 classic and 1 poorly differentiated we performed immunohistochemical tests for ini1 brachyury s100 and cytokeratins and conducted a genetic analysis on the smarcb1 coding sequence nm 003073 using the sanger method and multiplex ligation dependent probe amplification to detect abnormal copy numbers of the gene locus all 8 cases were positive for brachyury whereas there was no nuclear smarcb1 ini1 expression in 4 of the 8 cases including the poorly differentiated chordoma genetic analysis identified a missense mutation in 2 cases and a nonsense mutation associated with loss of smarcb1 ini1 protein and features of poorly differentiated tumor in 1 these mutations were novel variants occurring in heterozygosity and they were judged to be pathogenic by 3 different bioinformatic tools in 7 of 8 cases we performed multiplex ligation dependent probe amplification and 3 cases showed deletions at the smarcb1 locus our results confirm the pathogenic involvement of smarcb1 ini1 in childhood chordoma we also describe 3 novel pathogenic mutations.", "chordomas arise in the skull base and spine and usually occur in adults and are rare in the pediatric population cases of chordoma in pediatric age are often poorly differentiated showing cytologic atypia increased cellularity and mitosis and their aggressive behavior is associated with a high incidence of metastatic spread and a short patient survival recent studies have described loss of smarcb1 ini1 protein in poorly differentiated chordomas associated not with point mutations but with smarcb1 ini1 gene deletions instead in this study we considered immunohistochemistry and smarcb1 ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas 7 classic and 1 poorly differentiated we performed immunohistochemical tests for ini1 brachyury s100 and cytokeratins and conducted a genetic analysis on the smarcb1 coding sequence nm 003073 using the sanger method and multiplex ligation dependent probe amplification to detect abnormal copy numbers of the gene locus all 8 cases were positive for brachyury whereas there was no nuclear smarcb1 ini1 expression in 4 of the 8 cases including the poorly differentiated chordoma genetic analysis identified a missense mutation in 2 cases and a nonsense mutation associated with loss of smarcb1 ini1 protein and features of poorly differentiated tumor in 1 these mutations were novel variants occurring in heterozygosity and they were judged to be pathogenic by 3 different bioinformatic tools in 7 of 8 cases we performed multiplex ligation dependent probe amplification and 3 cases showed deletions at the smarcb1 locus our results confirm the pathogenic involvement of smarcb1 ini1 in childhood chordoma we also describe 3 novel pathogenic mutations.", "chordomas arise in the skull base and spine and usually occur in adults and are rare in the pediatric population cases of chordoma in pediatric age are often poorly differentiated showing cytologic atypia increased cellularity and mitosis and their aggressive behavior is associated with a high incidence of metastatic spread and a short patient survival recent studies have described loss of smarcb1 ini1 protein in poorly differentiated chordomas associated not with point mutations but with smarcb1 ini1 gene deletions instead in this study we considered immunohistochemistry and smarcb1 ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas 7 classic and 1 poorly differentiated we performed immunohistochemical tests for ini1 brachyury s100 and cytokeratins and conducted a genetic analysis on the smarcb1 coding sequence nm 003073 using the sanger method and multiplex ligation dependent probe amplification to detect abnormal copy numbers of the gene locus all 8 cases were positive for brachyury whereas there was no nuclear smarcb1 ini1 expression in 4 of the 8 cases including the poorly differentiated chordoma genetic analysis identified a missense mutation in 2 cases and a nonsense mutation associated with loss of smarcb1 ini1 protein and features of poorly differentiated tumor in 1 these mutations were novel variants occurring in heterozygosity and they were judged to be pathogenic by 3 different bioinformatic tools in 7 of 8 cases we performed multiplex ligation dependent probe amplification and 3 cases showed deletions at the smarcb1 locus our results confirm the pathogenic involvement of smarcb1 ini1 in childhood chordoma we also describe 3 novel pathogenic mutations.", "chordomas arise in the skull base and spine and usually occur in adults and are rare in the pediatric population cases of chordoma in pediatric age are often poorly differentiated showing cytologic atypia increased cellularity and mitosis and their aggressive behavior is associated with a high incidence of metastatic spread and a short patient survival recent studies have described loss of smarcb1 ini1 protein in poorly differentiated chordomas associated not with point mutations but with smarcb1 ini1 gene deletions instead in this study we considered immunohistochemistry and smarcb1 ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas 7 classic and 1 poorly differentiated we performed immunohistochemical tests for ini1 brachyury s100 and cytokeratins and conducted a genetic analysis on the smarcb1 coding sequence nm 003073 using the sanger method and multiplex ligation dependent probe amplification to detect abnormal copy numbers of the gene locus all 8 cases were positive for brachyury whereas there was no nuclear smarcb1 ini1 expression in 4 of the 8 cases including the poorly differentiated chordoma genetic analysis identified a missense mutation in 2 cases and a nonsense mutation associated with loss of smarcb1 ini1 protein and features of poorly differentiated tumor in 1 these mutations were novel variants occurring in heterozygosity and they were judged to be pathogenic by 3 different bioinformatic tools in 7 of 8 cases we performed multiplex ligation dependent probe amplification and 3 cases showed deletions at the smarcb1 locus our results confirm the pathogenic involvement of smarcb1 ini1 in childhood chordoma we also describe 3 novel pathogenic mutations.", "chordomas arise in the skull base and spine and usually occur in adults and are rare in the pediatric population cases of chordoma in pediatric age are often poorly differentiated showing cytologic atypia increased cellularity and mitosis and their aggressive behavior is associated with a high incidence of metastatic spread and a short patient survival recent studies have described loss of smarcb1 ini1 protein in poorly differentiated chordomas associated not with point mutations but with smarcb1 ini1 gene deletions instead in this study we considered immunohistochemistry and smarcb1 ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas 7 classic and 1 poorly differentiated we performed immunohistochemical tests for ini1 brachyury s100 and cytokeratins and conducted a genetic analysis on the smarcb1 coding sequence nm 003073 using the sanger method and multiplex ligation dependent probe amplification to detect abnormal copy numbers of the gene locus all 8 cases were positive for brachyury whereas there was no nuclear smarcb1 ini1 expression in 4 of the 8 cases including the poorly differentiated chordoma genetic analysis identified a missense mutation in 2 cases and a nonsense mutation associated with loss of smarcb1 ini1 protein and features of poorly differentiated tumor in 1 these mutations were novel variants occurring in heterozygosity and they were judged to be pathogenic by 3 different bioinformatic tools in 7 of 8 cases we performed multiplex ligation dependent probe amplification and 3 cases showed deletions at the smarcb1 locus our results confirm the pathogenic involvement of smarcb1 ini1 in childhood chordoma we also describe 3 novel pathogenic mutations.", "chordomas arise in the skull base and spine and usually occur in adults and are rare in the pediatric population cases of chordoma in pediatric age are often poorly differentiated showing cytologic atypia increased cellularity and mitosis and their aggressive behavior is associated with a high incidence of metastatic spread and a short patient survival recent studies have described loss of smarcb1 ini1 protein in poorly differentiated chordomas associated not with point mutations but with smarcb1 ini1 gene deletions instead in this study we considered immunohistochemistry and smarcb1 ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas 7 classic and 1 poorly differentiated we performed immunohistochemical tests for ini1 brachyury s100 and cytokeratins and conducted a genetic analysis on the smarcb1 coding sequence nm 003073 using the sanger method and multiplex ligation dependent probe amplification to detect abnormal copy numbers of the gene locus all 8 cases were positive for brachyury whereas there was no nuclear smarcb1 ini1 expression in 4 of the 8 cases including the poorly differentiated chordoma genetic analysis identified a missense mutation in 2 cases and a nonsense mutation associated with loss of smarcb1 ini1 protein and features of poorly differentiated tumor in 1 these mutations were novel variants occurring in heterozygosity and they were judged to be pathogenic by 3 different bioinformatic tools in 7 of 8 cases we performed multiplex ligation dependent probe amplification and 3 cases showed deletions at the smarcb1 locus our results confirm the pathogenic involvement of smarcb1 ini1 in childhood chordoma we also describe 3 novel pathogenic mutations.", "chordomas arise in the skull base and spine and usually occur in adults and are rare in the pediatric population cases of chordoma in pediatric age are often poorly differentiated showing cytologic atypia increased cellularity and mitosis and their aggressive behavior is associated with a high incidence of metastatic spread and a short patient survival recent studies have described loss of smarcb1 ini1 protein in poorly differentiated chordomas associated not with point mutations but with smarcb1 ini1 gene deletions instead in this study we considered immunohistochemistry and smarcb1 ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas 7 classic and 1 poorly differentiated we performed immunohistochemical tests for ini1 brachyury s100 and cytokeratins and conducted a genetic analysis on the smarcb1 coding sequence nm 003073 using the sanger method and multiplex ligation dependent probe amplification to detect abnormal copy numbers of the gene locus all 8 cases were positive for brachyury whereas there was no nuclear smarcb1 ini1 expression in 4 of the 8 cases including the poorly differentiated chordoma genetic analysis identified a missense mutation in 2 cases and a nonsense mutation associated with loss of smarcb1 ini1 protein and features of poorly differentiated tumor in 1 these mutations were novel variants occurring in heterozygosity and they were judged to be pathogenic by 3 different bioinformatic tools in 7 of 8 cases we performed multiplex ligation dependent probe amplification and 3 cases showed deletions at the smarcb1 locus our results confirm the pathogenic involvement of smarcb1 ini1 in childhood chordoma we also describe 3 novel pathogenic mutations.", "chordomas arise in the skull base and spine and usually occur in adults and are rare in the pediatric population cases of chordoma in pediatric age are often poorly differentiated showing cytologic atypia increased cellularity and mitosis and their aggressive behavior is associated with a high incidence of metastatic spread and a short patient survival recent studies have described loss of smarcb1 ini1 protein in poorly differentiated chordomas associated not with point mutations but with smarcb1 ini1 gene deletions instead in this study we considered immunohistochemistry and smarcb1 ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas 7 classic and 1 poorly differentiated we performed immunohistochemical tests for ini1 brachyury s100 and cytokeratins and conducted a genetic analysis on the smarcb1 coding sequence nm 003073 using the sanger method and multiplex ligation dependent probe amplification to detect abnormal copy numbers of the gene locus all 8 cases were positive for brachyury whereas there was no nuclear smarcb1 ini1 expression in 4 of the 8 cases including the poorly differentiated chordoma genetic analysis identified a missense mutation in 2 cases and a nonsense mutation associated with loss of smarcb1 ini1 protein and features of poorly differentiated tumor in 1 these mutations were novel variants occurring in heterozygosity and they were judged to be pathogenic by 3 different bioinformatic tools in 7 of 8 cases we performed multiplex ligation dependent probe amplification and 3 cases showed deletions at the smarcb1 locus our results confirm the pathogenic involvement of smarcb1 ini1 in childhood chordoma we also describe 3 novel pathogenic mutations.", "chordomas arise in the skull base and spine and usually occur in adults and are rare in the pediatric population cases of chordoma in pediatric age are often poorly differentiated showing cytologic atypia increased cellularity and mitosis and their aggressive behavior is associated with a high incidence of metastatic spread and a short patient survival recent studies have described loss of smarcb1 ini1 protein in poorly differentiated chordomas associated not with point mutations but with smarcb1 ini1 gene deletions instead in this study we considered immunohistochemistry and smarcb1 ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas 7 classic and 1 poorly differentiated we performed immunohistochemical tests for ini1 brachyury s100 and cytokeratins and conducted a genetic analysis on the smarcb1 coding sequence nm 003073 using the sanger method and multiplex ligation dependent probe amplification to detect abnormal copy numbers of the gene locus all 8 cases were positive for brachyury whereas there was no nuclear smarcb1 ini1 expression in 4 of the 8 cases including the poorly differentiated chordoma genetic analysis identified a missense mutation in 2 cases and a nonsense mutation associated with loss of smarcb1 ini1 protein and features of poorly differentiated tumor in 1 these mutations were novel variants occurring in heterozygosity and they were judged to be pathogenic by 3 different bioinformatic tools in 7 of 8 cases we performed multiplex ligation dependent probe amplification and 3 cases showed deletions at the smarcb1 locus our results confirm the pathogenic involvement of smarcb1 ini1 in childhood chordoma we also describe 3 novel pathogenic mutations.", "chordomas arise in the skull base and spine and usually occur in adults and are rare in the pediatric population cases of chordoma in pediatric age are often poorly differentiated showing cytologic atypia increased cellularity and mitosis and their aggressive behavior is associated with a high incidence of metastatic spread and a short patient survival recent studies have described loss of smarcb1 ini1 protein in poorly differentiated chordomas associated not with point mutations but with smarcb1 ini1 gene deletions instead in this study we considered immunohistochemistry and smarcb1 ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas 7 classic and 1 poorly differentiated we performed immunohistochemical tests for ini1 brachyury s100 and cytokeratins and conducted a genetic analysis on the smarcb1 coding sequence nm 003073 using the sanger method and multiplex ligation dependent probe amplification to detect abnormal copy numbers of the gene locus all 8 cases were positive for brachyury whereas there was no nuclear smarcb1 ini1 expression in 4 of the 8 cases including the poorly differentiated chordoma genetic analysis identified a missense mutation in 2 cases and a nonsense mutation associated with loss of smarcb1 ini1 protein and features of poorly differentiated tumor in 1 these mutations were novel variants occurring in heterozygosity and they were judged to be pathogenic by 3 different bioinformatic tools in 7 of 8 cases we performed multiplex ligation dependent probe amplification and 3 cases showed deletions at the smarcb1 locus our results confirm the pathogenic involvement of smarcb1 ini1 in childhood chordoma we also describe 3 novel pathogenic mutations.", "chordomas arise in the skull base and spine and usually occur in adults and are rare in the pediatric population cases of chordoma in pediatric age are often poorly differentiated showing cytologic atypia increased cellularity and mitosis and their aggressive behavior is associated with a high incidence of metastatic spread and a short patient survival recent studies have described loss of smarcb1 ini1 protein in poorly differentiated chordomas associated not with point mutations but with smarcb1 ini1 gene deletions instead in this study we considered immunohistochemistry and smarcb1 ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas 7 classic and 1 poorly differentiated we performed immunohistochemical tests for ini1 brachyury s100 and cytokeratins and conducted a genetic analysis on the smarcb1 coding sequence nm 003073 using the sanger method and multiplex ligation dependent probe amplification to detect abnormal copy numbers of the gene locus all 8 cases were positive for brachyury whereas there was no nuclear smarcb1 ini1 expression in 4 of the 8 cases including the poorly differentiated chordoma genetic analysis identified a missense mutation in 2 cases and a nonsense mutation associated with loss of smarcb1 ini1 protein and features of poorly differentiated tumor in 1 these mutations were novel variants occurring in heterozygosity and they were judged to be pathogenic by 3 different bioinformatic tools in 7 of 8 cases we performed multiplex ligation dependent probe amplification and 3 cases showed deletions at the smarcb1 locus our results confirm the pathogenic involvement of smarcb1 ini1 in childhood chordoma we also describe 3 novel pathogenic mutations.", "chordomas arise in the skull base and spine and usually occur in adults and are rare in the pediatric population cases of chordoma in pediatric age are often poorly differentiated showing cytologic atypia increased cellularity and mitosis and their aggressive behavior is associated with a high incidence of metastatic spread and a short patient survival recent studies have described loss of smarcb1 ini1 protein in poorly differentiated chordomas associated not with point mutations but with smarcb1 ini1 gene deletions instead in this study we considered immunohistochemistry and smarcb1 ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas 7 classic and 1 poorly differentiated we performed immunohistochemical tests for ini1 brachyury s100 and cytokeratins and conducted a genetic analysis on the smarcb1 coding sequence nm 003073 using the sanger method and multiplex ligation dependent probe amplification to detect abnormal copy numbers of the gene locus all 8 cases were positive for brachyury whereas there was no nuclear smarcb1 ini1 expression in 4 of the 8 cases including the poorly differentiated chordoma genetic analysis identified a missense mutation in 2 cases and a nonsense mutation associated with loss of smarcb1 ini1 protein and features of poorly differentiated tumor in 1 these mutations were novel variants occurring in heterozygosity and they were judged to be pathogenic by 3 different bioinformatic tools in 7 of 8 cases we performed multiplex ligation dependent probe amplification and 3 cases showed deletions at the smarcb1 locus our results confirm the pathogenic involvement of smarcb1 ini1 in childhood chordoma we also describe 3 novel pathogenic mutations.", "chordomas arise in the skull base and spine and usually occur in adults and are rare in the pediatric population cases of chordoma in pediatric age are often poorly differentiated showing cytologic atypia increased cellularity and mitosis and their aggressive behavior is associated with a high incidence of metastatic spread and a short patient survival recent studies have described loss of smarcb1 ini1 protein in poorly differentiated chordomas associated not with point mutations but with smarcb1 ini1 gene deletions instead in this study we considered immunohistochemistry and smarcb1 ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas 7 classic and 1 poorly differentiated we performed immunohistochemical tests for ini1 brachyury s100 and cytokeratins and conducted a genetic analysis on the smarcb1 coding sequence nm 003073 using the sanger method and multiplex ligation dependent probe amplification to detect abnormal copy numbers of the gene locus all 8 cases were positive for brachyury whereas there was no nuclear smarcb1 ini1 expression in 4 of the 8 cases including the poorly differentiated chordoma genetic analysis identified a missense mutation in 2 cases and a nonsense mutation associated with loss of smarcb1 ini1 protein and features of poorly differentiated tumor in 1 these mutations were novel variants occurring in heterozygosity and they were judged to be pathogenic by 3 different bioinformatic tools in 7 of 8 cases we performed multiplex ligation dependent probe amplification and 3 cases showed deletions at the smarcb1 locus our results confirm the pathogenic involvement of smarcb1 ini1 in childhood chordoma we also describe 3 novel pathogenic mutations.", "chordomas arise in the skull base and spine and usually occur in adults and are rare in the pediatric population cases of chordoma in pediatric age are often poorly differentiated showing cytologic atypia increased cellularity and mitosis and their aggressive behavior is associated with a high incidence of metastatic spread and a short patient survival recent studies have described loss of smarcb1 ini1 protein in poorly differentiated chordomas associated not with point mutations but with smarcb1 ini1 gene deletions instead in this study we considered immunohistochemistry and smarcb1 ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas 7 classic and 1 poorly differentiated we performed immunohistochemical tests for ini1 brachyury s100 and cytokeratins and conducted a genetic analysis on the smarcb1 coding sequence nm 003073 using the sanger method and multiplex ligation dependent probe amplification to detect abnormal copy numbers of the gene locus all 8 cases were positive for brachyury whereas there was no nuclear smarcb1 ini1 expression in 4 of the 8 cases including the poorly differentiated chordoma genetic analysis identified a missense mutation in 2 cases and a nonsense mutation associated with loss of smarcb1 ini1 protein and features of poorly differentiated tumor in 1 these mutations were novel variants occurring in heterozygosity and they were judged to be pathogenic by 3 different bioinformatic tools in 7 of 8 cases we performed multiplex ligation dependent probe amplification and 3 cases showed deletions at the smarcb1 locus our results confirm the pathogenic involvement of smarcb1 ini1 in childhood chordoma we also describe 3 novel pathogenic mutations.", "chordomas arise in the skull base and spine and usually occur in adults and are rare in the pediatric population cases of chordoma in pediatric age are often poorly differentiated showing cytologic atypia increased cellularity and mitosis and their aggressive behavior is associated with a high incidence of metastatic spread and a short patient survival recent studies have described loss of smarcb1 ini1 protein in poorly differentiated chordomas associated not with point mutations but with smarcb1 ini1 gene deletions instead in this study we considered immunohistochemistry and smarcb1 ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas 7 classic and 1 poorly differentiated we performed immunohistochemical tests for ini1 brachyury s100 and cytokeratins and conducted a genetic analysis on the smarcb1 coding sequence nm 003073 using the sanger method and multiplex ligation dependent probe amplification to detect abnormal copy numbers of the gene locus all 8 cases were positive for brachyury whereas there was no nuclear smarcb1 ini1 expression in 4 of the 8 cases including the poorly differentiated chordoma genetic analysis identified a missense mutation in 2 cases and a nonsense mutation associated with loss of smarcb1 ini1 protein and features of poorly differentiated tumor in 1 these mutations were novel variants occurring in heterozygosity and they were judged to be pathogenic by 3 different bioinformatic tools in 7 of 8 cases we performed multiplex ligation dependent probe amplification and 3 cases showed deletions at the smarcb1 locus our results confirm the pathogenic involvement of smarcb1 ini1 in childhood chordoma we also describe 3 novel pathogenic mutations.", "chordomas arise in the skull base and spine and usually occur in adults and are rare in the pediatric population cases of chordoma in pediatric age are often poorly differentiated showing cytologic atypia increased cellularity and mitosis and their aggressive behavior is associated with a high incidence of metastatic spread and a short patient survival recent studies have described loss of smarcb1 ini1 protein in poorly differentiated chordomas associated not with point mutations but with smarcb1 ini1 gene deletions instead in this study we considered immunohistochemistry and smarcb1 ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas 7 classic and 1 poorly differentiated we performed immunohistochemical tests for ini1 brachyury s100 and cytokeratins and conducted a genetic analysis on the smarcb1 coding sequence nm 003073 using the sanger method and multiplex ligation dependent probe amplification to detect abnormal copy numbers of the gene locus all 8 cases were positive for brachyury whereas there was no nuclear smarcb1 ini1 expression in 4 of the 8 cases including the poorly differentiated chordoma genetic analysis identified a missense mutation in 2 cases and a nonsense mutation associated with loss of smarcb1 ini1 protein and features of poorly differentiated tumor in 1 these mutations were novel variants occurring in heterozygosity and they were judged to be pathogenic by 3 different bioinformatic tools in 7 of 8 cases we performed multiplex ligation dependent probe amplification and 3 cases showed deletions at the smarcb1 locus our results confirm the pathogenic involvement of smarcb1 ini1 in childhood chordoma we also describe 3 novel pathogenic mutations.", "chordomas arise in the skull base and spine and usually occur in adults and are rare in the pediatric population cases of chordoma in pediatric age are often poorly differentiated showing cytologic atypia increased cellularity and mitosis and their aggressive behavior is associated with a high incidence of metastatic spread and a short patient survival recent studies have described loss of smarcb1 ini1 protein in poorly differentiated chordomas associated not with point mutations but with smarcb1 ini1 gene deletions instead in this study we considered immunohistochemistry and smarcb1 ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas 7 classic and 1 poorly differentiated we performed immunohistochemical tests for ini1 brachyury s100 and cytokeratins and conducted a genetic analysis on the smarcb1 coding sequence nm 003073 using the sanger method and multiplex ligation dependent probe amplification to detect abnormal copy numbers of the gene locus all 8 cases were positive for brachyury whereas there was no nuclear smarcb1 ini1 expression in 4 of the 8 cases including the poorly differentiated chordoma genetic analysis identified a missense mutation in 2 cases and a nonsense mutation associated with loss of smarcb1 ini1 protein and features of poorly differentiated tumor in 1 these mutations were novel variants occurring in heterozygosity and they were judged to be pathogenic by 3 different bioinformatic tools in 7 of 8 cases we performed multiplex ligation dependent probe amplification and 3 cases showed deletions at the smarcb1 locus our results confirm the pathogenic involvement of smarcb1 ini1 in childhood chordoma we also describe 3 novel pathogenic mutations.", "chordomas arise in the skull base and spine and usually occur in adults and are rare in the pediatric population cases of chordoma in pediatric age are often poorly differentiated showing cytologic atypia increased cellularity and mitosis and their aggressive behavior is associated with a high incidence of metastatic spread and a short patient survival recent studies have described loss of smarcb1 ini1 protein in poorly differentiated chordomas associated not with point mutations but with smarcb1 ini1 gene deletions instead in this study we considered immunohistochemistry and smarcb1 ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas 7 classic and 1 poorly differentiated we performed immunohistochemical tests for ini1 brachyury s100 and cytokeratins and conducted a genetic analysis on the smarcb1 coding sequence nm 003073 using the sanger method and multiplex ligation dependent probe amplification to detect abnormal copy numbers of the gene locus all 8 cases were positive for brachyury whereas there was no nuclear smarcb1 ini1 expression in 4 of the 8 cases including the poorly differentiated chordoma genetic analysis identified a missense mutation in 2 cases and a nonsense mutation associated with loss of smarcb1 ini1 protein and features of poorly differentiated tumor in 1 these mutations were novel variants occurring in heterozygosity and they were judged to be pathogenic by 3 different bioinformatic tools in 7 of 8 cases we performed multiplex ligation dependent probe amplification and 3 cases showed deletions at the smarcb1 locus our results confirm the pathogenic involvement of smarcb1 ini1 in childhood chordoma we also describe 3 novel pathogenic mutations.", "chordomas arise in the skull base and spine and usually occur in adults and are rare in the pediatric population cases of chordoma in pediatric age are often poorly differentiated showing cytologic atypia increased cellularity and mitosis and their aggressive behavior is associated with a high incidence of metastatic spread and a short patient survival recent studies have described loss of smarcb1 ini1 protein in poorly differentiated chordomas associated not with point mutations but with smarcb1 ini1 gene deletions instead in this study we considered immunohistochemistry and smarcb1 ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas 7 classic and 1 poorly differentiated we performed immunohistochemical tests for ini1 brachyury s100 and cytokeratins and conducted a genetic analysis on the smarcb1 coding sequence nm 003073 using the sanger method and multiplex ligation dependent probe amplification to detect abnormal copy numbers of the gene locus all 8 cases were positive for brachyury whereas there was no nuclear smarcb1 ini1 expression in 4 of the 8 cases including the poorly differentiated chordoma genetic analysis identified a missense mutation in 2 cases and a nonsense mutation associated with loss of smarcb1 ini1 protein and features of poorly differentiated tumor in 1 these mutations were novel variants occurring in heterozygosity and they were judged to be pathogenic by 3 different bioinformatic tools in 7 of 8 cases we performed multiplex ligation dependent probe amplification and 3 cases showed deletions at the smarcb1 locus our results confirm the pathogenic involvement of smarcb1 ini1 in childhood chordoma we also describe 3 novel pathogenic mutations.", "chordomas arise in the skull base and spine and usually occur in adults and are rare in the pediatric population cases of chordoma in pediatric age are often poorly differentiated showing cytologic atypia increased cellularity and mitosis and their aggressive behavior is associated with a high incidence of metastatic spread and a short patient survival recent studies have described loss of smarcb1 ini1 protein in poorly differentiated chordomas associated not with point mutations but with smarcb1 ini1 gene deletions instead in this study we considered immunohistochemistry and smarcb1 ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas 7 classic and 1 poorly differentiated we performed immunohistochemical tests for ini1 brachyury s100 and cytokeratins and conducted a genetic analysis on the smarcb1 coding sequence nm 003073 using the sanger method and multiplex ligation dependent probe amplification to detect abnormal copy numbers of the gene locus all 8 cases were positive for brachyury whereas there was no nuclear smarcb1 ini1 expression in 4 of the 8 cases including the poorly differentiated chordoma genetic analysis identified a missense mutation in 2 cases and a nonsense mutation associated with loss of smarcb1 ini1 protein and features of poorly differentiated tumor in 1 these mutations were novel variants occurring in heterozygosity and they were judged to be pathogenic by 3 different bioinformatic tools in 7 of 8 cases we performed multiplex ligation dependent probe amplification and 3 cases showed deletions at the smarcb1 locus our results confirm the pathogenic involvement of smarcb1 ini1 in childhood chordoma we also describe 3 novel pathogenic mutations.", "chordomas arise in the skull base and spine and usually occur in adults and are rare in the pediatric population cases of chordoma in pediatric age are often poorly differentiated showing cytologic atypia increased cellularity and mitosis and their aggressive behavior is associated with a high incidence of metastatic spread and a short patient survival recent studies have described loss of smarcb1 ini1 protein in poorly differentiated chordomas associated not with point mutations but with smarcb1 ini1 gene deletions instead in this study we considered immunohistochemistry and smarcb1 ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas 7 classic and 1 poorly differentiated we performed immunohistochemical tests for ini1 brachyury s100 and cytokeratins and conducted a genetic analysis on the smarcb1 coding sequence nm 003073 using the sanger method and multiplex ligation dependent probe amplification to detect abnormal copy numbers of the gene locus all 8 cases were positive for brachyury whereas there was no nuclear smarcb1 ini1 expression in 4 of the 8 cases including the poorly differentiated chordoma genetic analysis identified a missense mutation in 2 cases and a nonsense mutation associated with loss of smarcb1 ini1 protein and features of poorly differentiated tumor in 1 these mutations were novel variants occurring in heterozygosity and they were judged to be pathogenic by 3 different bioinformatic tools in 7 of 8 cases we performed multiplex ligation dependent probe amplification and 3 cases showed deletions at the smarcb1 locus our results confirm the pathogenic involvement of smarcb1 ini1 in childhood chordoma we also describe 3 novel pathogenic mutations.", "chordomas arise in the skull base and spine and usually occur in adults and are rare in the pediatric population cases of chordoma in pediatric age are often poorly differentiated showing cytologic atypia increased cellularity and mitosis and their aggressive behavior is associated with a high incidence of metastatic spread and a short patient survival recent studies have described loss of smarcb1 ini1 protein in poorly differentiated chordomas associated not with point mutations but with smarcb1 ini1 gene deletions instead in this study we considered immunohistochemistry and smarcb1 ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas 7 classic and 1 poorly differentiated we performed immunohistochemical tests for ini1 brachyury s100 and cytokeratins and conducted a genetic analysis on the smarcb1 coding sequence nm 003073 using the sanger method and multiplex ligation dependent probe amplification to detect abnormal copy numbers of the gene locus all 8 cases were positive for brachyury whereas there was no nuclear smarcb1 ini1 expression in 4 of the 8 cases including the poorly differentiated chordoma genetic analysis identified a missense mutation in 2 cases and a nonsense mutation associated with loss of smarcb1 ini1 protein and features of poorly differentiated tumor in 1 these mutations were novel variants occurring in heterozygosity and they were judged to be pathogenic by 3 different bioinformatic tools in 7 of 8 cases we performed multiplex ligation dependent probe amplification and 3 cases showed deletions at the smarcb1 locus our results confirm the pathogenic involvement of smarcb1 ini1 in childhood chordoma we also describe 3 novel pathogenic mutations.", "chordomas arise in the skull base and spine and usually occur in adults and are rare in the pediatric population cases of chordoma in pediatric age are often poorly differentiated showing cytologic atypia increased cellularity and mitosis and their aggressive behavior is associated with a high incidence of metastatic spread and a short patient survival recent studies have described loss of smarcb1 ini1 protein in poorly differentiated chordomas associated not with point mutations but with smarcb1 ini1 gene deletions instead in this study we considered immunohistochemistry and smarcb1 ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas 7 classic and 1 poorly differentiated we performed immunohistochemical tests for ini1 brachyury s100 and cytokeratins and conducted a genetic analysis on the smarcb1 coding sequence nm 003073 using the sanger method and multiplex ligation dependent probe amplification to detect abnormal copy numbers of the gene locus all 8 cases were positive for brachyury whereas there was no nuclear smarcb1 ini1 expression in 4 of the 8 cases including the poorly differentiated chordoma genetic analysis identified a missense mutation in 2 cases and a nonsense mutation associated with loss of smarcb1 ini1 protein and features of poorly differentiated tumor in 1 these mutations were novel variants occurring in heterozygosity and they were judged to be pathogenic by 3 different bioinformatic tools in 7 of 8 cases we performed multiplex ligation dependent probe amplification and 3 cases showed deletions at the smarcb1 locus our results confirm the pathogenic involvement of smarcb1 ini1 in childhood chordoma we also describe 3 novel pathogenic mutations.", "loss of smarcb1 ini1 expression is considered to be a hallmark for childhood chordomas ccs although mutation loss of 22q has strongly established the loss of smarcb1 ini1 in cancers the cause in ccs remains elusive recent studies suggest role of mirnas in regulation of smarcb1 ini1 expressions we examined 5 reported target predicted mirnas to smarcb1 ini1 in smarcb1 ini1 immunonegative and immunopositive cases and found upregulation of mir 671 5p and mir 193a 5p in smarcb1 ini1 immunonegative cases notably these two mirnas were significantly predicted to target tgf \u03b2 signaling suggestive of dysregulation of developmental and osteoblast regulation pathway in ccs overall we suggest mir 671 5p and mir 193a 5p mediated epigenetic mode of smarcb1 ini1 loss and downregulated tgf \u03b2 pathway in ccs.", "loss of smarcb1 ini1 expression is considered to be a hallmark for childhood chordomas ccs although mutation loss of 22q has strongly established the loss of smarcb1 ini1 in cancers the cause in ccs remains elusive recent studies suggest role of mirnas in regulation of smarcb1 ini1 expressions we examined 5 reported target predicted mirnas to smarcb1 ini1 in smarcb1 ini1 immunonegative and immunopositive cases and found upregulation of mir 671 5p and mir 193a 5p in smarcb1 ini1 immunonegative cases notably these two mirnas were significantly predicted to target tgf \u03b2 signaling suggestive of dysregulation of developmental and osteoblast regulation pathway in ccs overall we suggest mir 671 5p and mir 193a 5p mediated epigenetic mode of smarcb1 ini1 loss and downregulated tgf \u03b2 pathway in ccs.", "loss of smarcb1 ini1 expression is considered to be a hallmark for childhood chordomas ccs although mutation loss of 22q has strongly established the loss of smarcb1 ini1 in cancers the cause in ccs remains elusive recent studies suggest role of mirnas in regulation of smarcb1 ini1 expressions we examined 5 reported target predicted mirnas to smarcb1 ini1 in smarcb1 ini1 immunonegative and immunopositive cases and found upregulation of mir 671 5p and mir 193a 5p in smarcb1 ini1 immunonegative cases notably these two mirnas were significantly predicted to target tgf \u03b2 signaling suggestive of dysregulation of developmental and osteoblast regulation pathway in ccs overall we suggest mir 671 5p and mir 193a 5p mediated epigenetic mode of smarcb1 ini1 loss and downregulated tgf \u03b2 pathway in ccs.", "loss of smarcb1 ini1 expression is considered to be a hallmark for childhood chordomas ccs although mutation loss of 22q has strongly established the loss of smarcb1 ini1 in cancers the cause in ccs remains elusive recent studies suggest role of mirnas in regulation of smarcb1 ini1 expressions we examined 5 reported target predicted mirnas to smarcb1 ini1 in smarcb1 ini1 immunonegative and immunopositive cases and found upregulation of mir 671 5p and mir 193a 5p in smarcb1 ini1 immunonegative cases notably these two mirnas were significantly predicted to target tgf \u03b2 signaling suggestive of dysregulation of developmental and osteoblast regulation pathway in ccs overall we suggest mir 671 5p and mir 193a 5p mediated epigenetic mode of smarcb1 ini1 loss and downregulated tgf \u03b2 pathway in ccs.", "loss of smarcb1 ini1 expression is considered to be a hallmark for childhood chordomas ccs although mutation loss of 22q has strongly established the loss of smarcb1 ini1 in cancers the cause in ccs remains elusive recent studies suggest role of mirnas in regulation of smarcb1 ini1 expressions we examined 5 reported target predicted mirnas to smarcb1 ini1 in smarcb1 ini1 immunonegative and immunopositive cases and found upregulation of mir 671 5p and mir 193a 5p in smarcb1 ini1 immunonegative cases notably these two mirnas were significantly predicted to target tgf \u03b2 signaling suggestive of dysregulation of developmental and osteoblast regulation pathway in ccs overall we suggest mir 671 5p and mir 193a 5p mediated epigenetic mode of smarcb1 ini1 loss and downregulated tgf \u03b2 pathway in ccs.", "loss of smarcb1 ini1 expression is considered to be a hallmark for childhood chordomas ccs although mutation loss of 22q has strongly established the loss of smarcb1 ini1 in cancers the cause in ccs remains elusive recent studies suggest role of mirnas in regulation of smarcb1 ini1 expressions we examined 5 reported target predicted mirnas to smarcb1 ini1 in smarcb1 ini1 immunonegative and immunopositive cases and found upregulation of mir 671 5p and mir 193a 5p in smarcb1 ini1 immunonegative cases notably these two mirnas were significantly predicted to target tgf \u03b2 signaling suggestive of dysregulation of developmental and osteoblast regulation pathway in ccs overall we suggest mir 671 5p and mir 193a 5p mediated epigenetic mode of smarcb1 ini1 loss and downregulated tgf \u03b2 pathway in ccs.", "loss of smarcb1 ini1 expression is considered to be a hallmark for childhood chordomas ccs although mutation loss of 22q has strongly established the loss of smarcb1 ini1 in cancers the cause in ccs remains elusive recent studies suggest role of mirnas in regulation of smarcb1 ini1 expressions we examined 5 reported target predicted mirnas to smarcb1 ini1 in smarcb1 ini1 immunonegative and immunopositive cases and found upregulation of mir 671 5p and mir 193a 5p in smarcb1 ini1 immunonegative cases notably these two mirnas were significantly predicted to target tgf \u03b2 signaling suggestive of dysregulation of developmental and osteoblast regulation pathway in ccs overall we suggest mir 671 5p and mir 193a 5p mediated epigenetic mode of smarcb1 ini1 loss and downregulated tgf \u03b2 pathway in ccs.", "loss of smarcb1 ini1 expression is considered to be a hallmark for childhood chordomas ccs although mutation loss of 22q has strongly established the loss of smarcb1 ini1 in cancers the cause in ccs remains elusive recent studies suggest role of mirnas in regulation of smarcb1 ini1 expressions we examined 5 reported target predicted mirnas to smarcb1 ini1 in smarcb1 ini1 immunonegative and immunopositive cases and found upregulation of mir 671 5p and mir 193a 5p in smarcb1 ini1 immunonegative cases notably these two mirnas were significantly predicted to target tgf \u03b2 signaling suggestive of dysregulation of developmental and osteoblast regulation pathway in ccs overall we suggest mir 671 5p and mir 193a 5p mediated epigenetic mode of smarcb1 ini1 loss and downregulated tgf \u03b2 pathway in ccs.", "loss of smarcb1 ini1 expression is considered to be a hallmark for childhood chordomas ccs although mutation loss of 22q has strongly established the loss of smarcb1 ini1 in cancers the cause in ccs remains elusive recent studies suggest role of mirnas in regulation of smarcb1 ini1 expressions we examined 5 reported target predicted mirnas to smarcb1 ini1 in smarcb1 ini1 immunonegative and immunopositive cases and found upregulation of mir 671 5p and mir 193a 5p in smarcb1 ini1 immunonegative cases notably these two mirnas were significantly predicted to target tgf \u03b2 signaling suggestive of dysregulation of developmental and osteoblast regulation pathway in ccs overall we suggest mir 671 5p and mir 193a 5p mediated epigenetic mode of smarcb1 ini1 loss and downregulated tgf \u03b2 pathway in ccs.", "loss of smarcb1 ini1 expression is considered to be a hallmark for childhood chordomas ccs although mutation loss of 22q has strongly established the loss of smarcb1 ini1 in cancers the cause in ccs remains elusive recent studies suggest role of mirnas in regulation of smarcb1 ini1 expressions we examined 5 reported target predicted mirnas to smarcb1 ini1 in smarcb1 ini1 immunonegative and immunopositive cases and found upregulation of mir 671 5p and mir 193a 5p in smarcb1 ini1 immunonegative cases notably these two mirnas were significantly predicted to target tgf \u03b2 signaling suggestive of dysregulation of developmental and osteoblast regulation pathway in ccs overall we suggest mir 671 5p and mir 193a 5p mediated epigenetic mode of smarcb1 ini1 loss and downregulated tgf \u03b2 pathway in ccs.", "loss of smarcb1 ini1 expression is considered to be a hallmark for childhood chordomas ccs although mutation loss of 22q has strongly established the loss of smarcb1 ini1 in cancers the cause in ccs remains elusive recent studies suggest role of mirnas in regulation of smarcb1 ini1 expressions we examined 5 reported target predicted mirnas to smarcb1 ini1 in smarcb1 ini1 immunonegative and immunopositive cases and found upregulation of mir 671 5p and mir 193a 5p in smarcb1 ini1 immunonegative cases notably these two mirnas were significantly predicted to target tgf \u03b2 signaling suggestive of dysregulation of developmental and osteoblast regulation pathway in ccs overall we suggest mir 671 5p and mir 193a 5p mediated epigenetic mode of smarcb1 ini1 loss and downregulated tgf \u03b2 pathway in ccs.", "loss of smarcb1 ini1 expression is considered to be a hallmark for childhood chordomas ccs although mutation loss of 22q has strongly established the loss of smarcb1 ini1 in cancers the cause in ccs remains elusive recent studies suggest role of mirnas in regulation of smarcb1 ini1 expressions we examined 5 reported target predicted mirnas to smarcb1 ini1 in smarcb1 ini1 immunonegative and immunopositive cases and found upregulation of mir 671 5p and mir 193a 5p in smarcb1 ini1 immunonegative cases notably these two mirnas were significantly predicted to target tgf \u03b2 signaling suggestive of dysregulation of developmental and osteoblast regulation pathway in ccs overall we suggest mir 671 5p and mir 193a 5p mediated epigenetic mode of smarcb1 ini1 loss and downregulated tgf \u03b2 pathway in ccs.", "loss of smarcb1 ini1 expression is considered to be a hallmark for childhood chordomas ccs although mutation loss of 22q has strongly established the loss of smarcb1 ini1 in cancers the cause in ccs remains elusive recent studies suggest role of mirnas in regulation of smarcb1 ini1 expressions we examined 5 reported target predicted mirnas to smarcb1 ini1 in smarcb1 ini1 immunonegative and immunopositive cases and found upregulation of mir 671 5p and mir 193a 5p in smarcb1 ini1 immunonegative cases notably these two mirnas were significantly predicted to target tgf \u03b2 signaling suggestive of dysregulation of developmental and osteoblast regulation pathway in ccs overall we suggest mir 671 5p and mir 193a 5p mediated epigenetic mode of smarcb1 ini1 loss and downregulated tgf \u03b2 pathway in ccs.", "loss of smarcb1 ini1 expression is considered to be a hallmark for childhood chordomas ccs although mutation loss of 22q has strongly established the loss of smarcb1 ini1 in cancers the cause in ccs remains elusive recent studies suggest role of mirnas in regulation of smarcb1 ini1 expressions we examined 5 reported target predicted mirnas to smarcb1 ini1 in smarcb1 ini1 immunonegative and immunopositive cases and found upregulation of mir 671 5p and mir 193a 5p in smarcb1 ini1 immunonegative cases notably these two mirnas were significantly predicted to target tgf \u03b2 signaling suggestive of dysregulation of developmental and osteoblast regulation pathway in ccs overall we suggest mir 671 5p and mir 193a 5p mediated epigenetic mode of smarcb1 ini1 loss and downregulated tgf \u03b2 pathway in ccs.", "loss of smarcb1 ini1 expression is considered to be a hallmark for childhood chordomas ccs although mutation loss of 22q has strongly established the loss of smarcb1 ini1 in cancers the cause in ccs remains elusive recent studies suggest role of mirnas in regulation of smarcb1 ini1 expressions we examined 5 reported target predicted mirnas to smarcb1 ini1 in smarcb1 ini1 immunonegative and immunopositive cases and found upregulation of mir 671 5p and mir 193a 5p in smarcb1 ini1 immunonegative cases notably these two mirnas were significantly predicted to target tgf \u03b2 signaling suggestive of dysregulation of developmental and osteoblast regulation pathway in ccs overall we suggest mir 671 5p and mir 193a 5p mediated epigenetic mode of smarcb1 ini1 loss and downregulated tgf \u03b2 pathway in ccs.", "loss of smarcb1 ini1 expression is considered to be a hallmark for childhood chordomas ccs although mutation loss of 22q has strongly established the loss of smarcb1 ini1 in cancers the cause in ccs remains elusive recent studies suggest role of mirnas in regulation of smarcb1 ini1 expressions we examined 5 reported target predicted mirnas to smarcb1 ini1 in smarcb1 ini1 immunonegative and immunopositive cases and found upregulation of mir 671 5p and mir 193a 5p in smarcb1 ini1 immunonegative cases notably these two mirnas were significantly predicted to target tgf \u03b2 signaling suggestive of dysregulation of developmental and osteoblast regulation pathway in ccs overall we suggest mir 671 5p and mir 193a 5p mediated epigenetic mode of smarcb1 ini1 loss and downregulated tgf \u03b2 pathway in ccs.", "loss of smarcb1 ini1 expression is considered to be a hallmark for childhood chordomas ccs although mutation loss of 22q has strongly established the loss of smarcb1 ini1 in cancers the cause in ccs remains elusive recent studies suggest role of mirnas in regulation of smarcb1 ini1 expressions we examined 5 reported target predicted mirnas to smarcb1 ini1 in smarcb1 ini1 immunonegative and immunopositive cases and found upregulation of mir 671 5p and mir 193a 5p in smarcb1 ini1 immunonegative cases notably these two mirnas were significantly predicted to target tgf \u03b2 signaling suggestive of dysregulation of developmental and osteoblast regulation pathway in ccs overall we suggest mir 671 5p and mir 193a 5p mediated epigenetic mode of smarcb1 ini1 loss and downregulated tgf \u03b2 pathway in ccs.", "loss of smarcb1 ini1 expression is considered to be a hallmark for childhood chordomas ccs although mutation loss of 22q has strongly established the loss of smarcb1 ini1 in cancers the cause in ccs remains elusive recent studies suggest role of mirnas in regulation of smarcb1 ini1 expressions we examined 5 reported target predicted mirnas to smarcb1 ini1 in smarcb1 ini1 immunonegative and immunopositive cases and found upregulation of mir 671 5p and mir 193a 5p in smarcb1 ini1 immunonegative cases notably these two mirnas were significantly predicted to target tgf \u03b2 signaling suggestive of dysregulation of developmental and osteoblast regulation pathway in ccs overall we suggest mir 671 5p and mir 193a 5p mediated epigenetic mode of smarcb1 ini1 loss and downregulated tgf \u03b2 pathway in ccs.", "loss of smarcb1 ini1 expression is considered to be a hallmark for childhood chordomas ccs although mutation loss of 22q has strongly established the loss of smarcb1 ini1 in cancers the cause in ccs remains elusive recent studies suggest role of mirnas in regulation of smarcb1 ini1 expressions we examined 5 reported target predicted mirnas to smarcb1 ini1 in smarcb1 ini1 immunonegative and immunopositive cases and found upregulation of mir 671 5p and mir 193a 5p in smarcb1 ini1 immunonegative cases notably these two mirnas were significantly predicted to target tgf \u03b2 signaling suggestive of dysregulation of developmental and osteoblast regulation pathway in ccs overall we suggest mir 671 5p and mir 193a 5p mediated epigenetic mode of smarcb1 ini1 loss and downregulated tgf \u03b2 pathway in ccs.", "loss of smarcb1 ini1 expression is considered to be a hallmark for childhood chordomas ccs although mutation loss of 22q has strongly established the loss of smarcb1 ini1 in cancers the cause in ccs remains elusive recent studies suggest role of mirnas in regulation of smarcb1 ini1 expressions we examined 5 reported target predicted mirnas to smarcb1 ini1 in smarcb1 ini1 immunonegative and immunopositive cases and found upregulation of mir 671 5p and mir 193a 5p in smarcb1 ini1 immunonegative cases notably these two mirnas were significantly predicted to target tgf \u03b2 signaling suggestive of dysregulation of developmental and osteoblast regulation pathway in ccs overall we suggest mir 671 5p and mir 193a 5p mediated epigenetic mode of smarcb1 ini1 loss and downregulated tgf \u03b2 pathway in ccs.", "loss of smarcb1 ini1 expression is considered to be a hallmark for childhood chordomas ccs although mutation loss of 22q has strongly established the loss of smarcb1 ini1 in cancers the cause in ccs remains elusive recent studies suggest role of mirnas in regulation of smarcb1 ini1 expressions we examined 5 reported target predicted mirnas to smarcb1 ini1 in smarcb1 ini1 immunonegative and immunopositive cases and found upregulation of mir 671 5p and mir 193a 5p in smarcb1 ini1 immunonegative cases notably these two mirnas were significantly predicted to target tgf \u03b2 signaling suggestive of dysregulation of developmental and osteoblast regulation pathway in ccs overall we suggest mir 671 5p and mir 193a 5p mediated epigenetic mode of smarcb1 ini1 loss and downregulated tgf \u03b2 pathway in ccs.", "loss of smarcb1 ini1 expression is considered to be a hallmark for childhood chordomas ccs although mutation loss of 22q has strongly established the loss of smarcb1 ini1 in cancers the cause in ccs remains elusive recent studies suggest role of mirnas in regulation of smarcb1 ini1 expressions we examined 5 reported target predicted mirnas to smarcb1 ini1 in smarcb1 ini1 immunonegative and immunopositive cases and found upregulation of mir 671 5p and mir 193a 5p in smarcb1 ini1 immunonegative cases notably these two mirnas were significantly predicted to target tgf \u03b2 signaling suggestive of dysregulation of developmental and osteoblast regulation pathway in ccs overall we suggest mir 671 5p and mir 193a 5p mediated epigenetic mode of smarcb1 ini1 loss and downregulated tgf \u03b2 pathway in ccs.", "loss of smarcb1 ini1 expression is considered to be a hallmark for childhood chordomas ccs although mutation loss of 22q has strongly established the loss of smarcb1 ini1 in cancers the cause in ccs remains elusive recent studies suggest role of mirnas in regulation of smarcb1 ini1 expressions we examined 5 reported target predicted mirnas to smarcb1 ini1 in smarcb1 ini1 immunonegative and immunopositive cases and found upregulation of mir 671 5p and mir 193a 5p in smarcb1 ini1 immunonegative cases notably these two mirnas were significantly predicted to target tgf \u03b2 signaling suggestive of dysregulation of developmental and osteoblast regulation pathway in ccs overall we suggest mir 671 5p and mir 193a 5p mediated epigenetic mode of smarcb1 ini1 loss and downregulated tgf \u03b2 pathway in ccs.", "loss of smarcb1 ini1 expression is considered to be a hallmark for childhood chordomas ccs although mutation loss of 22q has strongly established the loss of smarcb1 ini1 in cancers the cause in ccs remains elusive recent studies suggest role of mirnas in regulation of smarcb1 ini1 expressions we examined 5 reported target predicted mirnas to smarcb1 ini1 in smarcb1 ini1 immunonegative and immunopositive cases and found upregulation of mir 671 5p and mir 193a 5p in smarcb1 ini1 immunonegative cases notably these two mirnas were significantly predicted to target tgf \u03b2 signaling suggestive of dysregulation of developmental and osteoblast regulation pathway in ccs overall we suggest mir 671 5p and mir 193a 5p mediated epigenetic mode of smarcb1 ini1 loss and downregulated tgf \u03b2 pathway in ccs.", "loss of smarcb1 ini1 expression is considered to be a hallmark for childhood chordomas ccs although mutation loss of 22q has strongly established the loss of smarcb1 ini1 in cancers the cause in ccs remains elusive recent studies suggest role of mirnas in regulation of smarcb1 ini1 expressions we examined 5 reported target predicted mirnas to smarcb1 ini1 in smarcb1 ini1 immunonegative and immunopositive cases and found upregulation of mir 671 5p and mir 193a 5p in smarcb1 ini1 immunonegative cases notably these two mirnas were significantly predicted to target tgf \u03b2 signaling suggestive of dysregulation of developmental and osteoblast regulation pathway in ccs overall we suggest mir 671 5p and mir 193a 5p mediated epigenetic mode of smarcb1 ini1 loss and downregulated tgf \u03b2 pathway in ccs.", "loss of smarcb1 ini1 expression is considered to be a hallmark for childhood chordomas ccs although mutation loss of 22q has strongly established the loss of smarcb1 ini1 in cancers the cause in ccs remains elusive recent studies suggest role of mirnas in regulation of smarcb1 ini1 expressions we examined 5 reported target predicted mirnas to smarcb1 ini1 in smarcb1 ini1 immunonegative and immunopositive cases and found upregulation of mir 671 5p and mir 193a 5p in smarcb1 ini1 immunonegative cases notably these two mirnas were significantly predicted to target tgf \u03b2 signaling suggestive of dysregulation of developmental and osteoblast regulation pathway in ccs overall we suggest mir 671 5p and mir 193a 5p mediated epigenetic mode of smarcb1 ini1 loss and downregulated tgf \u03b2 pathway in ccs.", "loss of smarcb1 ini1 expression is considered to be a hallmark for childhood chordomas ccs although mutation loss of 22q has strongly established the loss of smarcb1 ini1 in cancers the cause in ccs remains elusive recent studies suggest role of mirnas in regulation of smarcb1 ini1 expressions we examined 5 reported target predicted mirnas to smarcb1 ini1 in smarcb1 ini1 immunonegative and immunopositive cases and found upregulation of mir 671 5p and mir 193a 5p in smarcb1 ini1 immunonegative cases notably these two mirnas were significantly predicted to target tgf \u03b2 signaling suggestive of dysregulation of developmental and osteoblast regulation pathway in ccs overall we suggest mir 671 5p and mir 193a 5p mediated epigenetic mode of smarcb1 ini1 loss and downregulated tgf \u03b2 pathway in ccs.", "loss of smarcb1 ini1 expression is considered to be a hallmark for childhood chordomas ccs although mutation loss of 22q has strongly established the loss of smarcb1 ini1 in cancers the cause in ccs remains elusive recent studies suggest role of mirnas in regulation of smarcb1 ini1 expressions we examined 5 reported target predicted mirnas to smarcb1 ini1 in smarcb1 ini1 immunonegative and immunopositive cases and found upregulation of mir 671 5p and mir 193a 5p in smarcb1 ini1 immunonegative cases notably these two mirnas were significantly predicted to target tgf \u03b2 signaling suggestive of dysregulation of developmental and osteoblast regulation pathway in ccs overall we suggest mir 671 5p and mir 193a 5p mediated epigenetic mode of smarcb1 ini1 loss and downregulated tgf \u03b2 pathway in ccs.", "loss of smarcb1 ini1 expression is considered to be a hallmark for childhood chordomas ccs although mutation loss of 22q has strongly established the loss of smarcb1 ini1 in cancers the cause in ccs remains elusive recent studies suggest role of mirnas in regulation of smarcb1 ini1 expressions we examined 5 reported target predicted mirnas to smarcb1 ini1 in smarcb1 ini1 immunonegative and immunopositive cases and found upregulation of mir 671 5p and mir 193a 5p in smarcb1 ini1 immunonegative cases notably these two mirnas were significantly predicted to target tgf \u03b2 signaling suggestive of dysregulation of developmental and osteoblast regulation pathway in ccs overall we suggest mir 671 5p and mir 193a 5p mediated epigenetic mode of smarcb1 ini1 loss and downregulated tgf \u03b2 pathway in ccs.", "loss of smarcb1 ini1 expression is considered to be a hallmark for childhood chordomas ccs although mutation loss of 22q has strongly established the loss of smarcb1 ini1 in cancers the cause in ccs remains elusive recent studies suggest role of mirnas in regulation of smarcb1 ini1 expressions we examined 5 reported target predicted mirnas to smarcb1 ini1 in smarcb1 ini1 immunonegative and immunopositive cases and found upregulation of mir 671 5p and mir 193a 5p in smarcb1 ini1 immunonegative cases notably these two mirnas were significantly predicted to target tgf \u03b2 signaling suggestive of dysregulation of developmental and osteoblast regulation pathway in ccs overall we suggest mir 671 5p and mir 193a 5p mediated epigenetic mode of smarcb1 ini1 loss and downregulated tgf \u03b2 pathway in ccs.", "loss of smarcb1 ini1 expression is considered to be a hallmark for childhood chordomas ccs although mutation loss of 22q has strongly established the loss of smarcb1 ini1 in cancers the cause in ccs remains elusive recent studies suggest role of mirnas in regulation of smarcb1 ini1 expressions we examined 5 reported target predicted mirnas to smarcb1 ini1 in smarcb1 ini1 immunonegative and immunopositive cases and found upregulation of mir 671 5p and mir 193a 5p in smarcb1 ini1 immunonegative cases notably these two mirnas were significantly predicted to target tgf \u03b2 signaling suggestive of dysregulation of developmental and osteoblast regulation pathway in ccs overall we suggest mir 671 5p and mir 193a 5p mediated epigenetic mode of smarcb1 ini1 loss and downregulated tgf \u03b2 pathway in ccs.", "loss of smarcb1 ini1 expression is considered to be a hallmark for childhood chordomas ccs although mutation loss of 22q has strongly established the loss of smarcb1 ini1 in cancers the cause in ccs remains elusive recent studies suggest role of mirnas in regulation of smarcb1 ini1 expressions we examined 5 reported target predicted mirnas to smarcb1 ini1 in smarcb1 ini1 immunonegative and immunopositive cases and found upregulation of mir 671 5p and mir 193a 5p in smarcb1 ini1 immunonegative cases notably these two mirnas were significantly predicted to target tgf \u03b2 signaling suggestive of dysregulation of developmental and osteoblast regulation pathway in ccs overall we suggest mir 671 5p and mir 193a 5p mediated epigenetic mode of smarcb1 ini1 loss and downregulated tgf \u03b2 pathway in ccs.", "loss of smarcb1 ini1 expression is considered to be a hallmark for childhood chordomas ccs although mutation loss of 22q has strongly established the loss of smarcb1 ini1 in cancers the cause in ccs remains elusive recent studies suggest role of mirnas in regulation of smarcb1 ini1 expressions we examined 5 reported target predicted mirnas to smarcb1 ini1 in smarcb1 ini1 immunonegative and immunopositive cases and found upregulation of mir 671 5p and mir 193a 5p in smarcb1 ini1 immunonegative cases notably these two mirnas were significantly predicted to target tgf \u03b2 signaling suggestive of dysregulation of developmental and osteoblast regulation pathway in ccs overall we suggest mir 671 5p and mir 193a 5p mediated epigenetic mode of smarcb1 ini1 loss and downregulated tgf \u03b2 pathway in ccs.", "loss of smarcb1 ini1 expression is considered to be a hallmark for childhood chordomas ccs although mutation loss of 22q has strongly established the loss of smarcb1 ini1 in cancers the cause in ccs remains elusive recent studies suggest role of mirnas in regulation of smarcb1 ini1 expressions we examined 5 reported target predicted mirnas to smarcb1 ini1 in smarcb1 ini1 immunonegative and immunopositive cases and found upregulation of mir 671 5p and mir 193a 5p in smarcb1 ini1 immunonegative cases notably these two mirnas were significantly predicted to target tgf \u03b2 signaling suggestive of dysregulation of developmental and osteoblast regulation pathway in ccs overall we suggest mir 671 5p and mir 193a 5p mediated epigenetic mode of smarcb1 ini1 loss and downregulated tgf \u03b2 pathway in ccs.", "loss of smarcb1 ini1 expression is considered to be a hallmark for childhood chordomas ccs although mutation loss of 22q has strongly established the loss of smarcb1 ini1 in cancers the cause in ccs remains elusive recent studies suggest role of mirnas in regulation of smarcb1 ini1 expressions we examined 5 reported target predicted mirnas to smarcb1 ini1 in smarcb1 ini1 immunonegative and immunopositive cases and found upregulation of mir 671 5p and mir 193a 5p in smarcb1 ini1 immunonegative cases notably these two mirnas were significantly predicted to target tgf \u03b2 signaling suggestive of dysregulation of developmental and osteoblast regulation pathway in ccs overall we suggest mir 671 5p and mir 193a 5p mediated epigenetic mode of smarcb1 ini1 loss and downregulated tgf \u03b2 pathway in ccs.", "loss of smarcb1 ini1 expression is considered to be a hallmark for childhood chordomas ccs although mutation loss of 22q has strongly established the loss of smarcb1 ini1 in cancers the cause in ccs remains elusive recent studies suggest role of mirnas in regulation of smarcb1 ini1 expressions we examined 5 reported target predicted mirnas to smarcb1 ini1 in smarcb1 ini1 immunonegative and immunopositive cases and found upregulation of mir 671 5p and mir 193a 5p in smarcb1 ini1 immunonegative cases notably these two mirnas were significantly predicted to target tgf \u03b2 signaling suggestive of dysregulation of developmental and osteoblast regulation pathway in ccs overall we suggest mir 671 5p and mir 193a 5p mediated epigenetic mode of smarcb1 ini1 loss and downregulated tgf \u03b2 pathway in ccs.", "loss of smarcb1 ini1 expression is considered to be a hallmark for childhood chordomas ccs although mutation loss of 22q has strongly established the loss of smarcb1 ini1 in cancers the cause in ccs remains elusive recent studies suggest role of mirnas in regulation of smarcb1 ini1 expressions we examined 5 reported target predicted mirnas to smarcb1 ini1 in smarcb1 ini1 immunonegative and immunopositive cases and found upregulation of mir 671 5p and mir 193a 5p in smarcb1 ini1 immunonegative cases notably these two mirnas were significantly predicted to target tgf \u03b2 signaling suggestive of dysregulation of developmental and osteoblast regulation pathway in ccs overall we suggest mir 671 5p and mir 193a 5p mediated epigenetic mode of smarcb1 ini1 loss and downregulated tgf \u03b2 pathway in ccs.", "loss of smarcb1 ini1 expression is considered to be a hallmark for childhood chordomas ccs although mutation loss of 22q has strongly established the loss of smarcb1 ini1 in cancers the cause in ccs remains elusive recent studies suggest role of mirnas in regulation of smarcb1 ini1 expressions we examined 5 reported target predicted mirnas to smarcb1 ini1 in smarcb1 ini1 immunonegative and immunopositive cases and found upregulation of mir 671 5p and mir 193a 5p in smarcb1 ini1 immunonegative cases notably these two mirnas were significantly predicted to target tgf \u03b2 signaling suggestive of dysregulation of developmental and osteoblast regulation pathway in ccs overall we suggest mir 671 5p and mir 193a 5p mediated epigenetic mode of smarcb1 ini1 loss and downregulated tgf \u03b2 pathway in ccs.", "loss of smarcb1 ini1 expression is considered to be a hallmark for childhood chordomas ccs although mutation loss of 22q has strongly established the loss of smarcb1 ini1 in cancers the cause in ccs remains elusive recent studies suggest role of mirnas in regulation of smarcb1 ini1 expressions we examined 5 reported target predicted mirnas to smarcb1 ini1 in smarcb1 ini1 immunonegative and immunopositive cases and found upregulation of mir 671 5p and mir 193a 5p in smarcb1 ini1 immunonegative cases notably these two mirnas were significantly predicted to target tgf \u03b2 signaling suggestive of dysregulation of developmental and osteoblast regulation pathway in ccs overall we suggest mir 671 5p and mir 193a 5p mediated epigenetic mode of smarcb1 ini1 loss and downregulated tgf \u03b2 pathway in ccs.", "loss of smarcb1 ini1 expression is considered to be a hallmark for childhood chordomas ccs although mutation loss of 22q has strongly established the loss of smarcb1 ini1 in cancers the cause in ccs remains elusive recent studies suggest role of mirnas in regulation of smarcb1 ini1 expressions we examined 5 reported target predicted mirnas to smarcb1 ini1 in smarcb1 ini1 immunonegative and immunopositive cases and found upregulation of mir 671 5p and mir 193a 5p in smarcb1 ini1 immunonegative cases notably these two mirnas were significantly predicted to target tgf \u03b2 signaling suggestive of dysregulation of developmental and osteoblast regulation pathway in ccs overall we suggest mir 671 5p and mir 193a 5p mediated epigenetic mode of smarcb1 ini1 loss and downregulated tgf \u03b2 pathway in ccs.", "loss of smarcb1 ini1 expression is considered to be a hallmark for childhood chordomas ccs although mutation loss of 22q has strongly established the loss of smarcb1 ini1 in cancers the cause in ccs remains elusive recent studies suggest role of mirnas in regulation of smarcb1 ini1 expressions we examined 5 reported target predicted mirnas to smarcb1 ini1 in smarcb1 ini1 immunonegative and immunopositive cases and found upregulation of mir 671 5p and mir 193a 5p in smarcb1 ini1 immunonegative cases notably these two mirnas were significantly predicted to target tgf \u03b2 signaling suggestive of dysregulation of developmental and osteoblast regulation pathway in ccs overall we suggest mir 671 5p and mir 193a 5p mediated epigenetic mode of smarcb1 ini1 loss and downregulated tgf \u03b2 pathway in ccs.", "loss of smarcb1 ini1 expression is considered to be a hallmark for childhood chordomas ccs although mutation loss of 22q has strongly established the loss of smarcb1 ini1 in cancers the cause in ccs remains elusive recent studies suggest role of mirnas in regulation of smarcb1 ini1 expressions we examined 5 reported target predicted mirnas to smarcb1 ini1 in smarcb1 ini1 immunonegative and immunopositive cases and found upregulation of mir 671 5p and mir 193a 5p in smarcb1 ini1 immunonegative cases notably these two mirnas were significantly predicted to target tgf \u03b2 signaling suggestive of dysregulation of developmental and osteoblast regulation pathway in ccs overall we suggest mir 671 5p and mir 193a 5p mediated epigenetic mode of smarcb1 ini1 loss and downregulated tgf \u03b2 pathway in ccs.", "loss of smarcb1 ini1 expression is considered to be a hallmark for childhood chordomas ccs although mutation loss of 22q has strongly established the loss of smarcb1 ini1 in cancers the cause in ccs remains elusive recent studies suggest role of mirnas in regulation of smarcb1 ini1 expressions we examined 5 reported target predicted mirnas to smarcb1 ini1 in smarcb1 ini1 immunonegative and immunopositive cases and found upregulation of mir 671 5p and mir 193a 5p in smarcb1 ini1 immunonegative cases notably these two mirnas were significantly predicted to target tgf \u03b2 signaling suggestive of dysregulation of developmental and osteoblast regulation pathway in ccs overall we suggest mir 671 5p and mir 193a 5p mediated epigenetic mode of smarcb1 ini1 loss and downregulated tgf \u03b2 pathway in ccs.", "loss of smarcb1 ini1 expression is considered to be a hallmark for childhood chordomas ccs although mutation loss of 22q has strongly established the loss of smarcb1 ini1 in cancers the cause in ccs remains elusive recent studies suggest role of mirnas in regulation of smarcb1 ini1 expressions we examined 5 reported target predicted mirnas to smarcb1 ini1 in smarcb1 ini1 immunonegative and immunopositive cases and found upregulation of mir 671 5p and mir 193a 5p in smarcb1 ini1 immunonegative cases notably these two mirnas were significantly predicted to target tgf \u03b2 signaling suggestive of dysregulation of developmental and osteoblast regulation pathway in ccs overall we suggest mir 671 5p and mir 193a 5p mediated epigenetic mode of smarcb1 ini1 loss and downregulated tgf \u03b2 pathway in ccs.", "loss of smarcb1 ini1 expression is considered to be a hallmark for childhood chordomas ccs although mutation loss of 22q has strongly established the loss of smarcb1 ini1 in cancers the cause in ccs remains elusive recent studies suggest role of mirnas in regulation of smarcb1 ini1 expressions we examined 5 reported target predicted mirnas to smarcb1 ini1 in smarcb1 ini1 immunonegative and immunopositive cases and found upregulation of mir 671 5p and mir 193a 5p in smarcb1 ini1 immunonegative cases notably these two mirnas were significantly predicted to target tgf \u03b2 signaling suggestive of dysregulation of developmental and osteoblast regulation pathway in ccs overall we suggest mir 671 5p and mir 193a 5p mediated epigenetic mode of smarcb1 ini1 loss and downregulated tgf \u03b2 pathway in ccs.", "loss of smarcb1 ini1 expression is considered to be a hallmark for childhood chordomas ccs although mutation loss of 22q has strongly established the loss of smarcb1 ini1 in cancers the cause in ccs remains elusive recent studies suggest role of mirnas in regulation of smarcb1 ini1 expressions we examined 5 reported target predicted mirnas to smarcb1 ini1 in smarcb1 ini1 immunonegative and immunopositive cases and found upregulation of mir 671 5p and mir 193a 5p in smarcb1 ini1 immunonegative cases notably these two mirnas were significantly predicted to target tgf \u03b2 signaling suggestive of dysregulation of developmental and osteoblast regulation pathway in ccs overall we suggest mir 671 5p and mir 193a 5p mediated epigenetic mode of smarcb1 ini1 loss and downregulated tgf \u03b2 pathway in ccs.", "loss of smarcb1 ini1 expression is considered to be a hallmark for childhood chordomas ccs although mutation loss of 22q has strongly established the loss of smarcb1 ini1 in cancers the cause in ccs remains elusive recent studies suggest role of mirnas in regulation of smarcb1 ini1 expressions we examined 5 reported target predicted mirnas to smarcb1 ini1 in smarcb1 ini1 immunonegative and immunopositive cases and found upregulation of mir 671 5p and mir 193a 5p in smarcb1 ini1 immunonegative cases notably these two mirnas were significantly predicted to target tgf \u03b2 signaling suggestive of dysregulation of developmental and osteoblast regulation pathway in ccs overall we suggest mir 671 5p and mir 193a 5p mediated epigenetic mode of smarcb1 ini1 loss and downregulated tgf \u03b2 pathway in ccs.", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc).", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc).", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc).", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc).", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc).", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc).", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc).", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc).", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc).", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc).", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc).", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc).", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc).", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc).", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc).", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc).", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc).", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc).", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc).", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc).", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc).", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc).", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc).", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc).", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc).", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc).", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc).", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc).", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc).", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc).", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc).", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc).", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc).", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc).", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc).", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc).", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc).", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc).", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc).", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc).", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc).", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc).", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc).", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc).", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc).", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc).", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc).", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc)", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc)", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc)", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc)", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc)", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc)", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc)", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc)", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc)", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc)", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc)", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc)", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc)", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc)", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc)", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc)", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc)", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc)", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc)", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc)", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc)", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc)", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc)", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc)", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc)", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc)", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc)", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc)", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc)", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc)", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc)", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc)", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc)", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc)", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc)", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc)", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc)", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc)", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc)", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc)", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc)", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc)", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc)", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc)", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc)", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc)", "the diagnosis is all the more challenging that other poorly differentiated cancers lose smarcb1 expression, such as epithelioid sarcomas (es), renal medullary carcinomas (rmc) or undifferentiated chordomas (uc)", "in this study, we considered immunohistochemistry and smarcb1/ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas (7 classic and 1 poorly differentiated)", "in this study, we considered immunohistochemistry and smarcb1/ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas (7 classic and 1 poorly differentiated)", "in this study, we considered immunohistochemistry and smarcb1/ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas (7 classic and 1 poorly differentiated)", "in this study, we considered immunohistochemistry and smarcb1/ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas (7 classic and 1 poorly differentiated)", "in this study, we considered immunohistochemistry and smarcb1/ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas (7 classic and 1 poorly differentiated)", "in this study, we considered immunohistochemistry and smarcb1/ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas (7 classic and 1 poorly differentiated)", "in this study, we considered immunohistochemistry and smarcb1/ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas (7 classic and 1 poorly differentiated)", "in this study, we considered immunohistochemistry and smarcb1/ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas (7 classic and 1 poorly differentiated)", "in this study, we considered immunohistochemistry and smarcb1/ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas (7 classic and 1 poorly differentiated)", "in this study, we considered immunohistochemistry and smarcb1/ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas (7 classic and 1 poorly differentiated)", "in this study, we considered immunohistochemistry and smarcb1/ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas (7 classic and 1 poorly differentiated)", "in this study, we considered immunohistochemistry and smarcb1/ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas (7 classic and 1 poorly differentiated)", "in this study, we considered immunohistochemistry and smarcb1/ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas (7 classic and 1 poorly differentiated)", "in this study, we considered immunohistochemistry and smarcb1/ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas (7 classic and 1 poorly differentiated)", "in this study, we considered immunohistochemistry and smarcb1/ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas (7 classic and 1 poorly differentiated)", "in this study, we considered immunohistochemistry and smarcb1/ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas (7 classic and 1 poorly differentiated)", "in this study, we considered immunohistochemistry and smarcb1/ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas (7 classic and 1 poorly differentiated)", "in this study, we considered immunohistochemistry and smarcb1/ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas (7 classic and 1 poorly differentiated)", "in this study, we considered immunohistochemistry and smarcb1/ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas (7 classic and 1 poorly differentiated)", "in this study, we considered immunohistochemistry and smarcb1/ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas (7 classic and 1 poorly differentiated)", "in this study, we considered immunohistochemistry and smarcb1/ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas (7 classic and 1 poorly differentiated)", "in this study, we considered immunohistochemistry and smarcb1/ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas (7 classic and 1 poorly differentiated)", "in this study, we considered immunohistochemistry and smarcb1/ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas (7 classic and 1 poorly differentiated)", "in this study, we considered immunohistochemistry and smarcb1/ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas (7 classic and 1 poorly differentiated)", "in this study, we considered immunohistochemistry and smarcb1/ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas (7 classic and 1 poorly differentiated)", "in this study, we considered immunohistochemistry and smarcb1/ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas (7 classic and 1 poorly differentiated)", "in this study, we considered immunohistochemistry and smarcb1/ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas (7 classic and 1 poorly differentiated)", "in this study, we considered immunohistochemistry and smarcb1/ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas (7 classic and 1 poorly differentiated)", "in this study, we considered immunohistochemistry and smarcb1/ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas (7 classic and 1 poorly differentiated)", "in this study, we considered immunohistochemistry and smarcb1/ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas (7 classic and 1 poorly differentiated)", "in this study, we considered immunohistochemistry and smarcb1/ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas (7 classic and 1 poorly differentiated)", "in this study, we considered immunohistochemistry and smarcb1/ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas (7 classic and 1 poorly differentiated)", "in this study, we considered immunohistochemistry and smarcb1/ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas (7 classic and 1 poorly differentiated)", "in this study, we considered immunohistochemistry and smarcb1/ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas (7 classic and 1 poorly differentiated)", "in this study, we considered immunohistochemistry and smarcb1/ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas (7 classic and 1 poorly differentiated)", "in this study, we considered immunohistochemistry and smarcb1/ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas (7 classic and 1 poorly differentiated)", "in this study, we considered immunohistochemistry and smarcb1/ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas (7 classic and 1 poorly differentiated)", "in this study, we considered immunohistochemistry and smarcb1/ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas (7 classic and 1 poorly differentiated)", "in this study, we considered immunohistochemistry and smarcb1/ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas (7 classic and 1 poorly differentiated)", "in this study, we considered immunohistochemistry and smarcb1/ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas (7 classic and 1 poorly differentiated)", "in this study, we considered immunohistochemistry and smarcb1/ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas (7 classic and 1 poorly differentiated)", "in this study, we considered immunohistochemistry and smarcb1/ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas (7 classic and 1 poorly differentiated)", "in this study, we considered immunohistochemistry and smarcb1/ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas (7 classic and 1 poorly differentiated)", "in this study, we considered immunohistochemistry and smarcb1/ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas (7 classic and 1 poorly differentiated)", "in this study, we considered immunohistochemistry and smarcb1/ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas (7 classic and 1 poorly differentiated)", "in this study, we considered immunohistochemistry and smarcb1/ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas (7 classic and 1 poorly differentiated)", "in this study, we considered immunohistochemistry and smarcb1/ini1 mutational status to examine smarcb1 status in a series of pediatric chordomas (7 classic and 1 poorly differentiated)", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs).", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs).", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs).", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs).", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs).", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs).", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs).", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs).", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs).", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs).", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs).", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs).", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs).", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs).", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs).", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs).", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs).", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs).", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs).", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs).", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs).", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs).", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs).", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs).", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs).", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs).", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs).", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs).", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs).", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs).", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs).", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs).", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs).", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs).", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs).", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs).", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs).", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs).", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs).", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs).", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs).", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs).", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs).", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs).", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs).", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs).", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs).", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs)", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs)", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs)", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs)", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs)", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs)", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs)", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs)", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs)", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs)", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs)", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs)", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs)", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs)", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs)", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs)", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs)", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs)", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs)", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs)", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs)", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs)", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs)", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs)", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs)", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs)", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs)", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs)", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs)", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs)", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs)", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs)", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs)", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs)", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs)", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs)", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs)", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs)", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs)", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs)", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs)", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs)", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs)", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs)", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs)", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs)", "loss of smarcb1/ini1 expression is considered to be a hallmark for childhood chordomas (ccs)", "purpose this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "purpose this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "purpose this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "purpose this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "purpose this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "purpose this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "purpose this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "purpose this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "purpose this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "purpose this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "purpose this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "purpose this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "purpose this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "purpose this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "purpose this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "purpose this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "purpose this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "purpose this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "purpose this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "purpose this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "purpose this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "purpose this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "purpose this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "purpose this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "purpose this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "purpose this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "purpose this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "this study aims: (1) to identify patients with multiple sclerosis (ms) who are at high risk for obstructive sleep apnea (osa) by utilizing the stop-bang questionnaire and (2) to evaluate the relationship between osa risk as determined by the stop-bang questionnaire and self-reported sleepiness and fatigue using the epworth sleepiness scale (ess) and the fatigue severity scale (fss), respectively.", "we hypothesized that the stop-bang questionnaire, a screening tool for obstructive sleep apnea (osa), can predict difficult intubation.<br><b>patients and methods</b>: in this prospective cohort study, 200 adult surgical patients undergoing surgery under general anesthesia were studied to evaluate the usefulness of the stop-bang questionnaire for predicting difficult intubation.", "we hypothesized that the stop-bang questionnaire, a screening tool for obstructive sleep apnea (osa), can predict difficult intubation.<br><b>patients and methods</b>: in this prospective cohort study, 200 adult surgical patients undergoing surgery under general anesthesia were studied to evaluate the usefulness of the stop-bang questionnaire for predicting difficult intubation.", "we hypothesized that the stop-bang questionnaire, a screening tool for obstructive sleep apnea (osa), can predict difficult intubation.<br><b>patients and methods</b>: in this prospective cohort study, 200 adult surgical patients undergoing surgery under general anesthesia were studied to evaluate the usefulness of the stop-bang questionnaire for predicting difficult intubation.", "we hypothesized that the stop-bang questionnaire, a screening tool for obstructive sleep apnea (osa), can predict difficult intubation.<br><b>patients and methods</b>: in this prospective cohort study, 200 adult surgical patients undergoing surgery under general anesthesia were studied to evaluate the usefulness of the stop-bang questionnaire for predicting difficult intubation.", "we hypothesized that the stop-bang questionnaire, a screening tool for obstructive sleep apnea (osa), can predict difficult intubation.<br><b>patients and methods</b>: in this prospective cohort study, 200 adult surgical patients undergoing surgery under general anesthesia were studied to evaluate the usefulness of the stop-bang questionnaire for predicting difficult intubation.", "we hypothesized that the stop-bang questionnaire, a screening tool for obstructive sleep apnea (osa), can predict difficult intubation.<br><b>patients and methods</b>: in this prospective cohort study, 200 adult surgical patients undergoing surgery under general anesthesia were studied to evaluate the usefulness of the stop-bang questionnaire for predicting difficult intubation.", "we hypothesized that the stop-bang questionnaire, a screening tool for obstructive sleep apnea (osa), can predict difficult intubation.<br><b>patients and methods</b>: in this prospective cohort study, 200 adult surgical patients undergoing surgery under general anesthesia were studied to evaluate the usefulness of the stop-bang questionnaire for predicting difficult intubation.", "we hypothesized that the stop-bang questionnaire, a screening tool for obstructive sleep apnea (osa), can predict difficult intubation.<br><b>patients and methods</b>: in this prospective cohort study, 200 adult surgical patients undergoing surgery under general anesthesia were studied to evaluate the usefulness of the stop-bang questionnaire for predicting difficult intubation.", "we hypothesized that the stop-bang questionnaire, a screening tool for obstructive sleep apnea (osa), can predict difficult intubation.<br><b>patients and methods</b>: in this prospective cohort study, 200 adult surgical patients undergoing surgery under general anesthesia were studied to evaluate the usefulness of the stop-bang questionnaire for predicting difficult intubation.", "we hypothesized that the stop-bang questionnaire, a screening tool for obstructive sleep apnea (osa), can predict difficult intubation.<br><b>patients and methods</b>: in this prospective cohort study, 200 adult surgical patients undergoing surgery under general anesthesia were studied to evaluate the usefulness of the stop-bang questionnaire for predicting difficult intubation.", "we hypothesized that the stop-bang questionnaire, a screening tool for obstructive sleep apnea (osa), can predict difficult intubation.<br><b>patients and methods</b>: in this prospective cohort study, 200 adult surgical patients undergoing surgery under general anesthesia were studied to evaluate the usefulness of the stop-bang questionnaire for predicting difficult intubation.", "we hypothesized that the stop-bang questionnaire, a screening tool for obstructive sleep apnea (osa), can predict difficult intubation.<br><b>patients and methods</b>: in this prospective cohort study, 200 adult surgical patients undergoing surgery under general anesthesia were studied to evaluate the usefulness of the stop-bang questionnaire for predicting difficult intubation.", "we hypothesized that the stop-bang questionnaire, a screening tool for obstructive sleep apnea (osa), can predict difficult intubation.<br><b>patients and methods</b>: in this prospective cohort study, 200 adult surgical patients undergoing surgery under general anesthesia were studied to evaluate the usefulness of the stop-bang questionnaire for predicting difficult intubation.", "we hypothesized that the stop-bang questionnaire, a screening tool for obstructive sleep apnea (osa), can predict difficult intubation.<br><b>patients and methods</b>: in this prospective cohort study, 200 adult surgical patients undergoing surgery under general anesthesia were studied to evaluate the usefulness of the stop-bang questionnaire for predicting difficult intubation.", "we hypothesized that the stop-bang questionnaire, a screening tool for obstructive sleep apnea (osa), can predict difficult intubation.<br><b>patients and methods</b>: in this prospective cohort study, 200 adult surgical patients undergoing surgery under general anesthesia were studied to evaluate the usefulness of the stop-bang questionnaire for predicting difficult intubation.", "we hypothesized that the stop-bang questionnaire, a screening tool for obstructive sleep apnea (osa), can predict difficult intubation.<br><b>patients and methods</b>: in this prospective cohort study, 200 adult surgical patients undergoing surgery under general anesthesia were studied to evaluate the usefulness of the stop-bang questionnaire for predicting difficult intubation.", "we hypothesized that the stop-bang questionnaire, a screening tool for obstructive sleep apnea (osa), can predict difficult intubation.<br><b>patients and methods</b>: in this prospective cohort study, 200 adult surgical patients undergoing surgery under general anesthesia were studied to evaluate the usefulness of the stop-bang questionnaire for predicting difficult intubation.", "we hypothesized that the stop-bang questionnaire, a screening tool for obstructive sleep apnea (osa), can predict difficult intubation.<br><b>patients and methods</b>: in this prospective cohort study, 200 adult surgical patients undergoing surgery under general anesthesia were studied to evaluate the usefulness of the stop-bang questionnaire for predicting difficult intubation.", "we hypothesized that the stop-bang questionnaire, a screening tool for obstructive sleep apnea (osa), can predict difficult intubation.<br><b>patients and methods</b>: in this prospective cohort study, 200 adult surgical patients undergoing surgery under general anesthesia were studied to evaluate the usefulness of the stop-bang questionnaire for predicting difficult intubation.", "we hypothesized that the stop-bang questionnaire, a screening tool for obstructive sleep apnea (osa), can predict difficult intubation.<br><b>patients and methods</b>: in this prospective cohort study, 200 adult surgical patients undergoing surgery under general anesthesia were studied to evaluate the usefulness of the stop-bang questionnaire for predicting difficult intubation.", "we hypothesized that the stop-bang questionnaire, a screening tool for obstructive sleep apnea (osa), can predict difficult intubation.<br><b>patients and methods</b>: in this prospective cohort study, 200 adult surgical patients undergoing surgery under general anesthesia were studied to evaluate the usefulness of the stop-bang questionnaire for predicting difficult intubation.", "we hypothesized that the stop-bang questionnaire, a screening tool for obstructive sleep apnea (osa), can predict difficult intubation.<br><b>patients and methods</b>: in this prospective cohort study, 200 adult surgical patients undergoing surgery under general anesthesia were studied to evaluate the usefulness of the stop-bang questionnaire for predicting difficult intubation.", "we hypothesized that the stop-bang questionnaire, a screening tool for obstructive sleep apnea (osa), can predict difficult intubation.<br><b>patients and methods</b>: in this prospective cohort study, 200 adult surgical patients undergoing surgery under general anesthesia were studied to evaluate the usefulness of the stop-bang questionnaire for predicting difficult intubation.", "we hypothesized that the stop-bang questionnaire, a screening tool for obstructive sleep apnea (osa), can predict difficult intubation.<br><b>patients and methods</b>: in this prospective cohort study, 200 adult surgical patients undergoing surgery under general anesthesia were studied to evaluate the usefulness of the stop-bang questionnaire for predicting difficult intubation.", "we hypothesized that the stop-bang questionnaire, a screening tool for obstructive sleep apnea (osa), can predict difficult intubation.<br><b>patients and methods</b>: in this prospective cohort study, 200 adult surgical patients undergoing surgery under general anesthesia were studied to evaluate the usefulness of the stop-bang questionnaire for predicting difficult intubation.", "we hypothesized that the stop-bang questionnaire, a screening tool for obstructive sleep apnea (osa), can predict difficult intubation.<br><b>patients and methods</b>: in this prospective cohort study, 200 adult surgical patients undergoing surgery under general anesthesia were studied to evaluate the usefulness of the stop-bang questionnaire for predicting difficult intubation.", "we hypothesized that the stop-bang questionnaire, a screening tool for obstructive sleep apnea (osa), can predict difficult intubation.<br><b>patients and methods</b>: in this prospective cohort study, 200 adult surgical patients undergoing surgery under general anesthesia were studied to evaluate the usefulness of the stop-bang questionnaire for predicting difficult intubation.", "<b>purpose of review</b>: the present review aims to provide an update on the various practical applications of the stop-bang questionnaire in anesthesia, surgery, and perioperative medicine.<br><b>recent findings</b>: the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "<b>purpose of review</b>: the present review aims to provide an update on the various practical applications of the stop-bang questionnaire in anesthesia, surgery, and perioperative medicine.<br><b>recent findings</b>: the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "<b>purpose of review</b>: the present review aims to provide an update on the various practical applications of the stop-bang questionnaire in anesthesia, surgery, and perioperative medicine.<br><b>recent findings</b>: the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "<b>purpose of review</b>: the present review aims to provide an update on the various practical applications of the stop-bang questionnaire in anesthesia, surgery, and perioperative medicine.<br><b>recent findings</b>: the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "<b>purpose of review</b>: the present review aims to provide an update on the various practical applications of the stop-bang questionnaire in anesthesia, surgery, and perioperative medicine.<br><b>recent findings</b>: the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "<b>purpose of review</b>: the present review aims to provide an update on the various practical applications of the stop-bang questionnaire in anesthesia, surgery, and perioperative medicine.<br><b>recent findings</b>: the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "<b>purpose of review</b>: the present review aims to provide an update on the various practical applications of the stop-bang questionnaire in anesthesia, surgery, and perioperative medicine.<br><b>recent findings</b>: the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "<b>purpose of review</b>: the present review aims to provide an update on the various practical applications of the stop-bang questionnaire in anesthesia, surgery, and perioperative medicine.<br><b>recent findings</b>: the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "<b>purpose of review</b>: the present review aims to provide an update on the various practical applications of the stop-bang questionnaire in anesthesia, surgery, and perioperative medicine.<br><b>recent findings</b>: the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "<b>purpose of review</b>: the present review aims to provide an update on the various practical applications of the stop-bang questionnaire in anesthesia, surgery, and perioperative medicine.<br><b>recent findings</b>: the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "<b>purpose of review</b>: the present review aims to provide an update on the various practical applications of the stop-bang questionnaire in anesthesia, surgery, and perioperative medicine.<br><b>recent findings</b>: the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "<b>purpose of review</b>: the present review aims to provide an update on the various practical applications of the stop-bang questionnaire in anesthesia, surgery, and perioperative medicine.<br><b>recent findings</b>: the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "<b>purpose of review</b>: the present review aims to provide an update on the various practical applications of the stop-bang questionnaire in anesthesia, surgery, and perioperative medicine.<br><b>recent findings</b>: the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "<b>purpose of review</b>: the present review aims to provide an update on the various practical applications of the stop-bang questionnaire in anesthesia, surgery, and perioperative medicine.<br><b>recent findings</b>: the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "<b>purpose of review</b>: the present review aims to provide an update on the various practical applications of the stop-bang questionnaire in anesthesia, surgery, and perioperative medicine.<br><b>recent findings</b>: the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "<b>purpose of review</b>: the present review aims to provide an update on the various practical applications of the stop-bang questionnaire in anesthesia, surgery, and perioperative medicine.<br><b>recent findings</b>: the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "<b>purpose of review</b>: the present review aims to provide an update on the various practical applications of the stop-bang questionnaire in anesthesia, surgery, and perioperative medicine.<br><b>recent findings</b>: the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "<b>purpose of review</b>: the present review aims to provide an update on the various practical applications of the stop-bang questionnaire in anesthesia, surgery, and perioperative medicine.<br><b>recent findings</b>: the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "<b>purpose of review</b>: the present review aims to provide an update on the various practical applications of the stop-bang questionnaire in anesthesia, surgery, and perioperative medicine.<br><b>recent findings</b>: the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "<b>purpose of review</b>: the present review aims to provide an update on the various practical applications of the stop-bang questionnaire in anesthesia, surgery, and perioperative medicine.<br><b>recent findings</b>: the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "<b>purpose of review</b>: the present review aims to provide an update on the various practical applications of the stop-bang questionnaire in anesthesia, surgery, and perioperative medicine.<br><b>recent findings</b>: the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "<b>purpose of review</b>: the present review aims to provide an update on the various practical applications of the stop-bang questionnaire in anesthesia, surgery, and perioperative medicine.<br><b>recent findings</b>: the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "<b>purpose of review</b>: the present review aims to provide an update on the various practical applications of the stop-bang questionnaire in anesthesia, surgery, and perioperative medicine.<br><b>recent findings</b>: the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "<b>purpose of review</b>: the present review aims to provide an update on the various practical applications of the stop-bang questionnaire in anesthesia, surgery, and perioperative medicine.<br><b>recent findings</b>: the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "<b>purpose of review</b>: the present review aims to provide an update on the various practical applications of the stop-bang questionnaire in anesthesia, surgery, and perioperative medicine.<br><b>recent findings</b>: the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "<b>purpose of review</b>: the present review aims to provide an update on the various practical applications of the stop-bang questionnaire in anesthesia, surgery, and perioperative medicine.<br><b>recent findings</b>: the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "<b>purpose of review</b>: the present review aims to provide an update on the various practical applications of the stop-bang questionnaire in anesthesia, surgery, and perioperative medicine.<br><b>recent findings</b>: the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "<b>background</b>: the present study validates and evaluates the sensitivity and specificity of four internationally popular questionnaires, translated into chinese, for assessing suspected obstructive sleep apnea (osa) patients, namely, the berlin questionnaire, the asa checklist, the stop questionnaire and the stop-bang questionnaire.", "<b>background</b>: the present study validates and evaluates the sensitivity and specificity of four internationally popular questionnaires, translated into chinese, for assessing suspected obstructive sleep apnea (osa) patients, namely, the berlin questionnaire, the asa checklist, the stop questionnaire and the stop-bang questionnaire.", "<b>background</b>: the present study validates and evaluates the sensitivity and specificity of four internationally popular questionnaires, translated into chinese, for assessing suspected obstructive sleep apnea (osa) patients, namely, the berlin questionnaire, the asa checklist, the stop questionnaire and the stop-bang questionnaire.", "<b>background</b>: the present study validates and evaluates the sensitivity and specificity of four internationally popular questionnaires, translated into chinese, for assessing suspected obstructive sleep apnea (osa) patients, namely, the berlin questionnaire, the asa checklist, the stop questionnaire and the stop-bang questionnaire.", "<b>background</b>: the present study validates and evaluates the sensitivity and specificity of four internationally popular questionnaires, translated into chinese, for assessing suspected obstructive sleep apnea (osa) patients, namely, the berlin questionnaire, the asa checklist, the stop questionnaire and the stop-bang questionnaire.", "<b>background</b>: the present study validates and evaluates the sensitivity and specificity of four internationally popular questionnaires, translated into chinese, for assessing suspected obstructive sleep apnea (osa) patients, namely, the berlin questionnaire, the asa checklist, the stop questionnaire and the stop-bang questionnaire.", "<b>background</b>: the present study validates and evaluates the sensitivity and specificity of four internationally popular questionnaires, translated into chinese, for assessing suspected obstructive sleep apnea (osa) patients, namely, the berlin questionnaire, the asa checklist, the stop questionnaire and the stop-bang questionnaire.", "<b>background</b>: the present study validates and evaluates the sensitivity and specificity of four internationally popular questionnaires, translated into chinese, for assessing suspected obstructive sleep apnea (osa) patients, namely, the berlin questionnaire, the asa checklist, the stop questionnaire and the stop-bang questionnaire.", "<b>background</b>: the present study validates and evaluates the sensitivity and specificity of four internationally popular questionnaires, translated into chinese, for assessing suspected obstructive sleep apnea (osa) patients, namely, the berlin questionnaire, the asa checklist, the stop questionnaire and the stop-bang questionnaire.", "<b>background</b>: the present study validates and evaluates the sensitivity and specificity of four internationally popular questionnaires, translated into chinese, for assessing suspected obstructive sleep apnea (osa) patients, namely, the berlin questionnaire, the asa checklist, the stop questionnaire and the stop-bang questionnaire.", "<b>background</b>: the present study validates and evaluates the sensitivity and specificity of four internationally popular questionnaires, translated into chinese, for assessing suspected obstructive sleep apnea (osa) patients, namely, the berlin questionnaire, the asa checklist, the stop questionnaire and the stop-bang questionnaire.", "<b>background</b>: the present study validates and evaluates the sensitivity and specificity of four internationally popular questionnaires, translated into chinese, for assessing suspected obstructive sleep apnea (osa) patients, namely, the berlin questionnaire, the asa checklist, the stop questionnaire and the stop-bang questionnaire.", "<b>background</b>: the present study validates and evaluates the sensitivity and specificity of four internationally popular questionnaires, translated into chinese, for assessing suspected obstructive sleep apnea (osa) patients, namely, the berlin questionnaire, the asa checklist, the stop questionnaire and the stop-bang questionnaire.", "<b>background</b>: the present study validates and evaluates the sensitivity and specificity of four internationally popular questionnaires, translated into chinese, for assessing suspected obstructive sleep apnea (osa) patients, namely, the berlin questionnaire, the asa checklist, the stop questionnaire and the stop-bang questionnaire.", "<b>background</b>: the present study validates and evaluates the sensitivity and specificity of four internationally popular questionnaires, translated into chinese, for assessing suspected obstructive sleep apnea (osa) patients, namely, the berlin questionnaire, the asa checklist, the stop questionnaire and the stop-bang questionnaire.", "<b>background</b>: the present study validates and evaluates the sensitivity and specificity of four internationally popular questionnaires, translated into chinese, for assessing suspected obstructive sleep apnea (osa) patients, namely, the berlin questionnaire, the asa checklist, the stop questionnaire and the stop-bang questionnaire.", "<b>background</b>: the present study validates and evaluates the sensitivity and specificity of four internationally popular questionnaires, translated into chinese, for assessing suspected obstructive sleep apnea (osa) patients, namely, the berlin questionnaire, the asa checklist, the stop questionnaire and the stop-bang questionnaire.", "<b>background</b>: the present study validates and evaluates the sensitivity and specificity of four internationally popular questionnaires, translated into chinese, for assessing suspected obstructive sleep apnea (osa) patients, namely, the berlin questionnaire, the asa checklist, the stop questionnaire and the stop-bang questionnaire.", "<b>background</b>: the present study validates and evaluates the sensitivity and specificity of four internationally popular questionnaires, translated into chinese, for assessing suspected obstructive sleep apnea (osa) patients, namely, the berlin questionnaire, the asa checklist, the stop questionnaire and the stop-bang questionnaire.", "<b>background</b>: the present study validates and evaluates the sensitivity and specificity of four internationally popular questionnaires, translated into chinese, for assessing suspected obstructive sleep apnea (osa) patients, namely, the berlin questionnaire, the asa checklist, the stop questionnaire and the stop-bang questionnaire.", "<b>background</b>: the present study validates and evaluates the sensitivity and specificity of four internationally popular questionnaires, translated into chinese, for assessing suspected obstructive sleep apnea (osa) patients, namely, the berlin questionnaire, the asa checklist, the stop questionnaire and the stop-bang questionnaire.", "<b>background</b>: the present study validates and evaluates the sensitivity and specificity of four internationally popular questionnaires, translated into chinese, for assessing suspected obstructive sleep apnea (osa) patients, namely, the berlin questionnaire, the asa checklist, the stop questionnaire and the stop-bang questionnaire.", "<b>background</b>: the present study validates and evaluates the sensitivity and specificity of four internationally popular questionnaires, translated into chinese, for assessing suspected obstructive sleep apnea (osa) patients, namely, the berlin questionnaire, the asa checklist, the stop questionnaire and the stop-bang questionnaire.", "<b>background</b>: the present study validates and evaluates the sensitivity and specificity of four internationally popular questionnaires, translated into chinese, for assessing suspected obstructive sleep apnea (osa) patients, namely, the berlin questionnaire, the asa checklist, the stop questionnaire and the stop-bang questionnaire.", "<b>background</b>: the present study validates and evaluates the sensitivity and specificity of four internationally popular questionnaires, translated into chinese, for assessing suspected obstructive sleep apnea (osa) patients, namely, the berlin questionnaire, the asa checklist, the stop questionnaire and the stop-bang questionnaire.", "<b>background</b>: the present study validates and evaluates the sensitivity and specificity of four internationally popular questionnaires, translated into chinese, for assessing suspected obstructive sleep apnea (osa) patients, namely, the berlin questionnaire, the asa checklist, the stop questionnaire and the stop-bang questionnaire.", "<b>background</b>: the present study validates and evaluates the sensitivity and specificity of four internationally popular questionnaires, translated into chinese, for assessing suspected obstructive sleep apnea (osa) patients, namely, the berlin questionnaire, the asa checklist, the stop questionnaire and the stop-bang questionnaire.", "the aims of this study were to (1) explore the incidence of right-sided heart dysfunction (rhd) and stop-bang questionnaire responses consistent with obstructive sleep apnea (osa) and (2) assess the relationship between patients with stop-bang questionnaire responses consistent with osa and echocardiographic findings suggestive of rhd.", "the aims of this study were to (1) explore the incidence of right-sided heart dysfunction (rhd) and stop-bang questionnaire responses consistent with obstructive sleep apnea (osa) and (2) assess the relationship between patients with stop-bang questionnaire responses consistent with osa and echocardiographic findings suggestive of rhd.", "the aims of this study were to (1) explore the incidence of right-sided heart dysfunction (rhd) and stop-bang questionnaire responses consistent with obstructive sleep apnea (osa) and (2) assess the relationship between patients with stop-bang questionnaire responses consistent with osa and echocardiographic findings suggestive of rhd.", "the aims of this study were to (1) explore the incidence of right-sided heart dysfunction (rhd) and stop-bang questionnaire responses consistent with obstructive sleep apnea (osa) and (2) assess the relationship between patients with stop-bang questionnaire responses consistent with osa and echocardiographic findings suggestive of rhd.", "the aims of this study were to (1) explore the incidence of right-sided heart dysfunction (rhd) and stop-bang questionnaire responses consistent with obstructive sleep apnea (osa) and (2) assess the relationship between patients with stop-bang questionnaire responses consistent with osa and echocardiographic findings suggestive of rhd.", "the aims of this study were to (1) explore the incidence of right-sided heart dysfunction (rhd) and stop-bang questionnaire responses consistent with obstructive sleep apnea (osa) and (2) assess the relationship between patients with stop-bang questionnaire responses consistent with osa and echocardiographic findings suggestive of rhd.", "the aims of this study were to (1) explore the incidence of right-sided heart dysfunction (rhd) and stop-bang questionnaire responses consistent with obstructive sleep apnea (osa) and (2) assess the relationship between patients with stop-bang questionnaire responses consistent with osa and echocardiographic findings suggestive of rhd.", "the aims of this study were to (1) explore the incidence of right-sided heart dysfunction (rhd) and stop-bang questionnaire responses consistent with obstructive sleep apnea (osa) and (2) assess the relationship between patients with stop-bang questionnaire responses consistent with osa and echocardiographic findings suggestive of rhd.", "the aims of this study were to (1) explore the incidence of right-sided heart dysfunction (rhd) and stop-bang questionnaire responses consistent with obstructive sleep apnea (osa) and (2) assess the relationship between patients with stop-bang questionnaire responses consistent with osa and echocardiographic findings suggestive of rhd.", "the aims of this study were to (1) explore the incidence of right-sided heart dysfunction (rhd) and stop-bang questionnaire responses consistent with obstructive sleep apnea (osa) and (2) assess the relationship between patients with stop-bang questionnaire responses consistent with osa and echocardiographic findings suggestive of rhd.", "the aims of this study were to (1) explore the incidence of right-sided heart dysfunction (rhd) and stop-bang questionnaire responses consistent with obstructive sleep apnea (osa) and (2) assess the relationship between patients with stop-bang questionnaire responses consistent with osa and echocardiographic findings suggestive of rhd.", "the aims of this study were to (1) explore the incidence of right-sided heart dysfunction (rhd) and stop-bang questionnaire responses consistent with obstructive sleep apnea (osa) and (2) assess the relationship between patients with stop-bang questionnaire responses consistent with osa and echocardiographic findings suggestive of rhd.", "the aims of this study were to (1) explore the incidence of right-sided heart dysfunction (rhd) and stop-bang questionnaire responses consistent with obstructive sleep apnea (osa) and (2) assess the relationship between patients with stop-bang questionnaire responses consistent with osa and echocardiographic findings suggestive of rhd.", "the aims of this study were to (1) explore the incidence of right-sided heart dysfunction (rhd) and stop-bang questionnaire responses consistent with obstructive sleep apnea (osa) and (2) assess the relationship between patients with stop-bang questionnaire responses consistent with osa and echocardiographic findings suggestive of rhd.", "the aims of this study were to (1) explore the incidence of right-sided heart dysfunction (rhd) and stop-bang questionnaire responses consistent with obstructive sleep apnea (osa) and (2) assess the relationship between patients with stop-bang questionnaire responses consistent with osa and echocardiographic findings suggestive of rhd.", "the aims of this study were to (1) explore the incidence of right-sided heart dysfunction (rhd) and stop-bang questionnaire responses consistent with obstructive sleep apnea (osa) and (2) assess the relationship between patients with stop-bang questionnaire responses consistent with osa and echocardiographic findings suggestive of rhd.", "the aims of this study were to (1) explore the incidence of right-sided heart dysfunction (rhd) and stop-bang questionnaire responses consistent with obstructive sleep apnea (osa) and (2) assess the relationship between patients with stop-bang questionnaire responses consistent with osa and echocardiographic findings suggestive of rhd.", "the aims of this study were to (1) explore the incidence of right-sided heart dysfunction (rhd) and stop-bang questionnaire responses consistent with obstructive sleep apnea (osa) and (2) assess the relationship between patients with stop-bang questionnaire responses consistent with osa and echocardiographic findings suggestive of rhd.", "the aims of this study were to (1) explore the incidence of right-sided heart dysfunction (rhd) and stop-bang questionnaire responses consistent with obstructive sleep apnea (osa) and (2) assess the relationship between patients with stop-bang questionnaire responses consistent with osa and echocardiographic findings suggestive of rhd.", "the aims of this study were to (1) explore the incidence of right-sided heart dysfunction (rhd) and stop-bang questionnaire responses consistent with obstructive sleep apnea (osa) and (2) assess the relationship between patients with stop-bang questionnaire responses consistent with osa and echocardiographic findings suggestive of rhd.", "the aims of this study were to (1) explore the incidence of right-sided heart dysfunction (rhd) and stop-bang questionnaire responses consistent with obstructive sleep apnea (osa) and (2) assess the relationship between patients with stop-bang questionnaire responses consistent with osa and echocardiographic findings suggestive of rhd.", "the aims of this study were to (1) explore the incidence of right-sided heart dysfunction (rhd) and stop-bang questionnaire responses consistent with obstructive sleep apnea (osa) and (2) assess the relationship between patients with stop-bang questionnaire responses consistent with osa and echocardiographic findings suggestive of rhd.", "the aims of this study were to (1) explore the incidence of right-sided heart dysfunction (rhd) and stop-bang questionnaire responses consistent with obstructive sleep apnea (osa) and (2) assess the relationship between patients with stop-bang questionnaire responses consistent with osa and echocardiographic findings suggestive of rhd.", "the aims of this study were to (1) explore the incidence of right-sided heart dysfunction (rhd) and stop-bang questionnaire responses consistent with obstructive sleep apnea (osa) and (2) assess the relationship between patients with stop-bang questionnaire responses consistent with osa and echocardiographic findings suggestive of rhd.", "the aims of this study were to (1) explore the incidence of right-sided heart dysfunction (rhd) and stop-bang questionnaire responses consistent with obstructive sleep apnea (osa) and (2) assess the relationship between patients with stop-bang questionnaire responses consistent with osa and echocardiographic findings suggestive of rhd.", "the aims of this study were to (1) explore the incidence of right-sided heart dysfunction (rhd) and stop-bang questionnaire responses consistent with obstructive sleep apnea (osa) and (2) assess the relationship between patients with stop-bang questionnaire responses consistent with osa and echocardiographic findings suggestive of rhd.", "the aims of this study were to (1) explore the incidence of right-sided heart dysfunction (rhd) and stop-bang questionnaire responses consistent with obstructive sleep apnea (osa) and (2) assess the relationship between patients with stop-bang questionnaire responses consistent with osa and echocardiographic findings suggestive of rhd.", "subjects completed a questionnaire evaluating the presence and severity of ar and the stop-bang questionnaire (snoring, tiredness during daytime, observed apnea, high blood pressure, body mass index, age, neck circumference, gender), a validated screening method to identify obstructive sleep apnea syndrome risk.", "subjects completed a questionnaire evaluating the presence and severity of ar and the stop-bang questionnaire (snoring, tiredness during daytime, observed apnea, high blood pressure, body mass index, age, neck circumference, gender), a validated screening method to identify obstructive sleep apnea syndrome risk.", "subjects completed a questionnaire evaluating the presence and severity of ar and the stop-bang questionnaire (snoring, tiredness during daytime, observed apnea, high blood pressure, body mass index, age, neck circumference, gender), a validated screening method to identify obstructive sleep apnea syndrome risk.", "subjects completed a questionnaire evaluating the presence and severity of ar and the stop-bang questionnaire (snoring, tiredness during daytime, observed apnea, high blood pressure, body mass index, age, neck circumference, gender), a validated screening method to identify obstructive sleep apnea syndrome risk.", "subjects completed a questionnaire evaluating the presence and severity of ar and the stop-bang questionnaire (snoring, tiredness during daytime, observed apnea, high blood pressure, body mass index, age, neck circumference, gender), a validated screening method to identify obstructive sleep apnea syndrome risk.", "subjects completed a questionnaire evaluating the presence and severity of ar and the stop-bang questionnaire (snoring, tiredness during daytime, observed apnea, high blood pressure, body mass index, age, neck circumference, gender), a validated screening method to identify obstructive sleep apnea syndrome risk.", "subjects completed a questionnaire evaluating the presence and severity of ar and the stop-bang questionnaire (snoring, tiredness during daytime, observed apnea, high blood pressure, body mass index, age, neck circumference, gender), a validated screening method to identify obstructive sleep apnea syndrome risk.", "subjects completed a questionnaire evaluating the presence and severity of ar and the stop-bang questionnaire (snoring, tiredness during daytime, observed apnea, high blood pressure, body mass index, age, neck circumference, gender), a validated screening method to identify obstructive sleep apnea syndrome risk.", "subjects completed a questionnaire evaluating the presence and severity of ar and the stop-bang questionnaire (snoring, tiredness during daytime, observed apnea, high blood pressure, body mass index, age, neck circumference, gender), a validated screening method to identify obstructive sleep apnea syndrome risk.", "subjects completed a questionnaire evaluating the presence and severity of ar and the stop-bang questionnaire (snoring, tiredness during daytime, observed apnea, high blood pressure, body mass index, age, neck circumference, gender), a validated screening method to identify obstructive sleep apnea syndrome risk.", "subjects completed a questionnaire evaluating the presence and severity of ar and the stop-bang questionnaire (snoring, tiredness during daytime, observed apnea, high blood pressure, body mass index, age, neck circumference, gender), a validated screening method to identify obstructive sleep apnea syndrome risk.", "subjects completed a questionnaire evaluating the presence and severity of ar and the stop-bang questionnaire (snoring, tiredness during daytime, observed apnea, high blood pressure, body mass index, age, neck circumference, gender), a validated screening method to identify obstructive sleep apnea syndrome risk.", "subjects completed a questionnaire evaluating the presence and severity of ar and the stop-bang questionnaire (snoring, tiredness during daytime, observed apnea, high blood pressure, body mass index, age, neck circumference, gender), a validated screening method to identify obstructive sleep apnea syndrome risk.", "subjects completed a questionnaire evaluating the presence and severity of ar and the stop-bang questionnaire (snoring, tiredness during daytime, observed apnea, high blood pressure, body mass index, age, neck circumference, gender), a validated screening method to identify obstructive sleep apnea syndrome risk.", "subjects completed a questionnaire evaluating the presence and severity of ar and the stop-bang questionnaire (snoring, tiredness during daytime, observed apnea, high blood pressure, body mass index, age, neck circumference, gender), a validated screening method to identify obstructive sleep apnea syndrome risk.", "subjects completed a questionnaire evaluating the presence and severity of ar and the stop-bang questionnaire (snoring, tiredness during daytime, observed apnea, high blood pressure, body mass index, age, neck circumference, gender), a validated screening method to identify obstructive sleep apnea syndrome risk.", "subjects completed a questionnaire evaluating the presence and severity of ar and the stop-bang questionnaire (snoring, tiredness during daytime, observed apnea, high blood pressure, body mass index, age, neck circumference, gender), a validated screening method to identify obstructive sleep apnea syndrome risk.", "subjects completed a questionnaire evaluating the presence and severity of ar and the stop-bang questionnaire (snoring, tiredness during daytime, observed apnea, high blood pressure, body mass index, age, neck circumference, gender), a validated screening method to identify obstructive sleep apnea syndrome risk.", "subjects completed a questionnaire evaluating the presence and severity of ar and the stop-bang questionnaire (snoring, tiredness during daytime, observed apnea, high blood pressure, body mass index, age, neck circumference, gender), a validated screening method to identify obstructive sleep apnea syndrome risk.", "subjects completed a questionnaire evaluating the presence and severity of ar and the stop-bang questionnaire (snoring, tiredness during daytime, observed apnea, high blood pressure, body mass index, age, neck circumference, gender), a validated screening method to identify obstructive sleep apnea syndrome risk.", "subjects completed a questionnaire evaluating the presence and severity of ar and the stop-bang questionnaire (snoring, tiredness during daytime, observed apnea, high blood pressure, body mass index, age, neck circumference, gender), a validated screening method to identify obstructive sleep apnea syndrome risk.", "subjects completed a questionnaire evaluating the presence and severity of ar and the stop-bang questionnaire (snoring, tiredness during daytime, observed apnea, high blood pressure, body mass index, age, neck circumference, gender), a validated screening method to identify obstructive sleep apnea syndrome risk.", "subjects completed a questionnaire evaluating the presence and severity of ar and the stop-bang questionnaire (snoring, tiredness during daytime, observed apnea, high blood pressure, body mass index, age, neck circumference, gender), a validated screening method to identify obstructive sleep apnea syndrome risk.", "subjects completed a questionnaire evaluating the presence and severity of ar and the stop-bang questionnaire (snoring, tiredness during daytime, observed apnea, high blood pressure, body mass index, age, neck circumference, gender), a validated screening method to identify obstructive sleep apnea syndrome risk.", "subjects completed a questionnaire evaluating the presence and severity of ar and the stop-bang questionnaire (snoring, tiredness during daytime, observed apnea, high blood pressure, body mass index, age, neck circumference, gender), a validated screening method to identify obstructive sleep apnea syndrome risk.", "subjects completed a questionnaire evaluating the presence and severity of ar and the stop-bang questionnaire (snoring, tiredness during daytime, observed apnea, high blood pressure, body mass index, age, neck circumference, gender), a validated screening method to identify obstructive sleep apnea syndrome risk.", "subjects completed a questionnaire evaluating the presence and severity of ar and the stop-bang questionnaire (snoring, tiredness during daytime, observed apnea, high blood pressure, body mass index, age, neck circumference, gender), a validated screening method to identify obstructive sleep apnea syndrome risk.", "background: an accurate, clinical screening tool for obstructive sleep apnea (osa) that identifies patients for further diagnostic testing would assist in the diagnosis of this comorbidity. one example, the stop-bang questionnaire (sbq), has been validated as a screening tool with high sensitivity.", "background: an accurate, clinical screening tool for obstructive sleep apnea (osa) that identifies patients for further diagnostic testing would assist in the diagnosis of this comorbidity. one example, the stop-bang questionnaire (sbq), has been validated as a screening tool with high sensitivity.", "background: an accurate, clinical screening tool for obstructive sleep apnea (osa) that identifies patients for further diagnostic testing would assist in the diagnosis of this comorbidity. one example, the stop-bang questionnaire (sbq), has been validated as a screening tool with high sensitivity.", "background: an accurate, clinical screening tool for obstructive sleep apnea (osa) that identifies patients for further diagnostic testing would assist in the diagnosis of this comorbidity. one example, the stop-bang questionnaire (sbq), has been validated as a screening tool with high sensitivity.", "background: an accurate, clinical screening tool for obstructive sleep apnea (osa) that identifies patients for further diagnostic testing would assist in the diagnosis of this comorbidity. one example, the stop-bang questionnaire (sbq), has been validated as a screening tool with high sensitivity.", "background: an accurate, clinical screening tool for obstructive sleep apnea (osa) that identifies patients for further diagnostic testing would assist in the diagnosis of this comorbidity. one example, the stop-bang questionnaire (sbq), has been validated as a screening tool with high sensitivity.", "background: an accurate, clinical screening tool for obstructive sleep apnea (osa) that identifies patients for further diagnostic testing would assist in the diagnosis of this comorbidity. one example, the stop-bang questionnaire (sbq), has been validated as a screening tool with high sensitivity.", "background: an accurate, clinical screening tool for obstructive sleep apnea (osa) that identifies patients for further diagnostic testing would assist in the diagnosis of this comorbidity. one example, the stop-bang questionnaire (sbq), has been validated as a screening tool with high sensitivity.", "background: an accurate, clinical screening tool for obstructive sleep apnea (osa) that identifies patients for further diagnostic testing would assist in the diagnosis of this comorbidity. one example, the stop-bang questionnaire (sbq), has been validated as a screening tool with high sensitivity.", "background: an accurate, clinical screening tool for obstructive sleep apnea (osa) that identifies patients for further diagnostic testing would assist in the diagnosis of this comorbidity. one example, the stop-bang questionnaire (sbq), has been validated as a screening tool with high sensitivity.", "background: an accurate, clinical screening tool for obstructive sleep apnea (osa) that identifies patients for further diagnostic testing would assist in the diagnosis of this comorbidity. one example, the stop-bang questionnaire (sbq), has been validated as a screening tool with high sensitivity.", "background: an accurate, clinical screening tool for obstructive sleep apnea (osa) that identifies patients for further diagnostic testing would assist in the diagnosis of this comorbidity. one example, the stop-bang questionnaire (sbq), has been validated as a screening tool with high sensitivity.", "background: an accurate, clinical screening tool for obstructive sleep apnea (osa) that identifies patients for further diagnostic testing would assist in the diagnosis of this comorbidity. one example, the stop-bang questionnaire (sbq), has been validated as a screening tool with high sensitivity.", "background: an accurate, clinical screening tool for obstructive sleep apnea (osa) that identifies patients for further diagnostic testing would assist in the diagnosis of this comorbidity. one example, the stop-bang questionnaire (sbq), has been validated as a screening tool with high sensitivity.", "background: an accurate, clinical screening tool for obstructive sleep apnea (osa) that identifies patients for further diagnostic testing would assist in the diagnosis of this comorbidity. one example, the stop-bang questionnaire (sbq), has been validated as a screening tool with high sensitivity.", "background: an accurate, clinical screening tool for obstructive sleep apnea (osa) that identifies patients for further diagnostic testing would assist in the diagnosis of this comorbidity. one example, the stop-bang questionnaire (sbq), has been validated as a screening tool with high sensitivity.", "background: an accurate, clinical screening tool for obstructive sleep apnea (osa) that identifies patients for further diagnostic testing would assist in the diagnosis of this comorbidity. one example, the stop-bang questionnaire (sbq), has been validated as a screening tool with high sensitivity.", "background: an accurate, clinical screening tool for obstructive sleep apnea (osa) that identifies patients for further diagnostic testing would assist in the diagnosis of this comorbidity. one example, the stop-bang questionnaire (sbq), has been validated as a screening tool with high sensitivity.", "background: an accurate, clinical screening tool for obstructive sleep apnea (osa) that identifies patients for further diagnostic testing would assist in the diagnosis of this comorbidity. one example, the stop-bang questionnaire (sbq), has been validated as a screening tool with high sensitivity.", "background: an accurate, clinical screening tool for obstructive sleep apnea (osa) that identifies patients for further diagnostic testing would assist in the diagnosis of this comorbidity. one example, the stop-bang questionnaire (sbq), has been validated as a screening tool with high sensitivity.", "background: an accurate, clinical screening tool for obstructive sleep apnea (osa) that identifies patients for further diagnostic testing would assist in the diagnosis of this comorbidity. one example, the stop-bang questionnaire (sbq), has been validated as a screening tool with high sensitivity.", "background: an accurate, clinical screening tool for obstructive sleep apnea (osa) that identifies patients for further diagnostic testing would assist in the diagnosis of this comorbidity. one example, the stop-bang questionnaire (sbq), has been validated as a screening tool with high sensitivity.", "background: an accurate, clinical screening tool for obstructive sleep apnea (osa) that identifies patients for further diagnostic testing would assist in the diagnosis of this comorbidity. one example, the stop-bang questionnaire (sbq), has been validated as a screening tool with high sensitivity.", "background: an accurate, clinical screening tool for obstructive sleep apnea (osa) that identifies patients for further diagnostic testing would assist in the diagnosis of this comorbidity. one example, the stop-bang questionnaire (sbq), has been validated as a screening tool with high sensitivity.", "background: an accurate, clinical screening tool for obstructive sleep apnea (osa) that identifies patients for further diagnostic testing would assist in the diagnosis of this comorbidity. one example, the stop-bang questionnaire (sbq), has been validated as a screening tool with high sensitivity.", "background: an accurate, clinical screening tool for obstructive sleep apnea (osa) that identifies patients for further diagnostic testing would assist in the diagnosis of this comorbidity. one example, the stop-bang questionnaire (sbq), has been validated as a screening tool with high sensitivity.", "background: an accurate, clinical screening tool for obstructive sleep apnea (osa) that identifies patients for further diagnostic testing would assist in the diagnosis of this comorbidity. one example, the stop-bang questionnaire (sbq), has been validated as a screening tool with high sensitivity.", "the stop-bang questionnaire has been used to identify surgical patients at risk for undiagnosed obstructive sleep apnea (osa) by classifying patients as low risk (lr) if stop-bang score < 3 or high risk (hr) if stop-bang score \u2265 3.", "the stop-bang questionnaire has been used to identify surgical patients at risk for undiagnosed obstructive sleep apnea (osa) by classifying patients as low risk (lr) if stop-bang score < 3 or high risk (hr) if stop-bang score \u2265 3.", "the stop-bang questionnaire has been used to identify surgical patients at risk for undiagnosed obstructive sleep apnea (osa) by classifying patients as low risk (lr) if stop-bang score < 3 or high risk (hr) if stop-bang score \u2265 3.", "the stop-bang questionnaire has been used to identify surgical patients at risk for undiagnosed obstructive sleep apnea (osa) by classifying patients as low risk (lr) if stop-bang score < 3 or high risk (hr) if stop-bang score \u2265 3.", "the stop-bang questionnaire has been used to identify surgical patients at risk for undiagnosed obstructive sleep apnea (osa) by classifying patients as low risk (lr) if stop-bang score < 3 or high risk (hr) if stop-bang score \u2265 3.", "the stop-bang questionnaire has been used to identify surgical patients at risk for undiagnosed obstructive sleep apnea (osa) by classifying patients as low risk (lr) if stop-bang score < 3 or high risk (hr) if stop-bang score \u2265 3.", "the stop-bang questionnaire has been used to identify surgical patients at risk for undiagnosed obstructive sleep apnea (osa) by classifying patients as low risk (lr) if stop-bang score < 3 or high risk (hr) if stop-bang score \u2265 3.", "the stop-bang questionnaire has been used to identify surgical patients at risk for undiagnosed obstructive sleep apnea (osa) by classifying patients as low risk (lr) if stop-bang score < 3 or high risk (hr) if stop-bang score \u2265 3.", "the stop-bang questionnaire has been used to identify surgical patients at risk for undiagnosed obstructive sleep apnea (osa) by classifying patients as low risk (lr) if stop-bang score < 3 or high risk (hr) if stop-bang score \u2265 3.", "the stop-bang questionnaire has been used to identify surgical patients at risk for undiagnosed obstructive sleep apnea (osa) by classifying patients as low risk (lr) if stop-bang score < 3 or high risk (hr) if stop-bang score \u2265 3.", "the stop-bang questionnaire has been used to identify surgical patients at risk for undiagnosed obstructive sleep apnea (osa) by classifying patients as low risk (lr) if stop-bang score < 3 or high risk (hr) if stop-bang score \u2265 3.", "the stop-bang questionnaire has been used to identify surgical patients at risk for undiagnosed obstructive sleep apnea (osa) by classifying patients as low risk (lr) if stop-bang score < 3 or high risk (hr) if stop-bang score \u2265 3.", "the stop-bang questionnaire has been used to identify surgical patients at risk for undiagnosed obstructive sleep apnea (osa) by classifying patients as low risk (lr) if stop-bang score < 3 or high risk (hr) if stop-bang score \u2265 3.", "the stop-bang questionnaire has been used to identify surgical patients at risk for undiagnosed obstructive sleep apnea (osa) by classifying patients as low risk (lr) if stop-bang score < 3 or high risk (hr) if stop-bang score \u2265 3.", "the stop-bang questionnaire has been used to identify surgical patients at risk for undiagnosed obstructive sleep apnea (osa) by classifying patients as low risk (lr) if stop-bang score < 3 or high risk (hr) if stop-bang score \u2265 3.", "the stop-bang questionnaire has been used to identify surgical patients at risk for undiagnosed obstructive sleep apnea (osa) by classifying patients as low risk (lr) if stop-bang score < 3 or high risk (hr) if stop-bang score \u2265 3.", "the stop-bang questionnaire has been used to identify surgical patients at risk for undiagnosed obstructive sleep apnea (osa) by classifying patients as low risk (lr) if stop-bang score < 3 or high risk (hr) if stop-bang score \u2265 3.", "the stop-bang questionnaire has been used to identify surgical patients at risk for undiagnosed obstructive sleep apnea (osa) by classifying patients as low risk (lr) if stop-bang score < 3 or high risk (hr) if stop-bang score \u2265 3.", "the stop-bang questionnaire has been used to identify surgical patients at risk for undiagnosed obstructive sleep apnea (osa) by classifying patients as low risk (lr) if stop-bang score < 3 or high risk (hr) if stop-bang score \u2265 3.", "the stop-bang questionnaire has been used to identify surgical patients at risk for undiagnosed obstructive sleep apnea (osa) by classifying patients as low risk (lr) if stop-bang score < 3 or high risk (hr) if stop-bang score \u2265 3.", "the stop-bang questionnaire has been used to identify surgical patients at risk for undiagnosed obstructive sleep apnea (osa) by classifying patients as low risk (lr) if stop-bang score < 3 or high risk (hr) if stop-bang score \u2265 3.", "the stop-bang questionnaire has been used to identify surgical patients at risk for undiagnosed obstructive sleep apnea (osa) by classifying patients as low risk (lr) if stop-bang score < 3 or high risk (hr) if stop-bang score \u2265 3.", "the stop-bang questionnaire has been used to identify surgical patients at risk for undiagnosed obstructive sleep apnea (osa) by classifying patients as low risk (lr) if stop-bang score < 3 or high risk (hr) if stop-bang score \u2265 3.", "the stop-bang questionnaire has been used to identify surgical patients at risk for undiagnosed obstructive sleep apnea (osa) by classifying patients as low risk (lr) if stop-bang score < 3 or high risk (hr) if stop-bang score \u2265 3.", "the stop-bang questionnaire has been used to identify surgical patients at risk for undiagnosed obstructive sleep apnea (osa) by classifying patients as low risk (lr) if stop-bang score < 3 or high risk (hr) if stop-bang score \u2265 3.", "the stop-bang questionnaire has been used to identify surgical patients at risk for undiagnosed obstructive sleep apnea (osa) by classifying patients as low risk (lr) if stop-bang score < 3 or high risk (hr) if stop-bang score \u2265 3.", "the stop-bang questionnaire has been used to identify surgical patients at risk for undiagnosed obstructive sleep apnea (osa) by classifying patients as low risk (lr) if stop-bang score < 3 or high risk (hr) if stop-bang score \u2265 3.", "study objective: the aim of this study is to evaluate whether adding the item of \"apple body type\" to the stop-bang questionnaire enhances diagnostic performance of the questionnaire for detecting obstructive sleep apnea (osa).", "study objective: the aim of this study is to evaluate whether adding the item of \"apple body type\" to the stop-bang questionnaire enhances diagnostic performance of the questionnaire for detecting obstructive sleep apnea (osa).", "study objective: the aim of this study is to evaluate whether adding the item of \"apple body type\" to the stop-bang questionnaire enhances diagnostic performance of the questionnaire for detecting obstructive sleep apnea (osa).", "study objective: the aim of this study is to evaluate whether adding the item of \"apple body type\" to the stop-bang questionnaire enhances diagnostic performance of the questionnaire for detecting obstructive sleep apnea (osa).", "study objective: the aim of this study is to evaluate whether adding the item of \"apple body type\" to the stop-bang questionnaire enhances diagnostic performance of the questionnaire for detecting obstructive sleep apnea (osa).", "study objective: the aim of this study is to evaluate whether adding the item of \"apple body type\" to the stop-bang questionnaire enhances diagnostic performance of the questionnaire for detecting obstructive sleep apnea (osa).", "study objective: the aim of this study is to evaluate whether adding the item of \"apple body type\" to the stop-bang questionnaire enhances diagnostic performance of the questionnaire for detecting obstructive sleep apnea (osa).", "study objective: the aim of this study is to evaluate whether adding the item of \"apple body type\" to the stop-bang questionnaire enhances diagnostic performance of the questionnaire for detecting obstructive sleep apnea (osa).", "study objective: the aim of this study is to evaluate whether adding the item of \"apple body type\" to the stop-bang questionnaire enhances diagnostic performance of the questionnaire for detecting obstructive sleep apnea (osa).", "study objective: the aim of this study is to evaluate whether adding the item of \"apple body type\" to the stop-bang questionnaire enhances diagnostic performance of the questionnaire for detecting obstructive sleep apnea (osa).", "study objective: the aim of this study is to evaluate whether adding the item of \"apple body type\" to the stop-bang questionnaire enhances diagnostic performance of the questionnaire for detecting obstructive sleep apnea (osa).", "study objective: the aim of this study is to evaluate whether adding the item of \"apple body type\" to the stop-bang questionnaire enhances diagnostic performance of the questionnaire for detecting obstructive sleep apnea (osa).", "study objective: the aim of this study is to evaluate whether adding the item of \"apple body type\" to the stop-bang questionnaire enhances diagnostic performance of the questionnaire for detecting obstructive sleep apnea (osa).", "study objective: the aim of this study is to evaluate whether adding the item of \"apple body type\" to the stop-bang questionnaire enhances diagnostic performance of the questionnaire for detecting obstructive sleep apnea (osa).", "study objective: the aim of this study is to evaluate whether adding the item of \"apple body type\" to the stop-bang questionnaire enhances diagnostic performance of the questionnaire for detecting obstructive sleep apnea (osa).", "study objective: the aim of this study is to evaluate whether adding the item of \"apple body type\" to the stop-bang questionnaire enhances diagnostic performance of the questionnaire for detecting obstructive sleep apnea (osa).", "study objective: the aim of this study is to evaluate whether adding the item of \"apple body type\" to the stop-bang questionnaire enhances diagnostic performance of the questionnaire for detecting obstructive sleep apnea (osa).", "study objective: the aim of this study is to evaluate whether adding the item of \"apple body type\" to the stop-bang questionnaire enhances diagnostic performance of the questionnaire for detecting obstructive sleep apnea (osa).", "study objective: the aim of this study is to evaluate whether adding the item of \"apple body type\" to the stop-bang questionnaire enhances diagnostic performance of the questionnaire for detecting obstructive sleep apnea (osa).", "study objective: the aim of this study is to evaluate whether adding the item of \"apple body type\" to the stop-bang questionnaire enhances diagnostic performance of the questionnaire for detecting obstructive sleep apnea (osa).", "study objective: the aim of this study is to evaluate whether adding the item of \"apple body type\" to the stop-bang questionnaire enhances diagnostic performance of the questionnaire for detecting obstructive sleep apnea (osa).", "study objective: the aim of this study is to evaluate whether adding the item of \"apple body type\" to the stop-bang questionnaire enhances diagnostic performance of the questionnaire for detecting obstructive sleep apnea (osa).", "study objective: the aim of this study is to evaluate whether adding the item of \"apple body type\" to the stop-bang questionnaire enhances diagnostic performance of the questionnaire for detecting obstructive sleep apnea (osa).", "study objective: the aim of this study is to evaluate whether adding the item of \"apple body type\" to the stop-bang questionnaire enhances diagnostic performance of the questionnaire for detecting obstructive sleep apnea (osa).", "study objective: the aim of this study is to evaluate whether adding the item of \"apple body type\" to the stop-bang questionnaire enhances diagnostic performance of the questionnaire for detecting obstructive sleep apnea (osa).", "study objective: the aim of this study is to evaluate whether adding the item of \"apple body type\" to the stop-bang questionnaire enhances diagnostic performance of the questionnaire for detecting obstructive sleep apnea (osa).", "study objective: the aim of this study is to evaluate whether adding the item of \"apple body type\" to the stop-bang questionnaire enhances diagnostic performance of the questionnaire for detecting obstructive sleep apnea (osa).", "study objective to determine if a high score (\u2265 3) on the stop-bang screening questionnaire for obstructive sleep apnea (osa) predicts whether obese patients are at high risk for osa and increased risk of difficult airway.", "study objective to determine if a high score (\u2265 3) on the stop-bang screening questionnaire for obstructive sleep apnea (osa) predicts whether obese patients are at high risk for osa and increased risk of difficult airway.", "study objective to determine if a high score (\u2265 3) on the stop-bang screening questionnaire for obstructive sleep apnea (osa) predicts whether obese patients are at high risk for osa and increased risk of difficult airway.", "study objective to determine if a high score (\u2265 3) on the stop-bang screening questionnaire for obstructive sleep apnea (osa) predicts whether obese patients are at high risk for osa and increased risk of difficult airway.", "study objective to determine if a high score (\u2265 3) on the stop-bang screening questionnaire for obstructive sleep apnea (osa) predicts whether obese patients are at high risk for osa and increased risk of difficult airway.", "study objective to determine if a high score (\u2265 3) on the stop-bang screening questionnaire for obstructive sleep apnea (osa) predicts whether obese patients are at high risk for osa and increased risk of difficult airway.", "study objective to determine if a high score (\u2265 3) on the stop-bang screening questionnaire for obstructive sleep apnea (osa) predicts whether obese patients are at high risk for osa and increased risk of difficult airway.", "study objective to determine if a high score (\u2265 3) on the stop-bang screening questionnaire for obstructive sleep apnea (osa) predicts whether obese patients are at high risk for osa and increased risk of difficult airway.", "study objective to determine if a high score (\u2265 3) on the stop-bang screening questionnaire for obstructive sleep apnea (osa) predicts whether obese patients are at high risk for osa and increased risk of difficult airway.", "study objective to determine if a high score (\u2265 3) on the stop-bang screening questionnaire for obstructive sleep apnea (osa) predicts whether obese patients are at high risk for osa and increased risk of difficult airway.", "study objective to determine if a high score (\u2265 3) on the stop-bang screening questionnaire for obstructive sleep apnea (osa) predicts whether obese patients are at high risk for osa and increased risk of difficult airway.", "study objective to determine if a high score (\u2265 3) on the stop-bang screening questionnaire for obstructive sleep apnea (osa) predicts whether obese patients are at high risk for osa and increased risk of difficult airway.", "study objective to determine if a high score (\u2265 3) on the stop-bang screening questionnaire for obstructive sleep apnea (osa) predicts whether obese patients are at high risk for osa and increased risk of difficult airway.", "study objective to determine if a high score (\u2265 3) on the stop-bang screening questionnaire for obstructive sleep apnea (osa) predicts whether obese patients are at high risk for osa and increased risk of difficult airway.", "study objective to determine if a high score (\u2265 3) on the stop-bang screening questionnaire for obstructive sleep apnea (osa) predicts whether obese patients are at high risk for osa and increased risk of difficult airway.", "study objective to determine if a high score (\u2265 3) on the stop-bang screening questionnaire for obstructive sleep apnea (osa) predicts whether obese patients are at high risk for osa and increased risk of difficult airway.", "study objective to determine if a high score (\u2265 3) on the stop-bang screening questionnaire for obstructive sleep apnea (osa) predicts whether obese patients are at high risk for osa and increased risk of difficult airway.", "study objective to determine if a high score (\u2265 3) on the stop-bang screening questionnaire for obstructive sleep apnea (osa) predicts whether obese patients are at high risk for osa and increased risk of difficult airway.", "study objective to determine if a high score (\u2265 3) on the stop-bang screening questionnaire for obstructive sleep apnea (osa) predicts whether obese patients are at high risk for osa and increased risk of difficult airway.", "study objective to determine if a high score (\u2265 3) on the stop-bang screening questionnaire for obstructive sleep apnea (osa) predicts whether obese patients are at high risk for osa and increased risk of difficult airway.", "study objective to determine if a high score (\u2265 3) on the stop-bang screening questionnaire for obstructive sleep apnea (osa) predicts whether obese patients are at high risk for osa and increased risk of difficult airway.", "study objective to determine if a high score (\u2265 3) on the stop-bang screening questionnaire for obstructive sleep apnea (osa) predicts whether obese patients are at high risk for osa and increased risk of difficult airway.", "study objective to determine if a high score (\u2265 3) on the stop-bang screening questionnaire for obstructive sleep apnea (osa) predicts whether obese patients are at high risk for osa and increased risk of difficult airway.", "study objective to determine if a high score (\u2265 3) on the stop-bang screening questionnaire for obstructive sleep apnea (osa) predicts whether obese patients are at high risk for osa and increased risk of difficult airway.", "study objective to determine if a high score (\u2265 3) on the stop-bang screening questionnaire for obstructive sleep apnea (osa) predicts whether obese patients are at high risk for osa and increased risk of difficult airway.", "study objective to determine if a high score (\u2265 3) on the stop-bang screening questionnaire for obstructive sleep apnea (osa) predicts whether obese patients are at high risk for osa and increased risk of difficult airway.", "study objective to determine if a high score (\u2265 3) on the stop-bang screening questionnaire for obstructive sleep apnea (osa) predicts whether obese patients are at high risk for osa and increased risk of difficult airway.", "recent findings the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "recent findings the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "recent findings the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "recent findings the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "recent findings the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "recent findings the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "recent findings the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "recent findings the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "recent findings the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "recent findings the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "recent findings the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "recent findings the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "recent findings the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "recent findings the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "recent findings the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "recent findings the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "recent findings the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "recent findings the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "recent findings the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "recent findings the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "recent findings the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "recent findings the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "recent findings the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "recent findings the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "recent findings the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "recent findings the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "recent findings the stop-bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (osa).", "diagnostic accuracy of the berlin questionnaire, stop-bang, stop, and epworth sleepiness scale in detecting obstructive sleep apnea: a bivariate meta-analysis.", "diagnostic accuracy of the berlin questionnaire, stop-bang, stop, and epworth sleepiness scale in detecting obstructive sleep apnea: a bivariate meta-analysis.", "diagnostic accuracy of the berlin questionnaire, stop-bang, stop, and epworth sleepiness scale in detecting obstructive sleep apnea: a bivariate meta-analysis.", "diagnostic accuracy of the berlin questionnaire, stop-bang, stop, and epworth sleepiness scale in detecting obstructive sleep apnea: a bivariate meta-analysis.", "diagnostic accuracy of the berlin questionnaire, stop-bang, stop, and epworth sleepiness scale in detecting obstructive sleep apnea: a bivariate meta-analysis.", "diagnostic accuracy of the berlin questionnaire, stop-bang, stop, and epworth sleepiness scale in detecting obstructive sleep apnea: a bivariate meta-analysis.", "diagnostic accuracy of the berlin questionnaire, stop-bang, stop, and epworth sleepiness scale in detecting obstructive sleep apnea: a bivariate meta-analysis.", "diagnostic accuracy of the berlin questionnaire, stop-bang, stop, and epworth sleepiness scale in detecting obstructive sleep apnea: a bivariate meta-analysis.", "diagnostic accuracy of the berlin questionnaire, stop-bang, stop, and epworth sleepiness scale in detecting obstructive sleep apnea: a bivariate meta-analysis.", "diagnostic accuracy of the berlin questionnaire, stop-bang, stop, and epworth sleepiness scale in detecting obstructive sleep apnea: a bivariate meta-analysis.", "diagnostic accuracy of the berlin questionnaire, stop-bang, stop, and epworth sleepiness scale in detecting obstructive sleep apnea: a bivariate meta-analysis.", "diagnostic accuracy of the berlin questionnaire, stop-bang, stop, and epworth sleepiness scale in detecting obstructive sleep apnea: a bivariate meta-analysis.", "diagnostic accuracy of the berlin questionnaire, stop-bang, stop, and epworth sleepiness scale in detecting obstructive sleep apnea: a bivariate meta-analysis.", "diagnostic accuracy of the berlin questionnaire, stop-bang, stop, and epworth sleepiness scale in detecting obstructive sleep apnea: a bivariate meta-analysis.", "diagnostic accuracy of the berlin questionnaire, stop-bang, stop, and epworth sleepiness scale in detecting obstructive sleep apnea: a bivariate meta-analysis.", "diagnostic accuracy of the berlin questionnaire, stop-bang, stop, and epworth sleepiness scale in detecting obstructive sleep apnea: a bivariate meta-analysis.", "diagnostic accuracy of the berlin questionnaire, stop-bang, stop, and epworth sleepiness scale in detecting obstructive sleep apnea: a bivariate meta-analysis.", "diagnostic accuracy of the berlin questionnaire, stop-bang, stop, and epworth sleepiness scale in detecting obstructive sleep apnea: a bivariate meta-analysis.", "diagnostic accuracy of the berlin questionnaire, stop-bang, stop, and epworth sleepiness scale in detecting obstructive sleep apnea: a bivariate meta-analysis.", "diagnostic accuracy of the berlin questionnaire, stop-bang, stop, and epworth sleepiness scale in detecting obstructive sleep apnea: a bivariate meta-analysis.", "diagnostic accuracy of the berlin questionnaire, stop-bang, stop, and epworth sleepiness scale in detecting obstructive sleep apnea: a bivariate meta-analysis.", "diagnostic accuracy of the berlin questionnaire, stop-bang, stop, and epworth sleepiness scale in detecting obstructive sleep apnea: a bivariate meta-analysis.", "diagnostic accuracy of the berlin questionnaire, stop-bang, stop, and epworth sleepiness scale in detecting obstructive sleep apnea: a bivariate meta-analysis.", "diagnostic accuracy of the berlin questionnaire, stop-bang, stop, and epworth sleepiness scale in detecting obstructive sleep apnea: a bivariate meta-analysis.", "diagnostic accuracy of the berlin questionnaire, stop-bang, stop, and epworth sleepiness scale in detecting obstructive sleep apnea: a bivariate meta-analysis.", "diagnostic accuracy of the berlin questionnaire, stop-bang, stop, and epworth sleepiness scale in detecting obstructive sleep apnea: a bivariate meta-analysis.", "diagnostic accuracy of the berlin questionnaire, stop-bang, stop, and epworth sleepiness scale in detecting obstructive sleep apnea: a bivariate meta-analysis.", "validation of the stop-bang questionnaire as a screening tool for obstructive sleep apnea among different populations: a systematic review and meta-analysis.", "validation of the stop-bang questionnaire as a screening tool for obstructive sleep apnea among different populations: a systematic review and meta-analysis.", "validation of the stop-bang questionnaire as a screening tool for obstructive sleep apnea among different populations: a systematic review and meta-analysis.", "validation of the stop-bang questionnaire as a screening tool for obstructive sleep apnea among different populations: a systematic review and meta-analysis.", "validation of the stop-bang questionnaire as a screening tool for obstructive sleep apnea among different populations: a systematic review and meta-analysis.", "validation of the stop-bang questionnaire as a screening tool for obstructive sleep apnea among different populations: a systematic review and meta-analysis.", "validation of the stop-bang questionnaire as a screening tool for obstructive sleep apnea among different populations: a systematic review and meta-analysis.", "validation of the stop-bang questionnaire as a screening tool for obstructive sleep apnea among different populations: a systematic review and meta-analysis.", "validation of the stop-bang questionnaire as a screening tool for obstructive sleep apnea among different populations: a systematic review and meta-analysis.", "validation of the stop-bang questionnaire as a screening tool for obstructive sleep apnea among different populations: a systematic review and meta-analysis.", "validation of the stop-bang questionnaire as a screening tool for obstructive sleep apnea among different populations: a systematic review and meta-analysis.", "validation of the stop-bang questionnaire as a screening tool for obstructive sleep apnea among different populations: a systematic review and meta-analysis.", "validation of the stop-bang questionnaire as a screening tool for obstructive sleep apnea among different populations: a systematic review and meta-analysis.", "validation of the stop-bang questionnaire as a screening tool for obstructive sleep apnea among different populations: a systematic review and meta-analysis.", "validation of the stop-bang questionnaire as a screening tool for obstructive sleep apnea among different populations: a systematic review and meta-analysis.", "validation of the stop-bang questionnaire as a screening tool for obstructive sleep apnea among different populations: a systematic review and meta-analysis.", "validation of the stop-bang questionnaire as a screening tool for obstructive sleep apnea among different populations: a systematic review and meta-analysis.", "validation of the stop-bang questionnaire as a screening tool for obstructive sleep apnea among different populations: a systematic review and meta-analysis.", "validation of the stop-bang questionnaire as a screening tool for obstructive sleep apnea among different populations: a systematic review and meta-analysis.", "validation of the stop-bang questionnaire as a screening tool for obstructive sleep apnea among different populations: a systematic review and meta-analysis.", "validation of the stop-bang questionnaire as a screening tool for obstructive sleep apnea among different populations: a systematic review and meta-analysis.", "validation of the stop-bang questionnaire as a screening tool for obstructive sleep apnea among different populations: a systematic review and meta-analysis.", "validation of the stop-bang questionnaire as a screening tool for obstructive sleep apnea among different populations: a systematic review and meta-analysis.", "validation of the stop-bang questionnaire as a screening tool for obstructive sleep apnea among different populations: a systematic review and meta-analysis.", "validation of the stop-bang questionnaire as a screening tool for obstructive sleep apnea among different populations: a systematic review and meta-analysis.", "validation of the stop-bang questionnaire as a screening tool for obstructive sleep apnea among different populations: a systematic review and meta-analysis.", "validation of the stop-bang questionnaire as a screening tool for obstructive sleep apnea among different populations: a systematic review and meta-analysis.", "objective the stop-bang questionnaire was developed as a quick and simple screening tool for obstructive sleep apnea (osa) in preoperative clinics.", "objective the stop-bang questionnaire was developed as a quick and simple screening tool for obstructive sleep apnea (osa) in preoperative clinics.", "objective the stop-bang questionnaire was developed as a quick and simple screening tool for obstructive sleep apnea (osa) in preoperative clinics.", "objective the stop-bang questionnaire was developed as a quick and simple screening tool for obstructive sleep apnea (osa) in preoperative clinics.", "objective the stop-bang questionnaire was developed as a quick and simple screening tool for obstructive sleep apnea (osa) in preoperative clinics.", "objective the stop-bang questionnaire was developed as a quick and simple screening tool for obstructive sleep apnea (osa) in preoperative clinics.", "objective the stop-bang questionnaire was developed as a quick and simple screening tool for obstructive sleep apnea (osa) in preoperative clinics.", "objective the stop-bang questionnaire was developed as a quick and simple screening tool for obstructive sleep apnea (osa) in preoperative clinics.", "objective the stop-bang questionnaire was developed as a quick and simple screening tool for obstructive sleep apnea (osa) in preoperative clinics.", "objective the stop-bang questionnaire was developed as a quick and simple screening tool for obstructive sleep apnea (osa) in preoperative clinics.", "objective the stop-bang questionnaire was developed as a quick and simple screening tool for obstructive sleep apnea (osa) in preoperative clinics.", "objective the stop-bang questionnaire was developed as a quick and simple screening tool for obstructive sleep apnea (osa) in preoperative clinics.", "objective the stop-bang questionnaire was developed as a quick and simple screening tool for obstructive sleep apnea (osa) in preoperative clinics.", "objective the stop-bang questionnaire was developed as a quick and simple screening tool for obstructive sleep apnea (osa) in preoperative clinics.", "objective the stop-bang questionnaire was developed as a quick and simple screening tool for obstructive sleep apnea (osa) in preoperative clinics.", "objective the stop-bang questionnaire was developed as a quick and simple screening tool for obstructive sleep apnea (osa) in preoperative clinics.", "objective the stop-bang questionnaire was developed as a quick and simple screening tool for obstructive sleep apnea (osa) in preoperative clinics.", "objective the stop-bang questionnaire was developed as a quick and simple screening tool for obstructive sleep apnea (osa) in preoperative clinics.", "objective the stop-bang questionnaire was developed as a quick and simple screening tool for obstructive sleep apnea (osa) in preoperative clinics.", "objective the stop-bang questionnaire was developed as a quick and simple screening tool for obstructive sleep apnea (osa) in preoperative clinics.", "objective the stop-bang questionnaire was developed as a quick and simple screening tool for obstructive sleep apnea (osa) in preoperative clinics.", "objective the stop-bang questionnaire was developed as a quick and simple screening tool for obstructive sleep apnea (osa) in preoperative clinics.", "objective the stop-bang questionnaire was developed as a quick and simple screening tool for obstructive sleep apnea (osa) in preoperative clinics.", "objective the stop-bang questionnaire was developed as a quick and simple screening tool for obstructive sleep apnea (osa) in preoperative clinics.", "objective the stop-bang questionnaire was developed as a quick and simple screening tool for obstructive sleep apnea (osa) in preoperative clinics.", "objective the stop-bang questionnaire was developed as a quick and simple screening tool for obstructive sleep apnea (osa) in preoperative clinics.", "objective the stop-bang questionnaire was developed as a quick and simple screening tool for obstructive sleep apnea (osa) in preoperative clinics.", "validation of a portuguese version of the stop-bang questionnaire as a screening tool for obstructive sleep apnea: analysis in a sleep clinic.", "validation of a portuguese version of the stop-bang questionnaire as a screening tool for obstructive sleep apnea: analysis in a sleep clinic.", "validation of a portuguese version of the stop-bang questionnaire as a screening tool for obstructive sleep apnea: analysis in a sleep clinic.", "validation of a portuguese version of the stop-bang questionnaire as a screening tool for obstructive sleep apnea: analysis in a sleep clinic.", "validation of a portuguese version of the stop-bang questionnaire as a screening tool for obstructive sleep apnea: analysis in a sleep clinic.", "validation of a portuguese version of the stop-bang questionnaire as a screening tool for obstructive sleep apnea: analysis in a sleep clinic.", "validation of a portuguese version of the stop-bang questionnaire as a screening tool for obstructive sleep apnea: analysis in a sleep clinic.", "validation of a portuguese version of the stop-bang questionnaire as a screening tool for obstructive sleep apnea: analysis in a sleep clinic.", "validation of a portuguese version of the stop-bang questionnaire as a screening tool for obstructive sleep apnea: analysis in a sleep clinic.", "validation of a portuguese version of the stop-bang questionnaire as a screening tool for obstructive sleep apnea: analysis in a sleep clinic.", "validation of a portuguese version of the stop-bang questionnaire as a screening tool for obstructive sleep apnea: analysis in a sleep clinic.", "validation of a portuguese version of the stop-bang questionnaire as a screening tool for obstructive sleep apnea: analysis in a sleep clinic.", "validation of a portuguese version of the stop-bang questionnaire as a screening tool for obstructive sleep apnea: analysis in a sleep clinic.", "validation of a portuguese version of the stop-bang questionnaire as a screening tool for obstructive sleep apnea: analysis in a sleep clinic.", "validation of a portuguese version of the stop-bang questionnaire as a screening tool for obstructive sleep apnea: analysis in a sleep clinic.", "validation of a portuguese version of the stop-bang questionnaire as a screening tool for obstructive sleep apnea: analysis in a sleep clinic.", "validation of a portuguese version of the stop-bang questionnaire as a screening tool for obstructive sleep apnea: analysis in a sleep clinic.", "validation of a portuguese version of the stop-bang questionnaire as a screening tool for obstructive sleep apnea: analysis in a sleep clinic.", "validation of a portuguese version of the stop-bang questionnaire as a screening tool for obstructive sleep apnea: analysis in a sleep clinic.", "validation of a portuguese version of the stop-bang questionnaire as a screening tool for obstructive sleep apnea: analysis in a sleep clinic.", "validation of a portuguese version of the stop-bang questionnaire as a screening tool for obstructive sleep apnea: analysis in a sleep clinic.", "validation of a portuguese version of the stop-bang questionnaire as a screening tool for obstructive sleep apnea: analysis in a sleep clinic.", "validation of a portuguese version of the stop-bang questionnaire as a screening tool for obstructive sleep apnea: analysis in a sleep clinic.", "validation of a portuguese version of the stop-bang questionnaire as a screening tool for obstructive sleep apnea: analysis in a sleep clinic.", "validation of a portuguese version of the stop-bang questionnaire as a screening tool for obstructive sleep apnea: analysis in a sleep clinic.", "validation of a portuguese version of the stop-bang questionnaire as a screening tool for obstructive sleep apnea: analysis in a sleep clinic.", "validation of a portuguese version of the stop-bang questionnaire as a screening tool for obstructive sleep apnea: analysis in a sleep clinic.", "alternative scoring models of stop-bang questionnaire improve specificity to detect undiagnosed obstructive sleep apnea.", "alternative scoring models of stop-bang questionnaire improve specificity to detect undiagnosed obstructive sleep apnea.", "alternative scoring models of stop-bang questionnaire improve specificity to detect undiagnosed obstructive sleep apnea.", "alternative scoring models of stop-bang questionnaire improve specificity to detect undiagnosed obstructive sleep apnea.", "alternative scoring models of stop-bang questionnaire improve specificity to detect undiagnosed obstructive sleep apnea.", "alternative scoring models of stop-bang questionnaire improve specificity to detect undiagnosed obstructive sleep apnea.", "alternative scoring models of stop-bang questionnaire improve specificity to detect undiagnosed obstructive sleep apnea.", "alternative scoring models of stop-bang questionnaire improve specificity to detect undiagnosed obstructive sleep apnea.", "alternative scoring models of stop-bang questionnaire improve specificity to detect undiagnosed obstructive sleep apnea.", "alternative scoring models of stop-bang questionnaire improve specificity to detect undiagnosed obstructive sleep apnea.", "alternative scoring models of stop-bang questionnaire improve specificity to detect undiagnosed obstructive sleep apnea.", "alternative scoring models of stop-bang questionnaire improve specificity to detect undiagnosed obstructive sleep apnea.", "alternative scoring models of stop-bang questionnaire improve specificity to detect undiagnosed obstructive sleep apnea.", "alternative scoring models of stop-bang questionnaire improve specificity to detect undiagnosed obstructive sleep apnea.", "alternative scoring models of stop-bang questionnaire improve specificity to detect undiagnosed obstructive sleep apnea.", "alternative scoring models of stop-bang questionnaire improve specificity to detect undiagnosed obstructive sleep apnea.", "alternative scoring models of stop-bang questionnaire improve specificity to detect undiagnosed obstructive sleep apnea.", "alternative scoring models of stop-bang questionnaire improve specificity to detect undiagnosed obstructive sleep apnea.", "alternative scoring models of stop-bang questionnaire improve specificity to detect undiagnosed obstructive sleep apnea.", "alternative scoring models of stop-bang questionnaire improve specificity to detect undiagnosed obstructive sleep apnea.", "alternative scoring models of stop-bang questionnaire improve specificity to detect undiagnosed obstructive sleep apnea.", "alternative scoring models of stop-bang questionnaire improve specificity to detect undiagnosed obstructive sleep apnea.", "alternative scoring models of stop-bang questionnaire improve specificity to detect undiagnosed obstructive sleep apnea.", "alternative scoring models of stop-bang questionnaire improve specificity to detect undiagnosed obstructive sleep apnea.", "alternative scoring models of stop-bang questionnaire improve specificity to detect undiagnosed obstructive sleep apnea.", "alternative scoring models of stop-bang questionnaire improve specificity to detect undiagnosed obstructive sleep apnea.", "alternative scoring models of stop-bang questionnaire improve specificity to detect undiagnosed obstructive sleep apnea.", "the stop-bang questionnaire improves the detection of epilepsy patients at risk for obstructive sleep apnea.", "the stop-bang questionnaire improves the detection of epilepsy patients at risk for obstructive sleep apnea.", "the stop-bang questionnaire improves the detection of epilepsy patients at risk for obstructive sleep apnea.", "the stop-bang questionnaire improves the detection of epilepsy patients at risk for obstructive sleep apnea.", "the stop-bang questionnaire improves the detection of epilepsy patients at risk for obstructive sleep apnea.", "the stop-bang questionnaire improves the detection of epilepsy patients at risk for obstructive sleep apnea.", "the stop-bang questionnaire improves the detection of epilepsy patients at risk for obstructive sleep apnea.", "the stop-bang questionnaire improves the detection of epilepsy patients at risk for obstructive sleep apnea.", "the stop-bang questionnaire improves the detection of epilepsy patients at risk for obstructive sleep apnea.", "the stop-bang questionnaire improves the detection of epilepsy patients at risk for obstructive sleep apnea.", "the stop-bang questionnaire improves the detection of epilepsy patients at risk for obstructive sleep apnea.", "the stop-bang questionnaire improves the detection of epilepsy patients at risk for obstructive sleep apnea.", "the stop-bang questionnaire improves the detection of epilepsy patients at risk for obstructive sleep apnea.", "the stop-bang questionnaire improves the detection of epilepsy patients at risk for obstructive sleep apnea.", "the stop-bang questionnaire improves the detection of epilepsy patients at risk for obstructive sleep apnea.", "the stop-bang questionnaire improves the detection of epilepsy patients at risk for obstructive sleep apnea.", "the stop-bang questionnaire improves the detection of epilepsy patients at risk for obstructive sleep apnea.", "the stop-bang questionnaire improves the detection of epilepsy patients at risk for obstructive sleep apnea.", "the stop-bang questionnaire improves the detection of epilepsy patients at risk for obstructive sleep apnea.", "the stop-bang questionnaire improves the detection of epilepsy patients at risk for obstructive sleep apnea.", "the stop-bang questionnaire improves the detection of epilepsy patients at risk for obstructive sleep apnea.", "the stop-bang questionnaire improves the detection of epilepsy patients at risk for obstructive sleep apnea.", "the stop-bang questionnaire improves the detection of epilepsy patients at risk for obstructive sleep apnea.", "the stop-bang questionnaire improves the detection of epilepsy patients at risk for obstructive sleep apnea.", "the stop-bang questionnaire improves the detection of epilepsy patients at risk for obstructive sleep apnea.", "the stop-bang questionnaire improves the detection of epilepsy patients at risk for obstructive sleep apnea.", "the stop-bang questionnaire improves the detection of epilepsy patients at risk for obstructive sleep apnea.", "evaluation of the arabic version of stop-bang questionnaire as a screening tool for obstructive sleep apnea.", "evaluation of the arabic version of stop-bang questionnaire as a screening tool for obstructive sleep apnea.", "evaluation of the arabic version of stop-bang questionnaire as a screening tool for obstructive sleep apnea.", "evaluation of the arabic version of stop-bang questionnaire as a screening tool for obstructive sleep apnea.", "evaluation of the arabic version of stop-bang questionnaire as a screening tool for obstructive sleep apnea.", "evaluation of the arabic version of stop-bang questionnaire as a screening tool for obstructive sleep apnea.", "evaluation of the arabic version of stop-bang questionnaire as a screening tool for obstructive sleep apnea.", "evaluation of the arabic version of stop-bang questionnaire as a screening tool for obstructive sleep apnea.", "evaluation of the arabic version of stop-bang questionnaire as a screening tool for obstructive sleep apnea.", "evaluation of the arabic version of stop-bang questionnaire as a screening tool for obstructive sleep apnea.", "evaluation of the arabic version of stop-bang questionnaire as a screening tool for obstructive sleep apnea.", "evaluation of the arabic version of stop-bang questionnaire as a screening tool for obstructive sleep apnea.", "evaluation of the arabic version of stop-bang questionnaire as a screening tool for obstructive sleep apnea.", "evaluation of the arabic version of stop-bang questionnaire as a screening tool for obstructive sleep apnea.", "evaluation of the arabic version of stop-bang questionnaire as a screening tool for obstructive sleep apnea.", "evaluation of the arabic version of stop-bang questionnaire as a screening tool for obstructive sleep apnea.", "evaluation of the arabic version of stop-bang questionnaire as a screening tool for obstructive sleep apnea.", "evaluation of the arabic version of stop-bang questionnaire as a screening tool for obstructive sleep apnea.", "evaluation of the arabic version of stop-bang questionnaire as a screening tool for obstructive sleep apnea.", "evaluation of the arabic version of stop-bang questionnaire as a screening tool for obstructive sleep apnea.", "evaluation of the arabic version of stop-bang questionnaire as a screening tool for obstructive sleep apnea.", "evaluation of the arabic version of stop-bang questionnaire as a screening tool for obstructive sleep apnea.", "evaluation of the arabic version of stop-bang questionnaire as a screening tool for obstructive sleep apnea.", "evaluation of the arabic version of stop-bang questionnaire as a screening tool for obstructive sleep apnea.", "evaluation of the arabic version of stop-bang questionnaire as a screening tool for obstructive sleep apnea.", "evaluation of the arabic version of stop-bang questionnaire as a screening tool for obstructive sleep apnea.", "evaluation of the arabic version of stop-bang questionnaire as a screening tool for obstructive sleep apnea.", "modified mallampati score improves specificity of stop-bang questionnaire for obstructive sleep apnea.", "modified mallampati score improves specificity of stop-bang questionnaire for obstructive sleep apnea.", "modified mallampati score improves specificity of stop-bang questionnaire for obstructive sleep apnea.", "modified mallampati score improves specificity of stop-bang questionnaire for obstructive sleep apnea.", "modified mallampati score improves specificity of stop-bang questionnaire for obstructive sleep apnea.", "modified mallampati score improves specificity of stop-bang questionnaire for obstructive sleep apnea.", "modified mallampati score improves specificity of stop-bang questionnaire for obstructive sleep apnea.", "modified mallampati score improves specificity of stop-bang questionnaire for obstructive sleep apnea.", "modified mallampati score improves specificity of stop-bang questionnaire for obstructive sleep apnea.", "modified mallampati score improves specificity of stop-bang questionnaire for obstructive sleep apnea.", "modified mallampati score improves specificity of stop-bang questionnaire for obstructive sleep apnea.", "modified mallampati score improves specificity of stop-bang questionnaire for obstructive sleep apnea.", "modified mallampati score improves specificity of stop-bang questionnaire for obstructive sleep apnea.", "modified mallampati score improves specificity of stop-bang questionnaire for obstructive sleep apnea.", "modified mallampati score improves specificity of stop-bang questionnaire for obstructive sleep apnea.", "modified mallampati score improves specificity of stop-bang questionnaire for obstructive sleep apnea.", "modified mallampati score improves specificity of stop-bang questionnaire for obstructive sleep apnea.", "modified mallampati score improves specificity of stop-bang questionnaire for obstructive sleep apnea.", "modified mallampati score improves specificity of stop-bang questionnaire for obstructive sleep apnea.", "modified mallampati score improves specificity of stop-bang questionnaire for obstructive sleep apnea.", "modified mallampati score improves specificity of stop-bang questionnaire for obstructive sleep apnea.", "modified mallampati score improves specificity of stop-bang questionnaire for obstructive sleep apnea.", "modified mallampati score improves specificity of stop-bang questionnaire for obstructive sleep apnea.", "modified mallampati score improves specificity of stop-bang questionnaire for obstructive sleep apnea.", "modified mallampati score improves specificity of stop-bang questionnaire for obstructive sleep apnea.", "modified mallampati score improves specificity of stop-bang questionnaire for obstructive sleep apnea.", "modified mallampati score improves specificity of stop-bang questionnaire for obstructive sleep apnea.", "a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children.in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.one hundred patients with a complaint of sore throat were enrolled in the study. all the patients were examined clinically using the centor criteria. they were also examined for other signs and symptoms like petechial lesions over the palate, abdominal pain, and skin rash. all the patients were given rapid strep tests, and throat cultures were sent. no antibiotics were given until culture results were obtained.the sample size was 100 patients. all 100 had fever, sore throat, and erythema of tonsils. twenty of the 100 patients had tonsillar exudates, 85/100 had tender anterior cervical lymph nodes, and 86/100 had no cough. in total, 9 out of the 100 patients had positive throat cultures. we observed that petechiae over the palate, a very significant sign, is not included in the centor criteria. palatal petechiae were present in 8 out of the 100 patients. six out of these 8 with palatal petechiae had positive throat culture for strep (75%). only 7 out of 20 with exudates had positive strep culture. sixteen out of the 100 patients had rapid strep test positive. those 84/100 who had negative rapid strep also had negative throat culture.we used fisher's exact test, comparing throat culture positive and negative versus presence of exudates and palatal hemorrhages with positive and negative throat cultures and the resultant p value <.0001.our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children.in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.one hundred patients with a complaint of sore throat were enrolled in the study. all the patients were examined clinically using the centor criteria. they were also examined for other signs and symptoms like petechial lesions over the palate, abdominal pain, and skin rash. all the patients were given rapid strep tests, and throat cultures were sent. no antibiotics were given until culture results were obtained.the sample size was 100 patients. all 100 had fever, sore throat, and erythema of tonsils. twenty of the 100 patients had tonsillar exudates, 85/100 had tender anterior cervical lymph nodes, and 86/100 had no cough. in total, 9 out of the 100 patients had positive throat cultures. we observed that petechiae over the palate, a very significant sign, is not included in the centor criteria. palatal petechiae were present in 8 out of the 100 patients. six out of these 8 with palatal petechiae had positive throat culture for strep (75%). only 7 out of 20 with exudates had positive strep culture. sixteen out of the 100 patients had rapid strep test positive. those 84/100 who had negative rapid strep also had negative throat culture.we used fisher's exact test, comparing throat culture positive and negative versus presence of exudates and palatal hemorrhages with positive and negative throat cultures and the resultant p value <.0001.our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children.in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.one hundred patients with a complaint of sore throat were enrolled in the study. all the patients were examined clinically using the centor criteria. they were also examined for other signs and symptoms like petechial lesions over the palate, abdominal pain, and skin rash. all the patients were given rapid strep tests, and throat cultures were sent. no antibiotics were given until culture results were obtained.the sample size was 100 patients. all 100 had fever, sore throat, and erythema of tonsils. twenty of the 100 patients had tonsillar exudates, 85/100 had tender anterior cervical lymph nodes, and 86/100 had no cough. in total, 9 out of the 100 patients had positive throat cultures. we observed that petechiae over the palate, a very significant sign, is not included in the centor criteria. palatal petechiae were present in 8 out of the 100 patients. six out of these 8 with palatal petechiae had positive throat culture for strep (75%). only 7 out of 20 with exudates had positive strep culture. sixteen out of the 100 patients had rapid strep test positive. those 84/100 who had negative rapid strep also had negative throat culture.we used fisher's exact test, comparing throat culture positive and negative versus presence of exudates and palatal hemorrhages with positive and negative throat cultures and the resultant p value <.0001.our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children.in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.one hundred patients with a complaint of sore throat were enrolled in the study. all the patients were examined clinically using the centor criteria. they were also examined for other signs and symptoms like petechial lesions over the palate, abdominal pain, and skin rash. all the patients were given rapid strep tests, and throat cultures were sent. no antibiotics were given until culture results were obtained.the sample size was 100 patients. all 100 had fever, sore throat, and erythema of tonsils. twenty of the 100 patients had tonsillar exudates, 85/100 had tender anterior cervical lymph nodes, and 86/100 had no cough. in total, 9 out of the 100 patients had positive throat cultures. we observed that petechiae over the palate, a very significant sign, is not included in the centor criteria. palatal petechiae were present in 8 out of the 100 patients. six out of these 8 with palatal petechiae had positive throat culture for strep (75%). only 7 out of 20 with exudates had positive strep culture. sixteen out of the 100 patients had rapid strep test positive. those 84/100 who had negative rapid strep also had negative throat culture.we used fisher's exact test, comparing throat culture positive and negative versus presence of exudates and palatal hemorrhages with positive and negative throat cultures and the resultant p value <.0001.our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children.in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.one hundred patients with a complaint of sore throat were enrolled in the study. all the patients were examined clinically using the centor criteria. they were also examined for other signs and symptoms like petechial lesions over the palate, abdominal pain, and skin rash. all the patients were given rapid strep tests, and throat cultures were sent. no antibiotics were given until culture results were obtained.the sample size was 100 patients. all 100 had fever, sore throat, and erythema of tonsils. twenty of the 100 patients had tonsillar exudates, 85/100 had tender anterior cervical lymph nodes, and 86/100 had no cough. in total, 9 out of the 100 patients had positive throat cultures. we observed that petechiae over the palate, a very significant sign, is not included in the centor criteria. palatal petechiae were present in 8 out of the 100 patients. six out of these 8 with palatal petechiae had positive throat culture for strep (75%). only 7 out of 20 with exudates had positive strep culture. sixteen out of the 100 patients had rapid strep test positive. those 84/100 who had negative rapid strep also had negative throat culture.we used fisher's exact test, comparing throat culture positive and negative versus presence of exudates and palatal hemorrhages with positive and negative throat cultures and the resultant p value <.0001.our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children.in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.one hundred patients with a complaint of sore throat were enrolled in the study. all the patients were examined clinically using the centor criteria. they were also examined for other signs and symptoms like petechial lesions over the palate, abdominal pain, and skin rash. all the patients were given rapid strep tests, and throat cultures were sent. no antibiotics were given until culture results were obtained.the sample size was 100 patients. all 100 had fever, sore throat, and erythema of tonsils. twenty of the 100 patients had tonsillar exudates, 85/100 had tender anterior cervical lymph nodes, and 86/100 had no cough. in total, 9 out of the 100 patients had positive throat cultures. we observed that petechiae over the palate, a very significant sign, is not included in the centor criteria. palatal petechiae were present in 8 out of the 100 patients. six out of these 8 with palatal petechiae had positive throat culture for strep (75%). only 7 out of 20 with exudates had positive strep culture. sixteen out of the 100 patients had rapid strep test positive. those 84/100 who had negative rapid strep also had negative throat culture.we used fisher's exact test, comparing throat culture positive and negative versus presence of exudates and palatal hemorrhages with positive and negative throat cultures and the resultant p value <.0001.our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children.in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.one hundred patients with a complaint of sore throat were enrolled in the study. all the patients were examined clinically using the centor criteria. they were also examined for other signs and symptoms like petechial lesions over the palate, abdominal pain, and skin rash. all the patients were given rapid strep tests, and throat cultures were sent. no antibiotics were given until culture results were obtained.the sample size was 100 patients. all 100 had fever, sore throat, and erythema of tonsils. twenty of the 100 patients had tonsillar exudates, 85/100 had tender anterior cervical lymph nodes, and 86/100 had no cough. in total, 9 out of the 100 patients had positive throat cultures. we observed that petechiae over the palate, a very significant sign, is not included in the centor criteria. palatal petechiae were present in 8 out of the 100 patients. six out of these 8 with palatal petechiae had positive throat culture for strep (75%). only 7 out of 20 with exudates had positive strep culture. sixteen out of the 100 patients had rapid strep test positive. those 84/100 who had negative rapid strep also had negative throat culture.we used fisher's exact test, comparing throat culture positive and negative versus presence of exudates and palatal hemorrhages with positive and negative throat cultures and the resultant p value <.0001.our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children.in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.one hundred patients with a complaint of sore throat were enrolled in the study. all the patients were examined clinically using the centor criteria. they were also examined for other signs and symptoms like petechial lesions over the palate, abdominal pain, and skin rash. all the patients were given rapid strep tests, and throat cultures were sent. no antibiotics were given until culture results were obtained.the sample size was 100 patients. all 100 had fever, sore throat, and erythema of tonsils. twenty of the 100 patients had tonsillar exudates, 85/100 had tender anterior cervical lymph nodes, and 86/100 had no cough. in total, 9 out of the 100 patients had positive throat cultures. we observed that petechiae over the palate, a very significant sign, is not included in the centor criteria. palatal petechiae were present in 8 out of the 100 patients. six out of these 8 with palatal petechiae had positive throat culture for strep (75%). only 7 out of 20 with exudates had positive strep culture. sixteen out of the 100 patients had rapid strep test positive. those 84/100 who had negative rapid strep also had negative throat culture.we used fisher's exact test, comparing throat culture positive and negative versus presence of exudates and palatal hemorrhages with positive and negative throat cultures and the resultant p value <.0001.our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children.in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.one hundred patients with a complaint of sore throat were enrolled in the study. all the patients were examined clinically using the centor criteria. they were also examined for other signs and symptoms like petechial lesions over the palate, abdominal pain, and skin rash. all the patients were given rapid strep tests, and throat cultures were sent. no antibiotics were given until culture results were obtained.the sample size was 100 patients. all 100 had fever, sore throat, and erythema of tonsils. twenty of the 100 patients had tonsillar exudates, 85/100 had tender anterior cervical lymph nodes, and 86/100 had no cough. in total, 9 out of the 100 patients had positive throat cultures. we observed that petechiae over the palate, a very significant sign, is not included in the centor criteria. palatal petechiae were present in 8 out of the 100 patients. six out of these 8 with palatal petechiae had positive throat culture for strep (75%). only 7 out of 20 with exudates had positive strep culture. sixteen out of the 100 patients had rapid strep test positive. those 84/100 who had negative rapid strep also had negative throat culture.we used fisher's exact test, comparing throat culture positive and negative versus presence of exudates and palatal hemorrhages with positive and negative throat cultures and the resultant p value <.0001.our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children.in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.one hundred patients with a complaint of sore throat were enrolled in the study. all the patients were examined clinically using the centor criteria. they were also examined for other signs and symptoms like petechial lesions over the palate, abdominal pain, and skin rash. all the patients were given rapid strep tests, and throat cultures were sent. no antibiotics were given until culture results were obtained.the sample size was 100 patients. all 100 had fever, sore throat, and erythema of tonsils. twenty of the 100 patients had tonsillar exudates, 85/100 had tender anterior cervical lymph nodes, and 86/100 had no cough. in total, 9 out of the 100 patients had positive throat cultures. we observed that petechiae over the palate, a very significant sign, is not included in the centor criteria. palatal petechiae were present in 8 out of the 100 patients. six out of these 8 with palatal petechiae had positive throat culture for strep (75%). only 7 out of 20 with exudates had positive strep culture. sixteen out of the 100 patients had rapid strep test positive. those 84/100 who had negative rapid strep also had negative throat culture.we used fisher's exact test, comparing throat culture positive and negative versus presence of exudates and palatal hemorrhages with positive and negative throat cultures and the resultant p value <.0001.our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children.in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.one hundred patients with a complaint of sore throat were enrolled in the study. all the patients were examined clinically using the centor criteria. they were also examined for other signs and symptoms like petechial lesions over the palate, abdominal pain, and skin rash. all the patients were given rapid strep tests, and throat cultures were sent. no antibiotics were given until culture results were obtained.the sample size was 100 patients. all 100 had fever, sore throat, and erythema of tonsils. twenty of the 100 patients had tonsillar exudates, 85/100 had tender anterior cervical lymph nodes, and 86/100 had no cough. in total, 9 out of the 100 patients had positive throat cultures. we observed that petechiae over the palate, a very significant sign, is not included in the centor criteria. palatal petechiae were present in 8 out of the 100 patients. six out of these 8 with palatal petechiae had positive throat culture for strep (75%). only 7 out of 20 with exudates had positive strep culture. sixteen out of the 100 patients had rapid strep test positive. those 84/100 who had negative rapid strep also had negative throat culture.we used fisher's exact test, comparing throat culture positive and negative versus presence of exudates and palatal hemorrhages with positive and negative throat cultures and the resultant p value <.0001.our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children.in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.one hundred patients with a complaint of sore throat were enrolled in the study. all the patients were examined clinically using the centor criteria. they were also examined for other signs and symptoms like petechial lesions over the palate, abdominal pain, and skin rash. all the patients were given rapid strep tests, and throat cultures were sent. no antibiotics were given until culture results were obtained.the sample size was 100 patients. all 100 had fever, sore throat, and erythema of tonsils. twenty of the 100 patients had tonsillar exudates, 85/100 had tender anterior cervical lymph nodes, and 86/100 had no cough. in total, 9 out of the 100 patients had positive throat cultures. we observed that petechiae over the palate, a very significant sign, is not included in the centor criteria. palatal petechiae were present in 8 out of the 100 patients. six out of these 8 with palatal petechiae had positive throat culture for strep (75%). only 7 out of 20 with exudates had positive strep culture. sixteen out of the 100 patients had rapid strep test positive. those 84/100 who had negative rapid strep also had negative throat culture.we used fisher's exact test, comparing throat culture positive and negative versus presence of exudates and palatal hemorrhages with positive and negative throat cultures and the resultant p value <.0001.our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children.in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.one hundred patients with a complaint of sore throat were enrolled in the study. all the patients were examined clinically using the centor criteria. they were also examined for other signs and symptoms like petechial lesions over the palate, abdominal pain, and skin rash. all the patients were given rapid strep tests, and throat cultures were sent. no antibiotics were given until culture results were obtained.the sample size was 100 patients. all 100 had fever, sore throat, and erythema of tonsils. twenty of the 100 patients had tonsillar exudates, 85/100 had tender anterior cervical lymph nodes, and 86/100 had no cough. in total, 9 out of the 100 patients had positive throat cultures. we observed that petechiae over the palate, a very significant sign, is not included in the centor criteria. palatal petechiae were present in 8 out of the 100 patients. six out of these 8 with palatal petechiae had positive throat culture for strep (75%). only 7 out of 20 with exudates had positive strep culture. sixteen out of the 100 patients had rapid strep test positive. those 84/100 who had negative rapid strep also had negative throat culture.we used fisher's exact test, comparing throat culture positive and negative versus presence of exudates and palatal hemorrhages with positive and negative throat cultures and the resultant p value <.0001.our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children.in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.one hundred patients with a complaint of sore throat were enrolled in the study. all the patients were examined clinically using the centor criteria. they were also examined for other signs and symptoms like petechial lesions over the palate, abdominal pain, and skin rash. all the patients were given rapid strep tests, and throat cultures were sent. no antibiotics were given until culture results were obtained.the sample size was 100 patients. all 100 had fever, sore throat, and erythema of tonsils. twenty of the 100 patients had tonsillar exudates, 85/100 had tender anterior cervical lymph nodes, and 86/100 had no cough. in total, 9 out of the 100 patients had positive throat cultures. we observed that petechiae over the palate, a very significant sign, is not included in the centor criteria. palatal petechiae were present in 8 out of the 100 patients. six out of these 8 with palatal petechiae had positive throat culture for strep (75%). only 7 out of 20 with exudates had positive strep culture. sixteen out of the 100 patients had rapid strep test positive. those 84/100 who had negative rapid strep also had negative throat culture.we used fisher's exact test, comparing throat culture positive and negative versus presence of exudates and palatal hemorrhages with positive and negative throat cultures and the resultant p value <.0001.our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children.in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.one hundred patients with a complaint of sore throat were enrolled in the study. all the patients were examined clinically using the centor criteria. they were also examined for other signs and symptoms like petechial lesions over the palate, abdominal pain, and skin rash. all the patients were given rapid strep tests, and throat cultures were sent. no antibiotics were given until culture results were obtained.the sample size was 100 patients. all 100 had fever, sore throat, and erythema of tonsils. twenty of the 100 patients had tonsillar exudates, 85/100 had tender anterior cervical lymph nodes, and 86/100 had no cough. in total, 9 out of the 100 patients had positive throat cultures. we observed that petechiae over the palate, a very significant sign, is not included in the centor criteria. palatal petechiae were present in 8 out of the 100 patients. six out of these 8 with palatal petechiae had positive throat culture for strep (75%). only 7 out of 20 with exudates had positive strep culture. sixteen out of the 100 patients had rapid strep test positive. those 84/100 who had negative rapid strep also had negative throat culture.we used fisher's exact test, comparing throat culture positive and negative versus presence of exudates and palatal hemorrhages with positive and negative throat cultures and the resultant p value <.0001.our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children.in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.one hundred patients with a complaint of sore throat were enrolled in the study. all the patients were examined clinically using the centor criteria. they were also examined for other signs and symptoms like petechial lesions over the palate, abdominal pain, and skin rash. all the patients were given rapid strep tests, and throat cultures were sent. no antibiotics were given until culture results were obtained.the sample size was 100 patients. all 100 had fever, sore throat, and erythema of tonsils. twenty of the 100 patients had tonsillar exudates, 85/100 had tender anterior cervical lymph nodes, and 86/100 had no cough. in total, 9 out of the 100 patients had positive throat cultures. we observed that petechiae over the palate, a very significant sign, is not included in the centor criteria. palatal petechiae were present in 8 out of the 100 patients. six out of these 8 with palatal petechiae had positive throat culture for strep (75%). only 7 out of 20 with exudates had positive strep culture. sixteen out of the 100 patients had rapid strep test positive. those 84/100 who had negative rapid strep also had negative throat culture.we used fisher's exact test, comparing throat culture positive and negative versus presence of exudates and palatal hemorrhages with positive and negative throat cultures and the resultant p value <.0001.our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children.in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.one hundred patients with a complaint of sore throat were enrolled in the study. all the patients were examined clinically using the centor criteria. they were also examined for other signs and symptoms like petechial lesions over the palate, abdominal pain, and skin rash. all the patients were given rapid strep tests, and throat cultures were sent. no antibiotics were given until culture results were obtained.the sample size was 100 patients. all 100 had fever, sore throat, and erythema of tonsils. twenty of the 100 patients had tonsillar exudates, 85/100 had tender anterior cervical lymph nodes, and 86/100 had no cough. in total, 9 out of the 100 patients had positive throat cultures. we observed that petechiae over the palate, a very significant sign, is not included in the centor criteria. palatal petechiae were present in 8 out of the 100 patients. six out of these 8 with palatal petechiae had positive throat culture for strep (75%). only 7 out of 20 with exudates had positive strep culture. sixteen out of the 100 patients had rapid strep test positive. those 84/100 who had negative rapid strep also had negative throat culture.we used fisher's exact test, comparing throat culture positive and negative versus presence of exudates and palatal hemorrhages with positive and negative throat cultures and the resultant p value <.0001.our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children.in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.one hundred patients with a complaint of sore throat were enrolled in the study. all the patients were examined clinically using the centor criteria. they were also examined for other signs and symptoms like petechial lesions over the palate, abdominal pain, and skin rash. all the patients were given rapid strep tests, and throat cultures were sent. no antibiotics were given until culture results were obtained.the sample size was 100 patients. all 100 had fever, sore throat, and erythema of tonsils. twenty of the 100 patients had tonsillar exudates, 85/100 had tender anterior cervical lymph nodes, and 86/100 had no cough. in total, 9 out of the 100 patients had positive throat cultures. we observed that petechiae over the palate, a very significant sign, is not included in the centor criteria. palatal petechiae were present in 8 out of the 100 patients. six out of these 8 with palatal petechiae had positive throat culture for strep (75%). only 7 out of 20 with exudates had positive strep culture. sixteen out of the 100 patients had rapid strep test positive. those 84/100 who had negative rapid strep also had negative throat culture.we used fisher's exact test, comparing throat culture positive and negative versus presence of exudates and palatal hemorrhages with positive and negative throat cultures and the resultant p value <.0001.our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children.in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.one hundred patients with a complaint of sore throat were enrolled in the study. all the patients were examined clinically using the centor criteria. they were also examined for other signs and symptoms like petechial lesions over the palate, abdominal pain, and skin rash. all the patients were given rapid strep tests, and throat cultures were sent. no antibiotics were given until culture results were obtained.the sample size was 100 patients. all 100 had fever, sore throat, and erythema of tonsils. twenty of the 100 patients had tonsillar exudates, 85/100 had tender anterior cervical lymph nodes, and 86/100 had no cough. in total, 9 out of the 100 patients had positive throat cultures. we observed that petechiae over the palate, a very significant sign, is not included in the centor criteria. palatal petechiae were present in 8 out of the 100 patients. six out of these 8 with palatal petechiae had positive throat culture for strep (75%). only 7 out of 20 with exudates had positive strep culture. sixteen out of the 100 patients had rapid strep test positive. those 84/100 who had negative rapid strep also had negative throat culture.we used fisher's exact test, comparing throat culture positive and negative versus presence of exudates and palatal hemorrhages with positive and negative throat cultures and the resultant p value <.0001.our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children.in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.one hundred patients with a complaint of sore throat were enrolled in the study. all the patients were examined clinically using the centor criteria. they were also examined for other signs and symptoms like petechial lesions over the palate, abdominal pain, and skin rash. all the patients were given rapid strep tests, and throat cultures were sent. no antibiotics were given until culture results were obtained.the sample size was 100 patients. all 100 had fever, sore throat, and erythema of tonsils. twenty of the 100 patients had tonsillar exudates, 85/100 had tender anterior cervical lymph nodes, and 86/100 had no cough. in total, 9 out of the 100 patients had positive throat cultures. we observed that petechiae over the palate, a very significant sign, is not included in the centor criteria. palatal petechiae were present in 8 out of the 100 patients. six out of these 8 with palatal petechiae had positive throat culture for strep (75%). only 7 out of 20 with exudates had positive strep culture. sixteen out of the 100 patients had rapid strep test positive. those 84/100 who had negative rapid strep also had negative throat culture.we used fisher's exact test, comparing throat culture positive and negative versus presence of exudates and palatal hemorrhages with positive and negative throat cultures and the resultant p value <.0001.our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children.in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.one hundred patients with a complaint of sore throat were enrolled in the study. all the patients were examined clinically using the centor criteria. they were also examined for other signs and symptoms like petechial lesions over the palate, abdominal pain, and skin rash. all the patients were given rapid strep tests, and throat cultures were sent. no antibiotics were given until culture results were obtained.the sample size was 100 patients. all 100 had fever, sore throat, and erythema of tonsils. twenty of the 100 patients had tonsillar exudates, 85/100 had tender anterior cervical lymph nodes, and 86/100 had no cough. in total, 9 out of the 100 patients had positive throat cultures. we observed that petechiae over the palate, a very significant sign, is not included in the centor criteria. palatal petechiae were present in 8 out of the 100 patients. six out of these 8 with palatal petechiae had positive throat culture for strep (75%). only 7 out of 20 with exudates had positive strep culture. sixteen out of the 100 patients had rapid strep test positive. those 84/100 who had negative rapid strep also had negative throat culture.we used fisher's exact test, comparing throat culture positive and negative versus presence of exudates and palatal hemorrhages with positive and negative throat cultures and the resultant p value <.0001.our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children.in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.one hundred patients with a complaint of sore throat were enrolled in the study. all the patients were examined clinically using the centor criteria. they were also examined for other signs and symptoms like petechial lesions over the palate, abdominal pain, and skin rash. all the patients were given rapid strep tests, and throat cultures were sent. no antibiotics were given until culture results were obtained.the sample size was 100 patients. all 100 had fever, sore throat, and erythema of tonsils. twenty of the 100 patients had tonsillar exudates, 85/100 had tender anterior cervical lymph nodes, and 86/100 had no cough. in total, 9 out of the 100 patients had positive throat cultures. we observed that petechiae over the palate, a very significant sign, is not included in the centor criteria. palatal petechiae were present in 8 out of the 100 patients. six out of these 8 with palatal petechiae had positive throat culture for strep (75%). only 7 out of 20 with exudates had positive strep culture. sixteen out of the 100 patients had rapid strep test positive. those 84/100 who had negative rapid strep also had negative throat culture.we used fisher's exact test, comparing throat culture positive and negative versus presence of exudates and palatal hemorrhages with positive and negative throat cultures and the resultant p value <.0001.our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children.in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.one hundred patients with a complaint of sore throat were enrolled in the study. all the patients were examined clinically using the centor criteria. they were also examined for other signs and symptoms like petechial lesions over the palate, abdominal pain, and skin rash. all the patients were given rapid strep tests, and throat cultures were sent. no antibiotics were given until culture results were obtained.the sample size was 100 patients. all 100 had fever, sore throat, and erythema of tonsils. twenty of the 100 patients had tonsillar exudates, 85/100 had tender anterior cervical lymph nodes, and 86/100 had no cough. in total, 9 out of the 100 patients had positive throat cultures. we observed that petechiae over the palate, a very significant sign, is not included in the centor criteria. palatal petechiae were present in 8 out of the 100 patients. six out of these 8 with palatal petechiae had positive throat culture for strep (75%). only 7 out of 20 with exudates had positive strep culture. sixteen out of the 100 patients had rapid strep test positive. those 84/100 who had negative rapid strep also had negative throat culture.we used fisher's exact test, comparing throat culture positive and negative versus presence of exudates and palatal hemorrhages with positive and negative throat cultures and the resultant p value <.0001.our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children.in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.one hundred patients with a complaint of sore throat were enrolled in the study. all the patients were examined clinically using the centor criteria. they were also examined for other signs and symptoms like petechial lesions over the palate, abdominal pain, and skin rash. all the patients were given rapid strep tests, and throat cultures were sent. no antibiotics were given until culture results were obtained.the sample size was 100 patients. all 100 had fever, sore throat, and erythema of tonsils. twenty of the 100 patients had tonsillar exudates, 85/100 had tender anterior cervical lymph nodes, and 86/100 had no cough. in total, 9 out of the 100 patients had positive throat cultures. we observed that petechiae over the palate, a very significant sign, is not included in the centor criteria. palatal petechiae were present in 8 out of the 100 patients. six out of these 8 with palatal petechiae had positive throat culture for strep (75%). only 7 out of 20 with exudates had positive strep culture. sixteen out of the 100 patients had rapid strep test positive. those 84/100 who had negative rapid strep also had negative throat culture.we used fisher's exact test, comparing throat culture positive and negative versus presence of exudates and palatal hemorrhages with positive and negative throat cultures and the resultant p value <.0001.our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children.in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.one hundred patients with a complaint of sore throat were enrolled in the study. all the patients were examined clinically using the centor criteria. they were also examined for other signs and symptoms like petechial lesions over the palate, abdominal pain, and skin rash. all the patients were given rapid strep tests, and throat cultures were sent. no antibiotics were given until culture results were obtained.the sample size was 100 patients. all 100 had fever, sore throat, and erythema of tonsils. twenty of the 100 patients had tonsillar exudates, 85/100 had tender anterior cervical lymph nodes, and 86/100 had no cough. in total, 9 out of the 100 patients had positive throat cultures. we observed that petechiae over the palate, a very significant sign, is not included in the centor criteria. palatal petechiae were present in 8 out of the 100 patients. six out of these 8 with palatal petechiae had positive throat culture for strep (75%). only 7 out of 20 with exudates had positive strep culture. sixteen out of the 100 patients had rapid strep test positive. those 84/100 who had negative rapid strep also had negative throat culture.we used fisher's exact test, comparing throat culture positive and negative versus presence of exudates and palatal hemorrhages with positive and negative throat cultures and the resultant p value <.0001.our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children.in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.one hundred patients with a complaint of sore throat were enrolled in the study. all the patients were examined clinically using the centor criteria. they were also examined for other signs and symptoms like petechial lesions over the palate, abdominal pain, and skin rash. all the patients were given rapid strep tests, and throat cultures were sent. no antibiotics were given until culture results were obtained.the sample size was 100 patients. all 100 had fever, sore throat, and erythema of tonsils. twenty of the 100 patients had tonsillar exudates, 85/100 had tender anterior cervical lymph nodes, and 86/100 had no cough. in total, 9 out of the 100 patients had positive throat cultures. we observed that petechiae over the palate, a very significant sign, is not included in the centor criteria. palatal petechiae were present in 8 out of the 100 patients. six out of these 8 with palatal petechiae had positive throat culture for strep (75%). only 7 out of 20 with exudates had positive strep culture. sixteen out of the 100 patients had rapid strep test positive. those 84/100 who had negative rapid strep also had negative throat culture.we used fisher's exact test, comparing throat culture positive and negative versus presence of exudates and palatal hemorrhages with positive and negative throat cultures and the resultant p value <.0001.our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children.in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.one hundred patients with a complaint of sore throat were enrolled in the study. all the patients were examined clinically using the centor criteria. they were also examined for other signs and symptoms like petechial lesions over the palate, abdominal pain, and skin rash. all the patients were given rapid strep tests, and throat cultures were sent. no antibiotics were given until culture results were obtained.the sample size was 100 patients. all 100 had fever, sore throat, and erythema of tonsils. twenty of the 100 patients had tonsillar exudates, 85/100 had tender anterior cervical lymph nodes, and 86/100 had no cough. in total, 9 out of the 100 patients had positive throat cultures. we observed that petechiae over the palate, a very significant sign, is not included in the centor criteria. palatal petechiae were present in 8 out of the 100 patients. six out of these 8 with palatal petechiae had positive throat culture for strep (75%). only 7 out of 20 with exudates had positive strep culture. sixteen out of the 100 patients had rapid strep test positive. those 84/100 who had negative rapid strep also had negative throat culture.we used fisher's exact test, comparing throat culture positive and negative versus presence of exudates and palatal hemorrhages with positive and negative throat cultures and the resultant p value <.0001.our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children.in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.one hundred patients with a complaint of sore throat were enrolled in the study. all the patients were examined clinically using the centor criteria. they were also examined for other signs and symptoms like petechial lesions over the palate, abdominal pain, and skin rash. all the patients were given rapid strep tests, and throat cultures were sent. no antibiotics were given until culture results were obtained.the sample size was 100 patients. all 100 had fever, sore throat, and erythema of tonsils. twenty of the 100 patients had tonsillar exudates, 85/100 had tender anterior cervical lymph nodes, and 86/100 had no cough. in total, 9 out of the 100 patients had positive throat cultures. we observed that petechiae over the palate, a very significant sign, is not included in the centor criteria. palatal petechiae were present in 8 out of the 100 patients. six out of these 8 with palatal petechiae had positive throat culture for strep (75%). only 7 out of 20 with exudates had positive strep culture. sixteen out of the 100 patients had rapid strep test positive. those 84/100 who had negative rapid strep also had negative throat culture.we used fisher's exact test, comparing throat culture positive and negative versus presence of exudates and palatal hemorrhages with positive and negative throat cultures and the resultant p value <.0001.our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children.in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.one hundred patients with a complaint of sore throat were enrolled in the study. all the patients were examined clinically using the centor criteria. they were also examined for other signs and symptoms like petechial lesions over the palate, abdominal pain, and skin rash. all the patients were given rapid strep tests, and throat cultures were sent. no antibiotics were given until culture results were obtained.the sample size was 100 patients. all 100 had fever, sore throat, and erythema of tonsils. twenty of the 100 patients had tonsillar exudates, 85/100 had tender anterior cervical lymph nodes, and 86/100 had no cough. in total, 9 out of the 100 patients had positive throat cultures. we observed that petechiae over the palate, a very significant sign, is not included in the centor criteria. palatal petechiae were present in 8 out of the 100 patients. six out of these 8 with palatal petechiae had positive throat culture for strep (75%). only 7 out of 20 with exudates had positive strep culture. sixteen out of the 100 patients had rapid strep test positive. those 84/100 who had negative rapid strep also had negative throat culture.we used fisher's exact test, comparing throat culture positive and negative versus presence of exudates and palatal hemorrhages with positive and negative throat cultures and the resultant p value <.0001.our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children.in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.one hundred patients with a complaint of sore throat were enrolled in the study. all the patients were examined clinically using the centor criteria. they were also examined for other signs and symptoms like petechial lesions over the palate, abdominal pain, and skin rash. all the patients were given rapid strep tests, and throat cultures were sent. no antibiotics were given until culture results were obtained.the sample size was 100 patients. all 100 had fever, sore throat, and erythema of tonsils. twenty of the 100 patients had tonsillar exudates, 85/100 had tender anterior cervical lymph nodes, and 86/100 had no cough. in total, 9 out of the 100 patients had positive throat cultures. we observed that petechiae over the palate, a very significant sign, is not included in the centor criteria. palatal petechiae were present in 8 out of the 100 patients. six out of these 8 with palatal petechiae had positive throat culture for strep (75%). only 7 out of 20 with exudates had positive strep culture. sixteen out of the 100 patients had rapid strep test positive. those 84/100 who had negative rapid strep also had negative throat culture.we used fisher's exact test, comparing throat culture positive and negative versus presence of exudates and palatal hemorrhages with positive and negative throat cultures and the resultant p value <.0001.our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children.in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.one hundred patients with a complaint of sore throat were enrolled in the study. all the patients were examined clinically using the centor criteria. they were also examined for other signs and symptoms like petechial lesions over the palate, abdominal pain, and skin rash. all the patients were given rapid strep tests, and throat cultures were sent. no antibiotics were given until culture results were obtained.the sample size was 100 patients. all 100 had fever, sore throat, and erythema of tonsils. twenty of the 100 patients had tonsillar exudates, 85/100 had tender anterior cervical lymph nodes, and 86/100 had no cough. in total, 9 out of the 100 patients had positive throat cultures. we observed that petechiae over the palate, a very significant sign, is not included in the centor criteria. palatal petechiae were present in 8 out of the 100 patients. six out of these 8 with palatal petechiae had positive throat culture for strep (75%). only 7 out of 20 with exudates had positive strep culture. sixteen out of the 100 patients had rapid strep test positive. those 84/100 who had negative rapid strep also had negative throat culture.we used fisher's exact test, comparing throat culture positive and negative versus presence of exudates and palatal hemorrhages with positive and negative throat cultures and the resultant p value <.0001.our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children.in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.one hundred patients with a complaint of sore throat were enrolled in the study. all the patients were examined clinically using the centor criteria. they were also examined for other signs and symptoms like petechial lesions over the palate, abdominal pain, and skin rash. all the patients were given rapid strep tests, and throat cultures were sent. no antibiotics were given until culture results were obtained.the sample size was 100 patients. all 100 had fever, sore throat, and erythema of tonsils. twenty of the 100 patients had tonsillar exudates, 85/100 had tender anterior cervical lymph nodes, and 86/100 had no cough. in total, 9 out of the 100 patients had positive throat cultures. we observed that petechiae over the palate, a very significant sign, is not included in the centor criteria. palatal petechiae were present in 8 out of the 100 patients. six out of these 8 with palatal petechiae had positive throat culture for strep (75%). only 7 out of 20 with exudates had positive strep culture. sixteen out of the 100 patients had rapid strep test positive. those 84/100 who had negative rapid strep also had negative throat culture.we used fisher's exact test, comparing throat culture positive and negative versus presence of exudates and palatal hemorrhages with positive and negative throat cultures and the resultant p value <.0001.our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children.in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.one hundred patients with a complaint of sore throat were enrolled in the study. all the patients were examined clinically using the centor criteria. they were also examined for other signs and symptoms like petechial lesions over the palate, abdominal pain, and skin rash. all the patients were given rapid strep tests, and throat cultures were sent. no antibiotics were given until culture results were obtained.the sample size was 100 patients. all 100 had fever, sore throat, and erythema of tonsils. twenty of the 100 patients had tonsillar exudates, 85/100 had tender anterior cervical lymph nodes, and 86/100 had no cough. in total, 9 out of the 100 patients had positive throat cultures. we observed that petechiae over the palate, a very significant sign, is not included in the centor criteria. palatal petechiae were present in 8 out of the 100 patients. six out of these 8 with palatal petechiae had positive throat culture for strep (75%). only 7 out of 20 with exudates had positive strep culture. sixteen out of the 100 patients had rapid strep test positive. those 84/100 who had negative rapid strep also had negative throat culture.we used fisher's exact test, comparing throat culture positive and negative versus presence of exudates and palatal hemorrhages with positive and negative throat cultures and the resultant p value <.0001.our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children.in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.one hundred patients with a complaint of sore throat were enrolled in the study. all the patients were examined clinically using the centor criteria. they were also examined for other signs and symptoms like petechial lesions over the palate, abdominal pain, and skin rash. all the patients were given rapid strep tests, and throat cultures were sent. no antibiotics were given until culture results were obtained.the sample size was 100 patients. all 100 had fever, sore throat, and erythema of tonsils. twenty of the 100 patients had tonsillar exudates, 85/100 had tender anterior cervical lymph nodes, and 86/100 had no cough. in total, 9 out of the 100 patients had positive throat cultures. we observed that petechiae over the palate, a very significant sign, is not included in the centor criteria. palatal petechiae were present in 8 out of the 100 patients. six out of these 8 with palatal petechiae had positive throat culture for strep (75%). only 7 out of 20 with exudates had positive strep culture. sixteen out of the 100 patients had rapid strep test positive. those 84/100 who had negative rapid strep also had negative throat culture.we used fisher's exact test, comparing throat culture positive and negative versus presence of exudates and palatal hemorrhages with positive and negative throat cultures and the resultant p value <.0001.our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children.in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.one hundred patients with a complaint of sore throat were enrolled in the study. all the patients were examined clinically using the centor criteria. they were also examined for other signs and symptoms like petechial lesions over the palate, abdominal pain, and skin rash. all the patients were given rapid strep tests, and throat cultures were sent. no antibiotics were given until culture results were obtained.the sample size was 100 patients. all 100 had fever, sore throat, and erythema of tonsils. twenty of the 100 patients had tonsillar exudates, 85/100 had tender anterior cervical lymph nodes, and 86/100 had no cough. in total, 9 out of the 100 patients had positive throat cultures. we observed that petechiae over the palate, a very significant sign, is not included in the centor criteria. palatal petechiae were present in 8 out of the 100 patients. six out of these 8 with palatal petechiae had positive throat culture for strep (75%). only 7 out of 20 with exudates had positive strep culture. sixteen out of the 100 patients had rapid strep test positive. those 84/100 who had negative rapid strep also had negative throat culture.we used fisher's exact test, comparing throat culture positive and negative versus presence of exudates and palatal hemorrhages with positive and negative throat cultures and the resultant p value <.0001.our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children.in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.one hundred patients with a complaint of sore throat were enrolled in the study. all the patients were examined clinically using the centor criteria. they were also examined for other signs and symptoms like petechial lesions over the palate, abdominal pain, and skin rash. all the patients were given rapid strep tests, and throat cultures were sent. no antibiotics were given until culture results were obtained.the sample size was 100 patients. all 100 had fever, sore throat, and erythema of tonsils. twenty of the 100 patients had tonsillar exudates, 85/100 had tender anterior cervical lymph nodes, and 86/100 had no cough. in total, 9 out of the 100 patients had positive throat cultures. we observed that petechiae over the palate, a very significant sign, is not included in the centor criteria. palatal petechiae were present in 8 out of the 100 patients. six out of these 8 with palatal petechiae had positive throat culture for strep (75%). only 7 out of 20 with exudates had positive strep culture. sixteen out of the 100 patients had rapid strep test positive. those 84/100 who had negative rapid strep also had negative throat culture.we used fisher's exact test, comparing throat culture positive and negative versus presence of exudates and palatal hemorrhages with positive and negative throat cultures and the resultant p value <.0001.our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children.in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.one hundred patients with a complaint of sore throat were enrolled in the study. all the patients were examined clinically using the centor criteria. they were also examined for other signs and symptoms like petechial lesions over the palate, abdominal pain, and skin rash. all the patients were given rapid strep tests, and throat cultures were sent. no antibiotics were given until culture results were obtained.the sample size was 100 patients. all 100 had fever, sore throat, and erythema of tonsils. twenty of the 100 patients had tonsillar exudates, 85/100 had tender anterior cervical lymph nodes, and 86/100 had no cough. in total, 9 out of the 100 patients had positive throat cultures. we observed that petechiae over the palate, a very significant sign, is not included in the centor criteria. palatal petechiae were present in 8 out of the 100 patients. six out of these 8 with palatal petechiae had positive throat culture for strep (75%). only 7 out of 20 with exudates had positive strep culture. sixteen out of the 100 patients had rapid strep test positive. those 84/100 who had negative rapid strep also had negative throat culture.we used fisher's exact test, comparing throat culture positive and negative versus presence of exudates and palatal hemorrhages with positive and negative throat cultures and the resultant p value <.0001.our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children.in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.one hundred patients with a complaint of sore throat were enrolled in the study. all the patients were examined clinically using the centor criteria. they were also examined for other signs and symptoms like petechial lesions over the palate, abdominal pain, and skin rash. all the patients were given rapid strep tests, and throat cultures were sent. no antibiotics were given until culture results were obtained.the sample size was 100 patients. all 100 had fever, sore throat, and erythema of tonsils. twenty of the 100 patients had tonsillar exudates, 85/100 had tender anterior cervical lymph nodes, and 86/100 had no cough. in total, 9 out of the 100 patients had positive throat cultures. we observed that petechiae over the palate, a very significant sign, is not included in the centor criteria. palatal petechiae were present in 8 out of the 100 patients. six out of these 8 with palatal petechiae had positive throat culture for strep (75%). only 7 out of 20 with exudates had positive strep culture. sixteen out of the 100 patients had rapid strep test positive. those 84/100 who had negative rapid strep also had negative throat culture.we used fisher's exact test, comparing throat culture positive and negative versus presence of exudates and palatal hemorrhages with positive and negative throat cultures and the resultant p value <.0001.our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children.in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.one hundred patients with a complaint of sore throat were enrolled in the study. all the patients were examined clinically using the centor criteria. they were also examined for other signs and symptoms like petechial lesions over the palate, abdominal pain, and skin rash. all the patients were given rapid strep tests, and throat cultures were sent. no antibiotics were given until culture results were obtained.the sample size was 100 patients. all 100 had fever, sore throat, and erythema of tonsils. twenty of the 100 patients had tonsillar exudates, 85/100 had tender anterior cervical lymph nodes, and 86/100 had no cough. in total, 9 out of the 100 patients had positive throat cultures. we observed that petechiae over the palate, a very significant sign, is not included in the centor criteria. palatal petechiae were present in 8 out of the 100 patients. six out of these 8 with palatal petechiae had positive throat culture for strep (75%). only 7 out of 20 with exudates had positive strep culture. sixteen out of the 100 patients had rapid strep test positive. those 84/100 who had negative rapid strep also had negative throat culture.we used fisher's exact test, comparing throat culture positive and negative versus presence of exudates and palatal hemorrhages with positive and negative throat cultures and the resultant p value <.0001.our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children.in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.one hundred patients with a complaint of sore throat were enrolled in the study. all the patients were examined clinically using the centor criteria. they were also examined for other signs and symptoms like petechial lesions over the palate, abdominal pain, and skin rash. all the patients were given rapid strep tests, and throat cultures were sent. no antibiotics were given until culture results were obtained.the sample size was 100 patients. all 100 had fever, sore throat, and erythema of tonsils. twenty of the 100 patients had tonsillar exudates, 85/100 had tender anterior cervical lymph nodes, and 86/100 had no cough. in total, 9 out of the 100 patients had positive throat cultures. we observed that petechiae over the palate, a very significant sign, is not included in the centor criteria. palatal petechiae were present in 8 out of the 100 patients. six out of these 8 with palatal petechiae had positive throat culture for strep (75%). only 7 out of 20 with exudates had positive strep culture. sixteen out of the 100 patients had rapid strep test positive. those 84/100 who had negative rapid strep also had negative throat culture.we used fisher's exact test, comparing throat culture positive and negative versus presence of exudates and palatal hemorrhages with positive and negative throat cultures and the resultant p value <.0001.our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children.in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.one hundred patients with a complaint of sore throat were enrolled in the study. all the patients were examined clinically using the centor criteria. they were also examined for other signs and symptoms like petechial lesions over the palate, abdominal pain, and skin rash. all the patients were given rapid strep tests, and throat cultures were sent. no antibiotics were given until culture results were obtained.the sample size was 100 patients. all 100 had fever, sore throat, and erythema of tonsils. twenty of the 100 patients had tonsillar exudates, 85/100 had tender anterior cervical lymph nodes, and 86/100 had no cough. in total, 9 out of the 100 patients had positive throat cultures. we observed that petechiae over the palate, a very significant sign, is not included in the centor criteria. palatal petechiae were present in 8 out of the 100 patients. six out of these 8 with palatal petechiae had positive throat culture for strep (75%). only 7 out of 20 with exudates had positive strep culture. sixteen out of the 100 patients had rapid strep test positive. those 84/100 who had negative rapid strep also had negative throat culture.we used fisher's exact test, comparing throat culture positive and negative versus presence of exudates and palatal hemorrhages with positive and negative throat cultures and the resultant p value <.0001.our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "to determine the validity of the rapid antigen test rat osom strepa genzyme for the diagnosis of acute pharyngitis caused by group a beta haemolytic strep gabhs diagnostic techniques survey urban primary care centre spain all patients over 14 years old seen in 6 surgeries with sore throat and 2 or more centor criteria pharyngotonsillar exudate tender laterocervical nodes absence of coughing and or history or presence of fever pharyngeal swabs were taken from all the patients one for rat and another to send for culture in the microbiology department a total of 182 patients were evaluable with a mean age of 30 6 12 1 years of which 116 were women 63 7 63 patients had 2 centor criteria 83 had 3 and 36 the 4 criteria the culture was positive in 102 patients 56 with gabhs showing infection in forty 22 95 confidence interval ci 21 2 22 8 group c streptococcus was isolated in 26 patients 14 3 gabhs was higher among patients with four centor criteria 38 9 vs 25 3 observed among those with 3 criteria and 7 9 with 2 criteria p 001 sensitivity of rat was 95 with a specificity of 93 a positive predictive value of 79 2 and a negative predictive value of 98 5 these results show the usefulness of rat for diagnosing streptococcal pharyngitis its use should be spread to all primary care practices.", "to determine the validity of the rapid antigen test rat osom strepa genzyme for the diagnosis of acute pharyngitis caused by group a beta haemolytic strep gabhs diagnostic techniques survey urban primary care centre spain all patients over 14 years old seen in 6 surgeries with sore throat and 2 or more centor criteria pharyngotonsillar exudate tender laterocervical nodes absence of coughing and or history or presence of fever pharyngeal swabs were taken from all the patients one for rat and another to send for culture in the microbiology department a total of 182 patients were evaluable with a mean age of 30 6 12 1 years of which 116 were women 63 7 63 patients had 2 centor criteria 83 had 3 and 36 the 4 criteria the culture was positive in 102 patients 56 with gabhs showing infection in forty 22 95 confidence interval ci 21 2 22 8 group c streptococcus was isolated in 26 patients 14 3 gabhs was higher among patients with four centor criteria 38 9 vs 25 3 observed among those with 3 criteria and 7 9 with 2 criteria p 001 sensitivity of rat was 95 with a specificity of 93 a positive predictive value of 79 2 and a negative predictive value of 98 5 these results show the usefulness of rat for diagnosing streptococcal pharyngitis its use should be spread to all primary care practices.", "to determine the validity of the rapid antigen test rat osom strepa genzyme for the diagnosis of acute pharyngitis caused by group a beta haemolytic strep gabhs diagnostic techniques survey urban primary care centre spain all patients over 14 years old seen in 6 surgeries with sore throat and 2 or more centor criteria pharyngotonsillar exudate tender laterocervical nodes absence of coughing and or history or presence of fever pharyngeal swabs were taken from all the patients one for rat and another to send for culture in the microbiology department a total of 182 patients were evaluable with a mean age of 30 6 12 1 years of which 116 were women 63 7 63 patients had 2 centor criteria 83 had 3 and 36 the 4 criteria the culture was positive in 102 patients 56 with gabhs showing infection in forty 22 95 confidence interval ci 21 2 22 8 group c streptococcus was isolated in 26 patients 14 3 gabhs was higher among patients with four centor criteria 38 9 vs 25 3 observed among those with 3 criteria and 7 9 with 2 criteria p 001 sensitivity of rat was 95 with a specificity of 93 a positive predictive value of 79 2 and a negative predictive value of 98 5 these results show the usefulness of rat for diagnosing streptococcal pharyngitis its use should be spread to all primary care practices.", "to determine the validity of the rapid antigen test rat osom strepa genzyme for the diagnosis of acute pharyngitis caused by group a beta haemolytic strep gabhs diagnostic techniques survey urban primary care centre spain all patients over 14 years old seen in 6 surgeries with sore throat and 2 or more centor criteria pharyngotonsillar exudate tender laterocervical nodes absence of coughing and or history or presence of fever pharyngeal swabs were taken from all the patients one for rat and another to send for culture in the microbiology department a total of 182 patients were evaluable with a mean age of 30 6 12 1 years of which 116 were women 63 7 63 patients had 2 centor criteria 83 had 3 and 36 the 4 criteria the culture was positive in 102 patients 56 with gabhs showing infection in forty 22 95 confidence interval ci 21 2 22 8 group c streptococcus was isolated in 26 patients 14 3 gabhs was higher among patients with four centor criteria 38 9 vs 25 3 observed among those with 3 criteria and 7 9 with 2 criteria p 001 sensitivity of rat was 95 with a specificity of 93 a positive predictive value of 79 2 and a negative predictive value of 98 5 these results show the usefulness of rat for diagnosing streptococcal pharyngitis its use should be spread to all primary care practices.", "to determine the validity of the rapid antigen test rat osom strepa genzyme for the diagnosis of acute pharyngitis caused by group a beta haemolytic strep gabhs diagnostic techniques survey urban primary care centre spain all patients over 14 years old seen in 6 surgeries with sore throat and 2 or more centor criteria pharyngotonsillar exudate tender laterocervical nodes absence of coughing and or history or presence of fever pharyngeal swabs were taken from all the patients one for rat and another to send for culture in the microbiology department a total of 182 patients were evaluable with a mean age of 30 6 12 1 years of which 116 were women 63 7 63 patients had 2 centor criteria 83 had 3 and 36 the 4 criteria the culture was positive in 102 patients 56 with gabhs showing infection in forty 22 95 confidence interval ci 21 2 22 8 group c streptococcus was isolated in 26 patients 14 3 gabhs was higher among patients with four centor criteria 38 9 vs 25 3 observed among those with 3 criteria and 7 9 with 2 criteria p 001 sensitivity of rat was 95 with a specificity of 93 a positive predictive value of 79 2 and a negative predictive value of 98 5 these results show the usefulness of rat for diagnosing streptococcal pharyngitis its use should be spread to all primary care practices.", "to determine the validity of the rapid antigen test rat osom strepa genzyme for the diagnosis of acute pharyngitis caused by group a beta haemolytic strep gabhs diagnostic techniques survey urban primary care centre spain all patients over 14 years old seen in 6 surgeries with sore throat and 2 or more centor criteria pharyngotonsillar exudate tender laterocervical nodes absence of coughing and or history or presence of fever pharyngeal swabs were taken from all the patients one for rat and another to send for culture in the microbiology department a total of 182 patients were evaluable with a mean age of 30 6 12 1 years of which 116 were women 63 7 63 patients had 2 centor criteria 83 had 3 and 36 the 4 criteria the culture was positive in 102 patients 56 with gabhs showing infection in forty 22 95 confidence interval ci 21 2 22 8 group c streptococcus was isolated in 26 patients 14 3 gabhs was higher among patients with four centor criteria 38 9 vs 25 3 observed among those with 3 criteria and 7 9 with 2 criteria p 001 sensitivity of rat was 95 with a specificity of 93 a positive predictive value of 79 2 and a negative predictive value of 98 5 these results show the usefulness of rat for diagnosing streptococcal pharyngitis its use should be spread to all primary care practices.", "to determine the validity of the rapid antigen test rat osom strepa genzyme for the diagnosis of acute pharyngitis caused by group a beta haemolytic strep gabhs diagnostic techniques survey urban primary care centre spain all patients over 14 years old seen in 6 surgeries with sore throat and 2 or more centor criteria pharyngotonsillar exudate tender laterocervical nodes absence of coughing and or history or presence of fever pharyngeal swabs were taken from all the patients one for rat and another to send for culture in the microbiology department a total of 182 patients were evaluable with a mean age of 30 6 12 1 years of which 116 were women 63 7 63 patients had 2 centor criteria 83 had 3 and 36 the 4 criteria the culture was positive in 102 patients 56 with gabhs showing infection in forty 22 95 confidence interval ci 21 2 22 8 group c streptococcus was isolated in 26 patients 14 3 gabhs was higher among patients with four centor criteria 38 9 vs 25 3 observed among those with 3 criteria and 7 9 with 2 criteria p 001 sensitivity of rat was 95 with a specificity of 93 a positive predictive value of 79 2 and a negative predictive value of 98 5 these results show the usefulness of rat for diagnosing streptococcal pharyngitis its use should be spread to all primary care practices.", "to determine the validity of the rapid antigen test rat osom strepa genzyme for the diagnosis of acute pharyngitis caused by group a beta haemolytic strep gabhs diagnostic techniques survey urban primary care centre spain all patients over 14 years old seen in 6 surgeries with sore throat and 2 or more centor criteria pharyngotonsillar exudate tender laterocervical nodes absence of coughing and or history or presence of fever pharyngeal swabs were taken from all the patients one for rat and another to send for culture in the microbiology department a total of 182 patients were evaluable with a mean age of 30 6 12 1 years of which 116 were women 63 7 63 patients had 2 centor criteria 83 had 3 and 36 the 4 criteria the culture was positive in 102 patients 56 with gabhs showing infection in forty 22 95 confidence interval ci 21 2 22 8 group c streptococcus was isolated in 26 patients 14 3 gabhs was higher among patients with four centor criteria 38 9 vs 25 3 observed among those with 3 criteria and 7 9 with 2 criteria p 001 sensitivity of rat was 95 with a specificity of 93 a positive predictive value of 79 2 and a negative predictive value of 98 5 these results show the usefulness of rat for diagnosing streptococcal pharyngitis its use should be spread to all primary care practices.", "to determine the validity of the rapid antigen test rat osom strepa genzyme for the diagnosis of acute pharyngitis caused by group a beta haemolytic strep gabhs diagnostic techniques survey urban primary care centre spain all patients over 14 years old seen in 6 surgeries with sore throat and 2 or more centor criteria pharyngotonsillar exudate tender laterocervical nodes absence of coughing and or history or presence of fever pharyngeal swabs were taken from all the patients one for rat and another to send for culture in the microbiology department a total of 182 patients were evaluable with a mean age of 30 6 12 1 years of which 116 were women 63 7 63 patients had 2 centor criteria 83 had 3 and 36 the 4 criteria the culture was positive in 102 patients 56 with gabhs showing infection in forty 22 95 confidence interval ci 21 2 22 8 group c streptococcus was isolated in 26 patients 14 3 gabhs was higher among patients with four centor criteria 38 9 vs 25 3 observed among those with 3 criteria and 7 9 with 2 criteria p 001 sensitivity of rat was 95 with a specificity of 93 a positive predictive value of 79 2 and a negative predictive value of 98 5 these results show the usefulness of rat for diagnosing streptococcal pharyngitis its use should be spread to all primary care practices.", "to determine the validity of the rapid antigen test rat osom strepa genzyme for the diagnosis of acute pharyngitis caused by group a beta haemolytic strep gabhs diagnostic techniques survey urban primary care centre spain all patients over 14 years old seen in 6 surgeries with sore throat and 2 or more centor criteria pharyngotonsillar exudate tender laterocervical nodes absence of coughing and or history or presence of fever pharyngeal swabs were taken from all the patients one for rat and another to send for culture in the microbiology department a total of 182 patients were evaluable with a mean age of 30 6 12 1 years of which 116 were women 63 7 63 patients had 2 centor criteria 83 had 3 and 36 the 4 criteria the culture was positive in 102 patients 56 with gabhs showing infection in forty 22 95 confidence interval ci 21 2 22 8 group c streptococcus was isolated in 26 patients 14 3 gabhs was higher among patients with four centor criteria 38 9 vs 25 3 observed among those with 3 criteria and 7 9 with 2 criteria p 001 sensitivity of rat was 95 with a specificity of 93 a positive predictive value of 79 2 and a negative predictive value of 98 5 these results show the usefulness of rat for diagnosing streptococcal pharyngitis its use should be spread to all primary care practices.", "to determine the validity of the rapid antigen test rat osom strepa genzyme for the diagnosis of acute pharyngitis caused by group a beta haemolytic strep gabhs diagnostic techniques survey urban primary care centre spain all patients over 14 years old seen in 6 surgeries with sore throat and 2 or more centor criteria pharyngotonsillar exudate tender laterocervical nodes absence of coughing and or history or presence of fever pharyngeal swabs were taken from all the patients one for rat and another to send for culture in the microbiology department a total of 182 patients were evaluable with a mean age of 30 6 12 1 years of which 116 were women 63 7 63 patients had 2 centor criteria 83 had 3 and 36 the 4 criteria the culture was positive in 102 patients 56 with gabhs showing infection in forty 22 95 confidence interval ci 21 2 22 8 group c streptococcus was isolated in 26 patients 14 3 gabhs was higher among patients with four centor criteria 38 9 vs 25 3 observed among those with 3 criteria and 7 9 with 2 criteria p 001 sensitivity of rat was 95 with a specificity of 93 a positive predictive value of 79 2 and a negative predictive value of 98 5 these results show the usefulness of rat for diagnosing streptococcal pharyngitis its use should be spread to all primary care practices.", "to determine the validity of the rapid antigen test rat osom strepa genzyme for the diagnosis of acute pharyngitis caused by group a beta haemolytic strep gabhs diagnostic techniques survey urban primary care centre spain all patients over 14 years old seen in 6 surgeries with sore throat and 2 or more centor criteria pharyngotonsillar exudate tender laterocervical nodes absence of coughing and or history or presence of fever pharyngeal swabs were taken from all the patients one for rat and another to send for culture in the microbiology department a total of 182 patients were evaluable with a mean age of 30 6 12 1 years of which 116 were women 63 7 63 patients had 2 centor criteria 83 had 3 and 36 the 4 criteria the culture was positive in 102 patients 56 with gabhs showing infection in forty 22 95 confidence interval ci 21 2 22 8 group c streptococcus was isolated in 26 patients 14 3 gabhs was higher among patients with four centor criteria 38 9 vs 25 3 observed among those with 3 criteria and 7 9 with 2 criteria p 001 sensitivity of rat was 95 with a specificity of 93 a positive predictive value of 79 2 and a negative predictive value of 98 5 these results show the usefulness of rat for diagnosing streptococcal pharyngitis its use should be spread to all primary care practices.", "to determine the validity of the rapid antigen test rat osom strepa genzyme for the diagnosis of acute pharyngitis caused by group a beta haemolytic strep gabhs diagnostic techniques survey urban primary care centre spain all patients over 14 years old seen in 6 surgeries with sore throat and 2 or more centor criteria pharyngotonsillar exudate tender laterocervical nodes absence of coughing and or history or presence of fever pharyngeal swabs were taken from all the patients one for rat and another to send for culture in the microbiology department a total of 182 patients were evaluable with a mean age of 30 6 12 1 years of which 116 were women 63 7 63 patients had 2 centor criteria 83 had 3 and 36 the 4 criteria the culture was positive in 102 patients 56 with gabhs showing infection in forty 22 95 confidence interval ci 21 2 22 8 group c streptococcus was isolated in 26 patients 14 3 gabhs was higher among patients with four centor criteria 38 9 vs 25 3 observed among those with 3 criteria and 7 9 with 2 criteria p 001 sensitivity of rat was 95 with a specificity of 93 a positive predictive value of 79 2 and a negative predictive value of 98 5 these results show the usefulness of rat for diagnosing streptococcal pharyngitis its use should be spread to all primary care practices.", "to determine the validity of the rapid antigen test rat osom strepa genzyme for the diagnosis of acute pharyngitis caused by group a beta haemolytic strep gabhs diagnostic techniques survey urban primary care centre spain all patients over 14 years old seen in 6 surgeries with sore throat and 2 or more centor criteria pharyngotonsillar exudate tender laterocervical nodes absence of coughing and or history or presence of fever pharyngeal swabs were taken from all the patients one for rat and another to send for culture in the microbiology department a total of 182 patients were evaluable with a mean age of 30 6 12 1 years of which 116 were women 63 7 63 patients had 2 centor criteria 83 had 3 and 36 the 4 criteria the culture was positive in 102 patients 56 with gabhs showing infection in forty 22 95 confidence interval ci 21 2 22 8 group c streptococcus was isolated in 26 patients 14 3 gabhs was higher among patients with four centor criteria 38 9 vs 25 3 observed among those with 3 criteria and 7 9 with 2 criteria p 001 sensitivity of rat was 95 with a specificity of 93 a positive predictive value of 79 2 and a negative predictive value of 98 5 these results show the usefulness of rat for diagnosing streptococcal pharyngitis its use should be spread to all primary care practices.", "to determine the validity of the rapid antigen test rat osom strepa genzyme for the diagnosis of acute pharyngitis caused by group a beta haemolytic strep gabhs diagnostic techniques survey urban primary care centre spain all patients over 14 years old seen in 6 surgeries with sore throat and 2 or more centor criteria pharyngotonsillar exudate tender laterocervical nodes absence of coughing and or history or presence of fever pharyngeal swabs were taken from all the patients one for rat and another to send for culture in the microbiology department a total of 182 patients were evaluable with a mean age of 30 6 12 1 years of which 116 were women 63 7 63 patients had 2 centor criteria 83 had 3 and 36 the 4 criteria the culture was positive in 102 patients 56 with gabhs showing infection in forty 22 95 confidence interval ci 21 2 22 8 group c streptococcus was isolated in 26 patients 14 3 gabhs was higher among patients with four centor criteria 38 9 vs 25 3 observed among those with 3 criteria and 7 9 with 2 criteria p 001 sensitivity of rat was 95 with a specificity of 93 a positive predictive value of 79 2 and a negative predictive value of 98 5 these results show the usefulness of rat for diagnosing streptococcal pharyngitis its use should be spread to all primary care practices.", "to determine the validity of the rapid antigen test rat osom strepa genzyme for the diagnosis of acute pharyngitis caused by group a beta haemolytic strep gabhs diagnostic techniques survey urban primary care centre spain all patients over 14 years old seen in 6 surgeries with sore throat and 2 or more centor criteria pharyngotonsillar exudate tender laterocervical nodes absence of coughing and or history or presence of fever pharyngeal swabs were taken from all the patients one for rat and another to send for culture in the microbiology department a total of 182 patients were evaluable with a mean age of 30 6 12 1 years of which 116 were women 63 7 63 patients had 2 centor criteria 83 had 3 and 36 the 4 criteria the culture was positive in 102 patients 56 with gabhs showing infection in forty 22 95 confidence interval ci 21 2 22 8 group c streptococcus was isolated in 26 patients 14 3 gabhs was higher among patients with four centor criteria 38 9 vs 25 3 observed among those with 3 criteria and 7 9 with 2 criteria p 001 sensitivity of rat was 95 with a specificity of 93 a positive predictive value of 79 2 and a negative predictive value of 98 5 these results show the usefulness of rat for diagnosing streptococcal pharyngitis its use should be spread to all primary care practices.", "to determine the validity of the rapid antigen test rat osom strepa genzyme for the diagnosis of acute pharyngitis caused by group a beta haemolytic strep gabhs diagnostic techniques survey urban primary care centre spain all patients over 14 years old seen in 6 surgeries with sore throat and 2 or more centor criteria pharyngotonsillar exudate tender laterocervical nodes absence of coughing and or history or presence of fever pharyngeal swabs were taken from all the patients one for rat and another to send for culture in the microbiology department a total of 182 patients were evaluable with a mean age of 30 6 12 1 years of which 116 were women 63 7 63 patients had 2 centor criteria 83 had 3 and 36 the 4 criteria the culture was positive in 102 patients 56 with gabhs showing infection in forty 22 95 confidence interval ci 21 2 22 8 group c streptococcus was isolated in 26 patients 14 3 gabhs was higher among patients with four centor criteria 38 9 vs 25 3 observed among those with 3 criteria and 7 9 with 2 criteria p 001 sensitivity of rat was 95 with a specificity of 93 a positive predictive value of 79 2 and a negative predictive value of 98 5 these results show the usefulness of rat for diagnosing streptococcal pharyngitis its use should be spread to all primary care practices.", "to determine the validity of the rapid antigen test rat osom strepa genzyme for the diagnosis of acute pharyngitis caused by group a beta haemolytic strep gabhs diagnostic techniques survey urban primary care centre spain all patients over 14 years old seen in 6 surgeries with sore throat and 2 or more centor criteria pharyngotonsillar exudate tender laterocervical nodes absence of coughing and or history or presence of fever pharyngeal swabs were taken from all the patients one for rat and another to send for culture in the microbiology department a total of 182 patients were evaluable with a mean age of 30 6 12 1 years of which 116 were women 63 7 63 patients had 2 centor criteria 83 had 3 and 36 the 4 criteria the culture was positive in 102 patients 56 with gabhs showing infection in forty 22 95 confidence interval ci 21 2 22 8 group c streptococcus was isolated in 26 patients 14 3 gabhs was higher among patients with four centor criteria 38 9 vs 25 3 observed among those with 3 criteria and 7 9 with 2 criteria p 001 sensitivity of rat was 95 with a specificity of 93 a positive predictive value of 79 2 and a negative predictive value of 98 5 these results show the usefulness of rat for diagnosing streptococcal pharyngitis its use should be spread to all primary care practices.", "to determine the validity of the rapid antigen test rat osom strepa genzyme for the diagnosis of acute pharyngitis caused by group a beta haemolytic strep gabhs diagnostic techniques survey urban primary care centre spain all patients over 14 years old seen in 6 surgeries with sore throat and 2 or more centor criteria pharyngotonsillar exudate tender laterocervical nodes absence of coughing and or history or presence of fever pharyngeal swabs were taken from all the patients one for rat and another to send for culture in the microbiology department a total of 182 patients were evaluable with a mean age of 30 6 12 1 years of which 116 were women 63 7 63 patients had 2 centor criteria 83 had 3 and 36 the 4 criteria the culture was positive in 102 patients 56 with gabhs showing infection in forty 22 95 confidence interval ci 21 2 22 8 group c streptococcus was isolated in 26 patients 14 3 gabhs was higher among patients with four centor criteria 38 9 vs 25 3 observed among those with 3 criteria and 7 9 with 2 criteria p 001 sensitivity of rat was 95 with a specificity of 93 a positive predictive value of 79 2 and a negative predictive value of 98 5 these results show the usefulness of rat for diagnosing streptococcal pharyngitis its use should be spread to all primary care practices.", "to determine the validity of the rapid antigen test rat osom strepa genzyme for the diagnosis of acute pharyngitis caused by group a beta haemolytic strep gabhs diagnostic techniques survey urban primary care centre spain all patients over 14 years old seen in 6 surgeries with sore throat and 2 or more centor criteria pharyngotonsillar exudate tender laterocervical nodes absence of coughing and or history or presence of fever pharyngeal swabs were taken from all the patients one for rat and another to send for culture in the microbiology department a total of 182 patients were evaluable with a mean age of 30 6 12 1 years of which 116 were women 63 7 63 patients had 2 centor criteria 83 had 3 and 36 the 4 criteria the culture was positive in 102 patients 56 with gabhs showing infection in forty 22 95 confidence interval ci 21 2 22 8 group c streptococcus was isolated in 26 patients 14 3 gabhs was higher among patients with four centor criteria 38 9 vs 25 3 observed among those with 3 criteria and 7 9 with 2 criteria p 001 sensitivity of rat was 95 with a specificity of 93 a positive predictive value of 79 2 and a negative predictive value of 98 5 these results show the usefulness of rat for diagnosing streptococcal pharyngitis its use should be spread to all primary care practices.", "to determine the validity of the rapid antigen test rat osom strepa genzyme for the diagnosis of acute pharyngitis caused by group a beta haemolytic strep gabhs diagnostic techniques survey urban primary care centre spain all patients over 14 years old seen in 6 surgeries with sore throat and 2 or more centor criteria pharyngotonsillar exudate tender laterocervical nodes absence of coughing and or history or presence of fever pharyngeal swabs were taken from all the patients one for rat and another to send for culture in the microbiology department a total of 182 patients were evaluable with a mean age of 30 6 12 1 years of which 116 were women 63 7 63 patients had 2 centor criteria 83 had 3 and 36 the 4 criteria the culture was positive in 102 patients 56 with gabhs showing infection in forty 22 95 confidence interval ci 21 2 22 8 group c streptococcus was isolated in 26 patients 14 3 gabhs was higher among patients with four centor criteria 38 9 vs 25 3 observed among those with 3 criteria and 7 9 with 2 criteria p 001 sensitivity of rat was 95 with a specificity of 93 a positive predictive value of 79 2 and a negative predictive value of 98 5 these results show the usefulness of rat for diagnosing streptococcal pharyngitis its use should be spread to all primary care practices.", "to determine the validity of the rapid antigen test rat osom strepa genzyme for the diagnosis of acute pharyngitis caused by group a beta haemolytic strep gabhs diagnostic techniques survey urban primary care centre spain all patients over 14 years old seen in 6 surgeries with sore throat and 2 or more centor criteria pharyngotonsillar exudate tender laterocervical nodes absence of coughing and or history or presence of fever pharyngeal swabs were taken from all the patients one for rat and another to send for culture in the microbiology department a total of 182 patients were evaluable with a mean age of 30 6 12 1 years of which 116 were women 63 7 63 patients had 2 centor criteria 83 had 3 and 36 the 4 criteria the culture was positive in 102 patients 56 with gabhs showing infection in forty 22 95 confidence interval ci 21 2 22 8 group c streptococcus was isolated in 26 patients 14 3 gabhs was higher among patients with four centor criteria 38 9 vs 25 3 observed among those with 3 criteria and 7 9 with 2 criteria p 001 sensitivity of rat was 95 with a specificity of 93 a positive predictive value of 79 2 and a negative predictive value of 98 5 these results show the usefulness of rat for diagnosing streptococcal pharyngitis its use should be spread to all primary care practices.", "to determine the validity of the rapid antigen test rat osom strepa genzyme for the diagnosis of acute pharyngitis caused by group a beta haemolytic strep gabhs diagnostic techniques survey urban primary care centre spain all patients over 14 years old seen in 6 surgeries with sore throat and 2 or more centor criteria pharyngotonsillar exudate tender laterocervical nodes absence of coughing and or history or presence of fever pharyngeal swabs were taken from all the patients one for rat and another to send for culture in the microbiology department a total of 182 patients were evaluable with a mean age of 30 6 12 1 years of which 116 were women 63 7 63 patients had 2 centor criteria 83 had 3 and 36 the 4 criteria the culture was positive in 102 patients 56 with gabhs showing infection in forty 22 95 confidence interval ci 21 2 22 8 group c streptococcus was isolated in 26 patients 14 3 gabhs was higher among patients with four centor criteria 38 9 vs 25 3 observed among those with 3 criteria and 7 9 with 2 criteria p 001 sensitivity of rat was 95 with a specificity of 93 a positive predictive value of 79 2 and a negative predictive value of 98 5 these results show the usefulness of rat for diagnosing streptococcal pharyngitis its use should be spread to all primary care practices.", "to determine the validity of the rapid antigen test rat osom strepa genzyme for the diagnosis of acute pharyngitis caused by group a beta haemolytic strep gabhs diagnostic techniques survey urban primary care centre spain all patients over 14 years old seen in 6 surgeries with sore throat and 2 or more centor criteria pharyngotonsillar exudate tender laterocervical nodes absence of coughing and or history or presence of fever pharyngeal swabs were taken from all the patients one for rat and another to send for culture in the microbiology department a total of 182 patients were evaluable with a mean age of 30 6 12 1 years of which 116 were women 63 7 63 patients had 2 centor criteria 83 had 3 and 36 the 4 criteria the culture was positive in 102 patients 56 with gabhs showing infection in forty 22 95 confidence interval ci 21 2 22 8 group c streptococcus was isolated in 26 patients 14 3 gabhs was higher among patients with four centor criteria 38 9 vs 25 3 observed among those with 3 criteria and 7 9 with 2 criteria p 001 sensitivity of rat was 95 with a specificity of 93 a positive predictive value of 79 2 and a negative predictive value of 98 5 these results show the usefulness of rat for diagnosing streptococcal pharyngitis its use should be spread to all primary care practices.", "to determine the validity of the rapid antigen test rat osom strepa genzyme for the diagnosis of acute pharyngitis caused by group a beta haemolytic strep gabhs diagnostic techniques survey urban primary care centre spain all patients over 14 years old seen in 6 surgeries with sore throat and 2 or more centor criteria pharyngotonsillar exudate tender laterocervical nodes absence of coughing and or history or presence of fever pharyngeal swabs were taken from all the patients one for rat and another to send for culture in the microbiology department a total of 182 patients were evaluable with a mean age of 30 6 12 1 years of which 116 were women 63 7 63 patients had 2 centor criteria 83 had 3 and 36 the 4 criteria the culture was positive in 102 patients 56 with gabhs showing infection in forty 22 95 confidence interval ci 21 2 22 8 group c streptococcus was isolated in 26 patients 14 3 gabhs was higher among patients with four centor criteria 38 9 vs 25 3 observed among those with 3 criteria and 7 9 with 2 criteria p 001 sensitivity of rat was 95 with a specificity of 93 a positive predictive value of 79 2 and a negative predictive value of 98 5 these results show the usefulness of rat for diagnosing streptococcal pharyngitis its use should be spread to all primary care practices.", "to determine the validity of the rapid antigen test rat osom strepa genzyme for the diagnosis of acute pharyngitis caused by group a beta haemolytic strep gabhs diagnostic techniques survey urban primary care centre spain all patients over 14 years old seen in 6 surgeries with sore throat and 2 or more centor criteria pharyngotonsillar exudate tender laterocervical nodes absence of coughing and or history or presence of fever pharyngeal swabs were taken from all the patients one for rat and another to send for culture in the microbiology department a total of 182 patients were evaluable with a mean age of 30 6 12 1 years of which 116 were women 63 7 63 patients had 2 centor criteria 83 had 3 and 36 the 4 criteria the culture was positive in 102 patients 56 with gabhs showing infection in forty 22 95 confidence interval ci 21 2 22 8 group c streptococcus was isolated in 26 patients 14 3 gabhs was higher among patients with four centor criteria 38 9 vs 25 3 observed among those with 3 criteria and 7 9 with 2 criteria p 001 sensitivity of rat was 95 with a specificity of 93 a positive predictive value of 79 2 and a negative predictive value of 98 5 these results show the usefulness of rat for diagnosing streptococcal pharyngitis its use should be spread to all primary care practices.", "to determine the validity of the rapid antigen test rat osom strepa genzyme for the diagnosis of acute pharyngitis caused by group a beta haemolytic strep gabhs diagnostic techniques survey urban primary care centre spain all patients over 14 years old seen in 6 surgeries with sore throat and 2 or more centor criteria pharyngotonsillar exudate tender laterocervical nodes absence of coughing and or history or presence of fever pharyngeal swabs were taken from all the patients one for rat and another to send for culture in the microbiology department a total of 182 patients were evaluable with a mean age of 30 6 12 1 years of which 116 were women 63 7 63 patients had 2 centor criteria 83 had 3 and 36 the 4 criteria the culture was positive in 102 patients 56 with gabhs showing infection in forty 22 95 confidence interval ci 21 2 22 8 group c streptococcus was isolated in 26 patients 14 3 gabhs was higher among patients with four centor criteria 38 9 vs 25 3 observed among those with 3 criteria and 7 9 with 2 criteria p 001 sensitivity of rat was 95 with a specificity of 93 a positive predictive value of 79 2 and a negative predictive value of 98 5 these results show the usefulness of rat for diagnosing streptococcal pharyngitis its use should be spread to all primary care practices.", "to determine the validity of the rapid antigen test rat osom strepa genzyme for the diagnosis of acute pharyngitis caused by group a beta haemolytic strep gabhs diagnostic techniques survey urban primary care centre spain all patients over 14 years old seen in 6 surgeries with sore throat and 2 or more centor criteria pharyngotonsillar exudate tender laterocervical nodes absence of coughing and or history or presence of fever pharyngeal swabs were taken from all the patients one for rat and another to send for culture in the microbiology department a total of 182 patients were evaluable with a mean age of 30 6 12 1 years of which 116 were women 63 7 63 patients had 2 centor criteria 83 had 3 and 36 the 4 criteria the culture was positive in 102 patients 56 with gabhs showing infection in forty 22 95 confidence interval ci 21 2 22 8 group c streptococcus was isolated in 26 patients 14 3 gabhs was higher among patients with four centor criteria 38 9 vs 25 3 observed among those with 3 criteria and 7 9 with 2 criteria p 001 sensitivity of rat was 95 with a specificity of 93 a positive predictive value of 79 2 and a negative predictive value of 98 5 these results show the usefulness of rat for diagnosing streptococcal pharyngitis its use should be spread to all primary care practices.", "to determine the validity of the rapid antigen test rat osom strepa genzyme for the diagnosis of acute pharyngitis caused by group a beta haemolytic strep gabhs diagnostic techniques survey urban primary care centre spain all patients over 14 years old seen in 6 surgeries with sore throat and 2 or more centor criteria pharyngotonsillar exudate tender laterocervical nodes absence of coughing and or history or presence of fever pharyngeal swabs were taken from all the patients one for rat and another to send for culture in the microbiology department a total of 182 patients were evaluable with a mean age of 30 6 12 1 years of which 116 were women 63 7 63 patients had 2 centor criteria 83 had 3 and 36 the 4 criteria the culture was positive in 102 patients 56 with gabhs showing infection in forty 22 95 confidence interval ci 21 2 22 8 group c streptococcus was isolated in 26 patients 14 3 gabhs was higher among patients with four centor criteria 38 9 vs 25 3 observed among those with 3 criteria and 7 9 with 2 criteria p 001 sensitivity of rat was 95 with a specificity of 93 a positive predictive value of 79 2 and a negative predictive value of 98 5 these results show the usefulness of rat for diagnosing streptococcal pharyngitis its use should be spread to all primary care practices.", "to determine the validity of the rapid antigen test rat osom strepa genzyme for the diagnosis of acute pharyngitis caused by group a beta haemolytic strep gabhs diagnostic techniques survey urban primary care centre spain all patients over 14 years old seen in 6 surgeries with sore throat and 2 or more centor criteria pharyngotonsillar exudate tender laterocervical nodes absence of coughing and or history or presence of fever pharyngeal swabs were taken from all the patients one for rat and another to send for culture in the microbiology department a total of 182 patients were evaluable with a mean age of 30 6 12 1 years of which 116 were women 63 7 63 patients had 2 centor criteria 83 had 3 and 36 the 4 criteria the culture was positive in 102 patients 56 with gabhs showing infection in forty 22 95 confidence interval ci 21 2 22 8 group c streptococcus was isolated in 26 patients 14 3 gabhs was higher among patients with four centor criteria 38 9 vs 25 3 observed among those with 3 criteria and 7 9 with 2 criteria p 001 sensitivity of rat was 95 with a specificity of 93 a positive predictive value of 79 2 and a negative predictive value of 98 5 these results show the usefulness of rat for diagnosing streptococcal pharyngitis its use should be spread to all primary care practices.", "to determine the validity of the rapid antigen test rat osom strepa genzyme for the diagnosis of acute pharyngitis caused by group a beta haemolytic strep gabhs diagnostic techniques survey urban primary care centre spain all patients over 14 years old seen in 6 surgeries with sore throat and 2 or more centor criteria pharyngotonsillar exudate tender laterocervical nodes absence of coughing and or history or presence of fever pharyngeal swabs were taken from all the patients one for rat and another to send for culture in the microbiology department a total of 182 patients were evaluable with a mean age of 30 6 12 1 years of which 116 were women 63 7 63 patients had 2 centor criteria 83 had 3 and 36 the 4 criteria the culture was positive in 102 patients 56 with gabhs showing infection in forty 22 95 confidence interval ci 21 2 22 8 group c streptococcus was isolated in 26 patients 14 3 gabhs was higher among patients with four centor criteria 38 9 vs 25 3 observed among those with 3 criteria and 7 9 with 2 criteria p 001 sensitivity of rat was 95 with a specificity of 93 a positive predictive value of 79 2 and a negative predictive value of 98 5 these results show the usefulness of rat for diagnosing streptococcal pharyngitis its use should be spread to all primary care practices.", "to determine the validity of the rapid antigen test rat osom strepa genzyme for the diagnosis of acute pharyngitis caused by group a beta haemolytic strep gabhs diagnostic techniques survey urban primary care centre spain all patients over 14 years old seen in 6 surgeries with sore throat and 2 or more centor criteria pharyngotonsillar exudate tender laterocervical nodes absence of coughing and or history or presence of fever pharyngeal swabs were taken from all the patients one for rat and another to send for culture in the microbiology department a total of 182 patients were evaluable with a mean age of 30 6 12 1 years of which 116 were women 63 7 63 patients had 2 centor criteria 83 had 3 and 36 the 4 criteria the culture was positive in 102 patients 56 with gabhs showing infection in forty 22 95 confidence interval ci 21 2 22 8 group c streptococcus was isolated in 26 patients 14 3 gabhs was higher among patients with four centor criteria 38 9 vs 25 3 observed among those with 3 criteria and 7 9 with 2 criteria p 001 sensitivity of rat was 95 with a specificity of 93 a positive predictive value of 79 2 and a negative predictive value of 98 5 these results show the usefulness of rat for diagnosing streptococcal pharyngitis its use should be spread to all primary care practices.", "to determine the validity of the rapid antigen test rat osom strepa genzyme for the diagnosis of acute pharyngitis caused by group a beta haemolytic strep gabhs diagnostic techniques survey urban primary care centre spain all patients over 14 years old seen in 6 surgeries with sore throat and 2 or more centor criteria pharyngotonsillar exudate tender laterocervical nodes absence of coughing and or history or presence of fever pharyngeal swabs were taken from all the patients one for rat and another to send for culture in the microbiology department a total of 182 patients were evaluable with a mean age of 30 6 12 1 years of which 116 were women 63 7 63 patients had 2 centor criteria 83 had 3 and 36 the 4 criteria the culture was positive in 102 patients 56 with gabhs showing infection in forty 22 95 confidence interval ci 21 2 22 8 group c streptococcus was isolated in 26 patients 14 3 gabhs was higher among patients with four centor criteria 38 9 vs 25 3 observed among those with 3 criteria and 7 9 with 2 criteria p 001 sensitivity of rat was 95 with a specificity of 93 a positive predictive value of 79 2 and a negative predictive value of 98 5 these results show the usefulness of rat for diagnosing streptococcal pharyngitis its use should be spread to all primary care practices.", "to determine the validity of the rapid antigen test rat osom strepa genzyme for the diagnosis of acute pharyngitis caused by group a beta haemolytic strep gabhs diagnostic techniques survey urban primary care centre spain all patients over 14 years old seen in 6 surgeries with sore throat and 2 or more centor criteria pharyngotonsillar exudate tender laterocervical nodes absence of coughing and or history or presence of fever pharyngeal swabs were taken from all the patients one for rat and another to send for culture in the microbiology department a total of 182 patients were evaluable with a mean age of 30 6 12 1 years of which 116 were women 63 7 63 patients had 2 centor criteria 83 had 3 and 36 the 4 criteria the culture was positive in 102 patients 56 with gabhs showing infection in forty 22 95 confidence interval ci 21 2 22 8 group c streptococcus was isolated in 26 patients 14 3 gabhs was higher among patients with four centor criteria 38 9 vs 25 3 observed among those with 3 criteria and 7 9 with 2 criteria p 001 sensitivity of rat was 95 with a specificity of 93 a positive predictive value of 79 2 and a negative predictive value of 98 5 these results show the usefulness of rat for diagnosing streptococcal pharyngitis its use should be spread to all primary care practices.", "to determine the validity of the rapid antigen test rat osom strepa genzyme for the diagnosis of acute pharyngitis caused by group a beta haemolytic strep gabhs diagnostic techniques survey urban primary care centre spain all patients over 14 years old seen in 6 surgeries with sore throat and 2 or more centor criteria pharyngotonsillar exudate tender laterocervical nodes absence of coughing and or history or presence of fever pharyngeal swabs were taken from all the patients one for rat and another to send for culture in the microbiology department a total of 182 patients were evaluable with a mean age of 30 6 12 1 years of which 116 were women 63 7 63 patients had 2 centor criteria 83 had 3 and 36 the 4 criteria the culture was positive in 102 patients 56 with gabhs showing infection in forty 22 95 confidence interval ci 21 2 22 8 group c streptococcus was isolated in 26 patients 14 3 gabhs was higher among patients with four centor criteria 38 9 vs 25 3 observed among those with 3 criteria and 7 9 with 2 criteria p 001 sensitivity of rat was 95 with a specificity of 93 a positive predictive value of 79 2 and a negative predictive value of 98 5 these results show the usefulness of rat for diagnosing streptococcal pharyngitis its use should be spread to all primary care practices.", "to determine the validity of the rapid antigen test rat osom strepa genzyme for the diagnosis of acute pharyngitis caused by group a beta haemolytic strep gabhs diagnostic techniques survey urban primary care centre spain all patients over 14 years old seen in 6 surgeries with sore throat and 2 or more centor criteria pharyngotonsillar exudate tender laterocervical nodes absence of coughing and or history or presence of fever pharyngeal swabs were taken from all the patients one for rat and another to send for culture in the microbiology department a total of 182 patients were evaluable with a mean age of 30 6 12 1 years of which 116 were women 63 7 63 patients had 2 centor criteria 83 had 3 and 36 the 4 criteria the culture was positive in 102 patients 56 with gabhs showing infection in forty 22 95 confidence interval ci 21 2 22 8 group c streptococcus was isolated in 26 patients 14 3 gabhs was higher among patients with four centor criteria 38 9 vs 25 3 observed among those with 3 criteria and 7 9 with 2 criteria p 001 sensitivity of rat was 95 with a specificity of 93 a positive predictive value of 79 2 and a negative predictive value of 98 5 these results show the usefulness of rat for diagnosing streptococcal pharyngitis its use should be spread to all primary care practices.", "to determine the validity of the rapid antigen test rat osom strepa genzyme for the diagnosis of acute pharyngitis caused by group a beta haemolytic strep gabhs diagnostic techniques survey urban primary care centre spain all patients over 14 years old seen in 6 surgeries with sore throat and 2 or more centor criteria pharyngotonsillar exudate tender laterocervical nodes absence of coughing and or history or presence of fever pharyngeal swabs were taken from all the patients one for rat and another to send for culture in the microbiology department a total of 182 patients were evaluable with a mean age of 30 6 12 1 years of which 116 were women 63 7 63 patients had 2 centor criteria 83 had 3 and 36 the 4 criteria the culture was positive in 102 patients 56 with gabhs showing infection in forty 22 95 confidence interval ci 21 2 22 8 group c streptococcus was isolated in 26 patients 14 3 gabhs was higher among patients with four centor criteria 38 9 vs 25 3 observed among those with 3 criteria and 7 9 with 2 criteria p 001 sensitivity of rat was 95 with a specificity of 93 a positive predictive value of 79 2 and a negative predictive value of 98 5 these results show the usefulness of rat for diagnosing streptococcal pharyngitis its use should be spread to all primary care practices.", "to determine the validity of the rapid antigen test rat osom strepa genzyme for the diagnosis of acute pharyngitis caused by group a beta haemolytic strep gabhs diagnostic techniques survey urban primary care centre spain all patients over 14 years old seen in 6 surgeries with sore throat and 2 or more centor criteria pharyngotonsillar exudate tender laterocervical nodes absence of coughing and or history or presence of fever pharyngeal swabs were taken from all the patients one for rat and another to send for culture in the microbiology department a total of 182 patients were evaluable with a mean age of 30 6 12 1 years of which 116 were women 63 7 63 patients had 2 centor criteria 83 had 3 and 36 the 4 criteria the culture was positive in 102 patients 56 with gabhs showing infection in forty 22 95 confidence interval ci 21 2 22 8 group c streptococcus was isolated in 26 patients 14 3 gabhs was higher among patients with four centor criteria 38 9 vs 25 3 observed among those with 3 criteria and 7 9 with 2 criteria p 001 sensitivity of rat was 95 with a specificity of 93 a positive predictive value of 79 2 and a negative predictive value of 98 5 these results show the usefulness of rat for diagnosing streptococcal pharyngitis its use should be spread to all primary care practices.", "to determine the validity of the rapid antigen test rat osom strepa genzyme for the diagnosis of acute pharyngitis caused by group a beta haemolytic strep gabhs diagnostic techniques survey urban primary care centre spain all patients over 14 years old seen in 6 surgeries with sore throat and 2 or more centor criteria pharyngotonsillar exudate tender laterocervical nodes absence of coughing and or history or presence of fever pharyngeal swabs were taken from all the patients one for rat and another to send for culture in the microbiology department a total of 182 patients were evaluable with a mean age of 30 6 12 1 years of which 116 were women 63 7 63 patients had 2 centor criteria 83 had 3 and 36 the 4 criteria the culture was positive in 102 patients 56 with gabhs showing infection in forty 22 95 confidence interval ci 21 2 22 8 group c streptococcus was isolated in 26 patients 14 3 gabhs was higher among patients with four centor criteria 38 9 vs 25 3 observed among those with 3 criteria and 7 9 with 2 criteria p 001 sensitivity of rat was 95 with a specificity of 93 a positive predictive value of 79 2 and a negative predictive value of 98 5 these results show the usefulness of rat for diagnosing streptococcal pharyngitis its use should be spread to all primary care practices.", "to determine the validity of the rapid antigen test rat osom strepa genzyme for the diagnosis of acute pharyngitis caused by group a beta haemolytic strep gabhs diagnostic techniques survey urban primary care centre spain all patients over 14 years old seen in 6 surgeries with sore throat and 2 or more centor criteria pharyngotonsillar exudate tender laterocervical nodes absence of coughing and or history or presence of fever pharyngeal swabs were taken from all the patients one for rat and another to send for culture in the microbiology department a total of 182 patients were evaluable with a mean age of 30 6 12 1 years of which 116 were women 63 7 63 patients had 2 centor criteria 83 had 3 and 36 the 4 criteria the culture was positive in 102 patients 56 with gabhs showing infection in forty 22 95 confidence interval ci 21 2 22 8 group c streptococcus was isolated in 26 patients 14 3 gabhs was higher among patients with four centor criteria 38 9 vs 25 3 observed among those with 3 criteria and 7 9 with 2 criteria p 001 sensitivity of rat was 95 with a specificity of 93 a positive predictive value of 79 2 and a negative predictive value of 98 5 these results show the usefulness of rat for diagnosing streptococcal pharyngitis its use should be spread to all primary care practices.", "to determine the validity of the rapid antigen test rat osom strepa genzyme for the diagnosis of acute pharyngitis caused by group a beta haemolytic strep gabhs diagnostic techniques survey urban primary care centre spain all patients over 14 years old seen in 6 surgeries with sore throat and 2 or more centor criteria pharyngotonsillar exudate tender laterocervical nodes absence of coughing and or history or presence of fever pharyngeal swabs were taken from all the patients one for rat and another to send for culture in the microbiology department a total of 182 patients were evaluable with a mean age of 30 6 12 1 years of which 116 were women 63 7 63 patients had 2 centor criteria 83 had 3 and 36 the 4 criteria the culture was positive in 102 patients 56 with gabhs showing infection in forty 22 95 confidence interval ci 21 2 22 8 group c streptococcus was isolated in 26 patients 14 3 gabhs was higher among patients with four centor criteria 38 9 vs 25 3 observed among those with 3 criteria and 7 9 with 2 criteria p 001 sensitivity of rat was 95 with a specificity of 93 a positive predictive value of 79 2 and a negative predictive value of 98 5 these results show the usefulness of rat for diagnosing streptococcal pharyngitis its use should be spread to all primary care practices.", "objective. a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children. hypothesis. in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "objective. a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children. hypothesis. in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "objective. a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children. hypothesis. in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "objective. a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children. hypothesis. in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "objective. a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children. hypothesis. in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "objective. a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children. hypothesis. in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "objective. a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children. hypothesis. in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "objective. a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children. hypothesis. in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "objective. a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children. hypothesis. in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "objective. a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children. hypothesis. in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "objective. a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children. hypothesis. in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "objective. a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children. hypothesis. in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "objective. a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children. hypothesis. in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "objective. a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children. hypothesis. in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "objective. a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children. hypothesis. in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "objective. a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children. hypothesis. in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "objective. a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children. hypothesis. in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "objective. a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children. hypothesis. in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "objective. a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children. hypothesis. in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "objective. a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children. hypothesis. in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "objective. a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children. hypothesis. in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "objective. a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children. hypothesis. in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "objective. a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children. hypothesis. in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "objective. a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children. hypothesis. in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "objective. a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children. hypothesis. in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "objective. a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children. hypothesis. in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "objective. a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children. hypothesis. in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "objective. a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children. hypothesis. in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "objective. a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children. hypothesis. in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "objective. a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children. hypothesis. in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "objective. a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children. hypothesis. in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "objective. a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children. hypothesis. in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "objective. a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children. hypothesis. in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "objective. a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children. hypothesis. in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "objective. a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children. hypothesis. in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "objective. a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children. hypothesis. in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "objective. a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children. hypothesis. in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "objective. a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children. hypothesis. in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "objective. a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children. hypothesis. in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "objective. a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children. hypothesis. in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "objective. a study to determine if addition of palatal petechiae to centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children. hypothesis. in children, centor criteria does not cover all the symptoms and signs of acute strep pharyngitis. we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "main outcome measure the appropriateness of diagnosis of streptococcal pharyngitis according to the original and modified centor criteria and determinants of antibiotic dispensing including demographic characteristics of pharmacists, knowledge on pharyngitis, and attitudes and control beliefs on antibiotic dispensing.", "main outcome measure the appropriateness of diagnosis of streptococcal pharyngitis according to the original and modified centor criteria and determinants of antibiotic dispensing including demographic characteristics of pharmacists, knowledge on pharyngitis, and attitudes and control beliefs on antibiotic dispensing.", "main outcome measure the appropriateness of diagnosis of streptococcal pharyngitis according to the original and modified centor criteria and determinants of antibiotic dispensing including demographic characteristics of pharmacists, knowledge on pharyngitis, and attitudes and control beliefs on antibiotic dispensing.", "main outcome measure the appropriateness of diagnosis of streptococcal pharyngitis according to the original and modified centor criteria and determinants of antibiotic dispensing including demographic characteristics of pharmacists, knowledge on pharyngitis, and attitudes and control beliefs on antibiotic dispensing.", "main outcome measure the appropriateness of diagnosis of streptococcal pharyngitis according to the original and modified centor criteria and determinants of antibiotic dispensing including demographic characteristics of pharmacists, knowledge on pharyngitis, and attitudes and control beliefs on antibiotic dispensing.", "main outcome measure the appropriateness of diagnosis of streptococcal pharyngitis according to the original and modified centor criteria and determinants of antibiotic dispensing including demographic characteristics of pharmacists, knowledge on pharyngitis, and attitudes and control beliefs on antibiotic dispensing.", "main outcome measure the appropriateness of diagnosis of streptococcal pharyngitis according to the original and modified centor criteria and determinants of antibiotic dispensing including demographic characteristics of pharmacists, knowledge on pharyngitis, and attitudes and control beliefs on antibiotic dispensing.", "main outcome measure the appropriateness of diagnosis of streptococcal pharyngitis according to the original and modified centor criteria and determinants of antibiotic dispensing including demographic characteristics of pharmacists, knowledge on pharyngitis, and attitudes and control beliefs on antibiotic dispensing.", "main outcome measure the appropriateness of diagnosis of streptococcal pharyngitis according to the original and modified centor criteria and determinants of antibiotic dispensing including demographic characteristics of pharmacists, knowledge on pharyngitis, and attitudes and control beliefs on antibiotic dispensing.", "main outcome measure the appropriateness of diagnosis of streptococcal pharyngitis according to the original and modified centor criteria and determinants of antibiotic dispensing including demographic characteristics of pharmacists, knowledge on pharyngitis, and attitudes and control beliefs on antibiotic dispensing.", "main outcome measure the appropriateness of diagnosis of streptococcal pharyngitis according to the original and modified centor criteria and determinants of antibiotic dispensing including demographic characteristics of pharmacists, knowledge on pharyngitis, and attitudes and control beliefs on antibiotic dispensing.", "main outcome measure the appropriateness of diagnosis of streptococcal pharyngitis according to the original and modified centor criteria and determinants of antibiotic dispensing including demographic characteristics of pharmacists, knowledge on pharyngitis, and attitudes and control beliefs on antibiotic dispensing.", "main outcome measure the appropriateness of diagnosis of streptococcal pharyngitis according to the original and modified centor criteria and determinants of antibiotic dispensing including demographic characteristics of pharmacists, knowledge on pharyngitis, and attitudes and control beliefs on antibiotic dispensing.", "main outcome measure the appropriateness of diagnosis of streptococcal pharyngitis according to the original and modified centor criteria and determinants of antibiotic dispensing including demographic characteristics of pharmacists, knowledge on pharyngitis, and attitudes and control beliefs on antibiotic dispensing.", "main outcome measure the appropriateness of diagnosis of streptococcal pharyngitis according to the original and modified centor criteria and determinants of antibiotic dispensing including demographic characteristics of pharmacists, knowledge on pharyngitis, and attitudes and control beliefs on antibiotic dispensing.", "main outcome measure the appropriateness of diagnosis of streptococcal pharyngitis according to the original and modified centor criteria and determinants of antibiotic dispensing including demographic characteristics of pharmacists, knowledge on pharyngitis, and attitudes and control beliefs on antibiotic dispensing.", "main outcome measure the appropriateness of diagnosis of streptococcal pharyngitis according to the original and modified centor criteria and determinants of antibiotic dispensing including demographic characteristics of pharmacists, knowledge on pharyngitis, and attitudes and control beliefs on antibiotic dispensing.", "main outcome measure the appropriateness of diagnosis of streptococcal pharyngitis according to the original and modified centor criteria and determinants of antibiotic dispensing including demographic characteristics of pharmacists, knowledge on pharyngitis, and attitudes and control beliefs on antibiotic dispensing.", "main outcome measure the appropriateness of diagnosis of streptococcal pharyngitis according to the original and modified centor criteria and determinants of antibiotic dispensing including demographic characteristics of pharmacists, knowledge on pharyngitis, and attitudes and control beliefs on antibiotic dispensing.", "main outcome measure the appropriateness of diagnosis of streptococcal pharyngitis according to the original and modified centor criteria and determinants of antibiotic dispensing including demographic characteristics of pharmacists, knowledge on pharyngitis, and attitudes and control beliefs on antibiotic dispensing.", "main outcome measure the appropriateness of diagnosis of streptococcal pharyngitis according to the original and modified centor criteria and determinants of antibiotic dispensing including demographic characteristics of pharmacists, knowledge on pharyngitis, and attitudes and control beliefs on antibiotic dispensing.", "main outcome measure the appropriateness of diagnosis of streptococcal pharyngitis according to the original and modified centor criteria and determinants of antibiotic dispensing including demographic characteristics of pharmacists, knowledge on pharyngitis, and attitudes and control beliefs on antibiotic dispensing.", "main outcome measure the appropriateness of diagnosis of streptococcal pharyngitis according to the original and modified centor criteria and determinants of antibiotic dispensing including demographic characteristics of pharmacists, knowledge on pharyngitis, and attitudes and control beliefs on antibiotic dispensing.", "main outcome measure the appropriateness of diagnosis of streptococcal pharyngitis according to the original and modified centor criteria and determinants of antibiotic dispensing including demographic characteristics of pharmacists, knowledge on pharyngitis, and attitudes and control beliefs on antibiotic dispensing.", "main outcome measure the appropriateness of diagnosis of streptococcal pharyngitis according to the original and modified centor criteria and determinants of antibiotic dispensing including demographic characteristics of pharmacists, knowledge on pharyngitis, and attitudes and control beliefs on antibiotic dispensing.", "main outcome measure the appropriateness of diagnosis of streptococcal pharyngitis according to the original and modified centor criteria and determinants of antibiotic dispensing including demographic characteristics of pharmacists, knowledge on pharyngitis, and attitudes and control beliefs on antibiotic dispensing.", "main outcome measure the appropriateness of diagnosis of streptococcal pharyngitis according to the original and modified centor criteria and determinants of antibiotic dispensing including demographic characteristics of pharmacists, knowledge on pharyngitis, and attitudes and control beliefs on antibiotic dispensing.", "main outcome measure the appropriateness of diagnosis of streptococcal pharyngitis according to the original and modified centor criteria and determinants of antibiotic dispensing including demographic characteristics of pharmacists, knowledge on pharyngitis, and attitudes and control beliefs on antibiotic dispensing.", "main outcome measure the appropriateness of diagnosis of streptococcal pharyngitis according to the original and modified centor criteria and determinants of antibiotic dispensing including demographic characteristics of pharmacists, knowledge on pharyngitis, and attitudes and control beliefs on antibiotic dispensing.", "main outcome measure the appropriateness of diagnosis of streptococcal pharyngitis according to the original and modified centor criteria and determinants of antibiotic dispensing including demographic characteristics of pharmacists, knowledge on pharyngitis, and attitudes and control beliefs on antibiotic dispensing.", "main outcome measure the appropriateness of diagnosis of streptococcal pharyngitis according to the original and modified centor criteria and determinants of antibiotic dispensing including demographic characteristics of pharmacists, knowledge on pharyngitis, and attitudes and control beliefs on antibiotic dispensing.", "main outcome measure the appropriateness of diagnosis of streptococcal pharyngitis according to the original and modified centor criteria and determinants of antibiotic dispensing including demographic characteristics of pharmacists, knowledge on pharyngitis, and attitudes and control beliefs on antibiotic dispensing.", "main outcome measure the appropriateness of diagnosis of streptococcal pharyngitis according to the original and modified centor criteria and determinants of antibiotic dispensing including demographic characteristics of pharmacists, knowledge on pharyngitis, and attitudes and control beliefs on antibiotic dispensing.", "main outcome measure the appropriateness of diagnosis of streptococcal pharyngitis according to the original and modified centor criteria and determinants of antibiotic dispensing including demographic characteristics of pharmacists, knowledge on pharyngitis, and attitudes and control beliefs on antibiotic dispensing.", "main outcome measure the appropriateness of diagnosis of streptococcal pharyngitis according to the original and modified centor criteria and determinants of antibiotic dispensing including demographic characteristics of pharmacists, knowledge on pharyngitis, and attitudes and control beliefs on antibiotic dispensing.", "main outcome measure the appropriateness of diagnosis of streptococcal pharyngitis according to the original and modified centor criteria and determinants of antibiotic dispensing including demographic characteristics of pharmacists, knowledge on pharyngitis, and attitudes and control beliefs on antibiotic dispensing.", "main outcome measure the appropriateness of diagnosis of streptococcal pharyngitis according to the original and modified centor criteria and determinants of antibiotic dispensing including demographic characteristics of pharmacists, knowledge on pharyngitis, and attitudes and control beliefs on antibiotic dispensing.", "main outcome measure the appropriateness of diagnosis of streptococcal pharyngitis according to the original and modified centor criteria and determinants of antibiotic dispensing including demographic characteristics of pharmacists, knowledge on pharyngitis, and attitudes and control beliefs on antibiotic dispensing.", "main outcome measure the appropriateness of diagnosis of streptococcal pharyngitis according to the original and modified centor criteria and determinants of antibiotic dispensing including demographic characteristics of pharmacists, knowledge on pharyngitis, and attitudes and control beliefs on antibiotic dispensing.", "main outcome measure the appropriateness of diagnosis of streptococcal pharyngitis according to the original and modified centor criteria and determinants of antibiotic dispensing including demographic characteristics of pharmacists, knowledge on pharyngitis, and attitudes and control beliefs on antibiotic dispensing.", "main outcome measure the appropriateness of diagnosis of streptococcal pharyngitis according to the original and modified centor criteria and determinants of antibiotic dispensing including demographic characteristics of pharmacists, knowledge on pharyngitis, and attitudes and control beliefs on antibiotic dispensing.", "objective to ascertain the appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria and to identify factors related to antibiotic dispensing.", "objective to ascertain the appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria and to identify factors related to antibiotic dispensing.", "objective to ascertain the appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria and to identify factors related to antibiotic dispensing.", "objective to ascertain the appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria and to identify factors related to antibiotic dispensing.", "objective to ascertain the appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria and to identify factors related to antibiotic dispensing.", "objective to ascertain the appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria and to identify factors related to antibiotic dispensing.", "objective to ascertain the appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria and to identify factors related to antibiotic dispensing.", "objective to ascertain the appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria and to identify factors related to antibiotic dispensing.", "objective to ascertain the appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria and to identify factors related to antibiotic dispensing.", "objective to ascertain the appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria and to identify factors related to antibiotic dispensing.", "objective to ascertain the appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria and to identify factors related to antibiotic dispensing.", "objective to ascertain the appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria and to identify factors related to antibiotic dispensing.", "objective to ascertain the appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria and to identify factors related to antibiotic dispensing.", "objective to ascertain the appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria and to identify factors related to antibiotic dispensing.", "objective to ascertain the appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria and to identify factors related to antibiotic dispensing.", "objective to ascertain the appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria and to identify factors related to antibiotic dispensing.", "objective to ascertain the appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria and to identify factors related to antibiotic dispensing.", "objective to ascertain the appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria and to identify factors related to antibiotic dispensing.", "objective to ascertain the appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria and to identify factors related to antibiotic dispensing.", "objective to ascertain the appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria and to identify factors related to antibiotic dispensing.", "objective to ascertain the appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria and to identify factors related to antibiotic dispensing.", "objective to ascertain the appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria and to identify factors related to antibiotic dispensing.", "objective to ascertain the appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria and to identify factors related to antibiotic dispensing.", "objective to ascertain the appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria and to identify factors related to antibiotic dispensing.", "objective to ascertain the appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria and to identify factors related to antibiotic dispensing.", "objective to ascertain the appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria and to identify factors related to antibiotic dispensing.", "objective to ascertain the appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria and to identify factors related to antibiotic dispensing.", "objective to ascertain the appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria and to identify factors related to antibiotic dispensing.", "objective to ascertain the appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria and to identify factors related to antibiotic dispensing.", "objective to ascertain the appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria and to identify factors related to antibiotic dispensing.", "objective to ascertain the appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria and to identify factors related to antibiotic dispensing.", "objective to ascertain the appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria and to identify factors related to antibiotic dispensing.", "objective to ascertain the appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria and to identify factors related to antibiotic dispensing.", "objective to ascertain the appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria and to identify factors related to antibiotic dispensing.", "objective to ascertain the appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria and to identify factors related to antibiotic dispensing.", "objective to ascertain the appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria and to identify factors related to antibiotic dispensing.", "objective to ascertain the appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria and to identify factors related to antibiotic dispensing.", "objective to ascertain the appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria and to identify factors related to antibiotic dispensing.", "objective to ascertain the appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria and to identify factors related to antibiotic dispensing.", "objective to ascertain the appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria and to identify factors related to antibiotic dispensing.", "objective to ascertain the appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria and to identify factors related to antibiotic dispensing.", "conclusion. our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "conclusion. our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "conclusion. our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "conclusion. our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "conclusion. our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "conclusion. our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "conclusion. our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "conclusion. our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "conclusion. our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "conclusion. our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "conclusion. our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "conclusion. our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "conclusion. our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "conclusion. our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "conclusion. our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "conclusion. our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "conclusion. our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "conclusion. our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "conclusion. our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "conclusion. our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "conclusion. our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "conclusion. our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "conclusion. our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "conclusion. our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "conclusion. our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "conclusion. our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "conclusion. our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "conclusion. our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "conclusion. our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "conclusion. our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "conclusion. our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "conclusion. our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "conclusion. our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "conclusion. our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "conclusion. our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "conclusion. our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "conclusion. our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "conclusion. our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "conclusion. our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "conclusion. our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "conclusion. our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "conclusion pharmacists who are knowledgeable on the centor criteria are more likely to appropriately diagnose streptococcal pharyngitis and less likely to dispense antibiotics in such case.", "conclusion pharmacists who are knowledgeable on the centor criteria are more likely to appropriately diagnose streptococcal pharyngitis and less likely to dispense antibiotics in such case.", "conclusion pharmacists who are knowledgeable on the centor criteria are more likely to appropriately diagnose streptococcal pharyngitis and less likely to dispense antibiotics in such case.", "conclusion pharmacists who are knowledgeable on the centor criteria are more likely to appropriately diagnose streptococcal pharyngitis and less likely to dispense antibiotics in such case.", "conclusion pharmacists who are knowledgeable on the centor criteria are more likely to appropriately diagnose streptococcal pharyngitis and less likely to dispense antibiotics in such case.", "conclusion pharmacists who are knowledgeable on the centor criteria are more likely to appropriately diagnose streptococcal pharyngitis and less likely to dispense antibiotics in such case.", "conclusion pharmacists who are knowledgeable on the centor criteria are more likely to appropriately diagnose streptococcal pharyngitis and less likely to dispense antibiotics in such case.", "conclusion pharmacists who are knowledgeable on the centor criteria are more likely to appropriately diagnose streptococcal pharyngitis and less likely to dispense antibiotics in such case.", "conclusion pharmacists who are knowledgeable on the centor criteria are more likely to appropriately diagnose streptococcal pharyngitis and less likely to dispense antibiotics in such case.", "conclusion pharmacists who are knowledgeable on the centor criteria are more likely to appropriately diagnose streptococcal pharyngitis and less likely to dispense antibiotics in such case.", "conclusion pharmacists who are knowledgeable on the centor criteria are more likely to appropriately diagnose streptococcal pharyngitis and less likely to dispense antibiotics in such case.", "conclusion pharmacists who are knowledgeable on the centor criteria are more likely to appropriately diagnose streptococcal pharyngitis and less likely to dispense antibiotics in such case.", "conclusion pharmacists who are knowledgeable on the centor criteria are more likely to appropriately diagnose streptococcal pharyngitis and less likely to dispense antibiotics in such case.", "conclusion pharmacists who are knowledgeable on the centor criteria are more likely to appropriately diagnose streptococcal pharyngitis and less likely to dispense antibiotics in such case.", "conclusion pharmacists who are knowledgeable on the centor criteria are more likely to appropriately diagnose streptococcal pharyngitis and less likely to dispense antibiotics in such case.", "conclusion pharmacists who are knowledgeable on the centor criteria are more likely to appropriately diagnose streptococcal pharyngitis and less likely to dispense antibiotics in such case.", "conclusion pharmacists who are knowledgeable on the centor criteria are more likely to appropriately diagnose streptococcal pharyngitis and less likely to dispense antibiotics in such case.", "conclusion pharmacists who are knowledgeable on the centor criteria are more likely to appropriately diagnose streptococcal pharyngitis and less likely to dispense antibiotics in such case.", "conclusion pharmacists who are knowledgeable on the centor criteria are more likely to appropriately diagnose streptococcal pharyngitis and less likely to dispense antibiotics in such case.", "conclusion pharmacists who are knowledgeable on the centor criteria are more likely to appropriately diagnose streptococcal pharyngitis and less likely to dispense antibiotics in such case.", "conclusion pharmacists who are knowledgeable on the centor criteria are more likely to appropriately diagnose streptococcal pharyngitis and less likely to dispense antibiotics in such case.", "conclusion pharmacists who are knowledgeable on the centor criteria are more likely to appropriately diagnose streptococcal pharyngitis and less likely to dispense antibiotics in such case.", "conclusion pharmacists who are knowledgeable on the centor criteria are more likely to appropriately diagnose streptococcal pharyngitis and less likely to dispense antibiotics in such case.", "conclusion pharmacists who are knowledgeable on the centor criteria are more likely to appropriately diagnose streptococcal pharyngitis and less likely to dispense antibiotics in such case.", "conclusion pharmacists who are knowledgeable on the centor criteria are more likely to appropriately diagnose streptococcal pharyngitis and less likely to dispense antibiotics in such case.", "conclusion pharmacists who are knowledgeable on the centor criteria are more likely to appropriately diagnose streptococcal pharyngitis and less likely to dispense antibiotics in such case.", "conclusion pharmacists who are knowledgeable on the centor criteria are more likely to appropriately diagnose streptococcal pharyngitis and less likely to dispense antibiotics in such case.", "conclusion pharmacists who are knowledgeable on the centor criteria are more likely to appropriately diagnose streptococcal pharyngitis and less likely to dispense antibiotics in such case.", "conclusion pharmacists who are knowledgeable on the centor criteria are more likely to appropriately diagnose streptococcal pharyngitis and less likely to dispense antibiotics in such case.", "conclusion pharmacists who are knowledgeable on the centor criteria are more likely to appropriately diagnose streptococcal pharyngitis and less likely to dispense antibiotics in such case.", "conclusion pharmacists who are knowledgeable on the centor criteria are more likely to appropriately diagnose streptococcal pharyngitis and less likely to dispense antibiotics in such case.", "conclusion pharmacists who are knowledgeable on the centor criteria are more likely to appropriately diagnose streptococcal pharyngitis and less likely to dispense antibiotics in such case.", "conclusion pharmacists who are knowledgeable on the centor criteria are more likely to appropriately diagnose streptococcal pharyngitis and less likely to dispense antibiotics in such case.", "conclusion pharmacists who are knowledgeable on the centor criteria are more likely to appropriately diagnose streptococcal pharyngitis and less likely to dispense antibiotics in such case.", "conclusion pharmacists who are knowledgeable on the centor criteria are more likely to appropriately diagnose streptococcal pharyngitis and less likely to dispense antibiotics in such case.", "conclusion pharmacists who are knowledgeable on the centor criteria are more likely to appropriately diagnose streptococcal pharyngitis and less likely to dispense antibiotics in such case.", "conclusion pharmacists who are knowledgeable on the centor criteria are more likely to appropriately diagnose streptococcal pharyngitis and less likely to dispense antibiotics in such case.", "conclusion pharmacists who are knowledgeable on the centor criteria are more likely to appropriately diagnose streptococcal pharyngitis and less likely to dispense antibiotics in such case.", "conclusion pharmacists who are knowledgeable on the centor criteria are more likely to appropriately diagnose streptococcal pharyngitis and less likely to dispense antibiotics in such case.", "conclusion pharmacists who are knowledgeable on the centor criteria are more likely to appropriately diagnose streptococcal pharyngitis and less likely to dispense antibiotics in such case.", "conclusion pharmacists who are knowledgeable on the centor criteria are more likely to appropriately diagnose streptococcal pharyngitis and less likely to dispense antibiotics in such case.", "our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "our study concludes that addition of petechiae over the palate to centor criteria will increase the possibility of diagnosing acute group a streptococcal pharyngitis in children.", "we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "we hypothesize that addition of palatal petechiae to centor criteria will increase the possibility of clinical diagnosis of group a streptococcal pharyngitis in children.", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria.", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria.", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria.", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria.", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria.", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria.", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria.", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria.", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria.", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria.", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria.", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria.", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria.", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria.", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria.", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria.", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria.", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria.", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria.", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria.", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria.", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria.", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria.", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria.", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria.", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria.", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria.", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria.", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria.", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria.", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria.", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria.", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria.", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria.", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria.", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria.", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria.", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria.", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria.", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria.", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria.", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria", "appropriateness of diagnosis of streptococcal pharyngitis among thai community pharmacists according to the centor criteria", "supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-v sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant).", "supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-v sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant).", "supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-v sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant).", "supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-v sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant).", "supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-v sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant).", "supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-v sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant).", "supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-v sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant).", "supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-v sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant).", "supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-v sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant).", "supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-v sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant).", "supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-v sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant).", "supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-v sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant).", "supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-v sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant).", "supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-v sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant).", "supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-v sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant).", "supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-v sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant).", "supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-v sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant).", "supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-v sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant).", "supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-v sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant).", "supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-v sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant).", "supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-v sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant).", "supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-v sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant).", "supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-v sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant).", "supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-v sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant).", "supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-v sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant).", "supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-v sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant).", "supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-v sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant).", "supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-v sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant).", "supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-v sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant).", "supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-v sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant).", "supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-v sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant).", "supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-v sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant).", "supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-v sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant).", "supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-v sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant).", "supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-v sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant).", "supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-v sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant).", "supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-v sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant).", "supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-v sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant).", "supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-v sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant).", "supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-v sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant).", "supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-v sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant).", "supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-v sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant).", "supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-v sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant).", "supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-v sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant).", "supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-v sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant).", "supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-v sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant).", "supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-v sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant).", "supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-v sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant).", "supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-v sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant).", "to evaluate the usefulness of the ppfa sign, we compared the ppfa sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known ct signs of pneumoperitoneum.", "to evaluate the usefulness of the ppfa sign, we compared the ppfa sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known ct signs of pneumoperitoneum.", "to evaluate the usefulness of the ppfa sign, we compared the ppfa sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known ct signs of pneumoperitoneum.", "to evaluate the usefulness of the ppfa sign, we compared the ppfa sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known ct signs of pneumoperitoneum.", "to evaluate the usefulness of the ppfa sign, we compared the ppfa sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known ct signs of pneumoperitoneum.", "to evaluate the usefulness of the ppfa sign, we compared the ppfa sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known ct signs of pneumoperitoneum.", "to evaluate the usefulness of the ppfa sign, we compared the ppfa sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known ct signs of pneumoperitoneum.", "to evaluate the usefulness of the ppfa sign, we compared the ppfa sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known ct signs of pneumoperitoneum.", "to evaluate the usefulness of the ppfa sign, we compared the ppfa sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known ct signs of pneumoperitoneum.", "to evaluate the usefulness of the ppfa sign, we compared the ppfa sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known ct signs of pneumoperitoneum.", "to evaluate the usefulness of the ppfa sign, we compared the ppfa sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known ct signs of pneumoperitoneum.", "to evaluate the usefulness of the ppfa sign, we compared the ppfa sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known ct signs of pneumoperitoneum.", "to evaluate the usefulness of the ppfa sign, we compared the ppfa sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known ct signs of pneumoperitoneum.", "to evaluate the usefulness of the ppfa sign, we compared the ppfa sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known ct signs of pneumoperitoneum.", "to evaluate the usefulness of the ppfa sign, we compared the ppfa sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known ct signs of pneumoperitoneum.", "to evaluate the usefulness of the ppfa sign, we compared the ppfa sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known ct signs of pneumoperitoneum.", "to evaluate the usefulness of the ppfa sign, we compared the ppfa sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known ct signs of pneumoperitoneum.", "to evaluate the usefulness of the ppfa sign, we compared the ppfa sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known ct signs of pneumoperitoneum.", "to evaluate the usefulness of the ppfa sign, we compared the ppfa sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known ct signs of pneumoperitoneum.", "to evaluate the usefulness of the ppfa sign, we compared the ppfa sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known ct signs of pneumoperitoneum.", "to evaluate the usefulness of the ppfa sign, we compared the ppfa sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known ct signs of pneumoperitoneum.", "to evaluate the usefulness of the ppfa sign, we compared the ppfa sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known ct signs of pneumoperitoneum.", "to evaluate the usefulness of the ppfa sign, we compared the ppfa sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known ct signs of pneumoperitoneum.", "to evaluate the usefulness of the ppfa sign, we compared the ppfa sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known ct signs of pneumoperitoneum.", "to evaluate the usefulness of the ppfa sign, we compared the ppfa sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known ct signs of pneumoperitoneum.", "to evaluate the usefulness of the ppfa sign, we compared the ppfa sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known ct signs of pneumoperitoneum.", "to evaluate the usefulness of the ppfa sign, we compared the ppfa sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known ct signs of pneumoperitoneum.", "to evaluate the usefulness of the ppfa sign, we compared the ppfa sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known ct signs of pneumoperitoneum.", "to evaluate the usefulness of the ppfa sign, we compared the ppfa sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known ct signs of pneumoperitoneum.", "to evaluate the usefulness of the ppfa sign, we compared the ppfa sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known ct signs of pneumoperitoneum.", "to evaluate the usefulness of the ppfa sign, we compared the ppfa sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known ct signs of pneumoperitoneum.", "to evaluate the usefulness of the ppfa sign, we compared the ppfa sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known ct signs of pneumoperitoneum.", "to evaluate the usefulness of the ppfa sign, we compared the ppfa sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known ct signs of pneumoperitoneum.", "to evaluate the usefulness of the ppfa sign, we compared the ppfa sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known ct signs of pneumoperitoneum.", "to evaluate the usefulness of the ppfa sign, we compared the ppfa sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known ct signs of pneumoperitoneum.", "to evaluate the usefulness of the ppfa sign, we compared the ppfa sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known ct signs of pneumoperitoneum.", "to evaluate the usefulness of the ppfa sign, we compared the ppfa sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known ct signs of pneumoperitoneum.", "to evaluate the usefulness of the ppfa sign, we compared the ppfa sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known ct signs of pneumoperitoneum.", "to evaluate the usefulness of the ppfa sign, we compared the ppfa sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known ct signs of pneumoperitoneum.", "to evaluate the usefulness of the ppfa sign, we compared the ppfa sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known ct signs of pneumoperitoneum.", "to evaluate the usefulness of the ppfa sign, we compared the ppfa sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known ct signs of pneumoperitoneum.", "to evaluate the usefulness of the ppfa sign, we compared the ppfa sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known ct signs of pneumoperitoneum.", "to evaluate the usefulness of the ppfa sign, we compared the ppfa sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known ct signs of pneumoperitoneum.", "to evaluate the usefulness of the ppfa sign, we compared the ppfa sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known ct signs of pneumoperitoneum.", "to evaluate the usefulness of the ppfa sign, we compared the ppfa sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known ct signs of pneumoperitoneum.", "to evaluate the usefulness of the ppfa sign, we compared the ppfa sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known ct signs of pneumoperitoneum.", "to evaluate the usefulness of the ppfa sign, we compared the ppfa sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known ct signs of pneumoperitoneum.", "to evaluate the usefulness of the ppfa sign, we compared the ppfa sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known ct signs of pneumoperitoneum.", "to evaluate the usefulness of the ppfa sign, we compared the ppfa sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known ct signs of pneumoperitoneum.", "aberrant alk activity has been implicated in the oncogenesis of human cancers as a fusion protein in anaplastic large cell lymphoma, inflammatory myofibroblastic tumor, diffuse large b-cell lymphoma, systemic histiocytosis and nsclc or through mutations in the full length protein in hereditary familial neuroblastoma.", "aberrant alk activity has been implicated in the oncogenesis of human cancers as a fusion protein in anaplastic large cell lymphoma, inflammatory myofibroblastic tumor, diffuse large b-cell lymphoma, systemic histiocytosis and nsclc or through mutations in the full length protein in hereditary familial neuroblastoma.", "aberrant alk activity has been implicated in the oncogenesis of human cancers as a fusion protein in anaplastic large cell lymphoma, inflammatory myofibroblastic tumor, diffuse large b-cell lymphoma, systemic histiocytosis and nsclc or through mutations in the full length protein in hereditary familial neuroblastoma.", "aberrant alk activity has been implicated in the oncogenesis of human cancers as a fusion protein in anaplastic large cell lymphoma, inflammatory myofibroblastic tumor, diffuse large b-cell lymphoma, systemic histiocytosis and nsclc or through mutations in the full length protein in hereditary familial neuroblastoma.", "aberrant alk activity has been implicated in the oncogenesis of human cancers as a fusion protein in anaplastic large cell lymphoma, inflammatory myofibroblastic tumor, diffuse large b-cell lymphoma, systemic histiocytosis and nsclc or through mutations in the full length protein in hereditary familial neuroblastoma.", "aberrant alk activity has been implicated in the oncogenesis of human cancers as a fusion protein in anaplastic large cell lymphoma, inflammatory myofibroblastic tumor, diffuse large b-cell lymphoma, systemic histiocytosis and nsclc or through mutations in the full length protein in hereditary familial neuroblastoma.", "aberrant alk activity has been implicated in the oncogenesis of human cancers as a fusion protein in anaplastic large cell lymphoma, inflammatory myofibroblastic tumor, diffuse large b-cell lymphoma, systemic histiocytosis and nsclc or through mutations in the full length protein in hereditary familial neuroblastoma.", "aberrant alk activity has been implicated in the oncogenesis of human cancers as a fusion protein in anaplastic large cell lymphoma, inflammatory myofibroblastic tumor, diffuse large b-cell lymphoma, systemic histiocytosis and nsclc or through mutations in the full length protein in hereditary familial neuroblastoma.", "aberrant alk activity has been implicated in the oncogenesis of human cancers as a fusion protein in anaplastic large cell lymphoma, inflammatory myofibroblastic tumor, diffuse large b-cell lymphoma, systemic histiocytosis and nsclc or through mutations in the full length protein in hereditary familial neuroblastoma.", "aberrant alk activity has been implicated in the oncogenesis of human cancers as a fusion protein in anaplastic large cell lymphoma, inflammatory myofibroblastic tumor, diffuse large b-cell lymphoma, systemic histiocytosis and nsclc or through mutations in the full length protein in hereditary familial neuroblastoma.", "aberrant alk activity has been implicated in the oncogenesis of human cancers as a fusion protein in anaplastic large cell lymphoma, inflammatory myofibroblastic tumor, diffuse large b-cell lymphoma, systemic histiocytosis and nsclc or through mutations in the full length protein in hereditary familial neuroblastoma.", "aberrant alk activity has been implicated in the oncogenesis of human cancers as a fusion protein in anaplastic large cell lymphoma, inflammatory myofibroblastic tumor, diffuse large b-cell lymphoma, systemic histiocytosis and nsclc or through mutations in the full length protein in hereditary familial neuroblastoma.", "aberrant alk activity has been implicated in the oncogenesis of human cancers as a fusion protein in anaplastic large cell lymphoma, inflammatory myofibroblastic tumor, diffuse large b-cell lymphoma, systemic histiocytosis and nsclc or through mutations in the full length protein in hereditary familial neuroblastoma.", "aberrant alk activity has been implicated in the oncogenesis of human cancers as a fusion protein in anaplastic large cell lymphoma, inflammatory myofibroblastic tumor, diffuse large b-cell lymphoma, systemic histiocytosis and nsclc or through mutations in the full length protein in hereditary familial neuroblastoma.", "aberrant alk activity has been implicated in the oncogenesis of human cancers as a fusion protein in anaplastic large cell lymphoma, inflammatory myofibroblastic tumor, diffuse large b-cell lymphoma, systemic histiocytosis and nsclc or through mutations in the full length protein in hereditary familial neuroblastoma.", "aberrant alk activity has been implicated in the oncogenesis of human cancers as a fusion protein in anaplastic large cell lymphoma, inflammatory myofibroblastic tumor, diffuse large b-cell lymphoma, systemic histiocytosis and nsclc or through mutations in the full length protein in hereditary familial neuroblastoma.", "aberrant alk activity has been implicated in the oncogenesis of human cancers as a fusion protein in anaplastic large cell lymphoma, inflammatory myofibroblastic tumor, diffuse large b-cell lymphoma, systemic histiocytosis and nsclc or through mutations in the full length protein in hereditary familial neuroblastoma.", "background the translocations of the anaplastic lymphoma kinase (alk) gene with the echinoderm microtubule-associated protein-like 4 (eml4) gene on chromosome 2p have been identified in non-small-cell lung cancers (nsclcs) as oncogenic driver mutations.", "background the translocations of the anaplastic lymphoma kinase (alk) gene with the echinoderm microtubule-associated protein-like 4 (eml4) gene on chromosome 2p have been identified in non-small-cell lung cancers (nsclcs) as oncogenic driver mutations.", "background the translocations of the anaplastic lymphoma kinase (alk) gene with the echinoderm microtubule-associated protein-like 4 (eml4) gene on chromosome 2p have been identified in non-small-cell lung cancers (nsclcs) as oncogenic driver mutations.", "background the translocations of the anaplastic lymphoma kinase (alk) gene with the echinoderm microtubule-associated protein-like 4 (eml4) gene on chromosome 2p have been identified in non-small-cell lung cancers (nsclcs) as oncogenic driver mutations.", "background the translocations of the anaplastic lymphoma kinase (alk) gene with the echinoderm microtubule-associated protein-like 4 (eml4) gene on chromosome 2p have been identified in non-small-cell lung cancers (nsclcs) as oncogenic driver mutations.", "background the translocations of the anaplastic lymphoma kinase (alk) gene with the echinoderm microtubule-associated protein-like 4 (eml4) gene on chromosome 2p have been identified in non-small-cell lung cancers (nsclcs) as oncogenic driver mutations.", "background the translocations of the anaplastic lymphoma kinase (alk) gene with the echinoderm microtubule-associated protein-like 4 (eml4) gene on chromosome 2p have been identified in non-small-cell lung cancers (nsclcs) as oncogenic driver mutations.", "background the translocations of the anaplastic lymphoma kinase (alk) gene with the echinoderm microtubule-associated protein-like 4 (eml4) gene on chromosome 2p have been identified in non-small-cell lung cancers (nsclcs) as oncogenic driver mutations.", "background the translocations of the anaplastic lymphoma kinase (alk) gene with the echinoderm microtubule-associated protein-like 4 (eml4) gene on chromosome 2p have been identified in non-small-cell lung cancers (nsclcs) as oncogenic driver mutations.", "background the translocations of the anaplastic lymphoma kinase (alk) gene with the echinoderm microtubule-associated protein-like 4 (eml4) gene on chromosome 2p have been identified in non-small-cell lung cancers (nsclcs) as oncogenic driver mutations.", "background the translocations of the anaplastic lymphoma kinase (alk) gene with the echinoderm microtubule-associated protein-like 4 (eml4) gene on chromosome 2p have been identified in non-small-cell lung cancers (nsclcs) as oncogenic driver mutations.", "background the translocations of the anaplastic lymphoma kinase (alk) gene with the echinoderm microtubule-associated protein-like 4 (eml4) gene on chromosome 2p have been identified in non-small-cell lung cancers (nsclcs) as oncogenic driver mutations.", "background the translocations of the anaplastic lymphoma kinase (alk) gene with the echinoderm microtubule-associated protein-like 4 (eml4) gene on chromosome 2p have been identified in non-small-cell lung cancers (nsclcs) as oncogenic driver mutations.", "background the translocations of the anaplastic lymphoma kinase (alk) gene with the echinoderm microtubule-associated protein-like 4 (eml4) gene on chromosome 2p have been identified in non-small-cell lung cancers (nsclcs) as oncogenic driver mutations.", "background the translocations of the anaplastic lymphoma kinase (alk) gene with the echinoderm microtubule-associated protein-like 4 (eml4) gene on chromosome 2p have been identified in non-small-cell lung cancers (nsclcs) as oncogenic driver mutations.", "background the translocations of the anaplastic lymphoma kinase (alk) gene with the echinoderm microtubule-associated protein-like 4 (eml4) gene on chromosome 2p have been identified in non-small-cell lung cancers (nsclcs) as oncogenic driver mutations.", "background the translocations of the anaplastic lymphoma kinase (alk) gene with the echinoderm microtubule-associated protein-like 4 (eml4) gene on chromosome 2p have been identified in non-small-cell lung cancers (nsclcs) as oncogenic driver mutations.", "chromosomal rearrangements involving the tyrosine kinase anaplastic lymphoma kinase (alk) occur in a variety of human malignancies including non-small cell lung cancer (nsclc), anaplastic large cell lymphomas, and inflammatory myofibroblastic tumors.", "chromosomal rearrangements involving the tyrosine kinase anaplastic lymphoma kinase (alk) occur in a variety of human malignancies including non-small cell lung cancer (nsclc), anaplastic large cell lymphomas, and inflammatory myofibroblastic tumors.", "chromosomal rearrangements involving the tyrosine kinase anaplastic lymphoma kinase (alk) occur in a variety of human malignancies including non-small cell lung cancer (nsclc), anaplastic large cell lymphomas, and inflammatory myofibroblastic tumors.", "chromosomal rearrangements involving the tyrosine kinase anaplastic lymphoma kinase (alk) occur in a variety of human malignancies including non-small cell lung cancer (nsclc), anaplastic large cell lymphomas, and inflammatory myofibroblastic tumors.", "chromosomal rearrangements involving the tyrosine kinase anaplastic lymphoma kinase (alk) occur in a variety of human malignancies including non-small cell lung cancer (nsclc), anaplastic large cell lymphomas, and inflammatory myofibroblastic tumors.", "chromosomal rearrangements involving the tyrosine kinase anaplastic lymphoma kinase (alk) occur in a variety of human malignancies including non-small cell lung cancer (nsclc), anaplastic large cell lymphomas, and inflammatory myofibroblastic tumors.", "chromosomal rearrangements involving the tyrosine kinase anaplastic lymphoma kinase (alk) occur in a variety of human malignancies including non-small cell lung cancer (nsclc), anaplastic large cell lymphomas, and inflammatory myofibroblastic tumors.", "chromosomal rearrangements involving the tyrosine kinase anaplastic lymphoma kinase (alk) occur in a variety of human malignancies including non-small cell lung cancer (nsclc), anaplastic large cell lymphomas, and inflammatory myofibroblastic tumors.", "chromosomal rearrangements involving the tyrosine kinase anaplastic lymphoma kinase (alk) occur in a variety of human malignancies including non-small cell lung cancer (nsclc), anaplastic large cell lymphomas, and inflammatory myofibroblastic tumors.", "chromosomal rearrangements involving the tyrosine kinase anaplastic lymphoma kinase (alk) occur in a variety of human malignancies including non-small cell lung cancer (nsclc), anaplastic large cell lymphomas, and inflammatory myofibroblastic tumors.", "chromosomal rearrangements involving the tyrosine kinase anaplastic lymphoma kinase (alk) occur in a variety of human malignancies including non-small cell lung cancer (nsclc), anaplastic large cell lymphomas, and inflammatory myofibroblastic tumors.", "chromosomal rearrangements involving the tyrosine kinase anaplastic lymphoma kinase (alk) occur in a variety of human malignancies including non-small cell lung cancer (nsclc), anaplastic large cell lymphomas, and inflammatory myofibroblastic tumors.", "chromosomal rearrangements involving the tyrosine kinase anaplastic lymphoma kinase (alk) occur in a variety of human malignancies including non-small cell lung cancer (nsclc), anaplastic large cell lymphomas, and inflammatory myofibroblastic tumors.", "chromosomal rearrangements involving the tyrosine kinase anaplastic lymphoma kinase (alk) occur in a variety of human malignancies including non-small cell lung cancer (nsclc), anaplastic large cell lymphomas, and inflammatory myofibroblastic tumors.", "chromosomal rearrangements involving the tyrosine kinase anaplastic lymphoma kinase (alk) occur in a variety of human malignancies including non-small cell lung cancer (nsclc), anaplastic large cell lymphomas, and inflammatory myofibroblastic tumors.", "chromosomal rearrangements involving the tyrosine kinase anaplastic lymphoma kinase (alk) occur in a variety of human malignancies including non-small cell lung cancer (nsclc), anaplastic large cell lymphomas, and inflammatory myofibroblastic tumors.", "chromosomal rearrangements involving the tyrosine kinase anaplastic lymphoma kinase (alk) occur in a variety of human malignancies including non-small cell lung cancer (nsclc), anaplastic large cell lymphomas, and inflammatory myofibroblastic tumors.", "rearrangements of the anaplastic lymphoma kinase (alk) gene originally discovered nearly 20 years ago in the context of anaplastic large cell lymphoma were identified as oncogenic drivers in a subset of non-small cell lung cancers (nsclcs) in 2007.", "rearrangements of the anaplastic lymphoma kinase (alk) gene originally discovered nearly 20 years ago in the context of anaplastic large cell lymphoma were identified as oncogenic drivers in a subset of non-small cell lung cancers (nsclcs) in 2007.", "rearrangements of the anaplastic lymphoma kinase (alk) gene originally discovered nearly 20 years ago in the context of anaplastic large cell lymphoma were identified as oncogenic drivers in a subset of non-small cell lung cancers (nsclcs) in 2007.", "rearrangements of the anaplastic lymphoma kinase (alk) gene originally discovered nearly 20 years ago in the context of anaplastic large cell lymphoma were identified as oncogenic drivers in a subset of non-small cell lung cancers (nsclcs) in 2007.", "rearrangements of the anaplastic lymphoma kinase (alk) gene originally discovered nearly 20 years ago in the context of anaplastic large cell lymphoma were identified as oncogenic drivers in a subset of non-small cell lung cancers (nsclcs) in 2007.", "rearrangements of the anaplastic lymphoma kinase (alk) gene originally discovered nearly 20 years ago in the context of anaplastic large cell lymphoma were identified as oncogenic drivers in a subset of non-small cell lung cancers (nsclcs) in 2007.", "rearrangements of the anaplastic lymphoma kinase (alk) gene originally discovered nearly 20 years ago in the context of anaplastic large cell lymphoma were identified as oncogenic drivers in a subset of non-small cell lung cancers (nsclcs) in 2007.", "rearrangements of the anaplastic lymphoma kinase (alk) gene originally discovered nearly 20 years ago in the context of anaplastic large cell lymphoma were identified as oncogenic drivers in a subset of non-small cell lung cancers (nsclcs) in 2007.", "rearrangements of the anaplastic lymphoma kinase (alk) gene originally discovered nearly 20 years ago in the context of anaplastic large cell lymphoma were identified as oncogenic drivers in a subset of non-small cell lung cancers (nsclcs) in 2007.", "rearrangements of the anaplastic lymphoma kinase (alk) gene originally discovered nearly 20 years ago in the context of anaplastic large cell lymphoma were identified as oncogenic drivers in a subset of non-small cell lung cancers (nsclcs) in 2007.", "rearrangements of the anaplastic lymphoma kinase (alk) gene originally discovered nearly 20 years ago in the context of anaplastic large cell lymphoma were identified as oncogenic drivers in a subset of non-small cell lung cancers (nsclcs) in 2007.", "rearrangements of the anaplastic lymphoma kinase (alk) gene originally discovered nearly 20 years ago in the context of anaplastic large cell lymphoma were identified as oncogenic drivers in a subset of non-small cell lung cancers (nsclcs) in 2007.", "rearrangements of the anaplastic lymphoma kinase (alk) gene originally discovered nearly 20 years ago in the context of anaplastic large cell lymphoma were identified as oncogenic drivers in a subset of non-small cell lung cancers (nsclcs) in 2007.", "rearrangements of the anaplastic lymphoma kinase (alk) gene originally discovered nearly 20 years ago in the context of anaplastic large cell lymphoma were identified as oncogenic drivers in a subset of non-small cell lung cancers (nsclcs) in 2007.", "rearrangements of the anaplastic lymphoma kinase (alk) gene originally discovered nearly 20 years ago in the context of anaplastic large cell lymphoma were identified as oncogenic drivers in a subset of non-small cell lung cancers (nsclcs) in 2007.", "rearrangements of the anaplastic lymphoma kinase (alk) gene originally discovered nearly 20 years ago in the context of anaplastic large cell lymphoma were identified as oncogenic drivers in a subset of non-small cell lung cancers (nsclcs) in 2007.", "rearrangements of the anaplastic lymphoma kinase (alk) gene originally discovered nearly 20 years ago in the context of anaplastic large cell lymphoma were identified as oncogenic drivers in a subset of non-small cell lung cancers (nsclcs) in 2007.", "genetic rearrangements involving the tyrosine kinase anaplastic lymphoma kinase (alk) gene occur in non-small cell lung cancer (nsclc), anaplastic large cell lymphomoas, inflammatory myofibroblastic tumors, and other cancers.", "genetic rearrangements involving the tyrosine kinase anaplastic lymphoma kinase (alk) gene occur in non-small cell lung cancer (nsclc), anaplastic large cell lymphomoas, inflammatory myofibroblastic tumors, and other cancers.", "genetic rearrangements involving the tyrosine kinase anaplastic lymphoma kinase (alk) gene occur in non-small cell lung cancer (nsclc), anaplastic large cell lymphomoas, inflammatory myofibroblastic tumors, and other cancers.", "genetic rearrangements involving the tyrosine kinase anaplastic lymphoma kinase (alk) gene occur in non-small cell lung cancer (nsclc), anaplastic large cell lymphomoas, inflammatory myofibroblastic tumors, and other cancers.", "genetic rearrangements involving the tyrosine kinase anaplastic lymphoma kinase (alk) gene occur in non-small cell lung cancer (nsclc), anaplastic large cell lymphomoas, inflammatory myofibroblastic tumors, and other cancers.", "genetic rearrangements involving the tyrosine kinase anaplastic lymphoma kinase (alk) gene occur in non-small cell lung cancer (nsclc), anaplastic large cell lymphomoas, inflammatory myofibroblastic tumors, and other cancers.", "genetic rearrangements involving the tyrosine kinase anaplastic lymphoma kinase (alk) gene occur in non-small cell lung cancer (nsclc), anaplastic large cell lymphomoas, inflammatory myofibroblastic tumors, and other cancers.", "genetic rearrangements involving the tyrosine kinase anaplastic lymphoma kinase (alk) gene occur in non-small cell lung cancer (nsclc), anaplastic large cell lymphomoas, inflammatory myofibroblastic tumors, and other cancers.", "genetic rearrangements involving the tyrosine kinase anaplastic lymphoma kinase (alk) gene occur in non-small cell lung cancer (nsclc), anaplastic large cell lymphomoas, inflammatory myofibroblastic tumors, and other cancers.", "genetic rearrangements involving the tyrosine kinase anaplastic lymphoma kinase (alk) gene occur in non-small cell lung cancer (nsclc), anaplastic large cell lymphomoas, inflammatory myofibroblastic tumors, and other cancers.", "genetic rearrangements involving the tyrosine kinase anaplastic lymphoma kinase (alk) gene occur in non-small cell lung cancer (nsclc), anaplastic large cell lymphomoas, inflammatory myofibroblastic tumors, and other cancers.", "genetic rearrangements involving the tyrosine kinase anaplastic lymphoma kinase (alk) gene occur in non-small cell lung cancer (nsclc), anaplastic large cell lymphomoas, inflammatory myofibroblastic tumors, and other cancers.", "genetic rearrangements involving the tyrosine kinase anaplastic lymphoma kinase (alk) gene occur in non-small cell lung cancer (nsclc), anaplastic large cell lymphomoas, inflammatory myofibroblastic tumors, and other cancers.", "genetic rearrangements involving the tyrosine kinase anaplastic lymphoma kinase (alk) gene occur in non-small cell lung cancer (nsclc), anaplastic large cell lymphomoas, inflammatory myofibroblastic tumors, and other cancers.", "genetic rearrangements involving the tyrosine kinase anaplastic lymphoma kinase (alk) gene occur in non-small cell lung cancer (nsclc), anaplastic large cell lymphomoas, inflammatory myofibroblastic tumors, and other cancers.", "genetic rearrangements involving the tyrosine kinase anaplastic lymphoma kinase (alk) gene occur in non-small cell lung cancer (nsclc), anaplastic large cell lymphomoas, inflammatory myofibroblastic tumors, and other cancers.", "genetic rearrangements involving the tyrosine kinase anaplastic lymphoma kinase (alk) gene occur in non-small cell lung cancer (nsclc), anaplastic large cell lymphomoas, inflammatory myofibroblastic tumors, and other cancers.", "the anaplastic lymphoma kinase (alk) gene rearrangement identifies a population of nsclcs in whom dysregulation of alk-tyrosine kinase (-tk) leads to uncontrolled proliferation of cancer cells,", "the anaplastic lymphoma kinase (alk) gene rearrangement identifies a population of nsclcs in whom dysregulation of alk-tyrosine kinase (-tk) leads to uncontrolled proliferation of cancer cells,", "the anaplastic lymphoma kinase (alk) gene rearrangement identifies a population of nsclcs in whom dysregulation of alk-tyrosine kinase (-tk) leads to uncontrolled proliferation of cancer cells,", "the anaplastic lymphoma kinase (alk) gene rearrangement identifies a population of nsclcs in whom dysregulation of alk-tyrosine kinase (-tk) leads to uncontrolled proliferation of cancer cells,", "the anaplastic lymphoma kinase (alk) gene rearrangement identifies a population of nsclcs in whom dysregulation of alk-tyrosine kinase (-tk) leads to uncontrolled proliferation of cancer cells,", "the anaplastic lymphoma kinase (alk) gene rearrangement identifies a population of nsclcs in whom dysregulation of alk-tyrosine kinase (-tk) leads to uncontrolled proliferation of cancer cells,", "the anaplastic lymphoma kinase (alk) gene rearrangement identifies a population of nsclcs in whom dysregulation of alk-tyrosine kinase (-tk) leads to uncontrolled proliferation of cancer cells,", "the anaplastic lymphoma kinase (alk) gene rearrangement identifies a population of nsclcs in whom dysregulation of alk-tyrosine kinase (-tk) leads to uncontrolled proliferation of cancer cells,", "the anaplastic lymphoma kinase (alk) gene rearrangement identifies a population of nsclcs in whom dysregulation of alk-tyrosine kinase (-tk) leads to uncontrolled proliferation of cancer cells,", "the anaplastic lymphoma kinase (alk) gene rearrangement identifies a population of nsclcs in whom dysregulation of alk-tyrosine kinase (-tk) leads to uncontrolled proliferation of cancer cells,", "the anaplastic lymphoma kinase (alk) gene rearrangement identifies a population of nsclcs in whom dysregulation of alk-tyrosine kinase (-tk) leads to uncontrolled proliferation of cancer cells,", "the anaplastic lymphoma kinase (alk) gene rearrangement identifies a population of nsclcs in whom dysregulation of alk-tyrosine kinase (-tk) leads to uncontrolled proliferation of cancer cells,", "the anaplastic lymphoma kinase (alk) gene rearrangement identifies a population of nsclcs in whom dysregulation of alk-tyrosine kinase (-tk) leads to uncontrolled proliferation of cancer cells,", "the anaplastic lymphoma kinase (alk) gene rearrangement identifies a population of nsclcs in whom dysregulation of alk-tyrosine kinase (-tk) leads to uncontrolled proliferation of cancer cells,", "the anaplastic lymphoma kinase (alk) gene rearrangement identifies a population of nsclcs in whom dysregulation of alk-tyrosine kinase (-tk) leads to uncontrolled proliferation of cancer cells,", "the anaplastic lymphoma kinase (alk) gene rearrangement identifies a population of nsclcs in whom dysregulation of alk-tyrosine kinase (-tk) leads to uncontrolled proliferation of cancer cells,", "the anaplastic lymphoma kinase (alk) gene rearrangement identifies a population of nsclcs in whom dysregulation of alk-tyrosine kinase (-tk) leads to uncontrolled proliferation of cancer cells,", "the discovery of translocations involving the anaplastic lymphoma kinase (alk) receptor tyrosine kinase in a subset of non-small cell lung cancers has become a paradigm for precision medicine", "the discovery of translocations involving the anaplastic lymphoma kinase (alk) receptor tyrosine kinase in a subset of non-small cell lung cancers has become a paradigm for precision medicine", "the discovery of translocations involving the anaplastic lymphoma kinase (alk) receptor tyrosine kinase in a subset of non-small cell lung cancers has become a paradigm for precision medicine", "the discovery of translocations involving the anaplastic lymphoma kinase (alk) receptor tyrosine kinase in a subset of non-small cell lung cancers has become a paradigm for precision medicine", "the discovery of translocations involving the anaplastic lymphoma kinase (alk) receptor tyrosine kinase in a subset of non-small cell lung cancers has become a paradigm for precision medicine", "the discovery of translocations involving the anaplastic lymphoma kinase (alk) receptor tyrosine kinase in a subset of non-small cell lung cancers has become a paradigm for precision medicine", "the discovery of translocations involving the anaplastic lymphoma kinase (alk) receptor tyrosine kinase in a subset of non-small cell lung cancers has become a paradigm for precision medicine", "the discovery of translocations involving the anaplastic lymphoma kinase (alk) receptor tyrosine kinase in a subset of non-small cell lung cancers has become a paradigm for precision medicine", "the discovery of translocations involving the anaplastic lymphoma kinase (alk) receptor tyrosine kinase in a subset of non-small cell lung cancers has become a paradigm for precision medicine", "the discovery of translocations involving the anaplastic lymphoma kinase (alk) receptor tyrosine kinase in a subset of non-small cell lung cancers has become a paradigm for precision medicine", "the discovery of translocations involving the anaplastic lymphoma kinase (alk) receptor tyrosine kinase in a subset of non-small cell lung cancers has become a paradigm for precision medicine", "the discovery of translocations involving the anaplastic lymphoma kinase (alk) receptor tyrosine kinase in a subset of non-small cell lung cancers has become a paradigm for precision medicine", "the discovery of translocations involving the anaplastic lymphoma kinase (alk) receptor tyrosine kinase in a subset of non-small cell lung cancers has become a paradigm for precision medicine", "the discovery of translocations involving the anaplastic lymphoma kinase (alk) receptor tyrosine kinase in a subset of non-small cell lung cancers has become a paradigm for precision medicine", "the discovery of translocations involving the anaplastic lymphoma kinase (alk) receptor tyrosine kinase in a subset of non-small cell lung cancers has become a paradigm for precision medicine", "the discovery of translocations involving the anaplastic lymphoma kinase (alk) receptor tyrosine kinase in a subset of non-small cell lung cancers has become a paradigm for precision medicine", "the discovery of translocations involving the anaplastic lymphoma kinase (alk) receptor tyrosine kinase in a subset of non-small cell lung cancers has become a paradigm for precision medicine", "patients with non-small cell lung cancer (nsclc) who harbor anaplastic lymphoma kinase (alk) gene rearrangements can derive significant clinical benefit from alk tyrosine kinase inhibitor.", "patients with non-small cell lung cancer (nsclc) who harbor anaplastic lymphoma kinase (alk) gene rearrangements can derive significant clinical benefit from alk tyrosine kinase inhibitor.", "patients with non-small cell lung cancer (nsclc) who harbor anaplastic lymphoma kinase (alk) gene rearrangements can derive significant clinical benefit from alk tyrosine kinase inhibitor.", "patients with non-small cell lung cancer (nsclc) who harbor anaplastic lymphoma kinase (alk) gene rearrangements can derive significant clinical benefit from alk tyrosine kinase inhibitor.", "patients with non-small cell lung cancer (nsclc) who harbor anaplastic lymphoma kinase (alk) gene rearrangements can derive significant clinical benefit from alk tyrosine kinase inhibitor.", "patients with non-small cell lung cancer (nsclc) who harbor anaplastic lymphoma kinase (alk) gene rearrangements can derive significant clinical benefit from alk tyrosine kinase inhibitor.", "patients with non-small cell lung cancer (nsclc) who harbor anaplastic lymphoma kinase (alk) gene rearrangements can derive significant clinical benefit from alk tyrosine kinase inhibitor.", "patients with non-small cell lung cancer (nsclc) who harbor anaplastic lymphoma kinase (alk) gene rearrangements can derive significant clinical benefit from alk tyrosine kinase inhibitor.", "patients with non-small cell lung cancer (nsclc) who harbor anaplastic lymphoma kinase (alk) gene rearrangements can derive significant clinical benefit from alk tyrosine kinase inhibitor.", "patients with non-small cell lung cancer (nsclc) who harbor anaplastic lymphoma kinase (alk) gene rearrangements can derive significant clinical benefit from alk tyrosine kinase inhibitor.", "patients with non-small cell lung cancer (nsclc) who harbor anaplastic lymphoma kinase (alk) gene rearrangements can derive significant clinical benefit from alk tyrosine kinase inhibitor.", "patients with non-small cell lung cancer (nsclc) who harbor anaplastic lymphoma kinase (alk) gene rearrangements can derive significant clinical benefit from alk tyrosine kinase inhibitor.", "patients with non-small cell lung cancer (nsclc) who harbor anaplastic lymphoma kinase (alk) gene rearrangements can derive significant clinical benefit from alk tyrosine kinase inhibitor.", "patients with non-small cell lung cancer (nsclc) who harbor anaplastic lymphoma kinase (alk) gene rearrangements can derive significant clinical benefit from alk tyrosine kinase inhibitor.", "patients with non-small cell lung cancer (nsclc) who harbor anaplastic lymphoma kinase (alk) gene rearrangements can derive significant clinical benefit from alk tyrosine kinase inhibitor.", "patients with non-small cell lung cancer (nsclc) who harbor anaplastic lymphoma kinase (alk) gene rearrangements can derive significant clinical benefit from alk tyrosine kinase inhibitor.", "patients with non-small cell lung cancer (nsclc) who harbor anaplastic lymphoma kinase (alk) gene rearrangements can derive significant clinical benefit from alk tyrosine kinase inhibitor.", "this review summarises the latest research on the receptor tyrosine kinase alk, and how this information can guide the management of patients with cancer that is alk-positive.", "this review summarises the latest research on the receptor tyrosine kinase alk, and how this information can guide the management of patients with cancer that is alk-positive.", "this review summarises the latest research on the receptor tyrosine kinase alk, and how this information can guide the management of patients with cancer that is alk-positive.", "this review summarises the latest research on the receptor tyrosine kinase alk, and how this information can guide the management of patients with cancer that is alk-positive.", "this review summarises the latest research on the receptor tyrosine kinase alk, and how this information can guide the management of patients with cancer that is alk-positive.", "this review summarises the latest research on the receptor tyrosine kinase alk, and how this information can guide the management of patients with cancer that is alk-positive.", "this review summarises the latest research on the receptor tyrosine kinase alk, and how this information can guide the management of patients with cancer that is alk-positive.", "this review summarises the latest research on the receptor tyrosine kinase alk, and how this information can guide the management of patients with cancer that is alk-positive.", "this review summarises the latest research on the receptor tyrosine kinase alk, and how this information can guide the management of patients with cancer that is alk-positive.", "this review summarises the latest research on the receptor tyrosine kinase alk, and how this information can guide the management of patients with cancer that is alk-positive.", "this review summarises the latest research on the receptor tyrosine kinase alk, and how this information can guide the management of patients with cancer that is alk-positive.", "this review summarises the latest research on the receptor tyrosine kinase alk, and how this information can guide the management of patients with cancer that is alk-positive.", "this review summarises the latest research on the receptor tyrosine kinase alk, and how this information can guide the management of patients with cancer that is alk-positive.", "this review summarises the latest research on the receptor tyrosine kinase alk, and how this information can guide the management of patients with cancer that is alk-positive.", "this review summarises the latest research on the receptor tyrosine kinase alk, and how this information can guide the management of patients with cancer that is alk-positive.", "this review summarises the latest research on the receptor tyrosine kinase alk, and how this information can guide the management of patients with cancer that is alk-positive.", "this review summarises the latest research on the receptor tyrosine kinase alk, and how this information can guide the management of patients with cancer that is alk-positive.", "the anaplastic lymphoma kinase (alk) is a tyrosine kinase receptor that is involved in the pathogenesis of different types of human cancers, including neuroblastoma (nb)", "the anaplastic lymphoma kinase (alk) is a tyrosine kinase receptor that is involved in the pathogenesis of different types of human cancers, including neuroblastoma (nb)", "the anaplastic lymphoma kinase (alk) is a tyrosine kinase receptor that is involved in the pathogenesis of different types of human cancers, including neuroblastoma (nb)", "the anaplastic lymphoma kinase (alk) is a tyrosine kinase receptor that is involved in the pathogenesis of different types of human cancers, including neuroblastoma (nb)", "the anaplastic lymphoma kinase (alk) is a tyrosine kinase receptor that is involved in the pathogenesis of different types of human cancers, including neuroblastoma (nb)", "the anaplastic lymphoma kinase (alk) is a tyrosine kinase receptor that is involved in the pathogenesis of different types of human cancers, including neuroblastoma (nb)", "the anaplastic lymphoma kinase (alk) is a tyrosine kinase receptor that is involved in the pathogenesis of different types of human cancers, including neuroblastoma (nb)", "the anaplastic lymphoma kinase (alk) is a tyrosine kinase receptor that is involved in the pathogenesis of different types of human cancers, including neuroblastoma (nb)", "the anaplastic lymphoma kinase (alk) is a tyrosine kinase receptor that is involved in the pathogenesis of different types of human cancers, including neuroblastoma (nb)", "the anaplastic lymphoma kinase (alk) is a tyrosine kinase receptor that is involved in the pathogenesis of different types of human cancers, including neuroblastoma (nb)", "the anaplastic lymphoma kinase (alk) is a tyrosine kinase receptor that is involved in the pathogenesis of different types of human cancers, including neuroblastoma (nb)", "the anaplastic lymphoma kinase (alk) is a tyrosine kinase receptor that is involved in the pathogenesis of different types of human cancers, including neuroblastoma (nb)", "the anaplastic lymphoma kinase (alk) is a tyrosine kinase receptor that is involved in the pathogenesis of different types of human cancers, including neuroblastoma (nb)", "the anaplastic lymphoma kinase (alk) is a tyrosine kinase receptor that is involved in the pathogenesis of different types of human cancers, including neuroblastoma (nb)", "the anaplastic lymphoma kinase (alk) is a tyrosine kinase receptor that is involved in the pathogenesis of different types of human cancers, including neuroblastoma (nb)", "the anaplastic lymphoma kinase (alk) is a tyrosine kinase receptor that is involved in the pathogenesis of different types of human cancers, including neuroblastoma (nb)", "the anaplastic lymphoma kinase (alk) is a tyrosine kinase receptor that is involved in the pathogenesis of different types of human cancers, including neuroblastoma (nb)", "rearrangements in alk gene and eml4 gene were first described in 2007. this genomic aberration is found in about 2%-8% of non-small-cell lung cancer (nsclc) patients", "rearrangements in alk gene and eml4 gene were first described in 2007. this genomic aberration is found in about 2%-8% of non-small-cell lung cancer (nsclc) patients", "rearrangements in alk gene and eml4 gene were first described in 2007. this genomic aberration is found in about 2%-8% of non-small-cell lung cancer (nsclc) patients", "rearrangements in alk gene and eml4 gene were first described in 2007. this genomic aberration is found in about 2%-8% of non-small-cell lung cancer (nsclc) patients", "rearrangements in alk gene and eml4 gene were first described in 2007. this genomic aberration is found in about 2%-8% of non-small-cell lung cancer (nsclc) patients", "rearrangements in alk gene and eml4 gene were first described in 2007. this genomic aberration is found in about 2%-8% of non-small-cell lung cancer (nsclc) patients", "rearrangements in alk gene and eml4 gene were first described in 2007. this genomic aberration is found in about 2%-8% of non-small-cell lung cancer (nsclc) patients", "rearrangements in alk gene and eml4 gene were first described in 2007. this genomic aberration is found in about 2%-8% of non-small-cell lung cancer (nsclc) patients", "rearrangements in alk gene and eml4 gene were first described in 2007. this genomic aberration is found in about 2%-8% of non-small-cell lung cancer (nsclc) patients", "rearrangements in alk gene and eml4 gene were first described in 2007. this genomic aberration is found in about 2%-8% of non-small-cell lung cancer (nsclc) patients", "rearrangements in alk gene and eml4 gene were first described in 2007. this genomic aberration is found in about 2%-8% of non-small-cell lung cancer (nsclc) patients", "rearrangements in alk gene and eml4 gene were first described in 2007. this genomic aberration is found in about 2%-8% of non-small-cell lung cancer (nsclc) patients", "rearrangements in alk gene and eml4 gene were first described in 2007. this genomic aberration is found in about 2%-8% of non-small-cell lung cancer (nsclc) patients", "rearrangements in alk gene and eml4 gene were first described in 2007. this genomic aberration is found in about 2%-8% of non-small-cell lung cancer (nsclc) patients", "rearrangements in alk gene and eml4 gene were first described in 2007. this genomic aberration is found in about 2%-8% of non-small-cell lung cancer (nsclc) patients", "rearrangements in alk gene and eml4 gene were first described in 2007. this genomic aberration is found in about 2%-8% of non-small-cell lung cancer (nsclc) patients", "rearrangements in alk gene and eml4 gene were first described in 2007. this genomic aberration is found in about 2%-8% of non-small-cell lung cancer (nsclc) patients", "anaplastic lymphoma kinase (alk)-positive non-small cell lung cancer (nsclc) is sensitive to treatment with an alk-tyrosine kinase inhibitor (-tki).", "anaplastic lymphoma kinase (alk)-positive non-small cell lung cancer (nsclc) is sensitive to treatment with an alk-tyrosine kinase inhibitor (-tki).", "anaplastic lymphoma kinase (alk)-positive non-small cell lung cancer (nsclc) is sensitive to treatment with an alk-tyrosine kinase inhibitor (-tki).", "anaplastic lymphoma kinase (alk)-positive non-small cell lung cancer (nsclc) is sensitive to treatment with an alk-tyrosine kinase inhibitor (-tki).", "anaplastic lymphoma kinase (alk)-positive non-small cell lung cancer (nsclc) is sensitive to treatment with an alk-tyrosine kinase inhibitor (-tki).", "anaplastic lymphoma kinase (alk)-positive non-small cell lung cancer (nsclc) is sensitive to treatment with an alk-tyrosine kinase inhibitor (-tki).", "anaplastic lymphoma kinase (alk)-positive non-small cell lung cancer (nsclc) is sensitive to treatment with an alk-tyrosine kinase inhibitor (-tki).", "anaplastic lymphoma kinase (alk)-positive non-small cell lung cancer (nsclc) is sensitive to treatment with an alk-tyrosine kinase inhibitor (-tki).", "anaplastic lymphoma kinase (alk)-positive non-small cell lung cancer (nsclc) is sensitive to treatment with an alk-tyrosine kinase inhibitor (-tki).", "anaplastic lymphoma kinase (alk)-positive non-small cell lung cancer (nsclc) is sensitive to treatment with an alk-tyrosine kinase inhibitor (-tki).", "anaplastic lymphoma kinase (alk)-positive non-small cell lung cancer (nsclc) is sensitive to treatment with an alk-tyrosine kinase inhibitor (-tki).", "anaplastic lymphoma kinase (alk)-positive non-small cell lung cancer (nsclc) is sensitive to treatment with an alk-tyrosine kinase inhibitor (-tki).", "anaplastic lymphoma kinase (alk)-positive non-small cell lung cancer (nsclc) is sensitive to treatment with an alk-tyrosine kinase inhibitor (-tki).", "anaplastic lymphoma kinase (alk)-positive non-small cell lung cancer (nsclc) is sensitive to treatment with an alk-tyrosine kinase inhibitor (-tki).", "anaplastic lymphoma kinase (alk)-positive non-small cell lung cancer (nsclc) is sensitive to treatment with an alk-tyrosine kinase inhibitor (-tki).", "anaplastic lymphoma kinase (alk)-positive non-small cell lung cancer (nsclc) is sensitive to treatment with an alk-tyrosine kinase inhibitor (-tki).", "anaplastic lymphoma kinase (alk)-positive non-small cell lung cancer (nsclc) is sensitive to treatment with an alk-tyrosine kinase inhibitor (-tki).", "investigational alk inhibitor brigatinib is active in patients with alk-rearranged non-small cell lung cancer.", "investigational alk inhibitor brigatinib is active in patients with alk-rearranged non-small cell lung cancer.", "investigational alk inhibitor brigatinib is active in patients with alk-rearranged non-small cell lung cancer.", "investigational alk inhibitor brigatinib is active in patients with alk-rearranged non-small cell lung cancer.", "investigational alk inhibitor brigatinib is active in patients with alk-rearranged non-small cell lung cancer.", "investigational alk inhibitor brigatinib is active in patients with alk-rearranged non-small cell lung cancer.", "investigational alk inhibitor brigatinib is active in patients with alk-rearranged non-small cell lung cancer.", "investigational alk inhibitor brigatinib is active in patients with alk-rearranged non-small cell lung cancer.", "investigational alk inhibitor brigatinib is active in patients with alk-rearranged non-small cell lung cancer.", "investigational alk inhibitor brigatinib is active in patients with alk-rearranged non-small cell lung cancer.", "investigational alk inhibitor brigatinib is active in patients with alk-rearranged non-small cell lung cancer.", "investigational alk inhibitor brigatinib is active in patients with alk-rearranged non-small cell lung cancer.", "investigational alk inhibitor brigatinib is active in patients with alk-rearranged non-small cell lung cancer.", "investigational alk inhibitor brigatinib is active in patients with alk-rearranged non-small cell lung cancer.", "investigational alk inhibitor brigatinib is active in patients with alk-rearranged non-small cell lung cancer.", "investigational alk inhibitor brigatinib is active in patients with alk-rearranged non-small cell lung cancer.", "investigational alk inhibitor brigatinib is active in patients with alk-rearranged non-small cell lung cancer.", "insights into alk-driven cancers revealed through development of novel alk tyrosine kinase inhibitors.", "insights into alk-driven cancers revealed through development of novel alk tyrosine kinase inhibitors.", "insights into alk-driven cancers revealed through development of novel alk tyrosine kinase inhibitors.", "insights into alk-driven cancers revealed through development of novel alk tyrosine kinase inhibitors.", "insights into alk-driven cancers revealed through development of novel alk tyrosine kinase inhibitors.", "insights into alk-driven cancers revealed through development of novel alk tyrosine kinase inhibitors.", "insights into alk-driven cancers revealed through development of novel alk tyrosine kinase inhibitors.", "insights into alk-driven cancers revealed through development of novel alk tyrosine kinase inhibitors.", "insights into alk-driven cancers revealed through development of novel alk tyrosine kinase inhibitors.", "insights into alk-driven cancers revealed through development of novel alk tyrosine kinase inhibitors.", "insights into alk-driven cancers revealed through development of novel alk tyrosine kinase inhibitors.", "insights into alk-driven cancers revealed through development of novel alk tyrosine kinase inhibitors.", "insights into alk-driven cancers revealed through development of novel alk tyrosine kinase inhibitors.", "insights into alk-driven cancers revealed through development of novel alk tyrosine kinase inhibitors.", "insights into alk-driven cancers revealed through development of novel alk tyrosine kinase inhibitors.", "insights into alk-driven cancers revealed through development of novel alk tyrosine kinase inhibitors.", "insights into alk-driven cancers revealed through development of novel alk tyrosine kinase inhibitors.", "anaplastic lymphoma kinase (alk) rearrangement lung cancer responds to alk tyrosine kinase inhibitors.", "anaplastic lymphoma kinase (alk) rearrangement lung cancer responds to alk tyrosine kinase inhibitors.", "anaplastic lymphoma kinase (alk) rearrangement lung cancer responds to alk tyrosine kinase inhibitors.", "anaplastic lymphoma kinase (alk) rearrangement lung cancer responds to alk tyrosine kinase inhibitors.", "anaplastic lymphoma kinase (alk) rearrangement lung cancer responds to alk tyrosine kinase inhibitors.", "anaplastic lymphoma kinase (alk) rearrangement lung cancer responds to alk tyrosine kinase inhibitors.", "anaplastic lymphoma kinase (alk) rearrangement lung cancer responds to alk tyrosine kinase inhibitors.", "anaplastic lymphoma kinase (alk) rearrangement lung cancer responds to alk tyrosine kinase inhibitors.", "anaplastic lymphoma kinase (alk) rearrangement lung cancer responds to alk tyrosine kinase inhibitors.", "anaplastic lymphoma kinase (alk) rearrangement lung cancer responds to alk tyrosine kinase inhibitors.", "anaplastic lymphoma kinase (alk) rearrangement lung cancer responds to alk tyrosine kinase inhibitors.", "anaplastic lymphoma kinase (alk) rearrangement lung cancer responds to alk tyrosine kinase inhibitors.", "anaplastic lymphoma kinase (alk) rearrangement lung cancer responds to alk tyrosine kinase inhibitors.", "anaplastic lymphoma kinase (alk) rearrangement lung cancer responds to alk tyrosine kinase inhibitors.", "anaplastic lymphoma kinase (alk) rearrangement lung cancer responds to alk tyrosine kinase inhibitors.", "anaplastic lymphoma kinase (alk) rearrangement lung cancer responds to alk tyrosine kinase inhibitors.", "anaplastic lymphoma kinase (alk) rearrangement lung cancer responds to alk tyrosine kinase inhibitors.", "rearrangements involving the alk gene were identified in a variety of cancers,", "rearrangements involving the alk gene were identified in a variety of cancers,", "rearrangements involving the alk gene were identified in a variety of cancers,", "rearrangements involving the alk gene were identified in a variety of cancers,", "rearrangements involving the alk gene were identified in a variety of cancers,", "rearrangements involving the alk gene were identified in a variety of cancers,", "rearrangements involving the alk gene were identified in a variety of cancers,", "rearrangements involving the alk gene were identified in a variety of cancers,", "rearrangements involving the alk gene were identified in a variety of cancers,", "rearrangements involving the alk gene were identified in a variety of cancers,", "rearrangements involving the alk gene were identified in a variety of cancers,", "rearrangements involving the alk gene were identified in a variety of cancers,", "rearrangements involving the alk gene were identified in a variety of cancers,", "rearrangements involving the alk gene were identified in a variety of cancers,", "rearrangements involving the alk gene were identified in a variety of cancers,", "rearrangements involving the alk gene were identified in a variety of cancers,", "rearrangements involving the alk gene were identified in a variety of cancers,", "patients with alk-positive non-small-cell lung cancer.", "patients with alk-positive non-small-cell lung cancer.", "patients with alk-positive non-small-cell lung cancer.", "patients with alk-positive non-small-cell lung cancer.", "patients with alk-positive non-small-cell lung cancer.", "patients with alk-positive non-small-cell lung cancer.", "patients with alk-positive non-small-cell lung cancer.", "patients with alk-positive non-small-cell lung cancer.", "patients with alk-positive non-small-cell lung cancer.", "patients with alk-positive non-small-cell lung cancer.", "patients with alk-positive non-small-cell lung cancer.", "patients with alk-positive non-small-cell lung cancer.", "patients with alk-positive non-small-cell lung cancer.", "patients with alk-positive non-small-cell lung cancer.", "patients with alk-positive non-small-cell lung cancer.", "patients with alk-positive non-small-cell lung cancer.", "patients with alk-positive non-small-cell lung cancer.", "scores for the pneumonia severity index (psi); curb65 (confusion, urea, respiration, blood pressure; age>65\u2009years); infectious disease society of america (idsa) and american thoracic society (ats) guidelines for severe cap; acute physiology, chronic health evaluation (apache) ii; sequential organ failure assessment (sofa); and quick sofa (qsofa) were calculated.", "scores for the pneumonia severity index (psi); curb65 (confusion, urea, respiration, blood pressure; age>65\u2009years); infectious disease society of america (idsa) and american thoracic society (ats) guidelines for severe cap; acute physiology, chronic health evaluation (apache) ii; sequential organ failure assessment (sofa); and quick sofa (qsofa) were calculated.", "scores for the pneumonia severity index (psi); curb65 (confusion, urea, respiration, blood pressure; age>65\u2009years); infectious disease society of america (idsa) and american thoracic society (ats) guidelines for severe cap; acute physiology, chronic health evaluation (apache) ii; sequential organ failure assessment (sofa); and quick sofa (qsofa) were calculated.", "scores for the pneumonia severity index (psi); curb65 (confusion, urea, respiration, blood pressure; age>65\u2009years); infectious disease society of america (idsa) and american thoracic society (ats) guidelines for severe cap; acute physiology, chronic health evaluation (apache) ii; sequential organ failure assessment (sofa); and quick sofa (qsofa) were calculated.", "scores for the pneumonia severity index (psi); curb65 (confusion, urea, respiration, blood pressure; age>65\u2009years); infectious disease society of america (idsa) and american thoracic society (ats) guidelines for severe cap; acute physiology, chronic health evaluation (apache) ii; sequential organ failure assessment (sofa); and quick sofa (qsofa) were calculated.", "scores for the pneumonia severity index (psi); curb65 (confusion, urea, respiration, blood pressure; age>65\u2009years); infectious disease society of america (idsa) and american thoracic society (ats) guidelines for severe cap; acute physiology, chronic health evaluation (apache) ii; sequential organ failure assessment (sofa); and quick sofa (qsofa) were calculated.", "scores for the pneumonia severity index (psi); curb65 (confusion, urea, respiration, blood pressure; age>65\u2009years); infectious disease society of america (idsa) and american thoracic society (ats) guidelines for severe cap; acute physiology, chronic health evaluation (apache) ii; sequential organ failure assessment (sofa); and quick sofa (qsofa) were calculated.", "scores for the pneumonia severity index (psi); curb65 (confusion, urea, respiration, blood pressure; age>65\u2009years); infectious disease society of america (idsa) and american thoracic society (ats) guidelines for severe cap; acute physiology, chronic health evaluation (apache) ii; sequential organ failure assessment (sofa); and quick sofa (qsofa) were calculated.", "scores for the pneumonia severity index (psi); curb65 (confusion, urea, respiration, blood pressure; age>65\u2009years); infectious disease society of america (idsa) and american thoracic society (ats) guidelines for severe cap; acute physiology, chronic health evaluation (apache) ii; sequential organ failure assessment (sofa); and quick sofa (qsofa) were calculated.", "scores for the pneumonia severity index (psi); curb65 (confusion, urea, respiration, blood pressure; age>65\u2009years); infectious disease society of america (idsa) and american thoracic society (ats) guidelines for severe cap; acute physiology, chronic health evaluation (apache) ii; sequential organ failure assessment (sofa); and quick sofa (qsofa) were calculated.", "scores for the pneumonia severity index (psi); curb65 (confusion, urea, respiration, blood pressure; age>65\u2009years); infectious disease society of america (idsa) and american thoracic society (ats) guidelines for severe cap; acute physiology, chronic health evaluation (apache) ii; sequential organ failure assessment (sofa); and quick sofa (qsofa) were calculated.", "scores for the pneumonia severity index (psi); curb65 (confusion, urea, respiration, blood pressure; age>65\u2009years); infectious disease society of america (idsa) and american thoracic society (ats) guidelines for severe cap; acute physiology, chronic health evaluation (apache) ii; sequential organ failure assessment (sofa); and quick sofa (qsofa) were calculated.", "scores for the pneumonia severity index (psi); curb65 (confusion, urea, respiration, blood pressure; age>65\u2009years); infectious disease society of america (idsa) and american thoracic society (ats) guidelines for severe cap; acute physiology, chronic health evaluation (apache) ii; sequential organ failure assessment (sofa); and quick sofa (qsofa) were calculated.", "scores for the pneumonia severity index (psi); curb65 (confusion, urea, respiration, blood pressure; age>65\u2009years); infectious disease society of america (idsa) and american thoracic society (ats) guidelines for severe cap; acute physiology, chronic health evaluation (apache) ii; sequential organ failure assessment (sofa); and quick sofa (qsofa) were calculated.", "scores for the pneumonia severity index (psi); curb65 (confusion, urea, respiration, blood pressure; age>65\u2009years); infectious disease society of america (idsa) and american thoracic society (ats) guidelines for severe cap; acute physiology, chronic health evaluation (apache) ii; sequential organ failure assessment (sofa); and quick sofa (qsofa) were calculated.", "scores for the pneumonia severity index (psi); curb65 (confusion, urea, respiration, blood pressure; age>65\u2009years); infectious disease society of america (idsa) and american thoracic society (ats) guidelines for severe cap; acute physiology, chronic health evaluation (apache) ii; sequential organ failure assessment (sofa); and quick sofa (qsofa) were calculated.", "scores for the pneumonia severity index (psi); curb65 (confusion, urea, respiration, blood pressure; age>65\u2009years); infectious disease society of america (idsa) and american thoracic society (ats) guidelines for severe cap; acute physiology, chronic health evaluation (apache) ii; sequential organ failure assessment (sofa); and quick sofa (qsofa) were calculated.", "scores for the pneumonia severity index (psi); curb65 (confusion, urea, respiration, blood pressure; age>65\u2009years); infectious disease society of america (idsa) and american thoracic society (ats) guidelines for severe cap; acute physiology, chronic health evaluation (apache) ii; sequential organ failure assessment (sofa); and quick sofa (qsofa) were calculated.", "scores for the pneumonia severity index (psi); curb65 (confusion, urea, respiration, blood pressure; age>65\u2009years); infectious disease society of america (idsa) and american thoracic society (ats) guidelines for severe cap; acute physiology, chronic health evaluation (apache) ii; sequential organ failure assessment (sofa); and quick sofa (qsofa) were calculated.", "scores for the pneumonia severity index (psi); curb65 (confusion, urea, respiration, blood pressure; age>65\u2009years); infectious disease society of america (idsa) and american thoracic society (ats) guidelines for severe cap; acute physiology, chronic health evaluation (apache) ii; sequential organ failure assessment (sofa); and quick sofa (qsofa) were calculated.", "scores for the pneumonia severity index (psi); curb65 (confusion, urea, respiration, blood pressure; age>65\u2009years); infectious disease society of america (idsa) and american thoracic society (ats) guidelines for severe cap; acute physiology, chronic health evaluation (apache) ii; sequential organ failure assessment (sofa); and quick sofa (qsofa) were calculated.", "scores for the pneumonia severity index (psi); curb65 (confusion, urea, respiration, blood pressure; age>65\u2009years); infectious disease society of america (idsa) and american thoracic society (ats) guidelines for severe cap; acute physiology, chronic health evaluation (apache) ii; sequential organ failure assessment (sofa); and quick sofa (qsofa) were calculated.", "scores for the pneumonia severity index (psi); curb65 (confusion, urea, respiration, blood pressure; age>65\u2009years); infectious disease society of america (idsa) and american thoracic society (ats) guidelines for severe cap; acute physiology, chronic health evaluation (apache) ii; sequential organ failure assessment (sofa); and quick sofa (qsofa) were calculated.", "scores for the pneumonia severity index (psi); curb65 (confusion, urea, respiration, blood pressure; age>65\u2009years); infectious disease society of america (idsa) and american thoracic society (ats) guidelines for severe cap; acute physiology, chronic health evaluation (apache) ii; sequential organ failure assessment (sofa); and quick sofa (qsofa) were calculated.", "scores for the pneumonia severity index (psi); curb65 (confusion, urea, respiration, blood pressure; age>65\u2009years); infectious disease society of america (idsa) and american thoracic society (ats) guidelines for severe cap; acute physiology, chronic health evaluation (apache) ii; sequential organ failure assessment (sofa); and quick sofa (qsofa) were calculated.", "scores for the pneumonia severity index (psi); curb65 (confusion, urea, respiration, blood pressure; age>65\u2009years); infectious disease society of america (idsa) and american thoracic society (ats) guidelines for severe cap; acute physiology, chronic health evaluation (apache) ii; sequential organ failure assessment (sofa); and quick sofa (qsofa) were calculated.", "scores for the pneumonia severity index (psi); curb65 (confusion, urea, respiration, blood pressure; age>65\u2009years); infectious disease society of america (idsa) and american thoracic society (ats) guidelines for severe cap; acute physiology, chronic health evaluation (apache) ii; sequential organ failure assessment (sofa); and quick sofa (qsofa) were calculated.", "scores for the pneumonia severity index (psi); curb65 (confusion, urea, respiration, blood pressure; age>65\u2009years); infectious disease society of america (idsa) and american thoracic society (ats) guidelines for severe cap; acute physiology, chronic health evaluation (apache) ii; sequential organ failure assessment (sofa); and quick sofa (qsofa) were calculated.", "scores for the pneumonia severity index (psi); curb65 (confusion, urea, respiration, blood pressure; age>65\u2009years); infectious disease society of america (idsa) and american thoracic society (ats) guidelines for severe cap; acute physiology, chronic health evaluation (apache) ii; sequential organ failure assessment (sofa); and quick sofa (qsofa) were calculated.", "scores for the pneumonia severity index (psi); curb65 (confusion, urea, respiration, blood pressure; age>65\u2009years); infectious disease society of america (idsa) and american thoracic society (ats) guidelines for severe cap; acute physiology, chronic health evaluation (apache) ii; sequential organ failure assessment (sofa); and quick sofa (qsofa) were calculated.", "scores for the pneumonia severity index (psi); curb65 (confusion, urea, respiration, blood pressure; age>65\u2009years); infectious disease society of america (idsa) and american thoracic society (ats) guidelines for severe cap; acute physiology, chronic health evaluation (apache) ii; sequential organ failure assessment (sofa); and quick sofa (qsofa) were calculated.", "scores for the pneumonia severity index (psi); curb65 (confusion, urea, respiration, blood pressure; age>65\u2009years); infectious disease society of america (idsa) and american thoracic society (ats) guidelines for severe cap; acute physiology, chronic health evaluation (apache) ii; sequential organ failure assessment (sofa); and quick sofa (qsofa) were calculated.", "scores for the pneumonia severity index (psi); curb65 (confusion, urea, respiration, blood pressure; age>65\u2009years); infectious disease society of america (idsa) and american thoracic society (ats) guidelines for severe cap; acute physiology, chronic health evaluation (apache) ii; sequential organ failure assessment (sofa); and quick sofa (qsofa) were calculated.", "scores for the pneumonia severity index (psi); curb65 (confusion, urea, respiration, blood pressure; age>65\u2009years); infectious disease society of america (idsa) and american thoracic society (ats) guidelines for severe cap; acute physiology, chronic health evaluation (apache) ii; sequential organ failure assessment (sofa); and quick sofa (qsofa) were calculated.", "scores for the pneumonia severity index (psi); curb65 (confusion, urea, respiration, blood pressure; age>65\u2009years); infectious disease society of america (idsa) and american thoracic society (ats) guidelines for severe cap; acute physiology, chronic health evaluation (apache) ii; sequential organ failure assessment (sofa); and quick sofa (qsofa) were calculated.", "background an intervention trial found a trend for shorter length of stay (los) in patients with community-acquired pneumonia (cap) when the curb65 score was combined with the prognostic biomarker proadrenomedullin (proadm) (curb65-a).", "background an intervention trial found a trend for shorter length of stay (los) in patients with community-acquired pneumonia (cap) when the curb65 score was combined with the prognostic biomarker proadrenomedullin (proadm) (curb65-a).", "background an intervention trial found a trend for shorter length of stay (los) in patients with community-acquired pneumonia (cap) when the curb65 score was combined with the prognostic biomarker proadrenomedullin (proadm) (curb65-a).", "background an intervention trial found a trend for shorter length of stay (los) in patients with community-acquired pneumonia (cap) when the curb65 score was combined with the prognostic biomarker proadrenomedullin (proadm) (curb65-a).", "background an intervention trial found a trend for shorter length of stay (los) in patients with community-acquired pneumonia (cap) when the curb65 score was combined with the prognostic biomarker proadrenomedullin (proadm) (curb65-a).", "background an intervention trial found a trend for shorter length of stay (los) in patients with community-acquired pneumonia (cap) when the curb65 score was combined with the prognostic biomarker proadrenomedullin (proadm) (curb65-a).", "background an intervention trial found a trend for shorter length of stay (los) in patients with community-acquired pneumonia (cap) when the curb65 score was combined with the prognostic biomarker proadrenomedullin (proadm) (curb65-a).", "background an intervention trial found a trend for shorter length of stay (los) in patients with community-acquired pneumonia (cap) when the curb65 score was combined with the prognostic biomarker proadrenomedullin (proadm) (curb65-a).", "background an intervention trial found a trend for shorter length of stay (los) in patients with community-acquired pneumonia (cap) when the curb65 score was combined with the prognostic biomarker proadrenomedullin (proadm) (curb65-a).", "background an intervention trial found a trend for shorter length of stay (los) in patients with community-acquired pneumonia (cap) when the curb65 score was combined with the prognostic biomarker proadrenomedullin (proadm) (curb65-a).", "background an intervention trial found a trend for shorter length of stay (los) in patients with community-acquired pneumonia (cap) when the curb65 score was combined with the prognostic biomarker proadrenomedullin (proadm) (curb65-a).", "background an intervention trial found a trend for shorter length of stay (los) in patients with community-acquired pneumonia (cap) when the curb65 score was combined with the prognostic biomarker proadrenomedullin (proadm) (curb65-a).", "background an intervention trial found a trend for shorter length of stay (los) in patients with community-acquired pneumonia (cap) when the curb65 score was combined with the prognostic biomarker proadrenomedullin (proadm) (curb65-a).", "background an intervention trial found a trend for shorter length of stay (los) in patients with community-acquired pneumonia (cap) when the curb65 score was combined with the prognostic biomarker proadrenomedullin (proadm) (curb65-a).", "background an intervention trial found a trend for shorter length of stay (los) in patients with community-acquired pneumonia (cap) when the curb65 score was combined with the prognostic biomarker proadrenomedullin (proadm) (curb65-a).", "background an intervention trial found a trend for shorter length of stay (los) in patients with community-acquired pneumonia (cap) when the curb65 score was combined with the prognostic biomarker proadrenomedullin (proadm) (curb65-a).", "background an intervention trial found a trend for shorter length of stay (los) in patients with community-acquired pneumonia (cap) when the curb65 score was combined with the prognostic biomarker proadrenomedullin (proadm) (curb65-a).", "background an intervention trial found a trend for shorter length of stay (los) in patients with community-acquired pneumonia (cap) when the curb65 score was combined with the prognostic biomarker proadrenomedullin (proadm) (curb65-a).", "background an intervention trial found a trend for shorter length of stay (los) in patients with community-acquired pneumonia (cap) when the curb65 score was combined with the prognostic biomarker proadrenomedullin (proadm) (curb65-a).", "background an intervention trial found a trend for shorter length of stay (los) in patients with community-acquired pneumonia (cap) when the curb65 score was combined with the prognostic biomarker proadrenomedullin (proadm) (curb65-a).", "background an intervention trial found a trend for shorter length of stay (los) in patients with community-acquired pneumonia (cap) when the curb65 score was combined with the prognostic biomarker proadrenomedullin (proadm) (curb65-a).", "background an intervention trial found a trend for shorter length of stay (los) in patients with community-acquired pneumonia (cap) when the curb65 score was combined with the prognostic biomarker proadrenomedullin (proadm) (curb65-a).", "background an intervention trial found a trend for shorter length of stay (los) in patients with community-acquired pneumonia (cap) when the curb65 score was combined with the prognostic biomarker proadrenomedullin (proadm) (curb65-a).", "background an intervention trial found a trend for shorter length of stay (los) in patients with community-acquired pneumonia (cap) when the curb65 score was combined with the prognostic biomarker proadrenomedullin (proadm) (curb65-a).", "background an intervention trial found a trend for shorter length of stay (los) in patients with community-acquired pneumonia (cap) when the curb65 score was combined with the prognostic biomarker proadrenomedullin (proadm) (curb65-a).", "background an intervention trial found a trend for shorter length of stay (los) in patients with community-acquired pneumonia (cap) when the curb65 score was combined with the prognostic biomarker proadrenomedullin (proadm) (curb65-a).", "background an intervention trial found a trend for shorter length of stay (los) in patients with community-acquired pneumonia (cap) when the curb65 score was combined with the prognostic biomarker proadrenomedullin (proadm) (curb65-a).", "background an intervention trial found a trend for shorter length of stay (los) in patients with community-acquired pneumonia (cap) when the curb65 score was combined with the prognostic biomarker proadrenomedullin (proadm) (curb65-a).", "background an intervention trial found a trend for shorter length of stay (los) in patients with community-acquired pneumonia (cap) when the curb65 score was combined with the prognostic biomarker proadrenomedullin (proadm) (curb65-a).", "background an intervention trial found a trend for shorter length of stay (los) in patients with community-acquired pneumonia (cap) when the curb65 score was combined with the prognostic biomarker proadrenomedullin (proadm) (curb65-a).", "background an intervention trial found a trend for shorter length of stay (los) in patients with community-acquired pneumonia (cap) when the curb65 score was combined with the prognostic biomarker proadrenomedullin (proadm) (curb65-a).", "background an intervention trial found a trend for shorter length of stay (los) in patients with community-acquired pneumonia (cap) when the curb65 score was combined with the prognostic biomarker proadrenomedullin (proadm) (curb65-a).", "background an intervention trial found a trend for shorter length of stay (los) in patients with community-acquired pneumonia (cap) when the curb65 score was combined with the prognostic biomarker proadrenomedullin (proadm) (curb65-a).", "background an intervention trial found a trend for shorter length of stay (los) in patients with community-acquired pneumonia (cap) when the curb65 score was combined with the prognostic biomarker proadrenomedullin (proadm) (curb65-a).", "background an intervention trial found a trend for shorter length of stay (los) in patients with community-acquired pneumonia (cap) when the curb65 score was combined with the prognostic biomarker proadrenomedullin (proadm) (curb65-a).", "the cytokine response during pneumonia is different in bacterial vs viral infections; some of these cytokines correlate with clinical severity scales such as curb65 or sofa.", "the cytokine response during pneumonia is different in bacterial vs viral infections; some of these cytokines correlate with clinical severity scales such as curb65 or sofa.", "the cytokine response during pneumonia is different in bacterial vs viral infections; some of these cytokines correlate with clinical severity scales such as curb65 or sofa.", "the cytokine response during pneumonia is different in bacterial vs viral infections; some of these cytokines correlate with clinical severity scales such as curb65 or sofa.", "the cytokine response during pneumonia is different in bacterial vs viral infections; some of these cytokines correlate with clinical severity scales such as curb65 or sofa.", "the cytokine response during pneumonia is different in bacterial vs viral infections; some of these cytokines correlate with clinical severity scales such as curb65 or sofa.", "the cytokine response during pneumonia is different in bacterial vs viral infections; some of these cytokines correlate with clinical severity scales such as curb65 or sofa.", "the cytokine response during pneumonia is different in bacterial vs viral infections; some of these cytokines correlate with clinical severity scales such as curb65 or sofa.", "the cytokine response during pneumonia is different in bacterial vs viral infections; some of these cytokines correlate with clinical severity scales such as curb65 or sofa.", "the cytokine response during pneumonia is different in bacterial vs viral infections; some of these cytokines correlate with clinical severity scales such as curb65 or sofa.", "the cytokine response during pneumonia is different in bacterial vs viral infections; some of these cytokines correlate with clinical severity scales such as curb65 or sofa.", "the cytokine response during pneumonia is different in bacterial vs viral infections; some of these cytokines correlate with clinical severity scales such as curb65 or sofa.", "the cytokine response during pneumonia is different in bacterial vs viral infections; some of these cytokines correlate with clinical severity scales such as curb65 or sofa.", "the cytokine response during pneumonia is different in bacterial vs viral infections; some of these cytokines correlate with clinical severity scales such as curb65 or sofa.", "the cytokine response during pneumonia is different in bacterial vs viral infections; some of these cytokines correlate with clinical severity scales such as curb65 or sofa.", "the cytokine response during pneumonia is different in bacterial vs viral infections; some of these cytokines correlate with clinical severity scales such as curb65 or sofa.", "the cytokine response during pneumonia is different in bacterial vs viral infections; some of these cytokines correlate with clinical severity scales such as curb65 or sofa.", "the cytokine response during pneumonia is different in bacterial vs viral infections; some of these cytokines correlate with clinical severity scales such as curb65 or sofa.", "the cytokine response during pneumonia is different in bacterial vs viral infections; some of these cytokines correlate with clinical severity scales such as curb65 or sofa.", "the cytokine response during pneumonia is different in bacterial vs viral infections; some of these cytokines correlate with clinical severity scales such as curb65 or sofa.", "the cytokine response during pneumonia is different in bacterial vs viral infections; some of these cytokines correlate with clinical severity scales such as curb65 or sofa.", "the cytokine response during pneumonia is different in bacterial vs viral infections; some of these cytokines correlate with clinical severity scales such as curb65 or sofa.", "the cytokine response during pneumonia is different in bacterial vs viral infections; some of these cytokines correlate with clinical severity scales such as curb65 or sofa.", "the cytokine response during pneumonia is different in bacterial vs viral infections; some of these cytokines correlate with clinical severity scales such as curb65 or sofa.", "the cytokine response during pneumonia is different in bacterial vs viral infections; some of these cytokines correlate with clinical severity scales such as curb65 or sofa.", "the cytokine response during pneumonia is different in bacterial vs viral infections; some of these cytokines correlate with clinical severity scales such as curb65 or sofa.", "the cytokine response during pneumonia is different in bacterial vs viral infections; some of these cytokines correlate with clinical severity scales such as curb65 or sofa.", "the cytokine response during pneumonia is different in bacterial vs viral infections; some of these cytokines correlate with clinical severity scales such as curb65 or sofa.", "the cytokine response during pneumonia is different in bacterial vs viral infections; some of these cytokines correlate with clinical severity scales such as curb65 or sofa.", "the cytokine response during pneumonia is different in bacterial vs viral infections; some of these cytokines correlate with clinical severity scales such as curb65 or sofa.", "the cytokine response during pneumonia is different in bacterial vs viral infections; some of these cytokines correlate with clinical severity scales such as curb65 or sofa.", "the cytokine response during pneumonia is different in bacterial vs viral infections; some of these cytokines correlate with clinical severity scales such as curb65 or sofa.", "the cytokine response during pneumonia is different in bacterial vs viral infections; some of these cytokines correlate with clinical severity scales such as curb65 or sofa.", "the cytokine response during pneumonia is different in bacterial vs viral infections; some of these cytokines correlate with clinical severity scales such as curb65 or sofa.", "the cytokine response during pneumonia is different in bacterial vs viral infections; some of these cytokines correlate with clinical severity scales such as curb65 or sofa.", "prognostic performance of mr-pro-adrenomedullin in patients with community acquired pneumonia in the emergency department compared to clinical severity scores psi and curb.", "prognostic performance of mr-pro-adrenomedullin in patients with community acquired pneumonia in the emergency department compared to clinical severity scores psi and curb.", "prognostic performance of mr-pro-adrenomedullin in patients with community acquired pneumonia in the emergency department compared to clinical severity scores psi and curb.", "prognostic performance of mr-pro-adrenomedullin in patients with community acquired pneumonia in the emergency department compared to clinical severity scores psi and curb.", "prognostic performance of mr-pro-adrenomedullin in patients with community acquired pneumonia in the emergency department compared to clinical severity scores psi and curb.", "prognostic performance of mr-pro-adrenomedullin in patients with community acquired pneumonia in the emergency department compared to clinical severity scores psi and curb.", "prognostic performance of mr-pro-adrenomedullin in patients with community acquired pneumonia in the emergency department compared to clinical severity scores psi and curb.", "prognostic performance of mr-pro-adrenomedullin in patients with community acquired pneumonia in the emergency department compared to clinical severity scores psi and curb.", "prognostic performance of mr-pro-adrenomedullin in patients with community acquired pneumonia in the emergency department compared to clinical severity scores psi and curb.", "prognostic performance of mr-pro-adrenomedullin in patients with community acquired pneumonia in the emergency department compared to clinical severity scores psi and curb.", "prognostic performance of mr-pro-adrenomedullin in patients with community acquired pneumonia in the emergency department compared to clinical severity scores psi and curb.", "prognostic performance of mr-pro-adrenomedullin in patients with community acquired pneumonia in the emergency department compared to clinical severity scores psi and curb.", "prognostic performance of mr-pro-adrenomedullin in patients with community acquired pneumonia in the emergency department compared to clinical severity scores psi and curb.", "prognostic performance of mr-pro-adrenomedullin in patients with community acquired pneumonia in the emergency department compared to clinical severity scores psi and curb.", "prognostic performance of mr-pro-adrenomedullin in patients with community acquired pneumonia in the emergency department compared to clinical severity scores psi and curb.", "prognostic performance of mr-pro-adrenomedullin in patients with community acquired pneumonia in the emergency department compared to clinical severity scores psi and curb.", "prognostic performance of mr-pro-adrenomedullin in patients with community acquired pneumonia in the emergency department compared to clinical severity scores psi and curb.", "prognostic performance of mr-pro-adrenomedullin in patients with community acquired pneumonia in the emergency department compared to clinical severity scores psi and curb.", "prognostic performance of mr-pro-adrenomedullin in patients with community acquired pneumonia in the emergency department compared to clinical severity scores psi and curb.", "prognostic performance of mr-pro-adrenomedullin in patients with community acquired pneumonia in the emergency department compared to clinical severity scores psi and curb.", "prognostic performance of mr-pro-adrenomedullin in patients with community acquired pneumonia in the emergency department compared to clinical severity scores psi and curb.", "prognostic performance of mr-pro-adrenomedullin in patients with community acquired pneumonia in the emergency department compared to clinical severity scores psi and curb.", "prognostic performance of mr-pro-adrenomedullin in patients with community acquired pneumonia in the emergency department compared to clinical severity scores psi and curb.", "prognostic performance of mr-pro-adrenomedullin in patients with community acquired pneumonia in the emergency department compared to clinical severity scores psi and curb.", "prognostic performance of mr-pro-adrenomedullin in patients with community acquired pneumonia in the emergency department compared to clinical severity scores psi and curb.", "prognostic performance of mr-pro-adrenomedullin in patients with community acquired pneumonia in the emergency department compared to clinical severity scores psi and curb.", "prognostic performance of mr-pro-adrenomedullin in patients with community acquired pneumonia in the emergency department compared to clinical severity scores psi and curb.", "prognostic performance of mr-pro-adrenomedullin in patients with community acquired pneumonia in the emergency department compared to clinical severity scores psi and curb.", "prognostic performance of mr-pro-adrenomedullin in patients with community acquired pneumonia in the emergency department compared to clinical severity scores psi and curb.", "prognostic performance of mr-pro-adrenomedullin in patients with community acquired pneumonia in the emergency department compared to clinical severity scores psi and curb.", "prognostic performance of mr-pro-adrenomedullin in patients with community acquired pneumonia in the emergency department compared to clinical severity scores psi and curb.", "prognostic performance of mr-pro-adrenomedullin in patients with community acquired pneumonia in the emergency department compared to clinical severity scores psi and curb.", "prognostic performance of mr-pro-adrenomedullin in patients with community acquired pneumonia in the emergency department compared to clinical severity scores psi and curb.", "prognostic performance of mr-pro-adrenomedullin in patients with community acquired pneumonia in the emergency department compared to clinical severity scores psi and curb.", "prognostic performance of mr-pro-adrenomedullin in patients with community acquired pneumonia in the emergency department compared to clinical severity scores psi and curb.", "we aimed to derive a practical algorithm combining the curb65 score with proadm-levels in patients with community-acquired pneumonia (cap) and non-cap-lrti.", "we aimed to derive a practical algorithm combining the curb65 score with proadm-levels in patients with community-acquired pneumonia (cap) and non-cap-lrti.", "we aimed to derive a practical algorithm combining the curb65 score with proadm-levels in patients with community-acquired pneumonia (cap) and non-cap-lrti.", "we aimed to derive a practical algorithm combining the curb65 score with proadm-levels in patients with community-acquired pneumonia (cap) and non-cap-lrti.", "we aimed to derive a practical algorithm combining the curb65 score with proadm-levels in patients with community-acquired pneumonia (cap) and non-cap-lrti.", "we aimed to derive a practical algorithm combining the curb65 score with proadm-levels in patients with community-acquired pneumonia (cap) and non-cap-lrti.", "we aimed to derive a practical algorithm combining the curb65 score with proadm-levels in patients with community-acquired pneumonia (cap) and non-cap-lrti.", "we aimed to derive a practical algorithm combining the curb65 score with proadm-levels in patients with community-acquired pneumonia (cap) and non-cap-lrti.", "we aimed to derive a practical algorithm combining the curb65 score with proadm-levels in patients with community-acquired pneumonia (cap) and non-cap-lrti.", "we aimed to derive a practical algorithm combining the curb65 score with proadm-levels in patients with community-acquired pneumonia (cap) and non-cap-lrti.", "we aimed to derive a practical algorithm combining the curb65 score with proadm-levels in patients with community-acquired pneumonia (cap) and non-cap-lrti.", "we aimed to derive a practical algorithm combining the curb65 score with proadm-levels in patients with community-acquired pneumonia (cap) and non-cap-lrti.", "we aimed to derive a practical algorithm combining the curb65 score with proadm-levels in patients with community-acquired pneumonia (cap) and non-cap-lrti.", "we aimed to derive a practical algorithm combining the curb65 score with proadm-levels in patients with community-acquired pneumonia (cap) and non-cap-lrti.", "we aimed to derive a practical algorithm combining the curb65 score with proadm-levels in patients with community-acquired pneumonia (cap) and non-cap-lrti.", "we aimed to derive a practical algorithm combining the curb65 score with proadm-levels in patients with community-acquired pneumonia (cap) and non-cap-lrti.", "we aimed to derive a practical algorithm combining the curb65 score with proadm-levels in patients with community-acquired pneumonia (cap) and non-cap-lrti.", "we aimed to derive a practical algorithm combining the curb65 score with proadm-levels in patients with community-acquired pneumonia (cap) and non-cap-lrti.", "we aimed to derive a practical algorithm combining the curb65 score with proadm-levels in patients with community-acquired pneumonia (cap) and non-cap-lrti.", "we aimed to derive a practical algorithm combining the curb65 score with proadm-levels in patients with community-acquired pneumonia (cap) and non-cap-lrti.", "we aimed to derive a practical algorithm combining the curb65 score with proadm-levels in patients with community-acquired pneumonia (cap) and non-cap-lrti.", "we aimed to derive a practical algorithm combining the curb65 score with proadm-levels in patients with community-acquired pneumonia (cap) and non-cap-lrti.", "we aimed to derive a practical algorithm combining the curb65 score with proadm-levels in patients with community-acquired pneumonia (cap) and non-cap-lrti.", "we aimed to derive a practical algorithm combining the curb65 score with proadm-levels in patients with community-acquired pneumonia (cap) and non-cap-lrti.", "we aimed to derive a practical algorithm combining the curb65 score with proadm-levels in patients with community-acquired pneumonia (cap) and non-cap-lrti.", "we aimed to derive a practical algorithm combining the curb65 score with proadm-levels in patients with community-acquired pneumonia (cap) and non-cap-lrti.", "we aimed to derive a practical algorithm combining the curb65 score with proadm-levels in patients with community-acquired pneumonia (cap) and non-cap-lrti.", "we aimed to derive a practical algorithm combining the curb65 score with proadm-levels in patients with community-acquired pneumonia (cap) and non-cap-lrti.", "we aimed to derive a practical algorithm combining the curb65 score with proadm-levels in patients with community-acquired pneumonia (cap) and non-cap-lrti.", "we aimed to derive a practical algorithm combining the curb65 score with proadm-levels in patients with community-acquired pneumonia (cap) and non-cap-lrti.", "we aimed to derive a practical algorithm combining the curb65 score with proadm-levels in patients with community-acquired pneumonia (cap) and non-cap-lrti.", "we aimed to derive a practical algorithm combining the curb65 score with proadm-levels in patients with community-acquired pneumonia (cap) and non-cap-lrti.", "we aimed to derive a practical algorithm combining the curb65 score with proadm-levels in patients with community-acquired pneumonia (cap) and non-cap-lrti.", "we aimed to derive a practical algorithm combining the curb65 score with proadm-levels in patients with community-acquired pneumonia (cap) and non-cap-lrti.", "we aimed to derive a practical algorithm combining the curb65 score with proadm-levels in patients with community-acquired pneumonia (cap) and non-cap-lrti.", "the curb65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia.", "the curb65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia.", "the curb65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia.", "the curb65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia.", "the curb65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia.", "the curb65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia.", "the curb65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia.", "the curb65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia.", "the curb65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia.", "the curb65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia.", "the curb65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia.", "the curb65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia.", "the curb65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia.", "the curb65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia.", "the curb65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia.", "the curb65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia.", "the curb65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia.", "the curb65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia.", "the curb65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia.", "the curb65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia.", "the curb65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia.", "the curb65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia.", "the curb65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia.", "the curb65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia.", "the curb65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia.", "the curb65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia.", "the curb65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia.", "the curb65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia.", "the curb65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia.", "the curb65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia.", "the curb65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia.", "the curb65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia.", "the curb65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia.", "the curb65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia.", "the curb65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia.", "the curb65 score was developed to predict mortality risk in community acquired pneumonia.", "the curb65 score was developed to predict mortality risk in community acquired pneumonia.", "the curb65 score was developed to predict mortality risk in community acquired pneumonia.", "the curb65 score was developed to predict mortality risk in community acquired pneumonia.", "the curb65 score was developed to predict mortality risk in community acquired pneumonia.", "the curb65 score was developed to predict mortality risk in community acquired pneumonia.", "the curb65 score was developed to predict mortality risk in community acquired pneumonia.", "the curb65 score was developed to predict mortality risk in community acquired pneumonia.", "the curb65 score was developed to predict mortality risk in community acquired pneumonia.", "the curb65 score was developed to predict mortality risk in community acquired pneumonia.", "the curb65 score was developed to predict mortality risk in community acquired pneumonia.", "the curb65 score was developed to predict mortality risk in community acquired pneumonia.", "the curb65 score was developed to predict mortality risk in community acquired pneumonia.", "the curb65 score was developed to predict mortality risk in community acquired pneumonia.", "the curb65 score was developed to predict mortality risk in community acquired pneumonia.", "the curb65 score was developed to predict mortality risk in community acquired pneumonia.", "the curb65 score was developed to predict mortality risk in community acquired pneumonia.", "the curb65 score was developed to predict mortality risk in community acquired pneumonia.", "the curb65 score was developed to predict mortality risk in community acquired pneumonia.", "the curb65 score was developed to predict mortality risk in community acquired pneumonia.", "the curb65 score was developed to predict mortality risk in community acquired pneumonia.", "the curb65 score was developed to predict mortality risk in community acquired pneumonia.", "the curb65 score was developed to predict mortality risk in community acquired pneumonia.", "the curb65 score was developed to predict mortality risk in community acquired pneumonia.", "the curb65 score was developed to predict mortality risk in community acquired pneumonia.", "the curb65 score was developed to predict mortality risk in community acquired pneumonia.", "the curb65 score was developed to predict mortality risk in community acquired pneumonia.", "the curb65 score was developed to predict mortality risk in community acquired pneumonia.", "the curb65 score was developed to predict mortality risk in community acquired pneumonia.", "the curb65 score was developed to predict mortality risk in community acquired pneumonia.", "the curb65 score was developed to predict mortality risk in community acquired pneumonia.", "the curb65 score was developed to predict mortality risk in community acquired pneumonia.", "the curb65 score was developed to predict mortality risk in community acquired pneumonia.", "the curb65 score was developed to predict mortality risk in community acquired pneumonia.", "the curb65 score was developed to predict mortality risk in community acquired pneumonia.", "borderline personality disorder (bpd) is characterized by affective instability, but self-injurious behavior appears to have an emotion-regulating effect. we investigated whether pain-mediated affect regulation can be altered at the neural level by residential dialectical behavior therapy (dbt), providing adaptive emotion regulation techniques.", "borderline personality disorder (bpd) is characterized by affective instability, but self-injurious behavior appears to have an emotion-regulating effect. we investigated whether pain-mediated affect regulation can be altered at the neural level by residential dialectical behavior therapy (dbt), providing adaptive emotion regulation techniques.", "borderline personality disorder (bpd) is characterized by affective instability, but self-injurious behavior appears to have an emotion-regulating effect. we investigated whether pain-mediated affect regulation can be altered at the neural level by residential dialectical behavior therapy (dbt), providing adaptive emotion regulation techniques.", "borderline personality disorder (bpd) is characterized by affective instability, but self-injurious behavior appears to have an emotion-regulating effect. we investigated whether pain-mediated affect regulation can be altered at the neural level by residential dialectical behavior therapy (dbt), providing adaptive emotion regulation techniques.", "borderline personality disorder (bpd) is characterized by affective instability, but self-injurious behavior appears to have an emotion-regulating effect. we investigated whether pain-mediated affect regulation can be altered at the neural level by residential dialectical behavior therapy (dbt), providing adaptive emotion regulation techniques.", "borderline personality disorder (bpd) is characterized by affective instability, but self-injurious behavior appears to have an emotion-regulating effect. we investigated whether pain-mediated affect regulation can be altered at the neural level by residential dialectical behavior therapy (dbt), providing adaptive emotion regulation techniques.", "borderline personality disorder (bpd) is characterized by affective instability, but self-injurious behavior appears to have an emotion-regulating effect. we investigated whether pain-mediated affect regulation can be altered at the neural level by residential dialectical behavior therapy (dbt), providing adaptive emotion regulation techniques.", "borderline personality disorder (bpd) is characterized by affective instability, but self-injurious behavior appears to have an emotion-regulating effect. we investigated whether pain-mediated affect regulation can be altered at the neural level by residential dialectical behavior therapy (dbt), providing adaptive emotion regulation techniques.", "borderline personality disorder (bpd) is characterized by affective instability, but self-injurious behavior appears to have an emotion-regulating effect. we investigated whether pain-mediated affect regulation can be altered at the neural level by residential dialectical behavior therapy (dbt), providing adaptive emotion regulation techniques.", "borderline personality disorder (bpd) is characterized by affective instability, but self-injurious behavior appears to have an emotion-regulating effect. we investigated whether pain-mediated affect regulation can be altered at the neural level by residential dialectical behavior therapy (dbt), providing adaptive emotion regulation techniques.", "borderline personality disorder (bpd) is characterized by affective instability, but self-injurious behavior appears to have an emotion-regulating effect. we investigated whether pain-mediated affect regulation can be altered at the neural level by residential dialectical behavior therapy (dbt), providing adaptive emotion regulation techniques.", "borderline personality disorder (bpd) is characterized by affective instability, but self-injurious behavior appears to have an emotion-regulating effect. we investigated whether pain-mediated affect regulation can be altered at the neural level by residential dialectical behavior therapy (dbt), providing adaptive emotion regulation techniques.", "borderline personality disorder (bpd) is characterized by affective instability, but self-injurious behavior appears to have an emotion-regulating effect. we investigated whether pain-mediated affect regulation can be altered at the neural level by residential dialectical behavior therapy (dbt), providing adaptive emotion regulation techniques.", "borderline personality disorder (bpd) is characterized by affective instability, but self-injurious behavior appears to have an emotion-regulating effect. we investigated whether pain-mediated affect regulation can be altered at the neural level by residential dialectical behavior therapy (dbt), providing adaptive emotion regulation techniques.", "borderline personality disorder (bpd) is characterized by affective instability, but self-injurious behavior appears to have an emotion-regulating effect. we investigated whether pain-mediated affect regulation can be altered at the neural level by residential dialectical behavior therapy (dbt), providing adaptive emotion regulation techniques.", "borderline personality disorder (bpd) is characterized by affective instability, but self-injurious behavior appears to have an emotion-regulating effect. we investigated whether pain-mediated affect regulation can be altered at the neural level by residential dialectical behavior therapy (dbt), providing adaptive emotion regulation techniques.", "borderline personality disorder (bpd) is characterized by affective instability, but self-injurious behavior appears to have an emotion-regulating effect. we investigated whether pain-mediated affect regulation can be altered at the neural level by residential dialectical behavior therapy (dbt), providing adaptive emotion regulation techniques.", "borderline personality disorder (bpd) is characterized by affective instability, but self-injurious behavior appears to have an emotion-regulating effect. we investigated whether pain-mediated affect regulation can be altered at the neural level by residential dialectical behavior therapy (dbt), providing adaptive emotion regulation techniques.", "dialectical behavior therapy (dbt) was originally developed by marsha linehan (1991) for the treatment of borderline personality disorder, but because of the core deficits in emotion regulation in disruptive behavior disorders, dbt is also increasingly being recommended for the treatment of cd and apd.", "dialectical behavior therapy (dbt) was originally developed by marsha linehan (1991) for the treatment of borderline personality disorder, but because of the core deficits in emotion regulation in disruptive behavior disorders, dbt is also increasingly being recommended for the treatment of cd and apd.", "dialectical behavior therapy (dbt) was originally developed by marsha linehan (1991) for the treatment of borderline personality disorder, but because of the core deficits in emotion regulation in disruptive behavior disorders, dbt is also increasingly being recommended for the treatment of cd and apd.", "dialectical behavior therapy (dbt) was originally developed by marsha linehan (1991) for the treatment of borderline personality disorder, but because of the core deficits in emotion regulation in disruptive behavior disorders, dbt is also increasingly being recommended for the treatment of cd and apd.", "dialectical behavior therapy (dbt) was originally developed by marsha linehan (1991) for the treatment of borderline personality disorder, but because of the core deficits in emotion regulation in disruptive behavior disorders, dbt is also increasingly being recommended for the treatment of cd and apd.", "dialectical behavior therapy (dbt) was originally developed by marsha linehan (1991) for the treatment of borderline personality disorder, but because of the core deficits in emotion regulation in disruptive behavior disorders, dbt is also increasingly being recommended for the treatment of cd and apd.", "dialectical behavior therapy (dbt) was originally developed by marsha linehan (1991) for the treatment of borderline personality disorder, but because of the core deficits in emotion regulation in disruptive behavior disorders, dbt is also increasingly being recommended for the treatment of cd and apd.", "dialectical behavior therapy (dbt) was originally developed by marsha linehan (1991) for the treatment of borderline personality disorder, but because of the core deficits in emotion regulation in disruptive behavior disorders, dbt is also increasingly being recommended for the treatment of cd and apd.", "dialectical behavior therapy (dbt) was originally developed by marsha linehan (1991) for the treatment of borderline personality disorder, but because of the core deficits in emotion regulation in disruptive behavior disorders, dbt is also increasingly being recommended for the treatment of cd and apd.", "dialectical behavior therapy (dbt) was originally developed by marsha linehan (1991) for the treatment of borderline personality disorder, but because of the core deficits in emotion regulation in disruptive behavior disorders, dbt is also increasingly being recommended for the treatment of cd and apd.", "dialectical behavior therapy (dbt) was originally developed by marsha linehan (1991) for the treatment of borderline personality disorder, but because of the core deficits in emotion regulation in disruptive behavior disorders, dbt is also increasingly being recommended for the treatment of cd and apd.", "dialectical behavior therapy (dbt) was originally developed by marsha linehan (1991) for the treatment of borderline personality disorder, but because of the core deficits in emotion regulation in disruptive behavior disorders, dbt is also increasingly being recommended for the treatment of cd and apd.", "dialectical behavior therapy (dbt) was originally developed by marsha linehan (1991) for the treatment of borderline personality disorder, but because of the core deficits in emotion regulation in disruptive behavior disorders, dbt is also increasingly being recommended for the treatment of cd and apd.", "dialectical behavior therapy (dbt) was originally developed by marsha linehan (1991) for the treatment of borderline personality disorder, but because of the core deficits in emotion regulation in disruptive behavior disorders, dbt is also increasingly being recommended for the treatment of cd and apd.", "dialectical behavior therapy (dbt) was originally developed by marsha linehan (1991) for the treatment of borderline personality disorder, but because of the core deficits in emotion regulation in disruptive behavior disorders, dbt is also increasingly being recommended for the treatment of cd and apd.", "dialectical behavior therapy (dbt) was originally developed by marsha linehan (1991) for the treatment of borderline personality disorder, but because of the core deficits in emotion regulation in disruptive behavior disorders, dbt is also increasingly being recommended for the treatment of cd and apd.", "dialectical behavior therapy (dbt) was originally developed by marsha linehan (1991) for the treatment of borderline personality disorder, but because of the core deficits in emotion regulation in disruptive behavior disorders, dbt is also increasingly being recommended for the treatment of cd and apd.", "dialectical behavior therapy (dbt) was originally developed by marsha linehan (1991) for the treatment of borderline personality disorder, but because of the core deficits in emotion regulation in disruptive behavior disorders, dbt is also increasingly being recommended for the treatment of cd and apd.", "these results suggest that individuals with borderline personality disorder benefited equally from dialectical behavior therapy and a well-specified treatment delivered by psychiatrists with expertise in the treatment of borderline personality disorder..", "these results suggest that individuals with borderline personality disorder benefited equally from dialectical behavior therapy and a well-specified treatment delivered by psychiatrists with expertise in the treatment of borderline personality disorder..", "these results suggest that individuals with borderline personality disorder benefited equally from dialectical behavior therapy and a well-specified treatment delivered by psychiatrists with expertise in the treatment of borderline personality disorder..", "these results suggest that individuals with borderline personality disorder benefited equally from dialectical behavior therapy and a well-specified treatment delivered by psychiatrists with expertise in the treatment of borderline personality disorder..", "these results suggest that individuals with borderline personality disorder benefited equally from dialectical behavior therapy and a well-specified treatment delivered by psychiatrists with expertise in the treatment of borderline personality disorder..", "these results suggest that individuals with borderline personality disorder benefited equally from dialectical behavior therapy and a well-specified treatment delivered by psychiatrists with expertise in the treatment of borderline personality disorder..", "these results suggest that individuals with borderline personality disorder benefited equally from dialectical behavior therapy and a well-specified treatment delivered by psychiatrists with expertise in the treatment of borderline personality disorder..", "these results suggest that individuals with borderline personality disorder benefited equally from dialectical behavior therapy and a well-specified treatment delivered by psychiatrists with expertise in the treatment of borderline personality disorder..", "these results suggest that individuals with borderline personality disorder benefited equally from dialectical behavior therapy and a well-specified treatment delivered by psychiatrists with expertise in the treatment of borderline personality disorder..", "these results suggest that individuals with borderline personality disorder benefited equally from dialectical behavior therapy and a well-specified treatment delivered by psychiatrists with expertise in the treatment of borderline personality disorder..", "these results suggest that individuals with borderline personality disorder benefited equally from dialectical behavior therapy and a well-specified treatment delivered by psychiatrists with expertise in the treatment of borderline personality disorder..", "these results suggest that individuals with borderline personality disorder benefited equally from dialectical behavior therapy and a well-specified treatment delivered by psychiatrists with expertise in the treatment of borderline personality disorder..", "these results suggest that individuals with borderline personality disorder benefited equally from dialectical behavior therapy and a well-specified treatment delivered by psychiatrists with expertise in the treatment of borderline personality disorder..", "these results suggest that individuals with borderline personality disorder benefited equally from dialectical behavior therapy and a well-specified treatment delivered by psychiatrists with expertise in the treatment of borderline personality disorder..", "these results suggest that individuals with borderline personality disorder benefited equally from dialectical behavior therapy and a well-specified treatment delivered by psychiatrists with expertise in the treatment of borderline personality disorder..", "these results suggest that individuals with borderline personality disorder benefited equally from dialectical behavior therapy and a well-specified treatment delivered by psychiatrists with expertise in the treatment of borderline personality disorder..", "these results suggest that individuals with borderline personality disorder benefited equally from dialectical behavior therapy and a well-specified treatment delivered by psychiatrists with expertise in the treatment of borderline personality disorder..", "these results suggest that individuals with borderline personality disorder benefited equally from dialectical behavior therapy and a well-specified treatment delivered by psychiatrists with expertise in the treatment of borderline personality disorder..", "objective the authors describe the use of dialectical behavior therapy (dbt) in treating borderline personality disorder during psychiatry residency, and assess the status of dbt education within psychiatry residencies in the united states.", "objective the authors describe the use of dialectical behavior therapy (dbt) in treating borderline personality disorder during psychiatry residency, and assess the status of dbt education within psychiatry residencies in the united states.", "objective the authors describe the use of dialectical behavior therapy (dbt) in treating borderline personality disorder during psychiatry residency, and assess the status of dbt education within psychiatry residencies in the united states.", "objective the authors describe the use of dialectical behavior therapy (dbt) in treating borderline personality disorder during psychiatry residency, and assess the status of dbt education within psychiatry residencies in the united states.", "objective the authors describe the use of dialectical behavior therapy (dbt) in treating borderline personality disorder during psychiatry residency, and assess the status of dbt education within psychiatry residencies in the united states.", "objective the authors describe the use of dialectical behavior therapy (dbt) in treating borderline personality disorder during psychiatry residency, and assess the status of dbt education within psychiatry residencies in the united states.", "objective the authors describe the use of dialectical behavior therapy (dbt) in treating borderline personality disorder during psychiatry residency, and assess the status of dbt education within psychiatry residencies in the united states.", "objective the authors describe the use of dialectical behavior therapy (dbt) in treating borderline personality disorder during psychiatry residency, and assess the status of dbt education within psychiatry residencies in the united states.", "objective the authors describe the use of dialectical behavior therapy (dbt) in treating borderline personality disorder during psychiatry residency, and assess the status of dbt education within psychiatry residencies in the united states.", "objective the authors describe the use of dialectical behavior therapy (dbt) in treating borderline personality disorder during psychiatry residency, and assess the status of dbt education within psychiatry residencies in the united states.", "objective the authors describe the use of dialectical behavior therapy (dbt) in treating borderline personality disorder during psychiatry residency, and assess the status of dbt education within psychiatry residencies in the united states.", "objective the authors describe the use of dialectical behavior therapy (dbt) in treating borderline personality disorder during psychiatry residency, and assess the status of dbt education within psychiatry residencies in the united states.", "objective the authors describe the use of dialectical behavior therapy (dbt) in treating borderline personality disorder during psychiatry residency, and assess the status of dbt education within psychiatry residencies in the united states.", "objective the authors describe the use of dialectical behavior therapy (dbt) in treating borderline personality disorder during psychiatry residency, and assess the status of dbt education within psychiatry residencies in the united states.", "objective the authors describe the use of dialectical behavior therapy (dbt) in treating borderline personality disorder during psychiatry residency, and assess the status of dbt education within psychiatry residencies in the united states.", "objective the authors describe the use of dialectical behavior therapy (dbt) in treating borderline personality disorder during psychiatry residency, and assess the status of dbt education within psychiatry residencies in the united states.", "objective the authors describe the use of dialectical behavior therapy (dbt) in treating borderline personality disorder during psychiatry residency, and assess the status of dbt education within psychiatry residencies in the united states.", "objective the authors describe the use of dialectical behavior therapy (dbt) in treating borderline personality disorder during psychiatry residency, and assess the status of dbt education within psychiatry residencies in the united states.", "a central component of dialectical behavior therapy (dbt) is the teaching of specific behavioral skills with the aim of helping individuals with borderline personality disorder (bpd) replace maladaptive behaviors with skillful behavior.", "a central component of dialectical behavior therapy (dbt) is the teaching of specific behavioral skills with the aim of helping individuals with borderline personality disorder (bpd) replace maladaptive behaviors with skillful behavior.", "a central component of dialectical behavior therapy (dbt) is the teaching of specific behavioral skills with the aim of helping individuals with borderline personality disorder (bpd) replace maladaptive behaviors with skillful behavior.", "a central component of dialectical behavior therapy (dbt) is the teaching of specific behavioral skills with the aim of helping individuals with borderline personality disorder (bpd) replace maladaptive behaviors with skillful behavior.", "a central component of dialectical behavior therapy (dbt) is the teaching of specific behavioral skills with the aim of helping individuals with borderline personality disorder (bpd) replace maladaptive behaviors with skillful behavior.", "a central component of dialectical behavior therapy (dbt) is the teaching of specific behavioral skills with the aim of helping individuals with borderline personality disorder (bpd) replace maladaptive behaviors with skillful behavior.", "a central component of dialectical behavior therapy (dbt) is the teaching of specific behavioral skills with the aim of helping individuals with borderline personality disorder (bpd) replace maladaptive behaviors with skillful behavior.", "a central component of dialectical behavior therapy (dbt) is the teaching of specific behavioral skills with the aim of helping individuals with borderline personality disorder (bpd) replace maladaptive behaviors with skillful behavior.", "a central component of dialectical behavior therapy (dbt) is the teaching of specific behavioral skills with the aim of helping individuals with borderline personality disorder (bpd) replace maladaptive behaviors with skillful behavior.", "a central component of dialectical behavior therapy (dbt) is the teaching of specific behavioral skills with the aim of helping individuals with borderline personality disorder (bpd) replace maladaptive behaviors with skillful behavior.", "a central component of dialectical behavior therapy (dbt) is the teaching of specific behavioral skills with the aim of helping individuals with borderline personality disorder (bpd) replace maladaptive behaviors with skillful behavior.", "a central component of dialectical behavior therapy (dbt) is the teaching of specific behavioral skills with the aim of helping individuals with borderline personality disorder (bpd) replace maladaptive behaviors with skillful behavior.", "a central component of dialectical behavior therapy (dbt) is the teaching of specific behavioral skills with the aim of helping individuals with borderline personality disorder (bpd) replace maladaptive behaviors with skillful behavior.", "a central component of dialectical behavior therapy (dbt) is the teaching of specific behavioral skills with the aim of helping individuals with borderline personality disorder (bpd) replace maladaptive behaviors with skillful behavior.", "a central component of dialectical behavior therapy (dbt) is the teaching of specific behavioral skills with the aim of helping individuals with borderline personality disorder (bpd) replace maladaptive behaviors with skillful behavior.", "a central component of dialectical behavior therapy (dbt) is the teaching of specific behavioral skills with the aim of helping individuals with borderline personality disorder (bpd) replace maladaptive behaviors with skillful behavior.", "a central component of dialectical behavior therapy (dbt) is the teaching of specific behavioral skills with the aim of helping individuals with borderline personality disorder (bpd) replace maladaptive behaviors with skillful behavior.", "a central component of dialectical behavior therapy (dbt) is the teaching of specific behavioral skills with the aim of helping individuals with borderline personality disorder (bpd) replace maladaptive behaviors with skillful behavior.", "the authors describe the use of dialectical behavior therapy (dbt) in treating borderline personality disorder during psychiatry residency, and assess the status of dbt education within psychiatry residencies in the united states.", "the authors describe the use of dialectical behavior therapy (dbt) in treating borderline personality disorder during psychiatry residency, and assess the status of dbt education within psychiatry residencies in the united states.", "the authors describe the use of dialectical behavior therapy (dbt) in treating borderline personality disorder during psychiatry residency, and assess the status of dbt education within psychiatry residencies in the united states.", "the authors describe the use of dialectical behavior therapy (dbt) in treating borderline personality disorder during psychiatry residency, and assess the status of dbt education within psychiatry residencies in the united states.", "the authors describe the use of dialectical behavior therapy (dbt) in treating borderline personality disorder during psychiatry residency, and assess the status of dbt education within psychiatry residencies in the united states.", "the authors describe the use of dialectical behavior therapy (dbt) in treating borderline personality disorder during psychiatry residency, and assess the status of dbt education within psychiatry residencies in the united states.", "the authors describe the use of dialectical behavior therapy (dbt) in treating borderline personality disorder during psychiatry residency, and assess the status of dbt education within psychiatry residencies in the united states.", "the authors describe the use of dialectical behavior therapy (dbt) in treating borderline personality disorder during psychiatry residency, and assess the status of dbt education within psychiatry residencies in the united states.", "the authors describe the use of dialectical behavior therapy (dbt) in treating borderline personality disorder during psychiatry residency, and assess the status of dbt education within psychiatry residencies in the united states.", "the authors describe the use of dialectical behavior therapy (dbt) in treating borderline personality disorder during psychiatry residency, and assess the status of dbt education within psychiatry residencies in the united states.", "the authors describe the use of dialectical behavior therapy (dbt) in treating borderline personality disorder during psychiatry residency, and assess the status of dbt education within psychiatry residencies in the united states.", "the authors describe the use of dialectical behavior therapy (dbt) in treating borderline personality disorder during psychiatry residency, and assess the status of dbt education within psychiatry residencies in the united states.", "the authors describe the use of dialectical behavior therapy (dbt) in treating borderline personality disorder during psychiatry residency, and assess the status of dbt education within psychiatry residencies in the united states.", "the authors describe the use of dialectical behavior therapy (dbt) in treating borderline personality disorder during psychiatry residency, and assess the status of dbt education within psychiatry residencies in the united states.", "the authors describe the use of dialectical behavior therapy (dbt) in treating borderline personality disorder during psychiatry residency, and assess the status of dbt education within psychiatry residencies in the united states.", "the authors describe the use of dialectical behavior therapy (dbt) in treating borderline personality disorder during psychiatry residency, and assess the status of dbt education within psychiatry residencies in the united states.", "the authors describe the use of dialectical behavior therapy (dbt) in treating borderline personality disorder during psychiatry residency, and assess the status of dbt education within psychiatry residencies in the united states.", "the authors describe the use of dialectical behavior therapy (dbt) in treating borderline personality disorder during psychiatry residency, and assess the status of dbt education within psychiatry residencies in the united states.", "conclusions these results suggest that dialectical behavior therapy is a promising psychosocial intervention for improving interpersonal functioning among severely dysfunctional patients with borderline personality disorder.", "conclusions these results suggest that dialectical behavior therapy is a promising psychosocial intervention for improving interpersonal functioning among severely dysfunctional patients with borderline personality disorder.", "conclusions these results suggest that dialectical behavior therapy is a promising psychosocial intervention for improving interpersonal functioning among severely dysfunctional patients with borderline personality disorder.", "conclusions these results suggest that dialectical behavior therapy is a promising psychosocial intervention for improving interpersonal functioning among severely dysfunctional patients with borderline personality disorder.", "conclusions these results suggest that dialectical behavior therapy is a promising psychosocial intervention for improving interpersonal functioning among severely dysfunctional patients with borderline personality disorder.", "conclusions these results suggest that dialectical behavior therapy is a promising psychosocial intervention for improving interpersonal functioning among severely dysfunctional patients with borderline personality disorder.", "conclusions these results suggest that dialectical behavior therapy is a promising psychosocial intervention for improving interpersonal functioning among severely dysfunctional patients with borderline personality disorder.", "conclusions these results suggest that dialectical behavior therapy is a promising psychosocial intervention for improving interpersonal functioning among severely dysfunctional patients with borderline personality disorder.", "conclusions these results suggest that dialectical behavior therapy is a promising psychosocial intervention for improving interpersonal functioning among severely dysfunctional patients with borderline personality disorder.", "conclusions these results suggest that dialectical behavior therapy is a promising psychosocial intervention for improving interpersonal functioning among severely dysfunctional patients with borderline personality disorder.", "conclusions these results suggest that dialectical behavior therapy is a promising psychosocial intervention for improving interpersonal functioning among severely dysfunctional patients with borderline personality disorder.", "conclusions these results suggest that dialectical behavior therapy is a promising psychosocial intervention for improving interpersonal functioning among severely dysfunctional patients with borderline personality disorder.", "conclusions these results suggest that dialectical behavior therapy is a promising psychosocial intervention for improving interpersonal functioning among severely dysfunctional patients with borderline personality disorder.", "conclusions these results suggest that dialectical behavior therapy is a promising psychosocial intervention for improving interpersonal functioning among severely dysfunctional patients with borderline personality disorder.", "conclusions these results suggest that dialectical behavior therapy is a promising psychosocial intervention for improving interpersonal functioning among severely dysfunctional patients with borderline personality disorder.", "conclusions these results suggest that dialectical behavior therapy is a promising psychosocial intervention for improving interpersonal functioning among severely dysfunctional patients with borderline personality disorder.", "conclusions these results suggest that dialectical behavior therapy is a promising psychosocial intervention for improving interpersonal functioning among severely dysfunctional patients with borderline personality disorder.", "conclusions these results suggest that dialectical behavior therapy is a promising psychosocial intervention for improving interpersonal functioning among severely dysfunctional patients with borderline personality disorder.", "dialectical behavior therapy (dbt) was originally designed as a treatment of emotionally dysregulated, impulsive, and dramatic disorders (e.g., borderline personality disorder) and populations (e.g., parasuicidal women).", "dialectical behavior therapy (dbt) was originally designed as a treatment of emotionally dysregulated, impulsive, and dramatic disorders (e.g., borderline personality disorder) and populations (e.g., parasuicidal women).", "dialectical behavior therapy (dbt) was originally designed as a treatment of emotionally dysregulated, impulsive, and dramatic disorders (e.g., borderline personality disorder) and populations (e.g., parasuicidal women).", "dialectical behavior therapy (dbt) was originally designed as a treatment of emotionally dysregulated, impulsive, and dramatic disorders (e.g., borderline personality disorder) and populations (e.g., parasuicidal women).", "dialectical behavior therapy (dbt) was originally designed as a treatment of emotionally dysregulated, impulsive, and dramatic disorders (e.g., borderline personality disorder) and populations (e.g., parasuicidal women).", "dialectical behavior therapy (dbt) was originally designed as a treatment of emotionally dysregulated, impulsive, and dramatic disorders (e.g., borderline personality disorder) and populations (e.g., parasuicidal women).", "dialectical behavior therapy (dbt) was originally designed as a treatment of emotionally dysregulated, impulsive, and dramatic disorders (e.g., borderline personality disorder) and populations (e.g., parasuicidal women).", "dialectical behavior therapy (dbt) was originally designed as a treatment of emotionally dysregulated, impulsive, and dramatic disorders (e.g., borderline personality disorder) and populations (e.g., parasuicidal women).", "dialectical behavior therapy (dbt) was originally designed as a treatment of emotionally dysregulated, impulsive, and dramatic disorders (e.g., borderline personality disorder) and populations (e.g., parasuicidal women).", "dialectical behavior therapy (dbt) was originally designed as a treatment of emotionally dysregulated, impulsive, and dramatic disorders (e.g., borderline personality disorder) and populations (e.g., parasuicidal women).", "dialectical behavior therapy (dbt) was originally designed as a treatment of emotionally dysregulated, impulsive, and dramatic disorders (e.g., borderline personality disorder) and populations (e.g., parasuicidal women).", "dialectical behavior therapy (dbt) was originally designed as a treatment of emotionally dysregulated, impulsive, and dramatic disorders (e.g., borderline personality disorder) and populations (e.g., parasuicidal women).", "dialectical behavior therapy (dbt) was originally designed as a treatment of emotionally dysregulated, impulsive, and dramatic disorders (e.g., borderline personality disorder) and populations (e.g., parasuicidal women).", "dialectical behavior therapy (dbt) was originally designed as a treatment of emotionally dysregulated, impulsive, and dramatic disorders (e.g., borderline personality disorder) and populations (e.g., parasuicidal women).", "dialectical behavior therapy (dbt) was originally designed as a treatment of emotionally dysregulated, impulsive, and dramatic disorders (e.g., borderline personality disorder) and populations (e.g., parasuicidal women).", "dialectical behavior therapy (dbt) was originally designed as a treatment of emotionally dysregulated, impulsive, and dramatic disorders (e.g., borderline personality disorder) and populations (e.g., parasuicidal women).", "dialectical behavior therapy (dbt) was originally designed as a treatment of emotionally dysregulated, impulsive, and dramatic disorders (e.g., borderline personality disorder) and populations (e.g., parasuicidal women).", "dialectical behavior therapy (dbt) was originally designed as a treatment of emotionally dysregulated, impulsive, and dramatic disorders (e.g., borderline personality disorder) and populations (e.g., parasuicidal women).", "dialectical behavior therapy, an outpatient psychosocial treatment for chronically suicidal women with borderline personality disorder, has been adapted for use in a partial hospital program for women.", "dialectical behavior therapy, an outpatient psychosocial treatment for chronically suicidal women with borderline personality disorder, has been adapted for use in a partial hospital program for women.", "dialectical behavior therapy, an outpatient psychosocial treatment for chronically suicidal women with borderline personality disorder, has been adapted for use in a partial hospital program for women.", "dialectical behavior therapy, an outpatient psychosocial treatment for chronically suicidal women with borderline personality disorder, has been adapted for use in a partial hospital program for women.", "dialectical behavior therapy, an outpatient psychosocial treatment for chronically suicidal women with borderline personality disorder, has been adapted for use in a partial hospital program for women.", "dialectical behavior therapy, an outpatient psychosocial treatment for chronically suicidal women with borderline personality disorder, has been adapted for use in a partial hospital program for women.", "dialectical behavior therapy, an outpatient psychosocial treatment for chronically suicidal women with borderline personality disorder, has been adapted for use in a partial hospital program for women.", "dialectical behavior therapy, an outpatient psychosocial treatment for chronically suicidal women with borderline personality disorder, has been adapted for use in a partial hospital program for women.", "dialectical behavior therapy, an outpatient psychosocial treatment for chronically suicidal women with borderline personality disorder, has been adapted for use in a partial hospital program for women.", "dialectical behavior therapy, an outpatient psychosocial treatment for chronically suicidal women with borderline personality disorder, has been adapted for use in a partial hospital program for women.", "dialectical behavior therapy, an outpatient psychosocial treatment for chronically suicidal women with borderline personality disorder, has been adapted for use in a partial hospital program for women.", "dialectical behavior therapy, an outpatient psychosocial treatment for chronically suicidal women with borderline personality disorder, has been adapted for use in a partial hospital program for women.", "dialectical behavior therapy, an outpatient psychosocial treatment for chronically suicidal women with borderline personality disorder, has been adapted for use in a partial hospital program for women.", "dialectical behavior therapy, an outpatient psychosocial treatment for chronically suicidal women with borderline personality disorder, has been adapted for use in a partial hospital program for women.", "dialectical behavior therapy, an outpatient psychosocial treatment for chronically suicidal women with borderline personality disorder, has been adapted for use in a partial hospital program for women.", "dialectical behavior therapy, an outpatient psychosocial treatment for chronically suicidal women with borderline personality disorder, has been adapted for use in a partial hospital program for women.", "dialectical behavior therapy, an outpatient psychosocial treatment for chronically suicidal women with borderline personality disorder, has been adapted for use in a partial hospital program for women.", "dialectical behavior therapy, an outpatient psychosocial treatment for chronically suicidal women with borderline personality disorder, has been adapted for use in a partial hospital program for women.", "of evaluated psychological treatments in borderline personality disorder, dialectical behaviour therapy (dbt) has the strongest research support, followed by mentalization based therapy (mbt).", "of evaluated psychological treatments in borderline personality disorder, dialectical behaviour therapy (dbt) has the strongest research support, followed by mentalization based therapy (mbt).", "of evaluated psychological treatments in borderline personality disorder, dialectical behaviour therapy (dbt) has the strongest research support, followed by mentalization based therapy (mbt).", "of evaluated psychological treatments in borderline personality disorder, dialectical behaviour therapy (dbt) has the strongest research support, followed by mentalization based therapy (mbt).", "of evaluated psychological treatments in borderline personality disorder, dialectical behaviour therapy (dbt) has the strongest research support, followed by mentalization based therapy (mbt).", "of evaluated psychological treatments in borderline personality disorder, dialectical behaviour therapy (dbt) has the strongest research support, followed by mentalization based therapy (mbt).", "of evaluated psychological treatments in borderline personality disorder, dialectical behaviour therapy (dbt) has the strongest research support, followed by mentalization based therapy (mbt).", "of evaluated psychological treatments in borderline personality disorder, dialectical behaviour therapy (dbt) has the strongest research support, followed by mentalization based therapy (mbt).", "of evaluated psychological treatments in borderline personality disorder, dialectical behaviour therapy (dbt) has the strongest research support, followed by mentalization based therapy (mbt).", "of evaluated psychological treatments in borderline personality disorder, dialectical behaviour therapy (dbt) has the strongest research support, followed by mentalization based therapy (mbt).", "of evaluated psychological treatments in borderline personality disorder, dialectical behaviour therapy (dbt) has the strongest research support, followed by mentalization based therapy (mbt).", "of evaluated psychological treatments in borderline personality disorder, dialectical behaviour therapy (dbt) has the strongest research support, followed by mentalization based therapy (mbt).", "of evaluated psychological treatments in borderline personality disorder, dialectical behaviour therapy (dbt) has the strongest research support, followed by mentalization based therapy (mbt).", "of evaluated psychological treatments in borderline personality disorder, dialectical behaviour therapy (dbt) has the strongest research support, followed by mentalization based therapy (mbt).", "of evaluated psychological treatments in borderline personality disorder, dialectical behaviour therapy (dbt) has the strongest research support, followed by mentalization based therapy (mbt).", "of evaluated psychological treatments in borderline personality disorder, dialectical behaviour therapy (dbt) has the strongest research support, followed by mentalization based therapy (mbt).", "of evaluated psychological treatments in borderline personality disorder, dialectical behaviour therapy (dbt) has the strongest research support, followed by mentalization based therapy (mbt).", "of evaluated psychological treatments in borderline personality disorder, dialectical behaviour therapy (dbt) has the strongest research support, followed by mentalization based therapy (mbt).", "treatment of suicidal and deliberate self-harming patients with borderline personality disorder using dialectical behavioral therapy: the patients' and the therapists' perceptions.", "treatment of suicidal and deliberate self-harming patients with borderline personality disorder using dialectical behavioral therapy: the patients' and the therapists' perceptions.", "treatment of suicidal and deliberate self-harming patients with borderline personality disorder using dialectical behavioral therapy: the patients' and the therapists' perceptions.", "treatment of suicidal and deliberate self-harming patients with borderline personality disorder using dialectical behavioral therapy: the patients' and the therapists' perceptions.", "treatment of suicidal and deliberate self-harming patients with borderline personality disorder using dialectical behavioral therapy: the patients' and the therapists' perceptions.", "treatment of suicidal and deliberate self-harming patients with borderline personality disorder using dialectical behavioral therapy: the patients' and the therapists' perceptions.", "treatment of suicidal and deliberate self-harming patients with borderline personality disorder using dialectical behavioral therapy: the patients' and the therapists' perceptions.", "treatment of suicidal and deliberate self-harming patients with borderline personality disorder using dialectical behavioral therapy: the patients' and the therapists' perceptions.", "treatment of suicidal and deliberate self-harming patients with borderline personality disorder using dialectical behavioral therapy: the patients' and the therapists' perceptions.", "treatment of suicidal and deliberate self-harming patients with borderline personality disorder using dialectical behavioral therapy: the patients' and the therapists' perceptions.", "treatment of suicidal and deliberate self-harming patients with borderline personality disorder using dialectical behavioral therapy: the patients' and the therapists' perceptions.", "treatment of suicidal and deliberate self-harming patients with borderline personality disorder using dialectical behavioral therapy: the patients' and the therapists' perceptions.", "treatment of suicidal and deliberate self-harming patients with borderline personality disorder using dialectical behavioral therapy: the patients' and the therapists' perceptions.", "treatment of suicidal and deliberate self-harming patients with borderline personality disorder using dialectical behavioral therapy: the patients' and the therapists' perceptions.", "treatment of suicidal and deliberate self-harming patients with borderline personality disorder using dialectical behavioral therapy: the patients' and the therapists' perceptions.", "treatment of suicidal and deliberate self-harming patients with borderline personality disorder using dialectical behavioral therapy: the patients' and the therapists' perceptions.", "treatment of suicidal and deliberate self-harming patients with borderline personality disorder using dialectical behavioral therapy: the patients' and the therapists' perceptions.", "treatment of suicidal and deliberate self-harming patients with borderline personality disorder using dialectical behavioral therapy: the patients' and the therapists' perceptions.", "dialectical behavioral therapy and schema-focused therapy also caused a soaring remission rate of diagnostic borderline personality disorder criteria of 57% and 94%, respectively.", "dialectical behavioral therapy and schema-focused therapy also caused a soaring remission rate of diagnostic borderline personality disorder criteria of 57% and 94%, respectively.", "dialectical behavioral therapy and schema-focused therapy also caused a soaring remission rate of diagnostic borderline personality disorder criteria of 57% and 94%, respectively.", "dialectical behavioral therapy and schema-focused therapy also caused a soaring remission rate of diagnostic borderline personality disorder criteria of 57% and 94%, respectively.", "dialectical behavioral therapy and schema-focused therapy also caused a soaring remission rate of diagnostic borderline personality disorder criteria of 57% and 94%, respectively.", "dialectical behavioral therapy and schema-focused therapy also caused a soaring remission rate of diagnostic borderline personality disorder criteria of 57% and 94%, respectively.", "dialectical behavioral therapy and schema-focused therapy also caused a soaring remission rate of diagnostic borderline personality disorder criteria of 57% and 94%, respectively.", "dialectical behavioral therapy and schema-focused therapy also caused a soaring remission rate of diagnostic borderline personality disorder criteria of 57% and 94%, respectively.", "dialectical behavioral therapy and schema-focused therapy also caused a soaring remission rate of diagnostic borderline personality disorder criteria of 57% and 94%, respectively.", "dialectical behavioral therapy and schema-focused therapy also caused a soaring remission rate of diagnostic borderline personality disorder criteria of 57% and 94%, respectively.", "dialectical behavioral therapy and schema-focused therapy also caused a soaring remission rate of diagnostic borderline personality disorder criteria of 57% and 94%, respectively.", "dialectical behavioral therapy and schema-focused therapy also caused a soaring remission rate of diagnostic borderline personality disorder criteria of 57% and 94%, respectively.", "dialectical behavioral therapy and schema-focused therapy also caused a soaring remission rate of diagnostic borderline personality disorder criteria of 57% and 94%, respectively.", "dialectical behavioral therapy and schema-focused therapy also caused a soaring remission rate of diagnostic borderline personality disorder criteria of 57% and 94%, respectively.", "dialectical behavioral therapy and schema-focused therapy also caused a soaring remission rate of diagnostic borderline personality disorder criteria of 57% and 94%, respectively.", "dialectical behavioral therapy and schema-focused therapy also caused a soaring remission rate of diagnostic borderline personality disorder criteria of 57% and 94%, respectively.", "dialectical behavioral therapy and schema-focused therapy also caused a soaring remission rate of diagnostic borderline personality disorder criteria of 57% and 94%, respectively.", "dialectical behavioral therapy and schema-focused therapy also caused a soaring remission rate of diagnostic borderline personality disorder criteria of 57% and 94%, respectively.", "objective: dialectical behavior therapy (dbt) is an evidence-based psychosocial treatment with efficacy in reducing self-harm behaviors in borderline personality disorder (bpd).", "objective: dialectical behavior therapy (dbt) is an evidence-based psychosocial treatment with efficacy in reducing self-harm behaviors in borderline personality disorder (bpd).", "objective: dialectical behavior therapy (dbt) is an evidence-based psychosocial treatment with efficacy in reducing self-harm behaviors in borderline personality disorder (bpd).", "objective: dialectical behavior therapy (dbt) is an evidence-based psychosocial treatment with efficacy in reducing self-harm behaviors in borderline personality disorder (bpd).", "objective: dialectical behavior therapy (dbt) is an evidence-based psychosocial treatment with efficacy in reducing self-harm behaviors in borderline personality disorder (bpd).", "objective: dialectical behavior therapy (dbt) is an evidence-based psychosocial treatment with efficacy in reducing self-harm behaviors in borderline personality disorder (bpd).", "objective: dialectical behavior therapy (dbt) is an evidence-based psychosocial treatment with efficacy in reducing self-harm behaviors in borderline personality disorder (bpd).", "objective: dialectical behavior therapy (dbt) is an evidence-based psychosocial treatment with efficacy in reducing self-harm behaviors in borderline personality disorder (bpd).", "objective: dialectical behavior therapy (dbt) is an evidence-based psychosocial treatment with efficacy in reducing self-harm behaviors in borderline personality disorder (bpd).", "objective: dialectical behavior therapy (dbt) is an evidence-based psychosocial treatment with efficacy in reducing self-harm behaviors in borderline personality disorder (bpd).", "objective: dialectical behavior therapy (dbt) is an evidence-based psychosocial treatment with efficacy in reducing self-harm behaviors in borderline personality disorder (bpd).", "objective: dialectical behavior therapy (dbt) is an evidence-based psychosocial treatment with efficacy in reducing self-harm behaviors in borderline personality disorder (bpd).", "objective: dialectical behavior therapy (dbt) is an evidence-based psychosocial treatment with efficacy in reducing self-harm behaviors in borderline personality disorder (bpd).", "objective: dialectical behavior therapy (dbt) is an evidence-based psychosocial treatment with efficacy in reducing self-harm behaviors in borderline personality disorder (bpd).", "objective: dialectical behavior therapy (dbt) is an evidence-based psychosocial treatment with efficacy in reducing self-harm behaviors in borderline personality disorder (bpd).", "objective: dialectical behavior therapy (dbt) is an evidence-based psychosocial treatment with efficacy in reducing self-harm behaviors in borderline personality disorder (bpd).", "objective: dialectical behavior therapy (dbt) is an evidence-based psychosocial treatment with efficacy in reducing self-harm behaviors in borderline personality disorder (bpd).", "objective: dialectical behavior therapy (dbt) is an evidence-based psychosocial treatment with efficacy in reducing self-harm behaviors in borderline personality disorder (bpd).", "exploring the effectiveness of combined mentalization-based group therapy and dialectical behaviour therapy for inpatients with borderline personality disorder - a pilot study.", "exploring the effectiveness of combined mentalization-based group therapy and dialectical behaviour therapy for inpatients with borderline personality disorder - a pilot study.", "exploring the effectiveness of combined mentalization-based group therapy and dialectical behaviour therapy for inpatients with borderline personality disorder - a pilot study.", "exploring the effectiveness of combined mentalization-based group therapy and dialectical behaviour therapy for inpatients with borderline personality disorder - a pilot study.", "exploring the effectiveness of combined mentalization-based group therapy and dialectical behaviour therapy for inpatients with borderline personality disorder - a pilot study.", "exploring the effectiveness of combined mentalization-based group therapy and dialectical behaviour therapy for inpatients with borderline personality disorder - a pilot study.", "exploring the effectiveness of combined mentalization-based group therapy and dialectical behaviour therapy for inpatients with borderline personality disorder - a pilot study.", "exploring the effectiveness of combined mentalization-based group therapy and dialectical behaviour therapy for inpatients with borderline personality disorder - a pilot study.", "exploring the effectiveness of combined mentalization-based group therapy and dialectical behaviour therapy for inpatients with borderline personality disorder - a pilot study.", "exploring the effectiveness of combined mentalization-based group therapy and dialectical behaviour therapy for inpatients with borderline personality disorder - a pilot study.", "exploring the effectiveness of combined mentalization-based group therapy and dialectical behaviour therapy for inpatients with borderline personality disorder - a pilot study.", "exploring the effectiveness of combined mentalization-based group therapy and dialectical behaviour therapy for inpatients with borderline personality disorder - a pilot study.", "exploring the effectiveness of combined mentalization-based group therapy and dialectical behaviour therapy for inpatients with borderline personality disorder - a pilot study.", "exploring the effectiveness of combined mentalization-based group therapy and dialectical behaviour therapy for inpatients with borderline personality disorder - a pilot study.", "exploring the effectiveness of combined mentalization-based group therapy and dialectical behaviour therapy for inpatients with borderline personality disorder - a pilot study.", "exploring the effectiveness of combined mentalization-based group therapy and dialectical behaviour therapy for inpatients with borderline personality disorder - a pilot study.", "exploring the effectiveness of combined mentalization-based group therapy and dialectical behaviour therapy for inpatients with borderline personality disorder - a pilot study.", "exploring the effectiveness of combined mentalization-based group therapy and dialectical behaviour therapy for inpatients with borderline personality disorder - a pilot study.", "objectiveinvestigate influence and change of self-directedness (sd) in dialectical-behavior therapy (dbt) for 26 female outpatients with borderline personality disorder (bps).", "objectiveinvestigate influence and change of self-directedness (sd) in dialectical-behavior therapy (dbt) for 26 female outpatients with borderline personality disorder (bps).", "objectiveinvestigate influence and change of self-directedness (sd) in dialectical-behavior therapy (dbt) for 26 female outpatients with borderline personality disorder (bps).", "objectiveinvestigate influence and change of self-directedness (sd) in dialectical-behavior therapy (dbt) for 26 female outpatients with borderline personality disorder (bps).", "objectiveinvestigate influence and change of self-directedness (sd) in dialectical-behavior therapy (dbt) for 26 female outpatients with borderline personality disorder (bps).", "objectiveinvestigate influence and change of self-directedness (sd) in dialectical-behavior therapy (dbt) for 26 female outpatients with borderline personality disorder (bps).", "objectiveinvestigate influence and change of self-directedness (sd) in dialectical-behavior therapy (dbt) for 26 female outpatients with borderline personality disorder (bps).", "objectiveinvestigate influence and change of self-directedness (sd) in dialectical-behavior therapy (dbt) for 26 female outpatients with borderline personality disorder (bps).", "objectiveinvestigate influence and change of self-directedness (sd) in dialectical-behavior therapy (dbt) for 26 female outpatients with borderline personality disorder (bps).", "objectiveinvestigate influence and change of self-directedness (sd) in dialectical-behavior therapy (dbt) for 26 female outpatients with borderline personality disorder (bps).", "objectiveinvestigate influence and change of self-directedness (sd) in dialectical-behavior therapy (dbt) for 26 female outpatients with borderline personality disorder (bps).", "objectiveinvestigate influence and change of self-directedness (sd) in dialectical-behavior therapy (dbt) for 26 female outpatients with borderline personality disorder (bps).", "objectiveinvestigate influence and change of self-directedness (sd) in dialectical-behavior therapy (dbt) for 26 female outpatients with borderline personality disorder (bps).", "objectiveinvestigate influence and change of self-directedness (sd) in dialectical-behavior therapy (dbt) for 26 female outpatients with borderline personality disorder (bps).", "objectiveinvestigate influence and change of self-directedness (sd) in dialectical-behavior therapy (dbt) for 26 female outpatients with borderline personality disorder (bps).", "objectiveinvestigate influence and change of self-directedness (sd) in dialectical-behavior therapy (dbt) for 26 female outpatients with borderline personality disorder (bps).", "objectiveinvestigate influence and change of self-directedness (sd) in dialectical-behavior therapy (dbt) for 26 female outpatients with borderline personality disorder (bps).", "objectiveinvestigate influence and change of self-directedness (sd) in dialectical-behavior therapy (dbt) for 26 female outpatients with borderline personality disorder (bps).", "objective at present, the most frequently investigated psychosocial intervention for borderline personality disorder (bpd) is dialectical behavior therapy (dbt).", "objective at present, the most frequently investigated psychosocial intervention for borderline personality disorder (bpd) is dialectical behavior therapy (dbt).", "objective at present, the most frequently investigated psychosocial intervention for borderline personality disorder (bpd) is dialectical behavior therapy (dbt).", "objective at present, the most frequently investigated psychosocial intervention for borderline personality disorder (bpd) is dialectical behavior therapy (dbt).", "objective at present, the most frequently investigated psychosocial intervention for borderline personality disorder (bpd) is dialectical behavior therapy (dbt).", "objective at present, the most frequently investigated psychosocial intervention for borderline personality disorder (bpd) is dialectical behavior therapy (dbt).", "objective at present, the most frequently investigated psychosocial intervention for borderline personality disorder (bpd) is dialectical behavior therapy (dbt).", "objective at present, the most frequently investigated psychosocial intervention for borderline personality disorder (bpd) is dialectical behavior therapy (dbt).", "objective at present, the most frequently investigated psychosocial intervention for borderline personality disorder (bpd) is dialectical behavior therapy (dbt).", "objective at present, the most frequently investigated psychosocial intervention for borderline personality disorder (bpd) is dialectical behavior therapy (dbt).", "objective at present, the most frequently investigated psychosocial intervention for borderline personality disorder (bpd) is dialectical behavior therapy (dbt).", "objective at present, the most frequently investigated psychosocial intervention for borderline personality disorder (bpd) is dialectical behavior therapy (dbt).", "objective at present, the most frequently investigated psychosocial intervention for borderline personality disorder (bpd) is dialectical behavior therapy (dbt).", "objective at present, the most frequently investigated psychosocial intervention for borderline personality disorder (bpd) is dialectical behavior therapy (dbt).", "objective at present, the most frequently investigated psychosocial intervention for borderline personality disorder (bpd) is dialectical behavior therapy (dbt).", "objective at present, the most frequently investigated psychosocial intervention for borderline personality disorder (bpd) is dialectical behavior therapy (dbt).", "objective at present, the most frequently investigated psychosocial intervention for borderline personality disorder (bpd) is dialectical behavior therapy (dbt).", "objective at present, the most frequently investigated psychosocial intervention for borderline personality disorder (bpd) is dialectical behavior therapy (dbt).", "pain-mediated affect regulation is reduced after dialectical behavior therapy in borderline personality disorder: a longitudinal fmri study.", "pain-mediated affect regulation is reduced after dialectical behavior therapy in borderline personality disorder: a longitudinal fmri study.", "pain-mediated affect regulation is reduced after dialectical behavior therapy in borderline personality disorder: a longitudinal fmri study.", "pain-mediated affect regulation is reduced after dialectical behavior therapy in borderline personality disorder: a longitudinal fmri study.", "pain-mediated affect regulation is reduced after dialectical behavior therapy in borderline personality disorder: a longitudinal fmri study.", "pain-mediated affect regulation is reduced after dialectical behavior therapy in borderline personality disorder: a longitudinal fmri study.", "pain-mediated affect regulation is reduced after dialectical behavior therapy in borderline personality disorder: a longitudinal fmri study.", "pain-mediated affect regulation is reduced after dialectical behavior therapy in borderline personality disorder: a longitudinal fmri study.", "pain-mediated affect regulation is reduced after dialectical behavior therapy in borderline personality disorder: a longitudinal fmri study.", "pain-mediated affect regulation is reduced after dialectical behavior therapy in borderline personality disorder: a longitudinal fmri study.", "pain-mediated affect regulation is reduced after dialectical behavior therapy in borderline personality disorder: a longitudinal fmri study.", "pain-mediated affect regulation is reduced after dialectical behavior therapy in borderline personality disorder: a longitudinal fmri study.", "pain-mediated affect regulation is reduced after dialectical behavior therapy in borderline personality disorder: a longitudinal fmri study.", "pain-mediated affect regulation is reduced after dialectical behavior therapy in borderline personality disorder: a longitudinal fmri study.", "pain-mediated affect regulation is reduced after dialectical behavior therapy in borderline personality disorder: a longitudinal fmri study.", "pain-mediated affect regulation is reduced after dialectical behavior therapy in borderline personality disorder: a longitudinal fmri study.", "pain-mediated affect regulation is reduced after dialectical behavior therapy in borderline personality disorder: a longitudinal fmri study.", "pain-mediated affect regulation is reduced after dialectical behavior therapy in borderline personality disorder: a longitudinal fmri study.", "objective: dialectical behavior therapy (dbt) is an empirically supported treatment for outpatients with borderline personality disorder.", "objective: dialectical behavior therapy (dbt) is an empirically supported treatment for outpatients with borderline personality disorder.", "objective: dialectical behavior therapy (dbt) is an empirically supported treatment for outpatients with borderline personality disorder.", "objective: dialectical behavior therapy (dbt) is an empirically supported treatment for outpatients with borderline personality disorder.", "objective: dialectical behavior therapy (dbt) is an empirically supported treatment for outpatients with borderline personality disorder.", "objective: dialectical behavior therapy (dbt) is an empirically supported treatment for outpatients with borderline personality disorder.", "objective: dialectical behavior therapy (dbt) is an empirically supported treatment for outpatients with borderline personality disorder.", "objective: dialectical behavior therapy (dbt) is an empirically supported treatment for outpatients with borderline personality disorder.", "objective: dialectical behavior therapy (dbt) is an empirically supported treatment for outpatients with borderline personality disorder.", "objective: dialectical behavior therapy (dbt) is an empirically supported treatment for outpatients with borderline personality disorder.", "objective: dialectical behavior therapy (dbt) is an empirically supported treatment for outpatients with borderline personality disorder.", "objective: dialectical behavior therapy (dbt) is an empirically supported treatment for outpatients with borderline personality disorder.", "objective: dialectical behavior therapy (dbt) is an empirically supported treatment for outpatients with borderline personality disorder.", "objective: dialectical behavior therapy (dbt) is an empirically supported treatment for outpatients with borderline personality disorder.", "objective: dialectical behavior therapy (dbt) is an empirically supported treatment for outpatients with borderline personality disorder.", "objective: dialectical behavior therapy (dbt) is an empirically supported treatment for outpatients with borderline personality disorder.", "objective: dialectical behavior therapy (dbt) is an empirically supported treatment for outpatients with borderline personality disorder.", "objective: dialectical behavior therapy (dbt) is an empirically supported treatment for outpatients with borderline personality disorder.", "neural correlates of distraction in borderline personality disorder before and after dialectical behavior therapy.", "neural correlates of distraction in borderline personality disorder before and after dialectical behavior therapy.", "neural correlates of distraction in borderline personality disorder before and after dialectical behavior therapy.", "neural correlates of distraction in borderline personality disorder before and after dialectical behavior therapy.", "neural correlates of distraction in borderline personality disorder before and after dialectical behavior therapy.", "neural correlates of distraction in borderline personality disorder before and after dialectical behavior therapy.", "neural correlates of distraction in borderline personality disorder before and after dialectical behavior therapy.", "neural correlates of distraction in borderline personality disorder before and after dialectical behavior therapy.", "neural correlates of distraction in borderline personality disorder before and after dialectical behavior therapy.", "neural correlates of distraction in borderline personality disorder before and after dialectical behavior therapy.", "neural correlates of distraction in borderline personality disorder before and after dialectical behavior therapy.", "neural correlates of distraction in borderline personality disorder before and after dialectical behavior therapy.", "neural correlates of distraction in borderline personality disorder before and after dialectical behavior therapy.", "neural correlates of distraction in borderline personality disorder before and after dialectical behavior therapy.", "neural correlates of distraction in borderline personality disorder before and after dialectical behavior therapy.", "neural correlates of distraction in borderline personality disorder before and after dialectical behavior therapy.", "neural correlates of distraction in borderline personality disorder before and after dialectical behavior therapy.", "neural correlates of distraction in borderline personality disorder before and after dialectical behavior therapy.", "use of dialectical behavior therapy in borderline personality disorder: a view from residency.", "use of dialectical behavior therapy in borderline personality disorder: a view from residency.", "use of dialectical behavior therapy in borderline personality disorder: a view from residency.", "use of dialectical behavior therapy in borderline personality disorder: a view from residency.", "use of dialectical behavior therapy in borderline personality disorder: a view from residency.", "use of dialectical behavior therapy in borderline personality disorder: a view from residency.", "use of dialectical behavior therapy in borderline personality disorder: a view from residency.", "use of dialectical behavior therapy in borderline personality disorder: a view from residency.", "use of dialectical behavior therapy in borderline personality disorder: a view from residency.", "use of dialectical behavior therapy in borderline personality disorder: a view from residency.", "use of dialectical behavior therapy in borderline personality disorder: a view from residency.", "use of dialectical behavior therapy in borderline personality disorder: a view from residency.", "use of dialectical behavior therapy in borderline personality disorder: a view from residency.", "use of dialectical behavior therapy in borderline personality disorder: a view from residency.", "use of dialectical behavior therapy in borderline personality disorder: a view from residency.", "use of dialectical behavior therapy in borderline personality disorder: a view from residency.", "use of dialectical behavior therapy in borderline personality disorder: a view from residency.", "use of dialectical behavior therapy in borderline personality disorder: a view from residency.", "<b>background</b>: we investigated the validity of probe-to-bone testing in the diagnosis of osteomyelitis in a selected subgroup of patients clinically suspected of having diabetic foot osteomyelitis.<br><b>methods</b>: between january 1, 2007, and december 31, 2008, inpatients and outpatients with a diabetic foot ulcer were prospectively evaluated, and those having a clinical diagnosis of foot infection and at least one of the osteomyelitis clinical suspicion criteria were consecutively included in this study.<br><b>results</b>: sixty-five patients met the inclusion criteria and were prospectively enrolled in the study.", "<b>background</b>: we investigated the validity of probe-to-bone testing in the diagnosis of osteomyelitis in a selected subgroup of patients clinically suspected of having diabetic foot osteomyelitis.<br><b>methods</b>: between january 1, 2007, and december 31, 2008, inpatients and outpatients with a diabetic foot ulcer were prospectively evaluated, and those having a clinical diagnosis of foot infection and at least one of the osteomyelitis clinical suspicion criteria were consecutively included in this study.<br><b>results</b>: sixty-five patients met the inclusion criteria and were prospectively enrolled in the study.", "<b>background</b>: we investigated the validity of probe-to-bone testing in the diagnosis of osteomyelitis in a selected subgroup of patients clinically suspected of having diabetic foot osteomyelitis.<br><b>methods</b>: between january 1, 2007, and december 31, 2008, inpatients and outpatients with a diabetic foot ulcer were prospectively evaluated, and those having a clinical diagnosis of foot infection and at least one of the osteomyelitis clinical suspicion criteria were consecutively included in this study.<br><b>results</b>: sixty-five patients met the inclusion criteria and were prospectively enrolled in the study.", "<b>background</b>: we investigated the validity of probe-to-bone testing in the diagnosis of osteomyelitis in a selected subgroup of patients clinically suspected of having diabetic foot osteomyelitis.<br><b>methods</b>: between january 1, 2007, and december 31, 2008, inpatients and outpatients with a diabetic foot ulcer were prospectively evaluated, and those having a clinical diagnosis of foot infection and at least one of the osteomyelitis clinical suspicion criteria were consecutively included in this study.<br><b>results</b>: sixty-five patients met the inclusion criteria and were prospectively enrolled in the study.", "<b>background</b>: we investigated the validity of probe-to-bone testing in the diagnosis of osteomyelitis in a selected subgroup of patients clinically suspected of having diabetic foot osteomyelitis.<br><b>methods</b>: between january 1, 2007, and december 31, 2008, inpatients and outpatients with a diabetic foot ulcer were prospectively evaluated, and those having a clinical diagnosis of foot infection and at least one of the osteomyelitis clinical suspicion criteria were consecutively included in this study.<br><b>results</b>: sixty-five patients met the inclusion criteria and were prospectively enrolled in the study.", "<b>background</b>: we investigated the validity of probe-to-bone testing in the diagnosis of osteomyelitis in a selected subgroup of patients clinically suspected of having diabetic foot osteomyelitis.<br><b>methods</b>: between january 1, 2007, and december 31, 2008, inpatients and outpatients with a diabetic foot ulcer were prospectively evaluated, and those having a clinical diagnosis of foot infection and at least one of the osteomyelitis clinical suspicion criteria were consecutively included in this study.<br><b>results</b>: sixty-five patients met the inclusion criteria and were prospectively enrolled in the study.", "<b>background</b>: we investigated the validity of probe-to-bone testing in the diagnosis of osteomyelitis in a selected subgroup of patients clinically suspected of having diabetic foot osteomyelitis.<br><b>methods</b>: between january 1, 2007, and december 31, 2008, inpatients and outpatients with a diabetic foot ulcer were prospectively evaluated, and those having a clinical diagnosis of foot infection and at least one of the osteomyelitis clinical suspicion criteria were consecutively included in this study.<br><b>results</b>: sixty-five patients met the inclusion criteria and were prospectively enrolled in the study.", "<b>background</b>: we investigated the validity of probe-to-bone testing in the diagnosis of osteomyelitis in a selected subgroup of patients clinically suspected of having diabetic foot osteomyelitis.<br><b>methods</b>: between january 1, 2007, and december 31, 2008, inpatients and outpatients with a diabetic foot ulcer were prospectively evaluated, and those having a clinical diagnosis of foot infection and at least one of the osteomyelitis clinical suspicion criteria were consecutively included in this study.<br><b>results</b>: sixty-five patients met the inclusion criteria and were prospectively enrolled in the study.", "<b>background</b>: we investigated the validity of probe-to-bone testing in the diagnosis of osteomyelitis in a selected subgroup of patients clinically suspected of having diabetic foot osteomyelitis.<br><b>methods</b>: between january 1, 2007, and december 31, 2008, inpatients and outpatients with a diabetic foot ulcer were prospectively evaluated, and those having a clinical diagnosis of foot infection and at least one of the osteomyelitis clinical suspicion criteria were consecutively included in this study.<br><b>results</b>: sixty-five patients met the inclusion criteria and were prospectively enrolled in the study.", "<b>background</b>: we investigated the validity of probe-to-bone testing in the diagnosis of osteomyelitis in a selected subgroup of patients clinically suspected of having diabetic foot osteomyelitis.<br><b>methods</b>: between january 1, 2007, and december 31, 2008, inpatients and outpatients with a diabetic foot ulcer were prospectively evaluated, and those having a clinical diagnosis of foot infection and at least one of the osteomyelitis clinical suspicion criteria were consecutively included in this study.<br><b>results</b>: sixty-five patients met the inclusion criteria and were prospectively enrolled in the study.", "<b>background</b>: we investigated the validity of probe-to-bone testing in the diagnosis of osteomyelitis in a selected subgroup of patients clinically suspected of having diabetic foot osteomyelitis.<br><b>methods</b>: between january 1, 2007, and december 31, 2008, inpatients and outpatients with a diabetic foot ulcer were prospectively evaluated, and those having a clinical diagnosis of foot infection and at least one of the osteomyelitis clinical suspicion criteria were consecutively included in this study.<br><b>results</b>: sixty-five patients met the inclusion criteria and were prospectively enrolled in the study.", "<b>background</b>: we investigated the validity of probe-to-bone testing in the diagnosis of osteomyelitis in a selected subgroup of patients clinically suspected of having diabetic foot osteomyelitis.<br><b>methods</b>: between january 1, 2007, and december 31, 2008, inpatients and outpatients with a diabetic foot ulcer were prospectively evaluated, and those having a clinical diagnosis of foot infection and at least one of the osteomyelitis clinical suspicion criteria were consecutively included in this study.<br><b>results</b>: sixty-five patients met the inclusion criteria and were prospectively enrolled in the study.", "<b>background</b>: we investigated the validity of probe-to-bone testing in the diagnosis of osteomyelitis in a selected subgroup of patients clinically suspected of having diabetic foot osteomyelitis.<br><b>methods</b>: between january 1, 2007, and december 31, 2008, inpatients and outpatients with a diabetic foot ulcer were prospectively evaluated, and those having a clinical diagnosis of foot infection and at least one of the osteomyelitis clinical suspicion criteria were consecutively included in this study.<br><b>results</b>: sixty-five patients met the inclusion criteria and were prospectively enrolled in the study.", "<b>background</b>: we investigated the validity of probe-to-bone testing in the diagnosis of osteomyelitis in a selected subgroup of patients clinically suspected of having diabetic foot osteomyelitis.<br><b>methods</b>: between january 1, 2007, and december 31, 2008, inpatients and outpatients with a diabetic foot ulcer were prospectively evaluated, and those having a clinical diagnosis of foot infection and at least one of the osteomyelitis clinical suspicion criteria were consecutively included in this study.<br><b>results</b>: sixty-five patients met the inclusion criteria and were prospectively enrolled in the study.", "<b>background</b>: we investigated the validity of probe-to-bone testing in the diagnosis of osteomyelitis in a selected subgroup of patients clinically suspected of having diabetic foot osteomyelitis.<br><b>methods</b>: between january 1, 2007, and december 31, 2008, inpatients and outpatients with a diabetic foot ulcer were prospectively evaluated, and those having a clinical diagnosis of foot infection and at least one of the osteomyelitis clinical suspicion criteria were consecutively included in this study.<br><b>results</b>: sixty-five patients met the inclusion criteria and were prospectively enrolled in the study.", "<b>background</b>: we investigated the validity of probe-to-bone testing in the diagnosis of osteomyelitis in a selected subgroup of patients clinically suspected of having diabetic foot osteomyelitis.<br><b>methods</b>: between january 1, 2007, and december 31, 2008, inpatients and outpatients with a diabetic foot ulcer were prospectively evaluated, and those having a clinical diagnosis of foot infection and at least one of the osteomyelitis clinical suspicion criteria were consecutively included in this study.<br><b>results</b>: sixty-five patients met the inclusion criteria and were prospectively enrolled in the study.", "<b>background</b>: we investigated the validity of probe-to-bone testing in the diagnosis of osteomyelitis in a selected subgroup of patients clinically suspected of having diabetic foot osteomyelitis.<br><b>methods</b>: between january 1, 2007, and december 31, 2008, inpatients and outpatients with a diabetic foot ulcer were prospectively evaluated, and those having a clinical diagnosis of foot infection and at least one of the osteomyelitis clinical suspicion criteria were consecutively included in this study.<br><b>results</b>: sixty-five patients met the inclusion criteria and were prospectively enrolled in the study.", "<b>background</b>: we investigated the validity of probe-to-bone testing in the diagnosis of osteomyelitis in a selected subgroup of patients clinically suspected of having diabetic foot osteomyelitis.<br><b>methods</b>: between january 1, 2007, and december 31, 2008, inpatients and outpatients with a diabetic foot ulcer were prospectively evaluated, and those having a clinical diagnosis of foot infection and at least one of the osteomyelitis clinical suspicion criteria were consecutively included in this study.<br><b>results</b>: sixty-five patients met the inclusion criteria and were prospectively enrolled in the study.", "<b>background</b>: we investigated the validity of probe-to-bone testing in the diagnosis of osteomyelitis in a selected subgroup of patients clinically suspected of having diabetic foot osteomyelitis.<br><b>methods</b>: between january 1, 2007, and december 31, 2008, inpatients and outpatients with a diabetic foot ulcer were prospectively evaluated, and those having a clinical diagnosis of foot infection and at least one of the osteomyelitis clinical suspicion criteria were consecutively included in this study.<br><b>results</b>: sixty-five patients met the inclusion criteria and were prospectively enrolled in the study.", "<b>background</b>: we investigated the validity of probe-to-bone testing in the diagnosis of osteomyelitis in a selected subgroup of patients clinically suspected of having diabetic foot osteomyelitis.<br><b>methods</b>: between january 1, 2007, and december 31, 2008, inpatients and outpatients with a diabetic foot ulcer were prospectively evaluated, and those having a clinical diagnosis of foot infection and at least one of the osteomyelitis clinical suspicion criteria were consecutively included in this study.<br><b>results</b>: sixty-five patients met the inclusion criteria and were prospectively enrolled in the study.", "<b>background</b>: we investigated the validity of probe-to-bone testing in the diagnosis of osteomyelitis in a selected subgroup of patients clinically suspected of having diabetic foot osteomyelitis.<br><b>methods</b>: between january 1, 2007, and december 31, 2008, inpatients and outpatients with a diabetic foot ulcer were prospectively evaluated, and those having a clinical diagnosis of foot infection and at least one of the osteomyelitis clinical suspicion criteria were consecutively included in this study.<br><b>results</b>: sixty-five patients met the inclusion criteria and were prospectively enrolled in the study.", "<b>background</b>: we investigated the validity of probe-to-bone testing in the diagnosis of osteomyelitis in a selected subgroup of patients clinically suspected of having diabetic foot osteomyelitis.<br><b>methods</b>: between january 1, 2007, and december 31, 2008, inpatients and outpatients with a diabetic foot ulcer were prospectively evaluated, and those having a clinical diagnosis of foot infection and at least one of the osteomyelitis clinical suspicion criteria were consecutively included in this study.<br><b>results</b>: sixty-five patients met the inclusion criteria and were prospectively enrolled in the study.", "<b>background</b>: we investigated the validity of probe-to-bone testing in the diagnosis of osteomyelitis in a selected subgroup of patients clinically suspected of having diabetic foot osteomyelitis.<br><b>methods</b>: between january 1, 2007, and december 31, 2008, inpatients and outpatients with a diabetic foot ulcer were prospectively evaluated, and those having a clinical diagnosis of foot infection and at least one of the osteomyelitis clinical suspicion criteria were consecutively included in this study.<br><b>results</b>: sixty-five patients met the inclusion criteria and were prospectively enrolled in the study.", "<b>background</b>: we investigated the validity of probe-to-bone testing in the diagnosis of osteomyelitis in a selected subgroup of patients clinically suspected of having diabetic foot osteomyelitis.<br><b>methods</b>: between january 1, 2007, and december 31, 2008, inpatients and outpatients with a diabetic foot ulcer were prospectively evaluated, and those having a clinical diagnosis of foot infection and at least one of the osteomyelitis clinical suspicion criteria were consecutively included in this study.<br><b>results</b>: sixty-five patients met the inclusion criteria and were prospectively enrolled in the study.", "<b>background</b>: we investigated the validity of probe-to-bone testing in the diagnosis of osteomyelitis in a selected subgroup of patients clinically suspected of having diabetic foot osteomyelitis.<br><b>methods</b>: between january 1, 2007, and december 31, 2008, inpatients and outpatients with a diabetic foot ulcer were prospectively evaluated, and those having a clinical diagnosis of foot infection and at least one of the osteomyelitis clinical suspicion criteria were consecutively included in this study.<br><b>results</b>: sixty-five patients met the inclusion criteria and were prospectively enrolled in the study.", "<b>background</b>: we investigated the validity of probe-to-bone testing in the diagnosis of osteomyelitis in a selected subgroup of patients clinically suspected of having diabetic foot osteomyelitis.<br><b>methods</b>: between january 1, 2007, and december 31, 2008, inpatients and outpatients with a diabetic foot ulcer were prospectively evaluated, and those having a clinical diagnosis of foot infection and at least one of the osteomyelitis clinical suspicion criteria were consecutively included in this study.<br><b>results</b>: sixty-five patients met the inclusion criteria and were prospectively enrolled in the study.", "<b>background</b>: we investigated the validity of probe-to-bone testing in the diagnosis of osteomyelitis in a selected subgroup of patients clinically suspected of having diabetic foot osteomyelitis.<br><b>methods</b>: between january 1, 2007, and december 31, 2008, inpatients and outpatients with a diabetic foot ulcer were prospectively evaluated, and those having a clinical diagnosis of foot infection and at least one of the osteomyelitis clinical suspicion criteria were consecutively included in this study.<br><b>results</b>: sixty-five patients met the inclusion criteria and were prospectively enrolled in the study.", "<b>background</b>: we investigated the validity of probe-to-bone testing in the diagnosis of osteomyelitis in a selected subgroup of patients clinically suspected of having diabetic foot osteomyelitis.<br><b>methods</b>: between january 1, 2007, and december 31, 2008, inpatients and outpatients with a diabetic foot ulcer were prospectively evaluated, and those having a clinical diagnosis of foot infection and at least one of the osteomyelitis clinical suspicion criteria were consecutively included in this study.<br><b>results</b>: sixty-five patients met the inclusion criteria and were prospectively enrolled in the study.", "<b>background</b>: we investigated the validity of probe-to-bone testing in the diagnosis of osteomyelitis in a selected subgroup of patients clinically suspected of having diabetic foot osteomyelitis.<br><b>methods</b>: between january 1, 2007, and december 31, 2008, inpatients and outpatients with a diabetic foot ulcer were prospectively evaluated, and those having a clinical diagnosis of foot infection and at least one of the osteomyelitis clinical suspicion criteria were consecutively included in this study.<br><b>results</b>: sixty-five patients met the inclusion criteria and were prospectively enrolled in the study.", "magnetic resonance imaging (mri) has a higher sensitivity and specificity (90% and 79%) than plain radiography (54% and 68%) for diagnosing diabetic foot osteomyelitis. mri performs somewhat better than any of several common tests--probe to bone (ptb), erythrocyte sedimentation rate (esr)>70 mm/hr, c-reactive protein (crp)>14 mg/l, procalcitonin>0.3 ng/ml, and ulcer size>2 cm\u00b2--although ptb has the highest specificity of any test and is commonly used together with mri.", "magnetic resonance imaging (mri) has a higher sensitivity and specificity (90% and 79%) than plain radiography (54% and 68%) for diagnosing diabetic foot osteomyelitis. mri performs somewhat better than any of several common tests--probe to bone (ptb), erythrocyte sedimentation rate (esr)>70 mm/hr, c-reactive protein (crp)>14 mg/l, procalcitonin>0.3 ng/ml, and ulcer size>2 cm\u00b2--although ptb has the highest specificity of any test and is commonly used together with mri.", "magnetic resonance imaging (mri) has a higher sensitivity and specificity (90% and 79%) than plain radiography (54% and 68%) for diagnosing diabetic foot osteomyelitis. mri performs somewhat better than any of several common tests--probe to bone (ptb), erythrocyte sedimentation rate (esr)>70 mm/hr, c-reactive protein (crp)>14 mg/l, procalcitonin>0.3 ng/ml, and ulcer size>2 cm\u00b2--although ptb has the highest specificity of any test and is commonly used together with mri.", "magnetic resonance imaging (mri) has a higher sensitivity and specificity (90% and 79%) than plain radiography (54% and 68%) for diagnosing diabetic foot osteomyelitis. mri performs somewhat better than any of several common tests--probe to bone (ptb), erythrocyte sedimentation rate (esr)>70 mm/hr, c-reactive protein (crp)>14 mg/l, procalcitonin>0.3 ng/ml, and ulcer size>2 cm\u00b2--although ptb has the highest specificity of any test and is commonly used together with mri.", "magnetic resonance imaging (mri) has a higher sensitivity and specificity (90% and 79%) than plain radiography (54% and 68%) for diagnosing diabetic foot osteomyelitis. mri performs somewhat better than any of several common tests--probe to bone (ptb), erythrocyte sedimentation rate (esr)>70 mm/hr, c-reactive protein (crp)>14 mg/l, procalcitonin>0.3 ng/ml, and ulcer size>2 cm\u00b2--although ptb has the highest specificity of any test and is commonly used together with mri.", "magnetic resonance imaging (mri) has a higher sensitivity and specificity (90% and 79%) than plain radiography (54% and 68%) for diagnosing diabetic foot osteomyelitis. mri performs somewhat better than any of several common tests--probe to bone (ptb), erythrocyte sedimentation rate (esr)>70 mm/hr, c-reactive protein (crp)>14 mg/l, procalcitonin>0.3 ng/ml, and ulcer size>2 cm\u00b2--although ptb has the highest specificity of any test and is commonly used together with mri.", "magnetic resonance imaging (mri) has a higher sensitivity and specificity (90% and 79%) than plain radiography (54% and 68%) for diagnosing diabetic foot osteomyelitis. mri performs somewhat better than any of several common tests--probe to bone (ptb), erythrocyte sedimentation rate (esr)>70 mm/hr, c-reactive protein (crp)>14 mg/l, procalcitonin>0.3 ng/ml, and ulcer size>2 cm\u00b2--although ptb has the highest specificity of any test and is commonly used together with mri.", "magnetic resonance imaging (mri) has a higher sensitivity and specificity (90% and 79%) than plain radiography (54% and 68%) for diagnosing diabetic foot osteomyelitis. mri performs somewhat better than any of several common tests--probe to bone (ptb), erythrocyte sedimentation rate (esr)>70 mm/hr, c-reactive protein (crp)>14 mg/l, procalcitonin>0.3 ng/ml, and ulcer size>2 cm\u00b2--although ptb has the highest specificity of any test and is commonly used together with mri.", "magnetic resonance imaging (mri) has a higher sensitivity and specificity (90% and 79%) than plain radiography (54% and 68%) for diagnosing diabetic foot osteomyelitis. mri performs somewhat better than any of several common tests--probe to bone (ptb), erythrocyte sedimentation rate (esr)>70 mm/hr, c-reactive protein (crp)>14 mg/l, procalcitonin>0.3 ng/ml, and ulcer size>2 cm\u00b2--although ptb has the highest specificity of any test and is commonly used together with mri.", "magnetic resonance imaging (mri) has a higher sensitivity and specificity (90% and 79%) than plain radiography (54% and 68%) for diagnosing diabetic foot osteomyelitis. mri performs somewhat better than any of several common tests--probe to bone (ptb), erythrocyte sedimentation rate (esr)>70 mm/hr, c-reactive protein (crp)>14 mg/l, procalcitonin>0.3 ng/ml, and ulcer size>2 cm\u00b2--although ptb has the highest specificity of any test and is commonly used together with mri.", "magnetic resonance imaging (mri) has a higher sensitivity and specificity (90% and 79%) than plain radiography (54% and 68%) for diagnosing diabetic foot osteomyelitis. mri performs somewhat better than any of several common tests--probe to bone (ptb), erythrocyte sedimentation rate (esr)>70 mm/hr, c-reactive protein (crp)>14 mg/l, procalcitonin>0.3 ng/ml, and ulcer size>2 cm\u00b2--although ptb has the highest specificity of any test and is commonly used together with mri.", "magnetic resonance imaging (mri) has a higher sensitivity and specificity (90% and 79%) than plain radiography (54% and 68%) for diagnosing diabetic foot osteomyelitis. mri performs somewhat better than any of several common tests--probe to bone (ptb), erythrocyte sedimentation rate (esr)>70 mm/hr, c-reactive protein (crp)>14 mg/l, procalcitonin>0.3 ng/ml, and ulcer size>2 cm\u00b2--although ptb has the highest specificity of any test and is commonly used together with mri.", "magnetic resonance imaging (mri) has a higher sensitivity and specificity (90% and 79%) than plain radiography (54% and 68%) for diagnosing diabetic foot osteomyelitis. mri performs somewhat better than any of several common tests--probe to bone (ptb), erythrocyte sedimentation rate (esr)>70 mm/hr, c-reactive protein (crp)>14 mg/l, procalcitonin>0.3 ng/ml, and ulcer size>2 cm\u00b2--although ptb has the highest specificity of any test and is commonly used together with mri.", "magnetic resonance imaging (mri) has a higher sensitivity and specificity (90% and 79%) than plain radiography (54% and 68%) for diagnosing diabetic foot osteomyelitis. mri performs somewhat better than any of several common tests--probe to bone (ptb), erythrocyte sedimentation rate (esr)>70 mm/hr, c-reactive protein (crp)>14 mg/l, procalcitonin>0.3 ng/ml, and ulcer size>2 cm\u00b2--although ptb has the highest specificity of any test and is commonly used together with mri.", "magnetic resonance imaging (mri) has a higher sensitivity and specificity (90% and 79%) than plain radiography (54% and 68%) for diagnosing diabetic foot osteomyelitis. mri performs somewhat better than any of several common tests--probe to bone (ptb), erythrocyte sedimentation rate (esr)>70 mm/hr, c-reactive protein (crp)>14 mg/l, procalcitonin>0.3 ng/ml, and ulcer size>2 cm\u00b2--although ptb has the highest specificity of any test and is commonly used together with mri.", "magnetic resonance imaging (mri) has a higher sensitivity and specificity (90% and 79%) than plain radiography (54% and 68%) for diagnosing diabetic foot osteomyelitis. mri performs somewhat better than any of several common tests--probe to bone (ptb), erythrocyte sedimentation rate (esr)>70 mm/hr, c-reactive protein (crp)>14 mg/l, procalcitonin>0.3 ng/ml, and ulcer size>2 cm\u00b2--although ptb has the highest specificity of any test and is commonly used together with mri.", "magnetic resonance imaging (mri) has a higher sensitivity and specificity (90% and 79%) than plain radiography (54% and 68%) for diagnosing diabetic foot osteomyelitis. mri performs somewhat better than any of several common tests--probe to bone (ptb), erythrocyte sedimentation rate (esr)>70 mm/hr, c-reactive protein (crp)>14 mg/l, procalcitonin>0.3 ng/ml, and ulcer size>2 cm\u00b2--although ptb has the highest specificity of any test and is commonly used together with mri.", "magnetic resonance imaging (mri) has a higher sensitivity and specificity (90% and 79%) than plain radiography (54% and 68%) for diagnosing diabetic foot osteomyelitis. mri performs somewhat better than any of several common tests--probe to bone (ptb), erythrocyte sedimentation rate (esr)>70 mm/hr, c-reactive protein (crp)>14 mg/l, procalcitonin>0.3 ng/ml, and ulcer size>2 cm\u00b2--although ptb has the highest specificity of any test and is commonly used together with mri.", "magnetic resonance imaging (mri) has a higher sensitivity and specificity (90% and 79%) than plain radiography (54% and 68%) for diagnosing diabetic foot osteomyelitis. mri performs somewhat better than any of several common tests--probe to bone (ptb), erythrocyte sedimentation rate (esr)>70 mm/hr, c-reactive protein (crp)>14 mg/l, procalcitonin>0.3 ng/ml, and ulcer size>2 cm\u00b2--although ptb has the highest specificity of any test and is commonly used together with mri.", "magnetic resonance imaging (mri) has a higher sensitivity and specificity (90% and 79%) than plain radiography (54% and 68%) for diagnosing diabetic foot osteomyelitis. mri performs somewhat better than any of several common tests--probe to bone (ptb), erythrocyte sedimentation rate (esr)>70 mm/hr, c-reactive protein (crp)>14 mg/l, procalcitonin>0.3 ng/ml, and ulcer size>2 cm\u00b2--although ptb has the highest specificity of any test and is commonly used together with mri.", "magnetic resonance imaging (mri) has a higher sensitivity and specificity (90% and 79%) than plain radiography (54% and 68%) for diagnosing diabetic foot osteomyelitis. mri performs somewhat better than any of several common tests--probe to bone (ptb), erythrocyte sedimentation rate (esr)>70 mm/hr, c-reactive protein (crp)>14 mg/l, procalcitonin>0.3 ng/ml, and ulcer size>2 cm\u00b2--although ptb has the highest specificity of any test and is commonly used together with mri.", "magnetic resonance imaging (mri) has a higher sensitivity and specificity (90% and 79%) than plain radiography (54% and 68%) for diagnosing diabetic foot osteomyelitis. mri performs somewhat better than any of several common tests--probe to bone (ptb), erythrocyte sedimentation rate (esr)>70 mm/hr, c-reactive protein (crp)>14 mg/l, procalcitonin>0.3 ng/ml, and ulcer size>2 cm\u00b2--although ptb has the highest specificity of any test and is commonly used together with mri.", "magnetic resonance imaging (mri) has a higher sensitivity and specificity (90% and 79%) than plain radiography (54% and 68%) for diagnosing diabetic foot osteomyelitis. mri performs somewhat better than any of several common tests--probe to bone (ptb), erythrocyte sedimentation rate (esr)>70 mm/hr, c-reactive protein (crp)>14 mg/l, procalcitonin>0.3 ng/ml, and ulcer size>2 cm\u00b2--although ptb has the highest specificity of any test and is commonly used together with mri.", "magnetic resonance imaging (mri) has a higher sensitivity and specificity (90% and 79%) than plain radiography (54% and 68%) for diagnosing diabetic foot osteomyelitis. mri performs somewhat better than any of several common tests--probe to bone (ptb), erythrocyte sedimentation rate (esr)>70 mm/hr, c-reactive protein (crp)>14 mg/l, procalcitonin>0.3 ng/ml, and ulcer size>2 cm\u00b2--although ptb has the highest specificity of any test and is commonly used together with mri.", "magnetic resonance imaging (mri) has a higher sensitivity and specificity (90% and 79%) than plain radiography (54% and 68%) for diagnosing diabetic foot osteomyelitis. mri performs somewhat better than any of several common tests--probe to bone (ptb), erythrocyte sedimentation rate (esr)>70 mm/hr, c-reactive protein (crp)>14 mg/l, procalcitonin>0.3 ng/ml, and ulcer size>2 cm\u00b2--although ptb has the highest specificity of any test and is commonly used together with mri.", "magnetic resonance imaging (mri) has a higher sensitivity and specificity (90% and 79%) than plain radiography (54% and 68%) for diagnosing diabetic foot osteomyelitis. mri performs somewhat better than any of several common tests--probe to bone (ptb), erythrocyte sedimentation rate (esr)>70 mm/hr, c-reactive protein (crp)>14 mg/l, procalcitonin>0.3 ng/ml, and ulcer size>2 cm\u00b2--although ptb has the highest specificity of any test and is commonly used together with mri.", "magnetic resonance imaging (mri) has a higher sensitivity and specificity (90% and 79%) than plain radiography (54% and 68%) for diagnosing diabetic foot osteomyelitis. mri performs somewhat better than any of several common tests--probe to bone (ptb), erythrocyte sedimentation rate (esr)>70 mm/hr, c-reactive protein (crp)>14 mg/l, procalcitonin>0.3 ng/ml, and ulcer size>2 cm\u00b2--although ptb has the highest specificity of any test and is commonly used together with mri.", "magnetic resonance imaging (mri) has a higher sensitivity and specificity (90% and 79%) than plain radiography (54% and 68%) for diagnosing diabetic foot osteomyelitis. mri performs somewhat better than any of several common tests--probe to bone (ptb), erythrocyte sedimentation rate (esr)>70 mm/hr, c-reactive protein (crp)>14 mg/l, procalcitonin>0.3 ng/ml, and ulcer size>2 cm\u00b2--although ptb has the highest specificity of any test and is commonly used together with mri.", "magnetic resonance imaging (mri) has a higher sensitivity and specificity (90% and 79%) than plain radiography (54% and 68%) for diagnosing diabetic foot osteomyelitis. mri performs somewhat better than any of several common tests--probe to bone (ptb), erythrocyte sedimentation rate (esr)>70 mm/hr, c-reactive protein (crp)>14 mg/l, procalcitonin>0.3 ng/ml, and ulcer size>2 cm\u00b2--although ptb has the highest specificity of any test and is commonly used together with mri.", "wound area and depth were not found to be statistically significantly different between groups.<br><b>conclusions</b>: positive probe-to-bone test results and erythrocyte sedimentation rates greater than 70 mm/h provide some support for the diagnosis of diabetic foot osteomyelitis, but it is not strong; magnetic resonance imaging or bone biopsy will probably be required in cases of doubt.<br>", "wound area and depth were not found to be statistically significantly different between groups.<br><b>conclusions</b>: positive probe-to-bone test results and erythrocyte sedimentation rates greater than 70 mm/h provide some support for the diagnosis of diabetic foot osteomyelitis, but it is not strong; magnetic resonance imaging or bone biopsy will probably be required in cases of doubt.<br>", "wound area and depth were not found to be statistically significantly different between groups.<br><b>conclusions</b>: positive probe-to-bone test results and erythrocyte sedimentation rates greater than 70 mm/h provide some support for the diagnosis of diabetic foot osteomyelitis, but it is not strong; magnetic resonance imaging or bone biopsy will probably be required in cases of doubt.<br>", "wound area and depth were not found to be statistically significantly different between groups.<br><b>conclusions</b>: positive probe-to-bone test results and erythrocyte sedimentation rates greater than 70 mm/h provide some support for the diagnosis of diabetic foot osteomyelitis, but it is not strong; magnetic resonance imaging or bone biopsy will probably be required in cases of doubt.<br>", "wound area and depth were not found to be statistically significantly different between groups.<br><b>conclusions</b>: positive probe-to-bone test results and erythrocyte sedimentation rates greater than 70 mm/h provide some support for the diagnosis of diabetic foot osteomyelitis, but it is not strong; magnetic resonance imaging or bone biopsy will probably be required in cases of doubt.<br>", "wound area and depth were not found to be statistically significantly different between groups.<br><b>conclusions</b>: positive probe-to-bone test results and erythrocyte sedimentation rates greater than 70 mm/h provide some support for the diagnosis of diabetic foot osteomyelitis, but it is not strong; magnetic resonance imaging or bone biopsy will probably be required in cases of doubt.<br>", "wound area and depth were not found to be statistically significantly different between groups.<br><b>conclusions</b>: positive probe-to-bone test results and erythrocyte sedimentation rates greater than 70 mm/h provide some support for the diagnosis of diabetic foot osteomyelitis, but it is not strong; magnetic resonance imaging or bone biopsy will probably be required in cases of doubt.<br>", "wound area and depth were not found to be statistically significantly different between groups.<br><b>conclusions</b>: positive probe-to-bone test results and erythrocyte sedimentation rates greater than 70 mm/h provide some support for the diagnosis of diabetic foot osteomyelitis, but it is not strong; magnetic resonance imaging or bone biopsy will probably be required in cases of doubt.<br>", "wound area and depth were not found to be statistically significantly different between groups.<br><b>conclusions</b>: positive probe-to-bone test results and erythrocyte sedimentation rates greater than 70 mm/h provide some support for the diagnosis of diabetic foot osteomyelitis, but it is not strong; magnetic resonance imaging or bone biopsy will probably be required in cases of doubt.<br>", "wound area and depth were not found to be statistically significantly different between groups.<br><b>conclusions</b>: positive probe-to-bone test results and erythrocyte sedimentation rates greater than 70 mm/h provide some support for the diagnosis of diabetic foot osteomyelitis, but it is not strong; magnetic resonance imaging or bone biopsy will probably be required in cases of doubt.<br>", "wound area and depth were not found to be statistically significantly different between groups.<br><b>conclusions</b>: positive probe-to-bone test results and erythrocyte sedimentation rates greater than 70 mm/h provide some support for the diagnosis of diabetic foot osteomyelitis, but it is not strong; magnetic resonance imaging or bone biopsy will probably be required in cases of doubt.<br>", "wound area and depth were not found to be statistically significantly different between groups.<br><b>conclusions</b>: positive probe-to-bone test results and erythrocyte sedimentation rates greater than 70 mm/h provide some support for the diagnosis of diabetic foot osteomyelitis, but it is not strong; magnetic resonance imaging or bone biopsy will probably be required in cases of doubt.<br>", "wound area and depth were not found to be statistically significantly different between groups.<br><b>conclusions</b>: positive probe-to-bone test results and erythrocyte sedimentation rates greater than 70 mm/h provide some support for the diagnosis of diabetic foot osteomyelitis, but it is not strong; magnetic resonance imaging or bone biopsy will probably be required in cases of doubt.<br>", "wound area and depth were not found to be statistically significantly different between groups.<br><b>conclusions</b>: positive probe-to-bone test results and erythrocyte sedimentation rates greater than 70 mm/h provide some support for the diagnosis of diabetic foot osteomyelitis, but it is not strong; magnetic resonance imaging or bone biopsy will probably be required in cases of doubt.<br>", "wound area and depth were not found to be statistically significantly different between groups.<br><b>conclusions</b>: positive probe-to-bone test results and erythrocyte sedimentation rates greater than 70 mm/h provide some support for the diagnosis of diabetic foot osteomyelitis, but it is not strong; magnetic resonance imaging or bone biopsy will probably be required in cases of doubt.<br>", "wound area and depth were not found to be statistically significantly different between groups.<br><b>conclusions</b>: positive probe-to-bone test results and erythrocyte sedimentation rates greater than 70 mm/h provide some support for the diagnosis of diabetic foot osteomyelitis, but it is not strong; magnetic resonance imaging or bone biopsy will probably be required in cases of doubt.<br>", "wound area and depth were not found to be statistically significantly different between groups.<br><b>conclusions</b>: positive probe-to-bone test results and erythrocyte sedimentation rates greater than 70 mm/h provide some support for the diagnosis of diabetic foot osteomyelitis, but it is not strong; magnetic resonance imaging or bone biopsy will probably be required in cases of doubt.<br>", "wound area and depth were not found to be statistically significantly different between groups.<br><b>conclusions</b>: positive probe-to-bone test results and erythrocyte sedimentation rates greater than 70 mm/h provide some support for the diagnosis of diabetic foot osteomyelitis, but it is not strong; magnetic resonance imaging or bone biopsy will probably be required in cases of doubt.<br>", "wound area and depth were not found to be statistically significantly different between groups.<br><b>conclusions</b>: positive probe-to-bone test results and erythrocyte sedimentation rates greater than 70 mm/h provide some support for the diagnosis of diabetic foot osteomyelitis, but it is not strong; magnetic resonance imaging or bone biopsy will probably be required in cases of doubt.<br>", "wound area and depth were not found to be statistically significantly different between groups.<br><b>conclusions</b>: positive probe-to-bone test results and erythrocyte sedimentation rates greater than 70 mm/h provide some support for the diagnosis of diabetic foot osteomyelitis, but it is not strong; magnetic resonance imaging or bone biopsy will probably be required in cases of doubt.<br>", "wound area and depth were not found to be statistically significantly different between groups.<br><b>conclusions</b>: positive probe-to-bone test results and erythrocyte sedimentation rates greater than 70 mm/h provide some support for the diagnosis of diabetic foot osteomyelitis, but it is not strong; magnetic resonance imaging or bone biopsy will probably be required in cases of doubt.<br>", "wound area and depth were not found to be statistically significantly different between groups.<br><b>conclusions</b>: positive probe-to-bone test results and erythrocyte sedimentation rates greater than 70 mm/h provide some support for the diagnosis of diabetic foot osteomyelitis, but it is not strong; magnetic resonance imaging or bone biopsy will probably be required in cases of doubt.<br>", "wound area and depth were not found to be statistically significantly different between groups.<br><b>conclusions</b>: positive probe-to-bone test results and erythrocyte sedimentation rates greater than 70 mm/h provide some support for the diagnosis of diabetic foot osteomyelitis, but it is not strong; magnetic resonance imaging or bone biopsy will probably be required in cases of doubt.<br>", "wound area and depth were not found to be statistically significantly different between groups.<br><b>conclusions</b>: positive probe-to-bone test results and erythrocyte sedimentation rates greater than 70 mm/h provide some support for the diagnosis of diabetic foot osteomyelitis, but it is not strong; magnetic resonance imaging or bone biopsy will probably be required in cases of doubt.<br>", "wound area and depth were not found to be statistically significantly different between groups.<br><b>conclusions</b>: positive probe-to-bone test results and erythrocyte sedimentation rates greater than 70 mm/h provide some support for the diagnosis of diabetic foot osteomyelitis, but it is not strong; magnetic resonance imaging or bone biopsy will probably be required in cases of doubt.<br>", "wound area and depth were not found to be statistically significantly different between groups.<br><b>conclusions</b>: positive probe-to-bone test results and erythrocyte sedimentation rates greater than 70 mm/h provide some support for the diagnosis of diabetic foot osteomyelitis, but it is not strong; magnetic resonance imaging or bone biopsy will probably be required in cases of doubt.<br>", "wound area and depth were not found to be statistically significantly different between groups.<br><b>conclusions</b>: positive probe-to-bone test results and erythrocyte sedimentation rates greater than 70 mm/h provide some support for the diagnosis of diabetic foot osteomyelitis, but it is not strong; magnetic resonance imaging or bone biopsy will probably be required in cases of doubt.<br>", "wound area and depth were not found to be statistically significantly different between groups.<br><b>conclusions</b>: positive probe-to-bone test results and erythrocyte sedimentation rates greater than 70 mm/h provide some support for the diagnosis of diabetic foot osteomyelitis, but it is not strong; magnetic resonance imaging or bone biopsy will probably be required in cases of doubt.<br>", "wound area and depth were not found to be statistically significantly different between groups.<br><b>conclusions</b>: positive probe-to-bone test results and erythrocyte sedimentation rates greater than 70 mm/h provide some support for the diagnosis of diabetic foot osteomyelitis, but it is not strong; magnetic resonance imaging or bone biopsy will probably be required in cases of doubt.<br>", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis. this study demonstrates the importance of considering jointly clinical information (probe-to-bone test) and diagnostic tests (simple radiography) to increase agreement among clinicians on diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis. this study demonstrates the importance of considering jointly clinical information (probe-to-bone test) and diagnostic tests (simple radiography) to increase agreement among clinicians on diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis. this study demonstrates the importance of considering jointly clinical information (probe-to-bone test) and diagnostic tests (simple radiography) to increase agreement among clinicians on diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis. this study demonstrates the importance of considering jointly clinical information (probe-to-bone test) and diagnostic tests (simple radiography) to increase agreement among clinicians on diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis. this study demonstrates the importance of considering jointly clinical information (probe-to-bone test) and diagnostic tests (simple radiography) to increase agreement among clinicians on diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis. this study demonstrates the importance of considering jointly clinical information (probe-to-bone test) and diagnostic tests (simple radiography) to increase agreement among clinicians on diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis. this study demonstrates the importance of considering jointly clinical information (probe-to-bone test) and diagnostic tests (simple radiography) to increase agreement among clinicians on diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis. this study demonstrates the importance of considering jointly clinical information (probe-to-bone test) and diagnostic tests (simple radiography) to increase agreement among clinicians on diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis. this study demonstrates the importance of considering jointly clinical information (probe-to-bone test) and diagnostic tests (simple radiography) to increase agreement among clinicians on diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis. this study demonstrates the importance of considering jointly clinical information (probe-to-bone test) and diagnostic tests (simple radiography) to increase agreement among clinicians on diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis. this study demonstrates the importance of considering jointly clinical information (probe-to-bone test) and diagnostic tests (simple radiography) to increase agreement among clinicians on diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis. this study demonstrates the importance of considering jointly clinical information (probe-to-bone test) and diagnostic tests (simple radiography) to increase agreement among clinicians on diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis. this study demonstrates the importance of considering jointly clinical information (probe-to-bone test) and diagnostic tests (simple radiography) to increase agreement among clinicians on diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis. this study demonstrates the importance of considering jointly clinical information (probe-to-bone test) and diagnostic tests (simple radiography) to increase agreement among clinicians on diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis. this study demonstrates the importance of considering jointly clinical information (probe-to-bone test) and diagnostic tests (simple radiography) to increase agreement among clinicians on diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis. this study demonstrates the importance of considering jointly clinical information (probe-to-bone test) and diagnostic tests (simple radiography) to increase agreement among clinicians on diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis. this study demonstrates the importance of considering jointly clinical information (probe-to-bone test) and diagnostic tests (simple radiography) to increase agreement among clinicians on diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis. this study demonstrates the importance of considering jointly clinical information (probe-to-bone test) and diagnostic tests (simple radiography) to increase agreement among clinicians on diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis. this study demonstrates the importance of considering jointly clinical information (probe-to-bone test) and diagnostic tests (simple radiography) to increase agreement among clinicians on diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis. this study demonstrates the importance of considering jointly clinical information (probe-to-bone test) and diagnostic tests (simple radiography) to increase agreement among clinicians on diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis. this study demonstrates the importance of considering jointly clinical information (probe-to-bone test) and diagnostic tests (simple radiography) to increase agreement among clinicians on diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis. this study demonstrates the importance of considering jointly clinical information (probe-to-bone test) and diagnostic tests (simple radiography) to increase agreement among clinicians on diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis. this study demonstrates the importance of considering jointly clinical information (probe-to-bone test) and diagnostic tests (simple radiography) to increase agreement among clinicians on diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis. this study demonstrates the importance of considering jointly clinical information (probe-to-bone test) and diagnostic tests (simple radiography) to increase agreement among clinicians on diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis. this study demonstrates the importance of considering jointly clinical information (probe-to-bone test) and diagnostic tests (simple radiography) to increase agreement among clinicians on diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis. this study demonstrates the importance of considering jointly clinical information (probe-to-bone test) and diagnostic tests (simple radiography) to increase agreement among clinicians on diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis. this study demonstrates the importance of considering jointly clinical information (probe-to-bone test) and diagnostic tests (simple radiography) to increase agreement among clinicians on diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis. this study demonstrates the importance of considering jointly clinical information (probe-to-bone test) and diagnostic tests (simple radiography) to increase agreement among clinicians on diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis. this study demonstrates the importance of considering jointly clinical information (probe-to-bone test) and diagnostic tests (simple radiography) to increase agreement among clinicians on diagnosis of diabetic foot osteomyelitis.", "conclusions: clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions: clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions: clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions: clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions: clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions: clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions: clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions: clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions: clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions: clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions: clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions: clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions: clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions: clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions: clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions: clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions: clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions: clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions: clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions: clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions: clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions: clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions: clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions: clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions: clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions: clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions: clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions: clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions: clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "conclusions clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive.", "clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive..", "clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive..", "clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive..", "clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive..", "clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive..", "clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive..", "clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive..", "clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive..", "clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive..", "clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive..", "clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive..", "clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive..", "clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive..", "clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive..", "clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive..", "clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive..", "clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive..", "clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive..", "clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive..", "clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive..", "clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive..", "clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive..", "clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive..", "clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive..", "clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive..", "clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive..", "clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive..", "clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive..", "clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain x-ray, or especially both, are positive..", "inter-observer reproducibility of diagnosis of diabetic foot osteomyelitis based on a combination of probe-to-bone test and simple radiography.", "inter-observer reproducibility of diagnosis of diabetic foot osteomyelitis based on a combination of probe-to-bone test and simple radiography.", "inter-observer reproducibility of diagnosis of diabetic foot osteomyelitis based on a combination of probe-to-bone test and simple radiography.", "inter-observer reproducibility of diagnosis of diabetic foot osteomyelitis based on a combination of probe-to-bone test and simple radiography.", "inter-observer reproducibility of diagnosis of diabetic foot osteomyelitis based on a combination of probe-to-bone test and simple radiography.", "inter-observer reproducibility of diagnosis of diabetic foot osteomyelitis based on a combination of probe-to-bone test and simple radiography.", "inter-observer reproducibility of diagnosis of diabetic foot osteomyelitis based on a combination of probe-to-bone test and simple radiography.", "inter-observer reproducibility of diagnosis of diabetic foot osteomyelitis based on a combination of probe-to-bone test and simple radiography.", "inter-observer reproducibility of diagnosis of diabetic foot osteomyelitis based on a combination of probe-to-bone test and simple radiography.", "inter-observer reproducibility of diagnosis of diabetic foot osteomyelitis based on a combination of probe-to-bone test and simple radiography.", "inter-observer reproducibility of diagnosis of diabetic foot osteomyelitis based on a combination of probe-to-bone test and simple radiography.", "inter-observer reproducibility of diagnosis of diabetic foot osteomyelitis based on a combination of probe-to-bone test and simple radiography.", "inter-observer reproducibility of diagnosis of diabetic foot osteomyelitis based on a combination of probe-to-bone test and simple radiography.", "inter-observer reproducibility of diagnosis of diabetic foot osteomyelitis based on a combination of probe-to-bone test and simple radiography.", "inter-observer reproducibility of diagnosis of diabetic foot osteomyelitis based on a combination of probe-to-bone test and simple radiography.", "inter-observer reproducibility of diagnosis of diabetic foot osteomyelitis based on a combination of probe-to-bone test and simple radiography.", "inter-observer reproducibility of diagnosis of diabetic foot osteomyelitis based on a combination of probe-to-bone test and simple radiography.", "inter-observer reproducibility of diagnosis of diabetic foot osteomyelitis based on a combination of probe-to-bone test and simple radiography.", "inter-observer reproducibility of diagnosis of diabetic foot osteomyelitis based on a combination of probe-to-bone test and simple radiography.", "inter-observer reproducibility of diagnosis of diabetic foot osteomyelitis based on a combination of probe-to-bone test and simple radiography.", "inter-observer reproducibility of diagnosis of diabetic foot osteomyelitis based on a combination of probe-to-bone test and simple radiography.", "inter-observer reproducibility of diagnosis of diabetic foot osteomyelitis based on a combination of probe-to-bone test and simple radiography.", "inter-observer reproducibility of diagnosis of diabetic foot osteomyelitis based on a combination of probe-to-bone test and simple radiography.", "inter-observer reproducibility of diagnosis of diabetic foot osteomyelitis based on a combination of probe-to-bone test and simple radiography.", "inter-observer reproducibility of diagnosis of diabetic foot osteomyelitis based on a combination of probe-to-bone test and simple radiography.", "inter-observer reproducibility of diagnosis of diabetic foot osteomyelitis based on a combination of probe-to-bone test and simple radiography.", "inter-observer reproducibility of diagnosis of diabetic foot osteomyelitis based on a combination of probe-to-bone test and simple radiography.", "inter-observer reproducibility of diagnosis of diabetic foot osteomyelitis based on a combination of probe-to-bone test and simple radiography.", "inter-observer reproducibility of diagnosis of diabetic foot osteomyelitis based on a combination of probe-to-bone test and simple radiography.", "diagnosing diabetic foot osteomyelitis: is the combination of probe-to-bone test and plain radiography sufficient for high-risk inpatients?", "diagnosing diabetic foot osteomyelitis: is the combination of probe-to-bone test and plain radiography sufficient for high-risk inpatients?", "diagnosing diabetic foot osteomyelitis: is the combination of probe-to-bone test and plain radiography sufficient for high-risk inpatients?", "diagnosing diabetic foot osteomyelitis: is the combination of probe-to-bone test and plain radiography sufficient for high-risk inpatients?", "diagnosing diabetic foot osteomyelitis: is the combination of probe-to-bone test and plain radiography sufficient for high-risk inpatients?", "diagnosing diabetic foot osteomyelitis: is the combination of probe-to-bone test and plain radiography sufficient for high-risk inpatients?", "diagnosing diabetic foot osteomyelitis: is the combination of probe-to-bone test and plain radiography sufficient for high-risk inpatients?", "diagnosing diabetic foot osteomyelitis: is the combination of probe-to-bone test and plain radiography sufficient for high-risk inpatients?", "diagnosing diabetic foot osteomyelitis: is the combination of probe-to-bone test and plain radiography sufficient for high-risk inpatients?", "diagnosing diabetic foot osteomyelitis: is the combination of probe-to-bone test and plain radiography sufficient for high-risk inpatients?", "diagnosing diabetic foot osteomyelitis: is the combination of probe-to-bone test and plain radiography sufficient for high-risk inpatients?", "diagnosing diabetic foot osteomyelitis: is the combination of probe-to-bone test and plain radiography sufficient for high-risk inpatients?", "diagnosing diabetic foot osteomyelitis: is the combination of probe-to-bone test and plain radiography sufficient for high-risk inpatients?", "diagnosing diabetic foot osteomyelitis: is the combination of probe-to-bone test and plain radiography sufficient for high-risk inpatients?", "diagnosing diabetic foot osteomyelitis: is the combination of probe-to-bone test and plain radiography sufficient for high-risk inpatients?", "diagnosing diabetic foot osteomyelitis: is the combination of probe-to-bone test and plain radiography sufficient for high-risk inpatients?", "diagnosing diabetic foot osteomyelitis: is the combination of probe-to-bone test and plain radiography sufficient for high-risk inpatients?", "diagnosing diabetic foot osteomyelitis: is the combination of probe-to-bone test and plain radiography sufficient for high-risk inpatients?", "diagnosing diabetic foot osteomyelitis: is the combination of probe-to-bone test and plain radiography sufficient for high-risk inpatients?", "diagnosing diabetic foot osteomyelitis: is the combination of probe-to-bone test and plain radiography sufficient for high-risk inpatients?", "diagnosing diabetic foot osteomyelitis: is the combination of probe-to-bone test and plain radiography sufficient for high-risk inpatients?", "diagnosing diabetic foot osteomyelitis: is the combination of probe-to-bone test and plain radiography sufficient for high-risk inpatients?", "diagnosing diabetic foot osteomyelitis: is the combination of probe-to-bone test and plain radiography sufficient for high-risk inpatients?", "diagnosing diabetic foot osteomyelitis: is the combination of probe-to-bone test and plain radiography sufficient for high-risk inpatients?", "diagnosing diabetic foot osteomyelitis: is the combination of probe-to-bone test and plain radiography sufficient for high-risk inpatients?", "diagnosing diabetic foot osteomyelitis: is the combination of probe-to-bone test and plain radiography sufficient for high-risk inpatients?", "diagnosing diabetic foot osteomyelitis: is the combination of probe-to-bone test and plain radiography sufficient for high-risk inpatients?", "diagnosing diabetic foot osteomyelitis: is the combination of probe-to-bone test and plain radiography sufficient for high-risk inpatients?", "diagnosing diabetic foot osteomyelitis: is the combination of probe-to-bone test and plain radiography sufficient for high-risk inpatients?", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test and simple x-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis.", "probe-to-bone test for diagnosing diabetic foot osteomyelitis: reliable or relic?", "probe-to-bone test for diagnosing diabetic foot osteomyelitis: reliable or relic?", "probe-to-bone test for diagnosing diabetic foot osteomyelitis: reliable or relic?", "probe-to-bone test for diagnosing diabetic foot osteomyelitis: reliable or relic?", "probe-to-bone test for diagnosing diabetic foot osteomyelitis: reliable or relic?", "probe-to-bone test for diagnosing diabetic foot osteomyelitis: reliable or relic?", "probe-to-bone test for diagnosing diabetic foot osteomyelitis: reliable or relic?", "probe-to-bone test for diagnosing diabetic foot osteomyelitis: reliable or relic?", "probe-to-bone test for diagnosing diabetic foot osteomyelitis: reliable or relic?", "probe-to-bone test for diagnosing diabetic foot osteomyelitis: reliable or relic?", "probe-to-bone test for diagnosing diabetic foot osteomyelitis: reliable or relic?", "probe-to-bone test for diagnosing diabetic foot osteomyelitis: reliable or relic?", "probe-to-bone test for diagnosing diabetic foot osteomyelitis: reliable or relic?", "probe-to-bone test for diagnosing diabetic foot osteomyelitis: reliable or relic?", "probe-to-bone test for diagnosing diabetic foot osteomyelitis: reliable or relic?", "probe-to-bone test for diagnosing diabetic foot osteomyelitis: reliable or relic?", "probe-to-bone test for diagnosing diabetic foot osteomyelitis: reliable or relic?", "probe-to-bone test for diagnosing diabetic foot osteomyelitis: reliable or relic?", "probe-to-bone test for diagnosing diabetic foot osteomyelitis: reliable or relic?", "probe-to-bone test for diagnosing diabetic foot osteomyelitis: reliable or relic?", "probe-to-bone test for diagnosing diabetic foot osteomyelitis: reliable or relic?", "probe-to-bone test for diagnosing diabetic foot osteomyelitis: reliable or relic?", "probe-to-bone test for diagnosing diabetic foot osteomyelitis: reliable or relic?", "probe-to-bone test for diagnosing diabetic foot osteomyelitis: reliable or relic?", "probe-to-bone test for diagnosing diabetic foot osteomyelitis: reliable or relic?", "probe-to-bone test for diagnosing diabetic foot osteomyelitis: reliable or relic?", "probe-to-bone test for diagnosing diabetic foot osteomyelitis: reliable or relic?", "probe-to-bone test for diagnosing diabetic foot osteomyelitis: reliable or relic?", "probe-to-bone test for diagnosing diabetic foot osteomyelitis: reliable or relic?", "aims the gore reduce clinical study (reduce) aims to establish superiority of patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke or new silent brain infarct in patients who have had a cryptogenic stroke.", "aims the gore reduce clinical study (reduce) aims to establish superiority of patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke or new silent brain infarct in patients who have had a cryptogenic stroke.", "aims the gore reduce clinical study (reduce) aims to establish superiority of patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke or new silent brain infarct in patients who have had a cryptogenic stroke.", "aims the gore reduce clinical study (reduce) aims to establish superiority of patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke or new silent brain infarct in patients who have had a cryptogenic stroke.", "aims the gore reduce clinical study (reduce) aims to establish superiority of patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke or new silent brain infarct in patients who have had a cryptogenic stroke.", "aims the gore reduce clinical study (reduce) aims to establish superiority of patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke or new silent brain infarct in patients who have had a cryptogenic stroke.", "aims the gore reduce clinical study (reduce) aims to establish superiority of patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke or new silent brain infarct in patients who have had a cryptogenic stroke.", "aims the gore reduce clinical study (reduce) aims to establish superiority of patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke or new silent brain infarct in patients who have had a cryptogenic stroke.", "aims the gore reduce clinical study (reduce) aims to establish superiority of patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke or new silent brain infarct in patients who have had a cryptogenic stroke.", "aims the gore reduce clinical study (reduce) aims to establish superiority of patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke or new silent brain infarct in patients who have had a cryptogenic stroke.", "aims the gore reduce clinical study (reduce) aims to establish superiority of patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke or new silent brain infarct in patients who have had a cryptogenic stroke.", "aims the gore reduce clinical study (reduce) aims to establish superiority of patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke or new silent brain infarct in patients who have had a cryptogenic stroke.", "aims the gore reduce clinical study (reduce) aims to establish superiority of patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke or new silent brain infarct in patients who have had a cryptogenic stroke.", "aims the gore reduce clinical study (reduce) aims to establish superiority of patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke or new silent brain infarct in patients who have had a cryptogenic stroke.", "aims the gore reduce clinical study (reduce) aims to establish superiority of patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke or new silent brain infarct in patients who have had a cryptogenic stroke.", "aims the gore reduce clinical study (reduce) aims to establish superiority of patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke or new silent brain infarct in patients who have had a cryptogenic stroke.", "aims the gore reduce clinical study (reduce) aims to establish superiority of patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke or new silent brain infarct in patients who have had a cryptogenic stroke.", "aims the gore reduce clinical study (reduce) aims to establish superiority of patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke or new silent brain infarct in patients who have had a cryptogenic stroke.", "aims the gore reduce clinical study (reduce) aims to establish superiority of patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke or new silent brain infarct in patients who have had a cryptogenic stroke.", "aims the gore reduce clinical study (reduce) aims to establish superiority of patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke or new silent brain infarct in patients who have had a cryptogenic stroke.", "aims the gore reduce clinical study (reduce) aims to establish superiority of patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke or new silent brain infarct in patients who have had a cryptogenic stroke.", "aims the gore reduce clinical study (reduce) aims to establish superiority of patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke or new silent brain infarct in patients who have had a cryptogenic stroke.", "aims the gore reduce clinical study (reduce) aims to establish superiority of patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke or new silent brain infarct in patients who have had a cryptogenic stroke.", "aims the gore reduce clinical study (reduce) aims to establish superiority of patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke or new silent brain infarct in patients who have had a cryptogenic stroke.", "aims the gore reduce clinical study (reduce) aims to establish superiority of patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke or new silent brain infarct in patients who have had a cryptogenic stroke.", "aims the gore reduce clinical study (reduce) aims to establish superiority of patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke or new silent brain infarct in patients who have had a cryptogenic stroke.", "aims the gore reduce clinical study (reduce) aims to establish superiority of patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke or new silent brain infarct in patients who have had a cryptogenic stroke.", "aims the gore reduce clinical study (reduce) aims to establish superiority of patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke or new silent brain infarct in patients who have had a cryptogenic stroke.", "aims the gore reduce clinical study (reduce) aims to establish superiority of patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke or new silent brain infarct in patients who have had a cryptogenic stroke.", "aims the gore reduce clinical study (reduce) aims to establish superiority of patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke or new silent brain infarct in patients who have had a cryptogenic stroke.", "aims the gore reduce clinical study (reduce) aims to establish superiority of patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke or new silent brain infarct in patients who have had a cryptogenic stroke.", "aims the gore reduce clinical study (reduce) aims to establish superiority of patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke or new silent brain infarct in patients who have had a cryptogenic stroke.", "aims the gore reduce clinical study (reduce) aims to establish superiority of patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke or new silent brain infarct in patients who have had a cryptogenic stroke.", "aims the gore reduce clinical study (reduce) aims to establish superiority of patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke or new silent brain infarct in patients who have had a cryptogenic stroke.", "aims the gore reduce clinical study (reduce) aims to establish superiority of patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke or new silent brain infarct in patients who have had a cryptogenic stroke.", "aims the gore reduce clinical study (reduce) aims to establish superiority of patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke or new silent brain infarct in patients who have had a cryptogenic stroke.", "aims the gore reduce clinical study (reduce) aims to establish superiority of patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke or new silent brain infarct in patients who have had a cryptogenic stroke.", "aims the gore reduce clinical study (reduce) aims to establish superiority of patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke or new silent brain infarct in patients who have had a cryptogenic stroke.", "aims the gore reduce clinical study (reduce) aims to establish superiority of patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke or new silent brain infarct in patients who have had a cryptogenic stroke.", "patent foramen ovale closure with gore helex or cardioform septal occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: design of the randomized gore reduce clinical study.", "patent foramen ovale closure with gore helex or cardioform septal occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: design of the randomized gore reduce clinical study.", "patent foramen ovale closure with gore helex or cardioform septal occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: design of the randomized gore reduce clinical study.", "patent foramen ovale closure with gore helex or cardioform septal occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: design of the randomized gore reduce clinical study.", "patent foramen ovale closure with gore helex or cardioform septal occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: design of the randomized gore reduce clinical study.", "patent foramen ovale closure with gore helex or cardioform septal occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: design of the randomized gore reduce clinical study.", "patent foramen ovale closure with gore helex or cardioform septal occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: design of the randomized gore reduce clinical study.", "patent foramen ovale closure with gore helex or cardioform septal occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: design of the randomized gore reduce clinical study.", "patent foramen ovale closure with gore helex or cardioform septal occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: design of the randomized gore reduce clinical study.", "patent foramen ovale closure with gore helex or cardioform septal occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: design of the randomized gore reduce clinical study.", "patent foramen ovale closure with gore helex or cardioform septal occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: design of the randomized gore reduce clinical study.", "patent foramen ovale closure with gore helex or cardioform septal occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: design of the randomized gore reduce clinical study.", "patent foramen ovale closure with gore helex or cardioform septal occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: design of the randomized gore reduce clinical study.", "patent foramen ovale closure with gore helex or cardioform septal occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: design of the randomized gore reduce clinical study.", "patent foramen ovale closure with gore helex or cardioform septal occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: design of the randomized gore reduce clinical study.", "patent foramen ovale closure with gore helex or cardioform septal occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: design of the randomized gore reduce clinical study.", "patent foramen ovale closure with gore helex or cardioform septal occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: design of the randomized gore reduce clinical study.", "patent foramen ovale closure with gore helex or cardioform septal occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: design of the randomized gore reduce clinical study.", "patent foramen ovale closure with gore helex or cardioform septal occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: design of the randomized gore reduce clinical study.", "patent foramen ovale closure with gore helex or cardioform septal occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: design of the randomized gore reduce clinical study.", "patent foramen ovale closure with gore helex or cardioform septal occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: design of the randomized gore reduce clinical study.", "patent foramen ovale closure with gore helex or cardioform septal occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: design of the randomized gore reduce clinical study.", "patent foramen ovale closure with gore helex or cardioform septal occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: design of the randomized gore reduce clinical study.", "patent foramen ovale closure with gore helex or cardioform septal occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: design of the randomized gore reduce clinical study.", "patent foramen ovale closure with gore helex or cardioform septal occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: design of the randomized gore reduce clinical study.", "patent foramen ovale closure with gore helex or cardioform septal occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: design of the randomized gore reduce clinical study.", "patent foramen ovale closure with gore helex or cardioform septal occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: design of the randomized gore reduce clinical study.", "patent foramen ovale closure with gore helex or cardioform septal occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: design of the randomized gore reduce clinical study.", "patent foramen ovale closure with gore helex or cardioform septal occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: design of the randomized gore reduce clinical study.", "patent foramen ovale closure with gore helex or cardioform septal occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: design of the randomized gore reduce clinical study.", "patent foramen ovale closure with gore helex or cardioform septal occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: design of the randomized gore reduce clinical study.", "patent foramen ovale closure with gore helex or cardioform septal occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: design of the randomized gore reduce clinical study.", "patent foramen ovale closure with gore helex or cardioform septal occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: design of the randomized gore reduce clinical study.", "patent foramen ovale closure with gore helex or cardioform septal occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: design of the randomized gore reduce clinical study.", "patent foramen ovale closure with gore helex or cardioform septal occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: design of the randomized gore reduce clinical study.", "patent foramen ovale closure with gore helex or cardioform septal occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: design of the randomized gore reduce clinical study.", "patent foramen ovale closure with gore helex or cardioform septal occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: design of the randomized gore reduce clinical study.", "patent foramen ovale closure with gore helex or cardioform septal occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: design of the randomized gore reduce clinical study.", "patent foramen ovale closure with gore helex or cardioform septal occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: design of the randomized gore reduce clinical study.", "syndrome doege-potter is a paraneoplastic syndrome in which hypoglycemia is the result of tumors producing insulin growth factor-like (igf-ii) it is most often solitary fibrous tumor of the pleura (tfsp).", "syndrome doege-potter is a paraneoplastic syndrome in which hypoglycemia is the result of tumors producing insulin growth factor-like (igf-ii) it is most often solitary fibrous tumor of the pleura (tfsp).", "syndrome doege-potter is a paraneoplastic syndrome in which hypoglycemia is the result of tumors producing insulin growth factor-like (igf-ii) it is most often solitary fibrous tumor of the pleura (tfsp).", "syndrome doege-potter is a paraneoplastic syndrome in which hypoglycemia is the result of tumors producing insulin growth factor-like (igf-ii) it is most often solitary fibrous tumor of the pleura (tfsp).", "syndrome doege-potter is a paraneoplastic syndrome in which hypoglycemia is the result of tumors producing insulin growth factor-like (igf-ii) it is most often solitary fibrous tumor of the pleura (tfsp).", "syndrome doege-potter is a paraneoplastic syndrome in which hypoglycemia is the result of tumors producing insulin growth factor-like (igf-ii) it is most often solitary fibrous tumor of the pleura (tfsp).", "syndrome doege-potter is a paraneoplastic syndrome in which hypoglycemia is the result of tumors producing insulin growth factor-like (igf-ii) it is most often solitary fibrous tumor of the pleura (tfsp).", "syndrome doege-potter is a paraneoplastic syndrome in which hypoglycemia is the result of tumors producing insulin growth factor-like (igf-ii) it is most often solitary fibrous tumor of the pleura (tfsp).", "syndrome doege-potter is a paraneoplastic syndrome in which hypoglycemia is the result of tumors producing insulin growth factor-like (igf-ii) it is most often solitary fibrous tumor of the pleura (tfsp).", "syndrome doege-potter is a paraneoplastic syndrome in which hypoglycemia is the result of tumors producing insulin growth factor-like (igf-ii) it is most often solitary fibrous tumor of the pleura (tfsp).", "syndrome doege-potter is a paraneoplastic syndrome in which hypoglycemia is the result of tumors producing insulin growth factor-like (igf-ii) it is most often solitary fibrous tumor of the pleura (tfsp).", "syndrome doege-potter is a paraneoplastic syndrome in which hypoglycemia is the result of tumors producing insulin growth factor-like (igf-ii) it is most often solitary fibrous tumor of the pleura (tfsp).", "syndrome doege-potter is a paraneoplastic syndrome in which hypoglycemia is the result of tumors producing insulin growth factor-like (igf-ii) it is most often solitary fibrous tumor of the pleura (tfsp).", "syndrome doege-potter is a paraneoplastic syndrome in which hypoglycemia is the result of tumors producing insulin growth factor-like (igf-ii) it is most often solitary fibrous tumor of the pleura (tfsp).", "syndrome doege-potter is a paraneoplastic syndrome in which hypoglycemia is the result of tumors producing insulin growth factor-like (igf-ii) it is most often solitary fibrous tumor of the pleura (tfsp).", "syndrome doege-potter is a paraneoplastic syndrome in which hypoglycemia is the result of tumors producing insulin growth factor-like (igf-ii) it is most often solitary fibrous tumor of the pleura (tfsp).", "syndrome doege-potter is a paraneoplastic syndrome in which hypoglycemia is the result of tumors producing insulin growth factor-like (igf-ii) it is most often solitary fibrous tumor of the pleura (tfsp).", "syndrome doege-potter is a paraneoplastic syndrome in which hypoglycemia is the result of tumors producing insulin growth factor-like (igf-ii) it is most often solitary fibrous tumor of the pleura (tfsp).", "we describe a patient with doege-potter syndrome (solitary fibrous tumor of the pleura presenting with hypoglycemia) and illustrate several important lessons learned from the case.", "we describe a patient with doege-potter syndrome (solitary fibrous tumor of the pleura presenting with hypoglycemia) and illustrate several important lessons learned from the case.", "we describe a patient with doege-potter syndrome (solitary fibrous tumor of the pleura presenting with hypoglycemia) and illustrate several important lessons learned from the case.", "we describe a patient with doege-potter syndrome (solitary fibrous tumor of the pleura presenting with hypoglycemia) and illustrate several important lessons learned from the case.", "we describe a patient with doege-potter syndrome (solitary fibrous tumor of the pleura presenting with hypoglycemia) and illustrate several important lessons learned from the case.", "we describe a patient with doege-potter syndrome (solitary fibrous tumor of the pleura presenting with hypoglycemia) and illustrate several important lessons learned from the case.", "we describe a patient with doege-potter syndrome (solitary fibrous tumor of the pleura presenting with hypoglycemia) and illustrate several important lessons learned from the case.", "we describe a patient with doege-potter syndrome (solitary fibrous tumor of the pleura presenting with hypoglycemia) and illustrate several important lessons learned from the case.", "we describe a patient with doege-potter syndrome (solitary fibrous tumor of the pleura presenting with hypoglycemia) and illustrate several important lessons learned from the case.", "we describe a patient with doege-potter syndrome (solitary fibrous tumor of the pleura presenting with hypoglycemia) and illustrate several important lessons learned from the case.", "we describe a patient with doege-potter syndrome (solitary fibrous tumor of the pleura presenting with hypoglycemia) and illustrate several important lessons learned from the case.", "we describe a patient with doege-potter syndrome (solitary fibrous tumor of the pleura presenting with hypoglycemia) and illustrate several important lessons learned from the case.", "we describe a patient with doege-potter syndrome (solitary fibrous tumor of the pleura presenting with hypoglycemia) and illustrate several important lessons learned from the case.", "we describe a patient with doege-potter syndrome (solitary fibrous tumor of the pleura presenting with hypoglycemia) and illustrate several important lessons learned from the case.", "we describe a patient with doege-potter syndrome (solitary fibrous tumor of the pleura presenting with hypoglycemia) and illustrate several important lessons learned from the case.", "we describe a patient with doege-potter syndrome (solitary fibrous tumor of the pleura presenting with hypoglycemia) and illustrate several important lessons learned from the case.", "we describe a patient with doege-potter syndrome (solitary fibrous tumor of the pleura presenting with hypoglycemia) and illustrate several important lessons learned from the case.", "we describe a patient with doege-potter syndrome (solitary fibrous tumor of the pleura presenting with hypoglycemia) and illustrate several important lessons learned from the case.", "<b>introduction</b>: doege-potter syndrome is a paraneoplastic syndrome characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "<b>introduction</b>: doege-potter syndrome is a paraneoplastic syndrome characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "<b>introduction</b>: doege-potter syndrome is a paraneoplastic syndrome characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "<b>introduction</b>: doege-potter syndrome is a paraneoplastic syndrome characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "<b>introduction</b>: doege-potter syndrome is a paraneoplastic syndrome characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "<b>introduction</b>: doege-potter syndrome is a paraneoplastic syndrome characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "<b>introduction</b>: doege-potter syndrome is a paraneoplastic syndrome characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "<b>introduction</b>: doege-potter syndrome is a paraneoplastic syndrome characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "<b>introduction</b>: doege-potter syndrome is a paraneoplastic syndrome characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "<b>introduction</b>: doege-potter syndrome is a paraneoplastic syndrome characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "<b>introduction</b>: doege-potter syndrome is a paraneoplastic syndrome characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "<b>introduction</b>: doege-potter syndrome is a paraneoplastic syndrome characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "<b>introduction</b>: doege-potter syndrome is a paraneoplastic syndrome characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "<b>introduction</b>: doege-potter syndrome is a paraneoplastic syndrome characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "<b>introduction</b>: doege-potter syndrome is a paraneoplastic syndrome characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "<b>introduction</b>: doege-potter syndrome is a paraneoplastic syndrome characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "<b>introduction</b>: doege-potter syndrome is a paraneoplastic syndrome characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "<b>introduction</b>: doege-potter syndrome is a paraneoplastic syndrome characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "doege-potter syndrome is a paraneoplastic syndrome characterized by tumor-associated hypoglycemia secondary to a solitary fibrous tumor of the pleura.", "doege-potter syndrome is a paraneoplastic syndrome characterized by tumor-associated hypoglycemia secondary to a solitary fibrous tumor of the pleura.", "doege-potter syndrome is a paraneoplastic syndrome characterized by tumor-associated hypoglycemia secondary to a solitary fibrous tumor of the pleura.", "doege-potter syndrome is a paraneoplastic syndrome characterized by tumor-associated hypoglycemia secondary to a solitary fibrous tumor of the pleura.", "doege-potter syndrome is a paraneoplastic syndrome characterized by tumor-associated hypoglycemia secondary to a solitary fibrous tumor of the pleura.", "doege-potter syndrome is a paraneoplastic syndrome characterized by tumor-associated hypoglycemia secondary to a solitary fibrous tumor of the pleura.", "doege-potter syndrome is a paraneoplastic syndrome characterized by tumor-associated hypoglycemia secondary to a solitary fibrous tumor of the pleura.", "doege-potter syndrome is a paraneoplastic syndrome characterized by tumor-associated hypoglycemia secondary to a solitary fibrous tumor of the pleura.", "doege-potter syndrome is a paraneoplastic syndrome characterized by tumor-associated hypoglycemia secondary to a solitary fibrous tumor of the pleura.", "doege-potter syndrome is a paraneoplastic syndrome characterized by tumor-associated hypoglycemia secondary to a solitary fibrous tumor of the pleura.", "doege-potter syndrome is a paraneoplastic syndrome characterized by tumor-associated hypoglycemia secondary to a solitary fibrous tumor of the pleura.", "doege-potter syndrome is a paraneoplastic syndrome characterized by tumor-associated hypoglycemia secondary to a solitary fibrous tumor of the pleura.", "doege-potter syndrome is a paraneoplastic syndrome characterized by tumor-associated hypoglycemia secondary to a solitary fibrous tumor of the pleura.", "doege-potter syndrome is a paraneoplastic syndrome characterized by tumor-associated hypoglycemia secondary to a solitary fibrous tumor of the pleura.", "doege-potter syndrome is a paraneoplastic syndrome characterized by tumor-associated hypoglycemia secondary to a solitary fibrous tumor of the pleura.", "doege-potter syndrome is a paraneoplastic syndrome characterized by tumor-associated hypoglycemia secondary to a solitary fibrous tumor of the pleura.", "doege-potter syndrome is a paraneoplastic syndrome characterized by tumor-associated hypoglycemia secondary to a solitary fibrous tumor of the pleura.", "doege-potter syndrome is a paraneoplastic syndrome characterized by tumor-associated hypoglycemia secondary to a solitary fibrous tumor of the pleura.", "aim: doege-potter syndrome is a rare condition consisting of a mesenchymal tumor, either benign or malignant, accompanied by severe hypoglycemia.", "aim: doege-potter syndrome is a rare condition consisting of a mesenchymal tumor, either benign or malignant, accompanied by severe hypoglycemia.", "aim: doege-potter syndrome is a rare condition consisting of a mesenchymal tumor, either benign or malignant, accompanied by severe hypoglycemia.", "aim: doege-potter syndrome is a rare condition consisting of a mesenchymal tumor, either benign or malignant, accompanied by severe hypoglycemia.", "aim: doege-potter syndrome is a rare condition consisting of a mesenchymal tumor, either benign or malignant, accompanied by severe hypoglycemia.", "aim: doege-potter syndrome is a rare condition consisting of a mesenchymal tumor, either benign or malignant, accompanied by severe hypoglycemia.", "aim: doege-potter syndrome is a rare condition consisting of a mesenchymal tumor, either benign or malignant, accompanied by severe hypoglycemia.", "aim: doege-potter syndrome is a rare condition consisting of a mesenchymal tumor, either benign or malignant, accompanied by severe hypoglycemia.", "aim: doege-potter syndrome is a rare condition consisting of a mesenchymal tumor, either benign or malignant, accompanied by severe hypoglycemia.", "aim: doege-potter syndrome is a rare condition consisting of a mesenchymal tumor, either benign or malignant, accompanied by severe hypoglycemia.", "aim: doege-potter syndrome is a rare condition consisting of a mesenchymal tumor, either benign or malignant, accompanied by severe hypoglycemia.", "aim: doege-potter syndrome is a rare condition consisting of a mesenchymal tumor, either benign or malignant, accompanied by severe hypoglycemia.", "aim: doege-potter syndrome is a rare condition consisting of a mesenchymal tumor, either benign or malignant, accompanied by severe hypoglycemia.", "aim: doege-potter syndrome is a rare condition consisting of a mesenchymal tumor, either benign or malignant, accompanied by severe hypoglycemia.", "aim: doege-potter syndrome is a rare condition consisting of a mesenchymal tumor, either benign or malignant, accompanied by severe hypoglycemia.", "aim: doege-potter syndrome is a rare condition consisting of a mesenchymal tumor, either benign or malignant, accompanied by severe hypoglycemia.", "aim: doege-potter syndrome is a rare condition consisting of a mesenchymal tumor, either benign or malignant, accompanied by severe hypoglycemia.", "aim: doege-potter syndrome is a rare condition consisting of a mesenchymal tumor, either benign or malignant, accompanied by severe hypoglycemia.", "we present a case of doege-potter syndrome whose interest is to consider the tfsp as a cause of hypoglycemia in patients with pleural tumors.<br>", "we present a case of doege-potter syndrome whose interest is to consider the tfsp as a cause of hypoglycemia in patients with pleural tumors.<br>", "we present a case of doege-potter syndrome whose interest is to consider the tfsp as a cause of hypoglycemia in patients with pleural tumors.<br>", "we present a case of doege-potter syndrome whose interest is to consider the tfsp as a cause of hypoglycemia in patients with pleural tumors.<br>", "we present a case of doege-potter syndrome whose interest is to consider the tfsp as a cause of hypoglycemia in patients with pleural tumors.<br>", "we present a case of doege-potter syndrome whose interest is to consider the tfsp as a cause of hypoglycemia in patients with pleural tumors.<br>", "we present a case of doege-potter syndrome whose interest is to consider the tfsp as a cause of hypoglycemia in patients with pleural tumors.<br>", "we present a case of doege-potter syndrome whose interest is to consider the tfsp as a cause of hypoglycemia in patients with pleural tumors.<br>", "we present a case of doege-potter syndrome whose interest is to consider the tfsp as a cause of hypoglycemia in patients with pleural tumors.<br>", "we present a case of doege-potter syndrome whose interest is to consider the tfsp as a cause of hypoglycemia in patients with pleural tumors.<br>", "we present a case of doege-potter syndrome whose interest is to consider the tfsp as a cause of hypoglycemia in patients with pleural tumors.<br>", "we present a case of doege-potter syndrome whose interest is to consider the tfsp as a cause of hypoglycemia in patients with pleural tumors.<br>", "we present a case of doege-potter syndrome whose interest is to consider the tfsp as a cause of hypoglycemia in patients with pleural tumors.<br>", "we present a case of doege-potter syndrome whose interest is to consider the tfsp as a cause of hypoglycemia in patients with pleural tumors.<br>", "we present a case of doege-potter syndrome whose interest is to consider the tfsp as a cause of hypoglycemia in patients with pleural tumors.<br>", "we present a case of doege-potter syndrome whose interest is to consider the tfsp as a cause of hypoglycemia in patients with pleural tumors.<br>", "we present a case of doege-potter syndrome whose interest is to consider the tfsp as a cause of hypoglycemia in patients with pleural tumors.<br>", "we present a case of doege-potter syndrome whose interest is to consider the tfsp as a cause of hypoglycemia in patients with pleural tumors.<br>", "doege-potter syndrome is a paraneoplastic syndrome characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "doege-potter syndrome is a paraneoplastic syndrome characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "doege-potter syndrome is a paraneoplastic syndrome characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "doege-potter syndrome is a paraneoplastic syndrome characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "doege-potter syndrome is a paraneoplastic syndrome characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "doege-potter syndrome is a paraneoplastic syndrome characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "doege-potter syndrome is a paraneoplastic syndrome characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "doege-potter syndrome is a paraneoplastic syndrome characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "doege-potter syndrome is a paraneoplastic syndrome characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "doege-potter syndrome is a paraneoplastic syndrome characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "doege-potter syndrome is a paraneoplastic syndrome characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "doege-potter syndrome is a paraneoplastic syndrome characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "doege-potter syndrome is a paraneoplastic syndrome characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "doege-potter syndrome is a paraneoplastic syndrome characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "doege-potter syndrome is a paraneoplastic syndrome characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "doege-potter syndrome is a paraneoplastic syndrome characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "doege-potter syndrome is a paraneoplastic syndrome characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "doege-potter syndrome is a paraneoplastic syndrome characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "doege-potter syndrome\u00a0is a paraneoplastic\u00a0syndrome\u00a0characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "doege-potter syndrome\u00a0is a paraneoplastic\u00a0syndrome\u00a0characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "doege-potter syndrome\u00a0is a paraneoplastic\u00a0syndrome\u00a0characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "doege-potter syndrome\u00a0is a paraneoplastic\u00a0syndrome\u00a0characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "doege-potter syndrome\u00a0is a paraneoplastic\u00a0syndrome\u00a0characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "doege-potter syndrome\u00a0is a paraneoplastic\u00a0syndrome\u00a0characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "doege-potter syndrome\u00a0is a paraneoplastic\u00a0syndrome\u00a0characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "doege-potter syndrome\u00a0is a paraneoplastic\u00a0syndrome\u00a0characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "doege-potter syndrome\u00a0is a paraneoplastic\u00a0syndrome\u00a0characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "doege-potter syndrome\u00a0is a paraneoplastic\u00a0syndrome\u00a0characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "doege-potter syndrome\u00a0is a paraneoplastic\u00a0syndrome\u00a0characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "doege-potter syndrome\u00a0is a paraneoplastic\u00a0syndrome\u00a0characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "doege-potter syndrome\u00a0is a paraneoplastic\u00a0syndrome\u00a0characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "doege-potter syndrome\u00a0is a paraneoplastic\u00a0syndrome\u00a0characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "doege-potter syndrome\u00a0is a paraneoplastic\u00a0syndrome\u00a0characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "doege-potter syndrome\u00a0is a paraneoplastic\u00a0syndrome\u00a0characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "doege-potter syndrome\u00a0is a paraneoplastic\u00a0syndrome\u00a0characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "doege-potter syndrome\u00a0is a paraneoplastic\u00a0syndrome\u00a0characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor.", "her course was complicated by the development of recurrent fasting hypoglycemia, most likely secondary to doege-potter syndrome.", "her course was complicated by the development of recurrent fasting hypoglycemia, most likely secondary to doege-potter syndrome.", "her course was complicated by the development of recurrent fasting hypoglycemia, most likely secondary to doege-potter syndrome.", "her course was complicated by the development of recurrent fasting hypoglycemia, most likely secondary to doege-potter syndrome.", "her course was complicated by the development of recurrent fasting hypoglycemia, most likely secondary to doege-potter syndrome.", "her course was complicated by the development of recurrent fasting hypoglycemia, most likely secondary to doege-potter syndrome.", "her course was complicated by the development of recurrent fasting hypoglycemia, most likely secondary to doege-potter syndrome.", "her course was complicated by the development of recurrent fasting hypoglycemia, most likely secondary to doege-potter syndrome.", "her course was complicated by the development of recurrent fasting hypoglycemia, most likely secondary to doege-potter syndrome.", "her course was complicated by the development of recurrent fasting hypoglycemia, most likely secondary to doege-potter syndrome.", "her course was complicated by the development of recurrent fasting hypoglycemia, most likely secondary to doege-potter syndrome.", "her course was complicated by the development of recurrent fasting hypoglycemia, most likely secondary to doege-potter syndrome.", "her course was complicated by the development of recurrent fasting hypoglycemia, most likely secondary to doege-potter syndrome.", "her course was complicated by the development of recurrent fasting hypoglycemia, most likely secondary to doege-potter syndrome.", "her course was complicated by the development of recurrent fasting hypoglycemia, most likely secondary to doege-potter syndrome.", "her course was complicated by the development of recurrent fasting hypoglycemia, most likely secondary to doege-potter syndrome.", "her course was complicated by the development of recurrent fasting hypoglycemia, most likely secondary to doege-potter syndrome.", "her course was complicated by the development of recurrent fasting hypoglycemia, most likely secondary to doege-potter syndrome.", "metastatic extrapleural malignant solitary fibrous tumor presenting with hypoglycemia (doege-potter syndrome).", "metastatic extrapleural malignant solitary fibrous tumor presenting with hypoglycemia (doege-potter syndrome).", "metastatic extrapleural malignant solitary fibrous tumor presenting with hypoglycemia (doege-potter syndrome).", "metastatic extrapleural malignant solitary fibrous tumor presenting with hypoglycemia (doege-potter syndrome).", "metastatic extrapleural malignant solitary fibrous tumor presenting with hypoglycemia (doege-potter syndrome).", "metastatic extrapleural malignant solitary fibrous tumor presenting with hypoglycemia (doege-potter syndrome).", "metastatic extrapleural malignant solitary fibrous tumor presenting with hypoglycemia (doege-potter syndrome).", "metastatic extrapleural malignant solitary fibrous tumor presenting with hypoglycemia (doege-potter syndrome).", "metastatic extrapleural malignant solitary fibrous tumor presenting with hypoglycemia (doege-potter syndrome).", "metastatic extrapleural malignant solitary fibrous tumor presenting with hypoglycemia (doege-potter syndrome).", "metastatic extrapleural malignant solitary fibrous tumor presenting with hypoglycemia (doege-potter syndrome).", "metastatic extrapleural malignant solitary fibrous tumor presenting with hypoglycemia (doege-potter syndrome).", "metastatic extrapleural malignant solitary fibrous tumor presenting with hypoglycemia (doege-potter syndrome).", "metastatic extrapleural malignant solitary fibrous tumor presenting with hypoglycemia (doege-potter syndrome).", "metastatic extrapleural malignant solitary fibrous tumor presenting with hypoglycemia (doege-potter syndrome).", "metastatic extrapleural malignant solitary fibrous tumor presenting with hypoglycemia (doege-potter syndrome).", "metastatic extrapleural malignant solitary fibrous tumor presenting with hypoglycemia (doege-potter syndrome).", "metastatic extrapleural malignant solitary fibrous tumor presenting with hypoglycemia (doege-potter syndrome).", "f hypoglycemia is associated with a solitary fibrous tumor, it is referred to as the doege-potter syndrome.", "f hypoglycemia is associated with a solitary fibrous tumor, it is referred to as the doege-potter syndrome.", "f hypoglycemia is associated with a solitary fibrous tumor, it is referred to as the doege-potter syndrome.", "f hypoglycemia is associated with a solitary fibrous tumor, it is referred to as the doege-potter syndrome.", "f hypoglycemia is associated with a solitary fibrous tumor, it is referred to as the doege-potter syndrome.", "f hypoglycemia is associated with a solitary fibrous tumor, it is referred to as the doege-potter syndrome.", "f hypoglycemia is associated with a solitary fibrous tumor, it is referred to as the doege-potter syndrome.", "f hypoglycemia is associated with a solitary fibrous tumor, it is referred to as the doege-potter syndrome.", "f hypoglycemia is associated with a solitary fibrous tumor, it is referred to as the doege-potter syndrome.", "f hypoglycemia is associated with a solitary fibrous tumor, it is referred to as the doege-potter syndrome.", "f hypoglycemia is associated with a solitary fibrous tumor, it is referred to as the doege-potter syndrome.", "f hypoglycemia is associated with a solitary fibrous tumor, it is referred to as the doege-potter syndrome.", "f hypoglycemia is associated with a solitary fibrous tumor, it is referred to as the doege-potter syndrome.", "f hypoglycemia is associated with a solitary fibrous tumor, it is referred to as the doege-potter syndrome.", "f hypoglycemia is associated with a solitary fibrous tumor, it is referred to as the doege-potter syndrome.", "f hypoglycemia is associated with a solitary fibrous tumor, it is referred to as the doege-potter syndrome.", "f hypoglycemia is associated with a solitary fibrous tumor, it is referred to as the doege-potter syndrome.", "f hypoglycemia is associated with a solitary fibrous tumor, it is referred to as the doege-potter syndrome.", "large pleural tumor revealed by severe hypoglycemia: doege-potter syndrome.", "large pleural tumor revealed by severe hypoglycemia: doege-potter syndrome.", "large pleural tumor revealed by severe hypoglycemia: doege-potter syndrome.", "large pleural tumor revealed by severe hypoglycemia: doege-potter syndrome.", "large pleural tumor revealed by severe hypoglycemia: doege-potter syndrome.", "large pleural tumor revealed by severe hypoglycemia: doege-potter syndrome.", "large pleural tumor revealed by severe hypoglycemia: doege-potter syndrome.", "large pleural tumor revealed by severe hypoglycemia: doege-potter syndrome.", "large pleural tumor revealed by severe hypoglycemia: doege-potter syndrome.", "large pleural tumor revealed by severe hypoglycemia: doege-potter syndrome.", "large pleural tumor revealed by severe hypoglycemia: doege-potter syndrome.", "large pleural tumor revealed by severe hypoglycemia: doege-potter syndrome.", "large pleural tumor revealed by severe hypoglycemia: doege-potter syndrome.", "large pleural tumor revealed by severe hypoglycemia: doege-potter syndrome.", "large pleural tumor revealed by severe hypoglycemia: doege-potter syndrome.", "large pleural tumor revealed by severe hypoglycemia: doege-potter syndrome.", "large pleural tumor revealed by severe hypoglycemia: doege-potter syndrome.", "large pleural tumor revealed by severe hypoglycemia: doege-potter syndrome.", "background human rabies infection continues to be a significant public health burden globally, and is occasionally imported to high income settings where the milwaukee protocol for intensive care management has recently been employed, with limited success in improving survival.", "background human rabies infection continues to be a significant public health burden globally, and is occasionally imported to high income settings where the milwaukee protocol for intensive care management has recently been employed, with limited success in improving survival.", "background human rabies infection continues to be a significant public health burden globally, and is occasionally imported to high income settings where the milwaukee protocol for intensive care management has recently been employed, with limited success in improving survival.", "background human rabies infection continues to be a significant public health burden globally, and is occasionally imported to high income settings where the milwaukee protocol for intensive care management has recently been employed, with limited success in improving survival.", "background human rabies infection continues to be a significant public health burden globally, and is occasionally imported to high income settings where the milwaukee protocol for intensive care management has recently been employed, with limited success in improving survival.", "background human rabies infection continues to be a significant public health burden globally, and is occasionally imported to high income settings where the milwaukee protocol for intensive care management has recently been employed, with limited success in improving survival.", "background human rabies infection continues to be a significant public health burden globally, and is occasionally imported to high income settings where the milwaukee protocol for intensive care management has recently been employed, with limited success in improving survival.", "background human rabies infection continues to be a significant public health burden globally, and is occasionally imported to high income settings where the milwaukee protocol for intensive care management has recently been employed, with limited success in improving survival.", "background human rabies infection continues to be a significant public health burden globally, and is occasionally imported to high income settings where the milwaukee protocol for intensive care management has recently been employed, with limited success in improving survival.", "background human rabies infection continues to be a significant public health burden globally, and is occasionally imported to high income settings where the milwaukee protocol for intensive care management has recently been employed, with limited success in improving survival.", "background human rabies infection continues to be a significant public health burden globally, and is occasionally imported to high income settings where the milwaukee protocol for intensive care management has recently been employed, with limited success in improving survival.", "background human rabies infection continues to be a significant public health burden globally, and is occasionally imported to high income settings where the milwaukee protocol for intensive care management has recently been employed, with limited success in improving survival.", "background human rabies infection continues to be a significant public health burden globally, and is occasionally imported to high income settings where the milwaukee protocol for intensive care management has recently been employed, with limited success in improving survival.", "background human rabies infection continues to be a significant public health burden globally, and is occasionally imported to high income settings where the milwaukee protocol for intensive care management has recently been employed, with limited success in improving survival.", "background human rabies infection continues to be a significant public health burden globally, and is occasionally imported to high income settings where the milwaukee protocol for intensive care management has recently been employed, with limited success in improving survival.", "background human rabies infection continues to be a significant public health burden globally, and is occasionally imported to high income settings where the milwaukee protocol for intensive care management has recently been employed, with limited success in improving survival.", "background human rabies infection continues to be a significant public health burden globally, and is occasionally imported to high income settings where the milwaukee protocol for intensive care management has recently been employed, with limited success in improving survival.", "background human rabies infection continues to be a significant public health burden globally, and is occasionally imported to high income settings where the milwaukee protocol for intensive care management has recently been employed, with limited success in improving survival.", "background human rabies infection continues to be a significant public health burden globally, and is occasionally imported to high income settings where the milwaukee protocol for intensive care management has recently been employed, with limited success in improving survival.", "background human rabies infection continues to be a significant public health burden globally, and is occasionally imported to high income settings where the milwaukee protocol for intensive care management has recently been employed, with limited success in improving survival.", "background human rabies infection continues to be a significant public health burden globally, and is occasionally imported to high income settings where the milwaukee protocol for intensive care management has recently been employed, with limited success in improving survival.", "background human rabies infection continues to be a significant public health burden globally, and is occasionally imported to high income settings where the milwaukee protocol for intensive care management has recently been employed, with limited success in improving survival.", "background human rabies infection continues to be a significant public health burden globally, and is occasionally imported to high income settings where the milwaukee protocol for intensive care management has recently been employed, with limited success in improving survival.", "background human rabies infection continues to be a significant public health burden globally, and is occasionally imported to high income settings where the milwaukee protocol for intensive care management has recently been employed, with limited success in improving survival.", "background human rabies infection continues to be a significant public health burden globally, and is occasionally imported to high income settings where the milwaukee protocol for intensive care management has recently been employed, with limited success in improving survival.", "background human rabies infection continues to be a significant public health burden globally, and is occasionally imported to high income settings where the milwaukee protocol for intensive care management has recently been employed, with limited success in improving survival.", "background human rabies infection continues to be a significant public health burden globally, and is occasionally imported to high income settings where the milwaukee protocol for intensive care management has recently been employed, with limited success in improving survival.", "background human rabies infection continues to be a significant public health burden globally, and is occasionally imported to high income settings where the milwaukee protocol for intensive care management has recently been employed, with limited success in improving survival.", "background human rabies infection continues to be a significant public health burden globally, and is occasionally imported to high income settings where the milwaukee protocol for intensive care management has recently been employed, with limited success in improving survival.", "background human rabies infection continues to be a significant public health burden globally, and is occasionally imported to high income settings where the milwaukee protocol for intensive care management has recently been employed, with limited success in improving survival.", "background human rabies infection continues to be a significant public health burden globally, and is occasionally imported to high income settings where the milwaukee protocol for intensive care management has recently been employed, with limited success in improving survival.", "background human rabies infection continues to be a significant public health burden globally, and is occasionally imported to high income settings where the milwaukee protocol for intensive care management has recently been employed, with limited success in improving survival.", "background human rabies infection continues to be a significant public health burden globally, and is occasionally imported to high income settings where the milwaukee protocol for intensive care management has recently been employed, with limited success in improving survival.", "background human rabies infection continues to be a significant public health burden globally, and is occasionally imported to high income settings where the milwaukee protocol for intensive care management has recently been employed, with limited success in improving survival.", "therapies suggested in the milwaukee protocol include therapeutic coma, ketamine infusion, amantadine, and the screening/prophylaxis/management of cerebral vasospasm. none of these therapies can be substantiated in rabies or other forms of acute viral encephalitis.", "therapies suggested in the milwaukee protocol include therapeutic coma, ketamine infusion, amantadine, and the screening/prophylaxis/management of cerebral vasospasm. none of these therapies can be substantiated in rabies or other forms of acute viral encephalitis.", "therapies suggested in the milwaukee protocol include therapeutic coma, ketamine infusion, amantadine, and the screening/prophylaxis/management of cerebral vasospasm. none of these therapies can be substantiated in rabies or other forms of acute viral encephalitis.", "therapies suggested in the milwaukee protocol include therapeutic coma, ketamine infusion, amantadine, and the screening/prophylaxis/management of cerebral vasospasm. none of these therapies can be substantiated in rabies or other forms of acute viral encephalitis.", "therapies suggested in the milwaukee protocol include therapeutic coma, ketamine infusion, amantadine, and the screening/prophylaxis/management of cerebral vasospasm. none of these therapies can be substantiated in rabies or other forms of acute viral encephalitis.", "therapies suggested in the milwaukee protocol include therapeutic coma, ketamine infusion, amantadine, and the screening/prophylaxis/management of cerebral vasospasm. none of these therapies can be substantiated in rabies or other forms of acute viral encephalitis.", "therapies suggested in the milwaukee protocol include therapeutic coma, ketamine infusion, amantadine, and the screening/prophylaxis/management of cerebral vasospasm. none of these therapies can be substantiated in rabies or other forms of acute viral encephalitis.", "therapies suggested in the milwaukee protocol include therapeutic coma, ketamine infusion, amantadine, and the screening/prophylaxis/management of cerebral vasospasm. none of these therapies can be substantiated in rabies or other forms of acute viral encephalitis.", "therapies suggested in the milwaukee protocol include therapeutic coma, ketamine infusion, amantadine, and the screening/prophylaxis/management of cerebral vasospasm. none of these therapies can be substantiated in rabies or other forms of acute viral encephalitis.", "therapies suggested in the milwaukee protocol include therapeutic coma, ketamine infusion, amantadine, and the screening/prophylaxis/management of cerebral vasospasm. none of these therapies can be substantiated in rabies or other forms of acute viral encephalitis.", "therapies suggested in the milwaukee protocol include therapeutic coma, ketamine infusion, amantadine, and the screening/prophylaxis/management of cerebral vasospasm. none of these therapies can be substantiated in rabies or other forms of acute viral encephalitis.", "therapies suggested in the milwaukee protocol include therapeutic coma, ketamine infusion, amantadine, and the screening/prophylaxis/management of cerebral vasospasm. none of these therapies can be substantiated in rabies or other forms of acute viral encephalitis.", "therapies suggested in the milwaukee protocol include therapeutic coma, ketamine infusion, amantadine, and the screening/prophylaxis/management of cerebral vasospasm. none of these therapies can be substantiated in rabies or other forms of acute viral encephalitis.", "therapies suggested in the milwaukee protocol include therapeutic coma, ketamine infusion, amantadine, and the screening/prophylaxis/management of cerebral vasospasm. none of these therapies can be substantiated in rabies or other forms of acute viral encephalitis.", "therapies suggested in the milwaukee protocol include therapeutic coma, ketamine infusion, amantadine, and the screening/prophylaxis/management of cerebral vasospasm. none of these therapies can be substantiated in rabies or other forms of acute viral encephalitis.", "therapies suggested in the milwaukee protocol include therapeutic coma, ketamine infusion, amantadine, and the screening/prophylaxis/management of cerebral vasospasm. none of these therapies can be substantiated in rabies or other forms of acute viral encephalitis.", "therapies suggested in the milwaukee protocol include therapeutic coma, ketamine infusion, amantadine, and the screening/prophylaxis/management of cerebral vasospasm. none of these therapies can be substantiated in rabies or other forms of acute viral encephalitis.", "therapies suggested in the milwaukee protocol include therapeutic coma, ketamine infusion, amantadine, and the screening/prophylaxis/management of cerebral vasospasm. none of these therapies can be substantiated in rabies or other forms of acute viral encephalitis.", "therapies suggested in the milwaukee protocol include therapeutic coma, ketamine infusion, amantadine, and the screening/prophylaxis/management of cerebral vasospasm. none of these therapies can be substantiated in rabies or other forms of acute viral encephalitis.", "therapies suggested in the milwaukee protocol include therapeutic coma, ketamine infusion, amantadine, and the screening/prophylaxis/management of cerebral vasospasm. none of these therapies can be substantiated in rabies or other forms of acute viral encephalitis.", "therapies suggested in the milwaukee protocol include therapeutic coma, ketamine infusion, amantadine, and the screening/prophylaxis/management of cerebral vasospasm. none of these therapies can be substantiated in rabies or other forms of acute viral encephalitis.", "therapies suggested in the milwaukee protocol include therapeutic coma, ketamine infusion, amantadine, and the screening/prophylaxis/management of cerebral vasospasm. none of these therapies can be substantiated in rabies or other forms of acute viral encephalitis.", "therapies suggested in the milwaukee protocol include therapeutic coma, ketamine infusion, amantadine, and the screening/prophylaxis/management of cerebral vasospasm. none of these therapies can be substantiated in rabies or other forms of acute viral encephalitis.", "therapies suggested in the milwaukee protocol include therapeutic coma, ketamine infusion, amantadine, and the screening/prophylaxis/management of cerebral vasospasm. none of these therapies can be substantiated in rabies or other forms of acute viral encephalitis.", "therapies suggested in the milwaukee protocol include therapeutic coma, ketamine infusion, amantadine, and the screening/prophylaxis/management of cerebral vasospasm. none of these therapies can be substantiated in rabies or other forms of acute viral encephalitis.", "therapies suggested in the milwaukee protocol include therapeutic coma, ketamine infusion, amantadine, and the screening/prophylaxis/management of cerebral vasospasm. none of these therapies can be substantiated in rabies or other forms of acute viral encephalitis.", "therapies suggested in the milwaukee protocol include therapeutic coma, ketamine infusion, amantadine, and the screening/prophylaxis/management of cerebral vasospasm. none of these therapies can be substantiated in rabies or other forms of acute viral encephalitis.", "therapies suggested in the milwaukee protocol include therapeutic coma, ketamine infusion, amantadine, and the screening/prophylaxis/management of cerebral vasospasm. none of these therapies can be substantiated in rabies or other forms of acute viral encephalitis.", "therapies suggested in the milwaukee protocol include therapeutic coma, ketamine infusion, amantadine, and the screening/prophylaxis/management of cerebral vasospasm. none of these therapies can be substantiated in rabies or other forms of acute viral encephalitis.", "therapies suggested in the milwaukee protocol include therapeutic coma, ketamine infusion, amantadine, and the screening/prophylaxis/management of cerebral vasospasm. none of these therapies can be substantiated in rabies or other forms of acute viral encephalitis.", "therapies suggested in the milwaukee protocol include therapeutic coma, ketamine infusion, amantadine, and the screening/prophylaxis/management of cerebral vasospasm. none of these therapies can be substantiated in rabies or other forms of acute viral encephalitis.", "therapies suggested in the milwaukee protocol include therapeutic coma, ketamine infusion, amantadine, and the screening/prophylaxis/management of cerebral vasospasm. none of these therapies can be substantiated in rabies or other forms of acute viral encephalitis.", "therapies suggested in the milwaukee protocol include therapeutic coma, ketamine infusion, amantadine, and the screening/prophylaxis/management of cerebral vasospasm. none of these therapies can be substantiated in rabies or other forms of acute viral encephalitis.", "therapies suggested in the milwaukee protocol include therapeutic coma, ketamine infusion, amantadine, and the screening/prophylaxis/management of cerebral vasospasm. none of these therapies can be substantiated in rabies or other forms of acute viral encephalitis.", "rabies is virtually always fatal after clinical disease develops, and there have only been rare survivors. the milwaukee protocol, which includes therapeutic coma, has been shown to be ineffective and should no longer be used.", "rabies is virtually always fatal after clinical disease develops, and there have only been rare survivors. the milwaukee protocol, which includes therapeutic coma, has been shown to be ineffective and should no longer be used.", "rabies is virtually always fatal after clinical disease develops, and there have only been rare survivors. the milwaukee protocol, which includes therapeutic coma, has been shown to be ineffective and should no longer be used.", "rabies is virtually always fatal after clinical disease develops, and there have only been rare survivors. the milwaukee protocol, which includes therapeutic coma, has been shown to be ineffective and should no longer be used.", "rabies is virtually always fatal after clinical disease develops, and there have only been rare survivors. the milwaukee protocol, which includes therapeutic coma, has been shown to be ineffective and should no longer be used.", "rabies is virtually always fatal after clinical disease develops, and there have only been rare survivors. the milwaukee protocol, which includes therapeutic coma, has been shown to be ineffective and should no longer be used.", "rabies is virtually always fatal after clinical disease develops, and there have only been rare survivors. the milwaukee protocol, which includes therapeutic coma, has been shown to be ineffective and should no longer be used.", "rabies is virtually always fatal after clinical disease develops, and there have only been rare survivors. the milwaukee protocol, which includes therapeutic coma, has been shown to be ineffective and should no longer be used.", "rabies is virtually always fatal after clinical disease develops, and there have only been rare survivors. the milwaukee protocol, which includes therapeutic coma, has been shown to be ineffective and should no longer be used.", "rabies is virtually always fatal after clinical disease develops, and there have only been rare survivors. the milwaukee protocol, which includes therapeutic coma, has been shown to be ineffective and should no longer be used.", "rabies is virtually always fatal after clinical disease develops, and there have only been rare survivors. the milwaukee protocol, which includes therapeutic coma, has been shown to be ineffective and should no longer be used.", "rabies is virtually always fatal after clinical disease develops, and there have only been rare survivors. the milwaukee protocol, which includes therapeutic coma, has been shown to be ineffective and should no longer be used.", "rabies is virtually always fatal after clinical disease develops, and there have only been rare survivors. the milwaukee protocol, which includes therapeutic coma, has been shown to be ineffective and should no longer be used.", "rabies is virtually always fatal after clinical disease develops, and there have only been rare survivors. the milwaukee protocol, which includes therapeutic coma, has been shown to be ineffective and should no longer be used.", "rabies is virtually always fatal after clinical disease develops, and there have only been rare survivors. the milwaukee protocol, which includes therapeutic coma, has been shown to be ineffective and should no longer be used.", "rabies is virtually always fatal after clinical disease develops, and there have only been rare survivors. the milwaukee protocol, which includes therapeutic coma, has been shown to be ineffective and should no longer be used.", "rabies is virtually always fatal after clinical disease develops, and there have only been rare survivors. the milwaukee protocol, which includes therapeutic coma, has been shown to be ineffective and should no longer be used.", "rabies is virtually always fatal after clinical disease develops, and there have only been rare survivors. the milwaukee protocol, which includes therapeutic coma, has been shown to be ineffective and should no longer be used.", "rabies is virtually always fatal after clinical disease develops, and there have only been rare survivors. the milwaukee protocol, which includes therapeutic coma, has been shown to be ineffective and should no longer be used.", "rabies is virtually always fatal after clinical disease develops, and there have only been rare survivors. the milwaukee protocol, which includes therapeutic coma, has been shown to be ineffective and should no longer be used.", "rabies is virtually always fatal after clinical disease develops, and there have only been rare survivors. the milwaukee protocol, which includes therapeutic coma, has been shown to be ineffective and should no longer be used.", "rabies is virtually always fatal after clinical disease develops, and there have only been rare survivors. the milwaukee protocol, which includes therapeutic coma, has been shown to be ineffective and should no longer be used.", "rabies is virtually always fatal after clinical disease develops, and there have only been rare survivors. the milwaukee protocol, which includes therapeutic coma, has been shown to be ineffective and should no longer be used.", "rabies is virtually always fatal after clinical disease develops, and there have only been rare survivors. the milwaukee protocol, which includes therapeutic coma, has been shown to be ineffective and should no longer be used.", "rabies is virtually always fatal after clinical disease develops, and there have only been rare survivors. the milwaukee protocol, which includes therapeutic coma, has been shown to be ineffective and should no longer be used.", "rabies is virtually always fatal after clinical disease develops, and there have only been rare survivors. the milwaukee protocol, which includes therapeutic coma, has been shown to be ineffective and should no longer be used.", "rabies is virtually always fatal after clinical disease develops, and there have only been rare survivors. the milwaukee protocol, which includes therapeutic coma, has been shown to be ineffective and should no longer be used.", "rabies is virtually always fatal after clinical disease develops, and there have only been rare survivors. the milwaukee protocol, which includes therapeutic coma, has been shown to be ineffective and should no longer be used.", "rabies is virtually always fatal after clinical disease develops, and there have only been rare survivors. the milwaukee protocol, which includes therapeutic coma, has been shown to be ineffective and should no longer be used.", "rabies is virtually always fatal after clinical disease develops, and there have only been rare survivors. the milwaukee protocol, which includes therapeutic coma, has been shown to be ineffective and should no longer be used.", "rabies is virtually always fatal after clinical disease develops, and there have only been rare survivors. the milwaukee protocol, which includes therapeutic coma, has been shown to be ineffective and should no longer be used.", "rabies is virtually always fatal after clinical disease develops, and there have only been rare survivors. the milwaukee protocol, which includes therapeutic coma, has been shown to be ineffective and should no longer be used.", "rabies is virtually always fatal after clinical disease develops, and there have only been rare survivors. the milwaukee protocol, which includes therapeutic coma, has been shown to be ineffective and should no longer be used.", "rabies is virtually always fatal after clinical disease develops, and there have only been rare survivors. the milwaukee protocol, which includes therapeutic coma, has been shown to be ineffective and should no longer be used.", "this report summarizes the clinical course of disease in that patient, who was treated using the milwaukee protocol, an experimental treatment protocol similar to one used for the rabies survivor described in 2005.", "this report summarizes the clinical course of disease in that patient, who was treated using the milwaukee protocol, an experimental treatment protocol similar to one used for the rabies survivor described in 2005.", "this report summarizes the clinical course of disease in that patient, who was treated using the milwaukee protocol, an experimental treatment protocol similar to one used for the rabies survivor described in 2005.", "this report summarizes the clinical course of disease in that patient, who was treated using the milwaukee protocol, an experimental treatment protocol similar to one used for the rabies survivor described in 2005.", "this report summarizes the clinical course of disease in that patient, who was treated using the milwaukee protocol, an experimental treatment protocol similar to one used for the rabies survivor described in 2005.", "this report summarizes the clinical course of disease in that patient, who was treated using the milwaukee protocol, an experimental treatment protocol similar to one used for the rabies survivor described in 2005.", "this report summarizes the clinical course of disease in that patient, who was treated using the milwaukee protocol, an experimental treatment protocol similar to one used for the rabies survivor described in 2005.", "this report summarizes the clinical course of disease in that patient, who was treated using the milwaukee protocol, an experimental treatment protocol similar to one used for the rabies survivor described in 2005.", "this report summarizes the clinical course of disease in that patient, who was treated using the milwaukee protocol, an experimental treatment protocol similar to one used for the rabies survivor described in 2005.", "this report summarizes the clinical course of disease in that patient, who was treated using the milwaukee protocol, an experimental treatment protocol similar to one used for the rabies survivor described in 2005.", "this report summarizes the clinical course of disease in that patient, who was treated using the milwaukee protocol, an experimental treatment protocol similar to one used for the rabies survivor described in 2005.", "this report summarizes the clinical course of disease in that patient, who was treated using the milwaukee protocol, an experimental treatment protocol similar to one used for the rabies survivor described in 2005.", "this report summarizes the clinical course of disease in that patient, who was treated using the milwaukee protocol, an experimental treatment protocol similar to one used for the rabies survivor described in 2005.", "this report summarizes the clinical course of disease in that patient, who was treated using the milwaukee protocol, an experimental treatment protocol similar to one used for the rabies survivor described in 2005.", "this report summarizes the clinical course of disease in that patient, who was treated using the milwaukee protocol, an experimental treatment protocol similar to one used for the rabies survivor described in 2005.", "this report summarizes the clinical course of disease in that patient, who was treated using the milwaukee protocol, an experimental treatment protocol similar to one used for the rabies survivor described in 2005.", "this report summarizes the clinical course of disease in that patient, who was treated using the milwaukee protocol, an experimental treatment protocol similar to one used for the rabies survivor described in 2005.", "this report summarizes the clinical course of disease in that patient, who was treated using the milwaukee protocol, an experimental treatment protocol similar to one used for the rabies survivor described in 2005.", "this report summarizes the clinical course of disease in that patient, who was treated using the milwaukee protocol, an experimental treatment protocol similar to one used for the rabies survivor described in 2005.", "this report summarizes the clinical course of disease in that patient, who was treated using the milwaukee protocol, an experimental treatment protocol similar to one used for the rabies survivor described in 2005.", "this report summarizes the clinical course of disease in that patient, who was treated using the milwaukee protocol, an experimental treatment protocol similar to one used for the rabies survivor described in 2005.", "this report summarizes the clinical course of disease in that patient, who was treated using the milwaukee protocol, an experimental treatment protocol similar to one used for the rabies survivor described in 2005.", "this report summarizes the clinical course of disease in that patient, who was treated using the milwaukee protocol, an experimental treatment protocol similar to one used for the rabies survivor described in 2005.", "this report summarizes the clinical course of disease in that patient, who was treated using the milwaukee protocol, an experimental treatment protocol similar to one used for the rabies survivor described in 2005.", "this report summarizes the clinical course of disease in that patient, who was treated using the milwaukee protocol, an experimental treatment protocol similar to one used for the rabies survivor described in 2005.", "this report summarizes the clinical course of disease in that patient, who was treated using the milwaukee protocol, an experimental treatment protocol similar to one used for the rabies survivor described in 2005.", "this report summarizes the clinical course of disease in that patient, who was treated using the milwaukee protocol, an experimental treatment protocol similar to one used for the rabies survivor described in 2005.", "this report summarizes the clinical course of disease in that patient, who was treated using the milwaukee protocol, an experimental treatment protocol similar to one used for the rabies survivor described in 2005.", "this report summarizes the clinical course of disease in that patient, who was treated using the milwaukee protocol, an experimental treatment protocol similar to one used for the rabies survivor described in 2005.", "this report summarizes the clinical course of disease in that patient, who was treated using the milwaukee protocol, an experimental treatment protocol similar to one used for the rabies survivor described in 2005.", "this report summarizes the clinical course of disease in that patient, who was treated using the milwaukee protocol, an experimental treatment protocol similar to one used for the rabies survivor described in 2005.", "this report summarizes the clinical course of disease in that patient, who was treated using the milwaukee protocol, an experimental treatment protocol similar to one used for the rabies survivor described in 2005.", "this report summarizes the clinical course of disease in that patient, who was treated using the milwaukee protocol, an experimental treatment protocol similar to one used for the rabies survivor described in 2005.", "this report summarizes the clinical course of disease in that patient, who was treated using the milwaukee protocol, an experimental treatment protocol similar to one used for the rabies survivor described in 2005.", "the milwaukee protocol, which to date has five reported human rabies survivors associated with its use, has been suggested as a potential management pathway for human rabies.", "the milwaukee protocol, which to date has five reported human rabies survivors associated with its use, has been suggested as a potential management pathway for human rabies.", "the milwaukee protocol, which to date has five reported human rabies survivors associated with its use, has been suggested as a potential management pathway for human rabies.", "the milwaukee protocol, which to date has five reported human rabies survivors associated with its use, has been suggested as a potential management pathway for human rabies.", "the milwaukee protocol, which to date has five reported human rabies survivors associated with its use, has been suggested as a potential management pathway for human rabies.", "the milwaukee protocol, which to date has five reported human rabies survivors associated with its use, has been suggested as a potential management pathway for human rabies.", "the milwaukee protocol, which to date has five reported human rabies survivors associated with its use, has been suggested as a potential management pathway for human rabies.", "the milwaukee protocol, which to date has five reported human rabies survivors associated with its use, has been suggested as a potential management pathway for human rabies.", "the milwaukee protocol, which to date has five reported human rabies survivors associated with its use, has been suggested as a potential management pathway for human rabies.", "the milwaukee protocol, which to date has five reported human rabies survivors associated with its use, has been suggested as a potential management pathway for human rabies.", "the milwaukee protocol, which to date has five reported human rabies survivors associated with its use, has been suggested as a potential management pathway for human rabies.", "the milwaukee protocol, which to date has five reported human rabies survivors associated with its use, has been suggested as a potential management pathway for human rabies.", "the milwaukee protocol, which to date has five reported human rabies survivors associated with its use, has been suggested as a potential management pathway for human rabies.", "the milwaukee protocol, which to date has five reported human rabies survivors associated with its use, has been suggested as a potential management pathway for human rabies.", "the milwaukee protocol, which to date has five reported human rabies survivors associated with its use, has been suggested as a potential management pathway for human rabies.", "the milwaukee protocol, which to date has five reported human rabies survivors associated with its use, has been suggested as a potential management pathway for human rabies.", "the milwaukee protocol, which to date has five reported human rabies survivors associated with its use, has been suggested as a potential management pathway for human rabies.", "the milwaukee protocol, which to date has five reported human rabies survivors associated with its use, has been suggested as a potential management pathway for human rabies.", "the milwaukee protocol, which to date has five reported human rabies survivors associated with its use, has been suggested as a potential management pathway for human rabies.", "the milwaukee protocol, which to date has five reported human rabies survivors associated with its use, has been suggested as a potential management pathway for human rabies.", "the milwaukee protocol, which to date has five reported human rabies survivors associated with its use, has been suggested as a potential management pathway for human rabies.", "the milwaukee protocol, which to date has five reported human rabies survivors associated with its use, has been suggested as a potential management pathway for human rabies.", "the milwaukee protocol, which to date has five reported human rabies survivors associated with its use, has been suggested as a potential management pathway for human rabies.", "the milwaukee protocol, which to date has five reported human rabies survivors associated with its use, has been suggested as a potential management pathway for human rabies.", "the milwaukee protocol, which to date has five reported human rabies survivors associated with its use, has been suggested as a potential management pathway for human rabies.", "the milwaukee protocol, which to date has five reported human rabies survivors associated with its use, has been suggested as a potential management pathway for human rabies.", "the milwaukee protocol, which to date has five reported human rabies survivors associated with its use, has been suggested as a potential management pathway for human rabies.", "the milwaukee protocol, which to date has five reported human rabies survivors associated with its use, has been suggested as a potential management pathway for human rabies.", "the milwaukee protocol, which to date has five reported human rabies survivors associated with its use, has been suggested as a potential management pathway for human rabies.", "the milwaukee protocol, which to date has five reported human rabies survivors associated with its use, has been suggested as a potential management pathway for human rabies.", "the milwaukee protocol, which to date has five reported human rabies survivors associated with its use, has been suggested as a potential management pathway for human rabies.", "the milwaukee protocol, which to date has five reported human rabies survivors associated with its use, has been suggested as a potential management pathway for human rabies.", "the milwaukee protocol, which to date has five reported human rabies survivors associated with its use, has been suggested as a potential management pathway for human rabies.", "the milwaukee protocol, which to date has five reported human rabies survivors associated with its use, has been suggested as a potential management pathway for human rabies.", "the milwaukee protocol has been attributed to survival in rabies encephalitis despite a lack of scientific evidence supporting its therapeutic measures.", "the milwaukee protocol has been attributed to survival in rabies encephalitis despite a lack of scientific evidence supporting its therapeutic measures.", "the milwaukee protocol has been attributed to survival in rabies encephalitis despite a lack of scientific evidence supporting its therapeutic measures.", "the milwaukee protocol has been attributed to survival in rabies encephalitis despite a lack of scientific evidence supporting its therapeutic measures.", "the milwaukee protocol has been attributed to survival in rabies encephalitis despite a lack of scientific evidence supporting its therapeutic measures.", "the milwaukee protocol has been attributed to survival in rabies encephalitis despite a lack of scientific evidence supporting its therapeutic measures.", "the milwaukee protocol has been attributed to survival in rabies encephalitis despite a lack of scientific evidence supporting its therapeutic measures.", "the milwaukee protocol has been attributed to survival in rabies encephalitis despite a lack of scientific evidence supporting its therapeutic measures.", "the milwaukee protocol has been attributed to survival in rabies encephalitis despite a lack of scientific evidence supporting its therapeutic measures.", "the milwaukee protocol has been attributed to survival in rabies encephalitis despite a lack of scientific evidence supporting its therapeutic measures.", "the milwaukee protocol has been attributed to survival in rabies encephalitis despite a lack of scientific evidence supporting its therapeutic measures.", "the milwaukee protocol has been attributed to survival in rabies encephalitis despite a lack of scientific evidence supporting its therapeutic measures.", "the milwaukee protocol has been attributed to survival in rabies encephalitis despite a lack of scientific evidence supporting its therapeutic measures.", "the milwaukee protocol has been attributed to survival in rabies encephalitis despite a lack of scientific evidence supporting its therapeutic measures.", "the milwaukee protocol has been attributed to survival in rabies encephalitis despite a lack of scientific evidence supporting its therapeutic measures.", "the milwaukee protocol has been attributed to survival in rabies encephalitis despite a lack of scientific evidence supporting its therapeutic measures.", "the milwaukee protocol has been attributed to survival in rabies encephalitis despite a lack of scientific evidence supporting its therapeutic measures.", "the milwaukee protocol has been attributed to survival in rabies encephalitis despite a lack of scientific evidence supporting its therapeutic measures.", "the milwaukee protocol has been attributed to survival in rabies encephalitis despite a lack of scientific evidence supporting its therapeutic measures.", "the milwaukee protocol has been attributed to survival in rabies encephalitis despite a lack of scientific evidence supporting its therapeutic measures.", "the milwaukee protocol has been attributed to survival in rabies encephalitis despite a lack of scientific evidence supporting its therapeutic measures.", "the milwaukee protocol has been attributed to survival in rabies encephalitis despite a lack of scientific evidence supporting its therapeutic measures.", "the milwaukee protocol has been attributed to survival in rabies encephalitis despite a lack of scientific evidence supporting its therapeutic measures.", "the milwaukee protocol has been attributed to survival in rabies encephalitis despite a lack of scientific evidence supporting its therapeutic measures.", "the milwaukee protocol has been attributed to survival in rabies encephalitis despite a lack of scientific evidence supporting its therapeutic measures.", "the milwaukee protocol has been attributed to survival in rabies encephalitis despite a lack of scientific evidence supporting its therapeutic measures.", "the milwaukee protocol has been attributed to survival in rabies encephalitis despite a lack of scientific evidence supporting its therapeutic measures.", "the milwaukee protocol has been attributed to survival in rabies encephalitis despite a lack of scientific evidence supporting its therapeutic measures.", "the milwaukee protocol has been attributed to survival in rabies encephalitis despite a lack of scientific evidence supporting its therapeutic measures.", "the milwaukee protocol has been attributed to survival in rabies encephalitis despite a lack of scientific evidence supporting its therapeutic measures.", "the milwaukee protocol has been attributed to survival in rabies encephalitis despite a lack of scientific evidence supporting its therapeutic measures.", "the milwaukee protocol has been attributed to survival in rabies encephalitis despite a lack of scientific evidence supporting its therapeutic measures.", "the milwaukee protocol has been attributed to survival in rabies encephalitis despite a lack of scientific evidence supporting its therapeutic measures.", "the milwaukee protocol has been attributed to survival in rabies encephalitis despite a lack of scientific evidence supporting its therapeutic measures.", "in this first report of rabies in equatorial guinea, problems accompanying the application of the milwaukee protocol are described.", "in this first report of rabies in equatorial guinea, problems accompanying the application of the milwaukee protocol are described.", "in this first report of rabies in equatorial guinea, problems accompanying the application of the milwaukee protocol are described.", "in this first report of rabies in equatorial guinea, problems accompanying the application of the milwaukee protocol are described.", "in this first report of rabies in equatorial guinea, problems accompanying the application of the milwaukee protocol are described.", "in this first report of rabies in equatorial guinea, problems accompanying the application of the milwaukee protocol are described.", "in this first report of rabies in equatorial guinea, problems accompanying the application of the milwaukee protocol are described.", "in this first report of rabies in equatorial guinea, problems accompanying the application of the milwaukee protocol are described.", "in this first report of rabies in equatorial guinea, problems accompanying the application of the milwaukee protocol are described.", "in this first report of rabies in equatorial guinea, problems accompanying the application of the milwaukee protocol are described.", "in this first report of rabies in equatorial guinea, problems accompanying the application of the milwaukee protocol are described.", "in this first report of rabies in equatorial guinea, problems accompanying the application of the milwaukee protocol are described.", "in this first report of rabies in equatorial guinea, problems accompanying the application of the milwaukee protocol are described.", "in this first report of rabies in equatorial guinea, problems accompanying the application of the milwaukee protocol are described.", "in this first report of rabies in equatorial guinea, problems accompanying the application of the milwaukee protocol are described.", "in this first report of rabies in equatorial guinea, problems accompanying the application of the milwaukee protocol are described.", "in this first report of rabies in equatorial guinea, problems accompanying the application of the milwaukee protocol are described.", "in this first report of rabies in equatorial guinea, problems accompanying the application of the milwaukee protocol are described.", "in this first report of rabies in equatorial guinea, problems accompanying the application of the milwaukee protocol are described.", "in this first report of rabies in equatorial guinea, problems accompanying the application of the milwaukee protocol are described.", "in this first report of rabies in equatorial guinea, problems accompanying the application of the milwaukee protocol are described.", "in this first report of rabies in equatorial guinea, problems accompanying the application of the milwaukee protocol are described.", "in this first report of rabies in equatorial guinea, problems accompanying the application of the milwaukee protocol are described.", "in this first report of rabies in equatorial guinea, problems accompanying the application of the milwaukee protocol are described.", "in this first report of rabies in equatorial guinea, problems accompanying the application of the milwaukee protocol are described.", "in this first report of rabies in equatorial guinea, problems accompanying the application of the milwaukee protocol are described.", "in this first report of rabies in equatorial guinea, problems accompanying the application of the milwaukee protocol are described.", "in this first report of rabies in equatorial guinea, problems accompanying the application of the milwaukee protocol are described.", "in this first report of rabies in equatorial guinea, problems accompanying the application of the milwaukee protocol are described.", "in this first report of rabies in equatorial guinea, problems accompanying the application of the milwaukee protocol are described.", "in this first report of rabies in equatorial guinea, problems accompanying the application of the milwaukee protocol are described.", "in this first report of rabies in equatorial guinea, problems accompanying the application of the milwaukee protocol are described.", "in this first report of rabies in equatorial guinea, problems accompanying the application of the milwaukee protocol are described.", "in this first report of rabies in equatorial guinea, problems accompanying the application of the milwaukee protocol are described.", "caring for a patient with rabies: implications of the milwaukee protocol for infection control and public health measures.", "caring for a patient with rabies: implications of the milwaukee protocol for infection control and public health measures.", "caring for a patient with rabies: implications of the milwaukee protocol for infection control and public health measures.", "caring for a patient with rabies: implications of the milwaukee protocol for infection control and public health measures.", "caring for a patient with rabies: implications of the milwaukee protocol for infection control and public health measures.", "caring for a patient with rabies: implications of the milwaukee protocol for infection control and public health measures.", "caring for a patient with rabies: implications of the milwaukee protocol for infection control and public health measures.", "caring for a patient with rabies: implications of the milwaukee protocol for infection control and public health measures.", "caring for a patient with rabies: implications of the milwaukee protocol for infection control and public health measures.", "caring for a patient with rabies: implications of the milwaukee protocol for infection control and public health measures.", "caring for a patient with rabies: implications of the milwaukee protocol for infection control and public health measures.", "caring for a patient with rabies: implications of the milwaukee protocol for infection control and public health measures.", "caring for a patient with rabies: implications of the milwaukee protocol for infection control and public health measures.", "caring for a patient with rabies: implications of the milwaukee protocol for infection control and public health measures.", "caring for a patient with rabies: implications of the milwaukee protocol for infection control and public health measures.", "caring for a patient with rabies: implications of the milwaukee protocol for infection control and public health measures.", "caring for a patient with rabies: implications of the milwaukee protocol for infection control and public health measures.", "caring for a patient with rabies: implications of the milwaukee protocol for infection control and public health measures.", "caring for a patient with rabies: implications of the milwaukee protocol for infection control and public health measures.", "caring for a patient with rabies: implications of the milwaukee protocol for infection control and public health measures.", "caring for a patient with rabies: implications of the milwaukee protocol for infection control and public health measures.", "caring for a patient with rabies: implications of the milwaukee protocol for infection control and public health measures.", "caring for a patient with rabies: implications of the milwaukee protocol for infection control and public health measures.", "caring for a patient with rabies: implications of the milwaukee protocol for infection control and public health measures.", "caring for a patient with rabies: implications of the milwaukee protocol for infection control and public health measures.", "caring for a patient with rabies: implications of the milwaukee protocol for infection control and public health measures.", "caring for a patient with rabies: implications of the milwaukee protocol for infection control and public health measures.", "caring for a patient with rabies: implications of the milwaukee protocol for infection control and public health measures.", "caring for a patient with rabies: implications of the milwaukee protocol for infection control and public health measures.", "caring for a patient with rabies: implications of the milwaukee protocol for infection control and public health measures.", "caring for a patient with rabies: implications of the milwaukee protocol for infection control and public health measures.", "caring for a patient with rabies: implications of the milwaukee protocol for infection control and public health measures.", "caring for a patient with rabies: implications of the milwaukee protocol for infection control and public health measures.", "caring for a patient with rabies: implications of the milwaukee protocol for infection control and public health measures.", "critical appraisal of the milwaukee protocol for rabies: this failed approach should be abandoned.", "critical appraisal of the milwaukee protocol for rabies: this failed approach should be abandoned.", "critical appraisal of the milwaukee protocol for rabies: this failed approach should be abandoned.", "critical appraisal of the milwaukee protocol for rabies: this failed approach should be abandoned.", "critical appraisal of the milwaukee protocol for rabies: this failed approach should be abandoned.", "critical appraisal of the milwaukee protocol for rabies: this failed approach should be abandoned.", "critical appraisal of the milwaukee protocol for rabies: this failed approach should be abandoned.", "critical appraisal of the milwaukee protocol for rabies: this failed approach should be abandoned.", "critical appraisal of the milwaukee protocol for rabies: this failed approach should be abandoned.", "critical appraisal of the milwaukee protocol for rabies: this failed approach should be abandoned.", "critical appraisal of the milwaukee protocol for rabies: this failed approach should be abandoned.", "critical appraisal of the milwaukee protocol for rabies: this failed approach should be abandoned.", "critical appraisal of the milwaukee protocol for rabies: this failed approach should be abandoned.", "critical appraisal of the milwaukee protocol for rabies: this failed approach should be abandoned.", "critical appraisal of the milwaukee protocol for rabies: this failed approach should be abandoned.", "critical appraisal of the milwaukee protocol for rabies: this failed approach should be abandoned.", "critical appraisal of the milwaukee protocol for rabies: this failed approach should be abandoned.", "critical appraisal of the milwaukee protocol for rabies: this failed approach should be abandoned.", "critical appraisal of the milwaukee protocol for rabies: this failed approach should be abandoned.", "critical appraisal of the milwaukee protocol for rabies: this failed approach should be abandoned.", "critical appraisal of the milwaukee protocol for rabies: this failed approach should be abandoned.", "critical appraisal of the milwaukee protocol for rabies: this failed approach should be abandoned.", "critical appraisal of the milwaukee protocol for rabies: this failed approach should be abandoned.", "critical appraisal of the milwaukee protocol for rabies: this failed approach should be abandoned.", "critical appraisal of the milwaukee protocol for rabies: this failed approach should be abandoned.", "critical appraisal of the milwaukee protocol for rabies: this failed approach should be abandoned.", "critical appraisal of the milwaukee protocol for rabies: this failed approach should be abandoned.", "critical appraisal of the milwaukee protocol for rabies: this failed approach should be abandoned.", "critical appraisal of the milwaukee protocol for rabies: this failed approach should be abandoned.", "critical appraisal of the milwaukee protocol for rabies: this failed approach should be abandoned.", "critical appraisal of the milwaukee protocol for rabies: this failed approach should be abandoned.", "critical appraisal of the milwaukee protocol for rabies: this failed approach should be abandoned.", "critical appraisal of the milwaukee protocol for rabies: this failed approach should be abandoned.", "critical appraisal of the milwaukee protocol for rabies: this failed approach should be abandoned.", "the milwaukee protocol has proved to be ineffective for rabies and should no longer be used.", "the milwaukee protocol has proved to be ineffective for rabies and should no longer be used.", "the milwaukee protocol has proved to be ineffective for rabies and should no longer be used.", "the milwaukee protocol has proved to be ineffective for rabies and should no longer be used.", "the milwaukee protocol has proved to be ineffective for rabies and should no longer be used.", "the milwaukee protocol has proved to be ineffective for rabies and should no longer be used.", "the milwaukee protocol has proved to be ineffective for rabies and should no longer be used.", "the milwaukee protocol has proved to be ineffective for rabies and should no longer be used.", "the milwaukee protocol has proved to be ineffective for rabies and should no longer be used.", "the milwaukee protocol has proved to be ineffective for rabies and should no longer be used.", "the milwaukee protocol has proved to be ineffective for rabies and should no longer be used.", "the milwaukee protocol has proved to be ineffective for rabies and should no longer be used.", "the milwaukee protocol has proved to be ineffective for rabies and should no longer be used.", "the milwaukee protocol has proved to be ineffective for rabies and should no longer be used.", "the milwaukee protocol has proved to be ineffective for rabies and should no longer be used.", "the milwaukee protocol has proved to be ineffective for rabies and should no longer be used.", "the milwaukee protocol has proved to be ineffective for rabies and should no longer be used.", "the milwaukee protocol has proved to be ineffective for rabies and should no longer be used.", "the milwaukee protocol has proved to be ineffective for rabies and should no longer be used.", "the milwaukee protocol has proved to be ineffective for rabies and should no longer be used.", "the milwaukee protocol has proved to be ineffective for rabies and should no longer be used.", "the milwaukee protocol has proved to be ineffective for rabies and should no longer be used.", "the milwaukee protocol has proved to be ineffective for rabies and should no longer be used.", "the milwaukee protocol has proved to be ineffective for rabies and should no longer be used.", "the milwaukee protocol has proved to be ineffective for rabies and should no longer be used.", "the milwaukee protocol has proved to be ineffective for rabies and should no longer be used.", "the milwaukee protocol has proved to be ineffective for rabies and should no longer be used.", "the milwaukee protocol has proved to be ineffective for rabies and should no longer be used.", "the milwaukee protocol has proved to be ineffective for rabies and should no longer be used.", "the milwaukee protocol has proved to be ineffective for rabies and should no longer be used.", "the milwaukee protocol has proved to be ineffective for rabies and should no longer be used.", "the milwaukee protocol has proved to be ineffective for rabies and should no longer be used.", "the milwaukee protocol has proved to be ineffective for rabies and should no longer be used.", "the milwaukee protocol has proved to be ineffective for rabies and should no longer be used.", "applying the milwaukee protocol to treat canine rabies in equatorial guinea.", "applying the milwaukee protocol to treat canine rabies in equatorial guinea.", "applying the milwaukee protocol to treat canine rabies in equatorial guinea.", "applying the milwaukee protocol to treat canine rabies in equatorial guinea.", "applying the milwaukee protocol to treat canine rabies in equatorial guinea.", "applying the milwaukee protocol to treat canine rabies in equatorial guinea.", "applying the milwaukee protocol to treat canine rabies in equatorial guinea.", "applying the milwaukee protocol to treat canine rabies in equatorial guinea.", "applying the milwaukee protocol to treat canine rabies in equatorial guinea.", "applying the milwaukee protocol to treat canine rabies in equatorial guinea.", "applying the milwaukee protocol to treat canine rabies in equatorial guinea.", "applying the milwaukee protocol to treat canine rabies in equatorial guinea.", "applying the milwaukee protocol to treat canine rabies in equatorial guinea.", "applying the milwaukee protocol to treat canine rabies in equatorial guinea.", "applying the milwaukee protocol to treat canine rabies in equatorial guinea.", "applying the milwaukee protocol to treat canine rabies in equatorial guinea.", "applying the milwaukee protocol to treat canine rabies in equatorial guinea.", "applying the milwaukee protocol to treat canine rabies in equatorial guinea.", "applying the milwaukee protocol to treat canine rabies in equatorial guinea.", "applying the milwaukee protocol to treat canine rabies in equatorial guinea.", "applying the milwaukee protocol to treat canine rabies in equatorial guinea.", "applying the milwaukee protocol to treat canine rabies in equatorial guinea.", "applying the milwaukee protocol to treat canine rabies in equatorial guinea.", "applying the milwaukee protocol to treat canine rabies in equatorial guinea.", "applying the milwaukee protocol to treat canine rabies in equatorial guinea.", "applying the milwaukee protocol to treat canine rabies in equatorial guinea.", "applying the milwaukee protocol to treat canine rabies in equatorial guinea.", "applying the milwaukee protocol to treat canine rabies in equatorial guinea.", "applying the milwaukee protocol to treat canine rabies in equatorial guinea.", "applying the milwaukee protocol to treat canine rabies in equatorial guinea.", "applying the milwaukee protocol to treat canine rabies in equatorial guinea.", "applying the milwaukee protocol to treat canine rabies in equatorial guinea.", "applying the milwaukee protocol to treat canine rabies in equatorial guinea.", "applying the milwaukee protocol to treat canine rabies in equatorial guinea.", "the performance of a small-scale automated cryopreservation and storage system (mini-bioarchive system) used in the banking of umbilical cord blood (ucb) units was evaluated.", "the performance of a small-scale automated cryopreservation and storage system (mini-bioarchive system) used in the banking of umbilical cord blood (ucb) units was evaluated.", "the performance of a small-scale automated cryopreservation and storage system (mini-bioarchive system) used in the banking of umbilical cord blood (ucb) units was evaluated.", "the performance of a small-scale automated cryopreservation and storage system (mini-bioarchive system) used in the banking of umbilical cord blood (ucb) units was evaluated.", "the performance of a small-scale automated cryopreservation and storage system (mini-bioarchive system) used in the banking of umbilical cord blood (ucb) units was evaluated.", "the influence of membrane-free microcompartments resulting from crowding-induced liquid/liquid phase separation (llps) on the dynamic spatial organization of ftsz, the main component of the bacterial division machinery, has been studied using several llps systems.", "the influence of membrane-free microcompartments resulting from crowding-induced liquid/liquid phase separation (llps) on the dynamic spatial organization of ftsz, the main component of the bacterial division machinery, has been studied using several llps systems.", "the influence of membrane-free microcompartments resulting from crowding-induced liquid/liquid phase separation (llps) on the dynamic spatial organization of ftsz, the main component of the bacterial division machinery, has been studied using several llps systems.", "the influence of membrane-free microcompartments resulting from crowding-induced liquid/liquid phase separation (llps) on the dynamic spatial organization of ftsz, the main component of the bacterial division machinery, has been studied using several llps systems.", "the influence of membrane-free microcompartments resulting from crowding-induced liquid/liquid phase separation (llps) on the dynamic spatial organization of ftsz, the main component of the bacterial division machinery, has been studied using several llps systems.", "the influence of membrane-free microcompartments resulting from crowding-induced liquid/liquid phase separation (llps) on the dynamic spatial organization of ftsz, the main component of the bacterial division machinery, has been studied using several llps systems.", "the influence of membrane-free microcompartments resulting from crowding-induced liquid/liquid phase separation (llps) on the dynamic spatial organization of ftsz, the main component of the bacterial division machinery, has been studied using several llps systems.", "the influence of membrane-free microcompartments resulting from crowding-induced liquid/liquid phase separation (llps) on the dynamic spatial organization of ftsz, the main component of the bacterial division machinery, has been studied using several llps systems.", "the influence of membrane-free microcompartments resulting from crowding-induced liquid/liquid phase separation (llps) on the dynamic spatial organization of ftsz, the main component of the bacterial division machinery, has been studied using several llps systems.", "the influence of membrane-free microcompartments resulting from crowding-induced liquid/liquid phase separation (llps) on the dynamic spatial organization of ftsz, the main component of the bacterial division machinery, has been studied using several llps systems.", "the influence of membrane-free microcompartments resulting from crowding-induced liquid/liquid phase separation (llps) on the dynamic spatial organization of ftsz, the main component of the bacterial division machinery, has been studied using several llps systems.", "the influence of membrane-free microcompartments resulting from crowding-induced liquid/liquid phase separation (llps) on the dynamic spatial organization of ftsz, the main component of the bacterial division machinery, has been studied using several llps systems.", "the influence of membrane-free microcompartments resulting from crowding-induced liquid/liquid phase separation (llps) on the dynamic spatial organization of ftsz, the main component of the bacterial division machinery, has been studied using several llps systems.", "the influence of membrane-free microcompartments resulting from crowding-induced liquid/liquid phase separation (llps) on the dynamic spatial organization of ftsz, the main component of the bacterial division machinery, has been studied using several llps systems.", "the influence of membrane-free microcompartments resulting from crowding-induced liquid/liquid phase separation (llps) on the dynamic spatial organization of ftsz, the main component of the bacterial division machinery, has been studied using several llps systems.", "the influence of membrane-free microcompartments resulting from crowding-induced liquid/liquid phase separation (llps) on the dynamic spatial organization of ftsz, the main component of the bacterial division machinery, has been studied using several llps systems.", "the influence of membrane-free microcompartments resulting from crowding-induced liquid/liquid phase separation (llps) on the dynamic spatial organization of ftsz, the main component of the bacterial division machinery, has been studied using several llps systems.", "the influence of membrane-free microcompartments resulting from crowding-induced liquid/liquid phase separation (llps) on the dynamic spatial organization of ftsz, the main component of the bacterial division machinery, has been studied using several llps systems.", "the influence of membrane-free microcompartments resulting from crowding-induced liquid/liquid phase separation (llps) on the dynamic spatial organization of ftsz, the main component of the bacterial division machinery, has been studied using several llps systems.", "the influence of membrane-free microcompartments resulting from crowding-induced liquid/liquid phase separation (llps) on the dynamic spatial organization of ftsz, the main component of the bacterial division machinery, has been studied using several llps systems.", "the influence of membrane-free microcompartments resulting from crowding-induced liquid/liquid phase separation (llps) on the dynamic spatial organization of ftsz, the main component of the bacterial division machinery, has been studied using several llps systems.", "the influence of membrane-free microcompartments resulting from crowding-induced liquid/liquid phase separation (llps) on the dynamic spatial organization of ftsz, the main component of the bacterial division machinery, has been studied using several llps systems.", "the influence of membrane-free microcompartments resulting from crowding-induced liquid/liquid phase separation (llps) on the dynamic spatial organization of ftsz, the main component of the bacterial division machinery, has been studied using several llps systems.", "the influence of membrane-free microcompartments resulting from crowding-induced liquid/liquid phase separation (llps) on the dynamic spatial organization of ftsz, the main component of the bacterial division machinery, has been studied using several llps systems.", "the influence of membrane-free microcompartments resulting from crowding-induced liquid/liquid phase separation (llps) on the dynamic spatial organization of ftsz, the main component of the bacterial division machinery, has been studied using several llps systems.", "the influence of membrane-free microcompartments resulting from crowding-induced liquid/liquid phase separation (llps) on the dynamic spatial organization of ftsz, the main component of the bacterial division machinery, has been studied using several llps systems.", "this number remained relatively constant while the size of the vesicles increased until they attained their maximum diamtere of 100 nm.", "this number remained relatively constant while the size of the vesicles increased until they attained their maximum diamtere of 100 nm.", "this number remained relatively constant while the size of the vesicles increased until they attained their maximum diamtere of 100 nm.", "this number remained relatively constant while the size of the vesicles increased until they attained their maximum diamtere of 100 nm.", "this number remained relatively constant while the size of the vesicles increased until they attained their maximum diamtere of 100 nm.", "this number remained relatively constant while the size of the vesicles increased until they attained their maximum diamtere of 100 nm.", "this number remained relatively constant while the size of the vesicles increased until they attained their maximum diamtere of 100 nm.", "this number remained relatively constant while the size of the vesicles increased until they attained their maximum diamtere of 100 nm.", "this number remained relatively constant while the size of the vesicles increased until they attained their maximum diamtere of 100 nm.", "this number remained relatively constant while the size of the vesicles increased until they attained their maximum diamtere of 100 nm.", "this number remained relatively constant while the size of the vesicles increased until they attained their maximum diamtere of 100 nm.", "this number remained relatively constant while the size of the vesicles increased until they attained their maximum diamtere of 100 nm.", "this number remained relatively constant while the size of the vesicles increased until they attained their maximum diamtere of 100 nm.", "this number remained relatively constant while the size of the vesicles increased until they attained their maximum diamtere of 100 nm.", "this number remained relatively constant while the size of the vesicles increased until they attained their maximum diamtere of 100 nm.", "this number remained relatively constant while the size of the vesicles increased until they attained their maximum diamtere of 100 nm.", "this number remained relatively constant while the size of the vesicles increased until they attained their maximum diamtere of 100 nm.", "this number remained relatively constant while the size of the vesicles increased until they attained their maximum diamtere of 100 nm.", "this number remained relatively constant while the size of the vesicles increased until they attained their maximum diamtere of 100 nm.", "sclerostin is a soluble antagonist of wnt/\u03b2-catenin signaling secreted primarily by osteocytes. current evidence indicates that sclerostin likely functions as a local/paracrine regulator of bone metabolism rather than as an endocrine hormone.", "sclerostin is a soluble antagonist of wnt/\u03b2-catenin signaling secreted primarily by osteocytes. current evidence indicates that sclerostin likely functions as a local/paracrine regulator of bone metabolism rather than as an endocrine hormone.", "sclerostin is a soluble antagonist of wnt/\u03b2-catenin signaling secreted primarily by osteocytes. current evidence indicates that sclerostin likely functions as a local/paracrine regulator of bone metabolism rather than as an endocrine hormone.", "sclerostin is a soluble antagonist of wnt/\u03b2-catenin signaling secreted primarily by osteocytes. current evidence indicates that sclerostin likely functions as a local/paracrine regulator of bone metabolism rather than as an endocrine hormone.", "sclerostin is a soluble antagonist of wnt/\u03b2-catenin signaling secreted primarily by osteocytes. current evidence indicates that sclerostin likely functions as a local/paracrine regulator of bone metabolism rather than as an endocrine hormone.", "sclerostin is a soluble antagonist of wnt/\u03b2-catenin signaling secreted primarily by osteocytes. current evidence indicates that sclerostin likely functions as a local/paracrine regulator of bone metabolism rather than as an endocrine hormone.", "sclerostin is a soluble antagonist of wnt/\u03b2-catenin signaling secreted primarily by osteocytes. current evidence indicates that sclerostin likely functions as a local/paracrine regulator of bone metabolism rather than as an endocrine hormone.", "sclerostin is a soluble antagonist of wnt/\u03b2-catenin signaling secreted primarily by osteocytes. current evidence indicates that sclerostin likely functions as a local/paracrine regulator of bone metabolism rather than as an endocrine hormone.", "sclerostin is a soluble antagonist of wnt/\u03b2-catenin signaling secreted primarily by osteocytes. current evidence indicates that sclerostin likely functions as a local/paracrine regulator of bone metabolism rather than as an endocrine hormone.", "sclerostin is a soluble antagonist of wnt/\u03b2-catenin signaling secreted primarily by osteocytes. current evidence indicates that sclerostin likely functions as a local/paracrine regulator of bone metabolism rather than as an endocrine hormone.", "sclerostin is a soluble antagonist of wnt/\u03b2-catenin signaling secreted primarily by osteocytes. current evidence indicates that sclerostin likely functions as a local/paracrine regulator of bone metabolism rather than as an endocrine hormone.", "sclerostin is a soluble antagonist of wnt/\u03b2-catenin signaling secreted primarily by osteocytes. current evidence indicates that sclerostin likely functions as a local/paracrine regulator of bone metabolism rather than as an endocrine hormone.", "sclerostin is a soluble antagonist of wnt/\u03b2-catenin signaling secreted primarily by osteocytes. current evidence indicates that sclerostin likely functions as a local/paracrine regulator of bone metabolism rather than as an endocrine hormone.", "sclerostin is a soluble antagonist of wnt/\u03b2-catenin signaling secreted primarily by osteocytes. current evidence indicates that sclerostin likely functions as a local/paracrine regulator of bone metabolism rather than as an endocrine hormone.", "sclerostin is a soluble antagonist of wnt/\u03b2-catenin signaling secreted primarily by osteocytes. current evidence indicates that sclerostin likely functions as a local/paracrine regulator of bone metabolism rather than as an endocrine hormone.", "sclerostin is a soluble antagonist of wnt/\u03b2-catenin signaling secreted primarily by osteocytes. current evidence indicates that sclerostin likely functions as a local/paracrine regulator of bone metabolism rather than as an endocrine hormone.", "sclerostin is a soluble antagonist of wnt/\u03b2-catenin signaling secreted primarily by osteocytes. current evidence indicates that sclerostin likely functions as a local/paracrine regulator of bone metabolism rather than as an endocrine hormone.", "sclerostin is a soluble antagonist of wnt/\u03b2-catenin signaling secreted primarily by osteocytes. current evidence indicates that sclerostin likely functions as a local/paracrine regulator of bone metabolism rather than as an endocrine hormone.", "the glycoprotein sclerostin (scl; 22 kda), which is involved in bone metabolism,", "the glycoprotein sclerostin (scl; 22 kda), which is involved in bone metabolism,", "the glycoprotein sclerostin (scl; 22 kda), which is involved in bone metabolism,", "the glycoprotein sclerostin (scl; 22 kda), which is involved in bone metabolism,", "the glycoprotein sclerostin (scl; 22 kda), which is involved in bone metabolism,", "the glycoprotein sclerostin (scl; 22 kda), which is involved in bone metabolism,", "the glycoprotein sclerostin (scl; 22 kda), which is involved in bone metabolism,", "the glycoprotein sclerostin (scl; 22 kda), which is involved in bone metabolism,", "the glycoprotein sclerostin (scl; 22 kda), which is involved in bone metabolism,", "the glycoprotein sclerostin (scl; 22 kda), which is involved in bone metabolism,", "the glycoprotein sclerostin (scl; 22 kda), which is involved in bone metabolism,", "the glycoprotein sclerostin (scl; 22 kda), which is involved in bone metabolism,", "the glycoprotein sclerostin (scl; 22 kda), which is involved in bone metabolism,", "the glycoprotein sclerostin (scl; 22 kda), which is involved in bone metabolism,", "the glycoprotein sclerostin (scl; 22 kda), which is involved in bone metabolism,", "the glycoprotein sclerostin (scl; 22 kda), which is involved in bone metabolism,", "the glycoprotein sclerostin (scl; 22 kda), which is involved in bone metabolism,", "the glycoprotein sclerostin (scl; 22 kda), which is involved in bone metabolism,", "materials and methods this hipaa-compliant, institutional review board-approved study was performed at a tertiary care, academic medical center ed with approximately 60 000 annual visits and included all patients who were suspected of having pulmonary embolism (pe) and who underwent ct pulmonary angiography between january 1, 2011, and august 31, 2013. the requirement to obtain informed consent was waived. each ct order for pulmonary angiography was exposed to cds on the basis of the wells criteria.", "materials and methods this hipaa-compliant, institutional review board-approved study was performed at a tertiary care, academic medical center ed with approximately 60 000 annual visits and included all patients who were suspected of having pulmonary embolism (pe) and who underwent ct pulmonary angiography between january 1, 2011, and august 31, 2013. the requirement to obtain informed consent was waived. each ct order for pulmonary angiography was exposed to cds on the basis of the wells criteria.", "materials and methods this hipaa-compliant, institutional review board-approved study was performed at a tertiary care, academic medical center ed with approximately 60 000 annual visits and included all patients who were suspected of having pulmonary embolism (pe) and who underwent ct pulmonary angiography between january 1, 2011, and august 31, 2013. the requirement to obtain informed consent was waived. each ct order for pulmonary angiography was exposed to cds on the basis of the wells criteria.", "materials and methods this hipaa-compliant, institutional review board-approved study was performed at a tertiary care, academic medical center ed with approximately 60 000 annual visits and included all patients who were suspected of having pulmonary embolism (pe) and who underwent ct pulmonary angiography between january 1, 2011, and august 31, 2013. the requirement to obtain informed consent was waived. each ct order for pulmonary angiography was exposed to cds on the basis of the wells criteria.", "materials and methods this hipaa-compliant, institutional review board-approved study was performed at a tertiary care, academic medical center ed with approximately 60 000 annual visits and included all patients who were suspected of having pulmonary embolism (pe) and who underwent ct pulmonary angiography between january 1, 2011, and august 31, 2013. the requirement to obtain informed consent was waived. each ct order for pulmonary angiography was exposed to cds on the basis of the wells criteria.", "materials and methods this hipaa-compliant, institutional review board-approved study was performed at a tertiary care, academic medical center ed with approximately 60 000 annual visits and included all patients who were suspected of having pulmonary embolism (pe) and who underwent ct pulmonary angiography between january 1, 2011, and august 31, 2013. the requirement to obtain informed consent was waived. each ct order for pulmonary angiography was exposed to cds on the basis of the wells criteria.", "materials and methods this hipaa-compliant, institutional review board-approved study was performed at a tertiary care, academic medical center ed with approximately 60 000 annual visits and included all patients who were suspected of having pulmonary embolism (pe) and who underwent ct pulmonary angiography between january 1, 2011, and august 31, 2013. the requirement to obtain informed consent was waived. each ct order for pulmonary angiography was exposed to cds on the basis of the wells criteria.", "materials and methods this hipaa-compliant, institutional review board-approved study was performed at a tertiary care, academic medical center ed with approximately 60 000 annual visits and included all patients who were suspected of having pulmonary embolism (pe) and who underwent ct pulmonary angiography between january 1, 2011, and august 31, 2013. the requirement to obtain informed consent was waived. each ct order for pulmonary angiography was exposed to cds on the basis of the wells criteria.", "materials and methods this hipaa-compliant, institutional review board-approved study was performed at a tertiary care, academic medical center ed with approximately 60 000 annual visits and included all patients who were suspected of having pulmonary embolism (pe) and who underwent ct pulmonary angiography between january 1, 2011, and august 31, 2013. the requirement to obtain informed consent was waived. each ct order for pulmonary angiography was exposed to cds on the basis of the wells criteria.", "materials and methods this hipaa-compliant, institutional review board-approved study was performed at a tertiary care, academic medical center ed with approximately 60 000 annual visits and included all patients who were suspected of having pulmonary embolism (pe) and who underwent ct pulmonary angiography between january 1, 2011, and august 31, 2013. the requirement to obtain informed consent was waived. each ct order for pulmonary angiography was exposed to cds on the basis of the wells criteria.", "materials and methods this hipaa-compliant, institutional review board-approved study was performed at a tertiary care, academic medical center ed with approximately 60 000 annual visits and included all patients who were suspected of having pulmonary embolism (pe) and who underwent ct pulmonary angiography between january 1, 2011, and august 31, 2013. the requirement to obtain informed consent was waived. each ct order for pulmonary angiography was exposed to cds on the basis of the wells criteria.", "materials and methods this hipaa-compliant, institutional review board-approved study was performed at a tertiary care, academic medical center ed with approximately 60 000 annual visits and included all patients who were suspected of having pulmonary embolism (pe) and who underwent ct pulmonary angiography between january 1, 2011, and august 31, 2013. the requirement to obtain informed consent was waived. each ct order for pulmonary angiography was exposed to cds on the basis of the wells criteria.", "materials and methods this hipaa-compliant, institutional review board-approved study was performed at a tertiary care, academic medical center ed with approximately 60 000 annual visits and included all patients who were suspected of having pulmonary embolism (pe) and who underwent ct pulmonary angiography between january 1, 2011, and august 31, 2013. the requirement to obtain informed consent was waived. each ct order for pulmonary angiography was exposed to cds on the basis of the wells criteria.", "materials and methods this hipaa-compliant, institutional review board-approved study was performed at a tertiary care, academic medical center ed with approximately 60 000 annual visits and included all patients who were suspected of having pulmonary embolism (pe) and who underwent ct pulmonary angiography between january 1, 2011, and august 31, 2013. the requirement to obtain informed consent was waived. each ct order for pulmonary angiography was exposed to cds on the basis of the wells criteria.", "materials and methods this hipaa-compliant, institutional review board-approved study was performed at a tertiary care, academic medical center ed with approximately 60 000 annual visits and included all patients who were suspected of having pulmonary embolism (pe) and who underwent ct pulmonary angiography between january 1, 2011, and august 31, 2013. the requirement to obtain informed consent was waived. each ct order for pulmonary angiography was exposed to cds on the basis of the wells criteria.", "materials and methods this hipaa-compliant, institutional review board-approved study was performed at a tertiary care, academic medical center ed with approximately 60 000 annual visits and included all patients who were suspected of having pulmonary embolism (pe) and who underwent ct pulmonary angiography between january 1, 2011, and august 31, 2013. the requirement to obtain informed consent was waived. each ct order for pulmonary angiography was exposed to cds on the basis of the wells criteria.", "materials and methods this hipaa-compliant, institutional review board-approved study was performed at a tertiary care, academic medical center ed with approximately 60 000 annual visits and included all patients who were suspected of having pulmonary embolism (pe) and who underwent ct pulmonary angiography between january 1, 2011, and august 31, 2013. the requirement to obtain informed consent was waived. each ct order for pulmonary angiography was exposed to cds on the basis of the wells criteria.", "materials and methods this hipaa-compliant, institutional review board-approved study was performed at a tertiary care, academic medical center ed with approximately 60 000 annual visits and included all patients who were suspected of having pulmonary embolism (pe) and who underwent ct pulmonary angiography between january 1, 2011, and august 31, 2013. the requirement to obtain informed consent was waived. each ct order for pulmonary angiography was exposed to cds on the basis of the wells criteria.", "materials and methods this hipaa-compliant, institutional review board-approved study was performed at a tertiary care, academic medical center ed with approximately 60 000 annual visits and included all patients who were suspected of having pulmonary embolism (pe) and who underwent ct pulmonary angiography between january 1, 2011, and august 31, 2013. the requirement to obtain informed consent was waived. each ct order for pulmonary angiography was exposed to cds on the basis of the wells criteria.", "materials and methods this hipaa-compliant, institutional review board-approved study was performed at a tertiary care, academic medical center ed with approximately 60 000 annual visits and included all patients who were suspected of having pulmonary embolism (pe) and who underwent ct pulmonary angiography between january 1, 2011, and august 31, 2013. the requirement to obtain informed consent was waived. each ct order for pulmonary angiography was exposed to cds on the basis of the wells criteria.", "materials and methods this hipaa-compliant, institutional review board-approved study was performed at a tertiary care, academic medical center ed with approximately 60 000 annual visits and included all patients who were suspected of having pulmonary embolism (pe) and who underwent ct pulmonary angiography between january 1, 2011, and august 31, 2013. the requirement to obtain informed consent was waived. each ct order for pulmonary angiography was exposed to cds on the basis of the wells criteria.", "the immunoturbidimetric and rapid enzyme-linked immunosorbent assay d -dimer assays had similar sensitivities (94%) and specificities (45% versus 46%).<br><b>conclusion</b>: wells criteria have a moderate to substantial interrater agreement and reliably risk stratify pretest probability in patients with suspected pulmonary embolism.<br>", "the immunoturbidimetric and rapid enzyme-linked immunosorbent assay d -dimer assays had similar sensitivities (94%) and specificities (45% versus 46%).<br><b>conclusion</b>: wells criteria have a moderate to substantial interrater agreement and reliably risk stratify pretest probability in patients with suspected pulmonary embolism.<br>", "the immunoturbidimetric and rapid enzyme-linked immunosorbent assay d -dimer assays had similar sensitivities (94%) and specificities (45% versus 46%).<br><b>conclusion</b>: wells criteria have a moderate to substantial interrater agreement and reliably risk stratify pretest probability in patients with suspected pulmonary embolism.<br>", "the immunoturbidimetric and rapid enzyme-linked immunosorbent assay d -dimer assays had similar sensitivities (94%) and specificities (45% versus 46%).<br><b>conclusion</b>: wells criteria have a moderate to substantial interrater agreement and reliably risk stratify pretest probability in patients with suspected pulmonary embolism.<br>", "the immunoturbidimetric and rapid enzyme-linked immunosorbent assay d -dimer assays had similar sensitivities (94%) and specificities (45% versus 46%).<br><b>conclusion</b>: wells criteria have a moderate to substantial interrater agreement and reliably risk stratify pretest probability in patients with suspected pulmonary embolism.<br>", "the immunoturbidimetric and rapid enzyme-linked immunosorbent assay d -dimer assays had similar sensitivities (94%) and specificities (45% versus 46%).<br><b>conclusion</b>: wells criteria have a moderate to substantial interrater agreement and reliably risk stratify pretest probability in patients with suspected pulmonary embolism.<br>", "the immunoturbidimetric and rapid enzyme-linked immunosorbent assay d -dimer assays had similar sensitivities (94%) and specificities (45% versus 46%).<br><b>conclusion</b>: wells criteria have a moderate to substantial interrater agreement and reliably risk stratify pretest probability in patients with suspected pulmonary embolism.<br>", "the immunoturbidimetric and rapid enzyme-linked immunosorbent assay d -dimer assays had similar sensitivities (94%) and specificities (45% versus 46%).<br><b>conclusion</b>: wells criteria have a moderate to substantial interrater agreement and reliably risk stratify pretest probability in patients with suspected pulmonary embolism.<br>", "the immunoturbidimetric and rapid enzyme-linked immunosorbent assay d -dimer assays had similar sensitivities (94%) and specificities (45% versus 46%).<br><b>conclusion</b>: wells criteria have a moderate to substantial interrater agreement and reliably risk stratify pretest probability in patients with suspected pulmonary embolism.<br>", "the immunoturbidimetric and rapid enzyme-linked immunosorbent assay d -dimer assays had similar sensitivities (94%) and specificities (45% versus 46%).<br><b>conclusion</b>: wells criteria have a moderate to substantial interrater agreement and reliably risk stratify pretest probability in patients with suspected pulmonary embolism.<br>", "the immunoturbidimetric and rapid enzyme-linked immunosorbent assay d -dimer assays had similar sensitivities (94%) and specificities (45% versus 46%).<br><b>conclusion</b>: wells criteria have a moderate to substantial interrater agreement and reliably risk stratify pretest probability in patients with suspected pulmonary embolism.<br>", "the immunoturbidimetric and rapid enzyme-linked immunosorbent assay d -dimer assays had similar sensitivities (94%) and specificities (45% versus 46%).<br><b>conclusion</b>: wells criteria have a moderate to substantial interrater agreement and reliably risk stratify pretest probability in patients with suspected pulmonary embolism.<br>", "the immunoturbidimetric and rapid enzyme-linked immunosorbent assay d -dimer assays had similar sensitivities (94%) and specificities (45% versus 46%).<br><b>conclusion</b>: wells criteria have a moderate to substantial interrater agreement and reliably risk stratify pretest probability in patients with suspected pulmonary embolism.<br>", "the immunoturbidimetric and rapid enzyme-linked immunosorbent assay d -dimer assays had similar sensitivities (94%) and specificities (45% versus 46%).<br><b>conclusion</b>: wells criteria have a moderate to substantial interrater agreement and reliably risk stratify pretest probability in patients with suspected pulmonary embolism.<br>", "the immunoturbidimetric and rapid enzyme-linked immunosorbent assay d -dimer assays had similar sensitivities (94%) and specificities (45% versus 46%).<br><b>conclusion</b>: wells criteria have a moderate to substantial interrater agreement and reliably risk stratify pretest probability in patients with suspected pulmonary embolism.<br>", "the immunoturbidimetric and rapid enzyme-linked immunosorbent assay d -dimer assays had similar sensitivities (94%) and specificities (45% versus 46%).<br><b>conclusion</b>: wells criteria have a moderate to substantial interrater agreement and reliably risk stratify pretest probability in patients with suspected pulmonary embolism.<br>", "the immunoturbidimetric and rapid enzyme-linked immunosorbent assay d -dimer assays had similar sensitivities (94%) and specificities (45% versus 46%).<br><b>conclusion</b>: wells criteria have a moderate to substantial interrater agreement and reliably risk stratify pretest probability in patients with suspected pulmonary embolism.<br>", "the immunoturbidimetric and rapid enzyme-linked immunosorbent assay d -dimer assays had similar sensitivities (94%) and specificities (45% versus 46%).<br><b>conclusion</b>: wells criteria have a moderate to substantial interrater agreement and reliably risk stratify pretest probability in patients with suspected pulmonary embolism.<br>", "the immunoturbidimetric and rapid enzyme-linked immunosorbent assay d -dimer assays had similar sensitivities (94%) and specificities (45% versus 46%).<br><b>conclusion</b>: wells criteria have a moderate to substantial interrater agreement and reliably risk stratify pretest probability in patients with suspected pulmonary embolism.<br>", "the immunoturbidimetric and rapid enzyme-linked immunosorbent assay d -dimer assays had similar sensitivities (94%) and specificities (45% versus 46%).<br><b>conclusion</b>: wells criteria have a moderate to substantial interrater agreement and reliably risk stratify pretest probability in patients with suspected pulmonary embolism.<br>", "the immunoturbidimetric and rapid enzyme-linked immunosorbent assay d -dimer assays had similar sensitivities (94%) and specificities (45% versus 46%).<br><b>conclusion</b>: wells criteria have a moderate to substantial interrater agreement and reliably risk stratify pretest probability in patients with suspected pulmonary embolism.<br>", "objective: our objective was to evaluate the diagnostic value of computed tomography angiography (cta) and ventilation perfusion (v/q) scan in the assessment of pulmonary embolism (pe) by means of a bayesian statistical model.methods: wells criteria defined pretest probability.", "objective: our objective was to evaluate the diagnostic value of computed tomography angiography (cta) and ventilation perfusion (v/q) scan in the assessment of pulmonary embolism (pe) by means of a bayesian statistical model.methods: wells criteria defined pretest probability.", "objective: our objective was to evaluate the diagnostic value of computed tomography angiography (cta) and ventilation perfusion (v/q) scan in the assessment of pulmonary embolism (pe) by means of a bayesian statistical model.methods: wells criteria defined pretest probability.", "objective: our objective was to evaluate the diagnostic value of computed tomography angiography (cta) and ventilation perfusion (v/q) scan in the assessment of pulmonary embolism (pe) by means of a bayesian statistical model.methods: wells criteria defined pretest probability.", "objective: our objective was to evaluate the diagnostic value of computed tomography angiography (cta) and ventilation perfusion (v/q) scan in the assessment of pulmonary embolism (pe) by means of a bayesian statistical model.methods: wells criteria defined pretest probability.", "objective: our objective was to evaluate the diagnostic value of computed tomography angiography (cta) and ventilation perfusion (v/q) scan in the assessment of pulmonary embolism (pe) by means of a bayesian statistical model.methods: wells criteria defined pretest probability.", "objective: our objective was to evaluate the diagnostic value of computed tomography angiography (cta) and ventilation perfusion (v/q) scan in the assessment of pulmonary embolism (pe) by means of a bayesian statistical model.methods: wells criteria defined pretest probability.", "objective: our objective was to evaluate the diagnostic value of computed tomography angiography (cta) and ventilation perfusion (v/q) scan in the assessment of pulmonary embolism (pe) by means of a bayesian statistical model.methods: wells criteria defined pretest probability.", "objective: our objective was to evaluate the diagnostic value of computed tomography angiography (cta) and ventilation perfusion (v/q) scan in the assessment of pulmonary embolism (pe) by means of a bayesian statistical model.methods: wells criteria defined pretest probability.", "objective: our objective was to evaluate the diagnostic value of computed tomography angiography (cta) and ventilation perfusion (v/q) scan in the assessment of pulmonary embolism (pe) by means of a bayesian statistical model.methods: wells criteria defined pretest probability.", "objective: our objective was to evaluate the diagnostic value of computed tomography angiography (cta) and ventilation perfusion (v/q) scan in the assessment of pulmonary embolism (pe) by means of a bayesian statistical model.methods: wells criteria defined pretest probability.", "objective: our objective was to evaluate the diagnostic value of computed tomography angiography (cta) and ventilation perfusion (v/q) scan in the assessment of pulmonary embolism (pe) by means of a bayesian statistical model.methods: wells criteria defined pretest probability.", "objective: our objective was to evaluate the diagnostic value of computed tomography angiography (cta) and ventilation perfusion (v/q) scan in the assessment of pulmonary embolism (pe) by means of a bayesian statistical model.methods: wells criteria defined pretest probability.", "objective: our objective was to evaluate the diagnostic value of computed tomography angiography (cta) and ventilation perfusion (v/q) scan in the assessment of pulmonary embolism (pe) by means of a bayesian statistical model.methods: wells criteria defined pretest probability.", "objective: our objective was to evaluate the diagnostic value of computed tomography angiography (cta) and ventilation perfusion (v/q) scan in the assessment of pulmonary embolism (pe) by means of a bayesian statistical model.methods: wells criteria defined pretest probability.", "objective: our objective was to evaluate the diagnostic value of computed tomography angiography (cta) and ventilation perfusion (v/q) scan in the assessment of pulmonary embolism (pe) by means of a bayesian statistical model.methods: wells criteria defined pretest probability.", "objective: our objective was to evaluate the diagnostic value of computed tomography angiography (cta) and ventilation perfusion (v/q) scan in the assessment of pulmonary embolism (pe) by means of a bayesian statistical model.methods: wells criteria defined pretest probability.", "objective: our objective was to evaluate the diagnostic value of computed tomography angiography (cta) and ventilation perfusion (v/q) scan in the assessment of pulmonary embolism (pe) by means of a bayesian statistical model.methods: wells criteria defined pretest probability.", "objective: our objective was to evaluate the diagnostic value of computed tomography angiography (cta) and ventilation perfusion (v/q) scan in the assessment of pulmonary embolism (pe) by means of a bayesian statistical model.methods: wells criteria defined pretest probability.", "objective: our objective was to evaluate the diagnostic value of computed tomography angiography (cta) and ventilation perfusion (v/q) scan in the assessment of pulmonary embolism (pe) by means of a bayesian statistical model.methods: wells criteria defined pretest probability.", "objective: our objective was to evaluate the diagnostic value of computed tomography angiography (cta) and ventilation perfusion (v/q) scan in the assessment of pulmonary embolism (pe) by means of a bayesian statistical model.methods: wells criteria defined pretest probability.", "when wells criteria were trichotomized into low pretest probability (n=59, 44%), moderate pretest probability (n=61, 46%), or high pretest probability (n=14, 10%), the pulmonary embolism prevalence was 2%, 15%, and 43%, respectively.", "when wells criteria were trichotomized into low pretest probability (n=59, 44%), moderate pretest probability (n=61, 46%), or high pretest probability (n=14, 10%), the pulmonary embolism prevalence was 2%, 15%, and 43%, respectively.", "when wells criteria were trichotomized into low pretest probability (n=59, 44%), moderate pretest probability (n=61, 46%), or high pretest probability (n=14, 10%), the pulmonary embolism prevalence was 2%, 15%, and 43%, respectively.", "when wells criteria were trichotomized into low pretest probability (n=59, 44%), moderate pretest probability (n=61, 46%), or high pretest probability (n=14, 10%), the pulmonary embolism prevalence was 2%, 15%, and 43%, respectively.", "when wells criteria were trichotomized into low pretest probability (n=59, 44%), moderate pretest probability (n=61, 46%), or high pretest probability (n=14, 10%), the pulmonary embolism prevalence was 2%, 15%, and 43%, respectively.", "when wells criteria were trichotomized into low pretest probability (n=59, 44%), moderate pretest probability (n=61, 46%), or high pretest probability (n=14, 10%), the pulmonary embolism prevalence was 2%, 15%, and 43%, respectively.", "when wells criteria were trichotomized into low pretest probability (n=59, 44%), moderate pretest probability (n=61, 46%), or high pretest probability (n=14, 10%), the pulmonary embolism prevalence was 2%, 15%, and 43%, respectively.", "when wells criteria were trichotomized into low pretest probability (n=59, 44%), moderate pretest probability (n=61, 46%), or high pretest probability (n=14, 10%), the pulmonary embolism prevalence was 2%, 15%, and 43%, respectively.", "when wells criteria were trichotomized into low pretest probability (n=59, 44%), moderate pretest probability (n=61, 46%), or high pretest probability (n=14, 10%), the pulmonary embolism prevalence was 2%, 15%, and 43%, respectively.", "when wells criteria were trichotomized into low pretest probability (n=59, 44%), moderate pretest probability (n=61, 46%), or high pretest probability (n=14, 10%), the pulmonary embolism prevalence was 2%, 15%, and 43%, respectively.", "when wells criteria were trichotomized into low pretest probability (n=59, 44%), moderate pretest probability (n=61, 46%), or high pretest probability (n=14, 10%), the pulmonary embolism prevalence was 2%, 15%, and 43%, respectively.", "when wells criteria were trichotomized into low pretest probability (n=59, 44%), moderate pretest probability (n=61, 46%), or high pretest probability (n=14, 10%), the pulmonary embolism prevalence was 2%, 15%, and 43%, respectively.", "when wells criteria were trichotomized into low pretest probability (n=59, 44%), moderate pretest probability (n=61, 46%), or high pretest probability (n=14, 10%), the pulmonary embolism prevalence was 2%, 15%, and 43%, respectively.", "when wells criteria were trichotomized into low pretest probability (n=59, 44%), moderate pretest probability (n=61, 46%), or high pretest probability (n=14, 10%), the pulmonary embolism prevalence was 2%, 15%, and 43%, respectively.", "when wells criteria were trichotomized into low pretest probability (n=59, 44%), moderate pretest probability (n=61, 46%), or high pretest probability (n=14, 10%), the pulmonary embolism prevalence was 2%, 15%, and 43%, respectively.", "when wells criteria were trichotomized into low pretest probability (n=59, 44%), moderate pretest probability (n=61, 46%), or high pretest probability (n=14, 10%), the pulmonary embolism prevalence was 2%, 15%, and 43%, respectively.", "when wells criteria were trichotomized into low pretest probability (n=59, 44%), moderate pretest probability (n=61, 46%), or high pretest probability (n=14, 10%), the pulmonary embolism prevalence was 2%, 15%, and 43%, respectively.", "when wells criteria were trichotomized into low pretest probability (n=59, 44%), moderate pretest probability (n=61, 46%), or high pretest probability (n=14, 10%), the pulmonary embolism prevalence was 2%, 15%, and 43%, respectively.", "when wells criteria were trichotomized into low pretest probability (n=59, 44%), moderate pretest probability (n=61, 46%), or high pretest probability (n=14, 10%), the pulmonary embolism prevalence was 2%, 15%, and 43%, respectively.", "when wells criteria were trichotomized into low pretest probability (n=59, 44%), moderate pretest probability (n=61, 46%), or high pretest probability (n=14, 10%), the pulmonary embolism prevalence was 2%, 15%, and 43%, respectively.", "when wells criteria were trichotomized into low pretest probability (n=59, 44%), moderate pretest probability (n=61, 46%), or high pretest probability (n=14, 10%), the pulmonary embolism prevalence was 2%, 15%, and 43%, respectively.", "incremental diagnostic quality gain of cta over v/q scan in the assessment of pulmonary embolism by means of a wells score bayesian model: results from the acdc collaboration.", "incremental diagnostic quality gain of cta over v/q scan in the assessment of pulmonary embolism by means of a wells score bayesian model: results from the acdc collaboration.", "incremental diagnostic quality gain of cta over v/q scan in the assessment of pulmonary embolism by means of a wells score bayesian model: results from the acdc collaboration.", "incremental diagnostic quality gain of cta over v/q scan in the assessment of pulmonary embolism by means of a wells score bayesian model: results from the acdc collaboration.", "incremental diagnostic quality gain of cta over v/q scan in the assessment of pulmonary embolism by means of a wells score bayesian model: results from the acdc collaboration.", "incremental diagnostic quality gain of cta over v/q scan in the assessment of pulmonary embolism by means of a wells score bayesian model: results from the acdc collaboration.", "incremental diagnostic quality gain of cta over v/q scan in the assessment of pulmonary embolism by means of a wells score bayesian model: results from the acdc collaboration.", "incremental diagnostic quality gain of cta over v/q scan in the assessment of pulmonary embolism by means of a wells score bayesian model: results from the acdc collaboration.", "incremental diagnostic quality gain of cta over v/q scan in the assessment of pulmonary embolism by means of a wells score bayesian model: results from the acdc collaboration.", "incremental diagnostic quality gain of cta over v/q scan in the assessment of pulmonary embolism by means of a wells score bayesian model: results from the acdc collaboration.", "incremental diagnostic quality gain of cta over v/q scan in the assessment of pulmonary embolism by means of a wells score bayesian model: results from the acdc collaboration.", "incremental diagnostic quality gain of cta over v/q scan in the assessment of pulmonary embolism by means of a wells score bayesian model: results from the acdc collaboration.", "incremental diagnostic quality gain of cta over v/q scan in the assessment of pulmonary embolism by means of a wells score bayesian model: results from the acdc collaboration.", "incremental diagnostic quality gain of cta over v/q scan in the assessment of pulmonary embolism by means of a wells score bayesian model: results from the acdc collaboration.", "incremental diagnostic quality gain of cta over v/q scan in the assessment of pulmonary embolism by means of a wells score bayesian model: results from the acdc collaboration.", "incremental diagnostic quality gain of cta over v/q scan in the assessment of pulmonary embolism by means of a wells score bayesian model: results from the acdc collaboration.", "incremental diagnostic quality gain of cta over v/q scan in the assessment of pulmonary embolism by means of a wells score bayesian model: results from the acdc collaboration.", "incremental diagnostic quality gain of cta over v/q scan in the assessment of pulmonary embolism by means of a wells score bayesian model: results from the acdc collaboration.", "incremental diagnostic quality gain of cta over v/q scan in the assessment of pulmonary embolism by means of a wells score bayesian model: results from the acdc collaboration.", "incremental diagnostic quality gain of cta over v/q scan in the assessment of pulmonary embolism by means of a wells score bayesian model: results from the acdc collaboration.", "incremental diagnostic quality gain of cta over v/q scan in the assessment of pulmonary embolism by means of a wells score bayesian model: results from the acdc collaboration.", "when wells criteria were dichotomized into pulmonary embolism-unlikely (n=88, 66%) or pulmonary embolism-likely (n=46, 34%), the prevalence was 3% and 28%, respectively.", "when wells criteria were dichotomized into pulmonary embolism-unlikely (n=88, 66%) or pulmonary embolism-likely (n=46, 34%), the prevalence was 3% and 28%, respectively.", "when wells criteria were dichotomized into pulmonary embolism-unlikely (n=88, 66%) or pulmonary embolism-likely (n=46, 34%), the prevalence was 3% and 28%, respectively.", "when wells criteria were dichotomized into pulmonary embolism-unlikely (n=88, 66%) or pulmonary embolism-likely (n=46, 34%), the prevalence was 3% and 28%, respectively.", "when wells criteria were dichotomized into pulmonary embolism-unlikely (n=88, 66%) or pulmonary embolism-likely (n=46, 34%), the prevalence was 3% and 28%, respectively.", "when wells criteria were dichotomized into pulmonary embolism-unlikely (n=88, 66%) or pulmonary embolism-likely (n=46, 34%), the prevalence was 3% and 28%, respectively.", "when wells criteria were dichotomized into pulmonary embolism-unlikely (n=88, 66%) or pulmonary embolism-likely (n=46, 34%), the prevalence was 3% and 28%, respectively.", "when wells criteria were dichotomized into pulmonary embolism-unlikely (n=88, 66%) or pulmonary embolism-likely (n=46, 34%), the prevalence was 3% and 28%, respectively.", "when wells criteria were dichotomized into pulmonary embolism-unlikely (n=88, 66%) or pulmonary embolism-likely (n=46, 34%), the prevalence was 3% and 28%, respectively.", "when wells criteria were dichotomized into pulmonary embolism-unlikely (n=88, 66%) or pulmonary embolism-likely (n=46, 34%), the prevalence was 3% and 28%, respectively.", "when wells criteria were dichotomized into pulmonary embolism-unlikely (n=88, 66%) or pulmonary embolism-likely (n=46, 34%), the prevalence was 3% and 28%, respectively.", "when wells criteria were dichotomized into pulmonary embolism-unlikely (n=88, 66%) or pulmonary embolism-likely (n=46, 34%), the prevalence was 3% and 28%, respectively.", "when wells criteria were dichotomized into pulmonary embolism-unlikely (n=88, 66%) or pulmonary embolism-likely (n=46, 34%), the prevalence was 3% and 28%, respectively.", "when wells criteria were dichotomized into pulmonary embolism-unlikely (n=88, 66%) or pulmonary embolism-likely (n=46, 34%), the prevalence was 3% and 28%, respectively.", "when wells criteria were dichotomized into pulmonary embolism-unlikely (n=88, 66%) or pulmonary embolism-likely (n=46, 34%), the prevalence was 3% and 28%, respectively.", "when wells criteria were dichotomized into pulmonary embolism-unlikely (n=88, 66%) or pulmonary embolism-likely (n=46, 34%), the prevalence was 3% and 28%, respectively.", "when wells criteria were dichotomized into pulmonary embolism-unlikely (n=88, 66%) or pulmonary embolism-likely (n=46, 34%), the prevalence was 3% and 28%, respectively.", "when wells criteria were dichotomized into pulmonary embolism-unlikely (n=88, 66%) or pulmonary embolism-likely (n=46, 34%), the prevalence was 3% and 28%, respectively.", "when wells criteria were dichotomized into pulmonary embolism-unlikely (n=88, 66%) or pulmonary embolism-likely (n=46, 34%), the prevalence was 3% and 28%, respectively.", "when wells criteria were dichotomized into pulmonary embolism-unlikely (n=88, 66%) or pulmonary embolism-likely (n=46, 34%), the prevalence was 3% and 28%, respectively.", "when wells criteria were dichotomized into pulmonary embolism-unlikely (n=88, 66%) or pulmonary embolism-likely (n=46, 34%), the prevalence was 3% and 28%, respectively.", "background and aims: determining clinical probability of pulmonary embolism (pe) with wells scoring system is the first step towards diagnosis of pe.", "background and aims: determining clinical probability of pulmonary embolism (pe) with wells scoring system is the first step towards diagnosis of pe.", "background and aims: determining clinical probability of pulmonary embolism (pe) with wells scoring system is the first step towards diagnosis of pe.", "background and aims: determining clinical probability of pulmonary embolism (pe) with wells scoring system is the first step towards diagnosis of pe.", "background and aims: determining clinical probability of pulmonary embolism (pe) with wells scoring system is the first step towards diagnosis of pe.", "background and aims: determining clinical probability of pulmonary embolism (pe) with wells scoring system is the first step towards diagnosis of pe.", "background and aims: determining clinical probability of pulmonary embolism (pe) with wells scoring system is the first step towards diagnosis of pe.", "background and aims: determining clinical probability of pulmonary embolism (pe) with wells scoring system is the first step towards diagnosis of pe.", "background and aims: determining clinical probability of pulmonary embolism (pe) with wells scoring system is the first step towards diagnosis of pe.", "background and aims: determining clinical probability of pulmonary embolism (pe) with wells scoring system is the first step towards diagnosis of pe.", "background and aims: determining clinical probability of pulmonary embolism (pe) with wells scoring system is the first step towards diagnosis of pe.", "background and aims: determining clinical probability of pulmonary embolism (pe) with wells scoring system is the first step towards diagnosis of pe.", "background and aims: determining clinical probability of pulmonary embolism (pe) with wells scoring system is the first step towards diagnosis of pe.", "background and aims: determining clinical probability of pulmonary embolism (pe) with wells scoring system is the first step towards diagnosis of pe.", "background and aims: determining clinical probability of pulmonary embolism (pe) with wells scoring system is the first step towards diagnosis of pe.", "background and aims: determining clinical probability of pulmonary embolism (pe) with wells scoring system is the first step towards diagnosis of pe.", "background and aims: determining clinical probability of pulmonary embolism (pe) with wells scoring system is the first step towards diagnosis of pe.", "background and aims: determining clinical probability of pulmonary embolism (pe) with wells scoring system is the first step towards diagnosis of pe.", "background and aims: determining clinical probability of pulmonary embolism (pe) with wells scoring system is the first step towards diagnosis of pe.", "background and aims: determining clinical probability of pulmonary embolism (pe) with wells scoring system is the first step towards diagnosis of pe.", "background and aims: determining clinical probability of pulmonary embolism (pe) with wells scoring system is the first step towards diagnosis of pe.", "prospective validation of wells criteria in the evaluation of patients with suspected pulmonary embolism.", "prospective validation of wells criteria in the evaluation of patients with suspected pulmonary embolism.", "prospective validation of wells criteria in the evaluation of patients with suspected pulmonary embolism.", "prospective validation of wells criteria in the evaluation of patients with suspected pulmonary embolism.", "prospective validation of wells criteria in the evaluation of patients with suspected pulmonary embolism.", "prospective validation of wells criteria in the evaluation of patients with suspected pulmonary embolism.", "prospective validation of wells criteria in the evaluation of patients with suspected pulmonary embolism.", "prospective validation of wells criteria in the evaluation of patients with suspected pulmonary embolism.", "prospective validation of wells criteria in the evaluation of patients with suspected pulmonary embolism.", "prospective validation of wells criteria in the evaluation of patients with suspected pulmonary embolism.", "prospective validation of wells criteria in the evaluation of patients with suspected pulmonary embolism.", "prospective validation of wells criteria in the evaluation of patients with suspected pulmonary embolism.", "prospective validation of wells criteria in the evaluation of patients with suspected pulmonary embolism.", "prospective validation of wells criteria in the evaluation of patients with suspected pulmonary embolism.", "prospective validation of wells criteria in the evaluation of patients with suspected pulmonary embolism.", "prospective validation of wells criteria in the evaluation of patients with suspected pulmonary embolism.", "prospective validation of wells criteria in the evaluation of patients with suspected pulmonary embolism.", "prospective validation of wells criteria in the evaluation of patients with suspected pulmonary embolism.", "prospective validation of wells criteria in the evaluation of patients with suspected pulmonary embolism.", "prospective validation of wells criteria in the evaluation of patients with suspected pulmonary embolism.", "prospective validation of wells criteria in the evaluation of patients with suspected pulmonary embolism.", "correlation between the wells score and the quanadli index in patients with pulmonary embolism.", "correlation between the wells score and the quanadli index in patients with pulmonary embolism.", "correlation between the wells score and the quanadli index in patients with pulmonary embolism.", "correlation between the wells score and the quanadli index in patients with pulmonary embolism.", "correlation between the wells score and the quanadli index in patients with pulmonary embolism.", "correlation between the wells score and the quanadli index in patients with pulmonary embolism.", "correlation between the wells score and the quanadli index in patients with pulmonary embolism.", "correlation between the wells score and the quanadli index in patients with pulmonary embolism.", "correlation between the wells score and the quanadli index in patients with pulmonary embolism.", "correlation between the wells score and the quanadli index in patients with pulmonary embolism.", "correlation between the wells score and the quanadli index in patients with pulmonary embolism.", "correlation between the wells score and the quanadli index in patients with pulmonary embolism.", "correlation between the wells score and the quanadli index in patients with pulmonary embolism.", "correlation between the wells score and the quanadli index in patients with pulmonary embolism.", "correlation between the wells score and the quanadli index in patients with pulmonary embolism.", "correlation between the wells score and the quanadli index in patients with pulmonary embolism.", "correlation between the wells score and the quanadli index in patients with pulmonary embolism.", "correlation between the wells score and the quanadli index in patients with pulmonary embolism.", "correlation between the wells score and the quanadli index in patients with pulmonary embolism.", "correlation between the wells score and the quanadli index in patients with pulmonary embolism.", "correlation between the wells score and the quanadli index in patients with pulmonary embolism.", "<b>purpose</b>: the pharmacology, clinical efficacy, safety, dosage and administration, and role in therapy of dinutuximab for the treatment of high-risk pediatric neuroblastoma are reviewed.<br><b>summary</b>: dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "<b>purpose</b>: the pharmacology, clinical efficacy, safety, dosage and administration, and role in therapy of dinutuximab for the treatment of high-risk pediatric neuroblastoma are reviewed.<br><b>summary</b>: dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "<b>purpose</b>: the pharmacology, clinical efficacy, safety, dosage and administration, and role in therapy of dinutuximab for the treatment of high-risk pediatric neuroblastoma are reviewed.<br><b>summary</b>: dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "<b>purpose</b>: the pharmacology, clinical efficacy, safety, dosage and administration, and role in therapy of dinutuximab for the treatment of high-risk pediatric neuroblastoma are reviewed.<br><b>summary</b>: dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "<b>purpose</b>: the pharmacology, clinical efficacy, safety, dosage and administration, and role in therapy of dinutuximab for the treatment of high-risk pediatric neuroblastoma are reviewed.<br><b>summary</b>: dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "<b>purpose</b>: the pharmacology, clinical efficacy, safety, dosage and administration, and role in therapy of dinutuximab for the treatment of high-risk pediatric neuroblastoma are reviewed.<br><b>summary</b>: dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "<b>purpose</b>: the pharmacology, clinical efficacy, safety, dosage and administration, and role in therapy of dinutuximab for the treatment of high-risk pediatric neuroblastoma are reviewed.<br><b>summary</b>: dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "<b>purpose</b>: the pharmacology, clinical efficacy, safety, dosage and administration, and role in therapy of dinutuximab for the treatment of high-risk pediatric neuroblastoma are reviewed.<br><b>summary</b>: dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "<b>purpose</b>: the pharmacology, clinical efficacy, safety, dosage and administration, and role in therapy of dinutuximab for the treatment of high-risk pediatric neuroblastoma are reviewed.<br><b>summary</b>: dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "<b>purpose</b>: the pharmacology, clinical efficacy, safety, dosage and administration, and role in therapy of dinutuximab for the treatment of high-risk pediatric neuroblastoma are reviewed.<br><b>summary</b>: dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "<b>purpose</b>: the pharmacology, clinical efficacy, safety, dosage and administration, and role in therapy of dinutuximab for the treatment of high-risk pediatric neuroblastoma are reviewed.<br><b>summary</b>: dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "<b>purpose</b>: the pharmacology, clinical efficacy, safety, dosage and administration, and role in therapy of dinutuximab for the treatment of high-risk pediatric neuroblastoma are reviewed.<br><b>summary</b>: dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "<b>purpose</b>: the pharmacology, clinical efficacy, safety, dosage and administration, and role in therapy of dinutuximab for the treatment of high-risk pediatric neuroblastoma are reviewed.<br><b>summary</b>: dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "<b>purpose</b>: the pharmacology, clinical efficacy, safety, dosage and administration, and role in therapy of dinutuximab for the treatment of high-risk pediatric neuroblastoma are reviewed.<br><b>summary</b>: dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "<b>purpose</b>: the pharmacology, clinical efficacy, safety, dosage and administration, and role in therapy of dinutuximab for the treatment of high-risk pediatric neuroblastoma are reviewed.<br><b>summary</b>: dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "<b>purpose</b>: the pharmacology, clinical efficacy, safety, dosage and administration, and role in therapy of dinutuximab for the treatment of high-risk pediatric neuroblastoma are reviewed.<br><b>summary</b>: dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "<b>purpose</b>: the pharmacology, clinical efficacy, safety, dosage and administration, and role in therapy of dinutuximab for the treatment of high-risk pediatric neuroblastoma are reviewed.<br><b>summary</b>: dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "<b>purpose</b>: the pharmacology, clinical efficacy, safety, dosage and administration, and role in therapy of dinutuximab for the treatment of high-risk pediatric neuroblastoma are reviewed.<br><b>summary</b>: dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "<b>purpose</b>: the pharmacology, clinical efficacy, safety, dosage and administration, and role in therapy of dinutuximab for the treatment of high-risk pediatric neuroblastoma are reviewed.<br><b>summary</b>: dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "<b>purpose</b>: the pharmacology, clinical efficacy, safety, dosage and administration, and role in therapy of dinutuximab for the treatment of high-risk pediatric neuroblastoma are reviewed.<br><b>summary</b>: dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "<b>purpose</b>: the pharmacology, clinical efficacy, safety, dosage and administration, and role in therapy of dinutuximab for the treatment of high-risk pediatric neuroblastoma are reviewed.<br><b>summary</b>: dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "<b>purpose</b>: the pharmacology, clinical efficacy, safety, dosage and administration, and role in therapy of dinutuximab for the treatment of high-risk pediatric neuroblastoma are reviewed.<br><b>summary</b>: dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "<b>purpose</b>: the pharmacology, clinical efficacy, safety, dosage and administration, and role in therapy of dinutuximab for the treatment of high-risk pediatric neuroblastoma are reviewed.<br><b>summary</b>: dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "<b>purpose</b>: the pharmacology, clinical efficacy, safety, dosage and administration, and role in therapy of dinutuximab for the treatment of high-risk pediatric neuroblastoma are reviewed.<br><b>summary</b>: dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "<b>purpose</b>: the pharmacology, clinical efficacy, safety, dosage and administration, and role in therapy of dinutuximab for the treatment of high-risk pediatric neuroblastoma are reviewed.<br><b>summary</b>: dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "<b>purpose</b>: the pharmacology, clinical efficacy, safety, dosage and administration, and role in therapy of dinutuximab for the treatment of high-risk pediatric neuroblastoma are reviewed.<br><b>summary</b>: dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "<b>purpose</b>: the pharmacology, clinical efficacy, safety, dosage and administration, and role in therapy of dinutuximab for the treatment of high-risk pediatric neuroblastoma are reviewed.<br><b>summary</b>: dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "<b>purpose</b>: the pharmacology, clinical efficacy, safety, dosage and administration, and role in therapy of dinutuximab for the treatment of high-risk pediatric neuroblastoma are reviewed.<br><b>summary</b>: dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "<b>purpose</b>: the pharmacology, clinical efficacy, safety, dosage and administration, and role in therapy of dinutuximab for the treatment of high-risk pediatric neuroblastoma are reviewed.<br><b>summary</b>: dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "<b>purpose</b>: the pharmacology, clinical efficacy, safety, dosage and administration, and role in therapy of dinutuximab for the treatment of high-risk pediatric neuroblastoma are reviewed.<br><b>summary</b>: dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells. this intravenous drug is approved in the eu and usa as combination therapy with granulocyte-macrophage colony-stimulating factor (gm-csf), interleukin (il)-2 and isotretinoin for the postconsolidation treatment of patients with high-risk neuroblastoma.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells. this intravenous drug is approved in the eu and usa as combination therapy with granulocyte-macrophage colony-stimulating factor (gm-csf), interleukin (il)-2 and isotretinoin for the postconsolidation treatment of patients with high-risk neuroblastoma.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells. this intravenous drug is approved in the eu and usa as combination therapy with granulocyte-macrophage colony-stimulating factor (gm-csf), interleukin (il)-2 and isotretinoin for the postconsolidation treatment of patients with high-risk neuroblastoma.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells. this intravenous drug is approved in the eu and usa as combination therapy with granulocyte-macrophage colony-stimulating factor (gm-csf), interleukin (il)-2 and isotretinoin for the postconsolidation treatment of patients with high-risk neuroblastoma.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells. this intravenous drug is approved in the eu and usa as combination therapy with granulocyte-macrophage colony-stimulating factor (gm-csf), interleukin (il)-2 and isotretinoin for the postconsolidation treatment of patients with high-risk neuroblastoma.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells. this intravenous drug is approved in the eu and usa as combination therapy with granulocyte-macrophage colony-stimulating factor (gm-csf), interleukin (il)-2 and isotretinoin for the postconsolidation treatment of patients with high-risk neuroblastoma.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells. this intravenous drug is approved in the eu and usa as combination therapy with granulocyte-macrophage colony-stimulating factor (gm-csf), interleukin (il)-2 and isotretinoin for the postconsolidation treatment of patients with high-risk neuroblastoma.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells. this intravenous drug is approved in the eu and usa as combination therapy with granulocyte-macrophage colony-stimulating factor (gm-csf), interleukin (il)-2 and isotretinoin for the postconsolidation treatment of patients with high-risk neuroblastoma.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells. this intravenous drug is approved in the eu and usa as combination therapy with granulocyte-macrophage colony-stimulating factor (gm-csf), interleukin (il)-2 and isotretinoin for the postconsolidation treatment of patients with high-risk neuroblastoma.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells. this intravenous drug is approved in the eu and usa as combination therapy with granulocyte-macrophage colony-stimulating factor (gm-csf), interleukin (il)-2 and isotretinoin for the postconsolidation treatment of patients with high-risk neuroblastoma.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells. this intravenous drug is approved in the eu and usa as combination therapy with granulocyte-macrophage colony-stimulating factor (gm-csf), interleukin (il)-2 and isotretinoin for the postconsolidation treatment of patients with high-risk neuroblastoma.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells. this intravenous drug is approved in the eu and usa as combination therapy with granulocyte-macrophage colony-stimulating factor (gm-csf), interleukin (il)-2 and isotretinoin for the postconsolidation treatment of patients with high-risk neuroblastoma.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells. this intravenous drug is approved in the eu and usa as combination therapy with granulocyte-macrophage colony-stimulating factor (gm-csf), interleukin (il)-2 and isotretinoin for the postconsolidation treatment of patients with high-risk neuroblastoma.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells. this intravenous drug is approved in the eu and usa as combination therapy with granulocyte-macrophage colony-stimulating factor (gm-csf), interleukin (il)-2 and isotretinoin for the postconsolidation treatment of patients with high-risk neuroblastoma.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells. this intravenous drug is approved in the eu and usa as combination therapy with granulocyte-macrophage colony-stimulating factor (gm-csf), interleukin (il)-2 and isotretinoin for the postconsolidation treatment of patients with high-risk neuroblastoma.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells. this intravenous drug is approved in the eu and usa as combination therapy with granulocyte-macrophage colony-stimulating factor (gm-csf), interleukin (il)-2 and isotretinoin for the postconsolidation treatment of patients with high-risk neuroblastoma.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells. this intravenous drug is approved in the eu and usa as combination therapy with granulocyte-macrophage colony-stimulating factor (gm-csf), interleukin (il)-2 and isotretinoin for the postconsolidation treatment of patients with high-risk neuroblastoma.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells. this intravenous drug is approved in the eu and usa as combination therapy with granulocyte-macrophage colony-stimulating factor (gm-csf), interleukin (il)-2 and isotretinoin for the postconsolidation treatment of patients with high-risk neuroblastoma.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells. this intravenous drug is approved in the eu and usa as combination therapy with granulocyte-macrophage colony-stimulating factor (gm-csf), interleukin (il)-2 and isotretinoin for the postconsolidation treatment of patients with high-risk neuroblastoma.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells. this intravenous drug is approved in the eu and usa as combination therapy with granulocyte-macrophage colony-stimulating factor (gm-csf), interleukin (il)-2 and isotretinoin for the postconsolidation treatment of patients with high-risk neuroblastoma.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells. this intravenous drug is approved in the eu and usa as combination therapy with granulocyte-macrophage colony-stimulating factor (gm-csf), interleukin (il)-2 and isotretinoin for the postconsolidation treatment of patients with high-risk neuroblastoma.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells. this intravenous drug is approved in the eu and usa as combination therapy with granulocyte-macrophage colony-stimulating factor (gm-csf), interleukin (il)-2 and isotretinoin for the postconsolidation treatment of patients with high-risk neuroblastoma.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells. this intravenous drug is approved in the eu and usa as combination therapy with granulocyte-macrophage colony-stimulating factor (gm-csf), interleukin (il)-2 and isotretinoin for the postconsolidation treatment of patients with high-risk neuroblastoma.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells. this intravenous drug is approved in the eu and usa as combination therapy with granulocyte-macrophage colony-stimulating factor (gm-csf), interleukin (il)-2 and isotretinoin for the postconsolidation treatment of patients with high-risk neuroblastoma.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells. this intravenous drug is approved in the eu and usa as combination therapy with granulocyte-macrophage colony-stimulating factor (gm-csf), interleukin (il)-2 and isotretinoin for the postconsolidation treatment of patients with high-risk neuroblastoma.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells. this intravenous drug is approved in the eu and usa as combination therapy with granulocyte-macrophage colony-stimulating factor (gm-csf), interleukin (il)-2 and isotretinoin for the postconsolidation treatment of patients with high-risk neuroblastoma.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells. this intravenous drug is approved in the eu and usa as combination therapy with granulocyte-macrophage colony-stimulating factor (gm-csf), interleukin (il)-2 and isotretinoin for the postconsolidation treatment of patients with high-risk neuroblastoma.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells. this intravenous drug is approved in the eu and usa as combination therapy with granulocyte-macrophage colony-stimulating factor (gm-csf), interleukin (il)-2 and isotretinoin for the postconsolidation treatment of patients with high-risk neuroblastoma.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells. this intravenous drug is approved in the eu and usa as combination therapy with granulocyte-macrophage colony-stimulating factor (gm-csf), interleukin (il)-2 and isotretinoin for the postconsolidation treatment of patients with high-risk neuroblastoma.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells. this intravenous drug is approved in the eu and usa as combination therapy with granulocyte-macrophage colony-stimulating factor (gm-csf), interleukin (il)-2 and isotretinoin for the postconsolidation treatment of patients with high-risk neuroblastoma.", "severe adverse effects of dinutuximab include pain, hypersensitivity reactions, capillary leak syndrome, and hypotension.<br><b>conclusions</b>: dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "severe adverse effects of dinutuximab include pain, hypersensitivity reactions, capillary leak syndrome, and hypotension.<br><b>conclusions</b>: dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "severe adverse effects of dinutuximab include pain, hypersensitivity reactions, capillary leak syndrome, and hypotension.<br><b>conclusions</b>: dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "severe adverse effects of dinutuximab include pain, hypersensitivity reactions, capillary leak syndrome, and hypotension.<br><b>conclusions</b>: dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "severe adverse effects of dinutuximab include pain, hypersensitivity reactions, capillary leak syndrome, and hypotension.<br><b>conclusions</b>: dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "severe adverse effects of dinutuximab include pain, hypersensitivity reactions, capillary leak syndrome, and hypotension.<br><b>conclusions</b>: dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "severe adverse effects of dinutuximab include pain, hypersensitivity reactions, capillary leak syndrome, and hypotension.<br><b>conclusions</b>: dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "severe adverse effects of dinutuximab include pain, hypersensitivity reactions, capillary leak syndrome, and hypotension.<br><b>conclusions</b>: dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "severe adverse effects of dinutuximab include pain, hypersensitivity reactions, capillary leak syndrome, and hypotension.<br><b>conclusions</b>: dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "severe adverse effects of dinutuximab include pain, hypersensitivity reactions, capillary leak syndrome, and hypotension.<br><b>conclusions</b>: dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "severe adverse effects of dinutuximab include pain, hypersensitivity reactions, capillary leak syndrome, and hypotension.<br><b>conclusions</b>: dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "severe adverse effects of dinutuximab include pain, hypersensitivity reactions, capillary leak syndrome, and hypotension.<br><b>conclusions</b>: dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "severe adverse effects of dinutuximab include pain, hypersensitivity reactions, capillary leak syndrome, and hypotension.<br><b>conclusions</b>: dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "severe adverse effects of dinutuximab include pain, hypersensitivity reactions, capillary leak syndrome, and hypotension.<br><b>conclusions</b>: dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "severe adverse effects of dinutuximab include pain, hypersensitivity reactions, capillary leak syndrome, and hypotension.<br><b>conclusions</b>: dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "severe adverse effects of dinutuximab include pain, hypersensitivity reactions, capillary leak syndrome, and hypotension.<br><b>conclusions</b>: dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "severe adverse effects of dinutuximab include pain, hypersensitivity reactions, capillary leak syndrome, and hypotension.<br><b>conclusions</b>: dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "severe adverse effects of dinutuximab include pain, hypersensitivity reactions, capillary leak syndrome, and hypotension.<br><b>conclusions</b>: dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "severe adverse effects of dinutuximab include pain, hypersensitivity reactions, capillary leak syndrome, and hypotension.<br><b>conclusions</b>: dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "severe adverse effects of dinutuximab include pain, hypersensitivity reactions, capillary leak syndrome, and hypotension.<br><b>conclusions</b>: dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "severe adverse effects of dinutuximab include pain, hypersensitivity reactions, capillary leak syndrome, and hypotension.<br><b>conclusions</b>: dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "severe adverse effects of dinutuximab include pain, hypersensitivity reactions, capillary leak syndrome, and hypotension.<br><b>conclusions</b>: dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "severe adverse effects of dinutuximab include pain, hypersensitivity reactions, capillary leak syndrome, and hypotension.<br><b>conclusions</b>: dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "severe adverse effects of dinutuximab include pain, hypersensitivity reactions, capillary leak syndrome, and hypotension.<br><b>conclusions</b>: dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "severe adverse effects of dinutuximab include pain, hypersensitivity reactions, capillary leak syndrome, and hypotension.<br><b>conclusions</b>: dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "severe adverse effects of dinutuximab include pain, hypersensitivity reactions, capillary leak syndrome, and hypotension.<br><b>conclusions</b>: dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "severe adverse effects of dinutuximab include pain, hypersensitivity reactions, capillary leak syndrome, and hypotension.<br><b>conclusions</b>: dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "severe adverse effects of dinutuximab include pain, hypersensitivity reactions, capillary leak syndrome, and hypotension.<br><b>conclusions</b>: dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "severe adverse effects of dinutuximab include pain, hypersensitivity reactions, capillary leak syndrome, and hypotension.<br><b>conclusions</b>: dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "severe adverse effects of dinutuximab include pain, hypersensitivity reactions, capillary leak syndrome, and hypotension.<br><b>conclusions</b>: dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "dinutuximab is a chimeric, human-murine, anti-gd2 monoclonal antibody approved in combination with granulocyte-macrophage colony-stimulating factor (gm-csf), aldesleukin (interleukin-2 [il-2]), and isotretinoin (13-cis-retinoic acid [ra]) for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "dinutuximab is a chimeric, human-murine, anti-gd2 monoclonal antibody approved in combination with granulocyte-macrophage colony-stimulating factor (gm-csf), aldesleukin (interleukin-2 [il-2]), and isotretinoin (13-cis-retinoic acid [ra]) for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "dinutuximab is a chimeric, human-murine, anti-gd2 monoclonal antibody approved in combination with granulocyte-macrophage colony-stimulating factor (gm-csf), aldesleukin (interleukin-2 [il-2]), and isotretinoin (13-cis-retinoic acid [ra]) for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "dinutuximab is a chimeric, human-murine, anti-gd2 monoclonal antibody approved in combination with granulocyte-macrophage colony-stimulating factor (gm-csf), aldesleukin (interleukin-2 [il-2]), and isotretinoin (13-cis-retinoic acid [ra]) for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "dinutuximab is a chimeric, human-murine, anti-gd2 monoclonal antibody approved in combination with granulocyte-macrophage colony-stimulating factor (gm-csf), aldesleukin (interleukin-2 [il-2]), and isotretinoin (13-cis-retinoic acid [ra]) for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "dinutuximab is a chimeric, human-murine, anti-gd2 monoclonal antibody approved in combination with granulocyte-macrophage colony-stimulating factor (gm-csf), aldesleukin (interleukin-2 [il-2]), and isotretinoin (13-cis-retinoic acid [ra]) for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "dinutuximab is a chimeric, human-murine, anti-gd2 monoclonal antibody approved in combination with granulocyte-macrophage colony-stimulating factor (gm-csf), aldesleukin (interleukin-2 [il-2]), and isotretinoin (13-cis-retinoic acid [ra]) for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "dinutuximab is a chimeric, human-murine, anti-gd2 monoclonal antibody approved in combination with granulocyte-macrophage colony-stimulating factor (gm-csf), aldesleukin (interleukin-2 [il-2]), and isotretinoin (13-cis-retinoic acid [ra]) for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "dinutuximab is a chimeric, human-murine, anti-gd2 monoclonal antibody approved in combination with granulocyte-macrophage colony-stimulating factor (gm-csf), aldesleukin (interleukin-2 [il-2]), and isotretinoin (13-cis-retinoic acid [ra]) for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "dinutuximab is a chimeric, human-murine, anti-gd2 monoclonal antibody approved in combination with granulocyte-macrophage colony-stimulating factor (gm-csf), aldesleukin (interleukin-2 [il-2]), and isotretinoin (13-cis-retinoic acid [ra]) for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "dinutuximab is a chimeric, human-murine, anti-gd2 monoclonal antibody approved in combination with granulocyte-macrophage colony-stimulating factor (gm-csf), aldesleukin (interleukin-2 [il-2]), and isotretinoin (13-cis-retinoic acid [ra]) for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "dinutuximab is a chimeric, human-murine, anti-gd2 monoclonal antibody approved in combination with granulocyte-macrophage colony-stimulating factor (gm-csf), aldesleukin (interleukin-2 [il-2]), and isotretinoin (13-cis-retinoic acid [ra]) for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "dinutuximab is a chimeric, human-murine, anti-gd2 monoclonal antibody approved in combination with granulocyte-macrophage colony-stimulating factor (gm-csf), aldesleukin (interleukin-2 [il-2]), and isotretinoin (13-cis-retinoic acid [ra]) for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "dinutuximab is a chimeric, human-murine, anti-gd2 monoclonal antibody approved in combination with granulocyte-macrophage colony-stimulating factor (gm-csf), aldesleukin (interleukin-2 [il-2]), and isotretinoin (13-cis-retinoic acid [ra]) for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "dinutuximab is a chimeric, human-murine, anti-gd2 monoclonal antibody approved in combination with granulocyte-macrophage colony-stimulating factor (gm-csf), aldesleukin (interleukin-2 [il-2]), and isotretinoin (13-cis-retinoic acid [ra]) for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "dinutuximab is a chimeric, human-murine, anti-gd2 monoclonal antibody approved in combination with granulocyte-macrophage colony-stimulating factor (gm-csf), aldesleukin (interleukin-2 [il-2]), and isotretinoin (13-cis-retinoic acid [ra]) for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "dinutuximab is a chimeric, human-murine, anti-gd2 monoclonal antibody approved in combination with granulocyte-macrophage colony-stimulating factor (gm-csf), aldesleukin (interleukin-2 [il-2]), and isotretinoin (13-cis-retinoic acid [ra]) for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "dinutuximab is a chimeric, human-murine, anti-gd2 monoclonal antibody approved in combination with granulocyte-macrophage colony-stimulating factor (gm-csf), aldesleukin (interleukin-2 [il-2]), and isotretinoin (13-cis-retinoic acid [ra]) for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "dinutuximab is a chimeric, human-murine, anti-gd2 monoclonal antibody approved in combination with granulocyte-macrophage colony-stimulating factor (gm-csf), aldesleukin (interleukin-2 [il-2]), and isotretinoin (13-cis-retinoic acid [ra]) for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "dinutuximab is a chimeric, human-murine, anti-gd2 monoclonal antibody approved in combination with granulocyte-macrophage colony-stimulating factor (gm-csf), aldesleukin (interleukin-2 [il-2]), and isotretinoin (13-cis-retinoic acid [ra]) for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "dinutuximab is a chimeric, human-murine, anti-gd2 monoclonal antibody approved in combination with granulocyte-macrophage colony-stimulating factor (gm-csf), aldesleukin (interleukin-2 [il-2]), and isotretinoin (13-cis-retinoic acid [ra]) for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "dinutuximab is a chimeric, human-murine, anti-gd2 monoclonal antibody approved in combination with granulocyte-macrophage colony-stimulating factor (gm-csf), aldesleukin (interleukin-2 [il-2]), and isotretinoin (13-cis-retinoic acid [ra]) for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "dinutuximab is a chimeric, human-murine, anti-gd2 monoclonal antibody approved in combination with granulocyte-macrophage colony-stimulating factor (gm-csf), aldesleukin (interleukin-2 [il-2]), and isotretinoin (13-cis-retinoic acid [ra]) for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "dinutuximab is a chimeric, human-murine, anti-gd2 monoclonal antibody approved in combination with granulocyte-macrophage colony-stimulating factor (gm-csf), aldesleukin (interleukin-2 [il-2]), and isotretinoin (13-cis-retinoic acid [ra]) for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "dinutuximab is a chimeric, human-murine, anti-gd2 monoclonal antibody approved in combination with granulocyte-macrophage colony-stimulating factor (gm-csf), aldesleukin (interleukin-2 [il-2]), and isotretinoin (13-cis-retinoic acid [ra]) for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "dinutuximab is a chimeric, human-murine, anti-gd2 monoclonal antibody approved in combination with granulocyte-macrophage colony-stimulating factor (gm-csf), aldesleukin (interleukin-2 [il-2]), and isotretinoin (13-cis-retinoic acid [ra]) for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "dinutuximab is a chimeric, human-murine, anti-gd2 monoclonal antibody approved in combination with granulocyte-macrophage colony-stimulating factor (gm-csf), aldesleukin (interleukin-2 [il-2]), and isotretinoin (13-cis-retinoic acid [ra]) for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "dinutuximab is a chimeric, human-murine, anti-gd2 monoclonal antibody approved in combination with granulocyte-macrophage colony-stimulating factor (gm-csf), aldesleukin (interleukin-2 [il-2]), and isotretinoin (13-cis-retinoic acid [ra]) for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "dinutuximab is a chimeric, human-murine, anti-gd2 monoclonal antibody approved in combination with granulocyte-macrophage colony-stimulating factor (gm-csf), aldesleukin (interleukin-2 [il-2]), and isotretinoin (13-cis-retinoic acid [ra]) for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "dinutuximab is a chimeric, human-murine, anti-gd2 monoclonal antibody approved in combination with granulocyte-macrophage colony-stimulating factor (gm-csf), aldesleukin (interleukin-2 [il-2]), and isotretinoin (13-cis-retinoic acid [ra]) for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "this article summarizes the milestones in the development of dinutuximab leading to this first approval for use (in combination with granulocyte macrophage colony-stimulating factor, interleukin-2 and 13-cis retinoic acid) in the treatment of paediatric patients with high-risk neuroblastoma who achieve at least partial response to prior first-line multiagent, multimodality therapy.<br>", "this article summarizes the milestones in the development of dinutuximab leading to this first approval for use (in combination with granulocyte macrophage colony-stimulating factor, interleukin-2 and 13-cis retinoic acid) in the treatment of paediatric patients with high-risk neuroblastoma who achieve at least partial response to prior first-line multiagent, multimodality therapy.<br>", "this article summarizes the milestones in the development of dinutuximab leading to this first approval for use (in combination with granulocyte macrophage colony-stimulating factor, interleukin-2 and 13-cis retinoic acid) in the treatment of paediatric patients with high-risk neuroblastoma who achieve at least partial response to prior first-line multiagent, multimodality therapy.<br>", "this article summarizes the milestones in the development of dinutuximab leading to this first approval for use (in combination with granulocyte macrophage colony-stimulating factor, interleukin-2 and 13-cis retinoic acid) in the treatment of paediatric patients with high-risk neuroblastoma who achieve at least partial response to prior first-line multiagent, multimodality therapy.<br>", "this article summarizes the milestones in the development of dinutuximab leading to this first approval for use (in combination with granulocyte macrophage colony-stimulating factor, interleukin-2 and 13-cis retinoic acid) in the treatment of paediatric patients with high-risk neuroblastoma who achieve at least partial response to prior first-line multiagent, multimodality therapy.<br>", "this article summarizes the milestones in the development of dinutuximab leading to this first approval for use (in combination with granulocyte macrophage colony-stimulating factor, interleukin-2 and 13-cis retinoic acid) in the treatment of paediatric patients with high-risk neuroblastoma who achieve at least partial response to prior first-line multiagent, multimodality therapy.<br>", "this article summarizes the milestones in the development of dinutuximab leading to this first approval for use (in combination with granulocyte macrophage colony-stimulating factor, interleukin-2 and 13-cis retinoic acid) in the treatment of paediatric patients with high-risk neuroblastoma who achieve at least partial response to prior first-line multiagent, multimodality therapy.<br>", "this article summarizes the milestones in the development of dinutuximab leading to this first approval for use (in combination with granulocyte macrophage colony-stimulating factor, interleukin-2 and 13-cis retinoic acid) in the treatment of paediatric patients with high-risk neuroblastoma who achieve at least partial response to prior first-line multiagent, multimodality therapy.<br>", "this article summarizes the milestones in the development of dinutuximab leading to this first approval for use (in combination with granulocyte macrophage colony-stimulating factor, interleukin-2 and 13-cis retinoic acid) in the treatment of paediatric patients with high-risk neuroblastoma who achieve at least partial response to prior first-line multiagent, multimodality therapy.<br>", "this article summarizes the milestones in the development of dinutuximab leading to this first approval for use (in combination with granulocyte macrophage colony-stimulating factor, interleukin-2 and 13-cis retinoic acid) in the treatment of paediatric patients with high-risk neuroblastoma who achieve at least partial response to prior first-line multiagent, multimodality therapy.<br>", "this article summarizes the milestones in the development of dinutuximab leading to this first approval for use (in combination with granulocyte macrophage colony-stimulating factor, interleukin-2 and 13-cis retinoic acid) in the treatment of paediatric patients with high-risk neuroblastoma who achieve at least partial response to prior first-line multiagent, multimodality therapy.<br>", "this article summarizes the milestones in the development of dinutuximab leading to this first approval for use (in combination with granulocyte macrophage colony-stimulating factor, interleukin-2 and 13-cis retinoic acid) in the treatment of paediatric patients with high-risk neuroblastoma who achieve at least partial response to prior first-line multiagent, multimodality therapy.<br>", "this article summarizes the milestones in the development of dinutuximab leading to this first approval for use (in combination with granulocyte macrophage colony-stimulating factor, interleukin-2 and 13-cis retinoic acid) in the treatment of paediatric patients with high-risk neuroblastoma who achieve at least partial response to prior first-line multiagent, multimodality therapy.<br>", "this article summarizes the milestones in the development of dinutuximab leading to this first approval for use (in combination with granulocyte macrophage colony-stimulating factor, interleukin-2 and 13-cis retinoic acid) in the treatment of paediatric patients with high-risk neuroblastoma who achieve at least partial response to prior first-line multiagent, multimodality therapy.<br>", "this article summarizes the milestones in the development of dinutuximab leading to this first approval for use (in combination with granulocyte macrophage colony-stimulating factor, interleukin-2 and 13-cis retinoic acid) in the treatment of paediatric patients with high-risk neuroblastoma who achieve at least partial response to prior first-line multiagent, multimodality therapy.<br>", "this article summarizes the milestones in the development of dinutuximab leading to this first approval for use (in combination with granulocyte macrophage colony-stimulating factor, interleukin-2 and 13-cis retinoic acid) in the treatment of paediatric patients with high-risk neuroblastoma who achieve at least partial response to prior first-line multiagent, multimodality therapy.<br>", "this article summarizes the milestones in the development of dinutuximab leading to this first approval for use (in combination with granulocyte macrophage colony-stimulating factor, interleukin-2 and 13-cis retinoic acid) in the treatment of paediatric patients with high-risk neuroblastoma who achieve at least partial response to prior first-line multiagent, multimodality therapy.<br>", "this article summarizes the milestones in the development of dinutuximab leading to this first approval for use (in combination with granulocyte macrophage colony-stimulating factor, interleukin-2 and 13-cis retinoic acid) in the treatment of paediatric patients with high-risk neuroblastoma who achieve at least partial response to prior first-line multiagent, multimodality therapy.<br>", "this article summarizes the milestones in the development of dinutuximab leading to this first approval for use (in combination with granulocyte macrophage colony-stimulating factor, interleukin-2 and 13-cis retinoic acid) in the treatment of paediatric patients with high-risk neuroblastoma who achieve at least partial response to prior first-line multiagent, multimodality therapy.<br>", "this article summarizes the milestones in the development of dinutuximab leading to this first approval for use (in combination with granulocyte macrophage colony-stimulating factor, interleukin-2 and 13-cis retinoic acid) in the treatment of paediatric patients with high-risk neuroblastoma who achieve at least partial response to prior first-line multiagent, multimodality therapy.<br>", "this article summarizes the milestones in the development of dinutuximab leading to this first approval for use (in combination with granulocyte macrophage colony-stimulating factor, interleukin-2 and 13-cis retinoic acid) in the treatment of paediatric patients with high-risk neuroblastoma who achieve at least partial response to prior first-line multiagent, multimodality therapy.<br>", "this article summarizes the milestones in the development of dinutuximab leading to this first approval for use (in combination with granulocyte macrophage colony-stimulating factor, interleukin-2 and 13-cis retinoic acid) in the treatment of paediatric patients with high-risk neuroblastoma who achieve at least partial response to prior first-line multiagent, multimodality therapy.<br>", "this article summarizes the milestones in the development of dinutuximab leading to this first approval for use (in combination with granulocyte macrophage colony-stimulating factor, interleukin-2 and 13-cis retinoic acid) in the treatment of paediatric patients with high-risk neuroblastoma who achieve at least partial response to prior first-line multiagent, multimodality therapy.<br>", "this article summarizes the milestones in the development of dinutuximab leading to this first approval for use (in combination with granulocyte macrophage colony-stimulating factor, interleukin-2 and 13-cis retinoic acid) in the treatment of paediatric patients with high-risk neuroblastoma who achieve at least partial response to prior first-line multiagent, multimodality therapy.<br>", "this article summarizes the milestones in the development of dinutuximab leading to this first approval for use (in combination with granulocyte macrophage colony-stimulating factor, interleukin-2 and 13-cis retinoic acid) in the treatment of paediatric patients with high-risk neuroblastoma who achieve at least partial response to prior first-line multiagent, multimodality therapy.<br>", "this article summarizes the milestones in the development of dinutuximab leading to this first approval for use (in combination with granulocyte macrophage colony-stimulating factor, interleukin-2 and 13-cis retinoic acid) in the treatment of paediatric patients with high-risk neuroblastoma who achieve at least partial response to prior first-line multiagent, multimodality therapy.<br>", "this article summarizes the milestones in the development of dinutuximab leading to this first approval for use (in combination with granulocyte macrophage colony-stimulating factor, interleukin-2 and 13-cis retinoic acid) in the treatment of paediatric patients with high-risk neuroblastoma who achieve at least partial response to prior first-line multiagent, multimodality therapy.<br>", "this article summarizes the milestones in the development of dinutuximab leading to this first approval for use (in combination with granulocyte macrophage colony-stimulating factor, interleukin-2 and 13-cis retinoic acid) in the treatment of paediatric patients with high-risk neuroblastoma who achieve at least partial response to prior first-line multiagent, multimodality therapy.<br>", "this article summarizes the milestones in the development of dinutuximab leading to this first approval for use (in combination with granulocyte macrophage colony-stimulating factor, interleukin-2 and 13-cis retinoic acid) in the treatment of paediatric patients with high-risk neuroblastoma who achieve at least partial response to prior first-line multiagent, multimodality therapy.<br>", "this article summarizes the milestones in the development of dinutuximab leading to this first approval for use (in combination with granulocyte macrophage colony-stimulating factor, interleukin-2 and 13-cis retinoic acid) in the treatment of paediatric patients with high-risk neuroblastoma who achieve at least partial response to prior first-line multiagent, multimodality therapy.<br>", "dinutuximab administered in combination with gm-csf, il-2 and isotretinoin represents an important advance in the postconsolidation treatment of patients with high-risk neuroblastoma, with its benefits outweighing its risks in a patient population with a poor prognosis and limited therapeutic options.", "dinutuximab administered in combination with gm-csf, il-2 and isotretinoin represents an important advance in the postconsolidation treatment of patients with high-risk neuroblastoma, with its benefits outweighing its risks in a patient population with a poor prognosis and limited therapeutic options.", "dinutuximab administered in combination with gm-csf, il-2 and isotretinoin represents an important advance in the postconsolidation treatment of patients with high-risk neuroblastoma, with its benefits outweighing its risks in a patient population with a poor prognosis and limited therapeutic options.", "dinutuximab administered in combination with gm-csf, il-2 and isotretinoin represents an important advance in the postconsolidation treatment of patients with high-risk neuroblastoma, with its benefits outweighing its risks in a patient population with a poor prognosis and limited therapeutic options.", "dinutuximab administered in combination with gm-csf, il-2 and isotretinoin represents an important advance in the postconsolidation treatment of patients with high-risk neuroblastoma, with its benefits outweighing its risks in a patient population with a poor prognosis and limited therapeutic options.", "dinutuximab administered in combination with gm-csf, il-2 and isotretinoin represents an important advance in the postconsolidation treatment of patients with high-risk neuroblastoma, with its benefits outweighing its risks in a patient population with a poor prognosis and limited therapeutic options.", "dinutuximab administered in combination with gm-csf, il-2 and isotretinoin represents an important advance in the postconsolidation treatment of patients with high-risk neuroblastoma, with its benefits outweighing its risks in a patient population with a poor prognosis and limited therapeutic options.", "dinutuximab administered in combination with gm-csf, il-2 and isotretinoin represents an important advance in the postconsolidation treatment of patients with high-risk neuroblastoma, with its benefits outweighing its risks in a patient population with a poor prognosis and limited therapeutic options.", "dinutuximab administered in combination with gm-csf, il-2 and isotretinoin represents an important advance in the postconsolidation treatment of patients with high-risk neuroblastoma, with its benefits outweighing its risks in a patient population with a poor prognosis and limited therapeutic options.", "dinutuximab administered in combination with gm-csf, il-2 and isotretinoin represents an important advance in the postconsolidation treatment of patients with high-risk neuroblastoma, with its benefits outweighing its risks in a patient population with a poor prognosis and limited therapeutic options.", "dinutuximab administered in combination with gm-csf, il-2 and isotretinoin represents an important advance in the postconsolidation treatment of patients with high-risk neuroblastoma, with its benefits outweighing its risks in a patient population with a poor prognosis and limited therapeutic options.", "dinutuximab administered in combination with gm-csf, il-2 and isotretinoin represents an important advance in the postconsolidation treatment of patients with high-risk neuroblastoma, with its benefits outweighing its risks in a patient population with a poor prognosis and limited therapeutic options.", "dinutuximab administered in combination with gm-csf, il-2 and isotretinoin represents an important advance in the postconsolidation treatment of patients with high-risk neuroblastoma, with its benefits outweighing its risks in a patient population with a poor prognosis and limited therapeutic options.", "dinutuximab administered in combination with gm-csf, il-2 and isotretinoin represents an important advance in the postconsolidation treatment of patients with high-risk neuroblastoma, with its benefits outweighing its risks in a patient population with a poor prognosis and limited therapeutic options.", "dinutuximab administered in combination with gm-csf, il-2 and isotretinoin represents an important advance in the postconsolidation treatment of patients with high-risk neuroblastoma, with its benefits outweighing its risks in a patient population with a poor prognosis and limited therapeutic options.", "dinutuximab administered in combination with gm-csf, il-2 and isotretinoin represents an important advance in the postconsolidation treatment of patients with high-risk neuroblastoma, with its benefits outweighing its risks in a patient population with a poor prognosis and limited therapeutic options.", "dinutuximab administered in combination with gm-csf, il-2 and isotretinoin represents an important advance in the postconsolidation treatment of patients with high-risk neuroblastoma, with its benefits outweighing its risks in a patient population with a poor prognosis and limited therapeutic options.", "dinutuximab administered in combination with gm-csf, il-2 and isotretinoin represents an important advance in the postconsolidation treatment of patients with high-risk neuroblastoma, with its benefits outweighing its risks in a patient population with a poor prognosis and limited therapeutic options.", "dinutuximab administered in combination with gm-csf, il-2 and isotretinoin represents an important advance in the postconsolidation treatment of patients with high-risk neuroblastoma, with its benefits outweighing its risks in a patient population with a poor prognosis and limited therapeutic options.", "dinutuximab administered in combination with gm-csf, il-2 and isotretinoin represents an important advance in the postconsolidation treatment of patients with high-risk neuroblastoma, with its benefits outweighing its risks in a patient population with a poor prognosis and limited therapeutic options.", "dinutuximab administered in combination with gm-csf, il-2 and isotretinoin represents an important advance in the postconsolidation treatment of patients with high-risk neuroblastoma, with its benefits outweighing its risks in a patient population with a poor prognosis and limited therapeutic options.", "dinutuximab administered in combination with gm-csf, il-2 and isotretinoin represents an important advance in the postconsolidation treatment of patients with high-risk neuroblastoma, with its benefits outweighing its risks in a patient population with a poor prognosis and limited therapeutic options.", "dinutuximab administered in combination with gm-csf, il-2 and isotretinoin represents an important advance in the postconsolidation treatment of patients with high-risk neuroblastoma, with its benefits outweighing its risks in a patient population with a poor prognosis and limited therapeutic options.", "dinutuximab administered in combination with gm-csf, il-2 and isotretinoin represents an important advance in the postconsolidation treatment of patients with high-risk neuroblastoma, with its benefits outweighing its risks in a patient population with a poor prognosis and limited therapeutic options.", "dinutuximab administered in combination with gm-csf, il-2 and isotretinoin represents an important advance in the postconsolidation treatment of patients with high-risk neuroblastoma, with its benefits outweighing its risks in a patient population with a poor prognosis and limited therapeutic options.", "dinutuximab administered in combination with gm-csf, il-2 and isotretinoin represents an important advance in the postconsolidation treatment of patients with high-risk neuroblastoma, with its benefits outweighing its risks in a patient population with a poor prognosis and limited therapeutic options.", "dinutuximab administered in combination with gm-csf, il-2 and isotretinoin represents an important advance in the postconsolidation treatment of patients with high-risk neuroblastoma, with its benefits outweighing its risks in a patient population with a poor prognosis and limited therapeutic options.", "dinutuximab administered in combination with gm-csf, il-2 and isotretinoin represents an important advance in the postconsolidation treatment of patients with high-risk neuroblastoma, with its benefits outweighing its risks in a patient population with a poor prognosis and limited therapeutic options.", "dinutuximab administered in combination with gm-csf, il-2 and isotretinoin represents an important advance in the postconsolidation treatment of patients with high-risk neuroblastoma, with its benefits outweighing its risks in a patient population with a poor prognosis and limited therapeutic options.", "dinutuximab administered in combination with gm-csf, il-2 and isotretinoin represents an important advance in the postconsolidation treatment of patients with high-risk neuroblastoma, with its benefits outweighing its risks in a patient population with a poor prognosis and limited therapeutic options.", "conclusions dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "conclusions dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "conclusions dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "conclusions dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "conclusions dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "conclusions dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "conclusions dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "conclusions dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "conclusions dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "conclusions dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "conclusions dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "conclusions dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "conclusions dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "conclusions dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "conclusions dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "conclusions dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "conclusions dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "conclusions dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "conclusions dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "conclusions dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "conclusions dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "conclusions dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "conclusions dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "conclusions dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "conclusions dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "conclusions dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "conclusions dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "conclusions dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "conclusions dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "conclusions dinutuximab is the first anti-gd2 monoclonal antibody approved in combination with gm-csf, il-2, and ra for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.", "summary dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "summary dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "summary dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "summary dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "summary dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "summary dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "summary dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "summary dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "summary dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "summary dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "summary dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "summary dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "summary dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "summary dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "summary dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "summary dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "summary dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "summary dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "summary dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "summary dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "summary dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "summary dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "summary dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "summary dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "summary dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "summary dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "summary dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "summary dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "summary dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "summary dinutuximab (unituxin, united therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.", "immunotherapy with the anti-gd2 monoclonal antibody ch14.18, or dinutuximab, represents an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma and is now considered part of standard of care in this patient population.", "immunotherapy with the anti-gd2 monoclonal antibody ch14.18, or dinutuximab, represents an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma and is now considered part of standard of care in this patient population.", "immunotherapy with the anti-gd2 monoclonal antibody ch14.18, or dinutuximab, represents an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma and is now considered part of standard of care in this patient population.", "immunotherapy with the anti-gd2 monoclonal antibody ch14.18, or dinutuximab, represents an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma and is now considered part of standard of care in this patient population.", "immunotherapy with the anti-gd2 monoclonal antibody ch14.18, or dinutuximab, represents an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma and is now considered part of standard of care in this patient population.", "immunotherapy with the anti-gd2 monoclonal antibody ch14.18, or dinutuximab, represents an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma and is now considered part of standard of care in this patient population.", "immunotherapy with the anti-gd2 monoclonal antibody ch14.18, or dinutuximab, represents an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma and is now considered part of standard of care in this patient population.", "immunotherapy with the anti-gd2 monoclonal antibody ch14.18, or dinutuximab, represents an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma and is now considered part of standard of care in this patient population.", "immunotherapy with the anti-gd2 monoclonal antibody ch14.18, or dinutuximab, represents an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma and is now considered part of standard of care in this patient population.", "immunotherapy with the anti-gd2 monoclonal antibody ch14.18, or dinutuximab, represents an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma and is now considered part of standard of care in this patient population.", "immunotherapy with the anti-gd2 monoclonal antibody ch14.18, or dinutuximab, represents an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma and is now considered part of standard of care in this patient population.", "immunotherapy with the anti-gd2 monoclonal antibody ch14.18, or dinutuximab, represents an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma and is now considered part of standard of care in this patient population.", "immunotherapy with the anti-gd2 monoclonal antibody ch14.18, or dinutuximab, represents an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma and is now considered part of standard of care in this patient population.", "immunotherapy with the anti-gd2 monoclonal antibody ch14.18, or dinutuximab, represents an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma and is now considered part of standard of care in this patient population.", "immunotherapy with the anti-gd2 monoclonal antibody ch14.18, or dinutuximab, represents an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma and is now considered part of standard of care in this patient population.", "immunotherapy with the anti-gd2 monoclonal antibody ch14.18, or dinutuximab, represents an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma and is now considered part of standard of care in this patient population.", "immunotherapy with the anti-gd2 monoclonal antibody ch14.18, or dinutuximab, represents an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma and is now considered part of standard of care in this patient population.", "immunotherapy with the anti-gd2 monoclonal antibody ch14.18, or dinutuximab, represents an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma and is now considered part of standard of care in this patient population.", "immunotherapy with the anti-gd2 monoclonal antibody ch14.18, or dinutuximab, represents an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma and is now considered part of standard of care in this patient population.", "immunotherapy with the anti-gd2 monoclonal antibody ch14.18, or dinutuximab, represents an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma and is now considered part of standard of care in this patient population.", "immunotherapy with the anti-gd2 monoclonal antibody ch14.18, or dinutuximab, represents an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma and is now considered part of standard of care in this patient population.", "immunotherapy with the anti-gd2 monoclonal antibody ch14.18, or dinutuximab, represents an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma and is now considered part of standard of care in this patient population.", "immunotherapy with the anti-gd2 monoclonal antibody ch14.18, or dinutuximab, represents an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma and is now considered part of standard of care in this patient population.", "immunotherapy with the anti-gd2 monoclonal antibody ch14.18, or dinutuximab, represents an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma and is now considered part of standard of care in this patient population.", "immunotherapy with the anti-gd2 monoclonal antibody ch14.18, or dinutuximab, represents an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma and is now considered part of standard of care in this patient population.", "immunotherapy with the anti-gd2 monoclonal antibody ch14.18, or dinutuximab, represents an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma and is now considered part of standard of care in this patient population.", "immunotherapy with the anti-gd2 monoclonal antibody ch14.18, or dinutuximab, represents an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma and is now considered part of standard of care in this patient population.", "immunotherapy with the anti-gd2 monoclonal antibody ch14.18, or dinutuximab, represents an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma and is now considered part of standard of care in this patient population.", "immunotherapy with the anti-gd2 monoclonal antibody ch14.18, or dinutuximab, represents an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma and is now considered part of standard of care in this patient population.", "immunotherapy with the anti-gd2 monoclonal antibody ch14.18, or dinutuximab, represents an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma and is now considered part of standard of care in this patient population.", "the recommended dosage of dinutuximab is 17.5 mg/m<br><b>conclusion</b>: dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.<br>", "the recommended dosage of dinutuximab is 17.5 mg/m<br><b>conclusion</b>: dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.<br>", "the recommended dosage of dinutuximab is 17.5 mg/m<br><b>conclusion</b>: dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.<br>", "the recommended dosage of dinutuximab is 17.5 mg/m<br><b>conclusion</b>: dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.<br>", "the recommended dosage of dinutuximab is 17.5 mg/m<br><b>conclusion</b>: dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.<br>", "the recommended dosage of dinutuximab is 17.5 mg/m<br><b>conclusion</b>: dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.<br>", "the recommended dosage of dinutuximab is 17.5 mg/m<br><b>conclusion</b>: dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.<br>", "the recommended dosage of dinutuximab is 17.5 mg/m<br><b>conclusion</b>: dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.<br>", "the recommended dosage of dinutuximab is 17.5 mg/m<br><b>conclusion</b>: dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.<br>", "the recommended dosage of dinutuximab is 17.5 mg/m<br><b>conclusion</b>: dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.<br>", "the recommended dosage of dinutuximab is 17.5 mg/m<br><b>conclusion</b>: dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.<br>", "the recommended dosage of dinutuximab is 17.5 mg/m<br><b>conclusion</b>: dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.<br>", "the recommended dosage of dinutuximab is 17.5 mg/m<br><b>conclusion</b>: dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.<br>", "the recommended dosage of dinutuximab is 17.5 mg/m<br><b>conclusion</b>: dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.<br>", "the recommended dosage of dinutuximab is 17.5 mg/m<br><b>conclusion</b>: dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.<br>", "the recommended dosage of dinutuximab is 17.5 mg/m<br><b>conclusion</b>: dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.<br>", "the recommended dosage of dinutuximab is 17.5 mg/m<br><b>conclusion</b>: dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.<br>", "the recommended dosage of dinutuximab is 17.5 mg/m<br><b>conclusion</b>: dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.<br>", "the recommended dosage of dinutuximab is 17.5 mg/m<br><b>conclusion</b>: dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.<br>", "the recommended dosage of dinutuximab is 17.5 mg/m<br><b>conclusion</b>: dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.<br>", "the recommended dosage of dinutuximab is 17.5 mg/m<br><b>conclusion</b>: dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.<br>", "the recommended dosage of dinutuximab is 17.5 mg/m<br><b>conclusion</b>: dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.<br>", "the recommended dosage of dinutuximab is 17.5 mg/m<br><b>conclusion</b>: dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.<br>", "the recommended dosage of dinutuximab is 17.5 mg/m<br><b>conclusion</b>: dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.<br>", "the recommended dosage of dinutuximab is 17.5 mg/m<br><b>conclusion</b>: dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.<br>", "the recommended dosage of dinutuximab is 17.5 mg/m<br><b>conclusion</b>: dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.<br>", "the recommended dosage of dinutuximab is 17.5 mg/m<br><b>conclusion</b>: dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.<br>", "the recommended dosage of dinutuximab is 17.5 mg/m<br><b>conclusion</b>: dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.<br>", "the recommended dosage of dinutuximab is 17.5 mg/m<br><b>conclusion</b>: dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.<br>", "the recommended dosage of dinutuximab is 17.5 mg/m<br><b>conclusion</b>: dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.<br>", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells.", "dinutuximab (ch14.18; unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells.", "dinutuximab (formerly called ch14.18), a monoclonal antibody targeting the disialoganglioside gd2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma.", "dinutuximab (formerly called ch14.18), a monoclonal antibody targeting the disialoganglioside gd2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma.", "dinutuximab (formerly called ch14.18), a monoclonal antibody targeting the disialoganglioside gd2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma.", "dinutuximab (formerly called ch14.18), a monoclonal antibody targeting the disialoganglioside gd2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma.", "dinutuximab (formerly called ch14.18), a monoclonal antibody targeting the disialoganglioside gd2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma.", "dinutuximab (formerly called ch14.18), a monoclonal antibody targeting the disialoganglioside gd2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma.", "dinutuximab (formerly called ch14.18), a monoclonal antibody targeting the disialoganglioside gd2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma.", "dinutuximab (formerly called ch14.18), a monoclonal antibody targeting the disialoganglioside gd2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma.", "dinutuximab (formerly called ch14.18), a monoclonal antibody targeting the disialoganglioside gd2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma.", "dinutuximab (formerly called ch14.18), a monoclonal antibody targeting the disialoganglioside gd2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma.", "dinutuximab (formerly called ch14.18), a monoclonal antibody targeting the disialoganglioside gd2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma.", "dinutuximab (formerly called ch14.18), a monoclonal antibody targeting the disialoganglioside gd2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma.", "dinutuximab (formerly called ch14.18), a monoclonal antibody targeting the disialoganglioside gd2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma.", "dinutuximab (formerly called ch14.18), a monoclonal antibody targeting the disialoganglioside gd2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma.", "dinutuximab (formerly called ch14.18), a monoclonal antibody targeting the disialoganglioside gd2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma.", "dinutuximab (formerly called ch14.18), a monoclonal antibody targeting the disialoganglioside gd2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma.", "dinutuximab (formerly called ch14.18), a monoclonal antibody targeting the disialoganglioside gd2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma.", "dinutuximab (formerly called ch14.18), a monoclonal antibody targeting the disialoganglioside gd2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma.", "dinutuximab (formerly called ch14.18), a monoclonal antibody targeting the disialoganglioside gd2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma.", "dinutuximab (formerly called ch14.18), a monoclonal antibody targeting the disialoganglioside gd2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma.", "dinutuximab (formerly called ch14.18), a monoclonal antibody targeting the disialoganglioside gd2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma.", "dinutuximab (formerly called ch14.18), a monoclonal antibody targeting the disialoganglioside gd2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma.", "dinutuximab (formerly called ch14.18), a monoclonal antibody targeting the disialoganglioside gd2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma.", "dinutuximab (formerly called ch14.18), a monoclonal antibody targeting the disialoganglioside gd2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma.", "dinutuximab (formerly called ch14.18), a monoclonal antibody targeting the disialoganglioside gd2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma.", "dinutuximab (formerly called ch14.18), a monoclonal antibody targeting the disialoganglioside gd2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma.", "dinutuximab (formerly called ch14.18), a monoclonal antibody targeting the disialoganglioside gd2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma.", "dinutuximab (formerly called ch14.18), a monoclonal antibody targeting the disialoganglioside gd2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma.", "dinutuximab (formerly called ch14.18), a monoclonal antibody targeting the disialoganglioside gd2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma.", "dinutuximab (formerly called ch14.18), a monoclonal antibody targeting the disialoganglioside gd2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma.", "united therapeutics corporation and the national cancer institute are developing dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody targeting gd2, for the treatment of neuroblastoma.", "united therapeutics corporation and the national cancer institute are developing dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody targeting gd2, for the treatment of neuroblastoma.", "united therapeutics corporation and the national cancer institute are developing dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody targeting gd2, for the treatment of neuroblastoma.", "united therapeutics corporation and the national cancer institute are developing dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody targeting gd2, for the treatment of neuroblastoma.", "united therapeutics corporation and the national cancer institute are developing dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody targeting gd2, for the treatment of neuroblastoma.", "united therapeutics corporation and the national cancer institute are developing dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody targeting gd2, for the treatment of neuroblastoma.", "united therapeutics corporation and the national cancer institute are developing dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody targeting gd2, for the treatment of neuroblastoma.", "united therapeutics corporation and the national cancer institute are developing dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody targeting gd2, for the treatment of neuroblastoma.", "united therapeutics corporation and the national cancer institute are developing dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody targeting gd2, for the treatment of neuroblastoma.", "united therapeutics corporation and the national cancer institute are developing dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody targeting gd2, for the treatment of neuroblastoma.", "united therapeutics corporation and the national cancer institute are developing dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody targeting gd2, for the treatment of neuroblastoma.", "united therapeutics corporation and the national cancer institute are developing dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody targeting gd2, for the treatment of neuroblastoma.", "united therapeutics corporation and the national cancer institute are developing dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody targeting gd2, for the treatment of neuroblastoma.", "united therapeutics corporation and the national cancer institute are developing dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody targeting gd2, for the treatment of neuroblastoma.", "united therapeutics corporation and the national cancer institute are developing dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody targeting gd2, for the treatment of neuroblastoma.", "united therapeutics corporation and the national cancer institute are developing dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody targeting gd2, for the treatment of neuroblastoma.", "united therapeutics corporation and the national cancer institute are developing dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody targeting gd2, for the treatment of neuroblastoma.", "united therapeutics corporation and the national cancer institute are developing dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody targeting gd2, for the treatment of neuroblastoma.", "united therapeutics corporation and the national cancer institute are developing dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody targeting gd2, for the treatment of neuroblastoma.", "united therapeutics corporation and the national cancer institute are developing dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody targeting gd2, for the treatment of neuroblastoma.", "united therapeutics corporation and the national cancer institute are developing dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody targeting gd2, for the treatment of neuroblastoma.", "united therapeutics corporation and the national cancer institute are developing dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody targeting gd2, for the treatment of neuroblastoma.", "united therapeutics corporation and the national cancer institute are developing dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody targeting gd2, for the treatment of neuroblastoma.", "united therapeutics corporation and the national cancer institute are developing dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody targeting gd2, for the treatment of neuroblastoma.", "united therapeutics corporation and the national cancer institute are developing dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody targeting gd2, for the treatment of neuroblastoma.", "united therapeutics corporation and the national cancer institute are developing dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody targeting gd2, for the treatment of neuroblastoma.", "united therapeutics corporation and the national cancer institute are developing dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody targeting gd2, for the treatment of neuroblastoma.", "united therapeutics corporation and the national cancer institute are developing dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody targeting gd2, for the treatment of neuroblastoma.", "united therapeutics corporation and the national cancer institute are developing dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody targeting gd2, for the treatment of neuroblastoma.", "united therapeutics corporation and the national cancer institute are developing dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody targeting gd2, for the treatment of neuroblastoma.", "purpose: dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody against disialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma.", "purpose: dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody against disialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma.", "purpose: dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody against disialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma.", "purpose: dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody against disialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma.", "purpose: dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody against disialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma.", "purpose: dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody against disialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma.", "purpose: dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody against disialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma.", "purpose: dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody against disialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma.", "purpose: dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody against disialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma.", "purpose: dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody against disialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma.", "purpose: dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody against disialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma.", "purpose: dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody against disialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma.", "purpose: dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody against disialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma.", "purpose: dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody against disialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma.", "purpose: dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody against disialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma.", "purpose: dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody against disialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma.", "purpose: dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody against disialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma.", "purpose: dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody against disialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma.", "purpose: dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody against disialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma.", "purpose: dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody against disialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma.", "purpose: dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody against disialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma.", "purpose: dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody against disialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma.", "purpose: dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody against disialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma.", "purpose: dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody against disialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma.", "purpose: dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody against disialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma.", "purpose: dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody against disialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma.", "purpose: dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody against disialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma.", "purpose: dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody against disialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma.", "purpose: dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody against disialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma.", "purpose: dinutuximab (unituxin\u2122; ch14.18), a monoclonal antibody against disialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma.", "conclusion dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.", "conclusion dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.", "conclusion dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.", "conclusion dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.", "conclusion dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.", "conclusion dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.", "conclusion dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.", "conclusion dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.", "conclusion dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.", "conclusion dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.", "conclusion dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.", "conclusion dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.", "conclusion dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.", "conclusion dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.", "conclusion dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.", "conclusion dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.", "conclusion dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.", "conclusion dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.", "conclusion dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.", "conclusion dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.", "conclusion dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.", "conclusion dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.", "conclusion dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.", "conclusion dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.", "conclusion dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.", "conclusion dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.", "conclusion dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.", "conclusion dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.", "conclusion dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.", "conclusion dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.", "tgf\u03b2r1 blockade with galunisertib (ly2157299) enhances anti-neuroblastoma activity of the anti-gd2 antibody dinutuximab (ch14.18) with natural killer cells.", "tgf\u03b2r1 blockade with galunisertib (ly2157299) enhances anti-neuroblastoma activity of the anti-gd2 antibody dinutuximab (ch14.18) with natural killer cells.", "tgf\u03b2r1 blockade with galunisertib (ly2157299) enhances anti-neuroblastoma activity of the anti-gd2 antibody dinutuximab (ch14.18) with natural killer cells.", "tgf\u03b2r1 blockade with galunisertib (ly2157299) enhances anti-neuroblastoma activity of the anti-gd2 antibody dinutuximab (ch14.18) with natural killer cells.", "tgf\u03b2r1 blockade with galunisertib (ly2157299) enhances anti-neuroblastoma activity of the anti-gd2 antibody dinutuximab (ch14.18) with natural killer cells.", "tgf\u03b2r1 blockade with galunisertib (ly2157299) enhances anti-neuroblastoma activity of the anti-gd2 antibody dinutuximab (ch14.18) with natural killer cells.", "tgf\u03b2r1 blockade with galunisertib (ly2157299) enhances anti-neuroblastoma activity of the anti-gd2 antibody dinutuximab (ch14.18) with natural killer cells.", "tgf\u03b2r1 blockade with galunisertib (ly2157299) enhances anti-neuroblastoma activity of the anti-gd2 antibody dinutuximab (ch14.18) with natural killer cells.", "tgf\u03b2r1 blockade with galunisertib (ly2157299) enhances anti-neuroblastoma activity of the anti-gd2 antibody dinutuximab (ch14.18) with natural killer cells.", "tgf\u03b2r1 blockade with galunisertib (ly2157299) enhances anti-neuroblastoma activity of the anti-gd2 antibody dinutuximab (ch14.18) with natural killer cells.", "tgf\u03b2r1 blockade with galunisertib (ly2157299) enhances anti-neuroblastoma activity of the anti-gd2 antibody dinutuximab (ch14.18) with natural killer cells.", "tgf\u03b2r1 blockade with galunisertib (ly2157299) enhances anti-neuroblastoma activity of the anti-gd2 antibody dinutuximab (ch14.18) with natural killer cells.", "tgf\u03b2r1 blockade with galunisertib (ly2157299) enhances anti-neuroblastoma activity of the anti-gd2 antibody dinutuximab (ch14.18) with natural killer cells.", "tgf\u03b2r1 blockade with galunisertib (ly2157299) enhances anti-neuroblastoma activity of the anti-gd2 antibody dinutuximab (ch14.18) with natural killer cells.", "tgf\u03b2r1 blockade with galunisertib (ly2157299) enhances anti-neuroblastoma activity of the anti-gd2 antibody dinutuximab (ch14.18) with natural killer cells.", "tgf\u03b2r1 blockade with galunisertib (ly2157299) enhances anti-neuroblastoma activity of the anti-gd2 antibody dinutuximab (ch14.18) with natural killer cells.", "tgf\u03b2r1 blockade with galunisertib (ly2157299) enhances anti-neuroblastoma activity of the anti-gd2 antibody dinutuximab (ch14.18) with natural killer cells.", "tgf\u03b2r1 blockade with galunisertib (ly2157299) enhances anti-neuroblastoma activity of the anti-gd2 antibody dinutuximab (ch14.18) with natural killer cells.", "tgf\u03b2r1 blockade with galunisertib (ly2157299) enhances anti-neuroblastoma activity of the anti-gd2 antibody dinutuximab (ch14.18) with natural killer cells.", "tgf\u03b2r1 blockade with galunisertib (ly2157299) enhances anti-neuroblastoma activity of the anti-gd2 antibody dinutuximab (ch14.18) with natural killer cells.", "tgf\u03b2r1 blockade with galunisertib (ly2157299) enhances anti-neuroblastoma activity of the anti-gd2 antibody dinutuximab (ch14.18) with natural killer cells.", "tgf\u03b2r1 blockade with galunisertib (ly2157299) enhances anti-neuroblastoma activity of the anti-gd2 antibody dinutuximab (ch14.18) with natural killer cells.", "tgf\u03b2r1 blockade with galunisertib (ly2157299) enhances anti-neuroblastoma activity of the anti-gd2 antibody dinutuximab (ch14.18) with natural killer cells.", "tgf\u03b2r1 blockade with galunisertib (ly2157299) enhances anti-neuroblastoma activity of the anti-gd2 antibody dinutuximab (ch14.18) with natural killer cells.", "tgf\u03b2r1 blockade with galunisertib (ly2157299) enhances anti-neuroblastoma activity of the anti-gd2 antibody dinutuximab (ch14.18) with natural killer cells.", "tgf\u03b2r1 blockade with galunisertib (ly2157299) enhances anti-neuroblastoma activity of the anti-gd2 antibody dinutuximab (ch14.18) with natural killer cells.", "tgf\u03b2r1 blockade with galunisertib (ly2157299) enhances anti-neuroblastoma activity of the anti-gd2 antibody dinutuximab (ch14.18) with natural killer cells.", "tgf\u03b2r1 blockade with galunisertib (ly2157299) enhances anti-neuroblastoma activity of the anti-gd2 antibody dinutuximab (ch14.18) with natural killer cells.", "tgf\u03b2r1 blockade with galunisertib (ly2157299) enhances anti-neuroblastoma activity of the anti-gd2 antibody dinutuximab (ch14.18) with natural killer cells.", "tgf\u03b2r1 blockade with galunisertib (ly2157299) enhances anti-neuroblastoma activity of the anti-gd2 antibody dinutuximab (ch14.18) with natural killer cells.", "transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: a case series.", "transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: a case series.", "transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: a case series.", "transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: a case series.", "transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: a case series.", "transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: a case series.", "transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: a case series.", "transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: a case series.", "transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: a case series.", "transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: a case series.", "transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: a case series.", "transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: a case series.", "transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: a case series.", "transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: a case series.", "transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: a case series.", "transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: a case series.", "transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: a case series.", "transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: a case series.", "transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: a case series.", "transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: a case series.", "transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: a case series.", "transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: a case series.", "transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: a case series.", "transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: a case series.", "transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: a case series.", "transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: a case series.", "transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: a case series.", "transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: a case series.", "transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: a case series.", "transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: a case series.", "purpose: immunotherapy of high-risk neuroblastoma using the anti-gd2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity (adcc).", "purpose: immunotherapy of high-risk neuroblastoma using the anti-gd2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity (adcc).", "purpose: immunotherapy of high-risk neuroblastoma using the anti-gd2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity (adcc).", "purpose: immunotherapy of high-risk neuroblastoma using the anti-gd2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity (adcc).", "purpose: immunotherapy of high-risk neuroblastoma using the anti-gd2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity (adcc).", "purpose: immunotherapy of high-risk neuroblastoma using the anti-gd2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity (adcc).", "purpose: immunotherapy of high-risk neuroblastoma using the anti-gd2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity (adcc).", "purpose: immunotherapy of high-risk neuroblastoma using the anti-gd2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity (adcc).", "purpose: immunotherapy of high-risk neuroblastoma using the anti-gd2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity (adcc).", "purpose: immunotherapy of high-risk neuroblastoma using the anti-gd2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity (adcc).", "purpose: immunotherapy of high-risk neuroblastoma using the anti-gd2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity (adcc).", "purpose: immunotherapy of high-risk neuroblastoma using the anti-gd2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity (adcc).", "purpose: immunotherapy of high-risk neuroblastoma using the anti-gd2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity (adcc).", "purpose: immunotherapy of high-risk neuroblastoma using the anti-gd2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity (adcc).", "purpose: immunotherapy of high-risk neuroblastoma using the anti-gd2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity (adcc).", "purpose: immunotherapy of high-risk neuroblastoma using the anti-gd2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity (adcc).", "purpose: immunotherapy of high-risk neuroblastoma using the anti-gd2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity (adcc).", "purpose: immunotherapy of high-risk neuroblastoma using the anti-gd2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity (adcc).", "purpose: immunotherapy of high-risk neuroblastoma using the anti-gd2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity (adcc).", "purpose: immunotherapy of high-risk neuroblastoma using the anti-gd2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity (adcc).", "purpose: immunotherapy of high-risk neuroblastoma using the anti-gd2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity (adcc).", "purpose: immunotherapy of high-risk neuroblastoma using the anti-gd2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity (adcc).", "purpose: immunotherapy of high-risk neuroblastoma using the anti-gd2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity (adcc).", "purpose: immunotherapy of high-risk neuroblastoma using the anti-gd2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity (adcc).", "purpose: immunotherapy of high-risk neuroblastoma using the anti-gd2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity (adcc).", "purpose: immunotherapy of high-risk neuroblastoma using the anti-gd2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity (adcc).", "purpose: immunotherapy of high-risk neuroblastoma using the anti-gd2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity (adcc).", "purpose: immunotherapy of high-risk neuroblastoma using the anti-gd2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity (adcc).", "purpose: immunotherapy of high-risk neuroblastoma using the anti-gd2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity (adcc).", "purpose: immunotherapy of high-risk neuroblastoma using the anti-gd2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity (adcc).", "findings of the randomized phase iii study (anbl0032) led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma.", "findings of the randomized phase iii study (anbl0032) led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma.", "findings of the randomized phase iii study (anbl0032) led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma.", "findings of the randomized phase iii study (anbl0032) led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma.", "findings of the randomized phase iii study (anbl0032) led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma.", "findings of the randomized phase iii study (anbl0032) led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma.", "findings of the randomized phase iii study (anbl0032) led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma.", "findings of the randomized phase iii study (anbl0032) led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma.", "findings of the randomized phase iii study (anbl0032) led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma.", "findings of the randomized phase iii study (anbl0032) led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma.", "findings of the randomized phase iii study (anbl0032) led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma.", "findings of the randomized phase iii study (anbl0032) led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma.", "findings of the randomized phase iii study (anbl0032) led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma.", "findings of the randomized phase iii study (anbl0032) led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma.", "findings of the randomized phase iii study (anbl0032) led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma.", "findings of the randomized phase iii study (anbl0032) led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma.", "findings of the randomized phase iii study (anbl0032) led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma.", "findings of the randomized phase iii study (anbl0032) led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma.", "findings of the randomized phase iii study (anbl0032) led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma.", "findings of the randomized phase iii study (anbl0032) led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma.", "findings of the randomized phase iii study (anbl0032) led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma.", "findings of the randomized phase iii study (anbl0032) led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma.", "findings of the randomized phase iii study (anbl0032) led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma.", "findings of the randomized phase iii study (anbl0032) led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma.", "findings of the randomized phase iii study (anbl0032) led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma.", "findings of the randomized phase iii study (anbl0032) led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma.", "findings of the randomized phase iii study (anbl0032) led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma.", "findings of the randomized phase iii study (anbl0032) led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma.", "findings of the randomized phase iii study (anbl0032) led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma.", "findings of the randomized phase iii study (anbl0032) led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma.", "the us fda has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma in paediatric patients.", "the us fda has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma in paediatric patients.", "the us fda has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma in paediatric patients.", "the us fda has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma in paediatric patients.", "the us fda has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma in paediatric patients.", "the us fda has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma in paediatric patients.", "the us fda has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma in paediatric patients.", "the us fda has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma in paediatric patients.", "the us fda has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma in paediatric patients.", "the us fda has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma in paediatric patients.", "the us fda has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma in paediatric patients.", "the us fda has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma in paediatric patients.", "the us fda has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma in paediatric patients.", "the us fda has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma in paediatric patients.", "the us fda has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma in paediatric patients.", "the us fda has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma in paediatric patients.", "the us fda has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma in paediatric patients.", "the us fda has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma in paediatric patients.", "the us fda has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma in paediatric patients.", "the us fda has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma in paediatric patients.", "the us fda has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma in paediatric patients.", "the us fda has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma in paediatric patients.", "the us fda has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma in paediatric patients.", "the us fda has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma in paediatric patients.", "the us fda has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma in paediatric patients.", "the us fda has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma in paediatric patients.", "the us fda has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma in paediatric patients.", "the us fda has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma in paediatric patients.", "the us fda has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma in paediatric patients.", "the us fda has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma in paediatric patients.", "dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.", "dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.", "dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.", "dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.", "dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.", "dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.", "dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.", "dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.", "dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.", "dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.", "dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.", "dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.", "dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.", "dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.", "dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.", "dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.", "dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.", "dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.", "dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.", "dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.", "dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.", "dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.", "dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.", "dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.", "dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.", "dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.", "dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.", "dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.", "dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.", "dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.", "dinutuximab: a review in high-risk neuroblastoma.", "dinutuximab: a review in high-risk neuroblastoma.", "dinutuximab: a review in high-risk neuroblastoma.", "dinutuximab: a review in high-risk neuroblastoma.", "dinutuximab: a review in high-risk neuroblastoma.", "dinutuximab: a review in high-risk neuroblastoma.", "dinutuximab: a review in high-risk neuroblastoma.", "dinutuximab: a review in high-risk neuroblastoma.", "dinutuximab: a review in high-risk neuroblastoma.", "dinutuximab: a review in high-risk neuroblastoma.", "dinutuximab: a review in high-risk neuroblastoma.", "dinutuximab: a review in high-risk neuroblastoma.", "dinutuximab: a review in high-risk neuroblastoma.", "dinutuximab: a review in high-risk neuroblastoma.", "dinutuximab: a review in high-risk neuroblastoma.", "dinutuximab: a review in high-risk neuroblastoma.", "dinutuximab: a review in high-risk neuroblastoma.", "dinutuximab: a review in high-risk neuroblastoma.", "dinutuximab: a review in high-risk neuroblastoma.", "dinutuximab: a review in high-risk neuroblastoma.", "dinutuximab: a review in high-risk neuroblastoma.", "dinutuximab: a review in high-risk neuroblastoma.", "dinutuximab: a review in high-risk neuroblastoma.", "dinutuximab: a review in high-risk neuroblastoma.", "dinutuximab: a review in high-risk neuroblastoma.", "dinutuximab: a review in high-risk neuroblastoma.", "dinutuximab: a review in high-risk neuroblastoma.", "dinutuximab: a review in high-risk neuroblastoma.", "dinutuximab: a review in high-risk neuroblastoma.", "dinutuximab: a review in high-risk neuroblastoma.", "in order to determine the prevalence of latent infection due to mycobacterium tuberculosis in drug users and to provide centres for drug users with a practical tool for tuberculosis screening, 237 drug users were subjected to the monotest and, for reference purposes, to the mantoux test.", "in order to determine the prevalence of latent infection due to mycobacterium tuberculosis in drug users and to provide centres for drug users with a practical tool for tuberculosis screening, 237 drug users were subjected to the monotest and, for reference purposes, to the mantoux test.", "in order to determine the prevalence of latent infection due to mycobacterium tuberculosis in drug users and to provide centres for drug users with a practical tool for tuberculosis screening, 237 drug users were subjected to the monotest and, for reference purposes, to the mantoux test.", "in order to determine the prevalence of latent infection due to mycobacterium tuberculosis in drug users and to provide centres for drug users with a practical tool for tuberculosis screening, 237 drug users were subjected to the monotest and, for reference purposes, to the mantoux test.", "in order to determine the prevalence of latent infection due to mycobacterium tuberculosis in drug users and to provide centres for drug users with a practical tool for tuberculosis screening, 237 drug users were subjected to the monotest and, for reference purposes, to the mantoux test.", "in order to determine the prevalence of latent infection due to mycobacterium tuberculosis in drug users and to provide centres for drug users with a practical tool for tuberculosis screening, 237 drug users were subjected to the monotest and, for reference purposes, to the mantoux test.", "in order to determine the prevalence of latent infection due to mycobacterium tuberculosis in drug users and to provide centres for drug users with a practical tool for tuberculosis screening, 237 drug users were subjected to the monotest and, for reference purposes, to the mantoux test.", "in order to determine the prevalence of latent infection due to mycobacterium tuberculosis in drug users and to provide centres for drug users with a practical tool for tuberculosis screening, 237 drug users were subjected to the monotest and, for reference purposes, to the mantoux test.", "in order to determine the prevalence of latent infection due to mycobacterium tuberculosis in drug users and to provide centres for drug users with a practical tool for tuberculosis screening, 237 drug users were subjected to the monotest and, for reference purposes, to the mantoux test.", "in order to determine the prevalence of latent infection due to mycobacterium tuberculosis in drug users and to provide centres for drug users with a practical tool for tuberculosis screening, 237 drug users were subjected to the monotest and, for reference purposes, to the mantoux test.", "in order to determine the prevalence of latent infection due to mycobacterium tuberculosis in drug users and to provide centres for drug users with a practical tool for tuberculosis screening, 237 drug users were subjected to the monotest and, for reference purposes, to the mantoux test.", "in order to determine the prevalence of latent infection due to mycobacterium tuberculosis in drug users and to provide centres for drug users with a practical tool for tuberculosis screening, 237 drug users were subjected to the monotest and, for reference purposes, to the mantoux test.", "in order to determine the prevalence of latent infection due to mycobacterium tuberculosis in drug users and to provide centres for drug users with a practical tool for tuberculosis screening, 237 drug users were subjected to the monotest and, for reference purposes, to the mantoux test.", "in order to determine the prevalence of latent infection due to mycobacterium tuberculosis in drug users and to provide centres for drug users with a practical tool for tuberculosis screening, 237 drug users were subjected to the monotest and, for reference purposes, to the mantoux test.", "in order to determine the prevalence of latent infection due to mycobacterium tuberculosis in drug users and to provide centres for drug users with a practical tool for tuberculosis screening, 237 drug users were subjected to the monotest and, for reference purposes, to the mantoux test.", "in order to determine the prevalence of latent infection due to mycobacterium tuberculosis in drug users and to provide centres for drug users with a practical tool for tuberculosis screening, 237 drug users were subjected to the monotest and, for reference purposes, to the mantoux test.", "in order to determine the prevalence of latent infection due to mycobacterium tuberculosis in drug users and to provide centres for drug users with a practical tool for tuberculosis screening, 237 drug users were subjected to the monotest and, for reference purposes, to the mantoux test.", "in order to determine the prevalence of latent infection due to mycobacterium tuberculosis in drug users and to provide centres for drug users with a practical tool for tuberculosis screening, 237 drug users were subjected to the monotest and, for reference purposes, to the mantoux test.", "in order to determine the prevalence of latent infection due to mycobacterium tuberculosis in drug users and to provide centres for drug users with a practical tool for tuberculosis screening, 237 drug users were subjected to the monotest and, for reference purposes, to the mantoux test.", "in order to determine the prevalence of latent infection due to mycobacterium tuberculosis in drug users and to provide centres for drug users with a practical tool for tuberculosis screening, 237 drug users were subjected to the monotest and, for reference purposes, to the mantoux test.", "in order to determine the prevalence of latent infection due to mycobacterium tuberculosis in drug users and to provide centres for drug users with a practical tool for tuberculosis screening, 237 drug users were subjected to the monotest and, for reference purposes, to the mantoux test.", "in order to determine the prevalence of latent infection due to mycobacterium tuberculosis in drug users and to provide centres for drug users with a practical tool for tuberculosis screening, 237 drug users were subjected to the monotest and, for reference purposes, to the mantoux test.", "in order to determine the prevalence of latent infection due to mycobacterium tuberculosis in drug users and to provide centres for drug users with a practical tool for tuberculosis screening, 237 drug users were subjected to the monotest and, for reference purposes, to the mantoux test.", "in order to determine the prevalence of latent infection due to mycobacterium tuberculosis in drug users and to provide centres for drug users with a practical tool for tuberculosis screening, 237 drug users were subjected to the monotest and, for reference purposes, to the mantoux test.", "in order to determine the prevalence of latent infection due to mycobacterium tuberculosis in drug users and to provide centres for drug users with a practical tool for tuberculosis screening, 237 drug users were subjected to the monotest and, for reference purposes, to the mantoux test.", "in order to determine the prevalence of latent infection due to mycobacterium tuberculosis in drug users and to provide centres for drug users with a practical tool for tuberculosis screening, 237 drug users were subjected to the monotest and, for reference purposes, to the mantoux test.", "in order to determine the prevalence of latent infection due to mycobacterium tuberculosis in drug users and to provide centres for drug users with a practical tool for tuberculosis screening, 237 drug users were subjected to the monotest and, for reference purposes, to the mantoux test.", "in order to determine the prevalence of latent infection due to mycobacterium tuberculosis in drug users and to provide centres for drug users with a practical tool for tuberculosis screening, 237 drug users were subjected to the monotest and, for reference purposes, to the mantoux test.", "in order to determine the prevalence of latent infection due to mycobacterium tuberculosis in drug users and to provide centres for drug users with a practical tool for tuberculosis screening, 237 drug users were subjected to the monotest and, for reference purposes, to the mantoux test.", "in order to determine the prevalence of latent infection due to mycobacterium tuberculosis in drug users and to provide centres for drug users with a practical tool for tuberculosis screening, 237 drug users were subjected to the monotest and, for reference purposes, to the mantoux test.", "in order to determine the prevalence of latent infection due to mycobacterium tuberculosis in drug users and to provide centres for drug users with a practical tool for tuberculosis screening, 237 drug users were subjected to the monotest and, for reference purposes, to the mantoux test.", "in order to determine the prevalence of latent infection due to mycobacterium tuberculosis in drug users and to provide centres for drug users with a practical tool for tuberculosis screening, 237 drug users were subjected to the monotest and, for reference purposes, to the mantoux test.", "in order to determine the prevalence of latent infection due to mycobacterium tuberculosis in drug users and to provide centres for drug users with a practical tool for tuberculosis screening, 237 drug users were subjected to the monotest and, for reference purposes, to the mantoux test.", "in order to determine the prevalence of latent infection due to mycobacterium tuberculosis in drug users and to provide centres for drug users with a practical tool for tuberculosis screening, 237 drug users were subjected to the monotest and, for reference purposes, to the mantoux test.", "in order to determine the prevalence of latent infection due to mycobacterium tuberculosis in drug users and to provide centres for drug users with a practical tool for tuberculosis screening, 237 drug users were subjected to the monotest and, for reference purposes, to the mantoux test.", "diaskintest\u00ae test and mantoux test with 2te ppd-l were concurrently carried out in 300 children and adolescents with tuberculosis and followed up in risk groups at a tuberculosis dispensary to determine the sensitivity of the new skin test in active tuberculosis infection.", "diaskintest\u00ae test and mantoux test with 2te ppd-l were concurrently carried out in 300 children and adolescents with tuberculosis and followed up in risk groups at a tuberculosis dispensary to determine the sensitivity of the new skin test in active tuberculosis infection.", "diaskintest\u00ae test and mantoux test with 2te ppd-l were concurrently carried out in 300 children and adolescents with tuberculosis and followed up in risk groups at a tuberculosis dispensary to determine the sensitivity of the new skin test in active tuberculosis infection.", "diaskintest\u00ae test and mantoux test with 2te ppd-l were concurrently carried out in 300 children and adolescents with tuberculosis and followed up in risk groups at a tuberculosis dispensary to determine the sensitivity of the new skin test in active tuberculosis infection.", "diaskintest\u00ae test and mantoux test with 2te ppd-l were concurrently carried out in 300 children and adolescents with tuberculosis and followed up in risk groups at a tuberculosis dispensary to determine the sensitivity of the new skin test in active tuberculosis infection.", "diaskintest\u00ae test and mantoux test with 2te ppd-l were concurrently carried out in 300 children and adolescents with tuberculosis and followed up in risk groups at a tuberculosis dispensary to determine the sensitivity of the new skin test in active tuberculosis infection.", "diaskintest\u00ae test and mantoux test with 2te ppd-l were concurrently carried out in 300 children and adolescents with tuberculosis and followed up in risk groups at a tuberculosis dispensary to determine the sensitivity of the new skin test in active tuberculosis infection.", "diaskintest\u00ae test and mantoux test with 2te ppd-l were concurrently carried out in 300 children and adolescents with tuberculosis and followed up in risk groups at a tuberculosis dispensary to determine the sensitivity of the new skin test in active tuberculosis infection.", "diaskintest\u00ae test and mantoux test with 2te ppd-l were concurrently carried out in 300 children and adolescents with tuberculosis and followed up in risk groups at a tuberculosis dispensary to determine the sensitivity of the new skin test in active tuberculosis infection.", "diaskintest\u00ae test and mantoux test with 2te ppd-l were concurrently carried out in 300 children and adolescents with tuberculosis and followed up in risk groups at a tuberculosis dispensary to determine the sensitivity of the new skin test in active tuberculosis infection.", "diaskintest\u00ae test and mantoux test with 2te ppd-l were concurrently carried out in 300 children and adolescents with tuberculosis and followed up in risk groups at a tuberculosis dispensary to determine the sensitivity of the new skin test in active tuberculosis infection.", "diaskintest\u00ae test and mantoux test with 2te ppd-l were concurrently carried out in 300 children and adolescents with tuberculosis and followed up in risk groups at a tuberculosis dispensary to determine the sensitivity of the new skin test in active tuberculosis infection.", "diaskintest\u00ae test and mantoux test with 2te ppd-l were concurrently carried out in 300 children and adolescents with tuberculosis and followed up in risk groups at a tuberculosis dispensary to determine the sensitivity of the new skin test in active tuberculosis infection.", "diaskintest\u00ae test and mantoux test with 2te ppd-l were concurrently carried out in 300 children and adolescents with tuberculosis and followed up in risk groups at a tuberculosis dispensary to determine the sensitivity of the new skin test in active tuberculosis infection.", "diaskintest\u00ae test and mantoux test with 2te ppd-l were concurrently carried out in 300 children and adolescents with tuberculosis and followed up in risk groups at a tuberculosis dispensary to determine the sensitivity of the new skin test in active tuberculosis infection.", "diaskintest\u00ae test and mantoux test with 2te ppd-l were concurrently carried out in 300 children and adolescents with tuberculosis and followed up in risk groups at a tuberculosis dispensary to determine the sensitivity of the new skin test in active tuberculosis infection.", "diaskintest\u00ae test and mantoux test with 2te ppd-l were concurrently carried out in 300 children and adolescents with tuberculosis and followed up in risk groups at a tuberculosis dispensary to determine the sensitivity of the new skin test in active tuberculosis infection.", "diaskintest\u00ae test and mantoux test with 2te ppd-l were concurrently carried out in 300 children and adolescents with tuberculosis and followed up in risk groups at a tuberculosis dispensary to determine the sensitivity of the new skin test in active tuberculosis infection.", "diaskintest\u00ae test and mantoux test with 2te ppd-l were concurrently carried out in 300 children and adolescents with tuberculosis and followed up in risk groups at a tuberculosis dispensary to determine the sensitivity of the new skin test in active tuberculosis infection.", "diaskintest\u00ae test and mantoux test with 2te ppd-l were concurrently carried out in 300 children and adolescents with tuberculosis and followed up in risk groups at a tuberculosis dispensary to determine the sensitivity of the new skin test in active tuberculosis infection.", "diaskintest\u00ae test and mantoux test with 2te ppd-l were concurrently carried out in 300 children and adolescents with tuberculosis and followed up in risk groups at a tuberculosis dispensary to determine the sensitivity of the new skin test in active tuberculosis infection.", "diaskintest\u00ae test and mantoux test with 2te ppd-l were concurrently carried out in 300 children and adolescents with tuberculosis and followed up in risk groups at a tuberculosis dispensary to determine the sensitivity of the new skin test in active tuberculosis infection.", "diaskintest\u00ae test and mantoux test with 2te ppd-l were concurrently carried out in 300 children and adolescents with tuberculosis and followed up in risk groups at a tuberculosis dispensary to determine the sensitivity of the new skin test in active tuberculosis infection.", "diaskintest\u00ae test and mantoux test with 2te ppd-l were concurrently carried out in 300 children and adolescents with tuberculosis and followed up in risk groups at a tuberculosis dispensary to determine the sensitivity of the new skin test in active tuberculosis infection.", "diaskintest\u00ae test and mantoux test with 2te ppd-l were concurrently carried out in 300 children and adolescents with tuberculosis and followed up in risk groups at a tuberculosis dispensary to determine the sensitivity of the new skin test in active tuberculosis infection.", "diaskintest\u00ae test and mantoux test with 2te ppd-l were concurrently carried out in 300 children and adolescents with tuberculosis and followed up in risk groups at a tuberculosis dispensary to determine the sensitivity of the new skin test in active tuberculosis infection.", "diaskintest\u00ae test and mantoux test with 2te ppd-l were concurrently carried out in 300 children and adolescents with tuberculosis and followed up in risk groups at a tuberculosis dispensary to determine the sensitivity of the new skin test in active tuberculosis infection.", "diaskintest\u00ae test and mantoux test with 2te ppd-l were concurrently carried out in 300 children and adolescents with tuberculosis and followed up in risk groups at a tuberculosis dispensary to determine the sensitivity of the new skin test in active tuberculosis infection.", "diaskintest\u00ae test and mantoux test with 2te ppd-l were concurrently carried out in 300 children and adolescents with tuberculosis and followed up in risk groups at a tuberculosis dispensary to determine the sensitivity of the new skin test in active tuberculosis infection.", "diaskintest\u00ae test and mantoux test with 2te ppd-l were concurrently carried out in 300 children and adolescents with tuberculosis and followed up in risk groups at a tuberculosis dispensary to determine the sensitivity of the new skin test in active tuberculosis infection.", "diaskintest\u00ae test and mantoux test with 2te ppd-l were concurrently carried out in 300 children and adolescents with tuberculosis and followed up in risk groups at a tuberculosis dispensary to determine the sensitivity of the new skin test in active tuberculosis infection.", "diaskintest\u00ae test and mantoux test with 2te ppd-l were concurrently carried out in 300 children and adolescents with tuberculosis and followed up in risk groups at a tuberculosis dispensary to determine the sensitivity of the new skin test in active tuberculosis infection.", "diaskintest\u00ae test and mantoux test with 2te ppd-l were concurrently carried out in 300 children and adolescents with tuberculosis and followed up in risk groups at a tuberculosis dispensary to determine the sensitivity of the new skin test in active tuberculosis infection.", "diaskintest\u00ae test and mantoux test with 2te ppd-l were concurrently carried out in 300 children and adolescents with tuberculosis and followed up in risk groups at a tuberculosis dispensary to determine the sensitivity of the new skin test in active tuberculosis infection.", "diaskintest\u00ae test and mantoux test with 2te ppd-l were concurrently carried out in 300 children and adolescents with tuberculosis and followed up in risk groups at a tuberculosis dispensary to determine the sensitivity of the new skin test in active tuberculosis infection.", "the prevalence of tuberculosis infection among hospitalized patients in a pneumological department of an inner-city hospital was evaluated, using the intradermal tuberculin skin test (mantoux technique).", "the prevalence of tuberculosis infection among hospitalized patients in a pneumological department of an inner-city hospital was evaluated, using the intradermal tuberculin skin test (mantoux technique).", "the prevalence of tuberculosis infection among hospitalized patients in a pneumological department of an inner-city hospital was evaluated, using the intradermal tuberculin skin test (mantoux technique).", "the prevalence of tuberculosis infection among hospitalized patients in a pneumological department of an inner-city hospital was evaluated, using the intradermal tuberculin skin test (mantoux technique).", "the prevalence of tuberculosis infection among hospitalized patients in a pneumological department of an inner-city hospital was evaluated, using the intradermal tuberculin skin test (mantoux technique).", "the prevalence of tuberculosis infection among hospitalized patients in a pneumological department of an inner-city hospital was evaluated, using the intradermal tuberculin skin test (mantoux technique).", "the prevalence of tuberculosis infection among hospitalized patients in a pneumological department of an inner-city hospital was evaluated, using the intradermal tuberculin skin test (mantoux technique).", "the prevalence of tuberculosis infection among hospitalized patients in a pneumological department of an inner-city hospital was evaluated, using the intradermal tuberculin skin test (mantoux technique).", "the prevalence of tuberculosis infection among hospitalized patients in a pneumological department of an inner-city hospital was evaluated, using the intradermal tuberculin skin test (mantoux technique).", "the prevalence of tuberculosis infection among hospitalized patients in a pneumological department of an inner-city hospital was evaluated, using the intradermal tuberculin skin test (mantoux technique).", "the prevalence of tuberculosis infection among hospitalized patients in a pneumological department of an inner-city hospital was evaluated, using the intradermal tuberculin skin test (mantoux technique).", "the prevalence of tuberculosis infection among hospitalized patients in a pneumological department of an inner-city hospital was evaluated, using the intradermal tuberculin skin test (mantoux technique).", "the prevalence of tuberculosis infection among hospitalized patients in a pneumological department of an inner-city hospital was evaluated, using the intradermal tuberculin skin test (mantoux technique).", "the prevalence of tuberculosis infection among hospitalized patients in a pneumological department of an inner-city hospital was evaluated, using the intradermal tuberculin skin test (mantoux technique).", "the prevalence of tuberculosis infection among hospitalized patients in a pneumological department of an inner-city hospital was evaluated, using the intradermal tuberculin skin test (mantoux technique).", "the prevalence of tuberculosis infection among hospitalized patients in a pneumological department of an inner-city hospital was evaluated, using the intradermal tuberculin skin test (mantoux technique).", "the prevalence of tuberculosis infection among hospitalized patients in a pneumological department of an inner-city hospital was evaluated, using the intradermal tuberculin skin test (mantoux technique).", "the prevalence of tuberculosis infection among hospitalized patients in a pneumological department of an inner-city hospital was evaluated, using the intradermal tuberculin skin test (mantoux technique).", "the prevalence of tuberculosis infection among hospitalized patients in a pneumological department of an inner-city hospital was evaluated, using the intradermal tuberculin skin test (mantoux technique).", "the prevalence of tuberculosis infection among hospitalized patients in a pneumological department of an inner-city hospital was evaluated, using the intradermal tuberculin skin test (mantoux technique).", "the prevalence of tuberculosis infection among hospitalized patients in a pneumological department of an inner-city hospital was evaluated, using the intradermal tuberculin skin test (mantoux technique).", "the prevalence of tuberculosis infection among hospitalized patients in a pneumological department of an inner-city hospital was evaluated, using the intradermal tuberculin skin test (mantoux technique).", "the prevalence of tuberculosis infection among hospitalized patients in a pneumological department of an inner-city hospital was evaluated, using the intradermal tuberculin skin test (mantoux technique).", "the prevalence of tuberculosis infection among hospitalized patients in a pneumological department of an inner-city hospital was evaluated, using the intradermal tuberculin skin test (mantoux technique).", "the prevalence of tuberculosis infection among hospitalized patients in a pneumological department of an inner-city hospital was evaluated, using the intradermal tuberculin skin test (mantoux technique).", "the prevalence of tuberculosis infection among hospitalized patients in a pneumological department of an inner-city hospital was evaluated, using the intradermal tuberculin skin test (mantoux technique).", "the prevalence of tuberculosis infection among hospitalized patients in a pneumological department of an inner-city hospital was evaluated, using the intradermal tuberculin skin test (mantoux technique).", "the prevalence of tuberculosis infection among hospitalized patients in a pneumological department of an inner-city hospital was evaluated, using the intradermal tuberculin skin test (mantoux technique).", "the prevalence of tuberculosis infection among hospitalized patients in a pneumological department of an inner-city hospital was evaluated, using the intradermal tuberculin skin test (mantoux technique).", "the prevalence of tuberculosis infection among hospitalized patients in a pneumological department of an inner-city hospital was evaluated, using the intradermal tuberculin skin test (mantoux technique).", "the prevalence of tuberculosis infection among hospitalized patients in a pneumological department of an inner-city hospital was evaluated, using the intradermal tuberculin skin test (mantoux technique).", "the prevalence of tuberculosis infection among hospitalized patients in a pneumological department of an inner-city hospital was evaluated, using the intradermal tuberculin skin test (mantoux technique).", "the prevalence of tuberculosis infection among hospitalized patients in a pneumological department of an inner-city hospital was evaluated, using the intradermal tuberculin skin test (mantoux technique).", "the prevalence of tuberculosis infection among hospitalized patients in a pneumological department of an inner-city hospital was evaluated, using the intradermal tuberculin skin test (mantoux technique).", "the prevalence of tuberculosis infection among hospitalized patients in a pneumological department of an inner-city hospital was evaluated, using the intradermal tuberculin skin test (mantoux technique).", "he 100-year-old tuberculin skin test (mantoux) has been the only available diagnostic test for latent tuberculosis infection, despite its many well-known limitations.", "he 100-year-old tuberculin skin test (mantoux) has been the only available diagnostic test for latent tuberculosis infection, despite its many well-known limitations.", "he 100-year-old tuberculin skin test (mantoux) has been the only available diagnostic test for latent tuberculosis infection, despite its many well-known limitations.", "he 100-year-old tuberculin skin test (mantoux) has been the only available diagnostic test for latent tuberculosis infection, despite its many well-known limitations.", "he 100-year-old tuberculin skin test (mantoux) has been the only available diagnostic test for latent tuberculosis infection, despite its many well-known limitations.", "he 100-year-old tuberculin skin test (mantoux) has been the only available diagnostic test for latent tuberculosis infection, despite its many well-known limitations.", "he 100-year-old tuberculin skin test (mantoux) has been the only available diagnostic test for latent tuberculosis infection, despite its many well-known limitations.", "he 100-year-old tuberculin skin test (mantoux) has been the only available diagnostic test for latent tuberculosis infection, despite its many well-known limitations.", "he 100-year-old tuberculin skin test (mantoux) has been the only available diagnostic test for latent tuberculosis infection, despite its many well-known limitations.", "he 100-year-old tuberculin skin test (mantoux) has been the only available diagnostic test for latent tuberculosis infection, despite its many well-known limitations.", "he 100-year-old tuberculin skin test (mantoux) has been the only available diagnostic test for latent tuberculosis infection, despite its many well-known limitations.", "he 100-year-old tuberculin skin test (mantoux) has been the only available diagnostic test for latent tuberculosis infection, despite its many well-known limitations.", "he 100-year-old tuberculin skin test (mantoux) has been the only available diagnostic test for latent tuberculosis infection, despite its many well-known limitations.", "he 100-year-old tuberculin skin test (mantoux) has been the only available diagnostic test for latent tuberculosis infection, despite its many well-known limitations.", "he 100-year-old tuberculin skin test (mantoux) has been the only available diagnostic test for latent tuberculosis infection, despite its many well-known limitations.", "he 100-year-old tuberculin skin test (mantoux) has been the only available diagnostic test for latent tuberculosis infection, despite its many well-known limitations.", "he 100-year-old tuberculin skin test (mantoux) has been the only available diagnostic test for latent tuberculosis infection, despite its many well-known limitations.", "he 100-year-old tuberculin skin test (mantoux) has been the only available diagnostic test for latent tuberculosis infection, despite its many well-known limitations.", "he 100-year-old tuberculin skin test (mantoux) has been the only available diagnostic test for latent tuberculosis infection, despite its many well-known limitations.", "he 100-year-old tuberculin skin test (mantoux) has been the only available diagnostic test for latent tuberculosis infection, despite its many well-known limitations.", "he 100-year-old tuberculin skin test (mantoux) has been the only available diagnostic test for latent tuberculosis infection, despite its many well-known limitations.", "he 100-year-old tuberculin skin test (mantoux) has been the only available diagnostic test for latent tuberculosis infection, despite its many well-known limitations.", "he 100-year-old tuberculin skin test (mantoux) has been the only available diagnostic test for latent tuberculosis infection, despite its many well-known limitations.", "he 100-year-old tuberculin skin test (mantoux) has been the only available diagnostic test for latent tuberculosis infection, despite its many well-known limitations.", "he 100-year-old tuberculin skin test (mantoux) has been the only available diagnostic test for latent tuberculosis infection, despite its many well-known limitations.", "he 100-year-old tuberculin skin test (mantoux) has been the only available diagnostic test for latent tuberculosis infection, despite its many well-known limitations.", "he 100-year-old tuberculin skin test (mantoux) has been the only available diagnostic test for latent tuberculosis infection, despite its many well-known limitations.", "he 100-year-old tuberculin skin test (mantoux) has been the only available diagnostic test for latent tuberculosis infection, despite its many well-known limitations.", "he 100-year-old tuberculin skin test (mantoux) has been the only available diagnostic test for latent tuberculosis infection, despite its many well-known limitations.", "he 100-year-old tuberculin skin test (mantoux) has been the only available diagnostic test for latent tuberculosis infection, despite its many well-known limitations.", "he 100-year-old tuberculin skin test (mantoux) has been the only available diagnostic test for latent tuberculosis infection, despite its many well-known limitations.", "he 100-year-old tuberculin skin test (mantoux) has been the only available diagnostic test for latent tuberculosis infection, despite its many well-known limitations.", "he 100-year-old tuberculin skin test (mantoux) has been the only available diagnostic test for latent tuberculosis infection, despite its many well-known limitations.", "he 100-year-old tuberculin skin test (mantoux) has been the only available diagnostic test for latent tuberculosis infection, despite its many well-known limitations.", "he 100-year-old tuberculin skin test (mantoux) has been the only available diagnostic test for latent tuberculosis infection, despite its many well-known limitations.", "latent tuberculosis treatment was recommended in all mantoux-positive contacts.", "latent tuberculosis treatment was recommended in all mantoux-positive contacts.", "latent tuberculosis treatment was recommended in all mantoux-positive contacts.", "latent tuberculosis treatment was recommended in all mantoux-positive contacts.", "latent tuberculosis treatment was recommended in all mantoux-positive contacts.", "latent tuberculosis treatment was recommended in all mantoux-positive contacts.", "latent tuberculosis treatment was recommended in all mantoux-positive contacts.", "latent tuberculosis treatment was recommended in all mantoux-positive contacts.", "latent tuberculosis treatment was recommended in all mantoux-positive contacts.", "latent tuberculosis treatment was recommended in all mantoux-positive contacts.", "latent tuberculosis treatment was recommended in all mantoux-positive contacts.", "latent tuberculosis treatment was recommended in all mantoux-positive contacts.", "latent tuberculosis treatment was recommended in all mantoux-positive contacts.", "latent tuberculosis treatment was recommended in all mantoux-positive contacts.", "latent tuberculosis treatment was recommended in all mantoux-positive contacts.", "latent tuberculosis treatment was recommended in all mantoux-positive contacts.", "latent tuberculosis treatment was recommended in all mantoux-positive contacts.", "latent tuberculosis treatment was recommended in all mantoux-positive contacts.", "latent tuberculosis treatment was recommended in all mantoux-positive contacts.", "latent tuberculosis treatment was recommended in all mantoux-positive contacts.", "latent tuberculosis treatment was recommended in all mantoux-positive contacts.", "latent tuberculosis treatment was recommended in all mantoux-positive contacts.", "latent tuberculosis treatment was recommended in all mantoux-positive contacts.", "latent tuberculosis treatment was recommended in all mantoux-positive contacts.", "latent tuberculosis treatment was recommended in all mantoux-positive contacts.", "latent tuberculosis treatment was recommended in all mantoux-positive contacts.", "latent tuberculosis treatment was recommended in all mantoux-positive contacts.", "latent tuberculosis treatment was recommended in all mantoux-positive contacts.", "latent tuberculosis treatment was recommended in all mantoux-positive contacts.", "latent tuberculosis treatment was recommended in all mantoux-positive contacts.", "latent tuberculosis treatment was recommended in all mantoux-positive contacts.", "latent tuberculosis treatment was recommended in all mantoux-positive contacts.", "latent tuberculosis treatment was recommended in all mantoux-positive contacts.", "latent tuberculosis treatment was recommended in all mantoux-positive contacts.", "latent tuberculosis treatment was recommended in all mantoux-positive contacts.", "cts, which may occur in as many as 25% of patients who undergo carpal tunnel release, most commonly results from an incomplete transverse carpal ligament release or an incorrect initial diagnosis. patients with recurrent symptoms often have perineural fibrosis that tethers the median nerve.", "cts, which may occur in as many as 25% of patients who undergo carpal tunnel release, most commonly results from an incomplete transverse carpal ligament release or an incorrect initial diagnosis. patients with recurrent symptoms often have perineural fibrosis that tethers the median nerve.", "cts, which may occur in as many as 25% of patients who undergo carpal tunnel release, most commonly results from an incomplete transverse carpal ligament release or an incorrect initial diagnosis. patients with recurrent symptoms often have perineural fibrosis that tethers the median nerve.", "cts, which may occur in as many as 25% of patients who undergo carpal tunnel release, most commonly results from an incomplete transverse carpal ligament release or an incorrect initial diagnosis. patients with recurrent symptoms often have perineural fibrosis that tethers the median nerve.", "cts, which may occur in as many as 25% of patients who undergo carpal tunnel release, most commonly results from an incomplete transverse carpal ligament release or an incorrect initial diagnosis. patients with recurrent symptoms often have perineural fibrosis that tethers the median nerve.", "cts, which may occur in as many as 25% of patients who undergo carpal tunnel release, most commonly results from an incomplete transverse carpal ligament release or an incorrect initial diagnosis. patients with recurrent symptoms often have perineural fibrosis that tethers the median nerve.", "cts, which may occur in as many as 25% of patients who undergo carpal tunnel release, most commonly results from an incomplete transverse carpal ligament release or an incorrect initial diagnosis. patients with recurrent symptoms often have perineural fibrosis that tethers the median nerve.", "cts, which may occur in as many as 25% of patients who undergo carpal tunnel release, most commonly results from an incomplete transverse carpal ligament release or an incorrect initial diagnosis. patients with recurrent symptoms often have perineural fibrosis that tethers the median nerve.", "to define the relationship between body indices of healthy adults and cross-sectional areas of the carpal tunnel and median nerve and to obtain the nerve/tunnel index, which represents a new standard for diagnosing carpal tunnel syndrome using sonography.", "to define the relationship between body indices of healthy adults and cross-sectional areas of the carpal tunnel and median nerve and to obtain the nerve/tunnel index, which represents a new standard for diagnosing carpal tunnel syndrome using sonography.", "to define the relationship between body indices of healthy adults and cross-sectional areas of the carpal tunnel and median nerve and to obtain the nerve/tunnel index, which represents a new standard for diagnosing carpal tunnel syndrome using sonography.", "to define the relationship between body indices of healthy adults and cross-sectional areas of the carpal tunnel and median nerve and to obtain the nerve/tunnel index, which represents a new standard for diagnosing carpal tunnel syndrome using sonography.", "to define the relationship between body indices of healthy adults and cross-sectional areas of the carpal tunnel and median nerve and to obtain the nerve/tunnel index, which represents a new standard for diagnosing carpal tunnel syndrome using sonography.", "to define the relationship between body indices of healthy adults and cross-sectional areas of the carpal tunnel and median nerve and to obtain the nerve/tunnel index, which represents a new standard for diagnosing carpal tunnel syndrome using sonography.", "to define the relationship between body indices of healthy adults and cross-sectional areas of the carpal tunnel and median nerve and to obtain the nerve/tunnel index, which represents a new standard for diagnosing carpal tunnel syndrome using sonography.", "to define the relationship between body indices of healthy adults and cross-sectional areas of the carpal tunnel and median nerve and to obtain the nerve/tunnel index, which represents a new standard for diagnosing carpal tunnel syndrome using sonography.", "the carpal tunnel syndrome is a neuropathy due to trapping (focal lesion of the peripheral nerve due to a local cause); in this case, the median nerve is the most commonly involved.", "the carpal tunnel syndrome is a neuropathy due to trapping (focal lesion of the peripheral nerve due to a local cause); in this case, the median nerve is the most commonly involved.", "the carpal tunnel syndrome is a neuropathy due to trapping (focal lesion of the peripheral nerve due to a local cause); in this case, the median nerve is the most commonly involved.", "the carpal tunnel syndrome is a neuropathy due to trapping (focal lesion of the peripheral nerve due to a local cause); in this case, the median nerve is the most commonly involved.", "the carpal tunnel syndrome is a neuropathy due to trapping (focal lesion of the peripheral nerve due to a local cause); in this case, the median nerve is the most commonly involved.", "the carpal tunnel syndrome is a neuropathy due to trapping (focal lesion of the peripheral nerve due to a local cause); in this case, the median nerve is the most commonly involved.", "the carpal tunnel syndrome is a neuropathy due to trapping (focal lesion of the peripheral nerve due to a local cause); in this case, the median nerve is the most commonly involved.", "the carpal tunnel syndrome is a neuropathy due to trapping (focal lesion of the peripheral nerve due to a local cause); in this case, the median nerve is the most commonly involved.", "in this study, it was aimed to determine whether median nerve epineurectomy is beneficial in the surgical management of carpal tunnel syndrome", "in this study, it was aimed to determine whether median nerve epineurectomy is beneficial in the surgical management of carpal tunnel syndrome", "in this study, it was aimed to determine whether median nerve epineurectomy is beneficial in the surgical management of carpal tunnel syndrome", "in this study, it was aimed to determine whether median nerve epineurectomy is beneficial in the surgical management of carpal tunnel syndrome", "in this study, it was aimed to determine whether median nerve epineurectomy is beneficial in the surgical management of carpal tunnel syndrome", "in this study, it was aimed to determine whether median nerve epineurectomy is beneficial in the surgical management of carpal tunnel syndrome", "in this study, it was aimed to determine whether median nerve epineurectomy is beneficial in the surgical management of carpal tunnel syndrome", "in this study, it was aimed to determine whether median nerve epineurectomy is beneficial in the surgical management of carpal tunnel syndrome", "we believe that median nerve epineurectomy is unnecessary in the surgical management of primary cts since it has no influence on the midterm", "we believe that median nerve epineurectomy is unnecessary in the surgical management of primary cts since it has no influence on the midterm", "we believe that median nerve epineurectomy is unnecessary in the surgical management of primary cts since it has no influence on the midterm", "we believe that median nerve epineurectomy is unnecessary in the surgical management of primary cts since it has no influence on the midterm", "we believe that median nerve epineurectomy is unnecessary in the surgical management of primary cts since it has no influence on the midterm", "we believe that median nerve epineurectomy is unnecessary in the surgical management of primary cts since it has no influence on the midterm", "we believe that median nerve epineurectomy is unnecessary in the surgical management of primary cts since it has no influence on the midterm", "we believe that median nerve epineurectomy is unnecessary in the surgical management of primary cts since it has no influence on the midterm", "compression of the median nerve at the wrist, or carpal tunnel syndrome, is the most commonly recognized nerve entrapment syndrome.", "compression of the median nerve at the wrist, or carpal tunnel syndrome, is the most commonly recognized nerve entrapment syndrome.", "compression of the median nerve at the wrist, or carpal tunnel syndrome, is the most commonly recognized nerve entrapment syndrome.", "compression of the median nerve at the wrist, or carpal tunnel syndrome, is the most commonly recognized nerve entrapment syndrome.", "compression of the median nerve at the wrist, or carpal tunnel syndrome, is the most commonly recognized nerve entrapment syndrome.", "compression of the median nerve at the wrist, or carpal tunnel syndrome, is the most commonly recognized nerve entrapment syndrome.", "compression of the median nerve at the wrist, or carpal tunnel syndrome, is the most commonly recognized nerve entrapment syndrome.", "compression of the median nerve at the wrist, or carpal tunnel syndrome, is the most commonly recognized nerve entrapment syndrome.", "carpal tunnel syndrome is a complex of symptoms as a result of compression of the median nerve in the carpal tunnel.", "carpal tunnel syndrome is a complex of symptoms as a result of compression of the median nerve in the carpal tunnel.", "carpal tunnel syndrome is a complex of symptoms as a result of compression of the median nerve in the carpal tunnel.", "carpal tunnel syndrome is a complex of symptoms as a result of compression of the median nerve in the carpal tunnel.", "carpal tunnel syndrome is a complex of symptoms as a result of compression of the median nerve in the carpal tunnel.", "carpal tunnel syndrome is a complex of symptoms as a result of compression of the median nerve in the carpal tunnel.", "carpal tunnel syndrome is a complex of symptoms as a result of compression of the median nerve in the carpal tunnel.", "carpal tunnel syndrome is a complex of symptoms as a result of compression of the median nerve in the carpal tunnel.", "carpal tunnel syndrome (cts) is the most common median nerve neuropathy, accounting for 90% of all neuropathies", "carpal tunnel syndrome (cts) is the most common median nerve neuropathy, accounting for 90% of all neuropathies", "carpal tunnel syndrome (cts) is the most common median nerve neuropathy, accounting for 90% of all neuropathies", "carpal tunnel syndrome (cts) is the most common median nerve neuropathy, accounting for 90% of all neuropathies", "carpal tunnel syndrome (cts) is the most common median nerve neuropathy, accounting for 90% of all neuropathies", "carpal tunnel syndrome (cts) is the most common median nerve neuropathy, accounting for 90% of all neuropathies", "carpal tunnel syndrome (cts) is the most common median nerve neuropathy, accounting for 90% of all neuropathies", "carpal tunnel syndrome (cts) is the most common median nerve neuropathy, accounting for 90% of all neuropathies", "carpal tunnel syndrome (cts) is a focal compressive neuropathy of the median nerve at the level of the wrist.", "carpal tunnel syndrome (cts) is a focal compressive neuropathy of the median nerve at the level of the wrist.", "carpal tunnel syndrome (cts) is a focal compressive neuropathy of the median nerve at the level of the wrist.", "carpal tunnel syndrome (cts) is a focal compressive neuropathy of the median nerve at the level of the wrist.", "carpal tunnel syndrome (cts) is a focal compressive neuropathy of the median nerve at the level of the wrist.", "carpal tunnel syndrome (cts) is a focal compressive neuropathy of the median nerve at the level of the wrist.", "carpal tunnel syndrome (cts) is a focal compressive neuropathy of the median nerve at the level of the wrist.", "carpal tunnel syndrome (cts) is a focal compressive neuropathy of the median nerve at the level of the wrist.", "ultrasound is an established method of viewing the median nerve in the carpal tunnel syndrome (cts)", "ultrasound is an established method of viewing the median nerve in the carpal tunnel syndrome (cts)", "ultrasound is an established method of viewing the median nerve in the carpal tunnel syndrome (cts)", "ultrasound is an established method of viewing the median nerve in the carpal tunnel syndrome (cts)", "ultrasound is an established method of viewing the median nerve in the carpal tunnel syndrome (cts)", "ultrasound is an established method of viewing the median nerve in the carpal tunnel syndrome (cts)", "ultrasound is an established method of viewing the median nerve in the carpal tunnel syndrome (cts)", "ultrasound is an established method of viewing the median nerve in the carpal tunnel syndrome (cts)", "restricted motion of the median nerve in carpal tunnel syndrome.", "restricted motion of the median nerve in carpal tunnel syndrome.", "restricted motion of the median nerve in carpal tunnel syndrome.", "restricted motion of the median nerve in carpal tunnel syndrome.", "restricted motion of the median nerve in carpal tunnel syndrome.", "restricted motion of the median nerve in carpal tunnel syndrome.", "restricted motion of the median nerve in carpal tunnel syndrome.", "restricted motion of the median nerve in carpal tunnel syndrome.", "a 16-year-old boy developed left foot pain of unknown cause that was unresponsive to conservative treatment, associated with fever and difficulty walking. he was admitted to our hospital with osteomyelitis of the accessory and body of the navicular bone", "a 16-year-old boy developed left foot pain of unknown cause that was unresponsive to conservative treatment, associated with fever and difficulty walking. he was admitted to our hospital with osteomyelitis of the accessory and body of the navicular bone", "a 16-year-old boy developed left foot pain of unknown cause that was unresponsive to conservative treatment, associated with fever and difficulty walking. he was admitted to our hospital with osteomyelitis of the accessory and body of the navicular bone", "a 16-year-old boy developed left foot pain of unknown cause that was unresponsive to conservative treatment, associated with fever and difficulty walking. he was admitted to our hospital with osteomyelitis of the accessory and body of the navicular bone", "a 16-year-old boy developed left foot pain of unknown cause that was unresponsive to conservative treatment, associated with fever and difficulty walking. he was admitted to our hospital with osteomyelitis of the accessory and body of the navicular bone", "a 16-year-old boy developed left foot pain of unknown cause that was unresponsive to conservative treatment, associated with fever and difficulty walking. he was admitted to our hospital with osteomyelitis of the accessory and body of the navicular bone", "a 16-year-old boy developed left foot pain of unknown cause that was unresponsive to conservative treatment, associated with fever and difficulty walking. he was admitted to our hospital with osteomyelitis of the accessory and body of the navicular bone", "a 16-year-old boy developed left foot pain of unknown cause that was unresponsive to conservative treatment, associated with fever and difficulty walking. he was admitted to our hospital with osteomyelitis of the accessory and body of the navicular bone", "a 16-year-old boy developed left foot pain of unknown cause that was unresponsive to conservative treatment, associated with fever and difficulty walking. he was admitted to our hospital with osteomyelitis of the accessory and body of the navicular bone", "a 16-year-old boy developed left foot pain of unknown cause that was unresponsive to conservative treatment, associated with fever and difficulty walking. he was admitted to our hospital with osteomyelitis of the accessory and body of the navicular bone", "a 16-year-old boy developed left foot pain of unknown cause that was unresponsive to conservative treatment, associated with fever and difficulty walking. he was admitted to our hospital with osteomyelitis of the accessory and body of the navicular bone", "a 16-year-old boy developed left foot pain of unknown cause that was unresponsive to conservative treatment, associated with fever and difficulty walking. he was admitted to our hospital with osteomyelitis of the accessory and body of the navicular bone", "a 16-year-old boy developed left foot pain of unknown cause that was unresponsive to conservative treatment, associated with fever and difficulty walking. he was admitted to our hospital with osteomyelitis of the accessory and body of the navicular bone", "a 16-year-old boy developed left foot pain of unknown cause that was unresponsive to conservative treatment, associated with fever and difficulty walking. he was admitted to our hospital with osteomyelitis of the accessory and body of the navicular bone", "a 16-year-old boy developed left foot pain of unknown cause that was unresponsive to conservative treatment, associated with fever and difficulty walking. he was admitted to our hospital with osteomyelitis of the accessory and body of the navicular bone", "a 16-year-old boy developed left foot pain of unknown cause that was unresponsive to conservative treatment, associated with fever and difficulty walking. he was admitted to our hospital with osteomyelitis of the accessory and body of the navicular bone", "a 16-year-old boy developed left foot pain of unknown cause that was unresponsive to conservative treatment, associated with fever and difficulty walking. he was admitted to our hospital with osteomyelitis of the accessory and body of the navicular bone", "a 16-year-old boy developed left foot pain of unknown cause that was unresponsive to conservative treatment, associated with fever and difficulty walking. he was admitted to our hospital with osteomyelitis of the accessory and body of the navicular bone", "a 16-year-old boy developed left foot pain of unknown cause that was unresponsive to conservative treatment, associated with fever and difficulty walking. he was admitted to our hospital with osteomyelitis of the accessory and body of the navicular bone", "a 16-year-old boy developed left foot pain of unknown cause that was unresponsive to conservative treatment, associated with fever and difficulty walking. he was admitted to our hospital with osteomyelitis of the accessory and body of the navicular bone", "a 16-year-old boy developed left foot pain of unknown cause that was unresponsive to conservative treatment, associated with fever and difficulty walking. he was admitted to our hospital with osteomyelitis of the accessory and body of the navicular bone", "a 16-year-old boy developed left foot pain of unknown cause that was unresponsive to conservative treatment, associated with fever and difficulty walking. he was admitted to our hospital with osteomyelitis of the accessory and body of the navicular bone", "a 16-year-old boy developed left foot pain of unknown cause that was unresponsive to conservative treatment, associated with fever and difficulty walking. he was admitted to our hospital with osteomyelitis of the accessory and body of the navicular bone", "a 16-year-old boy developed left foot pain of unknown cause that was unresponsive to conservative treatment, associated with fever and difficulty walking. he was admitted to our hospital with osteomyelitis of the accessory and body of the navicular bone", "a 16-year-old boy developed left foot pain of unknown cause that was unresponsive to conservative treatment, associated with fever and difficulty walking. he was admitted to our hospital with osteomyelitis of the accessory and body of the navicular bone", "a 16-year-old boy developed left foot pain of unknown cause that was unresponsive to conservative treatment, associated with fever and difficulty walking. he was admitted to our hospital with osteomyelitis of the accessory and body of the navicular bone", "a 16-year-old boy developed left foot pain of unknown cause that was unresponsive to conservative treatment, associated with fever and difficulty walking. he was admitted to our hospital with osteomyelitis of the accessory and body of the navicular bone", "a 16-year-old boy developed left foot pain of unknown cause that was unresponsive to conservative treatment, associated with fever and difficulty walking. he was admitted to our hospital with osteomyelitis of the accessory and body of the navicular bone", "a 16-year-old boy developed left foot pain of unknown cause that was unresponsive to conservative treatment, associated with fever and difficulty walking. he was admitted to our hospital with osteomyelitis of the accessory and body of the navicular bone", "a 16-year-old boy developed left foot pain of unknown cause that was unresponsive to conservative treatment, associated with fever and difficulty walking. he was admitted to our hospital with osteomyelitis of the accessory and body of the navicular bone", "a 16-year-old boy developed left foot pain of unknown cause that was unresponsive to conservative treatment, associated with fever and difficulty walking. he was admitted to our hospital with osteomyelitis of the accessory and body of the navicular bone", "a 16-year-old boy developed left foot pain of unknown cause that was unresponsive to conservative treatment, associated with fever and difficulty walking. he was admitted to our hospital with osteomyelitis of the accessory and body of the navicular bone", "a 16-year-old boy developed left foot pain of unknown cause that was unresponsive to conservative treatment, associated with fever and difficulty walking. he was admitted to our hospital with osteomyelitis of the accessory and body of the navicular bone", "a 16-year-old boy developed left foot pain of unknown cause that was unresponsive to conservative treatment, associated with fever and difficulty walking. he was admitted to our hospital with osteomyelitis of the accessory and body of the navicular bone", "a 16-year-old boy developed left foot pain of unknown cause that was unresponsive to conservative treatment, associated with fever and difficulty walking. he was admitted to our hospital with osteomyelitis of the accessory and body of the navicular bone", "a 16-year-old boy developed left foot pain of unknown cause that was unresponsive to conservative treatment, associated with fever and difficulty walking. he was admitted to our hospital with osteomyelitis of the accessory and body of the navicular bone", "a 16-year-old boy developed left foot pain of unknown cause that was unresponsive to conservative treatment, associated with fever and difficulty walking. he was admitted to our hospital with osteomyelitis of the accessory and body of the navicular bone", "the accessory navicular (an) is an accessory ossicle anatomically located on the medial side of the foot, proximal to the navicular and continuous with the tibialis posterior tendon.", "the accessory navicular (an) is an accessory ossicle anatomically located on the medial side of the foot, proximal to the navicular and continuous with the tibialis posterior tendon.", "the accessory navicular (an) is an accessory ossicle anatomically located on the medial side of the foot, proximal to the navicular and continuous with the tibialis posterior tendon.", "the accessory navicular (an) is an accessory ossicle anatomically located on the medial side of the foot, proximal to the navicular and continuous with the tibialis posterior tendon.", "the accessory navicular (an) is an accessory ossicle anatomically located on the medial side of the foot, proximal to the navicular and continuous with the tibialis posterior tendon.", "the accessory navicular (an) is an accessory ossicle anatomically located on the medial side of the foot, proximal to the navicular and continuous with the tibialis posterior tendon.", "the accessory navicular (an) is an accessory ossicle anatomically located on the medial side of the foot, proximal to the navicular and continuous with the tibialis posterior tendon.", "the accessory navicular (an) is an accessory ossicle anatomically located on the medial side of the foot, proximal to the navicular and continuous with the tibialis posterior tendon.", "the accessory navicular (an) is an accessory ossicle anatomically located on the medial side of the foot, proximal to the navicular and continuous with the tibialis posterior tendon.", "the accessory navicular (an) is an accessory ossicle anatomically located on the medial side of the foot, proximal to the navicular and continuous with the tibialis posterior tendon.", "the accessory navicular (an) is an accessory ossicle anatomically located on the medial side of the foot, proximal to the navicular and continuous with the tibialis posterior tendon.", "the accessory navicular (an) is an accessory ossicle anatomically located on the medial side of the foot, proximal to the navicular and continuous with the tibialis posterior tendon.", "the accessory navicular (an) is an accessory ossicle anatomically located on the medial side of the foot, proximal to the navicular and continuous with the tibialis posterior tendon.", "the accessory navicular (an) is an accessory ossicle anatomically located on the medial side of the foot, proximal to the navicular and continuous with the tibialis posterior tendon.", "the accessory navicular (an) is an accessory ossicle anatomically located on the medial side of the foot, proximal to the navicular and continuous with the tibialis posterior tendon.", "the accessory navicular (an) is an accessory ossicle anatomically located on the medial side of the foot, proximal to the navicular and continuous with the tibialis posterior tendon.", "the accessory navicular (an) is an accessory ossicle anatomically located on the medial side of the foot, proximal to the navicular and continuous with the tibialis posterior tendon.", "the accessory navicular (an) is an accessory ossicle anatomically located on the medial side of the foot, proximal to the navicular and continuous with the tibialis posterior tendon.", "the accessory navicular (an) is an accessory ossicle anatomically located on the medial side of the foot, proximal to the navicular and continuous with the tibialis posterior tendon.", "the accessory navicular (an) is an accessory ossicle anatomically located on the medial side of the foot, proximal to the navicular and continuous with the tibialis posterior tendon.", "the accessory navicular (an) is an accessory ossicle anatomically located on the medial side of the foot, proximal to the navicular and continuous with the tibialis posterior tendon.", "the accessory navicular (an) is an accessory ossicle anatomically located on the medial side of the foot, proximal to the navicular and continuous with the tibialis posterior tendon.", "the accessory navicular (an) is an accessory ossicle anatomically located on the medial side of the foot, proximal to the navicular and continuous with the tibialis posterior tendon.", "the accessory navicular (an) is an accessory ossicle anatomically located on the medial side of the foot, proximal to the navicular and continuous with the tibialis posterior tendon.", "the accessory navicular (an) is an accessory ossicle anatomically located on the medial side of the foot, proximal to the navicular and continuous with the tibialis posterior tendon.", "the accessory navicular (an) is an accessory ossicle anatomically located on the medial side of the foot, proximal to the navicular and continuous with the tibialis posterior tendon.", "the accessory navicular (an) is an accessory ossicle anatomically located on the medial side of the foot, proximal to the navicular and continuous with the tibialis posterior tendon.", "the accessory navicular (an) is an accessory ossicle anatomically located on the medial side of the foot, proximal to the navicular and continuous with the tibialis posterior tendon.", "the accessory navicular (an) is an accessory ossicle anatomically located on the medial side of the foot, proximal to the navicular and continuous with the tibialis posterior tendon.", "the accessory navicular (an) is an accessory ossicle anatomically located on the medial side of the foot, proximal to the navicular and continuous with the tibialis posterior tendon.", "the accessory navicular (an) is an accessory ossicle anatomically located on the medial side of the foot, proximal to the navicular and continuous with the tibialis posterior tendon.", "the accessory navicular (an) is an accessory ossicle anatomically located on the medial side of the foot, proximal to the navicular and continuous with the tibialis posterior tendon.", "the accessory navicular (an) is an accessory ossicle anatomically located on the medial side of the foot, proximal to the navicular and continuous with the tibialis posterior tendon.", "the accessory navicular (an) is an accessory ossicle anatomically located on the medial side of the foot, proximal to the navicular and continuous with the tibialis posterior tendon.", "the accessory navicular (an) is an accessory ossicle anatomically located on the medial side of the foot, proximal to the navicular and continuous with the tibialis posterior tendon.", "the accessory navicular (an) is an accessory ossicle anatomically located on the medial side of the foot, proximal to the navicular and continuous with the tibialis posterior tendon.", "the accessory navicular (an) is an accessory ossicle anatomically located on the medial side of the foot, proximal to the navicular and continuous with the tibialis posterior tendon.", "we used proximity extension immunoassay (pea, proseek multiplex, olink) to assess the serum levels of ninety-two inflammation-related proteins in czech patients with sle (n\u00a0=\u00a075) and age-matched healthy control subjects (n\u00a0=\u00a023).", "we used proximity extension immunoassay (pea, proseek multiplex, olink) to assess the serum levels of ninety-two inflammation-related proteins in czech patients with sle (n\u00a0=\u00a075) and age-matched healthy control subjects (n\u00a0=\u00a023).", "we used proximity extension immunoassay (pea, proseek multiplex, olink) to assess the serum levels of ninety-two inflammation-related proteins in czech patients with sle (n\u00a0=\u00a075) and age-matched healthy control subjects (n\u00a0=\u00a023).", "we used proximity extension immunoassay (pea, proseek multiplex, olink) to assess the serum levels of ninety-two inflammation-related proteins in czech patients with sle (n\u00a0=\u00a075) and age-matched healthy control subjects (n\u00a0=\u00a023).", "we used proximity extension immunoassay (pea, proseek multiplex, olink) to assess the serum levels of ninety-two inflammation-related proteins in czech patients with sle (n\u00a0=\u00a075) and age-matched healthy control subjects (n\u00a0=\u00a023).", "we used proximity extension immunoassay (pea, proseek multiplex, olink) to assess the serum levels of ninety-two inflammation-related proteins in czech patients with sle (n\u00a0=\u00a075) and age-matched healthy control subjects (n\u00a0=\u00a023).", "we used proximity extension immunoassay (pea, proseek multiplex, olink) to assess the serum levels of ninety-two inflammation-related proteins in czech patients with sle (n\u00a0=\u00a075) and age-matched healthy control subjects (n\u00a0=\u00a023).", "we used proximity extension immunoassay (pea, proseek multiplex, olink) to assess the serum levels of ninety-two inflammation-related proteins in czech patients with sle (n\u00a0=\u00a075) and age-matched healthy control subjects (n\u00a0=\u00a023).", "we used proximity extension immunoassay (pea, proseek multiplex, olink) to assess the serum levels of ninety-two inflammation-related proteins in czech patients with sle (n\u00a0=\u00a075) and age-matched healthy control subjects (n\u00a0=\u00a023).", "we used proximity extension immunoassay (pea, proseek multiplex, olink) to assess the serum levels of ninety-two inflammation-related proteins in czech patients with sle (n\u00a0=\u00a075) and age-matched healthy control subjects (n\u00a0=\u00a023).", "we used proximity extension immunoassay (pea, proseek multiplex, olink) to assess the serum levels of ninety-two inflammation-related proteins in czech patients with sle (n\u00a0=\u00a075) and age-matched healthy control subjects (n\u00a0=\u00a023).", "we used proximity extension immunoassay (pea, proseek multiplex, olink) to assess the serum levels of ninety-two inflammation-related proteins in czech patients with sle (n\u00a0=\u00a075) and age-matched healthy control subjects (n\u00a0=\u00a023).", "we used proximity extension immunoassay (pea, proseek multiplex, olink) to assess the serum levels of ninety-two inflammation-related proteins in czech patients with sle (n\u00a0=\u00a075) and age-matched healthy control subjects (n\u00a0=\u00a023).", "we used proximity extension immunoassay (pea, proseek multiplex, olink) to assess the serum levels of ninety-two inflammation-related proteins in czech patients with sle (n\u00a0=\u00a075) and age-matched healthy control subjects (n\u00a0=\u00a023).", "we used proximity extension immunoassay (pea, proseek multiplex, olink) to assess the serum levels of ninety-two inflammation-related proteins in czech patients with sle (n\u00a0=\u00a075) and age-matched healthy control subjects (n\u00a0=\u00a023).", "we used proximity extension immunoassay (pea, proseek multiplex, olink) to assess the serum levels of ninety-two inflammation-related proteins in czech patients with sle (n\u00a0=\u00a075) and age-matched healthy control subjects (n\u00a0=\u00a023).", "using highly-sensitive proximity extension immunoassay on 92 cancer biomarkers (proseek", "using highly-sensitive proximity extension immunoassay on 92 cancer biomarkers (proseek", "using highly-sensitive proximity extension immunoassay on 92 cancer biomarkers (proseek", "using highly-sensitive proximity extension immunoassay on 92 cancer biomarkers (proseek", "using highly-sensitive proximity extension immunoassay on 92 cancer biomarkers (proseek", "using highly-sensitive proximity extension immunoassay on 92 cancer biomarkers (proseek", "using highly-sensitive proximity extension immunoassay on 92 cancer biomarkers (proseek", "using highly-sensitive proximity extension immunoassay on 92 cancer biomarkers (proseek", "using highly-sensitive proximity extension immunoassay on 92 cancer biomarkers (proseek", "using highly-sensitive proximity extension immunoassay on 92 cancer biomarkers (proseek", "using highly-sensitive proximity extension immunoassay on 92 cancer biomarkers (proseek", "using highly-sensitive proximity extension immunoassay on 92 cancer biomarkers (proseek", "using highly-sensitive proximity extension immunoassay on 92 cancer biomarkers (proseek", "using highly-sensitive proximity extension immunoassay on 92 cancer biomarkers (proseek", "using highly-sensitive proximity extension immunoassay on 92 cancer biomarkers (proseek", "using highly-sensitive proximity extension immunoassay on 92 cancer biomarkers (proseek", "biweekly intravenous (i.v.) administration of the ppmo restored the dystrophin expression in nearly 100% skeletal muscle fibers in all age groups. this was associated with the restoration of dystrophin-associated proteins including functional glycosylated dystroglycan and neuronal nitric synthase. however, therapeutic outcomes clearly depended on severity of the disease at the time the treatment started.", "biweekly intravenous (i.v.) administration of the ppmo restored the dystrophin expression in nearly 100% skeletal muscle fibers in all age groups. this was associated with the restoration of dystrophin-associated proteins including functional glycosylated dystroglycan and neuronal nitric synthase. however, therapeutic outcomes clearly depended on severity of the disease at the time the treatment started.", "biweekly intravenous (i.v.) administration of the ppmo restored the dystrophin expression in nearly 100% skeletal muscle fibers in all age groups. this was associated with the restoration of dystrophin-associated proteins including functional glycosylated dystroglycan and neuronal nitric synthase. however, therapeutic outcomes clearly depended on severity of the disease at the time the treatment started.", "biweekly intravenous (i.v.) administration of the ppmo restored the dystrophin expression in nearly 100% skeletal muscle fibers in all age groups. this was associated with the restoration of dystrophin-associated proteins including functional glycosylated dystroglycan and neuronal nitric synthase. however, therapeutic outcomes clearly depended on severity of the disease at the time the treatment started.", "biweekly intravenous (i.v.) administration of the ppmo restored the dystrophin expression in nearly 100% skeletal muscle fibers in all age groups. this was associated with the restoration of dystrophin-associated proteins including functional glycosylated dystroglycan and neuronal nitric synthase. however, therapeutic outcomes clearly depended on severity of the disease at the time the treatment started.", "biweekly intravenous (i.v.) administration of the ppmo restored the dystrophin expression in nearly 100% skeletal muscle fibers in all age groups. this was associated with the restoration of dystrophin-associated proteins including functional glycosylated dystroglycan and neuronal nitric synthase. however, therapeutic outcomes clearly depended on severity of the disease at the time the treatment started.", "biweekly intravenous (i.v.) administration of the ppmo restored the dystrophin expression in nearly 100% skeletal muscle fibers in all age groups. this was associated with the restoration of dystrophin-associated proteins including functional glycosylated dystroglycan and neuronal nitric synthase. however, therapeutic outcomes clearly depended on severity of the disease at the time the treatment started.", "biweekly intravenous (i.v.) administration of the ppmo restored the dystrophin expression in nearly 100% skeletal muscle fibers in all age groups. this was associated with the restoration of dystrophin-associated proteins including functional glycosylated dystroglycan and neuronal nitric synthase. however, therapeutic outcomes clearly depended on severity of the disease at the time the treatment started.", "biweekly intravenous (i.v.) administration of the ppmo restored the dystrophin expression in nearly 100% skeletal muscle fibers in all age groups. this was associated with the restoration of dystrophin-associated proteins including functional glycosylated dystroglycan and neuronal nitric synthase. however, therapeutic outcomes clearly depended on severity of the disease at the time the treatment started.", "biweekly intravenous (i.v.) administration of the ppmo restored the dystrophin expression in nearly 100% skeletal muscle fibers in all age groups. this was associated with the restoration of dystrophin-associated proteins including functional glycosylated dystroglycan and neuronal nitric synthase. however, therapeutic outcomes clearly depended on severity of the disease at the time the treatment started.", "biweekly intravenous (i.v.) administration of the ppmo restored the dystrophin expression in nearly 100% skeletal muscle fibers in all age groups. this was associated with the restoration of dystrophin-associated proteins including functional glycosylated dystroglycan and neuronal nitric synthase. however, therapeutic outcomes clearly depended on severity of the disease at the time the treatment started.", "biweekly intravenous (i.v.) administration of the ppmo restored the dystrophin expression in nearly 100% skeletal muscle fibers in all age groups. this was associated with the restoration of dystrophin-associated proteins including functional glycosylated dystroglycan and neuronal nitric synthase. however, therapeutic outcomes clearly depended on severity of the disease at the time the treatment started.", "biweekly intravenous (i.v.) administration of the ppmo restored the dystrophin expression in nearly 100% skeletal muscle fibers in all age groups. this was associated with the restoration of dystrophin-associated proteins including functional glycosylated dystroglycan and neuronal nitric synthase. however, therapeutic outcomes clearly depended on severity of the disease at the time the treatment started.", "biweekly intravenous (i.v.) administration of the ppmo restored the dystrophin expression in nearly 100% skeletal muscle fibers in all age groups. this was associated with the restoration of dystrophin-associated proteins including functional glycosylated dystroglycan and neuronal nitric synthase. however, therapeutic outcomes clearly depended on severity of the disease at the time the treatment started.", "biweekly intravenous (i.v.) administration of the ppmo restored the dystrophin expression in nearly 100% skeletal muscle fibers in all age groups. this was associated with the restoration of dystrophin-associated proteins including functional glycosylated dystroglycan and neuronal nitric synthase. however, therapeutic outcomes clearly depended on severity of the disease at the time the treatment started.", "biweekly intravenous (i.v.) administration of the ppmo restored the dystrophin expression in nearly 100% skeletal muscle fibers in all age groups. this was associated with the restoration of dystrophin-associated proteins including functional glycosylated dystroglycan and neuronal nitric synthase. however, therapeutic outcomes clearly depended on severity of the disease at the time the treatment started.", "biweekly intravenous (i.v.) administration of the ppmo restored the dystrophin expression in nearly 100% skeletal muscle fibers in all age groups. this was associated with the restoration of dystrophin-associated proteins including functional glycosylated dystroglycan and neuronal nitric synthase. however, therapeutic outcomes clearly depended on severity of the disease at the time the treatment started.", "biweekly intravenous (i.v.) administration of the ppmo restored the dystrophin expression in nearly 100% skeletal muscle fibers in all age groups. this was associated with the restoration of dystrophin-associated proteins including functional glycosylated dystroglycan and neuronal nitric synthase. however, therapeutic outcomes clearly depended on severity of the disease at the time the treatment started.", "biweekly intravenous (i.v.) administration of the ppmo restored the dystrophin expression in nearly 100% skeletal muscle fibers in all age groups. this was associated with the restoration of dystrophin-associated proteins including functional glycosylated dystroglycan and neuronal nitric synthase. however, therapeutic outcomes clearly depended on severity of the disease at the time the treatment started.", "biweekly intravenous (i.v.) administration of the ppmo restored the dystrophin expression in nearly 100% skeletal muscle fibers in all age groups. this was associated with the restoration of dystrophin-associated proteins including functional glycosylated dystroglycan and neuronal nitric synthase. however, therapeutic outcomes clearly depended on severity of the disease at the time the treatment started.", "biweekly intravenous (i.v.) administration of the ppmo restored the dystrophin expression in nearly 100% skeletal muscle fibers in all age groups. this was associated with the restoration of dystrophin-associated proteins including functional glycosylated dystroglycan and neuronal nitric synthase. however, therapeutic outcomes clearly depended on severity of the disease at the time the treatment started.", "biweekly intravenous (i.v.) administration of the ppmo restored the dystrophin expression in nearly 100% skeletal muscle fibers in all age groups. this was associated with the restoration of dystrophin-associated proteins including functional glycosylated dystroglycan and neuronal nitric synthase. however, therapeutic outcomes clearly depended on severity of the disease at the time the treatment started.", "biweekly intravenous (i.v.) administration of the ppmo restored the dystrophin expression in nearly 100% skeletal muscle fibers in all age groups. this was associated with the restoration of dystrophin-associated proteins including functional glycosylated dystroglycan and neuronal nitric synthase. however, therapeutic outcomes clearly depended on severity of the disease at the time the treatment started.", "biweekly intravenous (i.v.) administration of the ppmo restored the dystrophin expression in nearly 100% skeletal muscle fibers in all age groups. this was associated with the restoration of dystrophin-associated proteins including functional glycosylated dystroglycan and neuronal nitric synthase. however, therapeutic outcomes clearly depended on severity of the disease at the time the treatment started.", "biweekly intravenous (i.v.) administration of the ppmo restored the dystrophin expression in nearly 100% skeletal muscle fibers in all age groups. this was associated with the restoration of dystrophin-associated proteins including functional glycosylated dystroglycan and neuronal nitric synthase. however, therapeutic outcomes clearly depended on severity of the disease at the time the treatment started.", "biweekly intravenous (i.v.) administration of the ppmo restored the dystrophin expression in nearly 100% skeletal muscle fibers in all age groups. this was associated with the restoration of dystrophin-associated proteins including functional glycosylated dystroglycan and neuronal nitric synthase. however, therapeutic outcomes clearly depended on severity of the disease at the time the treatment started.", "biweekly intravenous (i.v.) administration of the ppmo restored the dystrophin expression in nearly 100% skeletal muscle fibers in all age groups. this was associated with the restoration of dystrophin-associated proteins including functional glycosylated dystroglycan and neuronal nitric synthase. however, therapeutic outcomes clearly depended on severity of the disease at the time the treatment started.", "biweekly intravenous (i.v.) administration of the ppmo restored the dystrophin expression in nearly 100% skeletal muscle fibers in all age groups. this was associated with the restoration of dystrophin-associated proteins including functional glycosylated dystroglycan and neuronal nitric synthase. however, therapeutic outcomes clearly depended on severity of the disease at the time the treatment started.", "biweekly intravenous (i.v.) administration of the ppmo restored the dystrophin expression in nearly 100% skeletal muscle fibers in all age groups. this was associated with the restoration of dystrophin-associated proteins including functional glycosylated dystroglycan and neuronal nitric synthase. however, therapeutic outcomes clearly depended on severity of the disease at the time the treatment started.", "biweekly intravenous (i.v.) administration of the ppmo restored the dystrophin expression in nearly 100% skeletal muscle fibers in all age groups. this was associated with the restoration of dystrophin-associated proteins including functional glycosylated dystroglycan and neuronal nitric synthase. however, therapeutic outcomes clearly depended on severity of the disease at the time the treatment started.", "biweekly intravenous (i.v.) administration of the ppmo restored the dystrophin expression in nearly 100% skeletal muscle fibers in all age groups. this was associated with the restoration of dystrophin-associated proteins including functional glycosylated dystroglycan and neuronal nitric synthase. however, therapeutic outcomes clearly depended on severity of the disease at the time the treatment started.", "biweekly intravenous (i.v.) administration of the ppmo restored the dystrophin expression in nearly 100% skeletal muscle fibers in all age groups. this was associated with the restoration of dystrophin-associated proteins including functional glycosylated dystroglycan and neuronal nitric synthase. however, therapeutic outcomes clearly depended on severity of the disease at the time the treatment started.", "biweekly intravenous (i.v.) administration of the ppmo restored the dystrophin expression in nearly 100% skeletal muscle fibers in all age groups. this was associated with the restoration of dystrophin-associated proteins including functional glycosylated dystroglycan and neuronal nitric synthase. however, therapeutic outcomes clearly depended on severity of the disease at the time the treatment started.", "biweekly intravenous (i.v.) administration of the ppmo restored the dystrophin expression in nearly 100% skeletal muscle fibers in all age groups. this was associated with the restoration of dystrophin-associated proteins including functional glycosylated dystroglycan and neuronal nitric synthase. however, therapeutic outcomes clearly depended on severity of the disease at the time the treatment started.", "biweekly intravenous (i.v.) administration of the ppmo restored the dystrophin expression in nearly 100% skeletal muscle fibers in all age groups. this was associated with the restoration of dystrophin-associated proteins including functional glycosylated dystroglycan and neuronal nitric synthase. however, therapeutic outcomes clearly depended on severity of the disease at the time the treatment started.", "biweekly intravenous (i.v.) administration of the ppmo restored the dystrophin expression in nearly 100% skeletal muscle fibers in all age groups. this was associated with the restoration of dystrophin-associated proteins including functional glycosylated dystroglycan and neuronal nitric synthase. however, therapeutic outcomes clearly depended on severity of the disease at the time the treatment started.", "biweekly intravenous (i.v.) administration of the ppmo restored the dystrophin expression in nearly 100% skeletal muscle fibers in all age groups. this was associated with the restoration of dystrophin-associated proteins including functional glycosylated dystroglycan and neuronal nitric synthase. however, therapeutic outcomes clearly depended on severity of the disease at the time the treatment started.", "biweekly intravenous (i.v.) administration of the ppmo restored the dystrophin expression in nearly 100% skeletal muscle fibers in all age groups. this was associated with the restoration of dystrophin-associated proteins including functional glycosylated dystroglycan and neuronal nitric synthase. however, therapeutic outcomes clearly depended on severity of the disease at the time the treatment started.", "by doing so, one is able to provide evidence for the presence of both active and degenerate centromeric satellite profiles on chromosome 2 in these archaic genomes, supporting the hypothesis that the chromosomal fusion event took place prior to our last common ancestor with denisovan and neandertal hominins and presenting a genomic reference for predicting karyotype in ancient genomic datasets.<br>", "by doing so, one is able to provide evidence for the presence of both active and degenerate centromeric satellite profiles on chromosome 2 in these archaic genomes, supporting the hypothesis that the chromosomal fusion event took place prior to our last common ancestor with denisovan and neandertal hominins and presenting a genomic reference for predicting karyotype in ancient genomic datasets.<br>", "by doing so, one is able to provide evidence for the presence of both active and degenerate centromeric satellite profiles on chromosome 2 in these archaic genomes, supporting the hypothesis that the chromosomal fusion event took place prior to our last common ancestor with denisovan and neandertal hominins and presenting a genomic reference for predicting karyotype in ancient genomic datasets.<br>", "by doing so, one is able to provide evidence for the presence of both active and degenerate centromeric satellite profiles on chromosome 2 in these archaic genomes, supporting the hypothesis that the chromosomal fusion event took place prior to our last common ancestor with denisovan and neandertal hominins and presenting a genomic reference for predicting karyotype in ancient genomic datasets.<br>", "by doing so, one is able to provide evidence for the presence of both active and degenerate centromeric satellite profiles on chromosome 2 in these archaic genomes, supporting the hypothesis that the chromosomal fusion event took place prior to our last common ancestor with denisovan and neandertal hominins and presenting a genomic reference for predicting karyotype in ancient genomic datasets.<br>", "by doing so, one is able to provide evidence for the presence of both active and degenerate centromeric satellite profiles on chromosome 2 in these archaic genomes, supporting the hypothesis that the chromosomal fusion event took place prior to our last common ancestor with denisovan and neandertal hominins and presenting a genomic reference for predicting karyotype in ancient genomic datasets.<br>", "by doing so, one is able to provide evidence for the presence of both active and degenerate centromeric satellite profiles on chromosome 2 in these archaic genomes, supporting the hypothesis that the chromosomal fusion event took place prior to our last common ancestor with denisovan and neandertal hominins and presenting a genomic reference for predicting karyotype in ancient genomic datasets.<br>", "by doing so, one is able to provide evidence for the presence of both active and degenerate centromeric satellite profiles on chromosome 2 in these archaic genomes, supporting the hypothesis that the chromosomal fusion event took place prior to our last common ancestor with denisovan and neandertal hominins and presenting a genomic reference for predicting karyotype in ancient genomic datasets.<br>", "by doing so, one is able to provide evidence for the presence of both active and degenerate centromeric satellite profiles on chromosome 2 in these archaic genomes, supporting the hypothesis that the chromosomal fusion event took place prior to our last common ancestor with denisovan and neandertal hominins and presenting a genomic reference for predicting karyotype in ancient genomic datasets.<br>", "by doing so, one is able to provide evidence for the presence of both active and degenerate centromeric satellite profiles on chromosome 2 in these archaic genomes, supporting the hypothesis that the chromosomal fusion event took place prior to our last common ancestor with denisovan and neandertal hominins and presenting a genomic reference for predicting karyotype in ancient genomic datasets.<br>", "by doing so, one is able to provide evidence for the presence of both active and degenerate centromeric satellite profiles on chromosome 2 in these archaic genomes, supporting the hypothesis that the chromosomal fusion event took place prior to our last common ancestor with denisovan and neandertal hominins and presenting a genomic reference for predicting karyotype in ancient genomic datasets.<br>", "by doing so, one is able to provide evidence for the presence of both active and degenerate centromeric satellite profiles on chromosome 2 in these archaic genomes, supporting the hypothesis that the chromosomal fusion event took place prior to our last common ancestor with denisovan and neandertal hominins and presenting a genomic reference for predicting karyotype in ancient genomic datasets.<br>", "by doing so, one is able to provide evidence for the presence of both active and degenerate centromeric satellite profiles on chromosome 2 in these archaic genomes, supporting the hypothesis that the chromosomal fusion event took place prior to our last common ancestor with denisovan and neandertal hominins and presenting a genomic reference for predicting karyotype in ancient genomic datasets.<br>", "we investigate the most recent product of a chromosome fusion event fixed in the human lineage, human chromosome 2, whose stability was acquired by the suppression of one centromere, resulting in a unique difference in chromosome number between humans (46 chromosomes) and our most closely related ape relatives (48 chromosomes).", "we investigate the most recent product of a chromosome fusion event fixed in the human lineage, human chromosome 2, whose stability was acquired by the suppression of one centromere, resulting in a unique difference in chromosome number between humans (46 chromosomes) and our most closely related ape relatives (48 chromosomes).", "we investigate the most recent product of a chromosome fusion event fixed in the human lineage, human chromosome 2, whose stability was acquired by the suppression of one centromere, resulting in a unique difference in chromosome number between humans (46 chromosomes) and our most closely related ape relatives (48 chromosomes).", "we investigate the most recent product of a chromosome fusion event fixed in the human lineage, human chromosome 2, whose stability was acquired by the suppression of one centromere, resulting in a unique difference in chromosome number between humans (46 chromosomes) and our most closely related ape relatives (48 chromosomes).", "we investigate the most recent product of a chromosome fusion event fixed in the human lineage, human chromosome 2, whose stability was acquired by the suppression of one centromere, resulting in a unique difference in chromosome number between humans (46 chromosomes) and our most closely related ape relatives (48 chromosomes).", "we investigate the most recent product of a chromosome fusion event fixed in the human lineage, human chromosome 2, whose stability was acquired by the suppression of one centromere, resulting in a unique difference in chromosome number between humans (46 chromosomes) and our most closely related ape relatives (48 chromosomes).", "we investigate the most recent product of a chromosome fusion event fixed in the human lineage, human chromosome 2, whose stability was acquired by the suppression of one centromere, resulting in a unique difference in chromosome number between humans (46 chromosomes) and our most closely related ape relatives (48 chromosomes).", "we investigate the most recent product of a chromosome fusion event fixed in the human lineage, human chromosome 2, whose stability was acquired by the suppression of one centromere, resulting in a unique difference in chromosome number between humans (46 chromosomes) and our most closely related ape relatives (48 chromosomes).", "we investigate the most recent product of a chromosome fusion event fixed in the human lineage, human chromosome 2, whose stability was acquired by the suppression of one centromere, resulting in a unique difference in chromosome number between humans (46 chromosomes) and our most closely related ape relatives (48 chromosomes).", "we investigate the most recent product of a chromosome fusion event fixed in the human lineage, human chromosome 2, whose stability was acquired by the suppression of one centromere, resulting in a unique difference in chromosome number between humans (46 chromosomes) and our most closely related ape relatives (48 chromosomes).", "we investigate the most recent product of a chromosome fusion event fixed in the human lineage, human chromosome 2, whose stability was acquired by the suppression of one centromere, resulting in a unique difference in chromosome number between humans (46 chromosomes) and our most closely related ape relatives (48 chromosomes).", "we investigate the most recent product of a chromosome fusion event fixed in the human lineage, human chromosome 2, whose stability was acquired by the suppression of one centromere, resulting in a unique difference in chromosome number between humans (46 chromosomes) and our most closely related ape relatives (48 chromosomes).", "we investigate the most recent product of a chromosome fusion event fixed in the human lineage, human chromosome 2, whose stability was acquired by the suppression of one centromere, resulting in a unique difference in chromosome number between humans (46 chromosomes) and our most closely related ape relatives (48 chromosomes).", "human chromosome 2 arose as a result of a telomeric fusion between acrocentric chromosomes, whereas chromosomes 4 and 19 in gorilla gorilla are the products of a reciprocal translocation between ancestral chromosomes, syntenic to human chromosomes 5 and 17, respectively.", "human chromosome 2 arose as a result of a telomeric fusion between acrocentric chromosomes, whereas chromosomes 4 and 19 in gorilla gorilla are the products of a reciprocal translocation between ancestral chromosomes, syntenic to human chromosomes 5 and 17, respectively.", "human chromosome 2 arose as a result of a telomeric fusion between acrocentric chromosomes, whereas chromosomes 4 and 19 in gorilla gorilla are the products of a reciprocal translocation between ancestral chromosomes, syntenic to human chromosomes 5 and 17, respectively.", "human chromosome 2 arose as a result of a telomeric fusion between acrocentric chromosomes, whereas chromosomes 4 and 19 in gorilla gorilla are the products of a reciprocal translocation between ancestral chromosomes, syntenic to human chromosomes 5 and 17, respectively.", "human chromosome 2 arose as a result of a telomeric fusion between acrocentric chromosomes, whereas chromosomes 4 and 19 in gorilla gorilla are the products of a reciprocal translocation between ancestral chromosomes, syntenic to human chromosomes 5 and 17, respectively.", "human chromosome 2 arose as a result of a telomeric fusion between acrocentric chromosomes, whereas chromosomes 4 and 19 in gorilla gorilla are the products of a reciprocal translocation between ancestral chromosomes, syntenic to human chromosomes 5 and 17, respectively.", "human chromosome 2 arose as a result of a telomeric fusion between acrocentric chromosomes, whereas chromosomes 4 and 19 in gorilla gorilla are the products of a reciprocal translocation between ancestral chromosomes, syntenic to human chromosomes 5 and 17, respectively.", "human chromosome 2 arose as a result of a telomeric fusion between acrocentric chromosomes, whereas chromosomes 4 and 19 in gorilla gorilla are the products of a reciprocal translocation between ancestral chromosomes, syntenic to human chromosomes 5 and 17, respectively.", "human chromosome 2 arose as a result of a telomeric fusion between acrocentric chromosomes, whereas chromosomes 4 and 19 in gorilla gorilla are the products of a reciprocal translocation between ancestral chromosomes, syntenic to human chromosomes 5 and 17, respectively.", "human chromosome 2 arose as a result of a telomeric fusion between acrocentric chromosomes, whereas chromosomes 4 and 19 in gorilla gorilla are the products of a reciprocal translocation between ancestral chromosomes, syntenic to human chromosomes 5 and 17, respectively.", "human chromosome 2 arose as a result of a telomeric fusion between acrocentric chromosomes, whereas chromosomes 4 and 19 in gorilla gorilla are the products of a reciprocal translocation between ancestral chromosomes, syntenic to human chromosomes 5 and 17, respectively.", "human chromosome 2 arose as a result of a telomeric fusion between acrocentric chromosomes, whereas chromosomes 4 and 19 in gorilla gorilla are the products of a reciprocal translocation between ancestral chromosomes, syntenic to human chromosomes 5 and 17, respectively.", "human chromosome 2 arose as a result of a telomeric fusion between acrocentric chromosomes, whereas chromosomes 4 and 19 in gorilla gorilla are the products of a reciprocal translocation between ancestral chromosomes, syntenic to human chromosomes 5 and 17, respectively.", "we propose a model where an ancestral human-chimpanzee pericentric inversion and the ancestral chromosome 2 fusion both predisposed and protected the chimpanzee and human genomes, respectively, to the formation of subtelomeric heterochromatin.", "we propose a model where an ancestral human-chimpanzee pericentric inversion and the ancestral chromosome 2 fusion both predisposed and protected the chimpanzee and human genomes, respectively, to the formation of subtelomeric heterochromatin.", "we propose a model where an ancestral human-chimpanzee pericentric inversion and the ancestral chromosome 2 fusion both predisposed and protected the chimpanzee and human genomes, respectively, to the formation of subtelomeric heterochromatin.", "we propose a model where an ancestral human-chimpanzee pericentric inversion and the ancestral chromosome 2 fusion both predisposed and protected the chimpanzee and human genomes, respectively, to the formation of subtelomeric heterochromatin.", "we propose a model where an ancestral human-chimpanzee pericentric inversion and the ancestral chromosome 2 fusion both predisposed and protected the chimpanzee and human genomes, respectively, to the formation of subtelomeric heterochromatin.", "we propose a model where an ancestral human-chimpanzee pericentric inversion and the ancestral chromosome 2 fusion both predisposed and protected the chimpanzee and human genomes, respectively, to the formation of subtelomeric heterochromatin.", "we propose a model where an ancestral human-chimpanzee pericentric inversion and the ancestral chromosome 2 fusion both predisposed and protected the chimpanzee and human genomes, respectively, to the formation of subtelomeric heterochromatin.", "we propose a model where an ancestral human-chimpanzee pericentric inversion and the ancestral chromosome 2 fusion both predisposed and protected the chimpanzee and human genomes, respectively, to the formation of subtelomeric heterochromatin.", "we propose a model where an ancestral human-chimpanzee pericentric inversion and the ancestral chromosome 2 fusion both predisposed and protected the chimpanzee and human genomes, respectively, to the formation of subtelomeric heterochromatin.", "we propose a model where an ancestral human-chimpanzee pericentric inversion and the ancestral chromosome 2 fusion both predisposed and protected the chimpanzee and human genomes, respectively, to the formation of subtelomeric heterochromatin.", "we propose a model where an ancestral human-chimpanzee pericentric inversion and the ancestral chromosome 2 fusion both predisposed and protected the chimpanzee and human genomes, respectively, to the formation of subtelomeric heterochromatin.", "we propose a model where an ancestral human-chimpanzee pericentric inversion and the ancestral chromosome 2 fusion both predisposed and protected the chimpanzee and human genomes, respectively, to the formation of subtelomeric heterochromatin.", "we propose a model where an ancestral human-chimpanzee pericentric inversion and the ancestral chromosome 2 fusion both predisposed and protected the chimpanzee and human genomes, respectively, to the formation of subtelomeric heterochromatin.", "we conclude that the locus cloned in cosmids c8.1 and c29b is the relic of an ancient telomere-telomere fusion and marks the point at which two ancestral ape chromosomes fused to give rise to human chromosome 2.", "we conclude that the locus cloned in cosmids c8.1 and c29b is the relic of an ancient telomere-telomere fusion and marks the point at which two ancestral ape chromosomes fused to give rise to human chromosome 2.", "we conclude that the locus cloned in cosmids c8.1 and c29b is the relic of an ancient telomere-telomere fusion and marks the point at which two ancestral ape chromosomes fused to give rise to human chromosome 2.", "we conclude that the locus cloned in cosmids c8.1 and c29b is the relic of an ancient telomere-telomere fusion and marks the point at which two ancestral ape chromosomes fused to give rise to human chromosome 2.", "we conclude that the locus cloned in cosmids c8.1 and c29b is the relic of an ancient telomere-telomere fusion and marks the point at which two ancestral ape chromosomes fused to give rise to human chromosome 2.", "we conclude that the locus cloned in cosmids c8.1 and c29b is the relic of an ancient telomere-telomere fusion and marks the point at which two ancestral ape chromosomes fused to give rise to human chromosome 2.", "we conclude that the locus cloned in cosmids c8.1 and c29b is the relic of an ancient telomere-telomere fusion and marks the point at which two ancestral ape chromosomes fused to give rise to human chromosome 2.", "we conclude that the locus cloned in cosmids c8.1 and c29b is the relic of an ancient telomere-telomere fusion and marks the point at which two ancestral ape chromosomes fused to give rise to human chromosome 2.", "we conclude that the locus cloned in cosmids c8.1 and c29b is the relic of an ancient telomere-telomere fusion and marks the point at which two ancestral ape chromosomes fused to give rise to human chromosome 2.", "we conclude that the locus cloned in cosmids c8.1 and c29b is the relic of an ancient telomere-telomere fusion and marks the point at which two ancestral ape chromosomes fused to give rise to human chromosome 2.", "we conclude that the locus cloned in cosmids c8.1 and c29b is the relic of an ancient telomere-telomere fusion and marks the point at which two ancestral ape chromosomes fused to give rise to human chromosome 2.", "we conclude that the locus cloned in cosmids c8.1 and c29b is the relic of an ancient telomere-telomere fusion and marks the point at which two ancestral ape chromosomes fused to give rise to human chromosome 2.", "we conclude that the locus cloned in cosmids c8.1 and c29b is the relic of an ancient telomere-telomere fusion and marks the point at which two ancestral ape chromosomes fused to give rise to human chromosome 2.", "our results suggest two possible centromere inactivation models to explain the evolutionarily stabilization of human chromosome 2 over the last 5-6 million years.", "our results suggest two possible centromere inactivation models to explain the evolutionarily stabilization of human chromosome 2 over the last 5-6 million years.", "our results suggest two possible centromere inactivation models to explain the evolutionarily stabilization of human chromosome 2 over the last 5-6 million years.", "our results suggest two possible centromere inactivation models to explain the evolutionarily stabilization of human chromosome 2 over the last 5-6 million years.", "our results suggest two possible centromere inactivation models to explain the evolutionarily stabilization of human chromosome 2 over the last 5-6 million years.", "our results suggest two possible centromere inactivation models to explain the evolutionarily stabilization of human chromosome 2 over the last 5-6 million years.", "our results suggest two possible centromere inactivation models to explain the evolutionarily stabilization of human chromosome 2 over the last 5-6 million years.", "our results suggest two possible centromere inactivation models to explain the evolutionarily stabilization of human chromosome 2 over the last 5-6 million years.", "our results suggest two possible centromere inactivation models to explain the evolutionarily stabilization of human chromosome 2 over the last 5-6 million years.", "our results suggest two possible centromere inactivation models to explain the evolutionarily stabilization of human chromosome 2 over the last 5-6 million years.", "our results suggest two possible centromere inactivation models to explain the evolutionarily stabilization of human chromosome 2 over the last 5-6 million years.", "our results suggest two possible centromere inactivation models to explain the evolutionarily stabilization of human chromosome 2 over the last 5-6 million years.", "our results suggest two possible centromere inactivation models to explain the evolutionarily stabilization of human chromosome 2 over the last 5-6 million years.", "human chromosome 2 is unique to the human lineage in being the product of a head-to-head fusion of two intermediate-sized ancestral chromosomes.", "human chromosome 2 is unique to the human lineage in being the product of a head-to-head fusion of two intermediate-sized ancestral chromosomes.", "human chromosome 2 is unique to the human lineage in being the product of a head-to-head fusion of two intermediate-sized ancestral chromosomes.", "human chromosome 2 is unique to the human lineage in being the product of a head-to-head fusion of two intermediate-sized ancestral chromosomes.", "human chromosome 2 is unique to the human lineage in being the product of a head-to-head fusion of two intermediate-sized ancestral chromosomes.", "human chromosome 2 is unique to the human lineage in being the product of a head-to-head fusion of two intermediate-sized ancestral chromosomes.", "human chromosome 2 is unique to the human lineage in being the product of a head-to-head fusion of two intermediate-sized ancestral chromosomes.", "human chromosome 2 is unique to the human lineage in being the product of a head-to-head fusion of two intermediate-sized ancestral chromosomes.", "human chromosome 2 is unique to the human lineage in being the product of a head-to-head fusion of two intermediate-sized ancestral chromosomes.", "human chromosome 2 is unique to the human lineage in being the product of a head-to-head fusion of two intermediate-sized ancestral chromosomes.", "human chromosome 2 is unique to the human lineage in being the product of a head-to-head fusion of two intermediate-sized ancestral chromosomes.", "human chromosome 2 is unique to the human lineage in being the product of a head-to-head fusion of two intermediate-sized ancestral chromosomes.", "human chromosome 2 is unique to the human lineage in being the product of a head-to-head fusion of two intermediate-sized ancestral chromosomes.", "human chromosome 2 is a product of a telomere fusion of two ancestral chromosomes and loss/degeneration of one of the two original centromeres.", "human chromosome 2 is a product of a telomere fusion of two ancestral chromosomes and loss/degeneration of one of the two original centromeres.", "human chromosome 2 is a product of a telomere fusion of two ancestral chromosomes and loss/degeneration of one of the two original centromeres.", "human chromosome 2 is a product of a telomere fusion of two ancestral chromosomes and loss/degeneration of one of the two original centromeres.", "human chromosome 2 is a product of a telomere fusion of two ancestral chromosomes and loss/degeneration of one of the two original centromeres.", "human chromosome 2 is a product of a telomere fusion of two ancestral chromosomes and loss/degeneration of one of the two original centromeres.", "human chromosome 2 is a product of a telomere fusion of two ancestral chromosomes and loss/degeneration of one of the two original centromeres.", "human chromosome 2 is a product of a telomere fusion of two ancestral chromosomes and loss/degeneration of one of the two original centromeres.", "human chromosome 2 is a product of a telomere fusion of two ancestral chromosomes and loss/degeneration of one of the two original centromeres.", "human chromosome 2 is a product of a telomere fusion of two ancestral chromosomes and loss/degeneration of one of the two original centromeres.", "human chromosome 2 is a product of a telomere fusion of two ancestral chromosomes and loss/degeneration of one of the two original centromeres.", "human chromosome 2 is a product of a telomere fusion of two ancestral chromosomes and loss/degeneration of one of the two original centromeres.", "human chromosome 2 is a product of a telomere fusion of two ancestral chromosomes and loss/degeneration of one of the two original centromeres.", "centromere destiny in dicentric chromosomes: new insights from the evolution of human chromosome 2 ancestral centromeric region.", "centromere destiny in dicentric chromosomes: new insights from the evolution of human chromosome 2 ancestral centromeric region.", "centromere destiny in dicentric chromosomes: new insights from the evolution of human chromosome 2 ancestral centromeric region.", "centromere destiny in dicentric chromosomes: new insights from the evolution of human chromosome 2 ancestral centromeric region.", "centromere destiny in dicentric chromosomes: new insights from the evolution of human chromosome 2 ancestral centromeric region.", "centromere destiny in dicentric chromosomes: new insights from the evolution of human chromosome 2 ancestral centromeric region.", "centromere destiny in dicentric chromosomes: new insights from the evolution of human chromosome 2 ancestral centromeric region.", "centromere destiny in dicentric chromosomes: new insights from the evolution of human chromosome 2 ancestral centromeric region.", "centromere destiny in dicentric chromosomes: new insights from the evolution of human chromosome 2 ancestral centromeric region.", "centromere destiny in dicentric chromosomes: new insights from the evolution of human chromosome 2 ancestral centromeric region.", "centromere destiny in dicentric chromosomes: new insights from the evolution of human chromosome 2 ancestral centromeric region.", "centromere destiny in dicentric chromosomes: new insights from the evolution of human chromosome 2 ancestral centromeric region.", "centromere destiny in dicentric chromosomes: new insights from the evolution of human chromosome 2 ancestral centromeric region.", "the evolution of african great ape subtelomeric heterochromatin and the fusion of human chromosome 2.", "the evolution of african great ape subtelomeric heterochromatin and the fusion of human chromosome 2.", "the evolution of african great ape subtelomeric heterochromatin and the fusion of human chromosome 2.", "the evolution of african great ape subtelomeric heterochromatin and the fusion of human chromosome 2.", "the evolution of african great ape subtelomeric heterochromatin and the fusion of human chromosome 2.", "the evolution of african great ape subtelomeric heterochromatin and the fusion of human chromosome 2.", "the evolution of african great ape subtelomeric heterochromatin and the fusion of human chromosome 2.", "the evolution of african great ape subtelomeric heterochromatin and the fusion of human chromosome 2.", "the evolution of african great ape subtelomeric heterochromatin and the fusion of human chromosome 2.", "the evolution of african great ape subtelomeric heterochromatin and the fusion of human chromosome 2.", "the evolution of african great ape subtelomeric heterochromatin and the fusion of human chromosome 2.", "the evolution of african great ape subtelomeric heterochromatin and the fusion of human chromosome 2.", "the evolution of african great ape subtelomeric heterochromatin and the fusion of human chromosome 2.", "it is known that human chromosome 2 originated from the fusion of two ancestral primate chromosomes.", "it is known that human chromosome 2 originated from the fusion of two ancestral primate chromosomes.", "it is known that human chromosome 2 originated from the fusion of two ancestral primate chromosomes.", "it is known that human chromosome 2 originated from the fusion of two ancestral primate chromosomes.", "it is known that human chromosome 2 originated from the fusion of two ancestral primate chromosomes.", "it is known that human chromosome 2 originated from the fusion of two ancestral primate chromosomes.", "it is known that human chromosome 2 originated from the fusion of two ancestral primate chromosomes.", "it is known that human chromosome 2 originated from the fusion of two ancestral primate chromosomes.", "it is known that human chromosome 2 originated from the fusion of two ancestral primate chromosomes.", "it is known that human chromosome 2 originated from the fusion of two ancestral primate chromosomes.", "it is known that human chromosome 2 originated from the fusion of two ancestral primate chromosomes.", "it is known that human chromosome 2 originated from the fusion of two ancestral primate chromosomes.", "it is known that human chromosome 2 originated from the fusion of two ancestral primate chromosomes.", "origin of human chromosome 2: an ancestral telomere-telomere fusion.", "origin of human chromosome 2: an ancestral telomere-telomere fusion.", "origin of human chromosome 2: an ancestral telomere-telomere fusion.", "origin of human chromosome 2: an ancestral telomere-telomere fusion.", "origin of human chromosome 2: an ancestral telomere-telomere fusion.", "origin of human chromosome 2: an ancestral telomere-telomere fusion.", "origin of human chromosome 2: an ancestral telomere-telomere fusion.", "origin of human chromosome 2: an ancestral telomere-telomere fusion.", "origin of human chromosome 2: an ancestral telomere-telomere fusion.", "origin of human chromosome 2: an ancestral telomere-telomere fusion.", "origin of human chromosome 2: an ancestral telomere-telomere fusion.", "origin of human chromosome 2: an ancestral telomere-telomere fusion.", "origin of human chromosome 2: an ancestral telomere-telomere fusion.", "approximately 2-4% of genetic material in human populations outside africa is derived from neanderthals who interbred with anatomically modern humans.", "approximately 2-4% of genetic material in human populations outside africa is derived from neanderthals who interbred with anatomically modern humans.", "approximately 2-4% of genetic material in human populations outside africa is derived from neanderthals who interbred with anatomically modern humans.", "approximately 2-4% of genetic material in human populations outside africa is derived from neanderthals who interbred with anatomically modern humans.", "approximately 2-4% of genetic material in human populations outside africa is derived from neanderthals who interbred with anatomically modern humans.", "approximately 2-4% of genetic material in human populations outside africa is derived from neanderthals who interbred with anatomically modern humans.", "approximately 2-4% of genetic material in human populations outside africa is derived from neanderthals who interbred with anatomically modern humans.", "approximately 2-4% of genetic material in human populations outside africa is derived from neanderthals who interbred with anatomically modern humans.", "approximately 2-4% of genetic material in human populations outside africa is derived from neanderthals who interbred with anatomically modern humans.", "approximately 2-4% of genetic material in human populations outside africa is derived from neanderthals who interbred with anatomically modern humans.", "approximately 2-4% of genetic material in human populations outside africa is derived from neanderthals who interbred with anatomically modern humans.", "approximately 2-4% of genetic material in human populations outside africa is derived from neanderthals who interbred with anatomically modern humans.", "approximately 2-4% of genetic material in human populations outside africa is derived from neanderthals who interbred with anatomically modern humans.", "approximately 2-4% of genetic material in human populations outside africa is derived from neanderthals who interbred with anatomically modern humans.", "approximately 2-4% of genetic material in human populations outside africa is derived from neanderthals who interbred with anatomically modern humans.", "our data further reveal that recently evolved enhancers can be associated with genes under positive selection, demonstrating the power of this approach for annotating regulatory adaptations in genomic sequences.", "our data further reveal that recently evolved enhancers can be associated with genes under positive selection, demonstrating the power of this approach for annotating regulatory adaptations in genomic sequences.", "our data further reveal that recently evolved enhancers can be associated with genes under positive selection, demonstrating the power of this approach for annotating regulatory adaptations in genomic sequences.", "our data further reveal that recently evolved enhancers can be associated with genes under positive selection, demonstrating the power of this approach for annotating regulatory adaptations in genomic sequences.", "our data further reveal that recently evolved enhancers can be associated with genes under positive selection, demonstrating the power of this approach for annotating regulatory adaptations in genomic sequences.", "our data further reveal that recently evolved enhancers can be associated with genes under positive selection, demonstrating the power of this approach for annotating regulatory adaptations in genomic sequences.", "our data further reveal that recently evolved enhancers can be associated with genes under positive selection, demonstrating the power of this approach for annotating regulatory adaptations in genomic sequences.", "our data further reveal that recently evolved enhancers can be associated with genes under positive selection, demonstrating the power of this approach for annotating regulatory adaptations in genomic sequences.", "our data further reveal that recently evolved enhancers can be associated with genes under positive selection, demonstrating the power of this approach for annotating regulatory adaptations in genomic sequences.", "our data further reveal that recently evolved enhancers can be associated with genes under positive selection, demonstrating the power of this approach for annotating regulatory adaptations in genomic sequences.", "our data further reveal that recently evolved enhancers can be associated with genes under positive selection, demonstrating the power of this approach for annotating regulatory adaptations in genomic sequences.", "our data further reveal that recently evolved enhancers can be associated with genes under positive selection, demonstrating the power of this approach for annotating regulatory adaptations in genomic sequences.", "our data further reveal that recently evolved enhancers can be associated with genes under positive selection, demonstrating the power of this approach for annotating regulatory adaptations in genomic sequences.", "our data further reveal that recently evolved enhancers can be associated with genes under positive selection, demonstrating the power of this approach for annotating regulatory adaptations in genomic sequences.", "our data further reveal that recently evolved enhancers can be associated with genes under positive selection, demonstrating the power of this approach for annotating regulatory adaptations in genomic sequences.", "our data further reveal that recently evolved enhancers can be associated with genes under positive selection, demonstrating the power of this approach for annotating regulatory adaptations in genomic sequences.", "our data further reveal that recently evolved enhancers can be associated with genes under positive selection, demonstrating the power of this approach for annotating regulatory adaptations in genomic sequences.", "our data further reveal that recently evolved enhancers can be associated with genes under positive selection, demonstrating the power of this approach for annotating regulatory adaptations in genomic sequences.", "our data further reveal that recently evolved enhancers can be associated with genes under positive selection, demonstrating the power of this approach for annotating regulatory adaptations in genomic sequences.", "our data further reveal that recently evolved enhancers can be associated with genes under positive selection, demonstrating the power of this approach for annotating regulatory adaptations in genomic sequences.", "our data further reveal that recently evolved enhancers can be associated with genes under positive selection, demonstrating the power of this approach for annotating regulatory adaptations in genomic sequences.", "our data further reveal that recently evolved enhancers can be associated with genes under positive selection, demonstrating the power of this approach for annotating regulatory adaptations in genomic sequences.", "our data further reveal that recently evolved enhancers can be associated with genes under positive selection, demonstrating the power of this approach for annotating regulatory adaptations in genomic sequences.", "our data further reveal that recently evolved enhancers can be associated with genes under positive selection, demonstrating the power of this approach for annotating regulatory adaptations in genomic sequences.", "we summarize recent case studies and genome-wide investigations that have uncovered diverse mechanisms though which new enhancers arise", "we summarize recent case studies and genome-wide investigations that have uncovered diverse mechanisms though which new enhancers arise", "we summarize recent case studies and genome-wide investigations that have uncovered diverse mechanisms though which new enhancers arise", "we summarize recent case studies and genome-wide investigations that have uncovered diverse mechanisms though which new enhancers arise", "we summarize recent case studies and genome-wide investigations that have uncovered diverse mechanisms though which new enhancers arise", "we summarize recent case studies and genome-wide investigations that have uncovered diverse mechanisms though which new enhancers arise", "we summarize recent case studies and genome-wide investigations that have uncovered diverse mechanisms though which new enhancers arise", "we summarize recent case studies and genome-wide investigations that have uncovered diverse mechanisms though which new enhancers arise", "we summarize recent case studies and genome-wide investigations that have uncovered diverse mechanisms though which new enhancers arise", "we summarize recent case studies and genome-wide investigations that have uncovered diverse mechanisms though which new enhancers arise", "we summarize recent case studies and genome-wide investigations that have uncovered diverse mechanisms though which new enhancers arise", "we summarize recent case studies and genome-wide investigations that have uncovered diverse mechanisms though which new enhancers arise", "we summarize recent case studies and genome-wide investigations that have uncovered diverse mechanisms though which new enhancers arise", "we summarize recent case studies and genome-wide investigations that have uncovered diverse mechanisms though which new enhancers arise", "we summarize recent case studies and genome-wide investigations that have uncovered diverse mechanisms though which new enhancers arise", "we summarize recent case studies and genome-wide investigations that have uncovered diverse mechanisms though which new enhancers arise", "we summarize recent case studies and genome-wide investigations that have uncovered diverse mechanisms though which new enhancers arise", "we summarize recent case studies and genome-wide investigations that have uncovered diverse mechanisms though which new enhancers arise", "we summarize recent case studies and genome-wide investigations that have uncovered diverse mechanisms though which new enhancers arise", "we summarize recent case studies and genome-wide investigations that have uncovered diverse mechanisms though which new enhancers arise", "we summarize recent case studies and genome-wide investigations that have uncovered diverse mechanisms though which new enhancers arise", "we summarize recent case studies and genome-wide investigations that have uncovered diverse mechanisms though which new enhancers arise", "we summarize recent case studies and genome-wide investigations that have uncovered diverse mechanisms though which new enhancers arise", "we summarize recent case studies and genome-wide investigations that have uncovered diverse mechanisms though which new enhancers arise", "recent comparative studies have begun to investigate the evolution of the sequence architecture within enhancers.", "recent comparative studies have begun to investigate the evolution of the sequence architecture within enhancers.", "recent comparative studies have begun to investigate the evolution of the sequence architecture within enhancers.", "recent comparative studies have begun to investigate the evolution of the sequence architecture within enhancers.", "recent comparative studies have begun to investigate the evolution of the sequence architecture within enhancers.", "recent comparative studies have begun to investigate the evolution of the sequence architecture within enhancers.", "recent comparative studies have begun to investigate the evolution of the sequence architecture within enhancers.", "recent comparative studies have begun to investigate the evolution of the sequence architecture within enhancers.", "recent comparative studies have begun to investigate the evolution of the sequence architecture within enhancers.", "recent comparative studies have begun to investigate the evolution of the sequence architecture within enhancers.", "recent comparative studies have begun to investigate the evolution of the sequence architecture within enhancers.", "recent comparative studies have begun to investigate the evolution of the sequence architecture within enhancers.", "recent comparative studies have begun to investigate the evolution of the sequence architecture within enhancers.", "recent comparative studies have begun to investigate the evolution of the sequence architecture within enhancers.", "recent comparative studies have begun to investigate the evolution of the sequence architecture within enhancers.", "recent comparative studies have begun to investigate the evolution of the sequence architecture within enhancers.", "recent comparative studies have begun to investigate the evolution of the sequence architecture within enhancers.", "recent comparative studies have begun to investigate the evolution of the sequence architecture within enhancers.", "recent comparative studies have begun to investigate the evolution of the sequence architecture within enhancers.", "recent comparative studies have begun to investigate the evolution of the sequence architecture within enhancers.", "recent comparative studies have begun to investigate the evolution of the sequence architecture within enhancers.", "recent comparative studies have begun to investigate the evolution of the sequence architecture within enhancers.", "recent comparative studies have begun to investigate the evolution of the sequence architecture within enhancers.", "recent comparative studies have begun to investigate the evolution of the sequence architecture within enhancers.", "we report that rapid evolution of enhancers is a universal feature of mammalian genomes.", "we report that rapid evolution of enhancers is a universal feature of mammalian genomes.", "we report that rapid evolution of enhancers is a universal feature of mammalian genomes.", "we report that rapid evolution of enhancers is a universal feature of mammalian genomes.", "we report that rapid evolution of enhancers is a universal feature of mammalian genomes.", "we report that rapid evolution of enhancers is a universal feature of mammalian genomes.", "we report that rapid evolution of enhancers is a universal feature of mammalian genomes.", "we report that rapid evolution of enhancers is a universal feature of mammalian genomes.", "we report that rapid evolution of enhancers is a universal feature of mammalian genomes.", "we report that rapid evolution of enhancers is a universal feature of mammalian genomes.", "we report that rapid evolution of enhancers is a universal feature of mammalian genomes.", "we report that rapid evolution of enhancers is a universal feature of mammalian genomes.", "we report that rapid evolution of enhancers is a universal feature of mammalian genomes.", "we report that rapid evolution of enhancers is a universal feature of mammalian genomes.", "we report that rapid evolution of enhancers is a universal feature of mammalian genomes.", "we report that rapid evolution of enhancers is a universal feature of mammalian genomes.", "we report that rapid evolution of enhancers is a universal feature of mammalian genomes.", "we report that rapid evolution of enhancers is a universal feature of mammalian genomes.", "we report that rapid evolution of enhancers is a universal feature of mammalian genomes.", "we report that rapid evolution of enhancers is a universal feature of mammalian genomes.", "we report that rapid evolution of enhancers is a universal feature of mammalian genomes.", "we report that rapid evolution of enhancers is a universal feature of mammalian genomes.", "we report that rapid evolution of enhancers is a universal feature of mammalian genomes.", "we report that rapid evolution of enhancers is a universal feature of mammalian genomes.", "to study the impact of genetic and lifestyle factors on protein biomarkers and develop personally normalized plasma protein profiles (pnppp) controlling for non-disease-related variance.", "to study the impact of genetic and lifestyle factors on protein biomarkers and develop personally normalized plasma protein profiles (pnppp) controlling for non-disease-related variance.", "to study the impact of genetic and lifestyle factors on protein biomarkers and develop personally normalized plasma protein profiles (pnppp) controlling for non-disease-related variance.", "to study the impact of genetic and lifestyle factors on protein biomarkers and develop personally normalized plasma protein profiles (pnppp) controlling for non-disease-related variance.", "to study the impact of genetic and lifestyle factors on protein biomarkers and develop personally normalized plasma protein profiles (pnppp) controlling for non-disease-related variance."], "id": ["58edf567eda5a57672000011_0", "58edf567eda5a57672000011_0", "58edf567eda5a57672000011_0", "58edf567eda5a57672000011_0", "58edf567eda5a57672000011_0", "58edf567eda5a57672000011_0", "58edf567eda5a57672000011_0", "58edf567eda5a57672000011_0", "58edf567eda5a57672000011_0", "58edf567eda5a57672000011_0", "58edf567eda5a57672000011_0", "58edf567eda5a57672000011_0", "58edf567eda5a57672000011_0", "58edf567eda5a57672000011_0", "58edf567eda5a57672000011_0", "58edf567eda5a57672000011_0", "58edf567eda5a57672000011_0", "58edf567eda5a57672000011_0", "58edf567eda5a57672000011_0", "58edf567eda5a57672000011_0", "58edf567eda5a57672000011_0", "58edf567eda5a57672000011_0", "58edf567eda5a57672000011_0", "58edf567eda5a57672000011_0", "58edf567eda5a57672000011_0", "58edf567eda5a57672000011_0", "58edf567eda5a57672000011_0", "58edf567eda5a57672000011_0", "58edf567eda5a57672000011_0", "58edf567eda5a57672000011_0", "58edf567eda5a57672000011_0", "58edf567eda5a57672000011_0", "58edf567eda5a57672000011_0", "58edf567eda5a57672000011_0", "58edf567eda5a57672000011_0", "58edf567eda5a57672000011_0", "58edf567eda5a57672000011_0", "58edf567eda5a57672000011_0", "58edf567eda5a57672000011_0", "58edf567eda5a57672000011_0", "58edf567eda5a57672000011_0", "58edf567eda5a57672000011_0", "58edf567eda5a57672000011_0", "58edf567eda5a57672000011_0", "58edf567eda5a57672000011_0", "58edf567eda5a57672000011_0", "58edf567eda5a57672000011_0", "58edf567eda5a57672000011_0", "58edf567eda5a57672000011_0", "58edf567eda5a57672000011_1", "58edf567eda5a57672000011_1", "58edf567eda5a57672000011_1", "58edf567eda5a57672000011_1", "58edf567eda5a57672000011_1", "58edf567eda5a57672000011_1", "58edf567eda5a57672000011_1", "58edf567eda5a57672000011_1", "58edf567eda5a57672000011_1", "58edf567eda5a57672000011_1", "58edf567eda5a57672000011_1", "58edf567eda5a57672000011_1", "58edf567eda5a57672000011_1", "58edf567eda5a57672000011_1", "58edf567eda5a57672000011_1", "58edf567eda5a57672000011_1", "58edf567eda5a57672000011_1", "58edf567eda5a57672000011_1", "58edf567eda5a57672000011_1", "58edf567eda5a57672000011_1", "58edf567eda5a57672000011_1", "58edf567eda5a57672000011_1", "58edf567eda5a57672000011_1", "58edf567eda5a57672000011_1", "58edf567eda5a57672000011_1", "58edf567eda5a57672000011_1", "58edf567eda5a57672000011_1", "58edf567eda5a57672000011_1", "58edf567eda5a57672000011_1", "58edf567eda5a57672000011_1", "58edf567eda5a57672000011_1", "58edf567eda5a57672000011_1", "58edf567eda5a57672000011_1", "58edf567eda5a57672000011_1", "58edf567eda5a57672000011_1", "58edf567eda5a57672000011_1", "58edf567eda5a57672000011_1", "58edf567eda5a57672000011_1", "58edf567eda5a57672000011_1", "58edf567eda5a57672000011_1", "58edf567eda5a57672000011_1", "58edf567eda5a57672000011_1", "58edf567eda5a57672000011_1", "58edf567eda5a57672000011_1", "58edf567eda5a57672000011_1", "58edf567eda5a57672000011_1", "58edf567eda5a57672000011_1", "58edf567eda5a57672000011_1", "58edf567eda5a57672000011_1", "58edf567eda5a57672000011_2", "58edf567eda5a57672000011_2", "58edf567eda5a57672000011_2", "58edf567eda5a57672000011_2", "58edf567eda5a57672000011_2", "58edf567eda5a57672000011_2", "58edf567eda5a57672000011_2", "58edf567eda5a57672000011_2", "58edf567eda5a57672000011_2", "58edf567eda5a57672000011_2", "58edf567eda5a57672000011_2", "58edf567eda5a57672000011_2", "58edf567eda5a57672000011_2", "58edf567eda5a57672000011_2", "58edf567eda5a57672000011_2", "58edf567eda5a57672000011_2", "58edf567eda5a57672000011_2", "58edf567eda5a57672000011_2", "58edf567eda5a57672000011_2", "58edf567eda5a57672000011_2", "58edf567eda5a57672000011_2", "58edf567eda5a57672000011_2", "58edf567eda5a57672000011_2", "58edf567eda5a57672000011_2", "58edf567eda5a57672000011_2", "58edf567eda5a57672000011_2", "58edf567eda5a57672000011_2", "58edf567eda5a57672000011_2", "58edf567eda5a57672000011_2", "58edf567eda5a57672000011_2", "58edf567eda5a57672000011_2", "58edf567eda5a57672000011_2", "58edf567eda5a57672000011_2", "58edf567eda5a57672000011_2", "58edf567eda5a57672000011_2", "58edf567eda5a57672000011_2", "58edf567eda5a57672000011_2", "58edf567eda5a57672000011_2", "58edf567eda5a57672000011_2", "58edf567eda5a57672000011_2", "58edf567eda5a57672000011_2", "58edf567eda5a57672000011_2", "58edf567eda5a57672000011_2", "58edf567eda5a57672000011_2", "58edf567eda5a57672000011_2", "58edf567eda5a57672000011_2", "58edf567eda5a57672000011_2", "58edf567eda5a57672000011_2", "58edf567eda5a57672000011_2", "58edf567eda5a57672000011_3", "58edf567eda5a57672000011_3", "58edf567eda5a57672000011_3", "58edf567eda5a57672000011_3", "58edf567eda5a57672000011_3", "58edf567eda5a57672000011_3", "58edf567eda5a57672000011_3", "58edf567eda5a57672000011_3", "58edf567eda5a57672000011_3", "58edf567eda5a57672000011_3", "58edf567eda5a57672000011_3", "58edf567eda5a57672000011_3", "58edf567eda5a57672000011_3", "58edf567eda5a57672000011_3", "58edf567eda5a57672000011_3", "58edf567eda5a57672000011_3", "58edf567eda5a57672000011_3", "58edf567eda5a57672000011_3", "58edf567eda5a57672000011_3", "58edf567eda5a57672000011_3", "58edf567eda5a57672000011_3", "58edf567eda5a57672000011_3", "58edf567eda5a57672000011_3", "58edf567eda5a57672000011_3", "58edf567eda5a57672000011_3", "58edf567eda5a57672000011_3", "58edf567eda5a57672000011_3", "58edf567eda5a57672000011_3", "58edf567eda5a57672000011_3", "58edf567eda5a57672000011_3", "58edf567eda5a57672000011_3", "58edf567eda5a57672000011_3", "58edf567eda5a57672000011_3", "58edf567eda5a57672000011_3", "58edf567eda5a57672000011_3", "58edf567eda5a57672000011_3", "58edf567eda5a57672000011_3", "58edf567eda5a57672000011_3", "58edf567eda5a57672000011_3", "58edf567eda5a57672000011_3", "58edf567eda5a57672000011_3", "58edf567eda5a57672000011_3", "58edf567eda5a57672000011_3", "58edf567eda5a57672000011_3", "58edf567eda5a57672000011_3", "58edf567eda5a57672000011_3", "58edf567eda5a57672000011_3", "58edf567eda5a57672000011_3", "58edf567eda5a57672000011_3", "5a67b2f7b750ff445500000f_4", "5a67b2f7b750ff445500000f_4", "5a67b2f7b750ff445500000f_4", "5a67b2f7b750ff445500000f_4", "5a67b2f7b750ff445500000f_4", "5a67b2f7b750ff445500000f_4", "5a67b2f7b750ff445500000f_4", "5a67b2f7b750ff445500000f_4", "5a67b2f7b750ff445500000f_4", "5a67b2f7b750ff445500000f_4", "5a67b2f7b750ff445500000f_4", "5a67b2f7b750ff445500000f_4", "5a67b2f7b750ff445500000f_4", "5a67b2f7b750ff445500000f_4", "5a67b2f7b750ff445500000f_4", "5a67b2f7b750ff445500000f_4", "5a67b2f7b750ff445500000f_4", "5a67b2f7b750ff445500000f_4", "5a67b2f7b750ff445500000f_4", "5a67b2f7b750ff445500000f_4", "5a67b2f7b750ff445500000f_4", "5a67b2f7b750ff445500000f_4", "5a67b2f7b750ff445500000f_4", "5a67b2f7b750ff445500000f_4", "5a67b2f7b750ff445500000f_4", "5a67b2f7b750ff445500000f_4", "5a67b2f7b750ff445500000f_4", "5a67b2f7b750ff445500000f_4", "5a67b2f7b750ff445500000f_4", "5a67b2f7b750ff445500000f_5", "5a67b2f7b750ff445500000f_5", "5a67b2f7b750ff445500000f_5", "5a67b2f7b750ff445500000f_5", "5a67b2f7b750ff445500000f_5", "5a67b2f7b750ff445500000f_5", "5a67b2f7b750ff445500000f_5", "5a67b2f7b750ff445500000f_5", "5a67b2f7b750ff445500000f_5", "5a67b2f7b750ff445500000f_5", "5a67b2f7b750ff445500000f_5", "5a67b2f7b750ff445500000f_5", "5a67b2f7b750ff445500000f_5", "5a67b2f7b750ff445500000f_5", "5a67b2f7b750ff445500000f_5", "5a67b2f7b750ff445500000f_5", "5a67b2f7b750ff445500000f_5", "5a67b2f7b750ff445500000f_5", "5a67b2f7b750ff445500000f_5", "5a67b2f7b750ff445500000f_5", "5a67b2f7b750ff445500000f_5", "5a67b2f7b750ff445500000f_5", "5a67b2f7b750ff445500000f_5", "5a67b2f7b750ff445500000f_5", "5a67b2f7b750ff445500000f_5", "5a67b2f7b750ff445500000f_5", "5a67b2f7b750ff445500000f_5", "5a67b2f7b750ff445500000f_5", "5a67b2f7b750ff445500000f_5", "5a67b2f7b750ff445500000f_6", "5a67b2f7b750ff445500000f_6", "5a67b2f7b750ff445500000f_6", "5a67b2f7b750ff445500000f_6", "5a67b2f7b750ff445500000f_6", "5a67b2f7b750ff445500000f_6", "5a67b2f7b750ff445500000f_6", "5a67b2f7b750ff445500000f_6", "5a67b2f7b750ff445500000f_6", "5a67b2f7b750ff445500000f_6", "5a67b2f7b750ff445500000f_6", "5a67b2f7b750ff445500000f_6", "5a67b2f7b750ff445500000f_6", "5a67b2f7b750ff445500000f_6", "5a67b2f7b750ff445500000f_6", "5a67b2f7b750ff445500000f_6", "5a67b2f7b750ff445500000f_6", "5a67b2f7b750ff445500000f_6", "5a67b2f7b750ff445500000f_6", "5a67b2f7b750ff445500000f_6", "5a67b2f7b750ff445500000f_6", "5a67b2f7b750ff445500000f_6", "5a67b2f7b750ff445500000f_6", "5a67b2f7b750ff445500000f_6", "5a67b2f7b750ff445500000f_6", "5a67b2f7b750ff445500000f_6", "5a67b2f7b750ff445500000f_6", "5a67b2f7b750ff445500000f_6", "5a67b2f7b750ff445500000f_6", "5a67b2f7b750ff445500000f_7", "5a67b2f7b750ff445500000f_7", "5a67b2f7b750ff445500000f_7", "5a67b2f7b750ff445500000f_7", "5a67b2f7b750ff445500000f_7", "5a67b2f7b750ff445500000f_7", "5a67b2f7b750ff445500000f_7", "5a67b2f7b750ff445500000f_7", "5a67b2f7b750ff445500000f_7", "5a67b2f7b750ff445500000f_7", "5a67b2f7b750ff445500000f_7", "5a67b2f7b750ff445500000f_7", "5a67b2f7b750ff445500000f_7", "5a67b2f7b750ff445500000f_7", "5a67b2f7b750ff445500000f_7", "5a67b2f7b750ff445500000f_7", "5a67b2f7b750ff445500000f_7", "5a67b2f7b750ff445500000f_7", "5a67b2f7b750ff445500000f_7", "5a67b2f7b750ff445500000f_7", "5a67b2f7b750ff445500000f_7", "5a67b2f7b750ff445500000f_7", "5a67b2f7b750ff445500000f_7", "5a67b2f7b750ff445500000f_7", "5a67b2f7b750ff445500000f_7", "5a67b2f7b750ff445500000f_7", "5a67b2f7b750ff445500000f_7", "5a67b2f7b750ff445500000f_7", "5a67b2f7b750ff445500000f_7", "5a67b2f7b750ff445500000f_8", "5a67b2f7b750ff445500000f_8", "5a67b2f7b750ff445500000f_8", "5a67b2f7b750ff445500000f_8", "5a67b2f7b750ff445500000f_8", "5a67b2f7b750ff445500000f_8", "5a67b2f7b750ff445500000f_8", "5a67b2f7b750ff445500000f_8", "5a67b2f7b750ff445500000f_8", "5a67b2f7b750ff445500000f_8", "5a67b2f7b750ff445500000f_8", "5a67b2f7b750ff445500000f_8", "5a67b2f7b750ff445500000f_8", "5a67b2f7b750ff445500000f_8", "5a67b2f7b750ff445500000f_8", "5a67b2f7b750ff445500000f_8", "5a67b2f7b750ff445500000f_8", "5a67b2f7b750ff445500000f_8", "5a67b2f7b750ff445500000f_8", "5a67b2f7b750ff445500000f_8", "5a67b2f7b750ff445500000f_8", "5a67b2f7b750ff445500000f_8", "5a67b2f7b750ff445500000f_8", "5a67b2f7b750ff445500000f_8", "5a67b2f7b750ff445500000f_8", "5a67b2f7b750ff445500000f_8", "5a67b2f7b750ff445500000f_8", "5a67b2f7b750ff445500000f_8", "5a67b2f7b750ff445500000f_8", "5a67b2f7b750ff445500000f_9", "5a67b2f7b750ff445500000f_9", "5a67b2f7b750ff445500000f_9", "5a67b2f7b750ff445500000f_9", "5a67b2f7b750ff445500000f_9", "5a67b2f7b750ff445500000f_9", "5a67b2f7b750ff445500000f_9", "5a67b2f7b750ff445500000f_9", "5a67b2f7b750ff445500000f_9", "5a67b2f7b750ff445500000f_9", "5a67b2f7b750ff445500000f_9", "5a67b2f7b750ff445500000f_9", "5a67b2f7b750ff445500000f_9", "5a67b2f7b750ff445500000f_9", "5a67b2f7b750ff445500000f_9", "5a67b2f7b750ff445500000f_9", "5a67b2f7b750ff445500000f_9", "5a67b2f7b750ff445500000f_9", "5a67b2f7b750ff445500000f_9", "5a67b2f7b750ff445500000f_9", "5a67b2f7b750ff445500000f_9", "5a67b2f7b750ff445500000f_9", "5a67b2f7b750ff445500000f_9", "5a67b2f7b750ff445500000f_9", "5a67b2f7b750ff445500000f_9", "5a67b2f7b750ff445500000f_9", "5a67b2f7b750ff445500000f_9", "5a67b2f7b750ff445500000f_9", "5a67b2f7b750ff445500000f_9", "5a67b2f7b750ff445500000f_10", "5a67b2f7b750ff445500000f_10", "5a67b2f7b750ff445500000f_10", "5a67b2f7b750ff445500000f_10", "5a67b2f7b750ff445500000f_10", "5a67b2f7b750ff445500000f_10", "5a67b2f7b750ff445500000f_10", "5a67b2f7b750ff445500000f_10", "5a67b2f7b750ff445500000f_10", "5a67b2f7b750ff445500000f_10", "5a67b2f7b750ff445500000f_10", "5a67b2f7b750ff445500000f_10", "5a67b2f7b750ff445500000f_10", "5a67b2f7b750ff445500000f_10", "5a67b2f7b750ff445500000f_10", "5a67b2f7b750ff445500000f_10", "5a67b2f7b750ff445500000f_10", "5a67b2f7b750ff445500000f_10", "5a67b2f7b750ff445500000f_10", "5a67b2f7b750ff445500000f_10", "5a67b2f7b750ff445500000f_10", "5a67b2f7b750ff445500000f_10", "5a67b2f7b750ff445500000f_10", "5a67b2f7b750ff445500000f_10", "5a67b2f7b750ff445500000f_10", "5a67b2f7b750ff445500000f_10", "5a67b2f7b750ff445500000f_10", "5a67b2f7b750ff445500000f_10", "5a67b2f7b750ff445500000f_10", "5a67b2f7b750ff445500000f_11", "5a67b2f7b750ff445500000f_11", "5a67b2f7b750ff445500000f_11", "5a67b2f7b750ff445500000f_11", "5a67b2f7b750ff445500000f_11", "5a67b2f7b750ff445500000f_11", "5a67b2f7b750ff445500000f_11", "5a67b2f7b750ff445500000f_11", "5a67b2f7b750ff445500000f_11", "5a67b2f7b750ff445500000f_11", "5a67b2f7b750ff445500000f_11", "5a67b2f7b750ff445500000f_11", "5a67b2f7b750ff445500000f_11", "5a67b2f7b750ff445500000f_11", "5a67b2f7b750ff445500000f_11", "5a67b2f7b750ff445500000f_11", "5a67b2f7b750ff445500000f_11", "5a67b2f7b750ff445500000f_11", "5a67b2f7b750ff445500000f_11", "5a67b2f7b750ff445500000f_11", "5a67b2f7b750ff445500000f_11", "5a67b2f7b750ff445500000f_11", "5a67b2f7b750ff445500000f_11", "5a67b2f7b750ff445500000f_11", "5a67b2f7b750ff445500000f_11", "5a67b2f7b750ff445500000f_11", "5a67b2f7b750ff445500000f_11", "5a67b2f7b750ff445500000f_11", "5a67b2f7b750ff445500000f_11", "5a67b2f7b750ff445500000f_12", "5a67b2f7b750ff445500000f_12", "5a67b2f7b750ff445500000f_12", "5a67b2f7b750ff445500000f_12", "5a67b2f7b750ff445500000f_12", "5a67b2f7b750ff445500000f_12", "5a67b2f7b750ff445500000f_12", "5a67b2f7b750ff445500000f_12", "5a67b2f7b750ff445500000f_12", "5a67b2f7b750ff445500000f_12", "5a67b2f7b750ff445500000f_12", "5a67b2f7b750ff445500000f_12", "5a67b2f7b750ff445500000f_12", "5a67b2f7b750ff445500000f_12", "5a67b2f7b750ff445500000f_12", "5a67b2f7b750ff445500000f_12", "5a67b2f7b750ff445500000f_12", "5a67b2f7b750ff445500000f_12", "5a67b2f7b750ff445500000f_12", "5a67b2f7b750ff445500000f_12", "5a67b2f7b750ff445500000f_12", "5a67b2f7b750ff445500000f_12", "5a67b2f7b750ff445500000f_12", "5a67b2f7b750ff445500000f_12", "5a67b2f7b750ff445500000f_12", "5a67b2f7b750ff445500000f_12", "5a67b2f7b750ff445500000f_12", "5a67b2f7b750ff445500000f_12", "5a67b2f7b750ff445500000f_12", "593ff22b70f9fc6f0f000023_13", "593ff22b70f9fc6f0f000023_13", "593ff22b70f9fc6f0f000023_13", "593ff22b70f9fc6f0f000023_13", "593ff22b70f9fc6f0f000023_13", "593ff22b70f9fc6f0f000023_13", "593ff22b70f9fc6f0f000023_13", "593ff22b70f9fc6f0f000023_13", "593ff22b70f9fc6f0f000023_13", "593ff22b70f9fc6f0f000023_13", "593ff22b70f9fc6f0f000023_13", "593ff22b70f9fc6f0f000023_13", "593ff22b70f9fc6f0f000023_13", "593ff22b70f9fc6f0f000023_13", "593ff22b70f9fc6f0f000023_13", "593ff22b70f9fc6f0f000023_13", "593ff22b70f9fc6f0f000023_13", "593ff22b70f9fc6f0f000023_13", "593ff22b70f9fc6f0f000023_13", "593ff22b70f9fc6f0f000023_13", "593ff22b70f9fc6f0f000023_13", "593ff22b70f9fc6f0f000023_13", "593ff22b70f9fc6f0f000023_13", "593ff22b70f9fc6f0f000023_13", "593ff22b70f9fc6f0f000023_13", "593ff22b70f9fc6f0f000023_13", "5a87ea1861bb38fb2400000d_14", "5a87ea1861bb38fb2400000d_14", "5a87ea1861bb38fb2400000d_14", "5a87ea1861bb38fb2400000d_14", "5a87ea1861bb38fb2400000d_14", "5a87ea1861bb38fb2400000d_14", "5a87ea1861bb38fb2400000d_14", "5a87ea1861bb38fb2400000d_14", "5a87ea1861bb38fb2400000d_14", "5a87ea1861bb38fb2400000d_14", "5a87ea1861bb38fb2400000d_14", "5a87ea1861bb38fb2400000d_14", "5a87ea1861bb38fb2400000d_14", "5a87ea1861bb38fb2400000d_14", "5a87ea1861bb38fb2400000d_14", "5a87ea1861bb38fb2400000d_14", "5a7617b183b0d9ea66000022_15", "5a7617b183b0d9ea66000022_15", "5a7617b183b0d9ea66000022_15", "5a7617b183b0d9ea66000022_15", "5a7617b183b0d9ea66000022_15", "5a7617b183b0d9ea66000022_15", "5a7617b183b0d9ea66000022_15", "5a7617b183b0d9ea66000022_15", "5a7617b183b0d9ea66000022_15", "5a7617b183b0d9ea66000022_15", "5a7617b183b0d9ea66000022_15", "5a7617b183b0d9ea66000022_15", "5a7617b183b0d9ea66000022_15", "5a7617b183b0d9ea66000022_15", "5a7617b183b0d9ea66000022_15", "5a7617b183b0d9ea66000022_15", "5a7617b183b0d9ea66000022_15", "5a7617b183b0d9ea66000022_15", "5a7617b183b0d9ea66000022_15", "5a7617b183b0d9ea66000022_15", "5a7617b183b0d9ea66000022_15", "5a7617b183b0d9ea66000022_15", "5a7617b183b0d9ea66000022_15", "5a7617b183b0d9ea66000022_16", "5a7617b183b0d9ea66000022_16", "5a7617b183b0d9ea66000022_16", "5a7617b183b0d9ea66000022_16", "5a7617b183b0d9ea66000022_16", "5a7617b183b0d9ea66000022_16", "5a7617b183b0d9ea66000022_16", "5a7617b183b0d9ea66000022_16", "5a7617b183b0d9ea66000022_16", "5a7617b183b0d9ea66000022_16", "5a7617b183b0d9ea66000022_16", "5a7617b183b0d9ea66000022_16", "5a7617b183b0d9ea66000022_16", "5a7617b183b0d9ea66000022_16", "5a7617b183b0d9ea66000022_16", "5a7617b183b0d9ea66000022_16", "5a7617b183b0d9ea66000022_16", "5a7617b183b0d9ea66000022_16", "5a7617b183b0d9ea66000022_16", "5a7617b183b0d9ea66000022_16", "5a7617b183b0d9ea66000022_16", "5a7617b183b0d9ea66000022_16", "5a7617b183b0d9ea66000022_16", "5a7617b183b0d9ea66000022_17", "5a7617b183b0d9ea66000022_17", "5a7617b183b0d9ea66000022_17", "5a7617b183b0d9ea66000022_17", "5a7617b183b0d9ea66000022_17", "5a7617b183b0d9ea66000022_17", "5a7617b183b0d9ea66000022_17", "5a7617b183b0d9ea66000022_17", "5a7617b183b0d9ea66000022_17", "5a7617b183b0d9ea66000022_17", "5a7617b183b0d9ea66000022_17", "5a7617b183b0d9ea66000022_17", "5a7617b183b0d9ea66000022_17", "5a7617b183b0d9ea66000022_17", "5a7617b183b0d9ea66000022_17", "5a7617b183b0d9ea66000022_17", "5a7617b183b0d9ea66000022_17", "5a7617b183b0d9ea66000022_17", "5a7617b183b0d9ea66000022_17", "5a7617b183b0d9ea66000022_17", "5a7617b183b0d9ea66000022_17", "5a7617b183b0d9ea66000022_17", "5a7617b183b0d9ea66000022_17", "5a7617b183b0d9ea66000022_18", "5a7617b183b0d9ea66000022_18", "5a7617b183b0d9ea66000022_18", "5a7617b183b0d9ea66000022_18", "5a7617b183b0d9ea66000022_18", "5a7617b183b0d9ea66000022_18", "5a7617b183b0d9ea66000022_18", "5a7617b183b0d9ea66000022_18", "5a7617b183b0d9ea66000022_18", "5a7617b183b0d9ea66000022_18", "5a7617b183b0d9ea66000022_18", "5a7617b183b0d9ea66000022_18", "5a7617b183b0d9ea66000022_18", "5a7617b183b0d9ea66000022_18", "5a7617b183b0d9ea66000022_18", "5a7617b183b0d9ea66000022_18", "5a7617b183b0d9ea66000022_18", "5a7617b183b0d9ea66000022_18", "5a7617b183b0d9ea66000022_18", "5a7617b183b0d9ea66000022_18", "5a7617b183b0d9ea66000022_18", "5a7617b183b0d9ea66000022_18", "5a7617b183b0d9ea66000022_18", "5a7617b183b0d9ea66000022_19", "5a7617b183b0d9ea66000022_19", "5a7617b183b0d9ea66000022_19", "5a7617b183b0d9ea66000022_19", "5a7617b183b0d9ea66000022_19", "5a7617b183b0d9ea66000022_19", "5a7617b183b0d9ea66000022_19", "5a7617b183b0d9ea66000022_19", "5a7617b183b0d9ea66000022_19", "5a7617b183b0d9ea66000022_19", "5a7617b183b0d9ea66000022_19", "5a7617b183b0d9ea66000022_19", "5a7617b183b0d9ea66000022_19", "5a7617b183b0d9ea66000022_19", "5a7617b183b0d9ea66000022_19", "5a7617b183b0d9ea66000022_19", "5a7617b183b0d9ea66000022_19", "5a7617b183b0d9ea66000022_19", "5a7617b183b0d9ea66000022_19", "5a7617b183b0d9ea66000022_19", "5a7617b183b0d9ea66000022_19", "5a7617b183b0d9ea66000022_19", "5a7617b183b0d9ea66000022_19", "5a7617b183b0d9ea66000022_20", "5a7617b183b0d9ea66000022_20", "5a7617b183b0d9ea66000022_20", "5a7617b183b0d9ea66000022_20", "5a7617b183b0d9ea66000022_20", "5a7617b183b0d9ea66000022_20", "5a7617b183b0d9ea66000022_20", "5a7617b183b0d9ea66000022_20", "5a7617b183b0d9ea66000022_20", "5a7617b183b0d9ea66000022_20", "5a7617b183b0d9ea66000022_20", "5a7617b183b0d9ea66000022_20", "5a7617b183b0d9ea66000022_20", "5a7617b183b0d9ea66000022_20", "5a7617b183b0d9ea66000022_20", "5a7617b183b0d9ea66000022_20", "5a7617b183b0d9ea66000022_20", "5a7617b183b0d9ea66000022_20", "5a7617b183b0d9ea66000022_20", "5a7617b183b0d9ea66000022_20", "5a7617b183b0d9ea66000022_20", "5a7617b183b0d9ea66000022_20", "5a7617b183b0d9ea66000022_20", "5a7617b183b0d9ea66000022_21", "5a7617b183b0d9ea66000022_21", "5a7617b183b0d9ea66000022_21", "5a7617b183b0d9ea66000022_21", "5a7617b183b0d9ea66000022_21", "5a7617b183b0d9ea66000022_21", "5a7617b183b0d9ea66000022_21", "5a7617b183b0d9ea66000022_21", "5a7617b183b0d9ea66000022_21", "5a7617b183b0d9ea66000022_21", "5a7617b183b0d9ea66000022_21", "5a7617b183b0d9ea66000022_21", "5a7617b183b0d9ea66000022_21", "5a7617b183b0d9ea66000022_21", "5a7617b183b0d9ea66000022_21", "5a7617b183b0d9ea66000022_21", "5a7617b183b0d9ea66000022_21", "5a7617b183b0d9ea66000022_21", "5a7617b183b0d9ea66000022_21", "5a7617b183b0d9ea66000022_21", "5a7617b183b0d9ea66000022_21", "5a7617b183b0d9ea66000022_21", "5a7617b183b0d9ea66000022_21", "5a7617b183b0d9ea66000022_22", "5a7617b183b0d9ea66000022_22", "5a7617b183b0d9ea66000022_22", "5a7617b183b0d9ea66000022_22", "5a7617b183b0d9ea66000022_22", "5a7617b183b0d9ea66000022_22", "5a7617b183b0d9ea66000022_22", "5a7617b183b0d9ea66000022_22", "5a7617b183b0d9ea66000022_22", "5a7617b183b0d9ea66000022_22", "5a7617b183b0d9ea66000022_22", "5a7617b183b0d9ea66000022_22", "5a7617b183b0d9ea66000022_22", "5a7617b183b0d9ea66000022_22", "5a7617b183b0d9ea66000022_22", "5a7617b183b0d9ea66000022_22", "5a7617b183b0d9ea66000022_22", "5a7617b183b0d9ea66000022_22", "5a7617b183b0d9ea66000022_22", "5a7617b183b0d9ea66000022_22", "5a7617b183b0d9ea66000022_22", "5a7617b183b0d9ea66000022_22", "5a7617b183b0d9ea66000022_22", "5a7237672dc08e987e000008_23", "5a7237672dc08e987e000008_23", "5a7237672dc08e987e000008_23", "5a7237672dc08e987e000008_23", "5a7237672dc08e987e000008_23", "5a7237672dc08e987e000008_23", "5a7237672dc08e987e000008_23", "5a7237672dc08e987e000008_23", "5a7237672dc08e987e000008_23", "5a7237672dc08e987e000008_23", "5a7237672dc08e987e000008_23", "5a7237672dc08e987e000008_23", "5a7237672dc08e987e000008_23", "5a7237672dc08e987e000008_23", "5a7237672dc08e987e000008_23", "5a7237672dc08e987e000008_23", "5a7237672dc08e987e000008_23", "5a7237672dc08e987e000008_23", "5a7237672dc08e987e000008_23", "5a7237672dc08e987e000008_23", "5a7237672dc08e987e000008_23", "5a7237672dc08e987e000008_23", "5a7237672dc08e987e000008_23", "5a7237672dc08e987e000008_23", "5a7237672dc08e987e000008_23", "5a7237672dc08e987e000008_23", "5a7237672dc08e987e000008_23", "5a7237672dc08e987e000008_23", "5a7237672dc08e987e000008_23", "5a7237672dc08e987e000008_23", "5a7237672dc08e987e000008_23", "5a7237672dc08e987e000008_23", "5a7237672dc08e987e000008_24", "5a7237672dc08e987e000008_24", "5a7237672dc08e987e000008_24", "5a7237672dc08e987e000008_24", "5a7237672dc08e987e000008_24", "5a7237672dc08e987e000008_24", "5a7237672dc08e987e000008_24", "5a7237672dc08e987e000008_24", "5a7237672dc08e987e000008_24", "5a7237672dc08e987e000008_24", "5a7237672dc08e987e000008_24", "5a7237672dc08e987e000008_24", "5a7237672dc08e987e000008_24", "5a7237672dc08e987e000008_24", "5a7237672dc08e987e000008_24", "5a7237672dc08e987e000008_24", "5a7237672dc08e987e000008_24", "5a7237672dc08e987e000008_24", "5a7237672dc08e987e000008_24", "5a7237672dc08e987e000008_24", "5a7237672dc08e987e000008_24", "5a7237672dc08e987e000008_24", "5a7237672dc08e987e000008_24", "5a7237672dc08e987e000008_24", "5a7237672dc08e987e000008_24", "5a7237672dc08e987e000008_24", "5a7237672dc08e987e000008_24", "5a7237672dc08e987e000008_24", "5a7237672dc08e987e000008_24", "5a7237672dc08e987e000008_24", "5a7237672dc08e987e000008_24", "5a7237672dc08e987e000008_24", "5a7237672dc08e987e000008_25", "5a7237672dc08e987e000008_25", "5a7237672dc08e987e000008_25", "5a7237672dc08e987e000008_25", "5a7237672dc08e987e000008_25", "5a7237672dc08e987e000008_25", "5a7237672dc08e987e000008_25", "5a7237672dc08e987e000008_25", "5a7237672dc08e987e000008_25", "5a7237672dc08e987e000008_25", "5a7237672dc08e987e000008_25", "5a7237672dc08e987e000008_25", "5a7237672dc08e987e000008_25", "5a7237672dc08e987e000008_25", "5a7237672dc08e987e000008_25", "5a7237672dc08e987e000008_25", "5a7237672dc08e987e000008_25", "5a7237672dc08e987e000008_25", "5a7237672dc08e987e000008_25", "5a7237672dc08e987e000008_25", "5a7237672dc08e987e000008_25", "5a7237672dc08e987e000008_25", "5a7237672dc08e987e000008_25", "5a7237672dc08e987e000008_25", "5a7237672dc08e987e000008_25", "5a7237672dc08e987e000008_25", "5a7237672dc08e987e000008_25", "5a7237672dc08e987e000008_25", "5a7237672dc08e987e000008_25", "5a7237672dc08e987e000008_25", "5a7237672dc08e987e000008_25", "5a7237672dc08e987e000008_25", "5a7237672dc08e987e000008_26", "5a7237672dc08e987e000008_26", "5a7237672dc08e987e000008_26", "5a7237672dc08e987e000008_26", "5a7237672dc08e987e000008_26", "5a7237672dc08e987e000008_26", "5a7237672dc08e987e000008_26", "5a7237672dc08e987e000008_26", "5a7237672dc08e987e000008_26", "5a7237672dc08e987e000008_26", "5a7237672dc08e987e000008_26", "5a7237672dc08e987e000008_26", "5a7237672dc08e987e000008_26", "5a7237672dc08e987e000008_26", "5a7237672dc08e987e000008_26", "5a7237672dc08e987e000008_26", "5a7237672dc08e987e000008_26", "5a7237672dc08e987e000008_26", "5a7237672dc08e987e000008_26", "5a7237672dc08e987e000008_26", "5a7237672dc08e987e000008_26", "5a7237672dc08e987e000008_26", "5a7237672dc08e987e000008_26", "5a7237672dc08e987e000008_26", "5a7237672dc08e987e000008_26", "5a7237672dc08e987e000008_26", "5a7237672dc08e987e000008_26", "5a7237672dc08e987e000008_26", "5a7237672dc08e987e000008_26", "5a7237672dc08e987e000008_26", "5a7237672dc08e987e000008_26", "5a7237672dc08e987e000008_26", "5a7237672dc08e987e000008_27", "5a7237672dc08e987e000008_27", "5a7237672dc08e987e000008_27", "5a7237672dc08e987e000008_27", "5a7237672dc08e987e000008_27", "5a7237672dc08e987e000008_27", "5a7237672dc08e987e000008_27", "5a7237672dc08e987e000008_27", "5a7237672dc08e987e000008_27", "5a7237672dc08e987e000008_27", "5a7237672dc08e987e000008_27", "5a7237672dc08e987e000008_27", "5a7237672dc08e987e000008_27", "5a7237672dc08e987e000008_27", "5a7237672dc08e987e000008_27", "5a7237672dc08e987e000008_27", "5a7237672dc08e987e000008_27", "5a7237672dc08e987e000008_27", "5a7237672dc08e987e000008_27", "5a7237672dc08e987e000008_27", "5a7237672dc08e987e000008_27", "5a7237672dc08e987e000008_27", "5a7237672dc08e987e000008_27", "5a7237672dc08e987e000008_27", "5a7237672dc08e987e000008_27", "5a7237672dc08e987e000008_27", "5a7237672dc08e987e000008_27", "5a7237672dc08e987e000008_27", "5a7237672dc08e987e000008_27", "5a7237672dc08e987e000008_27", "5a7237672dc08e987e000008_27", "5a7237672dc08e987e000008_27", "5a7237672dc08e987e000008_28", "5a7237672dc08e987e000008_28", "5a7237672dc08e987e000008_28", "5a7237672dc08e987e000008_28", "5a7237672dc08e987e000008_28", "5a7237672dc08e987e000008_28", "5a7237672dc08e987e000008_28", "5a7237672dc08e987e000008_28", "5a7237672dc08e987e000008_28", "5a7237672dc08e987e000008_28", "5a7237672dc08e987e000008_28", "5a7237672dc08e987e000008_28", "5a7237672dc08e987e000008_28", "5a7237672dc08e987e000008_28", "5a7237672dc08e987e000008_28", "5a7237672dc08e987e000008_28", "5a7237672dc08e987e000008_28", "5a7237672dc08e987e000008_28", "5a7237672dc08e987e000008_28", "5a7237672dc08e987e000008_28", "5a7237672dc08e987e000008_28", "5a7237672dc08e987e000008_28", "5a7237672dc08e987e000008_28", "5a7237672dc08e987e000008_28", "5a7237672dc08e987e000008_28", "5a7237672dc08e987e000008_28", "5a7237672dc08e987e000008_28", "5a7237672dc08e987e000008_28", "5a7237672dc08e987e000008_28", "5a7237672dc08e987e000008_28", "5a7237672dc08e987e000008_28", "5a7237672dc08e987e000008_28", "5a7237672dc08e987e000008_29", "5a7237672dc08e987e000008_29", "5a7237672dc08e987e000008_29", "5a7237672dc08e987e000008_29", "5a7237672dc08e987e000008_29", "5a7237672dc08e987e000008_29", "5a7237672dc08e987e000008_29", "5a7237672dc08e987e000008_29", "5a7237672dc08e987e000008_29", "5a7237672dc08e987e000008_29", "5a7237672dc08e987e000008_29", "5a7237672dc08e987e000008_29", "5a7237672dc08e987e000008_29", "5a7237672dc08e987e000008_29", "5a7237672dc08e987e000008_29", "5a7237672dc08e987e000008_29", "5a7237672dc08e987e000008_29", "5a7237672dc08e987e000008_29", "5a7237672dc08e987e000008_29", "5a7237672dc08e987e000008_29", "5a7237672dc08e987e000008_29", "5a7237672dc08e987e000008_29", "5a7237672dc08e987e000008_29", "5a7237672dc08e987e000008_29", "5a7237672dc08e987e000008_29", "5a7237672dc08e987e000008_29", "5a7237672dc08e987e000008_29", "5a7237672dc08e987e000008_29", "5a7237672dc08e987e000008_29", "5a7237672dc08e987e000008_29", "5a7237672dc08e987e000008_29", "5a7237672dc08e987e000008_29", "5a7237672dc08e987e000008_30", "5a7237672dc08e987e000008_30", "5a7237672dc08e987e000008_30", "5a7237672dc08e987e000008_30", "5a7237672dc08e987e000008_30", "5a7237672dc08e987e000008_30", "5a7237672dc08e987e000008_30", "5a7237672dc08e987e000008_30", "5a7237672dc08e987e000008_30", "5a7237672dc08e987e000008_30", "5a7237672dc08e987e000008_30", "5a7237672dc08e987e000008_30", "5a7237672dc08e987e000008_30", "5a7237672dc08e987e000008_30", "5a7237672dc08e987e000008_30", "5a7237672dc08e987e000008_30", "5a7237672dc08e987e000008_30", "5a7237672dc08e987e000008_30", "5a7237672dc08e987e000008_30", "5a7237672dc08e987e000008_30", "5a7237672dc08e987e000008_30", "5a7237672dc08e987e000008_30", "5a7237672dc08e987e000008_30", "5a7237672dc08e987e000008_30", "5a7237672dc08e987e000008_30", "5a7237672dc08e987e000008_30", "5a7237672dc08e987e000008_30", "5a7237672dc08e987e000008_30", "5a7237672dc08e987e000008_30", "5a7237672dc08e987e000008_30", "5a7237672dc08e987e000008_30", "5a7237672dc08e987e000008_30", "5a7237672dc08e987e000008_31", "5a7237672dc08e987e000008_31", "5a7237672dc08e987e000008_31", "5a7237672dc08e987e000008_31", "5a7237672dc08e987e000008_31", "5a7237672dc08e987e000008_31", "5a7237672dc08e987e000008_31", "5a7237672dc08e987e000008_31", "5a7237672dc08e987e000008_31", "5a7237672dc08e987e000008_31", "5a7237672dc08e987e000008_31", "5a7237672dc08e987e000008_31", "5a7237672dc08e987e000008_31", "5a7237672dc08e987e000008_31", "5a7237672dc08e987e000008_31", "5a7237672dc08e987e000008_31", "5a7237672dc08e987e000008_31", "5a7237672dc08e987e000008_31", "5a7237672dc08e987e000008_31", "5a7237672dc08e987e000008_31", "5a7237672dc08e987e000008_31", "5a7237672dc08e987e000008_31", "5a7237672dc08e987e000008_31", "5a7237672dc08e987e000008_31", "5a7237672dc08e987e000008_31", "5a7237672dc08e987e000008_31", "5a7237672dc08e987e000008_31", "5a7237672dc08e987e000008_31", "5a7237672dc08e987e000008_31", "5a7237672dc08e987e000008_31", "5a7237672dc08e987e000008_31", "5a7237672dc08e987e000008_31", "5a7237672dc08e987e000008_32", "5a7237672dc08e987e000008_32", "5a7237672dc08e987e000008_32", "5a7237672dc08e987e000008_32", "5a7237672dc08e987e000008_32", "5a7237672dc08e987e000008_32", "5a7237672dc08e987e000008_32", "5a7237672dc08e987e000008_32", "5a7237672dc08e987e000008_32", "5a7237672dc08e987e000008_32", "5a7237672dc08e987e000008_32", "5a7237672dc08e987e000008_32", "5a7237672dc08e987e000008_32", "5a7237672dc08e987e000008_32", "5a7237672dc08e987e000008_32", "5a7237672dc08e987e000008_32", "5a7237672dc08e987e000008_32", "5a7237672dc08e987e000008_32", "5a7237672dc08e987e000008_32", "5a7237672dc08e987e000008_32", "5a7237672dc08e987e000008_32", "5a7237672dc08e987e000008_32", "5a7237672dc08e987e000008_32", "5a7237672dc08e987e000008_32", "5a7237672dc08e987e000008_32", "5a7237672dc08e987e000008_32", "5a7237672dc08e987e000008_32", "5a7237672dc08e987e000008_32", "5a7237672dc08e987e000008_32", "5a7237672dc08e987e000008_32", "5a7237672dc08e987e000008_32", "5a7237672dc08e987e000008_32", "5a7237672dc08e987e000008_33", "5a7237672dc08e987e000008_33", "5a7237672dc08e987e000008_33", "5a7237672dc08e987e000008_33", "5a7237672dc08e987e000008_33", "5a7237672dc08e987e000008_33", "5a7237672dc08e987e000008_33", "5a7237672dc08e987e000008_33", "5a7237672dc08e987e000008_33", "5a7237672dc08e987e000008_33", "5a7237672dc08e987e000008_33", "5a7237672dc08e987e000008_33", "5a7237672dc08e987e000008_33", "5a7237672dc08e987e000008_33", "5a7237672dc08e987e000008_33", "5a7237672dc08e987e000008_33", "5a7237672dc08e987e000008_33", "5a7237672dc08e987e000008_33", "5a7237672dc08e987e000008_33", "5a7237672dc08e987e000008_33", "5a7237672dc08e987e000008_33", "5a7237672dc08e987e000008_33", "5a7237672dc08e987e000008_33", "5a7237672dc08e987e000008_33", "5a7237672dc08e987e000008_33", "5a7237672dc08e987e000008_33", "5a7237672dc08e987e000008_33", "5a7237672dc08e987e000008_33", "5a7237672dc08e987e000008_33", "5a7237672dc08e987e000008_33", "5a7237672dc08e987e000008_33", "5a7237672dc08e987e000008_33", "5a7237672dc08e987e000008_34", "5a7237672dc08e987e000008_34", "5a7237672dc08e987e000008_34", "5a7237672dc08e987e000008_34", "5a7237672dc08e987e000008_34", "5a7237672dc08e987e000008_34", "5a7237672dc08e987e000008_34", "5a7237672dc08e987e000008_34", "5a7237672dc08e987e000008_34", "5a7237672dc08e987e000008_34", "5a7237672dc08e987e000008_34", "5a7237672dc08e987e000008_34", "5a7237672dc08e987e000008_34", "5a7237672dc08e987e000008_34", "5a7237672dc08e987e000008_34", "5a7237672dc08e987e000008_34", "5a7237672dc08e987e000008_34", "5a7237672dc08e987e000008_34", "5a7237672dc08e987e000008_34", "5a7237672dc08e987e000008_34", "5a7237672dc08e987e000008_34", "5a7237672dc08e987e000008_34", "5a7237672dc08e987e000008_34", "5a7237672dc08e987e000008_34", "5a7237672dc08e987e000008_34", "5a7237672dc08e987e000008_34", "5a7237672dc08e987e000008_34", "5a7237672dc08e987e000008_34", "5a7237672dc08e987e000008_34", "5a7237672dc08e987e000008_34", "5a7237672dc08e987e000008_34", "5a7237672dc08e987e000008_34", "5a7237672dc08e987e000008_35", "5a7237672dc08e987e000008_35", "5a7237672dc08e987e000008_35", "5a7237672dc08e987e000008_35", "5a7237672dc08e987e000008_35", "5a7237672dc08e987e000008_35", "5a7237672dc08e987e000008_35", "5a7237672dc08e987e000008_35", "5a7237672dc08e987e000008_35", "5a7237672dc08e987e000008_35", "5a7237672dc08e987e000008_35", "5a7237672dc08e987e000008_35", "5a7237672dc08e987e000008_35", "5a7237672dc08e987e000008_35", "5a7237672dc08e987e000008_35", "5a7237672dc08e987e000008_35", "5a7237672dc08e987e000008_35", "5a7237672dc08e987e000008_35", "5a7237672dc08e987e000008_35", "5a7237672dc08e987e000008_35", "5a7237672dc08e987e000008_35", "5a7237672dc08e987e000008_35", "5a7237672dc08e987e000008_35", "5a7237672dc08e987e000008_35", "5a7237672dc08e987e000008_35", "5a7237672dc08e987e000008_35", "5a7237672dc08e987e000008_35", "5a7237672dc08e987e000008_35", "5a7237672dc08e987e000008_35", "5a7237672dc08e987e000008_35", "5a7237672dc08e987e000008_35", "5a7237672dc08e987e000008_35", "5a7237672dc08e987e000008_36", "5a7237672dc08e987e000008_36", "5a7237672dc08e987e000008_36", "5a7237672dc08e987e000008_36", "5a7237672dc08e987e000008_36", "5a7237672dc08e987e000008_36", "5a7237672dc08e987e000008_36", "5a7237672dc08e987e000008_36", "5a7237672dc08e987e000008_36", "5a7237672dc08e987e000008_36", "5a7237672dc08e987e000008_36", "5a7237672dc08e987e000008_36", "5a7237672dc08e987e000008_36", "5a7237672dc08e987e000008_36", "5a7237672dc08e987e000008_36", "5a7237672dc08e987e000008_36", "5a7237672dc08e987e000008_36", "5a7237672dc08e987e000008_36", "5a7237672dc08e987e000008_36", "5a7237672dc08e987e000008_36", "5a7237672dc08e987e000008_36", "5a7237672dc08e987e000008_36", "5a7237672dc08e987e000008_36", "5a7237672dc08e987e000008_36", "5a7237672dc08e987e000008_36", "5a7237672dc08e987e000008_36", "5a7237672dc08e987e000008_36", "5a7237672dc08e987e000008_36", "5a7237672dc08e987e000008_36", "5a7237672dc08e987e000008_36", "5a7237672dc08e987e000008_36", "5a7237672dc08e987e000008_36", "5a7237672dc08e987e000008_37", "5a7237672dc08e987e000008_37", "5a7237672dc08e987e000008_37", "5a7237672dc08e987e000008_37", "5a7237672dc08e987e000008_37", "5a7237672dc08e987e000008_37", "5a7237672dc08e987e000008_37", "5a7237672dc08e987e000008_37", "5a7237672dc08e987e000008_37", "5a7237672dc08e987e000008_37", "5a7237672dc08e987e000008_37", "5a7237672dc08e987e000008_37", "5a7237672dc08e987e000008_37", "5a7237672dc08e987e000008_37", "5a7237672dc08e987e000008_37", "5a7237672dc08e987e000008_37", "5a7237672dc08e987e000008_37", "5a7237672dc08e987e000008_37", "5a7237672dc08e987e000008_37", "5a7237672dc08e987e000008_37", "5a7237672dc08e987e000008_37", "5a7237672dc08e987e000008_37", "5a7237672dc08e987e000008_37", "5a7237672dc08e987e000008_37", "5a7237672dc08e987e000008_37", "5a7237672dc08e987e000008_37", "5a7237672dc08e987e000008_37", "5a7237672dc08e987e000008_37", "5a7237672dc08e987e000008_37", "5a7237672dc08e987e000008_37", "5a7237672dc08e987e000008_37", "5a7237672dc08e987e000008_37", "5a7237672dc08e987e000008_38", "5a7237672dc08e987e000008_38", "5a7237672dc08e987e000008_38", "5a7237672dc08e987e000008_38", "5a7237672dc08e987e000008_38", "5a7237672dc08e987e000008_38", "5a7237672dc08e987e000008_38", "5a7237672dc08e987e000008_38", "5a7237672dc08e987e000008_38", "5a7237672dc08e987e000008_38", "5a7237672dc08e987e000008_38", "5a7237672dc08e987e000008_38", "5a7237672dc08e987e000008_38", "5a7237672dc08e987e000008_38", "5a7237672dc08e987e000008_38", "5a7237672dc08e987e000008_38", "5a7237672dc08e987e000008_38", "5a7237672dc08e987e000008_38", "5a7237672dc08e987e000008_38", "5a7237672dc08e987e000008_38", "5a7237672dc08e987e000008_38", "5a7237672dc08e987e000008_38", "5a7237672dc08e987e000008_38", "5a7237672dc08e987e000008_38", "5a7237672dc08e987e000008_38", "5a7237672dc08e987e000008_38", "5a7237672dc08e987e000008_38", "5a7237672dc08e987e000008_38", "5a7237672dc08e987e000008_38", "5a7237672dc08e987e000008_38", "5a7237672dc08e987e000008_38", "5a7237672dc08e987e000008_38", "5a7237672dc08e987e000008_39", "5a7237672dc08e987e000008_39", "5a7237672dc08e987e000008_39", "5a7237672dc08e987e000008_39", "5a7237672dc08e987e000008_39", "5a7237672dc08e987e000008_39", "5a7237672dc08e987e000008_39", "5a7237672dc08e987e000008_39", "5a7237672dc08e987e000008_39", "5a7237672dc08e987e000008_39", "5a7237672dc08e987e000008_39", "5a7237672dc08e987e000008_39", "5a7237672dc08e987e000008_39", "5a7237672dc08e987e000008_39", "5a7237672dc08e987e000008_39", "5a7237672dc08e987e000008_39", "5a7237672dc08e987e000008_39", "5a7237672dc08e987e000008_39", "5a7237672dc08e987e000008_39", "5a7237672dc08e987e000008_39", "5a7237672dc08e987e000008_39", "5a7237672dc08e987e000008_39", "5a7237672dc08e987e000008_39", "5a7237672dc08e987e000008_39", "5a7237672dc08e987e000008_39", "5a7237672dc08e987e000008_39", "5a7237672dc08e987e000008_39", "5a7237672dc08e987e000008_39", "5a7237672dc08e987e000008_39", "5a7237672dc08e987e000008_39", "5a7237672dc08e987e000008_39", "5a7237672dc08e987e000008_39", "5a7237672dc08e987e000008_40", "5a7237672dc08e987e000008_40", "5a7237672dc08e987e000008_40", "5a7237672dc08e987e000008_40", "5a7237672dc08e987e000008_40", "5a7237672dc08e987e000008_40", "5a7237672dc08e987e000008_40", "5a7237672dc08e987e000008_40", "5a7237672dc08e987e000008_40", "5a7237672dc08e987e000008_40", "5a7237672dc08e987e000008_40", "5a7237672dc08e987e000008_40", "5a7237672dc08e987e000008_40", "5a7237672dc08e987e000008_40", "5a7237672dc08e987e000008_40", "5a7237672dc08e987e000008_40", "5a7237672dc08e987e000008_40", "5a7237672dc08e987e000008_40", "5a7237672dc08e987e000008_40", "5a7237672dc08e987e000008_40", "5a7237672dc08e987e000008_40", "5a7237672dc08e987e000008_40", "5a7237672dc08e987e000008_40", "5a7237672dc08e987e000008_40", "5a7237672dc08e987e000008_40", "5a7237672dc08e987e000008_40", "5a7237672dc08e987e000008_40", "5a7237672dc08e987e000008_40", "5a7237672dc08e987e000008_40", "5a7237672dc08e987e000008_40", "5a7237672dc08e987e000008_40", "5a7237672dc08e987e000008_40", "5a7237672dc08e987e000008_41", "5a7237672dc08e987e000008_41", "5a7237672dc08e987e000008_41", "5a7237672dc08e987e000008_41", "5a7237672dc08e987e000008_41", "5a7237672dc08e987e000008_41", "5a7237672dc08e987e000008_41", "5a7237672dc08e987e000008_41", "5a7237672dc08e987e000008_41", "5a7237672dc08e987e000008_41", "5a7237672dc08e987e000008_41", "5a7237672dc08e987e000008_41", "5a7237672dc08e987e000008_41", "5a7237672dc08e987e000008_41", "5a7237672dc08e987e000008_41", "5a7237672dc08e987e000008_41", "5a7237672dc08e987e000008_41", "5a7237672dc08e987e000008_41", "5a7237672dc08e987e000008_41", "5a7237672dc08e987e000008_41", "5a7237672dc08e987e000008_41", "5a7237672dc08e987e000008_41", "5a7237672dc08e987e000008_41", "5a7237672dc08e987e000008_41", "5a7237672dc08e987e000008_41", "5a7237672dc08e987e000008_41", "5a7237672dc08e987e000008_41", "5a7237672dc08e987e000008_41", "5a7237672dc08e987e000008_41", "5a7237672dc08e987e000008_41", "5a7237672dc08e987e000008_41", "5a7237672dc08e987e000008_41", "5a7237672dc08e987e000008_42", "5a7237672dc08e987e000008_42", "5a7237672dc08e987e000008_42", "5a7237672dc08e987e000008_42", "5a7237672dc08e987e000008_42", "5a7237672dc08e987e000008_42", "5a7237672dc08e987e000008_42", "5a7237672dc08e987e000008_42", "5a7237672dc08e987e000008_42", "5a7237672dc08e987e000008_42", "5a7237672dc08e987e000008_42", "5a7237672dc08e987e000008_42", "5a7237672dc08e987e000008_42", "5a7237672dc08e987e000008_42", "5a7237672dc08e987e000008_42", "5a7237672dc08e987e000008_42", "5a7237672dc08e987e000008_42", "5a7237672dc08e987e000008_42", "5a7237672dc08e987e000008_42", "5a7237672dc08e987e000008_42", "5a7237672dc08e987e000008_42", "5a7237672dc08e987e000008_42", "5a7237672dc08e987e000008_42", "5a7237672dc08e987e000008_42", "5a7237672dc08e987e000008_42", "5a7237672dc08e987e000008_42", "5a7237672dc08e987e000008_42", "5a7237672dc08e987e000008_42", "5a7237672dc08e987e000008_42", "5a7237672dc08e987e000008_42", "5a7237672dc08e987e000008_42", "5a7237672dc08e987e000008_42", "5a7237672dc08e987e000008_43", "5a7237672dc08e987e000008_43", "5a7237672dc08e987e000008_43", "5a7237672dc08e987e000008_43", "5a7237672dc08e987e000008_43", "5a7237672dc08e987e000008_43", "5a7237672dc08e987e000008_43", "5a7237672dc08e987e000008_43", "5a7237672dc08e987e000008_43", "5a7237672dc08e987e000008_43", "5a7237672dc08e987e000008_43", "5a7237672dc08e987e000008_43", "5a7237672dc08e987e000008_43", "5a7237672dc08e987e000008_43", "5a7237672dc08e987e000008_43", "5a7237672dc08e987e000008_43", "5a7237672dc08e987e000008_43", "5a7237672dc08e987e000008_43", "5a7237672dc08e987e000008_43", "5a7237672dc08e987e000008_43", "5a7237672dc08e987e000008_43", "5a7237672dc08e987e000008_43", "5a7237672dc08e987e000008_43", "5a7237672dc08e987e000008_43", "5a7237672dc08e987e000008_43", "5a7237672dc08e987e000008_43", "5a7237672dc08e987e000008_43", "5a7237672dc08e987e000008_43", "5a7237672dc08e987e000008_43", "5a7237672dc08e987e000008_43", "5a7237672dc08e987e000008_43", "5a7237672dc08e987e000008_43", "5a7237672dc08e987e000008_44", "5a7237672dc08e987e000008_44", "5a7237672dc08e987e000008_44", "5a7237672dc08e987e000008_44", "5a7237672dc08e987e000008_44", "5a7237672dc08e987e000008_44", "5a7237672dc08e987e000008_44", "5a7237672dc08e987e000008_44", "5a7237672dc08e987e000008_44", "5a7237672dc08e987e000008_44", "5a7237672dc08e987e000008_44", "5a7237672dc08e987e000008_44", "5a7237672dc08e987e000008_44", "5a7237672dc08e987e000008_44", "5a7237672dc08e987e000008_44", "5a7237672dc08e987e000008_44", "5a7237672dc08e987e000008_44", "5a7237672dc08e987e000008_44", "5a7237672dc08e987e000008_44", "5a7237672dc08e987e000008_44", "5a7237672dc08e987e000008_44", "5a7237672dc08e987e000008_44", "5a7237672dc08e987e000008_44", "5a7237672dc08e987e000008_44", "5a7237672dc08e987e000008_44", "5a7237672dc08e987e000008_44", "5a7237672dc08e987e000008_44", "5a7237672dc08e987e000008_44", "5a7237672dc08e987e000008_44", "5a7237672dc08e987e000008_44", "5a7237672dc08e987e000008_44", "5a7237672dc08e987e000008_44", "5a7237672dc08e987e000008_45", "5a7237672dc08e987e000008_45", "5a7237672dc08e987e000008_45", "5a7237672dc08e987e000008_45", "5a7237672dc08e987e000008_45", "5a7237672dc08e987e000008_45", "5a7237672dc08e987e000008_45", "5a7237672dc08e987e000008_45", "5a7237672dc08e987e000008_45", "5a7237672dc08e987e000008_45", "5a7237672dc08e987e000008_45", "5a7237672dc08e987e000008_45", "5a7237672dc08e987e000008_45", "5a7237672dc08e987e000008_45", "5a7237672dc08e987e000008_45", "5a7237672dc08e987e000008_45", "5a7237672dc08e987e000008_45", "5a7237672dc08e987e000008_45", "5a7237672dc08e987e000008_45", "5a7237672dc08e987e000008_45", "5a7237672dc08e987e000008_45", "5a7237672dc08e987e000008_45", "5a7237672dc08e987e000008_45", "5a7237672dc08e987e000008_45", "5a7237672dc08e987e000008_45", "5a7237672dc08e987e000008_45", "5a7237672dc08e987e000008_45", "5a7237672dc08e987e000008_45", "5a7237672dc08e987e000008_45", "5a7237672dc08e987e000008_45", "5a7237672dc08e987e000008_45", "5a7237672dc08e987e000008_45", "5a7237672dc08e987e000008_46", "5a7237672dc08e987e000008_46", "5a7237672dc08e987e000008_46", "5a7237672dc08e987e000008_46", "5a7237672dc08e987e000008_46", "5a7237672dc08e987e000008_46", "5a7237672dc08e987e000008_46", "5a7237672dc08e987e000008_46", "5a7237672dc08e987e000008_46", "5a7237672dc08e987e000008_46", "5a7237672dc08e987e000008_46", "5a7237672dc08e987e000008_46", "5a7237672dc08e987e000008_46", "5a7237672dc08e987e000008_46", "5a7237672dc08e987e000008_46", "5a7237672dc08e987e000008_46", "5a7237672dc08e987e000008_46", "5a7237672dc08e987e000008_46", "5a7237672dc08e987e000008_46", "5a7237672dc08e987e000008_46", "5a7237672dc08e987e000008_46", "5a7237672dc08e987e000008_46", "5a7237672dc08e987e000008_46", "5a7237672dc08e987e000008_46", "5a7237672dc08e987e000008_46", "5a7237672dc08e987e000008_46", "5a7237672dc08e987e000008_46", "5a7237672dc08e987e000008_46", "5a7237672dc08e987e000008_46", "5a7237672dc08e987e000008_46", "5a7237672dc08e987e000008_46", "5a7237672dc08e987e000008_46", "5a7237672dc08e987e000008_47", "5a7237672dc08e987e000008_47", "5a7237672dc08e987e000008_47", "5a7237672dc08e987e000008_47", "5a7237672dc08e987e000008_47", "5a7237672dc08e987e000008_47", "5a7237672dc08e987e000008_47", "5a7237672dc08e987e000008_47", "5a7237672dc08e987e000008_47", "5a7237672dc08e987e000008_47", "5a7237672dc08e987e000008_47", "5a7237672dc08e987e000008_47", "5a7237672dc08e987e000008_47", "5a7237672dc08e987e000008_47", "5a7237672dc08e987e000008_47", "5a7237672dc08e987e000008_47", "5a7237672dc08e987e000008_47", "5a7237672dc08e987e000008_47", "5a7237672dc08e987e000008_47", "5a7237672dc08e987e000008_47", "5a7237672dc08e987e000008_47", "5a7237672dc08e987e000008_47", "5a7237672dc08e987e000008_47", "5a7237672dc08e987e000008_47", "5a7237672dc08e987e000008_47", "5a7237672dc08e987e000008_47", "5a7237672dc08e987e000008_47", "5a7237672dc08e987e000008_47", "5a7237672dc08e987e000008_47", "5a7237672dc08e987e000008_47", "5a7237672dc08e987e000008_47", "5a7237672dc08e987e000008_47", "5a7237672dc08e987e000008_48", "5a7237672dc08e987e000008_48", "5a7237672dc08e987e000008_48", "5a7237672dc08e987e000008_48", "5a7237672dc08e987e000008_48", "5a7237672dc08e987e000008_48", "5a7237672dc08e987e000008_48", "5a7237672dc08e987e000008_48", "5a7237672dc08e987e000008_48", "5a7237672dc08e987e000008_48", "5a7237672dc08e987e000008_48", "5a7237672dc08e987e000008_48", "5a7237672dc08e987e000008_48", "5a7237672dc08e987e000008_48", "5a7237672dc08e987e000008_48", "5a7237672dc08e987e000008_48", "5a7237672dc08e987e000008_48", "5a7237672dc08e987e000008_48", "5a7237672dc08e987e000008_48", "5a7237672dc08e987e000008_48", "5a7237672dc08e987e000008_48", "5a7237672dc08e987e000008_48", "5a7237672dc08e987e000008_48", "5a7237672dc08e987e000008_48", "5a7237672dc08e987e000008_48", "5a7237672dc08e987e000008_48", "5a7237672dc08e987e000008_48", "5a7237672dc08e987e000008_48", "5a7237672dc08e987e000008_48", "5a7237672dc08e987e000008_48", "5a7237672dc08e987e000008_48", "5a7237672dc08e987e000008_48", "5a7237672dc08e987e000008_49", "5a7237672dc08e987e000008_49", "5a7237672dc08e987e000008_49", "5a7237672dc08e987e000008_49", "5a7237672dc08e987e000008_49", "5a7237672dc08e987e000008_49", "5a7237672dc08e987e000008_49", "5a7237672dc08e987e000008_49", "5a7237672dc08e987e000008_49", "5a7237672dc08e987e000008_49", "5a7237672dc08e987e000008_49", "5a7237672dc08e987e000008_49", "5a7237672dc08e987e000008_49", "5a7237672dc08e987e000008_49", "5a7237672dc08e987e000008_49", "5a7237672dc08e987e000008_49", "5a7237672dc08e987e000008_49", "5a7237672dc08e987e000008_49", "5a7237672dc08e987e000008_49", "5a7237672dc08e987e000008_49", "5a7237672dc08e987e000008_49", "5a7237672dc08e987e000008_49", "5a7237672dc08e987e000008_49", "5a7237672dc08e987e000008_49", "5a7237672dc08e987e000008_49", "5a7237672dc08e987e000008_49", "5a7237672dc08e987e000008_49", "5a7237672dc08e987e000008_49", "5a7237672dc08e987e000008_49", "5a7237672dc08e987e000008_49", "5a7237672dc08e987e000008_49", "5a7237672dc08e987e000008_49", "5a7237672dc08e987e000008_50", "5a7237672dc08e987e000008_50", "5a7237672dc08e987e000008_50", "5a7237672dc08e987e000008_50", "5a7237672dc08e987e000008_50", "5a7237672dc08e987e000008_50", "5a7237672dc08e987e000008_50", "5a7237672dc08e987e000008_50", "5a7237672dc08e987e000008_50", "5a7237672dc08e987e000008_50", "5a7237672dc08e987e000008_50", "5a7237672dc08e987e000008_50", "5a7237672dc08e987e000008_50", "5a7237672dc08e987e000008_50", "5a7237672dc08e987e000008_50", "5a7237672dc08e987e000008_50", "5a7237672dc08e987e000008_50", "5a7237672dc08e987e000008_50", "5a7237672dc08e987e000008_50", "5a7237672dc08e987e000008_50", "5a7237672dc08e987e000008_50", "5a7237672dc08e987e000008_50", "5a7237672dc08e987e000008_50", "5a7237672dc08e987e000008_50", "5a7237672dc08e987e000008_50", "5a7237672dc08e987e000008_50", "5a7237672dc08e987e000008_50", "5a7237672dc08e987e000008_50", "5a7237672dc08e987e000008_50", "5a7237672dc08e987e000008_50", "5a7237672dc08e987e000008_50", "5a7237672dc08e987e000008_50", "5a7237672dc08e987e000008_51", "5a7237672dc08e987e000008_51", "5a7237672dc08e987e000008_51", "5a7237672dc08e987e000008_51", "5a7237672dc08e987e000008_51", "5a7237672dc08e987e000008_51", "5a7237672dc08e987e000008_51", "5a7237672dc08e987e000008_51", "5a7237672dc08e987e000008_51", "5a7237672dc08e987e000008_51", "5a7237672dc08e987e000008_51", "5a7237672dc08e987e000008_51", "5a7237672dc08e987e000008_51", "5a7237672dc08e987e000008_51", "5a7237672dc08e987e000008_51", "5a7237672dc08e987e000008_51", "5a7237672dc08e987e000008_51", "5a7237672dc08e987e000008_51", "5a7237672dc08e987e000008_51", "5a7237672dc08e987e000008_51", "5a7237672dc08e987e000008_51", "5a7237672dc08e987e000008_51", "5a7237672dc08e987e000008_51", "5a7237672dc08e987e000008_51", "5a7237672dc08e987e000008_51", "5a7237672dc08e987e000008_51", "5a7237672dc08e987e000008_51", "5a7237672dc08e987e000008_51", "5a7237672dc08e987e000008_51", "5a7237672dc08e987e000008_51", "5a7237672dc08e987e000008_51", "5a7237672dc08e987e000008_51", "5a7237672dc08e987e000008_52", "5a7237672dc08e987e000008_52", "5a7237672dc08e987e000008_52", "5a7237672dc08e987e000008_52", "5a7237672dc08e987e000008_52", "5a7237672dc08e987e000008_52", "5a7237672dc08e987e000008_52", "5a7237672dc08e987e000008_52", "5a7237672dc08e987e000008_52", "5a7237672dc08e987e000008_52", "5a7237672dc08e987e000008_52", "5a7237672dc08e987e000008_52", "5a7237672dc08e987e000008_52", "5a7237672dc08e987e000008_52", "5a7237672dc08e987e000008_52", "5a7237672dc08e987e000008_52", "5a7237672dc08e987e000008_52", "5a7237672dc08e987e000008_52", "5a7237672dc08e987e000008_52", "5a7237672dc08e987e000008_52", "5a7237672dc08e987e000008_52", "5a7237672dc08e987e000008_52", "5a7237672dc08e987e000008_52", "5a7237672dc08e987e000008_52", "5a7237672dc08e987e000008_52", "5a7237672dc08e987e000008_52", "5a7237672dc08e987e000008_52", "5a7237672dc08e987e000008_52", "5a7237672dc08e987e000008_52", "5a7237672dc08e987e000008_52", "5a7237672dc08e987e000008_52", "5a7237672dc08e987e000008_52", "5a7237672dc08e987e000008_53", "5a7237672dc08e987e000008_53", "5a7237672dc08e987e000008_53", "5a7237672dc08e987e000008_53", "5a7237672dc08e987e000008_53", "5a7237672dc08e987e000008_53", "5a7237672dc08e987e000008_53", "5a7237672dc08e987e000008_53", "5a7237672dc08e987e000008_53", "5a7237672dc08e987e000008_53", "5a7237672dc08e987e000008_53", "5a7237672dc08e987e000008_53", "5a7237672dc08e987e000008_53", "5a7237672dc08e987e000008_53", "5a7237672dc08e987e000008_53", "5a7237672dc08e987e000008_53", "5a7237672dc08e987e000008_53", "5a7237672dc08e987e000008_53", "5a7237672dc08e987e000008_53", "5a7237672dc08e987e000008_53", "5a7237672dc08e987e000008_53", "5a7237672dc08e987e000008_53", "5a7237672dc08e987e000008_53", "5a7237672dc08e987e000008_53", "5a7237672dc08e987e000008_53", "5a7237672dc08e987e000008_53", "5a7237672dc08e987e000008_53", "5a7237672dc08e987e000008_53", "5a7237672dc08e987e000008_53", "5a7237672dc08e987e000008_53", "5a7237672dc08e987e000008_53", "5a7237672dc08e987e000008_53", "5a7237672dc08e987e000008_54", "5a7237672dc08e987e000008_54", "5a7237672dc08e987e000008_54", "5a7237672dc08e987e000008_54", "5a7237672dc08e987e000008_54", "5a7237672dc08e987e000008_54", "5a7237672dc08e987e000008_54", "5a7237672dc08e987e000008_54", "5a7237672dc08e987e000008_54", "5a7237672dc08e987e000008_54", "5a7237672dc08e987e000008_54", "5a7237672dc08e987e000008_54", "5a7237672dc08e987e000008_54", "5a7237672dc08e987e000008_54", "5a7237672dc08e987e000008_54", "5a7237672dc08e987e000008_54", "5a7237672dc08e987e000008_54", "5a7237672dc08e987e000008_54", "5a7237672dc08e987e000008_54", "5a7237672dc08e987e000008_54", "5a7237672dc08e987e000008_54", "5a7237672dc08e987e000008_54", "5a7237672dc08e987e000008_54", "5a7237672dc08e987e000008_54", "5a7237672dc08e987e000008_54", "5a7237672dc08e987e000008_54", "5a7237672dc08e987e000008_54", "5a7237672dc08e987e000008_54", "5a7237672dc08e987e000008_54", "5a7237672dc08e987e000008_54", "5a7237672dc08e987e000008_54", "5a7237672dc08e987e000008_54", "5a7237672dc08e987e000008_55", "5a7237672dc08e987e000008_55", "5a7237672dc08e987e000008_55", "5a7237672dc08e987e000008_55", "5a7237672dc08e987e000008_55", "5a7237672dc08e987e000008_55", "5a7237672dc08e987e000008_55", "5a7237672dc08e987e000008_55", "5a7237672dc08e987e000008_55", "5a7237672dc08e987e000008_55", "5a7237672dc08e987e000008_55", "5a7237672dc08e987e000008_55", "5a7237672dc08e987e000008_55", "5a7237672dc08e987e000008_55", "5a7237672dc08e987e000008_55", "5a7237672dc08e987e000008_55", "5a7237672dc08e987e000008_55", "5a7237672dc08e987e000008_55", "5a7237672dc08e987e000008_55", "5a7237672dc08e987e000008_55", "5a7237672dc08e987e000008_55", "5a7237672dc08e987e000008_55", "5a7237672dc08e987e000008_55", "5a7237672dc08e987e000008_55", "5a7237672dc08e987e000008_55", "5a7237672dc08e987e000008_55", "5a7237672dc08e987e000008_55", "5a7237672dc08e987e000008_55", "5a7237672dc08e987e000008_55", "5a7237672dc08e987e000008_55", "5a7237672dc08e987e000008_55", "5a7237672dc08e987e000008_55", "5a7237672dc08e987e000008_56", "5a7237672dc08e987e000008_56", "5a7237672dc08e987e000008_56", "5a7237672dc08e987e000008_56", "5a7237672dc08e987e000008_56", "5a7237672dc08e987e000008_56", "5a7237672dc08e987e000008_56", "5a7237672dc08e987e000008_56", "5a7237672dc08e987e000008_56", "5a7237672dc08e987e000008_56", "5a7237672dc08e987e000008_56", "5a7237672dc08e987e000008_56", "5a7237672dc08e987e000008_56", "5a7237672dc08e987e000008_56", "5a7237672dc08e987e000008_56", "5a7237672dc08e987e000008_56", "5a7237672dc08e987e000008_56", "5a7237672dc08e987e000008_56", "5a7237672dc08e987e000008_56", "5a7237672dc08e987e000008_56", "5a7237672dc08e987e000008_56", "5a7237672dc08e987e000008_56", "5a7237672dc08e987e000008_56", "5a7237672dc08e987e000008_56", "5a7237672dc08e987e000008_56", "5a7237672dc08e987e000008_56", "5a7237672dc08e987e000008_56", "5a7237672dc08e987e000008_56", "5a7237672dc08e987e000008_56", "5a7237672dc08e987e000008_56", "5a7237672dc08e987e000008_56", "5a7237672dc08e987e000008_56", "5a7237672dc08e987e000008_57", "5a7237672dc08e987e000008_57", "5a7237672dc08e987e000008_57", "5a7237672dc08e987e000008_57", "5a7237672dc08e987e000008_57", "5a7237672dc08e987e000008_57", "5a7237672dc08e987e000008_57", "5a7237672dc08e987e000008_57", "5a7237672dc08e987e000008_57", "5a7237672dc08e987e000008_57", "5a7237672dc08e987e000008_57", "5a7237672dc08e987e000008_57", "5a7237672dc08e987e000008_57", "5a7237672dc08e987e000008_57", "5a7237672dc08e987e000008_57", "5a7237672dc08e987e000008_57", "5a7237672dc08e987e000008_57", "5a7237672dc08e987e000008_57", "5a7237672dc08e987e000008_57", "5a7237672dc08e987e000008_57", "5a7237672dc08e987e000008_57", "5a7237672dc08e987e000008_57", "5a7237672dc08e987e000008_57", "5a7237672dc08e987e000008_57", "5a7237672dc08e987e000008_57", "5a7237672dc08e987e000008_57", "5a7237672dc08e987e000008_57", "5a7237672dc08e987e000008_57", "5a7237672dc08e987e000008_57", "5a7237672dc08e987e000008_57", "5a7237672dc08e987e000008_57", "5a7237672dc08e987e000008_57", "5a7237672dc08e987e000008_58", "5a7237672dc08e987e000008_58", "5a7237672dc08e987e000008_58", "5a7237672dc08e987e000008_58", "5a7237672dc08e987e000008_58", "5a7237672dc08e987e000008_58", "5a7237672dc08e987e000008_58", "5a7237672dc08e987e000008_58", "5a7237672dc08e987e000008_58", "5a7237672dc08e987e000008_58", "5a7237672dc08e987e000008_58", "5a7237672dc08e987e000008_58", "5a7237672dc08e987e000008_58", "5a7237672dc08e987e000008_58", "5a7237672dc08e987e000008_58", "5a7237672dc08e987e000008_58", "5a7237672dc08e987e000008_58", "5a7237672dc08e987e000008_58", "5a7237672dc08e987e000008_58", "5a7237672dc08e987e000008_58", "5a7237672dc08e987e000008_58", "5a7237672dc08e987e000008_58", "5a7237672dc08e987e000008_58", "5a7237672dc08e987e000008_58", "5a7237672dc08e987e000008_58", "5a7237672dc08e987e000008_58", "5a7237672dc08e987e000008_58", "5a7237672dc08e987e000008_58", "5a7237672dc08e987e000008_58", "5a7237672dc08e987e000008_58", "5a7237672dc08e987e000008_58", "5a7237672dc08e987e000008_58", "5a7346662dc08e987e00001a_59", "5a7346662dc08e987e00001a_59", "5a7346662dc08e987e00001a_59", "5a7346662dc08e987e00001a_59", "5a7346662dc08e987e00001a_59", "5a7346662dc08e987e00001a_59", "5a7346662dc08e987e00001a_59", "5a7346662dc08e987e00001a_59", "5a7346662dc08e987e00001a_59", "5a7346662dc08e987e00001a_59", "5a7346662dc08e987e00001a_59", "5a7346662dc08e987e00001a_59", "5a7346662dc08e987e00001a_59", "5a7346662dc08e987e00001a_59", "5a7346662dc08e987e00001a_59", "5a7346662dc08e987e00001a_59", "5a7346662dc08e987e00001a_60", "5a7346662dc08e987e00001a_60", "5a7346662dc08e987e00001a_60", "5a7346662dc08e987e00001a_60", "5a7346662dc08e987e00001a_60", "5a7346662dc08e987e00001a_60", "5a7346662dc08e987e00001a_60", "5a7346662dc08e987e00001a_60", "5a7346662dc08e987e00001a_60", "5a7346662dc08e987e00001a_60", "5a7346662dc08e987e00001a_60", "5a7346662dc08e987e00001a_60", "5a7346662dc08e987e00001a_60", "5a7346662dc08e987e00001a_60", "5a7346662dc08e987e00001a_60", "5a7346662dc08e987e00001a_60", "5a7346662dc08e987e00001a_61", "5a7346662dc08e987e00001a_61", "5a7346662dc08e987e00001a_61", "5a7346662dc08e987e00001a_61", "5a7346662dc08e987e00001a_61", "5a7346662dc08e987e00001a_61", "5a7346662dc08e987e00001a_61", "5a7346662dc08e987e00001a_61", "5a7346662dc08e987e00001a_61", "5a7346662dc08e987e00001a_61", "5a7346662dc08e987e00001a_61", "5a7346662dc08e987e00001a_61", "5a7346662dc08e987e00001a_61", "5a7346662dc08e987e00001a_61", "5a7346662dc08e987e00001a_61", "5a7346662dc08e987e00001a_61", "5a7346662dc08e987e00001a_62", "5a7346662dc08e987e00001a_62", "5a7346662dc08e987e00001a_62", "5a7346662dc08e987e00001a_62", "5a7346662dc08e987e00001a_62", "5a7346662dc08e987e00001a_62", "5a7346662dc08e987e00001a_62", "5a7346662dc08e987e00001a_62", "5a7346662dc08e987e00001a_62", "5a7346662dc08e987e00001a_62", "5a7346662dc08e987e00001a_62", "5a7346662dc08e987e00001a_62", "5a7346662dc08e987e00001a_62", "5a7346662dc08e987e00001a_62", "5a7346662dc08e987e00001a_62", "5a7346662dc08e987e00001a_62", "5a7346662dc08e987e00001a_63", "5a7346662dc08e987e00001a_63", "5a7346662dc08e987e00001a_63", "5a7346662dc08e987e00001a_63", "5a7346662dc08e987e00001a_63", "5a7346662dc08e987e00001a_63", "5a7346662dc08e987e00001a_63", "5a7346662dc08e987e00001a_63", "5a7346662dc08e987e00001a_63", "5a7346662dc08e987e00001a_63", "5a7346662dc08e987e00001a_63", "5a7346662dc08e987e00001a_63", "5a7346662dc08e987e00001a_63", "5a7346662dc08e987e00001a_63", "5a7346662dc08e987e00001a_63", "5a7346662dc08e987e00001a_63", "5a7234352dc08e987e000007_64", "5a7234352dc08e987e000007_64", "5a7234352dc08e987e000007_64", "5a7234352dc08e987e000007_64", "5a7234352dc08e987e000007_64", "5a7234352dc08e987e000007_64", "5a7234352dc08e987e000007_64", "5a7234352dc08e987e000007_64", "5a7234352dc08e987e000007_65", "5a7234352dc08e987e000007_65", "5a7234352dc08e987e000007_65", "5a7234352dc08e987e000007_65", "5a7234352dc08e987e000007_65", "5a7234352dc08e987e000007_65", "5a7234352dc08e987e000007_65", "5a7234352dc08e987e000007_65", "5a7234352dc08e987e000007_66", "5a7234352dc08e987e000007_66", "5a7234352dc08e987e000007_66", "5a7234352dc08e987e000007_66", "5a7234352dc08e987e000007_66", "5a7234352dc08e987e000007_66", "5a7234352dc08e987e000007_66", "5a7234352dc08e987e000007_66", "5a7234352dc08e987e000007_67", "5a7234352dc08e987e000007_67", "5a7234352dc08e987e000007_67", "5a7234352dc08e987e000007_67", "5a7234352dc08e987e000007_67", "5a7234352dc08e987e000007_67", "5a7234352dc08e987e000007_67", "5a7234352dc08e987e000007_67", "5a7234352dc08e987e000007_68", "5a7234352dc08e987e000007_68", "5a7234352dc08e987e000007_68", "5a7234352dc08e987e000007_68", "5a7234352dc08e987e000007_68", "5a7234352dc08e987e000007_68", "5a7234352dc08e987e000007_68", "5a7234352dc08e987e000007_68", "5a7234352dc08e987e000007_69", "5a7234352dc08e987e000007_69", "5a7234352dc08e987e000007_69", "5a7234352dc08e987e000007_69", "5a7234352dc08e987e000007_69", "5a7234352dc08e987e000007_69", "5a7234352dc08e987e000007_69", "5a7234352dc08e987e000007_69", "5a7234352dc08e987e000007_70", "5a7234352dc08e987e000007_70", "5a7234352dc08e987e000007_70", "5a7234352dc08e987e000007_70", "5a7234352dc08e987e000007_70", "5a7234352dc08e987e000007_70", "5a7234352dc08e987e000007_70", "5a7234352dc08e987e000007_70", "5a7234352dc08e987e000007_71", "5a7234352dc08e987e000007_71", "5a7234352dc08e987e000007_71", "5a7234352dc08e987e000007_71", "5a7234352dc08e987e000007_71", "5a7234352dc08e987e000007_71", "5a7234352dc08e987e000007_71", "5a7234352dc08e987e000007_71", "5a7234352dc08e987e000007_72", "5a7234352dc08e987e000007_72", "5a7234352dc08e987e000007_72", "5a7234352dc08e987e000007_72", "5a7234352dc08e987e000007_72", "5a7234352dc08e987e000007_72", "5a7234352dc08e987e000007_72", "5a7234352dc08e987e000007_72", "5a7234352dc08e987e000007_73", "5a7234352dc08e987e000007_73", "5a7234352dc08e987e000007_73", "5a7234352dc08e987e000007_73", "5a7234352dc08e987e000007_73", "5a7234352dc08e987e000007_73", "5a7234352dc08e987e000007_73", "5a7234352dc08e987e000007_73", "5a6e24a5b750ff445500003c_74", "5a6e24a5b750ff445500003c_74", "5a6e24a5b750ff445500003c_74", "5a6e24a5b750ff445500003c_74", "5a6e24a5b750ff445500003c_74", "5a6e24a5b750ff445500003c_74", "5a6e24a5b750ff445500003c_74", "5a6e24a5b750ff445500003c_74", "5a6e24a5b750ff445500003c_74", "5a6e24a5b750ff445500003c_74", "5a6e24a5b750ff445500003c_74", "5a6e24a5b750ff445500003c_74", "5a6e24a5b750ff445500003c_74", "5a6e24a5b750ff445500003c_74", "5a6e24a5b750ff445500003c_74", "5a6e24a5b750ff445500003c_74", "5a6e24a5b750ff445500003c_74", "5a6e24a5b750ff445500003c_74", "5a6e24a5b750ff445500003c_74", "5a6e24a5b750ff445500003c_74", "5a6e24a5b750ff445500003c_74", "5a6e24a5b750ff445500003c_74", "5a6e24a5b750ff445500003c_74", "5a6e24a5b750ff445500003c_74", "5a6e24a5b750ff445500003c_74", "5a6e24a5b750ff445500003c_74", "5a6e24a5b750ff445500003c_74", "5a6e24a5b750ff445500003c_74", "5a6e24a5b750ff445500003c_74", "5a6e24a5b750ff445500003c_74", "5a6e24a5b750ff445500003c_74", "5a6e24a5b750ff445500003c_74", "5a6e24a5b750ff445500003c_74", "5a6e24a5b750ff445500003c_74", "5a6e24a5b750ff445500003c_74", "5a6e24a5b750ff445500003c_74", "5a6e24a5b750ff445500003c_74", "5a6e24a5b750ff445500003c_74", "5a6e24a5b750ff445500003c_74", "5a6e24a5b750ff445500003c_74", "5a6e24a5b750ff445500003c_74", "5a6e24a5b750ff445500003c_74", "5a6e24a5b750ff445500003c_74", "5a6e24a5b750ff445500003c_74", "5a6e24a5b750ff445500003c_75", "5a6e24a5b750ff445500003c_75", "5a6e24a5b750ff445500003c_75", "5a6e24a5b750ff445500003c_75", "5a6e24a5b750ff445500003c_75", "5a6e24a5b750ff445500003c_75", "5a6e24a5b750ff445500003c_75", "5a6e24a5b750ff445500003c_75", "5a6e24a5b750ff445500003c_75", "5a6e24a5b750ff445500003c_75", "5a6e24a5b750ff445500003c_75", "5a6e24a5b750ff445500003c_75", "5a6e24a5b750ff445500003c_75", "5a6e24a5b750ff445500003c_75", "5a6e24a5b750ff445500003c_75", "5a6e24a5b750ff445500003c_75", "5a6e24a5b750ff445500003c_75", "5a6e24a5b750ff445500003c_75", "5a6e24a5b750ff445500003c_75", "5a6e24a5b750ff445500003c_75", "5a6e24a5b750ff445500003c_75", "5a6e24a5b750ff445500003c_75", "5a6e24a5b750ff445500003c_75", "5a6e24a5b750ff445500003c_75", "5a6e24a5b750ff445500003c_75", "5a6e24a5b750ff445500003c_75", "5a6e24a5b750ff445500003c_75", "5a6e24a5b750ff445500003c_75", "5a6e24a5b750ff445500003c_75", "5a6e24a5b750ff445500003c_75", "5a6e24a5b750ff445500003c_75", "5a6e24a5b750ff445500003c_75", "5a6e24a5b750ff445500003c_75", "5a6e24a5b750ff445500003c_75", "5a6e24a5b750ff445500003c_75", "5a6e24a5b750ff445500003c_75", "5a6e24a5b750ff445500003c_75", "5a6e24a5b750ff445500003c_75", "5a6e24a5b750ff445500003c_75", "5a6e24a5b750ff445500003c_75", "5a6e24a5b750ff445500003c_75", "5a6e24a5b750ff445500003c_75", "5a6e24a5b750ff445500003c_75", "5a6e24a5b750ff445500003c_75", "5a895f51fcd1d6a10c000004_76", "5a895f51fcd1d6a10c000004_76", "5a895f51fcd1d6a10c000004_76", "5a895f51fcd1d6a10c000004_76", "5a895f51fcd1d6a10c000004_76", "5a895f51fcd1d6a10c000004_76", "5a895f51fcd1d6a10c000004_76", "5a895f51fcd1d6a10c000004_76", "5a895f51fcd1d6a10c000004_76", "5a895f51fcd1d6a10c000004_76", "5a895f51fcd1d6a10c000004_76", "5a895f51fcd1d6a10c000004_76", "5a895f51fcd1d6a10c000004_76", "5a895f51fcd1d6a10c000004_76", "5a895f51fcd1d6a10c000004_76", "5a895f51fcd1d6a10c000004_76", "5a895f51fcd1d6a10c000004_76", "5a895f51fcd1d6a10c000004_76", "5a895f51fcd1d6a10c000004_76", "5a895f51fcd1d6a10c000004_76", "5a895f51fcd1d6a10c000004_76", "5a895f51fcd1d6a10c000004_76", "5a895f51fcd1d6a10c000004_76", "5a895f51fcd1d6a10c000004_76", "5a895f51fcd1d6a10c000004_76", "5a895f51fcd1d6a10c000004_76", "5a895f51fcd1d6a10c000004_76", "5a895f51fcd1d6a10c000004_77", "5a895f51fcd1d6a10c000004_77", "5a895f51fcd1d6a10c000004_77", "5a895f51fcd1d6a10c000004_77", "5a895f51fcd1d6a10c000004_77", "5a895f51fcd1d6a10c000004_77", "5a895f51fcd1d6a10c000004_77", "5a895f51fcd1d6a10c000004_77", "5a895f51fcd1d6a10c000004_77", "5a895f51fcd1d6a10c000004_77", "5a895f51fcd1d6a10c000004_77", "5a895f51fcd1d6a10c000004_77", "5a895f51fcd1d6a10c000004_77", "5a895f51fcd1d6a10c000004_77", "5a895f51fcd1d6a10c000004_77", "5a895f51fcd1d6a10c000004_77", "5a895f51fcd1d6a10c000004_77", "5a895f51fcd1d6a10c000004_77", "5a895f51fcd1d6a10c000004_77", "5a895f51fcd1d6a10c000004_77", "5a895f51fcd1d6a10c000004_77", "5a895f51fcd1d6a10c000004_77", "5a895f51fcd1d6a10c000004_77", "5a895f51fcd1d6a10c000004_77", "5a895f51fcd1d6a10c000004_77", "5a895f51fcd1d6a10c000004_77", "5a895f51fcd1d6a10c000004_77", "5a895f51fcd1d6a10c000004_78", "5a895f51fcd1d6a10c000004_78", "5a895f51fcd1d6a10c000004_78", "5a895f51fcd1d6a10c000004_78", "5a895f51fcd1d6a10c000004_78", "5a895f51fcd1d6a10c000004_78", "5a895f51fcd1d6a10c000004_78", "5a895f51fcd1d6a10c000004_78", "5a895f51fcd1d6a10c000004_78", "5a895f51fcd1d6a10c000004_78", "5a895f51fcd1d6a10c000004_78", "5a895f51fcd1d6a10c000004_78", "5a895f51fcd1d6a10c000004_78", "5a895f51fcd1d6a10c000004_78", "5a895f51fcd1d6a10c000004_78", "5a895f51fcd1d6a10c000004_78", "5a895f51fcd1d6a10c000004_78", "5a895f51fcd1d6a10c000004_78", "5a895f51fcd1d6a10c000004_78", "5a895f51fcd1d6a10c000004_78", "5a895f51fcd1d6a10c000004_78", "5a895f51fcd1d6a10c000004_78", "5a895f51fcd1d6a10c000004_78", "5a895f51fcd1d6a10c000004_78", "5a895f51fcd1d6a10c000004_78", "5a895f51fcd1d6a10c000004_78", "5a895f51fcd1d6a10c000004_78", "5a895f51fcd1d6a10c000004_79", "5a895f51fcd1d6a10c000004_79", "5a895f51fcd1d6a10c000004_79", "5a895f51fcd1d6a10c000004_79", "5a895f51fcd1d6a10c000004_79", "5a895f51fcd1d6a10c000004_79", "5a895f51fcd1d6a10c000004_79", "5a895f51fcd1d6a10c000004_79", "5a895f51fcd1d6a10c000004_79", "5a895f51fcd1d6a10c000004_79", "5a895f51fcd1d6a10c000004_79", "5a895f51fcd1d6a10c000004_79", "5a895f51fcd1d6a10c000004_79", "5a895f51fcd1d6a10c000004_79", "5a895f51fcd1d6a10c000004_79", "5a895f51fcd1d6a10c000004_79", "5a895f51fcd1d6a10c000004_79", "5a895f51fcd1d6a10c000004_79", "5a895f51fcd1d6a10c000004_79", "5a895f51fcd1d6a10c000004_79", "5a895f51fcd1d6a10c000004_79", "5a895f51fcd1d6a10c000004_79", "5a895f51fcd1d6a10c000004_79", "5a895f51fcd1d6a10c000004_79", "5a895f51fcd1d6a10c000004_79", "5a895f51fcd1d6a10c000004_79", "5a895f51fcd1d6a10c000004_79", "5a895f51fcd1d6a10c000004_80", "5a895f51fcd1d6a10c000004_80", "5a895f51fcd1d6a10c000004_80", "5a895f51fcd1d6a10c000004_80", "5a895f51fcd1d6a10c000004_80", "5a895f51fcd1d6a10c000004_80", "5a895f51fcd1d6a10c000004_80", "5a895f51fcd1d6a10c000004_80", "5a895f51fcd1d6a10c000004_80", "5a895f51fcd1d6a10c000004_80", "5a895f51fcd1d6a10c000004_80", "5a895f51fcd1d6a10c000004_80", "5a895f51fcd1d6a10c000004_80", "5a895f51fcd1d6a10c000004_80", "5a895f51fcd1d6a10c000004_80", "5a895f51fcd1d6a10c000004_80", "5a895f51fcd1d6a10c000004_80", "5a895f51fcd1d6a10c000004_80", "5a895f51fcd1d6a10c000004_80", "5a895f51fcd1d6a10c000004_80", "5a895f51fcd1d6a10c000004_80", "5a895f51fcd1d6a10c000004_80", "5a895f51fcd1d6a10c000004_80", "5a895f51fcd1d6a10c000004_80", "5a895f51fcd1d6a10c000004_80", "5a895f51fcd1d6a10c000004_80", "5a895f51fcd1d6a10c000004_80", "5a895f51fcd1d6a10c000004_81", "5a895f51fcd1d6a10c000004_81", "5a895f51fcd1d6a10c000004_81", "5a895f51fcd1d6a10c000004_81", "5a895f51fcd1d6a10c000004_81", "5a895f51fcd1d6a10c000004_81", "5a895f51fcd1d6a10c000004_81", "5a895f51fcd1d6a10c000004_81", "5a895f51fcd1d6a10c000004_81", "5a895f51fcd1d6a10c000004_81", "5a895f51fcd1d6a10c000004_81", "5a895f51fcd1d6a10c000004_81", "5a895f51fcd1d6a10c000004_81", "5a895f51fcd1d6a10c000004_81", "5a895f51fcd1d6a10c000004_81", "5a895f51fcd1d6a10c000004_81", "5a895f51fcd1d6a10c000004_81", "5a895f51fcd1d6a10c000004_81", "5a895f51fcd1d6a10c000004_81", "5a895f51fcd1d6a10c000004_81", "5a895f51fcd1d6a10c000004_81", "5a895f51fcd1d6a10c000004_81", "5a895f51fcd1d6a10c000004_81", "5a895f51fcd1d6a10c000004_81", "5a895f51fcd1d6a10c000004_81", "5a895f51fcd1d6a10c000004_81", "5a895f51fcd1d6a10c000004_81", "5a7d4e9afaa1ab7d2e000013_82", "5a7d4e9afaa1ab7d2e000013_82", "5a7d4e9afaa1ab7d2e000013_82", "5a7d4e9afaa1ab7d2e000013_82", "5a7d4e9afaa1ab7d2e000013_82", "5a7d4e9afaa1ab7d2e000013_82", "5a7d4e9afaa1ab7d2e000013_82", "5a7d4e9afaa1ab7d2e000013_82", "5a7d4e9afaa1ab7d2e000013_82", "5a7d4e9afaa1ab7d2e000013_82", "5a7d4e9afaa1ab7d2e000013_82", "5a7d4e9afaa1ab7d2e000013_82", "5a7d4e9afaa1ab7d2e000013_82", "5a7d4e9afaa1ab7d2e000013_82", "5a7d4e9afaa1ab7d2e000013_82", "5a7d4e9afaa1ab7d2e000013_82", "5a7d4e9afaa1ab7d2e000013_82", "5a7d4e9afaa1ab7d2e000013_82", "5a7d4e9afaa1ab7d2e000013_82", "5a7d4e9afaa1ab7d2e000013_82", "5a7d4e9afaa1ab7d2e000013_82", "5a7d4e9afaa1ab7d2e000013_82", "5a7d4e9afaa1ab7d2e000013_82", "5a86f074faa1ab7d2e00003a_83", "5a86f074faa1ab7d2e00003a_83", "5a86f074faa1ab7d2e00003a_83", "5a86f074faa1ab7d2e00003a_83", "5a86f074faa1ab7d2e00003a_83", "5a86f074faa1ab7d2e00003a_83", "5a86f074faa1ab7d2e00003a_83", "5a86f074faa1ab7d2e00003a_83", "5a86f074faa1ab7d2e00003a_83", "5a86f074faa1ab7d2e00003a_83", "5a86f074faa1ab7d2e00003a_83", "5a86f074faa1ab7d2e00003a_83", "5a86f074faa1ab7d2e00003a_83", "5a86f074faa1ab7d2e00003a_83", "5a86f074faa1ab7d2e00003a_83", "5a86f074faa1ab7d2e00003a_83", "5a86f074faa1ab7d2e00003a_83", "5a86f074faa1ab7d2e00003a_83", "5a86f074faa1ab7d2e00003a_83", "5a86f074faa1ab7d2e00003a_83", "5a86f074faa1ab7d2e00003a_83", "5a86f074faa1ab7d2e00003a_83", "5a86f074faa1ab7d2e00003a_83", "5a86f074faa1ab7d2e00003a_83", "5a86f074faa1ab7d2e00003a_83", "5a86f074faa1ab7d2e00003a_83", "5a86f074faa1ab7d2e00003a_83", "5a86f074faa1ab7d2e00003a_83", "5a86f074faa1ab7d2e00003a_83", "5a86f074faa1ab7d2e00003a_83", "5a86f074faa1ab7d2e00003a_83", "5a86f074faa1ab7d2e00003a_83", "5a86f074faa1ab7d2e00003a_83", "5a86f074faa1ab7d2e00003a_83", "5a86f074faa1ab7d2e00003a_83", "5a86f074faa1ab7d2e00003a_83", "5a86f074faa1ab7d2e00003a_83", "5a86f074faa1ab7d2e00003a_83", "5a86f074faa1ab7d2e00003a_83", "5a86f074faa1ab7d2e00003a_83", "5a86f074faa1ab7d2e00003a_83", "5a86f074faa1ab7d2e00003a_83", "5a86f074faa1ab7d2e00003a_83", "5a86f074faa1ab7d2e00003a_83", "5a86f074faa1ab7d2e00003a_83", "5a86f074faa1ab7d2e00003a_83", "5a86f074faa1ab7d2e00003a_83", "5a86f074faa1ab7d2e00003a_84", "5a86f074faa1ab7d2e00003a_84", "5a86f074faa1ab7d2e00003a_84", "5a86f074faa1ab7d2e00003a_84", "5a86f074faa1ab7d2e00003a_84", "5a86f074faa1ab7d2e00003a_84", "5a86f074faa1ab7d2e00003a_84", "5a86f074faa1ab7d2e00003a_84", "5a86f074faa1ab7d2e00003a_84", "5a86f074faa1ab7d2e00003a_84", "5a86f074faa1ab7d2e00003a_84", "5a86f074faa1ab7d2e00003a_84", "5a86f074faa1ab7d2e00003a_84", "5a86f074faa1ab7d2e00003a_84", "5a86f074faa1ab7d2e00003a_84", "5a86f074faa1ab7d2e00003a_84", "5a86f074faa1ab7d2e00003a_84", "5a86f074faa1ab7d2e00003a_84", "5a86f074faa1ab7d2e00003a_84", "5a86f074faa1ab7d2e00003a_84", "5a86f074faa1ab7d2e00003a_84", "5a86f074faa1ab7d2e00003a_84", "5a86f074faa1ab7d2e00003a_84", "5a86f074faa1ab7d2e00003a_84", "5a86f074faa1ab7d2e00003a_84", "5a86f074faa1ab7d2e00003a_84", "5a86f074faa1ab7d2e00003a_84", "5a86f074faa1ab7d2e00003a_84", "5a86f074faa1ab7d2e00003a_84", "5a86f074faa1ab7d2e00003a_84", "5a86f074faa1ab7d2e00003a_84", "5a86f074faa1ab7d2e00003a_84", "5a86f074faa1ab7d2e00003a_84", "5a86f074faa1ab7d2e00003a_84", "5a86f074faa1ab7d2e00003a_84", "5a86f074faa1ab7d2e00003a_84", "5a86f074faa1ab7d2e00003a_84", "5a86f074faa1ab7d2e00003a_84", "5a86f074faa1ab7d2e00003a_84", "5a86f074faa1ab7d2e00003a_84", "5a86f074faa1ab7d2e00003a_84", "5a86f074faa1ab7d2e00003a_84", "5a86f074faa1ab7d2e00003a_84", "5a86f074faa1ab7d2e00003a_84", "5a86f074faa1ab7d2e00003a_84", "5a86f074faa1ab7d2e00003a_84", "5a86f074faa1ab7d2e00003a_84", "5a86f074faa1ab7d2e00003a_85", "5a86f074faa1ab7d2e00003a_85", "5a86f074faa1ab7d2e00003a_85", "5a86f074faa1ab7d2e00003a_85", "5a86f074faa1ab7d2e00003a_85", "5a86f074faa1ab7d2e00003a_85", "5a86f074faa1ab7d2e00003a_85", "5a86f074faa1ab7d2e00003a_85", "5a86f074faa1ab7d2e00003a_85", "5a86f074faa1ab7d2e00003a_85", "5a86f074faa1ab7d2e00003a_85", "5a86f074faa1ab7d2e00003a_85", "5a86f074faa1ab7d2e00003a_85", "5a86f074faa1ab7d2e00003a_85", "5a86f074faa1ab7d2e00003a_85", "5a86f074faa1ab7d2e00003a_85", "5a86f074faa1ab7d2e00003a_85", "5a86f074faa1ab7d2e00003a_85", "5a86f074faa1ab7d2e00003a_85", "5a86f074faa1ab7d2e00003a_85", "5a86f074faa1ab7d2e00003a_85", "5a86f074faa1ab7d2e00003a_85", "5a86f074faa1ab7d2e00003a_85", "5a86f074faa1ab7d2e00003a_85", "5a86f074faa1ab7d2e00003a_85", "5a86f074faa1ab7d2e00003a_85", "5a86f074faa1ab7d2e00003a_85", "5a86f074faa1ab7d2e00003a_85", "5a86f074faa1ab7d2e00003a_85", "5a86f074faa1ab7d2e00003a_85", "5a86f074faa1ab7d2e00003a_85", "5a86f074faa1ab7d2e00003a_85", "5a86f074faa1ab7d2e00003a_85", "5a86f074faa1ab7d2e00003a_85", "5a86f074faa1ab7d2e00003a_85", "5a86f074faa1ab7d2e00003a_85", "5a86f074faa1ab7d2e00003a_85", "5a86f074faa1ab7d2e00003a_85", "5a86f074faa1ab7d2e00003a_85", "5a86f074faa1ab7d2e00003a_85", "5a86f074faa1ab7d2e00003a_85", "5a86f074faa1ab7d2e00003a_85", "5a86f074faa1ab7d2e00003a_85", "5a86f074faa1ab7d2e00003a_85", "5a86f074faa1ab7d2e00003a_85", "5a86f074faa1ab7d2e00003a_85", "5a86f074faa1ab7d2e00003a_85", "5a86f074faa1ab7d2e00003a_86", "5a86f074faa1ab7d2e00003a_86", "5a86f074faa1ab7d2e00003a_86", "5a86f074faa1ab7d2e00003a_86", "5a86f074faa1ab7d2e00003a_86", "5a86f074faa1ab7d2e00003a_86", "5a86f074faa1ab7d2e00003a_86", "5a86f074faa1ab7d2e00003a_86", "5a86f074faa1ab7d2e00003a_86", "5a86f074faa1ab7d2e00003a_86", "5a86f074faa1ab7d2e00003a_86", "5a86f074faa1ab7d2e00003a_86", "5a86f074faa1ab7d2e00003a_86", "5a86f074faa1ab7d2e00003a_86", "5a86f074faa1ab7d2e00003a_86", "5a86f074faa1ab7d2e00003a_86", "5a86f074faa1ab7d2e00003a_86", "5a86f074faa1ab7d2e00003a_86", "5a86f074faa1ab7d2e00003a_86", "5a86f074faa1ab7d2e00003a_86", "5a86f074faa1ab7d2e00003a_86", "5a86f074faa1ab7d2e00003a_86", "5a86f074faa1ab7d2e00003a_86", "5a86f074faa1ab7d2e00003a_86", "5a86f074faa1ab7d2e00003a_86", "5a86f074faa1ab7d2e00003a_86", "5a86f074faa1ab7d2e00003a_86", "5a86f074faa1ab7d2e00003a_86", "5a86f074faa1ab7d2e00003a_86", "5a86f074faa1ab7d2e00003a_86", "5a86f074faa1ab7d2e00003a_86", "5a86f074faa1ab7d2e00003a_86", "5a86f074faa1ab7d2e00003a_86", "5a86f074faa1ab7d2e00003a_86", "5a86f074faa1ab7d2e00003a_86", "5a86f074faa1ab7d2e00003a_86", "5a86f074faa1ab7d2e00003a_86", "5a86f074faa1ab7d2e00003a_86", "5a86f074faa1ab7d2e00003a_86", "5a86f074faa1ab7d2e00003a_86", "5a86f074faa1ab7d2e00003a_86", "5a86f074faa1ab7d2e00003a_86", "5a86f074faa1ab7d2e00003a_86", "5a86f074faa1ab7d2e00003a_86", "5a86f074faa1ab7d2e00003a_86", "5a86f074faa1ab7d2e00003a_86", "5a86f074faa1ab7d2e00003a_86", "5a86f074faa1ab7d2e00003a_87", "5a86f074faa1ab7d2e00003a_87", "5a86f074faa1ab7d2e00003a_87", "5a86f074faa1ab7d2e00003a_87", "5a86f074faa1ab7d2e00003a_87", "5a86f074faa1ab7d2e00003a_87", "5a86f074faa1ab7d2e00003a_87", "5a86f074faa1ab7d2e00003a_87", "5a86f074faa1ab7d2e00003a_87", "5a86f074faa1ab7d2e00003a_87", "5a86f074faa1ab7d2e00003a_87", "5a86f074faa1ab7d2e00003a_87", "5a86f074faa1ab7d2e00003a_87", "5a86f074faa1ab7d2e00003a_87", "5a86f074faa1ab7d2e00003a_87", "5a86f074faa1ab7d2e00003a_87", "5a86f074faa1ab7d2e00003a_87", "5a86f074faa1ab7d2e00003a_87", "5a86f074faa1ab7d2e00003a_87", "5a86f074faa1ab7d2e00003a_87", "5a86f074faa1ab7d2e00003a_87", "5a86f074faa1ab7d2e00003a_87", "5a86f074faa1ab7d2e00003a_87", "5a86f074faa1ab7d2e00003a_87", "5a86f074faa1ab7d2e00003a_87", "5a86f074faa1ab7d2e00003a_87", "5a86f074faa1ab7d2e00003a_87", "5a86f074faa1ab7d2e00003a_87", "5a86f074faa1ab7d2e00003a_87", "5a86f074faa1ab7d2e00003a_87", "5a86f074faa1ab7d2e00003a_87", "5a86f074faa1ab7d2e00003a_87", "5a86f074faa1ab7d2e00003a_87", "5a86f074faa1ab7d2e00003a_87", "5a86f074faa1ab7d2e00003a_87", "5a86f074faa1ab7d2e00003a_87", "5a86f074faa1ab7d2e00003a_87", "5a86f074faa1ab7d2e00003a_87", "5a86f074faa1ab7d2e00003a_87", "5a86f074faa1ab7d2e00003a_87", "5a86f074faa1ab7d2e00003a_87", "5a86f074faa1ab7d2e00003a_87", "5a86f074faa1ab7d2e00003a_87", "5a86f074faa1ab7d2e00003a_87", "5a86f074faa1ab7d2e00003a_87", "5a86f074faa1ab7d2e00003a_87", "5a86f074faa1ab7d2e00003a_87", "5a86f074faa1ab7d2e00003a_88", "5a86f074faa1ab7d2e00003a_88", "5a86f074faa1ab7d2e00003a_88", "5a86f074faa1ab7d2e00003a_88", "5a86f074faa1ab7d2e00003a_88", "5a86f074faa1ab7d2e00003a_88", "5a86f074faa1ab7d2e00003a_88", "5a86f074faa1ab7d2e00003a_88", "5a86f074faa1ab7d2e00003a_88", "5a86f074faa1ab7d2e00003a_88", "5a86f074faa1ab7d2e00003a_88", "5a86f074faa1ab7d2e00003a_88", "5a86f074faa1ab7d2e00003a_88", "5a86f074faa1ab7d2e00003a_88", "5a86f074faa1ab7d2e00003a_88", "5a86f074faa1ab7d2e00003a_88", "5a86f074faa1ab7d2e00003a_88", "5a86f074faa1ab7d2e00003a_88", "5a86f074faa1ab7d2e00003a_88", "5a86f074faa1ab7d2e00003a_88", "5a86f074faa1ab7d2e00003a_88", "5a86f074faa1ab7d2e00003a_88", "5a86f074faa1ab7d2e00003a_88", "5a86f074faa1ab7d2e00003a_88", "5a86f074faa1ab7d2e00003a_88", "5a86f074faa1ab7d2e00003a_88", "5a86f074faa1ab7d2e00003a_88", "5a86f074faa1ab7d2e00003a_88", "5a86f074faa1ab7d2e00003a_88", "5a86f074faa1ab7d2e00003a_88", "5a86f074faa1ab7d2e00003a_88", "5a86f074faa1ab7d2e00003a_88", "5a86f074faa1ab7d2e00003a_88", "5a86f074faa1ab7d2e00003a_88", "5a86f074faa1ab7d2e00003a_88", "5a86f074faa1ab7d2e00003a_88", "5a86f074faa1ab7d2e00003a_88", "5a86f074faa1ab7d2e00003a_88", "5a86f074faa1ab7d2e00003a_88", "5a86f074faa1ab7d2e00003a_88", "5a86f074faa1ab7d2e00003a_88", "5a86f074faa1ab7d2e00003a_88", "5a86f074faa1ab7d2e00003a_88", "5a86f074faa1ab7d2e00003a_88", "5a86f074faa1ab7d2e00003a_88", "5a86f074faa1ab7d2e00003a_88", "5a86f074faa1ab7d2e00003a_88", "5a86f074faa1ab7d2e00003a_89", "5a86f074faa1ab7d2e00003a_89", "5a86f074faa1ab7d2e00003a_89", "5a86f074faa1ab7d2e00003a_89", "5a86f074faa1ab7d2e00003a_89", "5a86f074faa1ab7d2e00003a_89", "5a86f074faa1ab7d2e00003a_89", "5a86f074faa1ab7d2e00003a_89", "5a86f074faa1ab7d2e00003a_89", "5a86f074faa1ab7d2e00003a_89", "5a86f074faa1ab7d2e00003a_89", "5a86f074faa1ab7d2e00003a_89", "5a86f074faa1ab7d2e00003a_89", "5a86f074faa1ab7d2e00003a_89", "5a86f074faa1ab7d2e00003a_89", "5a86f074faa1ab7d2e00003a_89", "5a86f074faa1ab7d2e00003a_89", "5a86f074faa1ab7d2e00003a_89", "5a86f074faa1ab7d2e00003a_89", "5a86f074faa1ab7d2e00003a_89", "5a86f074faa1ab7d2e00003a_89", "5a86f074faa1ab7d2e00003a_89", "5a86f074faa1ab7d2e00003a_89", "5a86f074faa1ab7d2e00003a_89", "5a86f074faa1ab7d2e00003a_89", "5a86f074faa1ab7d2e00003a_89", "5a86f074faa1ab7d2e00003a_89", "5a86f074faa1ab7d2e00003a_89", "5a86f074faa1ab7d2e00003a_89", "5a86f074faa1ab7d2e00003a_89", "5a86f074faa1ab7d2e00003a_89", "5a86f074faa1ab7d2e00003a_89", "5a86f074faa1ab7d2e00003a_89", "5a86f074faa1ab7d2e00003a_89", "5a86f074faa1ab7d2e00003a_89", "5a86f074faa1ab7d2e00003a_89", "5a86f074faa1ab7d2e00003a_89", "5a86f074faa1ab7d2e00003a_89", "5a86f074faa1ab7d2e00003a_89", "5a86f074faa1ab7d2e00003a_89", "5a86f074faa1ab7d2e00003a_89", "5a86f074faa1ab7d2e00003a_89", "5a86f074faa1ab7d2e00003a_89", "5a86f074faa1ab7d2e00003a_89", "5a86f074faa1ab7d2e00003a_89", "5a86f074faa1ab7d2e00003a_89", "5a86f074faa1ab7d2e00003a_89", "5a742d620384be9551000002_90", "5a742d620384be9551000002_90", "5a742d620384be9551000002_90", "5a742d620384be9551000002_90", "5a742d620384be9551000002_90", "5a742d620384be9551000002_90", "5a742d620384be9551000002_90", "5a742d620384be9551000002_90", "5a742d620384be9551000002_90", "5a742d620384be9551000002_90", "5a742d620384be9551000002_90", "5a742d620384be9551000002_90", "5a742d620384be9551000002_90", "5a742d620384be9551000002_90", "5a742d620384be9551000002_90", "5a742d620384be9551000002_90", "5a742d620384be9551000002_90", "5a742d620384be9551000002_90", "5a742d620384be9551000002_90", "5a742d620384be9551000002_90", "5a742d620384be9551000002_90", "5a742d620384be9551000002_90", "5a742d620384be9551000002_90", "5a742d620384be9551000002_90", "5a742d620384be9551000002_90", "5a742d620384be9551000002_90", "5a742d620384be9551000002_90", "5a742d620384be9551000002_91", "5a742d620384be9551000002_91", "5a742d620384be9551000002_91", "5a742d620384be9551000002_91", "5a742d620384be9551000002_91", "5a742d620384be9551000002_91", "5a742d620384be9551000002_91", "5a742d620384be9551000002_91", "5a742d620384be9551000002_91", "5a742d620384be9551000002_91", "5a742d620384be9551000002_91", "5a742d620384be9551000002_91", "5a742d620384be9551000002_91", "5a742d620384be9551000002_91", "5a742d620384be9551000002_91", "5a742d620384be9551000002_91", "5a742d620384be9551000002_91", "5a742d620384be9551000002_91", "5a742d620384be9551000002_91", "5a742d620384be9551000002_91", "5a742d620384be9551000002_91", "5a742d620384be9551000002_91", "5a742d620384be9551000002_91", "5a742d620384be9551000002_91", "5a742d620384be9551000002_91", "5a742d620384be9551000002_91", "5a742d620384be9551000002_91", "5a742d620384be9551000002_92", "5a742d620384be9551000002_92", "5a742d620384be9551000002_92", "5a742d620384be9551000002_92", "5a742d620384be9551000002_92", "5a742d620384be9551000002_92", "5a742d620384be9551000002_92", "5a742d620384be9551000002_92", "5a742d620384be9551000002_92", "5a742d620384be9551000002_92", "5a742d620384be9551000002_92", "5a742d620384be9551000002_92", "5a742d620384be9551000002_92", "5a742d620384be9551000002_92", "5a742d620384be9551000002_92", "5a742d620384be9551000002_92", "5a742d620384be9551000002_92", "5a742d620384be9551000002_92", "5a742d620384be9551000002_92", "5a742d620384be9551000002_92", "5a742d620384be9551000002_92", "5a742d620384be9551000002_92", "5a742d620384be9551000002_92", "5a742d620384be9551000002_92", "5a742d620384be9551000002_92", "5a742d620384be9551000002_92", "5a742d620384be9551000002_92", "5a742d620384be9551000002_93", "5a742d620384be9551000002_93", "5a742d620384be9551000002_93", "5a742d620384be9551000002_93", "5a742d620384be9551000002_93", "5a742d620384be9551000002_93", "5a742d620384be9551000002_93", "5a742d620384be9551000002_93", "5a742d620384be9551000002_93", "5a742d620384be9551000002_93", "5a742d620384be9551000002_93", "5a742d620384be9551000002_93", "5a742d620384be9551000002_93", "5a742d620384be9551000002_93", "5a742d620384be9551000002_93", "5a742d620384be9551000002_93", "5a742d620384be9551000002_93", "5a742d620384be9551000002_93", "5a742d620384be9551000002_93", "5a742d620384be9551000002_93", "5a742d620384be9551000002_93", "5a742d620384be9551000002_93", "5a742d620384be9551000002_93", "5a742d620384be9551000002_93", "5a742d620384be9551000002_93", "5a742d620384be9551000002_93", "5a742d620384be9551000002_93", "5a742d620384be9551000002_94", "5a742d620384be9551000002_94", "5a742d620384be9551000002_94", "5a742d620384be9551000002_94", "5a742d620384be9551000002_94", "5a742d620384be9551000002_94", "5a742d620384be9551000002_94", "5a742d620384be9551000002_94", "5a742d620384be9551000002_94", "5a742d620384be9551000002_94", "5a742d620384be9551000002_94", "5a742d620384be9551000002_94", "5a742d620384be9551000002_94", "5a742d620384be9551000002_94", "5a742d620384be9551000002_94", "5a742d620384be9551000002_94", "5a742d620384be9551000002_94", "5a742d620384be9551000002_94", "5a742d620384be9551000002_94", "5a742d620384be9551000002_94", "5a742d620384be9551000002_94", "5a742d620384be9551000002_94", "5a742d620384be9551000002_94", "5a742d620384be9551000002_94", "5a742d620384be9551000002_94", "5a742d620384be9551000002_94", "5a742d620384be9551000002_94", "5a742d620384be9551000002_95", "5a742d620384be9551000002_95", "5a742d620384be9551000002_95", "5a742d620384be9551000002_95", "5a742d620384be9551000002_95", "5a742d620384be9551000002_95", "5a742d620384be9551000002_95", "5a742d620384be9551000002_95", "5a742d620384be9551000002_95", "5a742d620384be9551000002_95", "5a742d620384be9551000002_95", "5a742d620384be9551000002_95", "5a742d620384be9551000002_95", "5a742d620384be9551000002_95", "5a742d620384be9551000002_95", "5a742d620384be9551000002_95", "5a742d620384be9551000002_95", "5a742d620384be9551000002_95", "5a742d620384be9551000002_95", "5a742d620384be9551000002_95", "5a742d620384be9551000002_95", "5a742d620384be9551000002_95", "5a742d620384be9551000002_95", "5a742d620384be9551000002_95", "5a742d620384be9551000002_95", "5a742d620384be9551000002_95", "5a742d620384be9551000002_95", "5a742d620384be9551000002_96", "5a742d620384be9551000002_96", "5a742d620384be9551000002_96", "5a742d620384be9551000002_96", "5a742d620384be9551000002_96", "5a742d620384be9551000002_96", "5a742d620384be9551000002_96", "5a742d620384be9551000002_96", "5a742d620384be9551000002_96", "5a742d620384be9551000002_96", "5a742d620384be9551000002_96", "5a742d620384be9551000002_96", "5a742d620384be9551000002_96", "5a742d620384be9551000002_96", "5a742d620384be9551000002_96", "5a742d620384be9551000002_96", "5a742d620384be9551000002_96", "5a742d620384be9551000002_96", "5a742d620384be9551000002_96", "5a742d620384be9551000002_96", "5a742d620384be9551000002_96", "5a742d620384be9551000002_96", "5a742d620384be9551000002_96", "5a742d620384be9551000002_96", "5a742d620384be9551000002_96", "5a742d620384be9551000002_96", "5a742d620384be9551000002_96", "5a742d620384be9551000002_97", "5a742d620384be9551000002_97", "5a742d620384be9551000002_97", "5a742d620384be9551000002_97", "5a742d620384be9551000002_97", "5a742d620384be9551000002_97", "5a742d620384be9551000002_97", "5a742d620384be9551000002_97", "5a742d620384be9551000002_97", "5a742d620384be9551000002_97", "5a742d620384be9551000002_97", "5a742d620384be9551000002_97", "5a742d620384be9551000002_97", "5a742d620384be9551000002_97", "5a742d620384be9551000002_97", "5a742d620384be9551000002_97", "5a742d620384be9551000002_97", "5a742d620384be9551000002_97", "5a742d620384be9551000002_97", "5a742d620384be9551000002_97", "5a742d620384be9551000002_97", "5a742d620384be9551000002_97", "5a742d620384be9551000002_97", "5a742d620384be9551000002_97", "5a742d620384be9551000002_97", "5a742d620384be9551000002_97", "5a742d620384be9551000002_97", "5a742d620384be9551000002_98", "5a742d620384be9551000002_98", "5a742d620384be9551000002_98", "5a742d620384be9551000002_98", "5a742d620384be9551000002_98", "5a742d620384be9551000002_98", "5a742d620384be9551000002_98", "5a742d620384be9551000002_98", "5a742d620384be9551000002_98", "5a742d620384be9551000002_98", "5a742d620384be9551000002_98", "5a742d620384be9551000002_98", "5a742d620384be9551000002_98", "5a742d620384be9551000002_98", "5a742d620384be9551000002_98", "5a742d620384be9551000002_98", "5a742d620384be9551000002_98", "5a742d620384be9551000002_98", "5a742d620384be9551000002_98", "5a742d620384be9551000002_98", "5a742d620384be9551000002_98", "5a742d620384be9551000002_98", "5a742d620384be9551000002_98", "5a742d620384be9551000002_98", "5a742d620384be9551000002_98", "5a742d620384be9551000002_98", "5a742d620384be9551000002_98", "5a742d620384be9551000002_99", "5a742d620384be9551000002_99", "5a742d620384be9551000002_99", "5a742d620384be9551000002_99", "5a742d620384be9551000002_99", "5a742d620384be9551000002_99", "5a742d620384be9551000002_99", "5a742d620384be9551000002_99", "5a742d620384be9551000002_99", "5a742d620384be9551000002_99", "5a742d620384be9551000002_99", "5a742d620384be9551000002_99", "5a742d620384be9551000002_99", "5a742d620384be9551000002_99", "5a742d620384be9551000002_99", "5a742d620384be9551000002_99", "5a742d620384be9551000002_99", "5a742d620384be9551000002_99", "5a742d620384be9551000002_99", "5a742d620384be9551000002_99", "5a742d620384be9551000002_99", "5a742d620384be9551000002_99", "5a742d620384be9551000002_99", "5a742d620384be9551000002_99", "5a742d620384be9551000002_99", "5a742d620384be9551000002_99", "5a742d620384be9551000002_99", "5a742d620384be9551000002_100", "5a742d620384be9551000002_100", "5a742d620384be9551000002_100", "5a742d620384be9551000002_100", "5a742d620384be9551000002_100", "5a742d620384be9551000002_100", "5a742d620384be9551000002_100", "5a742d620384be9551000002_100", "5a742d620384be9551000002_100", "5a742d620384be9551000002_100", "5a742d620384be9551000002_100", "5a742d620384be9551000002_100", "5a742d620384be9551000002_100", "5a742d620384be9551000002_100", "5a742d620384be9551000002_100", "5a742d620384be9551000002_100", "5a742d620384be9551000002_100", "5a742d620384be9551000002_100", "5a742d620384be9551000002_100", "5a742d620384be9551000002_100", "5a742d620384be9551000002_100", "5a742d620384be9551000002_100", "5a742d620384be9551000002_100", "5a742d620384be9551000002_100", "5a742d620384be9551000002_100", "5a742d620384be9551000002_100", "5a742d620384be9551000002_100", "5a742d620384be9551000002_101", "5a742d620384be9551000002_101", "5a742d620384be9551000002_101", "5a742d620384be9551000002_101", "5a742d620384be9551000002_101", "5a742d620384be9551000002_101", "5a742d620384be9551000002_101", "5a742d620384be9551000002_101", "5a742d620384be9551000002_101", "5a742d620384be9551000002_101", "5a742d620384be9551000002_101", "5a742d620384be9551000002_101", "5a742d620384be9551000002_101", "5a742d620384be9551000002_101", "5a742d620384be9551000002_101", "5a742d620384be9551000002_101", "5a742d620384be9551000002_101", "5a742d620384be9551000002_101", "5a742d620384be9551000002_101", "5a742d620384be9551000002_101", "5a742d620384be9551000002_101", "5a742d620384be9551000002_101", "5a742d620384be9551000002_101", "5a742d620384be9551000002_101", "5a742d620384be9551000002_101", "5a742d620384be9551000002_101", "5a742d620384be9551000002_101", "5a742d620384be9551000002_102", "5a742d620384be9551000002_102", "5a742d620384be9551000002_102", "5a742d620384be9551000002_102", "5a742d620384be9551000002_102", "5a742d620384be9551000002_102", "5a742d620384be9551000002_102", "5a742d620384be9551000002_102", "5a742d620384be9551000002_102", "5a742d620384be9551000002_102", "5a742d620384be9551000002_102", "5a742d620384be9551000002_102", "5a742d620384be9551000002_102", "5a742d620384be9551000002_102", "5a742d620384be9551000002_102", "5a742d620384be9551000002_102", "5a742d620384be9551000002_102", "5a742d620384be9551000002_102", "5a742d620384be9551000002_102", "5a742d620384be9551000002_102", "5a742d620384be9551000002_102", "5a742d620384be9551000002_102", "5a742d620384be9551000002_102", "5a742d620384be9551000002_102", "5a742d620384be9551000002_102", "5a742d620384be9551000002_102", "5a742d620384be9551000002_102", "5a742d620384be9551000002_103", "5a742d620384be9551000002_103", "5a742d620384be9551000002_103", "5a742d620384be9551000002_103", "5a742d620384be9551000002_103", "5a742d620384be9551000002_103", "5a742d620384be9551000002_103", "5a742d620384be9551000002_103", "5a742d620384be9551000002_103", "5a742d620384be9551000002_103", "5a742d620384be9551000002_103", "5a742d620384be9551000002_103", "5a742d620384be9551000002_103", "5a742d620384be9551000002_103", "5a742d620384be9551000002_103", "5a742d620384be9551000002_103", "5a742d620384be9551000002_103", "5a742d620384be9551000002_103", "5a742d620384be9551000002_103", "5a742d620384be9551000002_103", "5a742d620384be9551000002_103", "5a742d620384be9551000002_103", "5a742d620384be9551000002_103", "5a742d620384be9551000002_103", "5a742d620384be9551000002_103", "5a742d620384be9551000002_103", "5a742d620384be9551000002_103", "5a742d620384be9551000002_104", "5a742d620384be9551000002_104", "5a742d620384be9551000002_104", "5a742d620384be9551000002_104", "5a742d620384be9551000002_104", "5a742d620384be9551000002_104", "5a742d620384be9551000002_104", "5a742d620384be9551000002_104", "5a742d620384be9551000002_104", "5a742d620384be9551000002_104", "5a742d620384be9551000002_104", "5a742d620384be9551000002_104", "5a742d620384be9551000002_104", "5a742d620384be9551000002_104", "5a742d620384be9551000002_104", "5a742d620384be9551000002_104", "5a742d620384be9551000002_104", "5a742d620384be9551000002_104", "5a742d620384be9551000002_104", "5a742d620384be9551000002_104", "5a742d620384be9551000002_104", "5a742d620384be9551000002_104", "5a742d620384be9551000002_104", "5a742d620384be9551000002_104", "5a742d620384be9551000002_104", "5a742d620384be9551000002_104", "5a742d620384be9551000002_104", "5a742d620384be9551000002_105", "5a742d620384be9551000002_105", "5a742d620384be9551000002_105", "5a742d620384be9551000002_105", "5a742d620384be9551000002_105", "5a742d620384be9551000002_105", "5a742d620384be9551000002_105", "5a742d620384be9551000002_105", "5a742d620384be9551000002_105", "5a742d620384be9551000002_105", "5a742d620384be9551000002_105", "5a742d620384be9551000002_105", "5a742d620384be9551000002_105", "5a742d620384be9551000002_105", "5a742d620384be9551000002_105", "5a742d620384be9551000002_105", "5a742d620384be9551000002_105", "5a742d620384be9551000002_105", "5a742d620384be9551000002_105", "5a742d620384be9551000002_105", "5a742d620384be9551000002_105", "5a742d620384be9551000002_105", "5a742d620384be9551000002_105", "5a742d620384be9551000002_105", "5a742d620384be9551000002_105", "5a742d620384be9551000002_105", "5a742d620384be9551000002_105", "5a742d620384be9551000002_106", "5a742d620384be9551000002_106", "5a742d620384be9551000002_106", "5a742d620384be9551000002_106", "5a742d620384be9551000002_106", "5a742d620384be9551000002_106", "5a742d620384be9551000002_106", "5a742d620384be9551000002_106", "5a742d620384be9551000002_106", "5a742d620384be9551000002_106", "5a742d620384be9551000002_106", "5a742d620384be9551000002_106", "5a742d620384be9551000002_106", "5a742d620384be9551000002_106", "5a742d620384be9551000002_106", "5a742d620384be9551000002_106", "5a742d620384be9551000002_106", "5a742d620384be9551000002_106", "5a742d620384be9551000002_106", "5a742d620384be9551000002_106", "5a742d620384be9551000002_106", "5a742d620384be9551000002_106", "5a742d620384be9551000002_106", "5a742d620384be9551000002_106", "5a742d620384be9551000002_106", "5a742d620384be9551000002_106", "5a742d620384be9551000002_106", "5a742d620384be9551000002_107", "5a742d620384be9551000002_107", "5a742d620384be9551000002_107", "5a742d620384be9551000002_107", "5a742d620384be9551000002_107", "5a742d620384be9551000002_107", "5a742d620384be9551000002_107", "5a742d620384be9551000002_107", "5a742d620384be9551000002_107", "5a742d620384be9551000002_107", "5a742d620384be9551000002_107", "5a742d620384be9551000002_107", "5a742d620384be9551000002_107", "5a742d620384be9551000002_107", "5a742d620384be9551000002_107", "5a742d620384be9551000002_107", "5a742d620384be9551000002_107", "5a742d620384be9551000002_107", "5a742d620384be9551000002_107", "5a742d620384be9551000002_107", "5a742d620384be9551000002_107", "5a742d620384be9551000002_107", "5a742d620384be9551000002_107", "5a742d620384be9551000002_107", "5a742d620384be9551000002_107", "5a742d620384be9551000002_107", "5a742d620384be9551000002_107", "5a742d620384be9551000002_108", "5a742d620384be9551000002_108", "5a742d620384be9551000002_108", "5a742d620384be9551000002_108", "5a742d620384be9551000002_108", "5a742d620384be9551000002_108", "5a742d620384be9551000002_108", "5a742d620384be9551000002_108", "5a742d620384be9551000002_108", "5a742d620384be9551000002_108", "5a742d620384be9551000002_108", "5a742d620384be9551000002_108", "5a742d620384be9551000002_108", "5a742d620384be9551000002_108", "5a742d620384be9551000002_108", "5a742d620384be9551000002_108", "5a742d620384be9551000002_108", "5a742d620384be9551000002_108", "5a742d620384be9551000002_108", "5a742d620384be9551000002_108", "5a742d620384be9551000002_108", "5a742d620384be9551000002_108", "5a742d620384be9551000002_108", "5a742d620384be9551000002_108", "5a742d620384be9551000002_108", "5a742d620384be9551000002_108", "5a742d620384be9551000002_108", "5a742d620384be9551000002_109", "5a742d620384be9551000002_109", "5a742d620384be9551000002_109", "5a742d620384be9551000002_109", "5a742d620384be9551000002_109", "5a742d620384be9551000002_109", "5a742d620384be9551000002_109", "5a742d620384be9551000002_109", "5a742d620384be9551000002_109", "5a742d620384be9551000002_109", "5a742d620384be9551000002_109", "5a742d620384be9551000002_109", "5a742d620384be9551000002_109", "5a742d620384be9551000002_109", "5a742d620384be9551000002_109", "5a742d620384be9551000002_109", "5a742d620384be9551000002_109", "5a742d620384be9551000002_109", "5a742d620384be9551000002_109", "5a742d620384be9551000002_109", "5a742d620384be9551000002_109", "5a742d620384be9551000002_109", "5a742d620384be9551000002_109", "5a742d620384be9551000002_109", "5a742d620384be9551000002_109", "5a742d620384be9551000002_109", "5a742d620384be9551000002_109", "5a6f960fb750ff445500005c_110", "5a6f960fb750ff445500005c_110", "5a6f960fb750ff445500005c_110", "5a6f960fb750ff445500005c_110", "5a6f960fb750ff445500005c_110", "5a6f960fb750ff445500005c_110", "5a6f960fb750ff445500005c_110", "5a6f960fb750ff445500005c_110", "5a6f960fb750ff445500005c_110", "5a6f960fb750ff445500005c_110", "5a6f960fb750ff445500005c_110", "5a6f960fb750ff445500005c_110", "5a6f960fb750ff445500005c_110", "5a6f960fb750ff445500005c_110", "5a6f960fb750ff445500005c_110", "5a6f960fb750ff445500005c_110", "5a6f960fb750ff445500005c_110", "5a6f960fb750ff445500005c_110", "5a6f960fb750ff445500005c_110", "5a6f960fb750ff445500005c_110", "5a6f960fb750ff445500005c_110", "5a6f960fb750ff445500005c_110", "5a6f960fb750ff445500005c_110", "5a6f960fb750ff445500005c_110", "5a6f960fb750ff445500005c_110", "5a6f960fb750ff445500005c_110", "5a6f960fb750ff445500005c_110", "5a6f960fb750ff445500005c_110", "5a6f960fb750ff445500005c_110", "5a6f960fb750ff445500005c_110", "5a6f960fb750ff445500005c_110", "5a6f960fb750ff445500005c_110", "5a6f960fb750ff445500005c_110", "5a6f960fb750ff445500005c_110", "5a6f960fb750ff445500005c_110", "5a6f960fb750ff445500005c_110", "5a6f960fb750ff445500005c_110", "5a6f960fb750ff445500005c_110", "5a6f960fb750ff445500005c_110", "5a6f960fb750ff445500005c_110", "5a6f960fb750ff445500005c_110", "5a6f960fb750ff445500005c_111", "5a6f960fb750ff445500005c_111", "5a6f960fb750ff445500005c_111", "5a6f960fb750ff445500005c_111", "5a6f960fb750ff445500005c_111", "5a6f960fb750ff445500005c_111", "5a6f960fb750ff445500005c_111", "5a6f960fb750ff445500005c_111", "5a6f960fb750ff445500005c_111", "5a6f960fb750ff445500005c_111", "5a6f960fb750ff445500005c_111", "5a6f960fb750ff445500005c_111", "5a6f960fb750ff445500005c_111", "5a6f960fb750ff445500005c_111", "5a6f960fb750ff445500005c_111", "5a6f960fb750ff445500005c_111", "5a6f960fb750ff445500005c_111", "5a6f960fb750ff445500005c_111", "5a6f960fb750ff445500005c_111", "5a6f960fb750ff445500005c_111", "5a6f960fb750ff445500005c_111", "5a6f960fb750ff445500005c_111", "5a6f960fb750ff445500005c_111", "5a6f960fb750ff445500005c_111", "5a6f960fb750ff445500005c_111", "5a6f960fb750ff445500005c_111", "5a6f960fb750ff445500005c_111", "5a6f960fb750ff445500005c_111", "5a6f960fb750ff445500005c_111", "5a6f960fb750ff445500005c_111", "5a6f960fb750ff445500005c_111", "5a6f960fb750ff445500005c_111", "5a6f960fb750ff445500005c_111", "5a6f960fb750ff445500005c_111", "5a6f960fb750ff445500005c_111", "5a6f960fb750ff445500005c_111", "5a6f960fb750ff445500005c_111", "5a6f960fb750ff445500005c_111", "5a6f960fb750ff445500005c_111", "5a6f960fb750ff445500005c_111", "5a6f960fb750ff445500005c_111", "5a6f960fb750ff445500005c_112", "5a6f960fb750ff445500005c_112", "5a6f960fb750ff445500005c_112", "5a6f960fb750ff445500005c_112", "5a6f960fb750ff445500005c_112", "5a6f960fb750ff445500005c_112", "5a6f960fb750ff445500005c_112", "5a6f960fb750ff445500005c_112", "5a6f960fb750ff445500005c_112", "5a6f960fb750ff445500005c_112", "5a6f960fb750ff445500005c_112", "5a6f960fb750ff445500005c_112", "5a6f960fb750ff445500005c_112", "5a6f960fb750ff445500005c_112", "5a6f960fb750ff445500005c_112", "5a6f960fb750ff445500005c_112", "5a6f960fb750ff445500005c_112", "5a6f960fb750ff445500005c_112", "5a6f960fb750ff445500005c_112", "5a6f960fb750ff445500005c_112", "5a6f960fb750ff445500005c_112", "5a6f960fb750ff445500005c_112", "5a6f960fb750ff445500005c_112", "5a6f960fb750ff445500005c_112", "5a6f960fb750ff445500005c_112", "5a6f960fb750ff445500005c_112", "5a6f960fb750ff445500005c_112", "5a6f960fb750ff445500005c_112", "5a6f960fb750ff445500005c_112", "5a6f960fb750ff445500005c_112", "5a6f960fb750ff445500005c_112", "5a6f960fb750ff445500005c_112", "5a6f960fb750ff445500005c_112", "5a6f960fb750ff445500005c_112", "5a6f960fb750ff445500005c_112", "5a6f960fb750ff445500005c_112", "5a6f960fb750ff445500005c_112", "5a6f960fb750ff445500005c_112", "5a6f960fb750ff445500005c_112", "5a6f960fb750ff445500005c_112", "5a6f960fb750ff445500005c_112", "5a6f960fb750ff445500005c_113", "5a6f960fb750ff445500005c_113", "5a6f960fb750ff445500005c_113", "5a6f960fb750ff445500005c_113", "5a6f960fb750ff445500005c_113", "5a6f960fb750ff445500005c_113", "5a6f960fb750ff445500005c_113", "5a6f960fb750ff445500005c_113", "5a6f960fb750ff445500005c_113", "5a6f960fb750ff445500005c_113", "5a6f960fb750ff445500005c_113", "5a6f960fb750ff445500005c_113", "5a6f960fb750ff445500005c_113", "5a6f960fb750ff445500005c_113", "5a6f960fb750ff445500005c_113", "5a6f960fb750ff445500005c_113", "5a6f960fb750ff445500005c_113", "5a6f960fb750ff445500005c_113", "5a6f960fb750ff445500005c_113", "5a6f960fb750ff445500005c_113", "5a6f960fb750ff445500005c_113", "5a6f960fb750ff445500005c_113", "5a6f960fb750ff445500005c_113", "5a6f960fb750ff445500005c_113", "5a6f960fb750ff445500005c_113", "5a6f960fb750ff445500005c_113", "5a6f960fb750ff445500005c_113", "5a6f960fb750ff445500005c_113", "5a6f960fb750ff445500005c_113", "5a6f960fb750ff445500005c_113", "5a6f960fb750ff445500005c_113", "5a6f960fb750ff445500005c_113", "5a6f960fb750ff445500005c_113", "5a6f960fb750ff445500005c_113", "5a6f960fb750ff445500005c_113", "5a6f960fb750ff445500005c_113", "5a6f960fb750ff445500005c_113", "5a6f960fb750ff445500005c_113", "5a6f960fb750ff445500005c_113", "5a6f960fb750ff445500005c_113", "5a6f960fb750ff445500005c_113", "5a6f960fb750ff445500005c_114", "5a6f960fb750ff445500005c_114", "5a6f960fb750ff445500005c_114", "5a6f960fb750ff445500005c_114", "5a6f960fb750ff445500005c_114", "5a6f960fb750ff445500005c_114", "5a6f960fb750ff445500005c_114", "5a6f960fb750ff445500005c_114", "5a6f960fb750ff445500005c_114", "5a6f960fb750ff445500005c_114", "5a6f960fb750ff445500005c_114", "5a6f960fb750ff445500005c_114", "5a6f960fb750ff445500005c_114", "5a6f960fb750ff445500005c_114", "5a6f960fb750ff445500005c_114", "5a6f960fb750ff445500005c_114", "5a6f960fb750ff445500005c_114", "5a6f960fb750ff445500005c_114", "5a6f960fb750ff445500005c_114", "5a6f960fb750ff445500005c_114", "5a6f960fb750ff445500005c_114", "5a6f960fb750ff445500005c_114", "5a6f960fb750ff445500005c_114", "5a6f960fb750ff445500005c_114", "5a6f960fb750ff445500005c_114", "5a6f960fb750ff445500005c_114", "5a6f960fb750ff445500005c_114", "5a6f960fb750ff445500005c_114", "5a6f960fb750ff445500005c_114", "5a6f960fb750ff445500005c_114", "5a6f960fb750ff445500005c_114", "5a6f960fb750ff445500005c_114", "5a6f960fb750ff445500005c_114", "5a6f960fb750ff445500005c_114", "5a6f960fb750ff445500005c_114", "5a6f960fb750ff445500005c_114", "5a6f960fb750ff445500005c_114", "5a6f960fb750ff445500005c_114", "5a6f960fb750ff445500005c_114", "5a6f960fb750ff445500005c_114", "5a6f960fb750ff445500005c_114", "5a6f960fb750ff445500005c_115", "5a6f960fb750ff445500005c_115", "5a6f960fb750ff445500005c_115", "5a6f960fb750ff445500005c_115", "5a6f960fb750ff445500005c_115", "5a6f960fb750ff445500005c_115", "5a6f960fb750ff445500005c_115", "5a6f960fb750ff445500005c_115", "5a6f960fb750ff445500005c_115", "5a6f960fb750ff445500005c_115", "5a6f960fb750ff445500005c_115", "5a6f960fb750ff445500005c_115", "5a6f960fb750ff445500005c_115", "5a6f960fb750ff445500005c_115", "5a6f960fb750ff445500005c_115", "5a6f960fb750ff445500005c_115", "5a6f960fb750ff445500005c_115", "5a6f960fb750ff445500005c_115", "5a6f960fb750ff445500005c_115", "5a6f960fb750ff445500005c_115", "5a6f960fb750ff445500005c_115", "5a6f960fb750ff445500005c_115", "5a6f960fb750ff445500005c_115", "5a6f960fb750ff445500005c_115", "5a6f960fb750ff445500005c_115", "5a6f960fb750ff445500005c_115", "5a6f960fb750ff445500005c_115", "5a6f960fb750ff445500005c_115", "5a6f960fb750ff445500005c_115", "5a6f960fb750ff445500005c_115", "5a6f960fb750ff445500005c_115", "5a6f960fb750ff445500005c_115", "5a6f960fb750ff445500005c_115", "5a6f960fb750ff445500005c_115", "5a6f960fb750ff445500005c_115", "5a6f960fb750ff445500005c_115", "5a6f960fb750ff445500005c_115", "5a6f960fb750ff445500005c_115", "5a6f960fb750ff445500005c_115", "5a6f960fb750ff445500005c_115", "5a6f960fb750ff445500005c_115", "5a6f960fb750ff445500005c_116", "5a6f960fb750ff445500005c_116", "5a6f960fb750ff445500005c_116", "5a6f960fb750ff445500005c_116", "5a6f960fb750ff445500005c_116", "5a6f960fb750ff445500005c_116", "5a6f960fb750ff445500005c_116", "5a6f960fb750ff445500005c_116", "5a6f960fb750ff445500005c_116", "5a6f960fb750ff445500005c_116", "5a6f960fb750ff445500005c_116", "5a6f960fb750ff445500005c_116", "5a6f960fb750ff445500005c_116", "5a6f960fb750ff445500005c_116", "5a6f960fb750ff445500005c_116", "5a6f960fb750ff445500005c_116", "5a6f960fb750ff445500005c_116", "5a6f960fb750ff445500005c_116", "5a6f960fb750ff445500005c_116", "5a6f960fb750ff445500005c_116", "5a6f960fb750ff445500005c_116", "5a6f960fb750ff445500005c_116", "5a6f960fb750ff445500005c_116", "5a6f960fb750ff445500005c_116", "5a6f960fb750ff445500005c_116", "5a6f960fb750ff445500005c_116", "5a6f960fb750ff445500005c_116", "5a6f960fb750ff445500005c_116", "5a6f960fb750ff445500005c_116", "5a6f960fb750ff445500005c_116", "5a6f960fb750ff445500005c_116", "5a6f960fb750ff445500005c_116", "5a6f960fb750ff445500005c_116", "5a6f960fb750ff445500005c_116", "5a6f960fb750ff445500005c_116", "5a6f960fb750ff445500005c_116", "5a6f960fb750ff445500005c_116", "5a6f960fb750ff445500005c_116", "5a6f960fb750ff445500005c_116", "5a6f960fb750ff445500005c_116", "5a6f960fb750ff445500005c_116", "5a6f960fb750ff445500005c_117", "5a6f960fb750ff445500005c_117", "5a6f960fb750ff445500005c_117", "5a6f960fb750ff445500005c_117", "5a6f960fb750ff445500005c_117", "5a6f960fb750ff445500005c_117", "5a6f960fb750ff445500005c_117", "5a6f960fb750ff445500005c_117", "5a6f960fb750ff445500005c_117", "5a6f960fb750ff445500005c_117", "5a6f960fb750ff445500005c_117", "5a6f960fb750ff445500005c_117", "5a6f960fb750ff445500005c_117", "5a6f960fb750ff445500005c_117", "5a6f960fb750ff445500005c_117", "5a6f960fb750ff445500005c_117", "5a6f960fb750ff445500005c_117", "5a6f960fb750ff445500005c_117", "5a6f960fb750ff445500005c_117", "5a6f960fb750ff445500005c_117", "5a6f960fb750ff445500005c_117", "5a6f960fb750ff445500005c_117", "5a6f960fb750ff445500005c_117", "5a6f960fb750ff445500005c_117", "5a6f960fb750ff445500005c_117", "5a6f960fb750ff445500005c_117", "5a6f960fb750ff445500005c_117", "5a6f960fb750ff445500005c_117", "5a6f960fb750ff445500005c_117", "5a6f960fb750ff445500005c_117", "5a6f960fb750ff445500005c_117", "5a6f960fb750ff445500005c_117", "5a6f960fb750ff445500005c_117", "5a6f960fb750ff445500005c_117", "5a6f960fb750ff445500005c_117", "5a6f960fb750ff445500005c_117", "5a6f960fb750ff445500005c_117", "5a6f960fb750ff445500005c_117", "5a6f960fb750ff445500005c_117", "5a6f960fb750ff445500005c_117", "5a6f960fb750ff445500005c_117", "5a6f960fb750ff445500005c_118", "5a6f960fb750ff445500005c_118", "5a6f960fb750ff445500005c_118", "5a6f960fb750ff445500005c_118", "5a6f960fb750ff445500005c_118", "5a6f960fb750ff445500005c_118", "5a6f960fb750ff445500005c_118", "5a6f960fb750ff445500005c_118", "5a6f960fb750ff445500005c_118", "5a6f960fb750ff445500005c_118", "5a6f960fb750ff445500005c_118", "5a6f960fb750ff445500005c_118", "5a6f960fb750ff445500005c_118", "5a6f960fb750ff445500005c_118", "5a6f960fb750ff445500005c_118", "5a6f960fb750ff445500005c_118", "5a6f960fb750ff445500005c_118", "5a6f960fb750ff445500005c_118", "5a6f960fb750ff445500005c_118", "5a6f960fb750ff445500005c_118", "5a6f960fb750ff445500005c_118", "5a6f960fb750ff445500005c_118", "5a6f960fb750ff445500005c_118", "5a6f960fb750ff445500005c_118", "5a6f960fb750ff445500005c_118", "5a6f960fb750ff445500005c_118", "5a6f960fb750ff445500005c_118", "5a6f960fb750ff445500005c_118", "5a6f960fb750ff445500005c_118", "5a6f960fb750ff445500005c_118", "5a6f960fb750ff445500005c_118", "5a6f960fb750ff445500005c_118", "5a6f960fb750ff445500005c_118", "5a6f960fb750ff445500005c_118", "5a6f960fb750ff445500005c_118", "5a6f960fb750ff445500005c_118", "5a6f960fb750ff445500005c_118", "5a6f960fb750ff445500005c_118", "5a6f960fb750ff445500005c_118", "5a6f960fb750ff445500005c_118", "5a6f960fb750ff445500005c_118", "5a6f960fb750ff445500005c_119", "5a6f960fb750ff445500005c_119", "5a6f960fb750ff445500005c_119", "5a6f960fb750ff445500005c_119", "5a6f960fb750ff445500005c_119", "5a6f960fb750ff445500005c_119", "5a6f960fb750ff445500005c_119", "5a6f960fb750ff445500005c_119", "5a6f960fb750ff445500005c_119", "5a6f960fb750ff445500005c_119", "5a6f960fb750ff445500005c_119", "5a6f960fb750ff445500005c_119", "5a6f960fb750ff445500005c_119", "5a6f960fb750ff445500005c_119", "5a6f960fb750ff445500005c_119", "5a6f960fb750ff445500005c_119", "5a6f960fb750ff445500005c_119", "5a6f960fb750ff445500005c_119", "5a6f960fb750ff445500005c_119", "5a6f960fb750ff445500005c_119", "5a6f960fb750ff445500005c_119", "5a6f960fb750ff445500005c_119", "5a6f960fb750ff445500005c_119", "5a6f960fb750ff445500005c_119", "5a6f960fb750ff445500005c_119", "5a6f960fb750ff445500005c_119", "5a6f960fb750ff445500005c_119", "5a6f960fb750ff445500005c_119", "5a6f960fb750ff445500005c_119", "5a6f960fb750ff445500005c_119", "5a6f960fb750ff445500005c_119", "5a6f960fb750ff445500005c_119", "5a6f960fb750ff445500005c_119", "5a6f960fb750ff445500005c_119", "5a6f960fb750ff445500005c_119", "5a6f960fb750ff445500005c_119", "5a6f960fb750ff445500005c_119", "5a6f960fb750ff445500005c_119", "5a6f960fb750ff445500005c_119", "5a6f960fb750ff445500005c_119", "5a6f960fb750ff445500005c_119", "5a6f960fb750ff445500005c_120", "5a6f960fb750ff445500005c_120", "5a6f960fb750ff445500005c_120", "5a6f960fb750ff445500005c_120", "5a6f960fb750ff445500005c_120", "5a6f960fb750ff445500005c_120", "5a6f960fb750ff445500005c_120", "5a6f960fb750ff445500005c_120", "5a6f960fb750ff445500005c_120", "5a6f960fb750ff445500005c_120", "5a6f960fb750ff445500005c_120", "5a6f960fb750ff445500005c_120", "5a6f960fb750ff445500005c_120", "5a6f960fb750ff445500005c_120", "5a6f960fb750ff445500005c_120", "5a6f960fb750ff445500005c_120", "5a6f960fb750ff445500005c_120", "5a6f960fb750ff445500005c_120", "5a6f960fb750ff445500005c_120", "5a6f960fb750ff445500005c_120", "5a6f960fb750ff445500005c_120", "5a6f960fb750ff445500005c_120", "5a6f960fb750ff445500005c_120", "5a6f960fb750ff445500005c_120", "5a6f960fb750ff445500005c_120", "5a6f960fb750ff445500005c_120", "5a6f960fb750ff445500005c_120", "5a6f960fb750ff445500005c_120", "5a6f960fb750ff445500005c_120", "5a6f960fb750ff445500005c_120", "5a6f960fb750ff445500005c_120", "5a6f960fb750ff445500005c_120", "5a6f960fb750ff445500005c_120", "5a6f960fb750ff445500005c_120", "5a6f960fb750ff445500005c_120", "5a6f960fb750ff445500005c_120", "5a6f960fb750ff445500005c_120", "5a6f960fb750ff445500005c_120", "5a6f960fb750ff445500005c_120", "5a6f960fb750ff445500005c_120", "5a6f960fb750ff445500005c_120", "5a72329e2dc08e987e000006_121", "5a72329e2dc08e987e000006_121", "5a72329e2dc08e987e000006_121", "5a72329e2dc08e987e000006_121", "5a72329e2dc08e987e000006_121", "5a72329e2dc08e987e000006_121", "5a72329e2dc08e987e000006_121", "5a72329e2dc08e987e000006_121", "5a72329e2dc08e987e000006_121", "5a72329e2dc08e987e000006_121", "5a72329e2dc08e987e000006_121", "5a72329e2dc08e987e000006_121", "5a72329e2dc08e987e000006_121", "5a72329e2dc08e987e000006_121", "5a72329e2dc08e987e000006_121", "5a72329e2dc08e987e000006_121", "5a72329e2dc08e987e000006_121", "5a72329e2dc08e987e000006_121", "5a72329e2dc08e987e000006_121", "5a72329e2dc08e987e000006_121", "5a72329e2dc08e987e000006_121", "5a72329e2dc08e987e000006_121", "5a72329e2dc08e987e000006_121", "5a72329e2dc08e987e000006_121", "5a72329e2dc08e987e000006_121", "5a72329e2dc08e987e000006_121", "5a72329e2dc08e987e000006_121", "5a72329e2dc08e987e000006_121", "5a72329e2dc08e987e000006_121", "5a72329e2dc08e987e000006_121", "5a72329e2dc08e987e000006_121", "5a72329e2dc08e987e000006_121", "5a72329e2dc08e987e000006_121", "5a72329e2dc08e987e000006_121", "5a72329e2dc08e987e000006_121", "5a72329e2dc08e987e000006_121", "5a72329e2dc08e987e000006_121", "5a72329e2dc08e987e000006_121", "5a72329e2dc08e987e000006_121", "5a72329e2dc08e987e000006_121", "5a72329e2dc08e987e000006_121", "5a72329e2dc08e987e000006_121", "5a72329e2dc08e987e000006_121", "5a72329e2dc08e987e000006_121", "5a72329e2dc08e987e000006_121", "5a72329e2dc08e987e000006_121", "5a72329e2dc08e987e000006_121", "5a72329e2dc08e987e000006_121", "5a72329e2dc08e987e000006_121", "5a72329e2dc08e987e000006_122", "5a72329e2dc08e987e000006_122", "5a72329e2dc08e987e000006_122", "5a72329e2dc08e987e000006_122", "5a72329e2dc08e987e000006_122", "5a72329e2dc08e987e000006_122", "5a72329e2dc08e987e000006_122", "5a72329e2dc08e987e000006_122", "5a72329e2dc08e987e000006_122", "5a72329e2dc08e987e000006_122", "5a72329e2dc08e987e000006_122", "5a72329e2dc08e987e000006_122", "5a72329e2dc08e987e000006_122", "5a72329e2dc08e987e000006_122", "5a72329e2dc08e987e000006_122", "5a72329e2dc08e987e000006_122", "5a72329e2dc08e987e000006_122", "5a72329e2dc08e987e000006_122", "5a72329e2dc08e987e000006_122", "5a72329e2dc08e987e000006_122", "5a72329e2dc08e987e000006_122", "5a72329e2dc08e987e000006_122", "5a72329e2dc08e987e000006_122", "5a72329e2dc08e987e000006_122", "5a72329e2dc08e987e000006_122", "5a72329e2dc08e987e000006_122", "5a72329e2dc08e987e000006_122", "5a72329e2dc08e987e000006_122", "5a72329e2dc08e987e000006_122", "5a72329e2dc08e987e000006_122", "5a72329e2dc08e987e000006_122", "5a72329e2dc08e987e000006_122", "5a72329e2dc08e987e000006_122", "5a72329e2dc08e987e000006_122", "5a72329e2dc08e987e000006_122", "5a72329e2dc08e987e000006_122", "5a72329e2dc08e987e000006_122", "5a72329e2dc08e987e000006_122", "5a72329e2dc08e987e000006_122", "5a72329e2dc08e987e000006_122", "5a72329e2dc08e987e000006_122", "5a72329e2dc08e987e000006_122", "5a72329e2dc08e987e000006_122", "5a72329e2dc08e987e000006_122", "5a72329e2dc08e987e000006_122", "5a72329e2dc08e987e000006_122", "5a72329e2dc08e987e000006_122", "5a72329e2dc08e987e000006_122", "5a72329e2dc08e987e000006_122", "5a871a6861bb38fb24000009_123", "5a871a6861bb38fb24000009_123", "5a871a6861bb38fb24000009_123", "5a871a6861bb38fb24000009_123", "5a871a6861bb38fb24000009_123", "5a871a6861bb38fb24000009_123", "5a871a6861bb38fb24000009_123", "5a871a6861bb38fb24000009_123", "5a871a6861bb38fb24000009_123", "5a871a6861bb38fb24000009_123", "5a871a6861bb38fb24000009_123", "5a871a6861bb38fb24000009_123", "5a871a6861bb38fb24000009_123", "5a871a6861bb38fb24000009_123", "5a871a6861bb38fb24000009_123", "5a871a6861bb38fb24000009_123", "5a871a6861bb38fb24000009_123", "5a871a6861bb38fb24000009_124", "5a871a6861bb38fb24000009_124", "5a871a6861bb38fb24000009_124", "5a871a6861bb38fb24000009_124", "5a871a6861bb38fb24000009_124", "5a871a6861bb38fb24000009_124", "5a871a6861bb38fb24000009_124", "5a871a6861bb38fb24000009_124", "5a871a6861bb38fb24000009_124", "5a871a6861bb38fb24000009_124", "5a871a6861bb38fb24000009_124", "5a871a6861bb38fb24000009_124", "5a871a6861bb38fb24000009_124", "5a871a6861bb38fb24000009_124", "5a871a6861bb38fb24000009_124", "5a871a6861bb38fb24000009_124", "5a871a6861bb38fb24000009_124", "5a871a6861bb38fb24000009_125", "5a871a6861bb38fb24000009_125", "5a871a6861bb38fb24000009_125", "5a871a6861bb38fb24000009_125", "5a871a6861bb38fb24000009_125", "5a871a6861bb38fb24000009_125", "5a871a6861bb38fb24000009_125", "5a871a6861bb38fb24000009_125", "5a871a6861bb38fb24000009_125", "5a871a6861bb38fb24000009_125", "5a871a6861bb38fb24000009_125", "5a871a6861bb38fb24000009_125", "5a871a6861bb38fb24000009_125", "5a871a6861bb38fb24000009_125", "5a871a6861bb38fb24000009_125", "5a871a6861bb38fb24000009_125", "5a871a6861bb38fb24000009_125", "5a871a6861bb38fb24000009_126", "5a871a6861bb38fb24000009_126", "5a871a6861bb38fb24000009_126", "5a871a6861bb38fb24000009_126", "5a871a6861bb38fb24000009_126", "5a871a6861bb38fb24000009_126", "5a871a6861bb38fb24000009_126", "5a871a6861bb38fb24000009_126", "5a871a6861bb38fb24000009_126", "5a871a6861bb38fb24000009_126", "5a871a6861bb38fb24000009_126", "5a871a6861bb38fb24000009_126", "5a871a6861bb38fb24000009_126", "5a871a6861bb38fb24000009_126", "5a871a6861bb38fb24000009_126", "5a871a6861bb38fb24000009_126", "5a871a6861bb38fb24000009_126", "5a871a6861bb38fb24000009_127", "5a871a6861bb38fb24000009_127", "5a871a6861bb38fb24000009_127", "5a871a6861bb38fb24000009_127", "5a871a6861bb38fb24000009_127", "5a871a6861bb38fb24000009_127", "5a871a6861bb38fb24000009_127", "5a871a6861bb38fb24000009_127", "5a871a6861bb38fb24000009_127", "5a871a6861bb38fb24000009_127", "5a871a6861bb38fb24000009_127", "5a871a6861bb38fb24000009_127", "5a871a6861bb38fb24000009_127", "5a871a6861bb38fb24000009_127", "5a871a6861bb38fb24000009_127", "5a871a6861bb38fb24000009_127", "5a871a6861bb38fb24000009_127", "5a871a6861bb38fb24000009_128", "5a871a6861bb38fb24000009_128", "5a871a6861bb38fb24000009_128", "5a871a6861bb38fb24000009_128", "5a871a6861bb38fb24000009_128", "5a871a6861bb38fb24000009_128", "5a871a6861bb38fb24000009_128", "5a871a6861bb38fb24000009_128", "5a871a6861bb38fb24000009_128", "5a871a6861bb38fb24000009_128", "5a871a6861bb38fb24000009_128", "5a871a6861bb38fb24000009_128", "5a871a6861bb38fb24000009_128", "5a871a6861bb38fb24000009_128", "5a871a6861bb38fb24000009_128", "5a871a6861bb38fb24000009_128", "5a871a6861bb38fb24000009_128", "5a871a6861bb38fb24000009_129", "5a871a6861bb38fb24000009_129", "5a871a6861bb38fb24000009_129", "5a871a6861bb38fb24000009_129", "5a871a6861bb38fb24000009_129", "5a871a6861bb38fb24000009_129", "5a871a6861bb38fb24000009_129", "5a871a6861bb38fb24000009_129", "5a871a6861bb38fb24000009_129", "5a871a6861bb38fb24000009_129", "5a871a6861bb38fb24000009_129", "5a871a6861bb38fb24000009_129", "5a871a6861bb38fb24000009_129", "5a871a6861bb38fb24000009_129", "5a871a6861bb38fb24000009_129", "5a871a6861bb38fb24000009_129", "5a871a6861bb38fb24000009_129", "5a871a6861bb38fb24000009_130", "5a871a6861bb38fb24000009_130", "5a871a6861bb38fb24000009_130", "5a871a6861bb38fb24000009_130", "5a871a6861bb38fb24000009_130", "5a871a6861bb38fb24000009_130", "5a871a6861bb38fb24000009_130", "5a871a6861bb38fb24000009_130", "5a871a6861bb38fb24000009_130", "5a871a6861bb38fb24000009_130", "5a871a6861bb38fb24000009_130", "5a871a6861bb38fb24000009_130", "5a871a6861bb38fb24000009_130", "5a871a6861bb38fb24000009_130", "5a871a6861bb38fb24000009_130", "5a871a6861bb38fb24000009_130", "5a871a6861bb38fb24000009_130", "5a871a6861bb38fb24000009_131", "5a871a6861bb38fb24000009_131", "5a871a6861bb38fb24000009_131", "5a871a6861bb38fb24000009_131", "5a871a6861bb38fb24000009_131", "5a871a6861bb38fb24000009_131", "5a871a6861bb38fb24000009_131", "5a871a6861bb38fb24000009_131", "5a871a6861bb38fb24000009_131", "5a871a6861bb38fb24000009_131", "5a871a6861bb38fb24000009_131", "5a871a6861bb38fb24000009_131", "5a871a6861bb38fb24000009_131", "5a871a6861bb38fb24000009_131", "5a871a6861bb38fb24000009_131", "5a871a6861bb38fb24000009_131", "5a871a6861bb38fb24000009_131", "5a871a6861bb38fb24000009_132", "5a871a6861bb38fb24000009_132", "5a871a6861bb38fb24000009_132", "5a871a6861bb38fb24000009_132", "5a871a6861bb38fb24000009_132", "5a871a6861bb38fb24000009_132", "5a871a6861bb38fb24000009_132", "5a871a6861bb38fb24000009_132", "5a871a6861bb38fb24000009_132", "5a871a6861bb38fb24000009_132", "5a871a6861bb38fb24000009_132", "5a871a6861bb38fb24000009_132", "5a871a6861bb38fb24000009_132", "5a871a6861bb38fb24000009_132", "5a871a6861bb38fb24000009_132", "5a871a6861bb38fb24000009_132", "5a871a6861bb38fb24000009_132", "5a871a6861bb38fb24000009_133", "5a871a6861bb38fb24000009_133", "5a871a6861bb38fb24000009_133", "5a871a6861bb38fb24000009_133", "5a871a6861bb38fb24000009_133", "5a871a6861bb38fb24000009_133", "5a871a6861bb38fb24000009_133", "5a871a6861bb38fb24000009_133", "5a871a6861bb38fb24000009_133", "5a871a6861bb38fb24000009_133", "5a871a6861bb38fb24000009_133", "5a871a6861bb38fb24000009_133", "5a871a6861bb38fb24000009_133", "5a871a6861bb38fb24000009_133", "5a871a6861bb38fb24000009_133", "5a871a6861bb38fb24000009_133", "5a871a6861bb38fb24000009_133", "5a871a6861bb38fb24000009_134", "5a871a6861bb38fb24000009_134", "5a871a6861bb38fb24000009_134", "5a871a6861bb38fb24000009_134", "5a871a6861bb38fb24000009_134", "5a871a6861bb38fb24000009_134", "5a871a6861bb38fb24000009_134", "5a871a6861bb38fb24000009_134", "5a871a6861bb38fb24000009_134", "5a871a6861bb38fb24000009_134", "5a871a6861bb38fb24000009_134", "5a871a6861bb38fb24000009_134", "5a871a6861bb38fb24000009_134", "5a871a6861bb38fb24000009_134", "5a871a6861bb38fb24000009_134", "5a871a6861bb38fb24000009_134", "5a871a6861bb38fb24000009_134", "5a871a6861bb38fb24000009_135", "5a871a6861bb38fb24000009_135", "5a871a6861bb38fb24000009_135", "5a871a6861bb38fb24000009_135", "5a871a6861bb38fb24000009_135", "5a871a6861bb38fb24000009_135", "5a871a6861bb38fb24000009_135", "5a871a6861bb38fb24000009_135", "5a871a6861bb38fb24000009_135", "5a871a6861bb38fb24000009_135", "5a871a6861bb38fb24000009_135", "5a871a6861bb38fb24000009_135", "5a871a6861bb38fb24000009_135", "5a871a6861bb38fb24000009_135", "5a871a6861bb38fb24000009_135", "5a871a6861bb38fb24000009_135", "5a871a6861bb38fb24000009_135", "5a871a6861bb38fb24000009_136", "5a871a6861bb38fb24000009_136", "5a871a6861bb38fb24000009_136", "5a871a6861bb38fb24000009_136", "5a871a6861bb38fb24000009_136", "5a871a6861bb38fb24000009_136", "5a871a6861bb38fb24000009_136", "5a871a6861bb38fb24000009_136", "5a871a6861bb38fb24000009_136", "5a871a6861bb38fb24000009_136", "5a871a6861bb38fb24000009_136", "5a871a6861bb38fb24000009_136", "5a871a6861bb38fb24000009_136", "5a871a6861bb38fb24000009_136", "5a871a6861bb38fb24000009_136", "5a871a6861bb38fb24000009_136", "5a871a6861bb38fb24000009_136", "5a871a6861bb38fb24000009_137", "5a871a6861bb38fb24000009_137", "5a871a6861bb38fb24000009_137", "5a871a6861bb38fb24000009_137", "5a871a6861bb38fb24000009_137", "5a871a6861bb38fb24000009_137", "5a871a6861bb38fb24000009_137", "5a871a6861bb38fb24000009_137", "5a871a6861bb38fb24000009_137", "5a871a6861bb38fb24000009_137", "5a871a6861bb38fb24000009_137", "5a871a6861bb38fb24000009_137", "5a871a6861bb38fb24000009_137", "5a871a6861bb38fb24000009_137", "5a871a6861bb38fb24000009_137", "5a871a6861bb38fb24000009_137", "5a871a6861bb38fb24000009_137", "5a871a6861bb38fb24000009_138", "5a871a6861bb38fb24000009_138", "5a871a6861bb38fb24000009_138", "5a871a6861bb38fb24000009_138", "5a871a6861bb38fb24000009_138", "5a871a6861bb38fb24000009_138", "5a871a6861bb38fb24000009_138", "5a871a6861bb38fb24000009_138", "5a871a6861bb38fb24000009_138", "5a871a6861bb38fb24000009_138", "5a871a6861bb38fb24000009_138", "5a871a6861bb38fb24000009_138", "5a871a6861bb38fb24000009_138", "5a871a6861bb38fb24000009_138", "5a871a6861bb38fb24000009_138", "5a871a6861bb38fb24000009_138", "5a871a6861bb38fb24000009_138", "5a871a6861bb38fb24000009_139", "5a871a6861bb38fb24000009_139", "5a871a6861bb38fb24000009_139", "5a871a6861bb38fb24000009_139", "5a871a6861bb38fb24000009_139", "5a871a6861bb38fb24000009_139", "5a871a6861bb38fb24000009_139", "5a871a6861bb38fb24000009_139", "5a871a6861bb38fb24000009_139", "5a871a6861bb38fb24000009_139", "5a871a6861bb38fb24000009_139", "5a871a6861bb38fb24000009_139", "5a871a6861bb38fb24000009_139", "5a871a6861bb38fb24000009_139", "5a871a6861bb38fb24000009_139", "5a871a6861bb38fb24000009_139", "5a871a6861bb38fb24000009_139", "5a67ab79b750ff445500000b_140", "5a67ab79b750ff445500000b_140", "5a67ab79b750ff445500000b_140", "5a67ab79b750ff445500000b_140", "5a67ab79b750ff445500000b_140", "5a67ab79b750ff445500000b_140", "5a67ab79b750ff445500000b_140", "5a67ab79b750ff445500000b_140", "5a67ab79b750ff445500000b_140", "5a67ab79b750ff445500000b_140", "5a67ab79b750ff445500000b_140", "5a67ab79b750ff445500000b_140", "5a67ab79b750ff445500000b_140", "5a67ab79b750ff445500000b_140", "5a67ab79b750ff445500000b_140", "5a67ab79b750ff445500000b_140", "5a67ab79b750ff445500000b_140", "5a67ab79b750ff445500000b_140", "5a67ab79b750ff445500000b_140", "5a67ab79b750ff445500000b_140", "5a67ab79b750ff445500000b_140", "5a67ab79b750ff445500000b_140", "5a67ab79b750ff445500000b_140", "5a67ab79b750ff445500000b_140", "5a67ab79b750ff445500000b_140", "5a67ab79b750ff445500000b_140", "5a67ab79b750ff445500000b_140", "5a67ab79b750ff445500000b_140", "5a67ab79b750ff445500000b_140", "5a67ab79b750ff445500000b_140", "5a67ab79b750ff445500000b_140", "5a67ab79b750ff445500000b_140", "5a67ab79b750ff445500000b_140", "5a67ab79b750ff445500000b_140", "5a67ab79b750ff445500000b_140", "5a67ab79b750ff445500000b_141", "5a67ab79b750ff445500000b_141", "5a67ab79b750ff445500000b_141", "5a67ab79b750ff445500000b_141", "5a67ab79b750ff445500000b_141", "5a67ab79b750ff445500000b_141", "5a67ab79b750ff445500000b_141", "5a67ab79b750ff445500000b_141", "5a67ab79b750ff445500000b_141", "5a67ab79b750ff445500000b_141", "5a67ab79b750ff445500000b_141", "5a67ab79b750ff445500000b_141", "5a67ab79b750ff445500000b_141", "5a67ab79b750ff445500000b_141", "5a67ab79b750ff445500000b_141", "5a67ab79b750ff445500000b_141", "5a67ab79b750ff445500000b_141", "5a67ab79b750ff445500000b_141", "5a67ab79b750ff445500000b_141", "5a67ab79b750ff445500000b_141", "5a67ab79b750ff445500000b_141", "5a67ab79b750ff445500000b_141", "5a67ab79b750ff445500000b_141", "5a67ab79b750ff445500000b_141", "5a67ab79b750ff445500000b_141", "5a67ab79b750ff445500000b_141", "5a67ab79b750ff445500000b_141", "5a67ab79b750ff445500000b_141", "5a67ab79b750ff445500000b_141", "5a67ab79b750ff445500000b_141", "5a67ab79b750ff445500000b_141", "5a67ab79b750ff445500000b_141", "5a67ab79b750ff445500000b_141", "5a67ab79b750ff445500000b_141", "5a67ab79b750ff445500000b_141", "5a67ab79b750ff445500000b_142", "5a67ab79b750ff445500000b_142", "5a67ab79b750ff445500000b_142", "5a67ab79b750ff445500000b_142", "5a67ab79b750ff445500000b_142", "5a67ab79b750ff445500000b_142", "5a67ab79b750ff445500000b_142", "5a67ab79b750ff445500000b_142", "5a67ab79b750ff445500000b_142", "5a67ab79b750ff445500000b_142", "5a67ab79b750ff445500000b_142", "5a67ab79b750ff445500000b_142", "5a67ab79b750ff445500000b_142", "5a67ab79b750ff445500000b_142", "5a67ab79b750ff445500000b_142", "5a67ab79b750ff445500000b_142", "5a67ab79b750ff445500000b_142", "5a67ab79b750ff445500000b_142", "5a67ab79b750ff445500000b_142", "5a67ab79b750ff445500000b_142", "5a67ab79b750ff445500000b_142", "5a67ab79b750ff445500000b_142", "5a67ab79b750ff445500000b_142", "5a67ab79b750ff445500000b_142", "5a67ab79b750ff445500000b_142", "5a67ab79b750ff445500000b_142", "5a67ab79b750ff445500000b_142", "5a67ab79b750ff445500000b_142", "5a67ab79b750ff445500000b_142", "5a67ab79b750ff445500000b_142", "5a67ab79b750ff445500000b_142", "5a67ab79b750ff445500000b_142", "5a67ab79b750ff445500000b_142", "5a67ab79b750ff445500000b_142", "5a67ab79b750ff445500000b_142", "5a67ab79b750ff445500000b_143", "5a67ab79b750ff445500000b_143", "5a67ab79b750ff445500000b_143", "5a67ab79b750ff445500000b_143", "5a67ab79b750ff445500000b_143", "5a67ab79b750ff445500000b_143", "5a67ab79b750ff445500000b_143", "5a67ab79b750ff445500000b_143", "5a67ab79b750ff445500000b_143", "5a67ab79b750ff445500000b_143", "5a67ab79b750ff445500000b_143", "5a67ab79b750ff445500000b_143", "5a67ab79b750ff445500000b_143", "5a67ab79b750ff445500000b_143", "5a67ab79b750ff445500000b_143", "5a67ab79b750ff445500000b_143", "5a67ab79b750ff445500000b_143", "5a67ab79b750ff445500000b_143", "5a67ab79b750ff445500000b_143", "5a67ab79b750ff445500000b_143", "5a67ab79b750ff445500000b_143", "5a67ab79b750ff445500000b_143", "5a67ab79b750ff445500000b_143", "5a67ab79b750ff445500000b_143", "5a67ab79b750ff445500000b_143", "5a67ab79b750ff445500000b_143", "5a67ab79b750ff445500000b_143", "5a67ab79b750ff445500000b_143", "5a67ab79b750ff445500000b_143", "5a67ab79b750ff445500000b_143", "5a67ab79b750ff445500000b_143", "5a67ab79b750ff445500000b_143", "5a67ab79b750ff445500000b_143", "5a67ab79b750ff445500000b_143", "5a67ab79b750ff445500000b_143", "5a67ab79b750ff445500000b_144", "5a67ab79b750ff445500000b_144", "5a67ab79b750ff445500000b_144", "5a67ab79b750ff445500000b_144", "5a67ab79b750ff445500000b_144", "5a67ab79b750ff445500000b_144", "5a67ab79b750ff445500000b_144", "5a67ab79b750ff445500000b_144", "5a67ab79b750ff445500000b_144", "5a67ab79b750ff445500000b_144", "5a67ab79b750ff445500000b_144", "5a67ab79b750ff445500000b_144", "5a67ab79b750ff445500000b_144", "5a67ab79b750ff445500000b_144", "5a67ab79b750ff445500000b_144", "5a67ab79b750ff445500000b_144", "5a67ab79b750ff445500000b_144", "5a67ab79b750ff445500000b_144", "5a67ab79b750ff445500000b_144", "5a67ab79b750ff445500000b_144", "5a67ab79b750ff445500000b_144", "5a67ab79b750ff445500000b_144", "5a67ab79b750ff445500000b_144", "5a67ab79b750ff445500000b_144", "5a67ab79b750ff445500000b_144", "5a67ab79b750ff445500000b_144", "5a67ab79b750ff445500000b_144", "5a67ab79b750ff445500000b_144", "5a67ab79b750ff445500000b_144", "5a67ab79b750ff445500000b_144", "5a67ab79b750ff445500000b_144", "5a67ab79b750ff445500000b_144", "5a67ab79b750ff445500000b_144", "5a67ab79b750ff445500000b_144", "5a67ab79b750ff445500000b_144", "5a67ab79b750ff445500000b_145", "5a67ab79b750ff445500000b_145", "5a67ab79b750ff445500000b_145", "5a67ab79b750ff445500000b_145", "5a67ab79b750ff445500000b_145", "5a67ab79b750ff445500000b_145", "5a67ab79b750ff445500000b_145", "5a67ab79b750ff445500000b_145", "5a67ab79b750ff445500000b_145", "5a67ab79b750ff445500000b_145", "5a67ab79b750ff445500000b_145", "5a67ab79b750ff445500000b_145", "5a67ab79b750ff445500000b_145", "5a67ab79b750ff445500000b_145", "5a67ab79b750ff445500000b_145", "5a67ab79b750ff445500000b_145", "5a67ab79b750ff445500000b_145", "5a67ab79b750ff445500000b_145", "5a67ab79b750ff445500000b_145", "5a67ab79b750ff445500000b_145", "5a67ab79b750ff445500000b_145", "5a67ab79b750ff445500000b_145", "5a67ab79b750ff445500000b_145", "5a67ab79b750ff445500000b_145", "5a67ab79b750ff445500000b_145", "5a67ab79b750ff445500000b_145", "5a67ab79b750ff445500000b_145", "5a67ab79b750ff445500000b_145", "5a67ab79b750ff445500000b_145", "5a67ab79b750ff445500000b_145", "5a67ab79b750ff445500000b_145", "5a67ab79b750ff445500000b_145", "5a67ab79b750ff445500000b_145", "5a67ab79b750ff445500000b_145", "5a67ab79b750ff445500000b_145", "5a67ab79b750ff445500000b_146", "5a67ab79b750ff445500000b_146", "5a67ab79b750ff445500000b_146", "5a67ab79b750ff445500000b_146", "5a67ab79b750ff445500000b_146", "5a67ab79b750ff445500000b_146", "5a67ab79b750ff445500000b_146", "5a67ab79b750ff445500000b_146", "5a67ab79b750ff445500000b_146", "5a67ab79b750ff445500000b_146", "5a67ab79b750ff445500000b_146", "5a67ab79b750ff445500000b_146", "5a67ab79b750ff445500000b_146", "5a67ab79b750ff445500000b_146", "5a67ab79b750ff445500000b_146", "5a67ab79b750ff445500000b_146", "5a67ab79b750ff445500000b_146", "5a67ab79b750ff445500000b_146", "5a67ab79b750ff445500000b_146", "5a67ab79b750ff445500000b_146", "5a67ab79b750ff445500000b_146", "5a67ab79b750ff445500000b_146", "5a67ab79b750ff445500000b_146", "5a67ab79b750ff445500000b_146", "5a67ab79b750ff445500000b_146", "5a67ab79b750ff445500000b_146", "5a67ab79b750ff445500000b_146", "5a67ab79b750ff445500000b_146", "5a67ab79b750ff445500000b_146", "5a67ab79b750ff445500000b_146", "5a67ab79b750ff445500000b_146", "5a67ab79b750ff445500000b_146", "5a67ab79b750ff445500000b_146", "5a67ab79b750ff445500000b_146", "5a67ab79b750ff445500000b_146", "5a68f005b750ff4455000016_147", "5a68f005b750ff4455000016_147", "5a68f005b750ff4455000016_147", "5a68f005b750ff4455000016_147", "5a68f005b750ff4455000016_147", "5a68f005b750ff4455000016_147", "5a68f005b750ff4455000016_147", "5a68f005b750ff4455000016_147", "5a68f005b750ff4455000016_147", "5a68f005b750ff4455000016_147", "5a68f005b750ff4455000016_147", "5a68f005b750ff4455000016_147", "5a68f005b750ff4455000016_147", "5a68f005b750ff4455000016_147", "5a68f005b750ff4455000016_147", "5a68f005b750ff4455000016_147", "5a68f005b750ff4455000016_147", "5a68f005b750ff4455000016_147", "5a68f005b750ff4455000016_148", "5a68f005b750ff4455000016_148", "5a68f005b750ff4455000016_148", "5a68f005b750ff4455000016_148", "5a68f005b750ff4455000016_148", "5a68f005b750ff4455000016_148", "5a68f005b750ff4455000016_148", "5a68f005b750ff4455000016_148", "5a68f005b750ff4455000016_148", "5a68f005b750ff4455000016_148", "5a68f005b750ff4455000016_148", "5a68f005b750ff4455000016_148", "5a68f005b750ff4455000016_148", "5a68f005b750ff4455000016_148", "5a68f005b750ff4455000016_148", "5a68f005b750ff4455000016_148", "5a68f005b750ff4455000016_148", "5a68f005b750ff4455000016_148", "5a68f005b750ff4455000016_149", "5a68f005b750ff4455000016_149", "5a68f005b750ff4455000016_149", "5a68f005b750ff4455000016_149", "5a68f005b750ff4455000016_149", "5a68f005b750ff4455000016_149", "5a68f005b750ff4455000016_149", "5a68f005b750ff4455000016_149", "5a68f005b750ff4455000016_149", "5a68f005b750ff4455000016_149", "5a68f005b750ff4455000016_149", "5a68f005b750ff4455000016_149", "5a68f005b750ff4455000016_149", "5a68f005b750ff4455000016_149", "5a68f005b750ff4455000016_149", "5a68f005b750ff4455000016_149", "5a68f005b750ff4455000016_149", "5a68f005b750ff4455000016_149", "5a68f005b750ff4455000016_150", "5a68f005b750ff4455000016_150", "5a68f005b750ff4455000016_150", "5a68f005b750ff4455000016_150", "5a68f005b750ff4455000016_150", "5a68f005b750ff4455000016_150", "5a68f005b750ff4455000016_150", "5a68f005b750ff4455000016_150", "5a68f005b750ff4455000016_150", "5a68f005b750ff4455000016_150", "5a68f005b750ff4455000016_150", "5a68f005b750ff4455000016_150", "5a68f005b750ff4455000016_150", "5a68f005b750ff4455000016_150", "5a68f005b750ff4455000016_150", "5a68f005b750ff4455000016_150", "5a68f005b750ff4455000016_150", "5a68f005b750ff4455000016_150", "5a68f005b750ff4455000016_151", "5a68f005b750ff4455000016_151", "5a68f005b750ff4455000016_151", "5a68f005b750ff4455000016_151", "5a68f005b750ff4455000016_151", "5a68f005b750ff4455000016_151", "5a68f005b750ff4455000016_151", "5a68f005b750ff4455000016_151", "5a68f005b750ff4455000016_151", "5a68f005b750ff4455000016_151", "5a68f005b750ff4455000016_151", "5a68f005b750ff4455000016_151", "5a68f005b750ff4455000016_151", "5a68f005b750ff4455000016_151", "5a68f005b750ff4455000016_151", "5a68f005b750ff4455000016_151", "5a68f005b750ff4455000016_151", "5a68f005b750ff4455000016_151", "5a68f005b750ff4455000016_152", "5a68f005b750ff4455000016_152", "5a68f005b750ff4455000016_152", "5a68f005b750ff4455000016_152", "5a68f005b750ff4455000016_152", "5a68f005b750ff4455000016_152", "5a68f005b750ff4455000016_152", "5a68f005b750ff4455000016_152", "5a68f005b750ff4455000016_152", "5a68f005b750ff4455000016_152", "5a68f005b750ff4455000016_152", "5a68f005b750ff4455000016_152", "5a68f005b750ff4455000016_152", "5a68f005b750ff4455000016_152", "5a68f005b750ff4455000016_152", "5a68f005b750ff4455000016_152", "5a68f005b750ff4455000016_152", "5a68f005b750ff4455000016_152", "5a68f005b750ff4455000016_153", "5a68f005b750ff4455000016_153", "5a68f005b750ff4455000016_153", "5a68f005b750ff4455000016_153", "5a68f005b750ff4455000016_153", "5a68f005b750ff4455000016_153", "5a68f005b750ff4455000016_153", "5a68f005b750ff4455000016_153", "5a68f005b750ff4455000016_153", "5a68f005b750ff4455000016_153", "5a68f005b750ff4455000016_153", "5a68f005b750ff4455000016_153", "5a68f005b750ff4455000016_153", "5a68f005b750ff4455000016_153", "5a68f005b750ff4455000016_153", "5a68f005b750ff4455000016_153", "5a68f005b750ff4455000016_153", "5a68f005b750ff4455000016_153", "5a68f005b750ff4455000016_154", "5a68f005b750ff4455000016_154", "5a68f005b750ff4455000016_154", "5a68f005b750ff4455000016_154", "5a68f005b750ff4455000016_154", "5a68f005b750ff4455000016_154", "5a68f005b750ff4455000016_154", "5a68f005b750ff4455000016_154", "5a68f005b750ff4455000016_154", "5a68f005b750ff4455000016_154", "5a68f005b750ff4455000016_154", "5a68f005b750ff4455000016_154", "5a68f005b750ff4455000016_154", "5a68f005b750ff4455000016_154", "5a68f005b750ff4455000016_154", "5a68f005b750ff4455000016_154", "5a68f005b750ff4455000016_154", "5a68f005b750ff4455000016_154", "5a68f005b750ff4455000016_155", "5a68f005b750ff4455000016_155", "5a68f005b750ff4455000016_155", "5a68f005b750ff4455000016_155", "5a68f005b750ff4455000016_155", "5a68f005b750ff4455000016_155", "5a68f005b750ff4455000016_155", "5a68f005b750ff4455000016_155", "5a68f005b750ff4455000016_155", "5a68f005b750ff4455000016_155", "5a68f005b750ff4455000016_155", "5a68f005b750ff4455000016_155", "5a68f005b750ff4455000016_155", "5a68f005b750ff4455000016_155", "5a68f005b750ff4455000016_155", "5a68f005b750ff4455000016_155", "5a68f005b750ff4455000016_155", "5a68f005b750ff4455000016_155", "5a68f005b750ff4455000016_156", "5a68f005b750ff4455000016_156", "5a68f005b750ff4455000016_156", "5a68f005b750ff4455000016_156", "5a68f005b750ff4455000016_156", "5a68f005b750ff4455000016_156", "5a68f005b750ff4455000016_156", "5a68f005b750ff4455000016_156", "5a68f005b750ff4455000016_156", "5a68f005b750ff4455000016_156", "5a68f005b750ff4455000016_156", "5a68f005b750ff4455000016_156", "5a68f005b750ff4455000016_156", "5a68f005b750ff4455000016_156", "5a68f005b750ff4455000016_156", "5a68f005b750ff4455000016_156", "5a68f005b750ff4455000016_156", "5a68f005b750ff4455000016_156", "5a68f005b750ff4455000016_157", "5a68f005b750ff4455000016_157", "5a68f005b750ff4455000016_157", "5a68f005b750ff4455000016_157", "5a68f005b750ff4455000016_157", "5a68f005b750ff4455000016_157", "5a68f005b750ff4455000016_157", "5a68f005b750ff4455000016_157", "5a68f005b750ff4455000016_157", "5a68f005b750ff4455000016_157", "5a68f005b750ff4455000016_157", "5a68f005b750ff4455000016_157", "5a68f005b750ff4455000016_157", "5a68f005b750ff4455000016_157", "5a68f005b750ff4455000016_157", "5a68f005b750ff4455000016_157", "5a68f005b750ff4455000016_157", "5a68f005b750ff4455000016_157", "5a68f005b750ff4455000016_158", "5a68f005b750ff4455000016_158", "5a68f005b750ff4455000016_158", "5a68f005b750ff4455000016_158", "5a68f005b750ff4455000016_158", "5a68f005b750ff4455000016_158", "5a68f005b750ff4455000016_158", "5a68f005b750ff4455000016_158", "5a68f005b750ff4455000016_158", "5a68f005b750ff4455000016_158", "5a68f005b750ff4455000016_158", "5a68f005b750ff4455000016_158", "5a68f005b750ff4455000016_158", "5a68f005b750ff4455000016_158", "5a68f005b750ff4455000016_158", "5a68f005b750ff4455000016_158", "5a68f005b750ff4455000016_158", "5a68f005b750ff4455000016_158", "5a68f005b750ff4455000016_159", "5a68f005b750ff4455000016_159", "5a68f005b750ff4455000016_159", "5a68f005b750ff4455000016_159", "5a68f005b750ff4455000016_159", "5a68f005b750ff4455000016_159", "5a68f005b750ff4455000016_159", "5a68f005b750ff4455000016_159", "5a68f005b750ff4455000016_159", "5a68f005b750ff4455000016_159", "5a68f005b750ff4455000016_159", "5a68f005b750ff4455000016_159", "5a68f005b750ff4455000016_159", "5a68f005b750ff4455000016_159", "5a68f005b750ff4455000016_159", "5a68f005b750ff4455000016_159", "5a68f005b750ff4455000016_159", "5a68f005b750ff4455000016_159", "5a68f005b750ff4455000016_160", "5a68f005b750ff4455000016_160", "5a68f005b750ff4455000016_160", "5a68f005b750ff4455000016_160", "5a68f005b750ff4455000016_160", "5a68f005b750ff4455000016_160", "5a68f005b750ff4455000016_160", "5a68f005b750ff4455000016_160", "5a68f005b750ff4455000016_160", "5a68f005b750ff4455000016_160", "5a68f005b750ff4455000016_160", "5a68f005b750ff4455000016_160", "5a68f005b750ff4455000016_160", "5a68f005b750ff4455000016_160", "5a68f005b750ff4455000016_160", "5a68f005b750ff4455000016_160", "5a68f005b750ff4455000016_160", "5a68f005b750ff4455000016_160", "5a68f005b750ff4455000016_161", "5a68f005b750ff4455000016_161", "5a68f005b750ff4455000016_161", "5a68f005b750ff4455000016_161", "5a68f005b750ff4455000016_161", "5a68f005b750ff4455000016_161", "5a68f005b750ff4455000016_161", "5a68f005b750ff4455000016_161", "5a68f005b750ff4455000016_161", "5a68f005b750ff4455000016_161", "5a68f005b750ff4455000016_161", "5a68f005b750ff4455000016_161", "5a68f005b750ff4455000016_161", "5a68f005b750ff4455000016_161", "5a68f005b750ff4455000016_161", "5a68f005b750ff4455000016_161", "5a68f005b750ff4455000016_161", "5a68f005b750ff4455000016_161", "5a68f005b750ff4455000016_162", "5a68f005b750ff4455000016_162", "5a68f005b750ff4455000016_162", "5a68f005b750ff4455000016_162", "5a68f005b750ff4455000016_162", "5a68f005b750ff4455000016_162", "5a68f005b750ff4455000016_162", "5a68f005b750ff4455000016_162", "5a68f005b750ff4455000016_162", "5a68f005b750ff4455000016_162", "5a68f005b750ff4455000016_162", "5a68f005b750ff4455000016_162", "5a68f005b750ff4455000016_162", "5a68f005b750ff4455000016_162", "5a68f005b750ff4455000016_162", "5a68f005b750ff4455000016_162", "5a68f005b750ff4455000016_162", "5a68f005b750ff4455000016_162", "5a68f005b750ff4455000016_163", "5a68f005b750ff4455000016_163", "5a68f005b750ff4455000016_163", "5a68f005b750ff4455000016_163", "5a68f005b750ff4455000016_163", "5a68f005b750ff4455000016_163", "5a68f005b750ff4455000016_163", "5a68f005b750ff4455000016_163", "5a68f005b750ff4455000016_163", "5a68f005b750ff4455000016_163", "5a68f005b750ff4455000016_163", "5a68f005b750ff4455000016_163", "5a68f005b750ff4455000016_163", "5a68f005b750ff4455000016_163", "5a68f005b750ff4455000016_163", "5a68f005b750ff4455000016_163", "5a68f005b750ff4455000016_163", "5a68f005b750ff4455000016_163", "5a68f005b750ff4455000016_164", "5a68f005b750ff4455000016_164", "5a68f005b750ff4455000016_164", "5a68f005b750ff4455000016_164", "5a68f005b750ff4455000016_164", "5a68f005b750ff4455000016_164", "5a68f005b750ff4455000016_164", "5a68f005b750ff4455000016_164", "5a68f005b750ff4455000016_164", "5a68f005b750ff4455000016_164", "5a68f005b750ff4455000016_164", "5a68f005b750ff4455000016_164", "5a68f005b750ff4455000016_164", "5a68f005b750ff4455000016_164", "5a68f005b750ff4455000016_164", "5a68f005b750ff4455000016_164", "5a68f005b750ff4455000016_164", "5a68f005b750ff4455000016_164", "5a68f005b750ff4455000016_165", "5a68f005b750ff4455000016_165", "5a68f005b750ff4455000016_165", "5a68f005b750ff4455000016_165", "5a68f005b750ff4455000016_165", "5a68f005b750ff4455000016_165", "5a68f005b750ff4455000016_165", "5a68f005b750ff4455000016_165", "5a68f005b750ff4455000016_165", "5a68f005b750ff4455000016_165", "5a68f005b750ff4455000016_165", "5a68f005b750ff4455000016_165", "5a68f005b750ff4455000016_165", "5a68f005b750ff4455000016_165", "5a68f005b750ff4455000016_165", "5a68f005b750ff4455000016_165", "5a68f005b750ff4455000016_165", "5a68f005b750ff4455000016_165", "5a68f005b750ff4455000016_166", "5a68f005b750ff4455000016_166", "5a68f005b750ff4455000016_166", "5a68f005b750ff4455000016_166", "5a68f005b750ff4455000016_166", "5a68f005b750ff4455000016_166", "5a68f005b750ff4455000016_166", "5a68f005b750ff4455000016_166", "5a68f005b750ff4455000016_166", "5a68f005b750ff4455000016_166", "5a68f005b750ff4455000016_166", "5a68f005b750ff4455000016_166", "5a68f005b750ff4455000016_166", "5a68f005b750ff4455000016_166", "5a68f005b750ff4455000016_166", "5a68f005b750ff4455000016_166", "5a68f005b750ff4455000016_166", "5a68f005b750ff4455000016_166", "5a6f853ab750ff4455000055_167", "5a6f853ab750ff4455000055_167", "5a6f853ab750ff4455000055_167", "5a6f853ab750ff4455000055_167", "5a6f853ab750ff4455000055_167", "5a6f853ab750ff4455000055_167", "5a6f853ab750ff4455000055_167", "5a6f853ab750ff4455000055_167", "5a6f853ab750ff4455000055_167", "5a6f853ab750ff4455000055_167", "5a6f853ab750ff4455000055_167", "5a6f853ab750ff4455000055_167", "5a6f853ab750ff4455000055_167", "5a6f853ab750ff4455000055_167", "5a6f853ab750ff4455000055_167", "5a6f853ab750ff4455000055_167", "5a6f853ab750ff4455000055_167", "5a6f853ab750ff4455000055_167", "5a6f853ab750ff4455000055_167", "5a6f853ab750ff4455000055_167", "5a6f853ab750ff4455000055_167", "5a6f853ab750ff4455000055_167", "5a6f853ab750ff4455000055_167", "5a6f853ab750ff4455000055_167", "5a6f853ab750ff4455000055_167", "5a6f853ab750ff4455000055_167", "5a6f853ab750ff4455000055_167", "5a6f853ab750ff4455000055_167", "5a6f853ab750ff4455000055_167", "5a6f853ab750ff4455000055_168", "5a6f853ab750ff4455000055_168", "5a6f853ab750ff4455000055_168", "5a6f853ab750ff4455000055_168", "5a6f853ab750ff4455000055_168", "5a6f853ab750ff4455000055_168", "5a6f853ab750ff4455000055_168", "5a6f853ab750ff4455000055_168", "5a6f853ab750ff4455000055_168", "5a6f853ab750ff4455000055_168", "5a6f853ab750ff4455000055_168", "5a6f853ab750ff4455000055_168", "5a6f853ab750ff4455000055_168", "5a6f853ab750ff4455000055_168", "5a6f853ab750ff4455000055_168", "5a6f853ab750ff4455000055_168", "5a6f853ab750ff4455000055_168", "5a6f853ab750ff4455000055_168", "5a6f853ab750ff4455000055_168", "5a6f853ab750ff4455000055_168", "5a6f853ab750ff4455000055_168", "5a6f853ab750ff4455000055_168", "5a6f853ab750ff4455000055_168", "5a6f853ab750ff4455000055_168", "5a6f853ab750ff4455000055_168", "5a6f853ab750ff4455000055_168", "5a6f853ab750ff4455000055_168", "5a6f853ab750ff4455000055_168", "5a6f853ab750ff4455000055_168", "5a6f853ab750ff4455000055_169", "5a6f853ab750ff4455000055_169", "5a6f853ab750ff4455000055_169", "5a6f853ab750ff4455000055_169", "5a6f853ab750ff4455000055_169", "5a6f853ab750ff4455000055_169", "5a6f853ab750ff4455000055_169", "5a6f853ab750ff4455000055_169", "5a6f853ab750ff4455000055_169", "5a6f853ab750ff4455000055_169", "5a6f853ab750ff4455000055_169", "5a6f853ab750ff4455000055_169", "5a6f853ab750ff4455000055_169", "5a6f853ab750ff4455000055_169", "5a6f853ab750ff4455000055_169", "5a6f853ab750ff4455000055_169", "5a6f853ab750ff4455000055_169", "5a6f853ab750ff4455000055_169", "5a6f853ab750ff4455000055_169", "5a6f853ab750ff4455000055_169", "5a6f853ab750ff4455000055_169", "5a6f853ab750ff4455000055_169", "5a6f853ab750ff4455000055_169", "5a6f853ab750ff4455000055_169", "5a6f853ab750ff4455000055_169", "5a6f853ab750ff4455000055_169", "5a6f853ab750ff4455000055_169", "5a6f853ab750ff4455000055_169", "5a6f853ab750ff4455000055_169", "5a6f853ab750ff4455000055_170", "5a6f853ab750ff4455000055_170", "5a6f853ab750ff4455000055_170", "5a6f853ab750ff4455000055_170", "5a6f853ab750ff4455000055_170", "5a6f853ab750ff4455000055_170", "5a6f853ab750ff4455000055_170", "5a6f853ab750ff4455000055_170", "5a6f853ab750ff4455000055_170", "5a6f853ab750ff4455000055_170", "5a6f853ab750ff4455000055_170", "5a6f853ab750ff4455000055_170", "5a6f853ab750ff4455000055_170", "5a6f853ab750ff4455000055_170", "5a6f853ab750ff4455000055_170", "5a6f853ab750ff4455000055_170", "5a6f853ab750ff4455000055_170", "5a6f853ab750ff4455000055_170", "5a6f853ab750ff4455000055_170", "5a6f853ab750ff4455000055_170", "5a6f853ab750ff4455000055_170", "5a6f853ab750ff4455000055_170", "5a6f853ab750ff4455000055_170", "5a6f853ab750ff4455000055_170", "5a6f853ab750ff4455000055_170", "5a6f853ab750ff4455000055_170", "5a6f853ab750ff4455000055_170", "5a6f853ab750ff4455000055_170", "5a6f853ab750ff4455000055_170", "5a6f853ab750ff4455000055_171", "5a6f853ab750ff4455000055_171", "5a6f853ab750ff4455000055_171", "5a6f853ab750ff4455000055_171", "5a6f853ab750ff4455000055_171", "5a6f853ab750ff4455000055_171", "5a6f853ab750ff4455000055_171", "5a6f853ab750ff4455000055_171", "5a6f853ab750ff4455000055_171", "5a6f853ab750ff4455000055_171", "5a6f853ab750ff4455000055_171", "5a6f853ab750ff4455000055_171", "5a6f853ab750ff4455000055_171", "5a6f853ab750ff4455000055_171", "5a6f853ab750ff4455000055_171", "5a6f853ab750ff4455000055_171", "5a6f853ab750ff4455000055_171", "5a6f853ab750ff4455000055_171", "5a6f853ab750ff4455000055_171", "5a6f853ab750ff4455000055_171", "5a6f853ab750ff4455000055_171", "5a6f853ab750ff4455000055_171", "5a6f853ab750ff4455000055_171", "5a6f853ab750ff4455000055_171", "5a6f853ab750ff4455000055_171", "5a6f853ab750ff4455000055_171", "5a6f853ab750ff4455000055_171", "5a6f853ab750ff4455000055_171", "5a6f853ab750ff4455000055_171", "5a6f853ab750ff4455000055_172", "5a6f853ab750ff4455000055_172", "5a6f853ab750ff4455000055_172", "5a6f853ab750ff4455000055_172", "5a6f853ab750ff4455000055_172", "5a6f853ab750ff4455000055_172", "5a6f853ab750ff4455000055_172", "5a6f853ab750ff4455000055_172", "5a6f853ab750ff4455000055_172", "5a6f853ab750ff4455000055_172", "5a6f853ab750ff4455000055_172", "5a6f853ab750ff4455000055_172", "5a6f853ab750ff4455000055_172", "5a6f853ab750ff4455000055_172", "5a6f853ab750ff4455000055_172", "5a6f853ab750ff4455000055_172", "5a6f853ab750ff4455000055_172", "5a6f853ab750ff4455000055_172", "5a6f853ab750ff4455000055_172", "5a6f853ab750ff4455000055_172", "5a6f853ab750ff4455000055_172", "5a6f853ab750ff4455000055_172", "5a6f853ab750ff4455000055_172", "5a6f853ab750ff4455000055_172", "5a6f853ab750ff4455000055_172", "5a6f853ab750ff4455000055_172", "5a6f853ab750ff4455000055_172", "5a6f853ab750ff4455000055_172", "5a6f853ab750ff4455000055_172", "5a6f853ab750ff4455000055_173", "5a6f853ab750ff4455000055_173", "5a6f853ab750ff4455000055_173", "5a6f853ab750ff4455000055_173", "5a6f853ab750ff4455000055_173", "5a6f853ab750ff4455000055_173", "5a6f853ab750ff4455000055_173", "5a6f853ab750ff4455000055_173", "5a6f853ab750ff4455000055_173", "5a6f853ab750ff4455000055_173", "5a6f853ab750ff4455000055_173", "5a6f853ab750ff4455000055_173", "5a6f853ab750ff4455000055_173", "5a6f853ab750ff4455000055_173", "5a6f853ab750ff4455000055_173", "5a6f853ab750ff4455000055_173", "5a6f853ab750ff4455000055_173", "5a6f853ab750ff4455000055_173", "5a6f853ab750ff4455000055_173", "5a6f853ab750ff4455000055_173", "5a6f853ab750ff4455000055_173", "5a6f853ab750ff4455000055_173", "5a6f853ab750ff4455000055_173", "5a6f853ab750ff4455000055_173", "5a6f853ab750ff4455000055_173", "5a6f853ab750ff4455000055_173", "5a6f853ab750ff4455000055_173", "5a6f853ab750ff4455000055_173", "5a6f853ab750ff4455000055_173", "5a6f853ab750ff4455000055_174", "5a6f853ab750ff4455000055_174", "5a6f853ab750ff4455000055_174", "5a6f853ab750ff4455000055_174", "5a6f853ab750ff4455000055_174", "5a6f853ab750ff4455000055_174", "5a6f853ab750ff4455000055_174", "5a6f853ab750ff4455000055_174", "5a6f853ab750ff4455000055_174", "5a6f853ab750ff4455000055_174", "5a6f853ab750ff4455000055_174", "5a6f853ab750ff4455000055_174", "5a6f853ab750ff4455000055_174", "5a6f853ab750ff4455000055_174", "5a6f853ab750ff4455000055_174", "5a6f853ab750ff4455000055_174", "5a6f853ab750ff4455000055_174", "5a6f853ab750ff4455000055_174", "5a6f853ab750ff4455000055_174", "5a6f853ab750ff4455000055_174", "5a6f853ab750ff4455000055_174", "5a6f853ab750ff4455000055_174", "5a6f853ab750ff4455000055_174", "5a6f853ab750ff4455000055_174", "5a6f853ab750ff4455000055_174", "5a6f853ab750ff4455000055_174", "5a6f853ab750ff4455000055_174", "5a6f853ab750ff4455000055_174", "5a6f853ab750ff4455000055_174", "5a6f853ab750ff4455000055_175", "5a6f853ab750ff4455000055_175", "5a6f853ab750ff4455000055_175", "5a6f853ab750ff4455000055_175", "5a6f853ab750ff4455000055_175", "5a6f853ab750ff4455000055_175", "5a6f853ab750ff4455000055_175", "5a6f853ab750ff4455000055_175", "5a6f853ab750ff4455000055_175", "5a6f853ab750ff4455000055_175", "5a6f853ab750ff4455000055_175", "5a6f853ab750ff4455000055_175", "5a6f853ab750ff4455000055_175", "5a6f853ab750ff4455000055_175", "5a6f853ab750ff4455000055_175", "5a6f853ab750ff4455000055_175", "5a6f853ab750ff4455000055_175", "5a6f853ab750ff4455000055_175", "5a6f853ab750ff4455000055_175", "5a6f853ab750ff4455000055_175", "5a6f853ab750ff4455000055_175", "5a6f853ab750ff4455000055_175", "5a6f853ab750ff4455000055_175", "5a6f853ab750ff4455000055_175", "5a6f853ab750ff4455000055_175", "5a6f853ab750ff4455000055_175", "5a6f853ab750ff4455000055_175", "5a6f853ab750ff4455000055_175", "5a6f853ab750ff4455000055_175", "5a6f853ab750ff4455000055_176", "5a6f853ab750ff4455000055_176", "5a6f853ab750ff4455000055_176", "5a6f853ab750ff4455000055_176", "5a6f853ab750ff4455000055_176", "5a6f853ab750ff4455000055_176", "5a6f853ab750ff4455000055_176", "5a6f853ab750ff4455000055_176", "5a6f853ab750ff4455000055_176", "5a6f853ab750ff4455000055_176", "5a6f853ab750ff4455000055_176", "5a6f853ab750ff4455000055_176", "5a6f853ab750ff4455000055_176", "5a6f853ab750ff4455000055_176", "5a6f853ab750ff4455000055_176", "5a6f853ab750ff4455000055_176", "5a6f853ab750ff4455000055_176", "5a6f853ab750ff4455000055_176", "5a6f853ab750ff4455000055_176", "5a6f853ab750ff4455000055_176", "5a6f853ab750ff4455000055_176", "5a6f853ab750ff4455000055_176", "5a6f853ab750ff4455000055_176", "5a6f853ab750ff4455000055_176", "5a6f853ab750ff4455000055_176", "5a6f853ab750ff4455000055_176", "5a6f853ab750ff4455000055_176", "5a6f853ab750ff4455000055_176", "5a6f853ab750ff4455000055_176", "5a6f853ab750ff4455000055_177", "5a6f853ab750ff4455000055_177", "5a6f853ab750ff4455000055_177", "5a6f853ab750ff4455000055_177", "5a6f853ab750ff4455000055_177", "5a6f853ab750ff4455000055_177", "5a6f853ab750ff4455000055_177", "5a6f853ab750ff4455000055_177", "5a6f853ab750ff4455000055_177", "5a6f853ab750ff4455000055_177", "5a6f853ab750ff4455000055_177", "5a6f853ab750ff4455000055_177", "5a6f853ab750ff4455000055_177", "5a6f853ab750ff4455000055_177", "5a6f853ab750ff4455000055_177", "5a6f853ab750ff4455000055_177", "5a6f853ab750ff4455000055_177", "5a6f853ab750ff4455000055_177", "5a6f853ab750ff4455000055_177", "5a6f853ab750ff4455000055_177", "5a6f853ab750ff4455000055_177", "5a6f853ab750ff4455000055_177", "5a6f853ab750ff4455000055_177", "5a6f853ab750ff4455000055_177", "5a6f853ab750ff4455000055_177", "5a6f853ab750ff4455000055_177", "5a6f853ab750ff4455000055_177", "5a6f853ab750ff4455000055_177", "5a6f853ab750ff4455000055_177", "5a72302b2dc08e987e000005_178", "5a72302b2dc08e987e000005_178", "5a72302b2dc08e987e000005_178", "5a72302b2dc08e987e000005_178", "5a72302b2dc08e987e000005_178", "5a72302b2dc08e987e000005_178", "5a72302b2dc08e987e000005_178", "5a72302b2dc08e987e000005_178", "5a72302b2dc08e987e000005_178", "5a72302b2dc08e987e000005_178", "5a72302b2dc08e987e000005_178", "5a72302b2dc08e987e000005_178", "5a72302b2dc08e987e000005_178", "5a72302b2dc08e987e000005_178", "5a72302b2dc08e987e000005_178", "5a72302b2dc08e987e000005_178", "5a72302b2dc08e987e000005_178", "5a72302b2dc08e987e000005_178", "5a72302b2dc08e987e000005_178", "5a72302b2dc08e987e000005_178", "5a72302b2dc08e987e000005_178", "5a72302b2dc08e987e000005_178", "5a72302b2dc08e987e000005_178", "5a72302b2dc08e987e000005_178", "5a72302b2dc08e987e000005_178", "5a72302b2dc08e987e000005_178", "5a72302b2dc08e987e000005_178", "5a72302b2dc08e987e000005_178", "5a72302b2dc08e987e000005_178", "5a72302b2dc08e987e000005_178", "5a72302b2dc08e987e000005_178", "5a72302b2dc08e987e000005_178", "5a72302b2dc08e987e000005_178", "5a72302b2dc08e987e000005_178", "5a72302b2dc08e987e000005_178", "5a72302b2dc08e987e000005_178", "5a72302b2dc08e987e000005_178", "5a72302b2dc08e987e000005_178", "5a72302b2dc08e987e000005_178", "5a72302b2dc08e987e000005_179", "5a72302b2dc08e987e000005_179", "5a72302b2dc08e987e000005_179", "5a72302b2dc08e987e000005_179", "5a72302b2dc08e987e000005_179", "5a72302b2dc08e987e000005_179", "5a72302b2dc08e987e000005_179", "5a72302b2dc08e987e000005_179", "5a72302b2dc08e987e000005_179", "5a72302b2dc08e987e000005_179", "5a72302b2dc08e987e000005_179", "5a72302b2dc08e987e000005_179", "5a72302b2dc08e987e000005_179", "5a72302b2dc08e987e000005_179", "5a72302b2dc08e987e000005_179", "5a72302b2dc08e987e000005_179", "5a72302b2dc08e987e000005_179", "5a72302b2dc08e987e000005_179", "5a72302b2dc08e987e000005_179", "5a72302b2dc08e987e000005_179", "5a72302b2dc08e987e000005_179", "5a72302b2dc08e987e000005_179", "5a72302b2dc08e987e000005_179", "5a72302b2dc08e987e000005_179", "5a72302b2dc08e987e000005_179", "5a72302b2dc08e987e000005_179", "5a72302b2dc08e987e000005_179", "5a72302b2dc08e987e000005_179", "5a72302b2dc08e987e000005_179", "5a72302b2dc08e987e000005_179", "5a72302b2dc08e987e000005_179", "5a72302b2dc08e987e000005_179", "5a72302b2dc08e987e000005_179", "5a72302b2dc08e987e000005_179", "5a72302b2dc08e987e000005_179", "5a72302b2dc08e987e000005_179", "5a72302b2dc08e987e000005_179", "5a72302b2dc08e987e000005_179", "5a72302b2dc08e987e000005_179", "5a761ac3aacfb9cd4c000002_180", "5a761ac3aacfb9cd4c000002_180", "5a761ac3aacfb9cd4c000002_180", "5a761ac3aacfb9cd4c000002_180", "5a761ac3aacfb9cd4c000002_180", "5a761ac3aacfb9cd4c000002_180", "5a761ac3aacfb9cd4c000002_180", "5a761ac3aacfb9cd4c000002_180", "5a761ac3aacfb9cd4c000002_180", "5a761ac3aacfb9cd4c000002_180", "5a761ac3aacfb9cd4c000002_180", "5a761ac3aacfb9cd4c000002_180", "5a761ac3aacfb9cd4c000002_180", "5a761ac3aacfb9cd4c000002_180", "5a761ac3aacfb9cd4c000002_180", "5a761ac3aacfb9cd4c000002_180", "5a761ac3aacfb9cd4c000002_180", "5a761ac3aacfb9cd4c000002_180", "5a761ac3aacfb9cd4c000002_181", "5a761ac3aacfb9cd4c000002_181", "5a761ac3aacfb9cd4c000002_181", "5a761ac3aacfb9cd4c000002_181", "5a761ac3aacfb9cd4c000002_181", "5a761ac3aacfb9cd4c000002_181", "5a761ac3aacfb9cd4c000002_181", "5a761ac3aacfb9cd4c000002_181", "5a761ac3aacfb9cd4c000002_181", "5a761ac3aacfb9cd4c000002_181", "5a761ac3aacfb9cd4c000002_181", "5a761ac3aacfb9cd4c000002_181", "5a761ac3aacfb9cd4c000002_181", "5a761ac3aacfb9cd4c000002_181", "5a761ac3aacfb9cd4c000002_181", "5a761ac3aacfb9cd4c000002_181", "5a761ac3aacfb9cd4c000002_181", "5a761ac3aacfb9cd4c000002_181", "5a761ac3aacfb9cd4c000002_182", "5a761ac3aacfb9cd4c000002_182", "5a761ac3aacfb9cd4c000002_182", "5a761ac3aacfb9cd4c000002_182", "5a761ac3aacfb9cd4c000002_182", "5a761ac3aacfb9cd4c000002_182", "5a761ac3aacfb9cd4c000002_182", "5a761ac3aacfb9cd4c000002_182", "5a761ac3aacfb9cd4c000002_182", "5a761ac3aacfb9cd4c000002_182", "5a761ac3aacfb9cd4c000002_182", "5a761ac3aacfb9cd4c000002_182", "5a761ac3aacfb9cd4c000002_182", "5a761ac3aacfb9cd4c000002_182", "5a761ac3aacfb9cd4c000002_182", "5a761ac3aacfb9cd4c000002_182", "5a761ac3aacfb9cd4c000002_182", "5a761ac3aacfb9cd4c000002_182", "5a761ac3aacfb9cd4c000002_183", "5a761ac3aacfb9cd4c000002_183", "5a761ac3aacfb9cd4c000002_183", "5a761ac3aacfb9cd4c000002_183", "5a761ac3aacfb9cd4c000002_183", "5a761ac3aacfb9cd4c000002_183", "5a761ac3aacfb9cd4c000002_183", "5a761ac3aacfb9cd4c000002_183", "5a761ac3aacfb9cd4c000002_183", "5a761ac3aacfb9cd4c000002_183", "5a761ac3aacfb9cd4c000002_183", "5a761ac3aacfb9cd4c000002_183", "5a761ac3aacfb9cd4c000002_183", "5a761ac3aacfb9cd4c000002_183", "5a761ac3aacfb9cd4c000002_183", "5a761ac3aacfb9cd4c000002_183", "5a761ac3aacfb9cd4c000002_183", "5a761ac3aacfb9cd4c000002_183", "5a761ac3aacfb9cd4c000002_184", "5a761ac3aacfb9cd4c000002_184", "5a761ac3aacfb9cd4c000002_184", "5a761ac3aacfb9cd4c000002_184", "5a761ac3aacfb9cd4c000002_184", "5a761ac3aacfb9cd4c000002_184", "5a761ac3aacfb9cd4c000002_184", "5a761ac3aacfb9cd4c000002_184", "5a761ac3aacfb9cd4c000002_184", "5a761ac3aacfb9cd4c000002_184", "5a761ac3aacfb9cd4c000002_184", "5a761ac3aacfb9cd4c000002_184", "5a761ac3aacfb9cd4c000002_184", "5a761ac3aacfb9cd4c000002_184", "5a761ac3aacfb9cd4c000002_184", "5a761ac3aacfb9cd4c000002_184", "5a761ac3aacfb9cd4c000002_184", "5a761ac3aacfb9cd4c000002_184", "5a761ac3aacfb9cd4c000002_185", "5a761ac3aacfb9cd4c000002_185", "5a761ac3aacfb9cd4c000002_185", "5a761ac3aacfb9cd4c000002_185", "5a761ac3aacfb9cd4c000002_185", "5a761ac3aacfb9cd4c000002_185", "5a761ac3aacfb9cd4c000002_185", "5a761ac3aacfb9cd4c000002_185", "5a761ac3aacfb9cd4c000002_185", "5a761ac3aacfb9cd4c000002_185", "5a761ac3aacfb9cd4c000002_185", "5a761ac3aacfb9cd4c000002_185", "5a761ac3aacfb9cd4c000002_185", "5a761ac3aacfb9cd4c000002_185", "5a761ac3aacfb9cd4c000002_185", "5a761ac3aacfb9cd4c000002_185", "5a761ac3aacfb9cd4c000002_185", "5a761ac3aacfb9cd4c000002_185", "5a761ac3aacfb9cd4c000002_186", "5a761ac3aacfb9cd4c000002_186", "5a761ac3aacfb9cd4c000002_186", "5a761ac3aacfb9cd4c000002_186", "5a761ac3aacfb9cd4c000002_186", "5a761ac3aacfb9cd4c000002_186", "5a761ac3aacfb9cd4c000002_186", "5a761ac3aacfb9cd4c000002_186", "5a761ac3aacfb9cd4c000002_186", "5a761ac3aacfb9cd4c000002_186", "5a761ac3aacfb9cd4c000002_186", "5a761ac3aacfb9cd4c000002_186", "5a761ac3aacfb9cd4c000002_186", "5a761ac3aacfb9cd4c000002_186", "5a761ac3aacfb9cd4c000002_186", "5a761ac3aacfb9cd4c000002_186", "5a761ac3aacfb9cd4c000002_186", "5a761ac3aacfb9cd4c000002_186", "5a761ac3aacfb9cd4c000002_187", "5a761ac3aacfb9cd4c000002_187", "5a761ac3aacfb9cd4c000002_187", "5a761ac3aacfb9cd4c000002_187", "5a761ac3aacfb9cd4c000002_187", "5a761ac3aacfb9cd4c000002_187", "5a761ac3aacfb9cd4c000002_187", "5a761ac3aacfb9cd4c000002_187", "5a761ac3aacfb9cd4c000002_187", "5a761ac3aacfb9cd4c000002_187", "5a761ac3aacfb9cd4c000002_187", "5a761ac3aacfb9cd4c000002_187", "5a761ac3aacfb9cd4c000002_187", "5a761ac3aacfb9cd4c000002_187", "5a761ac3aacfb9cd4c000002_187", "5a761ac3aacfb9cd4c000002_187", "5a761ac3aacfb9cd4c000002_187", "5a761ac3aacfb9cd4c000002_187", "5a761ac3aacfb9cd4c000002_188", "5a761ac3aacfb9cd4c000002_188", "5a761ac3aacfb9cd4c000002_188", "5a761ac3aacfb9cd4c000002_188", "5a761ac3aacfb9cd4c000002_188", "5a761ac3aacfb9cd4c000002_188", "5a761ac3aacfb9cd4c000002_188", "5a761ac3aacfb9cd4c000002_188", "5a761ac3aacfb9cd4c000002_188", "5a761ac3aacfb9cd4c000002_188", "5a761ac3aacfb9cd4c000002_188", "5a761ac3aacfb9cd4c000002_188", "5a761ac3aacfb9cd4c000002_188", "5a761ac3aacfb9cd4c000002_188", "5a761ac3aacfb9cd4c000002_188", "5a761ac3aacfb9cd4c000002_188", "5a761ac3aacfb9cd4c000002_188", "5a761ac3aacfb9cd4c000002_188", "5a761ac3aacfb9cd4c000002_189", "5a761ac3aacfb9cd4c000002_189", "5a761ac3aacfb9cd4c000002_189", "5a761ac3aacfb9cd4c000002_189", "5a761ac3aacfb9cd4c000002_189", "5a761ac3aacfb9cd4c000002_189", "5a761ac3aacfb9cd4c000002_189", "5a761ac3aacfb9cd4c000002_189", "5a761ac3aacfb9cd4c000002_189", "5a761ac3aacfb9cd4c000002_189", "5a761ac3aacfb9cd4c000002_189", "5a761ac3aacfb9cd4c000002_189", "5a761ac3aacfb9cd4c000002_189", "5a761ac3aacfb9cd4c000002_189", "5a761ac3aacfb9cd4c000002_189", "5a761ac3aacfb9cd4c000002_189", "5a761ac3aacfb9cd4c000002_189", "5a761ac3aacfb9cd4c000002_189", "5a761ac3aacfb9cd4c000002_190", "5a761ac3aacfb9cd4c000002_190", "5a761ac3aacfb9cd4c000002_190", "5a761ac3aacfb9cd4c000002_190", "5a761ac3aacfb9cd4c000002_190", "5a761ac3aacfb9cd4c000002_190", "5a761ac3aacfb9cd4c000002_190", "5a761ac3aacfb9cd4c000002_190", "5a761ac3aacfb9cd4c000002_190", "5a761ac3aacfb9cd4c000002_190", "5a761ac3aacfb9cd4c000002_190", "5a761ac3aacfb9cd4c000002_190", "5a761ac3aacfb9cd4c000002_190", "5a761ac3aacfb9cd4c000002_190", "5a761ac3aacfb9cd4c000002_190", "5a761ac3aacfb9cd4c000002_190", "5a761ac3aacfb9cd4c000002_190", "5a761ac3aacfb9cd4c000002_190", "5a761ac3aacfb9cd4c000002_191", "5a761ac3aacfb9cd4c000002_191", "5a761ac3aacfb9cd4c000002_191", "5a761ac3aacfb9cd4c000002_191", "5a761ac3aacfb9cd4c000002_191", "5a761ac3aacfb9cd4c000002_191", "5a761ac3aacfb9cd4c000002_191", "5a761ac3aacfb9cd4c000002_191", "5a761ac3aacfb9cd4c000002_191", "5a761ac3aacfb9cd4c000002_191", "5a761ac3aacfb9cd4c000002_191", "5a761ac3aacfb9cd4c000002_191", "5a761ac3aacfb9cd4c000002_191", "5a761ac3aacfb9cd4c000002_191", "5a761ac3aacfb9cd4c000002_191", "5a761ac3aacfb9cd4c000002_191", "5a761ac3aacfb9cd4c000002_191", "5a761ac3aacfb9cd4c000002_191", "5a679e8cb750ff4455000006_192", "5a679e8cb750ff4455000006_192", "5a679e8cb750ff4455000006_192", "5a679e8cb750ff4455000006_192", "5a679e8cb750ff4455000006_192", "5a679e8cb750ff4455000006_192", "5a679e8cb750ff4455000006_192", "5a679e8cb750ff4455000006_192", "5a679e8cb750ff4455000006_192", "5a679e8cb750ff4455000006_192", "5a679e8cb750ff4455000006_192", "5a679e8cb750ff4455000006_192", "5a679e8cb750ff4455000006_192", "5a679e8cb750ff4455000006_192", "5a679e8cb750ff4455000006_192", "5a679e8cb750ff4455000006_192", "5a679e8cb750ff4455000006_192", "5a679e8cb750ff4455000006_192", "5a679e8cb750ff4455000006_192", "5a679e8cb750ff4455000006_192", "5a679e8cb750ff4455000006_192", "5a679e8cb750ff4455000006_192", "5a679e8cb750ff4455000006_192", "5a679e8cb750ff4455000006_192", "5a679e8cb750ff4455000006_192", "5a679e8cb750ff4455000006_192", "5a679e8cb750ff4455000006_192", "5a679e8cb750ff4455000006_192", "5a679e8cb750ff4455000006_192", "5a679e8cb750ff4455000006_192", "5a679e8cb750ff4455000006_192", "5a679e8cb750ff4455000006_192", "5a679e8cb750ff4455000006_192", "5a679e8cb750ff4455000006_192", "5a679e8cb750ff4455000006_193", "5a679e8cb750ff4455000006_193", "5a679e8cb750ff4455000006_193", "5a679e8cb750ff4455000006_193", "5a679e8cb750ff4455000006_193", "5a679e8cb750ff4455000006_193", "5a679e8cb750ff4455000006_193", "5a679e8cb750ff4455000006_193", "5a679e8cb750ff4455000006_193", "5a679e8cb750ff4455000006_193", "5a679e8cb750ff4455000006_193", "5a679e8cb750ff4455000006_193", "5a679e8cb750ff4455000006_193", "5a679e8cb750ff4455000006_193", "5a679e8cb750ff4455000006_193", "5a679e8cb750ff4455000006_193", "5a679e8cb750ff4455000006_193", "5a679e8cb750ff4455000006_193", "5a679e8cb750ff4455000006_193", "5a679e8cb750ff4455000006_193", "5a679e8cb750ff4455000006_193", "5a679e8cb750ff4455000006_193", "5a679e8cb750ff4455000006_193", "5a679e8cb750ff4455000006_193", "5a679e8cb750ff4455000006_193", "5a679e8cb750ff4455000006_193", "5a679e8cb750ff4455000006_193", "5a679e8cb750ff4455000006_193", "5a679e8cb750ff4455000006_193", "5a679e8cb750ff4455000006_193", "5a679e8cb750ff4455000006_193", "5a679e8cb750ff4455000006_193", "5a679e8cb750ff4455000006_193", "5a679e8cb750ff4455000006_193", "5a679e8cb750ff4455000006_194", "5a679e8cb750ff4455000006_194", "5a679e8cb750ff4455000006_194", "5a679e8cb750ff4455000006_194", "5a679e8cb750ff4455000006_194", "5a679e8cb750ff4455000006_194", "5a679e8cb750ff4455000006_194", "5a679e8cb750ff4455000006_194", "5a679e8cb750ff4455000006_194", "5a679e8cb750ff4455000006_194", "5a679e8cb750ff4455000006_194", "5a679e8cb750ff4455000006_194", "5a679e8cb750ff4455000006_194", "5a679e8cb750ff4455000006_194", "5a679e8cb750ff4455000006_194", "5a679e8cb750ff4455000006_194", "5a679e8cb750ff4455000006_194", "5a679e8cb750ff4455000006_194", "5a679e8cb750ff4455000006_194", "5a679e8cb750ff4455000006_194", "5a679e8cb750ff4455000006_194", "5a679e8cb750ff4455000006_194", "5a679e8cb750ff4455000006_194", "5a679e8cb750ff4455000006_194", "5a679e8cb750ff4455000006_194", "5a679e8cb750ff4455000006_194", "5a679e8cb750ff4455000006_194", "5a679e8cb750ff4455000006_194", "5a679e8cb750ff4455000006_194", "5a679e8cb750ff4455000006_194", "5a679e8cb750ff4455000006_194", "5a679e8cb750ff4455000006_194", "5a679e8cb750ff4455000006_194", "5a679e8cb750ff4455000006_194", "5a679e8cb750ff4455000006_195", "5a679e8cb750ff4455000006_195", "5a679e8cb750ff4455000006_195", "5a679e8cb750ff4455000006_195", "5a679e8cb750ff4455000006_195", "5a679e8cb750ff4455000006_195", "5a679e8cb750ff4455000006_195", "5a679e8cb750ff4455000006_195", "5a679e8cb750ff4455000006_195", "5a679e8cb750ff4455000006_195", "5a679e8cb750ff4455000006_195", "5a679e8cb750ff4455000006_195", "5a679e8cb750ff4455000006_195", "5a679e8cb750ff4455000006_195", "5a679e8cb750ff4455000006_195", "5a679e8cb750ff4455000006_195", "5a679e8cb750ff4455000006_195", "5a679e8cb750ff4455000006_195", "5a679e8cb750ff4455000006_195", "5a679e8cb750ff4455000006_195", "5a679e8cb750ff4455000006_195", "5a679e8cb750ff4455000006_195", "5a679e8cb750ff4455000006_195", "5a679e8cb750ff4455000006_195", "5a679e8cb750ff4455000006_195", "5a679e8cb750ff4455000006_195", "5a679e8cb750ff4455000006_195", "5a679e8cb750ff4455000006_195", "5a679e8cb750ff4455000006_195", "5a679e8cb750ff4455000006_195", "5a679e8cb750ff4455000006_195", "5a679e8cb750ff4455000006_195", "5a679e8cb750ff4455000006_195", "5a679e8cb750ff4455000006_195", "5a679e8cb750ff4455000006_196", "5a679e8cb750ff4455000006_196", "5a679e8cb750ff4455000006_196", "5a679e8cb750ff4455000006_196", "5a679e8cb750ff4455000006_196", "5a679e8cb750ff4455000006_196", "5a679e8cb750ff4455000006_196", "5a679e8cb750ff4455000006_196", "5a679e8cb750ff4455000006_196", "5a679e8cb750ff4455000006_196", "5a679e8cb750ff4455000006_196", "5a679e8cb750ff4455000006_196", "5a679e8cb750ff4455000006_196", "5a679e8cb750ff4455000006_196", "5a679e8cb750ff4455000006_196", "5a679e8cb750ff4455000006_196", "5a679e8cb750ff4455000006_196", "5a679e8cb750ff4455000006_196", "5a679e8cb750ff4455000006_196", "5a679e8cb750ff4455000006_196", "5a679e8cb750ff4455000006_196", "5a679e8cb750ff4455000006_196", "5a679e8cb750ff4455000006_196", "5a679e8cb750ff4455000006_196", "5a679e8cb750ff4455000006_196", "5a679e8cb750ff4455000006_196", "5a679e8cb750ff4455000006_196", "5a679e8cb750ff4455000006_196", "5a679e8cb750ff4455000006_196", "5a679e8cb750ff4455000006_196", "5a679e8cb750ff4455000006_196", "5a679e8cb750ff4455000006_196", "5a679e8cb750ff4455000006_196", "5a679e8cb750ff4455000006_196", "5a679e8cb750ff4455000006_197", "5a679e8cb750ff4455000006_197", "5a679e8cb750ff4455000006_197", "5a679e8cb750ff4455000006_197", "5a679e8cb750ff4455000006_197", "5a679e8cb750ff4455000006_197", "5a679e8cb750ff4455000006_197", "5a679e8cb750ff4455000006_197", "5a679e8cb750ff4455000006_197", "5a679e8cb750ff4455000006_197", "5a679e8cb750ff4455000006_197", "5a679e8cb750ff4455000006_197", "5a679e8cb750ff4455000006_197", "5a679e8cb750ff4455000006_197", "5a679e8cb750ff4455000006_197", "5a679e8cb750ff4455000006_197", "5a679e8cb750ff4455000006_197", "5a679e8cb750ff4455000006_197", "5a679e8cb750ff4455000006_197", "5a679e8cb750ff4455000006_197", "5a679e8cb750ff4455000006_197", "5a679e8cb750ff4455000006_197", "5a679e8cb750ff4455000006_197", "5a679e8cb750ff4455000006_197", "5a679e8cb750ff4455000006_197", "5a679e8cb750ff4455000006_197", "5a679e8cb750ff4455000006_197", "5a679e8cb750ff4455000006_197", "5a679e8cb750ff4455000006_197", "5a679e8cb750ff4455000006_197", "5a679e8cb750ff4455000006_197", "5a679e8cb750ff4455000006_197", "5a679e8cb750ff4455000006_197", "5a679e8cb750ff4455000006_197", "5a679e8cb750ff4455000006_198", "5a679e8cb750ff4455000006_198", "5a679e8cb750ff4455000006_198", "5a679e8cb750ff4455000006_198", "5a679e8cb750ff4455000006_198", "5a679e8cb750ff4455000006_198", "5a679e8cb750ff4455000006_198", "5a679e8cb750ff4455000006_198", "5a679e8cb750ff4455000006_198", "5a679e8cb750ff4455000006_198", "5a679e8cb750ff4455000006_198", "5a679e8cb750ff4455000006_198", "5a679e8cb750ff4455000006_198", "5a679e8cb750ff4455000006_198", "5a679e8cb750ff4455000006_198", "5a679e8cb750ff4455000006_198", "5a679e8cb750ff4455000006_198", "5a679e8cb750ff4455000006_198", "5a679e8cb750ff4455000006_198", "5a679e8cb750ff4455000006_198", "5a679e8cb750ff4455000006_198", "5a679e8cb750ff4455000006_198", "5a679e8cb750ff4455000006_198", "5a679e8cb750ff4455000006_198", "5a679e8cb750ff4455000006_198", "5a679e8cb750ff4455000006_198", "5a679e8cb750ff4455000006_198", "5a679e8cb750ff4455000006_198", "5a679e8cb750ff4455000006_198", "5a679e8cb750ff4455000006_198", "5a679e8cb750ff4455000006_198", "5a679e8cb750ff4455000006_198", "5a679e8cb750ff4455000006_198", "5a679e8cb750ff4455000006_198", "5a679e8cb750ff4455000006_199", "5a679e8cb750ff4455000006_199", "5a679e8cb750ff4455000006_199", "5a679e8cb750ff4455000006_199", "5a679e8cb750ff4455000006_199", "5a679e8cb750ff4455000006_199", "5a679e8cb750ff4455000006_199", "5a679e8cb750ff4455000006_199", "5a679e8cb750ff4455000006_199", "5a679e8cb750ff4455000006_199", "5a679e8cb750ff4455000006_199", "5a679e8cb750ff4455000006_199", "5a679e8cb750ff4455000006_199", "5a679e8cb750ff4455000006_199", "5a679e8cb750ff4455000006_199", "5a679e8cb750ff4455000006_199", "5a679e8cb750ff4455000006_199", "5a679e8cb750ff4455000006_199", "5a679e8cb750ff4455000006_199", "5a679e8cb750ff4455000006_199", "5a679e8cb750ff4455000006_199", "5a679e8cb750ff4455000006_199", "5a679e8cb750ff4455000006_199", "5a679e8cb750ff4455000006_199", "5a679e8cb750ff4455000006_199", "5a679e8cb750ff4455000006_199", "5a679e8cb750ff4455000006_199", "5a679e8cb750ff4455000006_199", "5a679e8cb750ff4455000006_199", "5a679e8cb750ff4455000006_199", "5a679e8cb750ff4455000006_199", "5a679e8cb750ff4455000006_199", "5a679e8cb750ff4455000006_199", "5a679e8cb750ff4455000006_199", "5a679e8cb750ff4455000006_200", "5a679e8cb750ff4455000006_200", "5a679e8cb750ff4455000006_200", "5a679e8cb750ff4455000006_200", "5a679e8cb750ff4455000006_200", "5a679e8cb750ff4455000006_200", "5a679e8cb750ff4455000006_200", "5a679e8cb750ff4455000006_200", "5a679e8cb750ff4455000006_200", "5a679e8cb750ff4455000006_200", "5a679e8cb750ff4455000006_200", "5a679e8cb750ff4455000006_200", "5a679e8cb750ff4455000006_200", "5a679e8cb750ff4455000006_200", "5a679e8cb750ff4455000006_200", "5a679e8cb750ff4455000006_200", "5a679e8cb750ff4455000006_200", "5a679e8cb750ff4455000006_200", "5a679e8cb750ff4455000006_200", "5a679e8cb750ff4455000006_200", "5a679e8cb750ff4455000006_200", "5a679e8cb750ff4455000006_200", "5a679e8cb750ff4455000006_200", "5a679e8cb750ff4455000006_200", "5a679e8cb750ff4455000006_200", "5a679e8cb750ff4455000006_200", "5a679e8cb750ff4455000006_200", "5a679e8cb750ff4455000006_200", "5a679e8cb750ff4455000006_200", "5a679e8cb750ff4455000006_200", "5a679e8cb750ff4455000006_200", "5a679e8cb750ff4455000006_200", "5a679e8cb750ff4455000006_200", "5a679e8cb750ff4455000006_200", "5a679e8cb750ff4455000006_201", "5a679e8cb750ff4455000006_201", "5a679e8cb750ff4455000006_201", "5a679e8cb750ff4455000006_201", "5a679e8cb750ff4455000006_201", "5a679e8cb750ff4455000006_201", "5a679e8cb750ff4455000006_201", "5a679e8cb750ff4455000006_201", "5a679e8cb750ff4455000006_201", "5a679e8cb750ff4455000006_201", "5a679e8cb750ff4455000006_201", "5a679e8cb750ff4455000006_201", "5a679e8cb750ff4455000006_201", "5a679e8cb750ff4455000006_201", "5a679e8cb750ff4455000006_201", "5a679e8cb750ff4455000006_201", "5a679e8cb750ff4455000006_201", "5a679e8cb750ff4455000006_201", "5a679e8cb750ff4455000006_201", "5a679e8cb750ff4455000006_201", "5a679e8cb750ff4455000006_201", "5a679e8cb750ff4455000006_201", "5a679e8cb750ff4455000006_201", "5a679e8cb750ff4455000006_201", "5a679e8cb750ff4455000006_201", "5a679e8cb750ff4455000006_201", "5a679e8cb750ff4455000006_201", "5a679e8cb750ff4455000006_201", "5a679e8cb750ff4455000006_201", "5a679e8cb750ff4455000006_201", "5a679e8cb750ff4455000006_201", "5a679e8cb750ff4455000006_201", "5a679e8cb750ff4455000006_201", "5a679e8cb750ff4455000006_201", "5a679e8cb750ff4455000006_202", "5a679e8cb750ff4455000006_202", "5a679e8cb750ff4455000006_202", "5a679e8cb750ff4455000006_202", "5a679e8cb750ff4455000006_202", "5a679e8cb750ff4455000006_202", "5a679e8cb750ff4455000006_202", "5a679e8cb750ff4455000006_202", "5a679e8cb750ff4455000006_202", "5a679e8cb750ff4455000006_202", "5a679e8cb750ff4455000006_202", "5a679e8cb750ff4455000006_202", "5a679e8cb750ff4455000006_202", "5a679e8cb750ff4455000006_202", "5a679e8cb750ff4455000006_202", "5a679e8cb750ff4455000006_202", "5a679e8cb750ff4455000006_202", "5a679e8cb750ff4455000006_202", "5a679e8cb750ff4455000006_202", "5a679e8cb750ff4455000006_202", "5a679e8cb750ff4455000006_202", "5a679e8cb750ff4455000006_202", "5a679e8cb750ff4455000006_202", "5a679e8cb750ff4455000006_202", "5a679e8cb750ff4455000006_202", "5a679e8cb750ff4455000006_202", "5a679e8cb750ff4455000006_202", "5a679e8cb750ff4455000006_202", "5a679e8cb750ff4455000006_202", "5a679e8cb750ff4455000006_202", "5a679e8cb750ff4455000006_202", "5a679e8cb750ff4455000006_202", "5a679e8cb750ff4455000006_202", "5a679e8cb750ff4455000006_202", "5a9d8a651d1251d03b00001f_203", "5a9d8a651d1251d03b00001f_203", "5a9d8a651d1251d03b00001f_203", "5a9d8a651d1251d03b00001f_203", "5a9d8a651d1251d03b00001f_203", "5aa6c800d6d6b54f79000012_204", "5aa6c800d6d6b54f79000012_204", "5aa6c800d6d6b54f79000012_204", "5aa6c800d6d6b54f79000012_204", "5aa6c800d6d6b54f79000012_204", "5aa6c800d6d6b54f79000012_204", "5aa6c800d6d6b54f79000012_204", "5aa6c800d6d6b54f79000012_204", "5aa6c800d6d6b54f79000012_204", "5aa6c800d6d6b54f79000012_204", "5aa6c800d6d6b54f79000012_204", "5aa6c800d6d6b54f79000012_204", "5aa6c800d6d6b54f79000012_204", "5aa6c800d6d6b54f79000012_204", "5aa6c800d6d6b54f79000012_204", "5aa6c800d6d6b54f79000012_204", "5aa6c800d6d6b54f79000012_204", "5aa6c800d6d6b54f79000012_204", "5aa6c800d6d6b54f79000012_204", "5aa6c800d6d6b54f79000012_204", "5aa6c800d6d6b54f79000012_204", "5aa6c800d6d6b54f79000012_204", "5aa6c800d6d6b54f79000012_204", "5aa6c800d6d6b54f79000012_204", "5aa6c800d6d6b54f79000012_204", "5aa6c800d6d6b54f79000012_204", "5a9d31711d1251d03b00001c_205", "5a9d31711d1251d03b00001c_205", "5a9d31711d1251d03b00001c_205", "5a9d31711d1251d03b00001c_205", "5a9d31711d1251d03b00001c_205", "5a9d31711d1251d03b00001c_205", "5a9d31711d1251d03b00001c_205", "5a9d31711d1251d03b00001c_205", "5a9d31711d1251d03b00001c_205", "5a9d31711d1251d03b00001c_205", "5a9d31711d1251d03b00001c_205", "5a9d31711d1251d03b00001c_205", "5a9d31711d1251d03b00001c_205", "5a9d31711d1251d03b00001c_205", "5a9d31711d1251d03b00001c_205", "5a9d31711d1251d03b00001c_205", "5a9d31711d1251d03b00001c_205", "5a9d31711d1251d03b00001c_205", "5a9d31711d1251d03b00001c_205", "5a9700adfcd1d6a10c00002c_206", "5a9700adfcd1d6a10c00002c_206", "5a9700adfcd1d6a10c00002c_206", "5a9700adfcd1d6a10c00002c_206", "5a9700adfcd1d6a10c00002c_206", "5a9700adfcd1d6a10c00002c_206", "5a9700adfcd1d6a10c00002c_206", "5a9700adfcd1d6a10c00002c_206", "5a9700adfcd1d6a10c00002c_206", "5a9700adfcd1d6a10c00002c_206", "5a9700adfcd1d6a10c00002c_206", "5a9700adfcd1d6a10c00002c_206", "5a9700adfcd1d6a10c00002c_206", "5a9700adfcd1d6a10c00002c_206", "5a9700adfcd1d6a10c00002c_206", "5a9700adfcd1d6a10c00002c_206", "5a9700adfcd1d6a10c00002c_206", "5a9700adfcd1d6a10c00002c_206", "5a9700adfcd1d6a10c00002c_207", "5a9700adfcd1d6a10c00002c_207", "5a9700adfcd1d6a10c00002c_207", "5a9700adfcd1d6a10c00002c_207", "5a9700adfcd1d6a10c00002c_207", "5a9700adfcd1d6a10c00002c_207", "5a9700adfcd1d6a10c00002c_207", "5a9700adfcd1d6a10c00002c_207", "5a9700adfcd1d6a10c00002c_207", "5a9700adfcd1d6a10c00002c_207", "5a9700adfcd1d6a10c00002c_207", "5a9700adfcd1d6a10c00002c_207", "5a9700adfcd1d6a10c00002c_207", "5a9700adfcd1d6a10c00002c_207", "5a9700adfcd1d6a10c00002c_207", "5a9700adfcd1d6a10c00002c_207", "5a9700adfcd1d6a10c00002c_207", "5a9700adfcd1d6a10c00002c_207", "5a7428090384be9551000001_208", "5a7428090384be9551000001_208", "5a7428090384be9551000001_208", "5a7428090384be9551000001_208", "5a7428090384be9551000001_208", "5a7428090384be9551000001_208", "5a7428090384be9551000001_208", "5a7428090384be9551000001_208", "5a7428090384be9551000001_208", "5a7428090384be9551000001_208", "5a7428090384be9551000001_208", "5a7428090384be9551000001_208", "5a7428090384be9551000001_208", "5a7428090384be9551000001_208", "5a7428090384be9551000001_208", "5a7428090384be9551000001_208", "5a7428090384be9551000001_208", "5a7428090384be9551000001_208", "5a7428090384be9551000001_208", "5a7428090384be9551000001_208", "5a7428090384be9551000001_208", "5a7428090384be9551000001_209", "5a7428090384be9551000001_209", "5a7428090384be9551000001_209", "5a7428090384be9551000001_209", "5a7428090384be9551000001_209", "5a7428090384be9551000001_209", "5a7428090384be9551000001_209", "5a7428090384be9551000001_209", "5a7428090384be9551000001_209", "5a7428090384be9551000001_209", "5a7428090384be9551000001_209", "5a7428090384be9551000001_209", "5a7428090384be9551000001_209", "5a7428090384be9551000001_209", "5a7428090384be9551000001_209", "5a7428090384be9551000001_209", "5a7428090384be9551000001_209", "5a7428090384be9551000001_209", "5a7428090384be9551000001_209", "5a7428090384be9551000001_209", "5a7428090384be9551000001_209", "5a7428090384be9551000001_210", "5a7428090384be9551000001_210", "5a7428090384be9551000001_210", "5a7428090384be9551000001_210", "5a7428090384be9551000001_210", "5a7428090384be9551000001_210", "5a7428090384be9551000001_210", "5a7428090384be9551000001_210", "5a7428090384be9551000001_210", "5a7428090384be9551000001_210", "5a7428090384be9551000001_210", "5a7428090384be9551000001_210", "5a7428090384be9551000001_210", "5a7428090384be9551000001_210", "5a7428090384be9551000001_210", "5a7428090384be9551000001_210", "5a7428090384be9551000001_210", "5a7428090384be9551000001_210", "5a7428090384be9551000001_210", "5a7428090384be9551000001_210", "5a7428090384be9551000001_210", "5a7428090384be9551000001_211", "5a7428090384be9551000001_211", "5a7428090384be9551000001_211", "5a7428090384be9551000001_211", "5a7428090384be9551000001_211", "5a7428090384be9551000001_211", "5a7428090384be9551000001_211", "5a7428090384be9551000001_211", "5a7428090384be9551000001_211", "5a7428090384be9551000001_211", "5a7428090384be9551000001_211", "5a7428090384be9551000001_211", "5a7428090384be9551000001_211", "5a7428090384be9551000001_211", "5a7428090384be9551000001_211", "5a7428090384be9551000001_211", "5a7428090384be9551000001_211", "5a7428090384be9551000001_211", "5a7428090384be9551000001_211", "5a7428090384be9551000001_211", "5a7428090384be9551000001_211", "5a7428090384be9551000001_212", "5a7428090384be9551000001_212", "5a7428090384be9551000001_212", "5a7428090384be9551000001_212", "5a7428090384be9551000001_212", "5a7428090384be9551000001_212", "5a7428090384be9551000001_212", "5a7428090384be9551000001_212", "5a7428090384be9551000001_212", "5a7428090384be9551000001_212", "5a7428090384be9551000001_212", "5a7428090384be9551000001_212", "5a7428090384be9551000001_212", "5a7428090384be9551000001_212", "5a7428090384be9551000001_212", "5a7428090384be9551000001_212", "5a7428090384be9551000001_212", "5a7428090384be9551000001_212", "5a7428090384be9551000001_212", "5a7428090384be9551000001_212", "5a7428090384be9551000001_212", "5a7428090384be9551000001_213", "5a7428090384be9551000001_213", "5a7428090384be9551000001_213", "5a7428090384be9551000001_213", "5a7428090384be9551000001_213", "5a7428090384be9551000001_213", "5a7428090384be9551000001_213", "5a7428090384be9551000001_213", "5a7428090384be9551000001_213", "5a7428090384be9551000001_213", "5a7428090384be9551000001_213", "5a7428090384be9551000001_213", "5a7428090384be9551000001_213", "5a7428090384be9551000001_213", "5a7428090384be9551000001_213", "5a7428090384be9551000001_213", "5a7428090384be9551000001_213", "5a7428090384be9551000001_213", "5a7428090384be9551000001_213", "5a7428090384be9551000001_213", "5a7428090384be9551000001_213", "5a7428090384be9551000001_214", "5a7428090384be9551000001_214", "5a7428090384be9551000001_214", "5a7428090384be9551000001_214", "5a7428090384be9551000001_214", "5a7428090384be9551000001_214", "5a7428090384be9551000001_214", "5a7428090384be9551000001_214", "5a7428090384be9551000001_214", "5a7428090384be9551000001_214", "5a7428090384be9551000001_214", "5a7428090384be9551000001_214", "5a7428090384be9551000001_214", "5a7428090384be9551000001_214", "5a7428090384be9551000001_214", "5a7428090384be9551000001_214", "5a7428090384be9551000001_214", "5a7428090384be9551000001_214", "5a7428090384be9551000001_214", "5a7428090384be9551000001_214", "5a7428090384be9551000001_214", "5a7428090384be9551000001_215", "5a7428090384be9551000001_215", "5a7428090384be9551000001_215", "5a7428090384be9551000001_215", "5a7428090384be9551000001_215", "5a7428090384be9551000001_215", "5a7428090384be9551000001_215", "5a7428090384be9551000001_215", "5a7428090384be9551000001_215", "5a7428090384be9551000001_215", "5a7428090384be9551000001_215", "5a7428090384be9551000001_215", "5a7428090384be9551000001_215", "5a7428090384be9551000001_215", "5a7428090384be9551000001_215", "5a7428090384be9551000001_215", "5a7428090384be9551000001_215", "5a7428090384be9551000001_215", "5a7428090384be9551000001_215", "5a7428090384be9551000001_215", "5a7428090384be9551000001_215", "5a7428090384be9551000001_216", "5a7428090384be9551000001_216", "5a7428090384be9551000001_216", "5a7428090384be9551000001_216", "5a7428090384be9551000001_216", "5a7428090384be9551000001_216", "5a7428090384be9551000001_216", "5a7428090384be9551000001_216", "5a7428090384be9551000001_216", "5a7428090384be9551000001_216", "5a7428090384be9551000001_216", "5a7428090384be9551000001_216", "5a7428090384be9551000001_216", "5a7428090384be9551000001_216", "5a7428090384be9551000001_216", "5a7428090384be9551000001_216", "5a7428090384be9551000001_216", "5a7428090384be9551000001_216", "5a7428090384be9551000001_216", "5a7428090384be9551000001_216", "5a7428090384be9551000001_216", "589a247078275d0c4a000035_217", "589a247078275d0c4a000035_217", "589a247078275d0c4a000035_217", "589a247078275d0c4a000035_217", "589a247078275d0c4a000035_217", "589a247078275d0c4a000035_217", "589a247078275d0c4a000035_217", "589a247078275d0c4a000035_217", "589a247078275d0c4a000035_217", "589a247078275d0c4a000035_217", "589a247078275d0c4a000035_217", "589a247078275d0c4a000035_217", "589a247078275d0c4a000035_217", "589a247078275d0c4a000035_217", "589a247078275d0c4a000035_217", "589a247078275d0c4a000035_217", "589a247078275d0c4a000035_217", "589a247078275d0c4a000035_217", "589a247078275d0c4a000035_217", "589a247078275d0c4a000035_217", "589a247078275d0c4a000035_217", "589a247078275d0c4a000035_217", "589a247078275d0c4a000035_217", "589a247078275d0c4a000035_217", "589a247078275d0c4a000035_217", "589a247078275d0c4a000035_217", "589a247078275d0c4a000035_217", "589a247078275d0c4a000035_217", "589a247078275d0c4a000035_217", "589a247078275d0c4a000035_217", "589a247078275d0c4a000035_218", "589a247078275d0c4a000035_218", "589a247078275d0c4a000035_218", "589a247078275d0c4a000035_218", "589a247078275d0c4a000035_218", "589a247078275d0c4a000035_218", "589a247078275d0c4a000035_218", "589a247078275d0c4a000035_218", "589a247078275d0c4a000035_218", "589a247078275d0c4a000035_218", "589a247078275d0c4a000035_218", "589a247078275d0c4a000035_218", "589a247078275d0c4a000035_218", "589a247078275d0c4a000035_218", "589a247078275d0c4a000035_218", "589a247078275d0c4a000035_218", "589a247078275d0c4a000035_218", "589a247078275d0c4a000035_218", "589a247078275d0c4a000035_218", "589a247078275d0c4a000035_218", "589a247078275d0c4a000035_218", "589a247078275d0c4a000035_218", "589a247078275d0c4a000035_218", "589a247078275d0c4a000035_218", "589a247078275d0c4a000035_218", "589a247078275d0c4a000035_218", "589a247078275d0c4a000035_218", "589a247078275d0c4a000035_218", "589a247078275d0c4a000035_218", "589a247078275d0c4a000035_218", "589a247078275d0c4a000035_219", "589a247078275d0c4a000035_219", "589a247078275d0c4a000035_219", "589a247078275d0c4a000035_219", "589a247078275d0c4a000035_219", "589a247078275d0c4a000035_219", "589a247078275d0c4a000035_219", "589a247078275d0c4a000035_219", "589a247078275d0c4a000035_219", "589a247078275d0c4a000035_219", "589a247078275d0c4a000035_219", "589a247078275d0c4a000035_219", "589a247078275d0c4a000035_219", "589a247078275d0c4a000035_219", "589a247078275d0c4a000035_219", "589a247078275d0c4a000035_219", "589a247078275d0c4a000035_219", "589a247078275d0c4a000035_219", "589a247078275d0c4a000035_219", "589a247078275d0c4a000035_219", "589a247078275d0c4a000035_219", "589a247078275d0c4a000035_219", "589a247078275d0c4a000035_219", "589a247078275d0c4a000035_219", "589a247078275d0c4a000035_219", "589a247078275d0c4a000035_219", "589a247078275d0c4a000035_219", "589a247078275d0c4a000035_219", "589a247078275d0c4a000035_219", "589a247078275d0c4a000035_219", "589a247078275d0c4a000035_220", "589a247078275d0c4a000035_220", "589a247078275d0c4a000035_220", "589a247078275d0c4a000035_220", "589a247078275d0c4a000035_220", "589a247078275d0c4a000035_220", "589a247078275d0c4a000035_220", "589a247078275d0c4a000035_220", "589a247078275d0c4a000035_220", "589a247078275d0c4a000035_220", "589a247078275d0c4a000035_220", "589a247078275d0c4a000035_220", "589a247078275d0c4a000035_220", "589a247078275d0c4a000035_220", "589a247078275d0c4a000035_220", "589a247078275d0c4a000035_220", "589a247078275d0c4a000035_220", "589a247078275d0c4a000035_220", "589a247078275d0c4a000035_220", "589a247078275d0c4a000035_220", "589a247078275d0c4a000035_220", "589a247078275d0c4a000035_220", "589a247078275d0c4a000035_220", "589a247078275d0c4a000035_220", "589a247078275d0c4a000035_220", "589a247078275d0c4a000035_220", "589a247078275d0c4a000035_220", "589a247078275d0c4a000035_220", "589a247078275d0c4a000035_220", "589a247078275d0c4a000035_220", "589a247078275d0c4a000035_221", "589a247078275d0c4a000035_221", "589a247078275d0c4a000035_221", "589a247078275d0c4a000035_221", "589a247078275d0c4a000035_221", "589a247078275d0c4a000035_221", "589a247078275d0c4a000035_221", "589a247078275d0c4a000035_221", "589a247078275d0c4a000035_221", "589a247078275d0c4a000035_221", "589a247078275d0c4a000035_221", "589a247078275d0c4a000035_221", "589a247078275d0c4a000035_221", "589a247078275d0c4a000035_221", "589a247078275d0c4a000035_221", "589a247078275d0c4a000035_221", "589a247078275d0c4a000035_221", "589a247078275d0c4a000035_221", "589a247078275d0c4a000035_221", "589a247078275d0c4a000035_221", "589a247078275d0c4a000035_221", "589a247078275d0c4a000035_221", "589a247078275d0c4a000035_221", "589a247078275d0c4a000035_221", "589a247078275d0c4a000035_221", "589a247078275d0c4a000035_221", "589a247078275d0c4a000035_221", "589a247078275d0c4a000035_221", "589a247078275d0c4a000035_221", "589a247078275d0c4a000035_221", "589a247078275d0c4a000035_222", "589a247078275d0c4a000035_222", "589a247078275d0c4a000035_222", "589a247078275d0c4a000035_222", "589a247078275d0c4a000035_222", "589a247078275d0c4a000035_222", "589a247078275d0c4a000035_222", "589a247078275d0c4a000035_222", "589a247078275d0c4a000035_222", "589a247078275d0c4a000035_222", "589a247078275d0c4a000035_222", "589a247078275d0c4a000035_222", "589a247078275d0c4a000035_222", "589a247078275d0c4a000035_222", "589a247078275d0c4a000035_222", "589a247078275d0c4a000035_222", "589a247078275d0c4a000035_222", "589a247078275d0c4a000035_222", "589a247078275d0c4a000035_222", "589a247078275d0c4a000035_222", "589a247078275d0c4a000035_222", "589a247078275d0c4a000035_222", "589a247078275d0c4a000035_222", "589a247078275d0c4a000035_222", "589a247078275d0c4a000035_222", "589a247078275d0c4a000035_222", "589a247078275d0c4a000035_222", "589a247078275d0c4a000035_222", "589a247078275d0c4a000035_222", "589a247078275d0c4a000035_222", "589a247078275d0c4a000035_223", "589a247078275d0c4a000035_223", "589a247078275d0c4a000035_223", "589a247078275d0c4a000035_223", "589a247078275d0c4a000035_223", "589a247078275d0c4a000035_223", "589a247078275d0c4a000035_223", "589a247078275d0c4a000035_223", "589a247078275d0c4a000035_223", "589a247078275d0c4a000035_223", "589a247078275d0c4a000035_223", "589a247078275d0c4a000035_223", "589a247078275d0c4a000035_223", "589a247078275d0c4a000035_223", "589a247078275d0c4a000035_223", "589a247078275d0c4a000035_223", "589a247078275d0c4a000035_223", "589a247078275d0c4a000035_223", "589a247078275d0c4a000035_223", "589a247078275d0c4a000035_223", "589a247078275d0c4a000035_223", "589a247078275d0c4a000035_223", "589a247078275d0c4a000035_223", "589a247078275d0c4a000035_223", "589a247078275d0c4a000035_223", "589a247078275d0c4a000035_223", "589a247078275d0c4a000035_223", "589a247078275d0c4a000035_223", "589a247078275d0c4a000035_223", "589a247078275d0c4a000035_223", "589a247078275d0c4a000035_224", "589a247078275d0c4a000035_224", "589a247078275d0c4a000035_224", "589a247078275d0c4a000035_224", "589a247078275d0c4a000035_224", "589a247078275d0c4a000035_224", "589a247078275d0c4a000035_224", "589a247078275d0c4a000035_224", "589a247078275d0c4a000035_224", "589a247078275d0c4a000035_224", "589a247078275d0c4a000035_224", "589a247078275d0c4a000035_224", "589a247078275d0c4a000035_224", "589a247078275d0c4a000035_224", "589a247078275d0c4a000035_224", "589a247078275d0c4a000035_224", "589a247078275d0c4a000035_224", "589a247078275d0c4a000035_224", "589a247078275d0c4a000035_224", "589a247078275d0c4a000035_224", "589a247078275d0c4a000035_224", "589a247078275d0c4a000035_224", "589a247078275d0c4a000035_224", "589a247078275d0c4a000035_224", "589a247078275d0c4a000035_224", "589a247078275d0c4a000035_224", "589a247078275d0c4a000035_224", "589a247078275d0c4a000035_224", "589a247078275d0c4a000035_224", "589a247078275d0c4a000035_224", "589a247078275d0c4a000035_225", "589a247078275d0c4a000035_225", "589a247078275d0c4a000035_225", "589a247078275d0c4a000035_225", "589a247078275d0c4a000035_225", "589a247078275d0c4a000035_225", "589a247078275d0c4a000035_225", "589a247078275d0c4a000035_225", "589a247078275d0c4a000035_225", "589a247078275d0c4a000035_225", "589a247078275d0c4a000035_225", "589a247078275d0c4a000035_225", "589a247078275d0c4a000035_225", "589a247078275d0c4a000035_225", "589a247078275d0c4a000035_225", "589a247078275d0c4a000035_225", "589a247078275d0c4a000035_225", "589a247078275d0c4a000035_225", "589a247078275d0c4a000035_225", "589a247078275d0c4a000035_225", "589a247078275d0c4a000035_225", "589a247078275d0c4a000035_225", "589a247078275d0c4a000035_225", "589a247078275d0c4a000035_225", "589a247078275d0c4a000035_225", "589a247078275d0c4a000035_225", "589a247078275d0c4a000035_225", "589a247078275d0c4a000035_225", "589a247078275d0c4a000035_225", "589a247078275d0c4a000035_225", "589a247078275d0c4a000035_226", "589a247078275d0c4a000035_226", "589a247078275d0c4a000035_226", "589a247078275d0c4a000035_226", "589a247078275d0c4a000035_226", "589a247078275d0c4a000035_226", "589a247078275d0c4a000035_226", "589a247078275d0c4a000035_226", "589a247078275d0c4a000035_226", "589a247078275d0c4a000035_226", "589a247078275d0c4a000035_226", "589a247078275d0c4a000035_226", "589a247078275d0c4a000035_226", "589a247078275d0c4a000035_226", "589a247078275d0c4a000035_226", "589a247078275d0c4a000035_226", "589a247078275d0c4a000035_226", "589a247078275d0c4a000035_226", "589a247078275d0c4a000035_226", "589a247078275d0c4a000035_226", "589a247078275d0c4a000035_226", "589a247078275d0c4a000035_226", "589a247078275d0c4a000035_226", "589a247078275d0c4a000035_226", "589a247078275d0c4a000035_226", "589a247078275d0c4a000035_226", "589a247078275d0c4a000035_226", "589a247078275d0c4a000035_226", "589a247078275d0c4a000035_226", "589a247078275d0c4a000035_226", "589a247078275d0c4a000035_227", "589a247078275d0c4a000035_227", "589a247078275d0c4a000035_227", "589a247078275d0c4a000035_227", "589a247078275d0c4a000035_227", "589a247078275d0c4a000035_227", "589a247078275d0c4a000035_227", "589a247078275d0c4a000035_227", "589a247078275d0c4a000035_227", "589a247078275d0c4a000035_227", "589a247078275d0c4a000035_227", "589a247078275d0c4a000035_227", "589a247078275d0c4a000035_227", "589a247078275d0c4a000035_227", "589a247078275d0c4a000035_227", "589a247078275d0c4a000035_227", "589a247078275d0c4a000035_227", "589a247078275d0c4a000035_227", "589a247078275d0c4a000035_227", "589a247078275d0c4a000035_227", "589a247078275d0c4a000035_227", "589a247078275d0c4a000035_227", "589a247078275d0c4a000035_227", "589a247078275d0c4a000035_227", "589a247078275d0c4a000035_227", "589a247078275d0c4a000035_227", "589a247078275d0c4a000035_227", "589a247078275d0c4a000035_227", "589a247078275d0c4a000035_227", "589a247078275d0c4a000035_227", "589a247078275d0c4a000035_228", "589a247078275d0c4a000035_228", "589a247078275d0c4a000035_228", "589a247078275d0c4a000035_228", "589a247078275d0c4a000035_228", "589a247078275d0c4a000035_228", "589a247078275d0c4a000035_228", "589a247078275d0c4a000035_228", "589a247078275d0c4a000035_228", "589a247078275d0c4a000035_228", "589a247078275d0c4a000035_228", "589a247078275d0c4a000035_228", "589a247078275d0c4a000035_228", "589a247078275d0c4a000035_228", "589a247078275d0c4a000035_228", "589a247078275d0c4a000035_228", "589a247078275d0c4a000035_228", "589a247078275d0c4a000035_228", "589a247078275d0c4a000035_228", "589a247078275d0c4a000035_228", "589a247078275d0c4a000035_228", "589a247078275d0c4a000035_228", "589a247078275d0c4a000035_228", "589a247078275d0c4a000035_228", "589a247078275d0c4a000035_228", "589a247078275d0c4a000035_228", "589a247078275d0c4a000035_228", "589a247078275d0c4a000035_228", "589a247078275d0c4a000035_228", "589a247078275d0c4a000035_228", "589a247078275d0c4a000035_229", "589a247078275d0c4a000035_229", "589a247078275d0c4a000035_229", "589a247078275d0c4a000035_229", "589a247078275d0c4a000035_229", "589a247078275d0c4a000035_229", "589a247078275d0c4a000035_229", "589a247078275d0c4a000035_229", "589a247078275d0c4a000035_229", "589a247078275d0c4a000035_229", "589a247078275d0c4a000035_229", "589a247078275d0c4a000035_229", "589a247078275d0c4a000035_229", "589a247078275d0c4a000035_229", "589a247078275d0c4a000035_229", "589a247078275d0c4a000035_229", "589a247078275d0c4a000035_229", "589a247078275d0c4a000035_229", "589a247078275d0c4a000035_229", "589a247078275d0c4a000035_229", "589a247078275d0c4a000035_229", "589a247078275d0c4a000035_229", "589a247078275d0c4a000035_229", "589a247078275d0c4a000035_229", "589a247078275d0c4a000035_229", "589a247078275d0c4a000035_229", "589a247078275d0c4a000035_229", "589a247078275d0c4a000035_229", "589a247078275d0c4a000035_229", "589a247078275d0c4a000035_229", "589a247078275d0c4a000035_230", "589a247078275d0c4a000035_230", "589a247078275d0c4a000035_230", "589a247078275d0c4a000035_230", "589a247078275d0c4a000035_230", "589a247078275d0c4a000035_230", "589a247078275d0c4a000035_230", "589a247078275d0c4a000035_230", "589a247078275d0c4a000035_230", "589a247078275d0c4a000035_230", "589a247078275d0c4a000035_230", "589a247078275d0c4a000035_230", "589a247078275d0c4a000035_230", "589a247078275d0c4a000035_230", "589a247078275d0c4a000035_230", "589a247078275d0c4a000035_230", "589a247078275d0c4a000035_230", "589a247078275d0c4a000035_230", "589a247078275d0c4a000035_230", "589a247078275d0c4a000035_230", "589a247078275d0c4a000035_230", "589a247078275d0c4a000035_230", "589a247078275d0c4a000035_230", "589a247078275d0c4a000035_230", "589a247078275d0c4a000035_230", "589a247078275d0c4a000035_230", "589a247078275d0c4a000035_230", "589a247078275d0c4a000035_230", "589a247078275d0c4a000035_230", "589a247078275d0c4a000035_230", "589a247078275d0c4a000035_231", "589a247078275d0c4a000035_231", "589a247078275d0c4a000035_231", "589a247078275d0c4a000035_231", "589a247078275d0c4a000035_231", "589a247078275d0c4a000035_231", "589a247078275d0c4a000035_231", "589a247078275d0c4a000035_231", "589a247078275d0c4a000035_231", "589a247078275d0c4a000035_231", "589a247078275d0c4a000035_231", "589a247078275d0c4a000035_231", "589a247078275d0c4a000035_231", "589a247078275d0c4a000035_231", "589a247078275d0c4a000035_231", "589a247078275d0c4a000035_231", "589a247078275d0c4a000035_231", "589a247078275d0c4a000035_231", "589a247078275d0c4a000035_231", "589a247078275d0c4a000035_231", "589a247078275d0c4a000035_231", "589a247078275d0c4a000035_231", "589a247078275d0c4a000035_231", "589a247078275d0c4a000035_231", "589a247078275d0c4a000035_231", "589a247078275d0c4a000035_231", "589a247078275d0c4a000035_231", "589a247078275d0c4a000035_231", "589a247078275d0c4a000035_231", "589a247078275d0c4a000035_231", "589a247078275d0c4a000035_232", "589a247078275d0c4a000035_232", "589a247078275d0c4a000035_232", "589a247078275d0c4a000035_232", "589a247078275d0c4a000035_232", "589a247078275d0c4a000035_232", "589a247078275d0c4a000035_232", "589a247078275d0c4a000035_232", "589a247078275d0c4a000035_232", "589a247078275d0c4a000035_232", "589a247078275d0c4a000035_232", "589a247078275d0c4a000035_232", "589a247078275d0c4a000035_232", "589a247078275d0c4a000035_232", "589a247078275d0c4a000035_232", "589a247078275d0c4a000035_232", "589a247078275d0c4a000035_232", "589a247078275d0c4a000035_232", "589a247078275d0c4a000035_232", "589a247078275d0c4a000035_232", "589a247078275d0c4a000035_232", "589a247078275d0c4a000035_232", "589a247078275d0c4a000035_232", "589a247078275d0c4a000035_232", "589a247078275d0c4a000035_232", "589a247078275d0c4a000035_232", "589a247078275d0c4a000035_232", "589a247078275d0c4a000035_232", "589a247078275d0c4a000035_232", "589a247078275d0c4a000035_232", "589a247078275d0c4a000035_233", "589a247078275d0c4a000035_233", "589a247078275d0c4a000035_233", "589a247078275d0c4a000035_233", "589a247078275d0c4a000035_233", "589a247078275d0c4a000035_233", "589a247078275d0c4a000035_233", "589a247078275d0c4a000035_233", "589a247078275d0c4a000035_233", "589a247078275d0c4a000035_233", "589a247078275d0c4a000035_233", "589a247078275d0c4a000035_233", "589a247078275d0c4a000035_233", "589a247078275d0c4a000035_233", "589a247078275d0c4a000035_233", "589a247078275d0c4a000035_233", "589a247078275d0c4a000035_233", "589a247078275d0c4a000035_233", "589a247078275d0c4a000035_233", "589a247078275d0c4a000035_233", "589a247078275d0c4a000035_233", "589a247078275d0c4a000035_233", "589a247078275d0c4a000035_233", "589a247078275d0c4a000035_233", "589a247078275d0c4a000035_233", "589a247078275d0c4a000035_233", "589a247078275d0c4a000035_233", "589a247078275d0c4a000035_233", "589a247078275d0c4a000035_233", "589a247078275d0c4a000035_233", "589a247078275d0c4a000035_234", "589a247078275d0c4a000035_234", "589a247078275d0c4a000035_234", "589a247078275d0c4a000035_234", "589a247078275d0c4a000035_234", "589a247078275d0c4a000035_234", "589a247078275d0c4a000035_234", "589a247078275d0c4a000035_234", "589a247078275d0c4a000035_234", "589a247078275d0c4a000035_234", "589a247078275d0c4a000035_234", "589a247078275d0c4a000035_234", "589a247078275d0c4a000035_234", "589a247078275d0c4a000035_234", "589a247078275d0c4a000035_234", "589a247078275d0c4a000035_234", "589a247078275d0c4a000035_234", "589a247078275d0c4a000035_234", "589a247078275d0c4a000035_234", "589a247078275d0c4a000035_234", "589a247078275d0c4a000035_234", "589a247078275d0c4a000035_234", "589a247078275d0c4a000035_234", "589a247078275d0c4a000035_234", "589a247078275d0c4a000035_234", "589a247078275d0c4a000035_234", "589a247078275d0c4a000035_234", "589a247078275d0c4a000035_234", "589a247078275d0c4a000035_234", "589a247078275d0c4a000035_234", "589a247078275d0c4a000035_235", "589a247078275d0c4a000035_235", "589a247078275d0c4a000035_235", "589a247078275d0c4a000035_235", "589a247078275d0c4a000035_235", "589a247078275d0c4a000035_235", "589a247078275d0c4a000035_235", "589a247078275d0c4a000035_235", "589a247078275d0c4a000035_235", "589a247078275d0c4a000035_235", "589a247078275d0c4a000035_235", "589a247078275d0c4a000035_235", "589a247078275d0c4a000035_235", "589a247078275d0c4a000035_235", "589a247078275d0c4a000035_235", "589a247078275d0c4a000035_235", "589a247078275d0c4a000035_235", "589a247078275d0c4a000035_235", "589a247078275d0c4a000035_235", "589a247078275d0c4a000035_235", "589a247078275d0c4a000035_235", "589a247078275d0c4a000035_235", "589a247078275d0c4a000035_235", "589a247078275d0c4a000035_235", "589a247078275d0c4a000035_235", "589a247078275d0c4a000035_235", "589a247078275d0c4a000035_235", "589a247078275d0c4a000035_235", "589a247078275d0c4a000035_235", "589a247078275d0c4a000035_235", "589a247078275d0c4a000035_236", "589a247078275d0c4a000035_236", "589a247078275d0c4a000035_236", "589a247078275d0c4a000035_236", "589a247078275d0c4a000035_236", "589a247078275d0c4a000035_236", "589a247078275d0c4a000035_236", "589a247078275d0c4a000035_236", "589a247078275d0c4a000035_236", "589a247078275d0c4a000035_236", "589a247078275d0c4a000035_236", "589a247078275d0c4a000035_236", "589a247078275d0c4a000035_236", "589a247078275d0c4a000035_236", "589a247078275d0c4a000035_236", "589a247078275d0c4a000035_236", "589a247078275d0c4a000035_236", "589a247078275d0c4a000035_236", "589a247078275d0c4a000035_236", "589a247078275d0c4a000035_236", "589a247078275d0c4a000035_236", "589a247078275d0c4a000035_236", "589a247078275d0c4a000035_236", "589a247078275d0c4a000035_236", "589a247078275d0c4a000035_236", "589a247078275d0c4a000035_236", "589a247078275d0c4a000035_236", "589a247078275d0c4a000035_236", "589a247078275d0c4a000035_236", "589a247078275d0c4a000035_236", "589a247078275d0c4a000035_237", "589a247078275d0c4a000035_237", "589a247078275d0c4a000035_237", "589a247078275d0c4a000035_237", "589a247078275d0c4a000035_237", "589a247078275d0c4a000035_237", "589a247078275d0c4a000035_237", "589a247078275d0c4a000035_237", "589a247078275d0c4a000035_237", "589a247078275d0c4a000035_237", "589a247078275d0c4a000035_237", "589a247078275d0c4a000035_237", "589a247078275d0c4a000035_237", "589a247078275d0c4a000035_237", "589a247078275d0c4a000035_237", "589a247078275d0c4a000035_237", "589a247078275d0c4a000035_237", "589a247078275d0c4a000035_237", "589a247078275d0c4a000035_237", "589a247078275d0c4a000035_237", "589a247078275d0c4a000035_237", "589a247078275d0c4a000035_237", "589a247078275d0c4a000035_237", "589a247078275d0c4a000035_237", "589a247078275d0c4a000035_237", "589a247078275d0c4a000035_237", "589a247078275d0c4a000035_237", "589a247078275d0c4a000035_237", "589a247078275d0c4a000035_237", "589a247078275d0c4a000035_237", "589a247078275d0c4a000035_238", "589a247078275d0c4a000035_238", "589a247078275d0c4a000035_238", "589a247078275d0c4a000035_238", "589a247078275d0c4a000035_238", "589a247078275d0c4a000035_238", "589a247078275d0c4a000035_238", "589a247078275d0c4a000035_238", "589a247078275d0c4a000035_238", "589a247078275d0c4a000035_238", "589a247078275d0c4a000035_238", "589a247078275d0c4a000035_238", "589a247078275d0c4a000035_238", "589a247078275d0c4a000035_238", "589a247078275d0c4a000035_238", "589a247078275d0c4a000035_238", "589a247078275d0c4a000035_238", "589a247078275d0c4a000035_238", "589a247078275d0c4a000035_238", "589a247078275d0c4a000035_238", "589a247078275d0c4a000035_238", "589a247078275d0c4a000035_238", "589a247078275d0c4a000035_238", "589a247078275d0c4a000035_238", "589a247078275d0c4a000035_238", "589a247078275d0c4a000035_238", "589a247078275d0c4a000035_238", "589a247078275d0c4a000035_238", "589a247078275d0c4a000035_238", "589a247078275d0c4a000035_238", "5ab147edfcf4565872000013_239", "5ab147edfcf4565872000013_239", "5ab147edfcf4565872000013_239", "5ab147edfcf4565872000013_239", "5ab147edfcf4565872000013_239", "5ab147edfcf4565872000013_239", "5ab147edfcf4565872000013_239", "5ab147edfcf4565872000013_239", "5ab147edfcf4565872000013_239", "5ab147edfcf4565872000013_239", "5ab147edfcf4565872000013_239", "5ab147edfcf4565872000013_239", "5ab147edfcf4565872000013_239", "5ab147edfcf4565872000013_239", "5ab147edfcf4565872000013_239", "5ab147edfcf4565872000013_239", "5ab147edfcf4565872000013_239", "5ab147edfcf4565872000013_239", "5ab147edfcf4565872000013_239", "5ab147edfcf4565872000013_239", "5ab147edfcf4565872000013_239", "5ab147edfcf4565872000013_239", "5ab147edfcf4565872000013_239", "5ab147edfcf4565872000013_239", "5ab147edfcf4565872000013_239", "5ab147edfcf4565872000013_239", "5ab147edfcf4565872000013_239", "5ab147edfcf4565872000013_239", "5ab147edfcf4565872000013_239", "5ab147edfcf4565872000013_239", "5ab147edfcf4565872000013_239", "5ab147edfcf4565872000013_239", "5ab147edfcf4565872000013_239", "5ab147edfcf4565872000013_239", "5ab147edfcf4565872000013_239", "5ab147edfcf4565872000013_240", "5ab147edfcf4565872000013_240", "5ab147edfcf4565872000013_240", "5ab147edfcf4565872000013_240", "5ab147edfcf4565872000013_240", "5ab147edfcf4565872000013_240", "5ab147edfcf4565872000013_240", "5ab147edfcf4565872000013_240", "5ab147edfcf4565872000013_240", "5ab147edfcf4565872000013_240", "5ab147edfcf4565872000013_240", "5ab147edfcf4565872000013_240", "5ab147edfcf4565872000013_240", "5ab147edfcf4565872000013_240", "5ab147edfcf4565872000013_240", "5ab147edfcf4565872000013_240", "5ab147edfcf4565872000013_240", "5ab147edfcf4565872000013_240", "5ab147edfcf4565872000013_240", "5ab147edfcf4565872000013_240", "5ab147edfcf4565872000013_240", "5ab147edfcf4565872000013_240", "5ab147edfcf4565872000013_240", "5ab147edfcf4565872000013_240", "5ab147edfcf4565872000013_240", "5ab147edfcf4565872000013_240", "5ab147edfcf4565872000013_240", "5ab147edfcf4565872000013_240", "5ab147edfcf4565872000013_240", "5ab147edfcf4565872000013_240", "5ab147edfcf4565872000013_240", "5ab147edfcf4565872000013_240", "5ab147edfcf4565872000013_240", "5ab147edfcf4565872000013_240", "5ab147edfcf4565872000013_240", "5ab147edfcf4565872000013_241", "5ab147edfcf4565872000013_241", "5ab147edfcf4565872000013_241", "5ab147edfcf4565872000013_241", "5ab147edfcf4565872000013_241", "5ab147edfcf4565872000013_241", "5ab147edfcf4565872000013_241", "5ab147edfcf4565872000013_241", "5ab147edfcf4565872000013_241", "5ab147edfcf4565872000013_241", "5ab147edfcf4565872000013_241", "5ab147edfcf4565872000013_241", "5ab147edfcf4565872000013_241", "5ab147edfcf4565872000013_241", "5ab147edfcf4565872000013_241", "5ab147edfcf4565872000013_241", "5ab147edfcf4565872000013_241", "5ab147edfcf4565872000013_241", "5ab147edfcf4565872000013_241", "5ab147edfcf4565872000013_241", "5ab147edfcf4565872000013_241", "5ab147edfcf4565872000013_241", "5ab147edfcf4565872000013_241", "5ab147edfcf4565872000013_241", "5ab147edfcf4565872000013_241", "5ab147edfcf4565872000013_241", "5ab147edfcf4565872000013_241", "5ab147edfcf4565872000013_241", "5ab147edfcf4565872000013_241", "5ab147edfcf4565872000013_241", "5ab147edfcf4565872000013_241", "5ab147edfcf4565872000013_241", "5ab147edfcf4565872000013_241", "5ab147edfcf4565872000013_241", "5ab147edfcf4565872000013_241", "5ab147edfcf4565872000013_242", "5ab147edfcf4565872000013_242", "5ab147edfcf4565872000013_242", "5ab147edfcf4565872000013_242", "5ab147edfcf4565872000013_242", "5ab147edfcf4565872000013_242", "5ab147edfcf4565872000013_242", "5ab147edfcf4565872000013_242", "5ab147edfcf4565872000013_242", "5ab147edfcf4565872000013_242", "5ab147edfcf4565872000013_242", "5ab147edfcf4565872000013_242", "5ab147edfcf4565872000013_242", "5ab147edfcf4565872000013_242", "5ab147edfcf4565872000013_242", "5ab147edfcf4565872000013_242", "5ab147edfcf4565872000013_242", "5ab147edfcf4565872000013_242", "5ab147edfcf4565872000013_242", "5ab147edfcf4565872000013_242", "5ab147edfcf4565872000013_242", "5ab147edfcf4565872000013_242", "5ab147edfcf4565872000013_242", "5ab147edfcf4565872000013_242", "5ab147edfcf4565872000013_242", "5ab147edfcf4565872000013_242", "5ab147edfcf4565872000013_242", "5ab147edfcf4565872000013_242", "5ab147edfcf4565872000013_242", "5ab147edfcf4565872000013_242", "5ab147edfcf4565872000013_242", "5ab147edfcf4565872000013_242", "5ab147edfcf4565872000013_242", "5ab147edfcf4565872000013_242", "5ab147edfcf4565872000013_242", "5ab147edfcf4565872000013_243", "5ab147edfcf4565872000013_243", "5ab147edfcf4565872000013_243", "5ab147edfcf4565872000013_243", "5ab147edfcf4565872000013_243", "5ab147edfcf4565872000013_243", "5ab147edfcf4565872000013_243", "5ab147edfcf4565872000013_243", "5ab147edfcf4565872000013_243", "5ab147edfcf4565872000013_243", "5ab147edfcf4565872000013_243", "5ab147edfcf4565872000013_243", "5ab147edfcf4565872000013_243", "5ab147edfcf4565872000013_243", "5ab147edfcf4565872000013_243", "5ab147edfcf4565872000013_243", "5ab147edfcf4565872000013_243", "5ab147edfcf4565872000013_243", "5ab147edfcf4565872000013_243", "5ab147edfcf4565872000013_243", "5ab147edfcf4565872000013_243", "5ab147edfcf4565872000013_243", "5ab147edfcf4565872000013_243", "5ab147edfcf4565872000013_243", "5ab147edfcf4565872000013_243", "5ab147edfcf4565872000013_243", "5ab147edfcf4565872000013_243", "5ab147edfcf4565872000013_243", "5ab147edfcf4565872000013_243", "5ab147edfcf4565872000013_243", "5ab147edfcf4565872000013_243", "5ab147edfcf4565872000013_243", "5ab147edfcf4565872000013_243", "5ab147edfcf4565872000013_243", "5ab147edfcf4565872000013_243", "5abcf010fcf4565872000023_244", "5abcf010fcf4565872000023_244", "5abcf010fcf4565872000023_244", "5abcf010fcf4565872000023_244", "5abcf010fcf4565872000023_244", "5abcf010fcf4565872000023_244", "5abcf010fcf4565872000023_244", "5abcf010fcf4565872000023_244", "5abcf010fcf4565872000023_245", "5abcf010fcf4565872000023_245", "5abcf010fcf4565872000023_245", "5abcf010fcf4565872000023_245", "5abcf010fcf4565872000023_245", "5abcf010fcf4565872000023_245", "5abcf010fcf4565872000023_245", "5abcf010fcf4565872000023_245", "5abcf010fcf4565872000023_246", "5abcf010fcf4565872000023_246", "5abcf010fcf4565872000023_246", "5abcf010fcf4565872000023_246", "5abcf010fcf4565872000023_246", "5abcf010fcf4565872000023_246", "5abcf010fcf4565872000023_246", "5abcf010fcf4565872000023_246", "5abcf010fcf4565872000023_247", "5abcf010fcf4565872000023_247", "5abcf010fcf4565872000023_247", "5abcf010fcf4565872000023_247", "5abcf010fcf4565872000023_247", "5abcf010fcf4565872000023_247", "5abcf010fcf4565872000023_247", "5abcf010fcf4565872000023_247", "5abcf010fcf4565872000023_248", "5abcf010fcf4565872000023_248", "5abcf010fcf4565872000023_248", "5abcf010fcf4565872000023_248", "5abcf010fcf4565872000023_248", "5abcf010fcf4565872000023_248", "5abcf010fcf4565872000023_248", "5abcf010fcf4565872000023_248", "5abcf010fcf4565872000023_249", "5abcf010fcf4565872000023_249", "5abcf010fcf4565872000023_249", "5abcf010fcf4565872000023_249", "5abcf010fcf4565872000023_249", "5abcf010fcf4565872000023_249", "5abcf010fcf4565872000023_249", "5abcf010fcf4565872000023_249", "5abcf010fcf4565872000023_250", "5abcf010fcf4565872000023_250", "5abcf010fcf4565872000023_250", "5abcf010fcf4565872000023_250", "5abcf010fcf4565872000023_250", "5abcf010fcf4565872000023_250", "5abcf010fcf4565872000023_250", "5abcf010fcf4565872000023_250", "5abcf010fcf4565872000023_251", "5abcf010fcf4565872000023_251", "5abcf010fcf4565872000023_251", "5abcf010fcf4565872000023_251", "5abcf010fcf4565872000023_251", "5abcf010fcf4565872000023_251", "5abcf010fcf4565872000023_251", "5abcf010fcf4565872000023_251", "5abcf010fcf4565872000023_252", "5abcf010fcf4565872000023_252", "5abcf010fcf4565872000023_252", "5abcf010fcf4565872000023_252", "5abcf010fcf4565872000023_252", "5abcf010fcf4565872000023_252", "5abcf010fcf4565872000023_252", "5abcf010fcf4565872000023_252", "5abcf010fcf4565872000023_253", "5abcf010fcf4565872000023_253", "5abcf010fcf4565872000023_253", "5abcf010fcf4565872000023_253", "5abcf010fcf4565872000023_253", "5abcf010fcf4565872000023_253", "5abcf010fcf4565872000023_253", "5abcf010fcf4565872000023_253", "5abcf010fcf4565872000023_254", "5abcf010fcf4565872000023_254", "5abcf010fcf4565872000023_254", "5abcf010fcf4565872000023_254", "5abcf010fcf4565872000023_254", "5abcf010fcf4565872000023_254", "5abcf010fcf4565872000023_254", "5abcf010fcf4565872000023_254", "5abd13e1fcf4565872000029_255", "5abd13e1fcf4565872000029_255", "5abd13e1fcf4565872000029_255", "5abd13e1fcf4565872000029_255", "5abd13e1fcf4565872000029_255", "5abd13e1fcf4565872000029_255", "5abd13e1fcf4565872000029_255", "5abd13e1fcf4565872000029_255", "5abd13e1fcf4565872000029_255", "5abd13e1fcf4565872000029_255", "5abd13e1fcf4565872000029_255", "5abd13e1fcf4565872000029_255", "5abd13e1fcf4565872000029_255", "5abd13e1fcf4565872000029_255", "5abd13e1fcf4565872000029_255", "5abd13e1fcf4565872000029_255", "5abd13e1fcf4565872000029_255", "5abd13e1fcf4565872000029_255", "5abd13e1fcf4565872000029_255", "5abd13e1fcf4565872000029_255", "5abd13e1fcf4565872000029_255", "5abd13e1fcf4565872000029_255", "5abd13e1fcf4565872000029_255", "5abd13e1fcf4565872000029_255", "5abd13e1fcf4565872000029_255", "5abd13e1fcf4565872000029_255", "5abd13e1fcf4565872000029_255", "5abd13e1fcf4565872000029_255", "5abd13e1fcf4565872000029_255", "5abd13e1fcf4565872000029_255", "5abd13e1fcf4565872000029_255", "5abd13e1fcf4565872000029_255", "5abd13e1fcf4565872000029_255", "5abd13e1fcf4565872000029_255", "5abd13e1fcf4565872000029_255", "5abd13e1fcf4565872000029_255", "5abd13e1fcf4565872000029_255", "5abd13e1fcf4565872000029_256", "5abd13e1fcf4565872000029_256", "5abd13e1fcf4565872000029_256", "5abd13e1fcf4565872000029_256", "5abd13e1fcf4565872000029_256", "5abd13e1fcf4565872000029_256", "5abd13e1fcf4565872000029_256", "5abd13e1fcf4565872000029_256", "5abd13e1fcf4565872000029_256", "5abd13e1fcf4565872000029_256", "5abd13e1fcf4565872000029_256", "5abd13e1fcf4565872000029_256", "5abd13e1fcf4565872000029_256", "5abd13e1fcf4565872000029_256", "5abd13e1fcf4565872000029_256", "5abd13e1fcf4565872000029_256", "5abd13e1fcf4565872000029_256", "5abd13e1fcf4565872000029_256", "5abd13e1fcf4565872000029_256", "5abd13e1fcf4565872000029_256", "5abd13e1fcf4565872000029_256", "5abd13e1fcf4565872000029_256", "5abd13e1fcf4565872000029_256", "5abd13e1fcf4565872000029_256", "5abd13e1fcf4565872000029_256", "5abd13e1fcf4565872000029_256", "5abd13e1fcf4565872000029_256", "5abd13e1fcf4565872000029_256", "5abd13e1fcf4565872000029_256", "5abd13e1fcf4565872000029_256", "5abd13e1fcf4565872000029_256", "5abd13e1fcf4565872000029_256", "5abd13e1fcf4565872000029_256", "5abd13e1fcf4565872000029_256", "5abd13e1fcf4565872000029_256", "5abd13e1fcf4565872000029_256", "5abd13e1fcf4565872000029_256", "5a9e202bde7cb99d40000002_257", "5a9e202bde7cb99d40000002_257", "5a9e202bde7cb99d40000002_257", "5a9e202bde7cb99d40000002_257", "5a9e202bde7cb99d40000002_257", "5a9e202bde7cb99d40000002_257", "5a9e202bde7cb99d40000002_257", "5a9e202bde7cb99d40000002_257", "5a9e202bde7cb99d40000002_257", "5a9e202bde7cb99d40000002_257", "5a9e202bde7cb99d40000002_257", "5a9e202bde7cb99d40000002_257", "5a9e202bde7cb99d40000002_257", "5a9e202bde7cb99d40000002_257", "5a9e202bde7cb99d40000002_257", "5a9e202bde7cb99d40000002_257", "5a9e202bde7cb99d40000002_258", "5a9e202bde7cb99d40000002_258", "5a9e202bde7cb99d40000002_258", "5a9e202bde7cb99d40000002_258", "5a9e202bde7cb99d40000002_258", "5a9e202bde7cb99d40000002_258", "5a9e202bde7cb99d40000002_258", "5a9e202bde7cb99d40000002_258", "5a9e202bde7cb99d40000002_258", "5a9e202bde7cb99d40000002_258", "5a9e202bde7cb99d40000002_258", "5a9e202bde7cb99d40000002_258", "5a9e202bde7cb99d40000002_258", "5a9e202bde7cb99d40000002_258", "5a9e202bde7cb99d40000002_258", "5a9e202bde7cb99d40000002_258", "5ac0a82d19833b0d7b000003_259", "5ac0a82d19833b0d7b000003_259", "5ac0a82d19833b0d7b000003_259", "5ac0a82d19833b0d7b000003_259", "5ac0a82d19833b0d7b000003_259", "5ac0a82d19833b0d7b000003_259", "5ac0a82d19833b0d7b000003_259", "5ac0a82d19833b0d7b000003_259", "5ac0a82d19833b0d7b000003_259", "5ac0a82d19833b0d7b000003_259", "5ac0a82d19833b0d7b000003_259", "5ac0a82d19833b0d7b000003_259", "5ac0a82d19833b0d7b000003_259", "5ac0a82d19833b0d7b000003_259", "5ac0a82d19833b0d7b000003_259", "5ac0a82d19833b0d7b000003_259", "5ac0a82d19833b0d7b000003_259", "5ac0a82d19833b0d7b000003_259", "5ac0a82d19833b0d7b000003_259", "5ac0a82d19833b0d7b000003_259", "5ac0a82d19833b0d7b000003_259", "5ac0a82d19833b0d7b000003_259", "5ac0a82d19833b0d7b000003_259", "5ac0a82d19833b0d7b000003_259", "5ac0a82d19833b0d7b000003_259", "5ac0a82d19833b0d7b000003_259", "5ac0a82d19833b0d7b000003_259", "5ac0a82d19833b0d7b000003_259", "5ac0a82d19833b0d7b000003_259", "5ac0a82d19833b0d7b000003_259", "5ac0a82d19833b0d7b000003_259", "5ac0a82d19833b0d7b000003_259", "5ac0a82d19833b0d7b000003_259", "5ac0a82d19833b0d7b000003_259", "5ac0a82d19833b0d7b000003_259", "5ac0a82d19833b0d7b000003_259", "5ac0a82d19833b0d7b000003_259", "5ac0a82d19833b0d7b000003_259", "5ace238e0340b9f05800000d_260", "5ace238e0340b9f05800000d_260", "5ace238e0340b9f05800000d_260", "5ace238e0340b9f05800000d_260", "5ace238e0340b9f05800000d_260", "5ace238e0340b9f05800000d_260", "5ace238e0340b9f05800000d_260", "5ace238e0340b9f05800000d_260", "5ace238e0340b9f05800000d_260", "5ace238e0340b9f05800000d_260", "5ace238e0340b9f05800000d_260", "5ace238e0340b9f05800000d_260", "5ace238e0340b9f05800000d_260", "5ace238e0340b9f05800000d_261", "5ace238e0340b9f05800000d_261", "5ace238e0340b9f05800000d_261", "5ace238e0340b9f05800000d_261", "5ace238e0340b9f05800000d_261", "5ace238e0340b9f05800000d_261", "5ace238e0340b9f05800000d_261", "5ace238e0340b9f05800000d_261", "5ace238e0340b9f05800000d_261", "5ace238e0340b9f05800000d_261", "5ace238e0340b9f05800000d_261", "5ace238e0340b9f05800000d_261", "5ace238e0340b9f05800000d_261", "5ace238e0340b9f05800000d_262", "5ace238e0340b9f05800000d_262", "5ace238e0340b9f05800000d_262", "5ace238e0340b9f05800000d_262", "5ace238e0340b9f05800000d_262", "5ace238e0340b9f05800000d_262", "5ace238e0340b9f05800000d_262", "5ace238e0340b9f05800000d_262", "5ace238e0340b9f05800000d_262", "5ace238e0340b9f05800000d_262", "5ace238e0340b9f05800000d_262", "5ace238e0340b9f05800000d_262", "5ace238e0340b9f05800000d_262", "5ace238e0340b9f05800000d_263", "5ace238e0340b9f05800000d_263", "5ace238e0340b9f05800000d_263", "5ace238e0340b9f05800000d_263", "5ace238e0340b9f05800000d_263", "5ace238e0340b9f05800000d_263", "5ace238e0340b9f05800000d_263", "5ace238e0340b9f05800000d_263", "5ace238e0340b9f05800000d_263", "5ace238e0340b9f05800000d_263", "5ace238e0340b9f05800000d_263", "5ace238e0340b9f05800000d_263", "5ace238e0340b9f05800000d_263", "5ace238e0340b9f05800000d_264", "5ace238e0340b9f05800000d_264", "5ace238e0340b9f05800000d_264", "5ace238e0340b9f05800000d_264", "5ace238e0340b9f05800000d_264", "5ace238e0340b9f05800000d_264", "5ace238e0340b9f05800000d_264", "5ace238e0340b9f05800000d_264", "5ace238e0340b9f05800000d_264", "5ace238e0340b9f05800000d_264", "5ace238e0340b9f05800000d_264", "5ace238e0340b9f05800000d_264", "5ace238e0340b9f05800000d_264", "5ace238e0340b9f05800000d_265", "5ace238e0340b9f05800000d_265", "5ace238e0340b9f05800000d_265", "5ace238e0340b9f05800000d_265", "5ace238e0340b9f05800000d_265", "5ace238e0340b9f05800000d_265", "5ace238e0340b9f05800000d_265", "5ace238e0340b9f05800000d_265", "5ace238e0340b9f05800000d_265", "5ace238e0340b9f05800000d_265", "5ace238e0340b9f05800000d_265", "5ace238e0340b9f05800000d_265", "5ace238e0340b9f05800000d_265", "5ace238e0340b9f05800000d_266", "5ace238e0340b9f05800000d_266", "5ace238e0340b9f05800000d_266", "5ace238e0340b9f05800000d_266", "5ace238e0340b9f05800000d_266", "5ace238e0340b9f05800000d_266", "5ace238e0340b9f05800000d_266", "5ace238e0340b9f05800000d_266", "5ace238e0340b9f05800000d_266", "5ace238e0340b9f05800000d_266", "5ace238e0340b9f05800000d_266", "5ace238e0340b9f05800000d_266", "5ace238e0340b9f05800000d_266", "5ace238e0340b9f05800000d_267", "5ace238e0340b9f05800000d_267", "5ace238e0340b9f05800000d_267", "5ace238e0340b9f05800000d_267", "5ace238e0340b9f05800000d_267", "5ace238e0340b9f05800000d_267", "5ace238e0340b9f05800000d_267", "5ace238e0340b9f05800000d_267", "5ace238e0340b9f05800000d_267", "5ace238e0340b9f05800000d_267", "5ace238e0340b9f05800000d_267", "5ace238e0340b9f05800000d_267", "5ace238e0340b9f05800000d_267", "5ace238e0340b9f05800000d_268", "5ace238e0340b9f05800000d_268", "5ace238e0340b9f05800000d_268", "5ace238e0340b9f05800000d_268", "5ace238e0340b9f05800000d_268", "5ace238e0340b9f05800000d_268", "5ace238e0340b9f05800000d_268", "5ace238e0340b9f05800000d_268", "5ace238e0340b9f05800000d_268", "5ace238e0340b9f05800000d_268", "5ace238e0340b9f05800000d_268", "5ace238e0340b9f05800000d_268", "5ace238e0340b9f05800000d_268", "5ace238e0340b9f05800000d_269", "5ace238e0340b9f05800000d_269", "5ace238e0340b9f05800000d_269", "5ace238e0340b9f05800000d_269", "5ace238e0340b9f05800000d_269", "5ace238e0340b9f05800000d_269", "5ace238e0340b9f05800000d_269", "5ace238e0340b9f05800000d_269", "5ace238e0340b9f05800000d_269", "5ace238e0340b9f05800000d_269", "5ace238e0340b9f05800000d_269", "5ace238e0340b9f05800000d_269", "5ace238e0340b9f05800000d_269", "5ace238e0340b9f05800000d_270", "5ace238e0340b9f05800000d_270", "5ace238e0340b9f05800000d_270", "5ace238e0340b9f05800000d_270", "5ace238e0340b9f05800000d_270", "5ace238e0340b9f05800000d_270", "5ace238e0340b9f05800000d_270", "5ace238e0340b9f05800000d_270", "5ace238e0340b9f05800000d_270", "5ace238e0340b9f05800000d_270", "5ace238e0340b9f05800000d_270", "5ace238e0340b9f05800000d_270", "5ace238e0340b9f05800000d_270", "5ace238e0340b9f05800000d_271", "5ace238e0340b9f05800000d_271", "5ace238e0340b9f05800000d_271", "5ace238e0340b9f05800000d_271", "5ace238e0340b9f05800000d_271", "5ace238e0340b9f05800000d_271", "5ace238e0340b9f05800000d_271", "5ace238e0340b9f05800000d_271", "5ace238e0340b9f05800000d_271", "5ace238e0340b9f05800000d_271", "5ace238e0340b9f05800000d_271", "5ace238e0340b9f05800000d_271", "5ace238e0340b9f05800000d_271", "5ace1a590340b9f05800000b_272", "5ace1a590340b9f05800000b_272", "5ace1a590340b9f05800000b_272", "5ace1a590340b9f05800000b_272", "5ace1a590340b9f05800000b_272", "5ace1a590340b9f05800000b_272", "5ace1a590340b9f05800000b_272", "5ace1a590340b9f05800000b_272", "5ace1a590340b9f05800000b_272", "5ace1a590340b9f05800000b_272", "5ace1a590340b9f05800000b_272", "5ace1a590340b9f05800000b_272", "5ace1a590340b9f05800000b_272", "5ace1a590340b9f05800000b_272", "5ace1a590340b9f05800000b_272", "5ac3699f0340b9f058000001_273", "5ac3699f0340b9f058000001_273", "5ac3699f0340b9f058000001_273", "5ac3699f0340b9f058000001_273", "5ac3699f0340b9f058000001_273", "5ac3699f0340b9f058000001_273", "5ac3699f0340b9f058000001_273", "5ac3699f0340b9f058000001_273", "5ac3699f0340b9f058000001_273", "5ac3699f0340b9f058000001_273", "5ac3699f0340b9f058000001_273", "5ac3699f0340b9f058000001_273", "5ac3699f0340b9f058000001_273", "5ac3699f0340b9f058000001_273", "5ac3699f0340b9f058000001_273", "5ac3699f0340b9f058000001_273", "5ac3699f0340b9f058000001_273", "5ac3699f0340b9f058000001_273", "5ac3699f0340b9f058000001_273", "5ac3699f0340b9f058000001_273", "5ac3699f0340b9f058000001_273", "5ac3699f0340b9f058000001_273", "5ac3699f0340b9f058000001_273", "5ac3699f0340b9f058000001_273", "5ac3699f0340b9f058000001_274", "5ac3699f0340b9f058000001_274", "5ac3699f0340b9f058000001_274", "5ac3699f0340b9f058000001_274", "5ac3699f0340b9f058000001_274", "5ac3699f0340b9f058000001_274", "5ac3699f0340b9f058000001_274", "5ac3699f0340b9f058000001_274", "5ac3699f0340b9f058000001_274", "5ac3699f0340b9f058000001_274", "5ac3699f0340b9f058000001_274", "5ac3699f0340b9f058000001_274", "5ac3699f0340b9f058000001_274", "5ac3699f0340b9f058000001_274", "5ac3699f0340b9f058000001_274", "5ac3699f0340b9f058000001_274", "5ac3699f0340b9f058000001_274", "5ac3699f0340b9f058000001_274", "5ac3699f0340b9f058000001_274", "5ac3699f0340b9f058000001_274", "5ac3699f0340b9f058000001_274", "5ac3699f0340b9f058000001_274", "5ac3699f0340b9f058000001_274", "5ac3699f0340b9f058000001_274", "5ac3699f0340b9f058000001_275", "5ac3699f0340b9f058000001_275", "5ac3699f0340b9f058000001_275", "5ac3699f0340b9f058000001_275", "5ac3699f0340b9f058000001_275", "5ac3699f0340b9f058000001_275", "5ac3699f0340b9f058000001_275", "5ac3699f0340b9f058000001_275", "5ac3699f0340b9f058000001_275", "5ac3699f0340b9f058000001_275", "5ac3699f0340b9f058000001_275", "5ac3699f0340b9f058000001_275", "5ac3699f0340b9f058000001_275", "5ac3699f0340b9f058000001_275", "5ac3699f0340b9f058000001_275", "5ac3699f0340b9f058000001_275", "5ac3699f0340b9f058000001_275", "5ac3699f0340b9f058000001_275", "5ac3699f0340b9f058000001_275", "5ac3699f0340b9f058000001_275", "5ac3699f0340b9f058000001_275", "5ac3699f0340b9f058000001_275", "5ac3699f0340b9f058000001_275", "5ac3699f0340b9f058000001_275", "5ac3699f0340b9f058000001_276", "5ac3699f0340b9f058000001_276", "5ac3699f0340b9f058000001_276", "5ac3699f0340b9f058000001_276", "5ac3699f0340b9f058000001_276", "5ac3699f0340b9f058000001_276", "5ac3699f0340b9f058000001_276", "5ac3699f0340b9f058000001_276", "5ac3699f0340b9f058000001_276", "5ac3699f0340b9f058000001_276", "5ac3699f0340b9f058000001_276", "5ac3699f0340b9f058000001_276", "5ac3699f0340b9f058000001_276", "5ac3699f0340b9f058000001_276", "5ac3699f0340b9f058000001_276", "5ac3699f0340b9f058000001_276", "5ac3699f0340b9f058000001_276", "5ac3699f0340b9f058000001_276", "5ac3699f0340b9f058000001_276", "5ac3699f0340b9f058000001_276", "5ac3699f0340b9f058000001_276", "5ac3699f0340b9f058000001_276", "5ac3699f0340b9f058000001_276", "5ac3699f0340b9f058000001_276", "5a9da59c4e03427e73000005_277", "5a9da59c4e03427e73000005_277", "5a9da59c4e03427e73000005_277", "5a9da59c4e03427e73000005_277", "5a9da59c4e03427e73000005_277"], "question": ["[PAD] [PAD] [PAD] [PAD] how many genes constitute the dosr regulon, controlled by the dormancy survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] how many genes form the dosr regulon, controlled by the dormancy survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] how many genes make up the dosr regulator, controlled by the drowsiness survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] how many genes make up the dosr regulon, which is controlled by the survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] how many genes make up the dosr regulator, which is controlled by the dormant survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] in mycobacterium tuberculosis, how many genes make up the dosr regulon, which is controlled by the sleep mode regulator (dosr)?", "[PAD] [PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulation, which regulates sleep-regulating survival (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] how many genes make up the dosr regulator, which is controlled by the resting survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulon controlled by the dosr at mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulator, controlled by the latency survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] how many genes constitute the dosr regulon controlled by the dormant survival regulator (dosr) in m. tuberculosis?", "[PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulon, controlled by the resting survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] how many genes make up the dosr regulon, controlled by the dormancy survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulon, controlled by the dormant survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulon that is controlled by the mycobacterium tuberculosis dormant regulator (dosr)?", "[PAD] how many genes make up the dosr regulon, which is controlled by the dormancy survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] how many genes make up the dosr regulon, which is controlled by the dormancy survival regulator (dosr) of mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulon, controlled by the latency survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulator controlled by the sleep survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulon controlled by the dormancy survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] how many genes make up the dosr regulator, which is controlled by the lethargy survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] how many genes make up dosr regulon, controlled by sleep survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] how many genes make up the dosr regulator, which is controlled by the dosr survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] how many genes controlled by the dormancy survival regulator (dosr) in mycobacterium tuberculosis constitute the dosr regulation?", "[PAD] how many genes make up the dosr regulon, which is regulated by the dormancy survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] how many genes make up the dosr regulation, which is controlled by the dormancy survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] how many genes are contained in the dulr regulon, controlled by the dormant survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulon regulated by the dormant survival regulator (dosr) of m. tuberculosis?", "[PAD] in mycobacterium tuberculosis, how many genes make up the dosr regulon, which is controlled by dosr (a dormant survival regulator)?", "[PAD] [PAD] [PAD] [PAD] [PAD] how many genes are made up of the dosr regulon, which is controlled by mycobacterium tuberculosis (dosr)?", "[PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulon under the control of the resting survival regulator (dosr) mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulator, controlled by the dormant survival regulator (dosr) in mycobacterium tuberculosis?", "what is the number of genes that make up the dosr regulon, controlled by the dormant survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] how many genes make up the regulon dosr, controlled by the sleep survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] how many dosr regulatory genes are regulated by the sleep survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] how many genes are there in the dosr regulon which is controlled by the dormant survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] how many genes is the dosr regulator, controlled by the rest survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] how many genes make up the dosr regulon controlled by the resting-state survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] how many genes does dosr regulon, which controls the resting survival regulator (dosr) in mycobacterium tuberculosis, make?", "[PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulator, controlled by the dormancy survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] how many genes make up the regulon dosr controlled by the resting survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulation, which is regulated by the stability regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] how many genes constitute the dosr regulon, controlled by the resting survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] how many genes make up the dosr regulator, which is regulated by the dormant survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] how many genes make up the dormancy survival regulator (dosr)-controlled dosr regulon in mycobacterium tuberculosis?", "[PAD] [PAD] how many genes make up the regulation of dosr, which is controlled by the resting survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what is the number of dosr regulated by mycobacterium tuberculosis controlled by dormant survival regulator (dosr)?", "[PAD] [PAD] [PAD] [PAD] how many genes constitute the dosr regulator, which is controlled by the dormant survival (dosr) regulator in mycobacterium tuberculosis?", "[PAD] [PAD] how many genes make up the dosr rule, which is regulated by the dormancy control regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] how many genes constitute the dosr regulon, controlled by the dormancy survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] how many genes form the dosr regulon, controlled by the dormancy survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] how many genes make up the dosr regulator, controlled by the drowsiness survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] how many genes make up the dosr regulon, which is controlled by the survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] how many genes make up the dosr regulator, which is controlled by the dormant survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] in mycobacterium tuberculosis, how many genes make up the dosr regulon, which is controlled by the sleep mode regulator (dosr)?", "[PAD] [PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulation, which regulates sleep-regulating survival (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] how many genes make up the dosr regulator, which is controlled by the resting survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulon controlled by the dosr at mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulator, controlled by the latency survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] how many genes constitute the dosr regulon controlled by the dormant survival regulator (dosr) in m. tuberculosis?", "[PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulon, controlled by the resting survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] how many genes make up the dosr regulon, controlled by the dormancy survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulon, controlled by the dormant survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulon that is controlled by the mycobacterium tuberculosis dormant regulator (dosr)?", "[PAD] how many genes make up the dosr regulon, which is controlled by the dormancy survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] how many genes make up the dosr regulon, which is controlled by the dormancy survival regulator (dosr) of mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulon, controlled by the latency survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulator controlled by the sleep survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulon controlled by the dormancy survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] how many genes make up the dosr regulator, which is controlled by the lethargy survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] how many genes make up dosr regulon, controlled by sleep survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] how many genes make up the dosr regulator, which is controlled by the dosr survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] how many genes controlled by the dormancy survival regulator (dosr) in mycobacterium tuberculosis constitute the dosr regulation?", "[PAD] how many genes make up the dosr regulon, which is regulated by the dormancy survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] how many genes make up the dosr regulation, which is controlled by the dormancy survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] how many genes are contained in the dulr regulon, controlled by the dormant survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulon regulated by the dormant survival regulator (dosr) of m. tuberculosis?", "[PAD] in mycobacterium tuberculosis, how many genes make up the dosr regulon, which is controlled by dosr (a dormant survival regulator)?", "[PAD] [PAD] [PAD] [PAD] [PAD] how many genes are made up of the dosr regulon, which is controlled by mycobacterium tuberculosis (dosr)?", "[PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulon under the control of the resting survival regulator (dosr) mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulator, controlled by the dormant survival regulator (dosr) in mycobacterium tuberculosis?", "what is the number of genes that make up the dosr regulon, controlled by the dormant survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] how many genes make up the regulon dosr, controlled by the sleep survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] how many dosr regulatory genes are regulated by the sleep survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] how many genes are there in the dosr regulon which is controlled by the dormant survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] how many genes is the dosr regulator, controlled by the rest survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] how many genes make up the dosr regulon controlled by the resting-state survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] how many genes does dosr regulon, which controls the resting survival regulator (dosr) in mycobacterium tuberculosis, make?", "[PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulator, controlled by the dormancy survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] how many genes make up the regulon dosr controlled by the resting survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulation, which is regulated by the stability regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] how many genes constitute the dosr regulon, controlled by the resting survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] how many genes make up the dosr regulator, which is regulated by the dormant survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] how many genes make up the dormancy survival regulator (dosr)-controlled dosr regulon in mycobacterium tuberculosis?", "[PAD] [PAD] how many genes make up the regulation of dosr, which is controlled by the resting survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what is the number of dosr regulated by mycobacterium tuberculosis controlled by dormant survival regulator (dosr)?", "[PAD] [PAD] [PAD] [PAD] how many genes constitute the dosr regulator, which is controlled by the dormant survival (dosr) regulator in mycobacterium tuberculosis?", "[PAD] [PAD] how many genes make up the dosr rule, which is regulated by the dormancy control regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] how many genes constitute the dosr regulon, controlled by the dormancy survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] how many genes form the dosr regulon, controlled by the dormancy survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] how many genes make up the dosr regulator, controlled by the drowsiness survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] how many genes make up the dosr regulon, which is controlled by the survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] how many genes make up the dosr regulator, which is controlled by the dormant survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] in mycobacterium tuberculosis, how many genes make up the dosr regulon, which is controlled by the sleep mode regulator (dosr)?", "[PAD] [PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulation, which regulates sleep-regulating survival (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] how many genes make up the dosr regulator, which is controlled by the resting survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulon controlled by the dosr at mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulator, controlled by the latency survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] how many genes constitute the dosr regulon controlled by the dormant survival regulator (dosr) in m. tuberculosis?", "[PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulon, controlled by the resting survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] how many genes make up the dosr regulon, controlled by the dormancy survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulon, controlled by the dormant survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulon that is controlled by the mycobacterium tuberculosis dormant regulator (dosr)?", "[PAD] how many genes make up the dosr regulon, which is controlled by the dormancy survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] how many genes make up the dosr regulon, which is controlled by the dormancy survival regulator (dosr) of mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulon, controlled by the latency survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulator controlled by the sleep survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulon controlled by the dormancy survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] how many genes make up the dosr regulator, which is controlled by the lethargy survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] how many genes make up dosr regulon, controlled by sleep survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] how many genes make up the dosr regulator, which is controlled by the dosr survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] how many genes controlled by the dormancy survival regulator (dosr) in mycobacterium tuberculosis constitute the dosr regulation?", "[PAD] how many genes make up the dosr regulon, which is regulated by the dormancy survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] how many genes make up the dosr regulation, which is controlled by the dormancy survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] how many genes are contained in the dulr regulon, controlled by the dormant survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulon regulated by the dormant survival regulator (dosr) of m. tuberculosis?", "[PAD] in mycobacterium tuberculosis, how many genes make up the dosr regulon, which is controlled by dosr (a dormant survival regulator)?", "[PAD] [PAD] [PAD] [PAD] [PAD] how many genes are made up of the dosr regulon, which is controlled by mycobacterium tuberculosis (dosr)?", "[PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulon under the control of the resting survival regulator (dosr) mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulator, controlled by the dormant survival regulator (dosr) in mycobacterium tuberculosis?", "what is the number of genes that make up the dosr regulon, controlled by the dormant survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] how many genes make up the regulon dosr, controlled by the sleep survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] how many dosr regulatory genes are regulated by the sleep survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] how many genes are there in the dosr regulon which is controlled by the dormant survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] how many genes is the dosr regulator, controlled by the rest survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] how many genes make up the dosr regulon controlled by the resting-state survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] how many genes does dosr regulon, which controls the resting survival regulator (dosr) in mycobacterium tuberculosis, make?", "[PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulator, controlled by the dormancy survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] how many genes make up the regulon dosr controlled by the resting survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulation, which is regulated by the stability regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] how many genes constitute the dosr regulon, controlled by the resting survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] how many genes make up the dosr regulator, which is regulated by the dormant survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] how many genes make up the dormancy survival regulator (dosr)-controlled dosr regulon in mycobacterium tuberculosis?", "[PAD] [PAD] how many genes make up the regulation of dosr, which is controlled by the resting survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what is the number of dosr regulated by mycobacterium tuberculosis controlled by dormant survival regulator (dosr)?", "[PAD] [PAD] [PAD] [PAD] how many genes constitute the dosr regulator, which is controlled by the dormant survival (dosr) regulator in mycobacterium tuberculosis?", "[PAD] [PAD] how many genes make up the dosr rule, which is regulated by the dormancy control regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] how many genes constitute the dosr regulon, controlled by the dormancy survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] how many genes form the dosr regulon, controlled by the dormancy survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] how many genes make up the dosr regulator, controlled by the drowsiness survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] how many genes make up the dosr regulon, which is controlled by the survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] how many genes make up the dosr regulator, which is controlled by the dormant survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] in mycobacterium tuberculosis, how many genes make up the dosr regulon, which is controlled by the sleep mode regulator (dosr)?", "[PAD] [PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulation, which regulates sleep-regulating survival (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] how many genes make up the dosr regulator, which is controlled by the resting survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulon controlled by the dosr at mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulator, controlled by the latency survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] how many genes constitute the dosr regulon controlled by the dormant survival regulator (dosr) in m. tuberculosis?", "[PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulon, controlled by the resting survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] how many genes make up the dosr regulon, controlled by the dormancy survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulon, controlled by the dormant survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulon that is controlled by the mycobacterium tuberculosis dormant regulator (dosr)?", "[PAD] how many genes make up the dosr regulon, which is controlled by the dormancy survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] how many genes make up the dosr regulon, which is controlled by the dormancy survival regulator (dosr) of mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulon, controlled by the latency survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulator controlled by the sleep survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulon controlled by the dormancy survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] how many genes make up the dosr regulator, which is controlled by the lethargy survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] how many genes make up dosr regulon, controlled by sleep survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] how many genes make up the dosr regulator, which is controlled by the dosr survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] how many genes controlled by the dormancy survival regulator (dosr) in mycobacterium tuberculosis constitute the dosr regulation?", "[PAD] how many genes make up the dosr regulon, which is regulated by the dormancy survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] how many genes make up the dosr regulation, which is controlled by the dormancy survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] how many genes are contained in the dulr regulon, controlled by the dormant survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulon regulated by the dormant survival regulator (dosr) of m. tuberculosis?", "[PAD] in mycobacterium tuberculosis, how many genes make up the dosr regulon, which is controlled by dosr (a dormant survival regulator)?", "[PAD] [PAD] [PAD] [PAD] [PAD] how many genes are made up of the dosr regulon, which is controlled by mycobacterium tuberculosis (dosr)?", "[PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulon under the control of the resting survival regulator (dosr) mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulator, controlled by the dormant survival regulator (dosr) in mycobacterium tuberculosis?", "what is the number of genes that make up the dosr regulon, controlled by the dormant survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] how many genes make up the regulon dosr, controlled by the sleep survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] how many dosr regulatory genes are regulated by the sleep survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] how many genes are there in the dosr regulon which is controlled by the dormant survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] how many genes is the dosr regulator, controlled by the rest survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] how many genes make up the dosr regulon controlled by the resting-state survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] how many genes does dosr regulon, which controls the resting survival regulator (dosr) in mycobacterium tuberculosis, make?", "[PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulator, controlled by the dormancy survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] how many genes make up the regulon dosr controlled by the resting survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] how many genes make up the dosr regulation, which is regulated by the stability regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] how many genes constitute the dosr regulon, controlled by the resting survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] how many genes make up the dosr regulator, which is regulated by the dormant survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] how many genes make up the dormancy survival regulator (dosr)-controlled dosr regulon in mycobacterium tuberculosis?", "[PAD] [PAD] how many genes make up the regulation of dosr, which is controlled by the resting survival regulator (dosr) in mycobacterium tuberculosis?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what is the number of dosr regulated by mycobacterium tuberculosis controlled by dormant survival regulator (dosr)?", "[PAD] [PAD] [PAD] [PAD] how many genes constitute the dosr regulator, which is controlled by the dormant survival (dosr) regulator in mycobacterium tuberculosis?", "[PAD] [PAD] how many genes make up the dosr rule, which is regulated by the dormancy control regulator (dosr) in mycobacterium tuberculosis?", "[PAD] which type of urinary incontinence is diagnosed with the q tip test?", "[PAD] what type of urinary incontinence is diagnosed with the q tip test?", "[PAD] what type of urinary incontinence is diagnosed with the q type test?", "[PAD] [PAD] what type of urinary incontinence is diagnosed by a q test?", "[PAD] what type of urinary incontinence is diagnosed with a type q test?", "[PAD] what type of urinary incontinence is diagnosed with a q tip test?", "what type of urinary incontinence can the q prompt test diagnose?", "[PAD] what type of urinary incontinence is diagnosed with a q type test?", "[PAD] what type of urinary incontinence is diagnosed by the q tip test?", "what type of urinary incontinence is diagnosed with the q-tip test?", "what type of urinary incontinence is diagnosed with a q-terminal test?", "[PAD] which type of urinary incontinence was diagnosed in the q tip test?", "what type of urinary incontinence is diagnosed with a q-tip test?", "[PAD] what type of urinary incontinence is determined by the q tip test?", "what types of urinary incontinence are diagnosed with the q-type test?", "[PAD] what type of urinary incontinence is diagnosed on a q tip test?", "what types of urinary incontinence are diagnosed with the q-tip test?", "what type of urinary incontinence can be diagnosed with the q tip test?", "[PAD] what type of urinary incontinence is detected by the q tip test?", "[PAD] what types of urinary incontinence are diagnosed with a q tip test?", "[PAD] q which type of urinary incontinence is diagnosed by the tip test?", "[PAD] [PAD] what types of incontinence are diagnosed with a q-tip test?", "[PAD] what type of urinary incontinence is diagnosed with the q peak test?", "what type of urinary incontinence is diagnosed by a q-type test?", "[PAD] what type of urinary incontinence is diagnosed with a q-tip?", "[PAD] what type of urinary incontinence is diagnosed with the k type test?", "[PAD] what type of urinary incontinence is detected by q-tip measurement?", "[PAD] what types of urinary incontinence are diagnosed with the late q test?", "[PAD] what type of urinary incontinence is diagnosed with q-tip test?", "[PAD] which type of urinary incontinence is diagnosed with the q tip test?", "[PAD] what type of urinary incontinence is diagnosed with the q tip test?", "[PAD] what type of urinary incontinence is diagnosed with the q type test?", "[PAD] [PAD] what type of urinary incontinence is diagnosed by a q test?", "[PAD] what type of urinary incontinence is diagnosed with a type q test?", "[PAD] what type of urinary incontinence is diagnosed with a q tip test?", "what type of urinary incontinence can the q prompt test diagnose?", "[PAD] what type of urinary incontinence is diagnosed with a q type test?", "[PAD] what type of urinary incontinence is diagnosed by the q tip test?", "what type of urinary incontinence is diagnosed with the q-tip test?", "what type of urinary incontinence is diagnosed with a q-terminal test?", "[PAD] which type of urinary incontinence was diagnosed in the q tip test?", "what type of urinary incontinence is diagnosed with a q-tip test?", "[PAD] what type of urinary incontinence is determined by the q tip test?", "what types of urinary incontinence are diagnosed with the q-type test?", "[PAD] what type of urinary incontinence is diagnosed on a q tip test?", "what types of urinary incontinence are diagnosed with the q-tip test?", "what type of urinary incontinence can be diagnosed with the q tip test?", "[PAD] what type of urinary incontinence is detected by the q tip test?", "[PAD] what types of urinary incontinence are diagnosed with a q tip test?", "[PAD] q which type of urinary incontinence is diagnosed by the tip test?", "[PAD] [PAD] what types of incontinence are diagnosed with a q-tip test?", "[PAD] what type of urinary incontinence is diagnosed with the q peak test?", "what type of urinary incontinence is diagnosed by a q-type test?", "[PAD] what type of urinary incontinence is diagnosed with a q-tip?", "[PAD] what type of urinary incontinence is diagnosed with the k type test?", "[PAD] what type of urinary incontinence is detected by q-tip measurement?", "[PAD] what types of urinary incontinence are diagnosed with the late q test?", "[PAD] what type of urinary incontinence is diagnosed with q-tip test?", "[PAD] which type of urinary incontinence is diagnosed with the q tip test?", "[PAD] what type of urinary incontinence is diagnosed with the q tip test?", "[PAD] what type of urinary incontinence is diagnosed with the q type test?", "[PAD] [PAD] what type of urinary incontinence is diagnosed by a q test?", "[PAD] what type of urinary incontinence is diagnosed with a type q test?", "[PAD] what type of urinary incontinence is diagnosed with a q tip test?", "what type of urinary incontinence can the q prompt test diagnose?", "[PAD] what type of urinary incontinence is diagnosed with a q type test?", "[PAD] what type of urinary incontinence is diagnosed by the q tip test?", "what type of urinary incontinence is diagnosed with the q-tip test?", "what type of urinary incontinence is diagnosed with a q-terminal test?", "[PAD] which type of urinary incontinence was diagnosed in the q tip test?", "what type of urinary incontinence is diagnosed with a q-tip test?", "[PAD] what type of urinary incontinence is determined by the q tip test?", "what types of urinary incontinence are diagnosed with the q-type test?", "[PAD] what type of urinary incontinence is diagnosed on a q tip test?", "what types of urinary incontinence are diagnosed with the q-tip test?", "what type of urinary incontinence can be diagnosed with the q tip test?", "[PAD] what type of urinary incontinence is detected by the q tip test?", "[PAD] what types of urinary incontinence are diagnosed with a q tip test?", "[PAD] q which type of urinary incontinence is diagnosed by the tip test?", "[PAD] [PAD] what types of incontinence are diagnosed with a q-tip test?", "[PAD] what type of urinary incontinence is diagnosed with the q peak test?", "what type of urinary incontinence is diagnosed by a q-type test?", "[PAD] what type of urinary incontinence is diagnosed with a q-tip?", "[PAD] what type of urinary incontinence is diagnosed with the k type test?", "[PAD] what type of urinary incontinence is detected by q-tip measurement?", "[PAD] what types of urinary incontinence are diagnosed with the late q test?", "[PAD] what type of urinary incontinence is diagnosed with q-tip test?", "[PAD] which type of urinary incontinence is diagnosed with the q tip test?", "[PAD] what type of urinary incontinence is diagnosed with the q tip test?", "[PAD] what type of urinary incontinence is diagnosed with the q type test?", "[PAD] [PAD] what type of urinary incontinence is diagnosed by a q test?", "[PAD] what type of urinary incontinence is diagnosed with a type q test?", "[PAD] what type of urinary incontinence is diagnosed with a q tip test?", "what type of urinary incontinence can the q prompt test diagnose?", "[PAD] what type of urinary incontinence is diagnosed with a q type test?", "[PAD] what type of urinary incontinence is diagnosed by the q tip test?", "what type of urinary incontinence is diagnosed with the q-tip test?", "what type of urinary incontinence is diagnosed with a q-terminal test?", "[PAD] which type of urinary incontinence was diagnosed in the q tip test?", "what type of urinary incontinence is diagnosed with a q-tip test?", "[PAD] what type of urinary incontinence is determined by the q tip test?", "what types of urinary incontinence are diagnosed with the q-type test?", "[PAD] what type of urinary incontinence is diagnosed on a q tip test?", "what types of urinary incontinence are diagnosed with the q-tip test?", "what type of urinary incontinence can be diagnosed with the q tip test?", "[PAD] what type of urinary incontinence is detected by the q tip test?", "[PAD] what types of urinary incontinence are diagnosed with a q tip test?", "[PAD] q which type of urinary incontinence is diagnosed by the tip test?", "[PAD] [PAD] what types of incontinence are diagnosed with a q-tip test?", "[PAD] what type of urinary incontinence is diagnosed with the q peak test?", "what type of urinary incontinence is diagnosed by a q-type test?", "[PAD] what type of urinary incontinence is diagnosed with a q-tip?", "[PAD] what type of urinary incontinence is diagnosed with the k type test?", "[PAD] what type of urinary incontinence is detected by q-tip measurement?", "[PAD] what types of urinary incontinence are diagnosed with the late q test?", "[PAD] what type of urinary incontinence is diagnosed with q-tip test?", "[PAD] which type of urinary incontinence is diagnosed with the q tip test?", "[PAD] what type of urinary incontinence is diagnosed with the q tip test?", "[PAD] what type of urinary incontinence is diagnosed with the q type test?", "[PAD] [PAD] what type of urinary incontinence is diagnosed by a q test?", "[PAD] what type of urinary incontinence is diagnosed with a type q test?", "[PAD] what type of urinary incontinence is diagnosed with a q tip test?", "what type of urinary incontinence can the q prompt test diagnose?", "[PAD] what type of urinary incontinence is diagnosed with a q type test?", "[PAD] what type of urinary incontinence is diagnosed by the q tip test?", "what type of urinary incontinence is diagnosed with the q-tip test?", "what type of urinary incontinence is diagnosed with a q-terminal test?", "[PAD] which type of urinary incontinence was diagnosed in the q tip test?", "what type of urinary incontinence is diagnosed with a q-tip test?", "[PAD] what type of urinary incontinence is determined by the q tip test?", "what types of urinary incontinence are diagnosed with the q-type test?", "[PAD] what type of urinary incontinence is diagnosed on a q tip test?", "what types of urinary incontinence are diagnosed with the q-tip test?", "what type of urinary incontinence can be diagnosed with the q tip test?", "[PAD] what type of urinary incontinence is detected by the q tip test?", "[PAD] what types of urinary incontinence are diagnosed with a q tip test?", "[PAD] q which type of urinary incontinence is diagnosed by the tip test?", "[PAD] [PAD] what types of incontinence are diagnosed with a q-tip test?", "[PAD] what type of urinary incontinence is diagnosed with the q peak test?", "what type of urinary incontinence is diagnosed by a q-type test?", "[PAD] what type of urinary incontinence is diagnosed with a q-tip?", "[PAD] what type of urinary incontinence is diagnosed with the k type test?", "[PAD] what type of urinary incontinence is detected by q-tip measurement?", "[PAD] what types of urinary incontinence are diagnosed with the late q test?", "[PAD] what type of urinary incontinence is diagnosed with q-tip test?", "[PAD] which type of urinary incontinence is diagnosed with the q tip test?", "[PAD] what type of urinary incontinence is diagnosed with the q tip test?", "[PAD] what type of urinary incontinence is diagnosed with the q type test?", "[PAD] [PAD] what type of urinary incontinence is diagnosed by a q test?", "[PAD] what type of urinary incontinence is diagnosed with a type q test?", "[PAD] what type of urinary incontinence is diagnosed with a q tip test?", "what type of urinary incontinence can the q prompt test diagnose?", "[PAD] what type of urinary incontinence is diagnosed with a q type test?", "[PAD] what type of urinary incontinence is diagnosed by the q tip test?", "what type of urinary incontinence is diagnosed with the q-tip test?", "what type of urinary incontinence is diagnosed with a q-terminal test?", "[PAD] which type of urinary incontinence was diagnosed in the q tip test?", "what type of urinary incontinence is diagnosed with a q-tip test?", "[PAD] what type of urinary incontinence is determined by the q tip test?", "what types of urinary incontinence are diagnosed with the q-type test?", "[PAD] what type of urinary incontinence is diagnosed on a q tip test?", "what types of urinary incontinence are diagnosed with the q-tip test?", "what type of urinary incontinence can be diagnosed with the q tip test?", "[PAD] what type of urinary incontinence is detected by the q tip test?", "[PAD] what types of urinary incontinence are diagnosed with a q tip test?", "[PAD] q which type of urinary incontinence is diagnosed by the tip test?", "[PAD] [PAD] what types of incontinence are diagnosed with a q-tip test?", "[PAD] what type of urinary incontinence is diagnosed with the q peak test?", "what type of urinary incontinence is diagnosed by a q-type test?", "[PAD] what type of urinary incontinence is diagnosed with a q-tip?", "[PAD] what type of urinary incontinence is diagnosed with the k type test?", "[PAD] what type of urinary incontinence is detected by q-tip measurement?", "[PAD] what types of urinary incontinence are diagnosed with the late q test?", "[PAD] what type of urinary incontinence is diagnosed with q-tip test?", "[PAD] which type of urinary incontinence is diagnosed with the q tip test?", "[PAD] what type of urinary incontinence is diagnosed with the q tip test?", "[PAD] what type of urinary incontinence is diagnosed with the q type test?", "[PAD] [PAD] what type of urinary incontinence is diagnosed by a q test?", "[PAD] what type of urinary incontinence is diagnosed with a type q test?", "[PAD] what type of urinary incontinence is diagnosed with a q tip test?", "what type of urinary incontinence can the q prompt test diagnose?", "[PAD] what type of urinary incontinence is diagnosed with a q type test?", "[PAD] what type of urinary incontinence is diagnosed by the q tip test?", "what type of urinary incontinence is diagnosed with the q-tip test?", "what type of urinary incontinence is diagnosed with a q-terminal test?", "[PAD] which type of urinary incontinence was diagnosed in the q tip test?", "what type of urinary incontinence is diagnosed with a q-tip test?", "[PAD] what type of urinary incontinence is determined by the q tip test?", "what types of urinary incontinence are diagnosed with the q-type test?", "[PAD] what type of urinary incontinence is diagnosed on a q tip test?", "what types of urinary incontinence are diagnosed with the q-tip test?", "what type of urinary incontinence can be diagnosed with the q tip test?", "[PAD] what type of urinary incontinence is detected by the q tip test?", "[PAD] what types of urinary incontinence are diagnosed with a q tip test?", "[PAD] q which type of urinary incontinence is diagnosed by the tip test?", "[PAD] [PAD] what types of incontinence are diagnosed with a q-tip test?", "[PAD] what type of urinary incontinence is diagnosed with the q peak test?", "what type of urinary incontinence is diagnosed by a q-type test?", "[PAD] what type of urinary incontinence is diagnosed with a q-tip?", "[PAD] what type of urinary incontinence is diagnosed with the k type test?", "[PAD] what type of urinary incontinence is detected by q-tip measurement?", "[PAD] what types of urinary incontinence are diagnosed with the late q test?", "[PAD] what type of urinary incontinence is diagnosed with q-tip test?", "[PAD] which type of urinary incontinence is diagnosed with the q tip test?", "[PAD] what type of urinary incontinence is diagnosed with the q tip test?", "[PAD] what type of urinary incontinence is diagnosed with the q type test?", "[PAD] [PAD] what type of urinary incontinence is diagnosed by a q test?", "[PAD] what type of urinary incontinence is diagnosed with a type q test?", "[PAD] what type of urinary incontinence is diagnosed with a q tip test?", "what type of urinary incontinence can the q prompt test diagnose?", "[PAD] what type of urinary incontinence is diagnosed with a q type test?", "[PAD] what type of urinary incontinence is diagnosed by the q tip test?", "what type of urinary incontinence is diagnosed with the q-tip test?", "what type of urinary incontinence is diagnosed with a q-terminal test?", "[PAD] which type of urinary incontinence was diagnosed in the q tip test?", "what type of urinary incontinence is diagnosed with a q-tip test?", "[PAD] what type of urinary incontinence is determined by the q tip test?", "what types of urinary incontinence are diagnosed with the q-type test?", "[PAD] what type of urinary incontinence is diagnosed on a q tip test?", "what types of urinary incontinence are diagnosed with the q-tip test?", "what type of urinary incontinence can be diagnosed with the q tip test?", "[PAD] what type of urinary incontinence is detected by the q tip test?", "[PAD] what types of urinary incontinence are diagnosed with a q tip test?", "[PAD] q which type of urinary incontinence is diagnosed by the tip test?", "[PAD] [PAD] what types of incontinence are diagnosed with a q-tip test?", "[PAD] what type of urinary incontinence is diagnosed with the q peak test?", "what type of urinary incontinence is diagnosed by a q-type test?", "[PAD] what type of urinary incontinence is diagnosed with a q-tip?", "[PAD] what type of urinary incontinence is diagnosed with the k type test?", "[PAD] what type of urinary incontinence is detected by q-tip measurement?", "[PAD] what types of urinary incontinence are diagnosed with the late q test?", "[PAD] what type of urinary incontinence is diagnosed with q-tip test?", "[PAD] which type of urinary incontinence is diagnosed with the q tip test?", "[PAD] what type of urinary incontinence is diagnosed with the q tip test?", "[PAD] what type of urinary incontinence is diagnosed with the q type test?", "[PAD] [PAD] what type of urinary incontinence is diagnosed by a q test?", "[PAD] what type of urinary incontinence is diagnosed with a type q test?", "[PAD] what type of urinary incontinence is diagnosed with a q tip test?", "what type of urinary incontinence can the q prompt test diagnose?", "[PAD] what type of urinary incontinence is diagnosed with a q type test?", "[PAD] what type of urinary incontinence is diagnosed by the q tip test?", "what type of urinary incontinence is diagnosed with the q-tip test?", "what type of urinary incontinence is diagnosed with a q-terminal test?", "[PAD] which type of urinary incontinence was diagnosed in the q tip test?", "what type of urinary incontinence is diagnosed with a q-tip test?", "[PAD] what type of urinary incontinence is determined by the q tip test?", "what types of urinary incontinence are diagnosed with the q-type test?", "[PAD] what type of urinary incontinence is diagnosed on a q tip test?", "what types of urinary incontinence are diagnosed with the q-tip test?", "what type of urinary incontinence can be diagnosed with the q tip test?", "[PAD] what type of urinary incontinence is detected by the q tip test?", "[PAD] what types of urinary incontinence are diagnosed with a q tip test?", "[PAD] q which type of urinary incontinence is diagnosed by the tip test?", "[PAD] [PAD] what types of incontinence are diagnosed with a q-tip test?", "[PAD] what type of urinary incontinence is diagnosed with the q peak test?", "what type of urinary incontinence is diagnosed by a q-type test?", "[PAD] what type of urinary incontinence is diagnosed with a q-tip?", "[PAD] what type of urinary incontinence is diagnosed with the k type test?", "[PAD] what type of urinary incontinence is detected by q-tip measurement?", "[PAD] what types of urinary incontinence are diagnosed with the late q test?", "[PAD] what type of urinary incontinence is diagnosed with q-tip test?", "[PAD] how many groucho-related genes (grg) are contained in the mouse genome?", "[PAD] how many groucho-related (grg) genes are found in the mouse genome?", "[PAD] [PAD] how many groucho-related genes (grg) are in the mouse genome?", "[PAD] how many grucho-related genes (grg) are contained in a muscle genome?", "[PAD] how many groucho-linked genes (grg) are there in the mouse genome?", "[PAD] how many groucho-related genes (grgs) are there in the mouse genome?", "[PAD] [PAD] [PAD] how many gene-related genes (grg) are contained in the mouse genome?", "[PAD] how many groucho-related genes (grgs) are contained in the mouse genome?", "[PAD] how many groucho-related genes (grg) are there in the mouse genome?", "[PAD] [PAD] how many groucho-associated genes (grgs) are in the mouse genome?", "[PAD] how many groucho -related genes (grg) are contained in the mouse genome?", "[PAD] [PAD] how many groucho-related genes (grgs) are in the mouse genome?", "[PAD] [PAD] how many grout-related genes (grg) are contained in the mouse genome?", "[PAD] how many groucho-related (grg) genes are contained in the mouse genome?", "[PAD] how many groucho-linked genes (grgs) are in the genome of mice?", "[PAD] [PAD] [PAD] how many groucho (grg) genes are involved in the mouse genome?", "[PAD] how many groucho-associated genes (grgs) are contained in the mouse genome?", "[PAD] how many groucho-related genes (grg) are present in the mouse genome?", "[PAD] [PAD] how many groko-related genes (grg) are there in the mouse genome?", "how many groucho-related genes (grgs) are in the genome of a mouse?", "[PAD] [PAD] how many groucho-related (grg) genes are in the mouse genome?", "[PAD] [PAD] how many groucho-related genes (grg) does the mouse genome contain?", "[PAD] [PAD] how many groucho (grg)-related genes are in the rat genome?", "[PAD] how many groucho-related genes (grg) are found in the mouse genome?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] how many genes (grg) are present in the mouse genome?", "[PAD] how many groucho-related genes (grg) are included in the mouse genome?", "[PAD] [PAD] [PAD] what is a coligo?", "[PAD] [PAD] [PAD] what is the colon?", "[PAD] [PAD] [PAD] [PAD] what is coligo?", "[PAD] [PAD] [PAD] what is a colic?", "[PAD] [PAD] [PAD] what is coligus?", "[PAD] [PAD] [PAD] [PAD] what is a colleague?", "[PAD] [PAD] what is a coligus?", "what is escherichia coli?", "[PAD] [PAD] [PAD] what is collegium?", "[PAD] [PAD] [PAD] what is colligo?", "[PAD] [PAD] what is e. coli?", "[PAD] [PAD] [PAD] what is cologne?", "[PAD] [PAD] [PAD] what is a collie?", "[PAD] [PAD] [PAD] what is koligo?", "[PAD] [PAD] [PAD] [PAD] what is colico?", "[PAD] [PAD] [PAD] what is collego?", "what is inhibited by a drug rilotumumab?", "[PAD] [PAD] [PAD] [PAD] [PAD] what does rilutumab prevent?", "[PAD] [PAD] [PAD] [PAD] what inhibits rilotumumab?", "[PAD] [PAD] [PAD] [PAD] what does rilotumumab inhibit?", "what is inhibited by the drug rilotumumab?", "[PAD] [PAD] [PAD] what does the drug rituximab inhibit?", "[PAD] [PAD] what does a rilotumumab drug prevent?", "[PAD] [PAD] [PAD] [PAD] what does rilotumumab prevent?", "[PAD] [PAD] [PAD] what prevents the drug rilotumumab?", "[PAD] [PAD] what inhibits a drug rilotumumab?", "[PAD] what is prevented by a rilotumumab drug?", "[PAD] what is inhibited by the drug rilotomumab?", "what is a drug inhibited by rilotumumab?", "[PAD] [PAD] what does the drug rilotumumab block?", "[PAD] [PAD] what inhibits the drug rilotumumab?", "what is inhibited by a rilotumumab drug?", "[PAD] what is blocked by the drug lilotumumab?", "[PAD] [PAD] what is inhibited by rilotumumab?", "[PAD] [PAD] [PAD] [PAD] [PAD] what does rilotomumab inhibit?", "[PAD] [PAD] what is blocking the drug rilotumumab?", "[PAD] [PAD] [PAD] [PAD] what can rilotumumab block?", "[PAD] [PAD] [PAD] [PAD] [PAD] what prevents relotomomab medicine?", "[PAD] [PAD] what is prevented by rilotumumab drug?", "what is inhibited by a drug rilotumumab?", "[PAD] [PAD] [PAD] [PAD] [PAD] what does rilutumab prevent?", "[PAD] [PAD] [PAD] [PAD] what inhibits rilotumumab?", "[PAD] [PAD] [PAD] [PAD] what does rilotumumab inhibit?", "what is inhibited by the drug rilotumumab?", "[PAD] [PAD] [PAD] what does the drug rituximab inhibit?", "[PAD] [PAD] what does a rilotumumab drug prevent?", "[PAD] [PAD] [PAD] [PAD] what does rilotumumab prevent?", "[PAD] [PAD] [PAD] what prevents the drug rilotumumab?", "[PAD] [PAD] what inhibits a drug rilotumumab?", "[PAD] what is prevented by a rilotumumab drug?", "[PAD] what is inhibited by the drug rilotomumab?", "what is a drug inhibited by rilotumumab?", "[PAD] [PAD] what does the drug rilotumumab block?", "[PAD] [PAD] what inhibits the drug rilotumumab?", "what is inhibited by a rilotumumab drug?", "[PAD] what is blocked by the drug lilotumumab?", "[PAD] [PAD] what is inhibited by rilotumumab?", "[PAD] [PAD] [PAD] [PAD] [PAD] what does rilotomumab inhibit?", "[PAD] [PAD] what is blocking the drug rilotumumab?", "[PAD] [PAD] [PAD] [PAD] what can rilotumumab block?", "[PAD] [PAD] [PAD] [PAD] [PAD] what prevents relotomomab medicine?", "[PAD] [PAD] what is prevented by rilotumumab drug?", "what is inhibited by a drug rilotumumab?", "[PAD] [PAD] [PAD] [PAD] [PAD] what does rilutumab prevent?", "[PAD] [PAD] [PAD] [PAD] what inhibits rilotumumab?", "[PAD] [PAD] [PAD] [PAD] what does rilotumumab inhibit?", "what is inhibited by the drug rilotumumab?", "[PAD] [PAD] [PAD] what does the drug rituximab inhibit?", "[PAD] [PAD] what does a rilotumumab drug prevent?", "[PAD] [PAD] [PAD] [PAD] what does rilotumumab prevent?", "[PAD] [PAD] [PAD] what prevents the drug rilotumumab?", "[PAD] [PAD] what inhibits a drug rilotumumab?", "[PAD] what is prevented by a rilotumumab drug?", "[PAD] what is inhibited by the drug rilotomumab?", "what is a drug inhibited by rilotumumab?", "[PAD] [PAD] what does the drug rilotumumab block?", "[PAD] [PAD] what inhibits the drug rilotumumab?", "what is inhibited by a rilotumumab drug?", "[PAD] what is blocked by the drug lilotumumab?", "[PAD] [PAD] what is inhibited by rilotumumab?", "[PAD] [PAD] [PAD] [PAD] [PAD] what does rilotomumab inhibit?", "[PAD] [PAD] what is blocking the drug rilotumumab?", "[PAD] [PAD] [PAD] [PAD] what can rilotumumab block?", "[PAD] [PAD] [PAD] [PAD] [PAD] what prevents relotomomab medicine?", "[PAD] [PAD] what is prevented by rilotumumab drug?", "what is inhibited by a drug rilotumumab?", "[PAD] [PAD] [PAD] [PAD] [PAD] what does rilutumab prevent?", "[PAD] [PAD] [PAD] [PAD] what inhibits rilotumumab?", "[PAD] [PAD] [PAD] [PAD] what does rilotumumab inhibit?", "what is inhibited by the drug rilotumumab?", "[PAD] [PAD] [PAD] what does the drug rituximab inhibit?", "[PAD] [PAD] what does a rilotumumab drug prevent?", "[PAD] [PAD] [PAD] [PAD] what does rilotumumab prevent?", "[PAD] [PAD] [PAD] what prevents the drug rilotumumab?", "[PAD] [PAD] what inhibits a drug rilotumumab?", "[PAD] what is prevented by a rilotumumab drug?", "[PAD] what is inhibited by the drug rilotomumab?", "what is a drug inhibited by rilotumumab?", "[PAD] [PAD] what does the drug rilotumumab block?", "[PAD] [PAD] what inhibits the drug rilotumumab?", "what is inhibited by a rilotumumab drug?", "[PAD] what is blocked by the drug lilotumumab?", "[PAD] [PAD] what is inhibited by rilotumumab?", "[PAD] [PAD] [PAD] [PAD] [PAD] what does rilotomumab inhibit?", "[PAD] [PAD] what is blocking the drug rilotumumab?", "[PAD] [PAD] [PAD] [PAD] what can rilotumumab block?", "[PAD] [PAD] [PAD] [PAD] [PAD] what prevents relotomomab medicine?", "[PAD] [PAD] what is prevented by rilotumumab drug?", "what is inhibited by a drug rilotumumab?", "[PAD] [PAD] [PAD] [PAD] [PAD] what does rilutumab prevent?", "[PAD] [PAD] [PAD] [PAD] what inhibits rilotumumab?", "[PAD] [PAD] [PAD] [PAD] what does rilotumumab inhibit?", "what is inhibited by the drug rilotumumab?", "[PAD] [PAD] [PAD] what does the drug rituximab inhibit?", "[PAD] [PAD] what does a rilotumumab drug prevent?", "[PAD] [PAD] [PAD] [PAD] what does rilotumumab prevent?", "[PAD] [PAD] [PAD] what prevents the drug rilotumumab?", "[PAD] [PAD] what inhibits a drug rilotumumab?", "[PAD] what is prevented by a rilotumumab drug?", "[PAD] what is inhibited by the drug rilotomumab?", "what is a drug inhibited by rilotumumab?", "[PAD] [PAD] what does the drug rilotumumab block?", "[PAD] [PAD] what inhibits the drug rilotumumab?", "what is inhibited by a rilotumumab drug?", "[PAD] what is blocked by the drug lilotumumab?", "[PAD] [PAD] what is inhibited by rilotumumab?", "[PAD] [PAD] [PAD] [PAD] [PAD] what does rilotomumab inhibit?", "[PAD] [PAD] what is blocking the drug rilotumumab?", "[PAD] [PAD] [PAD] [PAD] what can rilotumumab block?", "[PAD] [PAD] [PAD] [PAD] [PAD] what prevents relotomomab medicine?", "[PAD] [PAD] what is prevented by rilotumumab drug?", "what is inhibited by a drug rilotumumab?", "[PAD] [PAD] [PAD] [PAD] [PAD] what does rilutumab prevent?", "[PAD] [PAD] [PAD] [PAD] what inhibits rilotumumab?", "[PAD] [PAD] [PAD] [PAD] what does rilotumumab inhibit?", "what is inhibited by the drug rilotumumab?", "[PAD] [PAD] [PAD] what does the drug rituximab inhibit?", "[PAD] [PAD] what does a rilotumumab drug prevent?", "[PAD] [PAD] [PAD] [PAD] what does rilotumumab prevent?", "[PAD] [PAD] [PAD] what prevents the drug rilotumumab?", "[PAD] [PAD] what inhibits a drug rilotumumab?", "[PAD] what is prevented by a rilotumumab drug?", "[PAD] what is inhibited by the drug rilotomumab?", "what is a drug inhibited by rilotumumab?", "[PAD] [PAD] what does the drug rilotumumab block?", "[PAD] [PAD] what inhibits the drug rilotumumab?", "what is inhibited by a rilotumumab drug?", "[PAD] what is blocked by the drug lilotumumab?", "[PAD] [PAD] what is inhibited by rilotumumab?", "[PAD] [PAD] [PAD] [PAD] [PAD] what does rilotomumab inhibit?", "[PAD] [PAD] what is blocking the drug rilotumumab?", "[PAD] [PAD] [PAD] [PAD] what can rilotumumab block?", "[PAD] [PAD] [PAD] [PAD] [PAD] what prevents relotomomab medicine?", "[PAD] [PAD] what is prevented by rilotumumab drug?", "what is inhibited by a drug rilotumumab?", "[PAD] [PAD] [PAD] [PAD] [PAD] what does rilutumab prevent?", "[PAD] [PAD] [PAD] [PAD] what inhibits rilotumumab?", "[PAD] [PAD] [PAD] [PAD] what does rilotumumab inhibit?", "what is inhibited by the drug rilotumumab?", "[PAD] [PAD] [PAD] what does the drug rituximab inhibit?", "[PAD] [PAD] what does a rilotumumab drug prevent?", "[PAD] [PAD] [PAD] [PAD] what does rilotumumab prevent?", "[PAD] [PAD] [PAD] what prevents the drug rilotumumab?", "[PAD] [PAD] what inhibits a drug rilotumumab?", "[PAD] what is prevented by a rilotumumab drug?", "[PAD] what is inhibited by the drug rilotomumab?", "what is a drug inhibited by rilotumumab?", "[PAD] [PAD] what does the drug rilotumumab block?", "[PAD] [PAD] what inhibits the drug rilotumumab?", "what is inhibited by a rilotumumab drug?", "[PAD] what is blocked by the drug lilotumumab?", "[PAD] [PAD] what is inhibited by rilotumumab?", "[PAD] [PAD] [PAD] [PAD] [PAD] what does rilotomumab inhibit?", "[PAD] [PAD] what is blocking the drug rilotumumab?", "[PAD] [PAD] [PAD] [PAD] what can rilotumumab block?", "[PAD] [PAD] [PAD] [PAD] [PAD] what prevents relotomomab medicine?", "[PAD] [PAD] what is prevented by rilotumumab drug?", "what is inhibited by a drug rilotumumab?", "[PAD] [PAD] [PAD] [PAD] [PAD] what does rilutumab prevent?", "[PAD] [PAD] [PAD] [PAD] what inhibits rilotumumab?", "[PAD] [PAD] [PAD] [PAD] what does rilotumumab inhibit?", "what is inhibited by the drug rilotumumab?", "[PAD] [PAD] [PAD] what does the drug rituximab inhibit?", "[PAD] [PAD] what does a rilotumumab drug prevent?", "[PAD] [PAD] [PAD] [PAD] what does rilotumumab prevent?", "[PAD] [PAD] [PAD] what prevents the drug rilotumumab?", "[PAD] [PAD] what inhibits a drug rilotumumab?", "[PAD] what is prevented by a rilotumumab drug?", "[PAD] what is inhibited by the drug rilotomumab?", "what is a drug inhibited by rilotumumab?", "[PAD] [PAD] what does the drug rilotumumab block?", "[PAD] [PAD] what inhibits the drug rilotumumab?", "what is inhibited by a rilotumumab drug?", "[PAD] what is blocked by the drug lilotumumab?", "[PAD] [PAD] what is inhibited by rilotumumab?", "[PAD] [PAD] [PAD] [PAD] [PAD] what does rilotomumab inhibit?", "[PAD] [PAD] what is blocking the drug rilotumumab?", "[PAD] [PAD] [PAD] [PAD] what can rilotumumab block?", "[PAD] [PAD] [PAD] [PAD] [PAD] what prevents relotomomab medicine?", "[PAD] [PAD] what is prevented by rilotumumab drug?", "[PAD] [PAD] which drug can be reversed with idarucizumab?", "[PAD] [PAD] which medicine can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] what medication is reversible with idaruzumab?", "[PAD] [PAD] which medicine can be used against idarucizumab?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which drug can be reversed with administration?", "[PAD] [PAD] which drug can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] which drug can idarucizumab reverse?", "[PAD] [PAD] which medicine can be reversed by idarucizumab?", "[PAD] [PAD] which drug can be reversed by idarucizumab?", "[PAD] [PAD] what drug can be reversed with idarucizumab?", "[PAD] [PAD] what medicine can be reversed with idarucizumab?", "[PAD] [PAD] which medication can be returned to idarucizumab?", "[PAD] [PAD] [PAD] what medicine can be reversed with idaruzumab?", "[PAD] [PAD] which drug can be changed with idarucizumab?", "[PAD] [PAD] which medicine can be reversed with idarucizumab?", "[PAD] [PAD] which drugs can be reversed with idarucizumab?", "[PAD] [PAD] what are the side effects of idarucizumab?", "[PAD] [PAD] what drugs can be reversed with idarucizumab?", "which medicines can be remedied with idarucizumab?", "[PAD] [PAD] [PAD] what drugs can be reversed with idalucizumab?", "[PAD] [PAD] which medicine can be changed with idarucizumab?", "[PAD] [PAD] what drug can be substituted for idarucizumab?", "[PAD] [PAD] [PAD] which medicine can be changed with idarizizumab?", "[PAD] [PAD] which medication can be reversed with idarucizumab?", "[PAD] [PAD] [PAD] which drug can be reversed with idarosizumab?", "[PAD] [PAD] which drug can be discontinued with idarucizumab?", "[PAD] [PAD] what medications can be replaced with idarucizumab?", "[PAD] which drugs can be reversed too? idarucizumab?", "[PAD] [PAD] [PAD] which drug is reversible with idarucizumab?", "[PAD] [PAD] which medicine can be replaced with idarucizumab?", "[PAD] [PAD] [PAD] what drugs are reversible with idarucizumab?", "which drug can be contraindicated with idarucizumab?", "[PAD] [PAD] which drug can be reversed with idarucizumab?", "[PAD] [PAD] which medicine can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] what medication is reversible with idaruzumab?", "[PAD] [PAD] which medicine can be used against idarucizumab?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which drug can be reversed with administration?", "[PAD] [PAD] which drug can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] which drug can idarucizumab reverse?", "[PAD] [PAD] which medicine can be reversed by idarucizumab?", "[PAD] [PAD] which drug can be reversed by idarucizumab?", "[PAD] [PAD] what drug can be reversed with idarucizumab?", "[PAD] [PAD] what medicine can be reversed with idarucizumab?", "[PAD] [PAD] which medication can be returned to idarucizumab?", "[PAD] [PAD] [PAD] what medicine can be reversed with idaruzumab?", "[PAD] [PAD] which drug can be changed with idarucizumab?", "[PAD] [PAD] which medicine can be reversed with idarucizumab?", "[PAD] [PAD] which drugs can be reversed with idarucizumab?", "[PAD] [PAD] what are the side effects of idarucizumab?", "[PAD] [PAD] what drugs can be reversed with idarucizumab?", "which medicines can be remedied with idarucizumab?", "[PAD] [PAD] [PAD] what drugs can be reversed with idalucizumab?", "[PAD] [PAD] which medicine can be changed with idarucizumab?", "[PAD] [PAD] what drug can be substituted for idarucizumab?", "[PAD] [PAD] [PAD] which medicine can be changed with idarizizumab?", "[PAD] [PAD] which medication can be reversed with idarucizumab?", "[PAD] [PAD] [PAD] which drug can be reversed with idarosizumab?", "[PAD] [PAD] which drug can be discontinued with idarucizumab?", "[PAD] [PAD] what medications can be replaced with idarucizumab?", "[PAD] which drugs can be reversed too? idarucizumab?", "[PAD] [PAD] [PAD] which drug is reversible with idarucizumab?", "[PAD] [PAD] which medicine can be replaced with idarucizumab?", "[PAD] [PAD] [PAD] what drugs are reversible with idarucizumab?", "which drug can be contraindicated with idarucizumab?", "[PAD] [PAD] which drug can be reversed with idarucizumab?", "[PAD] [PAD] which medicine can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] what medication is reversible with idaruzumab?", "[PAD] [PAD] which medicine can be used against idarucizumab?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which drug can be reversed with administration?", "[PAD] [PAD] which drug can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] which drug can idarucizumab reverse?", "[PAD] [PAD] which medicine can be reversed by idarucizumab?", "[PAD] [PAD] which drug can be reversed by idarucizumab?", "[PAD] [PAD] what drug can be reversed with idarucizumab?", "[PAD] [PAD] what medicine can be reversed with idarucizumab?", "[PAD] [PAD] which medication can be returned to idarucizumab?", "[PAD] [PAD] [PAD] what medicine can be reversed with idaruzumab?", "[PAD] [PAD] which drug can be changed with idarucizumab?", "[PAD] [PAD] which medicine can be reversed with idarucizumab?", "[PAD] [PAD] which drugs can be reversed with idarucizumab?", "[PAD] [PAD] what are the side effects of idarucizumab?", "[PAD] [PAD] what drugs can be reversed with idarucizumab?", "which medicines can be remedied with idarucizumab?", "[PAD] [PAD] [PAD] what drugs can be reversed with idalucizumab?", "[PAD] [PAD] which medicine can be changed with idarucizumab?", "[PAD] [PAD] what drug can be substituted for idarucizumab?", "[PAD] [PAD] [PAD] which medicine can be changed with idarizizumab?", "[PAD] [PAD] which medication can be reversed with idarucizumab?", "[PAD] [PAD] [PAD] which drug can be reversed with idarosizumab?", "[PAD] [PAD] which drug can be discontinued with idarucizumab?", "[PAD] [PAD] what medications can be replaced with idarucizumab?", "[PAD] which drugs can be reversed too? idarucizumab?", "[PAD] [PAD] [PAD] which drug is reversible with idarucizumab?", "[PAD] [PAD] which medicine can be replaced with idarucizumab?", "[PAD] [PAD] [PAD] what drugs are reversible with idarucizumab?", "which drug can be contraindicated with idarucizumab?", "[PAD] [PAD] which drug can be reversed with idarucizumab?", "[PAD] [PAD] which medicine can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] what medication is reversible with idaruzumab?", "[PAD] [PAD] which medicine can be used against idarucizumab?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which drug can be reversed with administration?", "[PAD] [PAD] which drug can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] which drug can idarucizumab reverse?", "[PAD] [PAD] which medicine can be reversed by idarucizumab?", "[PAD] [PAD] which drug can be reversed by idarucizumab?", "[PAD] [PAD] what drug can be reversed with idarucizumab?", "[PAD] [PAD] what medicine can be reversed with idarucizumab?", "[PAD] [PAD] which medication can be returned to idarucizumab?", "[PAD] [PAD] [PAD] what medicine can be reversed with idaruzumab?", "[PAD] [PAD] which drug can be changed with idarucizumab?", "[PAD] [PAD] which medicine can be reversed with idarucizumab?", "[PAD] [PAD] which drugs can be reversed with idarucizumab?", "[PAD] [PAD] what are the side effects of idarucizumab?", "[PAD] [PAD] what drugs can be reversed with idarucizumab?", "which medicines can be remedied with idarucizumab?", "[PAD] [PAD] [PAD] what drugs can be reversed with idalucizumab?", "[PAD] [PAD] which medicine can be changed with idarucizumab?", "[PAD] [PAD] what drug can be substituted for idarucizumab?", "[PAD] [PAD] [PAD] which medicine can be changed with idarizizumab?", "[PAD] [PAD] which medication can be reversed with idarucizumab?", "[PAD] [PAD] [PAD] which drug can be reversed with idarosizumab?", "[PAD] [PAD] which drug can be discontinued with idarucizumab?", "[PAD] [PAD] what medications can be replaced with idarucizumab?", "[PAD] which drugs can be reversed too? idarucizumab?", "[PAD] [PAD] [PAD] which drug is reversible with idarucizumab?", "[PAD] [PAD] which medicine can be replaced with idarucizumab?", "[PAD] [PAD] [PAD] what drugs are reversible with idarucizumab?", "which drug can be contraindicated with idarucizumab?", "[PAD] [PAD] which drug can be reversed with idarucizumab?", "[PAD] [PAD] which medicine can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] what medication is reversible with idaruzumab?", "[PAD] [PAD] which medicine can be used against idarucizumab?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which drug can be reversed with administration?", "[PAD] [PAD] which drug can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] which drug can idarucizumab reverse?", "[PAD] [PAD] which medicine can be reversed by idarucizumab?", "[PAD] [PAD] which drug can be reversed by idarucizumab?", "[PAD] [PAD] what drug can be reversed with idarucizumab?", "[PAD] [PAD] what medicine can be reversed with idarucizumab?", "[PAD] [PAD] which medication can be returned to idarucizumab?", "[PAD] [PAD] [PAD] what medicine can be reversed with idaruzumab?", "[PAD] [PAD] which drug can be changed with idarucizumab?", "[PAD] [PAD] which medicine can be reversed with idarucizumab?", "[PAD] [PAD] which drugs can be reversed with idarucizumab?", "[PAD] [PAD] what are the side effects of idarucizumab?", "[PAD] [PAD] what drugs can be reversed with idarucizumab?", "which medicines can be remedied with idarucizumab?", "[PAD] [PAD] [PAD] what drugs can be reversed with idalucizumab?", "[PAD] [PAD] which medicine can be changed with idarucizumab?", "[PAD] [PAD] what drug can be substituted for idarucizumab?", "[PAD] [PAD] [PAD] which medicine can be changed with idarizizumab?", "[PAD] [PAD] which medication can be reversed with idarucizumab?", "[PAD] [PAD] [PAD] which drug can be reversed with idarosizumab?", "[PAD] [PAD] which drug can be discontinued with idarucizumab?", "[PAD] [PAD] what medications can be replaced with idarucizumab?", "[PAD] which drugs can be reversed too? idarucizumab?", "[PAD] [PAD] [PAD] which drug is reversible with idarucizumab?", "[PAD] [PAD] which medicine can be replaced with idarucizumab?", "[PAD] [PAD] [PAD] what drugs are reversible with idarucizumab?", "which drug can be contraindicated with idarucizumab?", "[PAD] [PAD] which drug can be reversed with idarucizumab?", "[PAD] [PAD] which medicine can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] what medication is reversible with idaruzumab?", "[PAD] [PAD] which medicine can be used against idarucizumab?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which drug can be reversed with administration?", "[PAD] [PAD] which drug can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] which drug can idarucizumab reverse?", "[PAD] [PAD] which medicine can be reversed by idarucizumab?", "[PAD] [PAD] which drug can be reversed by idarucizumab?", "[PAD] [PAD] what drug can be reversed with idarucizumab?", "[PAD] [PAD] what medicine can be reversed with idarucizumab?", "[PAD] [PAD] which medication can be returned to idarucizumab?", "[PAD] [PAD] [PAD] what medicine can be reversed with idaruzumab?", "[PAD] [PAD] which drug can be changed with idarucizumab?", "[PAD] [PAD] which medicine can be reversed with idarucizumab?", "[PAD] [PAD] which drugs can be reversed with idarucizumab?", "[PAD] [PAD] what are the side effects of idarucizumab?", "[PAD] [PAD] what drugs can be reversed with idarucizumab?", "which medicines can be remedied with idarucizumab?", "[PAD] [PAD] [PAD] what drugs can be reversed with idalucizumab?", "[PAD] [PAD] which medicine can be changed with idarucizumab?", "[PAD] [PAD] what drug can be substituted for idarucizumab?", "[PAD] [PAD] [PAD] which medicine can be changed with idarizizumab?", "[PAD] [PAD] which medication can be reversed with idarucizumab?", "[PAD] [PAD] [PAD] which drug can be reversed with idarosizumab?", "[PAD] [PAD] which drug can be discontinued with idarucizumab?", "[PAD] [PAD] what medications can be replaced with idarucizumab?", "[PAD] which drugs can be reversed too? idarucizumab?", "[PAD] [PAD] [PAD] which drug is reversible with idarucizumab?", "[PAD] [PAD] which medicine can be replaced with idarucizumab?", "[PAD] [PAD] [PAD] what drugs are reversible with idarucizumab?", "which drug can be contraindicated with idarucizumab?", "[PAD] [PAD] which drug can be reversed with idarucizumab?", "[PAD] [PAD] which medicine can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] what medication is reversible with idaruzumab?", "[PAD] [PAD] which medicine can be used against idarucizumab?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which drug can be reversed with administration?", "[PAD] [PAD] which drug can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] which drug can idarucizumab reverse?", "[PAD] [PAD] which medicine can be reversed by idarucizumab?", "[PAD] [PAD] which drug can be reversed by idarucizumab?", "[PAD] [PAD] what drug can be reversed with idarucizumab?", "[PAD] [PAD] what medicine can be reversed with idarucizumab?", "[PAD] [PAD] which medication can be returned to idarucizumab?", "[PAD] [PAD] [PAD] what medicine can be reversed with idaruzumab?", "[PAD] [PAD] which drug can be changed with idarucizumab?", "[PAD] [PAD] which medicine can be reversed with idarucizumab?", "[PAD] [PAD] which drugs can be reversed with idarucizumab?", "[PAD] [PAD] what are the side effects of idarucizumab?", "[PAD] [PAD] what drugs can be reversed with idarucizumab?", "which medicines can be remedied with idarucizumab?", "[PAD] [PAD] [PAD] what drugs can be reversed with idalucizumab?", "[PAD] [PAD] which medicine can be changed with idarucizumab?", "[PAD] [PAD] what drug can be substituted for idarucizumab?", "[PAD] [PAD] [PAD] which medicine can be changed with idarizizumab?", "[PAD] [PAD] which medication can be reversed with idarucizumab?", "[PAD] [PAD] [PAD] which drug can be reversed with idarosizumab?", "[PAD] [PAD] which drug can be discontinued with idarucizumab?", "[PAD] [PAD] what medications can be replaced with idarucizumab?", "[PAD] which drugs can be reversed too? idarucizumab?", "[PAD] [PAD] [PAD] which drug is reversible with idarucizumab?", "[PAD] [PAD] which medicine can be replaced with idarucizumab?", "[PAD] [PAD] [PAD] what drugs are reversible with idarucizumab?", "which drug can be contraindicated with idarucizumab?", "[PAD] [PAD] which drug can be reversed with idarucizumab?", "[PAD] [PAD] which medicine can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] what medication is reversible with idaruzumab?", "[PAD] [PAD] which medicine can be used against idarucizumab?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which drug can be reversed with administration?", "[PAD] [PAD] which drug can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] which drug can idarucizumab reverse?", "[PAD] [PAD] which medicine can be reversed by idarucizumab?", "[PAD] [PAD] which drug can be reversed by idarucizumab?", "[PAD] [PAD] what drug can be reversed with idarucizumab?", "[PAD] [PAD] what medicine can be reversed with idarucizumab?", "[PAD] [PAD] which medication can be returned to idarucizumab?", "[PAD] [PAD] [PAD] what medicine can be reversed with idaruzumab?", "[PAD] [PAD] which drug can be changed with idarucizumab?", "[PAD] [PAD] which medicine can be reversed with idarucizumab?", "[PAD] [PAD] which drugs can be reversed with idarucizumab?", "[PAD] [PAD] what are the side effects of idarucizumab?", "[PAD] [PAD] what drugs can be reversed with idarucizumab?", "which medicines can be remedied with idarucizumab?", "[PAD] [PAD] [PAD] what drugs can be reversed with idalucizumab?", "[PAD] [PAD] which medicine can be changed with idarucizumab?", "[PAD] [PAD] what drug can be substituted for idarucizumab?", "[PAD] [PAD] [PAD] which medicine can be changed with idarizizumab?", "[PAD] [PAD] which medication can be reversed with idarucizumab?", "[PAD] [PAD] [PAD] which drug can be reversed with idarosizumab?", "[PAD] [PAD] which drug can be discontinued with idarucizumab?", "[PAD] [PAD] what medications can be replaced with idarucizumab?", "[PAD] which drugs can be reversed too? idarucizumab?", "[PAD] [PAD] [PAD] which drug is reversible with idarucizumab?", "[PAD] [PAD] which medicine can be replaced with idarucizumab?", "[PAD] [PAD] [PAD] what drugs are reversible with idarucizumab?", "which drug can be contraindicated with idarucizumab?", "[PAD] [PAD] which drug can be reversed with idarucizumab?", "[PAD] [PAD] which medicine can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] what medication is reversible with idaruzumab?", "[PAD] [PAD] which medicine can be used against idarucizumab?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which drug can be reversed with administration?", "[PAD] [PAD] which drug can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] which drug can idarucizumab reverse?", "[PAD] [PAD] which medicine can be reversed by idarucizumab?", "[PAD] [PAD] which drug can be reversed by idarucizumab?", "[PAD] [PAD] what drug can be reversed with idarucizumab?", "[PAD] [PAD] what medicine can be reversed with idarucizumab?", "[PAD] [PAD] which medication can be returned to idarucizumab?", "[PAD] [PAD] [PAD] what medicine can be reversed with idaruzumab?", "[PAD] [PAD] which drug can be changed with idarucizumab?", "[PAD] [PAD] which medicine can be reversed with idarucizumab?", "[PAD] [PAD] which drugs can be reversed with idarucizumab?", "[PAD] [PAD] what are the side effects of idarucizumab?", "[PAD] [PAD] what drugs can be reversed with idarucizumab?", "which medicines can be remedied with idarucizumab?", "[PAD] [PAD] [PAD] what drugs can be reversed with idalucizumab?", "[PAD] [PAD] which medicine can be changed with idarucizumab?", "[PAD] [PAD] what drug can be substituted for idarucizumab?", "[PAD] [PAD] [PAD] which medicine can be changed with idarizizumab?", "[PAD] [PAD] which medication can be reversed with idarucizumab?", "[PAD] [PAD] [PAD] which drug can be reversed with idarosizumab?", "[PAD] [PAD] which drug can be discontinued with idarucizumab?", "[PAD] [PAD] what medications can be replaced with idarucizumab?", "[PAD] which drugs can be reversed too? idarucizumab?", "[PAD] [PAD] [PAD] which drug is reversible with idarucizumab?", "[PAD] [PAD] which medicine can be replaced with idarucizumab?", "[PAD] [PAD] [PAD] what drugs are reversible with idarucizumab?", "which drug can be contraindicated with idarucizumab?", "[PAD] [PAD] which drug can be reversed with idarucizumab?", "[PAD] [PAD] which medicine can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] what medication is reversible with idaruzumab?", "[PAD] [PAD] which medicine can be used against idarucizumab?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which drug can be reversed with administration?", "[PAD] [PAD] which drug can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] which drug can idarucizumab reverse?", "[PAD] [PAD] which medicine can be reversed by idarucizumab?", "[PAD] [PAD] which drug can be reversed by idarucizumab?", "[PAD] [PAD] what drug can be reversed with idarucizumab?", "[PAD] [PAD] what medicine can be reversed with idarucizumab?", "[PAD] [PAD] which medication can be returned to idarucizumab?", "[PAD] [PAD] [PAD] what medicine can be reversed with idaruzumab?", "[PAD] [PAD] which drug can be changed with idarucizumab?", "[PAD] [PAD] which medicine can be reversed with idarucizumab?", "[PAD] [PAD] which drugs can be reversed with idarucizumab?", "[PAD] [PAD] what are the side effects of idarucizumab?", "[PAD] [PAD] what drugs can be reversed with idarucizumab?", "which medicines can be remedied with idarucizumab?", "[PAD] [PAD] [PAD] what drugs can be reversed with idalucizumab?", "[PAD] [PAD] which medicine can be changed with idarucizumab?", "[PAD] [PAD] what drug can be substituted for idarucizumab?", "[PAD] [PAD] [PAD] which medicine can be changed with idarizizumab?", "[PAD] [PAD] which medication can be reversed with idarucizumab?", "[PAD] [PAD] [PAD] which drug can be reversed with idarosizumab?", "[PAD] [PAD] which drug can be discontinued with idarucizumab?", "[PAD] [PAD] what medications can be replaced with idarucizumab?", "[PAD] which drugs can be reversed too? idarucizumab?", "[PAD] [PAD] [PAD] which drug is reversible with idarucizumab?", "[PAD] [PAD] which medicine can be replaced with idarucizumab?", "[PAD] [PAD] [PAD] what drugs are reversible with idarucizumab?", "which drug can be contraindicated with idarucizumab?", "[PAD] [PAD] which drug can be reversed with idarucizumab?", "[PAD] [PAD] which medicine can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] what medication is reversible with idaruzumab?", "[PAD] [PAD] which medicine can be used against idarucizumab?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which drug can be reversed with administration?", "[PAD] [PAD] which drug can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] which drug can idarucizumab reverse?", "[PAD] [PAD] which medicine can be reversed by idarucizumab?", "[PAD] [PAD] which drug can be reversed by idarucizumab?", "[PAD] [PAD] what drug can be reversed with idarucizumab?", "[PAD] [PAD] what medicine can be reversed with idarucizumab?", "[PAD] [PAD] which medication can be returned to idarucizumab?", "[PAD] [PAD] [PAD] what medicine can be reversed with idaruzumab?", "[PAD] [PAD] which drug can be changed with idarucizumab?", "[PAD] [PAD] which medicine can be reversed with idarucizumab?", "[PAD] [PAD] which drugs can be reversed with idarucizumab?", "[PAD] [PAD] what are the side effects of idarucizumab?", "[PAD] [PAD] what drugs can be reversed with idarucizumab?", "which medicines can be remedied with idarucizumab?", "[PAD] [PAD] [PAD] what drugs can be reversed with idalucizumab?", "[PAD] [PAD] which medicine can be changed with idarucizumab?", "[PAD] [PAD] what drug can be substituted for idarucizumab?", "[PAD] [PAD] [PAD] which medicine can be changed with idarizizumab?", "[PAD] [PAD] which medication can be reversed with idarucizumab?", "[PAD] [PAD] [PAD] which drug can be reversed with idarosizumab?", "[PAD] [PAD] which drug can be discontinued with idarucizumab?", "[PAD] [PAD] what medications can be replaced with idarucizumab?", "[PAD] which drugs can be reversed too? idarucizumab?", "[PAD] [PAD] [PAD] which drug is reversible with idarucizumab?", "[PAD] [PAD] which medicine can be replaced with idarucizumab?", "[PAD] [PAD] [PAD] what drugs are reversible with idarucizumab?", "which drug can be contraindicated with idarucizumab?", "[PAD] [PAD] which drug can be reversed with idarucizumab?", "[PAD] [PAD] which medicine can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] what medication is reversible with idaruzumab?", "[PAD] [PAD] which medicine can be used against idarucizumab?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which drug can be reversed with administration?", "[PAD] [PAD] which drug can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] which drug can idarucizumab reverse?", "[PAD] [PAD] which medicine can be reversed by idarucizumab?", "[PAD] [PAD] which drug can be reversed by idarucizumab?", "[PAD] [PAD] what drug can be reversed with idarucizumab?", "[PAD] [PAD] what medicine can be reversed with idarucizumab?", "[PAD] [PAD] which medication can be returned to idarucizumab?", "[PAD] [PAD] [PAD] what medicine can be reversed with idaruzumab?", "[PAD] [PAD] which drug can be changed with idarucizumab?", "[PAD] [PAD] which medicine can be reversed with idarucizumab?", "[PAD] [PAD] which drugs can be reversed with idarucizumab?", "[PAD] [PAD] what are the side effects of idarucizumab?", "[PAD] [PAD] what drugs can be reversed with idarucizumab?", "which medicines can be remedied with idarucizumab?", "[PAD] [PAD] [PAD] what drugs can be reversed with idalucizumab?", "[PAD] [PAD] which medicine can be changed with idarucizumab?", "[PAD] [PAD] what drug can be substituted for idarucizumab?", "[PAD] [PAD] [PAD] which medicine can be changed with idarizizumab?", "[PAD] [PAD] which medication can be reversed with idarucizumab?", "[PAD] [PAD] [PAD] which drug can be reversed with idarosizumab?", "[PAD] [PAD] which drug can be discontinued with idarucizumab?", "[PAD] [PAD] what medications can be replaced with idarucizumab?", "[PAD] which drugs can be reversed too? idarucizumab?", "[PAD] [PAD] [PAD] which drug is reversible with idarucizumab?", "[PAD] [PAD] which medicine can be replaced with idarucizumab?", "[PAD] [PAD] [PAD] what drugs are reversible with idarucizumab?", "which drug can be contraindicated with idarucizumab?", "[PAD] [PAD] which drug can be reversed with idarucizumab?", "[PAD] [PAD] which medicine can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] what medication is reversible with idaruzumab?", "[PAD] [PAD] which medicine can be used against idarucizumab?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which drug can be reversed with administration?", "[PAD] [PAD] which drug can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] which drug can idarucizumab reverse?", "[PAD] [PAD] which medicine can be reversed by idarucizumab?", "[PAD] [PAD] which drug can be reversed by idarucizumab?", "[PAD] [PAD] what drug can be reversed with idarucizumab?", "[PAD] [PAD] what medicine can be reversed with idarucizumab?", "[PAD] [PAD] which medication can be returned to idarucizumab?", "[PAD] [PAD] [PAD] what medicine can be reversed with idaruzumab?", "[PAD] [PAD] which drug can be changed with idarucizumab?", "[PAD] [PAD] which medicine can be reversed with idarucizumab?", "[PAD] [PAD] which drugs can be reversed with idarucizumab?", "[PAD] [PAD] what are the side effects of idarucizumab?", "[PAD] [PAD] what drugs can be reversed with idarucizumab?", "which medicines can be remedied with idarucizumab?", "[PAD] [PAD] [PAD] what drugs can be reversed with idalucizumab?", "[PAD] [PAD] which medicine can be changed with idarucizumab?", "[PAD] [PAD] what drug can be substituted for idarucizumab?", "[PAD] [PAD] [PAD] which medicine can be changed with idarizizumab?", "[PAD] [PAD] which medication can be reversed with idarucizumab?", "[PAD] [PAD] [PAD] which drug can be reversed with idarosizumab?", "[PAD] [PAD] which drug can be discontinued with idarucizumab?", "[PAD] [PAD] what medications can be replaced with idarucizumab?", "[PAD] which drugs can be reversed too? idarucizumab?", "[PAD] [PAD] [PAD] which drug is reversible with idarucizumab?", "[PAD] [PAD] which medicine can be replaced with idarucizumab?", "[PAD] [PAD] [PAD] what drugs are reversible with idarucizumab?", "which drug can be contraindicated with idarucizumab?", "[PAD] [PAD] which drug can be reversed with idarucizumab?", "[PAD] [PAD] which medicine can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] what medication is reversible with idaruzumab?", "[PAD] [PAD] which medicine can be used against idarucizumab?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which drug can be reversed with administration?", "[PAD] [PAD] which drug can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] which drug can idarucizumab reverse?", "[PAD] [PAD] which medicine can be reversed by idarucizumab?", "[PAD] [PAD] which drug can be reversed by idarucizumab?", "[PAD] [PAD] what drug can be reversed with idarucizumab?", "[PAD] [PAD] what medicine can be reversed with idarucizumab?", "[PAD] [PAD] which medication can be returned to idarucizumab?", "[PAD] [PAD] [PAD] what medicine can be reversed with idaruzumab?", "[PAD] [PAD] which drug can be changed with idarucizumab?", "[PAD] [PAD] which medicine can be reversed with idarucizumab?", "[PAD] [PAD] which drugs can be reversed with idarucizumab?", "[PAD] [PAD] what are the side effects of idarucizumab?", "[PAD] [PAD] what drugs can be reversed with idarucizumab?", "which medicines can be remedied with idarucizumab?", "[PAD] [PAD] [PAD] what drugs can be reversed with idalucizumab?", "[PAD] [PAD] which medicine can be changed with idarucizumab?", "[PAD] [PAD] what drug can be substituted for idarucizumab?", "[PAD] [PAD] [PAD] which medicine can be changed with idarizizumab?", "[PAD] [PAD] which medication can be reversed with idarucizumab?", "[PAD] [PAD] [PAD] which drug can be reversed with idarosizumab?", "[PAD] [PAD] which drug can be discontinued with idarucizumab?", "[PAD] [PAD] what medications can be replaced with idarucizumab?", "[PAD] which drugs can be reversed too? idarucizumab?", "[PAD] [PAD] [PAD] which drug is reversible with idarucizumab?", "[PAD] [PAD] which medicine can be replaced with idarucizumab?", "[PAD] [PAD] [PAD] what drugs are reversible with idarucizumab?", "which drug can be contraindicated with idarucizumab?", "[PAD] [PAD] which drug can be reversed with idarucizumab?", "[PAD] [PAD] which medicine can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] what medication is reversible with idaruzumab?", "[PAD] [PAD] which medicine can be used against idarucizumab?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which drug can be reversed with administration?", "[PAD] [PAD] which drug can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] which drug can idarucizumab reverse?", "[PAD] [PAD] which medicine can be reversed by idarucizumab?", "[PAD] [PAD] which drug can be reversed by idarucizumab?", "[PAD] [PAD] what drug can be reversed with idarucizumab?", "[PAD] [PAD] what medicine can be reversed with idarucizumab?", "[PAD] [PAD] which medication can be returned to idarucizumab?", "[PAD] [PAD] [PAD] what medicine can be reversed with idaruzumab?", "[PAD] [PAD] which drug can be changed with idarucizumab?", "[PAD] [PAD] which medicine can be reversed with idarucizumab?", "[PAD] [PAD] which drugs can be reversed with idarucizumab?", "[PAD] [PAD] what are the side effects of idarucizumab?", "[PAD] [PAD] what drugs can be reversed with idarucizumab?", "which medicines can be remedied with idarucizumab?", "[PAD] [PAD] [PAD] what drugs can be reversed with idalucizumab?", "[PAD] [PAD] which medicine can be changed with idarucizumab?", "[PAD] [PAD] what drug can be substituted for idarucizumab?", "[PAD] [PAD] [PAD] which medicine can be changed with idarizizumab?", "[PAD] [PAD] which medication can be reversed with idarucizumab?", "[PAD] [PAD] [PAD] which drug can be reversed with idarosizumab?", "[PAD] [PAD] which drug can be discontinued with idarucizumab?", "[PAD] [PAD] what medications can be replaced with idarucizumab?", "[PAD] which drugs can be reversed too? idarucizumab?", "[PAD] [PAD] [PAD] which drug is reversible with idarucizumab?", "[PAD] [PAD] which medicine can be replaced with idarucizumab?", "[PAD] [PAD] [PAD] what drugs are reversible with idarucizumab?", "which drug can be contraindicated with idarucizumab?", "[PAD] [PAD] which drug can be reversed with idarucizumab?", "[PAD] [PAD] which medicine can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] what medication is reversible with idaruzumab?", "[PAD] [PAD] which medicine can be used against idarucizumab?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which drug can be reversed with administration?", "[PAD] [PAD] which drug can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] which drug can idarucizumab reverse?", "[PAD] [PAD] which medicine can be reversed by idarucizumab?", "[PAD] [PAD] which drug can be reversed by idarucizumab?", "[PAD] [PAD] what drug can be reversed with idarucizumab?", "[PAD] [PAD] what medicine can be reversed with idarucizumab?", "[PAD] [PAD] which medication can be returned to idarucizumab?", "[PAD] [PAD] [PAD] what medicine can be reversed with idaruzumab?", "[PAD] [PAD] which drug can be changed with idarucizumab?", "[PAD] [PAD] which medicine can be reversed with idarucizumab?", "[PAD] [PAD] which drugs can be reversed with idarucizumab?", "[PAD] [PAD] what are the side effects of idarucizumab?", "[PAD] [PAD] what drugs can be reversed with idarucizumab?", "which medicines can be remedied with idarucizumab?", "[PAD] [PAD] [PAD] what drugs can be reversed with idalucizumab?", "[PAD] [PAD] which medicine can be changed with idarucizumab?", "[PAD] [PAD] what drug can be substituted for idarucizumab?", "[PAD] [PAD] [PAD] which medicine can be changed with idarizizumab?", "[PAD] [PAD] which medication can be reversed with idarucizumab?", "[PAD] [PAD] [PAD] which drug can be reversed with idarosizumab?", "[PAD] [PAD] which drug can be discontinued with idarucizumab?", "[PAD] [PAD] what medications can be replaced with idarucizumab?", "[PAD] which drugs can be reversed too? idarucizumab?", "[PAD] [PAD] [PAD] which drug is reversible with idarucizumab?", "[PAD] [PAD] which medicine can be replaced with idarucizumab?", "[PAD] [PAD] [PAD] what drugs are reversible with idarucizumab?", "which drug can be contraindicated with idarucizumab?", "[PAD] [PAD] which drug can be reversed with idarucizumab?", "[PAD] [PAD] which medicine can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] what medication is reversible with idaruzumab?", "[PAD] [PAD] which medicine can be used against idarucizumab?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which drug can be reversed with administration?", "[PAD] [PAD] which drug can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] which drug can idarucizumab reverse?", "[PAD] [PAD] which medicine can be reversed by idarucizumab?", "[PAD] [PAD] which drug can be reversed by idarucizumab?", "[PAD] [PAD] what drug can be reversed with idarucizumab?", "[PAD] [PAD] what medicine can be reversed with idarucizumab?", "[PAD] [PAD] which medication can be returned to idarucizumab?", "[PAD] [PAD] [PAD] what medicine can be reversed with idaruzumab?", "[PAD] [PAD] which drug can be changed with idarucizumab?", "[PAD] [PAD] which medicine can be reversed with idarucizumab?", "[PAD] [PAD] which drugs can be reversed with idarucizumab?", "[PAD] [PAD] what are the side effects of idarucizumab?", "[PAD] [PAD] what drugs can be reversed with idarucizumab?", "which medicines can be remedied with idarucizumab?", "[PAD] [PAD] [PAD] what drugs can be reversed with idalucizumab?", "[PAD] [PAD] which medicine can be changed with idarucizumab?", "[PAD] [PAD] what drug can be substituted for idarucizumab?", "[PAD] [PAD] [PAD] which medicine can be changed with idarizizumab?", "[PAD] [PAD] which medication can be reversed with idarucizumab?", "[PAD] [PAD] [PAD] which drug can be reversed with idarosizumab?", "[PAD] [PAD] which drug can be discontinued with idarucizumab?", "[PAD] [PAD] what medications can be replaced with idarucizumab?", "[PAD] which drugs can be reversed too? idarucizumab?", "[PAD] [PAD] [PAD] which drug is reversible with idarucizumab?", "[PAD] [PAD] which medicine can be replaced with idarucizumab?", "[PAD] [PAD] [PAD] what drugs are reversible with idarucizumab?", "which drug can be contraindicated with idarucizumab?", "[PAD] [PAD] which drug can be reversed with idarucizumab?", "[PAD] [PAD] which medicine can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] what medication is reversible with idaruzumab?", "[PAD] [PAD] which medicine can be used against idarucizumab?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which drug can be reversed with administration?", "[PAD] [PAD] which drug can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] which drug can idarucizumab reverse?", "[PAD] [PAD] which medicine can be reversed by idarucizumab?", "[PAD] [PAD] which drug can be reversed by idarucizumab?", "[PAD] [PAD] what drug can be reversed with idarucizumab?", "[PAD] [PAD] what medicine can be reversed with idarucizumab?", "[PAD] [PAD] which medication can be returned to idarucizumab?", "[PAD] [PAD] [PAD] what medicine can be reversed with idaruzumab?", "[PAD] [PAD] which drug can be changed with idarucizumab?", "[PAD] [PAD] which medicine can be reversed with idarucizumab?", "[PAD] [PAD] which drugs can be reversed with idarucizumab?", "[PAD] [PAD] what are the side effects of idarucizumab?", "[PAD] [PAD] what drugs can be reversed with idarucizumab?", "which medicines can be remedied with idarucizumab?", "[PAD] [PAD] [PAD] what drugs can be reversed with idalucizumab?", "[PAD] [PAD] which medicine can be changed with idarucizumab?", "[PAD] [PAD] what drug can be substituted for idarucizumab?", "[PAD] [PAD] [PAD] which medicine can be changed with idarizizumab?", "[PAD] [PAD] which medication can be reversed with idarucizumab?", "[PAD] [PAD] [PAD] which drug can be reversed with idarosizumab?", "[PAD] [PAD] which drug can be discontinued with idarucizumab?", "[PAD] [PAD] what medications can be replaced with idarucizumab?", "[PAD] which drugs can be reversed too? idarucizumab?", "[PAD] [PAD] [PAD] which drug is reversible with idarucizumab?", "[PAD] [PAD] which medicine can be replaced with idarucizumab?", "[PAD] [PAD] [PAD] what drugs are reversible with idarucizumab?", "which drug can be contraindicated with idarucizumab?", "[PAD] [PAD] which drug can be reversed with idarucizumab?", "[PAD] [PAD] which medicine can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] what medication is reversible with idaruzumab?", "[PAD] [PAD] which medicine can be used against idarucizumab?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which drug can be reversed with administration?", "[PAD] [PAD] which drug can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] which drug can idarucizumab reverse?", "[PAD] [PAD] which medicine can be reversed by idarucizumab?", "[PAD] [PAD] which drug can be reversed by idarucizumab?", "[PAD] [PAD] what drug can be reversed with idarucizumab?", "[PAD] [PAD] what medicine can be reversed with idarucizumab?", "[PAD] [PAD] which medication can be returned to idarucizumab?", "[PAD] [PAD] [PAD] what medicine can be reversed with idaruzumab?", "[PAD] [PAD] which drug can be changed with idarucizumab?", "[PAD] [PAD] which medicine can be reversed with idarucizumab?", "[PAD] [PAD] which drugs can be reversed with idarucizumab?", "[PAD] [PAD] what are the side effects of idarucizumab?", "[PAD] [PAD] what drugs can be reversed with idarucizumab?", "which medicines can be remedied with idarucizumab?", "[PAD] [PAD] [PAD] what drugs can be reversed with idalucizumab?", "[PAD] [PAD] which medicine can be changed with idarucizumab?", "[PAD] [PAD] what drug can be substituted for idarucizumab?", "[PAD] [PAD] [PAD] which medicine can be changed with idarizizumab?", "[PAD] [PAD] which medication can be reversed with idarucizumab?", "[PAD] [PAD] [PAD] which drug can be reversed with idarosizumab?", "[PAD] [PAD] which drug can be discontinued with idarucizumab?", "[PAD] [PAD] what medications can be replaced with idarucizumab?", "[PAD] which drugs can be reversed too? idarucizumab?", "[PAD] [PAD] [PAD] which drug is reversible with idarucizumab?", "[PAD] [PAD] which medicine can be replaced with idarucizumab?", "[PAD] [PAD] [PAD] what drugs are reversible with idarucizumab?", "which drug can be contraindicated with idarucizumab?", "[PAD] [PAD] which drug can be reversed with idarucizumab?", "[PAD] [PAD] which medicine can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] what medication is reversible with idaruzumab?", "[PAD] [PAD] which medicine can be used against idarucizumab?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which drug can be reversed with administration?", "[PAD] [PAD] which drug can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] which drug can idarucizumab reverse?", "[PAD] [PAD] which medicine can be reversed by idarucizumab?", "[PAD] [PAD] which drug can be reversed by idarucizumab?", "[PAD] [PAD] what drug can be reversed with idarucizumab?", "[PAD] [PAD] what medicine can be reversed with idarucizumab?", "[PAD] [PAD] which medication can be returned to idarucizumab?", "[PAD] [PAD] [PAD] what medicine can be reversed with idaruzumab?", "[PAD] [PAD] which drug can be changed with idarucizumab?", "[PAD] [PAD] which medicine can be reversed with idarucizumab?", "[PAD] [PAD] which drugs can be reversed with idarucizumab?", "[PAD] [PAD] what are the side effects of idarucizumab?", "[PAD] [PAD] what drugs can be reversed with idarucizumab?", "which medicines can be remedied with idarucizumab?", "[PAD] [PAD] [PAD] what drugs can be reversed with idalucizumab?", "[PAD] [PAD] which medicine can be changed with idarucizumab?", "[PAD] [PAD] what drug can be substituted for idarucizumab?", "[PAD] [PAD] [PAD] which medicine can be changed with idarizizumab?", "[PAD] [PAD] which medication can be reversed with idarucizumab?", "[PAD] [PAD] [PAD] which drug can be reversed with idarosizumab?", "[PAD] [PAD] which drug can be discontinued with idarucizumab?", "[PAD] [PAD] what medications can be replaced with idarucizumab?", "[PAD] which drugs can be reversed too? idarucizumab?", "[PAD] [PAD] [PAD] which drug is reversible with idarucizumab?", "[PAD] [PAD] which medicine can be replaced with idarucizumab?", "[PAD] [PAD] [PAD] what drugs are reversible with idarucizumab?", "which drug can be contraindicated with idarucizumab?", "[PAD] [PAD] which drug can be reversed with idarucizumab?", "[PAD] [PAD] which medicine can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] what medication is reversible with idaruzumab?", "[PAD] [PAD] which medicine can be used against idarucizumab?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which drug can be reversed with administration?", "[PAD] [PAD] which drug can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] which drug can idarucizumab reverse?", "[PAD] [PAD] which medicine can be reversed by idarucizumab?", "[PAD] [PAD] which drug can be reversed by idarucizumab?", "[PAD] [PAD] what drug can be reversed with idarucizumab?", "[PAD] [PAD] what medicine can be reversed with idarucizumab?", "[PAD] [PAD] which medication can be returned to idarucizumab?", "[PAD] [PAD] [PAD] what medicine can be reversed with idaruzumab?", "[PAD] [PAD] which drug can be changed with idarucizumab?", "[PAD] [PAD] which medicine can be reversed with idarucizumab?", "[PAD] [PAD] which drugs can be reversed with idarucizumab?", "[PAD] [PAD] what are the side effects of idarucizumab?", "[PAD] [PAD] what drugs can be reversed with idarucizumab?", "which medicines can be remedied with idarucizumab?", "[PAD] [PAD] [PAD] what drugs can be reversed with idalucizumab?", "[PAD] [PAD] which medicine can be changed with idarucizumab?", "[PAD] [PAD] what drug can be substituted for idarucizumab?", "[PAD] [PAD] [PAD] which medicine can be changed with idarizizumab?", "[PAD] [PAD] which medication can be reversed with idarucizumab?", "[PAD] [PAD] [PAD] which drug can be reversed with idarosizumab?", "[PAD] [PAD] which drug can be discontinued with idarucizumab?", "[PAD] [PAD] what medications can be replaced with idarucizumab?", "[PAD] which drugs can be reversed too? idarucizumab?", "[PAD] [PAD] [PAD] which drug is reversible with idarucizumab?", "[PAD] [PAD] which medicine can be replaced with idarucizumab?", "[PAD] [PAD] [PAD] what drugs are reversible with idarucizumab?", "which drug can be contraindicated with idarucizumab?", "[PAD] [PAD] which drug can be reversed with idarucizumab?", "[PAD] [PAD] which medicine can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] what medication is reversible with idaruzumab?", "[PAD] [PAD] which medicine can be used against idarucizumab?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which drug can be reversed with administration?", "[PAD] [PAD] which drug can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] which drug can idarucizumab reverse?", "[PAD] [PAD] which medicine can be reversed by idarucizumab?", "[PAD] [PAD] which drug can be reversed by idarucizumab?", "[PAD] [PAD] what drug can be reversed with idarucizumab?", "[PAD] [PAD] what medicine can be reversed with idarucizumab?", "[PAD] [PAD] which medication can be returned to idarucizumab?", "[PAD] [PAD] [PAD] what medicine can be reversed with idaruzumab?", "[PAD] [PAD] which drug can be changed with idarucizumab?", "[PAD] [PAD] which medicine can be reversed with idarucizumab?", "[PAD] [PAD] which drugs can be reversed with idarucizumab?", "[PAD] [PAD] what are the side effects of idarucizumab?", "[PAD] [PAD] what drugs can be reversed with idarucizumab?", "which medicines can be remedied with idarucizumab?", "[PAD] [PAD] [PAD] what drugs can be reversed with idalucizumab?", "[PAD] [PAD] which medicine can be changed with idarucizumab?", "[PAD] [PAD] what drug can be substituted for idarucizumab?", "[PAD] [PAD] [PAD] which medicine can be changed with idarizizumab?", "[PAD] [PAD] which medication can be reversed with idarucizumab?", "[PAD] [PAD] [PAD] which drug can be reversed with idarosizumab?", "[PAD] [PAD] which drug can be discontinued with idarucizumab?", "[PAD] [PAD] what medications can be replaced with idarucizumab?", "[PAD] which drugs can be reversed too? idarucizumab?", "[PAD] [PAD] [PAD] which drug is reversible with idarucizumab?", "[PAD] [PAD] which medicine can be replaced with idarucizumab?", "[PAD] [PAD] [PAD] what drugs are reversible with idarucizumab?", "which drug can be contraindicated with idarucizumab?", "[PAD] [PAD] which drug can be reversed with idarucizumab?", "[PAD] [PAD] which medicine can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] what medication is reversible with idaruzumab?", "[PAD] [PAD] which medicine can be used against idarucizumab?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which drug can be reversed with administration?", "[PAD] [PAD] which drug can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] which drug can idarucizumab reverse?", "[PAD] [PAD] which medicine can be reversed by idarucizumab?", "[PAD] [PAD] which drug can be reversed by idarucizumab?", "[PAD] [PAD] what drug can be reversed with idarucizumab?", "[PAD] [PAD] what medicine can be reversed with idarucizumab?", "[PAD] [PAD] which medication can be returned to idarucizumab?", "[PAD] [PAD] [PAD] what medicine can be reversed with idaruzumab?", "[PAD] [PAD] which drug can be changed with idarucizumab?", "[PAD] [PAD] which medicine can be reversed with idarucizumab?", "[PAD] [PAD] which drugs can be reversed with idarucizumab?", "[PAD] [PAD] what are the side effects of idarucizumab?", "[PAD] [PAD] what drugs can be reversed with idarucizumab?", "which medicines can be remedied with idarucizumab?", "[PAD] [PAD] [PAD] what drugs can be reversed with idalucizumab?", "[PAD] [PAD] which medicine can be changed with idarucizumab?", "[PAD] [PAD] what drug can be substituted for idarucizumab?", "[PAD] [PAD] [PAD] which medicine can be changed with idarizizumab?", "[PAD] [PAD] which medication can be reversed with idarucizumab?", "[PAD] [PAD] [PAD] which drug can be reversed with idarosizumab?", "[PAD] [PAD] which drug can be discontinued with idarucizumab?", "[PAD] [PAD] what medications can be replaced with idarucizumab?", "[PAD] which drugs can be reversed too? idarucizumab?", "[PAD] [PAD] [PAD] which drug is reversible with idarucizumab?", "[PAD] [PAD] which medicine can be replaced with idarucizumab?", "[PAD] [PAD] [PAD] what drugs are reversible with idarucizumab?", "which drug can be contraindicated with idarucizumab?", "[PAD] [PAD] which drug can be reversed with idarucizumab?", "[PAD] [PAD] which medicine can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] what medication is reversible with idaruzumab?", "[PAD] [PAD] which medicine can be used against idarucizumab?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which drug can be reversed with administration?", "[PAD] [PAD] which drug can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] which drug can idarucizumab reverse?", "[PAD] [PAD] which medicine can be reversed by idarucizumab?", "[PAD] [PAD] which drug can be reversed by idarucizumab?", "[PAD] [PAD] what drug can be reversed with idarucizumab?", "[PAD] [PAD] what medicine can be reversed with idarucizumab?", "[PAD] [PAD] which medication can be returned to idarucizumab?", "[PAD] [PAD] [PAD] what medicine can be reversed with idaruzumab?", "[PAD] [PAD] which drug can be changed with idarucizumab?", "[PAD] [PAD] which medicine can be reversed with idarucizumab?", "[PAD] [PAD] which drugs can be reversed with idarucizumab?", "[PAD] [PAD] what are the side effects of idarucizumab?", "[PAD] [PAD] what drugs can be reversed with idarucizumab?", "which medicines can be remedied with idarucizumab?", "[PAD] [PAD] [PAD] what drugs can be reversed with idalucizumab?", "[PAD] [PAD] which medicine can be changed with idarucizumab?", "[PAD] [PAD] what drug can be substituted for idarucizumab?", "[PAD] [PAD] [PAD] which medicine can be changed with idarizizumab?", "[PAD] [PAD] which medication can be reversed with idarucizumab?", "[PAD] [PAD] [PAD] which drug can be reversed with idarosizumab?", "[PAD] [PAD] which drug can be discontinued with idarucizumab?", "[PAD] [PAD] what medications can be replaced with idarucizumab?", "[PAD] which drugs can be reversed too? idarucizumab?", "[PAD] [PAD] [PAD] which drug is reversible with idarucizumab?", "[PAD] [PAD] which medicine can be replaced with idarucizumab?", "[PAD] [PAD] [PAD] what drugs are reversible with idarucizumab?", "which drug can be contraindicated with idarucizumab?", "[PAD] [PAD] which drug can be reversed with idarucizumab?", "[PAD] [PAD] which medicine can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] what medication is reversible with idaruzumab?", "[PAD] [PAD] which medicine can be used against idarucizumab?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which drug can be reversed with administration?", "[PAD] [PAD] which drug can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] which drug can idarucizumab reverse?", "[PAD] [PAD] which medicine can be reversed by idarucizumab?", "[PAD] [PAD] which drug can be reversed by idarucizumab?", "[PAD] [PAD] what drug can be reversed with idarucizumab?", "[PAD] [PAD] what medicine can be reversed with idarucizumab?", "[PAD] [PAD] which medication can be returned to idarucizumab?", "[PAD] [PAD] [PAD] what medicine can be reversed with idaruzumab?", "[PAD] [PAD] which drug can be changed with idarucizumab?", "[PAD] [PAD] which medicine can be reversed with idarucizumab?", "[PAD] [PAD] which drugs can be reversed with idarucizumab?", "[PAD] [PAD] what are the side effects of idarucizumab?", "[PAD] [PAD] what drugs can be reversed with idarucizumab?", "which medicines can be remedied with idarucizumab?", "[PAD] [PAD] [PAD] what drugs can be reversed with idalucizumab?", "[PAD] [PAD] which medicine can be changed with idarucizumab?", "[PAD] [PAD] what drug can be substituted for idarucizumab?", "[PAD] [PAD] [PAD] which medicine can be changed with idarizizumab?", "[PAD] [PAD] which medication can be reversed with idarucizumab?", "[PAD] [PAD] [PAD] which drug can be reversed with idarosizumab?", "[PAD] [PAD] which drug can be discontinued with idarucizumab?", "[PAD] [PAD] what medications can be replaced with idarucizumab?", "[PAD] which drugs can be reversed too? idarucizumab?", "[PAD] [PAD] [PAD] which drug is reversible with idarucizumab?", "[PAD] [PAD] which medicine can be replaced with idarucizumab?", "[PAD] [PAD] [PAD] what drugs are reversible with idarucizumab?", "which drug can be contraindicated with idarucizumab?", "[PAD] [PAD] which drug can be reversed with idarucizumab?", "[PAD] [PAD] which medicine can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] what medication is reversible with idaruzumab?", "[PAD] [PAD] which medicine can be used against idarucizumab?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which drug can be reversed with administration?", "[PAD] [PAD] which drug can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] which drug can idarucizumab reverse?", "[PAD] [PAD] which medicine can be reversed by idarucizumab?", "[PAD] [PAD] which drug can be reversed by idarucizumab?", "[PAD] [PAD] what drug can be reversed with idarucizumab?", "[PAD] [PAD] what medicine can be reversed with idarucizumab?", "[PAD] [PAD] which medication can be returned to idarucizumab?", "[PAD] [PAD] [PAD] what medicine can be reversed with idaruzumab?", "[PAD] [PAD] which drug can be changed with idarucizumab?", "[PAD] [PAD] which medicine can be reversed with idarucizumab?", "[PAD] [PAD] which drugs can be reversed with idarucizumab?", "[PAD] [PAD] what are the side effects of idarucizumab?", "[PAD] [PAD] what drugs can be reversed with idarucizumab?", "which medicines can be remedied with idarucizumab?", "[PAD] [PAD] [PAD] what drugs can be reversed with idalucizumab?", "[PAD] [PAD] which medicine can be changed with idarucizumab?", "[PAD] [PAD] what drug can be substituted for idarucizumab?", "[PAD] [PAD] [PAD] which medicine can be changed with idarizizumab?", "[PAD] [PAD] which medication can be reversed with idarucizumab?", "[PAD] [PAD] [PAD] which drug can be reversed with idarosizumab?", "[PAD] [PAD] which drug can be discontinued with idarucizumab?", "[PAD] [PAD] what medications can be replaced with idarucizumab?", "[PAD] which drugs can be reversed too? idarucizumab?", "[PAD] [PAD] [PAD] which drug is reversible with idarucizumab?", "[PAD] [PAD] which medicine can be replaced with idarucizumab?", "[PAD] [PAD] [PAD] what drugs are reversible with idarucizumab?", "which drug can be contraindicated with idarucizumab?", "[PAD] [PAD] which drug can be reversed with idarucizumab?", "[PAD] [PAD] which medicine can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] what medication is reversible with idaruzumab?", "[PAD] [PAD] which medicine can be used against idarucizumab?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which drug can be reversed with administration?", "[PAD] [PAD] which drug can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] which drug can idarucizumab reverse?", "[PAD] [PAD] which medicine can be reversed by idarucizumab?", "[PAD] [PAD] which drug can be reversed by idarucizumab?", "[PAD] [PAD] what drug can be reversed with idarucizumab?", "[PAD] [PAD] what medicine can be reversed with idarucizumab?", "[PAD] [PAD] which medication can be returned to idarucizumab?", "[PAD] [PAD] [PAD] what medicine can be reversed with idaruzumab?", "[PAD] [PAD] which drug can be changed with idarucizumab?", "[PAD] [PAD] which medicine can be reversed with idarucizumab?", "[PAD] [PAD] which drugs can be reversed with idarucizumab?", "[PAD] [PAD] what are the side effects of idarucizumab?", "[PAD] [PAD] what drugs can be reversed with idarucizumab?", "which medicines can be remedied with idarucizumab?", "[PAD] [PAD] [PAD] what drugs can be reversed with idalucizumab?", "[PAD] [PAD] which medicine can be changed with idarucizumab?", "[PAD] [PAD] what drug can be substituted for idarucizumab?", "[PAD] [PAD] [PAD] which medicine can be changed with idarizizumab?", "[PAD] [PAD] which medication can be reversed with idarucizumab?", "[PAD] [PAD] [PAD] which drug can be reversed with idarosizumab?", "[PAD] [PAD] which drug can be discontinued with idarucizumab?", "[PAD] [PAD] what medications can be replaced with idarucizumab?", "[PAD] which drugs can be reversed too? idarucizumab?", "[PAD] [PAD] [PAD] which drug is reversible with idarucizumab?", "[PAD] [PAD] which medicine can be replaced with idarucizumab?", "[PAD] [PAD] [PAD] what drugs are reversible with idarucizumab?", "which drug can be contraindicated with idarucizumab?", "[PAD] [PAD] which drug can be reversed with idarucizumab?", "[PAD] [PAD] which medicine can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] what medication is reversible with idaruzumab?", "[PAD] [PAD] which medicine can be used against idarucizumab?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which drug can be reversed with administration?", "[PAD] [PAD] which drug can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] which drug can idarucizumab reverse?", "[PAD] [PAD] which medicine can be reversed by idarucizumab?", "[PAD] [PAD] which drug can be reversed by idarucizumab?", "[PAD] [PAD] what drug can be reversed with idarucizumab?", "[PAD] [PAD] what medicine can be reversed with idarucizumab?", "[PAD] [PAD] which medication can be returned to idarucizumab?", "[PAD] [PAD] [PAD] what medicine can be reversed with idaruzumab?", "[PAD] [PAD] which drug can be changed with idarucizumab?", "[PAD] [PAD] which medicine can be reversed with idarucizumab?", "[PAD] [PAD] which drugs can be reversed with idarucizumab?", "[PAD] [PAD] what are the side effects of idarucizumab?", "[PAD] [PAD] what drugs can be reversed with idarucizumab?", "which medicines can be remedied with idarucizumab?", "[PAD] [PAD] [PAD] what drugs can be reversed with idalucizumab?", "[PAD] [PAD] which medicine can be changed with idarucizumab?", "[PAD] [PAD] what drug can be substituted for idarucizumab?", "[PAD] [PAD] [PAD] which medicine can be changed with idarizizumab?", "[PAD] [PAD] which medication can be reversed with idarucizumab?", "[PAD] [PAD] [PAD] which drug can be reversed with idarosizumab?", "[PAD] [PAD] which drug can be discontinued with idarucizumab?", "[PAD] [PAD] what medications can be replaced with idarucizumab?", "[PAD] which drugs can be reversed too? idarucizumab?", "[PAD] [PAD] [PAD] which drug is reversible with idarucizumab?", "[PAD] [PAD] which medicine can be replaced with idarucizumab?", "[PAD] [PAD] [PAD] what drugs are reversible with idarucizumab?", "which drug can be contraindicated with idarucizumab?", "[PAD] [PAD] which drug can be reversed with idarucizumab?", "[PAD] [PAD] which medicine can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] what medication is reversible with idaruzumab?", "[PAD] [PAD] which medicine can be used against idarucizumab?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which drug can be reversed with administration?", "[PAD] [PAD] which drug can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] which drug can idarucizumab reverse?", "[PAD] [PAD] which medicine can be reversed by idarucizumab?", "[PAD] [PAD] which drug can be reversed by idarucizumab?", "[PAD] [PAD] what drug can be reversed with idarucizumab?", "[PAD] [PAD] what medicine can be reversed with idarucizumab?", "[PAD] [PAD] which medication can be returned to idarucizumab?", "[PAD] [PAD] [PAD] what medicine can be reversed with idaruzumab?", "[PAD] [PAD] which drug can be changed with idarucizumab?", "[PAD] [PAD] which medicine can be reversed with idarucizumab?", "[PAD] [PAD] which drugs can be reversed with idarucizumab?", "[PAD] [PAD] what are the side effects of idarucizumab?", "[PAD] [PAD] what drugs can be reversed with idarucizumab?", "which medicines can be remedied with idarucizumab?", "[PAD] [PAD] [PAD] what drugs can be reversed with idalucizumab?", "[PAD] [PAD] which medicine can be changed with idarucizumab?", "[PAD] [PAD] what drug can be substituted for idarucizumab?", "[PAD] [PAD] [PAD] which medicine can be changed with idarizizumab?", "[PAD] [PAD] which medication can be reversed with idarucizumab?", "[PAD] [PAD] [PAD] which drug can be reversed with idarosizumab?", "[PAD] [PAD] which drug can be discontinued with idarucizumab?", "[PAD] [PAD] what medications can be replaced with idarucizumab?", "[PAD] which drugs can be reversed too? idarucizumab?", "[PAD] [PAD] [PAD] which drug is reversible with idarucizumab?", "[PAD] [PAD] which medicine can be replaced with idarucizumab?", "[PAD] [PAD] [PAD] what drugs are reversible with idarucizumab?", "which drug can be contraindicated with idarucizumab?", "[PAD] [PAD] which drug can be reversed with idarucizumab?", "[PAD] [PAD] which medicine can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] what medication is reversible with idaruzumab?", "[PAD] [PAD] which medicine can be used against idarucizumab?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which drug can be reversed with administration?", "[PAD] [PAD] which drug can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] which drug can idarucizumab reverse?", "[PAD] [PAD] which medicine can be reversed by idarucizumab?", "[PAD] [PAD] which drug can be reversed by idarucizumab?", "[PAD] [PAD] what drug can be reversed with idarucizumab?", "[PAD] [PAD] what medicine can be reversed with idarucizumab?", "[PAD] [PAD] which medication can be returned to idarucizumab?", "[PAD] [PAD] [PAD] what medicine can be reversed with idaruzumab?", "[PAD] [PAD] which drug can be changed with idarucizumab?", "[PAD] [PAD] which medicine can be reversed with idarucizumab?", "[PAD] [PAD] which drugs can be reversed with idarucizumab?", "[PAD] [PAD] what are the side effects of idarucizumab?", "[PAD] [PAD] what drugs can be reversed with idarucizumab?", "which medicines can be remedied with idarucizumab?", "[PAD] [PAD] [PAD] what drugs can be reversed with idalucizumab?", "[PAD] [PAD] which medicine can be changed with idarucizumab?", "[PAD] [PAD] what drug can be substituted for idarucizumab?", "[PAD] [PAD] [PAD] which medicine can be changed with idarizizumab?", "[PAD] [PAD] which medication can be reversed with idarucizumab?", "[PAD] [PAD] [PAD] which drug can be reversed with idarosizumab?", "[PAD] [PAD] which drug can be discontinued with idarucizumab?", "[PAD] [PAD] what medications can be replaced with idarucizumab?", "[PAD] which drugs can be reversed too? idarucizumab?", "[PAD] [PAD] [PAD] which drug is reversible with idarucizumab?", "[PAD] [PAD] which medicine can be replaced with idarucizumab?", "[PAD] [PAD] [PAD] what drugs are reversible with idarucizumab?", "which drug can be contraindicated with idarucizumab?", "[PAD] [PAD] which drug can be reversed with idarucizumab?", "[PAD] [PAD] which medicine can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] what medication is reversible with idaruzumab?", "[PAD] [PAD] which medicine can be used against idarucizumab?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which drug can be reversed with administration?", "[PAD] [PAD] which drug can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] which drug can idarucizumab reverse?", "[PAD] [PAD] which medicine can be reversed by idarucizumab?", "[PAD] [PAD] which drug can be reversed by idarucizumab?", "[PAD] [PAD] what drug can be reversed with idarucizumab?", "[PAD] [PAD] what medicine can be reversed with idarucizumab?", "[PAD] [PAD] which medication can be returned to idarucizumab?", "[PAD] [PAD] [PAD] what medicine can be reversed with idaruzumab?", "[PAD] [PAD] which drug can be changed with idarucizumab?", "[PAD] [PAD] which medicine can be reversed with idarucizumab?", "[PAD] [PAD] which drugs can be reversed with idarucizumab?", "[PAD] [PAD] what are the side effects of idarucizumab?", "[PAD] [PAD] what drugs can be reversed with idarucizumab?", "which medicines can be remedied with idarucizumab?", "[PAD] [PAD] [PAD] what drugs can be reversed with idalucizumab?", "[PAD] [PAD] which medicine can be changed with idarucizumab?", "[PAD] [PAD] what drug can be substituted for idarucizumab?", "[PAD] [PAD] [PAD] which medicine can be changed with idarizizumab?", "[PAD] [PAD] which medication can be reversed with idarucizumab?", "[PAD] [PAD] [PAD] which drug can be reversed with idarosizumab?", "[PAD] [PAD] which drug can be discontinued with idarucizumab?", "[PAD] [PAD] what medications can be replaced with idarucizumab?", "[PAD] which drugs can be reversed too? idarucizumab?", "[PAD] [PAD] [PAD] which drug is reversible with idarucizumab?", "[PAD] [PAD] which medicine can be replaced with idarucizumab?", "[PAD] [PAD] [PAD] what drugs are reversible with idarucizumab?", "which drug can be contraindicated with idarucizumab?", "[PAD] [PAD] which drug can be reversed with idarucizumab?", "[PAD] [PAD] which medicine can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] what medication is reversible with idaruzumab?", "[PAD] [PAD] which medicine can be used against idarucizumab?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which drug can be reversed with administration?", "[PAD] [PAD] which drug can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] which drug can idarucizumab reverse?", "[PAD] [PAD] which medicine can be reversed by idarucizumab?", "[PAD] [PAD] which drug can be reversed by idarucizumab?", "[PAD] [PAD] what drug can be reversed with idarucizumab?", "[PAD] [PAD] what medicine can be reversed with idarucizumab?", "[PAD] [PAD] which medication can be returned to idarucizumab?", "[PAD] [PAD] [PAD] what medicine can be reversed with idaruzumab?", "[PAD] [PAD] which drug can be changed with idarucizumab?", "[PAD] [PAD] which medicine can be reversed with idarucizumab?", "[PAD] [PAD] which drugs can be reversed with idarucizumab?", "[PAD] [PAD] what are the side effects of idarucizumab?", "[PAD] [PAD] what drugs can be reversed with idarucizumab?", "which medicines can be remedied with idarucizumab?", "[PAD] [PAD] [PAD] what drugs can be reversed with idalucizumab?", "[PAD] [PAD] which medicine can be changed with idarucizumab?", "[PAD] [PAD] what drug can be substituted for idarucizumab?", "[PAD] [PAD] [PAD] which medicine can be changed with idarizizumab?", "[PAD] [PAD] which medication can be reversed with idarucizumab?", "[PAD] [PAD] [PAD] which drug can be reversed with idarosizumab?", "[PAD] [PAD] which drug can be discontinued with idarucizumab?", "[PAD] [PAD] what medications can be replaced with idarucizumab?", "[PAD] which drugs can be reversed too? idarucizumab?", "[PAD] [PAD] [PAD] which drug is reversible with idarucizumab?", "[PAD] [PAD] which medicine can be replaced with idarucizumab?", "[PAD] [PAD] [PAD] what drugs are reversible with idarucizumab?", "which drug can be contraindicated with idarucizumab?", "[PAD] [PAD] which drug can be reversed with idarucizumab?", "[PAD] [PAD] which medicine can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] what medication is reversible with idaruzumab?", "[PAD] [PAD] which medicine can be used against idarucizumab?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which drug can be reversed with administration?", "[PAD] [PAD] which drug can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] which drug can idarucizumab reverse?", "[PAD] [PAD] which medicine can be reversed by idarucizumab?", "[PAD] [PAD] which drug can be reversed by idarucizumab?", "[PAD] [PAD] what drug can be reversed with idarucizumab?", "[PAD] [PAD] what medicine can be reversed with idarucizumab?", "[PAD] [PAD] which medication can be returned to idarucizumab?", "[PAD] [PAD] [PAD] what medicine can be reversed with idaruzumab?", "[PAD] [PAD] which drug can be changed with idarucizumab?", "[PAD] [PAD] which medicine can be reversed with idarucizumab?", "[PAD] [PAD] which drugs can be reversed with idarucizumab?", "[PAD] [PAD] what are the side effects of idarucizumab?", "[PAD] [PAD] what drugs can be reversed with idarucizumab?", "which medicines can be remedied with idarucizumab?", "[PAD] [PAD] [PAD] what drugs can be reversed with idalucizumab?", "[PAD] [PAD] which medicine can be changed with idarucizumab?", "[PAD] [PAD] what drug can be substituted for idarucizumab?", "[PAD] [PAD] [PAD] which medicine can be changed with idarizizumab?", "[PAD] [PAD] which medication can be reversed with idarucizumab?", "[PAD] [PAD] [PAD] which drug can be reversed with idarosizumab?", "[PAD] [PAD] which drug can be discontinued with idarucizumab?", "[PAD] [PAD] what medications can be replaced with idarucizumab?", "[PAD] which drugs can be reversed too? idarucizumab?", "[PAD] [PAD] [PAD] which drug is reversible with idarucizumab?", "[PAD] [PAD] which medicine can be replaced with idarucizumab?", "[PAD] [PAD] [PAD] what drugs are reversible with idarucizumab?", "which drug can be contraindicated with idarucizumab?", "[PAD] [PAD] which drug can be reversed with idarucizumab?", "[PAD] [PAD] which medicine can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] what medication is reversible with idaruzumab?", "[PAD] [PAD] which medicine can be used against idarucizumab?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which drug can be reversed with administration?", "[PAD] [PAD] which drug can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] which drug can idarucizumab reverse?", "[PAD] [PAD] which medicine can be reversed by idarucizumab?", "[PAD] [PAD] which drug can be reversed by idarucizumab?", "[PAD] [PAD] what drug can be reversed with idarucizumab?", "[PAD] [PAD] what medicine can be reversed with idarucizumab?", "[PAD] [PAD] which medication can be returned to idarucizumab?", "[PAD] [PAD] [PAD] what medicine can be reversed with idaruzumab?", "[PAD] [PAD] which drug can be changed with idarucizumab?", "[PAD] [PAD] which medicine can be reversed with idarucizumab?", "[PAD] [PAD] which drugs can be reversed with idarucizumab?", "[PAD] [PAD] what are the side effects of idarucizumab?", "[PAD] [PAD] what drugs can be reversed with idarucizumab?", "which medicines can be remedied with idarucizumab?", "[PAD] [PAD] [PAD] what drugs can be reversed with idalucizumab?", "[PAD] [PAD] which medicine can be changed with idarucizumab?", "[PAD] [PAD] what drug can be substituted for idarucizumab?", "[PAD] [PAD] [PAD] which medicine can be changed with idarizizumab?", "[PAD] [PAD] which medication can be reversed with idarucizumab?", "[PAD] [PAD] [PAD] which drug can be reversed with idarosizumab?", "[PAD] [PAD] which drug can be discontinued with idarucizumab?", "[PAD] [PAD] what medications can be replaced with idarucizumab?", "[PAD] which drugs can be reversed too? idarucizumab?", "[PAD] [PAD] [PAD] which drug is reversible with idarucizumab?", "[PAD] [PAD] which medicine can be replaced with idarucizumab?", "[PAD] [PAD] [PAD] what drugs are reversible with idarucizumab?", "which drug can be contraindicated with idarucizumab?", "[PAD] [PAD] which drug can be reversed with idarucizumab?", "[PAD] [PAD] which medicine can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] what medication is reversible with idaruzumab?", "[PAD] [PAD] which medicine can be used against idarucizumab?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which drug can be reversed with administration?", "[PAD] [PAD] which drug can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] which drug can idarucizumab reverse?", "[PAD] [PAD] which medicine can be reversed by idarucizumab?", "[PAD] [PAD] which drug can be reversed by idarucizumab?", "[PAD] [PAD] what drug can be reversed with idarucizumab?", "[PAD] [PAD] what medicine can be reversed with idarucizumab?", "[PAD] [PAD] which medication can be returned to idarucizumab?", "[PAD] [PAD] [PAD] what medicine can be reversed with idaruzumab?", "[PAD] [PAD] which drug can be changed with idarucizumab?", "[PAD] [PAD] which medicine can be reversed with idarucizumab?", "[PAD] [PAD] which drugs can be reversed with idarucizumab?", "[PAD] [PAD] what are the side effects of idarucizumab?", "[PAD] [PAD] what drugs can be reversed with idarucizumab?", "which medicines can be remedied with idarucizumab?", "[PAD] [PAD] [PAD] what drugs can be reversed with idalucizumab?", "[PAD] [PAD] which medicine can be changed with idarucizumab?", "[PAD] [PAD] what drug can be substituted for idarucizumab?", "[PAD] [PAD] [PAD] which medicine can be changed with idarizizumab?", "[PAD] [PAD] which medication can be reversed with idarucizumab?", "[PAD] [PAD] [PAD] which drug can be reversed with idarosizumab?", "[PAD] [PAD] which drug can be discontinued with idarucizumab?", "[PAD] [PAD] what medications can be replaced with idarucizumab?", "[PAD] which drugs can be reversed too? idarucizumab?", "[PAD] [PAD] [PAD] which drug is reversible with idarucizumab?", "[PAD] [PAD] which medicine can be replaced with idarucizumab?", "[PAD] [PAD] [PAD] what drugs are reversible with idarucizumab?", "which drug can be contraindicated with idarucizumab?", "[PAD] [PAD] which drug can be reversed with idarucizumab?", "[PAD] [PAD] which medicine can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] what medication is reversible with idaruzumab?", "[PAD] [PAD] which medicine can be used against idarucizumab?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which drug can be reversed with administration?", "[PAD] [PAD] which drug can be canceled with idarucizumab?", "[PAD] [PAD] [PAD] [PAD] which drug can idarucizumab reverse?", "[PAD] [PAD] which medicine can be reversed by idarucizumab?", "[PAD] [PAD] which drug can be reversed by idarucizumab?", "[PAD] [PAD] what drug can be reversed with idarucizumab?", "[PAD] [PAD] what medicine can be reversed with idarucizumab?", "[PAD] [PAD] which medication can be returned to idarucizumab?", "[PAD] [PAD] [PAD] what medicine can be reversed with idaruzumab?", "[PAD] [PAD] which drug can be changed with idarucizumab?", "[PAD] [PAD] which medicine can be reversed with idarucizumab?", "[PAD] [PAD] which drugs can be reversed with idarucizumab?", "[PAD] [PAD] what are the side effects of idarucizumab?", "[PAD] [PAD] what drugs can be reversed with idarucizumab?", "which medicines can be remedied with idarucizumab?", "[PAD] [PAD] [PAD] what drugs can be reversed with idalucizumab?", "[PAD] [PAD] which medicine can be changed with idarucizumab?", "[PAD] [PAD] what drug can be substituted for idarucizumab?", "[PAD] [PAD] [PAD] which medicine can be changed with idarizizumab?", "[PAD] [PAD] which medication can be reversed with idarucizumab?", "[PAD] [PAD] [PAD] which drug can be reversed with idarosizumab?", "[PAD] [PAD] which drug can be discontinued with idarucizumab?", "[PAD] [PAD] what medications can be replaced with idarucizumab?", "[PAD] which drugs can be reversed too? idarucizumab?", "[PAD] [PAD] [PAD] which drug is reversible with idarucizumab?", "[PAD] [PAD] which medicine can be replaced with idarucizumab?", "[PAD] [PAD] [PAD] what drugs are reversible with idarucizumab?", "which drug can be contraindicated with idarucizumab?", "[PAD] [PAD] what causes \"puffy hand syndrome\"?", "[PAD] [PAD] [PAD] what causes \"swollen hands syndrome\"?", "[PAD] [PAD] [PAD] [PAD] [PAD] what causes swollen hand syndrome?", "[PAD] [PAD] [PAD] what causes \"swollen hand syndrome\"?", "[PAD] [PAD] [PAD] what causes \u201cswollen arm syndrome\u201d?", "[PAD] what causes \"bloated hand syndrome\"?", "[PAD] [PAD] [PAD] what causes \"blown arm syndrome\"?", "[PAD] [PAD] [PAD] [PAD] what causes poppy hand syndrome?", "[PAD] [PAD] [PAD] [PAD] what causes puffy hand syndrome?", "what are the causes of \"swollen hand syndrome\"?", "[PAD] [PAD] what causes \"buffy hand syndrome\"?", "[PAD] [PAD] [PAD] what causes \"swollen arm syndrome\"?", "[PAD] what causes 'bloated arm syndrome'?", "[PAD] what causes \"bloated arm syndrome\"?", "[PAD] [PAD] [PAD] [PAD] what caused \"swollen hands\"?", "[PAD] [PAD] what causes \"plump arm syndrome\"?", "[PAD] [PAD] what causes \"puffy hand syndrome\"?", "[PAD] [PAD] [PAD] what causes \"swollen hands syndrome\"?", "[PAD] [PAD] [PAD] [PAD] [PAD] what causes swollen hand syndrome?", "[PAD] [PAD] [PAD] what causes \"swollen hand syndrome\"?", "[PAD] [PAD] [PAD] what causes \u201cswollen arm syndrome\u201d?", "[PAD] what causes \"bloated hand syndrome\"?", "[PAD] [PAD] [PAD] what causes \"blown arm syndrome\"?", "[PAD] [PAD] [PAD] [PAD] what causes poppy hand syndrome?", "[PAD] [PAD] [PAD] [PAD] what causes puffy hand syndrome?", "what are the causes of \"swollen hand syndrome\"?", "[PAD] [PAD] what causes \"buffy hand syndrome\"?", "[PAD] [PAD] [PAD] what causes \"swollen arm syndrome\"?", "[PAD] what causes 'bloated arm syndrome'?", "[PAD] what causes \"bloated arm syndrome\"?", "[PAD] [PAD] [PAD] [PAD] what caused \"swollen hands\"?", "[PAD] [PAD] what causes \"plump arm syndrome\"?", "[PAD] [PAD] what causes \"puffy hand syndrome\"?", "[PAD] [PAD] [PAD] what causes \"swollen hands syndrome\"?", "[PAD] [PAD] [PAD] [PAD] [PAD] what causes swollen hand syndrome?", "[PAD] [PAD] [PAD] what causes \"swollen hand syndrome\"?", "[PAD] [PAD] [PAD] what causes \u201cswollen arm syndrome\u201d?", "[PAD] what causes \"bloated hand syndrome\"?", "[PAD] [PAD] [PAD] what causes \"blown arm syndrome\"?", "[PAD] [PAD] [PAD] [PAD] what causes poppy hand syndrome?", "[PAD] [PAD] [PAD] [PAD] what causes puffy hand syndrome?", "what are the causes of \"swollen hand syndrome\"?", "[PAD] [PAD] what causes \"buffy hand syndrome\"?", "[PAD] [PAD] [PAD] what causes \"swollen arm syndrome\"?", "[PAD] what causes 'bloated arm syndrome'?", "[PAD] what causes \"bloated arm syndrome\"?", "[PAD] [PAD] [PAD] [PAD] what caused \"swollen hands\"?", "[PAD] [PAD] what causes \"plump arm syndrome\"?", "[PAD] [PAD] what causes \"puffy hand syndrome\"?", "[PAD] [PAD] [PAD] what causes \"swollen hands syndrome\"?", "[PAD] [PAD] [PAD] [PAD] [PAD] what causes swollen hand syndrome?", "[PAD] [PAD] [PAD] what causes \"swollen hand syndrome\"?", "[PAD] [PAD] [PAD] what causes \u201cswollen arm syndrome\u201d?", "[PAD] what causes \"bloated hand syndrome\"?", "[PAD] [PAD] [PAD] what causes \"blown arm syndrome\"?", "[PAD] [PAD] [PAD] [PAD] what causes poppy hand syndrome?", "[PAD] [PAD] [PAD] [PAD] what causes puffy hand syndrome?", "what are the causes of \"swollen hand syndrome\"?", "[PAD] [PAD] what causes \"buffy hand syndrome\"?", "[PAD] [PAD] [PAD] what causes \"swollen arm syndrome\"?", "[PAD] what causes 'bloated arm syndrome'?", "[PAD] what causes \"bloated arm syndrome\"?", "[PAD] [PAD] [PAD] [PAD] what caused \"swollen hands\"?", "[PAD] [PAD] what causes \"plump arm syndrome\"?", "[PAD] [PAD] what causes \"puffy hand syndrome\"?", "[PAD] [PAD] [PAD] what causes \"swollen hands syndrome\"?", "[PAD] [PAD] [PAD] [PAD] [PAD] what causes swollen hand syndrome?", "[PAD] [PAD] [PAD] what causes \"swollen hand syndrome\"?", "[PAD] [PAD] [PAD] what causes \u201cswollen arm syndrome\u201d?", "[PAD] what causes \"bloated hand syndrome\"?", "[PAD] [PAD] [PAD] what causes \"blown arm syndrome\"?", "[PAD] [PAD] [PAD] [PAD] what causes poppy hand syndrome?", "[PAD] [PAD] [PAD] [PAD] what causes puffy hand syndrome?", "what are the causes of \"swollen hand syndrome\"?", "[PAD] [PAD] what causes \"buffy hand syndrome\"?", "[PAD] [PAD] [PAD] what causes \"swollen arm syndrome\"?", "[PAD] what causes 'bloated arm syndrome'?", "[PAD] what causes \"bloated arm syndrome\"?", "[PAD] [PAD] [PAD] [PAD] what caused \"swollen hands\"?", "[PAD] [PAD] what causes \"plump arm syndrome\"?", "[PAD] what is the most common histological diagnosis of \"butterfly glioma\"?", "[PAD] what is the most common histological diagnosis of 'butterfly glioma'?", "[PAD] [PAD] what histological diagnosis of \u201cbutterfly glioma\u201d is most common?", "[PAD] what is the most common histological diagnosis of \u201cbutterfly glioma\u201d?", "what is the most common histologic diagnosis of \"butterfly glioma\"?", "what is the most common histological diagnosis of \"butterfly glioblastoma\"?", "[PAD] [PAD] [PAD] what is the most common histological diagnosis of butterfly glioma?", "[PAD] what is the most common historical diagnosis of a \"butterfly glioma\"?", "[PAD] what is the most common histological diagnosis of \"butterfly glioma\"?", "[PAD] what is the most common histological diagnosis of 'butterfly glioma'?", "[PAD] [PAD] what histological diagnosis of \u201cbutterfly glioma\u201d is most common?", "[PAD] what is the most common histological diagnosis of \u201cbutterfly glioma\u201d?", "what is the most common histologic diagnosis of \"butterfly glioma\"?", "what is the most common histological diagnosis of \"butterfly glioblastoma\"?", "[PAD] [PAD] [PAD] what is the most common histological diagnosis of butterfly glioma?", "[PAD] what is the most common historical diagnosis of a \"butterfly glioma\"?", "[PAD] what is the most common histological diagnosis of \"butterfly glioma\"?", "[PAD] what is the most common histological diagnosis of 'butterfly glioma'?", "[PAD] [PAD] what histological diagnosis of \u201cbutterfly glioma\u201d is most common?", "[PAD] what is the most common histological diagnosis of \u201cbutterfly glioma\u201d?", "what is the most common histologic diagnosis of \"butterfly glioma\"?", "what is the most common histological diagnosis of \"butterfly glioblastoma\"?", "[PAD] [PAD] [PAD] what is the most common histological diagnosis of butterfly glioma?", "[PAD] what is the most common historical diagnosis of a \"butterfly glioma\"?", "[PAD] what is the most common histological diagnosis of \"butterfly glioma\"?", "[PAD] what is the most common histological diagnosis of 'butterfly glioma'?", "[PAD] [PAD] what histological diagnosis of \u201cbutterfly glioma\u201d is most common?", "[PAD] what is the most common histological diagnosis of \u201cbutterfly glioma\u201d?", "what is the most common histologic diagnosis of \"butterfly glioma\"?", "what is the most common histological diagnosis of \"butterfly glioblastoma\"?", "[PAD] [PAD] [PAD] what is the most common histological diagnosis of butterfly glioma?", "[PAD] what is the most common historical diagnosis of a \"butterfly glioma\"?", "[PAD] what is the most common histological diagnosis of \"butterfly glioma\"?", "[PAD] what is the most common histological diagnosis of 'butterfly glioma'?", "[PAD] [PAD] what histological diagnosis of \u201cbutterfly glioma\u201d is most common?", "[PAD] what is the most common histological diagnosis of \u201cbutterfly glioma\u201d?", "what is the most common histologic diagnosis of \"butterfly glioma\"?", "what is the most common histological diagnosis of \"butterfly glioblastoma\"?", "[PAD] [PAD] [PAD] what is the most common histological diagnosis of butterfly glioma?", "[PAD] what is the most common historical diagnosis of a \"butterfly glioma\"?", "[PAD] what is the most common histological diagnosis of \"butterfly glioma\"?", "[PAD] what is the most common histological diagnosis of 'butterfly glioma'?", "[PAD] [PAD] what histological diagnosis of \u201cbutterfly glioma\u201d is most common?", "[PAD] what is the most common histological diagnosis of \u201cbutterfly glioma\u201d?", "what is the most common histologic diagnosis of \"butterfly glioma\"?", "what is the most common histological diagnosis of \"butterfly glioblastoma\"?", "[PAD] [PAD] [PAD] what is the most common histological diagnosis of butterfly glioma?", "[PAD] what is the most common historical diagnosis of a \"butterfly glioma\"?", "[PAD] what is the most common histological diagnosis of \"butterfly glioma\"?", "[PAD] what is the most common histological diagnosis of 'butterfly glioma'?", "[PAD] [PAD] what histological diagnosis of \u201cbutterfly glioma\u201d is most common?", "[PAD] what is the most common histological diagnosis of \u201cbutterfly glioma\u201d?", "what is the most common histologic diagnosis of \"butterfly glioma\"?", "what is the most common histological diagnosis of \"butterfly glioblastoma\"?", "[PAD] [PAD] [PAD] what is the most common histological diagnosis of butterfly glioma?", "[PAD] what is the most common historical diagnosis of a \"butterfly glioma\"?", "[PAD] what is the most common histological diagnosis of \"butterfly glioma\"?", "[PAD] what is the most common histological diagnosis of 'butterfly glioma'?", "[PAD] [PAD] what histological diagnosis of \u201cbutterfly glioma\u201d is most common?", "[PAD] what is the most common histological diagnosis of \u201cbutterfly glioma\u201d?", "what is the most common histologic diagnosis of \"butterfly glioma\"?", "what is the most common histological diagnosis of \"butterfly glioblastoma\"?", "[PAD] [PAD] [PAD] what is the most common histological diagnosis of butterfly glioma?", "[PAD] what is the most common historical diagnosis of a \"butterfly glioma\"?", "[PAD] what is the most common histological diagnosis of \"butterfly glioma\"?", "[PAD] what is the most common histological diagnosis of 'butterfly glioma'?", "[PAD] [PAD] what histological diagnosis of \u201cbutterfly glioma\u201d is most common?", "[PAD] what is the most common histological diagnosis of \u201cbutterfly glioma\u201d?", "what is the most common histologic diagnosis of \"butterfly glioma\"?", "what is the most common histological diagnosis of \"butterfly glioblastoma\"?", "[PAD] [PAD] [PAD] what is the most common histological diagnosis of butterfly glioma?", "[PAD] what is the most common historical diagnosis of a \"butterfly glioma\"?", "[PAD] what is the most common histological diagnosis of \"butterfly glioma\"?", "[PAD] what is the most common histological diagnosis of 'butterfly glioma'?", "[PAD] [PAD] what histological diagnosis of \u201cbutterfly glioma\u201d is most common?", "[PAD] what is the most common histological diagnosis of \u201cbutterfly glioma\u201d?", "what is the most common histologic diagnosis of \"butterfly glioma\"?", "what is the most common histological diagnosis of \"butterfly glioblastoma\"?", "[PAD] [PAD] [PAD] what is the most common histological diagnosis of butterfly glioma?", "[PAD] what is the most common historical diagnosis of a \"butterfly glioma\"?", "[PAD] [PAD] which workflow in bioconductor has been developed for accessing human rna-seq samples?", "[PAD] [PAD] [PAD] [PAD] what workflow in bioconductor was developed for access to human rna sequence samples?", "[PAD] [PAD] [PAD] [PAD] what workflow in bioconductor has been developed to access human seq rna samples?", "[PAD] [PAD] what is the workflow of a bioconductor developed to access human rna-seq samples?", "[PAD] [PAD] [PAD] what workflow was developed in the bioconductor to access human rna-seq samples?", "[PAD] [PAD] [PAD] [PAD] [PAD] what workflow has been developed in bioconductor to access human rna segments?", "[PAD] [PAD] what workflow has been developed in the bioconductor to access human rna-seq samples?", "[PAD] [PAD] [PAD] what workflow in bioconductor has been designed to access human rna-seq samples?", "[PAD] [PAD] [PAD] [PAD] which workflow in bioconductor is designed to access human rna-seq samples?", "[PAD] [PAD] [PAD] what workflow in bioconductor has been developed to access human rna-seq samples?", "[PAD] [PAD] [PAD] which workflow in bioconductor has been developed to access human rna-seq samples?", "[PAD] [PAD] what workflow in the bioconductor has been developed to access human rna-seq samples?", "[PAD] [PAD] [PAD] [PAD] what workflow at bioconductor was developed to access human rna-seq samples?", "[PAD] [PAD] [PAD] [PAD] what workflow in bioconductor is designed to access human rna-seq samples?", "[PAD] [PAD] [PAD] [PAD] which bioconductor workflow was developed for accessing human rna-seq samples?", "[PAD] [PAD] [PAD] [PAD] what bioconductor workflow has been developed to obtain human rna-seq samples?", "[PAD] [PAD] [PAD] which workflow was created in the bioconductor to access human rna-seq samples?", "[PAD] [PAD] [PAD] [PAD] what workflow in bioconductor was designed to access human rna-seq samples?", "[PAD] [PAD] [PAD] [PAD] what bioconductor workflows have been developed to access human rna-seq samples?", "[PAD] [PAD] [PAD] what workflow in bioconductor was developed for access to human rna-seq samples?", "[PAD] [PAD] [PAD] [PAD] which workflow is developed in bioconductor to access human rna-seq samples?", "[PAD] [PAD] [PAD] [PAD] which bioconductor workflow has been developed to achieve human rna-seq samples?", "[PAD] [PAD] which workflows in bioconductors have been developed to access human rna-seq samples?", "[PAD] [PAD] [PAD] [PAD] what workflow in biomass is developed to access human rna-seq samples?", "[PAD] [PAD] [PAD] what workflow in bioconductor was developed for accessing human rna-seq samples?", "[PAD] [PAD] [PAD] [PAD] [PAD] which bioconductor workflow was developed to access human rna-seq samples?", "[PAD] [PAD] [PAD] what is the workflow for bioconductor developed to access human rna-seq samples?", "[PAD] [PAD] [PAD] [PAD] [PAD] which bioconductor workflow is designed to access human rna-seq samples?", "[PAD] [PAD] [PAD] [PAD] [PAD] which bioconductor workflow was developed to achieve human rna-seq samples?", "[PAD] [PAD] which workflow in bioconductors has been developed to access human rna-seq samples?", "[PAD] what workflow in the bioconductor has been developed for access to human rna-seq samples?", "[PAD] [PAD] [PAD] which workflow in the bioconductor was created to access human rna-seq samples?", "[PAD] [PAD] what workflow in bioconductor has been developed for accessing human rna-seq samples?", "[PAD] [PAD] [PAD] what workflow has been developed at bioconductor to access human rna sequencing samples?", "[PAD] [PAD] what workflow in the bioconductor has been developed to access human rna-sec samples?", "[PAD] [PAD] [PAD] [PAD] what bioconductor workflow has been developed to access human rna-seq samples?", "[PAD] [PAD] [PAD] [PAD] what workflow in bioconductor was developed to access human rna-seq samples?", "[PAD] [PAD] [PAD] what functional flow in bioconductor has been developed for obtaining human rna-seq samples?", "[PAD] [PAD] [PAD] [PAD] what workflow in bioconductor has been developed to access human rna seq samples?", "[PAD] [PAD] what workflows in bioconductor have been developed for accessing human rna-seq samples?", "[PAD] [PAD] [PAD] what workflow has been developed in bioconductor to access human rna-seq samples?", "[PAD] [PAD] which workflow has been developed in bioconductor for access to human rna-seq samples?", "what workflow in bio-conductors has been developed for accessing human rna-seq samples?", "[PAD] what workflow in bioconductor has been developed for accessing samples of human rna-sec?", "[PAD] [PAD] which workflow in bioconductor has been developed for accessing human rna-seq samples?", "[PAD] [PAD] [PAD] [PAD] what workflow in bioconductor was developed for access to human rna sequence samples?", "[PAD] [PAD] [PAD] [PAD] what workflow in bioconductor has been developed to access human seq rna samples?", "[PAD] [PAD] what is the workflow of a bioconductor developed to access human rna-seq samples?", "[PAD] [PAD] [PAD] what workflow was developed in the bioconductor to access human rna-seq samples?", "[PAD] [PAD] [PAD] [PAD] [PAD] what workflow has been developed in bioconductor to access human rna segments?", "[PAD] [PAD] what workflow has been developed in the bioconductor to access human rna-seq samples?", "[PAD] [PAD] [PAD] what workflow in bioconductor has been designed to access human rna-seq samples?", "[PAD] [PAD] [PAD] [PAD] which workflow in bioconductor is designed to access human rna-seq samples?", "[PAD] [PAD] [PAD] what workflow in bioconductor has been developed to access human rna-seq samples?", "[PAD] [PAD] [PAD] which workflow in bioconductor has been developed to access human rna-seq samples?", "[PAD] [PAD] what workflow in the bioconductor has been developed to access human rna-seq samples?", "[PAD] [PAD] [PAD] [PAD] what workflow at bioconductor was developed to access human rna-seq samples?", "[PAD] [PAD] [PAD] [PAD] what workflow in bioconductor is designed to access human rna-seq samples?", "[PAD] [PAD] [PAD] [PAD] which bioconductor workflow was developed for accessing human rna-seq samples?", "[PAD] [PAD] [PAD] [PAD] what bioconductor workflow has been developed to obtain human rna-seq samples?", "[PAD] [PAD] [PAD] which workflow was created in the bioconductor to access human rna-seq samples?", "[PAD] [PAD] [PAD] [PAD] what workflow in bioconductor was designed to access human rna-seq samples?", "[PAD] [PAD] [PAD] [PAD] what bioconductor workflows have been developed to access human rna-seq samples?", "[PAD] [PAD] [PAD] what workflow in bioconductor was developed for access to human rna-seq samples?", "[PAD] [PAD] [PAD] [PAD] which workflow is developed in bioconductor to access human rna-seq samples?", "[PAD] [PAD] [PAD] [PAD] which bioconductor workflow has been developed to achieve human rna-seq samples?", "[PAD] [PAD] which workflows in bioconductors have been developed to access human rna-seq samples?", "[PAD] [PAD] [PAD] [PAD] what workflow in biomass is developed to access human rna-seq samples?", "[PAD] [PAD] [PAD] what workflow in bioconductor was developed for accessing human rna-seq samples?", "[PAD] [PAD] [PAD] [PAD] [PAD] which bioconductor workflow was developed to access human rna-seq samples?", "[PAD] [PAD] [PAD] what is the workflow for bioconductor developed to access human rna-seq samples?", "[PAD] [PAD] [PAD] [PAD] [PAD] which bioconductor workflow is designed to access human rna-seq samples?", "[PAD] [PAD] [PAD] [PAD] [PAD] which bioconductor workflow was developed to achieve human rna-seq samples?", "[PAD] [PAD] which workflow in bioconductors has been developed to access human rna-seq samples?", "[PAD] what workflow in the bioconductor has been developed for access to human rna-seq samples?", "[PAD] [PAD] [PAD] which workflow in the bioconductor was created to access human rna-seq samples?", "[PAD] [PAD] what workflow in bioconductor has been developed for accessing human rna-seq samples?", "[PAD] [PAD] [PAD] what workflow has been developed at bioconductor to access human rna sequencing samples?", "[PAD] [PAD] what workflow in the bioconductor has been developed to access human rna-sec samples?", "[PAD] [PAD] [PAD] [PAD] what bioconductor workflow has been developed to access human rna-seq samples?", "[PAD] [PAD] [PAD] [PAD] what workflow in bioconductor was developed to access human rna-seq samples?", "[PAD] [PAD] [PAD] what functional flow in bioconductor has been developed for obtaining human rna-seq samples?", "[PAD] [PAD] [PAD] [PAD] what workflow in bioconductor has been developed to access human rna seq samples?", "[PAD] [PAD] what workflows in bioconductor have been developed for accessing human rna-seq samples?", "[PAD] [PAD] [PAD] what workflow has been developed in bioconductor to access human rna-seq samples?", "[PAD] [PAD] which workflow has been developed in bioconductor for access to human rna-seq samples?", "what workflow in bio-conductors has been developed for accessing human rna-seq samples?", "[PAD] what workflow in bioconductor has been developed for accessing samples of human rna-sec?", "[PAD] [PAD] what is the preferred orientation of ctcf binding sites for chromatin looping?", "[PAD] [PAD] what is the preferred orientation of ctcf binding sites for chromatin loosening?", "[PAD] [PAD] what is the preferred orientation of ctcf binding sites for the chromatin cycle?", "[PAD] [PAD] [PAD] what is the preferred orientation of ctcf binding sites for chromatin loops?", "[PAD] [PAD] what is the preferred orientation of ctcf junctions for a chromatin ring?", "[PAD] [PAD] what is the preferred direction of ctcf binding sites for chromatin looping?", "[PAD] [PAD] what is the preferred orientation of ctcf binding sites for the chromatin loop?", "[PAD] [PAD] what is the preferred targeting of ctcf binding sites for the chromatin loop?", "[PAD] [PAD] [PAD] [PAD] what is the preferred orientation of ctcf chromatin loop junctions?", "[PAD] [PAD] [PAD] what is the preferred orientation of ctcf binding sites for chromatin cycling?", "[PAD] [PAD] [PAD] what is the preferred orientation of the ctcf chromatin loop binding sites?", "[PAD] what is the preferred orientation of the ctcf binding sites for the chromatin loop?", "[PAD] [PAD] what is the recommended orientation of ctcf binding sites for the chromatin loop?", "[PAD] [PAD] [PAD] what is the preferred orientation of ctcf binding sites for chromatin loop?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the preferred ctcf site orientation for chromatin loops?", "[PAD] [PAD] what is the preferred direction of ctcf linking sites for the chromatin loop?", "[PAD] [PAD] [PAD] [PAD] what is the preferred ctcf binding site for chromatin looping?", "[PAD] what is the preferred orientation of the ctcf binding site for chromatin looping?", "[PAD] [PAD] [PAD] what is the preferred orientation for ctcf binding sites for chromatin bending?", "[PAD] what is the preferred orientation of the ctcf binding site of the chromatin loop?", "[PAD] what is the preferred orientation of the ctcf binding site for the chromatin loop?", "[PAD] [PAD] what is the preferred orientation of ctcf junctions for the chromatin ring?", "what is the preferred orientation of ctcf binding sites for the formation of chromatin loops?", "[PAD] [PAD] [PAD] what is the preferred orientation of ctcf binding sites for chromatin fusion?", "[PAD] [PAD] what is the recommended orientation of sites that close ctcf with chromatine loop?", "[PAD] [PAD] what is the preferred orientation of the ctcf capture site for chromatin loop?", "[PAD] [PAD] what is the preferred orientation of ctcf binding sites for chromatin cyclization?", "[PAD] [PAD] what is the preferred orientation of ctcf binding sites for chromatin looping?", "[PAD] [PAD] what is the preferred orientation of ctcf binding sites for chromatin loosening?", "[PAD] [PAD] what is the preferred orientation of ctcf binding sites for the chromatin cycle?", "[PAD] [PAD] [PAD] what is the preferred orientation of ctcf binding sites for chromatin loops?", "[PAD] [PAD] what is the preferred orientation of ctcf junctions for a chromatin ring?", "[PAD] [PAD] what is the preferred direction of ctcf binding sites for chromatin looping?", "[PAD] [PAD] what is the preferred orientation of ctcf binding sites for the chromatin loop?", "[PAD] [PAD] what is the preferred targeting of ctcf binding sites for the chromatin loop?", "[PAD] [PAD] [PAD] [PAD] what is the preferred orientation of ctcf chromatin loop junctions?", "[PAD] [PAD] [PAD] what is the preferred orientation of ctcf binding sites for chromatin cycling?", "[PAD] [PAD] [PAD] what is the preferred orientation of the ctcf chromatin loop binding sites?", "[PAD] what is the preferred orientation of the ctcf binding sites for the chromatin loop?", "[PAD] [PAD] what is the recommended orientation of ctcf binding sites for the chromatin loop?", "[PAD] [PAD] [PAD] what is the preferred orientation of ctcf binding sites for chromatin loop?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the preferred ctcf site orientation for chromatin loops?", "[PAD] [PAD] what is the preferred direction of ctcf linking sites for the chromatin loop?", "[PAD] [PAD] [PAD] [PAD] what is the preferred ctcf binding site for chromatin looping?", "[PAD] what is the preferred orientation of the ctcf binding site for chromatin looping?", "[PAD] [PAD] [PAD] what is the preferred orientation for ctcf binding sites for chromatin bending?", "[PAD] what is the preferred orientation of the ctcf binding site of the chromatin loop?", "[PAD] what is the preferred orientation of the ctcf binding site for the chromatin loop?", "[PAD] [PAD] what is the preferred orientation of ctcf junctions for the chromatin ring?", "what is the preferred orientation of ctcf binding sites for the formation of chromatin loops?", "[PAD] [PAD] [PAD] what is the preferred orientation of ctcf binding sites for chromatin fusion?", "[PAD] [PAD] what is the recommended orientation of sites that close ctcf with chromatine loop?", "[PAD] [PAD] what is the preferred orientation of the ctcf capture site for chromatin loop?", "[PAD] [PAD] what is the preferred orientation of ctcf binding sites for chromatin cyclization?", "[PAD] [PAD] what is the preferred orientation of ctcf binding sites for chromatin looping?", "[PAD] [PAD] what is the preferred orientation of ctcf binding sites for chromatin loosening?", "[PAD] [PAD] what is the preferred orientation of ctcf binding sites for the chromatin cycle?", "[PAD] [PAD] [PAD] what is the preferred orientation of ctcf binding sites for chromatin loops?", "[PAD] [PAD] what is the preferred orientation of ctcf junctions for a chromatin ring?", "[PAD] [PAD] what is the preferred direction of ctcf binding sites for chromatin looping?", "[PAD] [PAD] what is the preferred orientation of ctcf binding sites for the chromatin loop?", "[PAD] [PAD] what is the preferred targeting of ctcf binding sites for the chromatin loop?", "[PAD] [PAD] [PAD] [PAD] what is the preferred orientation of ctcf chromatin loop junctions?", "[PAD] [PAD] [PAD] what is the preferred orientation of ctcf binding sites for chromatin cycling?", "[PAD] [PAD] [PAD] what is the preferred orientation of the ctcf chromatin loop binding sites?", "[PAD] what is the preferred orientation of the ctcf binding sites for the chromatin loop?", "[PAD] [PAD] what is the recommended orientation of ctcf binding sites for the chromatin loop?", "[PAD] [PAD] [PAD] what is the preferred orientation of ctcf binding sites for chromatin loop?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the preferred ctcf site orientation for chromatin loops?", "[PAD] [PAD] what is the preferred direction of ctcf linking sites for the chromatin loop?", "[PAD] [PAD] [PAD] [PAD] what is the preferred ctcf binding site for chromatin looping?", "[PAD] what is the preferred orientation of the ctcf binding site for chromatin looping?", "[PAD] [PAD] [PAD] what is the preferred orientation for ctcf binding sites for chromatin bending?", "[PAD] what is the preferred orientation of the ctcf binding site of the chromatin loop?", "[PAD] what is the preferred orientation of the ctcf binding site for the chromatin loop?", "[PAD] [PAD] what is the preferred orientation of ctcf junctions for the chromatin ring?", "what is the preferred orientation of ctcf binding sites for the formation of chromatin loops?", "[PAD] [PAD] [PAD] what is the preferred orientation of ctcf binding sites for chromatin fusion?", "[PAD] [PAD] what is the recommended orientation of sites that close ctcf with chromatine loop?", "[PAD] [PAD] what is the preferred orientation of the ctcf capture site for chromatin loop?", "[PAD] [PAD] what is the preferred orientation of ctcf binding sites for chromatin cyclization?", "[PAD] [PAD] what is the preferred orientation of ctcf binding sites for chromatin looping?", "[PAD] [PAD] what is the preferred orientation of ctcf binding sites for chromatin loosening?", "[PAD] [PAD] what is the preferred orientation of ctcf binding sites for the chromatin cycle?", "[PAD] [PAD] [PAD] what is the preferred orientation of ctcf binding sites for chromatin loops?", "[PAD] [PAD] what is the preferred orientation of ctcf junctions for a chromatin ring?", "[PAD] [PAD] what is the preferred direction of ctcf binding sites for chromatin looping?", "[PAD] [PAD] what is the preferred orientation of ctcf binding sites for the chromatin loop?", "[PAD] [PAD] what is the preferred targeting of ctcf binding sites for the chromatin loop?", "[PAD] [PAD] [PAD] [PAD] what is the preferred orientation of ctcf chromatin loop junctions?", "[PAD] [PAD] [PAD] what is the preferred orientation of ctcf binding sites for chromatin cycling?", "[PAD] [PAD] [PAD] what is the preferred orientation of the ctcf chromatin loop binding sites?", "[PAD] what is the preferred orientation of the ctcf binding sites for the chromatin loop?", "[PAD] [PAD] what is the recommended orientation of ctcf binding sites for the chromatin loop?", "[PAD] [PAD] [PAD] what is the preferred orientation of ctcf binding sites for chromatin loop?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the preferred ctcf site orientation for chromatin loops?", "[PAD] [PAD] what is the preferred direction of ctcf linking sites for the chromatin loop?", "[PAD] [PAD] [PAD] [PAD] what is the preferred ctcf binding site for chromatin looping?", "[PAD] what is the preferred orientation of the ctcf binding site for chromatin looping?", "[PAD] [PAD] [PAD] what is the preferred orientation for ctcf binding sites for chromatin bending?", "[PAD] what is the preferred orientation of the ctcf binding site of the chromatin loop?", "[PAD] what is the preferred orientation of the ctcf binding site for the chromatin loop?", "[PAD] [PAD] what is the preferred orientation of ctcf junctions for the chromatin ring?", "what is the preferred orientation of ctcf binding sites for the formation of chromatin loops?", "[PAD] [PAD] [PAD] what is the preferred orientation of ctcf binding sites for chromatin fusion?", "[PAD] [PAD] what is the recommended orientation of sites that close ctcf with chromatine loop?", "[PAD] [PAD] what is the preferred orientation of the ctcf capture site for chromatin loop?", "[PAD] [PAD] what is the preferred orientation of ctcf binding sites for chromatin cyclization?", "[PAD] [PAD] what is the preferred orientation of ctcf binding sites for chromatin looping?", "[PAD] [PAD] what is the preferred orientation of ctcf binding sites for chromatin loosening?", "[PAD] [PAD] what is the preferred orientation of ctcf binding sites for the chromatin cycle?", "[PAD] [PAD] [PAD] what is the preferred orientation of ctcf binding sites for chromatin loops?", "[PAD] [PAD] what is the preferred orientation of ctcf junctions for a chromatin ring?", "[PAD] [PAD] what is the preferred direction of ctcf binding sites for chromatin looping?", "[PAD] [PAD] what is the preferred orientation of ctcf binding sites for the chromatin loop?", "[PAD] [PAD] what is the preferred targeting of ctcf binding sites for the chromatin loop?", "[PAD] [PAD] [PAD] [PAD] what is the preferred orientation of ctcf chromatin loop junctions?", "[PAD] [PAD] [PAD] what is the preferred orientation of ctcf binding sites for chromatin cycling?", "[PAD] [PAD] [PAD] what is the preferred orientation of the ctcf chromatin loop binding sites?", "[PAD] what is the preferred orientation of the ctcf binding sites for the chromatin loop?", "[PAD] [PAD] what is the recommended orientation of ctcf binding sites for the chromatin loop?", "[PAD] [PAD] [PAD] what is the preferred orientation of ctcf binding sites for chromatin loop?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the preferred ctcf site orientation for chromatin loops?", "[PAD] [PAD] what is the preferred direction of ctcf linking sites for the chromatin loop?", "[PAD] [PAD] [PAD] [PAD] what is the preferred ctcf binding site for chromatin looping?", "[PAD] what is the preferred orientation of the ctcf binding site for chromatin looping?", "[PAD] [PAD] [PAD] what is the preferred orientation for ctcf binding sites for chromatin bending?", "[PAD] what is the preferred orientation of the ctcf binding site of the chromatin loop?", "[PAD] what is the preferred orientation of the ctcf binding site for the chromatin loop?", "[PAD] [PAD] what is the preferred orientation of ctcf junctions for the chromatin ring?", "what is the preferred orientation of ctcf binding sites for the formation of chromatin loops?", "[PAD] [PAD] [PAD] what is the preferred orientation of ctcf binding sites for chromatin fusion?", "[PAD] [PAD] what is the recommended orientation of sites that close ctcf with chromatine loop?", "[PAD] [PAD] what is the preferred orientation of the ctcf capture site for chromatin loop?", "[PAD] [PAD] what is the preferred orientation of ctcf binding sites for chromatin cyclization?", "[PAD] [PAD] what is the preferred orientation of ctcf binding sites for chromatin looping?", "[PAD] [PAD] what is the preferred orientation of ctcf binding sites for chromatin loosening?", "[PAD] [PAD] what is the preferred orientation of ctcf binding sites for the chromatin cycle?", "[PAD] [PAD] [PAD] what is the preferred orientation of ctcf binding sites for chromatin loops?", "[PAD] [PAD] what is the preferred orientation of ctcf junctions for a chromatin ring?", "[PAD] [PAD] what is the preferred direction of ctcf binding sites for chromatin looping?", "[PAD] [PAD] what is the preferred orientation of ctcf binding sites for the chromatin loop?", "[PAD] [PAD] what is the preferred targeting of ctcf binding sites for the chromatin loop?", "[PAD] [PAD] [PAD] [PAD] what is the preferred orientation of ctcf chromatin loop junctions?", "[PAD] [PAD] [PAD] what is the preferred orientation of ctcf binding sites for chromatin cycling?", "[PAD] [PAD] [PAD] what is the preferred orientation of the ctcf chromatin loop binding sites?", "[PAD] what is the preferred orientation of the ctcf binding sites for the chromatin loop?", "[PAD] [PAD] what is the recommended orientation of ctcf binding sites for the chromatin loop?", "[PAD] [PAD] [PAD] what is the preferred orientation of ctcf binding sites for chromatin loop?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the preferred ctcf site orientation for chromatin loops?", "[PAD] [PAD] what is the preferred direction of ctcf linking sites for the chromatin loop?", "[PAD] [PAD] [PAD] [PAD] what is the preferred ctcf binding site for chromatin looping?", "[PAD] what is the preferred orientation of the ctcf binding site for chromatin looping?", "[PAD] [PAD] [PAD] what is the preferred orientation for ctcf binding sites for chromatin bending?", "[PAD] what is the preferred orientation of the ctcf binding site of the chromatin loop?", "[PAD] what is the preferred orientation of the ctcf binding site for the chromatin loop?", "[PAD] [PAD] what is the preferred orientation of ctcf junctions for the chromatin ring?", "what is the preferred orientation of ctcf binding sites for the formation of chromatin loops?", "[PAD] [PAD] [PAD] what is the preferred orientation of ctcf binding sites for chromatin fusion?", "[PAD] [PAD] what is the recommended orientation of sites that close ctcf with chromatine loop?", "[PAD] [PAD] what is the preferred orientation of the ctcf capture site for chromatin loop?", "[PAD] [PAD] what is the preferred orientation of ctcf binding sites for chromatin cyclization?", "[PAD] how many amino acids does davunetide consist of?", "[PAD] how many amino acids does daponitide consist of?", "[PAD] [PAD] [PAD] how many amino acids is davunetide?", "[PAD] [PAD] how many amino acids does davunetid contain?", "[PAD] [PAD] how many amino acids does davunetide contain?", "how many amino acids does dafneptide consist of?", "[PAD] how many amino acids does davunetid consist of?", "how many amino acids is davunetide made up of?", "[PAD] how many amino acids is davunetide made of?", "[PAD] [PAD] how many amino acids does davunetide have?", "[PAD] how much amino acid does davunetide consist of?", "[PAD] [PAD] how many amino acids are in davenutide?", "[PAD] how many amino acids are davunetide composed of?", "[PAD] [PAD] how many amino acids does dubnetide consist of?", "[PAD] how many amino acids does dabunetide consist of?", "[PAD] [PAD] what are the amino acids of davunetide?", "[PAD] how much do davunetide amino acids consist of?", "[PAD] [PAD] how many amino acids is davontide composed of?", "[PAD] how many amino acids does dawunetide consist of?", "[PAD] how many amino acids is davunetide composed of?", "[PAD] how many amino acids does davunatide consist of?", "[PAD] [PAD] [PAD] how many amino acids does devanitide contain?", "[PAD] [PAD] how many amino acids consists of davnetide?", "[PAD] [PAD] with which cancers has the loss of smarcb1 been associated?", "[PAD] [PAD] [PAD] with which cancers is the loss of smarcb1 associated?", "[PAD] [PAD] [PAD] what types of cancer are associated with loss of smrcb1?", "[PAD] [PAD] with what types of cancers has smarcb1 loss been associated?", "[PAD] [PAD] [PAD] [PAD] what cancer is associated with the loss of smrcb1?", "[PAD] [PAD] [PAD] [PAD] [PAD] what cancers are associated with smarcb1 loss?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what cancer is smarcb1 loss associated with?", "[PAD] [PAD] [PAD] [PAD] [PAD] what cancers have smarcb1 been associated with?", "[PAD] [PAD] [PAD] [PAD] [PAD] which cancers are associated with smarcb1 loss?", "[PAD] [PAD] what cancers has the loss of smarcb1 been associated with?", "[PAD] [PAD] which cancers are deletions of smarcb1 associated with?", "[PAD] [PAD] [PAD] [PAD] [PAD] which cancers are smarcb1 loss associated with?", "[PAD] [PAD] what types of cancer are associated with the loss of smarcb1?", "[PAD] [PAD] what cancers have the loss of smarcb1 been associated with?", "[PAD] [PAD] [PAD] [PAD] what cancers has smarcb1 loss been associated with?", "[PAD] [PAD] which cancers have been associated with the loss of smarcb1?", "[PAD] [PAD] to which cancers has the loss of smarcb1 been associated?", "[PAD] [PAD] [PAD] what cancers has loss of smarcb1 been associated with?", "[PAD] what types of cancer have been associated with the loss of smarcb1?", "[PAD] [PAD] [PAD] [PAD] which cancer is associated with the loss of smrcb1?", "[PAD] [PAD] [PAD] which cancers has loss of smarcb1 been associated with?", "[PAD] [PAD] [PAD] [PAD] what cancers has smrcb1 loss been associated with?", "[PAD] [PAD] [PAD] [PAD] [PAD] which cancers were associated with smarcb1 loss?", "[PAD] [PAD] [PAD] [PAD] what types of cancer are associated with smarcb1 loss?", "[PAD] [PAD] [PAD] [PAD] [PAD] loss of smarcb1 is associated with which cancer?", "[PAD] [PAD] what cancers have been associated with the loss of smarcb1?", "[PAD] [PAD] [PAD] [PAD] [PAD] what cancers have smarcb1 been linked to?", "[PAD] [PAD] [PAD] [PAD] [PAD] with what cancer is loss of smarcb1 associated?", "[PAD] [PAD] [PAD] which cancers were involved in the loss of smarcb1?", "[PAD] [PAD] [PAD] [PAD] which cancer is associated with the loss of smarcb1?", "[PAD] [PAD] [PAD] [PAD] what cancers are loss of smarcb1 associated with?", "[PAD] what forms of cancer have been associated with the loss of smarcb1?", "[PAD] [PAD] [PAD] what cancer has the loss of smarcb1 been associated with?", "[PAD] [PAD] [PAD] [PAD] [PAD] smarcb1 loss is associated with which cancers?", "[PAD] [PAD] [PAD] what cancers is the loss of smarcb1 associated with?", "[PAD] [PAD] [PAD] with which cancers was the loss of smarcb1 associated?", "[PAD] what type of cancer has been associated with the loss of smarcb1?", "[PAD] [PAD] what types of cancers are associated with loss of smarcb1?", "[PAD] [PAD] [PAD] [PAD] [PAD] which cancers is smarcb1 loss associated with?", "[PAD] [PAD] [PAD] [PAD] which cancers have smarcb1 loss been associated with?", "[PAD] [PAD] [PAD] loss of smarcb1 has been associated with which cancers?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what cancers is smarcb1 associated with?", "what types of cancers is the loss of smaarcb1 associated with?", "[PAD] [PAD] [PAD] [PAD] loss of smarcb1 is associated with which cancers?", "[PAD] [PAD] [PAD] [PAD] what cancers is loss of smarcb1 associated with?", "[PAD] [PAD] [PAD] with what cancers has loss of smarcb1 been associated?", "[PAD] [PAD] [PAD] [PAD] what concerts is the loss of smarcb1 associated with?", "[PAD] [PAD] with which cancers has the loss of smarcb1 been associated?", "[PAD] [PAD] [PAD] with which cancers is the loss of smarcb1 associated?", "[PAD] [PAD] [PAD] what types of cancer are associated with loss of smrcb1?", "[PAD] [PAD] with what types of cancers has smarcb1 loss been associated?", "[PAD] [PAD] [PAD] [PAD] what cancer is associated with the loss of smrcb1?", "[PAD] [PAD] [PAD] [PAD] [PAD] what cancers are associated with smarcb1 loss?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what cancer is smarcb1 loss associated with?", "[PAD] [PAD] [PAD] [PAD] [PAD] what cancers have smarcb1 been associated with?", "[PAD] [PAD] [PAD] [PAD] [PAD] which cancers are associated with smarcb1 loss?", "[PAD] [PAD] what cancers has the loss of smarcb1 been associated with?", "[PAD] [PAD] which cancers are deletions of smarcb1 associated with?", "[PAD] [PAD] [PAD] [PAD] [PAD] which cancers are smarcb1 loss associated with?", "[PAD] [PAD] what types of cancer are associated with the loss of smarcb1?", "[PAD] [PAD] what cancers have the loss of smarcb1 been associated with?", "[PAD] [PAD] [PAD] [PAD] what cancers has smarcb1 loss been associated with?", "[PAD] [PAD] which cancers have been associated with the loss of smarcb1?", "[PAD] [PAD] to which cancers has the loss of smarcb1 been associated?", "[PAD] [PAD] [PAD] what cancers has loss of smarcb1 been associated with?", "[PAD] what types of cancer have been associated with the loss of smarcb1?", "[PAD] [PAD] [PAD] [PAD] which cancer is associated with the loss of smrcb1?", "[PAD] [PAD] [PAD] which cancers has loss of smarcb1 been associated with?", "[PAD] [PAD] [PAD] [PAD] what cancers has smrcb1 loss been associated with?", "[PAD] [PAD] [PAD] [PAD] [PAD] which cancers were associated with smarcb1 loss?", "[PAD] [PAD] [PAD] [PAD] what types of cancer are associated with smarcb1 loss?", "[PAD] [PAD] [PAD] [PAD] [PAD] loss of smarcb1 is associated with which cancer?", "[PAD] [PAD] what cancers have been associated with the loss of smarcb1?", "[PAD] [PAD] [PAD] [PAD] [PAD] what cancers have smarcb1 been linked to?", "[PAD] [PAD] [PAD] [PAD] [PAD] with what cancer is loss of smarcb1 associated?", "[PAD] [PAD] [PAD] which cancers were involved in the loss of smarcb1?", "[PAD] [PAD] [PAD] [PAD] which cancer is associated with the loss of smarcb1?", "[PAD] [PAD] [PAD] [PAD] what cancers are loss of smarcb1 associated with?", "[PAD] what forms of cancer have been associated with the loss of smarcb1?", "[PAD] [PAD] [PAD] what cancer has the loss of smarcb1 been associated with?", "[PAD] [PAD] [PAD] [PAD] [PAD] smarcb1 loss is associated with which cancers?", "[PAD] [PAD] [PAD] what cancers is the loss of smarcb1 associated with?", "[PAD] [PAD] [PAD] with which cancers was the loss of smarcb1 associated?", "[PAD] what type of cancer has been associated with the loss of smarcb1?", "[PAD] [PAD] what types of cancers are associated with loss of smarcb1?", "[PAD] [PAD] [PAD] [PAD] [PAD] which cancers is smarcb1 loss associated with?", "[PAD] [PAD] [PAD] [PAD] which cancers have smarcb1 loss been associated with?", "[PAD] [PAD] [PAD] loss of smarcb1 has been associated with which cancers?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what cancers is smarcb1 associated with?", "what types of cancers is the loss of smaarcb1 associated with?", "[PAD] [PAD] [PAD] [PAD] loss of smarcb1 is associated with which cancers?", "[PAD] [PAD] [PAD] [PAD] what cancers is loss of smarcb1 associated with?", "[PAD] [PAD] [PAD] with what cancers has loss of smarcb1 been associated?", "[PAD] [PAD] [PAD] [PAD] what concerts is the loss of smarcb1 associated with?", "[PAD] [PAD] with which cancers has the loss of smarcb1 been associated?", "[PAD] [PAD] [PAD] with which cancers is the loss of smarcb1 associated?", "[PAD] [PAD] [PAD] what types of cancer are associated with loss of smrcb1?", "[PAD] [PAD] with what types of cancers has smarcb1 loss been associated?", "[PAD] [PAD] [PAD] [PAD] what cancer is associated with the loss of smrcb1?", "[PAD] [PAD] [PAD] [PAD] [PAD] what cancers are associated with smarcb1 loss?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what cancer is smarcb1 loss associated with?", "[PAD] [PAD] [PAD] [PAD] [PAD] what cancers have smarcb1 been associated with?", "[PAD] [PAD] [PAD] [PAD] [PAD] which cancers are associated with smarcb1 loss?", "[PAD] [PAD] what cancers has the loss of smarcb1 been associated with?", "[PAD] [PAD] which cancers are deletions of smarcb1 associated with?", "[PAD] [PAD] [PAD] [PAD] [PAD] which cancers are smarcb1 loss associated with?", "[PAD] [PAD] what types of cancer are associated with the loss of smarcb1?", "[PAD] [PAD] what cancers have the loss of smarcb1 been associated with?", "[PAD] [PAD] [PAD] [PAD] what cancers has smarcb1 loss been associated with?", "[PAD] [PAD] which cancers have been associated with the loss of smarcb1?", "[PAD] [PAD] to which cancers has the loss of smarcb1 been associated?", "[PAD] [PAD] [PAD] what cancers has loss of smarcb1 been associated with?", "[PAD] what types of cancer have been associated with the loss of smarcb1?", "[PAD] [PAD] [PAD] [PAD] which cancer is associated with the loss of smrcb1?", "[PAD] [PAD] [PAD] which cancers has loss of smarcb1 been associated with?", "[PAD] [PAD] [PAD] [PAD] what cancers has smrcb1 loss been associated with?", "[PAD] [PAD] [PAD] [PAD] [PAD] which cancers were associated with smarcb1 loss?", "[PAD] [PAD] [PAD] [PAD] what types of cancer are associated with smarcb1 loss?", "[PAD] [PAD] [PAD] [PAD] [PAD] loss of smarcb1 is associated with which cancer?", "[PAD] [PAD] what cancers have been associated with the loss of smarcb1?", "[PAD] [PAD] [PAD] [PAD] [PAD] what cancers have smarcb1 been linked to?", "[PAD] [PAD] [PAD] [PAD] [PAD] with what cancer is loss of smarcb1 associated?", "[PAD] [PAD] [PAD] which cancers were involved in the loss of smarcb1?", "[PAD] [PAD] [PAD] [PAD] which cancer is associated with the loss of smarcb1?", "[PAD] [PAD] [PAD] [PAD] what cancers are loss of smarcb1 associated with?", "[PAD] what forms of cancer have been associated with the loss of smarcb1?", "[PAD] [PAD] [PAD] what cancer has the loss of smarcb1 been associated with?", "[PAD] [PAD] [PAD] [PAD] [PAD] smarcb1 loss is associated with which cancers?", "[PAD] [PAD] [PAD] what cancers is the loss of smarcb1 associated with?", "[PAD] [PAD] [PAD] with which cancers was the loss of smarcb1 associated?", "[PAD] what type of cancer has been associated with the loss of smarcb1?", "[PAD] [PAD] what types of cancers are associated with loss of smarcb1?", "[PAD] [PAD] [PAD] [PAD] [PAD] which cancers is smarcb1 loss associated with?", "[PAD] [PAD] [PAD] [PAD] which cancers have smarcb1 loss been associated with?", "[PAD] [PAD] [PAD] loss of smarcb1 has been associated with which cancers?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what cancers is smarcb1 associated with?", "what types of cancers is the loss of smaarcb1 associated with?", "[PAD] [PAD] [PAD] [PAD] loss of smarcb1 is associated with which cancers?", "[PAD] [PAD] [PAD] [PAD] what cancers is loss of smarcb1 associated with?", "[PAD] [PAD] [PAD] with what cancers has loss of smarcb1 been associated?", "[PAD] [PAD] [PAD] [PAD] what concerts is the loss of smarcb1 associated with?", "[PAD] [PAD] with which cancers has the loss of smarcb1 been associated?", "[PAD] [PAD] [PAD] with which cancers is the loss of smarcb1 associated?", "[PAD] [PAD] [PAD] what types of cancer are associated with loss of smrcb1?", "[PAD] [PAD] with what types of cancers has smarcb1 loss been associated?", "[PAD] [PAD] [PAD] [PAD] what cancer is associated with the loss of smrcb1?", "[PAD] [PAD] [PAD] [PAD] [PAD] what cancers are associated with smarcb1 loss?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what cancer is smarcb1 loss associated with?", "[PAD] [PAD] [PAD] [PAD] [PAD] what cancers have smarcb1 been associated with?", "[PAD] [PAD] [PAD] [PAD] [PAD] which cancers are associated with smarcb1 loss?", "[PAD] [PAD] what cancers has the loss of smarcb1 been associated with?", "[PAD] [PAD] which cancers are deletions of smarcb1 associated with?", "[PAD] [PAD] [PAD] [PAD] [PAD] which cancers are smarcb1 loss associated with?", "[PAD] [PAD] what types of cancer are associated with the loss of smarcb1?", "[PAD] [PAD] what cancers have the loss of smarcb1 been associated with?", "[PAD] [PAD] [PAD] [PAD] what cancers has smarcb1 loss been associated with?", "[PAD] [PAD] which cancers have been associated with the loss of smarcb1?", "[PAD] [PAD] to which cancers has the loss of smarcb1 been associated?", "[PAD] [PAD] [PAD] what cancers has loss of smarcb1 been associated with?", "[PAD] what types of cancer have been associated with the loss of smarcb1?", "[PAD] [PAD] [PAD] [PAD] which cancer is associated with the loss of smrcb1?", "[PAD] [PAD] [PAD] which cancers has loss of smarcb1 been associated with?", "[PAD] [PAD] [PAD] [PAD] what cancers has smrcb1 loss been associated with?", "[PAD] [PAD] [PAD] [PAD] [PAD] which cancers were associated with smarcb1 loss?", "[PAD] [PAD] [PAD] [PAD] what types of cancer are associated with smarcb1 loss?", "[PAD] [PAD] [PAD] [PAD] [PAD] loss of smarcb1 is associated with which cancer?", "[PAD] [PAD] what cancers have been associated with the loss of smarcb1?", "[PAD] [PAD] [PAD] [PAD] [PAD] what cancers have smarcb1 been linked to?", "[PAD] [PAD] [PAD] [PAD] [PAD] with what cancer is loss of smarcb1 associated?", "[PAD] [PAD] [PAD] which cancers were involved in the loss of smarcb1?", "[PAD] [PAD] [PAD] [PAD] which cancer is associated with the loss of smarcb1?", "[PAD] [PAD] [PAD] [PAD] what cancers are loss of smarcb1 associated with?", "[PAD] what forms of cancer have been associated with the loss of smarcb1?", "[PAD] [PAD] [PAD] what cancer has the loss of smarcb1 been associated with?", "[PAD] [PAD] [PAD] [PAD] [PAD] smarcb1 loss is associated with which cancers?", "[PAD] [PAD] [PAD] what cancers is the loss of smarcb1 associated with?", "[PAD] [PAD] [PAD] with which cancers was the loss of smarcb1 associated?", "[PAD] what type of cancer has been associated with the loss of smarcb1?", "[PAD] [PAD] what types of cancers are associated with loss of smarcb1?", "[PAD] [PAD] [PAD] [PAD] [PAD] which cancers is smarcb1 loss associated with?", "[PAD] [PAD] [PAD] [PAD] which cancers have smarcb1 loss been associated with?", "[PAD] [PAD] [PAD] loss of smarcb1 has been associated with which cancers?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what cancers is smarcb1 associated with?", "what types of cancers is the loss of smaarcb1 associated with?", "[PAD] [PAD] [PAD] [PAD] loss of smarcb1 is associated with which cancers?", "[PAD] [PAD] [PAD] [PAD] what cancers is loss of smarcb1 associated with?", "[PAD] [PAD] [PAD] with what cancers has loss of smarcb1 been associated?", "[PAD] [PAD] [PAD] [PAD] what concerts is the loss of smarcb1 associated with?", "[PAD] [PAD] with which cancers has the loss of smarcb1 been associated?", "[PAD] [PAD] [PAD] with which cancers is the loss of smarcb1 associated?", "[PAD] [PAD] [PAD] what types of cancer are associated with loss of smrcb1?", "[PAD] [PAD] with what types of cancers has smarcb1 loss been associated?", "[PAD] [PAD] [PAD] [PAD] what cancer is associated with the loss of smrcb1?", "[PAD] [PAD] [PAD] [PAD] [PAD] what cancers are associated with smarcb1 loss?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what cancer is smarcb1 loss associated with?", "[PAD] [PAD] [PAD] [PAD] [PAD] what cancers have smarcb1 been associated with?", "[PAD] [PAD] [PAD] [PAD] [PAD] which cancers are associated with smarcb1 loss?", "[PAD] [PAD] what cancers has the loss of smarcb1 been associated with?", "[PAD] [PAD] which cancers are deletions of smarcb1 associated with?", "[PAD] [PAD] [PAD] [PAD] [PAD] which cancers are smarcb1 loss associated with?", "[PAD] [PAD] what types of cancer are associated with the loss of smarcb1?", "[PAD] [PAD] what cancers have the loss of smarcb1 been associated with?", "[PAD] [PAD] [PAD] [PAD] what cancers has smarcb1 loss been associated with?", "[PAD] [PAD] which cancers have been associated with the loss of smarcb1?", "[PAD] [PAD] to which cancers has the loss of smarcb1 been associated?", "[PAD] [PAD] [PAD] what cancers has loss of smarcb1 been associated with?", "[PAD] what types of cancer have been associated with the loss of smarcb1?", "[PAD] [PAD] [PAD] [PAD] which cancer is associated with the loss of smrcb1?", "[PAD] [PAD] [PAD] which cancers has loss of smarcb1 been associated with?", "[PAD] [PAD] [PAD] [PAD] what cancers has smrcb1 loss been associated with?", "[PAD] [PAD] [PAD] [PAD] [PAD] which cancers were associated with smarcb1 loss?", "[PAD] [PAD] [PAD] [PAD] what types of cancer are associated with smarcb1 loss?", "[PAD] [PAD] [PAD] [PAD] [PAD] loss of smarcb1 is associated with which cancer?", "[PAD] [PAD] what cancers have been associated with the loss of smarcb1?", "[PAD] [PAD] [PAD] [PAD] [PAD] what cancers have smarcb1 been linked to?", "[PAD] [PAD] [PAD] [PAD] [PAD] with what cancer is loss of smarcb1 associated?", "[PAD] [PAD] [PAD] which cancers were involved in the loss of smarcb1?", "[PAD] [PAD] [PAD] [PAD] which cancer is associated with the loss of smarcb1?", "[PAD] [PAD] [PAD] [PAD] what cancers are loss of smarcb1 associated with?", "[PAD] what forms of cancer have been associated with the loss of smarcb1?", "[PAD] [PAD] [PAD] what cancer has the loss of smarcb1 been associated with?", "[PAD] [PAD] [PAD] [PAD] [PAD] smarcb1 loss is associated with which cancers?", "[PAD] [PAD] [PAD] what cancers is the loss of smarcb1 associated with?", "[PAD] [PAD] [PAD] with which cancers was the loss of smarcb1 associated?", "[PAD] what type of cancer has been associated with the loss of smarcb1?", "[PAD] [PAD] what types of cancers are associated with loss of smarcb1?", "[PAD] [PAD] [PAD] [PAD] [PAD] which cancers is smarcb1 loss associated with?", "[PAD] [PAD] [PAD] [PAD] which cancers have smarcb1 loss been associated with?", "[PAD] [PAD] [PAD] loss of smarcb1 has been associated with which cancers?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what cancers is smarcb1 associated with?", "what types of cancers is the loss of smaarcb1 associated with?", "[PAD] [PAD] [PAD] [PAD] loss of smarcb1 is associated with which cancers?", "[PAD] [PAD] [PAD] [PAD] what cancers is loss of smarcb1 associated with?", "[PAD] [PAD] [PAD] with what cancers has loss of smarcb1 been associated?", "[PAD] [PAD] [PAD] [PAD] what concerts is the loss of smarcb1 associated with?", "[PAD] [PAD] with which cancers has the loss of smarcb1 been associated?", "[PAD] [PAD] [PAD] with which cancers is the loss of smarcb1 associated?", "[PAD] [PAD] [PAD] what types of cancer are associated with loss of smrcb1?", "[PAD] [PAD] with what types of cancers has smarcb1 loss been associated?", "[PAD] [PAD] [PAD] [PAD] what cancer is associated with the loss of smrcb1?", "[PAD] [PAD] [PAD] [PAD] [PAD] what cancers are associated with smarcb1 loss?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what cancer is smarcb1 loss associated with?", "[PAD] [PAD] [PAD] [PAD] [PAD] what cancers have smarcb1 been associated with?", "[PAD] [PAD] [PAD] [PAD] [PAD] which cancers are associated with smarcb1 loss?", "[PAD] [PAD] what cancers has the loss of smarcb1 been associated with?", "[PAD] [PAD] which cancers are deletions of smarcb1 associated with?", "[PAD] [PAD] [PAD] [PAD] [PAD] which cancers are smarcb1 loss associated with?", "[PAD] [PAD] what types of cancer are associated with the loss of smarcb1?", "[PAD] [PAD] what cancers have the loss of smarcb1 been associated with?", "[PAD] [PAD] [PAD] [PAD] what cancers has smarcb1 loss been associated with?", "[PAD] [PAD] which cancers have been associated with the loss of smarcb1?", "[PAD] [PAD] to which cancers has the loss of smarcb1 been associated?", "[PAD] [PAD] [PAD] what cancers has loss of smarcb1 been associated with?", "[PAD] what types of cancer have been associated with the loss of smarcb1?", "[PAD] [PAD] [PAD] [PAD] which cancer is associated with the loss of smrcb1?", "[PAD] [PAD] [PAD] which cancers has loss of smarcb1 been associated with?", "[PAD] [PAD] [PAD] [PAD] what cancers has smrcb1 loss been associated with?", "[PAD] [PAD] [PAD] [PAD] [PAD] which cancers were associated with smarcb1 loss?", "[PAD] [PAD] [PAD] [PAD] what types of cancer are associated with smarcb1 loss?", "[PAD] [PAD] [PAD] [PAD] [PAD] loss of smarcb1 is associated with which cancer?", "[PAD] [PAD] what cancers have been associated with the loss of smarcb1?", "[PAD] [PAD] [PAD] [PAD] [PAD] what cancers have smarcb1 been linked to?", "[PAD] [PAD] [PAD] [PAD] [PAD] with what cancer is loss of smarcb1 associated?", "[PAD] [PAD] [PAD] which cancers were involved in the loss of smarcb1?", "[PAD] [PAD] [PAD] [PAD] which cancer is associated with the loss of smarcb1?", "[PAD] [PAD] [PAD] [PAD] what cancers are loss of smarcb1 associated with?", "[PAD] what forms of cancer have been associated with the loss of smarcb1?", "[PAD] [PAD] [PAD] what cancer has the loss of smarcb1 been associated with?", "[PAD] [PAD] [PAD] [PAD] [PAD] smarcb1 loss is associated with which cancers?", "[PAD] [PAD] [PAD] what cancers is the loss of smarcb1 associated with?", "[PAD] [PAD] [PAD] with which cancers was the loss of smarcb1 associated?", "[PAD] what type of cancer has been associated with the loss of smarcb1?", "[PAD] [PAD] what types of cancers are associated with loss of smarcb1?", "[PAD] [PAD] [PAD] [PAD] [PAD] which cancers is smarcb1 loss associated with?", "[PAD] [PAD] [PAD] [PAD] which cancers have smarcb1 loss been associated with?", "[PAD] [PAD] [PAD] loss of smarcb1 has been associated with which cancers?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what cancers is smarcb1 associated with?", "what types of cancers is the loss of smaarcb1 associated with?", "[PAD] [PAD] [PAD] [PAD] loss of smarcb1 is associated with which cancers?", "[PAD] [PAD] [PAD] [PAD] what cancers is loss of smarcb1 associated with?", "[PAD] [PAD] [PAD] with what cancers has loss of smarcb1 been associated?", "[PAD] [PAD] [PAD] [PAD] what concerts is the loss of smarcb1 associated with?", "[PAD] [PAD] with which cancers has the loss of smarcb1 been associated?", "[PAD] [PAD] [PAD] with which cancers is the loss of smarcb1 associated?", "[PAD] [PAD] [PAD] what types of cancer are associated with loss of smrcb1?", "[PAD] [PAD] with what types of cancers has smarcb1 loss been associated?", "[PAD] [PAD] [PAD] [PAD] what cancer is associated with the loss of smrcb1?", "[PAD] [PAD] [PAD] [PAD] [PAD] what cancers are associated with smarcb1 loss?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what cancer is smarcb1 loss associated with?", "[PAD] [PAD] [PAD] [PAD] [PAD] what cancers have smarcb1 been associated with?", "[PAD] [PAD] [PAD] [PAD] [PAD] which cancers are associated with smarcb1 loss?", "[PAD] [PAD] what cancers has the loss of smarcb1 been associated with?", "[PAD] [PAD] which cancers are deletions of smarcb1 associated with?", "[PAD] [PAD] [PAD] [PAD] [PAD] which cancers are smarcb1 loss associated with?", "[PAD] [PAD] what types of cancer are associated with the loss of smarcb1?", "[PAD] [PAD] what cancers have the loss of smarcb1 been associated with?", "[PAD] [PAD] [PAD] [PAD] what cancers has smarcb1 loss been associated with?", "[PAD] [PAD] which cancers have been associated with the loss of smarcb1?", "[PAD] [PAD] to which cancers has the loss of smarcb1 been associated?", "[PAD] [PAD] [PAD] what cancers has loss of smarcb1 been associated with?", "[PAD] what types of cancer have been associated with the loss of smarcb1?", "[PAD] [PAD] [PAD] [PAD] which cancer is associated with the loss of smrcb1?", "[PAD] [PAD] [PAD] which cancers has loss of smarcb1 been associated with?", "[PAD] [PAD] [PAD] [PAD] what cancers has smrcb1 loss been associated with?", "[PAD] [PAD] [PAD] [PAD] [PAD] which cancers were associated with smarcb1 loss?", "[PAD] [PAD] [PAD] [PAD] what types of cancer are associated with smarcb1 loss?", "[PAD] [PAD] [PAD] [PAD] [PAD] loss of smarcb1 is associated with which cancer?", "[PAD] [PAD] what cancers have been associated with the loss of smarcb1?", "[PAD] [PAD] [PAD] [PAD] [PAD] what cancers have smarcb1 been linked to?", "[PAD] [PAD] [PAD] [PAD] [PAD] with what cancer is loss of smarcb1 associated?", "[PAD] [PAD] [PAD] which cancers were involved in the loss of smarcb1?", "[PAD] [PAD] [PAD] [PAD] which cancer is associated with the loss of smarcb1?", "[PAD] [PAD] [PAD] [PAD] what cancers are loss of smarcb1 associated with?", "[PAD] what forms of cancer have been associated with the loss of smarcb1?", "[PAD] [PAD] [PAD] what cancer has the loss of smarcb1 been associated with?", "[PAD] [PAD] [PAD] [PAD] [PAD] smarcb1 loss is associated with which cancers?", "[PAD] [PAD] [PAD] what cancers is the loss of smarcb1 associated with?", "[PAD] [PAD] [PAD] with which cancers was the loss of smarcb1 associated?", "[PAD] what type of cancer has been associated with the loss of smarcb1?", "[PAD] [PAD] what types of cancers are associated with loss of smarcb1?", "[PAD] [PAD] [PAD] [PAD] [PAD] which cancers is smarcb1 loss associated with?", "[PAD] [PAD] [PAD] [PAD] which cancers have smarcb1 loss been associated with?", "[PAD] [PAD] [PAD] loss of smarcb1 has been associated with which cancers?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what cancers is smarcb1 associated with?", "what types of cancers is the loss of smaarcb1 associated with?", "[PAD] [PAD] [PAD] [PAD] loss of smarcb1 is associated with which cancers?", "[PAD] [PAD] [PAD] [PAD] what cancers is loss of smarcb1 associated with?", "[PAD] [PAD] [PAD] with what cancers has loss of smarcb1 been associated?", "[PAD] [PAD] [PAD] [PAD] what concerts is the loss of smarcb1 associated with?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed with the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be calculated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risks can the stop-bang questionnaire assess?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be estimated using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang-questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] the risk of which disease can be estimated by the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what diseases can be assessed for risk using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the estimated risk of illness in the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can the stop-bang questionnaire estimate?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risks can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what is the risk of disease by using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] the risk of what disease can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what is the risk of the disease using the stop-bang questionnaire?", "what is the risk of a disease that can be estimated by the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated from the stop bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be estimated with a stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed with the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be calculated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risks can the stop-bang questionnaire assess?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be estimated using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang-questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] the risk of which disease can be estimated by the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what diseases can be assessed for risk using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the estimated risk of illness in the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can the stop-bang questionnaire estimate?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risks can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what is the risk of disease by using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] the risk of what disease can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what is the risk of the disease using the stop-bang questionnaire?", "what is the risk of a disease that can be estimated by the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated from the stop bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be estimated with a stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed with the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be calculated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risks can the stop-bang questionnaire assess?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be estimated using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang-questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] the risk of which disease can be estimated by the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what diseases can be assessed for risk using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the estimated risk of illness in the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can the stop-bang questionnaire estimate?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risks can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what is the risk of disease by using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] the risk of what disease can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what is the risk of the disease using the stop-bang questionnaire?", "what is the risk of a disease that can be estimated by the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated from the stop bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be estimated with a stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed with the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be calculated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risks can the stop-bang questionnaire assess?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be estimated using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang-questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] the risk of which disease can be estimated by the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what diseases can be assessed for risk using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the estimated risk of illness in the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can the stop-bang questionnaire estimate?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risks can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what is the risk of disease by using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] the risk of what disease can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what is the risk of the disease using the stop-bang questionnaire?", "what is the risk of a disease that can be estimated by the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated from the stop bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be estimated with a stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed with the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be calculated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risks can the stop-bang questionnaire assess?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be estimated using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang-questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] the risk of which disease can be estimated by the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what diseases can be assessed for risk using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the estimated risk of illness in the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can the stop-bang questionnaire estimate?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risks can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what is the risk of disease by using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] the risk of what disease can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what is the risk of the disease using the stop-bang questionnaire?", "what is the risk of a disease that can be estimated by the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated from the stop bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be estimated with a stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed with the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be calculated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risks can the stop-bang questionnaire assess?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be estimated using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang-questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] the risk of which disease can be estimated by the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what diseases can be assessed for risk using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the estimated risk of illness in the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can the stop-bang questionnaire estimate?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risks can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what is the risk of disease by using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] the risk of what disease can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what is the risk of the disease using the stop-bang questionnaire?", "what is the risk of a disease that can be estimated by the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated from the stop bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be estimated with a stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed with the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be calculated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risks can the stop-bang questionnaire assess?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be estimated using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang-questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] the risk of which disease can be estimated by the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what diseases can be assessed for risk using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the estimated risk of illness in the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can the stop-bang questionnaire estimate?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risks can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what is the risk of disease by using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] the risk of what disease can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what is the risk of the disease using the stop-bang questionnaire?", "what is the risk of a disease that can be estimated by the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated from the stop bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be estimated with a stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed with the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be calculated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risks can the stop-bang questionnaire assess?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be estimated using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang-questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] the risk of which disease can be estimated by the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what diseases can be assessed for risk using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the estimated risk of illness in the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can the stop-bang questionnaire estimate?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risks can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what is the risk of disease by using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] the risk of what disease can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what is the risk of the disease using the stop-bang questionnaire?", "what is the risk of a disease that can be estimated by the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated from the stop bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be estimated with a stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed with the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be calculated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risks can the stop-bang questionnaire assess?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be estimated using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang-questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] the risk of which disease can be estimated by the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what diseases can be assessed for risk using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the estimated risk of illness in the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can the stop-bang questionnaire estimate?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risks can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what is the risk of disease by using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] the risk of what disease can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what is the risk of the disease using the stop-bang questionnaire?", "what is the risk of a disease that can be estimated by the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated from the stop bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be estimated with a stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed with the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be calculated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risks can the stop-bang questionnaire assess?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be estimated using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang-questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] the risk of which disease can be estimated by the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what diseases can be assessed for risk using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the estimated risk of illness in the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can the stop-bang questionnaire estimate?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risks can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what is the risk of disease by using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] the risk of what disease can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what is the risk of the disease using the stop-bang questionnaire?", "what is the risk of a disease that can be estimated by the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated from the stop bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be estimated with a stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed with the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be calculated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risks can the stop-bang questionnaire assess?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be estimated using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang-questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] the risk of which disease can be estimated by the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what diseases can be assessed for risk using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the estimated risk of illness in the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can the stop-bang questionnaire estimate?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risks can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what is the risk of disease by using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] the risk of what disease can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what is the risk of the disease using the stop-bang questionnaire?", "what is the risk of a disease that can be estimated by the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated from the stop bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be estimated with a stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed with the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be calculated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risks can the stop-bang questionnaire assess?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be estimated using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang-questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] the risk of which disease can be estimated by the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what diseases can be assessed for risk using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the estimated risk of illness in the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can the stop-bang questionnaire estimate?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risks can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what is the risk of disease by using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] the risk of what disease can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what is the risk of the disease using the stop-bang questionnaire?", "what is the risk of a disease that can be estimated by the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated from the stop bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be estimated with a stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed with the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be calculated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risks can the stop-bang questionnaire assess?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be estimated using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang-questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] the risk of which disease can be estimated by the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what diseases can be assessed for risk using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the estimated risk of illness in the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can the stop-bang questionnaire estimate?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risks can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what is the risk of disease by using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] the risk of what disease can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what is the risk of the disease using the stop-bang questionnaire?", "what is the risk of a disease that can be estimated by the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated from the stop bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be estimated with a stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed with the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be calculated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risks can the stop-bang questionnaire assess?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be estimated using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang-questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] the risk of which disease can be estimated by the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what diseases can be assessed for risk using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the estimated risk of illness in the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can the stop-bang questionnaire estimate?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risks can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what is the risk of disease by using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] the risk of what disease can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what is the risk of the disease using the stop-bang questionnaire?", "what is the risk of a disease that can be estimated by the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated from the stop bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be estimated with a stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed with the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be calculated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risks can the stop-bang questionnaire assess?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be estimated using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang-questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] the risk of which disease can be estimated by the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what diseases can be assessed for risk using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the estimated risk of illness in the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can the stop-bang questionnaire estimate?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risks can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what is the risk of disease by using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] the risk of what disease can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what is the risk of the disease using the stop-bang questionnaire?", "what is the risk of a disease that can be estimated by the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated from the stop bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be estimated with a stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed with the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be calculated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risks can the stop-bang questionnaire assess?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be estimated using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang-questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] the risk of which disease can be estimated by the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what diseases can be assessed for risk using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the estimated risk of illness in the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can the stop-bang questionnaire estimate?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risks can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what is the risk of disease by using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] the risk of what disease can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what is the risk of the disease using the stop-bang questionnaire?", "what is the risk of a disease that can be estimated by the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated from the stop bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be estimated with a stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed with the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be calculated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risks can the stop-bang questionnaire assess?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be estimated using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang-questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] the risk of which disease can be estimated by the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what diseases can be assessed for risk using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the estimated risk of illness in the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can the stop-bang questionnaire estimate?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risks can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what is the risk of disease by using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] the risk of what disease can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what is the risk of the disease using the stop-bang questionnaire?", "what is the risk of a disease that can be estimated by the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated from the stop bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be estimated with a stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed with the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be calculated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risks can the stop-bang questionnaire assess?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be estimated using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang-questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] the risk of which disease can be estimated by the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what diseases can be assessed for risk using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the estimated risk of illness in the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can the stop-bang questionnaire estimate?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risks can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what is the risk of disease by using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] the risk of what disease can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what is the risk of the disease using the stop-bang questionnaire?", "what is the risk of a disease that can be estimated by the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated from the stop bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be estimated with a stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed with the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be calculated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risks can the stop-bang questionnaire assess?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be estimated using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang-questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] the risk of which disease can be estimated by the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what diseases can be assessed for risk using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the estimated risk of illness in the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can the stop-bang questionnaire estimate?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risks can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what is the risk of disease by using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] the risk of what disease can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what is the risk of the disease using the stop-bang questionnaire?", "what is the risk of a disease that can be estimated by the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated from the stop bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be estimated with a stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed with the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be calculated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be assessed with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risks can the stop-bang questionnaire assess?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease risk can be estimated using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be estimated with the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang-questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] the risk of which disease can be estimated by the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what diseases can be assessed for risk using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the estimated risk of illness in the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can the stop-bang questionnaire estimate?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease risks can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what is the risk of disease by using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] the risk of what disease can be assessed using the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what is the risk of the disease using the stop-bang questionnaire?", "what is the risk of a disease that can be estimated by the stop-bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated with the stop-bang survey?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease risk can be estimated from the stop bang questionnaire?", "[PAD] [PAD] [PAD] [PAD] what risk of disease can be estimated with a stop-bang questionnaire?", "[PAD] [PAD] centor criteria are used for which disease?", "[PAD] [PAD] sentor criteria are used for which disease?", "[PAD] for which disease are the centor criteria used?", "[PAD] [PAD] for what disease are centor criteria used?", "[PAD] [PAD] in which disease are the central criteria applied?", "[PAD] [PAD] what disease are centor criteria used for?", "[PAD] what diseases are the centor criteria used for?", "for which disease are the center's criteria used?", "[PAD] which centor criteria are used for which disease?", "[PAD] what disease are the centor criteria used for?", "[PAD] what disease is the centor criteria used for?", "[PAD] for which diseases are the centor criteria used?", "[PAD] [PAD] [PAD] for which disease are center criteria used?", "[PAD] [PAD] [PAD] for which disease are centric criteria used?", "[PAD] [PAD] centor criteria are used for what disease?", "[PAD] [PAD] what is the centor criteria used for?", "[PAD] the centor criteria are used for which disease?", "what disease are centor's criteria used for?", "[PAD] [PAD] for which disease are the center criteria used?", "for which disease are the senator's criteria used?", "[PAD] [PAD] what disease is the center criteria used for?", "[PAD] [PAD] [PAD] what are the central criteria used for?", "[PAD] what disease are the criteria of the center used?", "[PAD] which illness is the centor standard used for?", "[PAD] [PAD] for what diseases is the central criterion used?", "for which disease are the centre's criteria used?", "for which disease are the center's criteria applied?", "[PAD] [PAD] for which disease are centor criteria used?", "[PAD] the centor criteria are used for which diseases?", "[PAD] what centor criteria are used for which disease?", "[PAD] [PAD] santour criteria are used for which disease?", "what disease is used for the criteria of zentor?", "for which disease do centor's criteria apply?", "[PAD] [PAD] [PAD] medium parameters are used for what disease?", "[PAD] [PAD] [PAD] center criteria are used for which disease?", "[PAD] [PAD] what diseases does the center criteria apply to?", "[PAD] [PAD] what disease are the center criteria used for?", "[PAD] what is the standard of the center used for?", "[PAD] [PAD] what disease is the center criterion used for?", "[PAD] [PAD] the center criteria are used for which disease?", "[PAD] [PAD] centaur criteria are used for what disease?", "[PAD] [PAD] centor criteria are used for which disease?", "[PAD] [PAD] sentor criteria are used for which disease?", "[PAD] for which disease are the centor criteria used?", "[PAD] [PAD] for what disease are centor criteria used?", "[PAD] [PAD] in which disease are the central criteria applied?", "[PAD] [PAD] what disease are centor criteria used for?", "[PAD] what diseases are the centor criteria used for?", "for which disease are the center's criteria used?", "[PAD] which centor criteria are used for which disease?", "[PAD] what disease are the centor criteria used for?", "[PAD] what disease is the centor criteria used for?", "[PAD] for which diseases are the centor criteria used?", "[PAD] [PAD] [PAD] for which disease are center criteria used?", "[PAD] [PAD] [PAD] for which disease are centric criteria used?", "[PAD] [PAD] centor criteria are used for what disease?", "[PAD] [PAD] what is the centor criteria used for?", "[PAD] the centor criteria are used for which disease?", "what disease are centor's criteria used for?", "[PAD] [PAD] for which disease are the center criteria used?", "for which disease are the senator's criteria used?", "[PAD] [PAD] what disease is the center criteria used for?", "[PAD] [PAD] [PAD] what are the central criteria used for?", "[PAD] what disease are the criteria of the center used?", "[PAD] which illness is the centor standard used for?", "[PAD] [PAD] for what diseases is the central criterion used?", "for which disease are the centre's criteria used?", "for which disease are the center's criteria applied?", "[PAD] [PAD] for which disease are centor criteria used?", "[PAD] the centor criteria are used for which diseases?", "[PAD] what centor criteria are used for which disease?", "[PAD] [PAD] santour criteria are used for which disease?", "what disease is used for the criteria of zentor?", "for which disease do centor's criteria apply?", "[PAD] [PAD] [PAD] medium parameters are used for what disease?", "[PAD] [PAD] [PAD] center criteria are used for which disease?", "[PAD] [PAD] what diseases does the center criteria apply to?", "[PAD] [PAD] what disease are the center criteria used for?", "[PAD] what is the standard of the center used for?", "[PAD] [PAD] what disease is the center criterion used for?", "[PAD] [PAD] the center criteria are used for which disease?", "[PAD] [PAD] centaur criteria are used for what disease?", "[PAD] [PAD] centor criteria are used for which disease?", "[PAD] [PAD] sentor criteria are used for which disease?", "[PAD] for which disease are the centor criteria used?", "[PAD] [PAD] for what disease are centor criteria used?", "[PAD] [PAD] in which disease are the central criteria applied?", "[PAD] [PAD] what disease are centor criteria used for?", "[PAD] what diseases are the centor criteria used for?", "for which disease are the center's criteria used?", "[PAD] which centor criteria are used for which disease?", "[PAD] what disease are the centor criteria used for?", "[PAD] what disease is the centor criteria used for?", "[PAD] for which diseases are the centor criteria used?", "[PAD] [PAD] [PAD] for which disease are center criteria used?", "[PAD] [PAD] [PAD] for which disease are centric criteria used?", "[PAD] [PAD] centor criteria are used for what disease?", "[PAD] [PAD] what is the centor criteria used for?", "[PAD] the centor criteria are used for which disease?", "what disease are centor's criteria used for?", "[PAD] [PAD] for which disease are the center criteria used?", "for which disease are the senator's criteria used?", "[PAD] [PAD] what disease is the center criteria used for?", "[PAD] [PAD] [PAD] what are the central criteria used for?", "[PAD] what disease are the criteria of the center used?", "[PAD] which illness is the centor standard used for?", "[PAD] [PAD] for what diseases is the central criterion used?", "for which disease are the centre's criteria used?", "for which disease are the center's criteria applied?", "[PAD] [PAD] for which disease are centor criteria used?", "[PAD] the centor criteria are used for which diseases?", "[PAD] what centor criteria are used for which disease?", "[PAD] [PAD] santour criteria are used for which disease?", "what disease is used for the criteria of zentor?", "for which disease do centor's criteria apply?", "[PAD] [PAD] [PAD] medium parameters are used for what disease?", "[PAD] [PAD] [PAD] center criteria are used for which disease?", "[PAD] [PAD] what diseases does the center criteria apply to?", "[PAD] [PAD] what disease are the center criteria used for?", "[PAD] what is the standard of the center used for?", "[PAD] [PAD] what disease is the center criterion used for?", "[PAD] [PAD] the center criteria are used for which disease?", "[PAD] [PAD] centaur criteria are used for what disease?", "[PAD] [PAD] centor criteria are used for which disease?", "[PAD] [PAD] sentor criteria are used for which disease?", "[PAD] for which disease are the centor criteria used?", "[PAD] [PAD] for what disease are centor criteria used?", "[PAD] [PAD] in which disease are the central criteria applied?", "[PAD] [PAD] what disease are centor criteria used for?", "[PAD] what diseases are the centor criteria used for?", "for which disease are the center's criteria used?", "[PAD] which centor criteria are used for which disease?", "[PAD] what disease are the centor criteria used for?", "[PAD] what disease is the centor criteria used for?", "[PAD] for which diseases are the centor criteria used?", "[PAD] [PAD] [PAD] for which disease are center criteria used?", "[PAD] [PAD] [PAD] for which disease are centric criteria used?", "[PAD] [PAD] centor criteria are used for what disease?", "[PAD] [PAD] what is the centor criteria used for?", "[PAD] the centor criteria are used for which disease?", "what disease are centor's criteria used for?", "[PAD] [PAD] for which disease are the center criteria used?", "for which disease are the senator's criteria used?", "[PAD] [PAD] what disease is the center criteria used for?", "[PAD] [PAD] [PAD] what are the central criteria used for?", "[PAD] what disease are the criteria of the center used?", "[PAD] which illness is the centor standard used for?", "[PAD] [PAD] for what diseases is the central criterion used?", "for which disease are the centre's criteria used?", "for which disease are the center's criteria applied?", "[PAD] [PAD] for which disease are centor criteria used?", "[PAD] the centor criteria are used for which diseases?", "[PAD] what centor criteria are used for which disease?", "[PAD] [PAD] santour criteria are used for which disease?", "what disease is used for the criteria of zentor?", "for which disease do centor's criteria apply?", "[PAD] [PAD] [PAD] medium parameters are used for what disease?", "[PAD] [PAD] [PAD] center criteria are used for which disease?", "[PAD] [PAD] what diseases does the center criteria apply to?", "[PAD] [PAD] what disease are the center criteria used for?", "[PAD] what is the standard of the center used for?", "[PAD] [PAD] what disease is the center criterion used for?", "[PAD] [PAD] the center criteria are used for which disease?", "[PAD] [PAD] centaur criteria are used for what disease?", "[PAD] [PAD] centor criteria are used for which disease?", "[PAD] [PAD] sentor criteria are used for which disease?", "[PAD] for which disease are the centor criteria used?", "[PAD] [PAD] for what disease are centor criteria used?", "[PAD] [PAD] in which disease are the central criteria applied?", "[PAD] [PAD] what disease are centor criteria used for?", "[PAD] what diseases are the centor criteria used for?", "for which disease are the center's criteria used?", "[PAD] which centor criteria are used for which disease?", "[PAD] what disease are the centor criteria used for?", "[PAD] what disease is the centor criteria used for?", "[PAD] for which diseases are the centor criteria used?", "[PAD] [PAD] [PAD] for which disease are center criteria used?", "[PAD] [PAD] [PAD] for which disease are centric criteria used?", "[PAD] [PAD] centor criteria are used for what disease?", "[PAD] [PAD] what is the centor criteria used for?", "[PAD] the centor criteria are used for which disease?", "what disease are centor's criteria used for?", "[PAD] [PAD] for which disease are the center criteria used?", "for which disease are the senator's criteria used?", "[PAD] [PAD] what disease is the center criteria used for?", "[PAD] [PAD] [PAD] what are the central criteria used for?", "[PAD] what disease are the criteria of the center used?", "[PAD] which illness is the centor standard used for?", "[PAD] [PAD] for what diseases is the central criterion used?", "for which disease are the centre's criteria used?", "for which disease are the center's criteria applied?", "[PAD] [PAD] for which disease are centor criteria used?", "[PAD] the centor criteria are used for which diseases?", "[PAD] what centor criteria are used for which disease?", "[PAD] [PAD] santour criteria are used for which disease?", "what disease is used for the criteria of zentor?", "for which disease do centor's criteria apply?", "[PAD] [PAD] [PAD] medium parameters are used for what disease?", "[PAD] [PAD] [PAD] center criteria are used for which disease?", "[PAD] [PAD] what diseases does the center criteria apply to?", "[PAD] [PAD] what disease are the center criteria used for?", "[PAD] what is the standard of the center used for?", "[PAD] [PAD] what disease is the center criterion used for?", "[PAD] [PAD] the center criteria are used for which disease?", "[PAD] [PAD] centaur criteria are used for what disease?", "[PAD] [PAD] centor criteria are used for which disease?", "[PAD] [PAD] sentor criteria are used for which disease?", "[PAD] for which disease are the centor criteria used?", "[PAD] [PAD] for what disease are centor criteria used?", "[PAD] [PAD] in which disease are the central criteria applied?", "[PAD] [PAD] what disease are centor criteria used for?", "[PAD] what diseases are the centor criteria used for?", "for which disease are the center's criteria used?", "[PAD] which centor criteria are used for which disease?", "[PAD] what disease are the centor criteria used for?", "[PAD] what disease is the centor criteria used for?", "[PAD] for which diseases are the centor criteria used?", "[PAD] [PAD] [PAD] for which disease are center criteria used?", "[PAD] [PAD] [PAD] for which disease are centric criteria used?", "[PAD] [PAD] centor criteria are used for what disease?", "[PAD] [PAD] what is the centor criteria used for?", "[PAD] the centor criteria are used for which disease?", "what disease are centor's criteria used for?", "[PAD] [PAD] for which disease are the center criteria used?", "for which disease are the senator's criteria used?", "[PAD] [PAD] what disease is the center criteria used for?", "[PAD] [PAD] [PAD] what are the central criteria used for?", "[PAD] what disease are the criteria of the center used?", "[PAD] which illness is the centor standard used for?", "[PAD] [PAD] for what diseases is the central criterion used?", "for which disease are the centre's criteria used?", "for which disease are the center's criteria applied?", "[PAD] [PAD] for which disease are centor criteria used?", "[PAD] the centor criteria are used for which diseases?", "[PAD] what centor criteria are used for which disease?", "[PAD] [PAD] santour criteria are used for which disease?", "what disease is used for the criteria of zentor?", "for which disease do centor's criteria apply?", "[PAD] [PAD] [PAD] medium parameters are used for what disease?", "[PAD] [PAD] [PAD] center criteria are used for which disease?", "[PAD] [PAD] what diseases does the center criteria apply to?", "[PAD] [PAD] what disease are the center criteria used for?", "[PAD] what is the standard of the center used for?", "[PAD] [PAD] what disease is the center criterion used for?", "[PAD] [PAD] the center criteria are used for which disease?", "[PAD] [PAD] centaur criteria are used for what disease?", "[PAD] [PAD] centor criteria are used for which disease?", "[PAD] [PAD] sentor criteria are used for which disease?", "[PAD] for which disease are the centor criteria used?", "[PAD] [PAD] for what disease are centor criteria used?", "[PAD] [PAD] in which disease are the central criteria applied?", "[PAD] [PAD] what disease are centor criteria used for?", "[PAD] what diseases are the centor criteria used for?", "for which disease are the center's criteria used?", "[PAD] which centor criteria are used for which disease?", "[PAD] what disease are the centor criteria used for?", "[PAD] what disease is the centor criteria used for?", "[PAD] for which diseases are the centor criteria used?", "[PAD] [PAD] [PAD] for which disease are center criteria used?", "[PAD] [PAD] [PAD] for which disease are centric criteria used?", "[PAD] [PAD] centor criteria are used for what disease?", "[PAD] [PAD] what is the centor criteria used for?", "[PAD] the centor criteria are used for which disease?", "what disease are centor's criteria used for?", "[PAD] [PAD] for which disease are the center criteria used?", "for which disease are the senator's criteria used?", "[PAD] [PAD] what disease is the center criteria used for?", "[PAD] [PAD] [PAD] what are the central criteria used for?", "[PAD] what disease are the criteria of the center used?", "[PAD] which illness is the centor standard used for?", "[PAD] [PAD] for what diseases is the central criterion used?", "for which disease are the centre's criteria used?", "for which disease are the center's criteria applied?", "[PAD] [PAD] for which disease are centor criteria used?", "[PAD] the centor criteria are used for which diseases?", "[PAD] what centor criteria are used for which disease?", "[PAD] [PAD] santour criteria are used for which disease?", "what disease is used for the criteria of zentor?", "for which disease do centor's criteria apply?", "[PAD] [PAD] [PAD] medium parameters are used for what disease?", "[PAD] [PAD] [PAD] center criteria are used for which disease?", "[PAD] [PAD] what diseases does the center criteria apply to?", "[PAD] [PAD] what disease are the center criteria used for?", "[PAD] what is the standard of the center used for?", "[PAD] [PAD] what disease is the center criterion used for?", "[PAD] [PAD] the center criteria are used for which disease?", "[PAD] [PAD] centaur criteria are used for what disease?", "[PAD] [PAD] centor criteria are used for which disease?", "[PAD] [PAD] sentor criteria are used for which disease?", "[PAD] for which disease are the centor criteria used?", "[PAD] [PAD] for what disease are centor criteria used?", "[PAD] [PAD] in which disease are the central criteria applied?", "[PAD] [PAD] what disease are centor criteria used for?", "[PAD] what diseases are the centor criteria used for?", "for which disease are the center's criteria used?", "[PAD] which centor criteria are used for which disease?", "[PAD] what disease are the centor criteria used for?", "[PAD] what disease is the centor criteria used for?", "[PAD] for which diseases are the centor criteria used?", "[PAD] [PAD] [PAD] for which disease are center criteria used?", "[PAD] [PAD] [PAD] for which disease are centric criteria used?", "[PAD] [PAD] centor criteria are used for what disease?", "[PAD] [PAD] what is the centor criteria used for?", "[PAD] the centor criteria are used for which disease?", "what disease are centor's criteria used for?", "[PAD] [PAD] for which disease are the center criteria used?", "for which disease are the senator's criteria used?", "[PAD] [PAD] what disease is the center criteria used for?", "[PAD] [PAD] [PAD] what are the central criteria used for?", "[PAD] what disease are the criteria of the center used?", "[PAD] which illness is the centor standard used for?", "[PAD] [PAD] for what diseases is the central criterion used?", "for which disease are the centre's criteria used?", "for which disease are the center's criteria applied?", "[PAD] [PAD] for which disease are centor criteria used?", "[PAD] the centor criteria are used for which diseases?", "[PAD] what centor criteria are used for which disease?", "[PAD] [PAD] santour criteria are used for which disease?", "what disease is used for the criteria of zentor?", "for which disease do centor's criteria apply?", "[PAD] [PAD] [PAD] medium parameters are used for what disease?", "[PAD] [PAD] [PAD] center criteria are used for which disease?", "[PAD] [PAD] what diseases does the center criteria apply to?", "[PAD] [PAD] what disease are the center criteria used for?", "[PAD] what is the standard of the center used for?", "[PAD] [PAD] what disease is the center criterion used for?", "[PAD] [PAD] the center criteria are used for which disease?", "[PAD] [PAD] centaur criteria are used for what disease?", "[PAD] [PAD] centor criteria are used for which disease?", "[PAD] [PAD] sentor criteria are used for which disease?", "[PAD] for which disease are the centor criteria used?", "[PAD] [PAD] for what disease are centor criteria used?", "[PAD] [PAD] in which disease are the central criteria applied?", "[PAD] [PAD] what disease are centor criteria used for?", "[PAD] what diseases are the centor criteria used for?", "for which disease are the center's criteria used?", "[PAD] which centor criteria are used for which disease?", "[PAD] what disease are the centor criteria used for?", "[PAD] what disease is the centor criteria used for?", "[PAD] for which diseases are the centor criteria used?", "[PAD] [PAD] [PAD] for which disease are center criteria used?", "[PAD] [PAD] [PAD] for which disease are centric criteria used?", "[PAD] [PAD] centor criteria are used for what disease?", "[PAD] [PAD] what is the centor criteria used for?", "[PAD] the centor criteria are used for which disease?", "what disease are centor's criteria used for?", "[PAD] [PAD] for which disease are the center criteria used?", "for which disease are the senator's criteria used?", "[PAD] [PAD] what disease is the center criteria used for?", "[PAD] [PAD] [PAD] what are the central criteria used for?", "[PAD] what disease are the criteria of the center used?", "[PAD] which illness is the centor standard used for?", "[PAD] [PAD] for what diseases is the central criterion used?", "for which disease are the centre's criteria used?", "for which disease are the center's criteria applied?", "[PAD] [PAD] for which disease are centor criteria used?", "[PAD] the centor criteria are used for which diseases?", "[PAD] what centor criteria are used for which disease?", "[PAD] [PAD] santour criteria are used for which disease?", "what disease is used for the criteria of zentor?", "for which disease do centor's criteria apply?", "[PAD] [PAD] [PAD] medium parameters are used for what disease?", "[PAD] [PAD] [PAD] center criteria are used for which disease?", "[PAD] [PAD] what diseases does the center criteria apply to?", "[PAD] [PAD] what disease are the center criteria used for?", "[PAD] what is the standard of the center used for?", "[PAD] [PAD] what disease is the center criterion used for?", "[PAD] [PAD] the center criteria are used for which disease?", "[PAD] [PAD] centaur criteria are used for what disease?", "[PAD] [PAD] centor criteria are used for which disease?", "[PAD] [PAD] sentor criteria are used for which disease?", "[PAD] for which disease are the centor criteria used?", "[PAD] [PAD] for what disease are centor criteria used?", "[PAD] [PAD] in which disease are the central criteria applied?", "[PAD] [PAD] what disease are centor criteria used for?", "[PAD] what diseases are the centor criteria used for?", "for which disease are the center's criteria used?", "[PAD] which centor criteria are used for which disease?", "[PAD] what disease are the centor criteria used for?", "[PAD] what disease is the centor criteria used for?", "[PAD] for which diseases are the centor criteria used?", "[PAD] [PAD] [PAD] for which disease are center criteria used?", "[PAD] [PAD] [PAD] for which disease are centric criteria used?", "[PAD] [PAD] centor criteria are used for what disease?", "[PAD] [PAD] what is the centor criteria used for?", "[PAD] the centor criteria are used for which disease?", "what disease are centor's criteria used for?", "[PAD] [PAD] for which disease are the center criteria used?", "for which disease are the senator's criteria used?", "[PAD] [PAD] what disease is the center criteria used for?", "[PAD] [PAD] [PAD] what are the central criteria used for?", "[PAD] what disease are the criteria of the center used?", "[PAD] which illness is the centor standard used for?", "[PAD] [PAD] for what diseases is the central criterion used?", "for which disease are the centre's criteria used?", "for which disease are the center's criteria applied?", "[PAD] [PAD] for which disease are centor criteria used?", "[PAD] the centor criteria are used for which diseases?", "[PAD] what centor criteria are used for which disease?", "[PAD] [PAD] santour criteria are used for which disease?", "what disease is used for the criteria of zentor?", "for which disease do centor's criteria apply?", "[PAD] [PAD] [PAD] medium parameters are used for what disease?", "[PAD] [PAD] [PAD] center criteria are used for which disease?", "[PAD] [PAD] what diseases does the center criteria apply to?", "[PAD] [PAD] what disease are the center criteria used for?", "[PAD] what is the standard of the center used for?", "[PAD] [PAD] what disease is the center criterion used for?", "[PAD] [PAD] the center criteria are used for which disease?", "[PAD] [PAD] centaur criteria are used for what disease?", "[PAD] [PAD] centor criteria are used for which disease?", "[PAD] [PAD] sentor criteria are used for which disease?", "[PAD] for which disease are the centor criteria used?", "[PAD] [PAD] for what disease are centor criteria used?", "[PAD] [PAD] in which disease are the central criteria applied?", "[PAD] [PAD] what disease are centor criteria used for?", "[PAD] what diseases are the centor criteria used for?", "for which disease are the center's criteria used?", "[PAD] which centor criteria are used for which disease?", "[PAD] what disease are the centor criteria used for?", "[PAD] what disease is the centor criteria used for?", "[PAD] for which diseases are the centor criteria used?", "[PAD] [PAD] [PAD] for which disease are center criteria used?", "[PAD] [PAD] [PAD] for which disease are centric criteria used?", "[PAD] [PAD] centor criteria are used for what disease?", "[PAD] [PAD] what is the centor criteria used for?", "[PAD] the centor criteria are used for which disease?", "what disease are centor's criteria used for?", "[PAD] [PAD] for which disease are the center criteria used?", "for which disease are the senator's criteria used?", "[PAD] [PAD] what disease is the center criteria used for?", "[PAD] [PAD] [PAD] what are the central criteria used for?", "[PAD] what disease are the criteria of the center used?", "[PAD] which illness is the centor standard used for?", "[PAD] [PAD] for what diseases is the central criterion used?", "for which disease are the centre's criteria used?", "for which disease are the center's criteria applied?", "[PAD] [PAD] for which disease are centor criteria used?", "[PAD] the centor criteria are used for which diseases?", "[PAD] what centor criteria are used for which disease?", "[PAD] [PAD] santour criteria are used for which disease?", "what disease is used for the criteria of zentor?", "for which disease do centor's criteria apply?", "[PAD] [PAD] [PAD] medium parameters are used for what disease?", "[PAD] [PAD] [PAD] center criteria are used for which disease?", "[PAD] [PAD] what diseases does the center criteria apply to?", "[PAD] [PAD] what disease are the center criteria used for?", "[PAD] what is the standard of the center used for?", "[PAD] [PAD] what disease is the center criterion used for?", "[PAD] [PAD] the center criteria are used for which disease?", "[PAD] [PAD] centaur criteria are used for what disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] falciform ligament sign is characteristic to which disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] falciform ligament sign is characteristic of which disease?", "[PAD] [PAD] for which disease is the sign of the falciform ligament characteristic?", "[PAD] [PAD] [PAD] cruciate ligament sign is a characteristic feature of which disease?", "[PAD] [PAD] [PAD] [PAD] what disease is characterized by the sign of a false ligament?", "[PAD] [PAD] [PAD] [PAD] what disease is characterized by a false ligament symptom?", "[PAD] [PAD] [PAD] what diseases are characterized by a sign of a sickle ligament?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease is characterized by a fold-like ligament?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease is characterized by the falcipar ligament?", "[PAD] [PAD] [PAD] what disease is characterized by the sign of the sickle ligament?", "[PAD] [PAD] [PAD] [PAD] which disease is characterized by the falciform ligament sign?", "[PAD] [PAD] which disease is characterized by the sign of the falciform ligament?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease is characteristic of the falciform ligament?", "[PAD] [PAD] [PAD] [PAD] [PAD] falciform ligament signs are characteristic of which disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] falciform ligament sign is characteristic of what disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease is characterized by a falseform trait?", "[PAD] [PAD] [PAD] [PAD] the falciform ligament sign is characteristic in which disease?", "[PAD] [PAD] [PAD] [PAD] which disease is characterized by the falciform ligament mark?", "[PAD] [PAD] the sign of the falciform ligament is characteristic of which disease?", "[PAD] [PAD] [PAD] [PAD] which disease is characterized by the sign of false ligaments?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease is the falciform ligament characteristic of?", "[PAD] [PAD] [PAD] in which disease is the sign of the phallic ligament characteristic?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what are the hallmarks of false ligament disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] falciform ligament characteristic of which disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease is characterized by falciform ligament sign?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease is characterized by the falcis ligament mark?", "[PAD] [PAD] [PAD] [PAD] [PAD] falciform ligament marker is characteristic of any disease?", "[PAD] [PAD] the sign of the falciform ligament is characteristic of what disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease is characteristic of falciform ligament sign?", "[PAD] [PAD] the sign of the sickle cell ligament is characteristic of which disease?", "[PAD] [PAD] which disease is characteristic of the signs of the falciform ligament?", "[PAD] [PAD] [PAD] [PAD] [PAD] what diseases are characteristic of falciform ligament signs?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which disease is characterized by falsification?", "[PAD] [PAD] [PAD] [PAD] which disease has the characteristics of a falciform ligament?", "[PAD] [PAD] which disease is characterized by the sign of the phallic ligaments?", "[PAD] [PAD] [PAD] the sign of the sickle ligament is characteristic for which disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the characteristic sign of falsiform ligament?", "[PAD] [PAD] [PAD] for what disease is the sign of the sickle ligament characteristic?", "[PAD] [PAD] [PAD] [PAD] the sickle cell ligament sign is characteristic of which disease?", "what disease is characterized by a symptom of the falciform ligament?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which disease is characterized by falciform ligament?", "[PAD] [PAD] [PAD] [PAD] the falciform ligament sign is characteristic of which disease?", "[PAD] the sign of the falciform ligament is a characteristic of what disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] enfalciform mark is it specific to any disease?", "[PAD] [PAD] [PAD] [PAD] what disease is the falciform ligament sign characteristic of?", "[PAD] [PAD] [PAD] [PAD] which disease is characterized by a sign of facial ligaments?", "[PAD] [PAD] [PAD] [PAD] what are the signs of anterior cruciate ligament strain?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] falciform nappy sign typical of what disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] falsiform ligament sign is characteristic of what disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] falciform ligament sign is characteristic to which disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] falciform ligament sign is characteristic of which disease?", "[PAD] [PAD] for which disease is the sign of the falciform ligament characteristic?", "[PAD] [PAD] [PAD] cruciate ligament sign is a characteristic feature of which disease?", "[PAD] [PAD] [PAD] [PAD] what disease is characterized by the sign of a false ligament?", "[PAD] [PAD] [PAD] [PAD] what disease is characterized by a false ligament symptom?", "[PAD] [PAD] [PAD] what diseases are characterized by a sign of a sickle ligament?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease is characterized by a fold-like ligament?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease is characterized by the falcipar ligament?", "[PAD] [PAD] [PAD] what disease is characterized by the sign of the sickle ligament?", "[PAD] [PAD] [PAD] [PAD] which disease is characterized by the falciform ligament sign?", "[PAD] [PAD] which disease is characterized by the sign of the falciform ligament?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease is characteristic of the falciform ligament?", "[PAD] [PAD] [PAD] [PAD] [PAD] falciform ligament signs are characteristic of which disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] falciform ligament sign is characteristic of what disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease is characterized by a falseform trait?", "[PAD] [PAD] [PAD] [PAD] the falciform ligament sign is characteristic in which disease?", "[PAD] [PAD] [PAD] [PAD] which disease is characterized by the falciform ligament mark?", "[PAD] [PAD] the sign of the falciform ligament is characteristic of which disease?", "[PAD] [PAD] [PAD] [PAD] which disease is characterized by the sign of false ligaments?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease is the falciform ligament characteristic of?", "[PAD] [PAD] [PAD] in which disease is the sign of the phallic ligament characteristic?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what are the hallmarks of false ligament disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] falciform ligament characteristic of which disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease is characterized by falciform ligament sign?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease is characterized by the falcis ligament mark?", "[PAD] [PAD] [PAD] [PAD] [PAD] falciform ligament marker is characteristic of any disease?", "[PAD] [PAD] the sign of the falciform ligament is characteristic of what disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease is characteristic of falciform ligament sign?", "[PAD] [PAD] the sign of the sickle cell ligament is characteristic of which disease?", "[PAD] [PAD] which disease is characteristic of the signs of the falciform ligament?", "[PAD] [PAD] [PAD] [PAD] [PAD] what diseases are characteristic of falciform ligament signs?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which disease is characterized by falsification?", "[PAD] [PAD] [PAD] [PAD] which disease has the characteristics of a falciform ligament?", "[PAD] [PAD] which disease is characterized by the sign of the phallic ligaments?", "[PAD] [PAD] [PAD] the sign of the sickle ligament is characteristic for which disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the characteristic sign of falsiform ligament?", "[PAD] [PAD] [PAD] for what disease is the sign of the sickle ligament characteristic?", "[PAD] [PAD] [PAD] [PAD] the sickle cell ligament sign is characteristic of which disease?", "what disease is characterized by a symptom of the falciform ligament?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which disease is characterized by falciform ligament?", "[PAD] [PAD] [PAD] [PAD] the falciform ligament sign is characteristic of which disease?", "[PAD] the sign of the falciform ligament is a characteristic of what disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] enfalciform mark is it specific to any disease?", "[PAD] [PAD] [PAD] [PAD] what disease is the falciform ligament sign characteristic of?", "[PAD] [PAD] [PAD] [PAD] which disease is characterized by a sign of facial ligaments?", "[PAD] [PAD] [PAD] [PAD] what are the signs of anterior cruciate ligament strain?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] falciform nappy sign typical of what disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] falsiform ligament sign is characteristic of what disease?", "[PAD] what disease is the alk tyrosine kinase associated with?", "[PAD] with what disease is the alk tyrosine kinase associated?", "[PAD] [PAD] what disease is alk tyrosine kinase associated with?", "[PAD] [PAD] what disease is associated with alk tyrosine kinase?", "[PAD] what is the disease associated with alk tyrosine kinase?", "[PAD] [PAD] what diseases is alk tyrosine kinase associated with?", "[PAD] what diseases are alk tyrosine kinases associated with?", "[PAD] [PAD] which disease is alk tyrosine kinase associated with?", "[PAD] [PAD] alk tyrosine kinase is related to which disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is alk tyrosine kinase?", "[PAD] what disease is the alk tyrosine kinase linked to?", "[PAD] [PAD] what diseases are associated with alk tyrosine kinase?", "[PAD] [PAD] what diseases is alk tyrosine kinase linked to?", "je! alk tyrosine kinase is associated with what disease?", "[PAD] [PAD] alk tyrosine kinase is associated with which disease?", "[PAD] [PAD] what disease is alk tyrosine kinase involved in?", "[PAD] [PAD] what disease is tyrosine kinase alk associated with?", "[PAD] what disease is the alk tyrosine kinase associated with?", "[PAD] with what disease is the alk tyrosine kinase associated?", "[PAD] [PAD] what disease is alk tyrosine kinase associated with?", "[PAD] [PAD] what disease is associated with alk tyrosine kinase?", "[PAD] what is the disease associated with alk tyrosine kinase?", "[PAD] [PAD] what diseases is alk tyrosine kinase associated with?", "[PAD] what diseases are alk tyrosine kinases associated with?", "[PAD] [PAD] which disease is alk tyrosine kinase associated with?", "[PAD] [PAD] alk tyrosine kinase is related to which disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is alk tyrosine kinase?", "[PAD] what disease is the alk tyrosine kinase linked to?", "[PAD] [PAD] what diseases are associated with alk tyrosine kinase?", "[PAD] [PAD] what diseases is alk tyrosine kinase linked to?", "je! alk tyrosine kinase is associated with what disease?", "[PAD] [PAD] alk tyrosine kinase is associated with which disease?", "[PAD] [PAD] what disease is alk tyrosine kinase involved in?", "[PAD] [PAD] what disease is tyrosine kinase alk associated with?", "[PAD] what disease is the alk tyrosine kinase associated with?", "[PAD] with what disease is the alk tyrosine kinase associated?", "[PAD] [PAD] what disease is alk tyrosine kinase associated with?", "[PAD] [PAD] what disease is associated with alk tyrosine kinase?", "[PAD] what is the disease associated with alk tyrosine kinase?", "[PAD] [PAD] what diseases is alk tyrosine kinase associated with?", "[PAD] what diseases are alk tyrosine kinases associated with?", "[PAD] [PAD] which disease is alk tyrosine kinase associated with?", "[PAD] [PAD] alk tyrosine kinase is related to which disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is alk tyrosine kinase?", "[PAD] what disease is the alk tyrosine kinase linked to?", "[PAD] [PAD] what diseases are associated with alk tyrosine kinase?", "[PAD] [PAD] what diseases is alk tyrosine kinase linked to?", "je! alk tyrosine kinase is associated with what disease?", "[PAD] [PAD] alk tyrosine kinase is associated with which disease?", "[PAD] [PAD] what disease is alk tyrosine kinase involved in?", "[PAD] [PAD] what disease is tyrosine kinase alk associated with?", "[PAD] what disease is the alk tyrosine kinase associated with?", "[PAD] with what disease is the alk tyrosine kinase associated?", "[PAD] [PAD] what disease is alk tyrosine kinase associated with?", "[PAD] [PAD] what disease is associated with alk tyrosine kinase?", "[PAD] what is the disease associated with alk tyrosine kinase?", "[PAD] [PAD] what diseases is alk tyrosine kinase associated with?", "[PAD] what diseases are alk tyrosine kinases associated with?", "[PAD] [PAD] which disease is alk tyrosine kinase associated with?", "[PAD] [PAD] alk tyrosine kinase is related to which disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is alk tyrosine kinase?", "[PAD] what disease is the alk tyrosine kinase linked to?", "[PAD] [PAD] what diseases are associated with alk tyrosine kinase?", "[PAD] [PAD] what diseases is alk tyrosine kinase linked to?", "je! alk tyrosine kinase is associated with what disease?", "[PAD] [PAD] alk tyrosine kinase is associated with which disease?", "[PAD] [PAD] what disease is alk tyrosine kinase involved in?", "[PAD] [PAD] what disease is tyrosine kinase alk associated with?", "[PAD] what disease is the alk tyrosine kinase associated with?", "[PAD] with what disease is the alk tyrosine kinase associated?", "[PAD] [PAD] what disease is alk tyrosine kinase associated with?", "[PAD] [PAD] what disease is associated with alk tyrosine kinase?", "[PAD] what is the disease associated with alk tyrosine kinase?", "[PAD] [PAD] what diseases is alk tyrosine kinase associated with?", "[PAD] what diseases are alk tyrosine kinases associated with?", "[PAD] [PAD] which disease is alk tyrosine kinase associated with?", "[PAD] [PAD] alk tyrosine kinase is related to which disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is alk tyrosine kinase?", "[PAD] what disease is the alk tyrosine kinase linked to?", "[PAD] [PAD] what diseases are associated with alk tyrosine kinase?", "[PAD] [PAD] what diseases is alk tyrosine kinase linked to?", "je! alk tyrosine kinase is associated with what disease?", "[PAD] [PAD] alk tyrosine kinase is associated with which disease?", "[PAD] [PAD] what disease is alk tyrosine kinase involved in?", "[PAD] [PAD] what disease is tyrosine kinase alk associated with?", "[PAD] what disease is the alk tyrosine kinase associated with?", "[PAD] with what disease is the alk tyrosine kinase associated?", "[PAD] [PAD] what disease is alk tyrosine kinase associated with?", "[PAD] [PAD] what disease is associated with alk tyrosine kinase?", "[PAD] what is the disease associated with alk tyrosine kinase?", "[PAD] [PAD] what diseases is alk tyrosine kinase associated with?", "[PAD] what diseases are alk tyrosine kinases associated with?", "[PAD] [PAD] which disease is alk tyrosine kinase associated with?", "[PAD] [PAD] alk tyrosine kinase is related to which disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is alk tyrosine kinase?", "[PAD] what disease is the alk tyrosine kinase linked to?", "[PAD] [PAD] what diseases are associated with alk tyrosine kinase?", "[PAD] [PAD] what diseases is alk tyrosine kinase linked to?", "je! alk tyrosine kinase is associated with what disease?", "[PAD] [PAD] alk tyrosine kinase is associated with which disease?", "[PAD] [PAD] what disease is alk tyrosine kinase involved in?", "[PAD] [PAD] what disease is tyrosine kinase alk associated with?", "[PAD] what disease is the alk tyrosine kinase associated with?", "[PAD] with what disease is the alk tyrosine kinase associated?", "[PAD] [PAD] what disease is alk tyrosine kinase associated with?", "[PAD] [PAD] what disease is associated with alk tyrosine kinase?", "[PAD] what is the disease associated with alk tyrosine kinase?", "[PAD] [PAD] what diseases is alk tyrosine kinase associated with?", "[PAD] what diseases are alk tyrosine kinases associated with?", "[PAD] [PAD] which disease is alk tyrosine kinase associated with?", "[PAD] [PAD] alk tyrosine kinase is related to which disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is alk tyrosine kinase?", "[PAD] what disease is the alk tyrosine kinase linked to?", "[PAD] [PAD] what diseases are associated with alk tyrosine kinase?", "[PAD] [PAD] what diseases is alk tyrosine kinase linked to?", "je! alk tyrosine kinase is associated with what disease?", "[PAD] [PAD] alk tyrosine kinase is associated with which disease?", "[PAD] [PAD] what disease is alk tyrosine kinase involved in?", "[PAD] [PAD] what disease is tyrosine kinase alk associated with?", "[PAD] what disease is the alk tyrosine kinase associated with?", "[PAD] with what disease is the alk tyrosine kinase associated?", "[PAD] [PAD] what disease is alk tyrosine kinase associated with?", "[PAD] [PAD] what disease is associated with alk tyrosine kinase?", "[PAD] what is the disease associated with alk tyrosine kinase?", "[PAD] [PAD] what diseases is alk tyrosine kinase associated with?", "[PAD] what diseases are alk tyrosine kinases associated with?", "[PAD] [PAD] which disease is alk tyrosine kinase associated with?", "[PAD] [PAD] alk tyrosine kinase is related to which disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is alk tyrosine kinase?", "[PAD] what disease is the alk tyrosine kinase linked to?", "[PAD] [PAD] what diseases are associated with alk tyrosine kinase?", "[PAD] [PAD] what diseases is alk tyrosine kinase linked to?", "je! alk tyrosine kinase is associated with what disease?", "[PAD] [PAD] alk tyrosine kinase is associated with which disease?", "[PAD] [PAD] what disease is alk tyrosine kinase involved in?", "[PAD] [PAD] what disease is tyrosine kinase alk associated with?", "[PAD] what disease is the alk tyrosine kinase associated with?", "[PAD] with what disease is the alk tyrosine kinase associated?", "[PAD] [PAD] what disease is alk tyrosine kinase associated with?", "[PAD] [PAD] what disease is associated with alk tyrosine kinase?", "[PAD] what is the disease associated with alk tyrosine kinase?", "[PAD] [PAD] what diseases is alk tyrosine kinase associated with?", "[PAD] what diseases are alk tyrosine kinases associated with?", "[PAD] [PAD] which disease is alk tyrosine kinase associated with?", "[PAD] [PAD] alk tyrosine kinase is related to which disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is alk tyrosine kinase?", "[PAD] what disease is the alk tyrosine kinase linked to?", "[PAD] [PAD] what diseases are associated with alk tyrosine kinase?", "[PAD] [PAD] what diseases is alk tyrosine kinase linked to?", "je! alk tyrosine kinase is associated with what disease?", "[PAD] [PAD] alk tyrosine kinase is associated with which disease?", "[PAD] [PAD] what disease is alk tyrosine kinase involved in?", "[PAD] [PAD] what disease is tyrosine kinase alk associated with?", "[PAD] what disease is the alk tyrosine kinase associated with?", "[PAD] with what disease is the alk tyrosine kinase associated?", "[PAD] [PAD] what disease is alk tyrosine kinase associated with?", "[PAD] [PAD] what disease is associated with alk tyrosine kinase?", "[PAD] what is the disease associated with alk tyrosine kinase?", "[PAD] [PAD] what diseases is alk tyrosine kinase associated with?", "[PAD] what diseases are alk tyrosine kinases associated with?", "[PAD] [PAD] which disease is alk tyrosine kinase associated with?", "[PAD] [PAD] alk tyrosine kinase is related to which disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is alk tyrosine kinase?", "[PAD] what disease is the alk tyrosine kinase linked to?", "[PAD] [PAD] what diseases are associated with alk tyrosine kinase?", "[PAD] [PAD] what diseases is alk tyrosine kinase linked to?", "je! alk tyrosine kinase is associated with what disease?", "[PAD] [PAD] alk tyrosine kinase is associated with which disease?", "[PAD] [PAD] what disease is alk tyrosine kinase involved in?", "[PAD] [PAD] what disease is tyrosine kinase alk associated with?", "[PAD] what disease is the alk tyrosine kinase associated with?", "[PAD] with what disease is the alk tyrosine kinase associated?", "[PAD] [PAD] what disease is alk tyrosine kinase associated with?", "[PAD] [PAD] what disease is associated with alk tyrosine kinase?", "[PAD] what is the disease associated with alk tyrosine kinase?", "[PAD] [PAD] what diseases is alk tyrosine kinase associated with?", "[PAD] what diseases are alk tyrosine kinases associated with?", "[PAD] [PAD] which disease is alk tyrosine kinase associated with?", "[PAD] [PAD] alk tyrosine kinase is related to which disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is alk tyrosine kinase?", "[PAD] what disease is the alk tyrosine kinase linked to?", "[PAD] [PAD] what diseases are associated with alk tyrosine kinase?", "[PAD] [PAD] what diseases is alk tyrosine kinase linked to?", "je! alk tyrosine kinase is associated with what disease?", "[PAD] [PAD] alk tyrosine kinase is associated with which disease?", "[PAD] [PAD] what disease is alk tyrosine kinase involved in?", "[PAD] [PAD] what disease is tyrosine kinase alk associated with?", "[PAD] what disease is the alk tyrosine kinase associated with?", "[PAD] with what disease is the alk tyrosine kinase associated?", "[PAD] [PAD] what disease is alk tyrosine kinase associated with?", "[PAD] [PAD] what disease is associated with alk tyrosine kinase?", "[PAD] what is the disease associated with alk tyrosine kinase?", "[PAD] [PAD] what diseases is alk tyrosine kinase associated with?", "[PAD] what diseases are alk tyrosine kinases associated with?", "[PAD] [PAD] which disease is alk tyrosine kinase associated with?", "[PAD] [PAD] alk tyrosine kinase is related to which disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is alk tyrosine kinase?", "[PAD] what disease is the alk tyrosine kinase linked to?", "[PAD] [PAD] what diseases are associated with alk tyrosine kinase?", "[PAD] [PAD] what diseases is alk tyrosine kinase linked to?", "je! alk tyrosine kinase is associated with what disease?", "[PAD] [PAD] alk tyrosine kinase is associated with which disease?", "[PAD] [PAD] what disease is alk tyrosine kinase involved in?", "[PAD] [PAD] what disease is tyrosine kinase alk associated with?", "[PAD] what disease is the alk tyrosine kinase associated with?", "[PAD] with what disease is the alk tyrosine kinase associated?", "[PAD] [PAD] what disease is alk tyrosine kinase associated with?", "[PAD] [PAD] what disease is associated with alk tyrosine kinase?", "[PAD] what is the disease associated with alk tyrosine kinase?", "[PAD] [PAD] what diseases is alk tyrosine kinase associated with?", "[PAD] what diseases are alk tyrosine kinases associated with?", "[PAD] [PAD] which disease is alk tyrosine kinase associated with?", "[PAD] [PAD] alk tyrosine kinase is related to which disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is alk tyrosine kinase?", "[PAD] what disease is the alk tyrosine kinase linked to?", "[PAD] [PAD] what diseases are associated with alk tyrosine kinase?", "[PAD] [PAD] what diseases is alk tyrosine kinase linked to?", "je! alk tyrosine kinase is associated with what disease?", "[PAD] [PAD] alk tyrosine kinase is associated with which disease?", "[PAD] [PAD] what disease is alk tyrosine kinase involved in?", "[PAD] [PAD] what disease is tyrosine kinase alk associated with?", "[PAD] what disease is the alk tyrosine kinase associated with?", "[PAD] with what disease is the alk tyrosine kinase associated?", "[PAD] [PAD] what disease is alk tyrosine kinase associated with?", "[PAD] [PAD] what disease is associated with alk tyrosine kinase?", "[PAD] what is the disease associated with alk tyrosine kinase?", "[PAD] [PAD] what diseases is alk tyrosine kinase associated with?", "[PAD] what diseases are alk tyrosine kinases associated with?", "[PAD] [PAD] which disease is alk tyrosine kinase associated with?", "[PAD] [PAD] alk tyrosine kinase is related to which disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is alk tyrosine kinase?", "[PAD] what disease is the alk tyrosine kinase linked to?", "[PAD] [PAD] what diseases are associated with alk tyrosine kinase?", "[PAD] [PAD] what diseases is alk tyrosine kinase linked to?", "je! alk tyrosine kinase is associated with what disease?", "[PAD] [PAD] alk tyrosine kinase is associated with which disease?", "[PAD] [PAD] what disease is alk tyrosine kinase involved in?", "[PAD] [PAD] what disease is tyrosine kinase alk associated with?", "[PAD] what disease is the alk tyrosine kinase associated with?", "[PAD] with what disease is the alk tyrosine kinase associated?", "[PAD] [PAD] what disease is alk tyrosine kinase associated with?", "[PAD] [PAD] what disease is associated with alk tyrosine kinase?", "[PAD] what is the disease associated with alk tyrosine kinase?", "[PAD] [PAD] what diseases is alk tyrosine kinase associated with?", "[PAD] what diseases are alk tyrosine kinases associated with?", "[PAD] [PAD] which disease is alk tyrosine kinase associated with?", "[PAD] [PAD] alk tyrosine kinase is related to which disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is alk tyrosine kinase?", "[PAD] what disease is the alk tyrosine kinase linked to?", "[PAD] [PAD] what diseases are associated with alk tyrosine kinase?", "[PAD] [PAD] what diseases is alk tyrosine kinase linked to?", "je! alk tyrosine kinase is associated with what disease?", "[PAD] [PAD] alk tyrosine kinase is associated with which disease?", "[PAD] [PAD] what disease is alk tyrosine kinase involved in?", "[PAD] [PAD] what disease is tyrosine kinase alk associated with?", "[PAD] what disease is the alk tyrosine kinase associated with?", "[PAD] with what disease is the alk tyrosine kinase associated?", "[PAD] [PAD] what disease is alk tyrosine kinase associated with?", "[PAD] [PAD] what disease is associated with alk tyrosine kinase?", "[PAD] what is the disease associated with alk tyrosine kinase?", "[PAD] [PAD] what diseases is alk tyrosine kinase associated with?", "[PAD] what diseases are alk tyrosine kinases associated with?", "[PAD] [PAD] which disease is alk tyrosine kinase associated with?", "[PAD] [PAD] alk tyrosine kinase is related to which disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is alk tyrosine kinase?", "[PAD] what disease is the alk tyrosine kinase linked to?", "[PAD] [PAD] what diseases are associated with alk tyrosine kinase?", "[PAD] [PAD] what diseases is alk tyrosine kinase linked to?", "je! alk tyrosine kinase is associated with what disease?", "[PAD] [PAD] alk tyrosine kinase is associated with which disease?", "[PAD] [PAD] what disease is alk tyrosine kinase involved in?", "[PAD] [PAD] what disease is tyrosine kinase alk associated with?", "[PAD] what disease is the alk tyrosine kinase associated with?", "[PAD] with what disease is the alk tyrosine kinase associated?", "[PAD] [PAD] what disease is alk tyrosine kinase associated with?", "[PAD] [PAD] what disease is associated with alk tyrosine kinase?", "[PAD] what is the disease associated with alk tyrosine kinase?", "[PAD] [PAD] what diseases is alk tyrosine kinase associated with?", "[PAD] what diseases are alk tyrosine kinases associated with?", "[PAD] [PAD] which disease is alk tyrosine kinase associated with?", "[PAD] [PAD] alk tyrosine kinase is related to which disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is alk tyrosine kinase?", "[PAD] what disease is the alk tyrosine kinase linked to?", "[PAD] [PAD] what diseases are associated with alk tyrosine kinase?", "[PAD] [PAD] what diseases is alk tyrosine kinase linked to?", "je! alk tyrosine kinase is associated with what disease?", "[PAD] [PAD] alk tyrosine kinase is associated with which disease?", "[PAD] [PAD] what disease is alk tyrosine kinase involved in?", "[PAD] [PAD] what disease is tyrosine kinase alk associated with?", "[PAD] [PAD] curb65 score is used for stratification of which disease?", "[PAD] [PAD] the curb65 result is used for which disease stratification?", "is the curb65 score used in the stratification of which disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] for which disease is curb65 used?", "[PAD] [PAD] curb65 honey is used for stratification of which disease?", "[PAD] [PAD] what disease is the curb65 score used for stratification?", "[PAD] [PAD] the curb65 score is used to stratify which disease?", "[PAD] [PAD] [PAD] curb65 result is used to stratify which disease?", "[PAD] [PAD] which disease is the curb65 score used to stratify?", "[PAD] [PAD] [PAD] curb65 score is used to stratify which disease?", "[PAD] [PAD] for which disease stratification is the curb65 score used?", "[PAD] [PAD] curb65 score is used for stratification of what disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease is curb65 used to indicate?", "the curb65 score is used for the stratification of which disease?", "[PAD] curb65 score is used for the stratification of what disease?", "[PAD] [PAD] [PAD] [PAD] curb65 scores are used for disease stratification?", "[PAD] [PAD] what disease stratification is the curb65 score used for?", "[PAD] [PAD] which disease is the curb65 score used for stratification?", "[PAD] [PAD] curb65 score is used for stratification of any disease?", "[PAD] [PAD] the curb65 score is used to stratify what disease?", "[PAD] the curb65 score is used for stratification of which disease?", "[PAD] [PAD] which disease stratification is the curb65 score used for?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease is the curb65 score used for?", "[PAD] [PAD] for which disease stratification is the curb65 index used?", "[PAD] [PAD] the curb65 score is used for which disease stratification?", "[PAD] [PAD] is the curb65 score used to stratify which disease?", "[PAD] [PAD] [PAD] [PAD] curb65 score is used to classify which disease?", "[PAD] [PAD] [PAD] [PAD] which disease is curb65 used to stratify?", "[PAD] [PAD] the curb65 scale is used to stratify what disease?", "[PAD] [PAD] [PAD] is curb65 score used to stratify which disease?", "[PAD] [PAD] [PAD] [PAD] the curb65 mark is applied to what disease class?", "[PAD] [PAD] curb65 points are used for stratification of which disease?", "[PAD] [PAD] [PAD] which disease is the curb65 score used to classify?", "[PAD] [PAD] [PAD] [PAD] curb65 score is used for classification of which disease?", "[PAD] [PAD] the curb65 score is used for stratifying which disease?", "[PAD] [PAD] curb65 score is used for stratification of which disease?", "[PAD] [PAD] the curb65 result is used for which disease stratification?", "is the curb65 score used in the stratification of which disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] for which disease is curb65 used?", "[PAD] [PAD] curb65 honey is used for stratification of which disease?", "[PAD] [PAD] what disease is the curb65 score used for stratification?", "[PAD] [PAD] the curb65 score is used to stratify which disease?", "[PAD] [PAD] [PAD] curb65 result is used to stratify which disease?", "[PAD] [PAD] which disease is the curb65 score used to stratify?", "[PAD] [PAD] [PAD] curb65 score is used to stratify which disease?", "[PAD] [PAD] for which disease stratification is the curb65 score used?", "[PAD] [PAD] curb65 score is used for stratification of what disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease is curb65 used to indicate?", "the curb65 score is used for the stratification of which disease?", "[PAD] curb65 score is used for the stratification of what disease?", "[PAD] [PAD] [PAD] [PAD] curb65 scores are used for disease stratification?", "[PAD] [PAD] what disease stratification is the curb65 score used for?", "[PAD] [PAD] which disease is the curb65 score used for stratification?", "[PAD] [PAD] curb65 score is used for stratification of any disease?", "[PAD] [PAD] the curb65 score is used to stratify what disease?", "[PAD] the curb65 score is used for stratification of which disease?", "[PAD] [PAD] which disease stratification is the curb65 score used for?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease is the curb65 score used for?", "[PAD] [PAD] for which disease stratification is the curb65 index used?", "[PAD] [PAD] the curb65 score is used for which disease stratification?", "[PAD] [PAD] is the curb65 score used to stratify which disease?", "[PAD] [PAD] [PAD] [PAD] curb65 score is used to classify which disease?", "[PAD] [PAD] [PAD] [PAD] which disease is curb65 used to stratify?", "[PAD] [PAD] the curb65 scale is used to stratify what disease?", "[PAD] [PAD] [PAD] is curb65 score used to stratify which disease?", "[PAD] [PAD] [PAD] [PAD] the curb65 mark is applied to what disease class?", "[PAD] [PAD] curb65 points are used for stratification of which disease?", "[PAD] [PAD] [PAD] which disease is the curb65 score used to classify?", "[PAD] [PAD] [PAD] [PAD] curb65 score is used for classification of which disease?", "[PAD] [PAD] the curb65 score is used for stratifying which disease?", "[PAD] [PAD] curb65 score is used for stratification of which disease?", "[PAD] [PAD] the curb65 result is used for which disease stratification?", "is the curb65 score used in the stratification of which disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] for which disease is curb65 used?", "[PAD] [PAD] curb65 honey is used for stratification of which disease?", "[PAD] [PAD] what disease is the curb65 score used for stratification?", "[PAD] [PAD] the curb65 score is used to stratify which disease?", "[PAD] [PAD] [PAD] curb65 result is used to stratify which disease?", "[PAD] [PAD] which disease is the curb65 score used to stratify?", "[PAD] [PAD] [PAD] curb65 score is used to stratify which disease?", "[PAD] [PAD] for which disease stratification is the curb65 score used?", "[PAD] [PAD] curb65 score is used for stratification of what disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease is curb65 used to indicate?", "the curb65 score is used for the stratification of which disease?", "[PAD] curb65 score is used for the stratification of what disease?", "[PAD] [PAD] [PAD] [PAD] curb65 scores are used for disease stratification?", "[PAD] [PAD] what disease stratification is the curb65 score used for?", "[PAD] [PAD] which disease is the curb65 score used for stratification?", "[PAD] [PAD] curb65 score is used for stratification of any disease?", "[PAD] [PAD] the curb65 score is used to stratify what disease?", "[PAD] the curb65 score is used for stratification of which disease?", "[PAD] [PAD] which disease stratification is the curb65 score used for?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease is the curb65 score used for?", "[PAD] [PAD] for which disease stratification is the curb65 index used?", "[PAD] [PAD] the curb65 score is used for which disease stratification?", "[PAD] [PAD] is the curb65 score used to stratify which disease?", "[PAD] [PAD] [PAD] [PAD] curb65 score is used to classify which disease?", "[PAD] [PAD] [PAD] [PAD] which disease is curb65 used to stratify?", "[PAD] [PAD] the curb65 scale is used to stratify what disease?", "[PAD] [PAD] [PAD] is curb65 score used to stratify which disease?", "[PAD] [PAD] [PAD] [PAD] the curb65 mark is applied to what disease class?", "[PAD] [PAD] curb65 points are used for stratification of which disease?", "[PAD] [PAD] [PAD] which disease is the curb65 score used to classify?", "[PAD] [PAD] [PAD] [PAD] curb65 score is used for classification of which disease?", "[PAD] [PAD] the curb65 score is used for stratifying which disease?", "[PAD] [PAD] curb65 score is used for stratification of which disease?", "[PAD] [PAD] the curb65 result is used for which disease stratification?", "is the curb65 score used in the stratification of which disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] for which disease is curb65 used?", "[PAD] [PAD] curb65 honey is used for stratification of which disease?", "[PAD] [PAD] what disease is the curb65 score used for stratification?", "[PAD] [PAD] the curb65 score is used to stratify which disease?", "[PAD] [PAD] [PAD] curb65 result is used to stratify which disease?", "[PAD] [PAD] which disease is the curb65 score used to stratify?", "[PAD] [PAD] [PAD] curb65 score is used to stratify which disease?", "[PAD] [PAD] for which disease stratification is the curb65 score used?", "[PAD] [PAD] curb65 score is used for stratification of what disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease is curb65 used to indicate?", "the curb65 score is used for the stratification of which disease?", "[PAD] curb65 score is used for the stratification of what disease?", "[PAD] [PAD] [PAD] [PAD] curb65 scores are used for disease stratification?", "[PAD] [PAD] what disease stratification is the curb65 score used for?", "[PAD] [PAD] which disease is the curb65 score used for stratification?", "[PAD] [PAD] curb65 score is used for stratification of any disease?", "[PAD] [PAD] the curb65 score is used to stratify what disease?", "[PAD] the curb65 score is used for stratification of which disease?", "[PAD] [PAD] which disease stratification is the curb65 score used for?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease is the curb65 score used for?", "[PAD] [PAD] for which disease stratification is the curb65 index used?", "[PAD] [PAD] the curb65 score is used for which disease stratification?", "[PAD] [PAD] is the curb65 score used to stratify which disease?", "[PAD] [PAD] [PAD] [PAD] curb65 score is used to classify which disease?", "[PAD] [PAD] [PAD] [PAD] which disease is curb65 used to stratify?", "[PAD] [PAD] the curb65 scale is used to stratify what disease?", "[PAD] [PAD] [PAD] is curb65 score used to stratify which disease?", "[PAD] [PAD] [PAD] [PAD] the curb65 mark is applied to what disease class?", "[PAD] [PAD] curb65 points are used for stratification of which disease?", "[PAD] [PAD] [PAD] which disease is the curb65 score used to classify?", "[PAD] [PAD] [PAD] [PAD] curb65 score is used for classification of which disease?", "[PAD] [PAD] the curb65 score is used for stratifying which disease?", "[PAD] [PAD] curb65 score is used for stratification of which disease?", "[PAD] [PAD] the curb65 result is used for which disease stratification?", "is the curb65 score used in the stratification of which disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] for which disease is curb65 used?", "[PAD] [PAD] curb65 honey is used for stratification of which disease?", "[PAD] [PAD] what disease is the curb65 score used for stratification?", "[PAD] [PAD] the curb65 score is used to stratify which disease?", "[PAD] [PAD] [PAD] curb65 result is used to stratify which disease?", "[PAD] [PAD] which disease is the curb65 score used to stratify?", "[PAD] [PAD] [PAD] curb65 score is used to stratify which disease?", "[PAD] [PAD] for which disease stratification is the curb65 score used?", "[PAD] [PAD] curb65 score is used for stratification of what disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease is curb65 used to indicate?", "the curb65 score is used for the stratification of which disease?", "[PAD] curb65 score is used for the stratification of what disease?", "[PAD] [PAD] [PAD] [PAD] curb65 scores are used for disease stratification?", "[PAD] [PAD] what disease stratification is the curb65 score used for?", "[PAD] [PAD] which disease is the curb65 score used for stratification?", "[PAD] [PAD] curb65 score is used for stratification of any disease?", "[PAD] [PAD] the curb65 score is used to stratify what disease?", "[PAD] the curb65 score is used for stratification of which disease?", "[PAD] [PAD] which disease stratification is the curb65 score used for?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease is the curb65 score used for?", "[PAD] [PAD] for which disease stratification is the curb65 index used?", "[PAD] [PAD] the curb65 score is used for which disease stratification?", "[PAD] [PAD] is the curb65 score used to stratify which disease?", "[PAD] [PAD] [PAD] [PAD] curb65 score is used to classify which disease?", "[PAD] [PAD] [PAD] [PAD] which disease is curb65 used to stratify?", "[PAD] [PAD] the curb65 scale is used to stratify what disease?", "[PAD] [PAD] [PAD] is curb65 score used to stratify which disease?", "[PAD] [PAD] [PAD] [PAD] the curb65 mark is applied to what disease class?", "[PAD] [PAD] curb65 points are used for stratification of which disease?", "[PAD] [PAD] [PAD] which disease is the curb65 score used to classify?", "[PAD] [PAD] [PAD] [PAD] curb65 score is used for classification of which disease?", "[PAD] [PAD] the curb65 score is used for stratifying which disease?", "[PAD] [PAD] curb65 score is used for stratification of which disease?", "[PAD] [PAD] the curb65 result is used for which disease stratification?", "is the curb65 score used in the stratification of which disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] for which disease is curb65 used?", "[PAD] [PAD] curb65 honey is used for stratification of which disease?", "[PAD] [PAD] what disease is the curb65 score used for stratification?", "[PAD] [PAD] the curb65 score is used to stratify which disease?", "[PAD] [PAD] [PAD] curb65 result is used to stratify which disease?", "[PAD] [PAD] which disease is the curb65 score used to stratify?", "[PAD] [PAD] [PAD] curb65 score is used to stratify which disease?", "[PAD] [PAD] for which disease stratification is the curb65 score used?", "[PAD] [PAD] curb65 score is used for stratification of what disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease is curb65 used to indicate?", "the curb65 score is used for the stratification of which disease?", "[PAD] curb65 score is used for the stratification of what disease?", "[PAD] [PAD] [PAD] [PAD] curb65 scores are used for disease stratification?", "[PAD] [PAD] what disease stratification is the curb65 score used for?", "[PAD] [PAD] which disease is the curb65 score used for stratification?", "[PAD] [PAD] curb65 score is used for stratification of any disease?", "[PAD] [PAD] the curb65 score is used to stratify what disease?", "[PAD] the curb65 score is used for stratification of which disease?", "[PAD] [PAD] which disease stratification is the curb65 score used for?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease is the curb65 score used for?", "[PAD] [PAD] for which disease stratification is the curb65 index used?", "[PAD] [PAD] the curb65 score is used for which disease stratification?", "[PAD] [PAD] is the curb65 score used to stratify which disease?", "[PAD] [PAD] [PAD] [PAD] curb65 score is used to classify which disease?", "[PAD] [PAD] [PAD] [PAD] which disease is curb65 used to stratify?", "[PAD] [PAD] the curb65 scale is used to stratify what disease?", "[PAD] [PAD] [PAD] is curb65 score used to stratify which disease?", "[PAD] [PAD] [PAD] [PAD] the curb65 mark is applied to what disease class?", "[PAD] [PAD] curb65 points are used for stratification of which disease?", "[PAD] [PAD] [PAD] which disease is the curb65 score used to classify?", "[PAD] [PAD] [PAD] [PAD] curb65 score is used for classification of which disease?", "[PAD] [PAD] the curb65 score is used for stratifying which disease?", "[PAD] [PAD] curb65 score is used for stratification of which disease?", "[PAD] [PAD] the curb65 result is used for which disease stratification?", "is the curb65 score used in the stratification of which disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] for which disease is curb65 used?", "[PAD] [PAD] curb65 honey is used for stratification of which disease?", "[PAD] [PAD] what disease is the curb65 score used for stratification?", "[PAD] [PAD] the curb65 score is used to stratify which disease?", "[PAD] [PAD] [PAD] curb65 result is used to stratify which disease?", "[PAD] [PAD] which disease is the curb65 score used to stratify?", "[PAD] [PAD] [PAD] curb65 score is used to stratify which disease?", "[PAD] [PAD] for which disease stratification is the curb65 score used?", "[PAD] [PAD] curb65 score is used for stratification of what disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease is curb65 used to indicate?", "the curb65 score is used for the stratification of which disease?", "[PAD] curb65 score is used for the stratification of what disease?", "[PAD] [PAD] [PAD] [PAD] curb65 scores are used for disease stratification?", "[PAD] [PAD] what disease stratification is the curb65 score used for?", "[PAD] [PAD] which disease is the curb65 score used for stratification?", "[PAD] [PAD] curb65 score is used for stratification of any disease?", "[PAD] [PAD] the curb65 score is used to stratify what disease?", "[PAD] the curb65 score is used for stratification of which disease?", "[PAD] [PAD] which disease stratification is the curb65 score used for?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease is the curb65 score used for?", "[PAD] [PAD] for which disease stratification is the curb65 index used?", "[PAD] [PAD] the curb65 score is used for which disease stratification?", "[PAD] [PAD] is the curb65 score used to stratify which disease?", "[PAD] [PAD] [PAD] [PAD] curb65 score is used to classify which disease?", "[PAD] [PAD] [PAD] [PAD] which disease is curb65 used to stratify?", "[PAD] [PAD] the curb65 scale is used to stratify what disease?", "[PAD] [PAD] [PAD] is curb65 score used to stratify which disease?", "[PAD] [PAD] [PAD] [PAD] the curb65 mark is applied to what disease class?", "[PAD] [PAD] curb65 points are used for stratification of which disease?", "[PAD] [PAD] [PAD] which disease is the curb65 score used to classify?", "[PAD] [PAD] [PAD] [PAD] curb65 score is used for classification of which disease?", "[PAD] [PAD] the curb65 score is used for stratifying which disease?", "[PAD] [PAD] [PAD] which personality disorder is treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated with dialectical behavior therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated through dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated with dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated with dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated with dialectical behavior therapy?", "[PAD] [PAD] [PAD] which personality disorders are treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated by dialectical behavior therapy?", "what personality disorder is treated with the use of dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what personality disorders are treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] [PAD] what personality disorder is treated with dialect behavior therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorders are treated with dialectical behavior therapy?", "which personality disorder is treated with the help of dialectical behavioral therapy?", "[PAD] [PAD] what personality disorder can be treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what human disease is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated with dialectical behavior therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated through dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated with dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated with dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated with dialectical behavior therapy?", "[PAD] [PAD] [PAD] which personality disorders are treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated by dialectical behavior therapy?", "what personality disorder is treated with the use of dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what personality disorders are treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] [PAD] what personality disorder is treated with dialect behavior therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorders are treated with dialectical behavior therapy?", "which personality disorder is treated with the help of dialectical behavioral therapy?", "[PAD] [PAD] what personality disorder can be treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what human disease is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated with dialectical behavior therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated through dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated with dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated with dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated with dialectical behavior therapy?", "[PAD] [PAD] [PAD] which personality disorders are treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated by dialectical behavior therapy?", "what personality disorder is treated with the use of dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what personality disorders are treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] [PAD] what personality disorder is treated with dialect behavior therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorders are treated with dialectical behavior therapy?", "which personality disorder is treated with the help of dialectical behavioral therapy?", "[PAD] [PAD] what personality disorder can be treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what human disease is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated with dialectical behavior therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated through dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated with dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated with dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated with dialectical behavior therapy?", "[PAD] [PAD] [PAD] which personality disorders are treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated by dialectical behavior therapy?", "what personality disorder is treated with the use of dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what personality disorders are treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] [PAD] what personality disorder is treated with dialect behavior therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorders are treated with dialectical behavior therapy?", "which personality disorder is treated with the help of dialectical behavioral therapy?", "[PAD] [PAD] what personality disorder can be treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what human disease is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated with dialectical behavior therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated through dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated with dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated with dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated with dialectical behavior therapy?", "[PAD] [PAD] [PAD] which personality disorders are treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated by dialectical behavior therapy?", "what personality disorder is treated with the use of dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what personality disorders are treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] [PAD] what personality disorder is treated with dialect behavior therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorders are treated with dialectical behavior therapy?", "which personality disorder is treated with the help of dialectical behavioral therapy?", "[PAD] [PAD] what personality disorder can be treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what human disease is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated with dialectical behavior therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated through dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated with dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated with dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated with dialectical behavior therapy?", "[PAD] [PAD] [PAD] which personality disorders are treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated by dialectical behavior therapy?", "what personality disorder is treated with the use of dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what personality disorders are treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] [PAD] what personality disorder is treated with dialect behavior therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorders are treated with dialectical behavior therapy?", "which personality disorder is treated with the help of dialectical behavioral therapy?", "[PAD] [PAD] what personality disorder can be treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what human disease is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated with dialectical behavior therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated through dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated with dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated with dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated with dialectical behavior therapy?", "[PAD] [PAD] [PAD] which personality disorders are treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated by dialectical behavior therapy?", "what personality disorder is treated with the use of dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what personality disorders are treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] [PAD] what personality disorder is treated with dialect behavior therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorders are treated with dialectical behavior therapy?", "which personality disorder is treated with the help of dialectical behavioral therapy?", "[PAD] [PAD] what personality disorder can be treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what human disease is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated with dialectical behavior therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated through dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated with dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated with dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated with dialectical behavior therapy?", "[PAD] [PAD] [PAD] which personality disorders are treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated by dialectical behavior therapy?", "what personality disorder is treated with the use of dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what personality disorders are treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] [PAD] what personality disorder is treated with dialect behavior therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorders are treated with dialectical behavior therapy?", "which personality disorder is treated with the help of dialectical behavioral therapy?", "[PAD] [PAD] what personality disorder can be treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what human disease is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated with dialectical behavior therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated through dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated with dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated with dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated with dialectical behavior therapy?", "[PAD] [PAD] [PAD] which personality disorders are treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated by dialectical behavior therapy?", "what personality disorder is treated with the use of dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what personality disorders are treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] [PAD] what personality disorder is treated with dialect behavior therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorders are treated with dialectical behavior therapy?", "which personality disorder is treated with the help of dialectical behavioral therapy?", "[PAD] [PAD] what personality disorder can be treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what human disease is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated with dialectical behavior therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated through dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated with dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated with dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated with dialectical behavior therapy?", "[PAD] [PAD] [PAD] which personality disorders are treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated by dialectical behavior therapy?", "what personality disorder is treated with the use of dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what personality disorders are treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] [PAD] what personality disorder is treated with dialect behavior therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorders are treated with dialectical behavior therapy?", "which personality disorder is treated with the help of dialectical behavioral therapy?", "[PAD] [PAD] what personality disorder can be treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what human disease is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated with dialectical behavior therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated through dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated with dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated with dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated with dialectical behavior therapy?", "[PAD] [PAD] [PAD] which personality disorders are treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated by dialectical behavior therapy?", "what personality disorder is treated with the use of dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what personality disorders are treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] [PAD] what personality disorder is treated with dialect behavior therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorders are treated with dialectical behavior therapy?", "which personality disorder is treated with the help of dialectical behavioral therapy?", "[PAD] [PAD] what personality disorder can be treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what human disease is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated with dialectical behavior therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated through dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated with dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated with dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated with dialectical behavior therapy?", "[PAD] [PAD] [PAD] which personality disorders are treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated by dialectical behavior therapy?", "what personality disorder is treated with the use of dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what personality disorders are treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] [PAD] what personality disorder is treated with dialect behavior therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorders are treated with dialectical behavior therapy?", "which personality disorder is treated with the help of dialectical behavioral therapy?", "[PAD] [PAD] what personality disorder can be treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what human disease is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated with dialectical behavior therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated through dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated with dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated with dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated with dialectical behavior therapy?", "[PAD] [PAD] [PAD] which personality disorders are treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated by dialectical behavior therapy?", "what personality disorder is treated with the use of dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what personality disorders are treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] [PAD] what personality disorder is treated with dialect behavior therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorders are treated with dialectical behavior therapy?", "which personality disorder is treated with the help of dialectical behavioral therapy?", "[PAD] [PAD] what personality disorder can be treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what human disease is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated with dialectical behavior therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated through dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated with dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated with dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated with dialectical behavior therapy?", "[PAD] [PAD] [PAD] which personality disorders are treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated by dialectical behavior therapy?", "what personality disorder is treated with the use of dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what personality disorders are treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] [PAD] what personality disorder is treated with dialect behavior therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorders are treated with dialectical behavior therapy?", "which personality disorder is treated with the help of dialectical behavioral therapy?", "[PAD] [PAD] what personality disorder can be treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what human disease is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated with dialectical behavior therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated through dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated with dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated with dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated with dialectical behavior therapy?", "[PAD] [PAD] [PAD] which personality disorders are treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated by dialectical behavior therapy?", "what personality disorder is treated with the use of dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what personality disorders are treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] [PAD] what personality disorder is treated with dialect behavior therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorders are treated with dialectical behavior therapy?", "which personality disorder is treated with the help of dialectical behavioral therapy?", "[PAD] [PAD] what personality disorder can be treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what human disease is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated with dialectical behavior therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated through dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated with dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated with dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated with dialectical behavior therapy?", "[PAD] [PAD] [PAD] which personality disorders are treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated by dialectical behavior therapy?", "what personality disorder is treated with the use of dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what personality disorders are treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] [PAD] what personality disorder is treated with dialect behavior therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorders are treated with dialectical behavior therapy?", "which personality disorder is treated with the help of dialectical behavioral therapy?", "[PAD] [PAD] what personality disorder can be treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what human disease is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated with dialectical behavior therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated through dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated with dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated with dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated with dialectical behavior therapy?", "[PAD] [PAD] [PAD] which personality disorders are treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated by dialectical behavior therapy?", "what personality disorder is treated with the use of dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what personality disorders are treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] [PAD] what personality disorder is treated with dialect behavior therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorders are treated with dialectical behavior therapy?", "which personality disorder is treated with the help of dialectical behavioral therapy?", "[PAD] [PAD] what personality disorder can be treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what human disease is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated with dialectical behavior therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated through dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated with dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated with dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated with dialectical behavior therapy?", "[PAD] [PAD] [PAD] which personality disorders are treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated by dialectical behavior therapy?", "what personality disorder is treated with the use of dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what personality disorders are treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] [PAD] what personality disorder is treated with dialect behavior therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorders are treated with dialectical behavior therapy?", "which personality disorder is treated with the help of dialectical behavioral therapy?", "[PAD] [PAD] what personality disorder can be treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what human disease is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated with dialectical behavior therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated through dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated with dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated with dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated with dialectical behavior therapy?", "[PAD] [PAD] [PAD] which personality disorders are treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated by dialectical behavior therapy?", "what personality disorder is treated with the use of dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what personality disorders are treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] [PAD] what personality disorder is treated with dialect behavior therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorders are treated with dialectical behavior therapy?", "which personality disorder is treated with the help of dialectical behavioral therapy?", "[PAD] [PAD] what personality disorder can be treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what human disease is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated with dialectical behavior therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated through dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated with dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated with dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated with dialectical behavior therapy?", "[PAD] [PAD] [PAD] which personality disorders are treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated by dialectical behavior therapy?", "what personality disorder is treated with the use of dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what personality disorders are treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] [PAD] what personality disorder is treated with dialect behavior therapy?", "[PAD] [PAD] [PAD] which personality disorder is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] which personality disorders are treated with dialectical behavior therapy?", "which personality disorder is treated with the help of dialectical behavioral therapy?", "[PAD] [PAD] what personality disorder can be treated using dialectical behavior therapy?", "[PAD] [PAD] [PAD] what personality disorder is treated using dialectical behavioral therapy?", "[PAD] [PAD] [PAD] what human disease is treated using dialectical behavioral therapy?", "[PAD] which disease can be diagnosed with the \"probe to bone\" test?", "[PAD] what disease can be diagnosed with the \"probe to bone\" test?", "[PAD] [PAD] which disease can be diagnosed with a \"bone probe\" test?", "[PAD] [PAD] what disease can be diagnosed with a \"bone probe\" test?", "[PAD] [PAD] [PAD] what disease can be diagnosed with the probe to bone test?", "[PAD] what diseases can be diagnosed with the \"probe to bone\" test?", "[PAD] [PAD] what disease can be diagnosed with a probe to the bone test?", "[PAD] [PAD] [PAD] which disease can be diagnosed with a probe to bone test?", "[PAD] [PAD] what disease can be diagnosed with the \"bone probe\" test?", "[PAD] [PAD] [PAD] what diseases can a \"bone probe\" test diagnose?", "[PAD] [PAD] [PAD] what disease can be diagnosed with a probe to bone test?", "what disease can be diagnosed with the \"probe into the bone\" test?", "[PAD] which disease can be diagnosed using the \"probe to bone\" test?", "[PAD] what disease can be diagnosed with a \"probe to bone\" test?", "[PAD] [PAD] [PAD] which disease can be diagnosed with a \"bone probe\"?", "[PAD] [PAD] what diseases can be diagnosed with the \"bone testing\" test?", "[PAD] [PAD] what disease can be diagnosed by a \"bone test\" test?", "[PAD] what diseases can be diagnosed with a \"probe to bone\" test?", "[PAD] what disease can be diagnosed with the probe-to-bone test?", "[PAD] which diseases can be diagnosed with the \"probe to bone\" test?", "[PAD] [PAD] which disease can be diagnosed with the \"bone probe\" test?", "[PAD] what disease can be diagnosed with a bone-to-bone test?", "[PAD] which disease can be diagnosed with a \"probe to bone\" test?", "which disease can be diagnosed with the \"bone to the bone\" test?", "[PAD] [PAD] [PAD] [PAD] which disease can be diagnosed with the bone probe test?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease can be diagnosed with the bone test?", "[PAD] [PAD] [PAD] [PAD] what disease can be diagnosed with a bone probe test?", "[PAD] what diseases can be diagnosed with a test? \"bone investigation\"?", "[PAD] what disease can be diagnosed with the \"search for bone\" test?", "[PAD] which disease can be diagnosed with the \"probe to bone\" test?", "[PAD] what disease can be diagnosed with the \"probe to bone\" test?", "[PAD] [PAD] which disease can be diagnosed with a \"bone probe\" test?", "[PAD] [PAD] what disease can be diagnosed with a \"bone probe\" test?", "[PAD] [PAD] [PAD] what disease can be diagnosed with the probe to bone test?", "[PAD] what diseases can be diagnosed with the \"probe to bone\" test?", "[PAD] [PAD] what disease can be diagnosed with a probe to the bone test?", "[PAD] [PAD] [PAD] which disease can be diagnosed with a probe to bone test?", "[PAD] [PAD] what disease can be diagnosed with the \"bone probe\" test?", "[PAD] [PAD] [PAD] what diseases can a \"bone probe\" test diagnose?", "[PAD] [PAD] [PAD] what disease can be diagnosed with a probe to bone test?", "what disease can be diagnosed with the \"probe into the bone\" test?", "[PAD] which disease can be diagnosed using the \"probe to bone\" test?", "[PAD] what disease can be diagnosed with a \"probe to bone\" test?", "[PAD] [PAD] [PAD] which disease can be diagnosed with a \"bone probe\"?", "[PAD] [PAD] what diseases can be diagnosed with the \"bone testing\" test?", "[PAD] [PAD] what disease can be diagnosed by a \"bone test\" test?", "[PAD] what diseases can be diagnosed with a \"probe to bone\" test?", "[PAD] what disease can be diagnosed with the probe-to-bone test?", "[PAD] which diseases can be diagnosed with the \"probe to bone\" test?", "[PAD] [PAD] which disease can be diagnosed with the \"bone probe\" test?", "[PAD] what disease can be diagnosed with a bone-to-bone test?", "[PAD] which disease can be diagnosed with a \"probe to bone\" test?", "which disease can be diagnosed with the \"bone to the bone\" test?", "[PAD] [PAD] [PAD] [PAD] which disease can be diagnosed with the bone probe test?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease can be diagnosed with the bone test?", "[PAD] [PAD] [PAD] [PAD] what disease can be diagnosed with a bone probe test?", "[PAD] what diseases can be diagnosed with a test? \"bone investigation\"?", "[PAD] what disease can be diagnosed with the \"search for bone\" test?", "[PAD] which disease can be diagnosed with the \"probe to bone\" test?", "[PAD] what disease can be diagnosed with the \"probe to bone\" test?", "[PAD] [PAD] which disease can be diagnosed with a \"bone probe\" test?", "[PAD] [PAD] what disease can be diagnosed with a \"bone probe\" test?", "[PAD] [PAD] [PAD] what disease can be diagnosed with the probe to bone test?", "[PAD] what diseases can be diagnosed with the \"probe to bone\" test?", "[PAD] [PAD] what disease can be diagnosed with a probe to the bone test?", "[PAD] [PAD] [PAD] which disease can be diagnosed with a probe to bone test?", "[PAD] [PAD] what disease can be diagnosed with the \"bone probe\" test?", "[PAD] [PAD] [PAD] what diseases can a \"bone probe\" test diagnose?", "[PAD] [PAD] [PAD] what disease can be diagnosed with a probe to bone test?", "what disease can be diagnosed with the \"probe into the bone\" test?", "[PAD] which disease can be diagnosed using the \"probe to bone\" test?", "[PAD] what disease can be diagnosed with a \"probe to bone\" test?", "[PAD] [PAD] [PAD] which disease can be diagnosed with a \"bone probe\"?", "[PAD] [PAD] what diseases can be diagnosed with the \"bone testing\" test?", "[PAD] [PAD] what disease can be diagnosed by a \"bone test\" test?", "[PAD] what diseases can be diagnosed with a \"probe to bone\" test?", "[PAD] what disease can be diagnosed with the probe-to-bone test?", "[PAD] which diseases can be diagnosed with the \"probe to bone\" test?", "[PAD] [PAD] which disease can be diagnosed with the \"bone probe\" test?", "[PAD] what disease can be diagnosed with a bone-to-bone test?", "[PAD] which disease can be diagnosed with a \"probe to bone\" test?", "which disease can be diagnosed with the \"bone to the bone\" test?", "[PAD] [PAD] [PAD] [PAD] which disease can be diagnosed with the bone probe test?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease can be diagnosed with the bone test?", "[PAD] [PAD] [PAD] [PAD] what disease can be diagnosed with a bone probe test?", "[PAD] what diseases can be diagnosed with a test? \"bone investigation\"?", "[PAD] what disease can be diagnosed with the \"search for bone\" test?", "[PAD] which disease can be diagnosed with the \"probe to bone\" test?", "[PAD] what disease can be diagnosed with the \"probe to bone\" test?", "[PAD] [PAD] which disease can be diagnosed with a \"bone probe\" test?", "[PAD] [PAD] what disease can be diagnosed with a \"bone probe\" test?", "[PAD] [PAD] [PAD] what disease can be diagnosed with the probe to bone test?", "[PAD] what diseases can be diagnosed with the \"probe to bone\" test?", "[PAD] [PAD] what disease can be diagnosed with a probe to the bone test?", "[PAD] [PAD] [PAD] which disease can be diagnosed with a probe to bone test?", "[PAD] [PAD] what disease can be diagnosed with the \"bone probe\" test?", "[PAD] [PAD] [PAD] what diseases can a \"bone probe\" test diagnose?", "[PAD] [PAD] [PAD] what disease can be diagnosed with a probe to bone test?", "what disease can be diagnosed with the \"probe into the bone\" test?", "[PAD] which disease can be diagnosed using the \"probe to bone\" test?", "[PAD] what disease can be diagnosed with a \"probe to bone\" test?", "[PAD] [PAD] [PAD] which disease can be diagnosed with a \"bone probe\"?", "[PAD] [PAD] what diseases can be diagnosed with the \"bone testing\" test?", "[PAD] [PAD] what disease can be diagnosed by a \"bone test\" test?", "[PAD] what diseases can be diagnosed with a \"probe to bone\" test?", "[PAD] what disease can be diagnosed with the probe-to-bone test?", "[PAD] which diseases can be diagnosed with the \"probe to bone\" test?", "[PAD] [PAD] which disease can be diagnosed with the \"bone probe\" test?", "[PAD] what disease can be diagnosed with a bone-to-bone test?", "[PAD] which disease can be diagnosed with a \"probe to bone\" test?", "which disease can be diagnosed with the \"bone to the bone\" test?", "[PAD] [PAD] [PAD] [PAD] which disease can be diagnosed with the bone probe test?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease can be diagnosed with the bone test?", "[PAD] [PAD] [PAD] [PAD] what disease can be diagnosed with a bone probe test?", "[PAD] what diseases can be diagnosed with a test? \"bone investigation\"?", "[PAD] what disease can be diagnosed with the \"search for bone\" test?", "[PAD] which disease can be diagnosed with the \"probe to bone\" test?", "[PAD] what disease can be diagnosed with the \"probe to bone\" test?", "[PAD] [PAD] which disease can be diagnosed with a \"bone probe\" test?", "[PAD] [PAD] what disease can be diagnosed with a \"bone probe\" test?", "[PAD] [PAD] [PAD] what disease can be diagnosed with the probe to bone test?", "[PAD] what diseases can be diagnosed with the \"probe to bone\" test?", "[PAD] [PAD] what disease can be diagnosed with a probe to the bone test?", "[PAD] [PAD] [PAD] which disease can be diagnosed with a probe to bone test?", "[PAD] [PAD] what disease can be diagnosed with the \"bone probe\" test?", "[PAD] [PAD] [PAD] what diseases can a \"bone probe\" test diagnose?", "[PAD] [PAD] [PAD] what disease can be diagnosed with a probe to bone test?", "what disease can be diagnosed with the \"probe into the bone\" test?", "[PAD] which disease can be diagnosed using the \"probe to bone\" test?", "[PAD] what disease can be diagnosed with a \"probe to bone\" test?", "[PAD] [PAD] [PAD] which disease can be diagnosed with a \"bone probe\"?", "[PAD] [PAD] what diseases can be diagnosed with the \"bone testing\" test?", "[PAD] [PAD] what disease can be diagnosed by a \"bone test\" test?", "[PAD] what diseases can be diagnosed with a \"probe to bone\" test?", "[PAD] what disease can be diagnosed with the probe-to-bone test?", "[PAD] which diseases can be diagnosed with the \"probe to bone\" test?", "[PAD] [PAD] which disease can be diagnosed with the \"bone probe\" test?", "[PAD] what disease can be diagnosed with a bone-to-bone test?", "[PAD] which disease can be diagnosed with a \"probe to bone\" test?", "which disease can be diagnosed with the \"bone to the bone\" test?", "[PAD] [PAD] [PAD] [PAD] which disease can be diagnosed with the bone probe test?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease can be diagnosed with the bone test?", "[PAD] [PAD] [PAD] [PAD] what disease can be diagnosed with a bone probe test?", "[PAD] what diseases can be diagnosed with a test? \"bone investigation\"?", "[PAD] what disease can be diagnosed with the \"search for bone\" test?", "[PAD] which disease can be diagnosed with the \"probe to bone\" test?", "[PAD] what disease can be diagnosed with the \"probe to bone\" test?", "[PAD] [PAD] which disease can be diagnosed with a \"bone probe\" test?", "[PAD] [PAD] what disease can be diagnosed with a \"bone probe\" test?", "[PAD] [PAD] [PAD] what disease can be diagnosed with the probe to bone test?", "[PAD] what diseases can be diagnosed with the \"probe to bone\" test?", "[PAD] [PAD] what disease can be diagnosed with a probe to the bone test?", "[PAD] [PAD] [PAD] which disease can be diagnosed with a probe to bone test?", "[PAD] [PAD] what disease can be diagnosed with the \"bone probe\" test?", "[PAD] [PAD] [PAD] what diseases can a \"bone probe\" test diagnose?", "[PAD] [PAD] [PAD] what disease can be diagnosed with a probe to bone test?", "what disease can be diagnosed with the \"probe into the bone\" test?", "[PAD] which disease can be diagnosed using the \"probe to bone\" test?", "[PAD] what disease can be diagnosed with a \"probe to bone\" test?", "[PAD] [PAD] [PAD] which disease can be diagnosed with a \"bone probe\"?", "[PAD] [PAD] what diseases can be diagnosed with the \"bone testing\" test?", "[PAD] [PAD] what disease can be diagnosed by a \"bone test\" test?", "[PAD] what diseases can be diagnosed with a \"probe to bone\" test?", "[PAD] what disease can be diagnosed with the probe-to-bone test?", "[PAD] which diseases can be diagnosed with the \"probe to bone\" test?", "[PAD] [PAD] which disease can be diagnosed with the \"bone probe\" test?", "[PAD] what disease can be diagnosed with a bone-to-bone test?", "[PAD] which disease can be diagnosed with a \"probe to bone\" test?", "which disease can be diagnosed with the \"bone to the bone\" test?", "[PAD] [PAD] [PAD] [PAD] which disease can be diagnosed with the bone probe test?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease can be diagnosed with the bone test?", "[PAD] [PAD] [PAD] [PAD] what disease can be diagnosed with a bone probe test?", "[PAD] what diseases can be diagnosed with a test? \"bone investigation\"?", "[PAD] what disease can be diagnosed with the \"search for bone\" test?", "[PAD] which disease can be diagnosed with the \"probe to bone\" test?", "[PAD] what disease can be diagnosed with the \"probe to bone\" test?", "[PAD] [PAD] which disease can be diagnosed with a \"bone probe\" test?", "[PAD] [PAD] what disease can be diagnosed with a \"bone probe\" test?", "[PAD] [PAD] [PAD] what disease can be diagnosed with the probe to bone test?", "[PAD] what diseases can be diagnosed with the \"probe to bone\" test?", "[PAD] [PAD] what disease can be diagnosed with a probe to the bone test?", "[PAD] [PAD] [PAD] which disease can be diagnosed with a probe to bone test?", "[PAD] [PAD] what disease can be diagnosed with the \"bone probe\" test?", "[PAD] [PAD] [PAD] what diseases can a \"bone probe\" test diagnose?", "[PAD] [PAD] [PAD] what disease can be diagnosed with a probe to bone test?", "what disease can be diagnosed with the \"probe into the bone\" test?", "[PAD] which disease can be diagnosed using the \"probe to bone\" test?", "[PAD] what disease can be diagnosed with a \"probe to bone\" test?", "[PAD] [PAD] [PAD] which disease can be diagnosed with a \"bone probe\"?", "[PAD] [PAD] what diseases can be diagnosed with the \"bone testing\" test?", "[PAD] [PAD] what disease can be diagnosed by a \"bone test\" test?", "[PAD] what diseases can be diagnosed with a \"probe to bone\" test?", "[PAD] what disease can be diagnosed with the probe-to-bone test?", "[PAD] which diseases can be diagnosed with the \"probe to bone\" test?", "[PAD] [PAD] which disease can be diagnosed with the \"bone probe\" test?", "[PAD] what disease can be diagnosed with a bone-to-bone test?", "[PAD] which disease can be diagnosed with a \"probe to bone\" test?", "which disease can be diagnosed with the \"bone to the bone\" test?", "[PAD] [PAD] [PAD] [PAD] which disease can be diagnosed with the bone probe test?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease can be diagnosed with the bone test?", "[PAD] [PAD] [PAD] [PAD] what disease can be diagnosed with a bone probe test?", "[PAD] what diseases can be diagnosed with a test? \"bone investigation\"?", "[PAD] what disease can be diagnosed with the \"search for bone\" test?", "[PAD] which disease can be diagnosed with the \"probe to bone\" test?", "[PAD] what disease can be diagnosed with the \"probe to bone\" test?", "[PAD] [PAD] which disease can be diagnosed with a \"bone probe\" test?", "[PAD] [PAD] what disease can be diagnosed with a \"bone probe\" test?", "[PAD] [PAD] [PAD] what disease can be diagnosed with the probe to bone test?", "[PAD] what diseases can be diagnosed with the \"probe to bone\" test?", "[PAD] [PAD] what disease can be diagnosed with a probe to the bone test?", "[PAD] [PAD] [PAD] which disease can be diagnosed with a probe to bone test?", "[PAD] [PAD] what disease can be diagnosed with the \"bone probe\" test?", "[PAD] [PAD] [PAD] what diseases can a \"bone probe\" test diagnose?", "[PAD] [PAD] [PAD] what disease can be diagnosed with a probe to bone test?", "what disease can be diagnosed with the \"probe into the bone\" test?", "[PAD] which disease can be diagnosed using the \"probe to bone\" test?", "[PAD] what disease can be diagnosed with a \"probe to bone\" test?", "[PAD] [PAD] [PAD] which disease can be diagnosed with a \"bone probe\"?", "[PAD] [PAD] what diseases can be diagnosed with the \"bone testing\" test?", "[PAD] [PAD] what disease can be diagnosed by a \"bone test\" test?", "[PAD] what diseases can be diagnosed with a \"probe to bone\" test?", "[PAD] what disease can be diagnosed with the probe-to-bone test?", "[PAD] which diseases can be diagnosed with the \"probe to bone\" test?", "[PAD] [PAD] which disease can be diagnosed with the \"bone probe\" test?", "[PAD] what disease can be diagnosed with a bone-to-bone test?", "[PAD] which disease can be diagnosed with a \"probe to bone\" test?", "which disease can be diagnosed with the \"bone to the bone\" test?", "[PAD] [PAD] [PAD] [PAD] which disease can be diagnosed with the bone probe test?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease can be diagnosed with the bone test?", "[PAD] [PAD] [PAD] [PAD] what disease can be diagnosed with a bone probe test?", "[PAD] what diseases can be diagnosed with a test? \"bone investigation\"?", "[PAD] what disease can be diagnosed with the \"search for bone\" test?", "[PAD] which disease can be diagnosed with the \"probe to bone\" test?", "[PAD] what disease can be diagnosed with the \"probe to bone\" test?", "[PAD] [PAD] which disease can be diagnosed with a \"bone probe\" test?", "[PAD] [PAD] what disease can be diagnosed with a \"bone probe\" test?", "[PAD] [PAD] [PAD] what disease can be diagnosed with the probe to bone test?", "[PAD] what diseases can be diagnosed with the \"probe to bone\" test?", "[PAD] [PAD] what disease can be diagnosed with a probe to the bone test?", "[PAD] [PAD] [PAD] which disease can be diagnosed with a probe to bone test?", "[PAD] [PAD] what disease can be diagnosed with the \"bone probe\" test?", "[PAD] [PAD] [PAD] what diseases can a \"bone probe\" test diagnose?", "[PAD] [PAD] [PAD] what disease can be diagnosed with a probe to bone test?", "what disease can be diagnosed with the \"probe into the bone\" test?", "[PAD] which disease can be diagnosed using the \"probe to bone\" test?", "[PAD] what disease can be diagnosed with a \"probe to bone\" test?", "[PAD] [PAD] [PAD] which disease can be diagnosed with a \"bone probe\"?", "[PAD] [PAD] what diseases can be diagnosed with the \"bone testing\" test?", "[PAD] [PAD] what disease can be diagnosed by a \"bone test\" test?", "[PAD] what diseases can be diagnosed with a \"probe to bone\" test?", "[PAD] what disease can be diagnosed with the probe-to-bone test?", "[PAD] which diseases can be diagnosed with the \"probe to bone\" test?", "[PAD] [PAD] which disease can be diagnosed with the \"bone probe\" test?", "[PAD] what disease can be diagnosed with a bone-to-bone test?", "[PAD] which disease can be diagnosed with a \"probe to bone\" test?", "which disease can be diagnosed with the \"bone to the bone\" test?", "[PAD] [PAD] [PAD] [PAD] which disease can be diagnosed with the bone probe test?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease can be diagnosed with the bone test?", "[PAD] [PAD] [PAD] [PAD] what disease can be diagnosed with a bone probe test?", "[PAD] what diseases can be diagnosed with a test? \"bone investigation\"?", "[PAD] what disease can be diagnosed with the \"search for bone\" test?", "[PAD] which disease can be diagnosed with the \"probe to bone\" test?", "[PAD] what disease can be diagnosed with the \"probe to bone\" test?", "[PAD] [PAD] which disease can be diagnosed with a \"bone probe\" test?", "[PAD] [PAD] what disease can be diagnosed with a \"bone probe\" test?", "[PAD] [PAD] [PAD] what disease can be diagnosed with the probe to bone test?", "[PAD] what diseases can be diagnosed with the \"probe to bone\" test?", "[PAD] [PAD] what disease can be diagnosed with a probe to the bone test?", "[PAD] [PAD] [PAD] which disease can be diagnosed with a probe to bone test?", "[PAD] [PAD] what disease can be diagnosed with the \"bone probe\" test?", "[PAD] [PAD] [PAD] what diseases can a \"bone probe\" test diagnose?", "[PAD] [PAD] [PAD] what disease can be diagnosed with a probe to bone test?", "what disease can be diagnosed with the \"probe into the bone\" test?", "[PAD] which disease can be diagnosed using the \"probe to bone\" test?", "[PAD] what disease can be diagnosed with a \"probe to bone\" test?", "[PAD] [PAD] [PAD] which disease can be diagnosed with a \"bone probe\"?", "[PAD] [PAD] what diseases can be diagnosed with the \"bone testing\" test?", "[PAD] [PAD] what disease can be diagnosed by a \"bone test\" test?", "[PAD] what diseases can be diagnosed with a \"probe to bone\" test?", "[PAD] what disease can be diagnosed with the probe-to-bone test?", "[PAD] which diseases can be diagnosed with the \"probe to bone\" test?", "[PAD] [PAD] which disease can be diagnosed with the \"bone probe\" test?", "[PAD] what disease can be diagnosed with a bone-to-bone test?", "[PAD] which disease can be diagnosed with a \"probe to bone\" test?", "which disease can be diagnosed with the \"bone to the bone\" test?", "[PAD] [PAD] [PAD] [PAD] which disease can be diagnosed with the bone probe test?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease can be diagnosed with the bone test?", "[PAD] [PAD] [PAD] [PAD] what disease can be diagnosed with a bone probe test?", "[PAD] what diseases can be diagnosed with a test? \"bone investigation\"?", "[PAD] what disease can be diagnosed with the \"search for bone\" test?", "[PAD] which disease can be diagnosed with the \"probe to bone\" test?", "[PAD] what disease can be diagnosed with the \"probe to bone\" test?", "[PAD] [PAD] which disease can be diagnosed with a \"bone probe\" test?", "[PAD] [PAD] what disease can be diagnosed with a \"bone probe\" test?", "[PAD] [PAD] [PAD] what disease can be diagnosed with the probe to bone test?", "[PAD] what diseases can be diagnosed with the \"probe to bone\" test?", "[PAD] [PAD] what disease can be diagnosed with a probe to the bone test?", "[PAD] [PAD] [PAD] which disease can be diagnosed with a probe to bone test?", "[PAD] [PAD] what disease can be diagnosed with the \"bone probe\" test?", "[PAD] [PAD] [PAD] what diseases can a \"bone probe\" test diagnose?", "[PAD] [PAD] [PAD] what disease can be diagnosed with a probe to bone test?", "what disease can be diagnosed with the \"probe into the bone\" test?", "[PAD] which disease can be diagnosed using the \"probe to bone\" test?", "[PAD] what disease can be diagnosed with a \"probe to bone\" test?", "[PAD] [PAD] [PAD] which disease can be diagnosed with a \"bone probe\"?", "[PAD] [PAD] what diseases can be diagnosed with the \"bone testing\" test?", "[PAD] [PAD] what disease can be diagnosed by a \"bone test\" test?", "[PAD] what diseases can be diagnosed with a \"probe to bone\" test?", "[PAD] what disease can be diagnosed with the probe-to-bone test?", "[PAD] which diseases can be diagnosed with the \"probe to bone\" test?", "[PAD] [PAD] which disease can be diagnosed with the \"bone probe\" test?", "[PAD] what disease can be diagnosed with a bone-to-bone test?", "[PAD] which disease can be diagnosed with a \"probe to bone\" test?", "which disease can be diagnosed with the \"bone to the bone\" test?", "[PAD] [PAD] [PAD] [PAD] which disease can be diagnosed with the bone probe test?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease can be diagnosed with the bone test?", "[PAD] [PAD] [PAD] [PAD] what disease can be diagnosed with a bone probe test?", "[PAD] what diseases can be diagnosed with a test? \"bone investigation\"?", "[PAD] what disease can be diagnosed with the \"search for bone\" test?", "[PAD] [PAD] treatment of which disease was studied in the gore reduce clinical study?", "the treatment of which disease has been studied in the gore reduce clinical study?", "[PAD] [PAD] [PAD] [PAD] which disease was treated in the gore reduce clinical trial?", "[PAD] [PAD] [PAD] what disease has been studied in the gore reduce clinical study?", "[PAD] [PAD] [PAD] what disease treatment has been studied in gore reduce clinical research?", "[PAD] the treatment of which disease was studied in the gore reduce clinical trial?", "[PAD] [PAD] [PAD] which disease has been treated in the gore reduce clinical trial?", "[PAD] [PAD] [PAD] what disease treatment was studied in the gore reduce clinical study?", "[PAD] for which disease was the treatment studied in the gore reduce clinical study?", "[PAD] the treatment of which disease was studied in the clinical study gore reduce?", "[PAD] [PAD] treatment of which disease was studied in the clinical study gore reduce?", "[PAD] [PAD] [PAD] treatment of which disease was studied in gore reduce clinical study?", "[PAD] treatment of which disease has been studied in the gore reduce clinical study?", "[PAD] [PAD] [PAD] [PAD] which disease was studied in the gore reduce clinical trial?", "[PAD] [PAD] [PAD] [PAD] what disease was studied in the gore reduce clinical study?", "[PAD] [PAD] [PAD] [PAD] what treatment was studied at the gore reduce clinical study?", "[PAD] [PAD] [PAD] which disease treatment was studied in the gore reduce clinical trial?", "[PAD] [PAD] [PAD] [PAD] what disease was treated in the gore reduce clinical trial?", "[PAD] [PAD] [PAD] [PAD] what treatments were studied in the gore reduce clinical study?", "[PAD] [PAD] treatment of which disease was investigated in the gore reduce clinical study?", "[PAD] [PAD] [PAD] which disease treatment was studied in the gore reduces clinical study?", "[PAD] [PAD] [PAD] which disease has been studied in the gore reduce clinical trial?", "[PAD] [PAD] [PAD] what disease treatments were studied in the reduce gore clinical study?", "[PAD] [PAD] [PAD] what disease treatment was studied in the gore reduce clinical trial?", "what are the treatments for the diseases studied in the gore reduce clinical trial?", "[PAD] [PAD] [PAD] [PAD] what diseases were treated in the gore reduce clinical study?", "[PAD] [PAD] [PAD] what disease has been studied in the gore reduce clinical trial?", "[PAD] [PAD] treatment of which disease was studied in the gore reduce clinical trial?", "[PAD] [PAD] [PAD] which disease treatment was studied in the gore reduce clinical study?", "[PAD] [PAD] [PAD] [PAD] which treatment was studied in the gore reduce clinical trial?", "[PAD] [PAD] [PAD] [PAD] what disease was studied in the gore reduce clinical trial?", "[PAD] the treatment of which disease was studied in the gora reduce clinical study?", "[PAD] the treatment of which disease was studied in the gore reduce clinical study?", "[PAD] [PAD] [PAD] what disease treatment was researched in the gore reduce clinical study?", "[PAD] [PAD] [PAD] [PAD] which treatments were studied in the gore reduce clinical study?", "[PAD] [PAD] the treatment of which disease was studied in gore reduce clinical study?", "[PAD] [PAD] [PAD] what disease treatments were studied in the gore reduction clinical study?", "[PAD] [PAD] [PAD] treating which disease was studied in the gore reduce clinical study?", "[PAD] [PAD] [PAD] treatment of what disease is studied in the completely reduce clinical study?", "[PAD] [PAD] treatment of which disease was studied in the gore reduce clinical study?", "the treatment of which disease has been studied in the gore reduce clinical study?", "[PAD] [PAD] [PAD] [PAD] which disease was treated in the gore reduce clinical trial?", "[PAD] [PAD] [PAD] what disease has been studied in the gore reduce clinical study?", "[PAD] [PAD] [PAD] what disease treatment has been studied in gore reduce clinical research?", "[PAD] the treatment of which disease was studied in the gore reduce clinical trial?", "[PAD] [PAD] [PAD] which disease has been treated in the gore reduce clinical trial?", "[PAD] [PAD] [PAD] what disease treatment was studied in the gore reduce clinical study?", "[PAD] for which disease was the treatment studied in the gore reduce clinical study?", "[PAD] the treatment of which disease was studied in the clinical study gore reduce?", "[PAD] [PAD] treatment of which disease was studied in the clinical study gore reduce?", "[PAD] [PAD] [PAD] treatment of which disease was studied in gore reduce clinical study?", "[PAD] treatment of which disease has been studied in the gore reduce clinical study?", "[PAD] [PAD] [PAD] [PAD] which disease was studied in the gore reduce clinical trial?", "[PAD] [PAD] [PAD] [PAD] what disease was studied in the gore reduce clinical study?", "[PAD] [PAD] [PAD] [PAD] what treatment was studied at the gore reduce clinical study?", "[PAD] [PAD] [PAD] which disease treatment was studied in the gore reduce clinical trial?", "[PAD] [PAD] [PAD] [PAD] what disease was treated in the gore reduce clinical trial?", "[PAD] [PAD] [PAD] [PAD] what treatments were studied in the gore reduce clinical study?", "[PAD] [PAD] treatment of which disease was investigated in the gore reduce clinical study?", "[PAD] [PAD] [PAD] which disease treatment was studied in the gore reduces clinical study?", "[PAD] [PAD] [PAD] which disease has been studied in the gore reduce clinical trial?", "[PAD] [PAD] [PAD] what disease treatments were studied in the reduce gore clinical study?", "[PAD] [PAD] [PAD] what disease treatment was studied in the gore reduce clinical trial?", "what are the treatments for the diseases studied in the gore reduce clinical trial?", "[PAD] [PAD] [PAD] [PAD] what diseases were treated in the gore reduce clinical study?", "[PAD] [PAD] [PAD] what disease has been studied in the gore reduce clinical trial?", "[PAD] [PAD] treatment of which disease was studied in the gore reduce clinical trial?", "[PAD] [PAD] [PAD] which disease treatment was studied in the gore reduce clinical study?", "[PAD] [PAD] [PAD] [PAD] which treatment was studied in the gore reduce clinical trial?", "[PAD] [PAD] [PAD] [PAD] what disease was studied in the gore reduce clinical trial?", "[PAD] the treatment of which disease was studied in the gora reduce clinical study?", "[PAD] the treatment of which disease was studied in the gore reduce clinical study?", "[PAD] [PAD] [PAD] what disease treatment was researched in the gore reduce clinical study?", "[PAD] [PAD] [PAD] [PAD] which treatments were studied in the gore reduce clinical study?", "[PAD] [PAD] the treatment of which disease was studied in gore reduce clinical study?", "[PAD] [PAD] [PAD] what disease treatments were studied in the gore reduction clinical study?", "[PAD] [PAD] [PAD] treating which disease was studied in the gore reduce clinical study?", "[PAD] [PAD] [PAD] treatment of what disease is studied in the completely reduce clinical study?", "[PAD] what is the most common feature of the doege\u2013potter syndrome?", "[PAD] [PAD] what is the most common feature of doege-potter syndrome?", "[PAD] [PAD] what is the most common feature of doug-potter syndrome?", "[PAD] [PAD] what is the most common feature of doeg-potter syndrome?", "[PAD] [PAD] what are the most common features of doege-potter syndrome?", "[PAD] [PAD] [PAD] what is the most common feature of dodge potter syndrome?", "[PAD] [PAD] what is the most common sign of doege-potter syndrome?", "[PAD] [PAD] what is the most common characteristic of doege-potter syndrome?", "[PAD] [PAD] what is the most common feature of doge-potter syndrome?", "[PAD] [PAD] [PAD] what is the most common feature of doege potter syndrome?", "[PAD] [PAD] what is the most common feature of dodge-potter syndrome?", "what is the most common symptom of doege-potter syndrome?", "[PAD] [PAD] what are the most common signs of dj-potter syndrome?", "[PAD] [PAD] what is the most common feature of doege \u2013 potter syndrome?", "[PAD] [PAD] what is the most common feature of doedge-potter syndrome?", "[PAD] [PAD] what is the most common feature of doage-potter syndrome?", "[PAD] what is the most common symptom of dodge potter syndrome?", "[PAD] [PAD] what is the most common feature of the doege-free syndrome?", "[PAD] what is the most common feature of the doege\u2013potter syndrome?", "[PAD] [PAD] what is the most common feature of doege-potter syndrome?", "[PAD] [PAD] what is the most common feature of doug-potter syndrome?", "[PAD] [PAD] what is the most common feature of doeg-potter syndrome?", "[PAD] [PAD] what are the most common features of doege-potter syndrome?", "[PAD] [PAD] [PAD] what is the most common feature of dodge potter syndrome?", "[PAD] [PAD] what is the most common sign of doege-potter syndrome?", "[PAD] [PAD] what is the most common characteristic of doege-potter syndrome?", "[PAD] [PAD] what is the most common feature of doge-potter syndrome?", "[PAD] [PAD] [PAD] what is the most common feature of doege potter syndrome?", "[PAD] [PAD] what is the most common feature of dodge-potter syndrome?", "what is the most common symptom of doege-potter syndrome?", "[PAD] [PAD] what are the most common signs of dj-potter syndrome?", "[PAD] [PAD] what is the most common feature of doege \u2013 potter syndrome?", "[PAD] [PAD] what is the most common feature of doedge-potter syndrome?", "[PAD] [PAD] what is the most common feature of doage-potter syndrome?", "[PAD] what is the most common symptom of dodge potter syndrome?", "[PAD] [PAD] what is the most common feature of the doege-free syndrome?", "[PAD] what is the most common feature of the doege\u2013potter syndrome?", "[PAD] [PAD] what is the most common feature of doege-potter syndrome?", "[PAD] [PAD] what is the most common feature of doug-potter syndrome?", "[PAD] [PAD] what is the most common feature of doeg-potter syndrome?", "[PAD] [PAD] what are the most common features of doege-potter syndrome?", "[PAD] [PAD] [PAD] what is the most common feature of dodge potter syndrome?", "[PAD] [PAD] what is the most common sign of doege-potter syndrome?", "[PAD] [PAD] what is the most common characteristic of doege-potter syndrome?", "[PAD] [PAD] what is the most common feature of doge-potter syndrome?", "[PAD] [PAD] [PAD] what is the most common feature of doege potter syndrome?", "[PAD] [PAD] what is the most common feature of dodge-potter syndrome?", "what is the most common symptom of doege-potter syndrome?", "[PAD] [PAD] what are the most common signs of dj-potter syndrome?", "[PAD] [PAD] what is the most common feature of doege \u2013 potter syndrome?", "[PAD] [PAD] what is the most common feature of doedge-potter syndrome?", "[PAD] [PAD] what is the most common feature of doage-potter syndrome?", "[PAD] what is the most common symptom of dodge potter syndrome?", "[PAD] [PAD] what is the most common feature of the doege-free syndrome?", "[PAD] what is the most common feature of the doege\u2013potter syndrome?", "[PAD] [PAD] what is the most common feature of doege-potter syndrome?", "[PAD] [PAD] what is the most common feature of doug-potter syndrome?", "[PAD] [PAD] what is the most common feature of doeg-potter syndrome?", "[PAD] [PAD] what are the most common features of doege-potter syndrome?", "[PAD] [PAD] [PAD] what is the most common feature of dodge potter syndrome?", "[PAD] [PAD] what is the most common sign of doege-potter syndrome?", "[PAD] [PAD] what is the most common characteristic of doege-potter syndrome?", "[PAD] [PAD] what is the most common feature of doge-potter syndrome?", "[PAD] [PAD] [PAD] what is the most common feature of doege potter syndrome?", "[PAD] [PAD] what is the most common feature of dodge-potter syndrome?", "what is the most common symptom of doege-potter syndrome?", "[PAD] [PAD] what are the most common signs of dj-potter syndrome?", "[PAD] [PAD] what is the most common feature of doege \u2013 potter syndrome?", "[PAD] [PAD] what is the most common feature of doedge-potter syndrome?", "[PAD] [PAD] what is the most common feature of doage-potter syndrome?", "[PAD] what is the most common symptom of dodge potter syndrome?", "[PAD] [PAD] what is the most common feature of the doege-free syndrome?", "[PAD] what is the most common feature of the doege\u2013potter syndrome?", "[PAD] [PAD] what is the most common feature of doege-potter syndrome?", "[PAD] [PAD] what is the most common feature of doug-potter syndrome?", "[PAD] [PAD] what is the most common feature of doeg-potter syndrome?", "[PAD] [PAD] what are the most common features of doege-potter syndrome?", "[PAD] [PAD] [PAD] what is the most common feature of dodge potter syndrome?", "[PAD] [PAD] what is the most common sign of doege-potter syndrome?", "[PAD] [PAD] what is the most common characteristic of doege-potter syndrome?", "[PAD] [PAD] what is the most common feature of doge-potter syndrome?", "[PAD] [PAD] [PAD] what is the most common feature of doege potter syndrome?", "[PAD] [PAD] what is the most common feature of dodge-potter syndrome?", "what is the most common symptom of doege-potter syndrome?", "[PAD] [PAD] what are the most common signs of dj-potter syndrome?", "[PAD] [PAD] what is the most common feature of doege \u2013 potter syndrome?", "[PAD] [PAD] what is the most common feature of doedge-potter syndrome?", "[PAD] [PAD] what is the most common feature of doage-potter syndrome?", "[PAD] what is the most common symptom of dodge potter syndrome?", "[PAD] [PAD] what is the most common feature of the doege-free syndrome?", "[PAD] what is the most common feature of the doege\u2013potter syndrome?", "[PAD] [PAD] what is the most common feature of doege-potter syndrome?", "[PAD] [PAD] what is the most common feature of doug-potter syndrome?", "[PAD] [PAD] what is the most common feature of doeg-potter syndrome?", "[PAD] [PAD] what are the most common features of doege-potter syndrome?", "[PAD] [PAD] [PAD] what is the most common feature of dodge potter syndrome?", "[PAD] [PAD] what is the most common sign of doege-potter syndrome?", "[PAD] [PAD] what is the most common characteristic of doege-potter syndrome?", "[PAD] [PAD] what is the most common feature of doge-potter syndrome?", "[PAD] [PAD] [PAD] what is the most common feature of doege potter syndrome?", "[PAD] [PAD] what is the most common feature of dodge-potter syndrome?", "what is the most common symptom of doege-potter syndrome?", "[PAD] [PAD] what are the most common signs of dj-potter syndrome?", "[PAD] [PAD] what is the most common feature of doege \u2013 potter syndrome?", "[PAD] [PAD] what is the most common feature of doedge-potter syndrome?", "[PAD] [PAD] what is the most common feature of doage-potter syndrome?", "[PAD] what is the most common symptom of dodge potter syndrome?", "[PAD] [PAD] what is the most common feature of the doege-free syndrome?", "[PAD] what is the most common feature of the doege\u2013potter syndrome?", "[PAD] [PAD] what is the most common feature of doege-potter syndrome?", "[PAD] [PAD] what is the most common feature of doug-potter syndrome?", "[PAD] [PAD] what is the most common feature of doeg-potter syndrome?", "[PAD] [PAD] what are the most common features of doege-potter syndrome?", "[PAD] [PAD] [PAD] what is the most common feature of dodge potter syndrome?", "[PAD] [PAD] what is the most common sign of doege-potter syndrome?", "[PAD] [PAD] what is the most common characteristic of doege-potter syndrome?", "[PAD] [PAD] what is the most common feature of doge-potter syndrome?", "[PAD] [PAD] [PAD] what is the most common feature of doege potter syndrome?", "[PAD] [PAD] what is the most common feature of dodge-potter syndrome?", "what is the most common symptom of doege-potter syndrome?", "[PAD] [PAD] what are the most common signs of dj-potter syndrome?", "[PAD] [PAD] what is the most common feature of doege \u2013 potter syndrome?", "[PAD] [PAD] what is the most common feature of doedge-potter syndrome?", "[PAD] [PAD] what is the most common feature of doage-potter syndrome?", "[PAD] what is the most common symptom of dodge potter syndrome?", "[PAD] [PAD] what is the most common feature of the doege-free syndrome?", "[PAD] what is the most common feature of the doege\u2013potter syndrome?", "[PAD] [PAD] what is the most common feature of doege-potter syndrome?", "[PAD] [PAD] what is the most common feature of doug-potter syndrome?", "[PAD] [PAD] what is the most common feature of doeg-potter syndrome?", "[PAD] [PAD] what are the most common features of doege-potter syndrome?", "[PAD] [PAD] [PAD] what is the most common feature of dodge potter syndrome?", "[PAD] [PAD] what is the most common sign of doege-potter syndrome?", "[PAD] [PAD] what is the most common characteristic of doege-potter syndrome?", "[PAD] [PAD] what is the most common feature of doge-potter syndrome?", "[PAD] [PAD] [PAD] what is the most common feature of doege potter syndrome?", "[PAD] [PAD] what is the most common feature of dodge-potter syndrome?", "what is the most common symptom of doege-potter syndrome?", "[PAD] [PAD] what are the most common signs of dj-potter syndrome?", "[PAD] [PAD] what is the most common feature of doege \u2013 potter syndrome?", "[PAD] [PAD] what is the most common feature of doedge-potter syndrome?", "[PAD] [PAD] what is the most common feature of doage-potter syndrome?", "[PAD] what is the most common symptom of dodge potter syndrome?", "[PAD] [PAD] what is the most common feature of the doege-free syndrome?", "[PAD] what is the most common feature of the doege\u2013potter syndrome?", "[PAD] [PAD] what is the most common feature of doege-potter syndrome?", "[PAD] [PAD] what is the most common feature of doug-potter syndrome?", "[PAD] [PAD] what is the most common feature of doeg-potter syndrome?", "[PAD] [PAD] what are the most common features of doege-potter syndrome?", "[PAD] [PAD] [PAD] what is the most common feature of dodge potter syndrome?", "[PAD] [PAD] what is the most common sign of doege-potter syndrome?", "[PAD] [PAD] what is the most common characteristic of doege-potter syndrome?", "[PAD] [PAD] what is the most common feature of doge-potter syndrome?", "[PAD] [PAD] [PAD] what is the most common feature of doege potter syndrome?", "[PAD] [PAD] what is the most common feature of dodge-potter syndrome?", "what is the most common symptom of doege-potter syndrome?", "[PAD] [PAD] what are the most common signs of dj-potter syndrome?", "[PAD] [PAD] what is the most common feature of doege \u2013 potter syndrome?", "[PAD] [PAD] what is the most common feature of doedge-potter syndrome?", "[PAD] [PAD] what is the most common feature of doage-potter syndrome?", "[PAD] what is the most common symptom of dodge potter syndrome?", "[PAD] [PAD] what is the most common feature of the doege-free syndrome?", "[PAD] what is the most common feature of the doege\u2013potter syndrome?", "[PAD] [PAD] what is the most common feature of doege-potter syndrome?", "[PAD] [PAD] what is the most common feature of doug-potter syndrome?", "[PAD] [PAD] what is the most common feature of doeg-potter syndrome?", "[PAD] [PAD] what are the most common features of doege-potter syndrome?", "[PAD] [PAD] [PAD] what is the most common feature of dodge potter syndrome?", "[PAD] [PAD] what is the most common sign of doege-potter syndrome?", "[PAD] [PAD] what is the most common characteristic of doege-potter syndrome?", "[PAD] [PAD] what is the most common feature of doge-potter syndrome?", "[PAD] [PAD] [PAD] what is the most common feature of doege potter syndrome?", "[PAD] [PAD] what is the most common feature of dodge-potter syndrome?", "what is the most common symptom of doege-potter syndrome?", "[PAD] [PAD] what are the most common signs of dj-potter syndrome?", "[PAD] [PAD] what is the most common feature of doege \u2013 potter syndrome?", "[PAD] [PAD] what is the most common feature of doedge-potter syndrome?", "[PAD] [PAD] what is the most common feature of doage-potter syndrome?", "[PAD] what is the most common symptom of dodge potter syndrome?", "[PAD] [PAD] what is the most common feature of the doege-free syndrome?", "[PAD] what is the most common feature of the doege\u2013potter syndrome?", "[PAD] [PAD] what is the most common feature of doege-potter syndrome?", "[PAD] [PAD] what is the most common feature of doug-potter syndrome?", "[PAD] [PAD] what is the most common feature of doeg-potter syndrome?", "[PAD] [PAD] what are the most common features of doege-potter syndrome?", "[PAD] [PAD] [PAD] what is the most common feature of dodge potter syndrome?", "[PAD] [PAD] what is the most common sign of doege-potter syndrome?", "[PAD] [PAD] what is the most common characteristic of doege-potter syndrome?", "[PAD] [PAD] what is the most common feature of doge-potter syndrome?", "[PAD] [PAD] [PAD] what is the most common feature of doege potter syndrome?", "[PAD] [PAD] what is the most common feature of dodge-potter syndrome?", "what is the most common symptom of doege-potter syndrome?", "[PAD] [PAD] what are the most common signs of dj-potter syndrome?", "[PAD] [PAD] what is the most common feature of doege \u2013 potter syndrome?", "[PAD] [PAD] what is the most common feature of doedge-potter syndrome?", "[PAD] [PAD] what is the most common feature of doage-potter syndrome?", "[PAD] what is the most common symptom of dodge potter syndrome?", "[PAD] [PAD] what is the most common feature of the doege-free syndrome?", "[PAD] what is the most common feature of the doege\u2013potter syndrome?", "[PAD] [PAD] what is the most common feature of doege-potter syndrome?", "[PAD] [PAD] what is the most common feature of doug-potter syndrome?", "[PAD] [PAD] what is the most common feature of doeg-potter syndrome?", "[PAD] [PAD] what are the most common features of doege-potter syndrome?", "[PAD] [PAD] [PAD] what is the most common feature of dodge potter syndrome?", "[PAD] [PAD] what is the most common sign of doege-potter syndrome?", "[PAD] [PAD] what is the most common characteristic of doege-potter syndrome?", "[PAD] [PAD] what is the most common feature of doge-potter syndrome?", "[PAD] [PAD] [PAD] what is the most common feature of doege potter syndrome?", "[PAD] [PAD] what is the most common feature of dodge-potter syndrome?", "what is the most common symptom of doege-potter syndrome?", "[PAD] [PAD] what are the most common signs of dj-potter syndrome?", "[PAD] [PAD] what is the most common feature of doege \u2013 potter syndrome?", "[PAD] [PAD] what is the most common feature of doedge-potter syndrome?", "[PAD] [PAD] what is the most common feature of doage-potter syndrome?", "[PAD] what is the most common symptom of dodge potter syndrome?", "[PAD] [PAD] what is the most common feature of the doege-free syndrome?", "[PAD] [PAD] [PAD] milwaukee protocol was tested for treatment of which disease?", "[PAD] [PAD] milwaukee protocol has been tested for treatment of which disease?", "[PAD] [PAD] [PAD] [PAD] for which disease was the milwaukee protocol tested?", "[PAD] [PAD] the milwaukee protocol has been tested to treat which disease?", "[PAD] [PAD] [PAD] [PAD] for what disease was the milwaukee protocol tested?", "[PAD] [PAD] [PAD] what disease has the milwaukee protocol been tested for?", "[PAD] [PAD] [PAD] [PAD] what diseases were the milwaukee protocol tested for?", "[PAD] the milwaukee protocol was tested for the treatment of what disease?", "[PAD] [PAD] [PAD] for which diseases has the milwaukee protocol been tested?", "for the treatment of which disease has the milwaukee protocol been tested?", "[PAD] the milwaukee protocol was tested for the treatment of which disease?", "[PAD] [PAD] [PAD] [PAD] what disease was the milwaukee protocol tested for?", "[PAD] [PAD] reviewed the milwaukee protocol for the treatment of what disease?", "the milwaukee protocol has been tested for the treatment of what disease?", "[PAD] milwaukee protocol has been tested for the treatment of what disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] milwaukee protocol tested for treatment of disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] milwaukee protocol tested for what disease?", "[PAD] [PAD] [PAD] for which disease has the milwaukee protocol been tested?", "[PAD] [PAD] [PAD] [PAD] milwaukee protocol was tested to treat any disease?", "[PAD] the milwaukee protocol is tested for the treatment of what disease?", "the milwaukee protocol has been tested for the treatment of which disease?", "[PAD] [PAD] [PAD] [PAD] which disease has the milwaukee protocol tested for?", "[PAD] [PAD] [PAD] what diseases has the milwaukee protocol been tested for?", "[PAD] [PAD] [PAD] the milwaukee protocol was tested to treat which disease?", "the milwaukee protocol has been tested for the treatment of which diseases?", "has the milwaukee protocol been tested for the treatment of which disease?", "[PAD] [PAD] [PAD] [PAD] the milwaukee protocol was tested for which disease?", "[PAD] [PAD] the milwaukee protocol has been tested to treat what disease?", "[PAD] [PAD] [PAD] what condition has the milwaukee protocol been tested for?", "for the treatment of which diseases has the milwaukee protocol been tested?", "[PAD] [PAD] [PAD] what disease treatment was the milwaukee protocol tested for?", "[PAD] [PAD] [PAD] what is the milwaukee regimen being tested for?", "[PAD] [PAD] milwaukee's protocol for treating what disease was tested?", "[PAD] [PAD] milwaukee protocol has been tested for treatment of what disease?", "[PAD] [PAD] [PAD] milwaukee protocol was tested for treatment of which disease?", "[PAD] [PAD] milwaukee protocol has been tested for treatment of which disease?", "[PAD] [PAD] [PAD] [PAD] for which disease was the milwaukee protocol tested?", "[PAD] [PAD] the milwaukee protocol has been tested to treat which disease?", "[PAD] [PAD] [PAD] [PAD] for what disease was the milwaukee protocol tested?", "[PAD] [PAD] [PAD] what disease has the milwaukee protocol been tested for?", "[PAD] [PAD] [PAD] [PAD] what diseases were the milwaukee protocol tested for?", "[PAD] the milwaukee protocol was tested for the treatment of what disease?", "[PAD] [PAD] [PAD] for which diseases has the milwaukee protocol been tested?", "for the treatment of which disease has the milwaukee protocol been tested?", "[PAD] the milwaukee protocol was tested for the treatment of which disease?", "[PAD] [PAD] [PAD] [PAD] what disease was the milwaukee protocol tested for?", "[PAD] [PAD] reviewed the milwaukee protocol for the treatment of what disease?", "the milwaukee protocol has been tested for the treatment of what disease?", "[PAD] milwaukee protocol has been tested for the treatment of what disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] milwaukee protocol tested for treatment of disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] milwaukee protocol tested for what disease?", "[PAD] [PAD] [PAD] for which disease has the milwaukee protocol been tested?", "[PAD] [PAD] [PAD] [PAD] milwaukee protocol was tested to treat any disease?", "[PAD] the milwaukee protocol is tested for the treatment of what disease?", "the milwaukee protocol has been tested for the treatment of which disease?", "[PAD] [PAD] [PAD] [PAD] which disease has the milwaukee protocol tested for?", "[PAD] [PAD] [PAD] what diseases has the milwaukee protocol been tested for?", "[PAD] [PAD] [PAD] the milwaukee protocol was tested to treat which disease?", "the milwaukee protocol has been tested for the treatment of which diseases?", "has the milwaukee protocol been tested for the treatment of which disease?", "[PAD] [PAD] [PAD] [PAD] the milwaukee protocol was tested for which disease?", "[PAD] [PAD] the milwaukee protocol has been tested to treat what disease?", "[PAD] [PAD] [PAD] what condition has the milwaukee protocol been tested for?", "for the treatment of which diseases has the milwaukee protocol been tested?", "[PAD] [PAD] [PAD] what disease treatment was the milwaukee protocol tested for?", "[PAD] [PAD] [PAD] what is the milwaukee regimen being tested for?", "[PAD] [PAD] milwaukee's protocol for treating what disease was tested?", "[PAD] [PAD] milwaukee protocol has been tested for treatment of what disease?", "[PAD] [PAD] [PAD] milwaukee protocol was tested for treatment of which disease?", "[PAD] [PAD] milwaukee protocol has been tested for treatment of which disease?", "[PAD] [PAD] [PAD] [PAD] for which disease was the milwaukee protocol tested?", "[PAD] [PAD] the milwaukee protocol has been tested to treat which disease?", "[PAD] [PAD] [PAD] [PAD] for what disease was the milwaukee protocol tested?", "[PAD] [PAD] [PAD] what disease has the milwaukee protocol been tested for?", "[PAD] [PAD] [PAD] [PAD] what diseases were the milwaukee protocol tested for?", "[PAD] the milwaukee protocol was tested for the treatment of what disease?", "[PAD] [PAD] [PAD] for which diseases has the milwaukee protocol been tested?", "for the treatment of which disease has the milwaukee protocol been tested?", "[PAD] the milwaukee protocol was tested for the treatment of which disease?", "[PAD] [PAD] [PAD] [PAD] what disease was the milwaukee protocol tested for?", "[PAD] [PAD] reviewed the milwaukee protocol for the treatment of what disease?", "the milwaukee protocol has been tested for the treatment of what disease?", "[PAD] milwaukee protocol has been tested for the treatment of what disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] milwaukee protocol tested for treatment of disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] milwaukee protocol tested for what disease?", "[PAD] [PAD] [PAD] for which disease has the milwaukee protocol been tested?", "[PAD] [PAD] [PAD] [PAD] milwaukee protocol was tested to treat any disease?", "[PAD] the milwaukee protocol is tested for the treatment of what disease?", "the milwaukee protocol has been tested for the treatment of which disease?", "[PAD] [PAD] [PAD] [PAD] which disease has the milwaukee protocol tested for?", "[PAD] [PAD] [PAD] what diseases has the milwaukee protocol been tested for?", "[PAD] [PAD] [PAD] the milwaukee protocol was tested to treat which disease?", "the milwaukee protocol has been tested for the treatment of which diseases?", "has the milwaukee protocol been tested for the treatment of which disease?", "[PAD] [PAD] [PAD] [PAD] the milwaukee protocol was tested for which disease?", "[PAD] [PAD] the milwaukee protocol has been tested to treat what disease?", "[PAD] [PAD] [PAD] what condition has the milwaukee protocol been tested for?", "for the treatment of which diseases has the milwaukee protocol been tested?", "[PAD] [PAD] [PAD] what disease treatment was the milwaukee protocol tested for?", "[PAD] [PAD] [PAD] what is the milwaukee regimen being tested for?", "[PAD] [PAD] milwaukee's protocol for treating what disease was tested?", "[PAD] [PAD] milwaukee protocol has been tested for treatment of what disease?", "[PAD] [PAD] [PAD] milwaukee protocol was tested for treatment of which disease?", "[PAD] [PAD] milwaukee protocol has been tested for treatment of which disease?", "[PAD] [PAD] [PAD] [PAD] for which disease was the milwaukee protocol tested?", "[PAD] [PAD] the milwaukee protocol has been tested to treat which disease?", "[PAD] [PAD] [PAD] [PAD] for what disease was the milwaukee protocol tested?", "[PAD] [PAD] [PAD] what disease has the milwaukee protocol been tested for?", "[PAD] [PAD] [PAD] [PAD] what diseases were the milwaukee protocol tested for?", "[PAD] the milwaukee protocol was tested for the treatment of what disease?", "[PAD] [PAD] [PAD] for which diseases has the milwaukee protocol been tested?", "for the treatment of which disease has the milwaukee protocol been tested?", "[PAD] the milwaukee protocol was tested for the treatment of which disease?", "[PAD] [PAD] [PAD] [PAD] what disease was the milwaukee protocol tested for?", "[PAD] [PAD] reviewed the milwaukee protocol for the treatment of what disease?", "the milwaukee protocol has been tested for the treatment of what disease?", "[PAD] milwaukee protocol has been tested for the treatment of what disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] milwaukee protocol tested for treatment of disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] milwaukee protocol tested for what disease?", "[PAD] [PAD] [PAD] for which disease has the milwaukee protocol been tested?", "[PAD] [PAD] [PAD] [PAD] milwaukee protocol was tested to treat any disease?", "[PAD] the milwaukee protocol is tested for the treatment of what disease?", "the milwaukee protocol has been tested for the treatment of which disease?", "[PAD] [PAD] [PAD] [PAD] which disease has the milwaukee protocol tested for?", "[PAD] [PAD] [PAD] what diseases has the milwaukee protocol been tested for?", "[PAD] [PAD] [PAD] the milwaukee protocol was tested to treat which disease?", "the milwaukee protocol has been tested for the treatment of which diseases?", "has the milwaukee protocol been tested for the treatment of which disease?", "[PAD] [PAD] [PAD] [PAD] the milwaukee protocol was tested for which disease?", "[PAD] [PAD] the milwaukee protocol has been tested to treat what disease?", "[PAD] [PAD] [PAD] what condition has the milwaukee protocol been tested for?", "for the treatment of which diseases has the milwaukee protocol been tested?", "[PAD] [PAD] [PAD] what disease treatment was the milwaukee protocol tested for?", "[PAD] [PAD] [PAD] what is the milwaukee regimen being tested for?", "[PAD] [PAD] milwaukee's protocol for treating what disease was tested?", "[PAD] [PAD] milwaukee protocol has been tested for treatment of what disease?", "[PAD] [PAD] [PAD] milwaukee protocol was tested for treatment of which disease?", "[PAD] [PAD] milwaukee protocol has been tested for treatment of which disease?", "[PAD] [PAD] [PAD] [PAD] for which disease was the milwaukee protocol tested?", "[PAD] [PAD] the milwaukee protocol has been tested to treat which disease?", "[PAD] [PAD] [PAD] [PAD] for what disease was the milwaukee protocol tested?", "[PAD] [PAD] [PAD] what disease has the milwaukee protocol been tested for?", "[PAD] [PAD] [PAD] [PAD] what diseases were the milwaukee protocol tested for?", "[PAD] the milwaukee protocol was tested for the treatment of what disease?", "[PAD] [PAD] [PAD] for which diseases has the milwaukee protocol been tested?", "for the treatment of which disease has the milwaukee protocol been tested?", "[PAD] the milwaukee protocol was tested for the treatment of which disease?", "[PAD] [PAD] [PAD] [PAD] what disease was the milwaukee protocol tested for?", "[PAD] [PAD] reviewed the milwaukee protocol for the treatment of what disease?", "the milwaukee protocol has been tested for the treatment of what disease?", "[PAD] milwaukee protocol has been tested for the treatment of what disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] milwaukee protocol tested for treatment of disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] milwaukee protocol tested for what disease?", "[PAD] [PAD] [PAD] for which disease has the milwaukee protocol been tested?", "[PAD] [PAD] [PAD] [PAD] milwaukee protocol was tested to treat any disease?", "[PAD] the milwaukee protocol is tested for the treatment of what disease?", "the milwaukee protocol has been tested for the treatment of which disease?", "[PAD] [PAD] [PAD] [PAD] which disease has the milwaukee protocol tested for?", "[PAD] [PAD] [PAD] what diseases has the milwaukee protocol been tested for?", "[PAD] [PAD] [PAD] the milwaukee protocol was tested to treat which disease?", "the milwaukee protocol has been tested for the treatment of which diseases?", "has the milwaukee protocol been tested for the treatment of which disease?", "[PAD] [PAD] [PAD] [PAD] the milwaukee protocol was tested for which disease?", "[PAD] [PAD] the milwaukee protocol has been tested to treat what disease?", "[PAD] [PAD] [PAD] what condition has the milwaukee protocol been tested for?", "for the treatment of which diseases has the milwaukee protocol been tested?", "[PAD] [PAD] [PAD] what disease treatment was the milwaukee protocol tested for?", "[PAD] [PAD] [PAD] what is the milwaukee regimen being tested for?", "[PAD] [PAD] milwaukee's protocol for treating what disease was tested?", "[PAD] [PAD] milwaukee protocol has been tested for treatment of what disease?", "[PAD] [PAD] [PAD] milwaukee protocol was tested for treatment of which disease?", "[PAD] [PAD] milwaukee protocol has been tested for treatment of which disease?", "[PAD] [PAD] [PAD] [PAD] for which disease was the milwaukee protocol tested?", "[PAD] [PAD] the milwaukee protocol has been tested to treat which disease?", "[PAD] [PAD] [PAD] [PAD] for what disease was the milwaukee protocol tested?", "[PAD] [PAD] [PAD] what disease has the milwaukee protocol been tested for?", "[PAD] [PAD] [PAD] [PAD] what diseases were the milwaukee protocol tested for?", "[PAD] the milwaukee protocol was tested for the treatment of what disease?", "[PAD] [PAD] [PAD] for which diseases has the milwaukee protocol been tested?", "for the treatment of which disease has the milwaukee protocol been tested?", "[PAD] the milwaukee protocol was tested for the treatment of which disease?", "[PAD] [PAD] [PAD] [PAD] what disease was the milwaukee protocol tested for?", "[PAD] [PAD] reviewed the milwaukee protocol for the treatment of what disease?", "the milwaukee protocol has been tested for the treatment of what disease?", "[PAD] milwaukee protocol has been tested for the treatment of what disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] milwaukee protocol tested for treatment of disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] milwaukee protocol tested for what disease?", "[PAD] [PAD] [PAD] for which disease has the milwaukee protocol been tested?", "[PAD] [PAD] [PAD] [PAD] milwaukee protocol was tested to treat any disease?", "[PAD] the milwaukee protocol is tested for the treatment of what disease?", "the milwaukee protocol has been tested for the treatment of which disease?", "[PAD] [PAD] [PAD] [PAD] which disease has the milwaukee protocol tested for?", "[PAD] [PAD] [PAD] what diseases has the milwaukee protocol been tested for?", "[PAD] [PAD] [PAD] the milwaukee protocol was tested to treat which disease?", "the milwaukee protocol has been tested for the treatment of which diseases?", "has the milwaukee protocol been tested for the treatment of which disease?", "[PAD] [PAD] [PAD] [PAD] the milwaukee protocol was tested for which disease?", "[PAD] [PAD] the milwaukee protocol has been tested to treat what disease?", "[PAD] [PAD] [PAD] what condition has the milwaukee protocol been tested for?", "for the treatment of which diseases has the milwaukee protocol been tested?", "[PAD] [PAD] [PAD] what disease treatment was the milwaukee protocol tested for?", "[PAD] [PAD] [PAD] what is the milwaukee regimen being tested for?", "[PAD] [PAD] milwaukee's protocol for treating what disease was tested?", "[PAD] [PAD] milwaukee protocol has been tested for treatment of what disease?", "[PAD] [PAD] [PAD] milwaukee protocol was tested for treatment of which disease?", "[PAD] [PAD] milwaukee protocol has been tested for treatment of which disease?", "[PAD] [PAD] [PAD] [PAD] for which disease was the milwaukee protocol tested?", "[PAD] [PAD] the milwaukee protocol has been tested to treat which disease?", "[PAD] [PAD] [PAD] [PAD] for what disease was the milwaukee protocol tested?", "[PAD] [PAD] [PAD] what disease has the milwaukee protocol been tested for?", "[PAD] [PAD] [PAD] [PAD] what diseases were the milwaukee protocol tested for?", "[PAD] the milwaukee protocol was tested for the treatment of what disease?", "[PAD] [PAD] [PAD] for which diseases has the milwaukee protocol been tested?", "for the treatment of which disease has the milwaukee protocol been tested?", "[PAD] the milwaukee protocol was tested for the treatment of which disease?", "[PAD] [PAD] [PAD] [PAD] what disease was the milwaukee protocol tested for?", "[PAD] [PAD] reviewed the milwaukee protocol for the treatment of what disease?", "the milwaukee protocol has been tested for the treatment of what disease?", "[PAD] milwaukee protocol has been tested for the treatment of what disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] milwaukee protocol tested for treatment of disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] milwaukee protocol tested for what disease?", "[PAD] [PAD] [PAD] for which disease has the milwaukee protocol been tested?", "[PAD] [PAD] [PAD] [PAD] milwaukee protocol was tested to treat any disease?", "[PAD] the milwaukee protocol is tested for the treatment of what disease?", "the milwaukee protocol has been tested for the treatment of which disease?", "[PAD] [PAD] [PAD] [PAD] which disease has the milwaukee protocol tested for?", "[PAD] [PAD] [PAD] what diseases has the milwaukee protocol been tested for?", "[PAD] [PAD] [PAD] the milwaukee protocol was tested to treat which disease?", "the milwaukee protocol has been tested for the treatment of which diseases?", "has the milwaukee protocol been tested for the treatment of which disease?", "[PAD] [PAD] [PAD] [PAD] the milwaukee protocol was tested for which disease?", "[PAD] [PAD] the milwaukee protocol has been tested to treat what disease?", "[PAD] [PAD] [PAD] what condition has the milwaukee protocol been tested for?", "for the treatment of which diseases has the milwaukee protocol been tested?", "[PAD] [PAD] [PAD] what disease treatment was the milwaukee protocol tested for?", "[PAD] [PAD] [PAD] what is the milwaukee regimen being tested for?", "[PAD] [PAD] milwaukee's protocol for treating what disease was tested?", "[PAD] [PAD] milwaukee protocol has been tested for treatment of what disease?", "[PAD] [PAD] [PAD] milwaukee protocol was tested for treatment of which disease?", "[PAD] [PAD] milwaukee protocol has been tested for treatment of which disease?", "[PAD] [PAD] [PAD] [PAD] for which disease was the milwaukee protocol tested?", "[PAD] [PAD] the milwaukee protocol has been tested to treat which disease?", "[PAD] [PAD] [PAD] [PAD] for what disease was the milwaukee protocol tested?", "[PAD] [PAD] [PAD] what disease has the milwaukee protocol been tested for?", "[PAD] [PAD] [PAD] [PAD] what diseases were the milwaukee protocol tested for?", "[PAD] the milwaukee protocol was tested for the treatment of what disease?", "[PAD] [PAD] [PAD] for which diseases has the milwaukee protocol been tested?", "for the treatment of which disease has the milwaukee protocol been tested?", "[PAD] the milwaukee protocol was tested for the treatment of which disease?", "[PAD] [PAD] [PAD] [PAD] what disease was the milwaukee protocol tested for?", "[PAD] [PAD] reviewed the milwaukee protocol for the treatment of what disease?", "the milwaukee protocol has been tested for the treatment of what disease?", "[PAD] milwaukee protocol has been tested for the treatment of what disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] milwaukee protocol tested for treatment of disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] milwaukee protocol tested for what disease?", "[PAD] [PAD] [PAD] for which disease has the milwaukee protocol been tested?", "[PAD] [PAD] [PAD] [PAD] milwaukee protocol was tested to treat any disease?", "[PAD] the milwaukee protocol is tested for the treatment of what disease?", "the milwaukee protocol has been tested for the treatment of which disease?", "[PAD] [PAD] [PAD] [PAD] which disease has the milwaukee protocol tested for?", "[PAD] [PAD] [PAD] what diseases has the milwaukee protocol been tested for?", "[PAD] [PAD] [PAD] the milwaukee protocol was tested to treat which disease?", "the milwaukee protocol has been tested for the treatment of which diseases?", "has the milwaukee protocol been tested for the treatment of which disease?", "[PAD] [PAD] [PAD] [PAD] the milwaukee protocol was tested for which disease?", "[PAD] [PAD] the milwaukee protocol has been tested to treat what disease?", "[PAD] [PAD] [PAD] what condition has the milwaukee protocol been tested for?", "for the treatment of which diseases has the milwaukee protocol been tested?", "[PAD] [PAD] [PAD] what disease treatment was the milwaukee protocol tested for?", "[PAD] [PAD] [PAD] what is the milwaukee regimen being tested for?", "[PAD] [PAD] milwaukee's protocol for treating what disease was tested?", "[PAD] [PAD] milwaukee protocol has been tested for treatment of what disease?", "[PAD] [PAD] [PAD] milwaukee protocol was tested for treatment of which disease?", "[PAD] [PAD] milwaukee protocol has been tested for treatment of which disease?", "[PAD] [PAD] [PAD] [PAD] for which disease was the milwaukee protocol tested?", "[PAD] [PAD] the milwaukee protocol has been tested to treat which disease?", "[PAD] [PAD] [PAD] [PAD] for what disease was the milwaukee protocol tested?", "[PAD] [PAD] [PAD] what disease has the milwaukee protocol been tested for?", "[PAD] [PAD] [PAD] [PAD] what diseases were the milwaukee protocol tested for?", "[PAD] the milwaukee protocol was tested for the treatment of what disease?", "[PAD] [PAD] [PAD] for which diseases has the milwaukee protocol been tested?", "for the treatment of which disease has the milwaukee protocol been tested?", "[PAD] the milwaukee protocol was tested for the treatment of which disease?", "[PAD] [PAD] [PAD] [PAD] what disease was the milwaukee protocol tested for?", "[PAD] [PAD] reviewed the milwaukee protocol for the treatment of what disease?", "the milwaukee protocol has been tested for the treatment of what disease?", "[PAD] milwaukee protocol has been tested for the treatment of what disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] milwaukee protocol tested for treatment of disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] milwaukee protocol tested for what disease?", "[PAD] [PAD] [PAD] for which disease has the milwaukee protocol been tested?", "[PAD] [PAD] [PAD] [PAD] milwaukee protocol was tested to treat any disease?", "[PAD] the milwaukee protocol is tested for the treatment of what disease?", "the milwaukee protocol has been tested for the treatment of which disease?", "[PAD] [PAD] [PAD] [PAD] which disease has the milwaukee protocol tested for?", "[PAD] [PAD] [PAD] what diseases has the milwaukee protocol been tested for?", "[PAD] [PAD] [PAD] the milwaukee protocol was tested to treat which disease?", "the milwaukee protocol has been tested for the treatment of which diseases?", "has the milwaukee protocol been tested for the treatment of which disease?", "[PAD] [PAD] [PAD] [PAD] the milwaukee protocol was tested for which disease?", "[PAD] [PAD] the milwaukee protocol has been tested to treat what disease?", "[PAD] [PAD] [PAD] what condition has the milwaukee protocol been tested for?", "for the treatment of which diseases has the milwaukee protocol been tested?", "[PAD] [PAD] [PAD] what disease treatment was the milwaukee protocol tested for?", "[PAD] [PAD] [PAD] what is the milwaukee regimen being tested for?", "[PAD] [PAD] milwaukee's protocol for treating what disease was tested?", "[PAD] [PAD] milwaukee protocol has been tested for treatment of what disease?", "[PAD] [PAD] [PAD] milwaukee protocol was tested for treatment of which disease?", "[PAD] [PAD] milwaukee protocol has been tested for treatment of which disease?", "[PAD] [PAD] [PAD] [PAD] for which disease was the milwaukee protocol tested?", "[PAD] [PAD] the milwaukee protocol has been tested to treat which disease?", "[PAD] [PAD] [PAD] [PAD] for what disease was the milwaukee protocol tested?", "[PAD] [PAD] [PAD] what disease has the milwaukee protocol been tested for?", "[PAD] [PAD] [PAD] [PAD] what diseases were the milwaukee protocol tested for?", "[PAD] the milwaukee protocol was tested for the treatment of what disease?", "[PAD] [PAD] [PAD] for which diseases has the milwaukee protocol been tested?", "for the treatment of which disease has the milwaukee protocol been tested?", "[PAD] the milwaukee protocol was tested for the treatment of which disease?", "[PAD] [PAD] [PAD] [PAD] what disease was the milwaukee protocol tested for?", "[PAD] [PAD] reviewed the milwaukee protocol for the treatment of what disease?", "the milwaukee protocol has been tested for the treatment of what disease?", "[PAD] milwaukee protocol has been tested for the treatment of what disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] milwaukee protocol tested for treatment of disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] milwaukee protocol tested for what disease?", "[PAD] [PAD] [PAD] for which disease has the milwaukee protocol been tested?", "[PAD] [PAD] [PAD] [PAD] milwaukee protocol was tested to treat any disease?", "[PAD] the milwaukee protocol is tested for the treatment of what disease?", "the milwaukee protocol has been tested for the treatment of which disease?", "[PAD] [PAD] [PAD] [PAD] which disease has the milwaukee protocol tested for?", "[PAD] [PAD] [PAD] what diseases has the milwaukee protocol been tested for?", "[PAD] [PAD] [PAD] the milwaukee protocol was tested to treat which disease?", "the milwaukee protocol has been tested for the treatment of which diseases?", "has the milwaukee protocol been tested for the treatment of which disease?", "[PAD] [PAD] [PAD] [PAD] the milwaukee protocol was tested for which disease?", "[PAD] [PAD] the milwaukee protocol has been tested to treat what disease?", "[PAD] [PAD] [PAD] what condition has the milwaukee protocol been tested for?", "for the treatment of which diseases has the milwaukee protocol been tested?", "[PAD] [PAD] [PAD] what disease treatment was the milwaukee protocol tested for?", "[PAD] [PAD] [PAD] what is the milwaukee regimen being tested for?", "[PAD] [PAD] milwaukee's protocol for treating what disease was tested?", "[PAD] [PAD] milwaukee protocol has been tested for treatment of what disease?", "[PAD] [PAD] [PAD] milwaukee protocol was tested for treatment of which disease?", "[PAD] [PAD] milwaukee protocol has been tested for treatment of which disease?", "[PAD] [PAD] [PAD] [PAD] for which disease was the milwaukee protocol tested?", "[PAD] [PAD] the milwaukee protocol has been tested to treat which disease?", "[PAD] [PAD] [PAD] [PAD] for what disease was the milwaukee protocol tested?", "[PAD] [PAD] [PAD] what disease has the milwaukee protocol been tested for?", "[PAD] [PAD] [PAD] [PAD] what diseases were the milwaukee protocol tested for?", "[PAD] the milwaukee protocol was tested for the treatment of what disease?", "[PAD] [PAD] [PAD] for which diseases has the milwaukee protocol been tested?", "for the treatment of which disease has the milwaukee protocol been tested?", "[PAD] the milwaukee protocol was tested for the treatment of which disease?", "[PAD] [PAD] [PAD] [PAD] what disease was the milwaukee protocol tested for?", "[PAD] [PAD] reviewed the milwaukee protocol for the treatment of what disease?", "the milwaukee protocol has been tested for the treatment of what disease?", "[PAD] milwaukee protocol has been tested for the treatment of what disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] milwaukee protocol tested for treatment of disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] milwaukee protocol tested for what disease?", "[PAD] [PAD] [PAD] for which disease has the milwaukee protocol been tested?", "[PAD] [PAD] [PAD] [PAD] milwaukee protocol was tested to treat any disease?", "[PAD] the milwaukee protocol is tested for the treatment of what disease?", "the milwaukee protocol has been tested for the treatment of which disease?", "[PAD] [PAD] [PAD] [PAD] which disease has the milwaukee protocol tested for?", "[PAD] [PAD] [PAD] what diseases has the milwaukee protocol been tested for?", "[PAD] [PAD] [PAD] the milwaukee protocol was tested to treat which disease?", "the milwaukee protocol has been tested for the treatment of which diseases?", "has the milwaukee protocol been tested for the treatment of which disease?", "[PAD] [PAD] [PAD] [PAD] the milwaukee protocol was tested for which disease?", "[PAD] [PAD] the milwaukee protocol has been tested to treat what disease?", "[PAD] [PAD] [PAD] what condition has the milwaukee protocol been tested for?", "for the treatment of which diseases has the milwaukee protocol been tested?", "[PAD] [PAD] [PAD] what disease treatment was the milwaukee protocol tested for?", "[PAD] [PAD] [PAD] what is the milwaukee regimen being tested for?", "[PAD] [PAD] milwaukee's protocol for treating what disease was tested?", "[PAD] [PAD] milwaukee protocol has been tested for treatment of what disease?", "what is the bioarchive system?", "what is a bioarchive system?", "[PAD] what is a biological file system?", "what is the bioarchivo system?", "what is a bio-archive system?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is liquid liquid phase transition?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is liquid-phase transition?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the liquid phase transition?", "[PAD] [PAD] [PAD] [PAD] what is a liquid-liquid transformation?", "[PAD] [PAD] what is the transition from liquid to liquid phase?", "[PAD] [PAD] [PAD] what is a liquid-liquid phase transition?", "[PAD] [PAD] [PAD] [PAD] what is a liquid-phase transition?", "[PAD] [PAD] [PAD] [PAD] what is liquid-liquid phase transition?", "[PAD] [PAD] what is the transition of the current liquid phase?", "[PAD] [PAD] [PAD] [PAD] what is a liquid-liquid transition?", "[PAD] what is the transition of the liquid-liquid phase?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what is liquid phase transition?", "[PAD] what is the change in the liquid-liquid phase?", "[PAD] [PAD] what is liquid-to-liquid phase transition?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is a liquid phase transition?", "[PAD] [PAD] [PAD] [PAD] what is a liquid liquid phase transition?", "[PAD] [PAD] [PAD] [PAD] what is a liquid liquid phase change?", "[PAD] [PAD] [PAD] [PAD] what is the liquid phase phase transition?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what is liquid phase transfer?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] is liquid liquid phase transition?", "what is the transition from a liquid to a liquid phase?", "[PAD] [PAD] [PAD] what is the current-liquid phase transition?", "[PAD] [PAD] what is the transition of the liquid phase phase?", "[PAD] [PAD] [PAD] [PAD] what is liquid-liquid phase change?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the liquid phase transfer?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is fluid fluid phase transition?", "[PAD] [PAD] what is the approximate size of gas vesicles?", "[PAD] what is the approximate size of the gas vesicles?", "[PAD] [PAD] what is the approximate size of the gas bubbles?", "[PAD] [PAD] [PAD] what is the approximate size of the bubbles?", "[PAD] [PAD] [PAD] what is the approximate size of gas bags?", "what is the approximate size of the gas hydrocarbons?", "[PAD] [PAD] [PAD] what is the approximate size of gas bubbles?", "[PAD] [PAD] what is the approximate size of a gas bladder?", "[PAD] [PAD] what is the estimated size of the gas balloons?", "[PAD] what is the approximate size of the gas vesicle?", "[PAD] [PAD] what is the approximate size of the gas vehicle?", "[PAD] [PAD] [PAD] what is the approximate size of the bubble?", "[PAD] what is the estimated size of the gas vesicle?", "[PAD] [PAD] [PAD] what is the approximate size of gas vessels?", "je! what is the average size of gas vesicles?", "[PAD] [PAD] what is the approximate size of the gas bag?", "[PAD] what is the approximate size of the gas sacs?", "[PAD] [PAD] what is the estimated size of gas vesicles?", "[PAD] [PAD] what is the approximate size of the air bags?", "[PAD] [PAD] sclerostin regulates what process?", "[PAD] [PAD] sclerostin regulates which process?", "[PAD] [PAD] what process regulates sclerostin?", "[PAD] [PAD] what process regulates scleostin?", "which process is regulated by sclerostin?", "[PAD] [PAD] what process regulates sclerastin?", "[PAD] what process does sclerostin regulate?", "[PAD] [PAD] which process regulates sclerostin?", "[PAD] what process does sclerostin control?", "[PAD] [PAD] sclerostin controls which process?", "[PAD] [PAD] sclerostin regulates what processes?", "[PAD] [PAD] which process controls sclerostin?", "[PAD] the sclerostin regulates which process?", "[PAD] which process does sclerostin regulate?", "[PAD] what processes does sclerostin regulate?", "[PAD] what process does sclerostine regulate?", "[PAD] [PAD] what process controls sclerostin?", "[PAD] [PAD] sclerostin regulates that process?", "[PAD] [PAD] sclerostin regulates what process?", "[PAD] [PAD] sclerostin regulates which process?", "[PAD] [PAD] what process regulates sclerostin?", "[PAD] [PAD] what process regulates scleostin?", "which process is regulated by sclerostin?", "[PAD] [PAD] what process regulates sclerastin?", "[PAD] what process does sclerostin regulate?", "[PAD] [PAD] which process regulates sclerostin?", "[PAD] what process does sclerostin control?", "[PAD] [PAD] sclerostin controls which process?", "[PAD] [PAD] sclerostin regulates what processes?", "[PAD] [PAD] which process controls sclerostin?", "[PAD] the sclerostin regulates which process?", "[PAD] which process does sclerostin regulate?", "[PAD] what processes does sclerostin regulate?", "[PAD] what process does sclerostine regulate?", "[PAD] [PAD] what process controls sclerostin?", "[PAD] [PAD] sclerostin regulates that process?", "[PAD] [PAD] what can be predicted with the wells criteria?", "[PAD] [PAD] what can be predicted by the wells criteria?", "[PAD] [PAD] [PAD] what can be expected by wells standards?", "[PAD] what can be predicted by welsh standards?", "[PAD] [PAD] [PAD] what can be predicted by wells criteria?", "what can be predicted by the criteria of wales?", "what can be predicted by the welsh criteria?", "[PAD] [PAD] what can be predicted by wells' criteria?", "[PAD] [PAD] [PAD] [PAD] what does the wells criterion predict?", "[PAD] [PAD] what can be predicted with wells \u2019criteria?", "[PAD] [PAD] what can be predicted using the wells criteria?", "[PAD] [PAD] what can be predicted by the wells standard?", "[PAD] [PAD] [PAD] what can wells's criteria predict?", "[PAD] [PAD] what can be predicted with wells' criteria?", "[PAD] [PAD] what can be predicted from the wells criterion?", "[PAD] [PAD] [PAD] what can you predict with wells criteria?", "[PAD] [PAD] [PAD] what can you predict based on wells?", "[PAD] what can be predicted by the wales criteria?", "[PAD] [PAD] what can be predicted by wells \u2019criteria?", "[PAD] [PAD] [PAD] [PAD] [PAD] what wells criteria can predict?", "what can be predicted with the quality of wales?", "[PAD] [PAD] what can be predicted with the wells criteria?", "[PAD] [PAD] what can be predicted by the wells criteria?", "[PAD] [PAD] [PAD] what can be expected by wells standards?", "[PAD] what can be predicted by welsh standards?", "[PAD] [PAD] [PAD] what can be predicted by wells criteria?", "what can be predicted by the criteria of wales?", "what can be predicted by the welsh criteria?", "[PAD] [PAD] what can be predicted by wells' criteria?", "[PAD] [PAD] [PAD] [PAD] what does the wells criterion predict?", "[PAD] [PAD] what can be predicted with wells \u2019criteria?", "[PAD] [PAD] what can be predicted using the wells criteria?", "[PAD] [PAD] what can be predicted by the wells standard?", "[PAD] [PAD] [PAD] what can wells's criteria predict?", "[PAD] [PAD] what can be predicted with wells' criteria?", "[PAD] [PAD] what can be predicted from the wells criterion?", "[PAD] [PAD] [PAD] what can you predict with wells criteria?", "[PAD] [PAD] [PAD] what can you predict based on wells?", "[PAD] what can be predicted by the wales criteria?", "[PAD] [PAD] what can be predicted by wells \u2019criteria?", "[PAD] [PAD] [PAD] [PAD] [PAD] what wells criteria can predict?", "what can be predicted with the quality of wales?", "[PAD] [PAD] what can be predicted with the wells criteria?", "[PAD] [PAD] what can be predicted by the wells criteria?", "[PAD] [PAD] [PAD] what can be expected by wells standards?", "[PAD] what can be predicted by welsh standards?", "[PAD] [PAD] [PAD] what can be predicted by wells criteria?", "what can be predicted by the criteria of wales?", "what can be predicted by the welsh criteria?", "[PAD] [PAD] what can be predicted by wells' criteria?", "[PAD] [PAD] [PAD] [PAD] what does the wells criterion predict?", "[PAD] [PAD] what can be predicted with wells \u2019criteria?", "[PAD] [PAD] what can be predicted using the wells criteria?", "[PAD] [PAD] what can be predicted by the wells standard?", "[PAD] [PAD] [PAD] what can wells's criteria predict?", "[PAD] [PAD] what can be predicted with wells' criteria?", "[PAD] [PAD] what can be predicted from the wells criterion?", "[PAD] [PAD] [PAD] what can you predict with wells criteria?", "[PAD] [PAD] [PAD] what can you predict based on wells?", "[PAD] what can be predicted by the wales criteria?", "[PAD] [PAD] what can be predicted by wells \u2019criteria?", "[PAD] [PAD] [PAD] [PAD] [PAD] what wells criteria can predict?", "what can be predicted with the quality of wales?", "[PAD] [PAD] what can be predicted with the wells criteria?", "[PAD] [PAD] what can be predicted by the wells criteria?", "[PAD] [PAD] [PAD] what can be expected by wells standards?", "[PAD] what can be predicted by welsh standards?", "[PAD] [PAD] [PAD] what can be predicted by wells criteria?", "what can be predicted by the criteria of wales?", "what can be predicted by the welsh criteria?", "[PAD] [PAD] what can be predicted by wells' criteria?", "[PAD] [PAD] [PAD] [PAD] what does the wells criterion predict?", "[PAD] [PAD] what can be predicted with wells \u2019criteria?", "[PAD] [PAD] what can be predicted using the wells criteria?", "[PAD] [PAD] what can be predicted by the wells standard?", "[PAD] [PAD] [PAD] what can wells's criteria predict?", "[PAD] [PAD] what can be predicted with wells' criteria?", "[PAD] [PAD] what can be predicted from the wells criterion?", "[PAD] [PAD] [PAD] what can you predict with wells criteria?", "[PAD] [PAD] [PAD] what can you predict based on wells?", "[PAD] what can be predicted by the wales criteria?", "[PAD] [PAD] what can be predicted by wells \u2019criteria?", "[PAD] [PAD] [PAD] [PAD] [PAD] what wells criteria can predict?", "what can be predicted with the quality of wales?", "[PAD] [PAD] what can be predicted with the wells criteria?", "[PAD] [PAD] what can be predicted by the wells criteria?", "[PAD] [PAD] [PAD] what can be expected by wells standards?", "[PAD] what can be predicted by welsh standards?", "[PAD] [PAD] [PAD] what can be predicted by wells criteria?", "what can be predicted by the criteria of wales?", "what can be predicted by the welsh criteria?", "[PAD] [PAD] what can be predicted by wells' criteria?", "[PAD] [PAD] [PAD] [PAD] what does the wells criterion predict?", "[PAD] [PAD] what can be predicted with wells \u2019criteria?", "[PAD] [PAD] what can be predicted using the wells criteria?", "[PAD] [PAD] what can be predicted by the wells standard?", "[PAD] [PAD] [PAD] what can wells's criteria predict?", "[PAD] [PAD] what can be predicted with wells' criteria?", "[PAD] [PAD] what can be predicted from the wells criterion?", "[PAD] [PAD] [PAD] what can you predict with wells criteria?", "[PAD] [PAD] [PAD] what can you predict based on wells?", "[PAD] what can be predicted by the wales criteria?", "[PAD] [PAD] what can be predicted by wells \u2019criteria?", "[PAD] [PAD] [PAD] [PAD] [PAD] what wells criteria can predict?", "what can be predicted with the quality of wales?", "[PAD] [PAD] what can be predicted with the wells criteria?", "[PAD] [PAD] what can be predicted by the wells criteria?", "[PAD] [PAD] [PAD] what can be expected by wells standards?", "[PAD] what can be predicted by welsh standards?", "[PAD] [PAD] [PAD] what can be predicted by wells criteria?", "what can be predicted by the criteria of wales?", "what can be predicted by the welsh criteria?", "[PAD] [PAD] what can be predicted by wells' criteria?", "[PAD] [PAD] [PAD] [PAD] what does the wells criterion predict?", "[PAD] [PAD] what can be predicted with wells \u2019criteria?", "[PAD] [PAD] what can be predicted using the wells criteria?", "[PAD] [PAD] what can be predicted by the wells standard?", "[PAD] [PAD] [PAD] what can wells's criteria predict?", "[PAD] [PAD] what can be predicted with wells' criteria?", "[PAD] [PAD] what can be predicted from the wells criterion?", "[PAD] [PAD] [PAD] what can you predict with wells criteria?", "[PAD] [PAD] [PAD] what can you predict based on wells?", "[PAD] what can be predicted by the wales criteria?", "[PAD] [PAD] what can be predicted by wells \u2019criteria?", "[PAD] [PAD] [PAD] [PAD] [PAD] what wells criteria can predict?", "what can be predicted with the quality of wales?", "[PAD] [PAD] what can be predicted with the wells criteria?", "[PAD] [PAD] what can be predicted by the wells criteria?", "[PAD] [PAD] [PAD] what can be expected by wells standards?", "[PAD] what can be predicted by welsh standards?", "[PAD] [PAD] [PAD] what can be predicted by wells criteria?", "what can be predicted by the criteria of wales?", "what can be predicted by the welsh criteria?", "[PAD] [PAD] what can be predicted by wells' criteria?", "[PAD] [PAD] [PAD] [PAD] what does the wells criterion predict?", "[PAD] [PAD] what can be predicted with wells \u2019criteria?", "[PAD] [PAD] what can be predicted using the wells criteria?", "[PAD] [PAD] what can be predicted by the wells standard?", "[PAD] [PAD] [PAD] what can wells's criteria predict?", "[PAD] [PAD] what can be predicted with wells' criteria?", "[PAD] [PAD] what can be predicted from the wells criterion?", "[PAD] [PAD] [PAD] what can you predict with wells criteria?", "[PAD] [PAD] [PAD] what can you predict based on wells?", "[PAD] what can be predicted by the wales criteria?", "[PAD] [PAD] what can be predicted by wells \u2019criteria?", "[PAD] [PAD] [PAD] [PAD] [PAD] what wells criteria can predict?", "what can be predicted with the quality of wales?", "[PAD] [PAD] what can be predicted with the wells criteria?", "[PAD] [PAD] what can be predicted by the wells criteria?", "[PAD] [PAD] [PAD] what can be expected by wells standards?", "[PAD] what can be predicted by welsh standards?", "[PAD] [PAD] [PAD] what can be predicted by wells criteria?", "what can be predicted by the criteria of wales?", "what can be predicted by the welsh criteria?", "[PAD] [PAD] what can be predicted by wells' criteria?", "[PAD] [PAD] [PAD] [PAD] what does the wells criterion predict?", "[PAD] [PAD] what can be predicted with wells \u2019criteria?", "[PAD] [PAD] what can be predicted using the wells criteria?", "[PAD] [PAD] what can be predicted by the wells standard?", "[PAD] [PAD] [PAD] what can wells's criteria predict?", "[PAD] [PAD] what can be predicted with wells' criteria?", "[PAD] [PAD] what can be predicted from the wells criterion?", "[PAD] [PAD] [PAD] what can you predict with wells criteria?", "[PAD] [PAD] [PAD] what can you predict based on wells?", "[PAD] what can be predicted by the wales criteria?", "[PAD] [PAD] what can be predicted by wells \u2019criteria?", "[PAD] [PAD] [PAD] [PAD] [PAD] what wells criteria can predict?", "what can be predicted with the quality of wales?", "[PAD] [PAD] what can be predicted with the wells criteria?", "[PAD] [PAD] what can be predicted by the wells criteria?", "[PAD] [PAD] [PAD] what can be expected by wells standards?", "[PAD] what can be predicted by welsh standards?", "[PAD] [PAD] [PAD] what can be predicted by wells criteria?", "what can be predicted by the criteria of wales?", "what can be predicted by the welsh criteria?", "[PAD] [PAD] what can be predicted by wells' criteria?", "[PAD] [PAD] [PAD] [PAD] what does the wells criterion predict?", "[PAD] [PAD] what can be predicted with wells \u2019criteria?", "[PAD] [PAD] what can be predicted using the wells criteria?", "[PAD] [PAD] what can be predicted by the wells standard?", "[PAD] [PAD] [PAD] what can wells's criteria predict?", "[PAD] [PAD] what can be predicted with wells' criteria?", "[PAD] [PAD] what can be predicted from the wells criterion?", "[PAD] [PAD] [PAD] what can you predict with wells criteria?", "[PAD] [PAD] [PAD] what can you predict based on wells?", "[PAD] what can be predicted by the wales criteria?", "[PAD] [PAD] what can be predicted by wells \u2019criteria?", "[PAD] [PAD] [PAD] [PAD] [PAD] what wells criteria can predict?", "what can be predicted with the quality of wales?", "[PAD] dinutuximab is used for treatment of which disease?", "[PAD] [PAD] dinutuximab is used to treat which disease?", "[PAD] [PAD] [PAD] for which disease is dinutuximab used?", "[PAD] [PAD] [PAD] dinotuximab used to treat which disease?", "[PAD] [PAD] what disease is dinutuximab used to treat?", "[PAD] [PAD] what diseases are dinutuximab used to treat?", "for the treatment of which disease is dinutuximab used?", "[PAD] [PAD] dinutuximab is used to treat which diseases?", "[PAD] [PAD] which disease is used to treat dinutuximab?", "[PAD] [PAD] [PAD] what disease is dinutuximab used for?", "[PAD] [PAD] [PAD] what is dinutuximab used to treat?", "dinutuximab is used for the treatment of what disease?", "[PAD] [PAD] [PAD] what is dinutusimab used to treat?", "[PAD] [PAD] [PAD] is dinutuximab used to treat disease?", "[PAD] [PAD] dinotoximab is used to treat any disease?", "[PAD] [PAD] [PAD] [PAD] what is dinutuximab used for?", "[PAD] [PAD] dinutuximab is used to treat any disease?", "[PAD] [PAD] is dinutuximab used to treat the disease?", "[PAD] [PAD] which diseases are dinutuximab used to treat?", "[PAD] [PAD] [PAD] what diseases is dinutuximab used for?", "[PAD] [PAD] [PAD] which disease is dinutuximab used for?", "[PAD] [PAD] dinutoximab is used to treat which disease?", "dinutuximab is used for the treatment of which diseases?", "[PAD] [PAD] is dinutuximab used to treat any disease?", "dinutuximab is used for the treatment of which disease?", "[PAD] [PAD] what disease is used to treat dinutuximab?", "[PAD] [PAD] which disease is dinutuximab used to treat?", "[PAD] [PAD] [PAD] dinutuximab is used in which disease?", "[PAD] [PAD] what diseases is dinutuximab used to treat?", "[PAD] dinutuximab is used for treatment of what disease?", "[PAD] dinutuximab is used for treatment of which disease?", "[PAD] [PAD] dinutuximab is used to treat which disease?", "[PAD] [PAD] [PAD] for which disease is dinutuximab used?", "[PAD] [PAD] [PAD] dinotuximab used to treat which disease?", "[PAD] [PAD] what disease is dinutuximab used to treat?", "[PAD] [PAD] what diseases are dinutuximab used to treat?", "for the treatment of which disease is dinutuximab used?", "[PAD] [PAD] dinutuximab is used to treat which diseases?", "[PAD] [PAD] which disease is used to treat dinutuximab?", "[PAD] [PAD] [PAD] what disease is dinutuximab used for?", "[PAD] [PAD] [PAD] what is dinutuximab used to treat?", "dinutuximab is used for the treatment of what disease?", "[PAD] [PAD] [PAD] what is dinutusimab used to treat?", "[PAD] [PAD] [PAD] is dinutuximab used to treat disease?", "[PAD] [PAD] dinotoximab is used to treat any disease?", "[PAD] [PAD] [PAD] [PAD] what is dinutuximab used for?", "[PAD] [PAD] dinutuximab is used to treat any disease?", "[PAD] [PAD] is dinutuximab used to treat the disease?", "[PAD] [PAD] which diseases are dinutuximab used to treat?", "[PAD] [PAD] [PAD] what diseases is dinutuximab used for?", "[PAD] [PAD] [PAD] which disease is dinutuximab used for?", "[PAD] [PAD] dinutoximab is used to treat which disease?", "dinutuximab is used for the treatment of which diseases?", "[PAD] [PAD] is dinutuximab used to treat any disease?", "dinutuximab is used for the treatment of which disease?", "[PAD] [PAD] what disease is used to treat dinutuximab?", "[PAD] [PAD] which disease is dinutuximab used to treat?", "[PAD] [PAD] [PAD] dinutuximab is used in which disease?", "[PAD] [PAD] what diseases is dinutuximab used to treat?", "[PAD] dinutuximab is used for treatment of what disease?", "[PAD] dinutuximab is used for treatment of which disease?", "[PAD] [PAD] dinutuximab is used to treat which disease?", "[PAD] [PAD] [PAD] for which disease is dinutuximab used?", "[PAD] [PAD] [PAD] dinotuximab used to treat which disease?", "[PAD] [PAD] what disease is dinutuximab used to treat?", "[PAD] [PAD] what diseases are dinutuximab used to treat?", "for the treatment of which disease is dinutuximab used?", "[PAD] [PAD] dinutuximab is used to treat which diseases?", "[PAD] [PAD] which disease is used to treat dinutuximab?", "[PAD] [PAD] [PAD] what disease is dinutuximab used for?", "[PAD] [PAD] [PAD] what is dinutuximab used to treat?", "dinutuximab is used for the treatment of what disease?", "[PAD] [PAD] [PAD] what is dinutusimab used to treat?", "[PAD] [PAD] [PAD] is dinutuximab used to treat disease?", "[PAD] [PAD] dinotoximab is used to treat any disease?", "[PAD] [PAD] [PAD] [PAD] what is dinutuximab used for?", "[PAD] [PAD] dinutuximab is used to treat any disease?", "[PAD] [PAD] is dinutuximab used to treat the disease?", "[PAD] [PAD] which diseases are dinutuximab used to treat?", "[PAD] [PAD] [PAD] what diseases is dinutuximab used for?", "[PAD] [PAD] [PAD] which disease is dinutuximab used for?", "[PAD] [PAD] dinutoximab is used to treat which disease?", "dinutuximab is used for the treatment of which diseases?", "[PAD] [PAD] is dinutuximab used to treat any disease?", "dinutuximab is used for the treatment of which disease?", "[PAD] [PAD] what disease is used to treat dinutuximab?", "[PAD] [PAD] which disease is dinutuximab used to treat?", "[PAD] [PAD] [PAD] dinutuximab is used in which disease?", "[PAD] [PAD] what diseases is dinutuximab used to treat?", "[PAD] dinutuximab is used for treatment of what disease?", "[PAD] dinutuximab is used for treatment of which disease?", "[PAD] [PAD] dinutuximab is used to treat which disease?", "[PAD] [PAD] [PAD] for which disease is dinutuximab used?", "[PAD] [PAD] [PAD] dinotuximab used to treat which disease?", "[PAD] [PAD] what disease is dinutuximab used to treat?", "[PAD] [PAD] what diseases are dinutuximab used to treat?", "for the treatment of which disease is dinutuximab used?", "[PAD] [PAD] dinutuximab is used to treat which diseases?", "[PAD] [PAD] which disease is used to treat dinutuximab?", "[PAD] [PAD] [PAD] what disease is dinutuximab used for?", "[PAD] [PAD] [PAD] what is dinutuximab used to treat?", "dinutuximab is used for the treatment of what disease?", "[PAD] [PAD] [PAD] what is dinutusimab used to treat?", "[PAD] [PAD] [PAD] is dinutuximab used to treat disease?", "[PAD] [PAD] dinotoximab is used to treat any disease?", "[PAD] [PAD] [PAD] [PAD] what is dinutuximab used for?", "[PAD] [PAD] dinutuximab is used to treat any disease?", "[PAD] [PAD] is dinutuximab used to treat the disease?", "[PAD] [PAD] which diseases are dinutuximab used to treat?", "[PAD] [PAD] [PAD] what diseases is dinutuximab used for?", "[PAD] [PAD] [PAD] which disease is dinutuximab used for?", "[PAD] [PAD] dinutoximab is used to treat which disease?", "dinutuximab is used for the treatment of which diseases?", "[PAD] [PAD] is dinutuximab used to treat any disease?", "dinutuximab is used for the treatment of which disease?", "[PAD] [PAD] what disease is used to treat dinutuximab?", "[PAD] [PAD] which disease is dinutuximab used to treat?", "[PAD] [PAD] [PAD] dinutuximab is used in which disease?", "[PAD] [PAD] what diseases is dinutuximab used to treat?", "[PAD] dinutuximab is used for treatment of what disease?", "[PAD] dinutuximab is used for treatment of which disease?", "[PAD] [PAD] dinutuximab is used to treat which disease?", "[PAD] [PAD] [PAD] for which disease is dinutuximab used?", "[PAD] [PAD] [PAD] dinotuximab used to treat which disease?", "[PAD] [PAD] what disease is dinutuximab used to treat?", "[PAD] [PAD] what diseases are dinutuximab used to treat?", "for the treatment of which disease is dinutuximab used?", "[PAD] [PAD] dinutuximab is used to treat which diseases?", "[PAD] [PAD] which disease is used to treat dinutuximab?", "[PAD] [PAD] [PAD] what disease is dinutuximab used for?", "[PAD] [PAD] [PAD] what is dinutuximab used to treat?", "dinutuximab is used for the treatment of what disease?", "[PAD] [PAD] [PAD] what is dinutusimab used to treat?", "[PAD] [PAD] [PAD] is dinutuximab used to treat disease?", "[PAD] [PAD] dinotoximab is used to treat any disease?", "[PAD] [PAD] [PAD] [PAD] what is dinutuximab used for?", "[PAD] [PAD] dinutuximab is used to treat any disease?", "[PAD] [PAD] is dinutuximab used to treat the disease?", "[PAD] [PAD] which diseases are dinutuximab used to treat?", "[PAD] [PAD] [PAD] what diseases is dinutuximab used for?", "[PAD] [PAD] [PAD] which disease is dinutuximab used for?", "[PAD] [PAD] dinutoximab is used to treat which disease?", "dinutuximab is used for the treatment of which diseases?", "[PAD] [PAD] is dinutuximab used to treat any disease?", "dinutuximab is used for the treatment of which disease?", "[PAD] [PAD] what disease is used to treat dinutuximab?", "[PAD] [PAD] which disease is dinutuximab used to treat?", "[PAD] [PAD] [PAD] dinutuximab is used in which disease?", "[PAD] [PAD] what diseases is dinutuximab used to treat?", "[PAD] dinutuximab is used for treatment of what disease?", "[PAD] dinutuximab is used for treatment of which disease?", "[PAD] [PAD] dinutuximab is used to treat which disease?", "[PAD] [PAD] [PAD] for which disease is dinutuximab used?", "[PAD] [PAD] [PAD] dinotuximab used to treat which disease?", "[PAD] [PAD] what disease is dinutuximab used to treat?", "[PAD] [PAD] what diseases are dinutuximab used to treat?", "for the treatment of which disease is dinutuximab used?", "[PAD] [PAD] dinutuximab is used to treat which diseases?", "[PAD] [PAD] which disease is used to treat dinutuximab?", "[PAD] [PAD] [PAD] what disease is dinutuximab used for?", "[PAD] [PAD] [PAD] what is dinutuximab used to treat?", "dinutuximab is used for the treatment of what disease?", "[PAD] [PAD] [PAD] what is dinutusimab used to treat?", "[PAD] [PAD] [PAD] is dinutuximab used to treat disease?", "[PAD] [PAD] dinotoximab is used to treat any disease?", "[PAD] [PAD] [PAD] [PAD] what is dinutuximab used for?", "[PAD] [PAD] dinutuximab is used to treat any disease?", "[PAD] [PAD] is dinutuximab used to treat the disease?", "[PAD] [PAD] which diseases are dinutuximab used to treat?", "[PAD] [PAD] [PAD] what diseases is dinutuximab used for?", "[PAD] [PAD] [PAD] which disease is dinutuximab used for?", "[PAD] [PAD] dinutoximab is used to treat which disease?", "dinutuximab is used for the treatment of which diseases?", "[PAD] [PAD] is dinutuximab used to treat any disease?", "dinutuximab is used for the treatment of which disease?", "[PAD] [PAD] what disease is used to treat dinutuximab?", "[PAD] [PAD] which disease is dinutuximab used to treat?", "[PAD] [PAD] [PAD] dinutuximab is used in which disease?", "[PAD] [PAD] what diseases is dinutuximab used to treat?", "[PAD] dinutuximab is used for treatment of what disease?", "[PAD] dinutuximab is used for treatment of which disease?", "[PAD] [PAD] dinutuximab is used to treat which disease?", "[PAD] [PAD] [PAD] for which disease is dinutuximab used?", "[PAD] [PAD] [PAD] dinotuximab used to treat which disease?", "[PAD] [PAD] what disease is dinutuximab used to treat?", "[PAD] [PAD] what diseases are dinutuximab used to treat?", "for the treatment of which disease is dinutuximab used?", "[PAD] [PAD] dinutuximab is used to treat which diseases?", "[PAD] [PAD] which disease is used to treat dinutuximab?", "[PAD] [PAD] [PAD] what disease is dinutuximab used for?", "[PAD] [PAD] [PAD] what is dinutuximab used to treat?", "dinutuximab is used for the treatment of what disease?", "[PAD] [PAD] [PAD] what is dinutusimab used to treat?", "[PAD] [PAD] [PAD] is dinutuximab used to treat disease?", "[PAD] [PAD] dinotoximab is used to treat any disease?", "[PAD] [PAD] [PAD] [PAD] what is dinutuximab used for?", "[PAD] [PAD] dinutuximab is used to treat any disease?", "[PAD] [PAD] is dinutuximab used to treat the disease?", "[PAD] [PAD] which diseases are dinutuximab used to treat?", "[PAD] [PAD] [PAD] what diseases is dinutuximab used for?", "[PAD] [PAD] [PAD] which disease is dinutuximab used for?", "[PAD] [PAD] dinutoximab is used to treat which disease?", "dinutuximab is used for the treatment of which diseases?", "[PAD] [PAD] is dinutuximab used to treat any disease?", "dinutuximab is used for the treatment of which disease?", "[PAD] [PAD] what disease is used to treat dinutuximab?", "[PAD] [PAD] which disease is dinutuximab used to treat?", "[PAD] [PAD] [PAD] dinutuximab is used in which disease?", "[PAD] [PAD] what diseases is dinutuximab used to treat?", "[PAD] dinutuximab is used for treatment of what disease?", "[PAD] dinutuximab is used for treatment of which disease?", "[PAD] [PAD] dinutuximab is used to treat which disease?", "[PAD] [PAD] [PAD] for which disease is dinutuximab used?", "[PAD] [PAD] [PAD] dinotuximab used to treat which disease?", "[PAD] [PAD] what disease is dinutuximab used to treat?", "[PAD] [PAD] what diseases are dinutuximab used to treat?", "for the treatment of which disease is dinutuximab used?", "[PAD] [PAD] dinutuximab is used to treat which diseases?", "[PAD] [PAD] which disease is used to treat dinutuximab?", "[PAD] [PAD] [PAD] what disease is dinutuximab used for?", "[PAD] [PAD] [PAD] what is dinutuximab used to treat?", "dinutuximab is used for the treatment of what disease?", "[PAD] [PAD] [PAD] what is dinutusimab used to treat?", "[PAD] [PAD] [PAD] is dinutuximab used to treat disease?", "[PAD] [PAD] dinotoximab is used to treat any disease?", "[PAD] [PAD] [PAD] [PAD] what is dinutuximab used for?", "[PAD] [PAD] dinutuximab is used to treat any disease?", "[PAD] [PAD] is dinutuximab used to treat the disease?", "[PAD] [PAD] which diseases are dinutuximab used to treat?", "[PAD] [PAD] [PAD] what diseases is dinutuximab used for?", "[PAD] [PAD] [PAD] which disease is dinutuximab used for?", "[PAD] [PAD] dinutoximab is used to treat which disease?", "dinutuximab is used for the treatment of which diseases?", "[PAD] [PAD] is dinutuximab used to treat any disease?", "dinutuximab is used for the treatment of which disease?", "[PAD] [PAD] what disease is used to treat dinutuximab?", "[PAD] [PAD] which disease is dinutuximab used to treat?", "[PAD] [PAD] [PAD] dinutuximab is used in which disease?", "[PAD] [PAD] what diseases is dinutuximab used to treat?", "[PAD] dinutuximab is used for treatment of what disease?", "[PAD] dinutuximab is used for treatment of which disease?", "[PAD] [PAD] dinutuximab is used to treat which disease?", "[PAD] [PAD] [PAD] for which disease is dinutuximab used?", "[PAD] [PAD] [PAD] dinotuximab used to treat which disease?", "[PAD] [PAD] what disease is dinutuximab used to treat?", "[PAD] [PAD] what diseases are dinutuximab used to treat?", "for the treatment of which disease is dinutuximab used?", "[PAD] [PAD] dinutuximab is used to treat which diseases?", "[PAD] [PAD] which disease is used to treat dinutuximab?", "[PAD] [PAD] [PAD] what disease is dinutuximab used for?", "[PAD] [PAD] [PAD] what is dinutuximab used to treat?", "dinutuximab is used for the treatment of what disease?", "[PAD] [PAD] [PAD] what is dinutusimab used to treat?", "[PAD] [PAD] [PAD] is dinutuximab used to treat disease?", "[PAD] [PAD] dinotoximab is used to treat any disease?", "[PAD] [PAD] [PAD] [PAD] what is dinutuximab used for?", "[PAD] [PAD] dinutuximab is used to treat any disease?", "[PAD] [PAD] is dinutuximab used to treat the disease?", "[PAD] [PAD] which diseases are dinutuximab used to treat?", "[PAD] [PAD] [PAD] what diseases is dinutuximab used for?", "[PAD] [PAD] [PAD] which disease is dinutuximab used for?", "[PAD] [PAD] dinutoximab is used to treat which disease?", "dinutuximab is used for the treatment of which diseases?", "[PAD] [PAD] is dinutuximab used to treat any disease?", "dinutuximab is used for the treatment of which disease?", "[PAD] [PAD] what disease is used to treat dinutuximab?", "[PAD] [PAD] which disease is dinutuximab used to treat?", "[PAD] [PAD] [PAD] dinutuximab is used in which disease?", "[PAD] [PAD] what diseases is dinutuximab used to treat?", "[PAD] dinutuximab is used for treatment of what disease?", "[PAD] dinutuximab is used for treatment of which disease?", "[PAD] [PAD] dinutuximab is used to treat which disease?", "[PAD] [PAD] [PAD] for which disease is dinutuximab used?", "[PAD] [PAD] [PAD] dinotuximab used to treat which disease?", "[PAD] [PAD] what disease is dinutuximab used to treat?", "[PAD] [PAD] what diseases are dinutuximab used to treat?", "for the treatment of which disease is dinutuximab used?", "[PAD] [PAD] dinutuximab is used to treat which diseases?", "[PAD] [PAD] which disease is used to treat dinutuximab?", "[PAD] [PAD] [PAD] what disease is dinutuximab used for?", "[PAD] [PAD] [PAD] what is dinutuximab used to treat?", "dinutuximab is used for the treatment of what disease?", "[PAD] [PAD] [PAD] what is dinutusimab used to treat?", "[PAD] [PAD] [PAD] is dinutuximab used to treat disease?", "[PAD] [PAD] dinotoximab is used to treat any disease?", "[PAD] [PAD] [PAD] [PAD] what is dinutuximab used for?", "[PAD] [PAD] dinutuximab is used to treat any disease?", "[PAD] [PAD] is dinutuximab used to treat the disease?", "[PAD] [PAD] which diseases are dinutuximab used to treat?", "[PAD] [PAD] [PAD] what diseases is dinutuximab used for?", "[PAD] [PAD] [PAD] which disease is dinutuximab used for?", "[PAD] [PAD] dinutoximab is used to treat which disease?", "dinutuximab is used for the treatment of which diseases?", "[PAD] [PAD] is dinutuximab used to treat any disease?", "dinutuximab is used for the treatment of which disease?", "[PAD] [PAD] what disease is used to treat dinutuximab?", "[PAD] [PAD] which disease is dinutuximab used to treat?", "[PAD] [PAD] [PAD] dinutuximab is used in which disease?", "[PAD] [PAD] what diseases is dinutuximab used to treat?", "[PAD] dinutuximab is used for treatment of what disease?", "[PAD] dinutuximab is used for treatment of which disease?", "[PAD] [PAD] dinutuximab is used to treat which disease?", "[PAD] [PAD] [PAD] for which disease is dinutuximab used?", "[PAD] [PAD] [PAD] dinotuximab used to treat which disease?", "[PAD] [PAD] what disease is dinutuximab used to treat?", "[PAD] [PAD] what diseases are dinutuximab used to treat?", "for the treatment of which disease is dinutuximab used?", "[PAD] [PAD] dinutuximab is used to treat which diseases?", "[PAD] [PAD] which disease is used to treat dinutuximab?", "[PAD] [PAD] [PAD] what disease is dinutuximab used for?", "[PAD] [PAD] [PAD] what is dinutuximab used to treat?", "dinutuximab is used for the treatment of what disease?", "[PAD] [PAD] [PAD] what is dinutusimab used to treat?", "[PAD] [PAD] [PAD] is dinutuximab used to treat disease?", "[PAD] [PAD] dinotoximab is used to treat any disease?", "[PAD] [PAD] [PAD] [PAD] what is dinutuximab used for?", "[PAD] [PAD] dinutuximab is used to treat any disease?", "[PAD] [PAD] is dinutuximab used to treat the disease?", "[PAD] [PAD] which diseases are dinutuximab used to treat?", "[PAD] [PAD] [PAD] what diseases is dinutuximab used for?", "[PAD] [PAD] [PAD] which disease is dinutuximab used for?", "[PAD] [PAD] dinutoximab is used to treat which disease?", "dinutuximab is used for the treatment of which diseases?", "[PAD] [PAD] is dinutuximab used to treat any disease?", "dinutuximab is used for the treatment of which disease?", "[PAD] [PAD] what disease is used to treat dinutuximab?", "[PAD] [PAD] which disease is dinutuximab used to treat?", "[PAD] [PAD] [PAD] dinutuximab is used in which disease?", "[PAD] [PAD] what diseases is dinutuximab used to treat?", "[PAD] dinutuximab is used for treatment of what disease?", "[PAD] dinutuximab is used for treatment of which disease?", "[PAD] [PAD] dinutuximab is used to treat which disease?", "[PAD] [PAD] [PAD] for which disease is dinutuximab used?", "[PAD] [PAD] [PAD] dinotuximab used to treat which disease?", "[PAD] [PAD] what disease is dinutuximab used to treat?", "[PAD] [PAD] what diseases are dinutuximab used to treat?", "for the treatment of which disease is dinutuximab used?", "[PAD] [PAD] dinutuximab is used to treat which diseases?", "[PAD] [PAD] which disease is used to treat dinutuximab?", "[PAD] [PAD] [PAD] what disease is dinutuximab used for?", "[PAD] [PAD] [PAD] what is dinutuximab used to treat?", "dinutuximab is used for the treatment of what disease?", "[PAD] [PAD] [PAD] what is dinutusimab used to treat?", "[PAD] [PAD] [PAD] is dinutuximab used to treat disease?", "[PAD] [PAD] dinotoximab is used to treat any disease?", "[PAD] [PAD] [PAD] [PAD] what is dinutuximab used for?", "[PAD] [PAD] dinutuximab is used to treat any disease?", "[PAD] [PAD] is dinutuximab used to treat the disease?", "[PAD] [PAD] which diseases are dinutuximab used to treat?", "[PAD] [PAD] [PAD] what diseases is dinutuximab used for?", "[PAD] [PAD] [PAD] which disease is dinutuximab used for?", "[PAD] [PAD] dinutoximab is used to treat which disease?", "dinutuximab is used for the treatment of which diseases?", "[PAD] [PAD] is dinutuximab used to treat any disease?", "dinutuximab is used for the treatment of which disease?", "[PAD] [PAD] what disease is used to treat dinutuximab?", "[PAD] [PAD] which disease is dinutuximab used to treat?", "[PAD] [PAD] [PAD] dinutuximab is used in which disease?", "[PAD] [PAD] what diseases is dinutuximab used to treat?", "[PAD] dinutuximab is used for treatment of what disease?", "[PAD] dinutuximab is used for treatment of which disease?", "[PAD] [PAD] dinutuximab is used to treat which disease?", "[PAD] [PAD] [PAD] for which disease is dinutuximab used?", "[PAD] [PAD] [PAD] dinotuximab used to treat which disease?", "[PAD] [PAD] what disease is dinutuximab used to treat?", "[PAD] [PAD] what diseases are dinutuximab used to treat?", "for the treatment of which disease is dinutuximab used?", "[PAD] [PAD] dinutuximab is used to treat which diseases?", "[PAD] [PAD] which disease is used to treat dinutuximab?", "[PAD] [PAD] [PAD] what disease is dinutuximab used for?", "[PAD] [PAD] [PAD] what is dinutuximab used to treat?", "dinutuximab is used for the treatment of what disease?", "[PAD] [PAD] [PAD] what is dinutusimab used to treat?", "[PAD] [PAD] [PAD] is dinutuximab used to treat disease?", "[PAD] [PAD] dinotoximab is used to treat any disease?", "[PAD] [PAD] [PAD] [PAD] what is dinutuximab used for?", "[PAD] [PAD] dinutuximab is used to treat any disease?", "[PAD] [PAD] is dinutuximab used to treat the disease?", "[PAD] [PAD] which diseases are dinutuximab used to treat?", "[PAD] [PAD] [PAD] what diseases is dinutuximab used for?", "[PAD] [PAD] [PAD] which disease is dinutuximab used for?", "[PAD] [PAD] dinutoximab is used to treat which disease?", "dinutuximab is used for the treatment of which diseases?", "[PAD] [PAD] is dinutuximab used to treat any disease?", "dinutuximab is used for the treatment of which disease?", "[PAD] [PAD] what disease is used to treat dinutuximab?", "[PAD] [PAD] which disease is dinutuximab used to treat?", "[PAD] [PAD] [PAD] dinutuximab is used in which disease?", "[PAD] [PAD] what diseases is dinutuximab used to treat?", "[PAD] dinutuximab is used for treatment of what disease?", "[PAD] dinutuximab is used for treatment of which disease?", "[PAD] [PAD] dinutuximab is used to treat which disease?", "[PAD] [PAD] [PAD] for which disease is dinutuximab used?", "[PAD] [PAD] [PAD] dinotuximab used to treat which disease?", "[PAD] [PAD] what disease is dinutuximab used to treat?", "[PAD] [PAD] what diseases are dinutuximab used to treat?", "for the treatment of which disease is dinutuximab used?", "[PAD] [PAD] dinutuximab is used to treat which diseases?", "[PAD] [PAD] which disease is used to treat dinutuximab?", "[PAD] [PAD] [PAD] what disease is dinutuximab used for?", "[PAD] [PAD] [PAD] what is dinutuximab used to treat?", "dinutuximab is used for the treatment of what disease?", "[PAD] [PAD] [PAD] what is dinutusimab used to treat?", "[PAD] [PAD] [PAD] is dinutuximab used to treat disease?", "[PAD] [PAD] dinotoximab is used to treat any disease?", "[PAD] [PAD] [PAD] [PAD] what is dinutuximab used for?", "[PAD] [PAD] dinutuximab is used to treat any disease?", "[PAD] [PAD] is dinutuximab used to treat the disease?", "[PAD] [PAD] which diseases are dinutuximab used to treat?", "[PAD] [PAD] [PAD] what diseases is dinutuximab used for?", "[PAD] [PAD] [PAD] which disease is dinutuximab used for?", "[PAD] [PAD] dinutoximab is used to treat which disease?", "dinutuximab is used for the treatment of which diseases?", "[PAD] [PAD] is dinutuximab used to treat any disease?", "dinutuximab is used for the treatment of which disease?", "[PAD] [PAD] what disease is used to treat dinutuximab?", "[PAD] [PAD] which disease is dinutuximab used to treat?", "[PAD] [PAD] [PAD] dinutuximab is used in which disease?", "[PAD] [PAD] what diseases is dinutuximab used to treat?", "[PAD] dinutuximab is used for treatment of what disease?", "[PAD] dinutuximab is used for treatment of which disease?", "[PAD] [PAD] dinutuximab is used to treat which disease?", "[PAD] [PAD] [PAD] for which disease is dinutuximab used?", "[PAD] [PAD] [PAD] dinotuximab used to treat which disease?", "[PAD] [PAD] what disease is dinutuximab used to treat?", "[PAD] [PAD] what diseases are dinutuximab used to treat?", "for the treatment of which disease is dinutuximab used?", "[PAD] [PAD] dinutuximab is used to treat which diseases?", "[PAD] [PAD] which disease is used to treat dinutuximab?", "[PAD] [PAD] [PAD] what disease is dinutuximab used for?", "[PAD] [PAD] [PAD] what is dinutuximab used to treat?", "dinutuximab is used for the treatment of what disease?", "[PAD] [PAD] [PAD] what is dinutusimab used to treat?", "[PAD] [PAD] [PAD] is dinutuximab used to treat disease?", "[PAD] [PAD] dinotoximab is used to treat any disease?", "[PAD] [PAD] [PAD] [PAD] what is dinutuximab used for?", "[PAD] [PAD] dinutuximab is used to treat any disease?", "[PAD] [PAD] is dinutuximab used to treat the disease?", "[PAD] [PAD] which diseases are dinutuximab used to treat?", "[PAD] [PAD] [PAD] what diseases is dinutuximab used for?", "[PAD] [PAD] [PAD] which disease is dinutuximab used for?", "[PAD] [PAD] dinutoximab is used to treat which disease?", "dinutuximab is used for the treatment of which diseases?", "[PAD] [PAD] is dinutuximab used to treat any disease?", "dinutuximab is used for the treatment of which disease?", "[PAD] [PAD] what disease is used to treat dinutuximab?", "[PAD] [PAD] which disease is dinutuximab used to treat?", "[PAD] [PAD] [PAD] dinutuximab is used in which disease?", "[PAD] [PAD] what diseases is dinutuximab used to treat?", "[PAD] dinutuximab is used for treatment of what disease?", "[PAD] dinutuximab is used for treatment of which disease?", "[PAD] [PAD] dinutuximab is used to treat which disease?", "[PAD] [PAD] [PAD] for which disease is dinutuximab used?", "[PAD] [PAD] [PAD] dinotuximab used to treat which disease?", "[PAD] [PAD] what disease is dinutuximab used to treat?", "[PAD] [PAD] what diseases are dinutuximab used to treat?", "for the treatment of which disease is dinutuximab used?", "[PAD] [PAD] dinutuximab is used to treat which diseases?", "[PAD] [PAD] which disease is used to treat dinutuximab?", "[PAD] [PAD] [PAD] what disease is dinutuximab used for?", "[PAD] [PAD] [PAD] what is dinutuximab used to treat?", "dinutuximab is used for the treatment of what disease?", "[PAD] [PAD] [PAD] what is dinutusimab used to treat?", "[PAD] [PAD] [PAD] is dinutuximab used to treat disease?", "[PAD] [PAD] dinotoximab is used to treat any disease?", "[PAD] [PAD] [PAD] [PAD] what is dinutuximab used for?", "[PAD] [PAD] dinutuximab is used to treat any disease?", "[PAD] [PAD] is dinutuximab used to treat the disease?", "[PAD] [PAD] which diseases are dinutuximab used to treat?", "[PAD] [PAD] [PAD] what diseases is dinutuximab used for?", "[PAD] [PAD] [PAD] which disease is dinutuximab used for?", "[PAD] [PAD] dinutoximab is used to treat which disease?", "dinutuximab is used for the treatment of which diseases?", "[PAD] [PAD] is dinutuximab used to treat any disease?", "dinutuximab is used for the treatment of which disease?", "[PAD] [PAD] what disease is used to treat dinutuximab?", "[PAD] [PAD] which disease is dinutuximab used to treat?", "[PAD] [PAD] [PAD] dinutuximab is used in which disease?", "[PAD] [PAD] what diseases is dinutuximab used to treat?", "[PAD] dinutuximab is used for treatment of what disease?", "[PAD] dinutuximab is used for treatment of which disease?", "[PAD] [PAD] dinutuximab is used to treat which disease?", "[PAD] [PAD] [PAD] for which disease is dinutuximab used?", "[PAD] [PAD] [PAD] dinotuximab used to treat which disease?", "[PAD] [PAD] what disease is dinutuximab used to treat?", "[PAD] [PAD] what diseases are dinutuximab used to treat?", "for the treatment of which disease is dinutuximab used?", "[PAD] [PAD] dinutuximab is used to treat which diseases?", "[PAD] [PAD] which disease is used to treat dinutuximab?", "[PAD] [PAD] [PAD] what disease is dinutuximab used for?", "[PAD] [PAD] [PAD] what is dinutuximab used to treat?", "dinutuximab is used for the treatment of what disease?", "[PAD] [PAD] [PAD] what is dinutusimab used to treat?", "[PAD] [PAD] [PAD] is dinutuximab used to treat disease?", "[PAD] [PAD] dinotoximab is used to treat any disease?", "[PAD] [PAD] [PAD] [PAD] what is dinutuximab used for?", "[PAD] [PAD] dinutuximab is used to treat any disease?", "[PAD] [PAD] is dinutuximab used to treat the disease?", "[PAD] [PAD] which diseases are dinutuximab used to treat?", "[PAD] [PAD] [PAD] what diseases is dinutuximab used for?", "[PAD] [PAD] [PAD] which disease is dinutuximab used for?", "[PAD] [PAD] dinutoximab is used to treat which disease?", "dinutuximab is used for the treatment of which diseases?", "[PAD] [PAD] is dinutuximab used to treat any disease?", "dinutuximab is used for the treatment of which disease?", "[PAD] [PAD] what disease is used to treat dinutuximab?", "[PAD] [PAD] which disease is dinutuximab used to treat?", "[PAD] [PAD] [PAD] dinutuximab is used in which disease?", "[PAD] [PAD] what diseases is dinutuximab used to treat?", "[PAD] dinutuximab is used for treatment of what disease?", "[PAD] dinutuximab is used for treatment of which disease?", "[PAD] [PAD] dinutuximab is used to treat which disease?", "[PAD] [PAD] [PAD] for which disease is dinutuximab used?", "[PAD] [PAD] [PAD] dinotuximab used to treat which disease?", "[PAD] [PAD] what disease is dinutuximab used to treat?", "[PAD] [PAD] what diseases are dinutuximab used to treat?", "for the treatment of which disease is dinutuximab used?", "[PAD] [PAD] dinutuximab is used to treat which diseases?", "[PAD] [PAD] which disease is used to treat dinutuximab?", "[PAD] [PAD] [PAD] what disease is dinutuximab used for?", "[PAD] [PAD] [PAD] what is dinutuximab used to treat?", "dinutuximab is used for the treatment of what disease?", "[PAD] [PAD] [PAD] what is dinutusimab used to treat?", "[PAD] [PAD] [PAD] is dinutuximab used to treat disease?", "[PAD] [PAD] dinotoximab is used to treat any disease?", "[PAD] [PAD] [PAD] [PAD] what is dinutuximab used for?", "[PAD] [PAD] dinutuximab is used to treat any disease?", "[PAD] [PAD] is dinutuximab used to treat the disease?", "[PAD] [PAD] which diseases are dinutuximab used to treat?", "[PAD] [PAD] [PAD] what diseases is dinutuximab used for?", "[PAD] [PAD] [PAD] which disease is dinutuximab used for?", "[PAD] [PAD] dinutoximab is used to treat which disease?", "dinutuximab is used for the treatment of which diseases?", "[PAD] [PAD] is dinutuximab used to treat any disease?", "dinutuximab is used for the treatment of which disease?", "[PAD] [PAD] what disease is used to treat dinutuximab?", "[PAD] [PAD] which disease is dinutuximab used to treat?", "[PAD] [PAD] [PAD] dinutuximab is used in which disease?", "[PAD] [PAD] what diseases is dinutuximab used to treat?", "[PAD] dinutuximab is used for treatment of what disease?", "[PAD] dinutuximab is used for treatment of which disease?", "[PAD] [PAD] dinutuximab is used to treat which disease?", "[PAD] [PAD] [PAD] for which disease is dinutuximab used?", "[PAD] [PAD] [PAD] dinotuximab used to treat which disease?", "[PAD] [PAD] what disease is dinutuximab used to treat?", "[PAD] [PAD] what diseases are dinutuximab used to treat?", "for the treatment of which disease is dinutuximab used?", "[PAD] [PAD] dinutuximab is used to treat which diseases?", "[PAD] [PAD] which disease is used to treat dinutuximab?", "[PAD] [PAD] [PAD] what disease is dinutuximab used for?", "[PAD] [PAD] [PAD] what is dinutuximab used to treat?", "dinutuximab is used for the treatment of what disease?", "[PAD] [PAD] [PAD] what is dinutusimab used to treat?", "[PAD] [PAD] [PAD] is dinutuximab used to treat disease?", "[PAD] [PAD] dinotoximab is used to treat any disease?", "[PAD] [PAD] [PAD] [PAD] what is dinutuximab used for?", "[PAD] [PAD] dinutuximab is used to treat any disease?", "[PAD] [PAD] is dinutuximab used to treat the disease?", "[PAD] [PAD] which diseases are dinutuximab used to treat?", "[PAD] [PAD] [PAD] what diseases is dinutuximab used for?", "[PAD] [PAD] [PAD] which disease is dinutuximab used for?", "[PAD] [PAD] dinutoximab is used to treat which disease?", "dinutuximab is used for the treatment of which diseases?", "[PAD] [PAD] is dinutuximab used to treat any disease?", "dinutuximab is used for the treatment of which disease?", "[PAD] [PAD] what disease is used to treat dinutuximab?", "[PAD] [PAD] which disease is dinutuximab used to treat?", "[PAD] [PAD] [PAD] dinutuximab is used in which disease?", "[PAD] [PAD] what diseases is dinutuximab used to treat?", "[PAD] dinutuximab is used for treatment of what disease?", "[PAD] dinutuximab is used for treatment of which disease?", "[PAD] [PAD] dinutuximab is used to treat which disease?", "[PAD] [PAD] [PAD] for which disease is dinutuximab used?", "[PAD] [PAD] [PAD] dinotuximab used to treat which disease?", "[PAD] [PAD] what disease is dinutuximab used to treat?", "[PAD] [PAD] what diseases are dinutuximab used to treat?", "for the treatment of which disease is dinutuximab used?", "[PAD] [PAD] dinutuximab is used to treat which diseases?", "[PAD] [PAD] which disease is used to treat dinutuximab?", "[PAD] [PAD] [PAD] what disease is dinutuximab used for?", "[PAD] [PAD] [PAD] what is dinutuximab used to treat?", "dinutuximab is used for the treatment of what disease?", "[PAD] [PAD] [PAD] what is dinutusimab used to treat?", "[PAD] [PAD] [PAD] is dinutuximab used to treat disease?", "[PAD] [PAD] dinotoximab is used to treat any disease?", "[PAD] [PAD] [PAD] [PAD] what is dinutuximab used for?", "[PAD] [PAD] dinutuximab is used to treat any disease?", "[PAD] [PAD] is dinutuximab used to treat the disease?", "[PAD] [PAD] which diseases are dinutuximab used to treat?", "[PAD] [PAD] [PAD] what diseases is dinutuximab used for?", "[PAD] [PAD] [PAD] which disease is dinutuximab used for?", "[PAD] [PAD] dinutoximab is used to treat which disease?", "dinutuximab is used for the treatment of which diseases?", "[PAD] [PAD] is dinutuximab used to treat any disease?", "dinutuximab is used for the treatment of which disease?", "[PAD] [PAD] what disease is used to treat dinutuximab?", "[PAD] [PAD] which disease is dinutuximab used to treat?", "[PAD] [PAD] [PAD] dinutuximab is used in which disease?", "[PAD] [PAD] what diseases is dinutuximab used to treat?", "[PAD] dinutuximab is used for treatment of what disease?", "[PAD] dinutuximab is used for treatment of which disease?", "[PAD] [PAD] dinutuximab is used to treat which disease?", "[PAD] [PAD] [PAD] for which disease is dinutuximab used?", "[PAD] [PAD] [PAD] dinotuximab used to treat which disease?", "[PAD] [PAD] what disease is dinutuximab used to treat?", "[PAD] [PAD] what diseases are dinutuximab used to treat?", "for the treatment of which disease is dinutuximab used?", "[PAD] [PAD] dinutuximab is used to treat which diseases?", "[PAD] [PAD] which disease is used to treat dinutuximab?", "[PAD] [PAD] [PAD] what disease is dinutuximab used for?", "[PAD] [PAD] [PAD] what is dinutuximab used to treat?", "dinutuximab is used for the treatment of what disease?", "[PAD] [PAD] [PAD] what is dinutusimab used to treat?", "[PAD] [PAD] [PAD] is dinutuximab used to treat disease?", "[PAD] [PAD] dinotoximab is used to treat any disease?", "[PAD] [PAD] [PAD] [PAD] what is dinutuximab used for?", "[PAD] [PAD] dinutuximab is used to treat any disease?", "[PAD] [PAD] is dinutuximab used to treat the disease?", "[PAD] [PAD] which diseases are dinutuximab used to treat?", "[PAD] [PAD] [PAD] what diseases is dinutuximab used for?", "[PAD] [PAD] [PAD] which disease is dinutuximab used for?", "[PAD] [PAD] dinutoximab is used to treat which disease?", "dinutuximab is used for the treatment of which diseases?", "[PAD] [PAD] is dinutuximab used to treat any disease?", "dinutuximab is used for the treatment of which disease?", "[PAD] [PAD] what disease is used to treat dinutuximab?", "[PAD] [PAD] which disease is dinutuximab used to treat?", "[PAD] [PAD] [PAD] dinutuximab is used in which disease?", "[PAD] [PAD] what diseases is dinutuximab used to treat?", "[PAD] dinutuximab is used for treatment of what disease?", "[PAD] dinutuximab is used for treatment of which disease?", "[PAD] [PAD] dinutuximab is used to treat which disease?", "[PAD] [PAD] [PAD] for which disease is dinutuximab used?", "[PAD] [PAD] [PAD] dinotuximab used to treat which disease?", "[PAD] [PAD] what disease is dinutuximab used to treat?", "[PAD] [PAD] what diseases are dinutuximab used to treat?", "for the treatment of which disease is dinutuximab used?", "[PAD] [PAD] dinutuximab is used to treat which diseases?", "[PAD] [PAD] which disease is used to treat dinutuximab?", "[PAD] [PAD] [PAD] what disease is dinutuximab used for?", "[PAD] [PAD] [PAD] what is dinutuximab used to treat?", "dinutuximab is used for the treatment of what disease?", "[PAD] [PAD] [PAD] what is dinutusimab used to treat?", "[PAD] [PAD] [PAD] is dinutuximab used to treat disease?", "[PAD] [PAD] dinotoximab is used to treat any disease?", "[PAD] [PAD] [PAD] [PAD] what is dinutuximab used for?", "[PAD] [PAD] dinutuximab is used to treat any disease?", "[PAD] [PAD] is dinutuximab used to treat the disease?", "[PAD] [PAD] which diseases are dinutuximab used to treat?", "[PAD] [PAD] [PAD] what diseases is dinutuximab used for?", "[PAD] [PAD] [PAD] which disease is dinutuximab used for?", "[PAD] [PAD] dinutoximab is used to treat which disease?", "dinutuximab is used for the treatment of which diseases?", "[PAD] [PAD] is dinutuximab used to treat any disease?", "dinutuximab is used for the treatment of which disease?", "[PAD] [PAD] what disease is used to treat dinutuximab?", "[PAD] [PAD] which disease is dinutuximab used to treat?", "[PAD] [PAD] [PAD] dinutuximab is used in which disease?", "[PAD] [PAD] what diseases is dinutuximab used to treat?", "[PAD] dinutuximab is used for treatment of what disease?", "[PAD] [PAD] the mantoux test detects what latent infection/disease?", "[PAD] [PAD] the mantoux test detects which latent infection / disease?", "[PAD] [PAD] what latent infection / disease does the mantoux test detect?", "[PAD] [PAD] [PAD] [PAD] mantoux test detects any underlying infection/disease?", "[PAD] [PAD] [PAD] what hidden infection / disease does the mantoux test detect?", "[PAD] [PAD] what secret infection / disease does mantoux's test detect?", "[PAD] [PAD] [PAD] mantoux test detects what latent infection / disease?", "[PAD] [PAD] does the mantoux test detect any latent infection / disease?", "[PAD] [PAD] [PAD] what underlying infection/disease does the mantoux test detect?", "[PAD] [PAD] [PAD] [PAD] mantoux test reveals which latent infection / disease?", "[PAD] [PAD] does the mantoux test detect what latent infection / disease?", "[PAD] [PAD] [PAD] the mantoux test shows which latent infection / disease?", "[PAD] [PAD] the mantoux test detects which latent infection/disease?", "[PAD] [PAD] [PAD] does the mantoux test detect any hidden infections/diseases?", "[PAD] [PAD] what latent infection / illness does the mantoux test detect?", "[PAD] [PAD] does mantoux test detect which infection / disease is latent?", "[PAD] [PAD] what latent infection/disease does the mantoux test detect?", "[PAD] [PAD] does the mantoux test detect which infection / disease is inactive?", "[PAD] [PAD] [PAD] mantoux test detects which infection / disease is hidden?", "[PAD] [PAD] [PAD] mantoux test detects which latent infection/disease?", "[PAD] [PAD] what latent infection / disease does the mantoux test show?", "[PAD] [PAD] the mantoux test detects what latent infection / disease?", "[PAD] [PAD] [PAD] mantoux test detects which infection / latent disease?", "[PAD] [PAD] [PAD] which potential infections / diseases does the mantoux test detect?", "[PAD] [PAD] what latent infections/diseases does the mantoux test detect?", "the mantoux test detects what is a latent infection/disease?", "[PAD] [PAD] does the mantoux test detect which infection / disease is hidden?", "[PAD] [PAD] [PAD] [PAD] does mantoux test detect latent infection / disease?", "[PAD] [PAD] what latent infection/disease does the mantoux test reveal?", "[PAD] [PAD] which latent infection / disease does the mantoux test detect?", "[PAD] [PAD] what infection/latent disease does the mantoux test detect?", "[PAD] [PAD] the mantoux test detects what infection / disease is hidden?", "[PAD] [PAD] [PAD] does the mantoux test detect latent infections/diseases?", "[PAD] [PAD] [PAD] [PAD] [PAD] mentox test reveals which latent infection / disease?", "[PAD] [PAD] [PAD] mantoux test detects which latent infection / disease?", "[PAD] [PAD] the mantoux test detects what latent infection/disease?", "[PAD] [PAD] the mantoux test detects which latent infection / disease?", "[PAD] [PAD] what latent infection / disease does the mantoux test detect?", "[PAD] [PAD] [PAD] [PAD] mantoux test detects any underlying infection/disease?", "[PAD] [PAD] [PAD] what hidden infection / disease does the mantoux test detect?", "[PAD] [PAD] what secret infection / disease does mantoux's test detect?", "[PAD] [PAD] [PAD] mantoux test detects what latent infection / disease?", "[PAD] [PAD] does the mantoux test detect any latent infection / disease?", "[PAD] [PAD] [PAD] what underlying infection/disease does the mantoux test detect?", "[PAD] [PAD] [PAD] [PAD] mantoux test reveals which latent infection / disease?", "[PAD] [PAD] does the mantoux test detect what latent infection / disease?", "[PAD] [PAD] [PAD] the mantoux test shows which latent infection / disease?", "[PAD] [PAD] the mantoux test detects which latent infection/disease?", "[PAD] [PAD] [PAD] does the mantoux test detect any hidden infections/diseases?", "[PAD] [PAD] what latent infection / illness does the mantoux test detect?", "[PAD] [PAD] does mantoux test detect which infection / disease is latent?", "[PAD] [PAD] what latent infection/disease does the mantoux test detect?", "[PAD] [PAD] does the mantoux test detect which infection / disease is inactive?", "[PAD] [PAD] [PAD] mantoux test detects which infection / disease is hidden?", "[PAD] [PAD] [PAD] mantoux test detects which latent infection/disease?", "[PAD] [PAD] what latent infection / disease does the mantoux test show?", "[PAD] [PAD] the mantoux test detects what latent infection / disease?", "[PAD] [PAD] [PAD] mantoux test detects which infection / latent disease?", "[PAD] [PAD] [PAD] which potential infections / diseases does the mantoux test detect?", "[PAD] [PAD] what latent infections/diseases does the mantoux test detect?", "the mantoux test detects what is a latent infection/disease?", "[PAD] [PAD] does the mantoux test detect which infection / disease is hidden?", "[PAD] [PAD] [PAD] [PAD] does mantoux test detect latent infection / disease?", "[PAD] [PAD] what latent infection/disease does the mantoux test reveal?", "[PAD] [PAD] which latent infection / disease does the mantoux test detect?", "[PAD] [PAD] what infection/latent disease does the mantoux test detect?", "[PAD] [PAD] the mantoux test detects what infection / disease is hidden?", "[PAD] [PAD] [PAD] does the mantoux test detect latent infections/diseases?", "[PAD] [PAD] [PAD] [PAD] [PAD] mentox test reveals which latent infection / disease?", "[PAD] [PAD] [PAD] mantoux test detects which latent infection / disease?", "[PAD] [PAD] the mantoux test detects what latent infection/disease?", "[PAD] [PAD] the mantoux test detects which latent infection / disease?", "[PAD] [PAD] what latent infection / disease does the mantoux test detect?", "[PAD] [PAD] [PAD] [PAD] mantoux test detects any underlying infection/disease?", "[PAD] [PAD] [PAD] what hidden infection / disease does the mantoux test detect?", "[PAD] [PAD] what secret infection / disease does mantoux's test detect?", "[PAD] [PAD] [PAD] mantoux test detects what latent infection / disease?", "[PAD] [PAD] does the mantoux test detect any latent infection / disease?", "[PAD] [PAD] [PAD] what underlying infection/disease does the mantoux test detect?", "[PAD] [PAD] [PAD] [PAD] mantoux test reveals which latent infection / disease?", "[PAD] [PAD] does the mantoux test detect what latent infection / disease?", "[PAD] [PAD] [PAD] the mantoux test shows which latent infection / disease?", "[PAD] [PAD] the mantoux test detects which latent infection/disease?", "[PAD] [PAD] [PAD] does the mantoux test detect any hidden infections/diseases?", "[PAD] [PAD] what latent infection / illness does the mantoux test detect?", "[PAD] [PAD] does mantoux test detect which infection / disease is latent?", "[PAD] [PAD] what latent infection/disease does the mantoux test detect?", "[PAD] [PAD] does the mantoux test detect which infection / disease is inactive?", "[PAD] [PAD] [PAD] mantoux test detects which infection / disease is hidden?", "[PAD] [PAD] [PAD] mantoux test detects which latent infection/disease?", "[PAD] [PAD] what latent infection / disease does the mantoux test show?", "[PAD] [PAD] the mantoux test detects what latent infection / disease?", "[PAD] [PAD] [PAD] mantoux test detects which infection / latent disease?", "[PAD] [PAD] [PAD] which potential infections / diseases does the mantoux test detect?", "[PAD] [PAD] what latent infections/diseases does the mantoux test detect?", "the mantoux test detects what is a latent infection/disease?", "[PAD] [PAD] does the mantoux test detect which infection / disease is hidden?", "[PAD] [PAD] [PAD] [PAD] does mantoux test detect latent infection / disease?", "[PAD] [PAD] what latent infection/disease does the mantoux test reveal?", "[PAD] [PAD] which latent infection / disease does the mantoux test detect?", "[PAD] [PAD] what infection/latent disease does the mantoux test detect?", "[PAD] [PAD] the mantoux test detects what infection / disease is hidden?", "[PAD] [PAD] [PAD] does the mantoux test detect latent infections/diseases?", "[PAD] [PAD] [PAD] [PAD] [PAD] mentox test reveals which latent infection / disease?", "[PAD] [PAD] [PAD] mantoux test detects which latent infection / disease?", "[PAD] [PAD] the mantoux test detects what latent infection/disease?", "[PAD] [PAD] the mantoux test detects which latent infection / disease?", "[PAD] [PAD] what latent infection / disease does the mantoux test detect?", "[PAD] [PAD] [PAD] [PAD] mantoux test detects any underlying infection/disease?", "[PAD] [PAD] [PAD] what hidden infection / disease does the mantoux test detect?", "[PAD] [PAD] what secret infection / disease does mantoux's test detect?", "[PAD] [PAD] [PAD] mantoux test detects what latent infection / disease?", "[PAD] [PAD] does the mantoux test detect any latent infection / disease?", "[PAD] [PAD] [PAD] what underlying infection/disease does the mantoux test detect?", "[PAD] [PAD] [PAD] [PAD] mantoux test reveals which latent infection / disease?", "[PAD] [PAD] does the mantoux test detect what latent infection / disease?", "[PAD] [PAD] [PAD] the mantoux test shows which latent infection / disease?", "[PAD] [PAD] the mantoux test detects which latent infection/disease?", "[PAD] [PAD] [PAD] does the mantoux test detect any hidden infections/diseases?", "[PAD] [PAD] what latent infection / illness does the mantoux test detect?", "[PAD] [PAD] does mantoux test detect which infection / disease is latent?", "[PAD] [PAD] what latent infection/disease does the mantoux test detect?", "[PAD] [PAD] does the mantoux test detect which infection / disease is inactive?", "[PAD] [PAD] [PAD] mantoux test detects which infection / disease is hidden?", "[PAD] [PAD] [PAD] mantoux test detects which latent infection/disease?", "[PAD] [PAD] what latent infection / disease does the mantoux test show?", "[PAD] [PAD] the mantoux test detects what latent infection / disease?", "[PAD] [PAD] [PAD] mantoux test detects which infection / latent disease?", "[PAD] [PAD] [PAD] which potential infections / diseases does the mantoux test detect?", "[PAD] [PAD] what latent infections/diseases does the mantoux test detect?", "the mantoux test detects what is a latent infection/disease?", "[PAD] [PAD] does the mantoux test detect which infection / disease is hidden?", "[PAD] [PAD] [PAD] [PAD] does mantoux test detect latent infection / disease?", "[PAD] [PAD] what latent infection/disease does the mantoux test reveal?", "[PAD] [PAD] which latent infection / disease does the mantoux test detect?", "[PAD] [PAD] what infection/latent disease does the mantoux test detect?", "[PAD] [PAD] the mantoux test detects what infection / disease is hidden?", "[PAD] [PAD] [PAD] does the mantoux test detect latent infections/diseases?", "[PAD] [PAD] [PAD] [PAD] [PAD] mentox test reveals which latent infection / disease?", "[PAD] [PAD] [PAD] mantoux test detects which latent infection / disease?", "[PAD] [PAD] the mantoux test detects what latent infection/disease?", "[PAD] [PAD] the mantoux test detects which latent infection / disease?", "[PAD] [PAD] what latent infection / disease does the mantoux test detect?", "[PAD] [PAD] [PAD] [PAD] mantoux test detects any underlying infection/disease?", "[PAD] [PAD] [PAD] what hidden infection / disease does the mantoux test detect?", "[PAD] [PAD] what secret infection / disease does mantoux's test detect?", "[PAD] [PAD] [PAD] mantoux test detects what latent infection / disease?", "[PAD] [PAD] does the mantoux test detect any latent infection / disease?", "[PAD] [PAD] [PAD] what underlying infection/disease does the mantoux test detect?", "[PAD] [PAD] [PAD] [PAD] mantoux test reveals which latent infection / disease?", "[PAD] [PAD] does the mantoux test detect what latent infection / disease?", "[PAD] [PAD] [PAD] the mantoux test shows which latent infection / disease?", "[PAD] [PAD] the mantoux test detects which latent infection/disease?", "[PAD] [PAD] [PAD] does the mantoux test detect any hidden infections/diseases?", "[PAD] [PAD] what latent infection / illness does the mantoux test detect?", "[PAD] [PAD] does mantoux test detect which infection / disease is latent?", "[PAD] [PAD] what latent infection/disease does the mantoux test detect?", "[PAD] [PAD] does the mantoux test detect which infection / disease is inactive?", "[PAD] [PAD] [PAD] mantoux test detects which infection / disease is hidden?", "[PAD] [PAD] [PAD] mantoux test detects which latent infection/disease?", "[PAD] [PAD] what latent infection / disease does the mantoux test show?", "[PAD] [PAD] the mantoux test detects what latent infection / disease?", "[PAD] [PAD] [PAD] mantoux test detects which infection / latent disease?", "[PAD] [PAD] [PAD] which potential infections / diseases does the mantoux test detect?", "[PAD] [PAD] what latent infections/diseases does the mantoux test detect?", "the mantoux test detects what is a latent infection/disease?", "[PAD] [PAD] does the mantoux test detect which infection / disease is hidden?", "[PAD] [PAD] [PAD] [PAD] does mantoux test detect latent infection / disease?", "[PAD] [PAD] what latent infection/disease does the mantoux test reveal?", "[PAD] [PAD] which latent infection / disease does the mantoux test detect?", "[PAD] [PAD] what infection/latent disease does the mantoux test detect?", "[PAD] [PAD] the mantoux test detects what infection / disease is hidden?", "[PAD] [PAD] [PAD] does the mantoux test detect latent infections/diseases?", "[PAD] [PAD] [PAD] [PAD] [PAD] mentox test reveals which latent infection / disease?", "[PAD] [PAD] [PAD] mantoux test detects which latent infection / disease?", "[PAD] what nerve is involved in carpal tunnel syndrome?", "[PAD] which nerve is involved in carpal tunnel syndrome?", "what is the nerve that affects carpal tunnel syndrome?", "[PAD] which nerves are involved in carpal tunnel syndrome?", "[PAD] what nerves are involved in carpal tunnel syndrome?", "[PAD] which nerve is associated with carpal tunnel syndrome?", "[PAD] [PAD] what nerve does carpal tunnel syndrome have?", "[PAD] what nerve is affected in carpal tunnel syndrome?", "[PAD] what nerve is involved in carpal tunnel syndrome?", "[PAD] which nerve is involved in carpal tunnel syndrome?", "what is the nerve that affects carpal tunnel syndrome?", "[PAD] which nerves are involved in carpal tunnel syndrome?", "[PAD] what nerves are involved in carpal tunnel syndrome?", "[PAD] which nerve is associated with carpal tunnel syndrome?", "[PAD] [PAD] what nerve does carpal tunnel syndrome have?", "[PAD] what nerve is affected in carpal tunnel syndrome?", "[PAD] what nerve is involved in carpal tunnel syndrome?", "[PAD] which nerve is involved in carpal tunnel syndrome?", "what is the nerve that affects carpal tunnel syndrome?", "[PAD] which nerves are involved in carpal tunnel syndrome?", "[PAD] what nerves are involved in carpal tunnel syndrome?", "[PAD] which nerve is associated with carpal tunnel syndrome?", "[PAD] [PAD] what nerve does carpal tunnel syndrome have?", "[PAD] what nerve is affected in carpal tunnel syndrome?", "[PAD] what nerve is involved in carpal tunnel syndrome?", "[PAD] which nerve is involved in carpal tunnel syndrome?", "what is the nerve that affects carpal tunnel syndrome?", "[PAD] which nerves are involved in carpal tunnel syndrome?", "[PAD] what nerves are involved in carpal tunnel syndrome?", "[PAD] which nerve is associated with carpal tunnel syndrome?", "[PAD] [PAD] what nerve does carpal tunnel syndrome have?", "[PAD] what nerve is affected in carpal tunnel syndrome?", "[PAD] what nerve is involved in carpal tunnel syndrome?", "[PAD] which nerve is involved in carpal tunnel syndrome?", "what is the nerve that affects carpal tunnel syndrome?", "[PAD] which nerves are involved in carpal tunnel syndrome?", "[PAD] what nerves are involved in carpal tunnel syndrome?", "[PAD] which nerve is associated with carpal tunnel syndrome?", "[PAD] [PAD] what nerve does carpal tunnel syndrome have?", "[PAD] what nerve is affected in carpal tunnel syndrome?", "[PAD] what nerve is involved in carpal tunnel syndrome?", "[PAD] which nerve is involved in carpal tunnel syndrome?", "what is the nerve that affects carpal tunnel syndrome?", "[PAD] which nerves are involved in carpal tunnel syndrome?", "[PAD] what nerves are involved in carpal tunnel syndrome?", "[PAD] which nerve is associated with carpal tunnel syndrome?", "[PAD] [PAD] what nerve does carpal tunnel syndrome have?", "[PAD] what nerve is affected in carpal tunnel syndrome?", "[PAD] what nerve is involved in carpal tunnel syndrome?", "[PAD] which nerve is involved in carpal tunnel syndrome?", "what is the nerve that affects carpal tunnel syndrome?", "[PAD] which nerves are involved in carpal tunnel syndrome?", "[PAD] what nerves are involved in carpal tunnel syndrome?", "[PAD] which nerve is associated with carpal tunnel syndrome?", "[PAD] [PAD] what nerve does carpal tunnel syndrome have?", "[PAD] what nerve is affected in carpal tunnel syndrome?", "[PAD] what nerve is involved in carpal tunnel syndrome?", "[PAD] which nerve is involved in carpal tunnel syndrome?", "what is the nerve that affects carpal tunnel syndrome?", "[PAD] which nerves are involved in carpal tunnel syndrome?", "[PAD] what nerves are involved in carpal tunnel syndrome?", "[PAD] which nerve is associated with carpal tunnel syndrome?", "[PAD] [PAD] what nerve does carpal tunnel syndrome have?", "[PAD] what nerve is affected in carpal tunnel syndrome?", "[PAD] what nerve is involved in carpal tunnel syndrome?", "[PAD] which nerve is involved in carpal tunnel syndrome?", "what is the nerve that affects carpal tunnel syndrome?", "[PAD] which nerves are involved in carpal tunnel syndrome?", "[PAD] what nerves are involved in carpal tunnel syndrome?", "[PAD] which nerve is associated with carpal tunnel syndrome?", "[PAD] [PAD] what nerve does carpal tunnel syndrome have?", "[PAD] what nerve is affected in carpal tunnel syndrome?", "[PAD] what nerve is involved in carpal tunnel syndrome?", "[PAD] which nerve is involved in carpal tunnel syndrome?", "what is the nerve that affects carpal tunnel syndrome?", "[PAD] which nerves are involved in carpal tunnel syndrome?", "[PAD] what nerves are involved in carpal tunnel syndrome?", "[PAD] which nerve is associated with carpal tunnel syndrome?", "[PAD] [PAD] what nerve does carpal tunnel syndrome have?", "[PAD] what nerve is affected in carpal tunnel syndrome?", "[PAD] what nerve is involved in carpal tunnel syndrome?", "[PAD] which nerve is involved in carpal tunnel syndrome?", "what is the nerve that affects carpal tunnel syndrome?", "[PAD] which nerves are involved in carpal tunnel syndrome?", "[PAD] what nerves are involved in carpal tunnel syndrome?", "[PAD] which nerve is associated with carpal tunnel syndrome?", "[PAD] [PAD] what nerve does carpal tunnel syndrome have?", "[PAD] what nerve is affected in carpal tunnel syndrome?", "[PAD] [PAD] where in the body would the navicular bone be found?", "[PAD] [PAD] where in the body will the navicular bone be found?", "[PAD] [PAD] where on the body can the navicular bone be found?", "[PAD] [PAD] [PAD] [PAD] [PAD] where was the navy bone found in the body?", "[PAD] [PAD] where will the navicular bone be found in the body?", "[PAD] [PAD] [PAD] [PAD] [PAD] where would the navicular bone be found?", "[PAD] [PAD] [PAD] where in the body would the navicular bone be?", "[PAD] [PAD] where can the navicular bone be found on the body?", "[PAD] [PAD] where in the body would the navicular bone be located?", "[PAD] [PAD] [PAD] [PAD] where in the body would the coffin bone be found?", "[PAD] [PAD] [PAD] where on the body would the navicular bone be?", "[PAD] [PAD] [PAD] where in the body is the navicular bone found?", "[PAD] [PAD] where would the navicular bone be found in the body?", "[PAD] [PAD] [PAD] where is the navicular bone found in the body?", "[PAD] [PAD] where in the body would one find the navicular bone?", "[PAD] [PAD] [PAD] [PAD] where in the body would the bone marrow be?", "[PAD] [PAD] where in the body could the navicular bone be found?", "[PAD] [PAD] where will the navicular bone be located in the body?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] where is the clavicle in the body?", "[PAD] [PAD] [PAD] [PAD] [PAD] where can the navicular bone be found?", "[PAD] [PAD] [PAD] [PAD] where in the body would the estuary bone be found?", "in which part of the body would the navicular bone be found?", "[PAD] [PAD] [PAD] [PAD] where is the scaphoid bone on your body?", "[PAD] [PAD] where in the body can the navicular bone be found?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] where on the body would the spine be?", "[PAD] [PAD] [PAD] [PAD] where will the normal bone be found in the body?", "[PAD] [PAD] [PAD] [PAD] where is navicular bone found in the body?", "[PAD] [PAD] [PAD] where is the umbilical cord found in the body?", "[PAD] [PAD] where can the navicular bone be found in the body?", "[PAD] [PAD] where in the body would he find the navicular bone?", "[PAD] [PAD] [PAD] where in the body would the vicicular bone be found?", "[PAD] [PAD] where in the body would you find the navicular bone?", "[PAD] [PAD] [PAD] [PAD] [PAD] where would marine bone be found in the body?", "[PAD] [PAD] [PAD] [PAD] where are the navicular bones in the body?", "[PAD] [PAD] [PAD] where in the body is the navicular bone located?", "[PAD] [PAD] [PAD] [PAD] where will the nuclear bone be found in the body?", "[PAD] [PAD] [PAD] where in the body will the pelvis be found?", "[PAD] [PAD] where in the body would the navicular bone be found?", "[PAD] [PAD] where in the body will the navicular bone be found?", "[PAD] [PAD] where on the body can the navicular bone be found?", "[PAD] [PAD] [PAD] [PAD] [PAD] where was the navy bone found in the body?", "[PAD] [PAD] where will the navicular bone be found in the body?", "[PAD] [PAD] [PAD] [PAD] [PAD] where would the navicular bone be found?", "[PAD] [PAD] [PAD] where in the body would the navicular bone be?", "[PAD] [PAD] where can the navicular bone be found on the body?", "[PAD] [PAD] where in the body would the navicular bone be located?", "[PAD] [PAD] [PAD] [PAD] where in the body would the coffin bone be found?", "[PAD] [PAD] [PAD] where on the body would the navicular bone be?", "[PAD] [PAD] [PAD] where in the body is the navicular bone found?", "[PAD] [PAD] where would the navicular bone be found in the body?", "[PAD] [PAD] [PAD] where is the navicular bone found in the body?", "[PAD] [PAD] where in the body would one find the navicular bone?", "[PAD] [PAD] [PAD] [PAD] where in the body would the bone marrow be?", "[PAD] [PAD] where in the body could the navicular bone be found?", "[PAD] [PAD] where will the navicular bone be located in the body?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] where is the clavicle in the body?", "[PAD] [PAD] [PAD] [PAD] [PAD] where can the navicular bone be found?", "[PAD] [PAD] [PAD] [PAD] where in the body would the estuary bone be found?", "in which part of the body would the navicular bone be found?", "[PAD] [PAD] [PAD] [PAD] where is the scaphoid bone on your body?", "[PAD] [PAD] where in the body can the navicular bone be found?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] where on the body would the spine be?", "[PAD] [PAD] [PAD] [PAD] where will the normal bone be found in the body?", "[PAD] [PAD] [PAD] [PAD] where is navicular bone found in the body?", "[PAD] [PAD] [PAD] where is the umbilical cord found in the body?", "[PAD] [PAD] where can the navicular bone be found in the body?", "[PAD] [PAD] where in the body would he find the navicular bone?", "[PAD] [PAD] [PAD] where in the body would the vicicular bone be found?", "[PAD] [PAD] where in the body would you find the navicular bone?", "[PAD] [PAD] [PAD] [PAD] [PAD] where would marine bone be found in the body?", "[PAD] [PAD] [PAD] [PAD] where are the navicular bones in the body?", "[PAD] [PAD] [PAD] where in the body is the navicular bone located?", "[PAD] [PAD] [PAD] [PAD] where will the nuclear bone be found in the body?", "[PAD] [PAD] [PAD] where in the body will the pelvis be found?", "[PAD] which method is proseek based on?", "[PAD] on what method is proseek based?", "[PAD] what method is proseek based on?", "what method is the proseek based on?", "[PAD] [PAD] what methods does prose rely on?", "[PAD] [PAD] what is proseek based on?", "which method is the basis of proseek?", "[PAD] on what methods is proseek based?", "on what method is prussic based?", "[PAD] [PAD] what is prosec based on?", "[PAD] what is proseek's approach?", "[PAD] which method is based on proseek?", "[PAD] what methods is proseek based on?", "[PAD] [PAD] proseek depends on which method?", "[PAD] [PAD] [PAD] how does proseek work?", "[PAD] [PAD] [PAD] how is proseek based?", "[PAD] which method is proseek based on?", "[PAD] on what method is proseek based?", "[PAD] what method is proseek based on?", "what method is the proseek based on?", "[PAD] [PAD] what methods does prose rely on?", "[PAD] [PAD] what is proseek based on?", "which method is the basis of proseek?", "[PAD] on what methods is proseek based?", "on what method is prussic based?", "[PAD] [PAD] what is prosec based on?", "[PAD] what is proseek's approach?", "[PAD] which method is based on proseek?", "[PAD] what methods is proseek based on?", "[PAD] [PAD] proseek depends on which method?", "[PAD] [PAD] [PAD] how does proseek work?", "[PAD] [PAD] [PAD] how is proseek based?", "[PAD] [PAD] [PAD] [PAD] in what percentage of skeletal muscle fibers is dystrophin expression restored after ppmo- mediated exon skipping?", "[PAD] [PAD] [PAD] [PAD] [PAD] in what percentage of skeletal muscle fibers is dystrophin expression restored after ppmo-mediated exon skip?", "[PAD] [PAD] [PAD] [PAD] [PAD] in what percentage of skeletal muscle fibers does dystrophin expression return after ppmo-mediated exon crossing?", "[PAD] [PAD] [PAD] [PAD] in what proportion of skeletal muscle fibers is dystrophin expression restored after ppmo-mediated exon skipping?", "[PAD] [PAD] [PAD] in what percentage of skeletal muscle fibers does dystrophin expression recover after the release of ppmo-mediated exons?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] in what percentage of skeletal muscle fibers is dystrophic expression restored after ppmo-mediated exon jump?", "[PAD] [PAD] [PAD] what percentage of bone and muscle fibers is restored to dystrophin expression after exmo-skipping via ppmo?", "[PAD] [PAD] [PAD] [PAD] in what percentage of skeletal muscle fibers is dystrophin expression restored after ppmo-mediated exon omission?", "[PAD] [PAD] [PAD] [PAD] in what percentage of skeletal muscle fibers is dystrophin expression restored after ppmo-mediated exon skipping?", "[PAD] [PAD] [PAD] [PAD] at what percentage of skeletal muscle fibers is dystrophin expression restored after skipping ppmo-mediated exon?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what proportion of dystrophin expression is restored after ppmo-mediated exon skipping?", "[PAD] [PAD] [PAD] [PAD] [PAD] in what percentage of skeletal muscle fibers is dystrophin expression restored after ppmo-mediated exon jump?", "[PAD] [PAD] [PAD] [PAD] [PAD] what percentage of skeletal muscle fibers recover from dystrophin expression after ppmo-mediated exon skipping?", "[PAD] [PAD] [PAD] in what percentage of skeletal muscle fibers does dystrophin expression recover after bypassing a ppmo-mediated exon?", "[PAD] [PAD] [PAD] [PAD] [PAD] at what percentage of skeletal muscle fibers is dystrophin expression restored after ppmo-mediated exon jump?", "[PAD] [PAD] [PAD] [PAD] in what percentage of skeletal muscle fibers does dystrophin expression recover after ppmo-mediated exon omission?", "[PAD] [PAD] [PAD] [PAD] [PAD] at what percentage of skeletal muscle fibers are dystrophin expression restored after skipping exons from ppmo?", "[PAD] [PAD] [PAD] in what percentage of skeletal muscle mass is dystrophin expression restored after skipping an axon mediated by ppmo?", "[PAD] [PAD] [PAD] [PAD] in what percentage of skeletal muscle fibers is dystrophin expression restored after ppmo-mediated axon skipping?", "[PAD] [PAD] [PAD] [PAD] [PAD] what percentage of skeletal muscle fibers recover from dystrophin expression after ppmo-mediated exon omission?", "[PAD] [PAD] [PAD] [PAD] [PAD] in what percentage of skeletal muscle fibers is dystrophin expression recovered after ppmo-mediated exon release?", "[PAD] [PAD] [PAD] [PAD] [PAD] in what percentage of skeletal muscle fibers dystrophin expression is restored after ppmo-mediated exon jump?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what percentage of skeletal muscle fibers resists dystrophin expression after exon skipping through ppmo?", "[PAD] [PAD] [PAD] [PAD] [PAD] what percentage of skeletal muscle fibers is dystrophin expression restored after ppmo-mediated exon skipping?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what percentage of skeletal muscle fibers restore dystrophin expression after ppmo-mediated exon skipping?", "[PAD] [PAD] [PAD] [PAD] in what percentage of skeletal muscle fibers are dystrophin expression restored after ppmo-mediated exon skipping?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what percentage of skeletal muscle fibers restore dystrophin expression after ppmo-mediated exon release?", "[PAD] [PAD] [PAD] [PAD] [PAD] what percentage of skeletal muscle fibers are restored with dystrophin expression after ppmo-mediated exon passage?", "[PAD] [PAD] [PAD] [PAD] [PAD] in what percentage of skeletal muscle fibers is dystrophine expression restored after ppmo -mediated exons are skipped?", "[PAD] [PAD] [PAD] [PAD] at what percentage of skeletal muscle fibers is dystrophin expression restored after ppmo-mediated eson overflow?", "[PAD] [PAD] [PAD] [PAD] [PAD] in what percentage of skeletal muscle fibers is dystrophin expression restored after ppmo-mediated exon jumping?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] in what percentage of skeletal muscle fibers is dystrophin expression repaired by ppmo after exon jumping?", "[PAD] [PAD] [PAD] [PAD] in what percentage of skeletal muscle fibers does dystrophin expression recover after ppmo-mediated exon skipping?", "in what percentage of skeletal muscle fibers is the expression of dystrophin restored after jumping out of the ppmo-linked exon?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what percentage of skeletal muscle fibers restored dystrophin expression after ppmo-mediated exon crossing?", "[PAD] [PAD] [PAD] [PAD] [PAD] in what percentage of skeletal muscle fibers dystrophin expression is restored after ppmo-mediated excretion?", "[PAD] [PAD] [PAD] [PAD] what percentage of skeletal muscle fibers are restored to dystrophin expression after ppmo-mediated exon skipping?", "[PAD] [PAD] [PAD] [PAD] in what percentage of skeletal muscle fibers is dystrophin expression healthy after ppmo-mediated exon skipping?", "[PAD] which human chromosome is the product of fusion?", "[PAD] which human chromosome is a product of fusion?", "[PAD] which human chromosome is the result of fusion?", "which human chromosome is the product of a combination?", "[PAD] [PAD] which human chromosome is a fusion product?", "which human chromosome is the product of the fusion?", "[PAD] [PAD] which human chromosome is the fusion product?", "[PAD] [PAD] [PAD] [PAD] which human chromosome produces fusion?", "[PAD] what human chromosome is the product of fusion?", "which human chromosomes are the product of fusion?", "[PAD] which human chromosome is the product of synthesis?", "which human chromosome is the result of a combination?", "[PAD] which human chromosome is the product of connection?", "[PAD] which human chromosome is the product of fusion?", "[PAD] which human chromosome is a product of fusion?", "[PAD] which human chromosome is the result of fusion?", "which human chromosome is the product of a combination?", "[PAD] [PAD] which human chromosome is a fusion product?", "which human chromosome is the product of the fusion?", "[PAD] [PAD] which human chromosome is the fusion product?", "[PAD] [PAD] [PAD] [PAD] which human chromosome produces fusion?", "[PAD] what human chromosome is the product of fusion?", "which human chromosomes are the product of fusion?", "[PAD] which human chromosome is the product of synthesis?", "which human chromosome is the result of a combination?", "[PAD] which human chromosome is the product of connection?", "[PAD] which human chromosome is the product of fusion?", "[PAD] which human chromosome is a product of fusion?", "[PAD] which human chromosome is the result of fusion?", "which human chromosome is the product of a combination?", "[PAD] [PAD] which human chromosome is a fusion product?", "which human chromosome is the product of the fusion?", "[PAD] [PAD] which human chromosome is the fusion product?", "[PAD] [PAD] [PAD] [PAD] which human chromosome produces fusion?", "[PAD] what human chromosome is the product of fusion?", "which human chromosomes are the product of fusion?", "[PAD] which human chromosome is the product of synthesis?", "which human chromosome is the result of a combination?", "[PAD] which human chromosome is the product of connection?", "[PAD] which human chromosome is the product of fusion?", "[PAD] which human chromosome is a product of fusion?", "[PAD] which human chromosome is the result of fusion?", "which human chromosome is the product of a combination?", "[PAD] [PAD] which human chromosome is a fusion product?", "which human chromosome is the product of the fusion?", "[PAD] [PAD] which human chromosome is the fusion product?", "[PAD] [PAD] [PAD] [PAD] which human chromosome produces fusion?", "[PAD] what human chromosome is the product of fusion?", "which human chromosomes are the product of fusion?", "[PAD] which human chromosome is the product of synthesis?", "which human chromosome is the result of a combination?", "[PAD] which human chromosome is the product of connection?", "[PAD] which human chromosome is the product of fusion?", "[PAD] which human chromosome is a product of fusion?", "[PAD] which human chromosome is the result of fusion?", "which human chromosome is the product of a combination?", "[PAD] [PAD] which human chromosome is a fusion product?", "which human chromosome is the product of the fusion?", "[PAD] [PAD] which human chromosome is the fusion product?", "[PAD] [PAD] [PAD] [PAD] which human chromosome produces fusion?", "[PAD] what human chromosome is the product of fusion?", "which human chromosomes are the product of fusion?", "[PAD] which human chromosome is the product of synthesis?", "which human chromosome is the result of a combination?", "[PAD] which human chromosome is the product of connection?", "[PAD] which human chromosome is the product of fusion?", "[PAD] which human chromosome is a product of fusion?", "[PAD] which human chromosome is the result of fusion?", "which human chromosome is the product of a combination?", "[PAD] [PAD] which human chromosome is a fusion product?", "which human chromosome is the product of the fusion?", "[PAD] [PAD] which human chromosome is the fusion product?", "[PAD] [PAD] [PAD] [PAD] which human chromosome produces fusion?", "[PAD] what human chromosome is the product of fusion?", "which human chromosomes are the product of fusion?", "[PAD] which human chromosome is the product of synthesis?", "which human chromosome is the result of a combination?", "[PAD] which human chromosome is the product of connection?", "[PAD] which human chromosome is the product of fusion?", "[PAD] which human chromosome is a product of fusion?", "[PAD] which human chromosome is the result of fusion?", "which human chromosome is the product of a combination?", "[PAD] [PAD] which human chromosome is a fusion product?", "which human chromosome is the product of the fusion?", "[PAD] [PAD] which human chromosome is the fusion product?", "[PAD] [PAD] [PAD] [PAD] which human chromosome produces fusion?", "[PAD] what human chromosome is the product of fusion?", "which human chromosomes are the product of fusion?", "[PAD] which human chromosome is the product of synthesis?", "which human chromosome is the result of a combination?", "[PAD] which human chromosome is the product of connection?", "[PAD] which human chromosome is the product of fusion?", "[PAD] which human chromosome is a product of fusion?", "[PAD] which human chromosome is the result of fusion?", "which human chromosome is the product of a combination?", "[PAD] [PAD] which human chromosome is a fusion product?", "which human chromosome is the product of the fusion?", "[PAD] [PAD] which human chromosome is the fusion product?", "[PAD] [PAD] [PAD] [PAD] which human chromosome produces fusion?", "[PAD] what human chromosome is the product of fusion?", "which human chromosomes are the product of fusion?", "[PAD] which human chromosome is the product of synthesis?", "which human chromosome is the result of a combination?", "[PAD] which human chromosome is the product of connection?", "[PAD] which human chromosome is the product of fusion?", "[PAD] which human chromosome is a product of fusion?", "[PAD] which human chromosome is the result of fusion?", "which human chromosome is the product of a combination?", "[PAD] [PAD] which human chromosome is a fusion product?", "which human chromosome is the product of the fusion?", "[PAD] [PAD] which human chromosome is the fusion product?", "[PAD] [PAD] [PAD] [PAD] which human chromosome produces fusion?", "[PAD] what human chromosome is the product of fusion?", "which human chromosomes are the product of fusion?", "[PAD] which human chromosome is the product of synthesis?", "which human chromosome is the result of a combination?", "[PAD] which human chromosome is the product of connection?", "[PAD] which human chromosome is the product of fusion?", "[PAD] which human chromosome is a product of fusion?", "[PAD] which human chromosome is the result of fusion?", "which human chromosome is the product of a combination?", "[PAD] [PAD] which human chromosome is a fusion product?", "which human chromosome is the product of the fusion?", "[PAD] [PAD] which human chromosome is the fusion product?", "[PAD] [PAD] [PAD] [PAD] which human chromosome produces fusion?", "[PAD] what human chromosome is the product of fusion?", "which human chromosomes are the product of fusion?", "[PAD] which human chromosome is the product of synthesis?", "which human chromosome is the result of a combination?", "[PAD] which human chromosome is the product of connection?", "[PAD] which human chromosome is the product of fusion?", "[PAD] which human chromosome is a product of fusion?", "[PAD] which human chromosome is the result of fusion?", "which human chromosome is the product of a combination?", "[PAD] [PAD] which human chromosome is a fusion product?", "which human chromosome is the product of the fusion?", "[PAD] [PAD] which human chromosome is the fusion product?", "[PAD] [PAD] [PAD] [PAD] which human chromosome produces fusion?", "[PAD] what human chromosome is the product of fusion?", "which human chromosomes are the product of fusion?", "[PAD] which human chromosome is the product of synthesis?", "which human chromosome is the result of a combination?", "[PAD] which human chromosome is the product of connection?", "[PAD] which human chromosome is the product of fusion?", "[PAD] which human chromosome is a product of fusion?", "[PAD] which human chromosome is the result of fusion?", "which human chromosome is the product of a combination?", "[PAD] [PAD] which human chromosome is a fusion product?", "which human chromosome is the product of the fusion?", "[PAD] [PAD] which human chromosome is the fusion product?", "[PAD] [PAD] [PAD] [PAD] which human chromosome produces fusion?", "[PAD] what human chromosome is the product of fusion?", "which human chromosomes are the product of fusion?", "[PAD] which human chromosome is the product of synthesis?", "which human chromosome is the result of a combination?", "[PAD] which human chromosome is the product of connection?", "[PAD] [PAD] what percentage of homo sapiens dna is of neanderthal origin?", "[PAD] [PAD] what percentage of homo sapiens dna is of neandertal origin?", "[PAD] [PAD] what percentage of homo sapiens dna is of neanderthal ancestry?", "[PAD] [PAD] [PAD] [PAD] [PAD] what percentage of human dna is of reasonable neanderthal origin?", "[PAD] [PAD] what percentage of homo sapiens dna is from neanderthals?", "[PAD] [PAD] what percentage of homo sapiens dna came from neanderthals?", "[PAD] what is the percentage of homo sapiens dna of neanderthal origin?", "[PAD] [PAD] what percentage of homo sapiens dna comes from neanderthals?", "[PAD] [PAD] [PAD] [PAD] what percentage of homo sapiens dna is neanderthal?", "[PAD] what percentage of homo sapiens' dna is of neanderthal origin?", "what percentage of the dna of homo sapiens is of neanderthal origin?", "[PAD] [PAD] what percentage of homo sapiens dna is neanderthal in origin?", "[PAD] [PAD] [PAD] what percentage of homo sapiens dna has neanderthal origin?", "[PAD] [PAD] what percent of homo sapiens dna is of neanderthal origin?", "[PAD] [PAD] what percentage of homo sapiens dna is from neanderthal origin?", "[PAD] are human enhancers or promoters evolving faster?", "[PAD] are human improvers or promoters evolving faster?", "are human amplifiers or stimulants evolving faster?", "[PAD] are human amplifiers or promoters evolving faster?", "[PAD] are human promoters or promoters evolving faster?", "[PAD] do human enhancers or promoters evolve faster?", "[PAD] do human enhancers or promoters develop faster?", "are human enhancers or promoters progressing faster?", "[PAD] [PAD] [PAD] [PAD] will people improve or develop faster?", "[PAD] [PAD] [PAD] are human improvements or promotions evolving faster?", "[PAD] are human enhancers or promoters evolving rapidly?", "[PAD] [PAD] [PAD] are human strengths or incentives evolving faster?", "[PAD] are human enhancers or promoters developing faster?", "[PAD] are human enhancers or promoters emerging faster?", "[PAD] are human enhancers or enhancers evolving faster?", "[PAD] [PAD] are human enhancers or organizers growing faster?", "[PAD] [PAD] do human amplifiers evolve or promote faster?", "[PAD] do human amplifiers or promoters evolve faster?", "[PAD] [PAD] are human enhancers or developers changing rapidly?", "[PAD] [PAD] does the human supplement or promoter develop faster?", "[PAD] [PAD] are human developers or promoters evolving faster?", "[PAD] are human enhancers or promoters fast emerging?", "[PAD] do human boosters or promoters evolve faster?", "[PAD] are promoters or human promoters evolving faster?", "[PAD] are human enhancers or promoters evolving faster?", "[PAD] are human improvers or promoters evolving faster?", "are human amplifiers or stimulants evolving faster?", "[PAD] are human amplifiers or promoters evolving faster?", "[PAD] are human promoters or promoters evolving faster?", "[PAD] do human enhancers or promoters evolve faster?", "[PAD] do human enhancers or promoters develop faster?", "are human enhancers or promoters progressing faster?", "[PAD] [PAD] [PAD] [PAD] will people improve or develop faster?", "[PAD] [PAD] [PAD] are human improvements or promotions evolving faster?", "[PAD] are human enhancers or promoters evolving rapidly?", "[PAD] [PAD] [PAD] are human strengths or incentives evolving faster?", "[PAD] are human enhancers or promoters developing faster?", "[PAD] are human enhancers or promoters emerging faster?", "[PAD] are human enhancers or enhancers evolving faster?", "[PAD] [PAD] are human enhancers or organizers growing faster?", "[PAD] [PAD] do human amplifiers evolve or promote faster?", "[PAD] do human amplifiers or promoters evolve faster?", "[PAD] [PAD] are human enhancers or developers changing rapidly?", "[PAD] [PAD] does the human supplement or promoter develop faster?", "[PAD] [PAD] are human developers or promoters evolving faster?", "[PAD] are human enhancers or promoters fast emerging?", "[PAD] do human boosters or promoters evolve faster?", "[PAD] are promoters or human promoters evolving faster?", "[PAD] are human enhancers or promoters evolving faster?", "[PAD] are human improvers or promoters evolving faster?", "are human amplifiers or stimulants evolving faster?", "[PAD] are human amplifiers or promoters evolving faster?", "[PAD] are human promoters or promoters evolving faster?", "[PAD] do human enhancers or promoters evolve faster?", "[PAD] do human enhancers or promoters develop faster?", "are human enhancers or promoters progressing faster?", "[PAD] [PAD] [PAD] [PAD] will people improve or develop faster?", "[PAD] [PAD] [PAD] are human improvements or promotions evolving faster?", "[PAD] are human enhancers or promoters evolving rapidly?", "[PAD] [PAD] [PAD] are human strengths or incentives evolving faster?", "[PAD] are human enhancers or promoters developing faster?", "[PAD] are human enhancers or promoters emerging faster?", "[PAD] are human enhancers or enhancers evolving faster?", "[PAD] [PAD] are human enhancers or organizers growing faster?", "[PAD] [PAD] do human amplifiers evolve or promote faster?", "[PAD] do human amplifiers or promoters evolve faster?", "[PAD] [PAD] are human enhancers or developers changing rapidly?", "[PAD] [PAD] does the human supplement or promoter develop faster?", "[PAD] [PAD] are human developers or promoters evolving faster?", "[PAD] are human enhancers or promoters fast emerging?", "[PAD] do human boosters or promoters evolve faster?", "[PAD] are promoters or human promoters evolving faster?", "[PAD] are human enhancers or promoters evolving faster?", "[PAD] are human improvers or promoters evolving faster?", "are human amplifiers or stimulants evolving faster?", "[PAD] are human amplifiers or promoters evolving faster?", "[PAD] are human promoters or promoters evolving faster?", "[PAD] do human enhancers or promoters evolve faster?", "[PAD] do human enhancers or promoters develop faster?", "are human enhancers or promoters progressing faster?", "[PAD] [PAD] [PAD] [PAD] will people improve or develop faster?", "[PAD] [PAD] [PAD] are human improvements or promotions evolving faster?", "[PAD] are human enhancers or promoters evolving rapidly?", "[PAD] [PAD] [PAD] are human strengths or incentives evolving faster?", "[PAD] are human enhancers or promoters developing faster?", "[PAD] are human enhancers or promoters emerging faster?", "[PAD] are human enhancers or enhancers evolving faster?", "[PAD] [PAD] are human enhancers or organizers growing faster?", "[PAD] [PAD] do human amplifiers evolve or promote faster?", "[PAD] do human amplifiers or promoters evolve faster?", "[PAD] [PAD] are human enhancers or developers changing rapidly?", "[PAD] [PAD] does the human supplement or promoter develop faster?", "[PAD] [PAD] are human developers or promoters evolving faster?", "[PAD] are human enhancers or promoters fast emerging?", "[PAD] do human boosters or promoters evolve faster?", "[PAD] are promoters or human promoters evolving faster?", "[PAD] what is pnppp?", "[PAD] [PAD] [PAD] what is ipa?", "what is the pnppp?", "[PAD] [PAD] what is pnpp?", "[PAD] [PAD] [PAD] what is pppp?"], "title": ["58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "58edf567eda5a57672000011", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "5a67b2f7b750ff445500000f", "593ff22b70f9fc6f0f000023", "593ff22b70f9fc6f0f000023", "593ff22b70f9fc6f0f000023", "593ff22b70f9fc6f0f000023", "593ff22b70f9fc6f0f000023", "593ff22b70f9fc6f0f000023", "593ff22b70f9fc6f0f000023", "593ff22b70f9fc6f0f000023", "593ff22b70f9fc6f0f000023", "593ff22b70f9fc6f0f000023", "593ff22b70f9fc6f0f000023", "593ff22b70f9fc6f0f000023", "593ff22b70f9fc6f0f000023", "593ff22b70f9fc6f0f000023", "593ff22b70f9fc6f0f000023", "593ff22b70f9fc6f0f000023", "593ff22b70f9fc6f0f000023", "593ff22b70f9fc6f0f000023", "593ff22b70f9fc6f0f000023", "593ff22b70f9fc6f0f000023", "593ff22b70f9fc6f0f000023", "593ff22b70f9fc6f0f000023", "593ff22b70f9fc6f0f000023", "593ff22b70f9fc6f0f000023", "593ff22b70f9fc6f0f000023", "593ff22b70f9fc6f0f000023", "5a87ea1861bb38fb2400000d", "5a87ea1861bb38fb2400000d", "5a87ea1861bb38fb2400000d", "5a87ea1861bb38fb2400000d", "5a87ea1861bb38fb2400000d", "5a87ea1861bb38fb2400000d", "5a87ea1861bb38fb2400000d", "5a87ea1861bb38fb2400000d", "5a87ea1861bb38fb2400000d", "5a87ea1861bb38fb2400000d", "5a87ea1861bb38fb2400000d", "5a87ea1861bb38fb2400000d", "5a87ea1861bb38fb2400000d", "5a87ea1861bb38fb2400000d", "5a87ea1861bb38fb2400000d", "5a87ea1861bb38fb2400000d", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7617b183b0d9ea66000022", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7237672dc08e987e000008", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7346662dc08e987e00001a", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a7234352dc08e987e000007", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a6e24a5b750ff445500003c", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a895f51fcd1d6a10c000004", "5a7d4e9afaa1ab7d2e000013", "5a7d4e9afaa1ab7d2e000013", "5a7d4e9afaa1ab7d2e000013", "5a7d4e9afaa1ab7d2e000013", "5a7d4e9afaa1ab7d2e000013", "5a7d4e9afaa1ab7d2e000013", "5a7d4e9afaa1ab7d2e000013", "5a7d4e9afaa1ab7d2e000013", "5a7d4e9afaa1ab7d2e000013", "5a7d4e9afaa1ab7d2e000013", "5a7d4e9afaa1ab7d2e000013", "5a7d4e9afaa1ab7d2e000013", "5a7d4e9afaa1ab7d2e000013", "5a7d4e9afaa1ab7d2e000013", "5a7d4e9afaa1ab7d2e000013", "5a7d4e9afaa1ab7d2e000013", "5a7d4e9afaa1ab7d2e000013", "5a7d4e9afaa1ab7d2e000013", "5a7d4e9afaa1ab7d2e000013", "5a7d4e9afaa1ab7d2e000013", "5a7d4e9afaa1ab7d2e000013", "5a7d4e9afaa1ab7d2e000013", "5a7d4e9afaa1ab7d2e000013", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a86f074faa1ab7d2e00003a", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a742d620384be9551000002", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a6f960fb750ff445500005c", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a72329e2dc08e987e000006", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a871a6861bb38fb24000009", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a67ab79b750ff445500000b", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a68f005b750ff4455000016", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a6f853ab750ff4455000055", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a72302b2dc08e987e000005", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a761ac3aacfb9cd4c000002", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a679e8cb750ff4455000006", "5a9d8a651d1251d03b00001f", "5a9d8a651d1251d03b00001f", "5a9d8a651d1251d03b00001f", "5a9d8a651d1251d03b00001f", "5a9d8a651d1251d03b00001f", "5aa6c800d6d6b54f79000012", "5aa6c800d6d6b54f79000012", "5aa6c800d6d6b54f79000012", "5aa6c800d6d6b54f79000012", "5aa6c800d6d6b54f79000012", "5aa6c800d6d6b54f79000012", "5aa6c800d6d6b54f79000012", "5aa6c800d6d6b54f79000012", "5aa6c800d6d6b54f79000012", "5aa6c800d6d6b54f79000012", "5aa6c800d6d6b54f79000012", "5aa6c800d6d6b54f79000012", "5aa6c800d6d6b54f79000012", "5aa6c800d6d6b54f79000012", "5aa6c800d6d6b54f79000012", "5aa6c800d6d6b54f79000012", "5aa6c800d6d6b54f79000012", "5aa6c800d6d6b54f79000012", "5aa6c800d6d6b54f79000012", "5aa6c800d6d6b54f79000012", "5aa6c800d6d6b54f79000012", "5aa6c800d6d6b54f79000012", "5aa6c800d6d6b54f79000012", "5aa6c800d6d6b54f79000012", "5aa6c800d6d6b54f79000012", "5aa6c800d6d6b54f79000012", "5a9d31711d1251d03b00001c", "5a9d31711d1251d03b00001c", "5a9d31711d1251d03b00001c", "5a9d31711d1251d03b00001c", "5a9d31711d1251d03b00001c", "5a9d31711d1251d03b00001c", "5a9d31711d1251d03b00001c", "5a9d31711d1251d03b00001c", "5a9d31711d1251d03b00001c", "5a9d31711d1251d03b00001c", "5a9d31711d1251d03b00001c", "5a9d31711d1251d03b00001c", "5a9d31711d1251d03b00001c", "5a9d31711d1251d03b00001c", "5a9d31711d1251d03b00001c", "5a9d31711d1251d03b00001c", "5a9d31711d1251d03b00001c", "5a9d31711d1251d03b00001c", "5a9d31711d1251d03b00001c", "5a9700adfcd1d6a10c00002c", "5a9700adfcd1d6a10c00002c", "5a9700adfcd1d6a10c00002c", "5a9700adfcd1d6a10c00002c", "5a9700adfcd1d6a10c00002c", "5a9700adfcd1d6a10c00002c", "5a9700adfcd1d6a10c00002c", "5a9700adfcd1d6a10c00002c", "5a9700adfcd1d6a10c00002c", "5a9700adfcd1d6a10c00002c", "5a9700adfcd1d6a10c00002c", "5a9700adfcd1d6a10c00002c", "5a9700adfcd1d6a10c00002c", "5a9700adfcd1d6a10c00002c", "5a9700adfcd1d6a10c00002c", "5a9700adfcd1d6a10c00002c", "5a9700adfcd1d6a10c00002c", "5a9700adfcd1d6a10c00002c", "5a9700adfcd1d6a10c00002c", "5a9700adfcd1d6a10c00002c", "5a9700adfcd1d6a10c00002c", "5a9700adfcd1d6a10c00002c", "5a9700adfcd1d6a10c00002c", "5a9700adfcd1d6a10c00002c", "5a9700adfcd1d6a10c00002c", "5a9700adfcd1d6a10c00002c", "5a9700adfcd1d6a10c00002c", "5a9700adfcd1d6a10c00002c", "5a9700adfcd1d6a10c00002c", "5a9700adfcd1d6a10c00002c", "5a9700adfcd1d6a10c00002c", "5a9700adfcd1d6a10c00002c", "5a9700adfcd1d6a10c00002c", "5a9700adfcd1d6a10c00002c", "5a9700adfcd1d6a10c00002c", "5a9700adfcd1d6a10c00002c", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "5a7428090384be9551000001", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "589a247078275d0c4a000035", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5ab147edfcf4565872000013", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abcf010fcf4565872000023", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5abd13e1fcf4565872000029", "5a9e202bde7cb99d40000002", "5a9e202bde7cb99d40000002", "5a9e202bde7cb99d40000002", "5a9e202bde7cb99d40000002", "5a9e202bde7cb99d40000002", "5a9e202bde7cb99d40000002", "5a9e202bde7cb99d40000002", "5a9e202bde7cb99d40000002", "5a9e202bde7cb99d40000002", "5a9e202bde7cb99d40000002", "5a9e202bde7cb99d40000002", "5a9e202bde7cb99d40000002", "5a9e202bde7cb99d40000002", "5a9e202bde7cb99d40000002", "5a9e202bde7cb99d40000002", "5a9e202bde7cb99d40000002", "5a9e202bde7cb99d40000002", "5a9e202bde7cb99d40000002", "5a9e202bde7cb99d40000002", "5a9e202bde7cb99d40000002", "5a9e202bde7cb99d40000002", "5a9e202bde7cb99d40000002", "5a9e202bde7cb99d40000002", "5a9e202bde7cb99d40000002", "5a9e202bde7cb99d40000002", "5a9e202bde7cb99d40000002", "5a9e202bde7cb99d40000002", "5a9e202bde7cb99d40000002", "5a9e202bde7cb99d40000002", "5a9e202bde7cb99d40000002", "5a9e202bde7cb99d40000002", "5a9e202bde7cb99d40000002", "5ac0a82d19833b0d7b000003", "5ac0a82d19833b0d7b000003", "5ac0a82d19833b0d7b000003", "5ac0a82d19833b0d7b000003", "5ac0a82d19833b0d7b000003", "5ac0a82d19833b0d7b000003", "5ac0a82d19833b0d7b000003", "5ac0a82d19833b0d7b000003", "5ac0a82d19833b0d7b000003", "5ac0a82d19833b0d7b000003", "5ac0a82d19833b0d7b000003", "5ac0a82d19833b0d7b000003", "5ac0a82d19833b0d7b000003", "5ac0a82d19833b0d7b000003", "5ac0a82d19833b0d7b000003", "5ac0a82d19833b0d7b000003", "5ac0a82d19833b0d7b000003", "5ac0a82d19833b0d7b000003", "5ac0a82d19833b0d7b000003", "5ac0a82d19833b0d7b000003", "5ac0a82d19833b0d7b000003", "5ac0a82d19833b0d7b000003", "5ac0a82d19833b0d7b000003", "5ac0a82d19833b0d7b000003", "5ac0a82d19833b0d7b000003", "5ac0a82d19833b0d7b000003", "5ac0a82d19833b0d7b000003", "5ac0a82d19833b0d7b000003", "5ac0a82d19833b0d7b000003", "5ac0a82d19833b0d7b000003", "5ac0a82d19833b0d7b000003", "5ac0a82d19833b0d7b000003", "5ac0a82d19833b0d7b000003", "5ac0a82d19833b0d7b000003", "5ac0a82d19833b0d7b000003", "5ac0a82d19833b0d7b000003", "5ac0a82d19833b0d7b000003", "5ac0a82d19833b0d7b000003", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace238e0340b9f05800000d", "5ace1a590340b9f05800000b", "5ace1a590340b9f05800000b", "5ace1a590340b9f05800000b", "5ace1a590340b9f05800000b", "5ace1a590340b9f05800000b", "5ace1a590340b9f05800000b", "5ace1a590340b9f05800000b", "5ace1a590340b9f05800000b", "5ace1a590340b9f05800000b", "5ace1a590340b9f05800000b", "5ace1a590340b9f05800000b", "5ace1a590340b9f05800000b", "5ace1a590340b9f05800000b", "5ace1a590340b9f05800000b", "5ace1a590340b9f05800000b", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5ac3699f0340b9f058000001", "5a9da59c4e03427e73000005", "5a9da59c4e03427e73000005", "5a9da59c4e03427e73000005", "5a9da59c4e03427e73000005", "5a9da59c4e03427e73000005"], "new_id": ["0_0", "0_1", "0_2", "0_3", "0_4", "0_5", "0_6", "0_7", "0_8", "0_9", "0_10", "0_11", "0_12", "0_13", "0_14", "0_15", "0_16", "0_17", "0_18", "0_19", "0_20", "0_21", "0_22", "0_23", "0_24", "0_25", "0_26", "0_27", "0_28", "0_29", "0_30", "0_31", "0_32", "0_33", "0_34", "0_35", "0_36", "0_37", "0_38", "0_39", "0_40", "0_41", "0_42", "0_43", "0_44", "0_45", "0_46", "0_47", "0_48", "1_0", "1_1", "1_2", "1_3", "1_4", "1_5", "1_6", "1_7", "1_8", "1_9", "1_10", "1_11", "1_12", "1_13", "1_14", "1_15", "1_16", "1_17", "1_18", "1_19", "1_20", "1_21", "1_22", "1_23", "1_24", "1_25", "1_26", "1_27", "1_28", "1_29", "1_30", "1_31", "1_32", "1_33", "1_34", "1_35", "1_36", "1_37", "1_38", "1_39", "1_40", "1_41", "1_42", "1_43", "1_44", "1_45", "1_46", "1_47", "1_48", "2_0", "2_1", "2_2", "2_3", "2_4", "2_5", "2_6", "2_7", "2_8", "2_9", "2_10", "2_11", "2_12", "2_13", "2_14", "2_15", "2_16", "2_17", "2_18", "2_19", "2_20", "2_21", "2_22", "2_23", "2_24", "2_25", "2_26", "2_27", "2_28", "2_29", "2_30", "2_31", "2_32", "2_33", "2_34", "2_35", "2_36", "2_37", "2_38", "2_39", "2_40", "2_41", "2_42", "2_43", "2_44", "2_45", "2_46", "2_47", "2_48", "3_0", "3_1", "3_2", "3_3", "3_4", "3_5", "3_6", "3_7", "3_8", "3_9", "3_10", "3_11", "3_12", "3_13", "3_14", "3_15", "3_16", "3_17", "3_18", "3_19", "3_20", "3_21", "3_22", "3_23", "3_24", "3_25", "3_26", "3_27", "3_28", "3_29", "3_30", "3_31", "3_32", "3_33", "3_34", "3_35", "3_36", "3_37", "3_38", "3_39", "3_40", "3_41", "3_42", "3_43", "3_44", "3_45", "3_46", "3_47", "3_48", "4_0", "4_1", "4_2", "4_3", "4_4", "4_5", "4_6", "4_7", "4_8", "4_9", "4_10", "4_11", "4_12", "4_13", "4_14", "4_15", "4_16", "4_17", "4_18", "4_19", "4_20", "4_21", "4_22", "4_23", "4_24", "4_25", "4_26", "4_27", "4_28", "5_0", "5_1", "5_2", "5_3", "5_4", "5_5", "5_6", "5_7", "5_8", "5_9", "5_10", "5_11", "5_12", "5_13", "5_14", "5_15", "5_16", "5_17", "5_18", "5_19", "5_20", "5_21", "5_22", "5_23", "5_24", "5_25", "5_26", "5_27", "5_28", "6_0", "6_1", "6_2", "6_3", "6_4", "6_5", "6_6", "6_7", "6_8", "6_9", "6_10", "6_11", "6_12", "6_13", "6_14", "6_15", "6_16", "6_17", "6_18", "6_19", "6_20", "6_21", "6_22", "6_23", "6_24", "6_25", "6_26", "6_27", "6_28", "7_0", "7_1", "7_2", "7_3", "7_4", "7_5", "7_6", "7_7", "7_8", "7_9", "7_10", "7_11", "7_12", "7_13", "7_14", "7_15", "7_16", "7_17", "7_18", "7_19", "7_20", "7_21", "7_22", "7_23", "7_24", "7_25", "7_26", "7_27", "7_28", "8_0", "8_1", "8_2", "8_3", "8_4", "8_5", "8_6", "8_7", "8_8", "8_9", "8_10", "8_11", "8_12", "8_13", "8_14", "8_15", "8_16", "8_17", "8_18", "8_19", "8_20", "8_21", "8_22", "8_23", "8_24", "8_25", "8_26", "8_27", "8_28", "9_0", "9_1", "9_2", "9_3", "9_4", "9_5", "9_6", "9_7", "9_8", "9_9", "9_10", "9_11", "9_12", "9_13", "9_14", "9_15", "9_16", "9_17", "9_18", "9_19", "9_20", "9_21", "9_22", "9_23", "9_24", "9_25", "9_26", "9_27", "9_28", "10_0", "10_1", "10_2", "10_3", "10_4", "10_5", "10_6", "10_7", "10_8", "10_9", "10_10", "10_11", "10_12", "10_13", "10_14", "10_15", "10_16", "10_17", "10_18", "10_19", "10_20", "10_21", "10_22", "10_23", "10_24", "10_25", "10_26", "10_27", "10_28", "11_0", "11_1", "11_2", "11_3", "11_4", "11_5", "11_6", "11_7", "11_8", "11_9", "11_10", "11_11", "11_12", "11_13", "11_14", "11_15", "11_16", "11_17", "11_18", "11_19", "11_20", "11_21", "11_22", "11_23", "11_24", "11_25", "11_26", "11_27", "11_28", "12_0", "12_1", "12_2", "12_3", "12_4", "12_5", "12_6", "12_7", "12_8", "12_9", "12_10", "12_11", "12_12", "12_13", "12_14", "12_15", "12_16", "12_17", "12_18", "12_19", "12_20", "12_21", "12_22", "12_23", "12_24", "12_25", "12_26", "12_27", "12_28", "13_0", "13_1", "13_2", "13_3", "13_4", "13_5", "13_6", "13_7", "13_8", "13_9", "13_10", "13_11", "13_12", "13_13", "13_14", "13_15", "13_16", "13_17", "13_18", "13_19", "13_20", "13_21", "13_22", "13_23", "13_24", "13_25", "14_0", "14_1", "14_2", "14_3", "14_4", "14_5", "14_6", "14_7", "14_8", "14_9", "14_10", "14_11", "14_12", "14_13", "14_14", "14_15", "15_0", "15_1", "15_2", "15_3", "15_4", "15_5", "15_6", "15_7", "15_8", "15_9", "15_10", "15_11", "15_12", "15_13", "15_14", "15_15", "15_16", "15_17", "15_18", "15_19", "15_20", "15_21", "15_22", "16_0", "16_1", "16_2", "16_3", "16_4", "16_5", "16_6", "16_7", "16_8", "16_9", "16_10", "16_11", "16_12", "16_13", "16_14", "16_15", "16_16", "16_17", "16_18", "16_19", "16_20", "16_21", "16_22", "17_0", "17_1", "17_2", "17_3", "17_4", "17_5", "17_6", "17_7", "17_8", "17_9", "17_10", "17_11", "17_12", "17_13", "17_14", "17_15", "17_16", "17_17", "17_18", "17_19", "17_20", "17_21", "17_22", "18_0", "18_1", "18_2", "18_3", "18_4", "18_5", "18_6", "18_7", "18_8", "18_9", "18_10", "18_11", "18_12", "18_13", "18_14", "18_15", "18_16", "18_17", "18_18", "18_19", "18_20", "18_21", "18_22", "19_0", "19_1", "19_2", "19_3", "19_4", "19_5", "19_6", "19_7", "19_8", "19_9", "19_10", "19_11", "19_12", "19_13", "19_14", "19_15", "19_16", "19_17", "19_18", "19_19", "19_20", "19_21", "19_22", "20_0", "20_1", "20_2", "20_3", "20_4", "20_5", "20_6", "20_7", "20_8", "20_9", "20_10", "20_11", "20_12", "20_13", "20_14", "20_15", "20_16", "20_17", "20_18", "20_19", "20_20", "20_21", "20_22", "21_0", "21_1", "21_2", "21_3", "21_4", "21_5", "21_6", "21_7", "21_8", "21_9", "21_10", "21_11", "21_12", "21_13", "21_14", "21_15", "21_16", "21_17", "21_18", "21_19", "21_20", "21_21", "21_22", "22_0", "22_1", "22_2", "22_3", "22_4", "22_5", "22_6", "22_7", "22_8", "22_9", "22_10", "22_11", "22_12", "22_13", "22_14", "22_15", "22_16", "22_17", "22_18", "22_19", "22_20", "22_21", "22_22", "23_0", "23_1", "23_2", "23_3", "23_4", "23_5", "23_6", "23_7", "23_8", "23_9", "23_10", "23_11", "23_12", "23_13", "23_14", "23_15", "23_16", "23_17", "23_18", "23_19", "23_20", "23_21", "23_22", "23_23", "23_24", "23_25", "23_26", "23_27", "23_28", "23_29", "23_30", "23_31", "24_0", "24_1", "24_2", "24_3", "24_4", "24_5", "24_6", "24_7", "24_8", "24_9", "24_10", "24_11", "24_12", "24_13", "24_14", "24_15", "24_16", "24_17", "24_18", "24_19", "24_20", "24_21", "24_22", "24_23", "24_24", "24_25", "24_26", "24_27", "24_28", "24_29", "24_30", "24_31", "25_0", "25_1", "25_2", "25_3", "25_4", "25_5", "25_6", "25_7", "25_8", "25_9", "25_10", "25_11", "25_12", "25_13", "25_14", "25_15", "25_16", "25_17", "25_18", "25_19", "25_20", "25_21", "25_22", "25_23", "25_24", "25_25", "25_26", "25_27", "25_28", "25_29", "25_30", "25_31", "26_0", "26_1", "26_2", "26_3", "26_4", "26_5", "26_6", "26_7", "26_8", "26_9", "26_10", "26_11", "26_12", "26_13", "26_14", "26_15", "26_16", "26_17", "26_18", "26_19", "26_20", "26_21", "26_22", "26_23", "26_24", "26_25", "26_26", "26_27", "26_28", "26_29", "26_30", "26_31", "27_0", "27_1", "27_2", "27_3", "27_4", "27_5", "27_6", "27_7", "27_8", "27_9", "27_10", "27_11", "27_12", "27_13", "27_14", "27_15", "27_16", "27_17", "27_18", "27_19", "27_20", "27_21", "27_22", "27_23", "27_24", "27_25", "27_26", "27_27", "27_28", "27_29", "27_30", "27_31", "28_0", "28_1", "28_2", "28_3", "28_4", "28_5", "28_6", "28_7", "28_8", "28_9", "28_10", "28_11", "28_12", "28_13", "28_14", "28_15", "28_16", "28_17", "28_18", "28_19", "28_20", "28_21", "28_22", "28_23", "28_24", "28_25", "28_26", "28_27", "28_28", "28_29", "28_30", "28_31", "29_0", "29_1", "29_2", "29_3", "29_4", "29_5", "29_6", "29_7", "29_8", "29_9", "29_10", "29_11", "29_12", "29_13", "29_14", "29_15", "29_16", "29_17", "29_18", "29_19", "29_20", "29_21", "29_22", "29_23", "29_24", "29_25", "29_26", "29_27", "29_28", "29_29", "29_30", "29_31", "30_0", "30_1", "30_2", "30_3", "30_4", "30_5", "30_6", "30_7", "30_8", "30_9", "30_10", "30_11", "30_12", "30_13", "30_14", "30_15", "30_16", "30_17", "30_18", "30_19", "30_20", "30_21", "30_22", "30_23", "30_24", "30_25", "30_26", "30_27", "30_28", "30_29", "30_30", "30_31", "31_0", "31_1", "31_2", "31_3", "31_4", "31_5", "31_6", "31_7", "31_8", "31_9", "31_10", "31_11", "31_12", "31_13", "31_14", "31_15", "31_16", "31_17", "31_18", "31_19", "31_20", "31_21", "31_22", "31_23", "31_24", "31_25", "31_26", "31_27", "31_28", "31_29", "31_30", "31_31", "32_0", "32_1", "32_2", "32_3", "32_4", "32_5", "32_6", "32_7", "32_8", "32_9", "32_10", "32_11", "32_12", "32_13", "32_14", "32_15", "32_16", "32_17", "32_18", "32_19", "32_20", "32_21", "32_22", "32_23", "32_24", "32_25", "32_26", "32_27", "32_28", "32_29", "32_30", "32_31", "33_0", "33_1", "33_2", "33_3", "33_4", "33_5", "33_6", "33_7", "33_8", "33_9", "33_10", "33_11", "33_12", "33_13", "33_14", "33_15", "33_16", "33_17", "33_18", "33_19", "33_20", "33_21", "33_22", "33_23", "33_24", "33_25", "33_26", "33_27", "33_28", "33_29", "33_30", "33_31", "34_0", "34_1", "34_2", "34_3", "34_4", "34_5", "34_6", "34_7", "34_8", "34_9", "34_10", "34_11", "34_12", "34_13", "34_14", "34_15", "34_16", "34_17", "34_18", "34_19", "34_20", "34_21", "34_22", "34_23", "34_24", "34_25", "34_26", "34_27", "34_28", "34_29", "34_30", "34_31", "35_0", "35_1", "35_2", "35_3", "35_4", "35_5", "35_6", "35_7", "35_8", "35_9", "35_10", "35_11", "35_12", "35_13", "35_14", "35_15", "35_16", "35_17", "35_18", "35_19", "35_20", "35_21", "35_22", "35_23", "35_24", "35_25", "35_26", "35_27", "35_28", "35_29", "35_30", "35_31", "36_0", "36_1", "36_2", "36_3", "36_4", "36_5", "36_6", "36_7", "36_8", "36_9", "36_10", "36_11", "36_12", "36_13", "36_14", "36_15", "36_16", "36_17", "36_18", "36_19", "36_20", "36_21", "36_22", "36_23", "36_24", "36_25", "36_26", "36_27", "36_28", "36_29", "36_30", "36_31", "37_0", "37_1", "37_2", "37_3", "37_4", "37_5", "37_6", "37_7", "37_8", "37_9", "37_10", "37_11", "37_12", "37_13", "37_14", "37_15", "37_16", "37_17", "37_18", "37_19", "37_20", "37_21", "37_22", "37_23", "37_24", "37_25", "37_26", "37_27", "37_28", "37_29", "37_30", "37_31", "38_0", "38_1", "38_2", "38_3", "38_4", "38_5", "38_6", "38_7", "38_8", "38_9", "38_10", "38_11", "38_12", "38_13", "38_14", "38_15", "38_16", "38_17", "38_18", "38_19", "38_20", "38_21", "38_22", "38_23", "38_24", "38_25", "38_26", "38_27", "38_28", "38_29", "38_30", "38_31", "39_0", "39_1", "39_2", "39_3", "39_4", "39_5", "39_6", "39_7", "39_8", "39_9", "39_10", "39_11", "39_12", "39_13", "39_14", "39_15", "39_16", "39_17", "39_18", "39_19", "39_20", "39_21", "39_22", "39_23", "39_24", "39_25", "39_26", "39_27", "39_28", "39_29", "39_30", "39_31", "40_0", "40_1", "40_2", "40_3", "40_4", "40_5", "40_6", "40_7", "40_8", "40_9", "40_10", "40_11", "40_12", "40_13", "40_14", "40_15", "40_16", "40_17", "40_18", "40_19", "40_20", "40_21", "40_22", "40_23", "40_24", "40_25", "40_26", "40_27", "40_28", "40_29", "40_30", "40_31", "41_0", "41_1", "41_2", "41_3", "41_4", "41_5", "41_6", "41_7", "41_8", "41_9", "41_10", "41_11", "41_12", "41_13", "41_14", "41_15", "41_16", "41_17", "41_18", "41_19", "41_20", "41_21", "41_22", "41_23", "41_24", "41_25", "41_26", "41_27", "41_28", "41_29", "41_30", "41_31", "42_0", "42_1", "42_2", "42_3", "42_4", "42_5", "42_6", "42_7", "42_8", "42_9", "42_10", "42_11", "42_12", "42_13", "42_14", "42_15", "42_16", "42_17", "42_18", "42_19", "42_20", "42_21", "42_22", "42_23", "42_24", "42_25", "42_26", "42_27", "42_28", "42_29", "42_30", "42_31", "43_0", "43_1", "43_2", "43_3", "43_4", "43_5", "43_6", "43_7", "43_8", "43_9", "43_10", "43_11", "43_12", "43_13", "43_14", "43_15", "43_16", "43_17", "43_18", "43_19", "43_20", "43_21", "43_22", "43_23", "43_24", "43_25", "43_26", "43_27", "43_28", "43_29", "43_30", "43_31", "44_0", "44_1", "44_2", "44_3", "44_4", "44_5", "44_6", "44_7", "44_8", "44_9", "44_10", "44_11", "44_12", "44_13", "44_14", "44_15", "44_16", "44_17", "44_18", "44_19", "44_20", "44_21", "44_22", "44_23", "44_24", "44_25", "44_26", "44_27", "44_28", "44_29", "44_30", "44_31", "45_0", "45_1", "45_2", "45_3", "45_4", "45_5", "45_6", "45_7", "45_8", "45_9", "45_10", "45_11", "45_12", "45_13", "45_14", "45_15", "45_16", "45_17", "45_18", "45_19", "45_20", "45_21", "45_22", "45_23", "45_24", "45_25", "45_26", "45_27", "45_28", "45_29", "45_30", "45_31", "46_0", "46_1", "46_2", "46_3", "46_4", "46_5", "46_6", "46_7", "46_8", "46_9", "46_10", "46_11", "46_12", "46_13", "46_14", "46_15", "46_16", "46_17", "46_18", "46_19", "46_20", "46_21", "46_22", "46_23", "46_24", "46_25", "46_26", "46_27", "46_28", "46_29", "46_30", "46_31", "47_0", "47_1", "47_2", "47_3", "47_4", "47_5", "47_6", "47_7", "47_8", "47_9", "47_10", "47_11", "47_12", "47_13", "47_14", "47_15", "47_16", "47_17", "47_18", "47_19", "47_20", "47_21", "47_22", "47_23", "47_24", "47_25", "47_26", "47_27", "47_28", "47_29", "47_30", "47_31", "48_0", "48_1", "48_2", "48_3", "48_4", "48_5", "48_6", "48_7", "48_8", "48_9", "48_10", "48_11", "48_12", "48_13", "48_14", "48_15", "48_16", "48_17", "48_18", "48_19", "48_20", "48_21", "48_22", "48_23", "48_24", "48_25", "48_26", "48_27", "48_28", "48_29", "48_30", "48_31", "49_0", "49_1", "49_2", "49_3", "49_4", "49_5", "49_6", "49_7", "49_8", "49_9", "49_10", "49_11", "49_12", "49_13", "49_14", "49_15", "49_16", "49_17", "49_18", "49_19", "49_20", "49_21", "49_22", "49_23", "49_24", "49_25", "49_26", "49_27", "49_28", "49_29", "49_30", "49_31", "50_0", "50_1", "50_2", "50_3", "50_4", "50_5", "50_6", "50_7", "50_8", "50_9", "50_10", "50_11", "50_12", "50_13", "50_14", "50_15", "50_16", "50_17", "50_18", "50_19", "50_20", "50_21", "50_22", "50_23", "50_24", "50_25", "50_26", "50_27", "50_28", "50_29", "50_30", "50_31", "51_0", "51_1", "51_2", "51_3", "51_4", "51_5", "51_6", "51_7", "51_8", "51_9", "51_10", "51_11", "51_12", "51_13", "51_14", "51_15", "51_16", "51_17", "51_18", "51_19", "51_20", "51_21", "51_22", "51_23", "51_24", "51_25", "51_26", "51_27", "51_28", "51_29", "51_30", "51_31", "52_0", "52_1", "52_2", "52_3", "52_4", "52_5", "52_6", "52_7", "52_8", "52_9", "52_10", "52_11", "52_12", "52_13", "52_14", "52_15", "52_16", "52_17", "52_18", "52_19", "52_20", "52_21", "52_22", "52_23", "52_24", "52_25", "52_26", "52_27", "52_28", "52_29", "52_30", "52_31", "53_0", "53_1", "53_2", "53_3", "53_4", "53_5", "53_6", "53_7", "53_8", "53_9", "53_10", "53_11", "53_12", "53_13", "53_14", "53_15", "53_16", "53_17", "53_18", "53_19", "53_20", "53_21", "53_22", "53_23", "53_24", "53_25", "53_26", "53_27", "53_28", "53_29", "53_30", "53_31", "54_0", "54_1", "54_2", "54_3", "54_4", "54_5", "54_6", "54_7", "54_8", "54_9", "54_10", "54_11", "54_12", "54_13", "54_14", "54_15", "54_16", "54_17", "54_18", "54_19", "54_20", "54_21", "54_22", "54_23", "54_24", "54_25", "54_26", "54_27", "54_28", "54_29", "54_30", "54_31", "55_0", "55_1", "55_2", "55_3", "55_4", "55_5", "55_6", "55_7", "55_8", "55_9", "55_10", "55_11", "55_12", "55_13", "55_14", "55_15", "55_16", "55_17", "55_18", "55_19", "55_20", "55_21", "55_22", "55_23", "55_24", "55_25", "55_26", "55_27", "55_28", "55_29", "55_30", "55_31", "56_0", "56_1", "56_2", "56_3", "56_4", "56_5", "56_6", "56_7", "56_8", "56_9", "56_10", "56_11", "56_12", "56_13", "56_14", "56_15", "56_16", "56_17", "56_18", "56_19", "56_20", "56_21", "56_22", "56_23", "56_24", "56_25", "56_26", "56_27", "56_28", "56_29", "56_30", "56_31", "57_0", "57_1", "57_2", "57_3", "57_4", "57_5", "57_6", "57_7", "57_8", "57_9", "57_10", "57_11", "57_12", "57_13", "57_14", "57_15", "57_16", "57_17", "57_18", "57_19", "57_20", "57_21", "57_22", "57_23", "57_24", "57_25", "57_26", "57_27", "57_28", "57_29", "57_30", "57_31", "58_0", "58_1", "58_2", "58_3", "58_4", "58_5", "58_6", "58_7", "58_8", "58_9", "58_10", "58_11", "58_12", "58_13", "58_14", "58_15", "58_16", "58_17", "58_18", "58_19", "58_20", "58_21", "58_22", "58_23", "58_24", "58_25", "58_26", "58_27", "58_28", "58_29", "58_30", "58_31", "59_0", "59_1", "59_2", "59_3", "59_4", "59_5", "59_6", "59_7", "59_8", "59_9", "59_10", "59_11", "59_12", "59_13", "59_14", "59_15", "60_0", "60_1", "60_2", "60_3", "60_4", "60_5", "60_6", "60_7", "60_8", "60_9", "60_10", "60_11", "60_12", "60_13", "60_14", "60_15", "61_0", "61_1", "61_2", "61_3", "61_4", "61_5", "61_6", "61_7", "61_8", "61_9", "61_10", "61_11", "61_12", "61_13", "61_14", "61_15", "62_0", "62_1", "62_2", "62_3", "62_4", "62_5", "62_6", "62_7", "62_8", "62_9", "62_10", "62_11", "62_12", "62_13", "62_14", "62_15", "63_0", "63_1", "63_2", "63_3", "63_4", "63_5", "63_6", "63_7", "63_8", "63_9", "63_10", "63_11", "63_12", "63_13", "63_14", "63_15", "64_0", "64_1", "64_2", "64_3", "64_4", "64_5", "64_6", "64_7", "65_0", "65_1", "65_2", "65_3", "65_4", "65_5", "65_6", "65_7", "66_0", "66_1", "66_2", "66_3", "66_4", "66_5", "66_6", "66_7", "67_0", "67_1", "67_2", "67_3", "67_4", "67_5", "67_6", "67_7", "68_0", "68_1", "68_2", "68_3", "68_4", "68_5", "68_6", "68_7", "69_0", "69_1", "69_2", "69_3", "69_4", "69_5", "69_6", "69_7", "70_0", "70_1", "70_2", "70_3", "70_4", "70_5", "70_6", "70_7", "71_0", "71_1", "71_2", "71_3", "71_4", "71_5", "71_6", "71_7", "72_0", "72_1", "72_2", "72_3", "72_4", "72_5", "72_6", "72_7", "73_0", "73_1", "73_2", "73_3", "73_4", "73_5", "73_6", "73_7", "74_0", "74_1", "74_2", "74_3", "74_4", "74_5", "74_6", "74_7", "74_8", "74_9", "74_10", "74_11", "74_12", "74_13", "74_14", "74_15", "74_16", "74_17", "74_18", "74_19", "74_20", "74_21", "74_22", "74_23", "74_24", "74_25", "74_26", "74_27", "74_28", "74_29", "74_30", "74_31", "74_32", "74_33", "74_34", "74_35", "74_36", "74_37", "74_38", "74_39", "74_40", "74_41", "74_42", "74_43", "75_0", "75_1", "75_2", "75_3", "75_4", "75_5", "75_6", "75_7", "75_8", "75_9", "75_10", "75_11", "75_12", "75_13", "75_14", "75_15", "75_16", "75_17", "75_18", "75_19", "75_20", "75_21", "75_22", "75_23", "75_24", "75_25", "75_26", "75_27", "75_28", "75_29", "75_30", "75_31", "75_32", "75_33", "75_34", "75_35", "75_36", "75_37", "75_38", "75_39", "75_40", "75_41", "75_42", "75_43", "76_0", "76_1", "76_2", "76_3", "76_4", "76_5", "76_6", "76_7", "76_8", "76_9", "76_10", "76_11", "76_12", "76_13", "76_14", "76_15", "76_16", "76_17", "76_18", "76_19", "76_20", "76_21", "76_22", "76_23", "76_24", "76_25", "76_26", "77_0", "77_1", "77_2", "77_3", "77_4", "77_5", "77_6", "77_7", "77_8", "77_9", "77_10", "77_11", "77_12", "77_13", "77_14", "77_15", "77_16", "77_17", "77_18", "77_19", "77_20", "77_21", "77_22", "77_23", "77_24", "77_25", "77_26", "78_0", "78_1", "78_2", "78_3", "78_4", "78_5", "78_6", "78_7", "78_8", "78_9", "78_10", "78_11", "78_12", "78_13", "78_14", "78_15", "78_16", "78_17", "78_18", "78_19", "78_20", "78_21", "78_22", "78_23", "78_24", "78_25", "78_26", "79_0", "79_1", "79_2", "79_3", "79_4", "79_5", "79_6", "79_7", "79_8", "79_9", "79_10", "79_11", "79_12", "79_13", "79_14", "79_15", "79_16", "79_17", "79_18", "79_19", "79_20", "79_21", "79_22", "79_23", "79_24", "79_25", "79_26", "80_0", "80_1", "80_2", "80_3", "80_4", "80_5", "80_6", "80_7", "80_8", "80_9", "80_10", "80_11", "80_12", "80_13", "80_14", "80_15", "80_16", "80_17", "80_18", "80_19", "80_20", "80_21", "80_22", "80_23", "80_24", "80_25", "80_26", "81_0", "81_1", "81_2", "81_3", "81_4", "81_5", "81_6", "81_7", "81_8", "81_9", "81_10", "81_11", "81_12", "81_13", "81_14", "81_15", "81_16", "81_17", "81_18", "81_19", "81_20", "81_21", "81_22", "81_23", "81_24", "81_25", "81_26", "82_0", "82_1", "82_2", "82_3", "82_4", "82_5", "82_6", "82_7", "82_8", "82_9", "82_10", "82_11", "82_12", "82_13", "82_14", "82_15", "82_16", "82_17", "82_18", "82_19", "82_20", "82_21", "82_22", "83_0", "83_1", "83_2", "83_3", "83_4", "83_5", "83_6", "83_7", "83_8", "83_9", "83_10", "83_11", "83_12", "83_13", "83_14", "83_15", "83_16", "83_17", "83_18", "83_19", "83_20", "83_21", "83_22", "83_23", "83_24", "83_25", "83_26", "83_27", "83_28", "83_29", "83_30", "83_31", "83_32", "83_33", "83_34", "83_35", "83_36", "83_37", "83_38", "83_39", "83_40", "83_41", "83_42", "83_43", "83_44", "83_45", "83_46", "84_0", "84_1", "84_2", "84_3", "84_4", "84_5", "84_6", "84_7", "84_8", "84_9", "84_10", "84_11", "84_12", "84_13", "84_14", "84_15", "84_16", "84_17", "84_18", "84_19", "84_20", "84_21", "84_22", "84_23", "84_24", "84_25", "84_26", "84_27", "84_28", "84_29", "84_30", "84_31", "84_32", "84_33", "84_34", "84_35", "84_36", "84_37", "84_38", "84_39", "84_40", "84_41", "84_42", "84_43", "84_44", "84_45", "84_46", "85_0", "85_1", "85_2", "85_3", "85_4", "85_5", "85_6", "85_7", "85_8", "85_9", "85_10", "85_11", "85_12", "85_13", "85_14", "85_15", "85_16", "85_17", "85_18", "85_19", "85_20", "85_21", "85_22", "85_23", "85_24", "85_25", "85_26", "85_27", "85_28", "85_29", "85_30", "85_31", "85_32", "85_33", "85_34", "85_35", "85_36", "85_37", "85_38", "85_39", "85_40", "85_41", "85_42", "85_43", "85_44", "85_45", "85_46", "86_0", "86_1", "86_2", "86_3", "86_4", "86_5", "86_6", "86_7", "86_8", "86_9", "86_10", "86_11", "86_12", "86_13", "86_14", "86_15", "86_16", "86_17", "86_18", "86_19", "86_20", "86_21", "86_22", "86_23", "86_24", "86_25", "86_26", "86_27", "86_28", "86_29", "86_30", "86_31", "86_32", "86_33", "86_34", "86_35", "86_36", "86_37", "86_38", "86_39", "86_40", "86_41", "86_42", "86_43", "86_44", "86_45", "86_46", "87_0", "87_1", "87_2", "87_3", "87_4", "87_5", "87_6", "87_7", "87_8", "87_9", "87_10", "87_11", "87_12", "87_13", "87_14", "87_15", "87_16", "87_17", "87_18", "87_19", "87_20", "87_21", "87_22", "87_23", "87_24", "87_25", "87_26", "87_27", "87_28", "87_29", "87_30", "87_31", "87_32", "87_33", "87_34", "87_35", "87_36", "87_37", "87_38", "87_39", "87_40", "87_41", "87_42", "87_43", "87_44", "87_45", "87_46", "88_0", "88_1", "88_2", "88_3", "88_4", "88_5", "88_6", "88_7", "88_8", "88_9", "88_10", "88_11", "88_12", "88_13", "88_14", "88_15", "88_16", "88_17", "88_18", "88_19", "88_20", "88_21", "88_22", "88_23", "88_24", "88_25", "88_26", "88_27", "88_28", "88_29", "88_30", "88_31", "88_32", "88_33", "88_34", "88_35", "88_36", "88_37", "88_38", "88_39", "88_40", "88_41", "88_42", "88_43", "88_44", "88_45", "88_46", "89_0", "89_1", "89_2", "89_3", "89_4", "89_5", "89_6", "89_7", "89_8", "89_9", "89_10", "89_11", "89_12", "89_13", "89_14", "89_15", "89_16", "89_17", "89_18", "89_19", "89_20", "89_21", "89_22", "89_23", "89_24", "89_25", "89_26", "89_27", "89_28", "89_29", "89_30", "89_31", "89_32", "89_33", "89_34", "89_35", "89_36", "89_37", "89_38", "89_39", "89_40", "89_41", "89_42", "89_43", "89_44", "89_45", "89_46", "90_0", "90_1", "90_2", "90_3", "90_4", "90_5", "90_6", "90_7", "90_8", "90_9", "90_10", "90_11", "90_12", "90_13", "90_14", "90_15", "90_16", "90_17", "90_18", "90_19", "90_20", "90_21", "90_22", "90_23", "90_24", "90_25", "90_26", "91_0", "91_1", "91_2", "91_3", "91_4", "91_5", "91_6", "91_7", "91_8", "91_9", "91_10", "91_11", "91_12", "91_13", "91_14", "91_15", "91_16", "91_17", "91_18", "91_19", "91_20", "91_21", "91_22", "91_23", "91_24", "91_25", "91_26", "92_0", "92_1", "92_2", "92_3", "92_4", "92_5", "92_6", "92_7", "92_8", "92_9", "92_10", "92_11", "92_12", "92_13", "92_14", "92_15", "92_16", "92_17", "92_18", "92_19", "92_20", "92_21", "92_22", "92_23", "92_24", "92_25", "92_26", "93_0", "93_1", "93_2", "93_3", "93_4", "93_5", "93_6", "93_7", "93_8", "93_9", "93_10", "93_11", "93_12", "93_13", "93_14", "93_15", "93_16", "93_17", "93_18", "93_19", "93_20", "93_21", "93_22", "93_23", "93_24", "93_25", "93_26", "94_0", "94_1", "94_2", "94_3", "94_4", "94_5", "94_6", "94_7", "94_8", "94_9", "94_10", "94_11", "94_12", "94_13", "94_14", "94_15", "94_16", "94_17", "94_18", "94_19", "94_20", "94_21", "94_22", "94_23", "94_24", "94_25", "94_26", "95_0", "95_1", "95_2", "95_3", "95_4", "95_5", "95_6", "95_7", "95_8", "95_9", "95_10", "95_11", "95_12", "95_13", "95_14", "95_15", "95_16", "95_17", "95_18", "95_19", "95_20", "95_21", "95_22", "95_23", "95_24", "95_25", "95_26", "96_0", "96_1", "96_2", "96_3", "96_4", "96_5", "96_6", "96_7", "96_8", "96_9", "96_10", "96_11", "96_12", "96_13", "96_14", "96_15", "96_16", "96_17", "96_18", "96_19", "96_20", "96_21", "96_22", "96_23", "96_24", "96_25", "96_26", "97_0", "97_1", "97_2", "97_3", "97_4", "97_5", "97_6", "97_7", "97_8", "97_9", "97_10", "97_11", "97_12", "97_13", "97_14", "97_15", "97_16", "97_17", "97_18", "97_19", "97_20", "97_21", "97_22", "97_23", "97_24", "97_25", "97_26", "98_0", "98_1", "98_2", "98_3", "98_4", "98_5", "98_6", "98_7", "98_8", "98_9", "98_10", "98_11", "98_12", "98_13", "98_14", "98_15", "98_16", "98_17", "98_18", "98_19", "98_20", "98_21", "98_22", "98_23", "98_24", "98_25", "98_26", "99_0", "99_1", "99_2", "99_3", "99_4", "99_5", "99_6", "99_7", "99_8", "99_9", "99_10", "99_11", "99_12", "99_13", "99_14", "99_15", "99_16", "99_17", "99_18", "99_19", "99_20", "99_21", "99_22", "99_23", "99_24", "99_25", "99_26", "100_0", "100_1", "100_2", "100_3", "100_4", "100_5", "100_6", "100_7", "100_8", "100_9", "100_10", "100_11", "100_12", "100_13", "100_14", "100_15", "100_16", "100_17", "100_18", "100_19", "100_20", "100_21", "100_22", "100_23", "100_24", "100_25", "100_26", "101_0", "101_1", "101_2", "101_3", "101_4", "101_5", "101_6", "101_7", "101_8", "101_9", "101_10", "101_11", "101_12", "101_13", "101_14", "101_15", "101_16", "101_17", "101_18", "101_19", "101_20", "101_21", "101_22", "101_23", "101_24", "101_25", "101_26", "102_0", "102_1", "102_2", "102_3", "102_4", "102_5", "102_6", "102_7", "102_8", "102_9", "102_10", "102_11", "102_12", "102_13", "102_14", "102_15", "102_16", "102_17", "102_18", "102_19", "102_20", "102_21", "102_22", "102_23", "102_24", "102_25", "102_26", "103_0", "103_1", "103_2", "103_3", "103_4", "103_5", "103_6", "103_7", "103_8", "103_9", "103_10", "103_11", "103_12", "103_13", "103_14", "103_15", "103_16", "103_17", "103_18", "103_19", "103_20", "103_21", "103_22", "103_23", "103_24", "103_25", "103_26", "104_0", "104_1", "104_2", "104_3", "104_4", "104_5", "104_6", "104_7", "104_8", "104_9", "104_10", "104_11", "104_12", "104_13", "104_14", "104_15", "104_16", "104_17", "104_18", "104_19", "104_20", "104_21", "104_22", "104_23", "104_24", "104_25", "104_26", "105_0", "105_1", "105_2", "105_3", "105_4", "105_5", "105_6", "105_7", "105_8", "105_9", "105_10", "105_11", "105_12", "105_13", "105_14", "105_15", "105_16", "105_17", "105_18", "105_19", "105_20", "105_21", "105_22", "105_23", "105_24", "105_25", "105_26", "106_0", "106_1", "106_2", "106_3", "106_4", "106_5", "106_6", "106_7", "106_8", "106_9", "106_10", "106_11", "106_12", "106_13", "106_14", "106_15", "106_16", "106_17", "106_18", "106_19", "106_20", "106_21", "106_22", "106_23", "106_24", "106_25", "106_26", "107_0", "107_1", "107_2", "107_3", "107_4", "107_5", "107_6", "107_7", "107_8", "107_9", "107_10", "107_11", "107_12", "107_13", "107_14", "107_15", "107_16", "107_17", "107_18", "107_19", "107_20", "107_21", "107_22", "107_23", "107_24", "107_25", "107_26", "108_0", "108_1", "108_2", "108_3", "108_4", "108_5", "108_6", "108_7", "108_8", "108_9", "108_10", "108_11", "108_12", "108_13", "108_14", "108_15", "108_16", "108_17", "108_18", "108_19", "108_20", "108_21", "108_22", "108_23", "108_24", "108_25", "108_26", "109_0", "109_1", "109_2", "109_3", "109_4", "109_5", "109_6", "109_7", "109_8", "109_9", "109_10", "109_11", "109_12", "109_13", "109_14", "109_15", "109_16", "109_17", "109_18", "109_19", "109_20", "109_21", "109_22", "109_23", "109_24", "109_25", "109_26", "110_0", "110_1", "110_2", "110_3", "110_4", "110_5", "110_6", "110_7", "110_8", "110_9", "110_10", "110_11", "110_12", "110_13", "110_14", "110_15", "110_16", "110_17", "110_18", "110_19", "110_20", "110_21", "110_22", "110_23", "110_24", "110_25", "110_26", "110_27", "110_28", "110_29", "110_30", "110_31", "110_32", "110_33", "110_34", "110_35", "110_36", "110_37", "110_38", "110_39", "110_40", "111_0", "111_1", "111_2", "111_3", "111_4", "111_5", "111_6", "111_7", "111_8", "111_9", "111_10", "111_11", "111_12", "111_13", "111_14", "111_15", "111_16", "111_17", "111_18", "111_19", "111_20", "111_21", "111_22", "111_23", "111_24", "111_25", "111_26", "111_27", "111_28", "111_29", "111_30", "111_31", "111_32", "111_33", "111_34", "111_35", "111_36", "111_37", "111_38", "111_39", "111_40", "112_0", "112_1", "112_2", "112_3", "112_4", "112_5", "112_6", "112_7", "112_8", "112_9", "112_10", "112_11", "112_12", "112_13", "112_14", "112_15", "112_16", "112_17", "112_18", "112_19", "112_20", "112_21", "112_22", "112_23", "112_24", "112_25", "112_26", "112_27", "112_28", "112_29", "112_30", "112_31", "112_32", "112_33", "112_34", "112_35", "112_36", "112_37", "112_38", "112_39", "112_40", "113_0", "113_1", "113_2", "113_3", "113_4", "113_5", "113_6", "113_7", "113_8", "113_9", "113_10", "113_11", "113_12", "113_13", "113_14", "113_15", "113_16", "113_17", "113_18", "113_19", "113_20", "113_21", "113_22", "113_23", "113_24", "113_25", "113_26", "113_27", "113_28", "113_29", "113_30", "113_31", "113_32", "113_33", "113_34", "113_35", "113_36", "113_37", "113_38", "113_39", "113_40", "114_0", "114_1", "114_2", "114_3", "114_4", "114_5", "114_6", "114_7", "114_8", "114_9", "114_10", "114_11", "114_12", "114_13", "114_14", "114_15", "114_16", "114_17", "114_18", "114_19", "114_20", "114_21", "114_22", "114_23", "114_24", "114_25", "114_26", "114_27", "114_28", "114_29", "114_30", "114_31", "114_32", "114_33", "114_34", "114_35", "114_36", "114_37", "114_38", "114_39", "114_40", "115_0", "115_1", "115_2", "115_3", "115_4", "115_5", "115_6", "115_7", "115_8", "115_9", "115_10", "115_11", "115_12", "115_13", "115_14", "115_15", "115_16", "115_17", "115_18", "115_19", "115_20", "115_21", "115_22", "115_23", "115_24", "115_25", "115_26", "115_27", "115_28", "115_29", "115_30", "115_31", "115_32", "115_33", "115_34", "115_35", "115_36", "115_37", "115_38", "115_39", "115_40", "116_0", "116_1", "116_2", "116_3", "116_4", "116_5", "116_6", "116_7", "116_8", "116_9", "116_10", "116_11", "116_12", "116_13", "116_14", "116_15", "116_16", "116_17", "116_18", "116_19", "116_20", "116_21", "116_22", "116_23", "116_24", "116_25", "116_26", "116_27", "116_28", "116_29", "116_30", "116_31", "116_32", "116_33", "116_34", "116_35", "116_36", "116_37", "116_38", "116_39", "116_40", "117_0", "117_1", "117_2", "117_3", "117_4", "117_5", "117_6", "117_7", "117_8", "117_9", "117_10", "117_11", "117_12", "117_13", "117_14", "117_15", "117_16", "117_17", "117_18", "117_19", "117_20", "117_21", "117_22", "117_23", "117_24", "117_25", "117_26", "117_27", "117_28", "117_29", "117_30", "117_31", "117_32", "117_33", "117_34", "117_35", "117_36", "117_37", "117_38", "117_39", "117_40", "118_0", "118_1", "118_2", "118_3", "118_4", "118_5", "118_6", "118_7", "118_8", "118_9", "118_10", "118_11", "118_12", "118_13", "118_14", "118_15", "118_16", "118_17", "118_18", "118_19", "118_20", "118_21", "118_22", "118_23", "118_24", "118_25", "118_26", "118_27", "118_28", "118_29", "118_30", "118_31", "118_32", "118_33", "118_34", "118_35", "118_36", "118_37", "118_38", "118_39", "118_40", "119_0", "119_1", "119_2", "119_3", "119_4", "119_5", "119_6", "119_7", "119_8", "119_9", "119_10", "119_11", "119_12", "119_13", "119_14", "119_15", "119_16", "119_17", "119_18", "119_19", "119_20", "119_21", "119_22", "119_23", "119_24", "119_25", "119_26", "119_27", "119_28", "119_29", "119_30", "119_31", "119_32", "119_33", "119_34", "119_35", "119_36", "119_37", "119_38", "119_39", "119_40", "120_0", "120_1", "120_2", "120_3", "120_4", "120_5", "120_6", "120_7", "120_8", "120_9", "120_10", "120_11", "120_12", "120_13", "120_14", "120_15", "120_16", "120_17", "120_18", "120_19", "120_20", "120_21", "120_22", "120_23", "120_24", "120_25", "120_26", "120_27", "120_28", "120_29", "120_30", "120_31", "120_32", "120_33", "120_34", "120_35", "120_36", "120_37", "120_38", "120_39", "120_40", "121_0", "121_1", "121_2", "121_3", "121_4", "121_5", "121_6", "121_7", "121_8", "121_9", "121_10", "121_11", "121_12", "121_13", "121_14", "121_15", "121_16", "121_17", "121_18", "121_19", "121_20", "121_21", "121_22", "121_23", "121_24", "121_25", "121_26", "121_27", "121_28", "121_29", "121_30", "121_31", "121_32", "121_33", "121_34", "121_35", "121_36", "121_37", "121_38", "121_39", "121_40", "121_41", "121_42", "121_43", "121_44", "121_45", "121_46", "121_47", "121_48", "122_0", "122_1", "122_2", "122_3", "122_4", "122_5", "122_6", "122_7", "122_8", "122_9", "122_10", "122_11", "122_12", "122_13", "122_14", "122_15", "122_16", "122_17", "122_18", "122_19", "122_20", "122_21", "122_22", "122_23", "122_24", "122_25", "122_26", "122_27", "122_28", "122_29", "122_30", "122_31", "122_32", "122_33", "122_34", "122_35", "122_36", "122_37", "122_38", "122_39", "122_40", "122_41", "122_42", "122_43", "122_44", "122_45", "122_46", "122_47", "122_48", "123_0", "123_1", "123_2", "123_3", "123_4", "123_5", "123_6", "123_7", "123_8", "123_9", "123_10", "123_11", "123_12", "123_13", "123_14", "123_15", "123_16", "124_0", "124_1", "124_2", "124_3", "124_4", "124_5", "124_6", "124_7", "124_8", "124_9", "124_10", "124_11", "124_12", "124_13", "124_14", "124_15", "124_16", "125_0", "125_1", "125_2", "125_3", "125_4", "125_5", "125_6", "125_7", "125_8", "125_9", "125_10", "125_11", "125_12", "125_13", "125_14", "125_15", "125_16", "126_0", "126_1", "126_2", "126_3", "126_4", "126_5", "126_6", "126_7", "126_8", "126_9", "126_10", "126_11", "126_12", "126_13", "126_14", "126_15", "126_16", "127_0", "127_1", "127_2", "127_3", "127_4", "127_5", "127_6", "127_7", "127_8", "127_9", "127_10", "127_11", "127_12", "127_13", "127_14", "127_15", "127_16", "128_0", "128_1", "128_2", "128_3", "128_4", "128_5", "128_6", "128_7", "128_8", "128_9", "128_10", "128_11", "128_12", "128_13", "128_14", "128_15", "128_16", "129_0", "129_1", "129_2", "129_3", "129_4", "129_5", "129_6", "129_7", "129_8", "129_9", "129_10", "129_11", "129_12", "129_13", "129_14", "129_15", "129_16", "130_0", "130_1", "130_2", "130_3", "130_4", "130_5", "130_6", "130_7", "130_8", "130_9", "130_10", "130_11", "130_12", "130_13", "130_14", "130_15", "130_16", "131_0", "131_1", "131_2", "131_3", "131_4", "131_5", "131_6", "131_7", "131_8", "131_9", "131_10", "131_11", "131_12", "131_13", "131_14", "131_15", "131_16", "132_0", "132_1", "132_2", "132_3", "132_4", "132_5", "132_6", "132_7", "132_8", "132_9", "132_10", "132_11", "132_12", "132_13", "132_14", "132_15", "132_16", "133_0", "133_1", "133_2", "133_3", "133_4", "133_5", "133_6", "133_7", "133_8", "133_9", "133_10", "133_11", "133_12", "133_13", "133_14", "133_15", "133_16", "134_0", "134_1", "134_2", "134_3", "134_4", "134_5", "134_6", "134_7", "134_8", "134_9", "134_10", "134_11", "134_12", "134_13", "134_14", "134_15", "134_16", "135_0", "135_1", "135_2", "135_3", "135_4", "135_5", "135_6", "135_7", "135_8", "135_9", "135_10", "135_11", "135_12", "135_13", "135_14", "135_15", "135_16", "136_0", "136_1", "136_2", "136_3", "136_4", "136_5", "136_6", "136_7", "136_8", "136_9", "136_10", "136_11", "136_12", "136_13", "136_14", "136_15", "136_16", "137_0", "137_1", "137_2", "137_3", "137_4", "137_5", "137_6", "137_7", "137_8", "137_9", "137_10", "137_11", "137_12", "137_13", "137_14", "137_15", "137_16", "138_0", "138_1", "138_2", "138_3", "138_4", "138_5", "138_6", "138_7", "138_8", "138_9", "138_10", "138_11", "138_12", "138_13", "138_14", "138_15", "138_16", "139_0", "139_1", "139_2", "139_3", "139_4", "139_5", "139_6", "139_7", "139_8", "139_9", "139_10", "139_11", "139_12", "139_13", "139_14", "139_15", "139_16", "140_0", "140_1", "140_2", "140_3", "140_4", "140_5", "140_6", "140_7", "140_8", "140_9", "140_10", "140_11", "140_12", "140_13", "140_14", "140_15", "140_16", "140_17", "140_18", "140_19", "140_20", "140_21", "140_22", "140_23", "140_24", "140_25", "140_26", "140_27", "140_28", "140_29", "140_30", "140_31", "140_32", "140_33", "140_34", "141_0", "141_1", "141_2", "141_3", "141_4", "141_5", "141_6", "141_7", "141_8", "141_9", "141_10", "141_11", "141_12", "141_13", "141_14", "141_15", "141_16", "141_17", "141_18", "141_19", "141_20", "141_21", "141_22", "141_23", "141_24", "141_25", "141_26", "141_27", "141_28", "141_29", "141_30", "141_31", "141_32", "141_33", "141_34", "142_0", "142_1", "142_2", "142_3", "142_4", "142_5", "142_6", "142_7", "142_8", "142_9", "142_10", "142_11", "142_12", "142_13", "142_14", "142_15", "142_16", "142_17", "142_18", "142_19", "142_20", "142_21", "142_22", "142_23", "142_24", "142_25", "142_26", "142_27", "142_28", "142_29", "142_30", "142_31", "142_32", "142_33", "142_34", "143_0", "143_1", "143_2", "143_3", "143_4", "143_5", "143_6", "143_7", "143_8", "143_9", "143_10", "143_11", "143_12", "143_13", "143_14", "143_15", "143_16", "143_17", "143_18", "143_19", "143_20", "143_21", "143_22", "143_23", "143_24", "143_25", "143_26", "143_27", "143_28", "143_29", "143_30", "143_31", "143_32", "143_33", "143_34", "144_0", "144_1", "144_2", "144_3", "144_4", "144_5", "144_6", "144_7", "144_8", "144_9", "144_10", "144_11", "144_12", "144_13", "144_14", "144_15", "144_16", "144_17", "144_18", "144_19", "144_20", "144_21", "144_22", "144_23", "144_24", "144_25", "144_26", "144_27", "144_28", "144_29", "144_30", "144_31", "144_32", "144_33", "144_34", "145_0", "145_1", "145_2", "145_3", "145_4", "145_5", "145_6", "145_7", "145_8", "145_9", "145_10", "145_11", "145_12", "145_13", "145_14", "145_15", "145_16", "145_17", "145_18", "145_19", "145_20", "145_21", "145_22", "145_23", "145_24", "145_25", "145_26", "145_27", "145_28", "145_29", "145_30", "145_31", "145_32", "145_33", "145_34", "146_0", "146_1", "146_2", "146_3", "146_4", "146_5", "146_6", "146_7", "146_8", "146_9", "146_10", "146_11", "146_12", "146_13", "146_14", "146_15", "146_16", "146_17", "146_18", "146_19", "146_20", "146_21", "146_22", "146_23", "146_24", "146_25", "146_26", "146_27", "146_28", "146_29", "146_30", "146_31", "146_32", "146_33", "146_34", "147_0", "147_1", "147_2", "147_3", "147_4", "147_5", "147_6", "147_7", "147_8", "147_9", "147_10", "147_11", "147_12", "147_13", "147_14", "147_15", "147_16", "147_17", "148_0", "148_1", "148_2", "148_3", "148_4", "148_5", "148_6", "148_7", "148_8", "148_9", "148_10", "148_11", "148_12", "148_13", "148_14", "148_15", "148_16", "148_17", "149_0", "149_1", "149_2", "149_3", "149_4", "149_5", "149_6", "149_7", "149_8", "149_9", "149_10", "149_11", "149_12", "149_13", "149_14", "149_15", "149_16", "149_17", "150_0", "150_1", "150_2", "150_3", "150_4", "150_5", "150_6", "150_7", "150_8", "150_9", "150_10", "150_11", "150_12", "150_13", "150_14", "150_15", "150_16", "150_17", "151_0", "151_1", "151_2", "151_3", "151_4", "151_5", "151_6", "151_7", "151_8", "151_9", "151_10", "151_11", "151_12", "151_13", "151_14", "151_15", "151_16", "151_17", "152_0", "152_1", "152_2", "152_3", "152_4", "152_5", "152_6", "152_7", "152_8", "152_9", "152_10", "152_11", "152_12", "152_13", "152_14", "152_15", "152_16", "152_17", "153_0", "153_1", "153_2", "153_3", "153_4", "153_5", "153_6", "153_7", "153_8", "153_9", "153_10", "153_11", "153_12", "153_13", "153_14", "153_15", "153_16", "153_17", "154_0", "154_1", "154_2", "154_3", "154_4", "154_5", "154_6", "154_7", "154_8", "154_9", "154_10", "154_11", "154_12", "154_13", "154_14", "154_15", "154_16", "154_17", "155_0", "155_1", "155_2", "155_3", "155_4", "155_5", "155_6", "155_7", "155_8", "155_9", "155_10", "155_11", "155_12", "155_13", "155_14", "155_15", "155_16", "155_17", "156_0", "156_1", "156_2", "156_3", "156_4", "156_5", "156_6", "156_7", "156_8", "156_9", "156_10", "156_11", "156_12", "156_13", "156_14", "156_15", "156_16", "156_17", "157_0", "157_1", "157_2", "157_3", "157_4", "157_5", "157_6", "157_7", "157_8", "157_9", "157_10", "157_11", "157_12", "157_13", "157_14", "157_15", "157_16", "157_17", "158_0", "158_1", "158_2", "158_3", "158_4", "158_5", "158_6", "158_7", "158_8", "158_9", "158_10", "158_11", "158_12", "158_13", "158_14", "158_15", "158_16", "158_17", "159_0", "159_1", "159_2", "159_3", "159_4", "159_5", "159_6", "159_7", "159_8", "159_9", "159_10", "159_11", "159_12", "159_13", "159_14", "159_15", "159_16", "159_17", "160_0", "160_1", "160_2", "160_3", "160_4", "160_5", "160_6", "160_7", "160_8", "160_9", "160_10", "160_11", "160_12", "160_13", "160_14", "160_15", "160_16", "160_17", "161_0", "161_1", "161_2", "161_3", "161_4", "161_5", "161_6", "161_7", "161_8", "161_9", "161_10", "161_11", "161_12", "161_13", "161_14", "161_15", "161_16", "161_17", "162_0", "162_1", "162_2", "162_3", "162_4", "162_5", "162_6", "162_7", "162_8", "162_9", "162_10", "162_11", "162_12", "162_13", "162_14", "162_15", "162_16", "162_17", "163_0", "163_1", "163_2", "163_3", "163_4", "163_5", "163_6", "163_7", "163_8", "163_9", "163_10", "163_11", "163_12", "163_13", "163_14", "163_15", "163_16", "163_17", "164_0", "164_1", "164_2", "164_3", "164_4", "164_5", "164_6", "164_7", "164_8", "164_9", "164_10", "164_11", "164_12", "164_13", "164_14", "164_15", "164_16", "164_17", "165_0", "165_1", "165_2", "165_3", "165_4", "165_5", "165_6", "165_7", "165_8", "165_9", "165_10", "165_11", "165_12", "165_13", "165_14", "165_15", "165_16", "165_17", "166_0", "166_1", "166_2", "166_3", "166_4", "166_5", "166_6", "166_7", "166_8", "166_9", "166_10", "166_11", "166_12", "166_13", "166_14", "166_15", "166_16", "166_17", "167_0", "167_1", "167_2", "167_3", "167_4", "167_5", "167_6", "167_7", "167_8", "167_9", "167_10", "167_11", "167_12", "167_13", "167_14", "167_15", "167_16", "167_17", "167_18", "167_19", "167_20", "167_21", "167_22", "167_23", "167_24", "167_25", "167_26", "167_27", "167_28", "168_0", "168_1", "168_2", "168_3", "168_4", "168_5", "168_6", "168_7", "168_8", "168_9", "168_10", "168_11", "168_12", "168_13", "168_14", "168_15", "168_16", "168_17", "168_18", "168_19", "168_20", "168_21", "168_22", "168_23", "168_24", "168_25", "168_26", "168_27", "168_28", "169_0", "169_1", "169_2", "169_3", "169_4", "169_5", "169_6", "169_7", "169_8", "169_9", "169_10", "169_11", "169_12", "169_13", "169_14", "169_15", "169_16", "169_17", "169_18", "169_19", "169_20", "169_21", "169_22", "169_23", "169_24", "169_25", "169_26", "169_27", "169_28", "170_0", "170_1", "170_2", "170_3", "170_4", "170_5", "170_6", "170_7", "170_8", "170_9", "170_10", "170_11", "170_12", "170_13", "170_14", "170_15", "170_16", "170_17", "170_18", "170_19", "170_20", "170_21", "170_22", "170_23", "170_24", "170_25", "170_26", "170_27", "170_28", "171_0", "171_1", "171_2", "171_3", "171_4", "171_5", "171_6", "171_7", "171_8", "171_9", "171_10", "171_11", "171_12", "171_13", "171_14", "171_15", "171_16", "171_17", "171_18", "171_19", "171_20", "171_21", "171_22", "171_23", "171_24", "171_25", "171_26", "171_27", "171_28", "172_0", "172_1", "172_2", "172_3", "172_4", "172_5", "172_6", "172_7", "172_8", "172_9", "172_10", "172_11", "172_12", "172_13", "172_14", "172_15", "172_16", "172_17", "172_18", "172_19", "172_20", "172_21", "172_22", "172_23", "172_24", "172_25", "172_26", "172_27", "172_28", "173_0", "173_1", "173_2", "173_3", "173_4", "173_5", "173_6", "173_7", "173_8", "173_9", "173_10", "173_11", "173_12", "173_13", "173_14", "173_15", "173_16", "173_17", "173_18", "173_19", "173_20", "173_21", "173_22", "173_23", "173_24", "173_25", "173_26", "173_27", "173_28", "174_0", "174_1", "174_2", "174_3", "174_4", "174_5", "174_6", "174_7", "174_8", "174_9", "174_10", "174_11", "174_12", "174_13", "174_14", "174_15", "174_16", "174_17", "174_18", "174_19", "174_20", "174_21", "174_22", "174_23", "174_24", "174_25", "174_26", "174_27", "174_28", "175_0", "175_1", "175_2", "175_3", "175_4", "175_5", "175_6", "175_7", "175_8", "175_9", "175_10", "175_11", "175_12", "175_13", "175_14", "175_15", "175_16", "175_17", "175_18", "175_19", "175_20", "175_21", "175_22", "175_23", "175_24", "175_25", "175_26", "175_27", "175_28", "176_0", "176_1", "176_2", "176_3", "176_4", "176_5", "176_6", "176_7", "176_8", "176_9", "176_10", "176_11", "176_12", "176_13", "176_14", "176_15", "176_16", "176_17", "176_18", "176_19", "176_20", "176_21", "176_22", "176_23", "176_24", "176_25", "176_26", "176_27", "176_28", "177_0", "177_1", "177_2", "177_3", "177_4", "177_5", "177_6", "177_7", "177_8", "177_9", "177_10", "177_11", "177_12", "177_13", "177_14", "177_15", "177_16", "177_17", "177_18", "177_19", "177_20", "177_21", "177_22", "177_23", "177_24", "177_25", "177_26", "177_27", "177_28", "178_0", "178_1", "178_2", "178_3", "178_4", "178_5", "178_6", "178_7", "178_8", "178_9", "178_10", "178_11", "178_12", "178_13", "178_14", "178_15", "178_16", "178_17", "178_18", "178_19", "178_20", "178_21", "178_22", "178_23", "178_24", "178_25", "178_26", "178_27", "178_28", "178_29", "178_30", "178_31", "178_32", "178_33", "178_34", "178_35", "178_36", "178_37", "178_38", "179_0", "179_1", "179_2", "179_3", "179_4", "179_5", "179_6", "179_7", "179_8", "179_9", "179_10", "179_11", "179_12", "179_13", "179_14", "179_15", "179_16", "179_17", "179_18", "179_19", "179_20", "179_21", "179_22", "179_23", "179_24", "179_25", "179_26", "179_27", "179_28", "179_29", "179_30", "179_31", "179_32", "179_33", "179_34", "179_35", "179_36", "179_37", "179_38", "180_0", "180_1", "180_2", "180_3", "180_4", "180_5", "180_6", "180_7", "180_8", "180_9", "180_10", "180_11", "180_12", "180_13", "180_14", "180_15", "180_16", "180_17", "181_0", "181_1", "181_2", "181_3", "181_4", "181_5", "181_6", "181_7", "181_8", "181_9", "181_10", "181_11", "181_12", "181_13", "181_14", "181_15", "181_16", "181_17", "182_0", "182_1", "182_2", "182_3", "182_4", "182_5", "182_6", "182_7", "182_8", "182_9", "182_10", "182_11", "182_12", "182_13", "182_14", "182_15", "182_16", "182_17", "183_0", "183_1", "183_2", "183_3", "183_4", "183_5", "183_6", "183_7", "183_8", "183_9", "183_10", "183_11", "183_12", "183_13", "183_14", "183_15", "183_16", "183_17", "184_0", "184_1", "184_2", "184_3", "184_4", "184_5", "184_6", "184_7", "184_8", "184_9", "184_10", "184_11", "184_12", "184_13", "184_14", "184_15", "184_16", "184_17", "185_0", "185_1", "185_2", "185_3", "185_4", "185_5", "185_6", "185_7", "185_8", "185_9", "185_10", "185_11", "185_12", "185_13", "185_14", "185_15", "185_16", "185_17", "186_0", "186_1", "186_2", "186_3", "186_4", "186_5", "186_6", "186_7", "186_8", "186_9", "186_10", "186_11", "186_12", "186_13", "186_14", "186_15", "186_16", "186_17", "187_0", "187_1", "187_2", "187_3", "187_4", "187_5", "187_6", "187_7", "187_8", "187_9", "187_10", "187_11", "187_12", "187_13", "187_14", "187_15", "187_16", "187_17", "188_0", "188_1", "188_2", "188_3", "188_4", "188_5", "188_6", "188_7", "188_8", "188_9", "188_10", "188_11", "188_12", "188_13", "188_14", "188_15", "188_16", "188_17", "189_0", "189_1", "189_2", "189_3", "189_4", "189_5", "189_6", "189_7", "189_8", "189_9", "189_10", "189_11", "189_12", "189_13", "189_14", "189_15", "189_16", "189_17", "190_0", "190_1", "190_2", "190_3", "190_4", "190_5", "190_6", "190_7", "190_8", "190_9", "190_10", "190_11", "190_12", "190_13", "190_14", "190_15", "190_16", "190_17", "191_0", "191_1", "191_2", "191_3", "191_4", "191_5", "191_6", "191_7", "191_8", "191_9", "191_10", "191_11", "191_12", "191_13", "191_14", "191_15", "191_16", "191_17", "192_0", "192_1", "192_2", "192_3", "192_4", "192_5", "192_6", "192_7", "192_8", "192_9", "192_10", "192_11", "192_12", "192_13", "192_14", "192_15", "192_16", "192_17", "192_18", "192_19", "192_20", "192_21", "192_22", "192_23", "192_24", "192_25", "192_26", "192_27", "192_28", "192_29", "192_30", "192_31", "192_32", "192_33", "193_0", "193_1", "193_2", "193_3", "193_4", "193_5", "193_6", "193_7", "193_8", "193_9", "193_10", "193_11", "193_12", "193_13", "193_14", "193_15", "193_16", "193_17", "193_18", "193_19", "193_20", "193_21", "193_22", "193_23", "193_24", "193_25", "193_26", "193_27", "193_28", "193_29", "193_30", "193_31", "193_32", "193_33", "194_0", "194_1", "194_2", "194_3", "194_4", "194_5", "194_6", "194_7", "194_8", "194_9", "194_10", "194_11", "194_12", "194_13", "194_14", "194_15", "194_16", "194_17", "194_18", "194_19", "194_20", "194_21", "194_22", "194_23", "194_24", "194_25", "194_26", "194_27", "194_28", "194_29", "194_30", "194_31", "194_32", "194_33", "195_0", "195_1", "195_2", "195_3", "195_4", "195_5", "195_6", "195_7", "195_8", "195_9", "195_10", "195_11", "195_12", "195_13", "195_14", "195_15", "195_16", "195_17", "195_18", "195_19", "195_20", "195_21", "195_22", "195_23", "195_24", "195_25", "195_26", "195_27", "195_28", "195_29", "195_30", "195_31", "195_32", "195_33", "196_0", "196_1", "196_2", "196_3", "196_4", "196_5", "196_6", "196_7", "196_8", "196_9", "196_10", "196_11", "196_12", "196_13", "196_14", "196_15", "196_16", "196_17", "196_18", "196_19", "196_20", "196_21", "196_22", "196_23", "196_24", "196_25", "196_26", "196_27", "196_28", "196_29", "196_30", "196_31", "196_32", "196_33", "197_0", "197_1", "197_2", "197_3", "197_4", "197_5", "197_6", "197_7", "197_8", "197_9", "197_10", "197_11", "197_12", "197_13", "197_14", "197_15", "197_16", "197_17", "197_18", "197_19", "197_20", "197_21", "197_22", "197_23", "197_24", "197_25", "197_26", "197_27", "197_28", "197_29", "197_30", "197_31", "197_32", "197_33", "198_0", "198_1", "198_2", "198_3", "198_4", "198_5", "198_6", "198_7", "198_8", "198_9", "198_10", "198_11", "198_12", "198_13", "198_14", "198_15", "198_16", "198_17", "198_18", "198_19", "198_20", "198_21", "198_22", "198_23", "198_24", "198_25", "198_26", "198_27", "198_28", "198_29", "198_30", "198_31", "198_32", "198_33", "199_0", "199_1", "199_2", "199_3", "199_4", "199_5", "199_6", "199_7", "199_8", "199_9", "199_10", "199_11", "199_12", "199_13", "199_14", "199_15", "199_16", "199_17", "199_18", "199_19", "199_20", "199_21", "199_22", "199_23", "199_24", "199_25", "199_26", "199_27", "199_28", "199_29", "199_30", "199_31", "199_32", "199_33", "200_0", "200_1", "200_2", "200_3", "200_4", "200_5", "200_6", "200_7", "200_8", "200_9", "200_10", "200_11", "200_12", "200_13", "200_14", "200_15", "200_16", "200_17", "200_18", "200_19", "200_20", "200_21", "200_22", "200_23", "200_24", "200_25", "200_26", "200_27", "200_28", "200_29", "200_30", "200_31", "200_32", "200_33", "201_0", "201_1", "201_2", "201_3", "201_4", "201_5", "201_6", "201_7", "201_8", "201_9", "201_10", "201_11", "201_12", "201_13", "201_14", "201_15", "201_16", "201_17", "201_18", "201_19", "201_20", "201_21", "201_22", "201_23", "201_24", "201_25", "201_26", "201_27", "201_28", "201_29", "201_30", "201_31", "201_32", "201_33", "202_0", "202_1", "202_2", "202_3", "202_4", "202_5", "202_6", "202_7", "202_8", "202_9", "202_10", "202_11", "202_12", "202_13", "202_14", "202_15", "202_16", "202_17", "202_18", "202_19", "202_20", "202_21", "202_22", "202_23", "202_24", "202_25", "202_26", "202_27", "202_28", "202_29", "202_30", "202_31", "202_32", "202_33", "203_0", "203_1", "203_2", "203_3", "203_4", "204_0", "204_1", "204_2", "204_3", "204_4", "204_5", "204_6", "204_7", "204_8", "204_9", "204_10", "204_11", "204_12", "204_13", "204_14", "204_15", "204_16", "204_17", "204_18", "204_19", "204_20", "204_21", "204_22", "204_23", "204_24", "204_25", "205_0", "205_1", "205_2", "205_3", "205_4", "205_5", "205_6", "205_7", "205_8", "205_9", "205_10", "205_11", "205_12", "205_13", "205_14", "205_15", "205_16", "205_17", "205_18", "206_0", "206_1", "206_2", "206_3", "206_4", "206_5", "206_6", "206_7", "206_8", "206_9", "206_10", "206_11", "206_12", "206_13", "206_14", "206_15", "206_16", "206_17", "207_0", "207_1", "207_2", "207_3", "207_4", "207_5", "207_6", "207_7", "207_8", "207_9", "207_10", "207_11", "207_12", "207_13", "207_14", "207_15", "207_16", "207_17", "208_0", "208_1", "208_2", "208_3", "208_4", "208_5", "208_6", "208_7", "208_8", "208_9", "208_10", "208_11", "208_12", "208_13", "208_14", "208_15", "208_16", "208_17", "208_18", "208_19", "208_20", "209_0", "209_1", "209_2", "209_3", "209_4", "209_5", "209_6", "209_7", "209_8", "209_9", "209_10", "209_11", "209_12", "209_13", "209_14", "209_15", "209_16", "209_17", "209_18", "209_19", "209_20", "210_0", "210_1", "210_2", "210_3", "210_4", "210_5", "210_6", "210_7", "210_8", "210_9", "210_10", "210_11", "210_12", "210_13", "210_14", "210_15", "210_16", "210_17", "210_18", "210_19", "210_20", "211_0", "211_1", "211_2", "211_3", "211_4", "211_5", "211_6", "211_7", "211_8", "211_9", "211_10", "211_11", "211_12", "211_13", "211_14", "211_15", "211_16", "211_17", "211_18", "211_19", "211_20", "212_0", "212_1", "212_2", "212_3", "212_4", "212_5", "212_6", "212_7", "212_8", "212_9", "212_10", "212_11", "212_12", "212_13", "212_14", "212_15", "212_16", "212_17", "212_18", "212_19", "212_20", "213_0", "213_1", "213_2", "213_3", "213_4", "213_5", "213_6", "213_7", "213_8", "213_9", "213_10", "213_11", "213_12", "213_13", "213_14", "213_15", "213_16", "213_17", "213_18", "213_19", "213_20", "214_0", "214_1", "214_2", "214_3", "214_4", "214_5", "214_6", "214_7", "214_8", "214_9", "214_10", "214_11", "214_12", "214_13", "214_14", "214_15", "214_16", "214_17", "214_18", "214_19", "214_20", "215_0", "215_1", "215_2", "215_3", "215_4", "215_5", "215_6", "215_7", "215_8", "215_9", "215_10", "215_11", "215_12", "215_13", "215_14", "215_15", "215_16", "215_17", "215_18", "215_19", "215_20", "216_0", "216_1", "216_2", "216_3", "216_4", "216_5", "216_6", "216_7", "216_8", "216_9", "216_10", "216_11", "216_12", "216_13", "216_14", "216_15", "216_16", "216_17", "216_18", "216_19", "216_20", "217_0", "217_1", "217_2", "217_3", "217_4", "217_5", "217_6", "217_7", "217_8", "217_9", "217_10", "217_11", "217_12", "217_13", "217_14", "217_15", "217_16", "217_17", "217_18", "217_19", "217_20", "217_21", "217_22", "217_23", "217_24", "217_25", "217_26", "217_27", "217_28", "217_29", "218_0", "218_1", "218_2", "218_3", "218_4", "218_5", "218_6", "218_7", "218_8", "218_9", "218_10", "218_11", "218_12", "218_13", "218_14", "218_15", "218_16", "218_17", "218_18", "218_19", "218_20", "218_21", "218_22", "218_23", "218_24", "218_25", "218_26", "218_27", "218_28", "218_29", "219_0", "219_1", "219_2", "219_3", "219_4", "219_5", "219_6", "219_7", "219_8", "219_9", "219_10", "219_11", "219_12", "219_13", "219_14", "219_15", "219_16", "219_17", "219_18", "219_19", "219_20", "219_21", "219_22", "219_23", "219_24", "219_25", "219_26", "219_27", "219_28", "219_29", "220_0", "220_1", "220_2", "220_3", "220_4", "220_5", "220_6", "220_7", "220_8", "220_9", "220_10", "220_11", "220_12", "220_13", "220_14", "220_15", "220_16", "220_17", "220_18", "220_19", "220_20", "220_21", "220_22", "220_23", "220_24", "220_25", "220_26", "220_27", "220_28", "220_29", "221_0", "221_1", "221_2", "221_3", "221_4", "221_5", "221_6", "221_7", "221_8", "221_9", "221_10", "221_11", "221_12", "221_13", "221_14", "221_15", "221_16", "221_17", "221_18", "221_19", "221_20", "221_21", "221_22", "221_23", "221_24", "221_25", "221_26", "221_27", "221_28", "221_29", "222_0", "222_1", "222_2", "222_3", "222_4", "222_5", "222_6", "222_7", "222_8", "222_9", "222_10", "222_11", "222_12", "222_13", "222_14", "222_15", "222_16", "222_17", "222_18", "222_19", "222_20", "222_21", "222_22", "222_23", "222_24", "222_25", "222_26", "222_27", "222_28", "222_29", "223_0", "223_1", "223_2", "223_3", "223_4", "223_5", "223_6", "223_7", "223_8", "223_9", "223_10", "223_11", "223_12", "223_13", "223_14", "223_15", "223_16", "223_17", "223_18", "223_19", "223_20", "223_21", "223_22", "223_23", "223_24", "223_25", "223_26", "223_27", "223_28", "223_29", "224_0", "224_1", "224_2", "224_3", "224_4", "224_5", "224_6", "224_7", "224_8", "224_9", "224_10", "224_11", "224_12", "224_13", "224_14", "224_15", "224_16", "224_17", "224_18", "224_19", "224_20", "224_21", "224_22", "224_23", "224_24", "224_25", "224_26", "224_27", "224_28", "224_29", "225_0", "225_1", "225_2", "225_3", "225_4", "225_5", "225_6", "225_7", "225_8", "225_9", "225_10", "225_11", "225_12", "225_13", "225_14", "225_15", "225_16", "225_17", "225_18", "225_19", "225_20", "225_21", "225_22", "225_23", "225_24", "225_25", "225_26", "225_27", "225_28", "225_29", "226_0", "226_1", "226_2", "226_3", "226_4", "226_5", "226_6", "226_7", "226_8", "226_9", "226_10", "226_11", "226_12", "226_13", "226_14", "226_15", "226_16", "226_17", "226_18", "226_19", "226_20", "226_21", "226_22", "226_23", "226_24", "226_25", "226_26", "226_27", "226_28", "226_29", "227_0", "227_1", "227_2", "227_3", "227_4", "227_5", "227_6", "227_7", "227_8", "227_9", "227_10", "227_11", "227_12", "227_13", "227_14", "227_15", "227_16", "227_17", "227_18", "227_19", "227_20", "227_21", "227_22", "227_23", "227_24", "227_25", "227_26", "227_27", "227_28", "227_29", "228_0", "228_1", "228_2", "228_3", "228_4", "228_5", "228_6", "228_7", "228_8", "228_9", "228_10", "228_11", "228_12", "228_13", "228_14", "228_15", "228_16", "228_17", "228_18", "228_19", "228_20", "228_21", "228_22", "228_23", "228_24", "228_25", "228_26", "228_27", "228_28", "228_29", "229_0", "229_1", "229_2", "229_3", "229_4", "229_5", "229_6", "229_7", "229_8", "229_9", "229_10", "229_11", "229_12", "229_13", "229_14", "229_15", "229_16", "229_17", "229_18", "229_19", "229_20", "229_21", "229_22", "229_23", "229_24", "229_25", "229_26", "229_27", "229_28", "229_29", "230_0", "230_1", "230_2", "230_3", "230_4", "230_5", "230_6", "230_7", "230_8", "230_9", "230_10", "230_11", "230_12", "230_13", "230_14", "230_15", "230_16", "230_17", "230_18", "230_19", "230_20", "230_21", "230_22", "230_23", "230_24", "230_25", "230_26", "230_27", "230_28", "230_29", "231_0", "231_1", "231_2", "231_3", "231_4", "231_5", "231_6", "231_7", "231_8", "231_9", "231_10", "231_11", "231_12", "231_13", "231_14", "231_15", "231_16", "231_17", "231_18", "231_19", "231_20", "231_21", "231_22", "231_23", "231_24", "231_25", "231_26", "231_27", "231_28", "231_29", "232_0", "232_1", "232_2", "232_3", "232_4", "232_5", "232_6", "232_7", "232_8", "232_9", "232_10", "232_11", "232_12", "232_13", "232_14", "232_15", "232_16", "232_17", "232_18", "232_19", "232_20", "232_21", "232_22", "232_23", "232_24", "232_25", "232_26", "232_27", "232_28", "232_29", "233_0", "233_1", "233_2", "233_3", "233_4", "233_5", "233_6", "233_7", "233_8", "233_9", "233_10", "233_11", "233_12", "233_13", "233_14", "233_15", "233_16", "233_17", "233_18", "233_19", "233_20", "233_21", "233_22", "233_23", "233_24", "233_25", "233_26", "233_27", "233_28", "233_29", "234_0", "234_1", "234_2", "234_3", "234_4", "234_5", "234_6", "234_7", "234_8", "234_9", "234_10", "234_11", "234_12", "234_13", "234_14", "234_15", "234_16", "234_17", "234_18", "234_19", "234_20", "234_21", "234_22", "234_23", "234_24", "234_25", "234_26", "234_27", "234_28", "234_29", "235_0", "235_1", "235_2", "235_3", "235_4", "235_5", "235_6", "235_7", "235_8", "235_9", "235_10", "235_11", "235_12", "235_13", "235_14", "235_15", "235_16", "235_17", "235_18", "235_19", "235_20", "235_21", "235_22", "235_23", "235_24", "235_25", "235_26", "235_27", "235_28", "235_29", "236_0", "236_1", "236_2", "236_3", "236_4", "236_5", "236_6", "236_7", "236_8", "236_9", "236_10", "236_11", "236_12", "236_13", "236_14", "236_15", "236_16", "236_17", "236_18", "236_19", "236_20", "236_21", "236_22", "236_23", "236_24", "236_25", "236_26", "236_27", "236_28", "236_29", "237_0", "237_1", "237_2", "237_3", "237_4", "237_5", "237_6", "237_7", "237_8", "237_9", "237_10", "237_11", "237_12", "237_13", "237_14", "237_15", "237_16", "237_17", "237_18", "237_19", "237_20", "237_21", "237_22", "237_23", "237_24", "237_25", "237_26", "237_27", "237_28", "237_29", "238_0", "238_1", "238_2", "238_3", "238_4", "238_5", "238_6", "238_7", "238_8", "238_9", "238_10", "238_11", "238_12", "238_13", "238_14", "238_15", "238_16", "238_17", "238_18", "238_19", "238_20", "238_21", "238_22", "238_23", "238_24", "238_25", "238_26", "238_27", "238_28", "238_29", "239_0", "239_1", "239_2", "239_3", "239_4", "239_5", "239_6", "239_7", "239_8", "239_9", "239_10", "239_11", "239_12", "239_13", "239_14", "239_15", "239_16", "239_17", "239_18", "239_19", "239_20", "239_21", "239_22", "239_23", "239_24", "239_25", "239_26", "239_27", "239_28", "239_29", "239_30", "239_31", "239_32", "239_33", "239_34", "240_0", "240_1", "240_2", "240_3", "240_4", "240_5", "240_6", "240_7", "240_8", "240_9", "240_10", "240_11", "240_12", "240_13", "240_14", "240_15", "240_16", "240_17", "240_18", "240_19", "240_20", "240_21", "240_22", "240_23", "240_24", "240_25", "240_26", "240_27", "240_28", "240_29", "240_30", "240_31", "240_32", "240_33", "240_34", "241_0", "241_1", "241_2", "241_3", "241_4", "241_5", "241_6", "241_7", "241_8", "241_9", "241_10", "241_11", "241_12", "241_13", "241_14", "241_15", "241_16", "241_17", "241_18", "241_19", "241_20", "241_21", "241_22", "241_23", "241_24", "241_25", "241_26", "241_27", "241_28", "241_29", "241_30", "241_31", "241_32", "241_33", "241_34", "242_0", "242_1", "242_2", "242_3", "242_4", "242_5", "242_6", "242_7", "242_8", "242_9", "242_10", "242_11", "242_12", "242_13", "242_14", "242_15", "242_16", "242_17", "242_18", "242_19", "242_20", "242_21", "242_22", "242_23", "242_24", "242_25", "242_26", "242_27", "242_28", "242_29", "242_30", "242_31", "242_32", "242_33", "242_34", "243_0", "243_1", "243_2", "243_3", "243_4", "243_5", "243_6", "243_7", "243_8", "243_9", "243_10", "243_11", "243_12", "243_13", "243_14", "243_15", "243_16", "243_17", "243_18", "243_19", "243_20", "243_21", "243_22", "243_23", "243_24", "243_25", "243_26", "243_27", "243_28", "243_29", "243_30", "243_31", "243_32", "243_33", "243_34", "244_0", "244_1", "244_2", "244_3", "244_4", "244_5", "244_6", "244_7", "245_0", "245_1", "245_2", "245_3", "245_4", "245_5", "245_6", "245_7", "246_0", "246_1", "246_2", "246_3", "246_4", "246_5", "246_6", "246_7", "247_0", "247_1", "247_2", "247_3", "247_4", "247_5", "247_6", "247_7", "248_0", "248_1", "248_2", "248_3", "248_4", "248_5", "248_6", "248_7", "249_0", "249_1", "249_2", "249_3", "249_4", "249_5", "249_6", "249_7", "250_0", "250_1", "250_2", "250_3", "250_4", "250_5", "250_6", "250_7", "251_0", "251_1", "251_2", "251_3", "251_4", "251_5", "251_6", "251_7", "252_0", "252_1", "252_2", "252_3", "252_4", "252_5", "252_6", "252_7", "253_0", "253_1", "253_2", "253_3", "253_4", "253_5", "253_6", "253_7", "254_0", "254_1", "254_2", "254_3", "254_4", "254_5", "254_6", "254_7", "255_0", "255_1", "255_2", "255_3", "255_4", "255_5", "255_6", "255_7", "255_8", "255_9", "255_10", "255_11", "255_12", "255_13", "255_14", "255_15", "255_16", "255_17", "255_18", "255_19", "255_20", "255_21", "255_22", "255_23", "255_24", "255_25", "255_26", "255_27", "255_28", "255_29", "255_30", "255_31", "255_32", "255_33", "255_34", "255_35", "255_36", "256_0", "256_1", "256_2", "256_3", "256_4", "256_5", "256_6", "256_7", "256_8", "256_9", "256_10", "256_11", "256_12", "256_13", "256_14", "256_15", "256_16", "256_17", "256_18", "256_19", "256_20", "256_21", "256_22", "256_23", "256_24", "256_25", "256_26", "256_27", "256_28", "256_29", "256_30", "256_31", "256_32", "256_33", "256_34", "256_35", "256_36", "257_0", "257_1", "257_2", "257_3", "257_4", "257_5", "257_6", "257_7", "257_8", "257_9", "257_10", "257_11", "257_12", "257_13", "257_14", "257_15", "258_0", "258_1", "258_2", "258_3", "258_4", "258_5", "258_6", "258_7", "258_8", "258_9", "258_10", "258_11", "258_12", "258_13", "258_14", "258_15", "259_0", "259_1", "259_2", "259_3", "259_4", "259_5", "259_6", "259_7", "259_8", "259_9", "259_10", "259_11", "259_12", "259_13", "259_14", "259_15", "259_16", "259_17", "259_18", "259_19", "259_20", "259_21", "259_22", "259_23", "259_24", "259_25", "259_26", "259_27", "259_28", "259_29", "259_30", "259_31", "259_32", "259_33", "259_34", "259_35", "259_36", "259_37", "260_0", "260_1", "260_2", "260_3", "260_4", "260_5", "260_6", "260_7", "260_8", "260_9", "260_10", "260_11", "260_12", "261_0", "261_1", "261_2", "261_3", "261_4", "261_5", "261_6", "261_7", "261_8", "261_9", "261_10", "261_11", "261_12", "262_0", "262_1", "262_2", "262_3", "262_4", "262_5", "262_6", "262_7", "262_8", "262_9", "262_10", "262_11", "262_12", "263_0", "263_1", "263_2", "263_3", "263_4", "263_5", "263_6", "263_7", "263_8", "263_9", "263_10", "263_11", "263_12", "264_0", "264_1", "264_2", "264_3", "264_4", "264_5", "264_6", "264_7", "264_8", "264_9", "264_10", "264_11", "264_12", "265_0", "265_1", "265_2", "265_3", "265_4", "265_5", "265_6", "265_7", "265_8", "265_9", "265_10", "265_11", "265_12", "266_0", "266_1", "266_2", "266_3", "266_4", "266_5", "266_6", "266_7", "266_8", "266_9", "266_10", "266_11", "266_12", "267_0", "267_1", "267_2", "267_3", "267_4", "267_5", "267_6", "267_7", "267_8", "267_9", "267_10", "267_11", "267_12", "268_0", "268_1", "268_2", "268_3", "268_4", "268_5", "268_6", "268_7", "268_8", "268_9", "268_10", "268_11", "268_12", "269_0", "269_1", "269_2", "269_3", "269_4", "269_5", "269_6", "269_7", "269_8", "269_9", "269_10", "269_11", "269_12", "270_0", "270_1", "270_2", "270_3", "270_4", "270_5", "270_6", "270_7", "270_8", "270_9", "270_10", "270_11", "270_12", "271_0", "271_1", "271_2", "271_3", "271_4", "271_5", "271_6", "271_7", "271_8", "271_9", "271_10", "271_11", "271_12", "272_0", "272_1", "272_2", "272_3", "272_4", "272_5", "272_6", "272_7", "272_8", "272_9", "272_10", "272_11", "272_12", "272_13", "272_14", "273_0", "273_1", "273_2", "273_3", "273_4", "273_5", "273_6", "273_7", "273_8", "273_9", "273_10", "273_11", "273_12", "273_13", "273_14", "273_15", "273_16", "273_17", "273_18", "273_19", "273_20", "273_21", "273_22", "273_23", "274_0", "274_1", "274_2", "274_3", "274_4", "274_5", "274_6", "274_7", "274_8", "274_9", "274_10", "274_11", "274_12", "274_13", "274_14", "274_15", "274_16", "274_17", "274_18", "274_19", "274_20", "274_21", "274_22", "274_23", "275_0", "275_1", "275_2", "275_3", "275_4", "275_5", "275_6", "275_7", "275_8", "275_9", "275_10", "275_11", "275_12", "275_13", "275_14", "275_15", "275_16", "275_17", "275_18", "275_19", "275_20", "275_21", "275_22", "275_23", "276_0", "276_1", "276_2", "276_3", "276_4", "276_5", "276_6", "276_7", "276_8", "276_9", "276_10", "276_11", "276_12", "276_13", "276_14", "276_15", "276_16", "276_17", "276_18", "276_19", "276_20", "276_21", "276_22", "276_23", "277_0", "277_1", "277_2", "277_3", "277_4"]}